<SEC-DOCUMENT>0001641172-25-001613.txt : 20250331
<SEC-HEADER>0001641172-25-001613.hdr.sgml : 20250331
<ACCEPTANCE-DATETIME>20250331143009
ACCESSION NUMBER:		0001641172-25-001613
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		95
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250331
DATE AS OF CHANGE:		20250331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NanoVibronix, Inc.
		CENTRAL INDEX KEY:			0001326706
		STANDARD INDUSTRIAL CLASSIFICATION:	ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36445
		FILM NUMBER:		25791758

	BUSINESS ADDRESS:	
		STREET 1:		969 PRUITT AVE,
		CITY:			TYLER
		STATE:			TX
		ZIP:			77569
		BUSINESS PHONE:		(914) 233-3004

	MAIL ADDRESS:	
		STREET 1:		969 PRUITT AVE,
		CITY:			TYLER
		STATE:			TX
		ZIP:			77569

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Nano Vibronix, Inc.
		DATE OF NAME CHANGE:	20111206

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Nano Vibronix Inc
		DATE OF NAME CHANGE:	20050510
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:NAOV="http://nanovibronix.com/20241231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2024%2D(with%2DECD%2Dand%2DCYD) -->
<!-- Field: Set; Name: xdx; ID: xdx_03D_NAOV_nanovibronix.com_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20240101_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DEntityCentralIndexKey_0001326706 -->
<!-- Field: Set; Name: xdx; ID: xdx_076_XDX_form10%2Dk.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000004" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000005" name="dei:EntityCentralIndexKey">0001326706</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2024-12-31" id="xdx2ixbrl0093" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredIncomeNoncurrent" contextRef="AsOf2024-12-31" id="xdx2ixbrl0135" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0139" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2024-12-31" id="xdx2ixbrl0144" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0150" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0151" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0169" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0170" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0188" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0189" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0207" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0208" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0333" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0334" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0335" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0336" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0343" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0345" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0347" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0349" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0353" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0354" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0355" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0357" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0359" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0360" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0363" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0364" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0365" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0366" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0367" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0368" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0370" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0373" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0374" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0375" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0376" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0377" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0379" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0380" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0385" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0386" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0387" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0388" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0390" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0391" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0392" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0393" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0397" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0398" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0399" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0400" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0401" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0403" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0404" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:StockIssuedDuringPeriodValuesReverseStockSplits" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0409" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:StockIssuedDuringPeriodValuesReverseStockSplits" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0410" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:StockIssuedDuringPeriodValuesReverseStockSplits" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0411" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:StockIssuedDuringPeriodValuesReverseStockSplits" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0412" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:StockIssuedDuringPeriodValuesReverseStockSplits" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0413" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:StockIssuedDuringPeriodValuesReverseStockSplits" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0414" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:StockIssuedDuringPeriodValuesReverseStockSplits" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0415" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:StockIssuedDuringPeriodValuesReverseStockSplits" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0416" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:StockIssuedDuringPeriodValuesReverseStockSplits" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0417" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0421" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0422" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0423" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0424" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0425" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0426" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0427" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0431" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0432" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0433" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0434" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0441" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0443" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0445" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0447" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0451" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0452" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0453" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0454" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0461" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0463" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0465" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0467" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0471" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0472" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0473" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0474" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0475" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0477" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0478" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0481" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0482" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0483" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0484" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0485" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0486" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0488" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0491" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0492" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0493" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0494" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0496" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0497" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0498" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0503" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0504" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0505" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0506" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0507" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0508" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0509" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0510" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0511" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:StockIssuedDuringPeriodValuesReverseStockSplits" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0515" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:StockIssuedDuringPeriodValuesReverseStockSplits" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0516" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:StockIssuedDuringPeriodValuesReverseStockSplits" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0517" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:StockIssuedDuringPeriodValuesReverseStockSplits" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0518" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:StockIssuedDuringPeriodValuesReverseStockSplits" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0519" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:StockIssuedDuringPeriodValuesReverseStockSplits" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0520" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:StockIssuedDuringPeriodValuesReverseStockSplits" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0521" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:StockIssuedDuringPeriodValuesReverseStockSplits" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0522" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:StockIssuedDuringPeriodValuesReverseStockSplits" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0523" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0527" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0528" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0529" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0530" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0531" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0532" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0533" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0537" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0538" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0539" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0540" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0547" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0549" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0551" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0553" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0557" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0558" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0559" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0560" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0567" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0569" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0571" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0573" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0595" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainLossOnSaleOfInvestments" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0599" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:IncreaseDecreaseInAccruedSeverancePayNet" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0622" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0640" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0643" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0647" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember" id="xdx2ixbrl0830" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember" id="xdx2ixbrl0838" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember" id="xdx2ixbrl0876" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember" id="xdx2ixbrl0878" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember" id="xdx2ixbrl0880" name="NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" xs:nil="true"></ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember" id="xdx2ixbrl0886" name="NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm" xs:nil="true"></ix:nonNumeric>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember" id="xdx2ixbrl0888" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember" id="xdx2ixbrl0890" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember" id="xdx2ixbrl0892" name="NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" xs:nil="true"></ix:nonNumeric>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="xdx2ixbrl0988" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputExpectedDividendRateMember" id="xdx2ixbrl0992" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember" id="xdx2ixbrl0994" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember" id="xdx2ixbrl0996" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2024-12-31" id="xdx2ixbrl1000" name="us-gaap:WarrantsAndRightsOutstandingTerm" xs:nil="true"></ix:nonNumeric>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2023-01-012023-12-31_custom_PreWarrantMember_custom_PrivateInvestorsMember" id="xdx2ixbrl1012" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2023-01-012023-12-31_custom_PostWarrantMember_custom_PrivateInvestorsMember" id="xdx2ixbrl1014" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2024-01-012024-12-31_custom_PreWarrantMember_custom_PrivateInvestorsMember" id="xdx2ixbrl1024" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2024-01-012024-12-31_custom_PostWarrantMember_custom_PrivateInvestorsMember" id="xdx2ixbrl1026" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" contextRef="From2024-01-012024-12-31_custom_PreWarrantMember_custom_PrivateInvestorsMember" id="xdx2ixbrl1036" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" contextRef="From2024-01-012024-12-31_custom_PostWarrantMember_custom_PrivateInvestorsMember" id="xdx2ixbrl1038" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31_country_NZ" id="xdx2ixbrl1100" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31_custom_OtherCountryMember" id="xdx2ixbrl1103" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" contextRef="AsOf2024-12-31_custom_DerivativeAssetMember" id="xdx2ixbrl1167" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherAssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1171" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherAssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1172" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherAssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1173" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherAssetsFairValueDisclosure" contextRef="AsOf2024-12-31" id="xdx2ixbrl1174" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherAssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1176" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherAssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1177" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1215" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1216" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1218" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1219" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:DeferredTaxAssetsOfCapitalLossCarryforward" contextRef="AsOf2023-12-31" id="xdx2ixbrl1297" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2024-12-31" id="xdx2ixbrl1311" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2023-12-31" id="xdx2ixbrl1312" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="naov-20241231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-01-01to2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_SeriesDPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_SeriesDPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_SeriesEPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_SeriesEPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_SeriesFPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_SeriesFPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_PropertyPlantAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SaleOfEquitySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">NAOV:SaleOfEquitySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_OfficeEquipmentMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_OfficeEquipmentMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-152023-02-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-15</xbrli:startDate>
        <xbrli:endDate>2023-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-312024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-31</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-132025-03-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-13</xbrli:startDate>
        <xbrli:endDate>2025-03-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-122025-03-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-12</xbrli:startDate>
        <xbrli:endDate>2025-03-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-302023-08-30_custom_PurchaseAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-30</xbrli:startDate>
        <xbrli:endDate>2023-08-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-30_custom_PurchaseAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_A1WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:A1WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_A2WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:A2WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-30_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-30_custom_PurchaseAgreementMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-302023-08-30_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-30</xbrli:startDate>
        <xbrli:endDate>2023-08-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-05_custom_HCWainwrightAndCoLLCMember_custom_PlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:HCWainwrightAndCoLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:PlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_TwoThousandFourteenLongTermIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">NAOV:TwoThousandFourteenLongTermIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-092023-02-09_custom_TwoThousandFourteenLongTermIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">NAOV:TwoThousandFourteenLongTermIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-09</xbrli:startDate>
        <xbrli:endDate>2023-02-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-02-09_custom_TwoThousandFourteenLongTermIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">NAOV:TwoThousandFourteenLongTermIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-02-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_TwoThousandFourteenLongTermIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">NAOV:TwoThousandFourteenLongTermIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwoThousandAndTwentyFourLongTermIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">NAOV:TwoThousandAndTwentyFourLongTermIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-14_custom_TwoThousandAndTwentyFourLongTermIncentivePlanMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">NAOV:TwoThousandAndTwentyFourLongTermIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TwoThousandAndTwentyFourLongTermIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">NAOV:TwoThousandAndTwentyFourLongTermIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_EmployeeOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EmployeeOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-30_custom_A1WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:A1WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-30_custom_A2WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:A2WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-30_custom_HCWainwrightAndCoLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:HCWainwrightAndCoLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_PreWarrantMember_custom_PrivateInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:PreWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PrivateInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_PostWarrantMember_custom_PrivateInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:PostWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PrivateInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_PreWarrantMember_custom_PrivateInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:PreWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PrivateInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_PostWarrantMember_custom_PrivateInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:PostWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PrivateInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PreWarrantMember_custom_PrivateInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:PreWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PrivateInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PostWarrantMember_custom_PrivateInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:PostWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PrivateInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_PreWarrantMember_custom_PrivateInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:PreWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PrivateInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_PostWarrantMember_custom_PrivateInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:PostWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PrivateInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PreWarrantMember_custom_PrivateInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:PreWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PrivateInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PostWarrantMember_custom_PrivateInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:PostWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PrivateInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_EmployeeOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_EmployeeOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_SellingAndMarketingExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_SellingAndMarketingExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_StockOptionsEmployeeAndNonEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">NAOV:StockOptionsEmployeeAndNonEmployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_StockOptionsEmployeeAndNonEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">NAOV:StockOptionsEmployeeAndNonEmployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_srt_EuropeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_srt_EuropeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_country_AU">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_country_AU">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_country_IL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_country_IL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_country_NZ">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NZ</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_country_NZ">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NZ</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_OtherCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">NAOV:OtherCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_OtherCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">NAOV:OtherCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NAOV:CustomerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-04-09_custom_LicensingAgreementMember_custom_SanuwaveHealthIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:LicensingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-04-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-09-122024-09-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-12</xbrli:startDate>
        <xbrli:endDate>2024-09-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PriceAtValuationMember_custom_SanuwaveHealthIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">NAOV:PriceAtValuationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PriceAtValuationMember_custom_SanuwaveHealthIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">NAOV:PriceAtValuationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_SanuwaveHealthIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_SanuwaveHealthIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_SanuwaveHealthIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_SanuwaveHealthIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SanuwaveHealthIncMember_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SanuwaveHealthIncMember_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_SanuwaveHealthIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_SanuwaveHealthIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_DerivativeAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_DerivativeAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_DerivativeAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_DerivativeAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_DerivativeAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-252021-02-26">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-25</xbrli:startDate>
        <xbrli:endDate>2021-02-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-03-142022-03-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-14</xbrli:startDate>
        <xbrli:endDate>2022-03-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ArbitratorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:ArbitratorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ArbitratorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:ArbitratorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_PiersonFerdinandMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PiersonFerdinandMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-072025-01-07_custom_SecuritiesExchangeAgreementMember_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:SecuritiesExchangeAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-07</xbrli:startDate>
        <xbrli:endDate>2025-01-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-01_custom_SecuritiesExchangeAgreementMember_us-gaap_WarrantMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:SecuritiesExchangeAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-07_custom_SecuritiesExchangeAgreementMember_custom_PreFundedWarrantsMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:SecuritiesExchangeAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:PreFundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-07_custom_SecuritiesExchangeAgreementMember_custom_A1WarrantsMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:SecuritiesExchangeAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:A1WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-072025-01-07_custom_SecuritiesExchangeAgreementMember_custom_A1WarrantsMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:SecuritiesExchangeAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:A1WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-07</xbrli:startDate>
        <xbrli:endDate>2025-01-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-31_custom_SecuritiesExchangeAgreementMember_custom_PreFundedWarrantsMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:SecuritiesExchangeAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:PreFundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-28_custom_SecuritiesExchangeAgreementMember_custom_PreFundedWarrantsMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:SecuritiesExchangeAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:PreFundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-31_custom_SecuritiesExchangeAgreementMember_us-gaap_WarrantMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:SecuritiesExchangeAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-28_custom_SecuritiesExchangeAgreementMember_us-gaap_WarrantMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:SecuritiesExchangeAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-142025-02-14_custom_MergerAgreementMember_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:MergerAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-14</xbrli:startDate>
        <xbrli:endDate>2025-02-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-142025-02-14_custom_MergerAgreementMember_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:MergerAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-14</xbrli:startDate>
        <xbrli:endDate>2025-02-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-142025-02-14_custom_MergerAgreementMember_custom_SeriesXPreferredStockMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:MergerAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NAOV:SeriesXPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-14</xbrli:startDate>
        <xbrli:endDate>2025-02-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-142025-02-14_custom_MergerAgreementMember_custom_SeriesXPreferredStockMember_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:MergerAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NAOV:SeriesXPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-14</xbrli:startDate>
        <xbrli:endDate>2025-02-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-13_custom_SecuritiesExchangeAgreementMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:SecuritiesExchangeAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-26_us-gaap_SubsequentEventMember_custom_ENvueMedicalHoldingsCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:ENvueMedicalHoldingsCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-26_us-gaap_SubsequentEventMember_custom_ENvueMedicalHoldingsCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:ENvueMedicalHoldingsCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-04_us-gaap_SubsequentEventMember_custom_ENvueMedicalHoldingsCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:ENvueMedicalHoldingsCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-26_us-gaap_SubsequentEventMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-122025-03-12_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-12</xbrli:startDate>
        <xbrli:endDate>2025-03-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-132025-03-13_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-13</xbrli:startDate>
        <xbrli:endDate>2025-03-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-13_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 12pt"><b>Washington, D.C.
20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FORM <span id="xdx_905_edei--DocumentType_c20240101__20241231_zlcneNGLZox3"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000011" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Segoe UI Emoji,sans-serif"><span id="xdx_90A_edei--DocumentAnnualReport_c20240101__20241231_zdlEKiSZyCvg"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000012" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span>
</span><b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the fiscal year ended <span id="xdx_90B_edei--DocumentPeriodEndDate_c20240101__20241231_zTPW49oCTMzf"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:datemonthdayyearen" id="Fact000013" name="dei:DocumentPeriodEndDate"><span id="xdx_90B_edei--CurrentFiscalYearEndDate_c20240101__20241231_zrzEvqR0H7kl"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:datemonthdayen" id="Fact000014" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric></span>, <span id="xdx_90D_edei--DocumentFiscalYearFocus_c20240101__20241231_zMYdDoqrmcm7"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000015" name="dei:DocumentFiscalYearFocus">2024</ix:nonNumeric></span></ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>OR</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Segoe UI Emoji,sans-serif"><span id="xdx_90A_edei--DocumentTransitionReport_c20240101__20241231_zHbFCyh2wHhc"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000016" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>
</span><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the transition period from to</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Commission File Number: <span id="xdx_90F_edei--EntityFileNumber_c20240101__20241231_zCA9xExY5bvh"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000017" name="dei:EntityFileNumber">001-36445</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="xdx_900_edei--EntityRegistrantName_c20240101__20241231_zOS0G9gfPF74"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000018" name="dei:EntityRegistrantName">NanoVibronix, Inc.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(Exact name of registrant as specified in its charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><b><span id="xdx_904_edei--EntityIncorporationStateCountryCode_c20240101__20241231_zG69hkpcRGwb"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:stateprovnameen" id="Fact000019" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><b><span id="xdx_90C_edei--EntityTaxIdentificationNumber_c20240101__20241231_zrqBoh0tuYH8"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000020" name="dei:EntityTaxIdentificationNumber">01-0801232</ix:nonNumeric></span></b></td></tr>
  <tr style="vertical-align: top">
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(State or other jurisdiction of</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">incorporation or organization)</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(I.R.S. Employer</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Identification Number)</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td>&#160;</td></tr>

<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; text-align: center; width: 49%"><b><span id="xdx_907_edei--EntityAddressAddressLine1_c20240101__20241231_zaDkOeL4WIok"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000021" name="dei:EntityAddressAddressLine1">969 Pruitt Ave</ix:nonNumeric> </span><br/>
    <span id="xdx_909_edei--EntityAddressCityOrTown_c20240101__20241231_zKuJlIOLlLbc"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000022" name="dei:EntityAddressCityOrTown">Tyler</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressStateOrProvince_c20240101__20241231_zCxDXbGD4n1h"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:stateprovnameen" id="Fact000023" name="dei:EntityAddressStateOrProvince">Texas</ix:nonNumeric></span></b></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center; width: 49%"><b><span id="xdx_907_edei--EntityAddressPostalZipCode_c20240101__20241231_zsMt9G8YLKwf"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000024" name="dei:EntityAddressPostalZipCode">77569</ix:nonNumeric></span></b></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">(Address of principal executive office)</td>
    <td>&#160;</td>
    <td style="text-align: center">(Zip Code)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Registrant&#8217;s telephone number, including area
code: <b><span id="xdx_90D_edei--CityAreaCode_c20240101__20241231_zAaol8koBD73"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000025" name="dei:CityAreaCode">(914)</ix:nonNumeric></span> <span id="xdx_907_edei--LocalPhoneNumber_c20240101__20241231_zr11jfDrKlC3"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000026" name="dei:LocalPhoneNumber">233-3004</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Securities registered pursuant to Section 12(b) of
the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: Black 1pt solid; text-align: center; width: 38%"><b>Title of each class</b></td>
    <td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; width: 20%"><b>Trading Symbol</b></td>
    <td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; width: 38%"><b>Name of each exchange on which registered</b></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: center"><span id="xdx_90E_edei--Security12bTitle_c20240101__20241231_z5GdPsJMltah"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000027" name="dei:Security12bTitle">Common stock, par value $0.001 per share</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_902_edei--TradingSymbol_c20240101__20241231_zVnne0v53Ytj"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000028" name="dei:TradingSymbol">NAOV</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90F_edei--SecurityExchangeName_c20240101__20241231_z66od6j3Cl6l"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:exchnameen" id="Fact000029" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Capital Market</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Securities registered pursuant to Section 12(g) of
the Act: None</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark if the registrant is a well-known
seasoned issuer, as defined in Rule 405 of the Securities Act. Yes <span style="font-family: Segoe UI Emoji,sans-serif">&#9744;</span>
<span id="xdx_904_edei--EntityWellKnownSeasonedIssuer_c20240101__20241231_zptxCtwASQn8"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000030" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span> <span style="font-family: Segoe UI Emoji,sans-serif">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark if the registrant is not required
to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes <span style="font-family: Segoe UI Emoji,sans-serif">&#9744;
</span><span id="xdx_90E_edei--EntityVoluntaryFilers_c20240101__20241231_zrtEydj5TjZ7"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000031" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> <span style="font-family: Segoe UI Emoji,sans-serif">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant (1)
has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements
for the past 90 days. <span id="xdx_907_edei--EntityCurrentReportingStatus_c20240101__20241231_zOwWJAXMrIM8"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000032" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> <span style="font-family: Segoe UI Emoji,sans-serif">&#9746;</span> No <span style="font-family: Segoe UI Emoji,sans-serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant has
submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <span id="xdx_90E_edei--EntityInteractiveDataCurrent_c20240101__20241231_z3i9C93jai6d"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000033" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>
<span style="font-family: Segoe UI Emoji,sans-serif">&#9746;</span> No <span style="font-family: Segoe UI Emoji,sans-serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant is
a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.
See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221;
and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>Large accelerated filer</td>
    <td><span style="font-family: Segoe UI Emoji,sans-serif">&#9744;</span></td>
    <td>Accelerated filer</td>
    <td><span style="font-family: Segoe UI Emoji,sans-serif">&#9744;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span id="xdx_90C_edei--EntityFilerCategory_c20240101__20241231_zp0Itc77j4P8"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:entityfilercategoryen" id="Fact000034" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span></td>
    <td><span style="font-family: Segoe UI Emoji,sans-serif">&#9746;</span></td>
    <td>Smaller reporting company</td>
    <td><span style="font-family: Segoe UI Emoji,sans-serif"><span id="xdx_90B_edei--EntitySmallBusiness_c20240101__20241231_ztYugknXWvAd"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000035" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>Emerging growth company</td>
    <td><span style="font-family: Segoe UI Emoji,sans-serif"><span id="xdx_90D_edei--EntityEmergingGrowthCompany_c20240101__20241231_zhgIonkBlch1"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000036" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Segoe UI Emoji,sans-serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant has
filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting
under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C 7262(b)) by the registered public accounting firm that prepared or issued its
audit report. <span style="font-family: Segoe UI Emoji,sans-serif"><span id="xdx_90F_edei--IcfrAuditorAttestationFlag_c20240101__20241231_zaHXjATnfa2e"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000037" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If securities are registered pursuant to Section
12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction
of an error to previously issued financial statements. <span style="font-family: Segoe UI Emoji,sans-serif"><span id="xdx_906_edei--DocumentFinStmtErrorCorrectionFlag_c20240101__20241231_z5VLPKCuK0G5"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000038" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether any of those error
corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s
executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). <span style="font-family: Segoe UI Emoji,sans-serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant is
a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes <span style="font-family: Segoe UI Emoji,sans-serif">&#9744;</span>
No <span style="font-family: Segoe UI Emoji,sans-serif"><span id="xdx_909_edei--EntityShellCompany_dbF_c20240101__20241231_zH3EJb0AZ3Z7"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000039" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The aggregate market value of voting stock held by
non-affiliates as of June 30, 2024, the last business day of the registrant&#8217;s most recently completed second quarter and based
on the closing price of the registrant&#8217;s common stock as reported on the Nasdaq Capital Market, was approximately $<span id="xdx_905_edei--EntityPublicFloat_iI_pn5n6_c20240630_zA4FRiTapvzh"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2024-06-30" id="Fact000040" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.9</ix:nonFraction></span> Million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The number of shares outstanding of the registrant&#8217;s
common stock as of March 31, 2025, was <span id="xdx_905_edei--EntityCommonStockSharesOutstanding_iI_c20250331_zuK0rvUy0vpk"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2025-03-31" id="Fact000041" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">759,297</ix:nonFraction></span> shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>DOCUMENTS INCORPORATED BY REFERENCE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_90B_edei--DocumentsIncorporatedByReferenceTextBlock_c20240101__20241231_zzfyasDhPbml"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000042" name="dei:DocumentsIncorporatedByReferenceTextBlock">None</ix:nonNumeric></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NANOVIBRONIX, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2024</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>TABLE OF CONTENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b><a href="#a_001">PART I.</a></b></td>
    <td style="vertical-align: bottom; text-align: right; width: 0.5in">1</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="padding-left: 10.25pt"><a href="#a_002">ITEM 1: BUSINESS</a></td>
    <td style="vertical-align: bottom; text-align: right">1</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 10.25pt"><a href="#sw_001">ITEM 1A: RISK FACTORS</a></td>
    <td style="vertical-align: bottom; text-align: right">62</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="padding-left: 10.25pt"><a href="#sw_002">ITEM 1B: UNRESOLVED STAFF COMMENTS</a></td>
    <td style="vertical-align: bottom; text-align: right">108</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 10.25pt"><a href="#sw_003">ITEM 1C: CYBERSECURITY</a></td>
    <td style="vertical-align: bottom; text-align: right">108</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="padding-left: 10.25pt"><a href="#sw_004">ITEM 2: PROPERTIES</a></td>
    <td style="vertical-align: bottom; text-align: right">109</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 10.25pt"><a href="#sw_005">ITEM 3: LEGAL PROCEEDINGS</a></td>
    <td style="vertical-align: bottom; text-align: right">110</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="padding-left: 10.25pt"><a href="#sw_006">ITEM 4: MINE SAFETY DISCLOSURES</a></td>
    <td style="vertical-align: bottom; text-align: right">110</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b><a href="#sw_007">PART II.</a></b></td>
    <td style="vertical-align: bottom; text-align: right">111</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="padding-left: 10.25pt"><a href="#sw_008">ITEM 5: MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS, AND ISSUER PURCHASES OF EQUITY SECURITIES</a></td>
    <td style="vertical-align: bottom; text-align: right">111</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 10.25pt"><a href="#sw_009">ITEM 6: [RESERVED]</a></td>
    <td style="vertical-align: bottom; text-align: right">112</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="padding-left: 10.25pt"><a href="#sw_010">ITEM 7: MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></td>
    <td style="vertical-align: bottom; text-align: right">113</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 10.25pt"><a href="#sw_011">ITEM 7A: QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></td>
    <td style="vertical-align: bottom; text-align: right">122</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="padding-left: 10.25pt"><a href="#sw_012">ITEM 8: FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></td>
    <td style="vertical-align: bottom; text-align: right">122</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 10.25pt"><a href="#sw_013">ITEM 9: CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</a></td>
    <td style="vertical-align: bottom; text-align: right">122</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="padding-left: 10.25pt"><a href="#sw_014">ITEM 9A: CONTROLS AND PROCEDURES</a></td>
    <td style="vertical-align: bottom; text-align: right">122</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 10.25pt"><a href="#sw_015">ITEM 9B: OTHER INFORMATION</a></td>
    <td style="vertical-align: bottom; text-align: right">124</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="padding-left: 10.25pt"><span style="text-transform: uppercase"><a href="#sw_016">ITEM 9C: Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</a></span></td>
    <td style="vertical-align: bottom; text-align: right">124</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b><a href="#sw_017">PART III.</a></b></td>
    <td style="vertical-align: bottom; text-align: right">125</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="padding-left: 10.25pt"><a href="#sw_018">ITEM 10: DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE</a></td>
    <td style="vertical-align: bottom; text-align: right">125</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 10.25pt"><a href="#sw_019">ITEM 11: EXECUTIVE COMPENSATION</a></td>
    <td style="vertical-align: bottom; text-align: right">133</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="padding-left: 10.25pt"><a href="#me_001">ITEM 12: SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a></td>
    <td style="vertical-align: bottom; text-align: right">148</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 10.25pt"><a href="#me_002">ITEM 13: CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</a></td>
    <td style="vertical-align: bottom; text-align: right">149</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="padding-left: 10.25pt"><a href="#me_003">ITEM 14: PRINCIPAL ACCOUNTANT FEES AND SERVICES</a></td>
    <td style="vertical-align: bottom; text-align: right">150</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>PART IV.</b></td>
    <td style="text-align: right; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="padding-left: 10.25pt"><a href="#me_004">ITEM 15: EXHIBITS, FINANCIAL STATEMENT SCHEDULES</a></td>
    <td style="vertical-align: bottom; text-align: right">152</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 10.25pt"><a href="#me_005">ITEM 16: FORM 10-K SUMMARY</a></td>
    <td style="vertical-align: bottom; text-align: right">152</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><a href="#me_006">SIGNATURES</a></td>
    <td style="vertical-align: bottom; text-align: right">161</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>EXPLANATORY NOTE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 14, 2025, subsequent to the end of the
fiscal year ended December 31, 2024, the fiscal year to which this Annual Report on Form 10-K relates and as further described herein,
pursuant to the terms of that certain Agreement and Plan of Merger, dated as of February 14, 2025 (the &#8220;Merger Agreement&#8221;),
by and among NanoVibronix, Inc. (the &#8220;Company&#8221;) NVEH Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary
of NVEH Merger Sub I, Inc. (&#8220;First Merger Sub&#8221;), NVEH Merger Sub II, LLC, a Delaware limited liability company and a wholly-owned
subsidiary of the Company (&#8220;Second Merger Sub&#8221;), and Predecessor ENvue, the Company and Predecessor ENvue effected (i) a
merger of First Merger Sub with and into Predecessor ENvue, with the First Merger Sub ceasing to exist and Predecessor ENvue becoming
a wholly-owned subsidiary the Company and (ii) the merger of Predecessor ENvue with and into Second Merger Sub (the &#8220;Second Merger&#8221;
and, together with the First Merger, the &#8220;Merger&#8221;), with Second Merger Sub being the surviving entity of the Second Merger
(&#8220;Surviving Entity&#8221;). At the effective time of the Second Merger, the certificate of formation of the Surviving Entity was
amended and restated to, among other things, to change the name of the Surviving Entity to &#8220;ENvue Medical Holdings LLC.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Except as otherwise expressly provided herein, the
information in this Annual Report on Form 10-K does not reflect the consummation of the Merger which, as discussed above, occurred subsequent
to the period covered hereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="text-transform: uppercase"><b>Cautionary
Note Regarding Forward-Looking Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Annual Report on Form 10-K contains &#8220;forward-looking
statements,&#8221; which include information relating to future events, future financial performance, financial projections, strategies,
expectations, competitive environment and regulation. Words such as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221;
&#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;future,&#8221;
&#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; and similar expressions, as well as statements
in future tense, are intended to identify forward-looking statements. Forward-looking statements should not be read as a guarantee of
future performance or results and may not be accurate indications of when such performance or results will actually be achieved. Forward-looking
statements are based on information we have when those statements are made or our management&#8217;s good faith belief as of that time
with respect to future events, and are subject to a number of risks, and uncertainties and assumptions that could cause actual performance
or results to differ materially from those expressed in or suggested by the forward-looking statements. These risks are more fully described
in the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K. Important factors that could cause such differences include,
but are not limited to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td>Our history of losses and expectation of continued losses.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td style="text-align: justify">Global economic and political instability and conflicts, such as the conflict between Russia and
    Ukraine, could adversely affect our business, financial condition or results of operations.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td style="text-align: justify">Increasing inflation could adversely affect our business, financial condition, results of operations
    or cash flows.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td style="text-align: justify">Risks related to ENvue&#8217;s financial condition, business and operations, as well as legal, regulatory
    and compliance matters</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td style="text-align: justify">Our ability to raise funding for, and the timing of, clinical studies and eventual U.S. Food and
    Drug Administration (&#8220;FDA&#8221;) approval of our product candidates.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td style="text-align: justify">Regulatory actions that could adversely affect the price of or demand for our approved products.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td style="text-align: justify">Market acceptance of existing and new products.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td style="text-align: justify">Favorable or unfavorable decisions about our products from government regulators, insurance companies
    or other third-party payers (including CMS).</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td style="text-align: justify">Risks of product liability acclaims and the availability of insurance.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td>Our ability to generate internal growth.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td>Risks related to computer system failures and cyber-attacks.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td>Our ability to obtain regulatory approval in foreign jurisdictions.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td>Uncertainty regarding the success of our clinical trials for our products in development.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td>Risks related to our operations in Israel, including political, economic and military instability.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td>The price of our securities is volatile with limited trading volume.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td style="text-align: justify">Our ability to regain and maintain compliance with the continued listing requirements of Nasdaq and
    the risk that our common stock will be delisted if we cannot do so.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td style="text-align: justify">Our ability to maintain effective internal control over financial reporting and to remedy identified
    material weaknesses.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td style="text-align: justify">We are a &#8220;smaller reporting company&#8221; and have reduced disclosure obligations that may
    make our stock less attractive to investors.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td>Our intellectual property portfolio and our ability to protect our intellectual property rights.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td>Our ability to recruit and retain qualified regulatory and research and development personnel.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td>Unforeseen changes in healthcare reimbursement for any of our approved products.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td>The adoption of health policy changes and health care reform.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td>Lack of financial resources to adequately support our operations.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td>Difficulties in maintaining commercial scale manufacturing capacity and capability.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td>Changes in our relationship with key collaborators.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td style="text-align: justify">Changes in the market valuation or earnings of our competitors or companies viewed as similar to
    us.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td>Our failure to comply with regulatory guidelines.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td>Uncertainty in industry demand and patient wellness behavior.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td>General economic conditions and market conditions in the medical device industry.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td>Future sales of large blocks of our common stock, which may adversely impact our stock price.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td>Depth of the trading market in our common stock.</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The foregoing does not represent an exhaustive list
of matters that may be covered by the forward-looking statements contained herein or risk factors that we are faced with that may cause
our actual results to differ from those anticipated in our forward-looking statements. Please see &#8220;Item 1A. Risk Factors&#8221;
for additional risks which could adversely impact our business and financial performance. Moreover, new risks regularly emerge, and it
is not possible for us to predict or articulate all risks we face, nor can we assess the impact of all risks on our business or the extent
to which any risk, or combination of risks, may cause actual results to differ from those contained in any forward-looking statements.
All forward-looking statements included in this Annual Report on Form 10-K are based on information available to us on the date hereof.
Except to the extent required by applicable laws or rules, we undertake no obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Unless the context otherwise indicates or requires,
the terms &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; &#8220;NanoVibronix,&#8221; and the &#8220;Company,&#8221; as used in
this Annual Report on Form 10-K, refer to NanoVibronix, Inc. and its subsidiaries as a combined entity, except where otherwise stated
or where it is clear that the terms mean only NanoVibronix, Inc. exclusive of its subsidiaries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Trademarks</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have proprietary rights to certain trademarks
used in this Annual Report on Form 10-K that are important to our business, some of which are registered under applicable intellectual
property laws, including but not limited to UroShield&#8482;, PainShield&#8482; MD, PainShield&#8482; Plus, WoundShield&#8482;, UroShield&#174;,
PainShield&#174;, PainShield Plus&#174;, WoundShield&#174;, UroShield&#174;, NanoVibronix&#174;, Envizion Medical, ENsump, ENvue, ENgat, Envizion
(wordmark and logo), and ENvue&#8217;s logo in key countries, including the U.S., Europe, and China.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Solely for convenience, trademarks and trade names
referred to in this Annual Report appear without the &#8220;&#174;&#8221; or &#8220;&#8482;&#8221; symbols, but such references are not
intended to indicate, in any way, that we will not assert, to the fullest extent possible under applicable law, our rights or the rights
of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other companies&#8217; trademarks,
trade names or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. Each trademark,
trade name or service mark of any other company appearing in this Annual Report on Form 10-K is the property of its respective holder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_001"></span>PART I</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_002"></span>ITEM 1. BUSINESS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We were organized as a Delaware corporation in October
2003. On February 14, 2025, we consummated and completed the Merger pursuant to the Merger Agreement, as further described below. Following
the consummation of the Merger, NanoVibronix will conduct its operations through its two wholly-owned subsidiaries: (i) NanoVibronix
Ltd., a private company incorporated under the laws of the State of Israel (&#8220;Nano OpCo&#8221;) and (ii) ENvue Medical Holdings
LLC, a Delaware limited liability company (together with its respective subsidiaries, &#8220;Predecesor ENvue&#8221;). Nano OpCo focuses
on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered
at home, without the assistance of medical professionals. ENvue is a medical device company engaged in the research, development, production,
marketing, and sale of medical devices in the field of enteral feeding and are in the initial stage of commercializing our products.
The descriptions of the two business divisions, their corresponding products, and business models are detailed below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Reverse Stock Splits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 8, 2023, we effected a reverse stock
split of our common stock at a ratio of 1-for-20 (the &#8220;2023 Reverse Stock Split&#8221;, and on February 13, 2025, we effected a
reverse stock split of our common stock at a ratio of 1-for11 (the &#8220;2025 Reverse Stock Split&#8221; and together with the 2023
Reverse Stock Split, the Reverse Stock Splits&#8221;) pursuant a Certificate of Amendment to our Amended and Restated Certificate of
Incorporation. At the effective time of the 2023 Reverse Stock Split and the 2025 Reverse Stock Split, every 20 and 11 shares, respectively,
of our issued and outstanding common stock were converted automatically into one issued and outstanding share of common stock without
any change in the par value per share. Any fractional share of a stockholder resulting from the Reverse Stock Splits was rounded up to
the nearest whole number of shares. Proportional adjustments were made to the number of shares of our common stock issuable upon exercise
or conversion of the Company&#8217;s equity awards, warrants and other convertible securities, as well as the applicable exercise or
conversion price thereof. Except as otherwise indicated, all share and per-share figures in this Annual Report on Form 10-K have been
adjusted to reflect the Reverse Stock Splits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Recent Developments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2025 Reverse Stock Split</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 13, 2025, at 4:05 p.m., Eastern Time, pursuant
to a Certificate of Amendment to our Amended and Restated Certificate of Incorporation, as amended, 2025 Reverse Stock Split became effective.
Our common stock began trading on Nasdaq on a split-adjusted basis on March 14, 2025. See &#8220;Reverse Stock Splits&#8221; above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The Merger Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 14, 2025, pursuant to the terms of that
certain Agreement and Plan of Merger, dated as of February 14, 2025 (the &#8220;Merger Agreement&#8221;), by and among the Company, NVEH
Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of NVEH Merger Sub I, Inc. (&#8220;First Merger Sub&#8221;), NVEH
Merger Sub II, LLC, a Delaware limited liability company and a wholly-owned subsidiary of the Company (&#8220;Second Merger Sub&#8221;),
and Predecessor ENvue, the Company and Predecessor ENvue effected (i) a merger of First Merger Sub with and into Predecessor ENvue, with
the First Merger Sub ceasing to exist and Predecessor ENvue becoming a wholly-owned subsidiary the Company and (ii) the merger of Predecessor
ENvue with and into Second Merger Sub (the &#8220;Second Merger&#8221; and, together with the First Merger, the &#8220;Merger&#8221;),
with Second Merger Sub being the surviving entity of the Second Merger (&#8220;Surviving Entity&#8221;). At the effective time of the
Second Merger, the certificate of formation of the Surviving Entity was amended and restated to, among other things, to change the name
of the Surviving Entity to &#8220;ENvue Medical Holdings LLC.&#8221; In connection with the Merger Agreement, we issued (i) 1,734,995
shares of common stock (the &#8220;Merger Shares&#8221;), which such number of shares represented no more than 19.9% (the &#8220;Exchange
Cap&#8221;) of the outstanding shares of common stock as of immediately before the First Effective Time and (ii) 57,720 shares of Series
X Non-Voting Convertible Preferred Stock, par value $0.001 per share (the &#8220;Series X Preferred Stock&#8221;) in excess of the Exchange
Cap to the holders of Predecessor ENvue in consideration for 100% of Predecessor ENvue. Each share of Series X Preferred Stock will be
convertible into 1,000 shares of our common stock, subject to and contingent upon the affirmative vote of a majority of the shares of
common stock present or represented and entitled to vote at a meeting of stockholders of Company to approve, for purposes of the Nasdaq
Listing Rules, the issuance of shares of our common stock to the stockholders of Predecessor ENvue upon conversion of any and all shares
of Series X Preferred Stock in accordance with the terms of the Certificate of Designation for the Series X Preferred Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Merger was consummated and completed on February
14, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">After giving effect to the Merger, pursuant to the
terms and conditions of the Merger Agreement: (i) the holders of the outstanding equity of Predecessor ENvue immediately prior to the
effective time of the First Merger (&#8220;First Effective Time&#8221;) own 19.9% of the common stock of the Company and 85.0% of the
outstanding equity of the Company (assuming the Series X Preferred Stock is converting at a ratio of 1,000:1) immediately following the
First Effective Time, which following stockholder approval will allow the Series X Preferred Stock to convert to common stock of the
Company which may result in the holders of Predecessor ENvue to own 85% of the common stock of the Company, and (ii) the holders of our
outstanding equity immediately prior to the First Effective Time own 80.1% of the common stock of the Company and 15.0% of the outstanding
equity of the Company (assuming the Series X Preferred Stock is converting at a ratio of 1,000:1) immediately following the First Effective
Time, which following stockholder approval which will allow the Series X Preferred Stock to convert to common stock of the Company which
may result in our holders owning 15% of common stock of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Debenture Financing and Senior Convertible
Debenture</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 13, 2025, we entered into a Securities
Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with an institutional investor (the &#8220;Investor&#8221;), pursuant to which
we sold in a private placement, a senior convertible debenture (the &#8220;Debenture&#8221;) due the earlier of (i) the date that is
the 30-day anniversary of the effective date of stockholder approval (the &#8220;Debenture Stockholder Approval&#8221;) of the issuance
of the shares of common stock upon the conversion of the debenture (the &#8220;Debenture Financing&#8221;) and (ii) the date that is
nine months following the date of issuance of the Debenture (&#8220;Maturity Date&#8221;), having an aggregate principal amount of $500,000.
The closing of the Debenture Financing occurred on February 14, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 26, 2025 we amended
and restated the Debenture to increase the Principal Amount to $1,300,000 to provide for the funding by Alpha Capital Anstalt (the &#8220;Investor&#8221;)
to our subsidiary ENvue Medical Holdings, Corp. (&#8220;<b><i>ENvue</i></b>&#8221;), a wholly owned subsidiary of the Company of (i) an
aggregate of $250,000 by the Investor to ENvue on February 6, 2025, (ii) an aggregate of $250,000 by the Investor to ENvue on March 4,
2025, and (iii) and an aggregate of $300,000 by the Investor to ENvue on March 26, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On the Maturity Date, we shall pay the Investor in
cash or, at the option of the Investor, in the form of conversion shares, or a combination thereof, the entire outstanding principal
amount of the Debenture, together with accrued and unpaid interest thereon, the applicable exit fee and any other amounts due thereunder.
Following the receipt of Debenture Stockholder Approval, the Debenture shall be convertible, in whole or in part, into shares of common
stock, at the option of the Investor, at the initial conversion price of $0.8906 (the &#8220;Conversion Price&#8221;), which is subject
to customary anti-dilution adjustments, and which such Conversion Price shall not be lower than the floor price of $0.97812. The Debenture
bears interest at the rate of 8.0% per annum, payable on the Maturity Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 13, 2025, as amended on March 26,
2025, in connection with the Purchase Agreement and issuance of the Debenture, we entered into that certain Registration Rights
Agreement (the &#8220;Registration Rights Agreement&#8221;) with the Investor. Pursuant to the Registration Rights Agreement, the
Company is required to prepare and file a resale registration statement with the SEC within 30 calendar days following the closing
date of the amended Debenture Financing (the &#8220;Filing Deadline&#8221;). The Company shall use its commercially reasonable
efforts to cause such registration statement to be declared effective by the SEC within 60 calendar days of the Filing Deadline (or
within 90 calendar days if the SEC reviews the resale registration statement).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>January 2025 3(a)(9) Exchange</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 7, 2025, we entered into a securities
exchange agreement (the &#8220;Exchange Agreement&#8221;) with a certain institutional investor pursuant to which we agreed to issue
an aggregate of (i) 41,498 shares of common stock (the &#8220;3(a)(9) Shares&#8221;), (ii) a warrant to purchase up to 158,562
shares of common stock (the &#8220;January 2025 Warrant&#8221;), and (iii) a pre-funded warrant to purchase up to 178,132 shares
of common stock (the &#8220;January 2025 Pre-Funded Warrant&#8221;), in exchange for the A-1 Warrant held by the Holder to purchase
up to 264,271 shares of common stock at an exercise price of $16.17 per share (the &#8220;Exchange&#8221;). We cancelled the A-1
Warrant reacquired in the Exchange and the A-1 Warrant will not be reissued. The January 2025 Warrant has substantially the same
terms as the A-1 Warrant, except that the shares of common stock issuable upon exercise of the January 2025 Warrant are subject to
stockholder approval pursuant to the applicable rules and regulations of the Nasdaq, is exercisable for a term of five and one half
years from the date such stockholder approval is received and deemed effective under Delaware law, and has an exercise price of
$6.8296 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subsequent to the Exchange, the holder of the
January 2025 Pre-Funded Warrant exercised the January 2025 Pre-Funded Warrant in full on a cashless basis in full for an aggregate
of 228,354 shares of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The issuance in the Exchange of the 3(a)(9) Shares,
the January 2025 Warrant, the January 2025 Pre-Funded Warrant and the shares of common stock issuable upon the exercise thereof pursuant
to the Exchange Agreement was made in reliance on an exemption from registration under Section 3(a)(9) of the Securities Act</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Nano OpCo&#8217;s Business</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Nano OpCo&#8217;s primary products, which are in
various stages of clinical and market development, currently consist of:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#9679;</td>
    <td style="text-align: justify">UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm
    in urinary catheters, increase antibiotic efficacy and decrease pain and discomfort associated with urinary catheter use, which has
    been, and is being marketed in the U.S. under FDA&#8217;s policy of enforcement discretion which was effectuated during the COVID-19
    pandemic and is currently undergoing clinical testing that will, hopefully, support 510(k) clearance;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#9679;</td>
    <td style="text-align: justify">UroShield Ultra, is similar to UroShield, but is designed to prevent bacterial colonization and biofilm
    formation in urinary catheters to increase antibiotic efficacy and decrease pain and discomfort associated with urinary catheter
    use, utilizing two separate transducers which provide ultrasound energy to both sides of an indwelling catheter.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#9679;</td>
    <td style="text-align: justify">PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm and joint
    contractures by delivering a localized ultrasound effect to treat pain and induce soft tissue healing in a targeted area. Our PainShield
    family of products include:</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px">&#9675;</td>
    <td style="text-align: justify">PainShield MD, a single patch-based therapeutic ultrasound technology to treat pain, muscle spasm
    and joint contractures by delivering a localized ultrasound effect to treat pain and induce soft tissue healing in a targeted area.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px">&#9675;</td>
    <td style="text-align: justify">PainShield Plus, a dual patch-based therapeutic ultrasound technology to treat pain, muscle spasm
    and joint contractures by delivering a localized ultrasound effect to treat pain and induce soft tissue healing in a targeted area.
    Similar to PainShield MD, it has a dual ultrasound delivery; and</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 3pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px">&#9675;</td>
    <td style="text-align: justify">WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration
    and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each of UroShield, PainShield, and WoundShield employs
a small, disposable transducer that transmits low frequency, low intensity ultrasound acoustic waves that seek to repair and regenerate
tissue, musculoskeletal and vascular structures, and decrease biofilm formation, reduce blockage, and reduce pain related to urinary
catheters as well as reducing incidence of associated urinary tract infections. Through their size, effectiveness and ease of use, these
products are intended to eliminate the need for technicians and medical personnel to manually administer ultrasound treatment through
large transducers, thereby promoting patient independence and enabling more cost-effective home-based care.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PainShield MD is currently cleared for marketing
in the United States by the FDA. In September 2020, the FDA exercised its policy of enforcement discretion (&#8220;Enforcement Discretion&#8221;)
to allow distribution of the UroShield device in the U.S. during the COVID-19 pandemic. While the U.S. government has declared an end
to the public health emergency and had terminated Enforcement Discretion use for many medical devices, as of the date of this filing,
we have not been notified of any change in the regulatory status for the use of our UroShield device. However, we have removed the product
from the US market and have ceased all sales activities. Both PainShield and UroShield have CE Mark approval in the European Union, which
also permits sales in India and Ecuador, and a certificate allowing us to sell PainShield and UroShield in Israel. We have consummated
sales of PainShield and UroShield in the relevant markets, and we saw sales increase in 2024. WoundShield has not generated significant
revenue to date. Outside of the United States, we generally apply, through our distributor, for approval in a particular country for
a particular product only when we have a distributor in place with respect to such product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the United States, PainShield and UroShield require
a prescription from a licensed healthcare practitioner. If FDA clearance is obtained, we anticipate that WoundShield will require a prescription
from a licensed healthcare practitioner in the United States. As stated previously, UroShield was approved through the FDA under Enforcement
Discretion initially, for the duration of the COVID-19 pandemic and was intended to be sold directly to health care facilities and individuals.
Individuals would have required a prescription, but healthcare facilities would have deployed the use of Uroshield based upon clinical
need. However, in other countries in which we sell PainShield, UroShield, and WoundShield, such products are eligible for sale without
a prescription.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Insurance Coverage and Reimbursement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to the need to obtain regulatory approvals,
we anticipate that sales volumes and prices of NanoVibronix&#8217;s UroShield and PainShield, products will depend in large part on the
availability of insurance coverage and reimbursement from third party payers. Third party payers include governmental programs such as
Medicare and Medicaid and the Veterans Health Care network of facidlities in the United States, private insurance plans and workers&#8217;
compensation plans. We do not currently have reimbursement codes for use of WoundShield in any of the markets in which we have regulatory
authority to sell WoundShield. Of the markets in which we have regulatory authority to sell PainShield, prior to January 2020, we only
had reimbursement codes in the United States (i.e., CPT codes) for clinical use only. Effective as of January 2020, the U.S. Centers
for Medicare and Medicaid Services (&#8220;CMS&#8221;) approved our PainShield for reimbursement for Medicare beneficiaries on a national
basis. However, PainShield was not assigned a reimbursement value from CMS. The Company was denied reimbursement in September 2022 due
to a lack of &#8220;life-cycle&#8221; testing. The Company had engaged Carmel Labs in Israel to conduct this testing and submitted the
results to CMS with our 2023 application on January 3, 2023. On August 21, 2023, CMS, denied reimbursement with respect to PainShield
due to their request for additional longevity testing. We are currently evaluating whether to resubmit another application to CMS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">With respect to UroShield, which may be used in a
clinical and home setting, we currently have reimbursement in the United Kingdom (for supplies only), and throughout the VA system. We
are seeking reimbursement codes for use of our products in the markets in which we have regulatory authority, including the United States,
to sell such products. Our current ongoing research and planned research may facilitate our ability to obtain reimbursement codes, but
there is no guarantee that we will be successful in obtaining such codes quickly, or at all. We engaged Idonea Solutions, Inc., an FDA
consultant, to assist in our efforts to obtain clearance under the FDA&#8217;s policy of Enforcement Discretion, and obtain 510(k) clearance
which is still ongoing. During the past few of years the Company has entered into distribution partnerships for UroShield in the U.K.,
Australia, New Zealand, and Malta.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Nano OpCo&#8217;s Business Model</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All of Nano OpCo&#8217;s products consist of a reusable
controller device and a disposable component, which includes a transducer, and in the case of PainShield, a 30-day supply of adhering
patches. The controllers have a life expectancy of three years, while the UroShield disposable transducer has a life expectancy of up
to a month and must be replaced to provide the intended therapy. The components are purchased by either the distributor or end user for
use in any of the intended applications. Once the controller is purchased by the end user, recurring revenue will be realized by purchases
of replacement disposables to the extent that the end user continues treatment with our product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Nano OpCo&#8217;s products are intended to be distributed
directly by the us, independent distributors, and potential licensees. Distributor cost is discounted to account for their intended margins,
based upon purchase volumes and/or periodic purchase commitments, with the disposable transducer sold and distributed in the same fashion.
We currently have an established distributor network and are implementing certain criteria within such network to ensure the appropriate
assignment of a distributor or licensee. We are in the process of adding additional distributors to our network, and continue our efforts
to identify market leaders in various segments to private label both PainShield and UroShield.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also have a direct sales component, where we sell
directly to consumers, in order to satisfy customer demand generated through on-line advertising and social media. We have seen an increase
in demand as a direct result of an expanded social media and on-line advertising presence.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Nano OpCo&#8217;s business plan continues to focus
on these types of transactions/agreements. We continue to focus on the foundational aspects of each respective product, including the
design and performance of each, the reimbursement, regulatory status, and quality control, in order to strengthen our position with prospective
partners.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Ultrasound Technology and Nano OpCo&#8217;s
Products</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As noted above, Nano OpCo&#8217;s primary products
are based on the use of low frequency ultrasound, which delivers energy through mechanical vibrations in the form of sound waves. Ultrasound
has long been used in physical therapy, physical medicine, rehabilitation and sports medicine.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our proprietary PainShield technology consists of
a small, thin (1 millimeter) transducer that is capable of transmitting ultrasonic acoustic waves onto treatment surfaces with a radius
of up to 10 centimeters beyond the transducer. This technology allows us to treat pain by securing our transducers to the skin with a
separate adhesive patch, and portable self-adhering acoustic patch, thereby eliminating the need for technicians and medical personnel
to manually administer ultrasound therapy, which should reduce the cost of therapy. Moreover, we believe that, based upon the body of
evidence, the delivery of ultrasound through our portable devices may provide a competitive advantage over other existing therapies marketed
for similar intended use(s) (e.g., to treat pain associated with muscle, tendon, and contractures), as our technology is positioned to
directly target the affected areas of the body within the scope of the applicable FDA clearance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">While there are currently a number of products on
the market that treat pain through ultrasound therapy, we believe that our products may be preferable in certain instances because they
are portable, without the requirement to be plugged into an outlet and they have a frequency of 100kHz (in contrast to other devices,
which have a frequency of closer to 1MHz and above), which means our products, when functioning as intended and in accordance with applicable
design specifications, should not produce excessive heat that can damage tissue. Therefore, our products (i) can be self-administered
by the patient without the need to be moved about the treated area by the patient or a clinician, (ii) can be applied for a significantly
longer period without the risk of tissue damage and (iii) do not require the use of gel. We are also aware of one product, the SAM&#174;
Sport family of products, which received FDA approval after PainShield and has CE Mark approval, marketed by ZetrOZ, Inc., that we understand
may eliminate certain of these requirements and limitations, namely the requirement to be plugged in, the need for movement around the
treated area and the relatively short safe treatment period. However, we understand that this product does not generate surface acoustic
waves as our products do, which means that the treatment area is generally limited to that under the transducer, that the use of transmission
gel is still required, and that the transducer thickness is significantly greater than ours (approximately 1.5 cm). It is also our understanding
that the FDA has issued multiple contraindications for SAM&#174; Sport, which do not apply to the PainShield product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There has been an article published in 2019 on SAM&#174;
Sport4 regarding clinical evidence demonstrating that ultrasound dose timing (i.e. daily treatment) and duration significantly impact
benefits and treatment results. We are aware of a prospective randomized, double-blinded, placebo-controlled study on the effects of
the long-duration low-intensity ultrasound treatment using SAM&#174; Sport4 suggesting that ultrasound may be used as a conservative non-pharmaceutical
and non-invasive treatment option for patients with knee osteoarthritis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In general, ultrasound offers the benefits by increasing
local blood circulation, increasing vascular wall permeability, promoting protein secretion, promoting enzymatic reactions, accelerating
nitric oxide production, promoting angiogenesis (the formation of new blood vessels from pre-existing vessels) and promoting fibroblast
proliferation (fibroblasts are a type of cell that play a critical role in soft tissue healing). We believe that the body of evidence,
and the positive therapeutic effect that ultrasound has for various indications, potentially provides for future product development
opportunities for us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 50%; text-align: center"><span style="text-decoration: underline">Conventional Ultrasound</span></td>
    <td style="width: 50%; text-align: center"><span style="text-decoration: underline">PainShield Ultrasound</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><img src="form10-k_001.jpg" alt="" style="height: 196px; width: 310px"/></td>
    <td style="text-align: center"><img src="form10-k_002.jpg" alt="" style="height: 210px; width: 200px"/></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>Traditional ultrasound device and our portable
ultrasound patch-based device and a comparison of their energy distribution, where the X-axis represents treatment surface, and the Y-axis
represents ultrasound energy penetration depth within tissue.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The PainShield Plus was introduced in March 2022.
The new product design provides the same therapy as PainShield MD, but through two transducers which alternate in its duty cycle. This
dual transducer design provides for a broader treatment with three hours of therapy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In a comparison of a traditional ultrasound device
and our portable ultrasound patch-based device, the bulk wave conventional ultrasound machines with handheld transducers distribute the
energy deeply into the body, as shown above in diagram (A) on the left. In comparison, our device distributes the energy on the surface,
as shown in diagram (B), thereby meaningfully increasing the treatment area. Our transducers may also be incorporated into treatment
patches, including patches that are designed to deliver medicine and other compounds through the skin. The generation and delivery of
low frequency ultrasound over a period of time to a specific area has been termed &#8220;targeted slow-release ultrasound&#8221;. We
believe that this delivery method of ultrasound may be comparable to that of slow-release medication in the pharmaceutical industry.
This &#8220;targeted slow-release&#8221; capability is intended to allow for more frequent targeting of the intended treatment area and
thus may result in a more effective therapeutic response.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Micro Vibrations Technology and Nano OpCo&#8217;s
Products</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In a 2007 study, increase in mean blood flow to the
calf was higher in the vibration group than the placebo group. Improvements in local blood flow may be beneficial in the therapeutic
alleviation of pain or other symptoms resulting from acute or chronic injuries (C. Button et al., &#8220;The effect of multidirectional
mechanical vibration on peripheral circulation of humans&#8221;, University of Otago New Zealand, Clinical Physiology and functional
Imaging, 2007 27, p211-216). A study on the effect of whole body vibration on lower extremity skin blood flow suggests, that short duration
vibration alone significantly increases lower extremity skin blood flow, doubling skin blood flow for a minimum of 10 minutes following
treatment (Lohman et al., &#8220;The effect of whole body vibration on lower extremity skin blood flow in normal subjects&#8221;, Department
of Physical Therapy, Loma Linda university, USA, Med Sci Monit, 2007; 13(2) 71-76). Vibration has also been shown to stimulate angiogenesis
and growth factors such as vascular endothelial growth factor (Suhr F et al., &#8220;Effects of short-term vibration and hypoxia during
high intensity cycling exercise on circulating level of angiogenic regulators in humans&#8221;, J Appl Physiol, 2007, 103:474-483, Yue
Z. et al., &#8220;On the cardiovascular effects of whole-body vibration I. Longitudinal effects: hydrodynamic analysis&#8221;, Studies
Appl Math, 2007, 119:95-109).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Relative to soft tissue repair, it is well established
that increasing blood flow to the wound and peri-wound area helps accelerate the healing of ischemic wounds. Micro-vibrations applied
on the skin tissue increase local blood flow and oxygen delivery to the wound area and stimulate angiogenesis and growth factors that
are helpful for the wound healing process. Vibration therapy has been found to stimulate blood flow due to mechanical stresses of endothelial
cells resulting in increased production of nitric oxide and vasodilation, as well as increase soft tissue and skin circulation. (Maloney-Hinds
et al., &#8220;The Role of Nitric Oxide in Skin Blood Flow Increases due to vibration in healthy adults and adults with type 2 diabetes,&#8221;
School of Medicine, Loma Linda University. Ca. Diabetes Technology &amp; Therapeutics, 2009 p. 39-43). In addition, micro vibrations
induce skin surface nerve axon reflex and type IIa muscle fibers contraction rates, resulting in vasodilation (Nakagami et al., &#8220;Effect
of vibration on skin blood flow in an in vivo microcirculatory model&#8221;, The University of Tokyo, Bio-Science Trends 2007; 1 (3):
161-166). Ten minutes of vibration therapy with laser doppler revealed a consistent increase in water content of the upper dermis (TJ
Ryan et al., &#8220;The effect of mechanical forces (vibration or external compression) on the dermal water content of the upper dermis
and epidermis, assessed by high frequency ultrasound&#8221;, Oxford Wound Healing Institute, Journal of Tissue Viability, 2001. Of import
with respect to diabetic wounds, in which a prolonged inflammatory phase occurs, vibration vasodilation has generated an indirect anti-inflammatory
action, mainly by suppression of nuclear factor-k&#946;, the key gene for inflammatory mediators (Sackner, M.A., &#8220;Nitric Oxide
is released into circulation with whole-body, periodic acceleration&#8221;, Chest 2005;127;30-39).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Urinary catheter usage is associated with pain and
discomfort caused by the friction between the catheter surface and the urethral tissue. Generally, this friction is treated by applying
lubricating gels and low friction catheter coatings. These methods are effective for a short term during the catheter insertion as the
lubricating gel is quickly absorbed into the surrounding tissue and loses its effect and the catheter coatings lose their lubricity within
a few days, as the coating is covered by a thin film of mucous.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our UroShield product provides vibrations along the
surface of the urinary catheter that is in contact with urethral tissue. We believe that these vibrations create a continuous acoustic
lubrication effect along the surface of the indwelling catheter that is in contact with the surrounding tissue, thus reducing catheter-tissue
contact time, which may lessen trauma from urethra abrasion and adhesion. We have also shown in animals and in humans that the micro-vibration
technology can reduce the level of biofilm formation on urinary catheters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Nano OpCo&#8217;s Products</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Product Design, Packaging, Identity</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All of our products were redesigned in the fourth
quarter of 2019, with an updated look and improved performance. These new designs were coupled with new branding, packaging, instructional
manuals, and marketing materials. Beginning in the fourth quarter of 2019, our manufacturing in China, Singapore, and Israel commenced
producing the redesigned products for distribution and delivered their first completed units in April 2020. We currently complete assembly
in our facilities in Israel. Even though our ability to assemble our products has not been affected by the current political environment,
we cannot predict if future events may cause delays. Our 2023 production run established an ample supply of devices and monthly disposable
kits. The completed products can be used as a platform for either PainShield or UroShield. We do not anticipate a need to manufacture
additional devices through 2024. However, due to an increased demand of disposable monthly kits, we continue to produce at a high rate
to meet demand.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">UroShield</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">UroShield is intended to prevent bacterial colonization
and biofilm formation, increase antibiotic efficacy in the catheter lumen and decrease pain and discomfort associated with urinary catheter
use. It is designed to be used with any type of indwelling urinary catheter regardless of the material or coating. Use of the device
is contraindicated for use while there is an active UTI. We believe that UroShield may be the first medical device on the market that
attempts to simultaneously address all of the aforementioned catheter-related issues. UroShield is similar in design to PainShield, in
that it uses a driver unit that produces low frequency, low intensity ultrasound. The driver unit connects to a disposable transducer
that is clipped onto the external portion of the catheter to deliver ultrasound therapy to all catheter surfaces as well as the tissue
surrounding the catheter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Sans-Serif; margin: 0; text-align: center"><img src="form10-k_003.jpg" alt="" style="height: 200px; width: 300px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>Picture of UroShield with actuator</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Clinical studies of the UroShield system have supported
the following advantageous effects:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#9679;</td>
    <td style="text-align: justify"><b>Prevention or Reduction of Biofilm.</b> The low frequency ultrasound generated by UroShield has
    been shown to decrease adherence of bacteria to catheter surfaces, thereby reducing biofilm. Biofilm is the complex matrix required
    for bacteria to grow and cause infection. See the discussion of our Heidelberg 1 trial below.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify"><b>Decreased Catheter Associated Pain and Discomfort.</b> We believe that UroShield creates an acoustic
    envelope on the surfaces of the catheter, which decreases friction and tissue trauma, pain and discomfort caused by the catheter.
    In addition, in vivo (rabbit) studies have shown the tissue in contact with the catheter remains healthier and less traumatized as
    a result of the application of low frequency and low intensity ultrasound (Applebaum I, et.al., &#8220;The Effect of Acoustic Energy
    Induced By UroShield on Foley Catheter Related Trauma and Inflammation in a Rabbit Model&#8221; Department of Urology, Shaarey Zedek
    Medical Center and the Hadassah Hebrew University Medical School).</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify"><b>Acoustically Augmented Antibiotic Therapy.</b> Antibiotic resistance in biofilm bacteria is a
    well-known phenomenon. Although it has been known that ultrasound can increase antibiotic efficacy in in-vitro models, we do not
    believe that there has been a practical ultrasound-based medical device that was able to augment antibiotic efficacy in the clinical
    setting. In a clinical study, UroShield technology has been shown to eradicate biofilm-residing bacteria by greater than 85% when
    applied simultaneously with an antibiotic in three clinically relevant species, escherichia coli, staphylococcus epidermidis and
    pseudomonas aeruginosa (Banin E, et al., &#8220;Surface acoustic waves increase the susceptibility of Pseudomonas aeruginosa biofilms
    to antibiotic treatment,&#8221; Biofouling, August 2011; we supplied devices for this study, but had no further involvement with
    it).</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify"><b>Preservation of the Patency of Catheters.</b> We believe that low frequency ultrasound applied
    to catheters will add an anti-clogging effect and will preserve patency of catheters. This effect is achieved by ultrasound waves
    creating an acoustic layer on the inner lumen of the urinary catheter, thereby preventing adherence of biological material and biofilm
    formation. We believe that this anti-clogging benefit will help prevent local infection and sepsis secondary to catheter obstruction.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">UroShield has undergone a number of clinical trials.
The Heidelberg 1 trial, conducted in 2005-2006, which we sponsored, was a 22-patient randomized, double blind, sham-controlled, independent
trial that tested UroShield&#8217;s safety and ability to prevent biofilm in patients with an indwelling Foley catheter. The trial demonstrated
that UroShield prevented biofilm in all patients with the active device as compared to biofilm being found in seven of eleven of the
control patients. In addition, there was a marked decrease in pain, discomfort and spasm in the active UroShield patients, as evidenced
by a statistically significant decrease in the requirement for the medications required to treat urinary catheter associated pain and
discomfort (Ikinger U, &#8220;Biofilm Prevention by Surface Acoustic Nanowaves: A New Approach to Urinary Tract Infections?,&#8221; 25th
World Congress of Endourology and SWL, Cancun, Mexico, October 2007).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In a subsequent physician-sponsored trial, known
as Heidelberg 2, conducted in 2007, 40 patients who underwent radical prostatectomies were divided into two groups, with the active group
receiving one intra-operative dose of antibiotics and UroShield and the control group receiving one intra-operative dose of antibiotics
and then five subsequent doses over three days. At the end of the trial, the control group had four cases of bacteriuria, as compared
to one in the active group. In a third trial, a physician-sponsored open label trial, 10 patients who received emergency placement of
a urinary catheter due to acute obstruction were given a UroShield device and followed with regard to their pain, discomfort, spasm and
overall well-being. Within 24 hours, all patients showed improvement and increased toleration of the catheter (Zillich S., Ikinger U,
&#8220;Biofilmpr&#228;vention durch akustische Nanowellen: Ein neuer Aspekt bei katheterassoziierten Harnwegsinfektionen?,&#8221; Gesellschaft
f&#252;r Urologie, Heilbronn, Germany, May 2008). We supplied devices for this trial, but had no further involvement with it.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In 2022, the Company submitted to The National Institute
for Health and Care Excellence, for review, the findings from an independent evaluation of its UroShield device on patients who had used
the device for up to two years. Clinical data from the study conducted during 2020 by Coventry University&#8217;s Assistant Professor,
Ksenija Maravic da Silva, reported statistically significant outcomes for the device including a reduced number of UTIs, reduced instances
of prescribed antibiotics, reduced catheter blockages, reduced need for unplanned catheter changes and reduced pain reported as a result
of catheter associated complications. The study also provided important insights into the lives of those using the device, including
improvement of overall well-being, relating specifically to decreased levels of worry and increased ability to socialize. In addition,
patient feedback on product improvements was addressed and has been incorporated in the present commercially available device.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2022, UroShield was approved for sale
by the NHS internal supply organization, NHS Supply Chain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This contract with NHS Supply Chain provides dedicated
end-to-end supply chain service of our UroShield for every NHS healthcare organization. UroShield will be available to all patients who
need the device with full clinical support, through the NHS supply chain. It represents a significant opportunity for us to expand distribution
of UroShield as it will now be made available to all clinicians and their patients through the NHS organization&#8217;s own supply channel.
NHS Supply Chain manages the sourcing, delivery and supply of healthcare products and services for NHS trusts and healthcare organizations
across England and Wales. The organization processes more than eight million orders per year across 94,000 order points and 17,465 locations
serving as an integral part of the national healthcare system in the U.K. We are ramping up production to meet increase in demand that
we anticipate as a result of this exciting development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The original contract, which is designed to provide
new innovative products for healthcare providers, began in October 2022, and the recent extension signed in the fall of 2023, will merge
with the existing Urology and Stoma framework contract in February 2024 with optional extension periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the contract, NHS Supply Chain describes UroShield
as a disposable ultrasound device designed to reduce the risk of CAUTI by reducing bacterial colonization and biofilm formation on indwelling
urinary catheters. This ultimately translates into improved outcomes for patients and care provides, reduces the need for antibiotics,
catheter changes and washouts and incidence of hospital visits, thereby reducing nursing time, bed days and ambulance transfers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In the fourth quarter of
2024, we announced our entry a product and market evaluation with two prominent distributors for UroShield. These distributors will cover
Israel and South Africa.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Apogepha LOI and Term
Sheet</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We and our UK distributor
are in advanced discussions with NHS to expand coverage of UroShield. In December 2023, we announced we entered into a non-binding letter
of intent (the &#8220;LOI&#8221;) with Apogepha Arzneimittel GmbH (&#8220;Apogepha&#8221;) in which both parties will analyze the potential
for Apogepha to distribute our UroShield product in Germany and other European markets. Pursuant to the terms of the LOI, Apogepha will
commence a comprehensive market research study on how UroShield can fit into the pathway of care for patients with long term catheters.
The goal of the LOI, and subsequent findings, will be for both us and Apogepha to better understand the feasibility of a distribution
deal between both companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On October 9, 2024, we announced
that we and Apogepha had entered into a non-binding term sheet for the purpose of appointment of exclusive distributorship throughout
Germany. Both parties intend to enter into a biding agreement early in 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">A definitive and binding
partnership agreement is predicated upon successfully obtaining reimbursement through the GKV-SV German Health Reimbursement Authority.
The application for reimbursement has been submitted on behalf of Apogepha late in 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Standalone Services Agreement
with Veranex, Inc.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In March 2024, we entered
into a standalone services agreement (the &#8220;Veranex Agreement&#8221;) with Veranex, Inc. (&#8220;Veranex&#8221;), to provide certain
research and development services to assist with the development of our next generation of UroShield and PainShield products. The Veranex
Agreement has a term of approximately 50 weeks, subject to adjustments or earlier termination thereof in accordance with the terms of
the Agreement, with estimated fees and expenses of up to approximately $1.1 million subject to certain adjustments, including among other
things, revising the agreement in the event of changing assumptions or facts, unforeseen development deviations, or changes in scope.
We expect engineering of the new technology to eventually allow us to find a US manufacturing partner once the development process has
been completed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In December 2024, Veranex
completed the first element of the &#8220;next-gen&#8221; product development process. Prototypes of both the device and transducer element
were provided to our management team. It is anticipated that the completion of the process to be in the first half of 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Market for UroShield</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">According to the Centers for Disease Control and
Prevention, UTI is an infection involving any part of the urinary system, including urethra, bladder, ureters, and kidney. UTIs are the
most common type of healthcare-associated infection reported to the National Healthcare Safety Network (NHSN). Among UTIs acquired in
the hospital, approximately 75% are associated with a urinary catheter, which is a tube inserted into the bladder through the urethra
to drain urine. Approximately 15-25% of patients who are admitted to a hospital will have an indwelling catheter at some point during
their stay and 7% of nursing home residents are managed by long term catheterization. The most important risk factor for developing a
catheter-acquired urinary tract infection (CAUTI) is prolonged use of the urinary catheter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">CAUTI is the most common nosocomial infection in
hospitals and nursing homes, representing over 40% of all hospital-acquired infections (HAIs) and 20% of intensive care unit HAIs (Maki,
P and Tambyah, D. Engineering Out the Risk for Infection with Urinary Catheters., Emerging Infectious Diseases., Vol. 7, No. 2, March-April
2001). In addition, CAUTIs are the source for approximately 20% of healthcare acquired bacteremia in acute care and 50% in long-term
care facilities (Nicolle, Lindsay E. &#8220;Catheter Associated Urinary Tract Infections.&#8221; Antimicrobial Resistance and Infection
Control 3 (2014)). The risk of acquiring CAUTI depends on the method and duration of catheterization and patient susceptibility. Patients
requiring a urinary catheter have a daily risk of approximately five percent of developing bacteriuria and approximately 25% of patients
develop nosocomial bacteriuria or candiduria over one week (Maki, P and Tambyah, D. Engineering Out the Risk for Infection with Urinary
Catheters., Emerging Infectious Diseases., Vol. 7, No. 2, March-April 2001). Virtually all patients requiring indwelling urinary catheters
for longer than a month become bacteriuric.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">CAUTI occurs because urethral catheters inoculate
organisms into the bladder and promote colonization by providing a surface for bacterial adhesion and causing mucosal irritation. The
presence of a urinary catheter is the most important risk factor for bacteriuria. Once a catheter is placed, the daily incidence of bacteriuria
is 3-10%. Between 10% and 30% of patients who undergo short-term catheterization (i.e., 2-4 days) develop bacteriuria and are asymptomatic.
Between 90% and 100% of patients who undergo long-term catheterization develop bacteriuria. About 80% of nosocomial UTIs are related
to urethral catheterization; only 5-10% are related to genitourinary manipulation. (John L. Brusch, &#8220;Catheter-Related Urinary Tract
Infection&#8221;, Medscape, August 18, 2015).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The global catheter market size was valued at USD
37.3 billion in 2018 and is expected to witness a CAGR of 9.7% through 2026. Rising prevalence of chronic disorders leading to hospitalization
has fueled the growth of this market. The presence of multi-national manufacturers, improving medical facilities, supportive insurance
policies are also some of the key factors propelling the market growth. North America is the largest regional market due to the presence
of multi-national manufacturers and sophisticated healthcare infrastructure along with high product awareness levels. Asia Pacific is
projected to expand at the maximum CAGR of 10.4%, over the study period. According to a Grandview research report published 2018, there
are 25 million Foley catheters sold annually in the United States and 75 million catheters sold elsewhere yielding a total global Foley
catheter market of 100 million units worldwide. The cost to treat a simple CAUTI has been estimated at $13,793 per case (AHRQ), and the
cost of treating bacteremia has been estimated at $8,355 (NIH) per case, yielding a total healthcare burden of $830 million per year.
While there are currently both antibiotic and silver coated catheters in the market, they often sell for approximately $10 above the
non-antimicrobial equivalent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, for discharges on or after October 1,
2008, Medicare stopped authorizing its payment to hospitals in which patients have developed a catheter-associated urinary tract infection
that was not present on admission. This provides hospitals in the United States with a substantial financial incentive to reduce the
occurrence of such infections through the use of products such as UroShield, which help prevent infections hospitals would otherwise
have to treat without reimbursement. In addition, it has been noted that the Centers for Medicare &amp; Medicaid Services may fine hospitals
in the future when their patients develop CAUTI, which will likely increase the incentive of hospitals to invest in technologies that
may prevent this complication (Brown J, et al. &#8220;Never Events: Not Every Hospital-Acquired Infection Is Preventable, Clinical Infectious
Diseases, 2009, 49 (5)).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Competition for UroShield</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Several types of products have been introduced to
address the growing problem of catheter-acquired infection and biofilm formation on catheter surfaces. Manufacturers offer antibiotic-coated
and antiseptic-impregnated catheters. In addition, manufacturers have produced silver-coated catheters, which have been shown in small
studies to delay bacteriuria for about two to four days. However, larger studies did not corroborate this result; on the contrary, silver
hydrogel was associated with overgrowth of gram positive bacteria in the urine (Riley DK, Classen DC, &#8220;A large randomized clinical
trial of a silver-impregnated urinary catheter: lack of efficacy and staphylococcal superinfection,&#8221; Am. J. Med. 1995 April; 98(4):349-56).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">UroShield has been designed to be added to any type
of catheter, including Foley catheters and silver-coated catheters, to improve a catheter&#8217;s infection prevention performance. However,
in the United States, we do not have the requisite regulatory authorization to market UroShield for such use, as we have not yet obtained
FDA clearance or approval for UroShield, and the FDA&#8217;s temporary, COVID-19 related policy of Enforcement Discretion under which
we had previously marketed UroShield since September 2020 expressly excludes use with a coated catheter. As of the date of this filing,
we have removed the product from the US market and have ceased all sales activities. UroShield is not intended to replace any existing
products or technologies, but instead is intended to assist these existing products or technologies in preventing catheter-acquired urinary
injury and catheter associated complications.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Regulatory Strategy</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">UroShield received CE Mark approval in September
2007 and was also approved for sale by the Israeli Ministry of Health in 2008. We have maintained our CE mark approval until now and
expect that to continue going forward. We are able to sell UroShield in India and Ecuador based on our CE Mark. UroShield was granted
a Canadian medical device license in September 2016, although, due to a modification of regulatory standards in Canada, we have lost
our Canadian license. We are working toward reinstatement of our Canadian license. To that extent, we passed an audit in or around October
2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the European Union, UroShield has been marketed
for the prevention of CAUTI and biofilm formation, decreased pain and discomfort associated with urinary catheters and increased antibiotic
efficacy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2020, the FDA exercised its Enforcement
Discretion to allow distribution of the UroShield device in the United States. According to the FDA, &#8220;UroShield&#174; device could
use Intended Use Code (IUC) 081.006: Enforcement discretion per final guidance, and FDA product code QMK (extracorporeal acoustic wave
generating accessory to urological indwelling catheter for use during the COVID-19 pandemic)&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accordingly, the FDA&#8217;s Enforcement Discretion
temporarily cleared the way for import of UroShield to the U.S. during the COVID-19 pandemic, immensely expanding the company&#8217;s
addressable market for the device during this time period. As of the date of this report, we have not been notified of any change in
our Enforcement Discretion status, however, we have removed the product from the US market and have ceased all sales activities. The
device is designed to aid in the prevention of CAUTI incidence in patients requiring long-term indwelling catheterization, defined as
14 days or greater.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe the evidence presented to the FDA on UroShield
demonstrated decreases in the risk of catheter-associated urinary tract infections and related complications in patients using UroShield
who required long-term indwelling catheterization. We intend to seek long-term marketing authorization from the FDA through the <i>De
Novo</i> classification process for UroShield, which is a premarket pathway intended for devices that cannot pursue 510(k) clearance
because there is no substantially equivalent predicate device but which the applicant believes are sufficiently low-risk that they need
not undergo the rigorous premarket approval pathway to be deemed safe and effective for the applicable indications for use. We are currently
seeking advice from the FDA prior to submission. We also intend to seek advice and validation of supporting studies we intend to undertake
in advance of a <i>De Novo</i> application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA has made it clear that we will need to generate
more clinical study data in order to achieve) <i>De Novo</i> reclassification. Our intent is to conduct a community based PRO study (Patient
Reported Outcomes) measuring the impact UroShield will have on prevention of CAUTI, prevention of blockage, and prevention of pain. We
currently are in the early stages of putting together a team and plan to start this process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Studies completed to assess the safety of UroShield
for human use:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#9679;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A large animal model (female sheep) study has
    been conducted to establish local tissue response from a urinary catheter with UroShield attached as compared to a control group
    of animals with a urinary catheter with no UroShield attached.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The pre-clinical animal study was intended to
    demonstrate safety of UroShield device when used for 30-days with a urinary catheter. The study compared local tissue and organ response
    in two groups of 4 (female) sheep where one group was catheterized (urethral) using an uncoated silicone Foley catheter (only) and
    the other group was catheterized using an uncoated silicone Foley catheter with UroShield device attached to it. All catheters were
    identical in their size, material composition and manufacturer.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">After 30 days the animals were euthanized and
    local tissue and organs were examined. The results showed the group with UroShield device had fewer observations of swelling, redness
    or discharge at the vulva as compared to the group without UroShield. The animals did not exhibit signs of discomfort or pain during
    study period (of 30 days). The gross and histopathology findings were also very similar between the two groups.</p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#9679;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A comparative study of leachables from a urinary
    catheter with and without UroShield attached has been performed to demonstrate that the leachables with UroShield attached do not
    exceed toxicological safe limits allowed for a medical device.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The chemical characterization of leachables was
    intended to demonstrate safety for UroShield device for 30-day use with a urinary catheter. The study compared leachables from a
    group consisting of 3 uncoated silicone catheters with leachables from a group consisting of 3 uncoated silicone catheters with UroShield
    attached to it. All catheters were identical in their size, material composition and manufacturer.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The exhaustive extractions were performed with
    non-polar, polar and aqueous solvents. An additional simulated use extraction using Saline and Ethanol was performed. Overall, the
    extractables from both groups were comparable and toxicological evaluation showed that all compounds from extraction with UroShield
    were below the tolerable exposure limits. Most of the compounds had a margin of safety greater than 10 and 4 compounds had margin
    of safety between 1.5 and 10. Overall, the toxicological risk for using UroShield with a urinary catheter is similar or at even lower
    levels as compared to a catheter without UroShield attached.</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>UroShield Sales and Marketing</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Since the FDA exercised its Enforcement Discretion
to allow the distribution of the UroShield device in the United States, we have been actively seeking partnerships for marketing our
product in the United States. We believe the business opportunity for UroShield is in the hundreds of millions in U.S. dollars to the
extent that UroShield obtains permanent marketing authorization from the FDA, is recognized as effective and becomes widely adopted for
use on catheters, none of which can be guaranteed. To that end, we are seeking a strategic partnership with various companies which have
an existing &#8220;footprint&#8221; in the urology market. Those discussions and negotiations are ongoing at this time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have appointed distributors for UroShield in the
United Kingdom, Malta, Australia and New Zealand.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From time to time, we have had interest from strategic
companies in the catheter market to partner, license or acquire the UroShield technology. These strategic partners are active in the
urology market and may be interested in integrating UroShield as an accessory, into their respective range of products. Discussions with
these partners are ongoing. There has also been interest from other companies with various invasive line applications.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Clinical Trials</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To date, we have conducted the clinical trials set
forth below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 16%; text-align: justify"><b>Purpose</b></td>
    <td style="white-space: nowrap; width: 2%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 14%; text-align: justify"><b>Doctor/Location</b></td>
    <td style="white-space: nowrap; width: 2%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 14%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Time,</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>subjects</b></p></td>
    <td style="white-space: nowrap; width: 2%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 34%; text-align: justify"><b>Objectives</b></td>
    <td style="white-space: nowrap; width: 2%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 14%; text-align: justify"><b>Results</b></td></tr>
  <tr style="vertical-align: top">
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To assess the safety of the UroShield Double
    Blind, Comparative, Randomized Study for the Safety Evaluation of the UroShield System (HD1)</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td>
    <td style="text-align: justify">&#160;</td>
    <td>Dr. U. Ikinger, Salem Academic Hospital, University of Heidelberg, Germany</td>
    <td style="text-align: justify">&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2005-2006</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">22 patients</p></td>
    <td style="text-align: justify">&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To demonstrate that the use of the UroShield
    is safe and that the device is well tolerated by the patients and user friendly to the medical staff.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Efficacy objectives were to demonstrate that
    the UroShield helps in prevention of biofilm formation in comparison with the urinary catheter alone, as well as bacteriuria.</p></td>
    <td style="text-align: justify">&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">UroShield was both safe and well tolerated.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">UroShield proved efficacious in prevention of
    biofilm. Subjects required significantly less medications than the control group for catheter related pain and discomfort.</p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Double Blind, Comparative, Randomized Study for
    the Safety Evaluation of the UroShield System (HD2 <b>)</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Physician initiated</p></td>
    <td style="text-align: justify">&#160;</td>
    <td>Dr. U. Ikinger, Salem Academic Hospital, University of Heidelberg, Germany</td>
    <td style="text-align: justify">&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2007</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">40 patients</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">To demonstrate that the use of the UroShield is safe and helps in prevention of biofilm formation
    and UTI in comparison with the urinary catheter alone, as well as decrease antibiotic use.</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">In this trial, only 1/20 patients in UroShield device (no antibiotics) group developed urinary tract
    infection compared to 4/20 patients within control group treated with the antibiotic prophylaxis alone.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Effect of UroShield on Pain and Discomfort
    in Patients Released from the Emergency Room with Urinary Catheter Due to Urine Incontinence</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Physician initiated</p></td>
    <td style="text-align: justify">&#160;</td>
    <td>Shaare Zedek Medical Center Jerusalem, Israel.</td>
    <td style="text-align: justify">&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">2007</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">10 patients</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">The study aimed to assess the effectiveness of the UroShield in reducing pain and discomfort levels
    and improve the well-being of the subjects. Efficacy objectives included reduction of pain, spasm, burning and itching sensation
    levels of the subjects.</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">The results demonstrated a reduction in pain, itching, burning and spasm levels. Additionally, the
    well-being of the subjects showed a significant increase.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">The Use of the UroShield Device in Patients with Indwelling Urinary Catheters Open labeled, comparative,
    randomized study</td>
    <td style="text-align: justify">&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Dr. Shenfeld</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Shaare Zedek Medical Center Jerusalem, Israel.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td>
    <td style="text-align: justify">&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">2007-2009</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">40 patients</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td>
    <td style="text-align: justify">&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Patient complaints related to catheter regarding
    pain according to VAS scale and discomfort according to 0-10 scale</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Presence of Clinically Significant UTI</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Presence of Bacteriuria</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Presence of Biofilm</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Use of medication</p></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">UroShield device was effective in reducing postoperative catheter related pain discomfort and bladder
    spasms. There was also a notable trend towards reduction of bacteriuria.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 16%; text-align: justify"><b>Purpose</b></td>
    <td style="white-space: nowrap; width: 2%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 14%; text-align: justify"><b>Doctor/Location</b></td>
    <td style="white-space: nowrap; width: 2%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 14%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Time,</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>subjects</b></p></td>
    <td style="white-space: nowrap; width: 2%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 34%; text-align: justify"><b>Objectives</b></td>
    <td style="white-space: nowrap; width: 2%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 14%; text-align: justify"><b>Results</b></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">Evaluation of the UroShield in urinary and nephrostomies to reduce bacteriuria Physician initiated</td>
    <td style="text-align: justify">&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prof. P.Tenke,</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Hungary</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td>
    <td style="text-align: justify">&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">2010-2011</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">27 patients</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td>
    <td style="text-align: justify">&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9679; Pain, disability and QOL</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9679; Catheter patency</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9679; Bacteriuria / UTI</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9679; Hospitalization period</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9679; Analgesics and Antibiotics intake</p></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">Showed reduction in pain and significant decrease in bacteriuria rate.</td></tr>

<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">Double Blind, Randomized Control Study for Prevention of Bacterial Colonization and UTI
    associated with Indwelling Urinary Catheters</td>
    <td style="text-align: justify">&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Dr. Shira Markowitz</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Buffalo, NY</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td>
    <td style="text-align: justify">&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">2017</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">55 patients</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">To demonstrate the use of the UroShield reduces bacterial colonization on the urinary
    catheter</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">Final results entitled &#8220;The Effect of Surface Acoustic Waves on Bacterial Load
    and Preventing Catheter-Associated Urinary Tract Infections (CAUTI) in Long Term Indwelling Catheters,&#8221; which was published
    in the December 2018 issue of Medical &amp; Surgical Urology, a leading peer-reviewed journal in the field of urology.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">Mean improvement advantage in treatment vs control was 87.2K CFU, (t (53) 18.1, p&lt;0.001) at thirty
    days. At 60 days the mean improvement advantage in treatment vs control was 87.5K CFU, (t (53) 18.1, p&lt;0.001). At 90 days the
    mean improvement advantage in treatment vs control was 79.3K CFU, (t (53) 12.4, p&lt;0.001).</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>

  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">After cessation of treatment in the active group
    at 30 days, there was a minimal increase in CFU count at both 60 and 90 days. In the same group, there was no statistical difference
    in the decrease of CFU count from 30 to 60 days after treatment, t (28)=1. p= .326, however there was a marginally significant increase
    in CFU from 60 to 90 days for the active group (28)=1.7 p= 0.09.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At baseline, every enrolled patient had been
    treated for infection during the 90 days prior to enrollment. Compared to baseline, the treatment group showed significant statistical
    and clinical improvement (100%) at 30 days relative to the sham control (73%). There were no reported infections in the Treatment
    Group while in the control group there were seven reported infections.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At 90 days after treatment, the treatment group
    showed a significantly stronger improvement (89.7%) compared to the sham control (46.2%). There were three reported infection in
    the Treatment group, while in the control group there were fourteen reported infections requiring antimicrobial therapy. (logistic
    regression B=2.3, Wald Chi-Square (df=1) =10.1, p=0.001.)</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 16%; text-align: justify"><b>Purpose</b></td>
    <td style="white-space: nowrap; width: 2%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 14%; text-align: justify"><b>Doctor/Location</b></td>
    <td style="white-space: nowrap; width: 2%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 14%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Time,</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>subjects</b></p></td>
    <td style="white-space: nowrap; width: 2%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 34%; text-align: justify"><b>Objectives</b></td>
    <td style="white-space: nowrap; width: 2%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 14%; text-align: justify"><b>Results</b></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">UroShield Randomized Control trial</td>
    <td style="text-align: justify">&#160;</td>
    <td>5 different nursing facilities</td>
    <td style="text-align: justify">&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2017 - 2018</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">51 subjects</p></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">51 subjects were evaluated with 26 in the active/treatment group and 25 in the control group. All
    patients had been treated for at least one incident of a catheter-acquired urinary tract infection (CAUTI) requiring antibiotics
    in the preceding 6 months prior to trial initiation.</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">At the 90-day evaluation, 13 of 25 subjects (52%) in the control group developed a CAUTI requiring
    systemic antibiotics while only 1 of 26 patients (4%) in the UroShield&#8482; group required antibiotic. All study subjects had an
    initial colony count of greater than 100,000 CFU cultured from their urinary tract. At thirty days, all subjects within the control
    group showed no change in the number of their bacteria count which was greater than 100,000 CFU, while those in the treatment group
    showed a reduction to 10,000 CFU in 15 of 26 subjects and only 1,000 CFU in 10 of 26 subjects, proving a decrease in both bacterial
    colonization and the incidence of Urinary Tract Infection.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Recently Completed, Current, Ongoing and Planned
Clinical Trial</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we are able to locate a strategic partner or otherwise
obtain sufficient funding, we anticipate conducting the following clinical trial:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 18%; text-align: justify"><b>Trial</b></td>
    <td style="white-space: nowrap; width: 2%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 10%; text-align: justify"><b>Place</b></td>
    <td style="white-space: nowrap; width: 2%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 10%; text-align: justify"><b>Start Date/Timing</b></td>
    <td style="white-space: nowrap; width: 2%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 56%; text-align: justify"><b>Objectives</b></td></tr>
  <tr style="vertical-align: top">
    <td>UroShield FDA Administration trial 306 patient trial</td>
    <td style="text-align: justify">&#160;</td>
    <td>University of Michigan</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">April 2024</td>
    <td style="text-align: justify">&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Safety and efficacy of UroShield in urinary catheter
    related pain and infection and biofilm formation.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The results of previous clinical trials may not
    be predictive of future results, and the results of our planned clinical trial, if we are able to locate a strategic partner or otherwise
    obtain sufficient funding, may not satisfy the requirements of the FDA.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The initial part of the study is a pilot phase
    in order to verify clinical, logistical, and oversight of a potential broad study. The pilot phase was completed in the 4th quarter
    of 2024. The results satisfied the University of Michigan clinical team and subsequently recommended that we move to the broader
    study</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">PainShield</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PainShield is an ultrasound device, consisting of
a reusable driver unit and a disposable patch, which contains our proprietary therapeutic transducer. It delivers a localized ultrasound
effect to treat pain and induce soft tissue healing in a targeted area, while keeping the level of ultrasound energy at a safe and consistent
level of 0.4 watts. We believe that PainShield is the smallest and most portable therapeutic ultrasound device on the market and the
only product in which the ultrasound transducer is integrated in a therapeutic disposable application patch.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe the existing ultrasound therapy devices
being used for pain reduction are primarily large devices used exclusively by clinicians in medical settings. PainShield is able to deliver
ultrasound therapy without being located in a health care facility or clinic because it is portable, due to it being lightweight and
battery operated. Because it is patch based and easy to apply, PainShield does not require medical personnel to apply ultrasound therapy
to the patient. Some patient benefits reported in prior studies included ease of application and use, relatively quick recovery time,
high patient compliance, and potentially increased safety and efficacy over certain other devices that rely on higher-frequency ultrasound
(Adahan M, et al, &#8220;A Sound Solution to Tendonitis: Healing Tendon Tears With a Novel Low-Intensity, Low-Frequency Surface Acoustic
Ultrasound Patch,&#8221; American Academy of Physical Medicine and Rehabilitation Vol. 2, 685-687, July 2010). PainShield can be used
by patients at home or work or in a clinical setting and can be used even while the patient is sleeping. Its range of applications includes
acute and chronic pain reduction and anti-inflammatory treatment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>Picture of PainShield with Patch</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Sans-Serif; margin: 0; text-align: center"><img src="form10-k_004.jpg" alt="" style="height: 225px; width: 200px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In other countries outside the United States where
the product is approved for such use, PainShield is used to treat tendon disease and trigeminal neuralgia (a chronic pain condition that
affects the trigeminal or 5th cranial nerve, one of the most widely distributed nerves in the head); previously, the therapeutic options
for these disorders have been very limited. In the United States, PainShield is only cleared to treat pain, muscle spasms, and joint
contractures associated with or caused by various conditions or diseases. It has also been used to treat pelvic and abdominal pain. To
date, to the best of our knowledge, the primary treatment options for several of these conditions are pain medication and surgery. Several
additional causes of pain, and the treatment of that pain with the PainShield product, can be explored through clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 1, 2023, the Company launched its month-to-month
rental program for Painshield.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2024, we the Veranex Agreement with Veranex
to provide certain research and development services to assist with the development of our next generation of UroShield and PainShield
products. See &#8220;<i>Nano OpCo&#8217;s Products &#8211; UroShield,</i>&#8221; above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Market for PainShield</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pain-related complaints are one of the most common
reasons patients seek treatment from physicians (Prince V, &#8220;Pain Management in Patients with Substance-Use Disorders,&#8221; Pain
Management, PSAP-VII, Chronic Illnesses). According to Landro L, &#8220;New Ways to Treat Pain: Tricking the Brain, Blocking the Nerves
in Patients When all Else Has Failed,&#8221; Wall Street Journal, May 11, 2010, approximately 26% of adult Americans, or approximately
76.5 million people, suffer from chronic pain. The National Center for Health Statistics has estimated that approximately 54% of the
adult population experiences musculoskeletal pain. Studies have shown that low-frequency ultrasound treatment has yielded positive results
for a variety of indications, including tendon injuries and short-term pain relief (Warden SJ, &#8220;A new direction for ultrasound
therapy in sports medicine,&#8221; Sports Med. 2003; 33 (2):95-107), chronic low back pain (Ansari NN, Ebadi S, Talebian S, Naghdi S,
Mazaheri H, Olyaei G, Jalaie SA, &#8220;Randomized, Single Blind Placebo Controlled Clinical Trial on the Effect of Continuous Ultrasound
on Low Back Pain,&#8221; Electromyogr Clin Neurophysiol. 2006 Nov; 46(6):329-36) and sinusitis (Ansari NN, Naghdi S, Farhadi M, Jalaie
S, &#8220;A Preliminary Study Into the Effect of Low-Intensity Pulsed Ultrasound on Chronic Maxillary and Frontal Sinusitis,&#8221; Physiother
Theory Pract. 2007 Jul-Aug; 23(4):211-8). We believe that PainShield&#8217;s technology, portability and ease of use may result in it
becoming an attractive product in the pain management and therapy field.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Competition for PainShield</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There are numerous products and approaches currently
utilized to treat chronic pain. The pharmacological approach, which may be the most common, focuses on drug-related treatments with the
over-the-counter internal analgesic market estimated at $19 billion in 2019. Alternatively, there are a large number of non-pharmacological
pain treatment options available, such as ultrasound, transcutaneous electrical nerve stimulation, or TENS, laser therapy and pulsed
electromagnetic treatment. In addition, there are some technologies and devices in the market that utilize low frequency ultrasound or
patch technology. Many patients are initially prescribed anti-pain medication; however, ongoing use of drugs may cause substantial side
effects and lead to addiction. Therefore, patients and clinicians have shown increased interest in alternative pain therapy using medical
devices that do not carry these side effects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The currently available ultrasound treatments for
chronic pain have generally been accepted by the medical community as standard treatment for pain management. However, the traditional
ultrasound treatments, such as those manufactured or distributed by Mettler Electronics Corp, Metron USA and Zimmer MedizinSysteme, are
stationary devices found only in clinics and other health care facilities that need to be administered to patients by health care professionals.
We are aware of three companies that market smaller ultrasound devices capable of certain self-administered use for the treatment of
pain: Koalaty Products, Inc., Sun-Rain System Corp. and PhysioTEC. These devices generally function in the same manner, at the same frequency
and with the same administration and safety requirements and limitations as traditional, larger ultrasound devices. We are also aware
of one product, the SAM&#174; Sport4, which has recently received FDA approval and also has CE Mark approval, marketed by ZetrOZ, Inc.,
that we understand may eliminate certain of these requirements and limitations, namely the requirement to be plugged in, the need for
movement around the treated area and the relatively short safe treatment period. However, we understand that this product does not generate
surface acoustic waves as our products do, which means that the treatment area is generally limited to that under the transducer, that
the use of transmission gel is still required, and that the transducer thickness is significantly greater than ours (approximately 1.5cm).
It is also our understanding that the FDA has issued contraindications which do not apply to the PainShield product. In addition, there
are other patch-based methods of pain treatment, such as TENS therapy. TENS therapy may be painful and irritating for the patient due
to the muscle contractions resulting from the electrical pulses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PainShield combines the efficacy of ultrasound treatment
for pain with the ease of use and portability of a patch-based system. PainShield also may be self-administered by the patient, including
while the patient is sleeping. However, if we are unable to obtain widespread insurance coverage and reimbursement for PainShield, its
acceptance as a pain management treatment would likely be hindered, as patients may be reluctant to pay for the product out-of-pocket.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">CMS approved PainShield for reimbursement for Medicare
beneficiaries on a national basis in January 2020 although we have never received a reimbursement value. The Company was denied reimbursement
in September 2022 due to a lack of &#8220;life-cycle&#8221; testing. The Company had engaged Carmel Labs in Israel to conduct this testing
and submitted the results to CMS with our 2023 application on January 3, 2023. On August 21, 2023, CMS, denied reimbursement with respect
to PainShield due to their request for additional longevity testing. We are currently evaluating whether to resubmit another application
to CMS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our marketing efforts continue to expand in the direct
to consumer, Veterans Health Care network, and workers&#8217; compensation market. Relative to the VA market, we are currently represented
by Applied Medical and Delta Medical. Delta Medical is a Service Disabled Veteran Organization Small Business (SDVOSB). PainShield is
approaching the workers&#8217; compensation market through various sales agents and on a direct basis. Additionally, on March 1<sup>st</sup>,
2023, we established a rental program for direct to consumer marketing for patients without health insurance coverage.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Regulatory Strategy</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PainShield received 510(k) clearance from the FDA
in August 2008 as an ultrasonic diathermy device intended to apply ultrasonic energy to generate deep heat within body tissues for the
treatment of selected medical conditions, such as relief of pain, muscle spasms, and joint contractures. PainShield received CE Mark
approval in July 2008 and was also approved for sale by the Israeli Ministry of Health in 2010. We are able to sell PainShield in India
and Ecuador based on our CE Mark.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the United States, a prescription from a licensed
healthcare practitioner is required for the use of PainShield.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Recently, we announced our intention to pursue marketing
authorization for a non-prescription version of PainShield MD, which we refer to as PainShield Relief. The PainShield Relief is intended
to be an Over-The Counter (OTC) product, not requiring a prescription from a medical professional. We believe that such reclassification,
if approved by the FDA, will open up mass market opportunities which are currently not available to us due to the prescription requirement.
However, there is no assurance that we will be able to remove the prescription requirement for the use of PainShield Relief or that,
even if we accomplish such reclassification and the use of PainShield Relief no longer requires a prescription, PainShield Relief will
be successful commercially in the mass market or we will be able to generate significant revenues from the mass market opportunities,
if any.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In order to prove to the FDA that the requirement
for a physician prescription is not necessary to ensure safe and effective use of the product, proof of safety and consumer &#8220;usability&#8221;
needs to be established. We engaged User-View, Inc. to facilitate our Usability study and received the favorable results we expected.
The product packaging and all instruction documents have been modified in an effort to meet OTC standards. We also engaged an outside
laboratory to perform acoustic testing on all PainShield products. We previously anticipated submission of a 510(k) for PainShield Relief
to the FDA, for OTC use as a class 1 device, in early April 2022, but do not expect such submission to take place until 2025 as we are
evaluating whether any additional data or action steps are needed including potentially redesigning the product in appearance and functionality.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The PainShield Plus, is a dual applicator device,
which will also be submitted for specific clearance from the FDA. Submission for PainShield Plus was made in late February 2022. We received
FDA clearance in November 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the United States, PainShield falls under the
diathermy classification for the treatment of pain for initial reimbursement purposes. The permitted reimbursement codes can be used
in the outpatient supervised medical setting. We continue to work with the Centers for Medicare and Medicaid Services and private insurers
so that reimbursement can be extended to cover the administration of PainShield outside of health care facilities and clinics. We have
engaged outside legal counsel to assist with all aspects of reimbursement and FDA regulatory actions. In addition, we intend to conduct
clinical trials in order to pursue FDA authorization to market PainShield for a larger range of indications. The targeted reimbursement
would be based upon specific indications, where study data serves as justification for payment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>PainShield Sales and Marketing</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PainShield was introduced in 2009 as a treatment
for pain, such as tendonitis, sports injuries, pelvic pain, and neurologic pain, depending on the scope of the approval or clearance
from each applicable jurisdiction, and we have sold over 8,000 units since its introduction. We have entered into distribution agreements
in United States, Europe, Australia, and India for the distribution of PainShield. We intend to seek additional distribution opportunities
in Europe, East Asia and Ecuador. In addition, we sell PainShield directly to patients through our website in jurisdictions where direct-to-consumer
sale is permitted. We are continuously improving our marketing efforts in the U.S. market and throughout the world to establish licensing
and private label partnerships as well.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have identified a unique application for PainShield
in applicable foreign jurisdictions where such application is authorized, which is the treatment of a severe facial nerve pain called
Trigeminal Neuralgia, otherwise known as tic douloureux. The FDA lists facial application as a contraindication and has not cleared or
approved PainShield for such use in the United States. We are considering pursuing FDA approval of the PainShield for Trigeminal Neuralgia,
which will likely require additional data and clinical investigation to support an application for premarket approval (&#8220;PMA&#8221;)
for this indication, if such PMA is required by FDA. Two studies were performed in Israel, &#8220;A Randomized Control Trial Examining
the Efficacy of Low Intensity Low Frequency Surface Acoustic Wave Ultrasound in Trigeminal Neuralgia Pain&#8221;, and &#8220;A Sound
Solution for Trigeminal Neuralgia&#8221;. Two trials which enrolled a total of 16 and 15 patients respectively, both conducted at the
Sheba Medical Center in Israel, concluded that these studies support the hypothesis that the application of Low Intensity Low Frequency
Surface Acoustic Wave Ultrasound (LILF/SAW) may be associated with a clinically significant reduction of pain severity among patients
suffering from trigeminal neuralgia disease. One of the studies showed a reduction in pain among 73% of the participants. We believe
this to be an ideal market to address with the PainShield. With few existing treatment alternatives, we believe the PainShield could
prove to be a practical and safe alternative. A broader RCT, targeting 60 patients suffering from unilateral trigeminal neuralgia, was
also completed. The article was published on January 22, 2019, in the Journal of Anesthesiology and Pain Research, under the title &#8220;The
Effect of a Surface Acoustic Wave (SAW) Device on the Symptomatology of Trigeminal Neuralgia&#8221;. We cannot predict the success of
any future trials, nor can we guarantee that FDA will grant approval for such use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">GlobalData&#8217;s epidemiological analysis forecasts
that the total prevalent cases of trigeminal neuralgia in the seven major markets (United States, France, Germany, Italy, Spain, U.K
and Japan) will grow at 15% between 2012 and 2022. According to an estimate by Ronald Brisman, M.D., in 2013 the prevalence of trigeminal
neuralgia in the U.S. may have been as high as approximately 280,000 patients. With the favorable results from our current, ongoing study
(explained in detail below), we continue to plan to aggressively pursue this market in the foreign jurisdictions where PainShield has
been approved through direct marketing efforts and distributor relationships.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have also identified a market for PainShield in
the professional sports industry, where in some cases, reimbursement may be available from sports alumni organizations or, more likely,
self-pay. In order to pursue this market, we are exhibiting at sports trainer&#8217;s meetings, pursuing alumni associations, advertising
in their media, and have recently engaged a national distributor in the United States. Discussions and ongoing negotiations continue
with other appropriate distributors in these various market segments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Clinical Trials</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To date, we have conducted or are in the process
of conducting the clinical trials set forth below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 15%"><b>Purpose</b></td>
    <td style="white-space: nowrap; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 11%"><b>Doctor/Location</b></td>
    <td style="white-space: nowrap; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 11%"><b>Time, subjects</b></td>
    <td style="white-space: nowrap; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 19%"><b>Objectives</b></td>
    <td style="white-space: nowrap; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 36%"><b>Results</b></td></tr>
  <tr style="vertical-align: top">
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">A sound solution for Trigeminal Neuralgia Physician initiated</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td>
    <td style="text-align: justify">&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Dr. Ch. Adahan Sheba Medical Center</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td>
    <td style="text-align: justify">&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2009</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">15 patients</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td>
    <td style="text-align: justify">&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9679;Reduction in pain</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9679;Reduction in disability</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9679;Improvement of function and quality of
    life</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9679;Accelerating of healing</p></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">73% of the subjects experienced complete or near complete relief.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">Randomized control trial examining the efficacy of low intensity low frequency Surface Acoustic wave
    ultrasound in trigeminal neuralgia pain For Ph.D., Funded by Israeli Ministry of Health</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Dr. M. Zwecker Chaim Sheba Medical Center, Tel
    Hashomer, Israel</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2012-2012</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">16 patients</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9679;Reduction in pain</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9679;Reduction in disability</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9679;Improvement of function and quality of
    life</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9679;Accelerating of healing</p></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">In conclusion this study supports the hypothesis that the application of Low
    Intensity Low Frequency Surface Acoustic Wave Ultrasound (LILF/SAW) may be associated with a clinically significant reduction of
    pain severity among patients suffering from trigeminal neuralgia disease.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 15%"><b>Purpose</b></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 11%"><b>Doctor/Location</b></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 11%"><b>Time, subjects</b></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 19%"><b>Objectives</b></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 36%"><b>Results</b></td></tr>
  <tr style="vertical-align: top">
    <td>Treating Rutgers university athletic injuries with band aid sized ultrasound unit PainShield</td>
    <td style="text-align: justify">&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">R. Monaco,</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">G. Sherman,</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Rutgers University Athletic, Rutgers, New Jersey</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td>
    <td style="text-align: justify">&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2011</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">35 patients</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td>
    <td style="text-align: justify">&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9679;To assess the pain, functional capacity
    and discomfort of the subject</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9679;To assess the subject&#8217;s quality
    of life</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9679;To assess the injury status</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9679;To assess the efficacy of the treatment</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9679;To assess compliance factors</p></td>
    <td style="text-align: justify">&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Active group:</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">74% had improvement, 26% no change</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sham group:</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">56% no change, 44% had improvement</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This is an indication of the effectiveness of
    the device.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Lack of funding for statistical analysis has
    stopped this trial prior to fulfilment.</p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">Reduction of chronic abdominal and pelvic pain, urological and GI symptoms using wearable device
    delivering low frequency ultrasound</td>
    <td style="text-align: justify">&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">D. Wiseman,</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Synechion Institute for Pelvic Pain</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td>
    <td style="text-align: justify">&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2011</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">19 patients</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;To assess the efficacy of PainShield for pelvic and related pain</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">Improvement in pain related symptoms noted for all symptoms.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">The Effects of the NanoVibronix&#8217;s PainShield Surface Acoustic Waves on the Symptoms of Lateral
    Epicondylitis</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">Dr. David Lemak, a leading orthopedic surgeon with Birmingham Orthopedic and Sports Specialists.</td>
    <td style="text-align: justify">&#160;</td>
    <td>2019, 24 patients</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">A randomized, double blinded study for 30 days that evaluated the effectiveness and safety of PainShield
    Surface Acoustic Wave (SAW) technology on patients suffering from pain and discomfort, as well as limited mobility caused by the
    effects of chronic or acute lateral epicondylitis (LE) (&#8220;tennis elbow&#8221;).</td>
    <td style="text-align: justify">&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All patients in the study had symptoms of pain
    and point tenderness at the beginning of the study. Conversely, at the conclusion of the study, 91% of the patients in the PainShield
    control group had complete or partial resolution of symptoms. Patients used PainShield in conjunction with over-the-counter medication,
    as needed, but without the benefit of opioid-based prescription medication. The study concluded that the PainShield device is safe
    and effective in the treatment of tennis elbow.</p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">The Effect of a Surface Acoustic Wave (SAW) Device on the Symptomatology of Trigeminal Neuralgia</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">Shira Markowitz, MD, New York, NY</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">Early 2018 59 patients</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">To measure pain scores, quality of life, and breakthrough drug use of 59 patients with a diagnosis
    of unilateral trigeminal neuralgia.</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">There was a significant difference in the outcomes of the two groups relative to pain, quality of
    life, and breakthrough medications taken, which was directly correlated to pain experienced during treatment. Specifically, the treatment
    group experienced a 55.2% improvement in baseline pain scores versus 2.3% for the control group. The treatment group experienced
    a 46.4% reduction in breakthrough pain medication versus 1.5% for the control group.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we are able to obtain sufficient funding, we anticipate
conducting the following clinical trials:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 22%; text-align: justify"><b>Trial</b></td>
    <td style="white-space: nowrap; width: 2%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 16%; text-align: justify"><b>Place</b></td>
    <td style="white-space: nowrap; width: 2%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 16%; text-align: justify"><b>Start Date/Timing</b></td>
    <td style="white-space: nowrap; width: 2%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 40%; text-align: justify"><b>Objectives</b></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">Surface Acoustic Wave (PainShield) and its effectiveness on bone growth stimulation</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">To be determined</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">To be determined</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">Test the effect of Surface Acoustic Wave (SAW)/PainShield for bone growth stimulation</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">WoundShield</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our WoundShield product was granted the European
Wound Closure Customer Value Leadership Award, Ultrasound Therapy - Wound Closure in 2014. WoundShield is intended to treat acute and
chronic wounds with a disposable treatment patch that delivers localized therapeutic low frequency ultrasound. The WoundShield patch
has two configurations: one that is placed adjacent to the wound and another, called the instillation patch, that is placed on the wound
to enable instillation through sonophoresis, a process that increases the absorption of semisolid topical compounds, including medications,
into the skin. Based on studies conducted by BIO-EC Microbiology Laboratory and Rosenblum, we believe that our WoundShield product possesses
significant potential for the treatment of, among other things, diabetic foot ulcers and burns (Gasser P, Study Report delivered by BIO-EC
Microbiology Laboratory, Dec 2007, which we ordered, paid for, and provided devices for; Rosenblum J, &#8220;Surface Acoustic Wave Patch
Diathermy Generates Healing In Hard To Heal Wounds,&#8221; European Wound Management Association 2011, for which we supplied devices
but had no further involvement).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2020, we signed a license agreement with
Sanuwave Health, Inc. (&#8220;Sanuwave&#8221;) for the manufacture and delivery of our WoundShield technology. Under the terms of the
agreement, NanoVibronix received warrants to purchase up to 127,000 of Sanuwave stock upon signing and, will receive a $250,000 milestone
payment based on FDA approval, and 10% royalty on Sanuwave&#8217;s gross revenues from sales or rentals of WoundShield. In return, Sanuwave
has received the worldwide, exclusive rights to the Company&#8217;s WoundShield product and technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 12, 2024, the agreement with SanuWave
was terminated, and our Sanuwave warrants were cancelled.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Sans-Serif; margin: 0; text-align: center"><img src="form10-k_005.jpg" alt="" style="height: 168px; width: 180px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>Picture of WoundShield Driver and Instillation
Patch</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">WoundShield delivers surface acoustic waves to the
location of the wound. Surface acoustic waves move laterally across the surface of the wound, which enables the transfer of the acoustic
energy of the waves along the entire wound surface in a continuous and consistent mode, providing access to the waves&#8217; benefits
for a longer treatment period than conventional ultrasound without the need for supervision or a treatment session by a clinician.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The technology has been found to have a positive
effect on the epithelialization (healing by the growth of epithelial cells) of diabetic wounds, as well as on the stimulation of the
precursors of dermal and epidermal (skin) growth. As such, it is a useful adjunct to wound care by increasing dermal and epidermal growth,
including glycosaminoglycans, or GAGs (which bind to extracellular proteins like collagen, fibronectin, laminin, etc. and retain considerable
amounts of water, thus preserving the skin structure) as well as the amount of collagen (a protein that helps skin heal) and decreasing
the number of cells in mitosis (a type of cell division) (Rosenblum J, &#8220;Surface Acoustic Wave Patch Diathermy Generates Healing
In Hard To Heal Wounds,&#8221; European Wound Management Association 2011, for which we supplied devices which were precursors to WoundShield,
but had no further involvement). In addition, the WoundShield instillation patch allows for administration of therapeutic agents into
the wound area through a sonophoresis effect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Many key processes in wound healing are dependent
upon an adequate supply of oxygen. Diabetic foot ulcers are particularly in need of an adequate oxygen supply because the disease often
results from poor perfusion (blood flow) and decreased oxygen tension. Oxygen is also important for the immune system to combat bacteria,
synthesize collagen, help with fibroblast proliferation (fibroblasts are a type of cell that play a critical role in wound healing),
form oxidative (taking place in the presence of oxygen) pathways for adenosine triphosphate, or ATP, formation (ATP transports chemical
energy within cells for metabolism), and the nitric oxide dependent signaling pathways. It is generally believed that a lack of available
oxygen is a basic contributing factor in the perpetuation of these wounds. Wound healing experts have developed a technique of perfusing
ischemic wounds (which occur when blood flow is blocked) with hyper-oxygenated saline, while the wound is being treated with ultrasound,
also known as sonication. This localized oxygenation therapy has many advantages over the use of hyperbaric chambers (large chambers
in which the oxygen pressure is above normal), a common method for delivering oxygen to wounds, as it is more cost-effective, can be
done at the patient&#8217;s bedside and can be administered more frequently. The WoundShield instillation patch was tested as a potential
ultrasound technology for this localized oxygen therapy. In one study (Morykwas M, &#8220;Oxygen Therapy with Surface Acoustic Waveform
Sonication,&#8221; European Wound Management Association 2011; we supplied devices for this study, but had no further involvement with
it), oxygen sensors were placed in the wound bed to directly measure partial pressure of oxygen in an ischemic wound bed on a pig. The
wound was perfused with hyperbaric oxygen and sonicated using the WoundShield instillation patch. With surface acoustic wave ultrasound
technology, tissue oxygen levels (partial pressure of oxygen in the blood, or PaO2) were raised from a range of 20 mmHg (millimeters
of mercury) to 60 mmHg in peripheral (periwound) areas, a 3 centimeter distance away from the transducer, and from 40 mmHg to greater
than 100 mmHg in the central wound bed lying below the WoundShield instillation patch (see table below). The results of this study illustrated
that the WoundShield instillation patch allowed oxygen to directly enter into the wound. The direct entry of the oxygen increased the
amount of oxygen reaching the wound, which has been shown to advance the healing process. In addition, we believe that WoundShield&#8217;s
small size, lower cost and ease of use makes localized oxygen treatment commercially viable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Sans-Serif; margin: 0; text-align: center"><img src="form10-k_006.jpg" alt="" style="height: 192px; width: 250px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In 2012, results were published of a human feasibility
trial for the WoundShield instillation patch that was performed at Duke University in North Carolina. Seven patients were treated with
the WoundShield instillation patch for their wounds and average tissue oxygen levels (PaO2) increased by an average of 58% over baseline
(Covington S, &#8220;Ultrasound-Mediated Oxygen Delivery to Lower Extremity Wounds,&#8221; Wounds 2012; 24(8)). We supplied devices for
this trial, but had no further involvement with it.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Market for Wound-Healing Devices</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The global wound care device market totaled approximately
$20.8 billion in 2022 and it is expected to grow to $27.2 billion by 2027 at a CAGR of 65.4% during 2022-2027 (as reported by Markets
and Markets in June 2022). According to the Global Report on Diabetes produced by the World Health Organization (&#8220;WHO&#8221;) in
2016, globally, an estimated 422 million adults were living with diabetes in 2014, compared to 108 million in 1980. According to a report
entitled &#8220;Advances in Wound Closure Technology&#8221; by Frost and Sullivan (2005), foot complexities are the most frequent causes
for patients with diabetes to get hospitalized, with complications usually starting with the formation of skin ulcers. In addition, according
to the American Burn Association, approximately 486,000 patients received medical treatment annually for burn injuries in 2016 in the
United States. There are also policy-based factors that may increase the size of the wound care market. We anticipate that reimbursement
decisions with respect to hospital acquired wounds may create a large market opportunity for wound care products, including WoundShield.
Furthermore, in 2009, the Centers for Medicare and Medicaid Services announced that they would stop reimbursements for treatment of certain
complications that they believed were preventable with proper care. One such complication was surgical site infections after certain
elective procedures, including some orthopedic surgeries and bariatric surgery. We believe that such developments incentivize medical
care providers to invest in reducing the risk of infection through the use of wound care products, including WoundShield.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Competition for WoundShield</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The market for advanced wound care includes a number
of competitors, such as the 3M Company, Smith and Nephew plc and Convatec Inc., all of whom market wound-healing medical devices. Due
to their size, in general these companies may have significant advantages over us. These competitors have their own distribution networks
for their products, which gives them an advantage over us in reaching potential customers. In addition, they are vertically-integrated,
which may allow them to maximize efficiencies that we cannot achieve with our third-party suppliers and distributors. Finally, because
of their significantly greater resources, they could potentially choose to focus on research and development of technology similar to
ours, more than we are able to. In general, we believe that these competitors have, and will continue to have, substantially greater
financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel
resources than we do. However, we believe that our products differentiate us from these competitors, and we will be competitive on the
basis of our technology. We believe that the strength of these competitors may create an opportunity through strategic partnerships.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At present, ultrasound treatment for wounds is limited
only to wound debridement (removal of damaged tissue or foreign objects from a wound) and such products are marketed by Arobella Medical,
LLC, which produces the Qoustic Wound Therapy System, Misonix Inc., which produces SonicOne products, and Alliqua Biomedical, Inc., which
produces the MIST Therapy System. Due to their size, in general these companies may have the same advantages over us as discussed with
respect to our competitors in the paragraph above. However, these ultrasound devices are indicated for use only in medical clinics and
require an operator to deliver their treatment, thus limiting their use and application. The MIST Therapy System and Quostic Therapy
System are non-contact ultrasound device that delivers ultrasound through a mist that is applied directly on the wound.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe that these therapies are less advantageous
than WoundShield because they require an operator to deliver the treatment and the removal of bandages to target the wound bed. In contrast,
the WoundShield patch sits on normal skin bordering the open wound and no manipulation of the wound bandage is required. Moreover, WoundShield
can be self-administered, without an operator, in both clinics and home settings. We also believe that WoundShield will prove to be an
effective alternative to treating chronic wounds at a lower price than the existing products being used by medical practitioners. As
such, we believe that facilities that are reimbursed based upon diagnosis-related groups will be more inclined to adopt WoundShield because
it will provide the same therapeutic results at a significantly lower cost than traditional ultrasound therapies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are also aware of a small clinical study, for
which results were reported in August 2013, in which a small ultrasound device showed positive results in the treatment of venous ulcers,
a type of chronic wound. We understand that this product does not generate surface acoustic waves as our products do, which means that
the treatment area is generally limited to that of the transducer&#8217;s diameter. We believe our products would have certain other
advantages over this potential device, if developed, including that our products weigh less and are thinner. However, given the early
stage of development of this potential device, we cannot say with certainty how our products would compare.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The most common method of oxygen administration for
wound healing is hyperbaric oxygen therapy, especially to treat specific ulcerations in diabetic patients. Hyperbaric oxygen therapy
has been shown to increase vascular endothelial growth factor expression, which measures the creation of new blood vessels (Fok TC, at
el, &#8220;Hyperbaric oxygen results in increased vascular endothelial growth factor (VEGF) protein expression in rabbit calvarial critical-sized
defects&#8221;, Schulich School of Medicine and Dentistry, University of Western Ontario, Canada). The activation of endothelial cells
by VEGF sets in motion a series of steps toward the creation of new blood vessels (J Lewis et al., National Cancer Institute, Understanding
Cancer and Related Topics, Understanding Angiogenesis). We believe that the WoundShield instillation patch, which can be used as an oxygen
instillation system, will be complementary to, or in some cases an alternative to, the use of hyperbaric chamber therapy. This complementary
treatment option will allow the treating physician greater therapeutic versatility in treating wounds. For a certain populace of patients,
we believe that the WoundShield instillation patch could provide physicians with an alternative to hyperbaric oxygen therapy because
it provides the same benefits as hyperbaric oxygen therapy at a lower cost to the patient. There are a number of competitors in the hyperbaric
chamber therapy market, including approximately eight companies in the United States. Due to their size, in general these companies may
have the same advantages over us discussed with respect to our competitors in the first paragraph of this section. However, we believe
that the WoundShield instillation patch possesses certain advantages over the existing hyperbaric chamber therapy, including lower cost
and greater ease of use. In addition, we believe that the WoundShield instillation patch will not necessarily compete with hyperbaric
chamber therapy, but rather will often complement such therapy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">While we believe that WoundShield is well positioned
to capture a share of the wound care market, WoundShield may be unable to achieve its anticipated place in the wound care market due
to a number of factors, including, but not limited to, an inability to obtain the approval of the FDA , for which it is indicated and
its failure to be adopted by health care practitioners and facilities or patients because of its status as a new product in a market
that relies on patient-focused initiative to treat wounds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Regulatory Strategy</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For a general discussion of the FDA approval process
with respect to our products, and regulation of our products in general, see &#8220;- Government Regulation&#8221; below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not intend to seek FDA clearance in the short
term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>WoundShield Sales and Marketing</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">WoundShield has generated minimal revenues to date.
In March 2020, we signed a license agreement with Sanuwave Health, Inc. for the manufacture and delivery of our WoundShield technology.
On September 12, 2024, the agreement with SanuWave was terminated, and our Sanuwave warrants were cancelled.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Clinical Trials</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">With respect to WoundShield, to date, we have conducted
the following evaluation studies:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 10%; text-align: justify"><b>Purpose</b></td>
    <td style="width: 2%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 14%; text-align: justify"><b>Doctor/Location</b></td>
    <td style="width: 2%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 5%; text-align: justify"><b>Time, subjects</b></td>
    <td style="width: 2%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 20%; text-align: justify"><b>Objectives</b></td>
    <td style="width: 2%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 43%; text-align: justify"><b>Results</b></td></tr>
  <tr style="vertical-align: top">
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Clinical evaluation</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Physician initiated</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td>
    <td style="text-align: justify">&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Dr. J. Rosenblum,</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Shaare Zedek</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Medical Center</p></td>
    <td style="text-align: justify">&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2008</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">8 patients</p></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">To evaluate novel technology on wound healing in diabetic foot ulcers.</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">Therapy showed significant changes in wound, wound size was reduced, patients felt less pain, necrotic
    tissue was less adhesive, necrotic tissue decreased in size. The duration of the trial was one week.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Clinical evaluation</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Physician initiated</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td>
    <td style="text-align: justify">&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Dr. J. Rosenblum,</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Shaare Zedek</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Medical Center</p></td>
    <td style="text-align: justify">&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2010</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">8 patients</p></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">To evaluate novel technology on wound healing in diabetic foot ulcers.</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">The device, a precursor device to WoundShield using the same technology as WoundShield, had a positive
    effect on both epithelization of diabetic wounds and stimulating the precursors of dermal and epidermal growth. The duration of the
    trial was one week.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Clinical evaluation</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Physician initiated</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">Dr. S. Covington</td>
    <td style="text-align: justify">&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2010</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">7 patients</p></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">The study aimed to determine if hyper oxygenated saline delivered by surface acoustic waves improves
    tissue oxygenation in lower extremity wounds.</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">Surface acoustic wave technology in conjunction with oxygenated saline can increase interstitial
    oxygen in wound bed. This trial to validate proof of concept was put on hold due to financial constraints. The duration of the trial
    was two weeks.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Third Party Reimbursement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We anticipate that sales volumes and prices of the
products we commercialize will depend in large part on the availability of coverage and reimbursement from third party payers. Third
party payers include governmental programs such as Medicare and Medicaid, private insurance plans and workers&#8217; compensation plans,
Veterans Health Care network, among others. These third-party payers may deny coverage and reimbursement for a product or therapy, in
whole or in part, if they determine that the product or therapy was not medically appropriate or necessary. The third-party payers also
may place limitations on the types of physicians or clinicians that can perform specific types of procedures. In addition, third party
payers are increasingly challenging the prices charged for medical products and services. Some third -party payers must also pre-approve
coverage for new or innovative devices or therapies before they will reimburse health care providers who use the products or therapies.
Even though a new product may have been approved or cleared by the FDA for commercial distribution, we may find limited demand for the
device until adequate reimbursement has been obtained from governmental and private third -party payers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Over-the-counter products, such as the proposed PainShield
Relief product that we are developing, if ultimately cleared for marketing by the FDA, are generally not reimbursed by any third-party
payers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In international markets, reimbursement and healthcare
payment systems vary significantly by country, and many countries have instituted price ceilings on specific product lines and procedures.
There can be no assurance that procedures using our products will be considered medically reasonable and necessary for a specific indication,
that our products will be considered cost-effective by third party payers, that an adequate level of reimbursement will be available
or that the third -party payers&#8217; reimbursement policies will not adversely affect our ability to sell our products profitably.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the United States, some insured individuals are
receiving their medical care through managed care programs, which monitor and often require pre-approval of the services that a member
will receive. Some managed care programs are paying their providers on a per capita basis, which puts the providers at financial risk
for the services provided to their patients by paying these providers a predetermined payment per member per month, and consequently,
may limit the willingness of these providers to use certain products, including ours.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">One of the components in the reimbursement decision
by most private insurers and governmental payers, including the Centers for Medicare and Medicaid Services, which administers Medicare,
is the assignment of a billing code. Billing codes are used to identify the procedures performed when providers submit claims to third
party payers for reimbursement for medical services. They also generally form the basis for payment amounts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Obtaining reimbursement approval for a product from
any government or other third -party payer is a time-consuming and costly process that could require us or our distributors to provide
supporting scientific, clinical and cost-effectiveness data for the use of our product to each payer. Even if a code is obtained for
a product, a third -party payer must still make coverage and payment determinations. When a payer determines that a product is eligible
for reimbursement, the payer may impose coverage limitations that preclude payment for some uses that are approved by the FDA or other
foreign regulatory authorities. We believe that the overall escalating costs of medical products and services has led to, and will continue
to lead to, increased pressures on the health care industry to reduce the costs of products and services. In addition, health care reform
measures, as well as legislative and regulatory initiatives at the federal and state levels, create significant additional uncertainties.
There can be no assurance that third party coverage and reimbursement will be available or adequate, or that future legislation, regulation,
or reimbursement policies of third -party payers will not adversely affect the demand for our products or our ability to sell these products
on a profitable basis. The unavailability or inadequacy of third -party payer coverage or reimbursement would have a material adverse
effect on our business, operating results and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>UroShield. </b>If cleared or approved by the FDA
for the U.S. market, we expect these products to be used in inpatient settings and therefore reimbursed under the Diagnosis Related Group
(DRG) or per diem reimbursement system. In addition, in an outpatient or home setting, we anticipate that these products will initially
be purchased privately until a reimbursement code is obtained. However, we believe that if we can empirically demonstrate UroShield&#8217;s
efficacy in preventing recurrent hospitals admission in chronic Foley catheter patients and reducing overall per-patient cost, third
party payers may accelerate the reimbursement approval process since the device could reduce their overall per-patient cost. We believe
the natural progression of the adoption of this technology will allow for use in the home setting. We intend to pursue reimbursement
in the Medicare Part B code to support the use for long term catheter use and infection prevention in the home.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>PainShield. </b>Effective as of January 2020,
CMS approval for Medicare reimbursement was added through code K1004. The value of the reimbursement has not yet been confirmed. We continue
to work toward a favorable reimbursement with outside legal counsel and reimbursement consultants. The most recent application for reimbursement
from CMS/Medicare was submitted on January 3, 2023, in which CMS denied reimbursement due to their request for additional longevity testing.
We are currently evaluating whether to resubmit another application to CMS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>WoundShield. </b>We believe that the initial usage
of these products, if approved or cleared by the FDA, will be in the hospital setting. Reimbursement in the hospital setting is typically
governed by the DRG system, which is a prospective payment methodology that assigns a predetermined, fixed amount based on the patient&#8217;s
diagnoses. Sanuwave Health Inc., as the licensee of this technology, is responsible to apply for such reimbursement, but has not yet
done so.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>New Product Under Development</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In 2016, we started developing a device candidate
for the facial rejuvenation market called Renooskin. Previous in vitro studies on human skin were done showing that the SAW technology
provided skin rejuvenation comparable to Retinol A which is a well-accepted anti-aging cream. We have developed a head band like applicator
for the PainShield SAW treatment and are in the process of arranging for a pilot trial with a cosmetic dermatologist and/or plastic surgeon.
We believe that, subject to proof of efficacy of the Renooskin and receiving regulatory approval, neither of which are guaranteed, the
device candidate could potentially be sold in a non-reimbursement market since cosmetic devices are private pay. We are still considering
several paths towards commercialization but such actions are limited due to the lack of financial resources available to effectively
market the technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ENvue&#8217;s Business</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ENvue is a medical device company engaged in the
research, development, production, marketing, and sale of medical devices in the field of enteral feeding and is in the initial stage
of commercializing its products. Guided by its mission to be an innovation leader in the field of enteral feeding, ENvue is focused on
improving patient outcomes across the continuum of care, encompassing the development of advanced, personalized navigation solutions,
responding to the challenges of the everchanging healthcare environment, while continuously focusing on the customer. The medical device
marketed and sold by ENvue is the FDA 510(k)-cleared ENvue System, which assists in the insertion of a feeding tube into the digestive
system of patients requiring nutrition during hospitalization through in-body navigation (the &#8220;ENvue System&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The most common way to provide nutrition to patients
during hospitalization is through a feeding tube inserted through the nose or mouth into the stomach or small intestine (known as &#8220;enteral
nutrition&#8221;). Around 43 million feeding tubes are inserted annually worldwide (Enteral feeding devices, Global forecast to 2025;
Market &amp; Markets (&#8220;Markets &amp; Markets&#8221;)). Between 2-5% of these tubes are placed in the lungs leading to a 30% chance
of a collapsed lung or possible fatality (Aguilar-Nascimento, Kudsk, JPEN J Parenter Enteral Nutr 2007; Bourgault, Margo Halm Am J Crit
Care. 2009). Furthermore, between 20-50% of hospital patients (Bellanti, Francesco, et al. &#8220;Malnutrition in hospitalized old patients:
screening and diagnosis, clinical outcomes, and management.&#8221; Nutrients 14.4 (2022): 910.), including those in the intensive care
unit (&#8220;ICU&#8221;), are malnourished, with malnutrition having a significant impact on both clinical outcomes and healthcare systems.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Recognizing the critical need for early feeding in
small bowel and lower the risk of tube misplacement, ENvue applied its expertise in electromagnetic navigation and enteral feeding to
develop the ENvue System. The ENvue System, together with a dedicated feeding tube for the system, positioning sensors, and other components
developed by ENvue, is designed to efficiently and safely insert the feeding tube into the patient&#8217;s digestive system for the purpose
of providing nutrition. Furthermore, ENvue&#8217;s solution aims to provide faster nutrition delivery to the patient, potentially improving
their condition, and facilitating the insertion of the feeding tube into the small intestine, which we believe has advantages over insertion
into the stomach. ENvue believes that the ENvue System offers an efficient solution for feeding tube insertion and has the ability to
transform enteral feeding tube insertion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2019, ENvue received 510(k) market clearance
from U.S. Food and Drug Administration for the commercial marketing and sale of the ENvue System in the United States for use in adults
(aged 22 and over)<span style="font-family: Times New Roman, Times, Serif"><sup>1</sup></span>. During the first quarter of 2020, ENvue
began marketing and selling the ENvue System and its dedicated feeding tubes, and it is currently in the initial commercialization phase
of these products in the U.S.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>ENvue Strategy</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ENVue&#8217;s mission is to be an innovation leader
in the field of enteral feeding, focusing on improving patient outcomes across the continuum of care, encompassing the development of
advanced, personalized navigation solutions, responding to the challenges of the everchanging healthcare environment, while continuously
focusing on the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ENvue&#8217;s immediate target market for the ENvue
System includes hospitals in the United States, and ENvue is in the early stages of commercializing the system in this market. As of
the date of this filing, ENvue has engagements with hospitals in the United States for the implementation of ENvue Systems and the supply
of disposable enteral feeding tubes. As part of ENvue&#8217;s strategy to introduce and implement the ENvue System in the target market,
ENvue is seeking to expand its activities in the U.S. market and focus its marketing efforts on this market, and in the future, to consider
entering additional markets, subject to obtaining the necessary approvals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>1
</sup></span>According to FDA guidelines, an adult is defined as a person who is 22 years of age or older</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2021, ENvue decided to work towards expanding
the use of its ENvue System for procedures involving the insertion of a Peripherally Inserted Central Catheter (PICC) into central blood
vessels to verify the catheter&#8217;s correct placement in the patient&#8217;s blood vessels, instead of inserting it into the patient
&#8220;blindly&#8221; and performing an X-ray to confirm the correct placement of the catheter in the blood vessels. This development
was halted as part of ENvue&#8217;s efficiency and reduction measures when it was in the early stages of building a prototype. Development
has been reinitiated after the purchase by Envizion Holdings Corp.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ENvue has another separate development in the field
of enteral nutrition, which is a feeding tube (called NGAT) that simultaneously seals the esophagus and prevents fluid passage into the
respiratory tract, designed to prevent the occurrence of gastric reflux into the esophagus (called reflux) and aspiration into the lungs.
As of the date of this filing, ENvue has registered intellectual property rights concerning this product and has obtained 510(k) clearance
for marketing the product in the United States. The NGAT received a CE mark for marketing the product in European Union countries, but
such CE mark is no longer valid, as of February 25, 2019. ENvue is currently not marketing the product, as part of its intention to focus
its marketing efforts at this stage on the ENvue System only and its implementation in the relevant target market. Therefore, at this
time, there is no certainty regarding when ENvue will begin marketing the NGAT, should it choose to do so.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>ENvue Products</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 48px">I.</td>
    <td style="text-align: justify"><span style="text-decoration: underline">Enteral Feeding - General Background</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Enteral feeding is the most common method of providing
liquid nutrition and certain types of medications to critically ill patients who are hospitalized and require nutritional support, such
as those on ventilators, post-surgery patients, patients with disabilities or conditions that prevent them from eating fully or partially,
and premature infants (Welch, Teresa D. &#8220;Nutrition options in critical care unit patients.&#8221; Critical Care Nursing Clinics
30.1 (2018): 13-27 (&#8220;Welch 2018&#8221;); Milsom, S. A., et al. &#8220;Naso-enteric tube placement: a review of methods to confirm
tip location, global applicability and requirements.&#8221; World journal of surgery 39 (2015): 2243-2252 (&#8220;Milsom 2015&#8221;);
de Aguilar-Nascimento, Jos&#233; Eduardo, and Kenneth A. Kudsk. &#8220;Use of small-bore feeding tubes: successes and failures.&#8221;
Current Opinion in Clinical Nutrition &amp; Metabolic Care 10.3 (2007): 291-296 (&#8220;de Aguilar-Nascimento and Kudsk 2007&#8221;);
Koyfman, Leonid, et al. &#8220;The Placement of Post-pyloric Feeding Tubes Using DRX-Revolution Mobile X-Ray System in an ICU. A Case
Series.&#8221; The Journal of Critical Care Medicine 2.3 (2016): 131-134). The prevalence of malnutrition among critically ill patients
ranges from 30% to 50%, with some patients arriving at the hospital already malnourished and others potentially developing malnutrition
during hospitalization (Market &amp; Markets; Barker, Lisa A., Belinda S. Gout, and Timothy C. Crowe. &#8220;Hospital malnutrition: prevalence,
identification and impact on patients and the healthcare system.&#8221; International journal of environmental research and public health
8.2 (2011): 514-527; Wischmeyer, Paul E. &#8220;Malnutrition in the acutely ill patient: is it more than just protein and energy?&#8221;
South African Journal of Clinical Nutrition 24.3 (2011): S1-S7). It should be noted that there are critically ill patients who, due to
their medical condition, are unable to receive regular nutrition for many days.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Delays in providing nutrition to patients can lead
to a deterioration in their condition, as early insertion of the feeding tube and timely provision of nutrition can, in most cases, reduce
the severity of the illness, help preserve the integrity of the intestinal lining, reduce infections and complications, improve gastrointestinal
motility, and enhance immune response (Wang, Honggang, et al. &#8220;Early enteral nutrition reduced postoperative ileus and improved
the outcomes in patients with emergency intestinal surgery: results from a propensity score analysis.&#8221; Int J Clin Exp Med 10.4
(2017): 7040-7048). Moreover, early provision of nutrition may improve the patient&#8217;s condition and recovery rate, reduce possible
complications, shorten the stay in intensive care, and even lower mortality rates (Welch 2018). Consequently, early provision of nutrition
may also result in significant cost savings for the hospital. Therefore, in cases where regular nutrition cannot be provided to the patient
and enteral feeding is required, it should be provided as soon as possible (within 24-48 hours).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Enteral nutrition is administered, among other methods,
by inserting a feeding tube through the patient&#8217;s nose or mouth into the stomach or small intestine (Tatsumi, Hiroomi. &#8220;Enteral
tolerance in critically ill patients.&#8221; Journal of intensive care 7.1 (2019): 30 (&#8220;Tatsumi 2019&#8221;)). Each year, approximately
43 million nasogastric feeding tubes are inserted worldwide (about 14 million of them in the United States) (Market &amp; Markets). In
general, according to FDA guidelines, a feeding tube inserted into a patient should not remain in place for more than 30 days. However,
hospitals tend to remove/replace the tube more frequently (for example, in cases of tube blockage due to improperly dissolved medications
or accidental disconnection of the tube by the patient).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Feeding through a tube inserted through the patient&#8217;s
nose or mouth directly into the patient&#8217;s small intestine (Post-Pyloric Feeding), where nutrients are absorbed, requires more precise
insertion of the tube, and offers several advantages over gastric feeding. Feeding directly into the small intestine may reduce the risk
of medical complications, involve a lower risk of gastric reflux and respiratory infections and complications, provide higher caloric
intake for the patient, and require a shorter stay in the intensive care unit (Welch 2018; Sajid, M. S., et al. &#8220;An integrated
systematic review and meta-analysis of published randomized controlled trials evaluating nasogastric against postpyloris (nasoduodenal
and nasojejunal) feeding in critically ill patients admitted in intensive care unit.&#8221; European journal of clinical nutrition 68.4
(2014): 424-432; Jiyong, Jing, et al. &#8220;Effect of gastric versus post-pyloric feeding on the incidence of pneumonia in critically
ill patients: observations from traditional and Bayesian random-effects meta-analysis.&#8221; Clinical Nutrition 32.1 (2013): 8-15; Tatsumi
2019. As detailed below, the ENvue System is designed to facilitate the insertion of the feeding tube through the patient&#8217;s nasal
or oral route into the stomach or directly into the small intestine with accuracy and efficiency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Limitations of Existing Alternative Enteral Feeding
Methods</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To the best of ENvue&#8217;s knowledge, the most
common method currently used for inserting feeding tubes through the nose or mouth is the &#8220;blind&#8221; method, i.e., without visibility
inside the patient&#8217;s body to facilitate accurate navigation and placement. While for many years the &#8220;blind&#8221; insertion
method was considered harmless, it has been found that this method can cause serious and even fatal complications in patients (Market
&amp; Markets). Common complications among patients with feeding tubes inserted via the &#8220;blind&#8221; method include incorrect
insertion of the tube into the respiratory tract instead of the esophagus, aspiration (entry of food, saliva, or stomach acids into the
respiratory tract), lung collapse, sinus injuries, nosebleeds, and more (Rassias, Athos J., Perry A. Ball, and Howard L. Corwin. &#8220;A
prospective study of tracheopulmonary complications associated with the placement of narrow-bore enteral feeding tubes.&#8221; Critical
Care 2 (1998): 1-4; Prabhakaran, S., et al. &#8220;Nasoenteric tube complications.&#8221; Scandinavian Journal of Surgery 101.3 (2012):
147-155 (&#8220;Prabhakaran 2012&#8221;)). According to studies, of the approximately 43 million feeding tubes inserted worldwide each
year, about 1.72 million tubes are mistakenly inserted into patients&#8217; lungs, and of these, about 40% of patients suffered from
pneumothorax (air accumulation in the chest cavity, impairing the breathing process) (de Aguilar-Nascimento, Jose Eduardo, and Kenneth
A. Kudsk. &#8220;Clinical costs of feeding tube placement.&#8221; Journal of Parenteral and Enteral Nutrition 31.4 (2007): 269-273 (&#8220;de
Aguilar-Nascimento 2007&#8221;); Burns, Suzanne M., et al. &#8220;Detection of inadvertent airway intubation during gastric tube insertion:
capnography versus a colorimetric carbon dioxide detector.&#8221; American Journal of Critical Care 15.2 (2006): 188-195). Due to the
high frequency of feeding tube use, experts believe that even a relatively small percentage of cases where the feeding tube is incorrectly
inserted could impact a very large number of people (Prabhakaran 2012).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Incorrect insertion of the feeding tube into the
lungs can have further serious consequences for the patient, including worsening of their medical condition, which could lead to medical
harm and even death, extended hospitalization, significant costs for the hospital, and legal claims (de Aguilar-Nascimento 2007; Sparks,
Dorothy A., et al. &#8220;Pulmonary complications of 9931 narrow-bore nasoenteric tubes during blind placement: a critical review.&#8221;
Journal of Parenteral and Enteral Nutrition 35.5 (2011): 625-629).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">It should be noted that due to technical failures
and the prolonged time required for blind insertion of the feeding tube, attempts to insert feeding tubes directly into the small intestine
can result in delays in providing the necessary nutrition to the patient (as mentioned above, providing early nutrition to the patient
may improve their condition and prevent medical complications).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Given the difficulties, risks, and possible complications
associated with the blind insertion method of feeding tubes, as detailed above, the duration of insertion, and the challenge of inserting
it into the small intestine using this method, there is a noticeable trend towards using alternative methods for inserting feeding tubes
using technological or other means (Koopmann, Matthew C., et al. &#8220;A team-based protocol and electromagnetic technology eliminate
feeding tube placement complications.&#8221; Annals of surgery 253.2 (2011): 297-302 (&#8220;Koopman 2011&#8221;)), instead of relying
on the blind insertion method, as detailed below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There are significant limitations in the existing
alternative methods for inserting feeding tubes into patients and the various methods used to verify that the blindly inserted feeding
tube is located in the patient&#8217;s digestive system and not in the respiratory tract, the main ones of which are detailed below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Methods for Verifying the Placement of a Blindly
Inserted Feeding Tube</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Among the primary methods are measuring the distance
of the tube from the insertion site, measuring the volume of aspirate, measuring the pH level of the liquid aspirated from the tube (to
check acidity levels to ensure it is gastric juices), checking the carbon dioxide level of the air aspirated from the tube (to ensure
the tube is not located in the lungs), and using an X-ray (fluoroscopy), with the latter generally considered more accurate than the
others (de Aguilar-Nascimento and Kudsk 2007; Milsom 2015). However, these methods may not always identify errors accurately and in a
timely manner, and they allow correction of incorrect insertion and placement of the tube in the digestive system only after it has already
been inserted into the lung, which may have caused pneumothorax or lung perforation due to the insertion of the tube into the respiratory
tract (Powers, Jan, et al. &#8220;Elimination of radiographic confirmation for small-bowel feeding tubes in critical care.&#8221; American
Journal of Critical Care 22.6 (2013): 521-527.). Furthermore, the X-ray method has additional drawbacks, such as additional technical
costs, prolonged time consumption, delayed patient nutrition, and radiation exposure. Additionally, the pH measurement method has various
limitations, such as respiratory burden and, primarily, inaccuracies due to medication or other chemical treatment that affects the acidity
level in the patient&#8217;s digestive system (Bourgault, Annette M., and Margo A. Halm. &#8220;Feeding tube placement in adults: safe
verification method for blindly inserted tubes.&#8221; American Journal of Critical Care 18.1 (2009): 73-76).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 48px">II.</td>
    <td style="text-align: justify"><span style="text-decoration: underline">The ENvue System</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The core application of ENvue&#8217;s operations
is the ENvue System, which is a system for monitoring and correctly positioning feeding tubes in patients who require nutritional support
during hospitalization. The system includes the main unit (the system body), disposable (consumable) ENvue Feeding Tubes designed exclusively
for use with the system, sensors, and additional components developed by ENvue. These components, when used together, are intended to
facilitate more efficient, faster, and safer insertion of the feeding tube into the patient&#8217;s digestive system. The system uses
electromagnetic waves transmitted to the upper torso of the patient, utilizing sensors embedded in the dedicated feeding tube and sensors
attached to the patient&#8217;s body during the procedure, enabling monitoring and control of the feeding tube&#8217;s insertion path
in an effort to facilitate proper placement into the GI tract bypassing the airways. It should be noted that using the ENvue System will
not guarantee the absence of medical errors or adverse events in connection with a feeding tube placement. For example, five serious
adverse events have been reported in connection with tubes inserted in patients&#8217; lungs or pulmonary airway using the ENvue System.
After investigation and review of placement files, ENvue believes the reported serious adverse events were caused by user error.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Product Components and Features</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The system components are described in greater detail
below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 55%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">System Body</span></i></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The system body includes several components,
    including a screen displaying the feeding tube&#8217;s position and an electromagnetic field generator mounted on an adjustable arm.
    Before inserting the feeding tube and until the procedure is complete, the generator is positioned towards the patient&#8217;s chest
    and upper abdomen, emitting low-frequency electromagnetic waves throughout the procedure (see the illustration below).</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Once the feeding tube is inserted, the passive
    electromagnetic sensor inside the tube enters the generator&#8217;s transmission area, which detects the sensor&#8217;s movement
    and displays it graphically on the screen.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Reference Sensor</span></i></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An external, reusable sensor connected to the
    system and attached to the patient&#8217;s body in the armpit area is used to reference the feeding tube&#8217;s position within
    the patient&#8217;s body at any given moment. The reference sensor allows the system to remain accurate even if the patient moves
    during the procedure (due to coughing, etc.).</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Feeding Tube (Disposable Component)</span></i></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The dedicated feeding tube developed by ENvue
    is designed specifically for use with the ENvue System and is intended for placement in the stomach or small intestine. The feeding
    tube is single-use and features a dual connection: one for the nutrition source and another for the ENvue System.</p></td>
    <td style="width: 45%; text-align: center"><img src="form10-k_007.jpg" alt=""/></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the procedure, the other end of the tube is
inserted through the nose into the patient&#8217;s body. A passive electromagnetic sensor embedded in the tube allows the tube&#8217;s
path within the patient&#8217;s body to be tracked on the system&#8217;s screen.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of now, ENvue&#8217;s feeding tube has been cleared
in three different diameters: 8 Fr., 10 Fr., and 12 Fr.<sup>3</sup></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Sans-Serif; margin: 0; text-align: center"><img src="form10-k_008.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><sup>3 </sup>Fr. 1 = 0.3 mm.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>ENvue System Usage</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The ENvue System is used as follows: Throughout the
feeding tube insertion procedure, the ENvue System emits electromagnetic waves toward the patient&#8217;s upper body. Using the reference
sensor connected to the system, the operator marks several anatomical points on the patient&#8217;s upper body and attaches an additional
location sensor to the side of the patient&#8217;s chest, allowing the system to remain accurate even when the patient moves or coughs
during the procedure. The operator then inserts the dedicated feeding tube for the system through the patient&#8217;s nose or mouth into
the esophagus and further into the digestive system (small intestine or stomach) while viewing the tube&#8217;s path on the system&#8217;s
screen from several angles and receiving real-time alerts if the system detects the tube entering the patient&#8217;s airways, which
is intended to enable the operator to immediately correct the tube&#8217;s insertion path.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To the best of ENvue&#8217;s knowledge, using the
ENvue System allows the feeding tube insertion procedure to be completed within approximately 5-30 minutes on average, depending on the
patient&#8217;s condition, the operator&#8217;s technical ability, and other factors. In comparison, the time required for blind insertion
of a feeding tube through the nose or mouth, based on ENvue&#8217;s estimate and medical research, may take about 11-60 minutes (approximately
42 minutes on average) (Smithard, David, et al. &#8220;Electromagnetic sensor-guided enteral access systems: a literature review.&#8221;
Dysphagia 30 (2015): 275-285). Additionally, research shows that the time from blind insertion of a feeding tube to the start of feeding
the patient may take several hours, partly due to the need to verify the tube&#8217;s correct placement in the digestive system using
X-rays (Gray, Rebecca, et al. &#8220;Bedside electromagnetic-guided feeding tube placement: an improvement over traditional placement
technique?&#8221; Nutrition in Clinical Practice 22.4 (2007): 436-444).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Using alternative methods as mentioned during the
use of the ENvue System is not required by the FDA and is subject to the specific hospital&#8217;s policy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For illustration purposes, below are diagrams demonstrating
the use of the ENvue System:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Transmission of electromagnetic waves by the system
to the patient&#8217;s upper body throughout the procedure</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Sans-Serif; margin: 0; text-align: center"><img src="form10-k_009.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Real-time visualization of the feeding tube&#8217;s
insertion path within the patient&#8217;s body from multiple angles</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Sans-Serif; margin: 0; text-align: center"><img src="form10-k_010.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Receiving an alert for the detection of improper
insertion of the feeding tube</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Sans-Serif; margin: 0; text-align: center"><img src="form10-k_011.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Marketing Strategy</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The system, including the dedicated feeding tubes,
is marketed to hospitals, and was designed and developed after ENvue received feedback from healthcare professionals in the United States
regarding their needs, which helped tailor the system to the market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Using the technology on which the system is based,
it monitors the precise location of the feeding tube within the patient&#8217;s body, from the moment it is inserted through the patient&#8217;s
nose or mouth until it reaches the stomach or small intestine, and displays its location in real-time through an imaging display of the
patient&#8217;s body from several different angles on a screen. The display of the patient&#8217;s body on the screen is made possible
by using a reference sensor and marking anatomical landmarks on the patient&#8217;s body at the beginning of the procedure. Additionally,
ENvue was developing a feature designed to allow the ENvue System to overlay the real-time insertion of the feeding tube on an X-ray
image of the patient&#8217;s body. ENvue began a clinical trial for this feature, which was voluntarily suspended in December 2022 due
to lack of financing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In cases where the system detects a deviation in
the tube&#8217;s path towards the patient&#8217;s trachea, an immediate alert appears on the screen. This allows the operator to correct
the feeding tube&#8217;s insertion path immediately.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As part of its operations (up until the initiation
of insolvency proceedings), ENvue has marketed the ENvue System to its customers and continuously supplied them with consumable feeding
tubes, which are designed for use exclusively with the system. At the beginning of 2020, ENvue began marketing the system and feeding
tubes to hospitals in the United States, following the FDA clearance received in February 2019 for marketing the product in this territory
for adults (aged 22 and older) only.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As part of the FDA clearance process for the system
under the 510(k) pathway, ENvue was required to conduct a clinical trial in connection with the safety alert issued by the FDA regarding
the use of the Cortrak*2 Enteral Access System, which is another device that, like the ENvue System, is intended to facilitate enteral
feeding tube placement, but was recalled in April 2022 due to serious adverse events resulting from misplaced tubes in connection with
the use of the system. During the multi-center clinical trial conducted by ENvue<sup>4</sup>, 58 feeding tube insertions were performed
on 57 patients using the system, during which no feeding tubes were ultimately placed into the patients&#8217; lungs, and no harm was
caused to the patients&#8217; lungs during the procedures. In two cases, immediate correction of the tube insertion was performed following
the system&#8217;s alert of entry into the lung. Additionally, ENvue believes the trial results indicated ease of use of the system and
quick learning of how to operate it.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The unique solution developed by ENvue as part of
the ENvue System is intended to address, among other things, the risks and costs associated with existing methods for inserting the feeding
tube into the patient and the time required until the start of feeding due to delays caused by the need to verify the tube&#8217;s placement
in the patient, as described above. Using the ENvue System, including the dedicated feeding tube developed by ENvue, it is possible to
monitor the feeding tube insertion path into the patient and receive a real-time alert if the tube is inserted into the patient&#8217;s
respiratory tract. ENvue believes the system design may allow for accurate, reliable, and efficient tube insertion for the patient and
ease of use for the operator, which could potentially reduce the time required to insert the feeding tube and thereby reducing the time
until nutrition is provided to the patient.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><sup>4 </sup>The clinical trial lasted about a year,
during which ENvue was required to obtain the consent of the patients or their family members (depending on the patient&#8217;s medical
condition) for participation in the trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, ENvue believes using the system may
minimize the risk of complications resulting from improper tube insertion and the associated costs for the hospital, as well as shorten
the patient&#8217;s hospitalization duration and prevent exposure to radiation from performing multiple X-ray examinations to verify
the tube&#8217;s placement. Furthermore, using the system screen that displays the patient&#8217;s body dimensions, ENvue believes it
is easier to properly insert the feeding tube into the patient&#8217;s small intestine on the first attempt, which, as mentioned, is
preferable to gastric tube insertion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 48px">III.</td>
    <td style="text-align: justify"><span style="text-decoration: underline">Nutriseal Nasogastric Aspiration Tube </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ENvue also has another product in the field, a tube
designed for enteral nutrition called the Nutriseal Nasogastric Aspiration Tube (NGAT). This tube employs a sealing technique to prevent
stomach acid from refluxing into the esophagus and to prevent aspiration of stomach contents into the respiratory tract. NGAT has been
cleared for marketing in the U.S. and was approved in the European Union; however, as of now, ENvue is not manufacturing or marketing
it, and the EU approval is currently not valid.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NGAT is a feeding tube developed by Nutriseal Limited
Partnership (the rights to which were transferred to ENvue shortly after its establishment in 2017. NGAT is intended to serve as an enteral
feeding tube for patients needing nutritional support and for other uses in hospitalized patients. NGAT&#8217;s uniqueness compared to
other feeding tubes lies in its sealing technique around the patient&#8217;s esophagus, which can significantly reduce the risks associated
with nasoenteral feeding (feeding through a tube inserted through the nose into the stomach or small intestine), including esophageal
reflux (the backflow of stomach acid up the esophagus) and aspiration (inhalation) of stomach contents and food particles that may enter
the lungs and cause severe health complications, including pneumonia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NGAT was developed and designed for use in various
medical procedures, such as enteral feeding, gastric lavage, and gastric decompression, while reducing the risk of esophageal reflux
or aspiration. It should be noted that NGAT, in its current version, is intended for insertion without a navigation system, but future
iterations, if any, may be able to be used as a feeding tube connected to the ENvue System for navigation during the tube insertion process,
subject to applicable FDA clearance(s). Additionally, ENvue has developed other NGAT-b components, for which, as of now, ENvue has not
submitted applications for regulatory approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Product Components and Features</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NGAT includes a feeding tube composed of a single
central internal tube for delivering nutrients into the stomach and six internal suction tubes surrounding the central internal tube
(the &#8220;internal suction tubes&#8221;). NGAT contains small openings along its length, which, after the tube is inserted into the
patient&#8217;s body, are positioned along the esophagus and release low negative air pressure, creating a suction action that causes
the esophageal walls to contract inward, forming a seal around the tube that prevents stomach fluids from refluxing into the esophagus
and aspirating refluxed stomach fluids (the &#8220;aspiration mechanism&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NGAT is designed with two sealed suction areas located
at the end of the tube inserted into the patient&#8217;s body, where stomach fluids accumulate. The internal suction tubes are divided
into two sets of three suction tubes each, with each set connected to a different suction area. The operator can regulate the suction
between the two sealed suction areas using a branched valve located at the end of the tube that remains outside the patient&#8217;s body,
allowing suction to be applied to one sealed suction area at a time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NGAT can be connected to standard hospital suction
equipment, and its use does not require special equipment. This connection enables the operation of the aspiration mechanism as well
as performing gastric lavage procedures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Marketing Strategy</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ENvue may market NGAT in the U.S. for adult treatment
only (aged 22 and above) (FDA clearance in the 510(k) pathway). NGAT also received the European Union CE Mark for marketing in EU countries,
which is not valid as of February 25, 2019, and several patents related to this product have been registered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ENvue is not manufacturing or marketing NGAT as part
of its business strategy to focus its operations and marketing efforts in the coming years on the introduction and integration of the
ENvue System into relevant markets. ENvue&#8217;s decision regarding the commercialization of NGAT will be reviewed regularly by management
and will be determined, among other factors, by the financial resources available to ENvue, the pace of ENvue System adoption in the
market, and the potential impact of various factors on ENvue&#8217;s operations (including the risk factors to which ENvue is exposed).
Therefore, there is currently no certainty regarding the timing of NGAT&#8217;s commercialization by ENvue. It should be noted that NGAT
can potentially be used with the ENvue System, subject to the necessary FDA clearance(s), and ENvue may consider integrating NGAT within
the ENvue System&#8217;s use and submitting an updated 510(k) notification to FDA if it decides to commercially manufacture and market
NGAT in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 48px">IV.</td>
    <td><span style="text-decoration: underline">New Products</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>ENvue Feeding Tube and System for Use in Children
and Preterm Infants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This is a navigation system with dedicated feeding
tubes of smaller diameters, designed for use in children and preterm infants. ENvue has completed the initial product development process
and will begin preparations for conducting a clinical trial as part of the FDA approval process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Imaging Navigation (ENvue Plus)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This development allows the integration of medical
imaging (fluoroscopy, MRI, CT) into the ENvue System, enabling real-time navigation of the feeding tube based on the patient&#8217;s
anatomical information. In January 2022, ENvue completed the product development process, and is planning to initiate a clinical trial
to assess the ENvue System&#8217;s capability to perform internal tube navigation based on a chest X-ray image.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Peripherally Inserted Central Catheter (PICC)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This is a procedure for inserting a catheter into
central blood vessels to ensure the catheter&#8217;s proper placement in the patient&#8217;s blood vessels using the electromagnetic
navigation technology of the ENvue System. This development is expected to allow ENvue System users to perform PICC insertion with electromagnetic
navigation on X-ray images, with real-time alerts from the ENvue System about incorrect catheter placement in the patient&#8217;s body.
Inserting a catheter into central blood vessels is essential for administering medications, fluids, and nutrition and for taking continuous
blood samples from hospitalized patients.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Research and Development</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From its founding, ENvue has engaged in the research
and development of the ENvue System it developed&#8212;a system based on electromagnetic navigation technology for inserting a feeding
tube. In February 2019, ENvue received FDA clearance for the commercial marketing of the product in the U.S. for adults (aged 22 and
above) only.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ENvue&#8217;s research and development activities
have been focused mainly on product development and improvements and upgrades to various components that make up the ENvue System to
develop and improve performance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 48px">I.</td>
    <td style="text-align: justify"><span style="text-decoration: underline">Research and Development Investments</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Below are details regarding ENvue&#8217;s products
in various stages of research and development:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 20%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Product/</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Development Name</b></p></td>
    <td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 14%"><b>Product Purpose</b></td>
    <td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 14%"><b>Latest Development Stage </b></td>
    <td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 14%"><b>Expected Milestones in the Next 24 Months</b></td>
    <td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 14%"><b>Upcoming Milestone</b></td>
    <td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 14%"><b>ENvue&#8217;s Estimate on Product Marketing Start Date</b></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><b>ENvue Feeding Tube and System (1)</b></td>
    <td>&#160;</td>
    <td style="text-align: justify">Feeding tube for use in children and preemies</td>
    <td>&#160;</td>
    <td style="text-align: justify">Advanced prototype</td>
    <td>&#160;</td>
    <td style="text-align: justify">Final product before submission</td>
    <td>&#160;</td>
    <td style="text-align: justify">Continued product improvement and development of a .6 Fr diameter tube</td>
    <td>&#160;</td>
    <td style="text-align: justify">N/A</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-align: justify"><b>ENvue Plus (2) True Body Navigation</b></td>
    <td>&#160;</td>
    <td style="text-align: justify">Adults - Navigation on imaging modalities</td>
    <td>&#160;</td>
    <td style="text-align: justify">Advanced prototype</td>
    <td>&#160;</td>
    <td style="text-align: justify">Final product before submission</td>
    <td>&#160;</td>
    <td style="text-align: justify">FDA clearance (510(k))</td>
    <td>&#160;</td>
    <td style="text-align: justify">N/A</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><b>Peripherally Inserted Central Catheter (3)</b></td>
    <td>&#160;</td>
    <td style="text-align: justify">Central venous catheter insertion</td>
    <td>&#160;</td>
    <td style="text-align: justify">Prototype</td>
    <td>&#160;</td>
    <td style="text-align: justify">Advanced prototype</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">N/A</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">(1)</td>
    <td style="text-align: justify"><b>ENvue Feeding Tube and System</b> - In October 2021, ENvue announced the completion of the pre-clinical
    development process for the system and feeding tube designed for use in children and preemies (in this section: the &#8220;Product
    Candidate&#8221;). Upon completing the Product Candidate&#8217;s preclinical development, ENvue began preparations to conduct a clinical
    trial as part of the process to obtain FDA approval or clearance. However, in July 2023, ENvue halted its preparations for the trial
    and paused development of the Product Candidate indefinitely. As of the date hereof, activities have not yet resumed.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">(2)</td>
    <td style="text-align: justify"><b>ENvue Plus</b> - On January 19, 2022, ENvue announced the completion of the preclinical development
    of a product candidate that is designed to enable real-time navigation of the feeding tube insertion process on the patient&#8217;s
    X-ray (in this section: the &#8220;Development&#8221;). The Development includes, among other things, software and unique algorithms
    designed to allow performing the navigation procedure of feeding tubes in patients using the ENvue System, based on an X-ray (chest
    X-ray) taken of the patient before the procedure. Subject to a number of contingencies, such as, for example, successful completion
    of one or more clinical studies and FDA clearance for the Development, ENvue planned to sell the dedicated technology underlying
    the Development to its existing and future customers as an additional product intended for use alongside the ENvue System. In December
    2022, ENvue began making arrangements to sponsor a clinical trial to test the ability of the ENvue System to perform navigation of
    a feeding tube on a chest X-ray image overlaid on the ENvue screen, which were halted due to ENvue&#8217;s financial situation. ENvue
    intends to reinitiate these activities in 2025.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">(3)</td>
    <td style="text-align: justify"><b>Peripherally Inserted Central Catheter (PICC)</b> - In November 2021, ENvue announced the goal
    of expanding the cleared uses of the ENvue System to also include procedures for inserting a catheter into central blood vessels
    (PICC) to verify the correct positioning of the catheter in the patient&#8217;s blood vessels using the electromagnetic navigation
    technology on which the ENvue System is based. Additionally, the technology underlying ENvue&#8217;s ENvue System, which ENvue believes
    may also be suitable for the procedure of inserting feeding tubes into preemies and infants (as detailed above), may allow ENvue
    to develop and use components in very small sizes (Fr 4-6) for performing PICC procedures using the ENvue System. ENvue&#8217;s ultimate
    objective for this development was to enable ENvue System users to perform PICC insertion using electromagnetic navigation on an
    X-ray, while receiving real-time alerts from the ENvue System on incorrect catheter placement in the patient&#8217;s body, which
    would effectively allow hospitals using the ENvue System to perform two procedures with the system - feeding tube insertion and PICC
    insertion in patients. As mentioned above, ENvue&#8217;s research and development activities on this development have been halted
    in connection with the insolvency proceedings.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 48px">II.</td>
    <td style="text-align: justify"><span style="text-decoration: underline">Clinical Trials</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As part of the FDA clearance process for the system
under the 510(k) pathway, ENvue was required to conduct a clinical trial following the safety alert issued by the FDA regarding the use
of the Cortrak*2 Enteral Access System, which is another device that, like the ENvue System, is intended to facilitate enteral feeding
tube placement, but was recalled due to serious adverse events resulting from misplaced tubes in connection with the use of the system.
During the clinical trial conducted by ENvue<span style="font-family: Times New Roman, Times, Serif"><sup>2</sup></span>, 58 feeding
tube insertions were performed on 57 subjects using the system, during which no feeding tubes were ultimately placed into the patient&#8217;s
lung, and no harm was caused to the patient&#8217;s lung during the procedure. In two cases, immediate correction of the tube insertion
was performed following the system&#8217;s alert of entry into the airways. Additionally, ENvue believes the trial results indicated
ease of use of the system and quick learning of how to operate it.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>ENvue Customers</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ENvue&#8217;s current and potential customers are
hospitals in the U.S. As of 2023, there are approximately 5,222 hospitals in the U.S. that operate intensive care units, which constitute
the majority of ENvue&#8217;s potential customers (Fast Facts on U.S. Hospitals, 2024. American Hospital Association. https://www.aha.org/statistics/fast-facts-us-hospitals).
The primary users of ENvue&#8217;s products in these locations are medical staff, usually nurses and clinical dietitians. As of the date
hereof, ENvue&#8217;s customers include both hospitals in the U.S. with which ENvue has signed direct sales agreements and hospitals
within the hospital network with which ENvue has contracted under the agreement detailed below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ENvue is in the stage of commercializing its products,
and its sales activities in the U.S. were conducted directly with end customers. As part of ENvue&#8217;s strategy to introduce the ENvue
System into the U.S. market and expand its marketing efforts, ENvue may, in the future, consider partnering with a distributor or strategic
marketer, in addition to direct sales to customers in the U.S.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2022, ENvue entered into an exclusive distribution
agreement with an Israeli distribution company for the marketing and sale of its products to end customers in Israel.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The use of the ENvue System requires training. According
to the regulatory clearance granted to the ENvue System by the FDA, users of the system are required to undergo training provided by
ENvue using a training model developed by ENvue for system users. The training is usually provided in a concentrated manner to system
users on behalf of the hospital, lasts approximately 5 days, and includes both theoretical and practical components regarding the system
and its use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In general, at large hospitals in the U.S., centralized
procurement departments are responsible for the proposal submission process, contracting, and negotiations for the purchase of all capital
equipment. These departments emphasize economical and efficient operations. Typically, a hospital procurement department consists of
a procurement manager overseeing a team of senior and junior buyers. The process of purchasing medical systems usually begins with the
establishment of a Value Analysis Committee in the hospital, typically composed of physicians, nurses, procurement agents, professional
liability experts, supply chain management, and administrators. The committee coordinates discussions with suppliers, visits sites where
the systems are operated, and consults with colleagues from other hospitals. The main factors considered by the procurement committee
include (a) the hospital&#8217;s requirements based on a five-year forecast of patient needs (investment horizon may vary between hospitals);
(b) life cycle cost &#8211; total ownership cost; (c) economic considerations of cost recovery (cost versus revenue); (d) performance,
technical specifications, and physical data of the system; (e) workflow &#8211; capabilities, staff, and output; (f) service, spare parts,
and maintenance; (g) medical staff recommendations (quality of care).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ENvue is not dependent on a single customer. The
4 customers comprise 18.6% of ENvue&#8217;s revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>2
</sup></span>The clinical trial lasted about a year, during which the Company was required to obtain the consent of the patients or their
family members (depending on the patient&#8217;s medical condition) for participation in the trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Description of Key Terms of Engagement with End
Customers</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ENvue&#8217;s agreements with its customers for the
supply of the single-use-only ENvizion Medical Enteral Feeding Tubes (EFTs) based on purchase orders placed by the customer according
to their needs, under terms outlined below. It should be noted that ENvue&#8217;s EFT is specifically designed for use with the ENvue
System. Per the FDA clearance for the ENvue System, which includes ENvue&#8217;s EFT, the system cannot be used without this tube.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Negotiations with ENvue&#8217;s customers are usually
conducted by ENvue&#8217;s sales agents, following meetings with hospital procurement officials and a demonstration (Demo) of the system,
as well as evaluation by the medical staff through a few procedures of feeding tube insertion in patients. Based on ENvue&#8217;s experience
so far, the time from the demo to the receipt of a purchase order (PO) can take up to 6 months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under ENvue&#8217;s agreements with customers for
the purchase of the ENvue System, ENvue commits to manufacture, assemble, and supply the system components to the customer according
to schedules agreed upon by both parties for each engagement. Generally, the system is delivered to the customer within a few weeks,
and the feeding tubes are supplied within approximately one week from the customer&#8217;s purchase order.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In general, the consideration paid by the customer
for the purchase of the system and feeding tubes is determined through negotiation between the parties and according to ENvue&#8217;s
discretion. Payment for the supply of the system and feeding tubes is typically made within 30 days of delivery, according to the specific
engagement terms. It should be noted that in some cases, ENvue may provide the system to the customer in exchange for replacing a competitor&#8217;s
product owned by the customer, without any financial consideration (except for the payment the customer will be required to make for
the purchase of feeding tubes specifically for the system). The replaced competitor&#8217;s product is used by ENvue, among other things,
for training sessions it conducts for its customers on using the ENvue System instead of the competitor&#8217;s product, as well as for
ENvue&#8217;s research and development purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As part of the agreement with the customer for the
system supply, ENvue commits to provide the hospital staff with initial training on the system and its operation, as well as additional
training on updates and developments in the product, if any, and commits to provide maintenance services for the system if necessary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The agreement typically includes warranty periods
for the system and the consumable feeding tubes, for periods defined in the agreement (generally two years for the system and 30 days
for the feeding tubes), during which ENvue commits to provide repair or replacement services for defective components (defects) related
to components manufactured by ENvue, within a timeframe agreed upon by the parties and according to other terms set forth in the agreement.
During the warranty period, ENvue may provide the customer with any necessary software and/or hardware updates for the system, if any
is needed for use of the system. In general, ENvue does not have a refund policy for its products in most agreements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the agreement with the customer, it is generally
agreed that under certain conditions, ENvue will be liable for damages caused to the customer due to the use of the system (whether during
the warranty period or outside it), up to the amount paid by the customer for the products purchased from ENvue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, the terms of engagement with the customer
include standard cancellation clauses in appropriate circumstances (such as a material breach of the agreement, company insolvency, etc.).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As mentioned, customers who have purchased the ENvue
System place ad-hoc orders with ENvue for the purchase of consumable feeding tubes, according to the engagement terms outlined above.
Customers issue a purchase order to ENvue, and in response, ENvue ships the products, typically within a week. These orders are made
according to the customer&#8217;s needs and generally on a monthly basis, with the consideration determined by the price of the feeding
tube agreed upon by the parties within the agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>EnVue Sales and Marketing</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Until the suspension of marketing activities, which
resumed in July 2024, ENvue worked to build awareness of its products among hospitals and the U.S. medical community in several ways,
the main ones being detailed below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td style="text-align: justify"><b><i>Conducting Demonstrations for Potential Customers</i></b>: As part of ENvue&#8217;s marketing
    activities, ENvue&#8217;s sales agents periodically meet with hospital procurement officials, demonstrate (Demo) the system, and
    allow the medical staff to experience the system through several procedures of feeding tube insertion in patients.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td style="text-align: justify"><b><i>Engagements with Group Purchasing Organizations (GPOs)</i></b>: A GPO is an entity that helps
    healthcare providers, such as hospitals, nursing homes, and home health agencies, achieve savings and efficiency by aggregating purchasing
    volume and leveraging that to negotiate discounts with manufacturers, distributors, and suppliers. ENvue believes that if it enters
    into agreements with such organizations, it will allow for broader market penetration in relatively short timeframes.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td style="text-align: justify"><b><i>Website and Social Media</i></b>: ENvue&#8217;s website provides information about ENvue and
    ways to contact it. Additionally, ENvue operates several social media accounts, which include details about ENvue and its products,
    regular updates related to ENvue&#8217;s field of activity, and the medical device market.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td style="text-align: justify"><b><i>Press Releases and Public Relations</i></b>: ENvue publishes press releases related to agreements
    it has signed, new system deployments, regulatory approvals received, and relevant milestones, such as significant capital and debt
    raisings. The announcements published so far have generated media interest and have been covered in commercial media, national media,
    and technology publications.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td style="text-align: justify"><b><i>Participation in Events and Conferences</i></b>: ENvue participates in selected events in the
    healthcare and technology industries to meet with influencers and decision-makers in the field.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ENvue believes it is not dependent on any of its
marketing channels.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>ENvue Market Opportunity and Trends</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 48px">I.</td>
    <td style="text-align: justify"><span style="text-decoration: underline">Use of Enteral Nutrition Means </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ENvue operates in the market for enteral feeding
devices for hospitalized patients needing nutritional support. The importance and use of enteral nutrition means have been increasing
over the last decade, partly due to their many advantages compared to traditional nutrition methods in the market, such as parenteral
nutrition (intravenous nutrition). Currently, enteral nutrition methods are widely used in many countries worldwide. As of 2023, most
enteral nutrition use was in North America (32.0%), Europe (29.0%), and Asia (24.0%) (&#8220;Enteral Feeding Formulas Markt Size, Share,
and Trends 2025 to 2034&#8221;; available at: https://www.precedenceresearch.com/enteral-feeding-formulas-market).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Sans-Serif; margin: 0; text-align: center"><img src="form10-k_012.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The global enteral feeding devices market size was
valued at $4.3 billion in 2023 (Enteral Feeding Devices Market Trends; Grand View Research; available at: https://www.grandviewresearch.com/industry-analysis/enteral-feeding-devices-industry
&#8220;Grand View Research&#8221;) (of which about $2.84 billion was in the USA) (U.S. Enteral Nutrition Products Market Size, Share
&amp; Industry Analysis; Fortune Business Insights; available at: https://www.fortunebusinessinsights.com/u-s-enteral-nutrition-products-market-110143).
It is estimated that the market will grow at an annual rate (CAGR) (hereinafter: the &#8220;Growth Rate&#8221;) of approximately 5.0%
(about 4.4% in the USA) from 2024 to 2030, with the total market value expected to reach approximately $5.9 billion by 2030 (Grand View
Research).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Several factors may drive the growth of the enteral
nutrition market from 2024 to 2030, including rising healthcare costs, the increase in preterm births, aging populations, the growing
prevalence of chronic diseases such as diabetes, cancer, gastrointestinal diseases, and neurological disorders, the increasing awareness
of tube feeding, and improvements in healthcare systems in developing countries, among others.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">However, various factors, such as health risks, an
increase in the number of malfunctions during patient feeding, and complications related to tube feeding (such as faulty connections,
tube disconnections, and infections), may limit the market&#8217;s growth. Additionally, incomplete or no insurance coverage for using
these means in countries where it is required (mainly developing countries), as well as a lack of skilled medical personnel, are challenges
to market growth.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Furthermore, the rapid spread of the COVID-19 virus
worldwide, especially the increase in morbidity in the USA, heightened the need to improve patient nutrition, leading to increased demand
for nasal enteral feeding means.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In 2023, hospitals were the primary users of enteral
nutrition means (approximately 58.3% of global usage) (Grand View Research). The reasons for this include the technological advancements
of existing tube feeding methods, alongside the shift from intravenous nutrition to tube feeding, which supports the growing use of these
means in hospitals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The adult age group segment dominated the market
with a revenue share of 91.3% in 2023 (Grand View Research). Projections indicate that in the USA, this population is expected to remain
the primary group using enteral nutrition means, with an expected growth rate of approximately 6.7% from 2020 to 2025 and a market value
of approximately $3.9 billion by 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 48px">II.</td>
    <td style="text-align: justify"><span style="text-decoration: underline">The Use of Enteral Feeding Tubes</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Among all enteral feeding methods, the market value
of feeding tubes is the most dominant (approximately 45% in 2020). The use of enteral feeding tubes includes, among other things, the
insertion of an enteral feeding tube through the nose or mouth, as can be done using ENvue System. It should be noted that most feeding
tubes inserted through the mouth are intended for children and preterm infants. The ENvue System is only cleared for use in adults, but
ENvue believes that such clearance could potentially be expanded to include children and preterm infants if ENvue is able to initiate
and complete appropriately designed clinical studies that meet the endpoints necessary to demonstrate that the system and its EFTs can
be safely and effectively used in children and preterm infants and obtain the requisite FDA clearance for such use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">According to studies, approximately 43 million feeding
tubes are inserted annually worldwide (Markets &amp; Markets) through the nose, primarily in North America (approximately 35%), Europe
(approximately 28%), and Asia (approximately 24%), with an expected annual growth rate of approximately 5.5%, 5.9%, and 9.1%, respectively,
between 2020-2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Public Awareness</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In recent years, there has been a growing trend in
public awareness in Western countries, including the USA, regarding the importance of using aids to ensure the proper insertion of feeding
tubes into patients. This is mainly due to the increased awareness of the risks associated with current insertion methods, such as patient
lung injury, which can lead to lung collapse and even death. ENvue estimates that this trend may increase the demand for its product
in these countries due to its importance in minimizing the risks associated with feeding tube insertion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Awareness in the Medical Community</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The medical community&#8217;s awareness of performing
the feeding tube insertion procedure using ENvue&#8217;s product and the medical community&#8217;s adoption of the solution offered by
ENvue, instead of other methods and products in the market for performing the procedure, is significant and crucial for ENvue&#8217;s
success. Therefore, ENvue works with medical professionals in the USA to raise awareness among the medical community. Additionally, ENvue
works to raise awareness in this market, including through appearances at medical conferences, exhibitions, participation, and conducting
clinical studies for marketing purposes, as well as using various digital means.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Another development in the general environment in
which ENvue operates is the increasing use of the internet by medical professionals to obtain information on new technologies and alternatives
to existing methods for performing various medical procedures. Accordingly, ENvue works to deepen public awareness and awareness among
the medical community of the use of ENvue&#8217;s product as an alternative to existing methods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Medical studies published in recent years regarding
the risks associated with the use of existing methods for feeding tube insertion (mainly the &#8220;blind&#8221; insertion method), as
well as future studies on the subject, if published, may increase or decrease the demand for ENvue&#8217;s product in the field in which
it operates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In this context, it should be noted that the Patient
Safety Movement organization<sup>6</sup> published an article regarding the complications and risks associated with the insertion of
feeding tubes into patients, including ways to cope, guidelines, and recommendations for implementation by hospital staff. The article
emphasized the importance of proper feeding tube insertion in patients and identifying incorrect tube insertion to ensure patient safety
and the quality of medical care provided in the hospital, while reducing risks and preventing preventable damage. The article outlines,
among other things, guidelines, and actions to be taken by hospital medical staff to ensure proper placement of feeding tubes in the
patient&#8217;s body, including the limitations and risks associated with existing methods and technologies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><sup>6</sup></td>
    <td style="text-align: justify">The Patient Safety Movement Organization is an American organization consisting of medical professionals
    from around the world, with the goal of preventing deaths caused by errors during hospital treatments. See the link:</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 48px">III.</td>
    <td style="text-align: justify"><span style="text-decoration: underline">Entry Barries to the Target Market </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ENvue estimates that there are significant entry
barriers to the target market in which it operates. The main barriers to entry in ENvue&#8217;s field of activity are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td style="text-align: justify"><b><i>Scientifically and Clinically Proven Technological Development</i></b> - Pre-clinical and clinical
    work, which are usually essential conditions for marketing a medical product, as well as the ability to ensure that a product that
    appears promising from a technological perspective proves successful in the medical community, involve uncertainty, and create an
    entry barrier for competitors.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td style="text-align: justify"><b><i>Regulatory Constraints</i> - </b>The development, production, and sale of medical devices in
    the field typically require obtaining regulatory approvals and meeting various standards depending on the country where the relevant
    activity is conducted, including approvals required for conducting clinical trials in humans. A company that seeks to sell its products
    in a country where it does not have approval for sale will often be required to invest significant resources, both time and money,
    to obtain the approval and the preliminary processes. A company that is seeking to obtain similar regulatory approval or clearance
    to ENvue&#8217;s products or product candidates, will need to meet the same or similar requirements and conditions that ENvue was
    required to meet, which may include conducting a clinical trial, as ENvue was required to do to obtain FDA clearance under the 510(k)
    pathway for the commercial marketing of the ENvue System in the U.S.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td style="text-align: justify"><b><i>Intellectual Property Protection</i></b> - Products in the field are based on original technologies
    protected by patents or other intellectual property rights in various countries. Intellectual property protections may prevent similar
    products from being marketed in relevant countries for an extended period, potentially even decades.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td style="text-align: justify"><b><i>Initial Capital and Knowledge</i> - </b>The development of products or processes in the field
    requires significant initial capital, appropriate knowledge, and expertise. A product development project like ENvue&#8217;s products
    takes several years and requires extensive clinical, biological, physiological, and chemical knowledge. A lack of funding or the
    required knowledge and expertise to conduct the research and development could lead to the failure of the product&#8217;s development.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td style="text-align: justify"><b><i>Skilled Workforce</i></b> - Developing, licensing, and producing products in the field requires
    professional and skilled personnel. A company entering the field must recruit suitable personnel, and it may struggle to do so due
    to a lack of sufficient skilled and professional workers.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td style="text-align: justify"><b><i>Technological Risk</i> - </b>Entering the field involves the risk that after significant investment
    of money and time, the developing company may fail in developing the products, producing them, or obtaining the necessary approvals.
    Additionally, there is a risk that during or after the completion of the development and licensing processes, it may become apparent
    that a competitor of the developing company has developed a superior technology, giving them a competitive advantage.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td style="text-align: justify"><b><i>Marketing, Distribution, and Sales Capabilities</i> - </b>Companies operating in ENvue&#8217;s
    field of activity are required to establish, finance, and maintain a sales and marketing infrastructure, whether through an internal
    team or by engaging with external distributors. Each of the above options requires special and individual resources and connections
    in the field of activity, which constitutes a barrier to entry for competitors. Additionally, there is a need for suitable marketing
    and distribution channels to handle institutional bodies such as hospitals, which can compete against large companies operating in
    the field of ENvue&#8217;s products.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td style="text-align: justify"><b><i>Rate of Market Penetration</i> - </b>Penetrating the target market in the field of activity
    requires a long time, partly due to the entry barriers described above.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">https://patientsafetymovement.org/clinical/enteral-tube-safety/enteral-tube-safety-nasogastric-tube-ngt-placement-and-verification
And also: https://patientsafetyj.com/index.php/patientsaf/article/view/misplaced-nasogastric-tubes/219</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Competition for ENvue System</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ENvue industry is competitive and has been evolving
rapidly with the introduction of new products and technologies as well as the market activities of industry participants. The ENvue System
is indicated for use in adults 22 and over years of age to aid qualified operators in the placement of the ENvizion Medical Enteral Feeding
Tube of 8 Fr, 10 Fr, and 12 Fr into the stomach or small intestine of adult patients requiring enteral feeding. ENvue competes against
other companies that have developed similar devices in the market for enteral feeding devices for hospitalized patients needing nutritional
support.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In order to address the potential risks and complications
associated with the &#8220;blind&#8221; insertion method of feeding tubes and the drawbacks of standard methods for verifying the placement
of the feeding tube, several products have been developed over the years using technological tools to enable real-time monitoring of
the feeding tube&#8217;s placement within the patient&#8217;s body. Based on ENvue&#8217;s knowledge of the current landscape, there
are two technological products on the market intended for use(s) similar to that of the ENvue System: &#8220;IRIS Kangaroo Feeding Tube&#8221;
(&#8220;IRIS Kangaroo&#8221;) and &#8220;Cortrak 2 Enteral Access System&#8221; device (&#8220;Cortrak&#8221;). In addition, there are
companies at various stages of developing feeding tubes with different insertion methods that do not rely on intrabody navigation, and
as of the date of this filing, ENvue does not consider them part of its main competitors in the field of activity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 18%; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="width: 2%; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 28%; text-align: center"><span style="font-size: 10pt"><b>ENvue System</b></span></td>
    <td style="width: 2%; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 24%; text-align: center"><b>IRIS Kangaroo Feeding Tube</b></td>
    <td style="width: 2%; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 24%; text-align: center"><b>Cortrak 2 Enteral Access System</b></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">ENvue</td>
    <td>&#160;</td>
    <td style="text-align: justify">Cardinal Health</td>
    <td>&#160;</td>
    <td style="text-align: justify">Avanos Medical<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>3</sup></span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-align: justify"><b>Product Features and Usage</b></td>
    <td>&#160;</td>
    <td style="text-align: justify">A navigation system based on electromagnetic technology used to assist in the efficient, safe, and
    quick insertion of a dedicated feeding tube into patients, with real-time tracking of the tube&#8217;s insertion path and immediate
    alerts for incorrect insertion paths.</td>
    <td>&#160;</td>
    <td style="text-align: justify">A feeding tube with an optical fiber and a 3mm camera at the end, designed to assist the medical
    team in navigating the insertion path of the feeding tube into the patient&#8217;s stomach and then to the small intestine. The product
    has been in use since 2014.</td>
    <td>&#160;</td>
    <td style="text-align: justify">A feeding tube with an electromagnetic component installed at the end, which emits electromagnetic
    waves to a device placed on the patient, located in the Xiphoid Process area. This device receives the waves and displays the tube&#8217;s
    position on a monitor. The product has been in use for 15 years.</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-align: justify"><b>Market Share, to the best of ENvue&#8217;s knowledge</b></td>
    <td>&#160;</td>
    <td style="text-align: justify">Unknown</td>
    <td>&#160;</td>
    <td style="text-align: justify">Unknown</td>
    <td>&#160;</td>
    <td style="text-align: justify">Unknown</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">IRIS Kangaroo is a product that uses a camera attached
to the feeding tube. To the best of ENvue&#8217;s knowledge, inserting a feeding tube using this method has several limitations related
to the image quality inside the patient&#8217;s body, which makes it difficult to identify the tube&#8217;s location, and the need for
it to be operated by a specialist doctor in the field of gastroenterology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The second product, Cortrak, is based on electromagnetic
technology. This device displays the feeding tube insertion path in real-time and allows the operator to navigate the tube into the digestive
system. Preliminary studies have shown that inserting a feeding tube in this way may reduce the need for X-rays (Hemington-Gorse, S.
J., et al. &#8220;The use of the Cortrak Enteral Access System&#8482; for post-pyloric (PP) feeding tube placement in a Burns Intensive
Care Unit.&#8221; Burns 37.2 (2011): 277-280; Koopmann 2011). To the best of ENvue&#8217;s knowledge, the ENvue System is technologically
distinct from the Cortrak device in several respects, including: (1) performing a registration to the patient&#8217;s body that allows
for the display of the patient-specific chest contour according to individual dimensions on the system screen; (2) providing a graphical
and textual alert for feeding tube entry into the patient&#8217;s airway; (3) using the patient&#8217;s anatomical landmarks for the
navigation process; (4) additional sensors that enable accurate insertion of the feeding tube even if the patient moves (without the
need to place a device on the patient&#8217;s body); (5) a sensor embedded within the feeding tube; (6) three simultaneous vies; and
(7) responsive real time display of the tube tip pathway (40 image per second refresh rate) and more.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>3
</sup></span>To the best of ENvue&#8217;s knowledge, Avanos Medical acquired the product in 2016.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Further, in recent years, reports have been received
of incorrect insertion of feeding tubes using Cortrak device, and in January 2018, the FDA issued a Safety Alert<span style="font-family: Times New Roman, Times, Serif"><sup>4
</sup></span>following reports of cases where feeding tubes inserted using the Cortrak device were inserted into the lungs, despite the
device indicating placement in the stomach. Among these, dozens of cases of pneumothorax and deaths were reported, which may be associated
with the use of the device.<span style="font-family: Times New Roman, Times, Serif"><sup>5</sup></span> As part of the aforementioned
Safety Alert, the FDA published recommendations regarding the use of the Cortrak device, including that the feeding tube placement shown
by the device should not be relied upon exclusively. This Safety Alert highlights the need for improved technology to ensure the safety
and effectiveness of the feeding tube insertion procedure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">It should be noted that the safety alert published
by the FDA does not prohibit the sale and use of the Cortrak device. However, according to the FDA&#8217;s recommendations, the device&#8217;s
marketers were required, among other things, to adapt the user training model for the device, which is under active FDA supervision,
and this may affect the demand for the device and its adoption by hospitals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, on April 7, 2022, the FDA announced
that Avanos Medical issued a recall for the Cortrak device. According to the FDA&#8217;s announcement, the recall was due to Avanos Medical
reporting dozens of injury cases and 23 deaths resulting from misplaced feeding tubes in patients when the Cortrak device was used to
help with placement. The FDA classified the recall as Class I, the most serious type in this context, and noted that incorrect placement
of nasogastric or nasoenteric tubes could lead to serious injury or death. ENvue believes that the recall may have a positive impact
on ENvue&#8217;s operations since its products serve as a direct substitute for the Cortrak device.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The prices of feeding tubes inserted by the &#8220;blind&#8221;
method are lower than ENvue&#8217;s feeding tubes. However, as mentioned above, their use involves additional medical risks and complications
for the patient, which may impose significant costs on the hospital. Additionally, in general, the prices of the Cortrak device and the
feeding tubes used with the Cortrak device are in the same range as ENvue&#8217;s ENvue System and its feeding tubes. The prices of the
IRIS Kangaroo Feeding Tube are higher than ENvue&#8217;s feeding tubes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>ENvue&#8217;s Main Strategies for Dealing with
Competition</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">EnVue has historically dealt with competition in
its market by differentiating and developing the technology of its products, developing a training model for customers, investing in
the deployment of a service sales network, and an effective marketing strategy. Additionally, EnVue worked to protect its intellectual
property by registering its intellectual property rights in countries where it identifies potential activities, in order to maintain
the competitive advantage of its products in the field of activity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">EnVue estimates that the ENvue System it developed
provides it with a competitive advantage over other products available in the market, as well as the quality of the products and services
it provides, and its intellectual property protected by patents. The factors strengthening ENvue&#8217;s competitive position are described
in further detail below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">(1)</td>
    <td style="text-align: justify"><b>Technological Capability and Unique Operating Method of ENvue&#8217;s Product:</b> The ENvue System
    has an advantage over competing products by providing a stable real-time image of the patient&#8217;s body, regardless of patient
    and/or device movements. It also does not require special expertise and can be operated by a trained care provider. These advantages
    pose a challenge for competitors who struggle to achieve the same level of reliability and stability in products and services in
    the field of activity, including the unique and effective electromagnetic navigation method, which is partly patented.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>4
</sup></span>U.S. Food and Drugs Administration: https://www.fda.gov/medical-devices/letters-health-care-providers/feeding-tube-placement-systems-letter-health-care-providers</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>5
</sup></span>It should be noted that, to the best of ENvue&#8217;s knowledge, based on public sources, from 2017 to December 2020, there
were reports of 122 cases of feeding tubes being inserted into the lungs using the Cortrak device, of which 12 cases resulted in death,
which may be associated with its use (see: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/search.CFM).</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">(2)</td>
    <td style="text-align: justify"><b>Significant Technological Improvement Compared to Existing Methods:</b> To the best of ENvue&#8217;s
    knowledge, its product offers a technological improvement compared to other widely used methods in the field of activity, which is
    reflected in reducing the risks associated with inserting a feeding tube using alternative methods and devices. The product was tested,
    among other things, in a clinical trial conducted by ENvue and is regularly used by ENvue&#8217;s customers.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">(3)</td>
    <td style="text-align: justify"><b>Skilled and Experienced Workforce:</b> Prior to the opening of insolvency proceedings, ENvue employed
    workers and managers with technological, managerial, commercial, and operational expertise, supporting the creation of technological
    solutions in the field of enteral feeding, sales processes, and commercialization of ENvue&#8217;s products, managing production,
    and planning a supply chain that allows for rapid and reliable growth.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">(4)</td>
    <td style="text-align: justify"><b>Intellectual Property:</b> Some of ENvue&#8217;s developments and their operation are patented
    in a wide range of countries, including Israel, the U.S., Europe, China, and Japan. ENvue also owns registered trademarks in the
    U.S., Europe, and China.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Intellectual Property</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Intellectual Property Related to Nano OpCo&#8217;s
Business</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Stemming from a combination of patent, copyright,
trademark and trade secret laws, as well as non-disclosure agreements and other contracts, our intellectual property rights represent
a vital resource to the management of our company. Therefore, we are continuing our practice of investing in obtaining appropriate legal
protection for our innovations whenever possible and have adopted a more fully integrative approach to the management of our intellectual
property that mutually aligns with our ongoing R&amp;D strategies, commercial opportunities based on market analyses, and longer-term
business objectives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">From our patented technologies
to our trademarked brands, we believe our intellectual property has substantial value and has significantly contributed to our success
to date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">From our patented technologies
to our trademarked brands, we believe our intellectual property has substantial value and has significantly contributed to our success
to date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 48px">I.</td>
    <td style="text-align: justify"><span style="text-decoration: underline">Patents</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We seek patent protection for our inventions not
only to differentiate our products and technologies, but also to develop opportunities for licensing and securing our rights to profits
therefrom. With the aim of optimizing commercial and regulatory success, our proprietary technology and innovative applications thereof
are protected by a variety of patent claims. We believe that our granted patents and pending applications collectively protect our technology,
both in terms of our existing products, as well as our anticipated pipeline of new offerings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Our patent portfolio includes
at least the following issued patents, as well as a number of corresponding foreign patents in relevant jurisdictions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white">(1) U.S. Patent
No. 7,829,029 to &#8220;Acoustic Add-On Device for Biofilm Prevention in Urinary Catheter&#8221; (expiring on August 28, 2029). Foreign
counterparts include: European Patent No. 1998834 B1, and Chinese Patent No. CN 101616707 B.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white">(2) U.S. Patent
No. 9,028,748 to &#8220;System and Method for Surface Acoustic Wave Treatment of Medical Devices&#8221; (expiring on July 11, 2030);
and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white">(3) U.S. Patent
No. 9,585,977 directed to &#8220;System and Method for Surface Acoustic Waves Treatment of Skin&#8221; (expiring on August 20, 2033).
Foreign counterparts include: European Patent No. EP 1991129 B1, Chinese Patent No. CN 101431940 B, and Israeli Patent No. 193600.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white">&#160;</p>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">These patents are directed
to our proprietary surface acoustic wave (SAW) technology, including our commercialized PAINSHIELD, PAINSHIELD PLUS, WOUNDSHIELD and
UROSHIELD devices. Specifically, the patents provide for methods of generating SAW on surfaces of indwelling medical devices and to topical
and urological applications therefor, for alleviating pain and for wound healing, and for preventing formation of bacterial biofilms
on catheters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In addition to the above
patents, our pending patent applications are representative of our ongoing efforts to broaden our portfolio as we continue to develop
new applications for our ultrasound technology. Pending patent applications related to UROSHIELD devices are directed to <i>Multiple
Frequency Surface Acoustic Waves for Internal Medical Device</i> and <i>System, Device, and Method for Mitigating Bacterial Biofilms
Associated with Indwelling Medical Devices</i>, PCT application (PCT/US2024/018759). This patent application covers the next generation
of UROSHIELD devices operating at multiple frequencies and devices which are compatible in portable and wireless systems.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Pending patent applications
related to PAINSHIELD, PAINSHIELD PLUS, WOUNDSHIELD devices are directed to <i>Transdermal Patch of a Portable Ultrasound-Generating
System for Improved Delivery of Therapeutic Agents and Associated Methods of Treatment</i> and <i>Portable Ultrasound System and Methods
of Treating Facial Skin by Application of Surface Acoustic Waves</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Although not yet granted,
the aim of our growing number of patent applications is to secure our rights within additional industry sectors we foresee as most readily
benefiting from our technology. Therefore, looking beyond just pain management and urology, our patent applications relate to, <i>inter
alia:</i> novel transdermal patches uniquely configured to work with our ultrasound technology to additionally provide for improved absorption
and transdermal delivery of therapeutic agents during treatment; cosmetic applications of our ultrasound technology to provide anti-aging
benefits; and certain new or improved stand-alone therapeutic medical devices or so-called &#8220;indwelling medical devices&#8221; (e.g.,
catheters, intravenous (IV) needle assemblies, and percutaneous endoscopic gastronomy (PEG) tubes) that include our SAW-generating technology
to provide the accompanying antimicrobial effect for preventing infections typically associated with available indwelling devices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We intend to further grow our patent portfolio by
continuing to patent new technology as it is developed, to defend intellectual property as we believe necessary by actively pursuing
any infringements, to pursue commercial opportunities our patents provide for our innovations, and to continue to develop our brands
and trademarks.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 48px">II.</td>
    <td style="text-align: justify"><span style="text-decoration: underline">Trademarks</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to patent protection, we own numerous
registered trademarks for our commercialized WOUNDSHIELD (in the U.S. and Canada), NanoVibronix (in the U.S. and Canada), WOUNDSHIELD
(in the U.S. and Canada), PAINSHIELD (in the U.S. and Canada), and UROSHIELD (in the U.S.). Generally, the protection afforded by trademarks
is perpetual, subject to paying timely renewals and continuing proper use in commerce. In addition to the above, we expect to pursue
additional trademark registrations to the extent we believe they would be beneficial and cost-effective.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 48px">III.</td>
    <td style="text-align: justify"><span style="text-decoration: underline">Other Rights </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We regularly enter into,
and rely on, confidentiality and proprietary rights agreements with our employees, consultants, contractors and business partners to
protect our trade secrets, proprietary technology and other confidential information. We control the use of our proprietary technology
through relevant provisions, notifications, and disclaimers provided on our website, our customer terms of use, and our vendor terms
and conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Intellectual Property Related to ENvue Business</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In connection with the insolvency
proceedings, the court has approved the proposal by Alpha Capital Anstalt (a creditor of ENvue) to purchase all ENvue&#8217;s activities
and the proposal by Xperto to acquire the public shell, subject to the fulfillment of conditions precedent. Accordingly, subject to the
approval of the creditors&#8217; settlement by the court, all ENvue&#8217;s intangible assets are expected to be transferred to the ownership
of Alpha Capital Anstalt. It should be noted that as part of the loan agreement between the ENvue and Alpha Capital Anstalt from September
2023, ENvue pledged all its intellectual property assets to secure its obligations towards Alpha Capital Anstalt under the loan agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Below is a brief overview
of the status of ENvue&#8217;s main intellectual property assets as of February 6, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 48px">I.</td>
    <td style="text-align: justify"><span style="text-decoration: underline">Patents</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">ENvue regularly protects
its intellectual property rights by filing patent applications in its main target market - the USA - as well as in the main potential
target markets for its future activities. Generally, the lifespan of these patents, is 20 years from the earliest non-provisional patent
filing date. These anticipated expiration dates are without taking into account any and all possible patent term adjustments, extensions,
or abandonments, and assuming payment of all appropriate maintenance, renewal, annuity, and other governmental fees. ENvue continues
to evaluate its intellectual property portfolio as patents reach end of life to determine the optimal course for continuing to protect
its technology. ENvue owns all its patents. In 2022 and 2023, ENvue invested approximately $252,000 and $141,000, respectively, in patent-related
matters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Below are details about
the significant registered patents and significant patent applications owned by ENvue:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">1.</td>
    <td style="text-align: justify"><b>Nasogastric Tube</b> - A tube for insertion through the patient&#8217;s nose, intended for connection
    to a source of substances or pressure.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 92%; border-collapse: collapse; margin-left: 0.25in">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: justify"><b>Country</b></td>
    <td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: justify"><b>Status</b></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">Israel</td>
    <td>&#160;</td>
    <td style="text-align: justify">Granted</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">Germany</td>
    <td>&#160;</td>
    <td style="text-align: justify">Granted</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">United States</td>
    <td>&#160;</td>
    <td style="text-align: justify">Granted (5 patents)</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">China</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Granted (2 patents)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">2.</td>
    <td style="text-align: justify"><b>Nasogastric Tube</b> - A tube for insertion through the patient&#8217;s nose, intended for connection
    to a source of substances or pressure. The tube contains at least one main internal tube and one suction tube, which has at least
    one outlet used for suction with the purpose of preventing damage to the patient&#8217;s internal tissues.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 92%; border-collapse: collapse; margin-left: 0.25in">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: justify"><b>Country</b></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: justify"><b>Status</b></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">Israel</td>
    <td>&#160;</td>
    <td style="text-align: justify">Granted</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">United States</td>
    <td>&#160;</td>
    <td style="text-align: justify">Granted</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">3.</td>
    <td style="text-align: justify"><b>Nasogastric Tube</b> - A system that includes a tube for insertion through the patient&#8217;s
    nose, containing a feeding mechanism, a suction mechanism, and a gastric decompression mechanism.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 92%; border-collapse: collapse; margin-left: 0.25in">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: justify"><b>Country</b></td>
    <td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: justify"><b>Status</b></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">Europe (Validated in AT, CH/LI, DE, ES, FR, GB, and IT)</td>
    <td>&#160;</td>
    <td style="text-align: justify">Granted</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">4.</td>
    <td style="text-align: justify"><b>Enteral Feeding Pump</b> - A system of devices, including a pump for drawing fluids into the tube;
    a switching mechanism connected to at least four internal tubes installed in the feeding tube; and a controller designed to operate
    the mentioned pump and switching mechanism.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 92%; border-collapse: collapse; margin-left: 0.25in">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: justify"><b>Country</b></td>
    <td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: justify"><b>Status</b></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">Israel</td>
    <td>&#160;</td>
    <td style="text-align: justify">Granted</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">United States</td>
    <td>&#160;</td>
    <td style="text-align: justify">Granted</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">5.</td>
    <td style="text-align: justify"><b>Insertion Device Positioning Guidance System and Method</b> - A system and method for guiding
    the insertion and positioning of a device within a patient&#8217;s body. It includes an electromagnetic field generator that covers
    the treatment area, multiple sensors designed to provide indications of the tube&#8217;s position within the patient&#8217;s digestive
    system and the patient&#8217;s posture. Additionally, the system features a processor that collects and processes all data to create
    a three-dimensional anatomical map of the patient&#8217;s upper body, all of which functions independently of patient movement and
    various deviations.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 92%; border-collapse: collapse; margin-left: 0.25in">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: justify"><b>Country</b></td>
    <td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: justify"><b>Status</b></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">China</td>
    <td>&#160;</td>
    <td style="text-align: justify">Allowed</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">Japan</td>
    <td>&#160;</td>
    <td style="text-align: justify">Granted</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">United States</td>
    <td>&#160;</td>
    <td style="text-align: justify">Granted (4 patents and 1 allowed application)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;&#160;</p>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">6.</td>
    <td style="text-align: justify"><b>Feeding Tube with Electromagnetic Sensor</b> - Feeding tubes that include an electromagnetic sensor
    and a wire that runs along the length of the tube.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 92%; border-collapse: collapse; margin-left: 0.25in">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: justify"><b>Country</b></td>
    <td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: justify"><b>Status</b></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">Japan</td>
    <td>&#160;</td>
    <td style="text-align: justify">Granted</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">United States</td>
    <td>&#160;</td>
    <td style="text-align: justify">Granted (3 patents)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">7.</td>
    <td style="text-align: justify"><b>Insertion Device Positioning Guidance System and Method</b> - A system and method for guiding
    the insertion and positioning of a device within a patient&#8217;s body, including an electromagnetic field generator that covers
    the treatment area, multiple sensors designed to provide indications of the tube&#8217;s position within the patient&#8217;s digestive
    system, the patient&#8217;s posture, and other relevant factors. The system also includes a processor that collects and processes
    all the data to align a predefined anatomical map of a patient&#8217;s torso based on positions corresponding to locations on a patient&#8217;s
    upper body, all of which operates independently of patient movement and other deviations.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 92%; border-collapse: collapse; margin-left: 0.25in">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: justify"><b>Country</b></td>
    <td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: justify"><b>Status</b></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">Europe (Validated in AT, CH/LI, DE, ES, FR, GB, and IT)</td>
    <td>&#160;</td>
    <td style="text-align: justify">Granted</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">China</td>
    <td>&#160;</td>
    <td style="text-align: justify">1 Granted, 1 pending</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">Japan</td>
    <td>&#160;</td>
    <td style="text-align: justify">Granted</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">United States</td>
    <td>&#160;</td>
    <td style="text-align: justify">Granted (2 patents)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">8.</td>
    <td style="text-align: justify"><b>Insertion Device Positioning Guidance System and Method</b> - A system and method for guiding
    the insertion and positioning of a device within a patient&#8217;s body, which includes an electromagnetic field generator that covers
    the treatment area, multiple sensors designed to provide indications of the tube&#8217;s position within the patient&#8217;s digestive
    system, the patient&#8217;s posture, and other relevant factors. The system also includes a processor responsible for collecting
    and processing all the data to create a three-dimensional anatomical map of the patient&#8217;s upper torso and to facilitate visualization
    on the anatomical map of a position, orientation and/or path of a tip sensor, all of which functions independently of patient movement
    and other deviations.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 92%; border-collapse: collapse; margin-left: 0.25in">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: justify"><b>Country</b></td>
    <td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: justify"><b>Status</b></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">China</td>
    <td>&#160;</td>
    <td style="text-align: justify">2 Pending Applications</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">Japan</td>
    <td>&#160;</td>
    <td style="text-align: justify">Granted</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">United States</td>
    <td>&#160;</td>
    <td style="text-align: justify">Granted (3 patents)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">9.</td>
    <td style="text-align: justify"><b>Insertion Device Positioning Guidance System and Method</b> - A device, system, and method for
    guiding the insertion and positioning of an insertion tube within the patient&#8217;s body based on sensing of changes in an electromagnetic
    field.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 92%; border-collapse: collapse; margin-left: 0.25in">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: justify"><b>Country</b></td>
    <td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: justify"><b>Status</b></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">Israel</td>
    <td>&#160;</td>
    <td style="text-align: justify">Pending</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">Japan</td>
    <td>&#160;</td>
    <td style="text-align: justify">Pending</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">10.</td>
    <td style="text-align: justify"><b>Guidance System with Claviculae Position Sensors</b> - A device, system, and method for guiding
    the insertion and positioning of tube positioning within the patient&#8217;s body based on sensing of changes in an electromagnetic
    field using sensors positioned on a patient&#8217;s upper torso, where the calculation considers signals received from reference
    sensors located in the clavicle area of the patient.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 92%; border-collapse: collapse; margin-left: 0.25in">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: justify"><b>Country</b></td>
    <td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: justify"><b>Status</b></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">Israel</td>
    <td>&#160;</td>
    <td style="text-align: justify">Pending</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">Japan</td>
    <td>&#160;</td>
    <td style="text-align: justify">Pending</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;&#160;</p>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 48px">II.</td>
    <td style="text-align: justify"><span style="text-decoration: underline">Trademarks </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As of February 6, 2024,
ENvue owns the following trademarks: Envizion Medical, ENsump, ENvue, ENgat, Envizion (wordmark and logo), and ENvue&#8217;s logo in
key countries, including the U.S., Europe, and China.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On January 25, 2023, a request
was submitted by Hologic, Inc.<sup>10</sup> to narrow the list of goods described under the ENVIZION MEDICAL trademark in the U.S. ENvue
filed a partial voluntary surrender of its U.S. registration as to the following goods: Nasogastric aspiration tube; Medical devices,
namely, nasogastric tubes with integrated camera; Medical intubation equipment; nasogastric cameras for medical purposes; Medical integrated
camera for Nasogastric Aspiration Tubes; and Camera for placing a nasogastric tube in a patient&#8217;s esophagus, which was accepted
by the U.S. Patent and Trademark Office.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 48px">III.</td>
    <td style="text-align: justify"><span style="text-decoration: underline">Trade Secrets</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">ENvue also relies on trade
secrets relating to its products and technology, including its data processing algorithms, and maintains the confidentiality of such
proprietary information to protect aspects of its business that are not amenable to, or that ENvue does not consider appropriate for,
patent protection. ENvue seeks to protect its trade secrets and know-how by entering into confidentiality and invention assignment agreements
with employees, contractors, consultants, suppliers, customers, and other third parties, who have access to such information. These agreements
generally provide that all confidential information concerning ENvue&#8217;s business or financial affairs developed or made known to
the individual during the course of the individual&#8217;s relationship with ENvue are to be kept confidential and not disclosed to third
parties except in specific circumstances. If any such person misappropriated ENvue&#8217;s trade secrets or other know-how or confidential
information, there is no guarantee that ENvue would be able to prevail in obtaining damages or injunctive relief in a dispute regarding
such misappropriation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Despite these protections,
ENvue also notes that its employees may have been previously employed at other companies in the industry, including its competitors or
potential competitors. Although ENvue is not aware of any claims currently pending against it, ENvue may be subject to claims that these
employees or ENvue has inadvertently or otherwise used or disclosed trade secrets or other proprietary information of the former employers
of its employees. Litigation may be necessary to defend against these claims. Even if ENvue is successful in defending against these
claims, litigation could result in substantial costs and be a distraction to management. If ENvue fails in defending such claims, in
addition to paying money claims, ENvue may lose valuable intellectual property rights or personnel. A loss of key personnel or their
work product could hamper or prevent ENvue&#8217;s ability to commercialize product(s), which would materially adversely affect its commercial
development efforts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 48px">IV.</td>
    <td style="text-align: justify"><span style="text-decoration: underline">Designs</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As of approximately February
6, 2025, ENvue holds design patents for Sump Tube in the U.S. and Tube Assembly for Feeding and Suction in the U.S., Europe, and China.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Government Regulation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>U.S. Food and Drug Administration Regulation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each of our products must be approved, cleared by,
or registered with the U.S. Food and Drug Administration (&#8220;FDA&#8221;) before they can be marketed in the United States, and they
can only be marketed consistently with their respective approved or cleared indication(s) of use. Before and after approval or clearance
in the United States, our products, approved or cleared products and product candidates, are subject to extensive regulation by the FDA
under the Federal Food, Drug, and Cosmetic Act and/or the Public Health Service Act, as well as by other regulatory bodies. The FDA regulations
govern, among other things, the development, testing, manufacturing, labelling, safety, storage, record-keeping, market clearance or
approval, advertising and promotion, import and export, marketing and sales, distribution and market withdrawal and recalls of medical
devices and pharmaceutical products. PainShield MD and PainShield MD Plus have each already obtained 510(k) marketing clearance by the
FDA. We are in the process of conducting clinical and non-clinical testing to support a submission for FDA clearance for PainShield Relief
as an over-the-counter drug.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><sup>10</sup></td>
    <td style="text-align: justify">It should be noted that the application was submitted in response to the opposition filed by the
    subsidiary (Envizion Medical Inc.) in 2022 against the trademark registration application by Hologic, Inc. in the U.S. and Europe.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2020, the FDA exercised its Enforcement
Discretion to allow distribution of the UroShield device in the United States. According to the FDA, &#8220;UroShield&#174; device can
use Intended Use Code (IUC) 081.006: Enforcement Discretion per final guidance, and FDA product code QMK (extracorporeal acoustic wave
generating accessory to urological indwelling catheter for use during the COVID-19 pandemic)&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accordingly, the FDA&#8217;s Enforcement Discretion
temporarily cleared the way for import of UroShield to the U.S. during the COVID-19 pandemic, immensely expanding the company&#8217;s
addressable market for the device during this time period. As of the date of this report, we have not been notified of any change in
our Enforcement Discretion status and we will continue to operate under Enforcement Discretion guidelines, or until we are notified of
a change in status by a qualified regulatory body. The device is designed to aid in the prevention of CAUTI incidence in patients requiring
long-term indwelling catheterization, defined as 14 days or greater.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>FDA Approval or Clearance of Medical Devices</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the U.S., numerous laws and regulations govern
the processes by which medical devices are developed, manufactured, brought to market and marketed. These include the Federal Food, Drug,
and Cosmetic Act (&#8220;FD&amp;C Act&#8221;) and its implementing regulations issued by FDA, among others. Unless an exemption applies,
each medical device commercially distributed in the United States requires FDA clearance of a 510(k) premarket notification (&#8220;510(k)
clearance&#8221;), granting of a de novo request, or approval of an application for premarket approval (&#8220;PMA&#8221;). In general,
under the FD&amp;C Act, medical devices are classified in one of three classes on the basis of the controls necessary to reasonably assure
their safety and effectiveness. A medical device&#8217;s classification determines the level of FDA review and approval to which the
device is subject before it can be marketed to consumers:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td style="text-align: justify">Class I devices, the lowest-risk FDA device classification, include devices with the lowest risk
    to the patient and are those for which safety and effectiveness can be assured by adherence to FDA&#8217;s medical device general
    controls, including labeling, establishment registration, device product listing, adverse event reporting, and, for some products,
    adherence to good manufacturing practices through FDA&#8217;s Quality System Regulations.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#9679;</td>
    <td style="text-align: justify">Class II devices, moderate-risk devices, also require compliance with general controls and in some
    cases, special controls as deemed necessary by FDA to ensure the safety and effectiveness of the device. These special controls may
    include performance standards, particular labeling requirements, or post-market surveillance obligations. While most Class I devices
    are exempt from the 510(k) premarket notification requirement, typically a Class II device also requires pre-market review and 510(k)
    clearance as well as adherence to the Quality System Regulations/good manufacturing practices for devices.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#9679;</td>
    <td style="text-align: justify">Class III devices, high-risk devices that are often implantable or life-sustaining or novel devices,
    also require compliance with the medical device general controls and Quality System Regulations, and generally must be approved by
    FDA before entering the market through a PMA application. Approved PMAs can include post-approval conditions and post-market surveillance
    requirements, analogous to some of the special controls that may be imposed on Class II devices.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">WoundShield, PainShield and ENvue System are classified
as Class II medical devices and require U.S. Food and Drug Administration authorization prior to marketing, by means of 510(k) clearance.
Due to its nature and the lack of existing predicate devices on the market, UroShield is automatically classified as a Class III device
for which a PMA is required, <i>unless </i>our request for <i>De Novo </i>reclassification is successful, in which case, it will be classified
as a Class II device and subject to the same post market framework as 510(k)-cleared devices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To request marketing authorization by means of a
510(k) clearance, we must submit a pre-market notification demonstrating that the proposed device is substantially equivalent to a legally
marketed medical device (referred to as a &#8220;predicate device&#8221;). A finding of substantial equivalence requires that the proposed
new device (i), has the same intended use as a predicate device; (ii) has the same or similar technological characteristics as the predicate
device; (iii) is as safe and effective as the predicate device; and (iv) does not raise different questions of safety and effectiveness
than the predicate device. 510(k) submissions generally include, among other things, a description of the device and its manufacturing,
device labelling, medical devices to which the device is substantially equivalent, safety and biocompatibility information and the results
of performance testing. In some cases, a 510(k) submission must include data from human clinical studies. Marketing may commence only
when the FDA issues a clearance letter finding substantial equivalence. The typical duration to receive 510(k) approval is approximately
nine months from the date of the initial 510(k) submission, although there is no guarantee that the timing will not be longer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA may require us to perform clinical studies
to show a product candidate&#8217;s safety and efficacy in addition to technological equivalence in support of our filed 510(k). No matter
which regulatory pathway we may take in the future towards marketing products in the United States, we believe we will be required to
provide clinical proof of device effectiveness and safety.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">After a device receives 510(k) clearance, any product
modification that could significantly affect the safety or effectiveness of the product, or that would constitute a significant change
in intended use, requires a new 510(k) clearance or, if the device would no longer be substantially equivalent, would require a PMA.
If the FDA determines that the product does not qualify for 510(k) clearance, then a company must submit and the FDA must approve a PMA
before marketing can begin. An alternative to a new 510(k) submission is a &#8220;letter to File&#8221;, citing substantial equivalence
to a product which has been granted 510(k) clearance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A PMA application must provide a demonstration of
safety and effectiveness, which generally requires extensive nonclinical and clinical trial data. Information about the device and its
components, device design, manufacturing and labelling, among other information, must also be included in the PMA. As part of the PMA
review, the FDA will inspect the manufacturer&#8217;s facilities for compliance with quality system regulation requirements, which govern
testing, control, documentation and other aspects of quality assurance with respect to manufacturing. If the FDA determines the application
or manufacturing facilities are not acceptable, the FDA may outline the deficiencies in the submission and often will request additional
testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the
application does not satisfy the regulatory criteria for approval. During the review period, an FDA advisory committee, typically a panel
of clinicians and statisticians, is likely to be convened to review the application and recommend to the FDA whether, or upon what conditions,
the device should be approved. The FDA is not bound by the advisory panel decision. While the FDA often follows the panel&#8217;s recommendation,
there have been instances where the FDA has not. If the FDA finds the information satisfactory, it will approve the PMA. The PMA approval
can include post-approval conditions, including, among other things, restrictions on labelling, promotion, sale and distribution, or
requirements to do additional clinical studies post-approval. Even after approval of a PMA, a new PMA or PMA supplement is required to
authorize certain modifications to the device, its labelling or its manufacturing process. Supplements to a PMA often require the submission
of the same type of information required for an original PMA, except that the supplement is generally limited to that information needed
to support the proposed change from the product covered by the original PMA. The typical duration to receive PMA approval is approximately
two years from the date of submission of the initial PMA application, although there is no guarantee that the timing will not be longer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As stated above, we anticipate that we will seek
FDA authorization to market our UroShield product via the <i>De Novo</i> reclassification process. Medical device types that the FDA
has not previously classified as Class I, II, or III are automatically classified into Class III regardless of the level of risk they
ultimately pose to patients and/or users. The Food and Drug Administration Modernization Act of 1997 established a new route to market
for low to moderate risk medical devices that are automatically placed into Class III due to the absence of a predicate device, called
the &#8220;Request for Evaluation of Automatic Class III Designation,&#8221; or the <i>De Novo </i>classification procedure. This procedure
allows a manufacturer whose novel device is automatically classified into Class III to request down-classification of its medical device
into Class I or Class II based on a benefit-risk analysis demonstrating the device actually presents low or moderate risk, rather than
requiring the submission and approval of a PMA application. Prior to the enactment of the Food and Drug Administration Safety and Innovation
Act of 2012, or FDASIA, a medical device could only be eligible for <i>De Novo </i>classification if the manufacturer first submitted
a 510(k) premarket notification and received a determination from the FDA that the device was not substantially equivalent. FDASIA streamlined
the <i>De Novo </i>classification pathway by permitting manufacturers to request <i>De Novo </i>classification directly without first
submitting a 510(k) premarket notification to the FDA and receiving a not substantially equivalent determination. If the manufacturer
seeks reclassification into Class II, the manufacturer must include a draft proposal for special controls that are necessary to provide
a reasonable assurance of the safety and effectiveness of the medical device. In addition, the FDA may reject the reclassification petition
if it identifies a legally marketed predicate device that would be appropriate for a 510(k) or determines that the device is not low-to-moderate
risk or that general controls would be inadequate to control the risks and special controls cannot be developed. <i>De Novo </i>reclassification
requests are also subject to user fees, unless a specific exemption applies. If the device is not approved through <i>De Novo</i> review,
then it must go through the standard PMA process for Class III devices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Clinical Trials of Medical Devices</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Clinical trials are almost always required to support
a PMA application and are sometimes required for a <i>De Novo</i> classification request or 510(k) pre-market notification. In order
to conduct a clinical investigation involving human subjects for the purpose of demonstrating the safety and effectiveness of a medical
device, an investigator acting on behalf of the company must, among other things, apply for and obtain IRB approval of the proposed investigation.
In addition, if the clinical study involves a &#8220;significant risk&#8221; (as defined by the FDA) to human health, the company sponsoring
the investigation must also submit and obtain FDA approval of an IDE. An IDE must be supported by appropriate data, such as animal and
laboratory testing results, showing that it is safe to test the device in humans and that the testing protocol is scientifically sound.
The IDE must be approved in advance by the FDA for a specified number of study participants, unless the product is deemed a non-significant
risk device and eligible for abbreviated IDE requirements. Generally, clinical trials for a significant risk device may begin once the
IDE is approved by the FDA and the study protocol and informed consent are approved by a duly-appointed IRB at each clinical trial site.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">FDA&#8217;s IDE regulations govern investigational
device labelling, prohibit promotion, and specify an array of GCP requirements, which include, among other things, recordkeeping, reporting
and monitoring responsibilities of study sponsors and study investigators. Clinical trials must further comply with the FDA&#8217;s regulations
for IRB approval and for informed consent and other human subject protections. Required records and reports are subject to inspection
by the FDA. The results of clinical testing may be unfavorable or, even if the intended safety and efficacy success criteria are achieved,
may not be considered sufficient for the FDA to grant approval or clearance of a product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Post-Approval Regulation of Medical Devices</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">After a device is cleared or approved for marketing,
numerous and pervasive regulatory requirements continue to apply. These include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify">&#9679;</td>
    <td style="text-align: justify">the FDA quality systems regulation, which governs, among other things, how manufacturers design,
    test, manufacture, exercise quality control over, and document manufacturing of their products;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify">labelling and claims regulations, which prohibit the promotion of products for unapproved or &#8220;off-label&#8221;
    uses and impose other restrictions on labelling;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify">if applicable, the Electronic Product Regulations found in 21 CFR parts 1000-1050, which provide
    additional requirements applicable to electronic products, including records and reporting requirements; and</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify">the Medical Device Reporting regulation, which requires reporting to the FDA of certain adverse experiences
    associated with use of the product.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the FDA medical device reporting (&#8220;MDR&#8221;)
regulations, medical device manufacturers are required to report to the FDA information that a device has or may have caused or contributed
to a death or serious injury or has malfunctioned in a way that would likely cause or contribute to death or serious injury if the malfunction
of the device or a similar device of such manufacturer were to recur. The decision to file an MDR involves a judgment by the manufacturer.
If the FDA disagrees with the manufacturer&#8217;s determination, the FDA can take enforcement action.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, the FDA has the authority to require
the recall of commercialized products in the event of material deficiencies or defects in design or manufacture. The authority to require
a recall must be based on an FDA finding that there is reasonable probability that the device would cause serious adverse health consequences
or death. Manufacturers may, under their own initiative, recall a product if any distributed devices fail to meet established specifications,
are otherwise misbranded or adulterated, or if any other material deficiency is found. The FDA requires that certain classifications
of recalls be reported to the FDA within ten working days after the recall is initiated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The failure to comply with applicable device regulatory
requirements can result in enforcement action by the FDA, which may include any of the following sanctions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9679; warning letters, fines, injunctions, or civil
penalties;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9679; recalls, detentions or seizures of products;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9679; operating restrictions;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9679; delays in the introduction of products into
the market;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9679; total or partial suspension of production;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9679; delay or refusal of the FDA or other regulators
to grant 510(k) clearance or PMA approvals of new products;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9679; withdrawals of marketing authorization; or</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9679; in the most serious cases, criminal prosecution.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To ensure compliance with regulatory requirements,
medical device manufacturers are subject to market surveillance and periodic, pre-scheduled and unannounced inspections by the FDA, and
these inspections may include the manufacturing facilities of subcontractors and third-party component suppliers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Good Manufacturing Practices Requirements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As noted above, manufacturers of medical devices
are required to comply with the good manufacturing practices set forth in the quality system regulations promulgated under section 520
of the Food, Drug and Cosmetic Act as further set forth in the Code of Federal Regulations as 21 CFR Part 820. Current good manufacturing
practices (&#8220;CGMP&#8221;) regulations require, among other things, quality control and quality assurance as well as the corresponding
maintenance of records and documentation. The manufacturing facility for an approved product must meet current good manufacturing practices
requirements to the satisfaction of the FDA pursuant to a pre-PMA approval inspection before the facility can be used. Manufacturers,
including third party contract manufacturers, are also subject to periodic inspections by the FDA and other authorities to assess compliance
with applicable regulations. Failure to comply with or to promptly comply with statutory and regulatory requirements subjects a manufacturer,
and possibly us, to possible legal or regulatory action, including the seizure or recall of products, injunctions, consent decrees placing
significant restrictions on or suspending manufacturing operations, and civil and criminal penalties. Adverse experiences with the product
must be reported to the FDA and could result in the imposition of marketing restrictions through labelling changes or in product recall.
Product approvals may be withdrawn if compliance with regulatory requirements is not maintained or if problems concerning safety or efficacy
of the product occur following the approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>International Regulation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are subject to regulations and product registration
requirements in many foreign countries in which we may sell our products, including in the areas of product standards, packaging requirements,
labelling requirements, import and export restrictions and tariff regulations, duties and tax requirements. The time required to obtain
clearance required by foreign countries may be longer or shorter than that required for FDA clearance, and requirements for licensing
a product in a foreign country may differ significantly from UFDA requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There is currently no premarket government review
of medical devices in the European Economic Area (&#8220;EEA&#8221;). However, all medical devices placed on the market in the EEA must
meet the relevant essential requirements laid down in Annex I of Directive 93/42/EEC concerning medical devices, or the Medical Devices
Directive. The most fundamental essential requirement is that a medical device must be designed and manufactured in such a way that it
will not compromise the clinical condition or safety of patients, or the safety and health of users and others. In addition, the device
must achieve the performances intended by the manufacturer and be designed, manufactured, and packaged in a suitable manner. The European
Commission has adopted various standards applicable to medical devices. These include standards governing common requirements, such as
sterilization and safety of medical electrical equipment, and product standards for certain types of medical devices. There are also
harmonized standards relating to design and manufacture. While not mandatory, compliance with these standards is viewed as the easiest
way to satisfy the essential requirements as a practical matter. Compliance with a standard developed to implement an essential requirement
also creates a rebuttable presumption that the device satisfies that essential requirement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the European Union, the European Medicines Agency and the European Union Commission determined that PainShield, UroShield, and WoundShield
are to be regulated as medical device products. These products are classified as Class II devices. These devices are CE Marked and as
such can be marketed and distributed within the European Economic Area. We are required to be recertified each year for CE by Intertek,
which conducts an annual audit. The ENvue System received a European CE mark, indicating that ENvue affirms its product&#8217;s conformity
with European health, safety and environmental protection standards, in 2021.The audit procedure, which includes on-site visits at our
facility, requires us to provide Intertek with information and documentation concerning our management system and all applicable documents,
policies, procedures, manuals, and other information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 5, 2017, the European Parliament passed the Medical Devices Regulation (Regulation 2017/745), which repeals and replaces the EU
Medical Device Directive and became effective on May 26, 2021. The Medical Devices Regulation, among other things, is intended to establish
a uniform, transparent, predictable, and sustainable regulatory framework across the EEA for medical devices and ensure a high level
of safety and health while supporting innovation. The new regulations, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">strengthen
    the rules on placing devices on the market and reinforce surveillance once they are available;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">improve
    the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">set
    up a central database to provide patients, healthcare professionals, and the public with comprehensive information on products available
    in the E.U.; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">strengthen
    rules for the assessment of certain high-risk devices, such as implants, which may have to undergo an additional check by experts
    before they are placed on the market.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary regulatory bodies and paths in Asia, Australia, and Latin America are determined by the requisite country authority. In most
cases, establishment registration and device licensing are applied for at the applicable Ministry of Health through a local intermediary.
The requirements placed on the manufacturer are typically the same as those contained in ISO 9001 or ISO 13485, requirements for quality
management systems published by the International Organization of Standardization. In some countries outside Europe, we are or will be
able to sell on the basis of our CE Mark. We have the Health for PainShield, WoundShield and UroShield, a certificate by the Israel Ministry
of Health allowing us to sell PainShield, WoundShield and UroShield in Israel, a certificate allowing us to sell PainShield in Australia,
and we are able to sell PainShield, WoundShield and UroShield in India and Ecuador based on our CE Mark. In addition, our distributor
in Korea has applied for approval to sell PainShield and UroShield. We generally apply, through our distributor, for approval in a particular
country for a particular product only when we have a distributor in place with respect to such product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>European
Good Manufacturing Practices</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the European Union, the manufacture of medical devices is subject to good manufacturing practice, as set forth in the relevant laws and
guidelines of the European Union and its member states. Compliance with good manufacturing practice is generally assessed by the competent
regulatory authorities. Typically, quality system evaluation is performed by a notified body, which also recommends to the relevant competent
authority for the European Community CE Marking of a device. The competent authority may conduct inspections of relevant facilities,
and review manufacturing procedures, operating systems and personnel qualifications. In addition to obtaining approval for each product,
in many cases each device manufacturing facility must be audited on a periodic basis by the notified body. Further inspections may occur
over the life of the product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>U.S.
Fraud and Abuse and Other Health Care Laws</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, federal and state fraud and abuse laws prohibit the payment or receipt of kickbacks, bribes or other remuneration
intended to induce the purchase or recommendation of health care products and services. Other provisions of federal and state laws prohibit
presenting, or causing to be presented, to third party payers for reimbursement, claims that are false or fraudulent, or which are for
items or services that were not provided as claimed. In addition, other health care laws and regulations may apply, such as transparency
and reporting requirements, and privacy and security requirements. Violations of these laws can lead to civil and criminal penalties,
including exclusion from participation in federal and state health care programs. These laws are potentially applicable to manufacturers
of products regulated by the FDA as medical devices, such as us, and hospitals, physicians and other potential purchasers of such products.
The health care laws that may be applicable to our business or operations include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal Anti-Kickback Statute, which prohibits the offer, payment, solicitation or receipt of any form of remuneration in return
    for referring, ordering, leasing, purchasing or arranging for, or recommending the ordering, purchasing or leasing of, items or services
    payable by Medicare, Medicaid or any other federal health care program.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal
    false claims laws and civil monetary penalty laws, including the False Claims Act, that prohibit, among other things, individuals
    or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other government
    health care programs that are false or fraudulent, or making a false statement to avoid, decrease or conceal an obligation to pay
    money to the federal government.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits knowingly and wilfully executing,
    or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretences,
    representations, or promises, any of the money or property owned by, or under the custody or control of, any health care benefit
    program, and for knowingly and wilfully falsifying, concealing or covering up a material fact or making any materially false statements
    in connection with the delivery of or payment for health care benefits, items or services.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
    as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and its implementing regulations, which
    also impose obligations and requirements on health care providers, health plans, and healthcare clearinghouses as well as their respective
    business associates that perform certain services for them that involve the use or disclosure of individually identifiable health
    information, with respect to safeguarding the privacy and security of certain individually identifiable health information.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal transparency requirements under the Affordable Care Act, including the provision commonly referred to as the Physician Payments
    Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under
    Medicare, Medicaid or Children&#8217;s Health Insurance Program to report annually to Centers for Medicare and Medicaid Services,
    or CMS, information related to payments and other transfers of value to physicians and teaching hospitals, and ownership and investment
    interests held by physicians and their immediate family members.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Analogous
    state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may be broader in scope and apply
    to referrals and items or services reimbursed by both governmental and non-governmental third-party payers, including private insurers,
    many of which differ from each other in significant ways and often are not pre-empted by federal law, thus complicating compliance
    efforts.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Health
Information Privacy and Security Laws</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are numerous U.S. federal and state laws and regulations related to the privacy and security of Personally Identifiable Information (&#8220;PII&#8221;),
including health information. Among others, the federal Health Insurance Portability and Accountability Act of 1996, as amended by HITECH,
and their implementing regulations, which we collectively refer to as HIPAA, establish privacy and security standards that limit the
use and disclosure of Protected Health Information (&#8220;PHI&#8221;) and require covered entities and business associates to implement
administrative, physical, and technical safeguards to ensure the confidentiality, integrity, and availability of individually identifiable
health information in electronic form, among other requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Violations
of HIPAA may result in civil and criminal penalties. Our hospital customers are typically covered entities under HIPAA, and we are therefore
limited in the health information we may collect, receive, use, and disclose. To the extent we provide services that require the use
of PHI, we may be business associates of such covered entities and directly subject to HIPAA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
attorneys general also have the right to prosecute HIPAA violations committed against residents of their states, and HIPAA standards
have been used as the basis for the duty of care in state civil suits, such as those for negligence or recklessness in misusing personal
information. In addition, HIPAA mandates that HHS conduct periodic compliance audits of HIPAA covered entities and their business associates
for compliance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
states also have laws that protect the privacy and security of sensitive and personal information, including health information. These
laws may be similar to or even more protective than HIPAA and other federal privacy laws. For example, the laws of the State of California,
are more restrictive than HIPAA. Where state laws are more protective than HIPAA, we must comply with the state laws we are subject to.
California passed the California Consumer Privacy Act or CCPA on June 28, 2018, which went into effect January 1, 2020. On November 3,
2020, the California Privacy Rights Act of 2020 (&#8220;CPRA&#8221;), which amends the CCPA and adds new privacy protections that became
effective on January 1, 2023, was enacted through a ballot initiative. Records and information we maintain on our patients may be subject
to the CCPA if it is not covered by HIPAA. In certain cases, it may be necessary to modify our planned operations and procedures to comply
with these more stringent state laws. Not only may some of these state laws impose fines and penalties upon violators, but also some,
unlike HIPAA, may afford private rights of action to individuals who believe their personal information has been misused. In addition,
state and federal privacy laws subject to frequent change.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to HIPAA and state health information privacy laws, we may be subject to or restricted by other state and federal privacy laws,
including laws that prohibit unfair privacy and security practices and deceptive statements about privacy and security, laws that place
specific requirements on certain types of activities, such as data security and texting, and laws requiring holders of personal information
to maintain safeguards and to take certain actions in response to a data breach.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
data protection, privacy, and other laws and regulations are often more restrictive than those in the U.S. The E.U., for example, traditionally
has imposed stricter obligations under its laws and regulations relating to privacy, data protection and consumer protection than the
U.S. In May 2018, the GDPR, governing data practices and privacy in the E.U., became effective and replaced the data protection laws
of the individual member states. GDPR requires companies to meet stringent requirements regarding the handling of personal data of individuals
in the E.U. These more stringent requirements include expanded disclosures to inform members about how we may use their personal data,
increased controls on profiling members, and increased rights for members to access, control and delete their personal data. In addition,
there are mandatory data breach notification requirements. The law also includes significant penalties for non-compliance, which may
result in monetary penalties of up to 20 million Euros or 4% of a company&#8217;s worldwide turnover, whichever is higher. GDPR and other
similar regulations require companies to give specific types of notice and informed consent is required for the placement of a cookie
or similar technologies on a user&#8217;s device for online tracking for behavioral advertising and other purposes and for direct electronic
marketing, and the GDPR also imposes additional conditions in order to satisfy such consent, such as a prohibition on pre-checked consents.
It remains unclear how the U.K. data protection laws or regulations will develop in the medium to longer term and how data transfer to
the U.K. from the E.U. will be regulated. Outside of the E.U., there are many other countries with data protection laws, and new countries
are adopting data protection legislation with increasing frequency.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of these laws may require consent from individuals for the use of data for various purposes, including marketing, which may reduce our
ability to market our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no harmonized approach to these laws and regulations globally. Consequently, we increase our risk of non-compliance with applicable
foreign data protection laws and regulations when we expand internationally. We may need to change and limit the way we use personal
information in operating our business and may have difficulty maintaining a single operating model that is compliant. Compliance with
such laws and regulations will result in additional costs and may necessitate changes to our business practices and divergent operating
models, limit the effectiveness of our marketing activities, adversely affect our business, results of operations, and financial condition,
and subject us to additional liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Manufacturing
and Suppliers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nano
OpCo&#8217;s Products </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2018, we announced we appointed Quasar Engineering Ltd, as contract manufacturer for the PainShield, UroShield and WoundShield,
as well as other devices. Following our agreement with Sanuwave, Quasar is no longer the manufacturer of the WoundShield. Quasar is a
medical device manufacturer, located in China, with over 30 years of experience, serving major brands worldwide, with complex catheters,
disposables, and FDA regulated assemblies. Starting in the fourth quarter of 2019, we started using Quasar to manufacture all of our
newly redesigned products. Quasar temporarily shut down for sixty days in early 2020, due to the COVID-19 outbreak which led to a significant
delay in the production of goods needed to fulfil our sales orders, and became fully operational in April 2020. Presently, we are not
experiencing delays in the production of our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quasar
added a new manufacturing facility in Singapore late in the third quarter of 2022. Some of our product manufacturing moved to this plant
for final production and packaging. For the year 2023, through the current date, however, all of our programming and disposable kit manufacturing
are being performed in our facilities in Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
order certain component parts on an as-needed basis, generally from the manufacturer that provides us with the most competitive pricing.
Our most significant suppliers for these components are B Star, Inc and Plastic One. We do not have written agreements with any of these
suppliers, but we believe anyone could be easily replaced if necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ENvue
Products </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENvue
does not manufacture the products it sells. ENvue has contracted with suppliers for the supply of raw materials and various components
that make up the system, as well as for the assembly of the system and the specialized feeding tubes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate that there may be a limitation on the potential annual production capacity at the supplier that assembles the ENvue System.
It should be noted that the production volume during 2023 was significantly lower than this limitation, and the ENvue&#8217;s management
previously estimated that it can contract with an additional manufacturer if necessary. It should also be noted that several companies
with a global presence provide similar services to those of the current manufacturer, and ENvue previously estimated that, if necessary,
it could replace or expand the existing assembly capabilities within 6-9 months without significant cost changes. Since the beginning
of 2024, ENvue has only been purchasing spare parts and consumable feeding tubes for the systems held by its existing customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
there are only a few manufacturers worldwide that produce feeding tubes (made of polyurethane) used by ENvue to produce the specialized
feeding tubes for the ENvue System. Accordingly, terminating the contract with the feeding tube supplier could affect the production
capacity for our ENvue System for the time required to reorganize until we contract with an alternative supplier. However, we do not
anticipate difficulty in replacing this supplier with another.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Customers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently sell our products both directly through our website and indirectly via distribution agreements, with approximately 98% of our
sales coming through distributors and customers who are referred to us through sales agents, and the remaining 2% from consumers who
contact us through our website.  We
have exclusive and non-exclusive distribution agreements for our products with medical product distributors based in the United States,
in the United Kingdom and various countries throughout Europe, Australia, New Zealand, and Malta. For the year ended December 31, 2024,
our largest customer was Ultra Pain Products Inc, to whom our sales of products to them comprised approximately 31% of our total revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently in discussions with several distribution companies with access to various markets in the United States, Europe, and Asia,
as well as the Veterans Health Care network facilities. Our current agreements stipulate that distributors will be responsible for carrying
out local marketing activities and sales. We are responsible for training, providing marketing guidance, marketing materials, and technical
guidance. In addition, in most cases, all sales costs, including sales representatives, incentive programs, and marketing trials, will
be borne by the distributor. We expect any future distribution agreements to contain substantially similar stipulations. Under our current
agreements, distributors purchase our products from us at a fixed price. Our current agreements with distributors are generally for a
term of approximately two to three years and automatically renew for additional annual terms unless modified by either party. We also
service patients directly as a result of independent sales agents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 63; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
People and Human Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employees</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the completion of the Merger, NanoVibronix has 15 full-time employees and ENvue has 16 full-time employees. We also regularly work with
several independent consultants and other contract organizations to support our business and we regularly evaluate additional talent
to help support our product manufacturing, development, financial, and other capabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Diversity
and Inclusion</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that an inclusive culture is required to understand and develop products that benefit all patients. By embracing differences,
we aim to foster an environment of respect and trust in an effort to facilitate creativity, spark passion, and help us achieve better
outcomes for all those who work at the Company. We are committed to creating and maintaining a workplace free from discrimination or
harassment, including on the basis of any class protected by applicable law, and our recruitment, hiring, development, training, compensation,
and advancement practices are based on qualifications, performance, skills, and experience without regard to gender, race, or ethnicity.
Our management team and employees are expected to exhibit and promote honest, ethical, and respectful conduct in the workplace, including
adhering to the standards for appropriate behavior set forth in our code of conduct.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compensation
and Benefits</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
operate in a highly competitive environment for human capital, particularly as we seek to attract and retain talent with relevant experience
in the medical device sector. Therefore, we strive to provide a total rewards package to our employees that is competitive with our peer
companies, including competitive healthcare benefits and in certain cases, stock options. We also offer paid leave as mandated by government
regulations, flexible work schedules, and other benefits as mandated by government regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also offer key employees the benefit of equity ownership in NanoVibronix through stock option grants. We believe these grants both help
promote alignment between our employees and our stockholders and provide retention benefits, as the awards generally vest over a three-year
period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any employees that are represented by a labor union or that have entered into a collective bargaining agreement with the
Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Safety
and Wellness</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
NanoVibronix, we believe that health matters to everyone, and the safety health, and wellness of our employees is one of our top priorities.
We are committed to developing and fostering a work environment that is safe, professional, and promotes teamwork, diversity, and trust
in order to afford all of our employees the opportunity to contribute to the best of their abilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Seasonality</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s field of activity is not characterized by seasonality. It should be noted that hospitals, which are the current and potential
customers of the ENvue System, tend to concentrate their purchases of medical equipment in the last quarter of the year (end of the fiscal
year).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Legal
Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may become party to legal proceedings in the ordinary course of business. Such legal proceedings may negatively impact
our business and financial position, result in brand or reputational harm, and divert the attention of our management from core operations
of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Protrade
Proceeding</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 26, 2021, Protrade Systems, Inc. (&#8220;Protrade&#8221;) filed a Request for Arbitration (the &#8220;Request&#8221;) with the
International Court of Arbitration (the &#8220;ICA&#8221;) of the International Chamber of Commerce alleging the Company is in breach
of an Exclusive Distribution Agreement dated March 7, 2019 (the &#8220;Agreement&#8221;) between Protrade and the Company. Protrade alleges,
in part, that the Company has breached the Agreement by discontinuing the manufacture of the DV0057 Painshield MD device in favor of
an updated 10-100-001 Painshield MD device. Protrade claims damages estimated at $3 million. The Company vigorously defended the claims
asserted by Protrade.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 15, 2022, the arbitrator issued a final award, which, determined that (i) the Company had the right to terminate the Exclusive
Distribution Agreement; (ii) the Company did not breach the duty of good faith and fair dealing with regard to the Exclusive Distribution
Agreement; and (iii) the Company did not breach any confidentiality obligations to Protrade. Nevertheless, the arbitrator determined
that the Company did not comply with the obligation to supply Protrade with a year&#8217;s supply of patches, and awarded Protrade $1,500,250,
which consists of $1,432,000 for &#8220;lost profits&#8221; and $68,250 as reimbursement of arbitration costs, on the grounds that the
Company allegedly failed to supply Protrade with certain patches utilized by users of DV0057 Painshield MD device. The arbitrator based
the decision on the testimony of Protrade&#8217;s president who asserted that a user would use in excess of 33 patches per each device.
The Company believes that the number of patches per device alleged by Protrade is grossly inflated, and that these claims were not properly
raised before the arbitrator. Accordingly, on April 13, 2022, the Company submitted an application for the correction of the award which
the arbitrator denied on June 22, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 5, 2022, Protrade filed a Petition with the Supreme Court of New York Nassau County seeking to confirm the Award. On April 13,
2022, the Company submitted an application to the ICA seeking to correct an error in the award based on the evidence that the Company
only sold 2-3 reusable patches per device contrary to the 33 reusable patches claimed by Protrade. The same arbitrator who issued the
award, denied the application.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 22, 2022, the Company filed a cross-motion seeking to vacate arbitration award on the grounds that the arbitrator exceeded her authority,
that the award was procured by fraud, and that the arbitrator failed to follow procedures established by New York law. In particular,
the Company averred in its motion that Protrade&#8217;s witness made false statements in arbitration, and that the arbitrator resolved
a claim that was never raised by Protrade and that has no factual basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2022, the court issued a decision granting Protrade its petition to confirm the award and denying the cross-motion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 9, 2022, the Company filed a motion to re-argue and renew its cross-motion to vacate the arbitration decision based on newer
information that was not available during the initial hearing. On the same day, the Company also filed a notice of appeal with the Appellate
Division, Second Department. On March 21, 2023, the court denied the motion to re-argue and renew.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 10, 2023, the Company filed its appeal with the Appellate Division, Second Department. <span style="background-color: white">That
appeal is now fully briefed.&#160; In February 2025, the Second Department informed counsel for the Company that the Second Department
was beginning to process the appeal for calendaring.&#8221;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, and 2023, the Company accrued the amount of the arbitration award to Protrade of approximately $2.1 million and
$2.0 million, respectively, including interest which is classified in &#8220;Other accounts payable and accrued expenses&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Initiation
of Insolvency Proceedings Against Predecessor ENvue</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 31, 2024, Predecessor ENvue submitted a request to the Tel Aviv-Yafo District Court (the &#8220;Court&#8221;) for the issuance
of an order to open insolvency proceedings under the Insolvency and Economic Rehabilitation Law, 5778-2018 (the &#8220;Insolvency Law&#8221;).
On March 27, 2024, the Court issued an order to open proceedings for Predecessor ENvue and its temporary operation in accordance with
the provisions of Section 24 of the Insolvency Law. On May 15, 2024, the Court decided to approve the proposal of Alpha Capital Anstalt
(a creditor of Predecessor ENvue) as the winning bid for the acquisition of Predecessor ENvue&#8217;s activities and assets and to approve
the proposal of Experto</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFS
Financial Solutions Ltd. as the winning bid for the acquisition of Predecessor ENvue&#8217;s public shell, as well as to convene creditors&#8217;
meetings to approve an economic rehabilitation plan for Predecessor ENvue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 65; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
March 27, 2024, the powers of the Board of Directors and officers of Predecessor ENvue were suspended by the Court, and their temporary
operation was transferred to Attorney Guy Gissin as Trustee. From March 28, 2024, Predecessor ENvue&#8217;s shares have been suspended
from trading on the Tel Aviv Stock Exchange Ltd.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 16, 2024, the Court decided to approve the proposal of Alpha Capital Anstalt as the winning bid for the acquisition of Predecessor
ENvue&#8217;s activities and assets and on May 15, 2024 the court decided to approve the proposal of Experto IFS Financial Solutions
Ltd. as the winning bid for the acquisition of Predecessor ENvue&#8217;s public shell, as well as to convene creditors&#8217; meetings
to approve an economic rehabilitation plan for Predecessor ENvue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 27, 2024, Predecessor ENvue published a proposal for an economic rehabilitation plan, and on May 30, 2024, the aforementioned creditors&#8217;
meeting was held, where the economic rehabilitation plan was approved after removing provisions related to the assignment of creditors&#8217;
claims rights to the Trustee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 23, 2024, the court approved the agreement with Envizion Holdings Corp, a Delaware company (the &#8220;Purchaser&#8221;), a subsidiary
of Alpha Capital Anstalt, for the sale of Predecessor ENvue&#8217;s assets and operations</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2023, Predecessor ENvue was involved in the development of components and products to improve and upgrade the system as part of its research
and development activities, in order to optimize its use, expand its advantages and capabilities, and increase the potential target market.
As part of efficiency processes and cost-cutting measures in Predecessor ENvue, as of July 2023, Predecessor ENvue ceased its research
and development activities. The activities were resumed following the purchase of by Envizion Holdings Corp.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
light of the insolvency proceedings concerning Predecessor ENvue, from the beginning of 2024 until the purchase by Envizion Holdings
Corp., Predecessor ENvue has temporary paused its marketing activities and entering into agreements with new customers, and instead focused
on maintaining its existing operations by providing support for the systems held by its existing customers, updating system versions
as necessary, and supplying spare parts and consumable feeding tubes for these systems. Predecessor ENvue has since resumed all activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Available
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments thereto, are
filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;). The Company is subject to the informational requirements of
the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) and files or furnishes reports, proxy statements and
other information with the SEC. Such reports and other information filed by the Company with the SEC are available free of charge on
the Company&#8217;s website at <i>www.nanovibronix.com</i>, as soon as reasonably practicable after we have electronically filed with,
or furnished to, the SEC. The SEC maintains an internet site that contains reports, proxy and information statements and other information
regarding issuers that file electronically with the SEC at <i>www.sec.gov</i>. The contents of these websites are not incorporated into
this filing. Further, the Company&#8217;s references to website URLs are intended to be inactive textual references only.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sw_001"></span>ITEM
1A. RISK FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investing
in our common stock involves a high degree of risk. Before investing in our securities, you should carefully consider the following risks,
together with the financial and other information contained in this Annual Report on Form 10&#8211;K for the year ended December 31,
2024, and our other periodic filings with the SEC. Additional risks and uncertainties that we are unaware of may become important factors
that affect us. If any of the following events occur, our business, financial conditions and operating results may be materially and
adversely affected. In that event, the trading price of our common stock may decline, and you could lose all or part of your investment.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
of Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Below
is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not address
all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face,
can be found below under the heading &#8220;Risk Factors&#8221; and should be carefully considered, together with other information in
this Form 10-K and our other filings with the SEC, before making an investment decision regarding our securities.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to the Combined Company Following the Merger with Predecessor ENvue</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    intended benefits of the Merger may not be realized</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NanoVibronix
    may become involved in securities litigation or stockholder derivative litigation in connection with the Merger, and this could divert
    the attention of NanoVibronix management and harm the combined company&#8217;s business, and insurance coverage may not be sufficient
    to cover all related costs and damages.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NanoVibronix
    stockholders may not realize a benefit from the Merger commensurate with the ownership dilution they will experience in connection
    with the Merger.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to NanoVibronix&#8217;s Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have a history of losses, and we expect to continue to incur losses and may not achieve or maintain profitability</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we are unable to raise additional capital, our clinical trials and product development will be limited and our long-term viability
    will be threatened; however, if we do raise additional capital, your percentage ownership as a stockholder could decrease and constraints
    could be placed on the operations of our business.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we fail to obtain an adequate level of reimbursement for our approved products by third party payers, there may be no commercially
    viable markets for our approved products or the markets may be much smaller than expected.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    face the risk of product liability claims and may not be able to obtain insurance.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    product candidates may not be developed or commercialized successfully.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    need to increase the size of our organization in order to successfully manage our growth.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    failure to protect our intellectual property rights could diminish the value of our solutions, weaken our competitive position and
    reduce our revenue.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company&#8217;s financial statements have been prepared on a going concern basis, and do not include adjustments that might be necessary
    if the Company is unable to continue as a going concern. Management has substantial doubt about the Company&#8217;s ability to continue
    as a going concern.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    business and operations would suffer in the event of computer system failures, cyber-attacks or deficiencies in our cyber-security.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to the Regulation of NanoVibronix&#8217;s Products</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are subject to extensive governmental regulation, including the requirement of U.S. Food and Drug Administration approval or clearance
    before our product candidates may be marketed and after approval or clearance and during the marketing of our products.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">UroShield
    has not been cleared or approved by the FDA, nor has it undergone the same type of review as an FDA-approved or cleared device.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
    to obtain regulatory approval in foreign jurisdictions will prevent us from marketing our products abroad.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are uncertain regarding the success of our clinical trials for our products in development.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
    reform measures could adversely affect our business and financial results.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 67; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to NanoVibronix&#8217;s Operations in Israel</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-size: 12pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    conduct our operations in Israel and therefore our results may be adversely affected by political, economic and military instability
    in Israel and its region.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-size: 12pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
    a certain portion of our expenses is incurred in currencies other than the U.S. dollar, our results of operations may be harmed by
    currency fluctuations and inflation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to NanoVibronix&#8217;s Organization and NanoVibronix&#8217;s Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    price of our securities may be volatile, and the market price of our securities may drop below the price you pay.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have a significant number of warrants and options, and future sales of our common stock upon exercise of these options or warrants,
    or the perception that future sales may occur, may cause the market price of our common stock to decline, even if our business is
    doing well.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
    our shares of common stock are listed on Nasdaq, we currently have a limited trading volume, which results in higher price volatility
    for, and reduced liquidity of, our common stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we fail to comply with the continued listing requirements of Nasdaq, our common stock may be delisted and the price of our common
    stock and our ability to access the capital markets could be negatively impacted.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we fail to maintain effective internal control over financial reporting, our business, financial condition or results of operations
    may be adversely affected.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to ENvue</b>&#8217;<b>s Financial Condition, Business and Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    financial statement footnotes of the Company include disclosure regarding the substantial doubt about the ability of the Company
    to continue as a going concern. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    conduct certain of our operations in Israel. Conditions in Israel, including the October 2023 attack by Hamas and other terrorist
    organizations from the Gaza Strip and Israel&#8217;s war against them, may affect our operations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    impact of planned changes in the Israeli Judicial System on capital raising in the high-tech sector is difficult to predict. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to the ENvue System </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we are not successful in enhancing awareness of our ENvue System, driving adoption across our current target population and expanding
    the population of eligible patients, our sales, business, financial condition and results of operations will be negatively affected.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    commercial success and revenues will depend on the future adoption of the ENvue System into patient work streams in facilities and
    other healthcare settings. If we are unable to successfully drive interest in our ENvue System, our business, financial condition
    and results of operations would be harmed. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may be unable to compete successfully with competitive technologies, which could harm our sales, business, financial condition and
    results of operations. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
    of our ENvue System requires appropriate training and inadequate training may lead to negative clinician experiences, which could
    harm our business, financial condition, and results of operations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
    sales of our ENvue System may depend on providers&#8217; and patients&#8217; ability to obtain reimbursement from third-party payors,
    such as insurance carriers.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to ENvue Legal, Regulatory and Compliance Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Complying
    with regulations enforced by FDA and other regulatory authorities is expensive and time consuming, and failure to comply could result
    in substantial penalties.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may not receive the necessary authorizations to market future versions, if any, of our ENvue System or any future new product candidates,
    and any failure to timely do so may adversely affect our ability to grow our business.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    modifications to our products may require new 510(k) clearance or other marketing authorizations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to ENvue</b>&#8217;<b>s Intellectual Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    success depends in part on our proprietary technology, and if we are unable to successfully enforce our intellectual property rights,
    our competitive position may be harmed.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we infringe or violate the patents or proprietary rights of other parties or are subject to an intellectual property infringement
    or misappropriation claim, our ability to grow our business may be severely limited.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to NanoVibronix&#8217;s Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to the Combined Company Following the Merger with Predecessor ENvue</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
intended benefits of the Merger may not be realized.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Merger poses risks for NanoVibronix&#8217;s ongoing operations, including, among others:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that
    senior management&#8217;s attention may be diverted from the management of NanoVibronix&#8217;s current operations and development
    of its products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    and expenses associated with any undisclosed or potential liabilities; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen
    difficulties may arise in integrating ENvue&#8217;s business in the combined company.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the foregoing, NanoVibronix may be unable to realize the full strategic and financial benefits currently anticipated from
the Merger, and NanoVibronix cannot assure you that the Merger will be accretive to NanoVibronix in the near term or at all. Furthermore,
if NanoVibronix fails to realize the intended benefits of the Merger, the market price of NanoVibronix&#8217;s common stock could decline
to the extent that the market price reflects those benefits. NanoVibronix&#8217;s stockholders will have experienced substantial dilution
of their ownership interests in NanoVibronix without receiving any commensurate benefit, or only receiving part of the commensurate benefit
to the extent NanoVibronix is able to realize only part of the strategic and financial benefits currently anticipated from the Merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>NanoVibronix
may become involved in securities litigation or stockholder derivative litigation in connection with the Merger, and this could divert
the attention of NanoVibronix management and harm the combined company</i></b>&#8217;<b><i>s business, and insurance coverage may not
be sufficient to cover all related costs and damages.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
litigation or stockholder derivative litigation frequently follows the announcement of certain significant business transactions, such
as the sale of a business division or announcement of a business combination transaction. In the future, NanoVibronix may become involved
in this type of litigation in connection with the Merger. Litigation often is expensive and diverts management&#8217;s attention and
resources, which could adversely affect the business of NanoVibronix.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>NanoVibronix
stockholders may not realize a benefit from the Merger commensurate with the ownership dilution they will experience in connection with
the Merger.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
NanoVibronix is unable to realize the full strategic and financial benefits currently anticipated from the Merger, NanoVibronix stockholders
will have experienced substantial dilution of their ownership interests in the company without receiving any commensurate benefit, or
only receiving part of the commensurate benefit to the extent NanoVibronix is able to realize only part of the strategic and financial
benefits currently anticipated from the Merger. Furthermore, if we fail to realize the intended benefits of the Merger, the market price
of NanoVibronix common stock could decline to the extent that the market price reflects those benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
the Merger does not qualify as a &#8220;reorganization&#8221; under Section 368(a) of the Code, U.S. holders of ENvue may be required
to pay additional U.S. federal income taxes.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
U.S. federal income tax purposes, the Merger is intended to qualify as a &#8220;reorganization&#8221; within the meaning of Section 368(a)
of the Code.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Merger does not qualify as a &#8220;reorganization&#8221; within the meaning of Section 368(a) of the Code, a U.S. holder of ENvue
common stock generally would recognize gain or loss for U.S. federal income tax purposes on each share of ENvue common stock surrendered
in the Merger in an amount equal to the difference between the fair market value, at the time of the Merger, of the NanoVibronix common
stock received in the Merger and such holder&#8217;s adjusted tax basis in the ENvue common stock surrendered in the Merger. Gain or
loss must be calculated separately for each block of ENvue common stock exchanged by such U.S. holder if such blocks were acquired at
different times or for different prices. Any gain or loss recognized generally would be capital gain or loss, and generally would be
long-term capital gain or loss if the U.S. holder&#8217;s holding period in a particular block of ENvue common stock is more than one
year at the effective time of the Merger. Long-term capital gain of certain non-corporate taxpayers, including individuals, generally
is taxed at reduced U.S. federal income tax rates. The deductibility of capital losses is subject to limitations. A U.S. holder&#8217;s
tax basis in shares of NanoVibronix common stock received in the Merger would be equal to the fair market value thereof as of the effective
time of the Merger, and such U.S. holder&#8217;s holding period in such shares would begin on the day following the closing of the Merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 69; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
market price of NanoVibronix</i></b>&#8217;<b><i>s common stock after the Merger may be subject to significant fluctuations and volatility,
and the stockholders of the company may be unable to resell their shares at a profit and may incur losses.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price of NanoVibronix&#8217;s common stock could be subject to significant fluctuation following the Merger. The current business
of NanoVibronix differs from that of ENvue in important respects and, accordingly, the results of operations of the combined company
and the market price of our common stock following the Merger may be affected by factors different from those currently affecting the
results of operations of NanoVibronix. Market prices for securities of life sciences and medical technology companies in particular have
historically been particularly volatile and have shown extreme price and volume fluctuations that have often been unrelated or disproportionate
to the operating performance of those companies. Broad market and industry factors, as well as general economic, political and market
conditions such as recessions or interest rate changes, may seriously affect the market price of the combined company&#8217;s common
stock, regardless of the actual operating performance of NanoVibronix. Some of the factors that may cause the market price of NanoVibronix&#8217;s
common stock to fluctuate include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">investors
    reacting negatively to the effect on the combined company&#8217;s business and prospects from the Merger;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    announcement of new products, new developments, services or technological innovations by the combined company or the combined company&#8217;s
    competitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated quarterly increases or decreases in revenue, gross margin or earnings, and changes in the combined company&#8217;s
    business, operations or prospects;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    relating to strategic relationships, mergers, acquisitions, partnerships, collaborations, joint ventures, capital commitments, or
    other events by the combined company or the combined company&#8217;s competitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">conditions
    or trends in the life sciences and medical technology industries;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the economic performance or market valuations of other life sciences and medical technology companies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    market conditions or domestic or international macroeconomic and geopolitical factors unrelated to the combined company&#8217;s performance
    or financial condition;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sale
    of the combined company&#8217;s common stock by stockholders, including executives and directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">volatility
    and limitations in trading volumes of the combined company&#8217;s common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">volatility
    in the market prices and trading volumes of the life sciences and medical technology stocks;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    combined company&#8217;s ability to finance its business;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ability
    to secure resources and the necessary personnel to pursue the plans of the combined company;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to meet external expectations or management guidance;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the combined company&#8217;s capital structure or dividend policy, future issuances of securities, sales or distributions of large
    blocks of common stock by stockholders;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the combined company&#8217;s cash position;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements and events surrounding financing efforts, including debt and equity securities;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">analyst research reports, recommendations and changes in recommendations, price targets, and withdrawals of coverage;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">departures and additions of key personnel;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes and litigation related to intellectual properties, proprietary rights, and contractual obligations;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">investigations by regulators into the operations of the combined company or those of the combined company&#8217;s competitors;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in applicable laws, rules, regulations, or accounting practices and other dynamics; and</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other events or factors, many of which may be out of the combined company&#8217;s control.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the past, following periods of volatility in the overall market and the market prices of particular companies&#8217; securities, securities
class action litigation has often been instituted against these companies. Litigation of this type, if instituted against the combined
company, could result in substantial costs and a diversion of management&#8217;s attention and resources of the combined company. Any
adverse determination in any such litigation or any amounts paid to settle any such actual or threatened litigation could require that
the combined company make significant payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in the business operations, strategies and focus of the combined company following the Merger may not result in an improvement in the
value of NanoVibronix common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is currently anticipated that, following the Merger, NanoVibronix would focus some of its resources on executing ENvue&#8217;s current
business plan. Consequently, an investment in NanoVibronix&#8217;s common stock partially represents an investment in the business operations,
strategies and focus of ENvue. ENvue&#8217;s failure to successfully market the ENvue System, as well as its other products, will significantly
diminish the anticipated benefits of the Merger and have a material adverse effect on the business of NanoVibronix. There is no assurance
that NanoVibronix&#8217;s business operations, strategies or focus will be successful following the Merger, and the Merger could depress
the value of the NanoVibronix&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 71; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
concentration of the capital stock ownership with insiders of NanoVibronix after the Merger will likely limit the ability of the stockholders
of NanoVibronix to influence corporate matters.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the Merger, the executive officers, directors, five percent or greater stockholders, and the respective affiliated entities of NanoVibronix,
in the aggregate, beneficially own approximately 65% of NanoVibronix&#8217;s outstanding common stock. As a result, these stockholders,
acting together, have control over matters that require approval by NanoVibronix&#8217;s stockholders, including the election of directors
and approval of significant corporate transactions. Corporate actions might be taken even if other stockholders oppose them. This concentration
of ownership might also have the effect of delaying or preventing a corporate transaction that other stockholders may view as beneficial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>NanoVibronix
may be required to take write-downs or write-offs, restructuring and impairment or other charges that could have a significant negative
effect on its financial condition, results of operations and stock price, which could cause you to lose some or all of your investment.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
NanoVibronix has conducted due diligence on ENvue, there can be no assurances that our diligence revealed all material issues that may
be present in ENvue&#8217;s business, that all material issues through a customary amount of due diligence will be uncovered, or that
factors outside of NanoVibronix&#8217;s control will not later arise. As a result, NanoVibronix may be forced to later write-down or
write-off assets, restructure operations, or incur impairment or other charges that could result in losses. Even if due diligence successfully
identifies certain risks, unexpected risks may arise, and previously known risks may materialize in a manner not consistent with NanoVibronix&#8217;s
preliminary risk analysis. Even though these charges may be non-cash items and may not have an immediate impact on liquidity, the fact
that NanoVibronix reports charges of this nature could contribute to negative market perceptions about NanoVibronix or its securities.
In addition, charges of this nature may make future financing difficult to obtain on favorable terms or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pursuant
to the terms of the Merger Agreement, we are required to obtain stockholder approval for conversion of all outstanding shares of our
Series X Preferred Stock into shares of our common stock. We cannot guarantee that our stockholders will approve this matter.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the Merger Agreement, we agreed to take all action necessary under applicable law to obtain the requisite approval for the
conversion of all outstanding shares of Series X Preferred Stock issued in the Merger into shares of our common stock, as required by
the Nasdaq Listing Rules, at a stockholders meeting to be held as soon as practicable following the execution of the Merger Agreement,
which would be time consuming and costly. Additionally, if we breach any of our obligations and covenants set forth in the Series X Certificate
of Designation, then we shall, at the request of the requisite Series X Preferred Stock holders (the &#8220;Settlement Request&#8221;),
pay, out of funds legally available therefor, and prior to any payment in satisfaction of any redemption rights of any other class or
series of capital stock, an amount in cash equal to the stated value of the shares of Series X Preferred Stock held by each holder, with
such payment to be made within two (2) Business Days from the date of Settlement Request, and upon payment in full of the stated value
for such shares of Series X Preferred Stock, such shares shall be redeemed, retired and no longer be outstanding. Such Settlement Request
could therefore materially affect our results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to NanoVibronix&#8217;s Business </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have a history of losses, and we expect to continue to incur losses and may not achieve or maintain profitability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the fiscal year ended December 31, 2024, and 2023, we had a net loss of approximately $3.7 million and $3.7 million, respectively, with
revenues of approximately $2.5 million and $2.3 million, respectively. As of December 31, 2024, and 2023, we had an accumulated deficit
of approximately $70.0 million and $66.1 million, respectively. We expect to incur losses for at least the next year, as we continue
to incur expenses related to seeking U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval for UroShield, and market acceptance
of PainShield, which will require costly additional clinical trials and research, further product development and professional fees associated
with regulatory compliance. Even if we succeed in commercializing our new products, we may not be able to generate sufficient revenues
to cover our expenses and achieve profitability or be able to maintain profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 72; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
Company&#8217;s financial statements have been prepared on a going concern basis, and do not include adjustments that might be necessary
if the Company is unable to continue as a going concern. Management has substantial doubt about the Company&#8217;s ability to continue
as a going concern.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s unaudited condensed consolidated financial statements have been prepared on a going concern basis, which
contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. During the year ended
December 31, 2024, the Company&#8217;s cash used in operations was $2.5 million leaving a cash balance of $752,000 as of December
31, 2024. Because the Company does not have sufficient resources to fund our operations for the next twelve months from the date of
this filing, management has substantial doubt about the Company&#8217;s ability to continue as a going concern. In addition, the
Company has incurred additional short-term debt related to the merger transaction. The consolidated financial statements do not
include any adjustments relating to the recoverability and classification of asset amounts or the classification of liabilities that
might be necessary should the Company be unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will need to raise additional capital to finance its losses, debt obligations, and negative cash flows from operations and may continue to be dependent
on additional capital raising as long as our products do not reach commercial profitability. There are no assurances that the Company
would be able to raise additional capital on terms favorable to it. If the Company is unsuccessful in commercializing its products and
raising capital, it will need to reduce activities, curtail, or cease operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Global
economic and political instability and conflicts, such as the conflict between Russia and Ukraine, could adversely affect our business,
financial condition or results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business could be adversely affected by unstable economic and political conditions within the United States and foreign jurisdictions
and geopolitical conflicts, such as the conflict between Russia and Ukraine. While we do not have any customer or direct supplier relationships
in either country at this time, the current military conflict, and related sanctions, as well as export controls or actions that may
be initiated by nations including the United States, the European Union or Russia (e.g., potential cyberattacks, disruption of energy
flows, etc.) and other potential uncertainties could adversely affect our business and/or our supply chain, business partners, employees
or customers, and interrupt our ability to supply products, or otherwise adversely impact our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Increasing
inflation could adversely affect our business, financial condition, results of operations or cash flows.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inflation,
as well as some of the measures taken by or that may be taken by the governments in countries where we operate in an attempt to curb
inflation may have negative effects on the economies of those countries generally. If the United States or other countries where we operate
experience substantial inflation in the future, our business may be adversely affected. This could have a material adverse effect on
our business, financial condition, results of operations, or cash flows. Specifically, our existing distributor agreements limit the
amount that we can increase the price that we sell our products to the distributors. Accordingly, an inflationary environment, including
factors such as increasing freight and materials prices, could make it less profitable for us to do business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to raise additional capital, our clinical trials and product development will be limited and our long-term viability will
be threatened; however, if we do raise additional capital, your percentage ownership as a stockholder could decrease and constraints
could be placed on the operations of our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have experienced negative operating cash flows since our inception and have funded our operations primarily from proceeds of the sale
of our securities, with only limited revenue being generated from our product sales. In order to fully realize our business objectives,
we may need to raise additional capital. We will seek to raise such additional funds through equity or debt financings, or strategic
alliances with third parties, either alone or in combination with equity financings. These financings could result in substantial dilution
to the holders of our common stock, or require contractual or other restrictions on our operations or on alternatives that may be available
to us. If we raise additional funds by issuing debt securities, these debt securities could impose significant restrictions on our operations
through the imposition of restrictive covenants and requiring us to pledge assets in order to secure repayment. In addition, if we raise
funds through the sale of equity, we may issue equity securities with rights superior to our common stock, including voting rights, rights
to proceeds upon our liquidation or sale, rights to dividends and rights to appoint board members. There can be no assurance that we
will be able to complete a required financing on acceptable terms or at all. If such financing is not available on satisfactory terms,
or is not available in sufficient amounts, we may be required to delay, limit or eliminate the development of business opportunities.
The failure to procure such required financing could have a material adverse effect on our business, financial condition and results
of operations, or threaten our ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
variety of factors could impact the timing and amount of any required financings, including, without limitation:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen
    developments during our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in our receipt of required regulatory approvals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delayed
    market acceptance of our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated
    expenditures in our acquisition and defense of intellectual property rights, and/or the loss of those rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    failure to develop strategic alliances for the marketing of some of our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen
    changes in healthcare reimbursement for any of our approved products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack
    of financial resources to adequately support our operations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
    in maintaining commercial scale manufacturing capacity and capability;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated
    difficulties in operating in international markets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated
    financial resources needed to respond to technological changes and increased competition;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen
    problems in attracting and retaining qualified personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">enactment
    of new legislation or administrative regulations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    application to our business of new regulatory interpretations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">claims
    that might be brought in excess of our insurance coverage;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    failure to comply with regulatory guidelines;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    uncertainty in industry demand; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    delisting of our common stock from Nasdaq.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
required financing efforts may divert our management from their day-to-day activities, which may adversely affect its ability to develop
and commercialize our products. Moreover, if we complete additional financing by issuing equity securities, the percentage ownership
of its existing stockholders may be reduced, and accordingly these stockholders may experience substantial dilution. Given our need for
cash and that equity issuances are the most common type of fundraising for similarly situated companies, the risk of dilution is particularly
significant for our stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, although we have no present commitments or understandings to do so, we may seek to expand our operations and product lines
through acquisitions or joint ventures. Any acquisition or joint venture would likely increase our capital requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to obtain an adequate level of reimbursement for our approved products by third party payers, there may be no commercially viable
markets for our approved products or the markets may be much smaller than expected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
availability and levels of reimbursement by governmental and other third party payers affect the market for our commercial products.
The efficacy, safety, performance and cost-effectiveness of our product and product candidates, and of any competing products, will determine
the availability and level of reimbursement. Reimbursement and healthcare payment systems vary significantly by country, and include
both government sponsored healthcare and private insurance. To obtain reimbursement or pricing approval in some countries, we may be
required to produce clinical data, which may involve one or more clinical trials, that compares the cost-effectiveness of our approved
products to other available therapies. We may not obtain reimbursement or pricing approvals in markets we seek to enter in a timely manner,
if at all. Our failure to receive reimbursement or pricing approvals in target markets would negatively impact market acceptance of our
products in these jurisdictions, placing us at a material cost disadvantage to our competitors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain reimbursement approvals for our products, we believe that, in the future, reimbursement for any of our products or product
candidates may be subject to increased restrictions both in the United States and in international markets. Future legislation, regulation
or policies of third party payers that limit reimbursement may adversely affect the demand for our products currently under development
and our ability to sell our products on a profitable basis. In addition, third party payers continually attempt to contain or reduce
the costs of healthcare by challenging the prices charged for healthcare products and services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 74; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, specifically, health care providers, such as hospitals and clinics, and individual patients, generally rely on third-party
payers. Third-party reimbursement is dependent upon decisions by the Centers for Medicare and Medicaid Services, contracted Medicare
carriers or intermediaries, individual managed care organizations, private insurers, other governmental health programs and other payers
of health care costs. Failure to receive or maintain favorable coding, coverage and reimbursement determinations for our products by
these organizations could discourage medical practitioners from using or prescribing our products due to their costs. In addition, with
recent federal and state government initiatives directed at lowering the total cost of health care, the U.S. Congress and state legislatures
will likely continue to focus on health care reform including the reform of the Medicare and Medicaid programs, and on the cost of medical
products and services, which could limit reimbursement. Additionally, third-party payers are increasingly challenging the prices charged
for medical products and services, and imposing conditions on payment. We may be unable to sell our products on a profitable basis if
third-party payers deny coverage, provide low reimbursement rates or reduce their current levels of reimbursement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
medical device and therapeutic product industries are highly competitive and subject to rapid technological change. If our competitors
are able to develop and market products that are safer and more effective than any products we may develop, our commercial opportunities
will be reduced or eliminated.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends, in part, upon our ability to maintain a competitive position in the development of technologies and products. We face
competition from established medical device companies, such as Neurometrix Inc., Zetrox, (a subsidiary of the 3M Company) and Smith &amp;
Nephew plc, manufacturers of certain portable ultrasound devices capable of self-administered use, as well as from academic institutions,
government agencies, and private and public research institutions in the United States and abroad. Most, if not all, of our principal
competitors have significantly greater financial resources and expertise than we do in research and development, manufacturing, pre-clinical
testing, conducting clinical trials, obtaining regulatory approvals, marketing approved products, protecting and defending their intellectual
property rights and designing around the intellectual property rights of others. Other small or early-stage companies may also prove
to be significant competitors, particularly through collaborative arrangements, or mergers with, or acquisitions by, large and established
companies, or through the development of novel products and technologies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
industry in which we operate has undergone, and we expect it to continue to undergo, rapid and significant technological change, and
we expect competition to intensify as technological advances are made. Our competitors may be able to respond to changes in technology
or the marketplace faster than us. Our competitors may develop and commercialize medical devices that are safer or more effective or
are less expensive than any products that we may develop. We also compete with our competitors in recruiting and retaining qualified
scientific and management personnel, in establishing clinical trial sites and patient registration for clinical trials, and in acquiring
technologies complementary to our programs or advantageous to our business. Given our small size and lack of resources, we are often
at a disadvantage with our competitors in all of these areas, which could limit or eliminate our commercial opportunities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
face the risk of product liability claims and may not be able to obtain insurance.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business exposes us to the risk of product liability claims that are inherent in the development of medical devices and products. If
the use of one or more of our products harms people, we may be subject to costly and damaging product liability claims brought against
us by clinical trial participants, consumers, health care providers, pharmaceutical companies or others selling our products. We currently
carry clinical trial and product liability insurance for the products we sell. However, we cannot predict all of the possible harms or
side effects that may result and, therefore, the amount of insurance coverage we hold may not be adequate to cover all liabilities we
might incur. We intend to expand our insurance coverage to include the sale of additional commercial products as we obtain marketing
approval for our product candidates in development and as our sales expand, but we may be unable to obtain commercially reasonable product
liability insurance for such products. If we are unable to obtain insurance at an acceptable cost or otherwise protect against potential
product liability claims and we continue to make sales, or if our coverages turns out to be insufficient, we may be exposed to significant
liabilities, which may materially and adversely affect our business and financial position. If we are sued for any injury allegedly caused
by our products and do not have sufficient insurance coverage, our liability could exceed our total assets and our ability to pay the
liability. A product liability claim or series of claims brought against us would decrease our cash and could reduce our value or marketability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
product candidates may not be developed or commercialized successfully.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates are based on a technology that has not been used previously in the manner we propose and must compete with more established
treatments currently accepted as the standards of care. Market acceptance of our products will largely depend on our ability to demonstrate
their relative safety, efficacy, cost-effectiveness and ease of use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the risks that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or a foreign regulatory authority finds our product candidates ineffective or unsafe;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    do not receive necessary regulatory approvals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    regulatory review and approval process may take much longer than anticipated, requiring additional time, effort and expense to respond
    to regulatory comments and/or directives;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    are unable to get our product candidates in commercial quantities at reasonable costs; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    patient and physician community does not accept our product candidates.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our product development program may be curtailed, redirected, eliminated or delayed at any time for many reasons, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    or ambiguous results;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">undesirable
    side effects that delay or extend the trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability to locate, recruit, qualify and retain a sufficient number of clinical investigators or patients for our trials; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    delays or other regulatory actions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we currently have limited experience in marketing or selling our products, and we have a limited marketing and sales staff and distribution
capabilities. Developing a marketing and sales force is time-consuming and will involve the investment of significant amounts of financial
and management resources, and could delay the launch of new products or expansion of existing product sales. In addition, we compete
with many companies that currently have extensive and well-funded marketing and sales operations. If we fail to establish successful
marketing and sales capabilities or fail to enter into successful marketing arrangements with third parties, our ability to generate
revenues will suffer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
even if we enter into marketing and distributing arrangements with third parties, we may have limited or no control over the sales, marketing
and distribution activities of these third parties, and these third parties may not be successful or effective in selling and marketing
our products. If we fail to create successful and effective marketing and distribution channels, our ability to generate revenue and
achieve our anticipated growth could be adversely affected. If these distributors experience financial or other difficulties, sales of
our products could be reduced, and our business, financial condition and results of operations could be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot predict whether we will successfully develop and commercialize our product candidates. If we fail to do so, we will not be able
to generate substantial revenues, if any.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to retain our key management, or to attract and keep additional key personnel, we may be unable to successfully execute our business
plan.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends on our ability to attract, retain and motivate highly qualified management and personnel. As a small company with ten
full-time employees and six part-time employees, our success depends on the continuing contributions of our management team and qualified
personnel and on our ability to attract and retain highly qualified personnel. We face intense competition in our hiring efforts from
other medical device companies, as well as from universities and nonprofit research organizations, and we may have to pay higher salaries
to attract and retain qualified personnel. We are also at a disadvantage in recruiting and retaining key personnel as our small size
and limited resources may be viewed as providing a less stable environment, with fewer opportunities than would be the case at one of
our larger competitors. The loss of one or more of these individuals, or our inability to attract additional qualified personnel, could
substantially impair our ability to implement our business plan. In addition, the replacement of key personnel likely would involve significant
time and costs, and may significantly delay or prevent the achievement of our business objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 76; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
need to increase the size of our organization in order to successfully manage our growth.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage company with a small number of planned employees, and our management systems currently in place are not likely to
be adequate to support our future growth plans. Our ability to grow and to manage our growth effectively will require us to hire, train,
retain, manage and motivate additional employees and to implement and improve its operational, financial and management systems. These
demands also may require the hiring of additional senior management personnel or the development of additional expertise by our senior
management personnel. Hiring a significant number of additional employees, particularly those at the management level, would increase
our expenses significantly. Moreover, if we fail to expand and enhance its operational, financial and management systems in conjunction
with its potential future growth, such failure could have a material adverse effect on our business, financial condition and results
of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
failure to protect our intellectual property rights could diminish the value of our solutions, weaken our competitive position and reduce
our revenue.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
regard the protection of our intellectual property, which includes patents and patent applications, trade secrets, trademarks and domain
names, as critical to our success. We strive to protect our intellectual property rights by relying on federal, state and common law
rights, as well as contractual restrictions. We enter into confidentiality and invention assignment agreements with our employees, consultants
and contractors, and confidentiality agreements with parties with whom we conduct business in order to limit access to, and disclosure
and use of, our proprietary information. However, these contractual arrangements and the other steps we have taken to protect our intellectual
property may not prevent the misappropriation of our proprietary information or deter independent development of similar technologies
by others.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have patents, as well as pending patent applications, in both the United States and relevant foreign jurisdictions. There can be no assurance
that our patent applications will be approved, that any patents issued will adequately protect our intellectual property, or that these
patents will not be challenged by third parties or found to be invalid or unenforceable or that our patents would prevent a competitor
from designing around our claims in our patents. We have also obtained trademark registration in the United States and in foreign jurisdictions.
Effective trade secret, trademark and patent protection is expensive to develop and maintain, both in terms of initial and ongoing registration
requirements and the costs of defending our rights. We may be required to protect our intellectual property in an increasing number of
jurisdictions, a process that is expensive and may not be successful or which we may not pursue in every location. We may, over time,
increase our investment in protecting our intellectual property through additional patent filings that could be expensive and time-consuming.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have granted US issued patents, as well as issued patents in Europe and China and a number of corresponding foreign patents in other
relevant jurisdictions, covering UROSHIELD devices and have expiration dates ranging from May of 2023 to July of 2030. We also have pending
patent applications related to UROSHIELD devices, which would have expected expiration dates, if granted, ranging from December of 2041
to March of 2044.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted
patents related to PAINSHIELD, PAINSHIELD PLUS, WOUNDSHIELD have expiration dates of August of 2033 in the United States, and February
of 2027 in Europe, China and Israel. We also have pending patent applications related to PAINSHIELD, PAINSHIELD PLUS, WOUNDSHIELD devices,
which would have expected expiration dates, if granted, ranging from September of 2040 to December of 2041.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Monitoring
unauthorized use of our intellectual property is difficult and costly. Our efforts to protect our proprietary rights may not be adequate
to prevent misappropriation of our intellectual property. We may not be able to detect unauthorized use of, or take appropriate steps
to enforce, our intellectual property rights. Further, our competitors may independently develop technologies that are similar to ours
but which avoid the scope of our intellectual property rights. Further, the laws in the United States and elsewhere change rapidly, and
any future changes could adversely affect us and our intellectual property. Our failure to meaningfully protect our intellectual property
could result in competitors offering solutions that incorporate our most technologically advanced features, which could seriously reduce
demand for our products. In addition, we may in the future need to initiate infringement claims or litigation. Litigation, whether as
a plaintiff or a defendant, can be expensive, time-consuming and may divert the efforts of our technical staff and managerial personnel,
which could harm our business, whether or not the litigation results in a determination that is unfavorable to us. In addition, litigation
is inherently uncertain, and thus we may not be able to stop our competitors from infringing our intellectual property rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 77; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
could incur substantial costs and disruption to our business as a result of any dispute related to, or claim of infringement of another
party&#8217;s intellectual property rights, which could harm our business and operating results.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
recent years, there has been significant litigation in the United States over patents and other intellectual property rights. From time
to time, we may face allegations that we or customers who use our products have infringed the trademarks, copyrights, patents and other
intellectual property rights of third parties, including allegations made by our competitors or by non-practicing entities, or that we
or our customers have misappropriated the intellectual property rights of such third parties. We cannot predict whether assertions of
third party intellectual property rights or claims arising from these assertions will substantially harm our business and operating results.
If we are forced to defend any infringement or misappropriation claims or attacks on the validity of our intellectual property rights,
whether they are with or without merit or are ultimately determined in our favor, we may face costly litigation and diversion of technical
and management personnel. Most of our competitors have substantially greater resources than we do and are able to sustain the cost of
complex intellectual property litigation to a greater extent and for longer periods of time than we could. Furthermore, an adverse outcome
of a dispute may require us, among other things: to pay damages, potentially including treble damages and attorneys&#8217; fees, if we
are found to have willfully infringed a party&#8217;s patent or other intellectual property rights; to cease making, licensing or using
products that are alleged to incorporate or make use of the intellectual property of others; to expend additional development resources
to redesign our products; and to enter into potentially unfavorable royalty or license agreements in order to obtain the rights to use
necessary technologies. Royalty or licensing agreements, if required, may be unavailable on terms acceptable to us, or at all. In any
event, we may need to license intellectual property which would require us to pay royalties or make one-time payments. Even if these
matters do not result in litigation or are resolved in our favor or without significant cash settlements, the time and resources necessary
to resolve them could harm our business, operating results, financial condition and reputation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
face risks associated with litigation and claims.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may, in the future, be involved in one or more lawsuits, claims or other proceedings. These suits could concern issues including contract
disputes, employment actions, employee benefits, taxes, environmental, health and safety, fraud and abuse, personal injury and product
liability matters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 26, 2021, Protrade Systems, Inc. (&#8220;Protrade&#8221;) filed a Request for Arbitration (the &#8220;Request&#8221;) with the
International Court of Arbitration (the &#8220;ICA&#8221;) of the International Chamber of Commerce alleging the Company is in breach
of an Exclusive Distribution Agreement dated March 7, 2019 (the &#8220;Agreement&#8221;) between Protrade and the Company. Protrade alleges,
in part, that the Company has breached the Agreement by discontinuing the manufacture of the DV0057 Painshield MD device in favor of
an updated 10-100-001 Painshield MD device. Protrade claims damages estimated at $3 million. The Company vigorously defended the claims
asserted by Protrade.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 15, 2022, the arbitrator issued a final award, which, determined that (i) the Company had the right to terminate the Exclusive
Distribution Agreement; (ii) the Company did not breach the duty of good faith and fair dealing with regard to the Exclusive Distribution
Agreement; and (iii) the Company did not breach any confidentiality obligations to Protrade. Nevertheless, the arbitrator determined
that the Company did not comply with the obligation to supply Protrade with a year&#8217;s supply of patches, and awarded Protrade $1,500,250,
which consists of $1,432,000 for &#8220;lost profits&#8221; and $68,250 as reimbursement of arbitration costs, on the grounds that the
Company allegedly failed to supply Protrade with certain patches utilized by users of DV0057 Painshield MD device. The arbitrator based
the decision on the testimony of Protrade&#8217;s president who asserted that a user would use in excess of 33 patches per each device.
The Company believes that the number of patches per device alleged by Protrade is grossly inflated, and that these claims were not properly
raised before the arbitrator. Accordingly, on April 13, 2022, the Company submitted an application for the correction of the award which
the arbitrator denied on June 22, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 5, 2022, Protrade filed a Petition with the Supreme Court of New York Nassau County seeking to confirm the Award. On April 13,
2022, the Company submitted an application to the ICA seeking to correct an error in the award based on the evidence that the Company
only sold 2-3 reusable patches per device contrary to the 33 reusable patches claimed by Protrade. The same arbitrator who issued the
award, denied the application.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 22, 2022, the Company filed a cross-motion seeking to vacate arbitration award on the grounds that the arbitrator exceeded her authority,
that the award was procured by fraud, and that the arbitrator failed to follow procedures established by New York law. In particular,
the Company averred in its motion that Protrade&#8217;s witness made false statements in arbitration, and that the arbitrator resolved
a claim that was never raised by Protrade and that has no factual basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2022, the court issued a decision granting Protrade its petition to confirm the award and denying the cross-motion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 9, 2022, the Company filed a motion to re-argue and renew its cross-motion to vacate the arbitration decision based on newer
information that was not available during the initial hearing. On the same day, the Company also filed a notice of appeal with the Appellate
Division, Second Department. On March 21, 2023, the court denied the motion to re-argue and renew.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 10, 2023, the Company filed its appeal with the Appellate Division, Second Department. That appeal is now fully briefed. In February 2025, the Second Department informed counsel for the Company that the Second Department
was beginning to process the appeal for calendaring.&#8221; </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, and 2023, the Company accrued the amount of the arbitration award to Protrade of approximately $2.1 and $2.0
million, respectively, including interest which is classified in &#8220;Other accounts payable and accrued
expenses&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business and operations would suffer in the event of computer system failures, cyber-attacks or deficiencies in our cyber-security.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of our business, we collect and store sensitive data, including intellectual property, research data, our proprietary
business information and that of our suppliers, technical information about our products, clinical trial plans and employee records.
Similarly, our third-party providers possess certain of our sensitive data and confidential information. The secure maintenance of this
information is critical to our operations and business strategy. Despite the implementation of security measures, our internal computer
systems, and those of third parties on which we rely, are vulnerable to damage from computer viruses, malware, ransomware, cyber fraud,
natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet, attachments
to emails, persons inside our organization, or persons with access to systems inside our organization. The risk of a security breach
or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists,
has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased.
Any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, encrypted, lost
or stolen. Any such access, inappropriate disclosure of confidential or proprietary information or other loss of information, including
our data being breached at third-party providers, could result in legal claims or proceedings, liability or financial loss under laws
that protect the privacy of personal information, disruption of our operations or our product development programs and damage to our
reputation, which could adversely affect our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may acquire businesses or products, or form strategic alliances, in the future, and may not realize the benefits of such acquisitions.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NanoVibronix
may acquire additional businesses or products, form strategic alliances, or create joint ventures with third parties that the Company
believes will complement or augment its existing business. If NanoVibronix acquires businesses with promising markets or technologies,
it may not be able to realize the benefit of acquiring such businesses if it is unable to successfully integrate them with its existing
operations and company culture. NanoVibronix may encounter numerous difficulties in developing, manufacturing, and marketing any new
products resulting from a strategic alliance or acquisition that delay or prevent it from realizing their expected benefits or enhancing
its business. There is no assurance that, following any such acquisition, the combined company will achieve the synergies expected to
justify the transaction, which could result in a material adverse effect on the combined company&#8217;s business and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 79; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Certain
stockholders could attempt to influence changes within NanoVibronix, which could adversely affect NanoVibronix</i></b>&#8217;<b><i>s
operations, financial condition and the value of NanoVibronix</i></b>&#8217;<b><i>s common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NanoVibronix&#8217;s
stockholders may from time to time seek to acquire a controlling stake in NanoVibronix, engage in proxy solicitations, advance stockholder
proposals or otherwise attempt to effect changes. Campaigns by stockholders to effect changes at publicly traded companies are sometimes
led by investors seeking to increase short-term stockholder value through actions such as financial restructuring, increased debt, special
dividends, stock repurchases or sales of assets or the entire company. Responding to proxy contests and other actions by activist stockholders
can be costly and time-consuming. These actions could adversely affect the combined company&#8217;s operations, financial condition,
and the value of NanoVibronix&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to NanoVibronix&#8217;s Regulatory and Compliance Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are subject to extensive governmental regulation, including the requirement of U.S. Food and Drug Administration approval or clearance
before our product candidates may be marketed and after approval or clearance and during the marketing of our products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process of obtaining FDA approval is lengthy, expensive and uncertain, and we cannot be sure that our additional product candidates will
be approved in a timely fashion, or at all. If the FDA does not approve or clear our product candidates in a timely fashion, or at all,
our business and financial condition would likely be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
before and after approval or clearance of our product candidates, we, our product candidates, our suppliers and our contract manufacturers
are subject to extensive regulation by governmental authorities in the United States and other countries. Failure to comply with applicable
requirements could result in, among other things, any of the following actions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    issuance of Form 483 or Warning Letters, which may be made public and may lead to further regulatory or enforcement actions, or similar
    letters by other regulatory authorities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines
    and other monetary penalties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated
    expenditures;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in FDA approval and clearance, or FDA refusal to approve or clear a product candidate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    recall or seizure;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruption
    of manufacturing or clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operating
    restrictions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunction
    or other restrictions imposed on our operations, including closing our facilities or our contract manufacturers&#8217; facilities;
    or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">criminal
    prosecutions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the approval and clearance requirements, numerous other regulatory requirements apply, both before and after approval or
clearance, to us, our products and product candidates, and our suppliers and contract manufacturers. These include requirements related
to the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">testing
    and quality control;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 24px; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">quality
    assurance;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">labelling;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">advertising;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">promotion
    (including the prohibition on promoting devices for &#8220;off-label&#8221; uses);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">distribution;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">export;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reporting
    to the FDA certain adverse experiences associated with the use of the products, as well as our discovery of defects or a product&#8217;s
    failure to comply with design specifications or applicable law; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    additional approvals or clearances for certain modifications to the products or their labelling or claims.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also subject to inspection by the FDA to determine our compliance with regulatory requirements, as are our suppliers and contract
manufacturers, and we cannot be sure that the FDA will not identify compliance issues that may disrupt production or distribution, or
require substantial resources to correct. We also cannot be sure that the FDA will agree with our analysis of, conclusions regarding,
or handling of various situations that arise with our products. If it is determined that we failed to comply with any of our regulatory
obligations, we could be subject to a wide range of enforcement actions that could limit our ability to continue to successfully commercialize
impacted products or otherwise adversely impact us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA&#8217;s requirements may change and additional government regulations may be promulgated that could affect us, our product candidates,
and our suppliers and contract manufacturers. We cannot predict the likelihood, nature or extent of government regulation that may arise
from future legislation or administrative action. There can be no assurance that we will not be required to incur significant costs to
comply with such laws and regulations in the future, or that such laws or regulations will not have a material adverse effect upon our
business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>UroShield
has not been cleared or approved by the FDA, nor has it undergone the same type of review as an FDA-approved or cleared device.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2020, the FDA exercised its Enforcement Discretion to allow distribution of our UroShield device in the United States. According
to the FDA, &#8220;UroShield device could use Intended Use Code (IUC) 081.006: Enforcement discretion per final guidance, and FDA product
code QMK (extracorporeal acoustic wave generating accessory to urological indwelling catheter for use during the COVID-19 pandemic)&#8221;
Accordingly, the FDA&#8217;s Enforcement Discretion temporarily cleared the way for import of UroShield to the U.S. during the COVID-19
pandemic, immensely expanding the company&#8217;s addressable market for the device during this time period. As of the date of this report,
we have not been notified of any change in our Enforcement Discretion status and we will continue to operate under Enforcement Discretion
guidelines, or until we are notified of a change in status by a qualified regulatory body. The device is designed to aid in the prevention
of CAUTI incidence in patients requiring long-term indwelling catheterization, defined as 14 days or greater.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
temporary authorization was limited to use as an extracorporeal acoustic wave generating accessory to urological indwelling catheter
for use during the COVID-19 pandemic. The U.S. government has since-terminated the public health emergency, and FDA recently confirmed
via guidance that the applicable policy of Enforcement Discretion under which UroShield was marketed during the pandemic will expire
in November 2023. Accordingly, if we do not obtain FDA approval or clearance by the expiration of the applicable Enforcement Discretion
policy in November 2023, we will have to discontinue distribution of UroShield in the U.S. until FDA grants the requisite premarket authorization,
which may not occur in a timely manner, if at all. There is no guarantee that our collaborators or customers will purchase or use the
UroShield, that any sales of UroShield by us will generate any revenue or profits, or that we will ever be successful in obtaining FDA
clearance or approval for the UroShield.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to obtain regulatory approval in foreign jurisdictions will prevent us from marketing our products abroad.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International
sales of our products and any of our product candidates that we commercialize are subject to the regulatory requirements of each country
in which the products are sold. Accordingly, the introduction of our product candidates in markets outside the United States where we
do not already possess regulatory approval will be subject to regulatory approvals in those jurisdictions. The regulatory review process
varies from country to country. Many countries impose product standards, packaging and labelling requirements, and import restrictions
on medical devices. In addition, each country has its own tariff regulations, duties and tax requirements, as well as reimbursement and
healthcare payment systems. The approval by foreign government authorities is unpredictable and uncertain, and can be expensive. We may
be required to perform additional pre-clinical, clinical or post-approval studies even if FDA approval has been obtained. Our ability
to market our approved products could be substantially limited due to delays in receipt of, or failure to receive, the necessary approvals
or clearances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 81; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are uncertain regarding the success of our clinical trials for our products in development.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that all of our novel lines of product candidates in development, which currently consists of only RenooSkin, will require clinical
trials to determine their safety and efficacy by regulatory bodies in their target markets, including the FDA and various foreign regulators.
There can be no assurance that we will be able to successfully complete the U.S. and foreign regulatory approval processes for products
in development. In addition, there can be no assurance that we will not encounter additional problems that will cause us to delay, suspend
or terminate our clinical trials. In addition, we cannot make any assurance that clinical trials will be deemed sufficient in size and
scope to satisfy regulatory approval requirements, or, if completed, will ultimately demonstrate our products to be safe and efficacious.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Healthcare
reform measures could adversely affect our business and financial results.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare
system in ways that may adversely affect our business and financial results. Federal and state lawmakers regularly propose and, at times,
enact legislation that could result in significant changes to the healthcare system, some of which are intended to contain or reduce
the costs of medical products and services. Current and future legislative proposals to further reform healthcare or reduce healthcare
costs may limit coverage of or lower reimbursement for our products. The cost containment measures that payers and providers are instituting
and the effect of any healthcare reform initiative implemented in the future could impact our revenue from the sale of our products.
For example, the Patient Protection and Affordable Act of 2010, commonly referred to as the Affordable Care Act, contains a number of
provisions, including those governing enrollment in federal healthcare programs, reimbursement changes and fraud and abuse measures,
all of which will impact existing government healthcare programs and will result in the development of new programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been executive, judicial and Congressional challenges to certain aspects of the Affordable Care Act for over a decade. However,
as of the Supreme Court&#8217;s ruling ordering the dismissal of, arguably, the most promising case challenging the Affordable Care Act
to-date in June 2021, it appears that the Affordable Care Act will remain in-effect in its current form for the foreseeable future. We
cannot predict what additional challenges to the Affordable Care Act may arise in the future, the outcome thereof, or the impact any
such actions may have on our business. Additionally, the Biden administration has introduced various measures in recent years, focusing
on healthcare and medical-product pricing, in particular. It remains to be seen how these measures will affect our business and there
is uncertainty as to what other healthcare programs and regulations may be implemented or changed at the federal and/or state level in
the U.S., but it is possible that such initiatives could have an adverse effect on our ability to obtain FDA approval or clearance and/or
successfully commercialize products in the U.S. in the future. For example, any changes that reduce, or impede the ability of healthcare
providers to obtain reimbursement for medical procedures in which the products we currently, or intend to, commercialize are used, or
that reduce medical procedure volumes, could adversely affect our operations and/or future business plans. The financial impact of U.S.
healthcare reform legislation over the next few years will depend on a number of factors, including the policies reflected in implementing
regulations and guidance and changes in sales volumes for medical devices affected by the legislation. From time to time, legislation
is drafted, introduced, and passed that could significantly change the statutory provisions governing coverage, reimbursement, pricing,
and marketing of medical device products. In addition, third-party payor coverage and reimbursement policies are often revised or interpreted
in ways that may significantly affect our business and our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with the U.S. federal and state fraud and abuse and other health care laws and regulations, we could be subject to
criminal and civil penalties and exclusion from the Medicare and Medicaid programs, which would have a material adverse effect on our
business and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our financial relationships with health care providers and others who provide products or services to federal health care program
beneficiaries are potentially governed by the federal and state fraud and abuse laws, and other health care laws and regulations may
be or become applicable to our business and operations and expose us to risk. For example:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal Anti-Kickback Statute, which prohibits the offer, payment, solicitation or receipt of any form of remuneration in return
    for referring, ordering, leasing, purchasing or arranging for, or recommending the ordering, purchasing or leasing of, items or services
    payable by Medicare, Medicaid or any other federal health care program.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 82; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal
    false claims laws and civil monetary penalty laws, including the False Claims Act, that prohibit, among other things, individuals
    or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other government
    health care programs that are false or fraudulent, or making a false statement to avoid, decrease or conceal an obligation to pay
    money to the federal government.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits knowingly and willfully executing,
    or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses,
    representations, or promises, any of the money or property owned by, or under the custody or control of, any health care benefit
    program, and for knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statements
    in connection with the delivery of or payment for health care benefits, items or services.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
    as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and its implementing regulations, which
    also impose obligations and requirements on health care providers, health plans, and healthcare clearinghouses as well as their respective
    business associates that perform certain services for them that involve the use or disclosure of individually identifiable health
    information, with respect to safeguarding the privacy and security of certain individually identifiable health information.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal transparency requirements under the Affordable Care Act, including the provision commonly referred to as the Physician Payments
    Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under
    Medicare, Medicaid or Children&#8217;s Health Insurance Program to report annually to Centers for Medicare and Medicaid Services,
    or CMS, information related to payments and other transfers of value to physicians and teaching hospitals, and ownership and investment
    interests held by physicians and their immediate family members.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Analogous
    state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may be broader in scope and apply
    to referrals and items or services reimbursed by both governmental and non-governmental third-party payers, including private insurers,
    many of which differ from each other in significant ways and often are not pre-empted by federal law, thus complicating compliance
    efforts.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our
business activities could be subject to challenge under one or more of such laws. In addition, recent health care reform legislation
has strengthened these laws. Efforts to ensure that our business arrangements with third parties and our operations are compliant with
applicable health care laws and regulations will involve the expenditure of appropriate, and possibly significant, resources. If we are
found to be in violation of any current or future statutes or regulations involving applicable fraud and abuse or other health care laws
and regulations, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment,
exclusion from government funded health care programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished
profits and future earnings, which could have a material adverse effect on our business, results of operations and financial condition.
If any physicians or other health care providers or entities with whom we expect to do business are found to not be in compliance with
applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded health
care programs, which could adversely affect our ability to operate our business and our results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to NanoVibronix&#8217;s Operations in Israel </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
conduct our operations in Israel. Conditions in Israel, including the recent attack by Hamas and other terrorist organizations from the
Gaza Strip, and the region, and Israel&#8217;s war against them, may affect our operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we are incorporated under the laws of the state of Israel and our operations are conducted in Israel, our business and operations are
directly affected by economic, political, geopolitical, and military conditions in Israel. Since the establishment of the State of Israel
in 1948, a number of armed conflicts have occurred between Israel and its neighboring countries and terrorist organizations active in
the region. These conflicts have involved missile strikes, hostile infiltrations, and terrorism against civilian targets in various parts
of Israel, which have negatively affected business conditions in Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 83; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian
and military targets. Hamas also launched extensive rocket attacks on the Israeli population and industrial centers located along Israel&#8217;s
border with the Gaza Strip and in other areas within the State of Israel. Following the attack, Israel&#8217;s security cabinet declared
war against Hamas and a military campaign against the terrorist organization commenced in parallel to their continued rocket and terror
attacks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the attack by Hamas on Israel&#8217;s southern border, Hezbollah in Lebanon has also launched missiles, rockets, and shooting attacks
against Israeli military sites, troops, and Israeli towns in northern Israel. In response to these attacks, the Israeli army has carried
out a number of targeted strikes on sites belonging to Hezbollah in southern Lebanon and begun conducting a limited ground operation
in southern Lebanon, which has the potential to escalate into a wider regional conflict.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, Iran recently launched direct attacks on Israel. Iran is also believed to have a strong influence among extremist groups in
the region, such as Hamas in Gaza, Hezbollah in Lebanon, the Houthi movement in Yemen and various rebel militia groups in Syria and Iraq.
The Houthis, a military organization based in Yemen, have launched a series of attacks on global shipping routes in the Red Sea, as well
as direct attacks on various parts of Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
incidents contribute to regional instability and could potentially escalate into broader conflicts with Iran and its proxies in the middle
east, affecting Israel&#8217;s political and trade relations, especially with neighboring countries and global allies. The situation
remains fluid, and the potential for further escalation exists.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
hostilities involving Israel, or the interruption or curtailment of trade within Israel or between Israel and its trading partners, or
the ability to ship our products overseas, could adversely affect our operations and results of operations and could make it more difficult
for us to raise capital. Parties with whom we may do business have sometimes declined to travel to Israel during periods of heightened
unrest or tension, forcing us to make alternative arrangements when necessary. The conflict situation in Israel could cause situations
where medical product certifying or auditing bodies could not be able to visit manufacturing facilities of our subcontractors in Israel
in order to review our certifications or clearances, thus possibly leading to temporary suspensions or even cancellations of our product
clearances or certifications. The conflict situation in Israel could also result in parties with whom we have agreements involving performance
in Israel claiming that they are not obligated to perform their commitments under those agreements pursuant to force majeure provisions
in such agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been travel advisories issued related to travel to Israel, restriction on travel, and delays and disruptions as related to imports
and exports may be imposed in the future. An inability to receive supplies and materials, shortages of materials or difficulties in procuring
our materials, among others, or conversely, our ability to ship products to our US facilities or overseas customers, may adversely impact
our ability to commercialize and manufacture our product candidates and products in a timely manner. This could cause a number of delays
and/or issues for our operations, including delay of the review of our product candidates by regulatory agencies, which in turn would
have a material adverse impact on our ability to commercialize our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
members of our management and employees are located and reside in Israel. Shelter-in-place and work-from-home measures, government-imposed
restrictions on movement and travel, and other precautions taken to address the ongoing conflict may temporarily disrupt our management
and employees&#8217; ability to effectively perform their daily tasks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
IDF, the national military of Israel, is a conscripted military service, subject to certain exceptions. None of our employees are subject
to military service in the IDF and have been called to serve, but many do serve on guard duty in their local communities from time to
time. It is possible that there will be further military reserve duty call-ups in the future, which may affect our business due to a
shortage of skilled labor and loss of institutional knowledge, and necessary mitigation measures we may take to respond to a decrease
in labor availability, such as overtime and third-party outsourcing, for example, which may have unintended negative effects and adversely
impact our results of operations, liquidity, or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 84; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is currently not possible to predict the duration or severity of the ongoing conflict or its effects on our business, operations, and
financial conditions. The ongoing conflict is rapidly evolving and developing, and could disrupt our business and operations, interrupt
our sources and availability of supply, and hamper our ability to raise additional funds or sell our securities, among others.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because
a certain portion of our expenses is incurred in currencies other than the U.S. dollar, our results of operations may be harmed by currency
fluctuations and inflation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our revenues from future licensing agreements to be denominated mainly in U.S. dollars or in Euros. We pay a substantial portion
of our expenses in U.S. dollars; however, a portion of our expenses, related to salaries of the employees in Israel and payment to part
of the service providers in Israel and other territories, are paid in New Israeli Shekels, or NIS, and in other currencies. In addition,
a portion of our financial assets is held in NIS and in other currencies. As a result, we are exposed to the currency fluctuation risks,
and we do not attempt to hedge against such risks. For example, if the NIS strengthens against the U.S. dollar, our reported expenses
in U.S. dollars may be higher than anticipated. In addition, if the NIS weakens against the U.S. dollar, the U.S. dollar value of our
financial assets held in NIS will decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>It
may be difficult for investors in the United States to enforce any judgments obtained against us or any of our directors or officers.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Almost
all of our assets are located outside the United States, although we do maintain a permanent place of business within the United States.
In addition, some of our officers and directors are nationals and/or residents of countries other than the United States, and all or
a substantial portion of such persons&#8217; assets are located outside the United States. As a result, it may be difficult for investors
to enforce within the United States any judgments obtained against us or any of our non-U.S. directors or officers, including judgments
predicated upon the civil liability provisions of the securities laws of the United States or any state thereof. Additionally, it may
be difficult to assert U.S. securities law claims in actions originally instituted outside of the United States. Israeli courts may refuse
to hear a U.S. securities law claim because Israeli courts may not be the most appropriate forums in which to bring such a claim. Even
if an Israeli court agrees to hear a claim, it may determine that the Israeli law, and not U.S. law, is applicable to the claim. Further,
if U.S. law is found to be applicable, certain content of applicable U.S. law must be proved as a fact, which can be a time-consuming
and costly process, and certain matters of procedure would still be governed by the Israeli law. Consequently, you may be effectively
prevented from pursuing remedies under U.S. federal and state securities laws against us or any of our non-U.S. directors or officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to NanoVibronix&#8217;s Organization and Securities </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
price of our securities may be volatile, and the market price of our securities may drop below the price you pay.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that the price of our securities will fluctuate significantly. Market prices for securities of early-stage medical device companies
have historically been particularly volatile. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section and elsewhere
in this Annual Report, these factors include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">progress,
    or lack of progress, in developing and commercializing our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">favorable
    or unfavorable decisions about our products or intellectual property from government regulators, insurance companies or other third-party
    payers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to recruit and retain qualified regulatory and research and development personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in investors&#8217; and securities analysts&#8217; perception of the business risks and conditions of our business;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in our relationship with key collaborators;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the market valuation or earnings of our competitors or companies viewed as similar to us;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in key personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">depth
    of the trading market in our common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in our capital structure, such as future issuances of securities or the incurrence of additional debt;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    granting or exercise of employee stock options or other equity awards;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">realization
    of any of the risks described under this section entitled &#8220;Risk Factors&#8221;; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    market and economic conditions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 85; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
recent years, the stock markets, in general, have experienced extreme price and volume fluctuations especially in the biotechnology sector.
Broad market and industry factors may materially harm the market price of shares of our common stock. In the past, following periods
of volatility in the market price of a company&#8217;s securities, securities class action litigation has often been instituted against
that company. If we were involved in any similar litigation, we could incur substantial costs and our management&#8217;s attention and
resources could be diverted. In the recent past, the U.S. and global markets have been experiencing volatility and disruption following
the escalation of geopolitical tensions and the start of the military conflict between Russia and Ukraine, and Israel and certain hostile
entities. A continuation or worsening of the levels of market disruption and volatility could have an adverse effect on our ability to
access capital, on our business, results of operations and financial condition, and on the market price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have a significant number of warrants and options, and future sales of our common stock upon exercise of these options or warrants, or
the perception that future sales may occur, may cause the market price of our common stock to decline, even if our business is doing
well.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of a significant number of shares of our common stock in the public market could harm the market price of our common stock and make it
more difficult for us to raise funds through future offerings of common stock. Our stockholders and the holders of our outstanding warrants
and options, upon exercise of these options or warrants, may sell substantial amounts of our common stock in the public market. The availability
of these shares of our common stock for resale in the public market has the potential to cause the supply of our common stock to exceed
investor demand, thereby decreasing the price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the fact that our stockholders and holders of our warrants and options can sell substantial amounts of our common stock in
the public market, whether or not sales have occurred or are occurring, could make it more difficult for us to raise additional financing
through the sale of equity or equity-related securities in the future at a time and price that we deem reasonable or appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Although
our shares of common stock are listed on Nasdaq, we currently have a limited trading volume, which results in higher price volatility
for, and reduced liquidity of, our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
our shares of common stock are listed on Nasdaq under the symbol &#8220;NAOV,&#8221; trading volume in our common stock has been limited
and an active trading market for our shares of common stock may never develop or be maintained. The absence of an active trading market
increases price volatility and reduces the liquidity of our common stock. As long as this condition continues, the sale of a significant
number of shares of common stock at any particular time could be difficult to achieve at the market prices prevailing immediately before
such shares are offered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with the continued listing requirements of Nasdaq, our common stock may be delisted and the price of our common stock
and our ability to access the capital markets could be negatively impacted.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is currently listed for trading on Nasdaq. We must satisfy Nasdaq&#8217;s continued listing requirements, including, among
other things, a minimum stockholders&#8217; equity of&#8201;$2.5 million and a minimum closing bid price of $1.00 per share or risk
delisting, which would have a material adverse effect on our business. A delisting of our common stock from Nasdaq could materially reduce
the liquidity of our common stock and result in a corresponding material reduction in the price of our common stock. In addition, delisting
could harm our ability to raise capital through alternative financing sources on terms acceptable to us, or at all, and may result in
the potential loss of confidence by investors, suppliers, customers and employees and fewer business development opportunities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 10, 2024, we received the Letter from the Staff of The Nasdaq Stock Market LLC indicating that, based upon the closing bid price
of our common stock for the 30 consecutive business days between February 27, 2024 and April 9, 2024, we did not meet the minimum bid
price of $1.00 per share required for continued listing on Nasdaq pursuant to the Bid Price Rule. The Letter also indicated that we were
provided with a compliance period of 180 calendar days, or until October 7, 2024, in which to regain compliance with the Bid Price Rule
pursuant to Nasdaq Listing Rule 5810(c)(3)(A). We did not regain compliance with the Bid Price Rule by October 7, 2024, and on October
8, 2024, Nasdaq notified us that our securities were subject to delisting from Nasdaq unless we timely requested a hearing before the
Panel. We subsequently timely requested a hearing before the Panel, which was held on December 5, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 86; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 19, 2024, we received an additional deficiency notice from the Staff indicating that we no longer satisfied the $2.5 million
stockholders&#8217; equity requirement set forth in the Equity Rule for continued listing on Nasdaq. The Staff indicated that our non-compliance
with the Equity Rule would be considered by the Panel at the Hearing and could serve as an additional basis for delisting of our securities
from Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 26, 2024, we received the Decision Letter from the Panel granting a limited extension of time for us to demonstrate compliance
with the Bid Price Rule and the Equity Rule for continued listing on Nasdaq, subject to the following conditions: (i) on or before February
27, 2025, we will have obtained stockholder approval to effect a reverse stock split of our common stock; (ii) on or before March 31,
2025, we shall have effected a reverse stock split and, thereafter, maintain a $1.00 closing bid price of our common stock for a minimum
of ten consecutive trading days; (iii) on or before March 31, 2025, we are required to demonstrate compliance with the Equity Rule by
filing public disclosure with the SEC and demonstrate long-term compliance with the Equity Rule; and (iv) on or before March 31, 2025,
we are required to demonstrate compliance with all continued listing requirements for Nasdaq. On February 24, 2025, we obtained approval
from our stockholders to file a certificate of amendment to our Certificate of Incorporation to effectuate the 2025 Reverse Stock Split,
among others, and on March 13, 2025, the 2025 Reverse Stock Split became effective. As of the date of this Annual Report on Form 10-K,
we have not formally regained compliance with listing rules of Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that we will ultimately regain compliance with all applicable requirements
for continued listing on Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
there is no assurance that we will maintain compliance with such minimum listing requirements if we regain compliance with all applicable
requirements for continued listing on Nasdaq. If our common stock were delisted from Nasdaq, trading of our common stock would most likely
take place on an over-the-counter market established for unlisted securities, such as the OTCQB or the Pink Market maintained by OTC
Markets Group Inc. An investor would likely find it less convenient to sell, or to obtain accurate quotations in seeking to buy, our
common stock on an over-the-counter market, and many investors would likely not buy or sell our common stock due to difficulty in accessing
over-the-counter markets, policies preventing them from trading in securities not listed on a national exchange or other reasons. In
addition, as a delisted security, our common stock would be subject to SEC rules as a &#8220;penny stock,&#8221; which impose additional
disclosure requirements on broker-dealers. The regulations relating to penny stocks, coupled with the typically higher cost per trade
to the investor of penny stocks due to factors such as broker commissions generally representing a higher percentage of the price of
a penny stock than of a higher-priced stock, would further limit the ability of investors to trade in our common stock. In addition,
delisting could harm our ability to raise capital through alternative financing sources on terms acceptable to us, or at all, and may
result in the potential loss of confidence by investors, suppliers, customers and employees and fewer business development opportunities.
For these reasons and others, delisting would adversely affect the liquidity, trading volume and price of our common stock, causing the
value of an investment in us to decrease and having an adverse effect on our business, financial condition and results of operations,
including our ability to attract and retain qualified employees and to raise capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are a smaller reporting company, and we cannot be certain if the reduced disclosure requirements applicable to our filing status will
make our common stock less attractive to investors.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a &#8220;smaller reporting company&#8221; and, thus, have certain decreased disclosure obligations in our SEC filings, including,
among other things, simplified executive compensation disclosures and only being required to provide two years of audited financial statements
in annual reports. Decreased disclosures in our SEC filings due to our status as a &#8220;smaller reporting company&#8221; may make it
harder for investors to analyze our results of operations and financial prospects and may make our common stock a less attractive investment.
If some investors find our common stock less attractive, there may be a less active trading market for our common stock and our stock
price may be more volatile.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 87; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Anti-takeover
provisions of our certificate of incorporation, our bylaws and Delaware law could make an acquisition of us, which may be beneficial
to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove the current members of our board
and management.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
provisions of our amended and restated certificate of incorporation and bylaws could discourage, delay or prevent a Merger, acquisition
or other change of control that stockholders may consider favorable, including transactions in which you might otherwise receive a premium
for your shares. Furthermore, these provisions could prevent or frustrate attempts by our stockholders to replace or remove members of
our Board of Directors (the &#8220;Board&#8221; or &#8220;Board of Directors&#8221;). These provisions also could limit the price that
investors might be willing to pay in the future for our securities, thereby depressing the market price of our securities. Stockholders
who wish to participate in these transactions may not have the opportunity to do so. These provisions, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allow
    the authorized number of directors to be changed only by resolution of our Board;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">authorize
    our Board to issue, without stockholder approval, preferred stock, the rights of which will be determined at the discretion of the
    Board and that, if issued, could operate as a &#8220;poison pill&#8221; to dilute the stock ownership of a potential hostile acquirer
    to prevent an acquisition that our Board does not approve;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
    advance notice requirements for stockholder nominations to our Board or for stockholder proposals that can be acted on at stockholder
    meetings; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limit
    who may call a stockholder meeting.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we are governed by the provisions of Section 203 of the Delaware General Corporation Law that may, unless certain criteria
are met, prohibit large stockholders, in particular those owning 15% or more of the voting rights on our common stock, from merging or
combining with us for a prescribed period of time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
securities or industry analysts do not publish research or reports or publish unfavorable research about our business, the price of our
securities and their trading volume could decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our securities will depend in part on the research and reports that securities or industry analysts publish about
us or our business. Currently there is only one research coverage by a securities and industry analyst. If one or more of the analysts
who covers us downgrades our securities, the price of our securities would likely decline. If one or more of these analysts ceases to
cover us or fails to publish regular reports on us, interest in the purchase of our securities could decrease, which could cause the
price of our securities and their trading volume to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to ongoing restrictions related to grants from the Israeli Office of the Chief Scientist.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
our Israeli subsidiary, as of December 31, 2017, we received grants of $437,000 from the Office of the Chief Scientist of the Israeli
Ministry of Industry, Trade and Labor, or the Office of the Chief Scientist, for research and development programs related to products
that we are not currently commercializing or marketing. Because we are no longer developing the product to which the grants relate, we
do not believe that we are subject to any material conditions with respect to the grants, except for the restrictions on our ability
to make certain transfers of the technology or intellectual property related to these grants described below. We could in the future
determine to apply for further grants. If we receive any such grants, we would have to comply with specified conditions, including paying
royalties with respect to grants received. If we fail to comply with these conditions in the future, sanctions might be imposed on us,
such as grants could be cancelled and we could be required to refund any payments previously received under these programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Israeli Encouragement of Industrial Research and Development Law, any products developed with grants from the Office of the Chief
Scientist are required to be manufactured in Israel and certain payments may be required in connection with the change of control of
the grant recipient and the financing, mortgaging, production, exportation, licensing and transfer or sale of its technology and intellectual
property to third parties, which will require the Office of the Chief Scientist&#8217;s prior consent and, in case such a third party
is outside of Israel, extended royalties and/or other fees. This could have a material adverse effect on and significant cash flow consequences
to us if, and when, any technologies, intellectual property or manufacturing rights are exported, transferred or licensed to third parties
outside Israel. If the Office of the Chief Scientist does not wish to give its consent in any required situation or transaction, we would
need to negotiate a resolution with the Office of the Chief Scientist. In any event, such a transaction, assuming it was approved by
the Office of the Chief Scientist, would involve monetary payments, such as royalties or fees, of not less than the applicable funding
received from the Office of the Chief Scientist plus interest, not to exceed, in aggregate, six times the applicable funding received
from the Office of the Chief Scientist.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 88; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because
we do not expect to pay cash dividends for the foreseeable future, you must rely on appreciation of our common stock price for any return
on your investment. Even if we change that policy, we may be restricted from paying dividends on our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not intend to pay cash dividends on shares of our common stock for the foreseeable future. Any determination to pay dividends in the
future will be at the discretion of our Board and will depend upon results of operations, financial performance, contractual restrictions,
restrictions imposed by applicable law and other factors our Board deems relevant. Accordingly, you will have to rely on capital appreciation,
if any, to earn a return on your investment in our common stock. Investors seeking cash dividends in the foreseeable future should not
purchase our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
ability to use our net operating loss carry forwards and certain other tax attributes may be limited.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to utilize our federal net operating loss, carry forwards and federal tax credit may be limited under Sections 382 and 383 of
the Internal Revenue Code of 1986, as amended. The limitations apply if an &#8220;ownership change,&#8221; as defined by Section 382,
occurs. Generally, an ownership change occurs if the percentage of the value of the stock that is owned by one or more direct or indirect
&#8220;five percent shareholders&#8221; increases by more than 50% over their lowest ownership percentage at any time during the applicable
testing period (typically three years). If we have experienced an &#8220;ownership change&#8221; at any time since our formation, we
may already be subject to limitations on our ability to utilize our existing net operating losses and other tax attributes to offset
taxable income. In addition, future changes in our stock ownership, which may be outside of our control, may trigger an &#8220;ownership
change&#8221; and, consequently, Section 382 and 383 limitations. As a result, if we earn net taxable income, our ability to use our
pre-change net operating loss carry forwards and other tax attributes to offset U.S. federal taxable income may be subject to limitations,
which could potentially result in increased future tax liability to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to maintain effective internal control over financial reporting, our business, financial condition or results of operations may
be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public reporting company, we are required to establish and maintain effective internal control over financial reporting. Failure to
establish such internal control, or any failure of such internal control once established, could adversely impact our public disclosures
regarding our business, financial condition or results of operations. Any failure of our internal control over financial reporting could
also prevent us from maintaining accurate accounting records and discovering accounting errors and financial frauds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rules
adopted by the Securities and Exchange Commission pursuant to Section 404 of Sarbanes-Oxley Act of 2002 require annual assessment of
our internal control over financial reporting. The standards that must be met for management to assess the internal control over financial
reporting as effective are complex, and require significant documentation, testing and possible remediation to meet the detailed standards.
We may encounter problems or delays in completing activities necessary to make an assessment of our internal control over financial reporting.
If we cannot assess our internal control over financial reporting as effective, investor confidence and share value may be negatively
impacted. In addition, management&#8217;s assessment of internal control over financial reporting may identify weaknesses and conditions
that need to be addressed in our internal control over financial reporting or other matters that may raise concerns for investors. Any
actual or perceived weaknesses and conditions that need to be addressed in our internal control over financial reporting (including those
weaknesses identified in our periodic reports), or disclosure of management&#8217;s assessment of our internal control over financial
reporting may have an adverse impact on the price of our securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
disclosed in Part II, Item 9A, &#8220;Controls and Procedures,&#8221; in this Annual Report on Form 10-K, we have identified material
weaknesses in our internal control over financial reporting due to lack of adequate controls over management&#8217;s review procedures
for processing, recording and reviewing transactions related to certain contracts, accounting memos and certain monthly closing procedures.
Therefore, we concluded that our internal control over financial reporting and related disclosure controls and procedures were not effective
as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to ENvue </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>References
in this section to the </i>&#8220;<i>Company,</i>&#8221; &#8220;<i>we,</i>&#8221; &#8220;our,&#8221; <i>or </i>&#8220;<i>us</i>&#8221;
<i>generally refer to ENvue Medical Holdings, Corp. and its subsidiaries.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 89; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to ENvue</b>&#8217;<b>s Financial Condition, Business and Operations </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
financial statement footnotes of the Company include disclosure regarding the substantial doubt about the ability of the Company to continue
as a going concern. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENvue&#8217;s
financial statement footnotes include disclosure regarding the substantial doubt about our ability to continue as a going concern and
indicated that, as of December 31, 2024, they had recurring losses with minimal revenue from
operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
strengthen our liquidity in the foreseeable future, we have taken the following measures: (i) negotiating with existing and new investors
to raise additional capital; and (ii) taking various cost control measures to reduce the operational cash burn. While our management
believes that we can continue raising additional equity capital to continue in operational existence for the foreseeable future, if we
are unable to raise additional capital, we may be required to take additional measures to conserve liquidity. No assurances can be provided
that new financing will be available to us on commercially acceptable terms, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are subject to operating risks, including excess or constrained capacity and operational inefficiencies, which could adversely affect
our results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to operating risks, including excess or constrained capacity and pressure on our internal systems and personnel. In order
to manage current and anticipated future operations effectively, we must continually implement and improve our operational, financial
and management information systems, hire, train, motivate, manage and retain employees. We may be unable to balance near-term efforts
to meet existing demand with future customer demand, including adding personnel, creating scalable, secure and robust systems and operations,
and automating processes needed for long term efficiencies. Any such failure could have a material impact on our business, operations
and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
products and information technology systems are critical to our business. Issues with product development or enhancements, IT system
integration, implementation, updates and upgrades could disrupt our operations and have a material impact on our business and operating
results.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on the efficient, uninterrupted and secure operation of our IT systems and are dependent on key third-party software embedded in
our products and IT systems as well as third-party hosted IT systems to support our operations. All software and IT systems are vulnerable
to damage, cyber-attacks or interruption from a variety of sources. To effectively manage and improve our operations, our IT systems
and applications require an ongoing commitment of significant expenditures and resources to maintain, protect, upgrade, enhance and restore
existing systems and develop new systems to keep pace with continuing changes in information processing technology, evolving industry
and regulatory standards, increasingly sophisticated cyber threats, and changing consumer preferences. Failure to adequately protect
and maintain the integrity of our products and IT systems may result in a material effect on our financial position, results of operations
and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to continuously upgrade and issue new releases of our products and customer-facing software applications, upon which our operations
depend. Software applications and products containing software frequently contain errors or defects, especially when first introduced
or when new versions are released. Additionally, the third-party software integrated into or interoperable with our products and services
will routinely reach end of life, and as a consequence, may be exposed to additional vulnerabilities, including increased security risks,
errors and malfunctions that may be irreparable or difficult to repair. The discovery of a defect, error or security vulnerability in
our products, software applications or IT systems, incompatibility with future customers&#8217; computer operating systems and hardware
configurations with a new release or upgraded version or the failure of our products or primary IT systems may cause adverse consequences,
including: delay or loss of revenues, significant remediation costs, delay in market acceptance, loss of data, disclosure of financial,
health or other personal information of any customers or patients, product recalls, damage to our reputation, or increased service costs,
any of which could have a material effect on our business, financial condition or results of our operations and the operations of our
potential customers or our business partners.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 90; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
operations and financial performance depend on global and regional economic conditions. Inflation, fluctuations in currency exchange
rates, changes in consumer confidence and demand, and weakness in general economic conditions and threats, or actual recessions, could
materially affect our business, results of operations, and financial condition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Macroeconomic
conditions impact consumer confidence and discretionary spending, which could adversely affect demand for any products we bring to market.
Consumer spending habits are affected by, among other things, inflation, fluctuations in currency exchange rates, weakness in general
economic conditions, threats or actual recessions, pandemics, wars and military actions, levels of employment, wages, debt obligations,
discretionary income, interest rates, volatility in capital, and consumer confidence and perceptions of current and future economic conditions.
Changes and uncertainty can, among other things, drive GPOs, hospitals, nursing homes and other customers towards other options in the
marketplace that may cost less than our products. The recent declines in, or uncertain economic outlooks for, the U.S., European and
certain other international economies has and may continue to adversely affect consumer and healthcare practice spending. The increase
in the cost of fuel and energy, food and other essential items along with elevated interest rates could reduce consumers&#8217; disposable
income, resulting in less discretionary spending for products like ours. Decreases in disposable income and discretionary spending or
change in consumer confidence and spending habits may adversely affect our revenues and operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we have not taken on financial obligations from banking institutions and the impact of rising interest rates (in Israel and globally)
on our financing expenses and income has not been significant, inflation continues to adversely impact spending and trade activities
worldwide and we are unable to predict the impacts of higher inflation on global and regional economies. Higher inflation has also increased
domestic and international shipping costs, raw material prices, and labor rates, which could adversely impact the costs of producing,
procuring and shipping any products we bring to market. If similar trends continue our ability to recover these cost increases through
price increases may have limited effectiveness, resulting in downward pressure on our operating results. Attempts to offset cost increases
with price increases could reduce sales, increase customer dissatisfaction or otherwise harm our reputation. Further, we are unable to
predict the impact of efforts by central banks and federal, state and local governments to combat elevated levels of inflation. If their
efforts to reduce inflation are too aggressive, they may lead to a recession. Alternatively, if they are insufficient or are not sustained
long enough to lower inflation to more acceptable levels, consumer spending may be adversely impacted for a prolonged period of time.
Any of these events could materially affect our business and operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business could be impacted by political events, trade and other international disputes, war, and terrorism, including the military conflict
between Russia and Ukraine.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Political
events, trade and other international disputes, war, and terrorism could harm or disrupt international commerce and the global economy
and could have a material effect on our business as well as our potential customers, suppliers, contract manufacturers, distributors,
and other business partners.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Political
events, trade and other international disputes, wars, and terrorism can lead to unexpected tariffs or trade restrictions, which could
adversely impact our business. These increased costs could adversely impact our gross margin and make our products less competitive or
reduce demand. Countries could also adopt other measures, such as controls on imports or exports of goods, technology or data, that could
adversely impact our operations and supply chain and limit our ability to offer products and services. These measures could require us
to take various actions, including changing suppliers or restructuring business relationships. Complying with new or changed trade restrictions
is expensive, time-consuming and disruptive to our operations. Such restrictions can be announced with little or no advance notice and
we may be unable to effectively mitigate the adverse impacts of such measures. If disputes and conflicts escalate in the future, actions
by governments in response could be significantly more severe and restrictive and could materially affect our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Political
unrest, threats, tensions, actions and responses to any social, economic, business, geopolitical, military, terrorism, or acts of war
involving key commercial, development or manufacturing markets such as China, Mexico, Israel, Europe, or other countries or regions could
materially impact any international operations we undertake. For example, our employees in Israel could be obligated to perform annual
reserve duty in the Israeli military and be called for additional active duty under emergency circumstances. If any of these events or
conditions occur, the impact on us, our employees and potential customers is uncertain, particularly if emergency circumstances, armed
conflicts or an escalation in political instability or violence disrupts our product development, data or information exchange, payroll
or banking operations, product or materials shipping by us or our suppliers and other unanticipated business disruptions, interruptions
and limitations in telecommunication services or critical systems or applications reliant on a stable and uninterrupted communications
infrastructure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 91; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
and global markets are experiencing volatility and disruption following the escalation of geopolitical tensions and the start of the
military conflict between Russia and Ukraine. On February 24, 2022, a full-scale military invasion of Ukraine by Russian troops was reported.
In response to the military conflict, the United States and other North Atlantic Treaty Organization member states, as well as non-member
states, announced targeted economic sanctions on Russia, including certain Russian citizens and enterprises, and the continuation of
the conflict may trigger additional economic and other sanctions. The potential impacts of the conflict and related sanctions could include
supply chain and logistics disruptions, macro financial impacts resulting from the exclusion of Russian financial institutions from the
global banking system, volatility in foreign exchange rates and interest rates, inflationary pressures on raw materials and energy and
heightened cybersecurity threats. We have no way to predict the progress or outcome of the conflict in Ukraine or the reactions by governments,
businesses or consumers. A prolonged conflict, intensified military activities or more extensive sanctions impacting the region and the
resulting economic impact could have a material effect on our business, results of operations, financial condition, liquidity, growth
prospects and business outlook.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
conduct certain of our operations in Israel. Conditions in Israel, including the October 2023 attack by Hamas and other terrorist organizations
from the Gaza Strip and Israel</i></b>&#8217;<b><i>s war against them, may affect our operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have 4 full-time employees, including 4 employees who are members of senior management, as well as engagements with 5 contractors,
who are located in and/or reside in Israel. As a result, our business and operations are directly affected by economic, political, geopolitical
and military conditions in Israel. Since the establishment of the State of Israel in 1948, a number of armed conflicts have occurred
between Israel and its neighboring countries and terrorist organizations active in the region. These conflicts have involved missile
strikes, hostile infiltrations and terrorism against civilian targets in various parts of Israel, which have negatively affected business
conditions in Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian
and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#8217;s
border with the Gaza Strip and in other areas within the State of Israel. Following the attack, Israel&#8217;s security cabinet declared
war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror
attacks. Moreover, the clash between Israel and Hezbollah in Lebanon, may escalate in the future into a greater regional conflict.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
hostilities involving Israel could adversely affect our operations and results of operations. Shelter-in-place and work-from-home measures,
government-imposed restrictions on movement and travel and other precautions taken to address the ongoing conflict may temporarily disrupt
our employees&#8217; ability to effectively perform their daily tasks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Israel Defense Force (the &#8220;IDF&#8221;), the national military of Israel, is a conscripted military service, subject to certain
exceptions. Several of our employees are subject to military service in the IDF and have been and may be called to serve. It is possible
that there will be further or longer military reserve duty call-ups in the future, which may affect our business due to a shortage of
skilled labor and loss of institutional knowledge, and necessary mitigation measures we may take to respond to a decrease in labor availability,
such as overtime and third-party outsourcing, for example, which may have unintended negative effects and adversely impact our results
of operations, liquidity or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is currently not possible to predict the duration or severity of the ongoing conflict or its effects on our business, operations and
financial conditions. The ongoing conflict is rapidly evolving and developing, and could disrupt our business and operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 92; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
impact of planned changes in the Israeli Judicial System on capital raising in the high-tech sector is difficult to predict. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January and February 2023, the Israeli government began promoting a plan to implement changes in the judicial system in Israel, as well
as additional legislative changes. According to various assessments and publications, the proposed changes (some of which have already
passed the first, second, and even third readings in the Knesset) are causing significant controversy and, therefore, may also impact
the performance and resilience of the Israeli economy. According to some forecasts, this plan may lead, among other things, to a downgrade
in Israel&#8217;s credit rating, damage to the local currency, increased inflation, a reduction in investments in the Israeli economy,
capital outflow from Israel, an increase in the cost of capital raising in the Israeli economy, and harm to the activity of the economic
sector in general and the high-tech sector in particular. The forecast from the Bank of Israel&#8217;s research unit in July 2023 provided
evidence of a decline in the volume of fundraising for investments in start-up companies in Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
October 2023, following the start of Israel-Hamas war, public and media focus on legislative changes has diminished. It is currently
not possible to predict whether the legislative efforts will be renewed and or their effects on our business, operations and financial
conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
&#8220;Israeli identity&#8221; may have negative impact on our sales. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Part
of our management, and the majority of development, are based in Israel, while all our product sales including operations are made outside
of Israel. Accordingly, the political status of the State of Israel may impact our activity. The Israeli identity sometimes serves as
a sales promoter (due to the recognition of Israel&#8217;s technological advantages), while in other cases, it may be a disadvantage
and could even lead to the cancellation of deals (such as within the framework of coordinated efforts to boycott Israeli products and/or
divest from Israel). Additionally, some countries worldwide have imposed or may impose restrictions on doing business in or with Israeli
companies from time to time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
operations may be impacted by natural disasters, which may become more frequent or severe as a result of climate change and may adversely
impact our business and operating results as well as those of our potential customers and suppliers.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
disasters can impact us and our potential customers, as well as suppliers critical to our operations. Natural disasters include earthquakes,
tsunamis, floods, droughts, hurricanes, wildfires, and other extreme weather conditions that can cause deaths, injuries, and critical
health crises, power outages, restrictions and shortages of food, water, shelter, and medical supplies, telecommunications failures,
materials scarcity, price volatility and other ramifications. Climate change is likely to increase both the frequency and severity of
natural disasters and, consequently, risks to our business and operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
effects of climate change on regional and global economies could change the supply, demand or availability of sources of energy or other
resources material to our products and operations and affect the availability or cost of natural resources and goods and services on
which we and our suppliers rely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to the ENvue System</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are not successful in enhancing awareness of our ENvue System, driving adoption across our current target population and expanding
the population of eligible patients, our sales, business, financial condition and results of operations will be negatively affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business currently depends primarily on our ability to successfully market our ENvue System, which involves successfully engaging with
group purchasing organizations or GPOs (i.e. entities that assist healthcare providers, such as hospitals, nursing homes, and home health
agencies, to achieve savings and efficiency by using aggregate purchasing volume to negotiate discounts with manufacturers, distributors,
and other suppliers) to increase adoption of and utilization our ENvue System.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
medical community&#8217;s awareness of performing the feeding tube insertion procedure using our product and the medical community&#8217;s
adoption of the solution offered by us, instead of existing methods and products in the market for performing the procedure, is significant
and crucial for our success. We are aiming to increase awareness about our ENvue System, work with medical professionals in the United
States to raise awareness among the medical community and grow the number of facilities that utilize our ENvue System, but there can
be no assurance that we will succeed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 93; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
commercial success of our ENvue System will continue to depend on a number of factors, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    actual and perceived effectiveness and clinical benefit, of our ENvue System;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    prevalence and severity of any adverse patient events involving our ENvue System;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to provide earlier awareness of and education about our ENvue System to GPOs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    degree to which medical professionals and GPOs adopt our ENvue System;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    availability, relative cost and perceived advantages and disadvantages of alternative technologies or treatment methods for cognitive
    disorders;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    results of future clinical and other studies relating to the health, economic or other benefits of our ENvue System;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    key thought leaders in the medical community accept that our future clinical utility is sufficiently meaningful to influence their
    decision to adopt our ENvue System;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent to which we are successful in educating medical professionals, GPOs and patients about the benefits of our ENvue System;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reputation among GPOs and medical professionals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to predict product performance;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    strength of our marketing and distribution infrastructure, including our ability to drive adoption and utilization of our ENvue System;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain, maintain, protect, enforce and defend our intellectual property rights, including those covering our ENvue System;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to maintain compliance with all legal and regulatory requirements, including FDA medical device postmarket surveillance regulations
    applicable to our ENvue System; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to continue to attract and retain key talent.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to market and sell our ENvue System cost-effectively, our sales, business, financial condition and results of operations will
be negatively affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
commercial success and revenues will depend on the future adoption of the ENvue System into patient work streams in facilities and other
healthcare settings. If we are unable to successfully drive interest in our ENvue System, our business, financial condition and results
of operations would be harmed. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success and revenues will depend in large part on the future adoption of the ENvue System into patient work streams in facilities
and other healthcare settings. Our revenues are based and are expected to be based on the sale of the ENvue System and the sale of the
dedicated feeding tubes (which are consumable products) to hospitals. Hospital procurement budgets, including capital equipment budgets,
are sometimes shared by the entire institution or several departments within it. As such, expenses related to the purchase of other equipment
by certain departments of a medical institution may reduce the budgets available for the purchase of our products by other departments
interested in purchasing them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 94; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to successfully scale our marketing, training and quality control systems our business, financial condition and results
of operations would be harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
began our marketing and sales activities in the beginning of 2020, and as of the date of this filing, we have not yet begun large-scale
production and marketing. Accordingly, the use of the ENvue System has not yet been tested and proven on a large commercial scale. We
are a continuous process of receiving feedback from product users, developing, and improving products, distributing the improved products,
and continuously reviewing our training procedures and quality control. We estimate that we will need to develop our marketing, training,
and quality control systems to a scale not currently available to us (or alternatively, enter into an agreement with a strategic distributor
or marketer who has such capabilities). There is no assurance that we will be able to do so in a way that allows us to achieve our objectives.
If we are unable to successfully implement such marketing, training and quality control systems our business, financial condition and
results of operations would be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be unable to compete successfully with competitive technologies, which could harm our sales, business, financial condition and results
of operations. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
industry is competitive and has been evolving rapidly. As of February 13, 2019, the ENvue System and ENvue Feeding Tube has received
FDA clearance for marketing in the U.S. under the 510(k) procedure for use in adults (age 22 and older). As we continue to engage with
target GPOs to increase adoption of and utilization our ENvue System, we expect to face competition in the market from competing technologies,
as well as competition from new companies that may enter the market or introduce new technologies in the future. Third-party payors may
encourage the use of competitors&#8217; products due to lower costs of competing products or alternatives. Additionally, treating physicians
may promote the use of other competitors&#8217; products or alternative therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current and future competitors may include large, well-capitalized companies with significant market share and resources. They may have
more established sales and marketing programs than we do and have greater name recognition. In addition to competing for market share,
competitors may develop or acquire patents or other rights that may limit our ability to compete.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the competitive advantages of our ENvue System will be important factors in our future success. Our continued success depends
on, among other things, our ability to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 24px; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully
    engage with GPOs to increase adoption of and utilization our ENvue System;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract
    and retain skilled research, development, sales, marketing and clinical personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue
    to innovate in order to improve our ENvue System and enhance the patient and provider experience;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adequately
    predict and respond to product performance and safety;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
    and maintain regulatory clearances, including for expanded indications;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cost-effectively
    market and sell our ENvue System;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain,
    maintain, protect, enforce and defend our intellectual property rights and operate our business without infringing, misappropriating
    or otherwise violating the intellectual property rights of others; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acquire
    products or technologies complementary to or necessary for our business.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
medical device industry is intensely competitive, subject to rapid change and significantly affected by new product introductions and
other market activities of industry participants. There can be no assurance that other companies or institutions will not succeed in
developing or marketing devices and products that are more effective than our ENvue System or that would render our ENvue System obsolete
or noncompetitive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 95; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use
of our ENvue System requires appropriate training and inadequate training may lead to negative clinician experiences, which could harm
our business, financial condition, and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
successful use of our ENvue System depends in part on the training and skill of the clinician. According to the regulatory clearance
of the ENvue System by the FDA, users of the system are required to undergo training provided by us, according to a unique and easy-to-implement
training model developed by us for system users. The training is usually provided in a concentrated manner to system users on behalf
of the hospital, lasts approximately five days, and includes both theoretical and practical components regarding the system and its use.
Providers could experience difficulty using our ENvue System. Moreover, medical providers rely on their previous medical training and
experience when recommending or utilizing our ENvue System, and we cannot guarantee that all clinicians will have the necessary skills
to properly utilize the ENvue System. We cannot be certain that clinicians that will use our ENvue System will have received sufficient
training, and clinicians who have not received adequate training may nonetheless attempt to use our ENvue System with their patients.
If medical providers utilize our ENvue System incorrectly, or without adhering to or completing all relevant training, their patient
outcomes may not be consistent with the outcomes achieved in our research studies and any future clinical studies. Adverse safety outcomes
that arise from improper or incorrect use of our ENvue System may negatively impact the perception of patient benefit and the safety
of our ENvue System, notwithstanding results from our research studies and any future clinical studies. These results could limit adoption
of our ENvue System, which would harm our sales, business, financial condition, and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are highly dependent on our senior management team and key personnel, and our business could be harmed if we are unable to attract and
retain personnel necessary for our success.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are highly dependent on our senior management and key personnel. Our success will depend on our ability to retain senior management and
to attract and retain qualified personnel in the future, including sales and marketing professionals, engineers, scientists, data science
specialists and other highly skilled personnel and to integrate current and additional personnel in all departments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competition
for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable
terms, or at all. To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have issued stock
options that vest over time, restricted share units subject to vesting conditions, and certain performance warrants. The value to employees
of stock options that vest over time may be significantly affected by fluctuations in our stock price that are beyond our control, and
may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees,
members of our management and other key personnel may terminate their employment with us on short notice. Our employment arrangements
with our employees provide for at-will employment, which means that any of our employees could leave our employment at any time, with
or without notice. We also do not maintain &#8220;key man&#8221; insurance policies on the lives of these individuals or the lives of
any of our other employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
we engage with GPOs and target medical providers to increase adoption of and utilization our ENvue System, expand our product offerings
in the future and increase our future marketing efforts, we will need to build and expand the reach of our marketing and sales networks.
Our future success will depend largely on our ability to continue to hire, train, retain and motivate skilled employees with significant
technical knowledge in various areas. An inability to attract, hire, train and retain employees will harm our sales, business, financial
condition, and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
expect to increase the size of our organization in the future, and we may experience difficulties in managing the operational elements
or timing of this growth. If we are unable to manage or appropriately time the anticipated growth of our business, our future revenue
and operating results may be harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of February 9, 2025, we have 16 employees and consultants, of whom ten employees and consultants operate in the United States as part
of the Company&#8217;s subsidiary. As our sales and marketing strategies evolve and as we continue commercialization of our ENvue System,
we may need additional managerial, operational, sales, marketing, financial and other personnel. Future growth would impose significant
added responsibilities on members of management, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying,
    recruiting, integrating, maintaining and motivating additional employees;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 96; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 24px; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">managing
    our internal development efforts effectively, while complying with our contractual obligations to contractors and other third parties;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">improving
    our operational, financial and management controls, reporting systems and procedures.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future financial performance and our ability to successfully market and sell our ENvue System will depend, in part, on our ability to
effectively manage or time any future growth, and our management may also have to divert a disproportionate amount of attention away
from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
demand for our ENvue System increases in the future, we will need to expand customer service, billing and systems processes and enhance
our internal quality assurance program. We cannot be certain that any increases in scale, related improvements and quality assurance
will be successfully implemented or that appropriate personnel will be available to facilitate the growth of our business. If we encounter
difficulty meeting market demand, quality standards or clinician expectations, our reputation will be harmed and our business will suffer.
Additionally, additional growth may result in higher fixed costs and may slow our ability to reduce costs in the face of a sudden decline
in demand for our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to achieve or maintain satisfactory pricing and margins for our ENvue System, which could harm our business and results
of operations. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
medical device industry has a history of price competition, and we can give no assurance that we will be able to maintain satisfactory
prices for our ENvue System or any future products at competitive levels. The pricing of our products could be impacted by several factors,
including change of supplies, price changes of components, and shipping costs. If we are forced to lower or are unable to increase the
price we charge for our ENvue System, our gross margins will decrease, which will harm our ability to invest in and grow our business.
If we are unable to maintain our prices, or if our costs increase and we are unable to offset such increase with an increase in our prices,
our margins could erode, which could harm our business and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Future
sales of our ENvue System may depend on providers&#8217; and patients</i></b>&#8217; <b><i>ability to obtain reimbursement from third-party
payors, such as insurance carriers.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
sales of our ENvue System may depend on our provider customers&#8217; and patients&#8217; ability to obtain reimbursement from third-party
payors, such as insurance carriers. Our customers typically rely significantly on insurance or third-party reimbursement for the treatment
and care they provide to patients. Any reduction in insurance or other third-party payor reimbursement for such patient care may cause
negative price pressure that affects their ability to purchase our ENvue System, which would reduce our revenues. Without a corresponding
reduction in the cost to produce such products, the result would be a reduction in our overall gross profit. Similarly, any increase
in the cost of such products would likely reduce our overall gross profit unless there was a corresponding increase in third-party payor
reimbursement. Failure by our provider customers or their patients to obtain or maintain coverage or to secure adequate reimbursement
for treatment by third-party payors could have an adverse effect on our business, results of operations, and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
results of operations may be harmed if we are unable to accurately forecast clinician demand for our ENvue System or any future products.
</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to accurately forecast demand for our ENvue System or our future our products could be negatively affected by many factors, including
our failure to accurately manage our expansion strategy, product introductions by competitors, our inability to forecast the lifecycle
of our products, an increase or decrease in customer demand for our products or for competitor products, our failure to accurately forecast
customer adoption of new products, unanticipated changes in general market conditions or regulatory matters and weakening of economic
conditions or consumer confidence in future economic conditions. For us to succeed, it is essential to introduce and integrate the ENvue
System into our target market, including through the creation of strategic partnerships and the establishment of effective marketing
and distribution networks, as well as the successful execution of commercial validation of the ENvue System. Inventory levels in excess
of customer demand may result in inventory write-downs or write-offs, which would cause our gross margin to be adversely affected and
could impair the strength of our brand, which may negatively affect our business, financial condition, and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 97; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Adoption
of our ENvue System depends on positive clinical data as well as medical providers&#8217; acceptance of the data and our products, and
negative clinical data, publicly reported adverse events, or perceptions among these medical providers would harm our sales, business,
financial condition, and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rate of adoption and sales of our products is heavily influenced by clinical data. There can be no assurance that future clinical studies,
including those to demonstrate the efficacy of our ENvue System or future products in current target patient populations and those to
support label retention and expansion for our products, will demonstrate clinical utility and effectiveness. Unfavorable or inconsistent
clinical data from future clinical studies conducted by us, our competitors, or third parties, adverse events publicly reported by us,
patients, or healthcare providers, or the negative interpretation of our clinical data internally and externally, including by customers,
competitors, patients, and regulators could harm our business, financial condition, and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rate of adoption and sales of our products are also influenced by clinician perceptions. Negative perceptions of our products by medical
providers, including due to negative clinical data or adverse events, could result in decreased adoption or use of our products, which
would harm our business, financial condition, and results of operations. Further, if we are not able to attain strong working relationships
with medical providers and receive their advice and input, the marketing of our products could suffer, which could harm our business,
financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future success also depends upon patients having an experience with our products that meets their expectations in order to increase clinician
demand for our products as a result of positive feedback and word-of-mouth. Patients may experience negative clinical outcomes if the
performing medical providers are not adequately trained on use of our ENvue System. If the results of our products do not meet the expectations
of the patients or their providers it could discourage continuing use of our device or referring our products to others. Dissatisfied
providers or patients may express negative opinions through social media, advocacy, or other publicity. Any failure to meet provider
or patient expectations and any resulting negative publicity could harm our reputation and future sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to ENvue Legal, Regulatory and Compliance Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Complying
with regulations enforced by FDA and other regulatory authorities is expensive and time consuming, and failure to comply could result
in substantial penalties.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product, the ENvue System (for which we have obtained FDA 510(k) clearance), and our future products are considered medical devices and,
accordingly, are subject to rigorous regulation by government agencies in the U.S. and other countries in which we intend to sell our
products. Compliance with these rigorous regulations will affect capital expenditures, earnings and the competitive position of the Company.
These regulations vary from country to country but cover, among other things, the following activities with respect to medical devices:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">design,
    development and manufacturing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">testing,
    labeling, content and language of instructions for use and storage;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    storage and safety;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">marketing,
    sales and distribution;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pre-market
    clearance or approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">record
    keeping procedures;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">advertising
    and promotion;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recalls
    and field safety corrective actions;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 98; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">post-market
    surveillance;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">post-market
    approval studies; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    import and export.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
regulations to which we are subject are complex. Regulatory changes could result in restrictions on our ability to carry on or expand
our operations, higher than anticipated costs, or lower than anticipated sales. Our failure to comply with applicable regulatory requirements
could result in enforcement action by FDA or state agencies, which may include any of the following sanctions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warning
    letters, fines, injunctions, consent decrees, and civil penalties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">repair,
    replacement, refunds, recall, or seizure of our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operating
    restrictions or partial suspension or total shutdown of production;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusing
    our requests for 510(k) clearance or pre-market approval of new products, new intended uses, or modifications to existing products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawing
    clearance or pre-market approvals that have already been granted; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">criminal
    prosecution.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of these events were to occur, they could harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not receive the necessary authorizations to market future versions, if any, of our ENvue System or any future new product candidates,
and any failure to timely do so may adversely affect our ability to grow our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
we can sell a new medical device in the U.S., or market a new use of, new claim for, or significant modification to a legally marketed
device, we must first obtain either FDA 510(k) clearance or pre-market approval, unless an exemption applies. In the 510(k) clearance
process, before a device may be marketed, the applicant must submit a premarket notification to FDA under Section 510(k) of the FD&amp;C
Act, and FDA must determine that a proposed device is &#8220;substantially equivalent&#8221; to a legally-marketed &#8220;predicate&#8221;
device. To be &#8220;substantially equivalent,&#8221; the proposed device must have the same intended use as the predicate device, and
either have the same technological characteristics as the predicate device or have different technological characteristics, not raise
different questions of safety or effectiveness than the predicate device, and be as safe and as effective as the predicate device. The
510(k) clearance process can be expensive and uncertain and typically takes from three to 12 months, but may last significantly longer.
Clinical data may be required in connection with an application for 510(k) clearance. Furthermore, even if we are granted regulatory
clearances, they may include limitations on the indications for use or intended uses of the device, which may limit the market for the
device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ENvue System is a Class II medical device and received FDA clearance under the 510(k) pathway for marketing to adults (ages 22 and above)
only.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
can delay, limit, or deny 510(k) clearance, or approval or reclassification, of a device for many reasons, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 24px; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be unable to demonstrate to FDA&#8217;s satisfaction that the product candidate or modifications are substantially equivalent
    to a proposed predicate device or safe and effective for their intended uses;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be unable to demonstrate that the clinical and other benefits of the device outweigh the risks; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    applicable regulatory authority may identify deficiencies in our submissions or in the facilities or processes of our third party
    contract manufacturers.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 99; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
delay or failure to obtain necessary regulatory clearances or approvals could harm our business. For example, if we decide to market
the ENvue System for a broader or additional indication(s) for use and/or make any material modifications to any element of the device
and/or the manufacturing or distribution thereof in the future, an additional 510(k) submission, and FDA clearance thereof, will be required
prior to making any promotional communications expressly or impliedly claiming that the device may be used for such indication(s) and/or
prior to making such modification, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, FDA may change its policies, adopt additional regulations, revise existing regulations, or take other actions, or Congress
may enact different or additional statutory requirements, which may prevent or delay clearance of our future products under development
or impact our ability to modify our currently marketed products on a timely basis. Such policy, statutory, or regulatory changes could
impose additional requirements upon us that could delay our ability to obtain new 510(k) clearances, increase the costs of compliance,
or restrict our ability to maintain our current marketing authorizations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
received our European CE mark, indicating that we affirm our product&#8217;s conformity with European health, safety and environmental
protection standards, in 2021. We will also need to obtain regulatory approval in other foreign jurisdictions in which we plan to market
and sell our products. The time required to obtain registrations or approvals, if required by other countries, may be longer than that
required for FDA clearance, and requirements for such registrations, clearances, or approvals may significantly differ from FDA requirements.
If we modify our products, we may need to apply for additional regulatory approvals before we are permitted to sell the modified product.
In addition, we may not continue to meet the quality and safety standards required to maintain the authorizations that we have received.
If we are unable to maintain our authorizations in a particular country, we will no longer be able to sell the applicable product in
that country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
to comply with these rules, regulations, self-regulatory codes, circulars, and orders could result in significant civil and criminal
penalties and costs and could have a material adverse impact on our business. Also, these regulations may be interpreted or applied by
a prosecutorial, regulatory, or judicial authority in a manner that could require us to make changes in our operations or incur substantial
defense and settlement expenses. Even unsuccessful challenges by regulatory authorities or private relators could result in reputational
harm and the incurring of substantial costs. In addition, many of these laws are vague or indefinite and have not been interpreted by
the courts and have been subject to frequent modification and varied interpretation by prosecutorial and regulatory authorities, increasing
compliance risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Certain
modifications to our products may require new 510(k) clearance or other marketing authorizations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
a medical device is permitted to be legally marketed in the U.S. pursuant to a 510(k) clearance, a medical device developer may be required
to notify FDA of certain modifications to the device. Medical device developers determine in the first instance whether a change to a
product requires a new premarket submission, but FDA may review any such decision.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
our ENvue System received 510(k) clearance in February 2019, we may in the future apply for 510(k) clearance for updated components of
our ENvue System, which must, then, be found by the FDA to be substantially equivalent to the cleared ENvue System and, thus, may not
be lawfully marketed in the U.S. until FDA make a substantial equivalence determination and issues the requisite 510(k) clearance for
the updated ENvue System. Although the development of our ENvue System has been carefully monitored and documented by professionals who
are experienced in the FDA clearance process, there is no assurance that the FDA will agree that an updated component of our ENvue System
is substantially equivalent to the cleared ENvue System and allow the updated ENvue System to be marketed in the United States. The FDA
may determine that the device is not substantially equivalent and require a premarket approval (&#8220;PMA&#8221;) or, more likely, a
<i>de novo</i> reclassification, and/or require further information, such as additional test data, including data from additional clinical
studies, before it is able to make a determination regarding substantial equivalence or PMA. By requesting additional information, the
FDA can delay market introduction of an updated ENvue System and increase the resources needed to gain clearance or PMA. Delays in receipt
of or failure to receive any necessary 510(k) clearance, de novo classification, or PMA, or the imposition of stringent restrictions
for our ENvue System, could have a material adverse effect on our business, results of operations and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 100; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the future, we may make other modifications to our products, including our ENvue System, and determine, based on our review of the applicable
FDA regulations and guidance, that in certain instances new 510(k) clearances or other premarket submissions are not required. If FDA
disagrees with our determinations, we may be subject to a wide range of enforcement actions, including, for example, a warning letter,
among other consequences, after which we will likely have to cease marketing the applicable modified product and/or to recall distributed
units of such modified product until we obtain the requisite clearance or approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Ongoing
changes in healthcare regulation could negatively affect our revenues, business and financial condition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
United States healthcare system has been continually evolving at the federal and state level due to comprehensive reforms relating to
the payment for, the availability of and reimbursement for healthcare services. Key reforms have ranged from fundamentally changing federal
and state healthcare reimbursement programs, including providing comprehensive healthcare coverage to the public under government-funded
programs, to minor modifications to existing programs, and many have been challenged (with some being overturned or modified) along the
way. One example, among countless others, is the Patient Protection and Affordable Care Act (the &#8220;Affordable Care Act&#8221;),
which was the most significant federal healthcare reform law enacted in the U.S. in recent history. The Affordable Care Act has undergone
substantial challenges and changes since its enactment in 2010, and numerous other federal healthcare reform legislation, executive orders,
and judicial rulings have been implemented in the years since, most of which have been or are aimed at lowering healthcare costs in the
U.S. To the extent any such reform measures or any future initiatives reduce reimbursement or coverage eligibility or amount(s) for treatment
involving our ENvue System and/or any future products we may market in the U.S. (if any), our business may be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
reform initiatives will continue to be proposed and may reduce healthcare related funding. It is impossible to predict the ultimate content
and timing of any healthcare reform legislation and its resulting impact on us. If significant reforms are made to the healthcare system
in the United States, or in other jurisdictions, those reforms may increase our costs or otherwise negatively effect on our business,
results of operations, and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 5, 2017, the European Parliament passed the Medical Devices Regulation (Regulation 2017/745), which repeals and replaces the EU
Medical Device Directive and became effective on May 26, 2021. The Medical Devices Regulation, among other things, is intended to establish
a uniform, transparent, predictable, and sustainable regulatory framework across the EEA for medical devices and ensure a high level
of safety and health while supporting innovation. The new regulations, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">strengthen
    the rules on placing devices on the market and reinforce surveillance once they are available;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
    explicit provisions on manufacturers&#8217; responsibilities for the follow-up of the quality, performance and safety of devices
    placed on the market;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">improve
    the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">set
    up a central database to provide patients, healthcare professionals and the public with comprehensive information on products available
    in the European Union; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">strengthen
    rules for the assessment of certain high-risk devices, such as implants, which may have to undergo an additional check by experts
    before they are placed on the market.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
modifications may have an effect on the way we conduct our business in the EEA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
change in the laws or regulations that govern the clearance and approval processes relating to our current, planned and future products
could make it more difficult and costly to obtain clearance or approval for new products or to produce, market and distribute existing
products. Significant delays in receiving clearance or approval or the failure to receive clearance or approval for our new products
would have an adverse effect on our ability to expand our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 101; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
products may cause or contribute to adverse medical events that we are required to report to FDA and other governmental authorities,
and if we fail to do so, we would be subject to sanctions that could harm our reputation, business, results of operations, and financial
condition. The discovery of serious safety issues with our products, or a recall of our products either voluntarily or at the direction
of FDA or another governmental authority, could have a negative impact on us.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are required to timely file various reports with FDA, including reports required by the medical device reporting regulations which require
us to report to FDA when we receive or become aware of information that reasonably suggests that one of our products may have caused
or contributed to a death or serious injury or malfunctioned in a way that, if the malfunction were to recur in the device or a similar
device that we market, could cause or contribute to a death or serious injury. If we fail to comply with our reporting obligations, FDA
or other governmental authorities could take action, including warning letters, untitled letters, administrative actions, criminal prosecution,
imposition of civil monetary penalties, revocation of our device clearance, seizure of our products, or delay in clearance of future
products. FDA and certain foreign regulatory bodies have the authority to require the recall of commercialized products under certain
circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
government-mandated or voluntary recall by us could occur as a result of an unacceptable risk to health, component failures, malfunctions,
labeling or design deficiencies, packaging defects, or other deficiencies, or failures to comply with applicable regulations. If we do
not adequately address problems associated with our devices, we may face additional regulatory requirements or enforcement action, including
required new marketing authorizations, FDA warning letters, product seizure, injunctions, administrative penalties, or civil or criminal
proceedings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may initiate voluntary withdrawals, removals, or corrections for our products in the future that we determine do not require notification
of FDA because no material compliance issue or safety risk is involved. If FDA disagrees with our determinations, it could require us
to report those actions and we may be subject to enforcement action. A future recall announcement or other corrective action could harm
our financial results and reputation, potentially lead to product liability claims against us, require the dedication of our time and
capital, and negatively affect our sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, FDA&#8217;s and other regulatory authorities&#8217; policies may change, and additional government regulations may be enacted
that could prevent, limit, or delay regulatory clearance or approval of our future products. For example, in November 2018, FDA announced
that it plans to develop proposals to drive manufacturers utilizing the 510(k) pathway toward the use of newer predicates. It is unclear
the extent to which any proposals, if adopted, could impose additional regulatory requirements on us that could delay our ability to
obtain new 510(k) clearances, increase the costs of compliance, or restrict our ability to maintain our current clearances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative
or executive action, either in the U.S. or abroad. For example, the Trump Administration previously enacted several executive actions
that could impose significant burdens on, or otherwise materially delay, FDA&#8217;s ability to engage in routine regulatory and oversight
activities. It is difficult to predict how these executive actions and executive actions that may be taken under the Biden Administration
or future administrations may affect FDA&#8217;s ability to exercise its regulatory authority. If these executive actions impose constraints
on FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in internet regulations could adversely affect our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Laws,
rules, and regulations governing internet communications, advertising, and e-commerce are dynamic, and the extent of future government
regulation is uncertain. Federal and state regulations govern various aspects of our online business, including intellectual property
ownership and infringement, trade secrets, the distribution of electronic communications, marketing and advertising, user privacy and
data security, search engines, and internet tracking technologies. Future taxation on the use of the internet or e-commerce transactions
could also be imposed. Existing or future regulation or taxation could increase our operating expenses and expose us to significant liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 102; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Disruptions
at the FDA, other agencies or notified bodies caused by funding shortages or global health concerns could hinder their ability to hire,
retain, or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, cleared or
approved, or commercialized in a timely manner, or at all, which could negatively impact our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ability of the FDA, other agencies and notified bodies to review and authorize or certify for marketing new products can be affected
by a variety of factors, including government budget and funding levels, statutory, regulatory and policy changes, agency&#8217;s or
notified body&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise
affect the agency&#8217;s or notified body&#8217;s ability to perform routine functions. Average review times at the FDA and other agencies
and notified bodies have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund
research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at
the FDA, other agencies and notified bodies may also slow the time necessary for new medical devices or modifications to be reviewed
and/or cleared, approved or certified by necessary agencies or notified bodies, which would adversely affect our business. For example,
over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had
to furlough critical FDA employees and stop critical activities. If a prolonged government shutdown occurs, or if global health concerns,
including pandemics, were to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other
regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process
our regulatory submissions, which could have a material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the EU, notified bodies must be officially designated to certify products and services in accordance with the MDR, which regulates the
development and sale of medical devices in Europe. While several notified bodies have been designated, the COVID-19 pandemic significantly
slowed down their designation process and the current designated notified bodies are facing a large amount of requests with the new regulation,
as a consequence of which review times have lengthened although a regulation amending the EU MDR was adopted in March 2023, extending
existing transitional provisions to December 31, 2028. This situation could significantly impact the ability of notified bodies to timely
review and process our regulatory submissions, which could have a material adverse effect on our business in the EU and EEA (which consists
of the 27 EU member states plus Norway, Liechtenstein and Iceland).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
misuse or off-label use of our ENvue System may harm our reputation in the marketplace, result in injuries that lead to product liability
suits or result in costly investigations, fines or sanctions by regulatory bodies, particularly if we are deemed to have engaged in the
promotion of these uses, any of which could be costly to our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ENvue System is a Class II medical device cleared by FDA for commercialization in the U.S. to aid qualified operators in the placement
of ENvue Medical Enteral Feeding Tube into the stomach or small intestine pursuant to the 510(k) notification process in February 2019
for use in adults (aged 22 and over). We, thus, are not currently able to promote the ENvue System for any other indications for use
or make any promotional claims that are inconsistent with, or outside the scope of, such FDA clearance (often referred to as &#8220;off-label&#8221;
claims). However, the assessment of whether a given claim is or is not consistent with a given FDA clearance or approval can often be
subjective, and we cannot guarantee that FDA will always agree with our position regarding a particular claim or that all of our employees,
representatives, and agents will abide by our marketing policies. If FDA determines that we have promoted any product without the requisite
clearance or approval and/or for an off-label or unapproved use, it could take any number of enforcement actions against us, including
(among others), issuing untitled or warning letters and/or pursuing an injunction, seizure, civil fine and/or criminal penalties. It
is also possible that other federal, state or foreign enforcement authorities might take action under other regulatory authority, such
as laws prohibiting false claims for reimbursement, any of which would have a material adverse effect on our financial condition and/or
business as a whole.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we must have competent and reliable scientific evidence or, where applicable, other adequate substantiation for each reasonable interpretation
of every promotional claim we make. In particular, comparative or superiority claims generally require adequate, well controlled, head-to-head
clinical studies, comparing the product to the applicable competing products. To the extent we make any claims, or are otherwise held
responsible for third-party claims about any product we may market in the United States, without the requisite clinical substantiation,
we could be subject to enforcement action by FDA and/or the Federal Trade Commission (FTC), as well as a competitor challenge via the
National Advertising Division (NAD) of the Better Business Bureau. Our plans to utilize social media as a primary promotional tool for
our device(s) increases the applicable enforcement risk, as it makes it easier for our employees, affiliates, and any third parties with
which we may have a relationship and/or arrangement under which we are deemed responsible for such party&#8217;s claims about our product(s)
to disseminate promotional claims about our product(s) that may be inconsistent with applicable regulations governing device promotions.
Further, consumers can bring private false-advertising lawsuits, including class actions, against us for any material misrepresentations
and/or deceptive or unsubstantiated claims (among other similar causes of action) in our promotional materials or other advertising.
Any of the foregoing could have a material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 103; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to certain federal, state, and foreign fraud and abuse laws, health information privacy and security laws, and transparency
laws, which, if violated, could subject us to substantial penalties. Additionally, any challenge to or investigation into our practices
under these laws could cause adverse publicity and be costly to respond to, and thus could harm our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are numerous U.S. federal and state, as well as foreign, laws pertaining to healthcare fraud and abuse, including anti-kickback, false
claims, and physician transparency laws. Efforts to ensure that our business arrangements with third parties will comply with applicable
healthcare laws and regulations may involve substantial costs. Our business practices and relationships with providers and patients are
subject to scrutiny under these laws. We may also be subject to patient information privacy and security regulation by both the federal
government and the states and foreign jurisdictions in which we conduct our business. The healthcare laws and regulations that may affect
our ability to operate include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal healthcare Medicare and Medicaid Patient Protection Act of 1987 (the &#8220;Anti-Kickback Statute&#8221;), which prohibits,
    among other things, persons, and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration,
    directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease,
    order, or arrange for or recommend a good or service, for which payment may be made, in whole or in part, under federal healthcare
    programs, such as Medicare and Medicaid. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of
    value. The government can establish a violation of the Anti-Kickback Statute without proving that a person or entity had actual knowledge
    of the law or a specific intent to violate. Moreover, the government may assert that a claim including items or services resulting
    from a violation of the federal healthcare Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal
    civil False Claims Act. Although there are a number of statutory exceptions and regulatory safe harbors to the federal healthcare
    Anti-Kickback Statute protecting certain common business arrangements and activities from prosecution or regulatory sanctions, the
    exceptions and safe harbors are drawn narrowly. Practices that involve remuneration to those who prescribe, purchase, or recommend
    medical device products, including discounts, or engaging individuals as speakers, consultants, or advisors, may be subject to scrutiny
    if they do not fit squarely within an exception or safe harbor. Our practices may not in all cases meet all of the criteria for safe
    harbor protection from anti- kickback liability. Moreover, there are no safe harbors for many common practices, such as reimbursement
    support programs, educational or research grants, or charitable donations;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal civil False Claims Act, which prohibits, among other things, individuals or entities from knowingly presenting, or causing
    to be presented, false or fraudulent claims for payment of federal government funds, and knowingly making, using or causing to be
    made or used a false record or statement material to a false or fraudulent claim to avoid, decrease or conceal an obligation to pay
    money to the federal government. Private individuals, commonly known as &#8220;whistleblowers,&#8221; can bring civil False Claims
    Act qui tam actions, on behalf of the government and such individuals and may share in amounts paid by the entity to the government
    in recovery or settlement. False Claims Act liability is potentially significant in the healthcare industry because the statute provides
    for treble damages and serious mandatory penalties for each false or fraudulent claim or statement. The government may assert that
    a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent
    claim under the federal civil False Claims Act. Many pharmaceutical and medical device manufacturers have been investigated and have
    reached substantial settlements under the federal civil False Claims Act in connection with alleged off-label promotion of their
    products and allegedly providing free products to customers with the expectation that the customers would bill federal health care
    programs for the product. In addition, manufacturers can be held liable under the federal civil False Claims Act even when they do
    not submit claims directly to government payers if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims.
    There are also criminal penalties, including imprisonment and criminal fines, for making or presenting false, fictitious or fraudulent
    claims to the federal government;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 104; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health
    Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which created additional federal criminal statutes that
    prohibit, among other things, knowingly and willfully executing or attempting to execute a scheme to defraud any healthcare benefit
    program, including private third-party payers, knowingly and willfully embezzling or stealing from a healthcare benefit program,
    willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering
    up a material fact or making any materially false, fictitious or fraudulent statements or representations, or making or using any
    false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry in connection
    with the delivery of, or payment for, healthcare benefits, items or services. Similar to the federal healthcare Anti-Kickback Statute,
    a person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Physician Payments Sunshine Act under the Affordable Care Act, which requires certain manufacturers of drugs, devices, biologics
    and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with
    certain exceptions) to report annually to the United States Department of Health and Human Services, Centers for Medicare and Medicaid
    Services, information related to payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists,
    podiatrists and chiropractors) and teaching hospitals, and applicable manufacturers and group purchasing organizations, as well as
    ownership and investment interests held by physicians and their immediate family members. Since January 2022, applicable manufacturers
    are also required to report information regarding payments and transfers of value provided to physician assistants, nurse practitioners,
    clinical nurse specialists, certified nurse anesthetists, and certified nurse-midwives;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
    as amended by Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), and their respective implementing
    regulations, which imposes privacy, security, and breach reporting obligations with respect to Protected Health Information (&#8220;PHI&#8221;),
    upon entities subject to the law, such as health plans, healthcare clearinghouses and certain healthcare providers, and their respective
    business associates that perform services on their behalf that involve PHI. HITECH also created new tiers of civil monetary penalties,
    amended HIPAA to make HIPAA compliance as well as civil and criminal penalties directly applicable to business associates, and gave
    state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the HIPAA laws
    and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">analogous
    state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply
    to items or services reimbursed by any third-party payer, including commercial insurers or patients; state laws that require device
    companies to comply with the industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated
    by the federal government or otherwise restrict payments that may be made to healthcare providers and other potential referral sources;
    state and local laws that require the licensure of sales representatives; state laws that require device manufacturers to report
    information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures
    and pricing information; data privacy and security laws and regulations in foreign jurisdictions that may be more stringent than
    those in the United States (such as the EU, which adopted the General Data Protection Regulation, which became effective in May 2018);
    state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other
    in significant ways and may not have the same effect, thus complicating compliance efforts; and state laws related to insurance fraud
    in the case of claims involving private insurers.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
laws and regulations, among other things, constrain our business, marketing, and other promotional activities by limiting the kinds of
financial arrangements, including sales programs, we may have with physicians or other potential purchasers of our products. We have
also entered into consulting agreements with physicians, which are subject to these laws. Further, while we do not submit claims and
our future customers will make the ultimate decision on how to submit claims, we may provide reimbursement guidance and support regarding
our products. Due to the breadth of these laws, the narrowness of statutory exceptions and regulatory safe harbors available, and the
range of interpretations to which they are subject, it is possible that some of our current or future practices might be challenged under
one or more of these laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 105; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which
has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. For example, U.S. federal
and state regulatory and enforcement agencies continue to actively investigate violations of healthcare laws and regulations, including
pursuing novel theories of liability under these laws. These government agencies recently have increased regulatory scrutiny and enforcement
activity with respect to manufacturer reimbursement support activities and patient support programs, including bringing criminal charges
or civil enforcement actions under the federal healthcare Anti-Kickback statute, federal civil False Claims Act, the health care fraud
statute, and HIPAA privacy provisions. Responding to investigations can be time and resource consuming and can divert management&#8217;s
attention from the business. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our
business. Even an unsuccessful challenge or investigation into our practices could cause adverse publicity, and be costly to respond
to.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our operations are found to be in violation of any of the healthcare laws or regulations described above or any other healthcare regulations
that apply to us, we may be subject to administrative, civil and criminal penalties, damages, fines, disgorgement, substantial monetary
penalties, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, imprisonment, additional reporting
obligations, and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance
with these laws, reputational harm, and the curtailment or restructuring of our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business could be adversely affected by professional and legal challenges to our business model or by new state actions restricting our
ability to provide our products and services in certain states.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
the success of our business will be dependent on the widespread adaptation of our ENvue System as an efficient and safer solution for
feeding tube insertion compared to the alternative methods currently available on the market, clinicians and medical professionals across
multiple geographies will be needed to use our ENvue System and provide positive feedback and results. This will expose the Company to
legal risk of patients or medical providers who may have a negative experience with our ENvue System filing lawsuits claiming damages
or other claims. Although the Company will seek insurance coverage for such legal actions, there is no assurance that the amount of coverage
will be sufficient to cover these claims. In addition, such legal actions from consumers and medical providers may result in material
and adverse effects on our ability to continue to conduct business due to negative press.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Security
breaches, data breaches, cyber attacks, other cybersecurity incidents or the failure to comply with privacy, security and data protection
laws could materially impact our operations, patient care could suffer, we could be liable for damages, and our business, operations
and reputation could be harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to retain confidential customer personal and financial, patient health information and our own proprietary information and data
essential to our business operations. We will rely upon the effective operation of our IT systems, and those of our service providers,
vendors, and other third parties to safeguard the information and data. Additionally, our success may be dependent on the success of
healthcare providers, many of whom are comprised of individual or small operations with limited IT experience and inadequate or untested
security protocols, in managing data privacy and data security requirements. It is critical that the facilities, infrastructure and IT
systems on which we depend to run our business and the products we develop remain secure and be perceived by the marketplace and our
potential customers to be secure. Despite the implementation of security features in our products and security measures in our IT systems,
we and our service providers, vendors, and other third parties may become subject to physical break-ins, computer viruses or other malicious
code, unauthorized or fraudulent access, programming errors or other technical malfunctions, hacking or phishing attacks, malware, ransomware,
employee error or malfeasance, cyber attacks, and other breaches of IT systems or similar disruptive actions, including by organized
groups and nation-state actors. For example, we may experience cybersecurity incidents and unauthorized internal employee exfiltration
of company information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the frequency of third-party cyber-attacks has increased over the last several years. The military conflict in Ukraine may cause nation-state
actors or hackers sympathetic to either side of the conflict to carry out cyber-attacks to achieve their goals, which may include espionage,
information gathering operations, monetary gain, ransomware, disruption, and destruction. Significant service disruptions, breaches in
our infrastructure and IT systems or other cybersecurity incidents could expose us to litigation or regulatory investigations, impair
our reputation and competitive position, be distracting to our management, and require significant time and resources to address. Affected
parties or regulatory agencies could initiate legal or regulatory action against us, which could prevent us from resolving the issues
quickly or force us to resolve them in unanticipated ways, cause us to incur significant expense and liability, or result in judicial
or governmental orders forcing us to cease operations or modify our business practices in ways that could materially limit or restrict
the products and services we provide. Concerns over our privacy practices could adversely affect others&#8217; perception of us and deter
potential customers, patients and partners from using our products. In addition, patient care could suffer, and we could be liable if
our products or IT systems fail to deliver accurate and complete information in a timely manner. We have internal monitoring and detection
systems as well as cybersecurity and other forms of insurance coverage related to a breach event covering expenses for notification,
credit monitoring, investigation, crisis management, public relations and legal advice. However, damages and claims arising from such
incidents may not be covered or may exceed the amount of any coverage and do not cover the time and effort we may incur investigating
and responding to any incidents, which may be material. The costs to eliminate, mitigate or recover from security problems and cyber
attacks and incidents could be material and depending on the nature and extent of the problem and the networks or products impacted,
may result in network or systems interruptions, decreased product sales, or data loss that may have a material impact on our operations,
net revenues and operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 106; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business will expose us to potential liability for the quality and safety of our products and services, how we advertise and market those
products and services and how and to whom we sell them, and we may incur substantial expenses or be found liable for substantial damages
or penalties if we are subject to claims or litigation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
products and services involve an inherent risk of claims concerning their design, manufacture, safety and performance, how they are marketed
and advertised in a complex framework of highly regulated domestic and international laws and regulations, how we package, bundle or
sell them to potential customers, who may be private individuals or companies or public entities such as hospitals and clinics, and how
we train and support doctors, their staffs and patients who administer or use our products. Moreover, consumer products and services
are routinely subject to claims of false, deceptive or misleading advertising, consumer fraud and unfair business practices. Additionally,
we may be held liable if any product we develop or manufacture or services we offer or perform causes injury or is otherwise found unhealthy.
If our products are safe but they are promoted for off-label usage, we may be investigated, fined or have our products or services enjoined
or clearances rescinded or we may be required to defend ourselves in litigation. Although we maintain insurance for product liability,
business practices and other types of activities we make or offer, coverage may not be available on acceptable terms, if at all, and
may be insufficient for actual liabilities. Any claim for product liability, sales, advertising and business practices, regardless of
its merit or eventual outcome, could result in material legal defense costs and damage our reputation, increase our expenses and divert
management&#8217;s attention.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Increased
focus on current and anticipated environmental, social and governance (</i></b>&#8220;<b><i>ESG</i></b>&#8221;<b><i>) laws and increased
scrutiny of our ESG policies and practices may materially increase our costs, expose us to potential liability, adversely impact our
reputation, employee retention, willingness of potential customers and suppliers to do business with us and willingness of investors
to invest in us.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations are subject to a variety of existing local, regional and global ESG laws and regulations, and we will likely be required to
comply with new, broader, more complex and more costly laws and regulations that focus on ESG matters. Our compliance obligations will
likely span all aspects of our business and operations, including product design and development, materials sourcing and other procurement
activities, product packaging, product safety, energy and natural resources usage, facilities design and utilization, recycling and collection,
transportation, disposal activities and workers&#8217; rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Environmental
regulations related to greenhouse gases are expected to have an increasingly larger impact on our or our suppliers&#8217; energy sources.
Many U.S. and foreign regulators have enacted or are considering enacting new or additional disclosure requirements or limits on the
emissions of greenhouse gases, including, but not limited to, carbon dioxide and methane, from power generation units using fossil fuels.
The effects of greenhouse gas emission limits on power generation are subject to significant uncertainties, including the timing of any
new requirements, levels of emissions reductions and the scope and types of emissions regulated. These limits may have the effect of
increasing our costs and those of our suppliers and could result in manufacturing, transportation and supply chain disruptions and delays
if clean energy alternatives are not readily available in adequate amounts when required. Moreover, alternative energy sources, coupled
with reduced investments in traditional energy sources and infrastructure, may fail to provide the predictable, reliable, and consistent
energy that we, our suppliers and other businesses need for operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 107; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Meeting
our obligations under existing ESG laws, rules, or regulations is already costly to us and our suppliers, and we expect those costs to
increase as new laws are enacted, possibly materially. Additionally, we expect regulators to perform investigations, inspections and
periodically audit our compliance with these laws and regulations, and we cannot provide assurance that our efforts or operations will
be compliant. If we fail to comply with any requirements, we could be subject to significant penalties or liabilities and we may be required
to implement new and materially more costly processes and procedures to come into compliance. Further, these laws are subject to unpredictable
changes. Even if we successfully comply with these laws and regulations, our suppliers may fail to comply. We may also suffer financial
and reputational harm if future customers require, and we are unable to deliver, certification that our products are conflict free. In
all of these situations, our future customers may stop purchasing products from us, and may take legal action against us, which could
harm our reputation, revenues and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor
advocacy groups, institutional investors, investment funds, proxy advisory services, stockholders, and consumers are also increasingly
focused on corporate ESG practices. Additionally, public interest and legislative pressure related to public companies&#8217; ESG practices
continues to grow. If our ESG practices fail to meet investors&#8217; or other industry stakeholders&#8217; evolving expectations and
standards, including environmental stewardship, support for local communities, board of director and employee diversity, human capital
management, employee health and safety practices, product quality, supply chain management, corporate governance and transparency and
employing ESG strategies in our operations, our brand, reputation and employee retention may be negatively impacted, potential customers
and suppliers may be unwilling to do business with us and investors may be unwilling to invest in us. In addition, as we work to align
our ESG practices with industry standards, we have expanded and will likely continue to expand our disclosures in these areas. We also
expect to incur additional costs and require additional resources to monitor, report, and comply with our various ESG practices. If we
fail to adopt ESG standards or practices as quickly as stakeholders desire, report on our ESG efforts or practices accurately, or satisfy
the disclosure and other expectations of stakeholders, our reputation, business, financial performance, growth, and stock price may be
adversely impacted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are subject to consumer protection laws that regulate our marketing practices and prohibit unfair or deceptive acts or practices. Our
actual or perceived failure to comply with such obligations could harm our business, and changes in such regulations or laws could require
us to modify our products, marketing or advertising efforts.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the marketing or advertisement of our products and services, we could be the target of claims relating to false, misleading,
deceptive, or otherwise noncompliant advertising or marketing practices, including under the auspices of the FTC and state consumer protection
statutes. If we rely on third parties to provide any marketing and advertising of our products and services, we could be liable for,
or face reputational harm as a result of, their marketing practices if, for example, they fail to comply with applicable statutory and
regulatory requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are found to have breached any consumer protection, advertising, unfair competition, or other laws or regulations, we may be subject
to enforcement actions that require us to change our marketing and business practices in a manner which may negatively impact us. This
could also result in litigation, fines, penalties, and adverse publicity that could cause reputational harm and loss of patient trust,
which could have an adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to ENvue</b>&#8217;<b>s Intellectual Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>References
in this section to the </i>&#8220;<i>Company,</i>&#8221; &#8220;<i>we,</i>&#8221; &#8220;our,&#8221; <i>or </i>&#8220;<i>us</i>&#8221;
<i>generally refer to ENvue Medical Holdings, Corp.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
success depends in part on our proprietary technology, and if we are unable to successfully enforce our intellectual property rights,
our competitive position may be harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success will depend in part on our ability to maintain existing intellectual property and to obtain and maintain further intellectual
property protection for our products and services, both in the U.S. and in other countries. We intend to protect our intellectual property
rights, including our AI technology and related algorithms, through a combination of patent, trademark, copyright, and trade secret laws,
as well as third-party confidentiality and assignment agreements. Our inability to do so could harm our competitive position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 108; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on our portfolio of issued and pending patent applications in the U.S. and other countries to protect a large part of our intellectual
property and our competitive position; however, our currently pending or future patent filings may not result in the issuance of patents.
While we generally apply for patents in those countries where we intend to make, have made, use, or sell patented products, we may not
accurately predict all of the countries where patent protection will ultimately be desirable. If we fail to timely file for a patent,
we may be precluded from doing so at a later date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
rights are territorial, and patent protection extends only to those countries where we have issued patents. Filing, prosecuting and defending
patents on our products and our future products in all countries and jurisdictions throughout the world would be prohibitively expensive,
and our intellectual property rights in some countries outside the United States could be less extensive than those in the United States.
Many countries do not protect intellectual property to the same extent as the U.S. or Europe, and their litigation processes differ.
Competitors may successfully challenge or avoid our patents, or manufacture products in countries where we have not applied for patent
protection. Changes in the patent laws in the U.S. or other countries may diminish the value of our patent rights. As a result of these
and other factors, the scope, validity, enforceability, and commercial value of our patent rights are uncertain and unpredictable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
the patent positions of medical device companies involve complex legal and factual questions, and, therefore, the issuance, scope, validity
and enforceability of any patent claims that we may obtain cannot be predicted with certainty. The issuance of a patent, while presumed
valid and enforceable, is not conclusive as to its validity or its enforceability and it may not provide us with adequate proprietary
protection or competitive advantages against competitors with similar products. Any patents issued to us may be challenged, invalidated,
held unenforceable, circumvented, or may not be sufficiently broad to prevent third parties from producing competing products similar
in design to our products. In addition, any protection afforded by foreign patents may be more limited than that provided under U.S.
patent and intellectual property laws. There can be no assurance that any of our patents, any patents licensed to us, or any patents
which we may be issued in the future, will provide us with a competitive advantage or afford us protection against infringement by others,
or that the patents will not be successfully challenged or circumvented by third parties, including our competitors. Further, there can
be no assurance that we will have adequate resources to enforce our patents. Competitors may also be able to design around our patents.
Other parties may develop and obtain patent protection for more effective technologies, designs or methods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to enforce our patent rights depends on our ability to detect infringement. It is difficult to detect infringers who do not advertise
the components that are used in their products. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#8217;s
or potential competitor&#8217;s product, particularly in litigation in countries other than the U.S. that do not provide an extensive
discovery procedure. Any litigation to enforce or defend our patent rights, if any, even if we were to prevail, could be costly and time-consuming
and would divert the attention of our management and key personnel from our business operations. We may not prevail in any lawsuits that
we initiate and the damages or other remedies awarded if we were to prevail may not be commercially meaningful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
advances in AI technology may generate developments that existing IP laws do not adequately protect. The legislative and regulatory environment
is out of our control, may change rapidly and unpredictably, and may negatively influence our revenue, costs, earnings, and growth. Some
rules and regulations may be subject to litigation or other challenges that delay or modify their implementation and impact on us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also may seek to rely on protection of copyright, trade secrets, know how, and confidential and proprietary information. We generally
enter into confidentiality and non-compete agreements with our employees, consultants, and collaborative partners upon their commencement
of a relationship with us. However, these agreements may not provide meaningful protection against the unauthorized use or disclosure
of our trade secrets or other confidential information, and adequate remedies may not exist if unauthorized use or disclosure were to
occur. The exposure of our trade secrets and other proprietary information would impair our competitive advantages and could have a material
adverse effect on our operating results, financial condition, and future growth prospects. In particular, a failure to protect our proprietary
rights might allow competitors to copy our technology, which could adversely affect our pricing and market share. We may not be able
to prevent the unauthorized disclosure or use of our technical knowledge or trade secrets by consultants, vendors, former employees and
current employees. Further, other parties may independently develop substantially equivalent know-how and technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 109; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently own registered trademarks for our ENvue System, and we intend to rely on both registered and common law rights for our trademarks
in the future. There can be no assurance that our future trademark applications will be approved. Third parties may also oppose our trademark
applications, or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could
be forced to rebrand our products and services, which could result in loss of brand recognition, and could require us to devote resources
to advertising and marketing new brands. Further, there can be no assurance that competitors will not infringe our trademarks, or that
we will have adequate resources to enforce our trademarks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Litigation,
interferences, oppositions, re-exams, inter partes reviews, post grant reviews, or other proceedings are, have been, and may in the future
be necessary in some instances to determine the validity and scope of certain of our proprietary rights, and in other instances to determine
the validity, scope, or non-infringement of certain proprietary rights claimed by third parties to be pertinent to the manufacture, use,
or sale of our products or provision of our services. These types of proceedings are unpredictable and may be protracted, expensive,
and distracting to management. The outcome of such proceedings could adversely affect the validity and scope of our patent or other proprietary
rights, hinder our ability to manufacture and market our products and provide our services, require us to seek a license for the infringed
product or technology, or result in the assessment of significant monetary damages. An unfavorable ruling could include monetary damages
or, in cases where injunctive relief is sought, an injunction prohibiting us from selling our products or providing our services. Any
of these results from litigation could adversely affect our business, financial condition, and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successful
cybersecurity attacks, data breaches, unapproved use of machine learning or AI tools, or other security incidents could result in the
loss of IP and key technological advantages. Security incidents could result in, for example, unauthorized access to, disclosure, modification,
misuse, loss, or destruction of company, patient, or other third party data; theft or import of sensitive, regulated, or confidential
data including personal information and IP, such as key innovations in AI; the loss of access to critical data or systems through ransomware;
and business delays.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we infringe or violate the patents or proprietary rights of other parties or are subject to an intellectual property infringement or
misappropriation claim, our ability to grow our business may be severely limited.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success also depends upon our ability, and the ability of any third party with which we may partner, to develop, manufacture,
market and sell our products, if approved, and use our patent-protected technologies without infringing the patents of third parties.
Extensive litigation over patents and other intellectual property rights is common in the medical device industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not have identified all patents, published applications or published literature that affect our business either by blocking our ability
to commercialize our products, by preventing the patentability of one or more aspects of our products, or by covering the same or similar
technologies that may affect our ability to market our products. For example, we may not have conducted a patent clearance search sufficient
to identify potentially obstructing third party patent rights. Moreover, patent applications in the United States are maintained in confidence
for up to 18 months after their filing. In some cases, however, patent applications remain confidential in the U.S. Patent and Trademark
Office, or the USPTO, for the entire time prior to issuance as a U.S. patent. Patent applications filed in countries outside of the United
States are not typically published until at least 18 months from their first filing date. Similarly, publication of discoveries in the
scientific or patent literature often lags behind actual discoveries. We cannot be certain that we were the first to invent, or the first
to file, patent applications covering our products. We also may not know if our competitors filed patent applications for technology
covered by our pending applications or if we were the first to invent the technology that is the subject of our patent applications.
Competitors may have filed patent applications or received patents and may obtain additional patents and proprietary rights that block
or compete with our patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may therefore in the future be the subject of patent or other litigation. From time to time, we may in the future receive letters from
third parties drawing our attention to their patent rights. While we do not believe that we infringe upon any valid and enforceable rights
that have been brought to our attention, and we take necessary steps to ensure that we do not infringe on the rights of others, there
may be other more pertinent rights of which we are presently unaware. The defense and prosecution of intellectual property suits, interference
proceedings, and related legal and administrative proceedings could result in substantial expense to us and significant diversion of
effort by our technical and management personnel. An adverse determination of any litigation or interference proceeding to which we may
become a party could subject us to significant liabilities. An adverse determination of this nature could also put our patents at risk
of being invalidated or interpreted narrowly or require us to seek licenses from third parties. Licenses may not be available on commercially
reasonable terms or at all, in which event, our business would be materially adversely affected. Intellectual property litigation or
claims could force us to cease developing, selling or otherwise commercializing one or more of our products; to pay substantial damages
for past use of the asserted intellectual property; and redesign, or rename in the case of trademark claims, our product(s) to avoid
such third party rights, which may not be possible or which could be costly and time-consuming. Any of these risks coming to fruition
could have a material adverse effect on our business, results of operations, financial condition and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 110; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
failure to secure trademark registrations could adversely affect our ability to market our products and operate our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
future trademark applications in the United States and any other jurisdictions where we may file may not be allowed registration, and
we may not be able to maintain or enforce our registered trademarks. During trademark registration proceedings, we may receive rejections.
Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the
USPTO and in corresponding foreign agencies, third parties are given an opportunity to oppose pending trademark applications and to seek
to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our applications and/or registrations, and
our applications and/or registrations may not survive such proceedings. Failure to secure such trademark registrations in the United
States and in foreign jurisdictions could adversely affect our ability to market our products and our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
is common in the medical device industry, we may employ individuals who were previously employed at other companies similar to ours,
including our competitors or potential competitors. We may become subject to claims that these employees or we have inadvertently or
otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to
defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs
and be a distraction to management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Obtaining
and maintaining patent protection depends on compliance with various procedures and other requirements, and our patent protection could
be reduced or eliminated in case of non-compliance with these requirements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodic
maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the relevant
patent agencies in several stages over the lifetime of the patents and /or applications. The relevant patent agencies require compliance
with a number of procedural, documentary, fee payment and other provisions during the patent application process. In many cases, an inadvertent
lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations
in which the failure to comply with the relevant requirements can result in the abandonment or lapse of the patent or patent application,
resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able
to use our technologies and know-how which could have a material adverse effect on our business, prospects, financial condition and results
of operation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patent
terms may be inadequate to protect our competitive position on our products for an adequate amount of time.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents
have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally
20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection
it affords, is limited. Even if patents covering our products are obtained, once the patent life has expired for a product, we may be
open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of
new products, patents protecting such products might expire before or shortly after such products are commercialized. As a result, our
patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 111; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to claims challenging the inventorship of our patents and other intellectual property.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual
property as an inventor or co-inventor or an author. For example, we may have inventorship or ownership disputes arise from conflicting
obligations of consultants or others who are involved in developing our products. Litigation may be necessary to defend against these
and other claims challenging inventorship or our ownership of our patents or other intellectual property. If we fail in defending any
such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of,
or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are
successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other
employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
use AI in our business, and challenges with properly managing its use could result in reputational harm, competitive harm, and legal
liability, and adversely affect our results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
incorporate AI solutions into our ENvue System, services, and features, and these applications are important in our operations. Our competitors
or other third parties may incorporate AI into their products more quickly or more successfully than us, which could impair our ability
to compete effectively and adversely affect our results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
if the content, analyses, or recommendations that AI applications assist in producing are or are alleged to be deficient, inaccurate,
or biased, our business, financial condition, and results of operations may be adversely affected. Our use of AI and machine learning
is subject to risks related to flaws in our algorithms and datasets that may be insufficient or contain biased information. The development
of AI technologies is complex, and there are several challenges associated with achieving the desired level of accuracy, efficiency,
and reliability. The algorithms and models used in our AI systems may have limitations, including biases, errors, or inability to handle
certain data types or scenarios. There is a risk of system failures, disruptions, or vulnerabilities that could compromise the integrity,
security, or privacy of our platform. These failures could result in reputational damage, legal liabilities, or loss of user confidence,
which could materially affect our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
use of AI applications has resulted in, and may in the future result in, cybersecurity incidents that implicate the personal data of
patients and users of such applications. Any such cybersecurity incidents related to our use of AI applications could adversely affect
our reputation and results of operations. AI also presents emerging ethical issues, and if our use of AI becomes controversial, we may
experience brand or reputational harm, competitive harm, or legal liability. The rapid evolution of AI, including potential government
regulation of AI, will require significant resources to develop, test and maintain our platform, services, and features to help us implement
AI ethically in order to minimize unintended, harmful impact.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legislative
and governmental activity in the privacy area may result in new laws or regulations that are applicable to us and that may hinder our
business, for example, by restricting use or sharing of patient data, limiting our ability to provide certain data to our customers,
limiting our ability to develop or modify our AI systems, or otherwise regulating AI and machine learning, including the use of algorithms
and automated processing in ways that could materially affect our business, or which may lead to significant increases in the cost of
compliance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to the 2025 Reverse Stock Split</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
2025 Reverse Stock Split may not increase the price of our common stock over the long-term and our common stock may be delisted.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal purpose of the 2025 Reverse Stock Split was to increase the trading price of our common stock to meet the minimum stock price
standards of Nasdaq. However, the effect of a reverse stock split on the market price of our common stock cannot be predicted with any
certainty, and we cannot assure you that a reverse stock split will accomplish this objective for any meaningful period of time, or at
all. While we expect that the reduction in the number of outstanding shares of common stock will proportionally increase the market price
of our common stock, we cannot assure you that a reverse stock split will increase the market price of our common stock by a multiple
of any reverse stock split ratio, or result in any permanent or sustained increase in the market price of our common stock sufficient
to regain compliance with the conditions required by the Panel. The market price of our common stock may be affected by other factors
which may be unrelated to the number of shares outstanding, including our business and financial performance, general market conditions,
and prospects for future success.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 112; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
can be no assurance that we will satisfy the conditions required by the Panel regarding the market price or ultimately regain compliance
with all applicable requirements for continued listing on Nasdaq and maintain listing of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are delisted from Nasdaq, among other things, it will increase the difficulty in our ability to raise money through the sale of our
securities. A delisting of our common stock from Nasdaq could materially reduce the liquidity of our common stock and result in a corresponding
material reduction in the price of our common stock. In addition, delisting could harm our ability to raise capital through alternative
financing sources on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors, suppliers, customers
and employees and fewer business development opportunities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
2025 Reverse Stock Split may decrease the liquidity of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2025 Reverse Stock Split reduced the total number of outstanding shares of common stock, which may lead to reduced trading and a smaller
number of market makers for our common stock, particularly if the price per share of our common stock does not increase as a result of
a reverse stock split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
2025 Reverse Stock Split may result in some stockholders owning &#8220;odd lots&#8221; that may be more difficult to sell or require
greater transaction costs per share to sell.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2025 Reverse Stock Split had the effect of increasing the number of stockholders who own &#8220;odd lots&#8221; of less than 100 shares
of common stock. A purchase or sale of less than 100 shares of common stock (an &#8220;odd lot&#8221; transaction) may result in incrementally
higher trading costs through certain brokers, particularly &#8220;full service&#8221; brokers. Therefore, those stockholders who own
fewer than 100 shares of common stock following a reverse stock split may be required to pay higher transaction costs if they sell their
common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
2025 Reverse Stock Split may lead to a decrease in our overall market capitalization.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reverse stock split, including the 2025 Reverse Stock Split, may be viewed negatively by the market and, consequently, could lead to
a decrease in our overall market capitalization. If the per share market price of our common stock does not increase in proportion to
the reverse stock split ratio, or following such increase does not maintain or exceed such price, then our value, as measured by our
market capitalization, will be reduced. Additionally, any reduction in our market capitalization may be magnified as a result of the
smaller number of total shares of common stock outstanding following a reverse stock split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sw_002"></span>ITEM
1B. UNRESOLVED STAFF COMMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sw_003"></span>ITEM
1C. CYBERSECURITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_98E_ecyd--CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_iB_c20240101__20241231_gBFCRMPFAIAMT-VZ_zlZZfg5fU0uc" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" continuedAt="ConU000046-01" escape="true" id="Fact000046" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
operate in the biotechnology sector, which is subject to various cybersecurity risks that could adversely affect our business, financial
condition, and results of operations, including intellectual property theft; fraud; extortion; harm to employees or customers; violation
of privacy laws and other litigation and legal risk; and reputational risk. We recognize the critical importance of developing, implementing,
and maintaining robust cybersecurity measures to safeguard our information systems and protect the confidentiality, integrity, and availability
of our data. We currently have security measures in place to protect our clients, patients, customers, employees,&#8204; and vendor information
and prevent data loss and other security breaches, including a cybersecurity risk assessment program. We also only use third party software
for accounting, billing and payroll that have successful SOC 1 type 2 compliance. Both management and the Board are actively involved
in the continuous assessment of risks from cybersecurity threats, including prevention, mitigation, detection, and remediation of cybersecurity
incidents.</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 113; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_985_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_db_c20240101__20241231_z5VFzXQ9Ss4f" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000047" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>O<span id="xdx_C04_gBFCRMPFAIAMT-VZ_zCWam0ACpJCc"><ix:continuation continuedAt="ConU000046-02" id="ConU000046-01">ur
current cybersecurity risk <span id="xdx_909_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zf9DwAAmVsKk" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000048" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag">assessment</ix:nonNumeric></span> program consists of an annual review of our risks and policies. The program outlines governance,
policies and procedures, and technology we use to oversee and identify risks from cybersecurity threats and is informed by previous cybersecurity
incidents we have observed both within the Company and in our industry.</ix:continuation></span></span></span></ix:nonNumeric></p>

<div id="xdx_C06_gBFCRMPFAIAMT-VZ_zLAtKwr6McZk"><ix:continuation continuedAt="ConU000046-03" id="ConU000046-02"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecyd--CybersecurityRiskBoardOfDirectorsOversightTextBlock_dbF_c20240101__20241231_zEXGSX4wxK0l" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000049" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock">Our
General Manager, who is responsible for overseeing our business operations, with oversight from senior management and the nominating
and the Corporate Governance Committee of our Board are responsible for day-to-day assessment and management of risks from cybersecurity
threats, including the prevention, mitigation, detection, and remediation of cybersecurity incidents. We also use the services of an
outside consulting firm to monitor activity and advise the company of cybersecurity protocols.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_dbF_c20240101__20241231_zy1oEP85IMt8" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000050" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">The
Nominating and Corporate Governance Committee of the Board is responsible for oversight of risks from cybersecurity threats in conjunction
with management.</ix:nonNumeric></span> <span id="xdx_902_ecyd--CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_dbF_c20240101__20241231_zHh5FebJQeR" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000051" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">The committee receives interim reports and updates from the senior management, and management has committed to updating
the full Board on a quarterly basis with respect to the management of risks from cybersecurity threats. Such reports cover the Company&#8217;s
information technology security program, including its current status, capabilities, objectives and plans, as well as the evolving cybersecurity
threat landscape.</ix:nonNumeric></span> <span id="xdx_90C_ecyd--CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_c20240101__20241231_zmxUV4IcXI02" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000052" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">Additionally, the Nominating and Corporate Governance Committee considers risks from cybersecurity threats as part
of its oversight of the Company&#8217;s business strategy, risk management, and financial oversight by requiring quarterly updates from
management at its Board meetings.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecyd--CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_dbF_c20240101__20241231_zDHf85LkjJv2" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000053" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">We
routinely undertake activities to prevent, detect, and minimize the effects of cybersecurity incidents, including an annual risk review,
policy reviews and revisions. In addition, we maintain business continuity, contingency, and recovery plans for use in the event of a
cybersecurity incident by the administering of local and cloud based back up of files. and emails.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
engaged and used the advice of a <span id="xdx_908_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_zBTCkr33832l" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000054" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag">third-party</ix:nonNumeric></span> consultant to help us assess and identify risks from cybersecurity threats, including the
threat of a cybersecurity incident, and manage our risk assessment program. Among other things, these providers have recommended installation
of Check Point Firewall and ESET Protect Advanced cloud based anti-virus, as well as site periodic evaluations of the work stations and
onsite storage equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also engaged third party consultants to prepare policies and procedures to oversee and identify the risks from cybersecurity threats
associated with our use of <span id="xdx_90C_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20240101__20241231_zdVmydKWbCKj" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000055" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">third-party</ix:nonNumeric></span> service providers and we continue to monitor that all third-party software providers remain in
compliance with SOC 1 protocols.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this report, <span id="xdx_90F_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240101__20241231_z7DONbS7NdSi" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000056" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">no</ix:nonNumeric></span> cybersecurity incident (or aggregation of incidents) or cybersecurity threat has materially affected our
results of operations or financial condition. However, an actual or perceived breach of our security could damage our reputation, and
cause existing clients/customers to discontinue. As well as prevent us from attracting new clients/customers, and interfere with the
progress of our clinical trials, or interfere with our efforts to pursue regulatory approvals for our product candidates, or subject
us to third-party lawsuits, regulatory fines or other actions or liabilities, any of which could adversely affect our business, operating
results or financial condition. For further information, see &#8220;Risk Factors-<i>Our business and operations would suffer in the event
of computer system failures, cyber-attacks or deficiencies in our cyber-security</i>&#8221; in Item 1A of this Annual Report on Form
10-K. We currently do not carry a cyber liability insurance policy, but are evaluating whether to acquire one to mitigate any financial
impact of a cybersecurity breach.</span></p>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_C02_gBFCRMPFAIAMT-VZ_zDQAKcBUtqb1"><ix:continuation id="ConU000046-03"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></ix:continuation></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sw_004"></span>ITEM
2. PROPERTIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
lease an office and manufacturing facility in Nesher, Israel and maintain an office in Tyler, Texas. Our lease, for a space of approximately
284 square meters, for the facility in Nesher expired on December 31, 2023, and we decided not to renew the lease. In March 2024, we
entered into a new three year lease for an office and manufacturing facility in Nesher for approximately $2,500 per month, with the option
to terminate the lease anytime with four months notice after the first twelve months. The space is approximately 180 square meters. We
paid approximately $4,200 per month under our former lease. We pay $1,200 per month for our Tyler, Texas office, although we do not have
a lease. We believe that our facilities are adequate to meet our current and proposed needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENvue
has previously entered into a lease agreement for its headquarters office in Israel (Tel Aviv). Additionally, ENvue has entered into
an agreement for storage, inventory management, order processing, and shipping services in the U.S. (Arlington Heights, Illinois).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 114; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sw_005"></span>ITEM
3. LEGAL PROCEEDINGS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may be involved in certain claims and litigation arising out of the ordinary course and conduct of business. Management
assesses such claims and, if it considers that it is probable that an asset had been impaired or a liability had been incurred and the
amount of loss can be reasonably estimated, provisions for loss are made based on management&#8217;s assessment of the most likely outcome.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Protrade
Proceeding</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 26, 2021, Protrade Systems, Inc. (&#8220;Protrade&#8221;) filed a Request for Arbitration (the &#8220;Request&#8221;) with the
International Court of Arbitration (the &#8220;ICA&#8221;) of the International Chamber of Commerce alleging the Company is in breach
of an Exclusive Distribution Agreement dated March 7, 2019 (the &#8220;Agreement&#8221;) between Protrade and the Company. Protrade alleges,
in part, that the Company has breached the Agreement by discontinuing the manufacture of the DV0057 Painshield MD device in favor of
an updated 10-100-001 Painshield MD device. Protrade claims damages estimated at $3 million. The Company vigorously defended the claims
asserted by Protrade.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 15, 2022, the arbitrator issued a final award, which, determined that (i) the Company had the right to terminate the Exclusive
Distribution Agreement; (ii) the Company did not breach the duty of good faith and fair dealing with regard to the Exclusive Distribution
Agreement; and (iii) the Company did not breach any confidentiality obligations to Protrade. Nevertheless, the arbitrator determined
that the Company did not comply with the obligation to supply Protrade with a year&#8217;s supply of patches, and awarded Protrade $1,500,250,
which consists of $1,432,000 for &#8220;lost profits&#8221; and $68,250 as reimbursement of arbitration costs, on the grounds that the
Company allegedly failed to supply Protrade with certain patches utilized by users of DV0057 Painshield MD device. The arbitrator based
the decision on the testimony of Protrade&#8217;s president who asserted that a user would use in excess of 33 patches per each device.
The Company believes that the number of patches per device alleged by Protrade is grossly inflated, and that these claims were not properly
raised before the arbitrator. Accordingly, on April 13, 2022, the Company submitted an application for the correction of the award which
the arbitrator denied on June 22, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 5, 2022, Protrade filed a Petition with the Supreme Court of New York Nassau County seeking to confirm the Award. On April 13,
2022, the Company submitted an application to the ICA seeking to correct an error in the award based on the evidence that the Company
only sold 2-3 reusable patches per device contrary to the 33 reusable patches claimed by Protrade. The same arbitrator who issued the
award, denied the application.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 22, 2022, the Company filed a cross-motion seeking to vacate arbitration award on the grounds that the arbitrator exceeded her authority,
that the award was procured by fraud, and that the arbitrator failed to follow procedures established by New York law. In particular,
the Company averred in its motion that Protrade&#8217;s witness made false statements in arbitration, and that the arbitrator resolved
a claim that was never raised by Protrade and that has no factual basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2022, the court issued a decision granting Protrade its petition to confirm the award and denying the cross-motion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 9, 2022, the Company filed a motion to re-argue and renew its cross-motion to vacate the arbitration decision based on newer
information that was not available during the initial hearing. On the same day, the Company also filed a notice of appeal with the Appellate
Division, Second Department. On March 21, 2023, the court denied the motion to re-argue and renew.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 10, 2023, the Company filed its appeal with the Appellate Division, Second Department. That appeal is now fully briefed. In February 2025, the Second Department informed counsel for the Company that the Second Department
was beginning to process the appeal for calendaring.&#8221; </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, and 2023, the Company accrued the amount of the arbitration award to Protrade of approximately $2.1 and $2.0
million, respectively, including interest which is classified in &#8220;Other accounts payable and accrued
expenses&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
also &#8220;Item 8. Financial Statements and Supplementary Data - Note 12. Commitments and Contingencies,&#8221; which information is
incorporated herein by reference, for a description of pending and recent litigation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sw_006"></span>ITEM
4. MINE SAFETY DISCLOSURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 115; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sw_007"></span>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sw_008"></span>ITEM
5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on Nasdaq under the symbol &#8220;NAOV&#8221; since November 8, 2017. Prior to that date, our common stock was
quoted on the OTCQB over-the-counter marketplace under the symbol &#8220;NAOV&#8221; since April 10, 2015. Prior to April 10, 2015, there
was no established public trading market for our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related
Stockholder Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, we had 759,297 issued and outstanding shares of common stock and 57,720 shares of Series X Non-Voting
Convertible Preferred Stock. The common stock was held by 101 holders of record and the Series X Preferred Stock was held
by 1 holders of record. The actual number of holders of our common stock is greater than the number of record holders, and
includes stockholders who are beneficial owners, but whose shares are held in street names by brokers or other nominees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Authorized
Capital and Preferred Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 3, 2021, we filed a proxy statement in connection with a special meeting of stockholders that was held on March 31, 2021, and ultimately
adjourned until May 6, 2021, to (i) ratify the increase in the number of authorized shares of common stock from 20,000,000 to 24,109,635
and the issuance of such 4,109,635 shares of common stock, and (ii) further increase the number of our authorized shares of common stock.
On May 6, 2021, the Company&#8217;s stockholders voted to approve the ratification of the increase in the number of authorized shares
of common stock from 20,000,000 to 24,109,635 and the issuance of such 373,603 shares of common stock to be effective as of December
4, 2020, but the stockholders did not approve a further increase in the number of its authorized shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 17, 2021, the Company&#8217;s stockholders voted to approve an amendment to our Amended and Restated Certificate of Incorporation
to increase the number of shares of our common stock authorized for issuance from 24,109,635 shares to 40,000,000 shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, there were no shares of our Series C Preferred Stock issued and outstanding. Each share of our Series C Preferred
Stock is convertible into one share of our common stock (subject to adjustment as provided in the related designation of preferences)
at any time at the option of the holder, provided that the holder would be prohibited from converting Series C Preferred Stock into shares
of our common stock if, as a result of such conversion, the holder, together with its affiliates, would beneficially own more than 9.99%
of the total number of shares of our common stock then issued and outstanding. This limitation may be waived upon not less than 61 days&#8217;
prior written notice to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, there were no shares of our Series D Preferred Stock outstanding. Each share of our Series D Preferred Stock is
convertible into one thousand shares of our common stock (subject to adjustment as provided in the related designation of preferences)
at any time at the option of the holder, provided that the holder would be prohibited from converting Series D Preferred Stock into shares
of our common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 9.99% of the total
number of shares of our common stock then issued and outstanding. This limitation may be waived upon not less than 61 days&#8217; prior
written notice to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, there were no shares of our Series E Preferred Stock issued and outstanding. Each share of our Series E Preferred
Stock is convertible into one share of our common stock (subject to adjustment as provided in the related designation of preferences)
at any time at the option of the holder, provided that the holder would be prohibited from converting Series E Preferred Stock into shares
of our common stock if, as a result of such conversion, the holder, together with its affiliates, would beneficially own more than 9.99%
of the total number of shares of our common stock then issued and outstanding. This limitation may be waived upon not less than 61 days&#8217;
prior written notice to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 116; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, there were no shares of our Series F Preferred Stock issued and outstanding. Each share of Series F Preferred Stock
entitles the holder thereof to 1,000,000 votes per share (and, for the avoidance of doubt, each fraction of a share of Series F Preferred
Stock has a ratable number of votes). Thus, each one-thousandth of a share of Series F Preferred Stock entitles the holder thereof to
1,000 votes. The outstanding shares of Series F Preferred Stock will vote together with the outstanding shares of common stock of the
Company as a single class exclusively with respect to (1) any proposal to adopt an amendment to Certificate of Incorporation to reclassify
the outstanding shares of common stock at a ratio specified in or determined in accordance with the terms of such amendment and (2) any
proposal to adjourn any meeting of stockholders called for the purpose of voting on the matters mentioned in the aforementioned proposal.
The Series F Preferred Stock is not entitled to vote on any other matter, except to the extent required under the Delaware General Corporation
Law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, there were 57,720 shares of our Series X Preferred Stock issued and outstanding. The conversion price for each share
of Series X Preferred Stock shall be $0.6063. The conversion ratio (the &#8220;Conversion Ratio&#8221;) for each share of Series X Preferred
Stock is determined by dividing the Stated Value (as defined in the Series X Certificate of Designations, as defined below) of each share
of Series X Preferred Stock, initially valued at $606.3756, divided by the conversion price which provides an implied Conversion Ratio
of 1,000 shares of common stock issuable upon the conversion of each share of Series X Preferred Stock, subject to adjustment as provided
in the Certificate of Designations of the Series X Non-Voting Convertible Preferred Stock (the &#8220;Series X Certificate of Designations&#8221;).
Effective as of 5:00 p.m. Eastern Time on the fourth business day after the approval of the shares of common stock issuable upon conversion
of the Series X Preferred Stock (the &#8220;Series X Stockholder Approval&#8221;), each share of Series X Preferred Stock then outstanding
shall automatically convert into a number of shares of common stock equal to the Conversion Ratio, subject to applicable beneficial ownership
limitations. Subject the terms of the Series X Certificate of Designations, the Series X Preferred Stock is also convertible, at the
option of the holder, at any time and from time to time following 5:00 p.m. Eastern Time on the third business day after the date that
the Series X Stockholder Approval, into a number of shares of common stock equal to the Conversion Ratio, subject to the applicable beneficial
ownership limitations. Except as otherwise provided in the Series X Certificate of Designations, or as required by the DGCL, the Series
X Preferred Stock shall have no voting rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Sales of Unregistered Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
sales of unregistered securities during the year ended December 31, 2024, were previously disclosed in a Quarterly Report on Form 10-Q
or a Current Report on Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issuer
Purchases of Equity Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
did not purchase any of our registered equity securities during the period covered by this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividends</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not paid any cash dividends to our stockholders since inception and do not plan to pay cash dividends in the foreseeable future.
Any future declaration of dividends will depend on our earnings, capital requirements, financial condition, prospects and any other factors
that our board of directors deems relevant, as well as compliance with the requirements of state law. In general, as a Delaware corporation,
we may pay dividends out of surplus capital or, if there is no surplus capital, out of net profits for the fiscal year in which a dividend
is declared and/or the preceding fiscal year. We currently intend to retain earnings, if any, for reinvestment in our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sw_009"></span>ITEM
6. RESERVED</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 117; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sw_010"></span>ITEM
7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations is intended to provide a reader of our financial statements
with a narrative from the perspective of our management on our financial condition, results of operations, liquidity, and certain other
factors that may affect our future results. You should read the following discussion and analysis of financial condition and results
of operations in conjunction with our consolidated financial statements and the related notes thereto included elsewhere in this Annual
Report on Form 10-K. In addition to historical information, the following discussion and analysis includes forward-looking information
that involves risks, uncertainties and assumptions. Our actual results and the timing of events could differ materially from those anticipated
by these forward-looking statements as a result of many factors, including those discussed under &#8220;Item 1A. Risk Factors&#8221;
and elsewhere in this Annual Report on Form 10 -K. See &#8220;Item 1. Business - Cautionary Note Regarding Forward-Looking Statement;
Risk Factors Summary&#8221; included elsewhere in this Annual Report on Form 10 -K.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a medical device company focusing on non-invasive biological response-activating devices that target wound healing and pain therapy
and can be administered at home, without the assistance of medical professionals. Our WoundShield, PainShield and UroShield products
are backed by novel technology which relates to ultrasound delivery through surface acoustic waves.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reverse
Stock Splits</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 8, 2023, we effected a reverse stock split of our common stock at a ratio of 1-for-20 (the &#8220;2023 Reverse Stock Split&#8221;,
and on February 13, 2025, we effected a reverse stock split of our common stock at a ratio of 1-for11 (the &#8220;2025 Reverse Stock
Split&#8221; and together with the 2023 Reverse Stock Split, the Reverse Stock Splits&#8221;) pursuant a Certificate of Amendment to
our Amended and Restated Certificate of Incorporation. At the effective time of the 2023 Reverse Stock Split and the 2025 Reverse Stock
Split, every 20 and 11 shares, respectively, of our issued and outstanding common stock were converted automatically into one issued
and outstanding share of common stock without any change in the par value per share. Any fractional share of a stockholder resulting
from the Reverse Stock Splits was rounded up to the nearest whole number of shares. Proportional adjustments were made to the number
of shares of our common stock issuable upon exercise or conversion of the Company&#8217;s equity awards, warrants and other convertible
securities, as well as the applicable exercise or conversion price thereof. Except as otherwise indicated, all share and per-share figures
in this Annual Report on Form 10-K have been adjusted to reflect the Reverse Stock Splits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Developments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2025
Reverse Stock Split</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 13, 2025, at 4:05 p.m., Eastern Time, pursuant to a Certificate of Amendment to our Amended and Restated Certificate of Incorporation,
as amended, 2025 Reverse Stock Split became effective. Our common stock began trading on Nasdaq on a split-adjusted basis on March 14,
2025. See &#8220;Reverse Stock Splits&#8221; above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
Merger Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2025, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of February 14, 2025 (the &#8220;Merger
Agreement&#8221;), by and among the Company, NVEH Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of NVEH Merger
Sub I, Inc. (&#8220;First Merger Sub&#8221;), NVEH Merger Sub II, LLC, a Delaware limited liability company and a wholly-owned subsidiary
of the Company (&#8220;Second Merger Sub&#8221;), and ENvue Medical Holdings, Corp. (&#8220;Predecessor ENvue&#8221;), the Company and
Predecessor ENvue effected (i) a merger of First Merger Sub with and into Predecessor ENvue, with the First Merger Sub ceasing to exist
and Predecessor ENvue becoming a wholly-owned subsidiary the Company and (ii) the merger of Predecessor ENvue with and into Second Merger
Sub (the &#8220;Second Merger&#8221; and, together with the First Merger, the &#8220;Merger&#8221;), with Second Merger Sub being the
surviving entity of the Second Merger (&#8220;Surviving Entity&#8221;). At the effective time of the Second Merger, the certificate of
formation of the Surviving Entity was amended and restated to, among other things, to change the name of the Surviving Entity to &#8220;ENvue
Medical Holdings LLC.&#8221; In connection with the Merger Agreement, we issued (i) 1,734,995 shares of common stock (the &#8220;Merger
Shares&#8221;), which such number of shares represented no more than 19.9% (the &#8220;Exchange Cap&#8221;) of the outstanding shares
of common stock as of immediately before the First Effective Time and (ii) 57,720 shares of Series X Non-Voting Convertible Preferred
Stock, par value $0.001 per share (the &#8220;Series X Preferred Stock&#8221;) in excess of the Exchange Cap to the holders of Predecessor
ENvue in consideration for 100% of Predecessor ENvue. Each share of Series X Preferred Stock will be convertible into 1,000 shares of
our common stock, subject to and contingent upon the affirmative vote of a majority of the shares of common stock present or represented
and entitled to vote at a meeting of stockholders of Company to approve, for purposes of the Nasdaq Listing Rules, the issuance of shares
of our common stock to the stockholders of Predecessor ENvue upon conversion of any and all shares of Series X Preferred Stock in accordance
with the terms of the Certificate of Designation for the Series X Preferred Stock. The Merger was consummated and completed on February
14, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 118; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
giving effect to the Merger, pursuant to the terms and conditions of the Merger Agreement: (i) the holders of the outstanding equity
of Predecessor ENvue immediately prior to the effective time of the First Merger (&#8220;First Effective Time&#8221;) own 19.9% of the
common stock of the Company and 85.0% of the outstanding equity of the Company (assuming the Series X Preferred Stock is converting at
a ratio of 1,000:1) immediately following the First Effective Time, which following stockholder approval will allow the Series X Preferred
Stock to convert to common stock of the Company which may result in the holders of Predecessor ENvue to own 85% of the common stock of
the Company, and (ii) the holders of our outstanding equity immediately prior to the First Effective Time own 80.1% of the common stock
of the Company and 15.0% of the outstanding equity of the Company (assuming the Series X Preferred Stock is converting at a ratio of
1,000:1) immediately following the First Effective Time, which following stockholder approval which will allow the Series X Preferred
Stock to convert to common stock of the Company which may result in our holders owning 15% of common stock of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Debenture
Financing and Senior Convertible Debenture</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 13, 2025, we entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with an institutional investor
(the &#8220;Investor&#8221;), pursuant to which we sold in a private placement, a senior convertible debenture (the &#8220;Debenture&#8221;)
due the earlier of (i) the date that is the 30-day anniversary of the effective date of stockholder approval (the &#8220;Debenture Stockholder
Approval&#8221;) of the issuance of the shares of common stock upon the conversion of the debenture (the &#8220;Debenture Financing&#8221;)
and (ii) the date that is nine months following the date of issuance of the Debenture (&#8220;Maturity Date&#8221;), having an aggregate
principal amount of $500,000. The closing of the Debenture Financing occurred on February 14, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">On March 26, 2025 we amended
and restated the Debenture to increase the Principal Amount to $1,300,000 to provide for the funding by Alpha Capital Anstalt (the &#8220;Investor&#8221;)
to our subsidiary ENvue Medical Holdings, Corp. (&#8220;<b><i>ENvue</i></b>&#8221;), a wholly owned subsidiary of the Company of (i) an
aggregate of $250,000 by the Investor to ENvue on February 6, 2025, (ii) an aggregate of $250,000 by the Investor to ENvue on March 4,
2025, and (iii) and an aggregate of $300,000 by the Investor to ENvue on March 26, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">On the Maturity Date, we shall pay the Investor in
cash or, at the option of the Investor, in the form of conversion shares, or a combination thereof, the entire outstanding principal amount
of the Debenture, together with accrued and unpaid interest thereon, the applicable exit fee and any other amounts due thereunder. Following
the receipt of Debenture Stockholder Approval, the Debenture shall be convertible, in whole or in part, into shares of common stock, at
the option of the Investor, at the initial conversion price of $4.8906 (the &#8220;Conversion Price&#8221;), which is subject to customary
anti-dilution adjustments, and which such Conversion Price shall not be lower than the floor price of $0.97812. The Debenture bears interest
at the rate of 8.0% per annum, payable on the Maturity Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">On February 13, 2025, as amended on March 26, 2025,
in connection with the Purchase Agreement and issuance of the Debenture, we entered into that certain Registration Rights Agreement (the
&#8220;Registration Rights Agreement&#8221;) with the Investor. Pursuant to the Registration Rights Agreement, the Company is required
to prepare and file a resale registration statement with the SEC within 30 calendar days following the closing date of the amended Debenture
Financing (the &#8220;Filing Deadline&#8221;). The Company shall use its commercially reasonable efforts to cause such registration statement
to be declared effective by the SEC within 60 calendar days of the Filing Deadline (or within 90 calendar days if the SEC reviews the
resale registration statement).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>January
2025 3(a)(9) Exchange</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 7, 2025, we entered into a securities exchange agreement (the &#8220;Exchange Agreement&#8221;) with a certain institutional
investor pursuant to which we agreed to issue an aggregate of (i) 41,498 shares of common stock (the &#8220;3(a)(9) Shares&#8221;),
(ii) a warrant to purchase up to 158,562 shares of common stock (the &#8220;January 2025 Warrant&#8221;), and (iii) a pre-funded
warrant to purchase up to 178,132 shares of common stock (the &#8220;January 2025 Pre-Funded Warrant&#8221;), in exchange for the
A-1 Warrant held by the Holder to purchase up to 264,271 shares of common stock at an exercise price of $16,17 per share (the
&#8220;Exchange&#8221;). We cancelled the A-1 Warrant reacquired in the Exchange and the A-1 Warrant will not be reissued. The
January 2025 Warrant has substantially the same terms as the A-1 Warrant, except that the shares of common stock issuable upon
exercise of the January 2025 Warrant are subject to stockholder approval pursuant to the applicable rules and regulations of the
Nasdaq, is exercisable for a term of five and one half years from the date such stockholder approval is received and deemed
effective under Delaware law, and has an exercise price of $6.8296 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 119; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to the Exchange, the holder of the January 2025 Pre-Funded Warrant exercised the January 2025 Pre-Funded Warrant in full on a cashless
basis in full for an aggregate of 228,354 shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance in the Exchange of the 3(a)(9) Shares, the January 2025 Warrant, the January 2025 Pre-Funded Warrant and the shares of common
stock issuable upon the exercise thereof pursuant to the Exchange Agreement was made in reliance on an exemption from registration under
Section 3(a)(9) of the Securities Act</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
operations in Israel</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we are incorporated under the laws of the state of Israel and our operations are conducted in Israel, our business and operations are
directly affected by economic, political, geopolitical, and military conditions in Israel. Since the establishment of the State of Israel
in 1948, a number of armed conflicts have occurred between Israel and its neighboring countries and terrorist organizations active in
the region. These conflicts have involved missile strikes, hostile infiltrations and terrorism against civilian targets in various parts
of Israel, which have negatively affected business conditions in Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
recently, in October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of
attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located
along Israel&#8217;s border with the Gaza Strip and in other areas within the State of Israel. Following the attack, Israel&#8217;s security
cabinet declared war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued
rocket and terror attacks. Moreover, the clash between Israel and Hezbollah in Lebanon, may escalate in the future into a greater regional
conflict, especially in the northern part of Israel where our Israel office is located which stores approximately $1.8 million worth
of our inventory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
hostilities involving Israel, or the interruption or curtailment of trade within Israel or between Israel and its trading partners, or
the ability to ship our products overseas, could adversely affect our operations and results of operations and could make it more difficult
for us to raise capital. Parties with whom we may do business have sometimes declined to travel to Israel during periods of heightened
unrest or tension, forcing us to make alternative arrangements when necessary. The conflict situation in Israel could cause situations
where medical product certifying or auditing bodies could not be able to visit manufacturing facilities of our subcontractors in Israel
in order to review our certifications or clearances, thus possibly leading to temporary suspensions or even cancellations of our product
clearances or certifications. The conflict situation in Israel could also result in parties with whom we have agreements involving performance
in Israel claiming that they are not obligated to perform their commitments under those agreements pursuant to force majeure provisions
in such agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been travel advisories imposed as related to travel to Israel, and restriction on travel, or delays and disruptions as related to
imports and exports may be imposed in the future. An inability to receive supplies and materials, shortages of materials or difficulties
in procuring our materials, among others, or conversely, our ability to ship products to our US facilities or overseas customers, may
adversely impact our ability to commercialize and manufacture our product candidates and products in a timely manner. This could cause
a number of delays and/or issues for our operations, including delay of the review of our product candidates by regulatory agencies,
which in turn would have a material adverse impact on our ability to commercialize our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
members of our management and employees are located and reside in Israel. Shelter-in-place and work-from-home measures, government-imposed
restrictions on movement and travel and other precautions taken to address the ongoing conflict may temporarily disrupt our management
and employees&#8217; ability to effectively perform their daily tasks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 120; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
IDF, the national military of Israel, is a conscripted military service, subject to certain exceptions. None of our employees are subject
to military service in the IDF and have been called to serve, but many do serve on guard duty in their local communities from time to
time. It is possible that there will be further military reserve duty call-ups in the future, which may affect our business due to a
shortage of skilled labor and loss of institutional knowledge, and necessary mitigation measures we may take to respond to a decrease
in labor availability, such as overtime and third-party outsourcing, for example, which may have unintended negative effects and adversely
impact our results of operations, liquidity or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is currently not possible to predict the duration or severity of the ongoing conflict or its effects on our business, operations and
financial conditions. The ongoing conflict is rapidly evolving and developing, and could disrupt our business and operations, interrupt
our sources and availability of supply and hamper our ability to raise additional funds or sell our securities, among others.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Protrade
Proceeding</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 26, 2021, Protrade Systems, Inc. (&#8220;Protrade&#8221;) filed a Request for Arbitration (the &#8220;Request&#8221;) with the
International Court of Arbitration (the &#8220;ICA&#8221;) of the International Chamber of Commerce alleging the Company is in breach
of an Exclusive Distribution Agreement dated March 7, 2019 (the &#8220;Agreement&#8221;) between Protrade and the Company. Protrade alleges,
in part, that the Company has breached the Agreement by discontinuing the manufacture of the DV0057 Painshield MD device in favor of
an updated 10-100-001 Painshield MD device. Protrade claims damages estimated at $3 million. The Company vigorously defended the claims
asserted by Protrade.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 15, 2022, the arbitrator issued a final award, which, determined that (i) the Company had the right to terminate the Exclusive
Distribution Agreement; (ii) the Company did not breach the duty of good faith and fair dealing with regard to the Exclusive Distribution
Agreement; and (iii) the Company did not breach any confidentiality obligations to Protrade. Nevertheless, the arbitrator determined
that the Company did not comply with the obligation to supply Protrade with a year&#8217;s supply of patches, and awarded Protrade $1,500,250,
which consists of $1,432,000 for &#8220;lost profits&#8221; and $68,250 as reimbursement of arbitration costs, on the grounds that the
Company allegedly failed to supply Protrade with certain patches utilized by users of DV0057 Painshield MD device. The arbitrator based
the decision on the testimony of Protrade&#8217;s president who asserted that a user would use in excess of 33 patches per each device.
The Company believes that the number of patches per device alleged by Protrade is grossly inflated, and that these claims were not properly
raised before the arbitrator. Accordingly, on April 13, 2022, the Company submitted an application for the correction of the award which
the arbitrator denied on June 22, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 22, 2022, the Company filed a cross-motion seeking to vacate arbitration award on the grounds that the arbitrator exceeded her authority,
that the award was procured by fraud, and that the arbitrator failed to follow procedures established by New York law. In particular,
the Company averred in its motion that Protrade&#8217;s witness made false statements in arbitration, and that the arbitrator resolved
a claim that was never raised by Protrade and that has no factual basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2022, the court issued a decision granting Protrade its petition to confirm the award and denying the cross-motion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 9, 2022, the Company filed a motion to re-argue and renew its cross-motion to vacate the arbitration decision based on newer
information that was not available during the initial hearing. On the same day, the Company also filed a notice of appeal with the Appellate
Division, Second Department. On March 21, 2023, the court denied the motion to re-argue and renew.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 10, 2023, the Company filed its appeal with the Appellate Division, Second Department. That appeal is now fully briefed. In February 2025, the Second Department informed counsel for the Company that the Second Department
was beginning to process the appeal for calendaring.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, and 2023, the Company accrued the amount of the arbitration award to Protrade of approximately $2.1 and $2.0
million, respectively, including interest which is classified in &#8220;Other accounts payable and accrued
expenses&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 121; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Business
Developments</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nasdaq
Deficiency and Hearings Panel Decision</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently do not meet the continued listing requirements of the Nasdaq Capital Market (&#8220;Nasdaq&#8221;). As previously disclosed,
on April 10, 2024, we received a letter (the &#8220;Letter&#8221;) from the Listing Qualifications Department (the &#8220;Staff&#8221;)
of The Nasdaq Stock Market LLC indicating that, based upon the closing bid price of our Common Stock for the 30 consecutive business
days between February 27, 2024 and April 9, 2024, we did not meet the minimum bid price of $1.00 per share required for continued listing
on Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) (the &#8220;Bid Price Rule&#8221;). The Letter also indicated that we were provided
with a compliance period of 180 calendar days, or until October 7, 2024, in which to regain compliance with the Bid Price Rule pursuant
to Nasdaq Listing Rule 5810(c)(3)(A). We did not regain compliance with the Bid Price Rule by October 7, 2024, and on October 8, 2024,
Nasdaq notified us that our securities were subject to delisting from Nasdaq unless we timely requested a hearing before the Nasdaq Hearings
Panel (the &#8220;Panel&#8221;). We subsequently timely requested a hearing before the Panel, which was held on December 5, 2024 (the
&#8220;Hearing&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 19, 2024, we received an additional deficiency notice from the Staff indicating that we no longer satisfied the $2.5 million
stockholders&#8217; equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) (the &#8220;Equity Rule&#8221;) for continued listing
on Nasdaq. The Staff indicated that our non-compliance with the Equity Rule would be considered by the Panel at the Hearing and could
serve as an additional basis for delisting of our securities from Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 26, 2024, we received a decision letter (the &#8220;Decision Letter&#8221;) from the Panel granting a limited extension of time
for us to demonstrate compliance with the Bid Price Rule and the Equity Rule for continued listing on Nasdaq, subject to the following
conditions: (i) on or before February 27, 2025, we will have obtained stockholder approval to effect the Reverse Stock Split; (ii) on
or before March 31, 2025, we shall have effected the Reverse Stock Split and, thereafter, maintain a $1.00 closing bid price of the our
common stock for a minimum of ten consecutive trading days; (iii) on or before March 31, 2025, we are required to demonstrate compliance
with the Equity Rule by filing public disclosure with the SEC and demonstrate long-term compliance with the Equity Rule; and (iv) on
or before March 31, 2025, we are required to demonstrate compliance with all continued listing requirements for Nasdaq. On February 24,
2025, we obtained approval from our stockholders to file a certificate of amendment to our Certificate of Incorporation to effectuate
the 2025 Reverse Stock Split, among others, and on March 13, 2025, the 2025 Reverse Stock Split became effective. As of the date of this
Annual Report on Form 10-K, we have not regained compliance with listing rules of Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
there can be no assurance that we will be able to maintain compliance. If we fail to satisfy another Nasdaq requirement for continued
listing, Nasdaq staff could provide notice that our common stock will become subject to delisting. In such event, Nasdaq rules permit
us to appeal the decision to reject its proposed compliance plan or any delisting determination to a Nasdaq Hearings Panel. Accordingly,
there can be no guarantee that we will be able to maintain our Nasdaq listing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 122; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Significant Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
management&#8217;s discussion and analysis of financial condition and results of operations is based on our financial statements, which
have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions
that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial
statements, and the reported amounts of revenue and expenses during the reported period. In accordance with U.S. GAAP, we base our estimates
on historical experience and on various other assumptions we believe to be reasonable under the circumstances. Actual results may differ
from these estimates if conditions differ from our assumptions. While our significant accounting policies are more fully described in
Note 3 in the &#8220;Notes to Financial Statements&#8221;, we believe the following accounting policies are critical to the process of
making significant estimates in preparation of our financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inventory</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
are stated at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course
of business, less reasonably predictable costs of completion, disposal, and transportation. Cost is determined using the &#8220;first-in,
first-out&#8221; method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
write-offs are provided to cover risks arising from slow-moving items or technological obsolescence. The Company periodically evaluates
the quantities on hand relative to current and historical selling prices and historical and projected sales volume. Based on this evaluation,
provisions are made when required to write-down inventory to its net market value. As of December 31, 2024, and 2023, there was no allowance
on inventory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Impairment
of Long-Lived Assets</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
reviews for impairment whenever events or changes in circumstances indicate that the carrying amount of property and equipment may not
be recoverable under the provisions of accounting for the impairment of long-lived assets. If it is determined that an impairment loss
has occurred based upon expected future cash flows, the loss is recognized in the Consolidated Statements of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sequencing</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adopted a sequencing policy under ASC 815-40-35 whereby if reclassification of contracts from equity to liabilities is necessary
pursuant to ASC 815 due to the Company&#8217;s inability to demonstrate it has sufficient authorized shares. This was due to the Company
committing more shares than authorized. While temporary suspensions are in place to keep the potential exercises beneath the number authorized,
certain instruments are classified as liabilities, after allocating available authorized shares on the basis of the most recent grant
date of potentially dilutive instruments. Pursuant to ASC 815, issuances of securities granted as compensation in a share-based payment
arrangement are not subject to the sequencing policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue
recognition</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is the Company&#8217;s policy that revenues from product sales is recognized in accordance with ASC 606 &#8220;Revenue Recognition.&#8221;
Five basic steps must be followed before revenue can be recognized; (1) identifying the contract(s) with a customer that create(s) enforceable
rights and obligations; (2) identifying the performance obligations in the contract, such as promising to transfer goods or services
to a customer; (3) determining the transaction price, meaning the amount of consideration in a contract to which an entity expects to
be entitled in exchange for transferring promised goods or services to a customer; (4) allocating the transaction price to the performance
obligations in the contract, which requires the company to allocate the transaction price to each performance obligation on the basis
of the relative standalone selling prices of each distinct good or services promised in the contract; and (5) recognizing revenue when
(or as) the entity satisfies a performance obligation by transferring a promised good or service to a customer. The amount of revenue
recognized is the amount allocated to the satisfied performance obligation. Adoption of ASC 606 has not changed the timing and nature
of the Company&#8217;s revenue recognition and there has been no material effect on the Company&#8217;s financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from product sales is recorded at the net sales price, or &#8220;transaction price,&#8221; which includes estimates of variable consideration
that result from coupons, discounts, chargebacks and distributor fees, processing fees, as well as allowances for returns and government
rebates. The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue.
Collectability of revenue is reasonably assured based on historical evidence of collectability between the Company and its customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 123; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues
from sales to distributors are recognized at the time the products are delivered to the distributors (&#8220;sell-in&#8221;). The Company
does not grant rights of return, credits, rebates, price protection, or other privileges on its products to distributors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-based
compensation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on the Black-Scholes option pricing model for estimating the fair value of stock-based awards granted, and expected volatility is
based on the historical volatilities of peer company&#8217;s common stock. Stock options generally vest over one or two years from the
grant date and generally have ten-year contractual terms. Information about the assumptions used in the calculation of stock-based compensation
expense is set forth in Notes 3 and 6 in the &#8220;Notes to Financial Statements&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income
taxes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for income taxes in accordance with ASC 740, &#8220;Income Taxes&#8221;. This topic prescribes the use of the liability method
whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and tax bases
of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected
to reverse. We provide full valuation allowance, to reduce deferred tax assets to the amount that is more likely than not to be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
implemented a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position taken
or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not
that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals
or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% (cumulative basis)
likely to be realized upon ultimate settlement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize interest and penalties related to uncertain tax positions on the income tax expense line in the accompanying consolidated statement
of operations. Accrued interest and penalties are included on the related tax liability line in the consolidated balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently
issued accounting standards</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">In December 2023, the FASB issued ASU 2023-09, Income
Taxes (Topic 740) &#8211; Improvements to Income Tax Disclosures (ASU 2023-09). ASU 2023-09 requires that an entity, on an annual basis,
disclose additional income tax information, primarily related to the rate reconciliation and income taxes paid. The amendment in the ASU
is intended to enhance the transparency and decision usefulness of income tax disclosures. The ASU&#8217;s amendments are effective for
annual periods beginning after December 15, 2024. The adoption of Topic 740 did not have a material -effect on the Company&#8217;s consolidated
financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
a summary of recent accounting pronouncements applicable to our consolidated financial statements see Note 3, &#8220;Summary of Significant
Accounting Policies&#8221; to the Consolidated Financial Statements included in Part IV, Item 15 of this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Year
Ended December 31, 2024, Compared to Year Ended December 31, 2023</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenues</i>.
For the years ended December 31, 2024, and 2023, our revenues were approximately $2,558,000 and $2,283,000, respectively, an increase
of approximately 12%, or $275,000, between the periods. The increase was due to increased revenues from customers from Veteran Administration
facilities and through workman&#8217;s compensation programs who are referred to us from certain sales representatives, and our largest
direct medical equipment distributor in 2024. Our revenues may fluctuate as we add new consumers or when existing distributors or consumers
make large purchases of our products during one period and no purchases during another period. Therefore, any growth or decrease in revenues
by quarter may not be linear or consistent. We do not anticipate that our revenues will be impacted by inflation or changing prices in
the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2024, the percentage of revenues attributable to our products was: PainShield MD &#8211; 45%, PainShield
Plus &#8211; 28%, Monthly Kits - 27%. For the year ended December 31, 2023, the percentage of revenues attributable to our products was:
PainShield &#8211; 93% and UroShield &#8211; 7%. For the years ended December 31, 2024, and 2023, the portion of our revenues that was
derived from our largest direct medical equipment distributor, Ultra Pain Products LLC, were 31% and 38%, respectively, and customers
introduced by our sales representatives were 67% and 41%, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 124; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Gross
Profit</i>. For the years ended December 31, 2024, and 2023, gross profit was approximately $1,508,000 and $1,537,000, respectively,
a decrease of approximately 2% or $29,000. The increase was mainly due to the increase in revenues in 2024. The decrease in the gross
margin percentage was due to lowering our wholesale sales price awarded to customers from Veteran Administration facilities or through
workman&#8217;s compensation programs who are referred to us from certain sales representatives, which became effective in the second
quarter of 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
profit as a percentage of revenues were approximately 59% and 67% for the years ended December 31, 2024, and 2023, respectively. The
increase in gross profit as a percentage of revenues is mainly due to the reasons described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development Expenses</i>. For the years ended December 31, 2024, and 2023, research and development expenses were approximately $909,000
and $185,000, respectively, an increase of approximately 391%, or $724,000 between the periods. The increase was due to the costs of
our product development project which we started in 2024 as well as the cost of our clinical trial test program with the University of
Michigan which took place in 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses as a percentage of total revenues were approximately 36% and 8% for the years ended December 31, 2024, and 2023,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development expenses consist mainly of expenses related to subcontracting research and development and clinical trial activities,
as well as payroll expenses to employees, and the associated facilities&#8217; costs, who are involved with research and development
activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Selling
and Marketing Expenses</i>. For the years ended December 31, 2024, and 2023, selling and marketing expenses were approximately $720,000
and $864,000, respectively, a decrease of approximately 17%, or $144,000 between the periods. The decrease was due to consulting fees
and costs incurred  related to the website development project which was completed in
2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling
and marketing expenses as a percentage of total revenues were approximately 28% and 38% for the years ended December 31, 2024, and 2023,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling
and marketing expenses consist mainly of payroll expenses to direct sales and marketing employees, stock-based compensation expenses,
travel expenses, conventions, advertising and marketing expenses, rent and facilities expenses associated with and allocated to selling
and marketing activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative Expenses</i>. For the years ended December 31, 2024, and 2023, general and administrative expenses were approximately
$3,461,000 and $3,924,000, respectively, a decrease of approximately 12%, or $463,000 between the periods. The decrease was mainly due
to a decrease of legal fees related to securities and litigation matters, as well as accounting fees incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
general and administrative expenses consist mainly of payroll expenses for management and administrative employees, stock-based compensation
expenses, accounting, legal and facilities expenses associated with general and administrative activities and costs associated with being
a publicly traded company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses as a percentage of total revenues were approximately 135% and 172% for the years ended December 31, 2024,
and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interest
expense</i>. For the years ended December 31, 2024, and 2023, our interest expenses were $135,000 and $135,000, respectively. This pertains
to the interest on the Company&#8217;s judgment liability in the current and prior years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Income
tax expense. </i>For the years ended December 31, 2024, and 2023, our income tax expense was approximately $19,000 and $29,000, respectively.
The tax expense is computed by multiplying income before taxes at our Israeli subsidiary by the appropriate tax rate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 125; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
Loss</i>. Our net loss decreased by approximately 6,000 or less than 1%, to approximately $3,705,000 for the year ended December 31,
2024, from approximately $3,711,000 during the same period in 2023. The decrease in net loss resulted primarily from the factors described
above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred net losses of approximately $3,705,000 during the year ended December 31, 2024, which primarily consisted of increased
revenues and increased gross margins offset by our operating expenses. We also had negative cash flow from operating activities of $2,516,000
for the year ended December 31, 2024. Although we received proceeds from the exercise of certain prefunded warrants amounting to $1,000
and had a cash balance of just over $752,000 as of December 31, 2024, we expect to continue to incur losses and negative cash flows from
operating activities, and therefore, we do not have sufficient resources to fund our operation for the next twelve months from the date
of this filing causing us to have substantial doubt of our ability to continue as a going concern. We will need to continue to raise
additional capital to finance its losses and negative cash flows from operations beyond the next years and may continue to be dependent
on additional capital raising as long as our products do not reach commercial profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, we met our short-term liquidity requirements from our existing cash reserves. Our future capital requirements
and the adequacy of our available funds will depend on many factors, including our ability to successfully commercialize our products,
our development of future products and competing technological and market developments as well as our ability to overcome obstacles that
may be presented due to developments caused by the coronavirus outbreak. We expect to continue to incur losses and negative flows from
operations. We intend to use the proceeds generated from equity financings, or strategic alliances with third parties, either alone or
in combination with equity financing to meet our short-term liquidity requirements as well as to advance our long-term plans. There are
no assurances that we are able to raise additional capital, as required, on terms favorable to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any material commitments to capital expenditures as of December 31, 2024, and we are not aware of any material trends in
capital resources that would impact our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, we have no off-balance sheet transactions, arrangements, obligations (including contingent obligations), or other
relationships with unconsolidated entities or other persons that have, or may have, a material effect on our financial condition, changes
in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Summary
of Cash Flow</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General</i>.
As of December 31, 2024, we had cash of approximately $752,000, compared to approximately $3,283,000 as of December 31, 2023. We have
historically met our cash needs through a combination of issuance of equity, borrowing activities and sales. Our cash requirements are
generally for product development, research and development costs, marketing and sales activities, general and administrative costs,
capital expenditures and general working capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
used in our operating activities was approximately $2,516,000 for the years ended December 31, 2024, and approximately $3,602,000 for
the same period in 2023. The decrease in our net cash used in operating activities in the amount of $1,086,000 is mainly attributable
to the sale of inventory that was mostly paid in 2023 and changes in working capital accounts, partially offset by decrease in noncash
expenses of interest expense and stock compensation expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
used in our investing activities was approximately $3,000 and $1,000 for the years ended December 31, 2024, and 2023, respectively, from
purchases of fixed assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
provided by financing activities during the year ended December 31, 2024, was approximately $1,000, which was primarily composed of the
net proceeds received from the exercise of prefunded warrants. Our future capital requirements and the adequacy of available funds will
depend on many factors, including our ability to successfully commercialize our products, our development of future products and competing
technological and market developments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 126; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Factors
That May Affect Future Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our future operating results will continue to be subject to quarterly variations based upon a wide variety of factors, including
the ordering patterns of our distributors, timing of regulatory approvals, the implementation of various phases of our clinical trials
and manufacturing efficiencies due to the learning curve of utilizing new materials and equipment as well issues that may continue to
occur due to the development of the coronavirus outbreak. Our operating results could also be impacted by the hostilities in Israel,
and the Middle East, including the interruption or curtailment of trade within Israel or between Israel and its trading partners, or
the ability to ship our products overseas or a weakening of the Euro and strengthening of the New Israeli Shekel, or NIS, both against
the U.S. dollar. Lastly, other economic conditions we cannot foresee may affect customer demand, such as individual country reimbursement
policies pertaining to our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sw_011"></span>ITEM
7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sw_012"></span>ITEM
8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
consolidated financial statements and the relevant notes to those statements are attached to this report beginning on page F-1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sw_013"></span>ITEM
9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sw_014"></span>ITEM
9A. CONTROLS AND PROCEDURES.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Disclosure
Controls and Procedures</i>.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) that are designed to ensure
that information required to be disclosed in the Company&#8217;s Exchange Act reports is recorded, processed, summarized and reported
within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to the Company&#8217;s
management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required
disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Limitations
on Effectiveness of Controls and Procedures</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
designing and evaluating our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act),
management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance
of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that
there are resource constraints, and that management is required to apply judgment in evaluating the benefits of possible controls and
procedures relative to their costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Evaluation
of Disclosure Controls and Procedures</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the PCAOB standards, a control deficiency exists when the design or operation of a control does not allow management or employees, in
the normal course of performing their assigned functions, to prevent or detect misstatements on a timely basis. A significant deficiency
is a deficiency, or a combination of deficiencies, in internal control over financial reporting that is less severe than a material weakness,
yet important enough to merit the attention by those responsible for oversight of the company&#8217;s financial reporting. A material
weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable
possibility that a material misstatement of the company&#8217;s annual or interim financial statements will not be prevented or detected
on a timely basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 127; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the supervision and with the participation of our management, including our principal executive officer and principal financial officer,
we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) and Rule 15d-15(e)
promulgated under the Exchange Act. Our management including the Chief Executive Officer and Chief Financial Officer has determined that,
as of December 31, 2024, the Company&#8217;s disclosure controls and procedures are effective and has concluded the consolidated financial
statements for the periods covered by and included in this Annual Report fairly present, in all material respects, our financial position,
results of operations and cash flows for the periods presented in conformity with U.S. GAAP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management&#8217;s
Report on Internal Control Over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over
financial reporting is defined in Rule 13a-15(f) and Rule 15d-15(f) under the Exchange Act as a process designed by, or under the supervision
of, the Company&#8217;s principal executive and principal financial officers and effected by the company&#8217;s board of directors,
management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation
of financial statements for external purposes in accordance with U.S. GAAP. Internal control over financial reporting includes policies
and procedures that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pertain
    to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the
    assets of the Company;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
    reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with
    U.S. generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance
    with authorizations of management and directors of the Company; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
    reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company&#8217;s
    assets that could have a material effect on the financial statements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of
any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions,
or that the degree of compliance with policies and procedures may deteriorate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
the participation of the Chief Executive Officer and Chief Financial Officer, our management conducted an evaluation of the effectiveness
of our internal control over financial reporting as of December 31, 2023 based on the criteria set forth by the Committee of Sponsoring
Organizations of the Treadway Commission, known as COSO, in Internal Control &#8212; Integrated Framework (2013). Based on this evaluation,
our management, including the Chief Executive Officer and Chief Financial Officer, has concluded that our internal control over financial
reporting was effective as of December 31, 2024, as a result of the material weakness described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
material weakness is defined as a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that
there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or
detected on a timely basis. In previously filed Annual Reports on Form 10-K&#8217;s, we disclosed material weaknesses related to the
design and effectiveness of our internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
did not have adequate controls in place to ensure adequate review, including the controls over managements review procedures for processing,
recording and reviewing transactions related to certain contracts, accounting memos and certain monthly closing procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a smaller reporting company, the Company is not required to include in this Annual Report on Form 10-K a report on the effectiveness
of internal control over financial reporting by the Company&#8217;s independent registered public accounting firm.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Management&#8217;s
Remediation Plans</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have implemented certain measures to address the identified material weakness. These measures include increasing the use of
an accounting firm to provide and enhance our financial reporting and reviewing our closing procedures as well as improving our internal
controls. We intend to continue to take steps to remediate the material weakness described above and further evolve our internal controls
and processes. We will not be able to remediate these material weaknesses until these steps have been completed and have been operating
effectively for a sufficient period of time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 128; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following remedial actions were taken through the year ended December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 91%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
assistance from a current finance and accounting third-party service provider, the Company was able to formalize our risk assessment
process, policies and procedures, implementing revised control activities, controls documentation, and ongoing monitoring activities
related to the internal controls over financial reporting including testing documentation to provide evidence that our system of internal
controls over financial reporting meets the requirements of the COSO 2013 framework, and provide a foundation for the Company to communicate
internal control deficiencies in a timely manner to those parties responsible for taking corrective action.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expanded
    consultations with third party specialists on complex accounting matters, financial reporting and regulatory filings, and create
    enhanced documentation to support a more precise review process, as well as enhanced monitoring of the review process, and effective
    enhanced monitoring of the review process, and an effective system of training of use and review of our inventory recording systems.
    &#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the period covered by this Annual Report on Form 10-K, we have not been able to remediate the material weaknesses identified above. Although
the Company has taken numerous steps, our remediation plan is not complete because we did not have adequate controls in place to ensure
adequate review, including the controls over managements review procedures for processing, recording and reviewing transactions related
to certain contracts, accounting memos and certain monthly closing procedures, and our remediation plan has not operated for a sufficient
period of time for the Company to complete testing to conclude that our newly implemented controls and procedures were operating effectively
as of December 31, 2024. We plan to enhance our testing plans and improve procedures to implement and maintain adequate controls
over our financial processes and reporting in the future, and maintain a system of testing to ensure our controls, procedures and management
are operating effectively. To address these internal control deficiencies, management will continue to perform additional analyses and
other procedures to ensure that the financial statements included herein fairly present, in all material respects, our financial position,
results of operations and cash flows for the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under the direction of the audit committee of the Board of Directors, management will continue to review and make necessary
changes to the overall design of the Company&#8217;s internal control environment, as well as to refine policies and procedures to improve
the overall effectiveness of internal control over financial reporting of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in Internal Control over Financial Reporting</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, there were several changes in our internal control over financial reporting that management believes
has materially improved our internal controls over financial reporting. These implemented changes included, but not necessarily limited
to: (i) conduct of a comprehensive review of existing controls related to information technology and systems relevant to financial statement
preparation; (ii) establishment of a formalized written set of policies and procedures, including testing documentation, to ensure compliance
with the COSO 2013 framework and maintaining comprehensive documentation of all control procedures, policies, and testing documentation;
(iii) development and implementation of proper accounting and reconciliation procedures for tracking the number of securities issued;
(iv) development and formalization of appropriate IT policies, including segregation of duties and monitoring procedures; and (v) engagement
of third-party consultants with expertise in internal controls and regulatory compliance to provide guidance and assistance in enhancing
control frameworks and addressing deficiencies effectively. In additional to the foregoing, from time to time, we make changes to our
internal control over financial reporting that are intended to enhance its effectiveness, and which do not have a material effect on
our overall internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sw_015"></span>ITEM
9B. OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--NoInsiderTradingFlag_dbT_c20240101__20241231_zMvWr6aYDR1g" title="No insider trading flag" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000058" name="NAOV:NoInsiderTradingFlag">None</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sw_016"></span>ITEM
9C. DISCLOSURES REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 129; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sw_017"></span>PART
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sw_018"></span>ITEM
10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the name, age and positions of each director as of March 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 50%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position
    with the Company</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    Murphy</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    Fashek(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of the Board</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Martin
    Goldstein, M.D.(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas
    R. Mika(1)(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aurora
    Cassirer(1)(2)(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Doron
    Besser, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zeev
    Rotstein, M.D.(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    member of Compensation Committee.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    member of Audit Committee.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    member of Nominating and Corporate Governance Committee.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following sets forth biographical information and the qualifications and skills for each director:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Brian
Murphy, Chief Executive Officer and Director</i></b>. Mr. Murphy has served as our chief executive officer and director since October
2016. Mr. Murphy has over 25 years of senior sales, operations and general management experience in medical device and medical technology
companies, including ATI Medical Equipment Corporation, Mountain Medical Equipment Inc. and Healthdyne Technologies Inc. From 2012 to
2016, Mr. Murphy served in various roles at MiMedx Group, Inc., where he initiated and managed the commercial sales and national accounts
efforts within the advanced wound care segment. From 2010 to 2012, Mr. Murphy was the chief executive officer of O2 Insights, Inc., a
start-up wound care diagnostics company, and led the sale of the company to Systagenix Ltd. in June 2012. From 2008 to 2010, Mr. Murphy
served as vice president of sales for ConvaTec and led the negative pressure wound therapy business. From 1992 to 2008, Mr. Murphy served
a total of 17 years at Kinetic Concepts, Inc. (KCI) in various positions overseeing sales, operations and general management. Mr. Murphy
holds a bachelor of arts degree in communications from Southern Illinois University. Mr. Murphy&#8217;s qualifications to serve on our
Board include his significant sales, operations and general management experience in medical device and medical technology companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Christopher
Fashek, Chairman of the Board</i>. </b>Mr. Fashek has served as our director and chairman of the Board since November 2016. Mr. Fashek
is an accomplished healthcare executive with a record of leading global medical-device and pharmaceutical businesses. Mr. Fashek led
the team that introduced V.A.C.<sup>&#174; </sup>therapy, a negative pressure wound therapy, to both the clinical community, and patients
with serious or complex wounds. From June 2018, to 2020, Mr. Fashek has served as Chief Executive Officer and Director of Brain Sentinel,
Inc. Mr. Fashek currently serves as a Director of the Wound Healing Foundation (WHF), and Bravida Medical. From 1995 to 2007, Mr. Fashek
served as the Vice Chairman, Chief Executive Officer, and President of KCI USA. From 2008 to 2011, Mr. Fashek was the Chairman of the
Board of Directors at Systagenix, Ltd. From 2014 to 2015, Mr. Fashek was the Chairman of the Board of Directors and Chief Executive Officer
of Spiracur, Inc. Mr. Fashek currently serves as Chairman of MedTech Solutions Group, LLC, a global commercial Medsurge business in San
Antonio, Texas. Mr. Fashek has a Bachelor of Arts degree from Upsala College and Master of Business Administration from Fairleigh Dickinson
University. Mr. Fashek is recognized as developing highly productive and profitable leadership teams and corporate cultures, while taking
multiple healthcare products from idealization to commercialization, as well as turning around under-performing corporations to profitability.
Mr. Fashek&#8217;s extensive experience as an executive and leadership positions in the global medical device and pharmaceutical businesses,
as well as his network of industry partners, provide him the appropriate experience to serve on our Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 130; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Martin
Goldstein, M.D., Director</i>.</b> Dr. Goldstein has served as our director since March 25, 2015 and is on our Corporate Governance Committee.
He has been a practicing urologist for more than 20 years and is also an accomplished healthcare entrepreneur. For more than ten years
Dr Goldstein presided over New Jersey Urology, one the largest urology group practices in the country. As President, he successfully
navigated New Jersey Urology through two private equity transactions and the subsequent acquisition by Village MD. He now serves as the
National Urology Service Line Chief for Village MD/Summit Health, a Walgreens &amp; Cigna backed healthcare company. Previously, he served
as Senior Vice President of Corporate Development and Acquisitions of Urology Management Associates, a private equity backed entity providing
administrative practice management services to independent urology groups. Dr. Goldstein is a co-founder and executive board member of
Metropolitan Surgery Center, a large multispecialty ambulatory surgery center. Dr. Goldstein brings to our Board his medical practice
and healthcare business expertise. He is expected to make a valuable contribution in connection with marketing and facilitating the acceptance
of our product offerings within the medical community. He has provided assistance with the U.S. Food and Drug Administration regulatory
approval process of our products, particularly our urology offerings, and will continue to advise on new product development and innovations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Thomas
R. Mika, Director</i>.</b> Mr. Mika has served as our director since April 27, 2015. Mr. Mika has over 30 years of senior management,
finance and consulting experience. Mr. Mika is currently executive vice president and chief financial officer of POET Technologies, Inc.
(TSX Venture: PTK, NASDAQ: POET) and previously served as chief executive officer of CollabRx, Inc. (NASDAQ: CLRX) and its predecessor,
Tegal Corporation (NASDAQ: TGAL). CollabRx was a pioneer in clinical decision-support and precision oncology based on genomic testing.
Mr. Mika was the chairman and chief executive officer of Tegal since March 2005, which became CollabRx in 2012, and served as its Chief
Financial Officer since 2002. From 1992 to 2002, Mr. Mika served on the Company&#8217;s Board, which included periods of service as the
chairman of the compensation committee and a member of the audit committee. Previously, Mr. Mika co-founded IMTEC, a boutique investment
and consulting firm whose areas of focus included health care, pharmaceuticals, media and information technology. As a partner of IMTEC,
Mr. Mika served clients in the United States, Europe and Japan over a period of 20 years, taking on the role of chief executive officer
in several ventures. Earlier in his career, Mr. Mika was a managing consultant with Cresap, McCormick &amp; Paget and a policy analyst
for the National Science Foundation. Mr. Mika holds a bachelor of science degree in Microbiology from the University of Illinois at Urbana-Champaign
and a master of business administration degree from the Harvard Graduate School of Business. Mr. Mika&#8217;s qualifications to serve
on our Board include his significant strategic and business insight from his prior service on the Board of other publicly held companies,
as well as his substantial senior management, finance and consulting experience.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aurora
Cassirer<i>, Director</i>.</b> Ms. Cassirer has served on the Board since January 2022 and serves as the chair of the corporate governance
committee. Ms. Cassirer is also a member of our compensation committee. Ms. Cassirer is a highly experienced attorney, currently practicing
at Pierson Ferdinand LLP in the Business Litigation Section. She has previously served as a partner in other prominent law firms for
more than 30 years, including at Troutman Pepper Hamilton Sanders LLP, where she served on the Executive and Compensation Committee and
was the Managing Partner of its New York office for many years. Ms. Cassirer has a sophisticated practice focusing on business litigation
and corporate governance issues, as well as securities fraud and derivative litigation. Ms. Cassirer has developed a particular niche
in dealing with publicly and privately held biotech/healthtech and biopharma companies. Ms. Cassirer has been listed as AV Preeminent
by Martindale-Hubbell consistently for the last 20 years as well as being listed in Law &amp; Politics&#8217; New York Super Lawyers
for excellence in Business Litigation every year since 2008. Previously, Ms. Cassirer served as Chair of the Advisory Board of ReferWell,
f/k/a Urgent Consult, LLC, a start-up in the health tech business, and served on the Board of Advisors of Live Care LLC, a start-up engaged
in the remote monitoring of patients. Ms. Cassirer also served on the Board of Directors of Kids in Need of Defense (KIND), a not-for-profit
organization where she served on its Compensation Committee. Ms. Cassirer is also a member of the Board of Friends of Jerusalem College
of Technology and serves on its Development Committee. Ms. Cassirer currently serves as co-chair of the New York State Bar Association
International Corporate Compliance Committee. Ms. Cassirer received her JD from New York University. Ms. Cassirer&#8217;s extensive legal
experience and deep knowledge of corporate governance make her well-qualified to serve on our Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 131; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Zeev
Rotstein, M.D.</i></b> Professor Rotstein is an internationally recognized cardiologist and expert in health management systems, with
decades of experience across consultancy and academia. Professor Rotstein worked for 36 years at Sheba Medical Center (&#8220;Sheba&#8221;)
in Tel Hashomer, Israel. He started as a senior cardiologist in 1977, served as Deputy Director during 1988 to 1999, served as Director
of Sheba&#8217;s Acute Care Hospital during 1999-2004, and served as Director General, during 2004-2016, at which time Sheba was considered
one of the top hospitals in the world. During 2016-2021, Prof. Rotstein was the CEO and Director General of the Hadassah Medical Center
in Jerusalem. Professor Rotstein graduated from the Sackler School of Medicine at Tel Aviv University. He received his Master of Health
Administration (MHA) from the Leon Recanti Graduate School of Business Administration at Tel Aviv University and was certified by the
Israel Ministry of Health as a specialist in Health Systems Management. Additionally, he has held fellowships at the New York Department
of Health, Tufts University, and the School of Hygiene and Public Health of Johns Hopkins Bloomberg School of Public Health. Professor
Rotstein&#8217;s experience and knowledge of the health management industry provide him the appropriate experience to serve on our Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Doron
Besser, M.D. </i></b>Doron Besser is the CEO and President of ENvue Medical. Prior to ENvue, Dr. Besser served as CEO of Angioslide Ltd.,
a company specializing in innovative, cost effective angioplasty products. Dr. Besser guided the company through its infancy stages,
which included complicated animal and human trials, to FDA clearance, CE approval and initial market penetration in Europe and the US.
Dr. Besser also served as VP of Clinical and Marketing and VP of Business Development at superDimension, a leader in minimally-invasive
pulmonology devices. Dr. Besser helped lead superDimension from its inception, serving on the core team that identified opportunities
within the pulmonology market. In 2012, Covidien acquired superDimension for approximately $300 million. As a seasoned entrepreneur,
Dr. Besser specializes in identifying breakthrough technologies and developing them throughout all product development phases, including
international sales and marketing activities. Dr. Besser holds a Doctor of Medicine degree from Munich&#8217;s Ludwig-Maximilians University.
Dr. Besser&#8217;s experience in the healthcare industry provides him the appropriate experience to serve on our Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive
Officers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the names, ages and positions of our executive officers and certain significant employees as of March 31,
2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Age</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Position</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    Murphy</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stephen
    Brown</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harold
    Jacob, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Medical Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
see the biography of Mr. Murphy above in the section &#8220;<i>Board of Directors</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stephen
Brown, Chief Financial Officer</i>. </b>Mr. Brown has served as our chief financial officer since October 5, 2020. Previously, Mr. Brown
served as the Company&#8217;s Chief Financial Officer from February 3, 2015, through April 30, 2019 and continued to serve as a financial
consultant for the Company until his appointment as Chief Financial Officer on October 5, 2020. Mr. Brown previously served as Chief
Financial Officer for IDT Corporation (NYSE: IDT) from April 1995 to January 2009, during which time he oversaw the initial public offering
of a start-up telecommunications company and guided it through the spin-offs of two subsidiaries, various public offerings and bank facilities.
During his tenure at IDT, Mr. Brown also served on IDT&#8217;s board of directors for six years and on the board of directors of Net2Phone
Inc. for five years. Mr. Brown was also the founder and chairman of IDT Entertainment Inc., a movie studio and media subsidiary of IDT.
From 2009 to the present, Mr. Brown has served as a managing partner of The Mcguffin Group Financial, a financial and business consulting
firm concentrating on advising early stage and micro-cap companies. He is also a partner in an accounting and tax practice, Brown, Brown
and Associates. Mr. Brown was formerly a certified public accountant, is a member of the Academy of Television Arts and Sciences and
serves on the board of directors for several educational institutions, including on the Board of Governors for Touro College.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Harold
Jacob, M.D., Chief Medical Officer</i>. </b>Dr. Jacob has served as our chief medical officer since March 1, 2014, and as our director
since September 2003 through February 14, 2025. From September 2003 to February 4, 2014, Dr. Jacob served as chairman of the board of
directors of the Company (the &#8220;Board&#8221;), and from September 2003 to March 1, 2014, Dr. Jacob served as our chief executive
officer. Dr. Jacob also performed the functions of a principal financial officer until April 1, 2014. Dr. Jacob is our co-founder and
has worked extensively in medical device development. Dr. Jacob also served part-time as an attending gastroenterologist at Shaare Zedek
Medical Center in Jerusalem, Israel from 2004 to March 2011. Since April 2011, he has been an attending physician in Gastroenterology
at Hadassah University Hospital in Jerusalem, Israel. From 1999 to the present, Dr. Jacob has served as the president of Medical Instrument
Development Inc., which provides consulting services to start-up and early stage companies and patents its own proprietary medical devices.
From 1997 to 2003, Dr. Jacob served as director of medical affairs at Given Imaging Ltd., a company that developed the first swallowable
wireless pill camera for inspection of the intestines. Dr. Jacob also formerly served as a director for Oramed Pharmaceuticals Inc.,
a pharmaceutical company focused on the development of innovative orally ingestible capsule medication.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 132; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CORPORATE
GOVERNANCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NanoVibronix,
Inc., with the oversight of the Board and its committees, operates within a comprehensive plan of corporate governance for the purpose
of defining independence, assigning responsibilities, setting high standards of professional and personal conduct and assuring compliance
with such responsibilities and standards. We regularly monitor developments in the area of corporate governance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Code
of Business Conduct and Ethics</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted a code of business conduct and ethics that applies to all of our officers, directors and employees. The code of business
conduct and ethics addresses, among other things, competition and fair dealing, conflicts of interest, financial matters and external
reporting, our funds and assets, confidentiality and corporate opportunity requirements and the process for reporting violations of the
code of business conduct and ethics, employee misconduct, improper conflicts of interest or other violations. A copy of the code of ethics
was attached as Exhibit 14.1 to our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, and filed with the Securities
and Exchange Commission on March 31, 2017. If we amend or grant a waiver of one or more of the provisions of our code of business conduct
and ethics, we intend to satisfy the requirements under Item 5.05 of Form 8-K regarding the disclosure of amendments to, or waivers from,
provisions of our code of business conduct and ethics that apply to our principal executive, financial and accounting officers by posting
the required information on our website at <i>www.nanovibronix.com</i> within four business days following the date of such amendment
or waiver.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
Composition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation and Bylaws provide that our Board will consist of such number of directors as determined from time to time
by resolution adopted by our Board. The size of our Board is currently fixed at eight directors. Subject to any rights applicable to
any then outstanding preferred stock, any vacancies or newly created directorships resulting from an increase in the authorized number
of directors may be filled by a majority of the directors then in office. Each member of our Board is elected for a one-year term and
is elected at each annual meeting of stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no formal policy regarding Board diversity. Our Board believes that each director should have a basic understanding of our principal
operational and financial objectives and plans and strategies, our results of operations and financial condition and relative standing
in relation to our competitors. We take into consideration the overall composition and diversity of the Board and areas of expertise
that director nominees may be able to offer, including business experience, knowledge, abilities and customer relationships. Generally,
we will strive to assemble a Board that brings to us a variety of perspectives and skills derived from business and professional experience
as we may deem are in our and our stockholders&#8217; best interests. In doing so, we will also consider candidates with appropriate
non-business backgrounds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Independence and Committee Qualifications</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently listed on The Nasdaq Capital Market and therefore rely on the definition of independence set forth in the Nasdaq Listing
Rules (&#8220;Nasdaq Rules&#8221;). Under the Nasdaq Rules, a director only qualifies as an &#8220;independent director&#8221; if, in
the opinion of that company&#8217;s board of directors, that person does not have a relationship that would interfere with the exercise
of independent judgment in carrying out the responsibilities of a director.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to be considered to be independent for purposes of Rule 10A-3, a member of an audit committee of a listed company may not, other
than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee: (1) accept, directly
or indirectly, any consulting, advisory or other compensatory fee from the listed company or any of its subsidiaries or (2) be an affiliated
person of the listed company or any of its subsidiaries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board undertook a review of its composition, the composition of its committees and the independence of each director. Based upon information
requested from and provided by each director concerning his or her background, employment and affiliations, including family relationships,
our Board has determined that Christopher Fashek, Martin Goldstein, M.D., Thomas R. Mika, Aurora Cassirer, and Zeev Rotstein or five
of our seven directors, do not have a relationship (other than being a director and/or a stockholder) that would interfere with the exercise
of independent judgment in carrying out the responsibilities of a director and that each of these directors is &#8220;independent&#8221;
as that term is defined under the Nasdaq Rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 133; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board also determined that (i) Thomas Mika and Aurora Cassirer and Zeev Rotstein, who compose our Audit Committee, (ii) Aurora Cassirer,
Thomas Mika and Zev Rotstein, who compose our Compensation Committee, and (iii) Martin Goldstein, Christopher Fashek and Aurora Cassirer,
who compose our Nominating and Corporate Governance Committee, each satisfy the independence standards for those committees established
by the applicable rules and regulations of the SEC and the Nasdaq Rules. In making this determination, our Board considered the relationships
that each non-employee director has with us and all other facts and circumstances our Board deemed relevant in determining their independence,
including the beneficial ownership of our capital stock by each non-employee director. We intend to comply with all size and independence
requirements for committees within the applicable time periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
Committees, Meetings and Attendance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, the Board held 6 meetings. We expect our directors to attend Board meetings, meetings
of any committees and subcommittees on which they serve and each annual meeting of stockholders, either in person or by teleconference.
During the year ended December 31, 2024, each director attended at least 75% of the total number of meetings held by the Board and Board
committees of which such director was a member. Last year&#8217;s annual meeting was not attended by any directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board currently has three standing committees which consist of an audit committee (the &#8220;Audit Committee&#8221;), a nominating and
corporate governance committee (the &#8220;Nominating and Corporate Governance Committee&#8221;) and a compensation committee (the &#8220;Compensation
Committee&#8221;), each of which has the composition and responsibilities described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of these committees operates under a charter that has been approved by our Board. The current charter of each of these committees is
available on our website at <i>www.nanovibronix.com</i> in the &#8220;Governance&#8221; section under &#8220;Investors.&#8221; The reference
to our website address does not constitute incorporation by reference of the information contained at or available through our website,
and you should not consider it to be a part of this proxy statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
Committee.</b> The Audit Committee is comprised of of Messrs. Thomas Mika (chair), Aurora Cassirer and Professor Rotstein, each of whom
our Board has determined to be financially literate and qualify as an independent director under Sections 5605(a)(2) and 5605(c)(2) of
the Nasdaq Rules and Rule 10A-3(b)(1) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). In addition,
Mr. Thomas Mika qualifies as an &#8220;audit committee financial expert,&#8221; as defined in Item 407(d)(5)(ii) of Regulation S-K. Our
Board also determined that each member of our Audit Committee can read and understand fundamental financial statements in accordance
with applicable requirements. In arriving at these determinations, the Board examined each Audit Committee member&#8217;s scope of experience
and the nature of their employment in the corporate finance sector.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
function of the Audit Committee is to assist the Board in its oversight of (1) the integrity of our financial statements, (2) our compliance
with legal and regulatory requirements, (3) the qualifications, independence and performance of our independent auditors and (4) audit
and non-audit fees and services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audit committee met 4 times during the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to each of Mr. Ferguson and Ms. Schroeder&#8217;s resignation from the Board and all committees thereto on February 14, 2025, each of
Mr. Ferguson and Ms. Schroeder were financially literate and qualified as independent directors under Sections 5605(a)(2) and 5605(c)(2)
of the Nasdaq Rules and Rule 10A-3(b)(1) of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nominating
and Corporate Governance Committee.</b> The Nominating and Corporate Governance Committee is comprised of Ms. Aurora Cassirer (chair)
and Martin Goldstein and Christopher Fashek, each of whom our Board has determined qualifies as an independent director under Section
5605(a)(2) of the Nasdaq Rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 134; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary function of the Nominating and Corporate Governance Committee is to identify individuals qualified to become board members, consistent
with criteria approved by the Board, and select the director nominees for election at each annual meeting of stockholders as well as
reviewing the Company&#8217;s corporate governance policies and any related matters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Nominating and Corporate Governance Committee met 1 time during the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to Ms. Schroeder&#8217;s resignation from the Board and all committees thereto on February 14, 2025, Ms. Schroeder qualified as an independent
director under Section 5604(a)(2) of the Nasdaq Rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
Committee.</b> The Compensation Committee is comprised of Thomas Mika and Ms. Aurora Cassirer, each of whom our Board has determined
qualifies as an independent director under Sections 5605(a)(2) and 5605(d)(2) of the Nasdaq Rules, as an &#8220;outside director&#8221;
for purposes of Section 162(m) of the Internal Revenue Code and as a &#8220;non-employee director&#8221; for purposes of Section 16b-3
under the Exchange Act. The function of the compensation committee will be to discharge the Board&#8217;s responsibilities relating to
compensation of our directors and executives and our overall compensation programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary objective of the Compensation Committee will be to develop and implement compensation policies and plans that are appropriate
for us in light of all relevant circumstances and which provide incentives that further our long-term strategic plan and are consistent
with our culture and the overall goal of enhancing enduring stockholder value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee met 4 times during the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to Mr. Ferguson&#8217;s resignation from the Board and all committees thereto, Mr. Ferguson qualified as an independent director under
Sections 5605(a)(2) and 5605(d)(2) of the Nasdaq Rules, as an &#8220;outside director&#8221; for purposes of Section 162(m) of the Internal
Revenue Code and as a &#8220;non-employee director&#8221; for purposes of Section 16b-3 under the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
Leadership Structure</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board is committed to promoting our effective, independent governance. Our Board believes it is in our best interests and the best interests
of our stockholders for the Board to have the flexibility to select the best director to serve as chairman at any given time, regardless
of whether that director is an independent director or the chief executive officer. Consequently, we do not have a policy governing whether
the roles of chairman of the Board and chief executive officer should be separate or combined. This decision is made by our Board, based
on our best interests considering the circumstances at the time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
the offices of the chairman of the Board and the chief executive officer are held by two different people. Christopher Fashek is our
independent, non-executive chairman of the Board, and Brian Murphy is our chief executive officer. The chief executive officer will be
responsible for our day-to-day leadership and performance, while the chairman of the Board will provide guidance to the chief executive
officer and set the agenda for board meetings and preside over meetings of the Board. We believe that separation of the positions will
reinforce the independence of the Board in its oversight of our business and affairs, and create an environment that is more conducive
to objective evaluation and oversight of management&#8217;s performance, increasing management accountability and improving the ability
of the Board to monitor whether management&#8217;s actions are in our best interests and those of our stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Role
in Risk Oversight</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board oversees an enterprise-wide approach to risk management, designed to support the achievement of business objectives, including
organizational and strategic objectives, to improve long-term organizational performance and enhance stockholder value. The involvement
of our Board in setting our business strategy is a key part of its assessment of management&#8217;s plans for risk management and its
determination of what constitutes an appropriate level of risk for the company. The participation of our Board in our risk oversight
process includes receiving regular reports from members of senior management on areas of material risk to our company, including operational,
financial, legal and regulatory, and strategic and reputational risks, including cybersecurity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 135; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board continually reviews the Company&#8217;s controls and procedures that involve cybersecurity matters to determine the potential material
impact to our financial results, operations, and/or reputation to insure such incidents are immediately reported by management to the
Board, or individual members or committees thereof, as appropriate, in accordance with our escalation framework.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
our Board has the ultimate responsibility for the risk management process, senior management and various committees of our Board will
also have responsibility for certain areas of risk management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
senior management team is responsible for day-to-day risk management and regularly reports on risks to our full Board or a relevant committee.
Our finance and regulatory personnel serve as the primary monitoring and evaluation function for company-wide policies and procedures,
and manage the day-to-day oversight of the risk management strategy for our ongoing business. This oversight includes identifying, evaluating,
and addressing potential risks that may exist at the enterprise, strategic, financial, operational, compliance and reporting levels.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audit committee will focus on monitoring and discussing our major financial risk exposures and the steps management has taken to monitor
and control such exposures, including our risk assessment and risk management policies. As appropriate, the audit committee will provide
reports to and receive direction from the full Board regarding our risk management policies and guidelines, as well as the audit committee&#8217;s
risk oversight activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the compensation committee will assess our compensation policies to confirm that the compensation policies and practices do
not encourage unnecessary risk taking. The compensation committee will review and discuss the relationship between risk management policies
and practices, corporate strategy and senior executive compensation and, when appropriate, report on the findings from the discussions
to our Board. Our compensation committee intends to set performance metrics that will create incentives for our senior executives that
encourage an appropriate level of risk-taking that is commensurate with our short-term and long-term strategies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Communications
with Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board welcomes communication from our stockholders. Stockholders and other interested parties who wish to communicate with a member or
members of our Board or a committee thereof may do so by addressing correspondence to the Board member, members or committee, c/o NanoVibronix,
Inc., 969 Pruitt Place, Tyler TX 75703, ATTN: Brian Murphy, Chief Executive Officer. Our Chief Executive Officer will review and forward
correspondence to the appropriate person or persons.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
communications received as set forth in the preceding paragraph will be opened by the Chief Executive Officer for the sole purpose of
determining whether the contents represent a message to our directors. Any contents that are not in the nature of advertising, promotions
of a product or service or patently offensive material will be forwarded promptly to the addressee(s). In the case of communications
to the Board or any group or committee of directors, the Chief Executive Officer will make sufficient copies of the contents to send
to each director who is a member of the group or committee to whom the communication is addressed. If the amount of correspondence received
through the foregoing process becomes excessive, our Board may consider approving a process for review, organization and screening of
the correspondence by the corporate secretary or another appropriate person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Family
Relationships</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no family relationships among our directors and executive officers, or person nominated or chosen by the Company to become a director
or executive officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 136; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Involvement
in Certain Legal Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of our directors or executive officers has been involved in any of the following events during the past ten years:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the
    time of the bankruptcy or within two years prior to that time;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor
    offences);</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">being
    subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction,
    permanently or temporarily enjoining, barring, suspending or otherwise limiting his or her involvement in any type of business, securities
    or banking activities; or</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">being
    found by a court of competent jurisdiction (in a civil action), the SEC or the Commodity Futures Trading Commission to have violated
    a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Insider
Trading Policy and Anti-Hedging Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eecd--InsiderTrdPoliciesProcNotAdoptedTextBlock_c20240101__20241231_zcHzqEp85EY3" title="Disclosure - Insider Trading Policies and Procedures" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBQb2xpY2llcyBhbmQgUHJvY2VkdXJlcwA_"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000060" name="ecd:InsiderTrdPoliciesProcNotAdoptedTextBlock">We
maintain an insider trading policy that applies to our officers and directors that prohibits trading our securities during certain established
periods and when in possession of material non-public information. It also prohibits, unless approved in advance in limited circumstances
by the policy administrator, the hedging of our securities, including short sales or purchases or sales of derivative securities based
on our securities, and the use of our securities to secure a margin or other loan. Since the adoption of our insider trading policy,
the policy administrator has not granted any such exemptions to the policy&#8217;s general prohibition on hedging or pledging. While
the Company is not subject to the insider trading policy, the company does not trade in its securities when it is in possession of material
nonpublic information other than pursuant to previously adopted Rule 10b5-1 trading plans.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section
16(a) Beneficial Ownership Reporting Compliance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
16(a) of the Exchange Act requires that each of our directors and executive officers, and any other person who owns more than ten percent
(10%) of our common stock, file with the SEC initial reports of ownership and reports of changes in ownership of our common stock. To
our knowledge, based solely on information furnished to us and written representations by such persons that no such other reports were
required to be filed, we believe that all such SEC filing requirements were met in a timely manner during the year ended December 31,
2024, other than with respect to the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 26, 2024, a Form 4 for each of Aurora Cassirer, Martin Goldstein, Michael Ferguson, Thomas Mika, Harold Jacob and Maria Schroeder
was filed late due to an administrative error, to report the grant of stock options granted under the 2024 Plan, which such stock options
were granted on January 23, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 137; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sw_019"></span>ITEM
11. EXECUTIVE COMPENSATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the names and positions of: (i) each person who served as our principal executive officer during the year
ended December 31, 2024, (ii) the two most highly compensated executive officers, other than our principal executive officer, who were
serving as executive officers, as determined in accordance with the rules and regulations promulgated by the SEC, as of December 31,
2024, (iii) up to two additional individuals for whom disclosure would have been provided pursuant to clause (ii) but for the fact that
the person was not serving as our executive officer at December 31, 2024 (collectively our &#8220;Named Executive Officers&#8221;):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    Murphy</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stephen
    Brown</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
Compensation Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth all compensation earned, in all capacities, during the fiscal years ended December 31, 2024, and 2023 by our
Named Executive Officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name and Principal</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></p></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Salary <br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Bonus<br/> ($)(1)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Option Awards<br/> ($)(2)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">All Other Compensation<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total<br/> ($)(2)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 22%; text-align: left">Brian Murphy</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2024</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">308,750</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">73,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">42,285</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">424,035</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">82,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">159,631</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">541,861</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stephen Brown</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">257,292</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,428</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">306,220</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">361,667</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    incentive compensation payments earned.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    accordance with SEC rules, the amounts in this column reflect the dollar amounts to be recognized for financial statement reporting
    purposes with respect to the twelve-month period ended December 31, 2023, in accordance with ASC Topic 718. Fair value is based on
    the Black-Scholes option pricing model using the market price of the underlying shares at the grant date. For additional discussion
    of the valuation assumptions used in determining stock-based compensation and the grant date fair value for stock options, see &#8220;<i>Management&#8217;s
    Discussion and Analysis of Financial Condition and Results of Operation - Critical Accounting Policies - Stock-based compensation</i>&#8221;
    and Note 3- &#8220;<i>Significant Accounting Policies</i>&#8221; and Note 7- &#8220;<i>Stockholders&#8217; Equity (Deficiency)&#8221;
    to our audited consolidated financial statements for the fiscal year ended December 31, 2023</i>, included herein.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Narrative
Disclosure to Summary Compensation Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into agreements with each of our Named Executive Officers. A description of each of these agreements follows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Brian
Murphy, Chief Executive Officer</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2022
Murphy Employment Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 1, 2022, we entered into an employment agreement with Mr. Murphy (the &#8220;2022 Murphy Employment Agreement&#8221;), with an
annual base salary of $300,000 less applicable payroll deductions and tax withholdings for all services rendered by him under the 2022
Murphy Employment Agreement and a target bonus in an amount of up to $100,000, less applicable payroll deductions and tax withholdings,
based on the extent to which Mr. Murphy has met performance criteria for the year, as determined in good faith by the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 138; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, pursuant to the 2022 Murphy Employment Agreement, Mr. Murphy is eligible to receive certain stock options, restricted stock,
stock appreciation rights or similar stock-based rights granted to Mr. Murphy as set forth separately in applicable award agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2022 Murphy Employment Agreement had a term of two years and also contained certain noncompetition, non-solicitation, non-disparagement,
confidentiality and assignment of work product requirements for Mr. Murphy. Prior to the 2022 Murphy Employment Agreement, we previously
entered into an employment agreement with Mr. Murphy, effective as of October 13, 2016, and which expired on October 13, 2019, after
which Mr. Murphy became an employee at will until the 2022 Murphy Employment Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2024
Murphy Employment Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 20, 2024, we entered into a new employment with Mr. Murphy (the &#8220;2024 Murphy Employment Agreement&#8221;), pursuant to
which the parties agreed to have Mr. Murphy continue to serve as our Chief Executive Officer, effective September 20, 2024, through August
31, 2025, unless earlier terminated by either party pursuant to the 2024 Murphy Employment Agreement. The 2022 Murphy Employment Agreement
terminated upon effectiveness of the 2024 Murphy Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
consideration for his services as Chief Executive Officer, Mr. Murphy will be entitled to receive (i) an annual base salary of $321,000,
less applicable payroll deductions and tax withholdings; (ii) reimbursement of any reasonable and customary, documented out-of-pocket
expenses actually incurred by Mr. Murphy in connection with the performance of his services under the 2024 Murphy Employment Agreement;
and (iii) an annual bonus of up to $100,000, less applicable payroll deductions and tax withholdings, based on the extent to which Mr.
Murphy met performance criteria for the calendar year, as determined by us in good faith. Mr. Murphy may also be eligible to receive
certain grants of incentive stock options to purchase shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
party may terminate the 2024 Murphy Employment Agreement at any time upon ninety (90) days written notice. Upon termination of Mr. Murphy&#8217;s
employment, we shall pay Mr. Murphy (i) any unpaid salary accrued through the date of termination, (ii) any accrued and unpaid vacation
or similar pay to which Mr. Murphy is entitled as a matter of law or Company policy, and (iii) any unreimbursed expenses properly incurred
prior to the date of termination (the &#8220;Murphy Accrued Obligations&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event we terminate Mr. Murphy&#8217;s employment for cause, we shall have no further liability or obligation to Mr. Murphy under
the 2024 Murphy Employment Agreement or in connection with Mr. Murphy&#8217;s employment, except for the Murphy Accrued Obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2024 Murphy Employment Agreement also contains certain standard non-competition, non-solicitation, confidentiality, and assignment of
inventions requirements for Mr. Murphy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2024, and December 31, 2023, the compensation committee approved performance bonuses of $73,000 and $82,500,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stephen
Brown, Chief Financial Officer</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2022
Brown Employment Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 1, 2022, we entered into a new employment agreement with Mr. Brown (the &#8220;2022 Brown Employment Agreement&#8221;), with
an annual base salary of $250,000 less applicable payroll deductions and tax withholdings for all services rendered by him under the
employment agreement and a target bonus in an amount of up to $50,000, less applicable payroll deductions and tax withholdings, based
on the extent to which Mr. Brown has met performance criteria for the year, as determined in good faith by the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2022 Brown Employment Agreement had an initial term of two years and thereafter automatically renewed on an annual basis unless written
notification is provided by Mr. Brown or the Company of the desire to not renew for the subsequent year. The 2022 Brown Employment Agreement
also contained certain noncompetition, non-solicitation, non-disparagement, confidentiality and assignment of work product requirements
for Mr. Brown. Prior to the 2022 Brown Employment Agreement, we previously entered into an employment agreement with Mr. Brown on October
5, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 139; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2024
Brown Employment Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 20, 2024, the Company entered into a new employment agreement with Mr. Brown (the &#8220;2024 Brown Employment Agreement&#8221;),
pursuant to which the parties agreed to have Mr. Brown continue to serve as Chief Financial Officer of the Company, effective September
20, 2024, through August 31, 2025, unless earlier terminated by either party pursuant to the 2024 Brown Agreement. The 2022 Brown Employment
Agreement terminated upon effectiveness of the 2024 Brown Employment Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
consideration for his services as Chief Financial Officer, Mr. Brown will be entitled to receive (i) an annual base salary of $267,500,
less applicable payroll deductions and tax withholdings; (ii) reimbursement of any reasonable and customary, documented out-of-pocket
expenses actually incurred by Mr. Brown in connection with the performance of his services under the 2024 Brown Employment Agreement;
and (iii) an annual bonus of up to $50,000, less applicable payroll deductions and tax withholdings, based on the extent to which Mr.
Brown has met performance criteria for the calendar year, as determined by us in good faith. Mr. Brown may also be eligible to receive
certain grants of incentive stock options to purchase shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
party may terminate the 2024 Brown Agreement at any time upon ninety (90) days written notice. Upon termination of Mr. Brown&#8217;s
employment, we shall pay Mr. Brown (i) any unpaid salary accrued through the date of termination, (ii) any accrued and unpaid vacation
or similar pay to which Mr. Brown is entitled as a matter of law or Company policy, and (iii) any unreimbursed expenses properly incurred
prior to the date of termination (the &#8220;Brown Accrued Obligations&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event we terminate Mr. Brown&#8217;s employment for cause, we shall have no further liability or obligation to Mr. Brown under the
2024 Brown Employment Agreement or in connection with Mr. Brown&#8217;s employment, except for the Brown Accrued Obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2024 Brown Agreement also contains certain standard non-competition, non-solicitation, confidentiality, and assignment of inventions
requirements for Mr. Brown.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2024, and 2023, the compensation committee approved performance bonuses of $22,500 and $42,500, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 15, 2023, Mr. Brown was granted options to purchase 1,273 shares of common stock at an exercise price of $13.64 per share, which
were fully vested on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Retirement,
Health, Welfare and Additional Benefits</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our Named Executive Officers are eligible to participate in our employee benefit plans and programs, including medical benefits, to
the same extent as our other full-time employees, subject to the terms and eligibility requirements of those plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2004
Global Share Option Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2004, our Board adopted the 2004 Global Share Option Plan, pursuant to which 36,364 shares of our common stock were reserved
for issuance as awards to employees, directors, consultants and other service providers. The purpose of the 2004 Global Share Option
Plan was to provide an incentive to attract and retain directors, officers, consultants, advisors and employees, to encourage a sense
of proprietorship and stimulate an active interest of such persons in our development and financial success. The 2004 Global Share Option
Plan which was administered by our Board expired on February 28, 2014.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 140; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->135<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2014
Long-Term Incentive Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 28, 2014, our stockholders approved the NanoVibronix, Inc. 2014 Long-Term Incentive Plan (the &#8220;2014 Plan&#8221;), which
was adopted by our Board on February 19, 2014.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the 2014 Plan, we originally reserved a total of five million (5,000,000) shares of our common stock for issuance pursuant to awards
to key employees, key contractors, and non-employee directors, of which, the maximum number of shares of common stock covering awards
of stock options or stock appreciation rights that could be granted to certain of our executive officers during any calendar year was
one million (1,000,000) shares. On May 7, 2014, we effected a one-for-seven reverse stock split of our common stock. Consequently, the
number of shares of our common stock reserved for issuance pursuant to awards under the 2014 Plan was reduced to seven hundred fourteen
thousand two hundred eighty-six (714,286) shares, and the maximum number of shares of our common stock covered by awards of stock options
or stock appreciation rights that could be granted to certain of our executive officers during any calendar year was reduced to one hundred
forty-two thousand eight hundred fifty-seven (142,857) shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 13, 2018, the stockholders approved an amendment to the 2014 Plan to increase the number of shares of our common stock reserved
for issuance pursuant to awards under the 2014 Plan by an additional seven hundred and fifty thousand (750,000) shares of our common
stock to one million four hundred sixty-four thousand two hundred eighty-six (1,464,286) shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 13, 2019, the stockholders approved a second amendment to the 2014 Plan to increase (i) the number of shares of our common stock
available for issuance pursuant to awards under the 2014 Plan by four hundred thousand (400,000) shares of our common stock, to a total
of one million eight hundred and sixty-four thousand two hundred eighty-six (1,864,286) shares of our common stock and (ii) the maximum
number of shares of our common stock covering awards of stock options or stock appreciation rights that could be granted to certain of
our executive officers during any calendar year was increased to three hundred fifty-four thousand two hundred fourteen (354,214) shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 29, 2021, the stockholders approved a third amendment to the 2014 Plan that (i) intended to increase the number of shares of
our common stock available for issuance pursuant to awards under the 2014 Plan by one million five hundred thousand (1,500,000) shares
of our common stock to a total of three million three hundred sixty-four thousand two-hundred eighty-six (3,364,286) shares of our common
stock, but a scrivener&#8217;s error in this amendment only increased the number of shares of our common stock available for issuance
pursuant to awards under the 2014 Plan to a total of three million three hundred forty-six thousand two-hundred eighty-six (3,346,286)
shares of our common stock, and (ii) increased the maximum number of shares of our common stock covering awards of stock options or stock
appreciation rights that could be granted to certain of our executive officers during any calendar year to six hundred sixty-nine thousand
two-hundred fifty-seven (669,257) shares of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 15, 2022, the stockholders approved a fourth amendment to the 2014 Plan to increase (i) the number of shares of our common stock
available for issuance pursuant to awards under the 2014 Plan by one million five hundred and eighteen thousand (1,518,000) shares of
our common stock, to a total of four million eight hundred and sixty-four thousand two hundred eighty-six (4,864,286) shares of our common
stock. On February 9, 2023, we effected a one-for-twenty reverse stock split of our common stock. Consequently, the number of shares
of our common stock reserved for issuance pursuant to awards under the 2014 Plan was reduced to two hundred forty-three thousand two
hundred fourteen (243,214) shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 19, 2024, the 2014 Plan expired in accordance with its terms. Any awards granted on or before such date will continue to be
effective in accordance with their terms and conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description
of the 2014 Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Purpose.
</i>The purpose of the 2014 Plan was to enable us to remain competitive and innovative in our ability to attract and retain the services
of key employees, key contractors, and non-employee directors. The 2014 Plan provided for the granting of incentive stock options, nonqualified
stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, dividend equivalent rights, and
other awards, which may be granted singly, in combination, or in tandem, and which may be paid in cash or shares of our common stock.
The 2014 Plan provided flexibility to our compensation methods in order to adapt the compensation of key employees, key contractors,
and non-employee directors to a changing business environment, after giving due consideration to competitive conditions and the impact
of applicable tax laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 141; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->136<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Effective
Date and Expiration.</i> The 2014 Plan was originally approved by our Board on February 19, 2014, and became effective upon stockholder
approval on February 28, 2014. The 2014 Plan terminated on February 19, 2024. No award may be made under the 2014 Plan after its termination
date, but awards made prior to the termination date may extend beyond that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Share
Authorization.</i> Subject to certain adjustments, the number of shares of our common stock that were reserved for issuance pursuant
to awards under the 2014 Plan was one million eight hundred and sixty-four thousand two hundred eighty- six (1,864,286) shares, of which
100% were able to be delivered pursuant to incentive stock options. Subject to certain adjustments, with respect to any participant who
is an officer of our company and subject to Section 16 of the Exchange Act, or a &#8220;covered employee&#8221; as defined in Section
162(m)(3) of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), a maximum of three hundred fifty four thousand two
hundred fourteen (354,214) shares may be granted in any one year in the form of stock options or stock appreciation rights to such participant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
to be issued may be made available from authorized but unissued shares of our common stock, shares held by us in our treasury, or shares
purchased by us on the open market or otherwise. During the term of the 2014 Plan, we at all times reserved and kept enough shares available
to satisfy the requirements of the 2014 Plan. In the event that previously acquired shares were delivered to us in full or partial payment
of the option price for the exercise of a stock option granted under the 2014 Plan, the number of shares available for future awards
under the 2014 Plan would have been reduced only by the net number of shares issued upon the exercise of the stock option or settlement
of an award. Awards that may be satisfied either by the issuance of common stock or by cash or other consideration would have been counted
against the maximum number of shares that could have been issued under the 2014 Plan only during the period that the award is outstanding
or to the extent the award is ultimately satisfied by the issuance of shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Administration.
</i>The 2014 Plan was administered by the compensation committee of our Board (the &#8220;Committee&#8221;). At any time there was no
Committee to administer the 2014 Plan, any reference to the Committee is a reference to the Board. The Committee would determine the
persons to whom awards are to be made; determine the type, size, and terms of awards; interpret the 2014 Plan; establish and revise rules
and regulations relating to the 2014 Plan and any sub-plans, including, without limitation, any sub-plans for awards made to participants
who are not residents of the United States; establish performance goals for awards and certify the extent of their achievement; and make
any other determinations that it believes necessary for the administration of the 2014 Plan. The Committee had the ability to delegate
certain duties to one or more of our officers as provided in the 2014 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Eligibility.
</i>Employees (including any employee who is also a director or an officer), contractors, and non-employee directors of us or our subsidiaries
whose judgment, initiative, and efforts contributed to or may be expected to contribute to our successful performance were eligible to
participate in the 2014 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Options.</i> The Committee had the ability to grant either incentive stock options (&#8220;ISOs&#8221;) qualifying under Section 422
of the Code or nonqualified stock options, provided that only employees of us and our subsidiaries (excluding subsidiaries that are not
corporations) are eligible to receive ISOs. Stock options could not be granted with an option price less than 100% of the fair market
value of a share of common stock on the date the stock option is granted. If an ISO was granted to an employee who owns or is deemed
to own more than 10% of the combined voting power of all classes of our stock (or any parent or subsidiary), the option price was to
be at least 110% of the fair market value of a share of common stock on the date of grant. The Committee had the ability to determine
the terms of each stock option at the time of grant, including, without limitation, the methods by or forms in which shares will be delivered
to participants. The maximum term of each option, the times at which each option will be exercisable, and provisions requiring forfeiture
of unexercised options at or following termination of employment or service generally were fixed by the Committee, except that the Committee
could not grant stock options with a term exceeding 10 years or, in the case of an ISO granted to an employee who owns or is deemed to
own more than 10% of the combined voting power of all classes of our stock (or any parent or subsidiary), a term exceeding five years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recipients
of stock options may pay the option price (i) in cash, check, bank draft, or money order payable to the order of the Company; (ii) by
delivering to us shares of Common Stock (included restricted stock) already owned by the participant having a fair market value equal
to the aggregate option price and that the participant has not acquired from us within six months prior to the exercise date; (iii) by
delivering to us or our designated agent an executed irrevocable option exercise form together with irrevocable instructions from the
participant to a broker or dealer, reasonably acceptable to us, to sell certain of the shares purchased upon the exercise of the option
or to pledge such shares to the broker as collateral for a loan from the broker and to deliver to us the amount of sale or loan proceeds
necessary to pay the purchase price; and (iv) by any other form of valid consideration that is acceptable to the Committee in its sole
discretion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 142; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->137<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024
Long-Term Incentive Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Description
of the 2024 Plan</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Purpose</i>.
The purpose of the 2024 Plan is to enable us to remain competitive and innovative in our ability to attract and retain the services of
key employees, key contractors, and outside directors. The 2024 Plan provides for the granting of incentive stock options, nonqualified
stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, dividend equivalent rights, and
other awards, which may be granted singly, in combination, or in tandem, and which may be paid in cash or shares of our common stock.
The 2024 Plan is expected to provide flexibility to our compensation methods in order to adapt the compensation of key employees, key
contractors, and outside directors to a changing business environment, after giving due consideration to competitive conditions and the
impact of applicable tax laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Effective
Date and Expiration</i>. The 2024 Plan was originally approved by our Board on November 6, 2023, subject to stockholder approval. The
2024 Plan will be effective upon approval by our stockholders (such date being, the &#8220;Effective Date&#8221;), and the 2024 Plan
will terminate on the tenth anniversary of the Effective Date, unless sooner terminated by our Board. No award may be made under the
2024 Plan after its termination date, but awards made prior to the termination date may extend beyond that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Share
Authorization</i>. Subject to certain adjustments and to increase by any shares subject to Prior Plan Awards (defined below) that are
eligible for reuse, the number of shares of our common stock that are reserved for issuance pursuant to awards under the 2024 Plan is
six hundred thousand (600,000) shares, of which 100% may be delivered pursuant to incentive stock options. &#8220;Prior Plan Awards&#8221;
means (i) any awards under the Prior Plan (defined below) that are outstanding on the Effective Date and that, on or after the Effective
Date, are forfeited, expire, or are canceled; and (ii) any shares subject to awards relating to common stock under the Prior Plan that,
on or after the Effective Date, are settled in cash. &#8220;Prior Plan&#8221; means the 2014 Plan. Any awards outstanding under the Prior
Plan as of the Effective Date will continue to be governed by the terms and conditions of the Prior Plan and the applicable award agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
to be issued may be made available from authorized but unissued shares of our common stock, shares held by us in our treasury, or shares
purchased by us on the open market or otherwise. During the term of the 2024 Plan, we will at all times reserve and keep enough shares
available to satisfy the requirements of the 2024 Plan. If an award under the 2024 Plan or any Prior Plan Award is cancelled, forfeited,
or expires, in whole or in part, the shares subject to such forfeited, expired, or cancelled award may again be awarded under the 2024
Plan. In the event that previously acquired shares are delivered to us in full or partial payment of the option price for the exercise
of a stock option granted under the 2024 Plan, the number of shares available for future awards under the 2024 Plan shall be reduced
only by the net number of shares issued upon the exercise of the stock option or settlement of an award. Awards that may be satisfied
either by the issuance of common stock or by cash or other consideration shall be counted against the maximum number of shares that may
be issued under the 2024 Plan only during the period that the award is outstanding or to the extent the award is ultimately satisfied
by the issuance of shares. An award will not reduce the number of shares that may be issued pursuant to the 2024 Plan if the settlement
of the award will not require the issuance of shares, as, for example, a stock appreciation right that can be satisfied only by the payment
of cash. Only shares forfeited back to us; shares cancelled on account of termination, expiration, or lapse of an award; shares surrendered
in payment of the option price of an option; or shares withheld for payment of applicable employment taxes and/or withholding obligations
resulting from the exercise of a stock option shall again be available for grant as incentive stock options under the 2024 Plan, but
shall not increase the maximum number of shares described above as the maximum number of shares that may be delivered pursuant to incentive
stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Limitation
on Outside Director Awards</i>. Outside directors may not be granted awards under the 2024 Plan in any calendar year that exceed seven
hundred thousand dollars ($700,000) in the aggregate (with the fair market value of any equity awards determined as of the date of grant),
other than a one-time award granted to a newly appointed or elected outside director not to exceed an additional seven hundred thousand
dollars ($700,000) in the aggregate; provided, however, that these limits shall not apply to any awards made pursuant to a deferred compensation
arrangement in lieu of all or a portion of cash retainers otherwise payable to an outside director.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 143; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->138<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Administration</i>.
The 2024 Plan is administered by the compensation committee of our Board (the &#8220;Committee&#8221;). At any time there is no Committee
to administer the 2024 Plan, any reference to the Committee is a reference to the Board. The Committee will determine the persons to
whom awards are to be made; determine the type, size, and terms of awards; interpret the 2024 Plan; establish and revise rules and regulations
relating to the 2024 Plan and any sub-plans, including, without limitation, any sub-plans for awards made to participants who are not
residents of the United States; establish performance goals for awards and certify the extent of their achievement; and make any other
determinations that it believes necessary for the administration of the 2024 Plan. The Committee may delegate certain duties to one or
more of our officers as provided in the 2024 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Eligibility</i>.
Employees (including any employee who is also a director or an officer), contractors, and outside directors of us or our subsidiaries
whose judgment, initiative, and efforts contributed to or may be expected to contribute to our successful performance are eligible to
participate in the 2024 Plan. As of the date of this Annual Report on Form 10-K, we had 7 employees, 9 contractors, and 5 non-employee
directors who would be eligible for awards under the 2024 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Options</i>. The Committee may grant either incentive stock options (&#8220;ISOs&#8221;) qualifying under Section 422 of the Internal
Revenue Code of 1986, as amended (the &#8220;Code&#8221;) or nonqualified stock options, provided that only employees of us and our subsidiaries
(excluding subsidiaries that are not corporations) are eligible to receive ISOs. Stock options may not be granted with an option price
less than 100% of the fair market value of a share of common stock on the date the stock option is granted. If an ISO is granted to an
employee who owns or is deemed to own more than 10% of the combined voting power of all classes of our stock (or any parent or subsidiary),
the option price shall be at least 110% of the fair market value of a share of common stock on the date of grant. The Committee will
determine the terms of each stock option at the time of grant, including, without limitation, the methods by or forms in which shares
will be delivered to participants. The maximum term of each option, the times at which each option will be exercisable, and provisions
requiring forfeiture of unexercised options at or following termination of employment or service generally are fixed by the Committee,
except that the Committee may not grant stock options with a term exceeding 10 years or, in the case of an ISO granted to an employee
who owns or is deemed to own more than 10% of the combined voting power of all classes of our stock (or any parent or subsidiary), a
term exceeding five years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recipients
of stock options may pay the option price (i) in cash, check, bank draft, or money order payable to the order of the Company; (ii) by
delivering to us shares of common stock (included restricted stock) already owned by the participant having a fair market value equal
to the aggregate option price and that the participant has not acquired from us within six months prior to the exercise date; (iii) by
delivering to us or our designated agent an executed irrevocable option exercise form together with irrevocable instructions from the
participant to a broker or dealer, reasonably acceptable to us, to sell certain of the shares purchased upon the exercise of the option
or to pledge such shares to the broker as collateral for a loan from the broker and to deliver to us the amount of sale or loan proceeds
necessary to pay the purchase price; and (iv) by any other form of valid consideration that is acceptable to the Committee in its sole
discretion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Appreciation Rights</i>. The Committee is authorized to grant stock appreciation rights (&#8220;SARs&#8221;) as a stand-alone award,
or freestanding SARs, or in conjunction with options granted under the 2024 Plan, or tandem SARs. SARs entitle a participant to receive
an amount equal to the excess of the fair market value of a share of common stock on the date of exercise over the fair market value
of a share of our common stock on the date of grant. The grant price of a SAR cannot be less than 100% of the fair market value of a
share of our common stock on the date of grant. The Committee will determine the terms of each SAR at the time of the grant, including,
without limitation, the methods by or forms in which shares will be delivered to participants. The maximum term of each SAR, the times
at which each SAR will be exercisable, and provisions requiring forfeiture of unexercised SARs at or following termination of employment
or service generally are fixed by the Committee, except that no freestanding SAR may have a term exceeding 10 years and no tandem SAR
may have a term exceeding the term of the option granted in conjunction with the tandem SAR. Distributions to the recipient may be made
in common stock, cash, or a combination of both as determined by the Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 144; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->139<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock and Restricted Stock Units</i>. The Committee is authorized to grant restricted stock and restricted stock units. Restricted stock
consists of shares of our common stock that may not be sold, assigned, transferred, pledged, hypothecated, encumbered, or otherwise disposed
of, and that may be forfeited in the event of certain terminations of employment or service, prior to the end of a restricted period
as specified by the Committee. Restricted stock units are the right to receive shares of common stock at a future date in accordance
with the terms of such grant upon the attainment of certain conditions specified by the Committee, which include a substantial risk of
forfeiture and restrictions on their sale or other transfer by the participant. The Committee determines the eligible participants to
whom, and the time or times at which, grants of restricted stock or restricted stock units will be made; the number of shares or units
to be granted; the price to be paid, if any; the time or times within which the shares covered by such grants will be subject to forfeiture;
the time or times at which the restrictions will terminate; and all other terms and conditions of the grants. Restrictions or conditions
could include, but are not limited to, the attainment of performance goals (as described below), continuous service with us, the passage
of time, or other restrictions or conditions. Except as otherwise provided in the 2024 Plan or the applicable award agreement, a participant
shall have, with respect to shares of restricted stock, all of the rights of a stockholder of the Company holding the class of common
stock that is the subject of the restricted stock, including, if applicable, the right to vote the common stock and the right to receive
any dividends thereon.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividend
Equivalent Rights</i>. The Committee is authorized to grant a dividend equivalent right to any participant, either as a component of
another award or as a separate award, conferring on the participant the right to receive credits based on the cash dividends that would
have been paid on the shares of common stock specified in the award as if such shares were held by the participant. The terms and conditions
of the dividend equivalent right shall be specified by the grant. Dividend equivalents credited to the holder of a dividend equivalent
right may be paid currently or may be deemed to be reinvested in additional shares. Any such reinvestment shall be at the fair market
value at the time thereof. A dividend equivalent right may be settled in cash, shares, or a combination thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Performance
Awards</i>. The Committee may grant performance awards payable in cash, shares of common stock, other consideration, or a combination
thereof at the end of a specified performance period. Payment will be contingent upon achieving pre-established performance goals (as
discussed below) by the end of the performance period. The Committee will determine the length of the performance period, the maximum
payment value of an award, and the minimum performance goals required before payment will be made, so long as such provisions are not
inconsistent with the terms of the 2024 Plan, and to the extent an award is subject to Section 409A of the Code, are in compliance with
the applicable requirements of Section 409A of the Code and any applicable regulations or guidance issued thereunder. In certain circumstances,
the Committee may, in its discretion, determine that the amount payable with respect to certain performance awards will be reduced from
the amount of any potential awards, if the Committee determines, in its sole discretion, that the established performance measures or
objectives are no longer suitable because of a change in our business, operations, corporate structure, or for other reasons that the
Committee deemed satisfactory, in which case, the Committee may modify the performance measures or objectives and/or the performance
period as the Committee deems appropriate in its sole discretion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Performance
Goals</i>. Awards under the 2024 Plan may be made subject to the attainment of performance goals relating to one or more business criteria
which, where applicable, shall consist of one or more or any combination of the following criteria (the &#8220;Performance Criteria&#8221;):
cash flow; cost; revenues; sales; ratio of debt to debt plus equity; net borrowing, credit quality, or debt ratings; profit before tax;
economic profit; earnings before interest and taxes; earnings before interest, taxes, depreciation, and amortization; gross margin; earnings
per share (whether on a pre-tax, after-tax, operational, or other basis); operating earnings; capital expenditures; expenses or expense
levels; economic value added; ratio of operating earnings to capital spending or any other operating ratios; free cash flow; net profit;
net sales; net asset value per share; the accomplishment of mergers, acquisitions, dispositions, public offerings, or similar extraordinary
business transactions; sales growth; price of the shares; return on assets, equity, or stockholders&#8217; equity; market share; inventory
levels, inventory turn, or shrinkage; or total return to stockholders. Any Performance Criteria may be used to measure our performance
as a whole or any of our business units and may be measured relative to a peer group or index. Any Performance Criteria may include or
exclude (i) events that are of an unusual nature or indicate infrequency of occurrence; (ii) gains or losses on the disposition of a
business; (iii) changes in tax or accounting regulations or laws; (iv) the effect of a merger or acquisition, as identified in our quarterly
and annual earnings releases; or (v) other similar occurrences. In all other respects, Performance Criteria shall be calculated in accordance
with our financial statements, under generally accepted accounting principles, or under a methodology established by the Committee prior
to the issuance of an award, which is consistently applied and identified in the Company&#8217;s audited financial statements, including
in footnotes, or the Compensation Discussion and Analysis section of the Company&#8217;s annual report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 145; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->140<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Israeli
Awards</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
persons subject to the Israeli Income Tax Ordinance [New Version], 5721-1961 (the &#8220;Ordinance&#8221;), the Committee is authorized
to grant stock options pursuant to the terms of the Israeli Appendix. The Committee may grant to participants who are employees and office
holders options under Section 102 of the Ordinance (&#8220;Section 102 Options&#8221;) and to Controlling Shareholders (as defined in
the Israeli Appendix) and outside participants options under Section 3(i) of the Ordinance (&#8220;Section 3(i) Options&#8221;). The
Committee may designate Section 102 Options as &#8220;Approved 102 Options,&#8221; for which the options and shares upon exercise must
be held in trust and granted through a trustee, or as &#8220;Unapproved 102 Options,&#8221; for which the options and shares upon exercise
do not have to be held in trust. As described further below, the determination of the Committee as to the taxation route of the stock
options, the type of option, and duration of time the option and shares upon exercise are held in trust will determine the tax consequences
to the participant. Of the Approved 102 Options, the Committee may grant options as &#8220;Ordinary Income Options,&#8221; for which
the options and shares upon exercise must be held in trust for twelve (12) months from the date of grant, or as &#8220;Capital Gain Options,&#8221;
for which the options and shares upon exercise must be held in trust for twenty-four (24) months from the date of grant. If the requirements
of the Approved 102 Options are not met, the options are regarded as Unapproved 102 Options. Section 3(i) Options and the shares upon
exercise may, but need not, be held in trust as well, depending upon the agreement between the Committee, the participant, and the trustee
of the trust. Israeli participants can be granted other types of options under the 2024 Plan, but some of them will require a pre-ruling
from the Israeli Tax Authorities in order to be deemed Approved 102 Options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Awards</i>. The Committee may grant other forms of awards, based upon, payable in, or that otherwise relate to, in whole or in part,
shares of common stock, if the Committee determines that such other form of award is consistent with the purpose and restrictions of
the 2024 Plan. The terms and conditions of such other form of award shall be specified by the grant. Such other awards may be granted
for no cash consideration, for such minimum consideration as may be required by applicable law, or for such other consideration as may
be specified by the grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Vesting,
Forfeiture, Recoupment and Assignment</i>. The Committee, in its sole discretion, may determine that an award will be immediately vested
in whole or in part, or that all or any portion may not be vested until a date, or dates, subsequent to its date of grant, or until the
occurrence of one or more specified events, subject in any case to the terms of the 2024 Plan. If the Committee imposes conditions upon
vesting, then, except as otherwise provided below, subsequent to the date of grant, the Committee may, in its sole discretion, accelerate
the date on which all or any portion of the award may be vested.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Committee may impose on any award at the time of grant or thereafter, such additional terms and conditions as the Committee determines,
including terms requiring forfeiture of awards in the event of a participant&#8217;s termination of service. The Committee will specify
the circumstances on which performance awards may be forfeited in the event of a termination of service by a participant prior to the
end of a performance period or settlement of awards. Except as otherwise determined by the Committee, restricted stock will be forfeited
upon a participant&#8217;s termination of service during the applicable restriction period. In addition, we may recoup all or any portion
of any shares or cash paid to a participant in connection with any award in the event of a restatement of our financial statements as
set forth in our clawback policy, as such policy may be approved or modified by our Board from time to time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Awards
granted under the 2024 Plan generally are not assignable or transferable except by will or by the laws of descent and distribution, except
that the Committee may, in its discretion and pursuant to the terms of an award agreement, permit transfers of certain award of nonqualified
stock options or SARs to (i) the spouse (or former spouse), children, or grandchildren of the participant (&#8220;Immediate Family Members&#8221;);
(ii) a trust or trusts for the exclusive benefit of such Immediate Family Members; (iii) a partnership in which the only partners are
(x) such Immediate Family Members, and/or (y) entities which are controlled by Immediate Family Members; (iv) an entity exempt from federal
income tax pursuant to Section 501(c)(3) of the Code or any successor provision; or (v) a split interest trust or pooled income fund
described in Section 2522(c)(2) of the Code or any successor provision, provided that (x) there shall be no consideration for any such
transfer, (y) the applicable award agreement pursuant to which such award is granted must be approved by the Committee and must expressly
provide for such transferability, and (z) subsequent transfers of transferred awards shall be prohibited except those by will or the
laws of descent and distribution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 146; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->141<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Adjustments
Upon Changes in Capitalization</i>. In the event that any dividend or other distribution, recapitalization, stock split, reverse stock
split, rights offering, reorganization, merger, consolidation, split-up, spin-off, split-off, combination, subdivision, repurchase, or
exchange of shares of common stock or other securities of the Company, issuance of warrants or other rights to purchase shares of common
stock or other securities of the Company, or other similar corporate transaction or event affects the fair value of an award, then the
Committee shall adjust any or all of the following so that the fair value of the award immediately after the transaction or event is
equal to the fair value of the award immediately prior to the transaction or event (i) the number of shares and type of common stock
(or the securities or property) which thereafter may be made the subject of awards; (ii) the number of shares and type of common stock
(or other securities or property) subject to outstanding awards; (iii) the number of shares and type of common stock (or other securities
or property) specified as the annual per-participant limitation under the 2024 Plan; (iv) the option price of each outstanding award;
(v) the amount, if any, we pay for forfeited shares in accordance with the terms of the 2024 Plan; and (vi) the number of or exercise
price of shares then subject to outstanding SARs previously granted and unexercised under the 2024 Plan to the end that the same proportion
of our issued and outstanding shares of common stock in each instance shall remain subject to exercise at the same aggregate exercise
price; provided, however, that the number of shares of common stock (or other securities or property) subject to any award shall always
be a whole number. Notwithstanding the foregoing, no such adjustment shall be made or authorized to the extent that such adjustment would
cause the 2024 Plan or any stock option to violate Section 422 of the Code or Section 409A of the Code. All such adjustments must be
made in accordance with the rules of any securities exchange, stock market, or stock quotation system to which we are subject.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amendment
or Discontinuance of the 2024 Plan</i>. The Board may, at any time and from time to time, without the consent of participants, alter,
amend, revise, suspend, or discontinue the 2024 Plan in whole or in part; provided, however, that (i) no amendment that requires stockholder
approval in order for the 2024 Plan and any awards under the 2024 Plan to continue to comply with Sections 421 and 422 of the Code (including
any successors to such sections, or other applicable law) or any applicable requirements of any securities exchange or inter-dealer quotation
system on which our stock is listed or traded, shall be effective unless such amendment is approved by the requisite vote of our stockholders
entitled to vote on the amendment; and (ii) unless required by law, no action by the Board regarding amendment or discontinuance of the
2024 Plan may adversely affect any rights of any participants or obligations of us to any participants with respect to any outstanding
awards under the 2024 Plan without the consent of the affected participant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>U.S.
Federal Income Tax Consequences</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a brief summary of certain U.S. federal income tax consequences relating to the transactions described under the 2024 Plan
as set forth below. This summary does not purport to address all aspects of U.S. federal income taxation and does not describe state,
local, or foreign tax consequences. This discussion is based upon provisions of the Code and the Treasury Regulations issued thereunder,
and judicial and administrative interpretations under the Code and Treasury Regulations, all as in effect as of the date hereof, and
all of which are subject to change (possibly on a retroactive basis) or different interpretation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Law
Affecting Deferred Compensation</i>. In 2004, Section 409A was added to the Code to regulate all types of deferred compensation. If the
requirements of Section 409A of the Code are not satisfied, deferred compensation and earnings thereon will be subject to tax as it vests,
plus an interest charge at the underpayment rate plus 1% and a 20% penalty tax. Certain performance awards, stock options, stock appreciation
rights, restricted stock units, and certain types of restricted stock are subject to Section 409A of the Code.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Incentive
Stock Options</i>. A participant will not recognize income at the time an ISO is granted. When a participant exercises an ISO, a participant
also generally will not be required to recognize income (either as ordinary income or capital gain). However, to the extent that the
fair market value (determined as of the date of grant) of the shares with respect to which the participant&#8217;s ISOs are exercisable
for the first time during any year exceeds $100,000, the ISOs for the shares over $100,000 will be treated as nonqualified stock options,
and not ISOs, for U.S. federal tax purposes, and the participant will recognize income as if the ISOs were nonqualified stock options.
In addition to the foregoing, if the fair market value of the shares received upon exercise of an ISO exceeds the exercise price, then
the excess may be deemed a tax preference adjustment for purposes of the U.S. federal alternative minimum tax calculation. The federal
alternative minimum tax may produce significant tax repercussions depending upon the participant&#8217;s particular tax status.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 147; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->142<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax treatment of any shares acquired by exercise of an ISO will depend upon whether the participant disposes of his or her shares prior
to the later of: (i) two years after the date the ISO was granted or (ii) one year after the shares were transferred to the participant
upon exercise of the ISO (referred to as the &#8220;Holding Period&#8221;). If a participant disposes of shares acquired by exercise
of an ISO after the expiration of the Holding Period, any amount received in excess of the participant&#8217;s tax basis for such shares
will be treated as a short-term or long-term capital gain, depending upon how long the participant has held the shares. If the amount
received is less than the participant&#8217;s tax basis for such shares, the loss will be treated as a short-term or long-term capital
loss, depending upon how long the participant has held the shares. If the participant disposes of shares acquired by exercise of an ISO
prior to the expiration of the Holding Period, the disposition will be considered a &#8220;disqualifying disposition.&#8221; If the amount
received for the shares is greater than the fair market value of the shares on the exercise date, then the difference between the ISO&#8217;s
exercise price and the fair market value of the shares at the time of exercise will be treated as ordinary income for the tax year in
which the &#8220;disqualifying disposition&#8221; occurs. The participant&#8217;s basis in the shares will be increased by an amount
equal to the amount treated as ordinary income due to such &#8220;disqualifying disposition.&#8221; In addition, the amount received
in such &#8220;disqualifying disposition&#8221; over the participant&#8217;s increased basis in the shares will be treated as capital
gain. However, if the price received for shares acquired by exercise of an ISO is less than the fair market value of the shares on the
exercise date and the disposition is a transaction in which the participant sustains a loss which otherwise would be recognizable under
the Code, then the amount of ordinary income that the participant will recognize is the excess, if any, of the amount realized on the
&#8220;disqualifying disposition&#8221; over the basis of the shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nonqualified
Stock Options</i>. A participant generally will not recognize income at the time a nonqualified stock option is granted. When a participant
exercises a nonqualified stock option, the difference between the option price and any higher market value of the shares of common stock
on the date of exercise will be treated as compensation taxable as ordinary income to the participant. The participant&#8217;s tax basis
for the shares acquired under a nonqualified stock option will be equal to the option price paid for such shares, plus any amounts included
in the participant&#8217;s income as compensation. When a participant disposes of shares acquired by exercise of a nonqualified stock
option, any amount received in excess of the participant&#8217;s tax basis for such shares will be treated as short-term or long-term
capital gain, depending upon how long the participant has held the shares. If the amount received is less than the participant&#8217;s
tax basis for such shares, the loss will be treated as a short-term or long-term capital loss, depending upon how long the participant
has held the shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Special
Rule if Option Price is Paid for in Shares</i>. If a participant pays the option price of a nonqualified stock option with previously-owned
shares of our common stock and the transaction is not a disqualifying disposition of shares previously acquired under an ISO, the shares
received equal to the number of shares surrendered are treated as having been received in a tax-free exchange. The participant&#8217;s
tax basis and holding period for these shares received will be equal to the participant&#8217;s tax basis and holding period for the
shares surrendered. The shares received in excess of the number of shares surrendered will be treated as compensation taxable as ordinary
income to the participant to the extent of their fair market value. The participant&#8217;s tax basis in these shares will be equal to
their fair market value on the date of exercise, and the participant&#8217;s holding period for such shares will begin on the date of
exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the use of previously acquired shares to pay the exercise price of a nonqualified stock option constitutes a disqualifying disposition
of shares previously acquired under an ISO, the participant will have ordinary income as a result of the disqualifying disposition in
an amount equal to the excess of the fair market value of the shares surrendered, determined at the time such shares were originally
acquired on exercise of the ISO, over the aggregate option price paid for such shares. As discussed above, a disqualifying disposition
of shares previously acquired under an ISO occurs when the participant disposes of such shares before the end of the Holding Period.
The other tax results from paying the exercise price with previously-owned shares are as described above, except that the participant&#8217;s
tax basis in the shares that are treated as having been received in a tax-free exchange will be increased by the amount of ordinary income
recognized by the participant as a result of the disqualifying disposition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 148; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->143<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock</i>. A participant who receives restricted stock generally will recognize as ordinary income the excess, if any, of the fair market
value of the shares granted as restricted stock at such time as the shares are no longer subject to forfeiture or restrictions, over
the amount paid, if any, by the participant for such shares. However, a participant who receives restricted stock may make an election
under Section 83(b) of the Code within 30 days of the date of transfer of the shares to recognize ordinary income on the date of transfer
of the shares equal to the excess of the fair market value of such shares (determined without regard to the restrictions on such shares)
over the purchase price, if any, of such shares. If a participant does not make an election under Section 83(b) of the Code, then the
participant will recognize as ordinary income any dividends received with respect to such shares. At the time of sale of such shares,
any gain or loss realized by the participant will be treated as either short-term or long-term capital gain (or loss) depending on the
holding period. For purposes of determining any gain or loss realized, the participant&#8217;s tax basis will be the amount previously
taxable as ordinary income, plus the purchase price paid by the participant, if any, for such shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Appreciation Rights</i>. Generally, a participant who receives a stand-alone SAR will not recognize taxable income at the time the stand-alone
SAR is granted, provided that the SAR is exempt from or complies with Section 409A of the Code. If an employee receives the appreciation
inherent in the SARs in cash, the cash will be taxed as ordinary income to the recipient at the time it is received. If a recipient receives
the appreciation inherent in the SARs in stock, the spread between the then current market value and the grant price, if any, will be
taxed as ordinary income to the employee at the time it is received. In general, there will be no federal income tax deduction allowed
to us upon the grant or termination of SARs. However, upon the exercise of a SAR, we will be entitled to a deduction equal to the amount
of ordinary income the recipient is required to recognize as a result of the exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Awards.</i> In the case of an award of restricted stock units, performance awards, dividend equivalent rights, or other stock or cash
awards, the recipient will generally recognize ordinary income in an amount equal to any cash received and the fair market value of any
shares received on the date of payment or delivery, provided that the award is exempt from or complies with Section 409A of the Code.
In that taxable year, we will receive a federal income tax deduction in an amount equal to the ordinary income which the participant
has recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Federal
Tax Withholding</i>. Any ordinary income realized by a participant upon the exercise of an award under the 2024 Plan is subject to withholding
of U.S. federal, state, and local income tax and to withholding of the participant&#8217;s share of tax under the Federal Insurance Contribution
Act and the Federal Unemployment Tax Act. To satisfy our federal income tax withholding requirements, we will have the right to require
that, as a condition to delivery of any certificate for shares of common stock or the registration of the shares in the participant&#8217;s
name, the participant remit to us an amount sufficient to satisfy the withholding requirements. Alternatively, we may withhold a portion
of the shares (valued at fair market value) that otherwise would be issued to the participant to satisfy all or part of the withholding
tax obligations or may, if we consent, accept delivery of shares (that the participant has not acquired from us within six months prior
to the date of exercise) with an aggregate fair market value that equals or exceeds the required tax withholding payment. Withholding
does not represent an increase in the participant&#8217;s total income tax obligation, since it is fully credited toward his or her tax
liability for the year. Additionally, withholding does not affect the participant&#8217;s tax basis in the shares. Compensation income
realized and tax withheld will be reflected on Forms W-2 supplied by us to employees by January 31 of the succeeding year. Deferred compensation
that is subject to Section 409A of the Code will be subject to certain federal income tax withholding and reporting requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Tax
Consequences to Us</i>. To the extent that a participant recognizes ordinary income in the circumstances described above, we will be
entitled to a corresponding deduction provided that, among other things, the income meets the test of reasonableness, is an ordinary
and necessary business expense, is not an &#8220;excess parachute payment&#8221; within the meaning of Section 280G of the Code, and
is not disallowed by the $1,000,000 limitation on certain executive compensation under Section 162(m) of the Code. While deductibility
of executive compensation for federal income tax purposes is among the factors the Board and Committee consider when structuring executive
compensation arrangements, it is not the sole or primary factor considered. We retain the flexibility to authorize compensation that
may not be deductible if we believe it is in the best interests of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Million
Dollar Deduction Limit and Other Tax Matters</i>. We may not deduct compensation of more than $1,000,000 that is paid to &#8220;covered
employees&#8221; (as defined in Section 162(m) of the Code), which include (i) an individual (or, in certain circumstances, his or her
beneficiaries) who, at any time during the taxable year, is either our principal executive officer or principal financial officer; (ii)
an individual who is among our three highest compensated officers for the taxable year (other than an individual who was either our principal
executive officer or principal financial officer at any time during the taxable year); or (iii) anyone who was a covered employee for
purposes of Section 162(m) of the Code for any tax year beginning on or after January 1, 2018. This limitation on deductions (x) only
applies to compensation paid by a publicly-traded corporation (and not compensation paid by non-corporate entities) and (z) may not apply
to certain types of compensation, such as qualified performance-based compensation that is payable pursuant to a written, binding contract
that was in effect as of November 2, 2018, so long as the contract is not materially modified after that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 149; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->144<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an individual&#8217;s rights under the 2024 Plan are accelerated as a result of a change in control and the individual is a &#8220;disqualified
individual&#8221; under Section 280G of the Code, the value of any such accelerated rights received by such individual may be included
in determining whether or not such individual has received an &#8220;excess parachute payment&#8221; under Section 280G of the Code,
which could result in (i) the imposition of a 20% federal excise tax (in addition to federal income tax) payable by the individual on
the value of such accelerated rights, and (ii) the loss by us of a compensation deduction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Israeli
Income Tax Consequences</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description of the Israel income tax consequences of awards under Israeli Appendix of the 2024 Plan is general and does not
purport to be complete.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 102 of the Ordinance, which came into effect on January 1, 2003, options, shares, and other securities (including Restricted
Shares) (together &#8220;Options&#8221;) may be granted through a trustee (i.e., Approved 102 Options) or not through a trustee (i.e.,
Unapproved 102 Options). The following is a brief discussion of the tax consequences applicable to both types of Section 102 Options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Grant
Through a Trustee</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
granted through a trustee and held in trust are made either through the capital gains tax track (i.e., Capital Gains Options) or the
compensation income tax track (i.e., Ordinary Income Options). Capital Gains Options and Ordinary Income Options can be granted only
through a trustee. Under the capital gains tax track, the Capital Gains Options and the underlying shares have to be held in trust for
at least twenty-four (24) months from their date of grant. Any gain made on the sale of shares following the twenty-four (24) month period
is subject to a capital gains tax at a current rate of 25%; the amount of gain is the difference between the sales proceeds from the
sale of shares and the exercise price paid for such shares. Generally, Capital Gains Options are not taxed on their date of grant. However,
in the event that the exercise price of the options is less than the fair market value of the Company&#8217;s common stock on the date
of grant, a portion of the gain will be deemed compensation income, taxable at the personal marginal tax rate of the participant. The
payment of such tax is made at the time of exercise of the Capital Gains Options. The portion of the gain that is deemed compensation
income is the difference between the average value of the shares as listed on the stock exchange during the thirty (30) day period prior
to the date of grant and the exercise price of the option. If the Capital Gains Options or the underlying shares of such options are
sold by the trustee or transferred from the trustee to the beneficiary before the end of the twenty-four (24) month period, any resulting
income (cash or equivalent) is taxed as compensation income. If the options have not been exercised and transferred from the trustee
to the beneficiary, the taxable amount of income is the value of the option. If the options have been exercised, the taxable amount of
income is the difference between the aggregate fair market value of the shares at the time of such sale or transfer and the aggregate
exercise price paid for such shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the compensation income tax track, the Ordinary Income Options and the underlying shares have to be held in trust for at least twelve
(12) months from their date of grant. Any gain made on the sale of shares is subject to compensation income tax at the personal marginal
tax rate of the respective participant; the amount of gain is the difference between the sales proceeds from the sale of shares and the
exercise price paid for such shares. Ordinary Income Options are not taxed on their date of grant, but rather when the options or the
underlying shares of such options are sold by the trustee or transferred from the trustee to the beneficiary. At such time, if the options
have not been exercised, the taxable amount of income is value of the Option. If the Options have been exercised, the taxable amount
of income is the difference between the aggregate fair market value of the shares at the time of such sale or transfer and the aggregate
exercise price paid for such shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
corporate tax deduction is available for the employer in the tax year in which tax is withheld. The deductible amount is equal to any
amount included by a participant as compensation income, except when a participant is granted Capital Gains Options, including in the
event that such Capital Gains Options or the underlying shares of such options are sold by the trustee or transferred from the trustee
to the beneficiary before the end of the applicable twenty-four (24) month period. In such event, any resulting income to the participant
is deemed to be compensation income for tax purposes, but there would be no corresponding corporate tax deduction available to the employer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 150; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->145<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Grant
Not Through a Trustee</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the case of Options not made through a trustee, if the shares are non-marketable securities, the Option will not be subject to tax at
the date of grant of the option or the exercise of the Option. However, ordinary income tax will be payable upon the sale of the shares
acquired upon exercise of the Option. The taxable amount will be the sales proceeds less the aggregate exercise price paid by the participant.
If the shares covered by the option have a market value, then the value of the Option is treated as compensation income, and subject
to tax at the date of grant. There is no tax upon the exercise of the Option. However, capital gains tax will be payable on the sale
of the shares upon exercise of the Option. The taxable amount will be the sales proceeds, less the value that was taxed at the date of
grant and the aggregate exercise price paid by the participant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Grant
of Section 3(i) Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
under Section 3(i) of the Ordinance may be granted to Controlling Shareholders, consultants, and controlling stockholders (which are
excluded from the term employees under Section 102 of the Ordinance). Grants of Options for shares which are non-marketable are not taxed
under the income tax rules on the date of grant, but such event creates VAT liability. However, they are subject to tax at the time of
exercise at the ordinary income tax rate, and at the day such shares are sold at the capital gains tax rate. The difference between the
fair market value of the shares at the time of exercise and the exercise price is taxed at the ordinary income tax rate. Any gain above
such value at the time of sale of the shares is taxed at the capital gains rate. Grants of Options for shares which have a market value
are subject to tax on the date of grant, exercise of the Option, and the sale of the shares. The value of the Option is taxed on the
date of grant at the ordinary income tax rate. The difference between the fair market value of the shares at the time of exercise and
the sum of the exercise price and the amounts previously taxed at grant, is taxed at the ordinary income tax rate. Any gain above such
value at the time of sale of the shares is taxed at the capital gains rate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Stock Incentives</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
other awards under the Israeli Appendix need tax ruling from the Israeli Tax Authority for the postponement of the tax event arising
from the issuance thereof. Otherwise, there is an immediate tax event.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Outstanding
Equity Awards at December 31, 2024</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides certain information as of December 31, 2024, with respect to our equity compensation plans under which our equity
securities were authorized for issuance:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(a)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(b)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(c)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Plan Category</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>securities to</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>be issued upon exercise of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>outstanding</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>options,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>warrants, and</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>rights</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>exercise price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>outstanding</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>options,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>warrants and</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>rights</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>securities remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>available for future</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>issuance under</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>equity</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>compensation plans</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(excluding</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>securities reflected</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>in column (a))</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity compensation plans approved by security holders<sup>(1)</sup></b></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">45,059</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">9.24</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Equity compensation plans not approved by security holders</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45,059</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9.24</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    shares available for issuance under the 2014 Plan and the 2024 Plan as of December 31, 2024, pursuant to outstanding awards. The
    2014 Plan expired on February 19, 2024, and no further equity awards may be granted under the 2014 Plan.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 151; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->146<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DIRECTOR
COMPENSATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the compensation earned by persons who served on our Board during the fiscal year ended December 31, 2024, who
are not one of our Named Executive Officers. Other than as set forth in the table and described more fully below, we did not pay any
compensation, reimburse any expense of, make any equity awards or non-equity awards to, or pay any other compensation to any of the other
members of our Board for their services rendered in such period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Name</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Fees earned or</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">paid in cash ($)</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option Awards</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($) <sup>(1)</sup></b></span></p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher Fashek <sup>(2)</sup></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">158,750</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">26,428</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">185,178</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas Mika <sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,712</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,712</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Ferguson <sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,712</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,712</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Martin Goldstein <sup>(5)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,299</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,299</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harold Jacob, M. D. <sup>(6)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,543</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,543</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aurora Cassirer <sup>(7)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,712</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,712</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maria Schroeder <sup>(8)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,712</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,712</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)
</sup>In accordance with SEC rules, the amounts in this column reflect the dollar amounts to be recognized for financial statement reporting
purposes with respect to the 2023 fiscal year in accordance with ASC Topic 718. Fair value is based on the Black-Scholes option pricing
model using the market price of the underlying shares at the grant date. For additional discussion of the valuation assumptions used
in determining stock-based compensation and the grant date fair value for stock options, see &#8220;<i>Management&#8217;s Discussion
and Analysis of Financial Condition and Results of Operation - Critical Accounting Policies - Stock-based compensation</i>&#8221; and
Note 3- &#8220;<i>Significant Accounting Policies</i>&#8221; and Note 6- &#8220;<i>Stockholders&#8217; Equity</i>&#8221; to our audited
consolidated financial statements for the fiscal year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)
</sup>As of December 31, 2024, Mr. Fashek had outstanding options representing the right to purchase 6,159 shares of our common stock
and no outstanding stock awards of shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(3)
</sup>As of December 31, 2024, Mr. Mika had outstanding options representing the right to purchase 3,636 shares of our common stock and
no outstanding stock awards of shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(4)
</sup>As of December 31, 2024, Mr. Ferguson had outstanding options representing the right to purchase 3,636 shares of our common stock
and no outstanding stock awards of shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(5)
</sup>As of December 31, 2024, Mr. Goldstein had outstanding options representing the right to purchase 3,909 shares of our common stock
and no outstanding stock awards of shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(6)
</sup>As of December 31, 2024, Dr. Jacob had outstanding options representing the right to purchase 1,818 shares of our common stock
and no outstanding stock awards of shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(7)
</sup>As of December 31, 2024, Ms. Cassirer had outstanding options representing the right to purchase 3,636 shares of our common stock
and no outstanding stock awards of shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(8)
</sup>As of December 31, 2024, Ms. Schroeder had outstanding options representing the right to purchase 3,636 shares of our common stock
and no outstanding stock awards of shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 13, 2016, we entered into an agreement with Christopher Fashek to serve as the chairman of our Board. Under this agreement Mr.
Fashek was paid $100,000 per year payable in semi-monthly installments. On November 1, 2018, the Compensation committee voted to increase
Mr. Fashek&#8217;s consulting fee to $150,000 per year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 29, 2023, we entered into an option cancellation and release agreement with each of Brian Murphy, Christopher Fashek, Martin
Goldstein, Michael Ferguson, Stephen Brown, Aurora Cassirer, Dr. Harold Jacob, Maria Schroeder and Thomas Mika (collectively, the &#8220;Option
Holders&#8221;), pursuant to which the parties agreed to cancel options to purchase an aggregate of 9,276 shares of common stock at exercise
prices ranging from $98.34 to $565.40 (the &#8220;Options&#8221;) previously granted to each of the Option Holders. In exchange for the
cancellation of the Options, we paid $1.00 to each Option Holder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
other compensation was paid to our non-employee directors other than as noted in the table above for the one-year period ended December
31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 152; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->147<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_001"></span>ITEM
12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information with respect to the beneficial ownership of our common stock as of March 31, 2025, by:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    person known by us to beneficially own more than 5.0% of our common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    of our directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    of our Named Executive Officers; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    of our directors and executive officers as a group.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
percentages of common stock beneficially owned are reported on the basis of regulations of the SEC governing the determination of beneficial
ownership of securities. Under the rules of the SEC, a person is deemed to be a beneficial owner of a security if that person has or
shares voting power, which includes the power to vote or to direct the voting of the security, or investment power, which includes the
power to dispose of or to direct the disposition of the security.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as indicated in the footnotes to this table, each beneficial owner named in the table below has sole voting and sole investment power
with respect to all shares beneficially owned and each person&#8217;s address is c/o NanoVibronix, Inc., 969 Pruitt Place, Tyler TX 75703.
As of March 31, 2025, we had 759,297 shares of common stock, 0 shares of Series C Preferred Stock, 0 shares of Series D Preferred Stock,
0 shares of Series E Preferred Stock, 0 shares of Series F Preferred Stock and 57,720 shares of Series X Preferred Stock outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Name of Beneficial
    Owner</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of Shares Beneficially Owned <sup>(1)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage
    of Shares Outstanding <sup>(1)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">5% Owners</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Armistice Capital, LLC</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36,690</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(2)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%<sup>(2)</sup></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Alpha Capital Anstalt</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right">157,727</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(3)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right">18.4</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Directors and Executive
    Officers</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stephen Brown</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,836</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(4)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Martin Goldstein, M.D.</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,909</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(5)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Thomas R. Mika</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,636</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(6)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Christopher Fashek</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,159</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(7)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Brian Murphy</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,091</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(8)</sup></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.0</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Aurora Cassirer</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,645</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(9)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Doron Besser, M.D.</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,818</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(10)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Zeev Rotstein, M.D.</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">All directors and executive
    officers as a group (9 persons)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">39,095</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5.1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>*</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    ownership of less than 1%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    of common stock beneficially owned and the respective percentages of beneficial ownership of common stock assume the exercise of
    all options, warrants and other securities convertible into common stock beneficially owned by such person or entity currently exercisable
    or exercisable within 60 days of March 31, 2025. Shares issuable pursuant to the exercise of stock options and warrants exercisable
    within 60 days are deemed outstanding and held by the holder of such options or warrants for computing the percentage of outstanding
    common stock beneficially owned by such person, but are not deemed outstanding for computing the percentage of outstanding common
    stock beneficially owned by any other person.</span></td></tr>

</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 153; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->148<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    shares are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the &#8220;Master Fund&#8221;)
    and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (&#8220;Armistice Capital&#8221;), as the investment
    manager of the Master Fund and (ii) Steven Boyd, as the Managing Member of Armistice Capital. Comprised of 36,690 shares of common
    stock issuable upon the exercise of the Warrants and excludes 121,872 shares of common stock issuable upon the exercise of the
    January 2025 Warrant. The January 2025 Warrant is subject to a beneficial ownership limitation of 4.99% and may not be exercised
    until issuance of the shares of common stock upon exercise of the January 2025 Warrant has been approved by the stockholders. The
    address of Armistice Capital, LLC is c/o Armistice Capital, LLC, 510 Madison Avenue, 7<sup>th</sup> Floor, New York, NY 10022.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The shares are held by Alpha Capital Anstalt, a company based in Vaduz
Liechtenstein, comprised of 33,182 shares of common stock and 36,690 shares of common stock issuable upon the exercise of the February
2025 Warrants and excludes 38,480 shares of common stock issuable upon the exercise of the 2025 Warrants which are subject to the nefecial
ownership limitation of 9.9% as well as shares of common stock issuable upon the exercise of the Preferred Stock The address of Alpha
Capital Anstalt is Lettstrasse 32, FL-9490, Furstentums, Vaduz, Austria, Liechtenstein.</p>
</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(3)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprised
    of 18 shares of common stock held by Mr. Brown and 5,818 shares of common stock that may be purchased by Mr. Brown upon exercise
    of stock options that are currently exercisable or exercisable within 60 days following March 31, 2025.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(4)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprised
    of 3,909 shares of common stock that may be purchased by Dr. Goldstein upon exercise of stock options that are currently exercisable
    or exercisable within 60 days following March 31, 2025.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(5)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprised
    of 3,636 shares of common stock that may be purchased by Mr. Mika upon exercise of stock options that are currently exercisable
    or exercisable within 60 days following March 31, 2025.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(6)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprised
    of 341 shares of common stock held by Mr. Fashek and 5,818 shares of common stock that may be purchased by Mr. Fashek upon exercise
    of stock options that are currently exercisable or exercisable within 60 days following March 31, 2025.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(7)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprised
    of 9,091 shares of common stock that may be purchased by Mr. Murphy upon exercise of stock options that are currently exercisable
    or exercisable within 60 days following March 31, 2025.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(8)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprised
    of 9 shares of common stock held by Ms. Cassirer and 3,636 shares of common stock that may be purchased by Ms. Cassirer upon exercise
    of stock options that are currently exercisable or exercisable within 60 days following March 31, 2025.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprised
    of 6,818 shares of common stock held by Dr. Besser as of March 31, 2025.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_002"></span>ITEM
13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related
Parties Transactions Approval Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
we do not enter into related party transactions unless the members of the Board who do not have an interest in the potential transaction
have reviewed the transaction and determined that (i) we would not be able to obtain better terms by engaging in a transaction with a
non-related party and (ii) the transaction is in our best interest. In approving or rejecting any such proposal, our Board considers
all of the relevant facts and circumstances of the related party transaction and the related party&#8217;s relationship and interest
in the transaction. This policy applies generally to any transaction in which we are to be a participant and the amount involved exceeds
the lesser of $120,000 or one percent of the average of our total assets at year-end for the previous two completed fiscal years, and
in which any related person had or will have a direct or indirect material interest. This policy is not currently in writing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee is charged with reviewing, approving and overseeing any transaction between us and any related person (as defined in
Item 404 of Regulation S-K) and any other potential conflict of interest situations in accordance with Company policies and procedures.
All of the transactions described below were entered into prior to the establishment of our audit committee and were evaluated in accordance
with the policy described in the paragraph above. Prior to approving such transactions, the material facts as to a director&#8217;s or
officer&#8217;s relationship or interest as to the agreement or transaction were disclosed to our Board. Our Board took this information
into account when evaluating the transaction and in determining whether such transaction was fair to us and in the best interest of all
of our stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 154; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->149<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transactions
with Related Parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2022 we engaged the law firm FisherBroyles LLP to handle our litigation matter with Protrade Systems, Inc. For the year ended December
31, 2023, we have accrued and paid legal fees of FisherBroyles LLP equal to $360,000, which fees were recorded as part of &#8220;General
and administrative expenses&#8221; in our condensed consolidated statements of operations. As has been previously disclosed, one of our
board members, Aurora Cassirer, was a partner at FisherBroyles LLP. Ms. Cassirer did not provide any legal services or legal advice to
the Company<b>.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 1, 2024, Ms. Cassirer left FisherBroyles to become a partner at Pierson Ferdinand. Pierson Ferdinand was paid $69,000 during the year ended December 31, 2024. Ms. Cassirer does not provide any legal services or legal advice to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 29, 2023, we entered into an option cancellation and release agreement with each of Brian Murphy, Christopher Fashek, Martin
Goldstein, Michael Ferguson, Stephen Brown, Aurora Cassirer, Dr. Harold Jacob, Maria Schroeder and Thomas Mika, our directors and officers,
pursuant to which the parties agreed to cancel the Options previously granted to each of the option holders. In exchange for the cancellation
of the Options, we paid $1.00 to each option holder. See &#8220;<i>Director Compensation</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than compensation agreements and other arrangements which are described as required under &#8220;Director Compensation&#8221; and &#8220;Executive
Compensation&#8221; and the transactions described above, since January 1, 2023, there has not been, and there is not currently proposed,
any transaction or series of similar transactions to which we were or will be a party in which the amount involved exceeded or will exceed
the lesser of $120,000 or the average of our total assets at year-end for the last two completed fiscal years and in which any director,
executive officer, holder of 5% or more of any class of our capital stock, or any member of their immediate family had or will have a
direct or indirect material interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_003"></span>ITEM
14. PRINCIPAL ACCOUNTING FEES AND SERVICES.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 6, 2023, we dismissed Marcum LLP (&#8220;Marcum&#8221;) as our independent registered public accounting firm, effective as of
December 7, 2023. This decision was approved by the Audit Committee. The reports of Marcum on our consolidated financial statements for
the years ended December 31, 2022, and 2021, did not contain an adverse opinion or a disclaimer of opinion, and was not qualified or
modified as to uncertainty, audit scope, or accounting principles, except Marcum&#8217;s report on our consolidated financial statements
as of and for the years ended December 31, 2022, and 2021, contained an explanatory paragraph stating there was substantial doubt about
our ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2022 and December 31, 2021, and the subsequent interim period through December 7, 2023, there were no disagreements
(as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304 of Regulation S-K) with Marcum on any matter
of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved
to the satisfaction of Marcum, would have caused Marcum to make reference to the subject matter of the disagreements in connection with
its reports on the Company&#8217;s consolidated financial statements for such years. Also during this time, there were no &#8220;reportable
events,&#8221; as defined in Item 304(a)(1)(v) of Regulation S-K, except that, for the years ended December 31, 2022 and December 31,
2021 and for each of the quarters within the years ended December 31, 2022 and 2021, management identified deficiencies in the Company&#8217;s
design and effectiveness of their internal control over financial reporting that were considered to be material weaknesses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 7, 2023, we engaged Zwick CPA, PLLC (&#8220;Zwick&#8221;) as our independent registered public accounting firm for the fiscal
year ending December 31, 2023, effective immediately. The engagement was approved by the Audit Committee. During the fiscal years ended
December 31, 2022 and December 31, 2021, and the subsequent interim period through December 7, 2023, neither us nor anyone on our behalf
has consulted with Zwick regarding (i) the application of accounting principles to any specified transaction, either completed or proposed,
or the type of audit opinion that might be rendered on our financial statements, and neither a written report nor oral advice was provided
to us that Zwick concluded was an important factor considered by us in reaching a decision as to any accounting, auditing, or financial
reporting issue, or (ii) any matter that was either the subject of a &#8220;disagreement,&#8221; as defined in Item 304(a)(1)(iv) of
Regulation S-K, or a &#8220;reportable event,&#8221; as defined in Item 304(a)(1)(v) of Regulation S-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 155; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->150<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the fees billed or expected to be billed to us by Zwick, our independent registered public accountants, for
professional services rendered with respect to the fiscal years ended December 31, 2024, and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Zwick CPA, PLLC</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Audit fees (1)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">146,735</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">274,338</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Audit-related fees (2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax fees (3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">All other fees (4)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">75,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">146,735</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">349,338</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Audit
    Fees</i>. This category includes the fees related to the audit of our annual financial statements and the review of our interim quarterly
    financial statements and services that are normally provided by our independent registered public accounting firm in connection with
    its engagements for those years. This category also includes advice on audit and accounting matters that arose during, or as a result
    of, the audit or the review of our interim financial statements.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Audit-Related
    Fees. </i>This category typically consists of assurance and related services by our independent registered public accounting firm
    that are reasonably related to the performance of the audit or review of our financial statements and are not reported above under
    &#8220;Audit Fees.&#8221; The services for the fees disclosed under this category include consents regarding equity issuances.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Tax
    Fees</i>. This category typically consists of professional services rendered by our independent registered public accounting firm
    for tax compliance and tax advice.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>All
    Other Fees</i>. This category includes aggregate fees billed in each of the last two fiscal years for Marcum LLP and the last fiscal
    year for Zwick CPA, PLLC for products and services provided by the relevant independent registered public accounting firm other than
    the services reported in the categories above.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pre-Approval
Policies and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Audit Committee&#8217;s pre-approval policies and procedures, the audit committee is required to pre-approve the audit and non-audit
services performed by our independent registered public accounting firm. On an annual basis, the Audit Committee pre-approves a list
of services that may be provided by the independent registered public accounting firm without obtaining specific pre-approval from the
audit committee. In addition, the Audit Committee sets pre-approved fee levels for each of the listed services. Any type of service that
is not included on the list of pre-approved services must be specifically approved by the Audit Committee or its designee. Any proposed
service that is included on the list of pre-approved services but will cause the pre-approved fee level to be exceeded will also require
specific pre-approval by the Audit Committee or its designee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee has delegated pre-approval authority to the Audit Committee chairman and any pre-approved actions by the Audit Committee
chairman as designee are reported to the Audit Committee for approval at its next scheduled meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the services rendered by Zwick were pre-approved by the Audit Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board considered the audit fees, audit-related fees, tax fees and other fees paid to our accountants, as disclosed above, and determined
that the payment of such fees was compatible with maintaining the independence of the accountants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 156; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->151<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_004"></span>ITEM
15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following documents are filed as part of this Annual Report on Form 10-K:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Statements:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_008">Report of Independent Registered Public Accounting Firm</a> (PCAOB ID: <span id="xdx_907_edei--AuditorFirmId_c20240101__20241231_zZtZ6E8WbjV8"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000061" name="dei:AuditorFirmId">549</ix:nonNumeric></span>)</span></td>
    <td style="width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_009">Consolidated Balance Sheets as of December 31, 2024, and 2023</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_010">Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2024, and 2023</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_011">Consolidated Statements of Changes in Stockholders&#8217; Equity for the years ended December 31, 2024, and 2023</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_012">Consolidated Statements of Cash Flows for the years ended December 31, 2024, and 2023</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_013">Notes to Consolidated Financial Statements</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Statement Schedules:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&#8220;Index to Exhibits&#8221; for a description of our exhibits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_005"></span>ITEM
16. FORM 10-K SUMMARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<!-- Field: Page; Sequence: 157; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->152<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_008"></span>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Board of Directors and Shareholders of NanoVibronix, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Opinion
on the Financial Statements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_981_edei--AuditorOpinionTextBlock_c20240101__20241231_zuIO5nGTfNi3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000062" name="dei:AuditorOpinionTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of NanoVibronix, Inc. (the &#8220;Company&#8221;) as of December 31, 2024,
and the related consolidated statements of operations, comprehensive loss, stockholders&#8217; equity and cash flows for the year then
ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements
present fairly, in all material respects, the financial position of the Company as of December 31, 2024, and the results of its operations
and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going
Concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared assuming that the entity will continue as a going concern. As discussed
in Note 2 to the financial statements, the entity has suffered recurring losses from operations and needs to raise additional funds to
meet its obligations and sustain its operations. These conditions raise substantial doubt about its ability to continue as a going concern.
Management&#8217;s plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include
any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis
for Opinion</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the entity&#8217;s management. Our responsibility is to express an opinion on these financial
statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United
States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit,
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the entity&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides
a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Critical
Audit Matters</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Critical
audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be
communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and
(2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
Zwick CPA, PLLC</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--AuditorName_c20240101__20241231_zLQL31ig5EZ5"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000063" name="dei:AuditorName">Zwick
CPA, PLLC</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--AuditorLocation_c20240101__20241231_zmjodnjwFxMa"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000064" name="dei:AuditorLocation">Southfield,
Michigan</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2025</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 158; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_009"></span>NanoVibronix,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Balance Sheets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Amounts
in thousands except share and per share data)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_301_111_pn3n3_zLcyy4StlWIk" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20241231_zcNzPRfbJAig" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20231231_zRdBsD1kKaVc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">ASSETS:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--Cash_i02I_pn3n3_maACzEl3_zMgJjhJRVXg9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 64%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2024-12-31" id="Fact000072" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">752</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2023-12-31" id="Fact000073" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,283</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccountsReceivableNetCurrent_i02I_pn3n3_maACzEl3_zJ88doDEWoVe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Trade receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2024-12-31" id="Fact000075" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">98</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2023-12-31" id="Fact000076" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">318</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_pn3n3_maACzEl3_zrlPqae0S5f7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Prepaid expenses and other accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000078" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">290</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000079" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">154</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--InventoryNet_i02I_pn3n3_maACzEl3_zOSNRnm2Fme" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Inventory</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2024-12-31" id="Fact000081" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,191</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2023-12-31" id="Fact000082" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,732</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsCurrent_i02TI_pn3n3_mtACzEl3_maAza1P_zfHm7CQSM7gl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000084" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,331</ix:nonFraction> </td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000085" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,487</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsNoncurrentAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Noncurrent assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentNet_i02I_pn3n3_maANzltu_zhUW8ZDEvheg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Fixed assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact000090" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000091" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OtherAssetsNoncurrent_i02I_pn3n3_maANzltu_zqlRXfuFgQLi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0093">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2023-12-31" id="Fact000094" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--SeveranceAssetsNoncurent_i02I_pn3n3_maANzltu_zKwVXnLEdlN1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Severance pay fund</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NAOV:SeveranceAssetsNoncurent" contextRef="AsOf2024-12-31" id="Fact000096" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">173</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NAOV:SeveranceAssetsNoncurent" contextRef="AsOf2023-12-31" id="Fact000097" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">174</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_pn3n3_maANzltu_zQ6XenqJo62" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Operating lease right-of-use assets, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="Fact000099" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">116</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact000100" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsNoncurrent_i02TI_pn3n3_mtANzltu_maAza1P_zW6jLSMuxpTk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total non-current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2024-12-31" id="Fact000102" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">298</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2023-12-31" id="Fact000103" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">187</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--Assets_i01TI_pn3n3_mtAza1P_zqZaHD0T9Rn9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact000105" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,629</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact000106" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,674</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrentAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AccountsPayableCurrent_i02I_pn3n3_maLCznpH_zGXMZXFcPXx2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Trade payables</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-12-31" id="Fact000114" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">47</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000115" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">138</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OtherAccountsPayableAndAccruedLiabilities_i02I_pn3n3_maLCznpH_zc2uMaGZMOR" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Other accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="AsOf2024-12-31" id="Fact000117" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,608</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="AsOf2023-12-31" id="Fact000118" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,265</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredIncomeCurrent_i02I_pn3n3_maLCznpH_zebrPNPDqTf5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Deferred revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeCurrent" contextRef="AsOf2024-12-31" id="Fact000120" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeCurrent" contextRef="AsOf2023-12-31" id="Fact000121" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">46</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_pn3n3_maLCznpH_zCrZD9XFkozi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Operating lease liabilities, current</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact000123" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">52</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" id="Fact000124" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LiabilitiesCurrent_i02TI_pn3n3_mtLCznpH_maLzilm_zg0aEBuXWFac" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total current liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000126" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,722</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000127" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,454</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesNoncurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OtherAccruedLiabilitiesNoncurrent_i02I_pn3n3_maLzilm_zHo60lTnVlw1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued severance pay</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesNoncurrent" contextRef="AsOf2024-12-31" id="Fact000132" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">216</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesNoncurrent" contextRef="AsOf2023-12-31" id="Fact000133" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">217</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredIncomeNoncurrent_i02I_pn3n3_maLzilm_z6bqSr2N1Cr6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Deferred revenue &#8211; long term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0135">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeNoncurrent" contextRef="AsOf2023-12-31" id="Fact000136" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_pn3n3_maLzilm_z3BmR7lnGs4k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Operating lease liabilities, non-current</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" id="Fact000138" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">64</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0139">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--Liabilities_i01TI_pn3n3_mtLzilm_maLASEz2Gy_zVv1k5vWN6X4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-12-31" id="Fact000141" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,002</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-12-31" id="Fact000142" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,686</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CommitmentsAndContingencies_i01I_pn3n3_maLASEz2Gy_z2ePwDn4Evc8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Commitments and contingencies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0144">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stockholders&#8217; equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PreferredStockValue_i02I_pn3n3_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zizSfj68Qrx9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Series C Preferred stock of $<span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zrYUS4qNz1ni" title="Preferred stock, par value"><span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zJlLWLkrpPub" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact000153" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact000155" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value - Authorized: <span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zl69GazSh3a7" title="Preferred stock, shares authorized"><span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zRmDBT88oF7c" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact000157" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact000159" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,000,000</ix:nonFraction></ix:nonFraction></span></span> shares at both December 31, 2024, and 2023; Issued and outstanding: <span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zWFqbu7Jdu7c" title="Preferred stock, shares issued"><span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zRjHUDdMv9w4" title="Preferred stock, shares outstanding"><span id="xdx_901_eus-gaap--PreferredStockSharesIssued_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zJgyqdvn3Svh" title="Preferred stock, shares issued"><span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zFG4Qhp6VL3h" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact000161" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact000163" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact000165" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact000167" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares at both December 31, 2024, and 2023, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0150">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0151">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PreferredStockValue_i02I_pn3n3_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zoPQoCEyP3Ll" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Series D Preferred stock of $<span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_z0mMenLELec9" title="Preferred stock, par value"><span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zPKuKhuyfOv" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31_us-gaap_SeriesDPreferredStockMember" id="Fact000172" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31_us-gaap_SeriesDPreferredStockMember" id="Fact000174" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value - Authorized: <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zSIaBwgTLau8" title="Preferred stock, shares authorized"><span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_z7pHUqdJvHz1" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31_us-gaap_SeriesDPreferredStockMember" id="Fact000176" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31_us-gaap_SeriesDPreferredStockMember" id="Fact000178" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">506</ix:nonFraction></ix:nonFraction></span></span> shares at both December 31, 2024, and 2023; Issued and outstanding: <span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_z0kXmoHavvOd" title="Preferred stock, shares issued"><span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_z4JHpTG3lBJk" title="Preferred stock, shares outstanding"><span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zylUv14EQh15" title="Preferred stock, shares issued"><span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_z2Rz7iv5wa1" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31_us-gaap_SeriesDPreferredStockMember" id="Fact000180" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_SeriesDPreferredStockMember" id="Fact000182" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31_us-gaap_SeriesDPreferredStockMember" id="Fact000184" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_SeriesDPreferredStockMember" id="Fact000186" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span> </span>shares at both December 31, 2024, and 2023, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0169">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0170">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PreferredStockValue_i02I_pn3n3_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zihmbmP4ikz5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Series E Preferred stock of $<span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_z0GPaTzO2fke" title="Preferred stock, par value"><span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zmt5D73IAzNl" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31_us-gaap_SeriesEPreferredStockMember" id="Fact000191" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31_us-gaap_SeriesEPreferredStockMember" id="Fact000193" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value - Authorized: <span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zXnGJZeaXoeb" title="Preferred stock, shares authorized"><span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zthh9NhqQlKb" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31_us-gaap_SeriesEPreferredStockMember" id="Fact000195" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31_us-gaap_SeriesEPreferredStockMember" id="Fact000197" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,999,494</ix:nonFraction></ix:nonFraction></span></span> shares at both December 31, 2024, and 2023, respectively; Issued and outstanding: <span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_z0yNhs9c6Iyc" title="Preferred stock, shares issued"><span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zTqs0symEbXi" title="Preferred stock, shares outstanding"><span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zxSAwOfCkpg2" title="Preferred stock, shares issued"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zBkTFDM45N08" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31_us-gaap_SeriesEPreferredStockMember" id="Fact000199" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_SeriesEPreferredStockMember" id="Fact000201" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31_us-gaap_SeriesEPreferredStockMember" id="Fact000203" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_SeriesEPreferredStockMember" id="Fact000205" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares at both December 31, 2024, and 2023, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0188">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0189">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PreferredStockValue_i02I_pn3n3_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zN92S4yKicN5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Series F Preferred stock of $<span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zx0x7MydxCHe" title="Preferred stock, par value"><span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zEgZTWmPQM7" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31_us-gaap_SeriesFPreferredStockMember" id="Fact000210" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31_us-gaap_SeriesFPreferredStockMember" id="Fact000212" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span> par value - Authorized: <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zD5b0D97xs7i" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31_us-gaap_SeriesFPreferredStockMember" id="Fact000214" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000</ix:nonFraction></span> and <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zbM9wKfzhr11" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31_us-gaap_SeriesFPreferredStockMember" id="Fact000216" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span> shares at December 31, 2024, and 2023, respectively; Issued and outstanding: <span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zuK1Z2Wrydt2" title="Preferred stock, shares issued"><span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zUSMVUmqDQcd" title="Preferred stock, shares outstanding"><span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zErhI8YQMpV8" title="Preferred stock, shares issued"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zGBUkYqsIaTc" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31_us-gaap_SeriesFPreferredStockMember" id="Fact000218" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_SeriesFPreferredStockMember" id="Fact000220" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31_us-gaap_SeriesFPreferredStockMember" id="Fact000222" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_SeriesFPreferredStockMember" id="Fact000224" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares at both December 31, 2024 and 2023, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0207">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0208">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PreferredStockValue_i02I_pn3n3_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_maSEzzvy_zmJYDi0S5p9d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred
    stock value</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CommonStockValue_i02I_maSEzzvy_zcR8dobFeMZj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Common stock of $<span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241231_zCogYiD8V5me" title="Common stock, par value"><span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231_z0XSjlOBFFf4" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000232" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000234" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value - Authorized: <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231_zy6ehJEpnPS7" title="Common stock, shares authorized"><span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_zcA9FoIo2SG" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000236" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000238" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000,000</ix:nonFraction></ix:nonFraction></span></span> shares at December 31, 2024, and December 31, 2023, respectively; Issued and outstanding: <span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_pid_c20241231_zoC7l3RROSRd" title="Common stock, shares issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231_zXDlcvfjDEb1" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000240" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000242" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">378,941</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_pid_c20231231_zgfAEwQnb4u9" title="Common stock, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231_zd81yBixveTa" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000244" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000246" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">186,028</ix:nonFraction></ix:nonFraction></span></span> shares at December 31, 2024, and December 31, 2023, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31" id="Fact000229" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" id="Fact000230" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AdditionalPaidInCapital_i02I_pn3n3_maSEzzvy_zIrAL6aE0n6e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Additional paid in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-12-31" id="Fact000248" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">70,505</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31" id="Fact000249" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">70,149</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i02I_pn3n3_maSEzzvy_zXPnUfJZ6oC3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accumulated other comprehensive income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2024-12-31" id="Fact000251" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">80</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2023-12-31" id="Fact000252" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">67</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_pn3n3_maSEzzvy_ziGO5cCc0b1h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Accumulated deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000254" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">69,801</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact000255" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">66,096</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--StockholdersEquity_i02TI_pn3n3_mtSEzzvy_maLASEz2Gy_z7I56vm0FoQk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Total stockholders&#8217; equity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000257" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">627</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000258" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,988</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pn3n3_mtLASEz2Gy_zvDzqY4dzOvf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders&#8217; equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000260" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,629</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000261" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,674</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>


<!-- Field: Page; Sequence: 159 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_010"></span>NanoVibronix,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Statements of Operations and Comprehensive Loss</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Amounts
in thousands except share and per share data)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_113_pn3n3_zbXco3L7r4gb" summary="xdx: Statement - Consolidated Statements of Operations and Comprehensive Loss" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20240101__20241231_znM1J2knVNs9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20231231_zyb18OCzy2F2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maGPzYHt_zKpgT2WBWU6k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 64%">Revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-01to2024-12-31" id="Fact000263" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,558</ix:nonFraction> </td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31" id="Fact000264" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,283</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CostOfRevenue_msGPzYHt_zVVVLcUVgSP8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Cost of revenues</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2024-01-01to2024-12-31" id="Fact000266" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,050</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-01-012023-12-31" id="Fact000267" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">746</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--GrossProfit_iT_pn3n3_mtGPzYHt_maOILzb5b_zOBjWRlQQoVj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2024-01-01to2024-12-31" id="Fact000269" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,508</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2023-01-012023-12-31" id="Fact000270" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,537</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingExpensesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpense_i01_pn3n3_maOEzDNX_zTKvN6eR0Er4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000275" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">909</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31" id="Fact000276" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">185</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--SellingAndMarketingExpense_i01_pn3n3_maOEzDNX_zqj3oup8DA68" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Selling and marketing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000278" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">720</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="From2023-01-012023-12-31" id="Fact000279" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">864</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--GeneralAndAdministrativeExpense_i01_pn3n3_maOEzDNX_zj7fwIFNaeE8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000281" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,461</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31" id="Fact000282" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,924</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingExpenses_i01T_pn3n3_msOILzb5b_mtOEzDNX_zoDlMAoC4pE6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-01to2024-12-31" id="Fact000284" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,090</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-012023-12-31" id="Fact000285" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,973</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingIncomeLoss_iT_pn3n3_mtOILzb5b_maILFCOzLFZ_zvRDSr7pQt6l" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000287" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,582</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000288" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,436</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--InterestExpense_iN_di_msILFCOzLFZ_z2tRgdnMe851" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000290" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">135</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-012023-12-31" id="Fact000291" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">135</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_ecustom--FinancialIncomeExpensesNet_maILFCOzLFZ_zLGP7t83wwF8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Financial expense, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="NAOV:FinancialIncomeExpensesNet" contextRef="From2024-01-01to2024-12-31" id="Fact000293" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">31</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="NAOV:FinancialIncomeExpensesNet" contextRef="From2023-01-012023-12-31" id="Fact000294" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">111</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_pn3n3_maNILzeFO_mtILFCOzLFZ_zLOxrSdrHy2d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss before taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-01-01to2024-12-31" id="Fact000296" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,686</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-01-012023-12-31" id="Fact000297" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,682</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iN_pn3n3_di_msNILzeFO_zyaxeN4aDdn5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Income tax expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="Fact000299" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact000300" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_iT_pn3n3_mtNILzeFO_zAtiD2X7iimb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000302" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,705</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000303" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,711</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss available for holders of common stock, Series C Preferred Stock and Series D Preferred Stock</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--EarningsPerShareBasic_pid_c20240101__20241231_zwDH5PtCAPMa" title="Basic net loss available for holders of common stock" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_pid_c20240101__20241231_zSYwjlY2FXYf" title="Diluted net loss available for holders of common stock" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000305" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-01to2024-12-31" id="Fact000307" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">13.73</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231_zF7o9SMXjz6e" title="Basic net loss available for holders of common stock" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_900_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231_zOmdybVfDF2l" title="Diluted net loss available for holders of common stock" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-12-31" id="Fact000309" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-12-31" id="Fact000311" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">23.32</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted average common stock outstanding:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20241231_zkPp0immXIHh" title="Weighted average common stock outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20241231_zn70vHzemGK1" title="Weighted average common stock outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000313" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-01to2024-12-31" id="Fact000315" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">269,848</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20231231_zYqKeh5nMZb8" title="Weighted average common stock outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20231231_zl181HeD9Og" title="Weighted average common stock outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31" id="Fact000317" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31" id="Fact000319" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">159,105</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLossAbstract_iB_z2RD3eYbfrmg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Comprehensive loss:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_i01_pn3n3_maCINOTziN0_z2Dw273GkU82" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Net loss available to common stockholders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000324" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,705</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-01-012023-12-31" id="Fact000325" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,711</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_i01_pn3n3_maCINOTziN0_zRMH1if7Ys5c" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Change in foreign currency translation adjustments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-01-01to2024-12-31" id="Fact000327" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-12-31" id="Fact000328" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">49</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--ComprehensiveIncomeNetOfTax_i01T_pn3n3_mtCINOTziN0_zupXU0QYffYb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Comprehensive loss available to common stockholders</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-01-01to2024-12-31" id="Fact000330" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,718</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-01-012023-12-31" id="Fact000331" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,760</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 160 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_011"></span>NanoVibronix,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Statement of Stockholders&#8217; Equity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_114_pn3n3_zlP9ROj95h5a" summary="xdx: Statement - Consolidated Statement of Stockholders' Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesCPreferredStockMember_zCuMx9h0aXd7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesDPreferredStockMember_z2YH2eCwMF61" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesEPreferredStockMember_zGOGuXNcQgZ1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesFPreferredStockMember_zyF4NqTmHBij" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zu1L0ONB0kXg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zShuww8aIfaa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zUoApoLOfOv8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Income</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zcCTBoFvg1H2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BA_zkHtUViWBKzl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Series C</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Preferred Stock</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Series D</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Preferred Stock</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Series E</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Preferred Stock</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Series
F<br/>Preferred Stock</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Additional Paid - in</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Accumulated Other Comprehensive</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Total Stockholders&#8217;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Income</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_434_c20230101__20231231_eus-gaap--StockholdersEquity_iS_pn3n3_zXk1vzUDrjf4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%">Balance, December 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zpeT7x2WOcMl" title="Balance, shares" style="width: 1%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0343">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 1%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0333">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zmV5qN1MXZp9" title="Balance, shares" style="width: 1%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0345">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 1%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0334">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zlCDbMPRx6j7" title="Balance, shares" style="width: 1%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0347">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 1%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0335">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zwffQT2yiTLb" title="Balance, shares" style="width: 1%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0349">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 1%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0336">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOb1QA3INNl4" title="Balance, shares" style="width: 1%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000351" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">149,195</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 1%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000337" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 1%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000338" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">65,634</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 1%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000339" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">18</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 1%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000340" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">62,385</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 1%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000341" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,233</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_pn3n3_zrxnIQ2ESixf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0353">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0354">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0355">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0356">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0357">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000358" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">293</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0359">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0360">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-12-31" id="Fact000361" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">293</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_pn3n3_zksEUhdMEr8i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Currency translation adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0363">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0364">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0365">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0366">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0367">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0368">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000369" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">49</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0370">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-12-31" id="Fact000371" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">49</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_pn3n3_zMpcT7zmCXsi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercise of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0373">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0374">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0375">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0376">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoQFtYZo8Oec" title="Exercise of pre-funded warrants, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000383" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">496</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0377">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000378" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0379">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0380">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-12-31" id="Fact000381" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--StockIssuedDuringPeriodValuePrefundedWarrantsExercised_pn3n3_zKuFNE9VWn1a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercise of pre-funded warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0385">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0386">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0387">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0388">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--StockIssuedDuringPeriodSharesPrefundedWarrantsExercised_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMvHRPe1VgIl" title="Exercise of pre-funded warrants, shares" style="text-align: right"><ix:nonFraction name="NAOV:StockIssuedDuringPeriodSharesPrefundedWarrantsExercised" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000395" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,543</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0389">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0390">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0391">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0392">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0393">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_zI2XuuSI2G65" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Issuance of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0397">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0398">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0399">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0400">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zG2vAA3fIKg" title="Issuance of Common stock, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000407" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,364</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0401">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000402" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,215</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0403">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0404">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31" id="Fact000405" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,215</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--StockIssuedDuringPeriodValuesReverseStockSplits_pn3n3_z0N1NAM5Gsul" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Rounding up of fractional shares duer to reverse stock split</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0409">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0410">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0411">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0412">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoPumlaRrqri" title="Rounding-up of fractional shares due to reverse stock split, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000419" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,430</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0413">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0414">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0415">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0416">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0417">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_pn3n3_zRm9OAORBMzk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0421">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0422">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0423">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0424">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0425">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0426">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0427">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="Fact000428" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,711</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000429" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,711</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43B_c20240101__20241231_eus-gaap--StockholdersEquity_iS_pn3n3_zmNMdqnw2dNj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Balance, December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_ziUVHYeAG8rl" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0441">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0431">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zjMnwHQLO5Vb" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0443">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0432">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zijhMthhluSg" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0445">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0433">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zG4m9FkuAMGl" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0447">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0434">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNv6I15VcmHi" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000449" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">186,028</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000435" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000436" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">70,149</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000437" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">67</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000438" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">66,096</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000439" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,988</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43C_c20240101__20241231_eus-gaap--StockholdersEquity_iS_pn3n3_zeMB1NpzXBCd" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zRCOlJD87We3" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0461">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0451">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zVJpd70khqIa" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0463">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0452">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zxCiyq2girE7" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0465">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0453">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zm8yAaG5ANQ5" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0467">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0454">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKR2TWCwyYB4" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000469" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">186,028</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000455" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000456" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">70,149</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000457" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">67</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000458" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">66,096</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000459" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,988</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_pn3n3_zm4fHGnCBwh7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0471">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0472">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0473">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0474">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0475">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000476" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">356</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0477">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0478">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-01to2024-12-31" id="Fact000479" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">356</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_pn3n3_zQo32LaXVqvl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Currency translation adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0481">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0482">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0483">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0484">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0485">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0486">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000487" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0488">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-01-01to2024-12-31" id="Fact000489" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--StockIssuedDuringPeriodValuePrefundedWarrantsExercised_pn3n3_z4BrT6UYXYHk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercise of pre-funded warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0491">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0492">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0493">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0494">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--StockIssuedDuringPeriodSharesPrefundedWarrantsExercised_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqWsnhgKzeYj" title="Exercise of pre-funded warrants, shares" style="text-align: right"><ix:nonFraction name="NAOV:StockIssuedDuringPeriodSharesPrefundedWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000501" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">125,818</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000495" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0496">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0497">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0498">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised" contextRef="From2024-01-01to2024-12-31" id="Fact000499" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_zoPuq6wkdIBf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Issuance of common stock upon exercise of pre-funded warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0503">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0504">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0505">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0506">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znlUqJ2hyZxk" title="Issuance of common stock upon exercise of pre-funded warrants, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000513" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">67,091</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0507">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0508">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0509">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0510">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0511">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--StockIssuedDuringPeriodValuesReverseStockSplits_pn3n3_zwOqPw9LHJl2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Rounding-up of fractional shares due to reverse stock split</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0515">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0516">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0517">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0518">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcM9uQUwHER6" title="Rounding-up of fractional shares due to reverse stock split, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000525" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0519">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0520">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0521">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0522">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0523">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLoss_pn3n3_znZac9CNGqth" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0527">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0528">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0529">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0530">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0531">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0532">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0533">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="Fact000534" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,705</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000535" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,705</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_431_c20240101__20241231_eus-gaap--StockholdersEquity_iE_pn3n3_zRKEjEumXUHg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Balance, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zywYqG2TOtmg" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0547">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0537">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zYWMv1MbeZOb" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0549">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0538">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zPU4kwC8PSx7" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0551">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0539">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zWzcKDpZDOPc" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0553">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0540">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKSqOhuoFx1f" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000555" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">378,941</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000541" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000542" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">70,505</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000543" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">80</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000544" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">69,801</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000545" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">627</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_437_c20240101__20241231_eus-gaap--StockholdersEquity_iE_pn3n3_zsmJfoLS63Rk" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zZPsg6Xucfxg" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0567">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0557">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zCrvx2TLvXf6" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0569">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0558">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zXFQ11ZXtGx9" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0571">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0559">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zN9cGchH9MAc" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0573">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0560">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgCktG7qCrG4" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000575" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">378,941</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000561" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000562" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">70,505</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000563" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">80</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000564" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">69,801</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000565" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">627</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 161 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_012"></span>NanoVibronix,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Statements of Cash Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Amounts
in thousands except share and per share data)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_112_zJEo30u3F1Nh" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240101__20241231_zas4Fi8kYp47" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231_zZfQTbbva5C9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash flows from operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_i01_pn3n3_maNCPBUz3YD_zMOlN4iQ7xHh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000580" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,705</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000581" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,711</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DepreciationDepletionAndAmortization_i02_pn3n3_maNCPBUz3YD_zHYVzVpdwDs1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2024-01-01to2024-12-31" id="Fact000586" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2023-01-012023-12-31" id="Fact000587" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ShareBasedCompensation_i02_pn3n3_maNCPBUz3YD_z4w8yHsqswhg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-01to2024-12-31" id="Fact000589" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">356</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31" id="Fact000590" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">293</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--NoncashInterestExpense_i02_pn3n3_maNCPBUz3YD_z7RzdB1DO94h" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Noncash interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NAOV:NoncashInterestExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000592" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NAOV:NoncashInterestExpense" contextRef="From2023-01-012023-12-31" id="Fact000593" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">135</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--EquitySecuritiesFvNiGainLoss_i02N_pn3n3_di_msNCPBUz3YD_z80TcIINscVf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Change in fair value of equity investment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0595">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="From2023-01-012023-12-31" id="Fact000596" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--GainLossOnSaleOfInvestments_i02N_pn3n3_di_msNCPBUz3YD_zCE8ue3vEaI7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Gain/Loss on termination of investment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnSaleOfInvestments" contextRef="From2024-01-01to2024-12-31" id="Fact000598" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0599">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_ziKdoMadDnzk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInAccountsReceivable_i02N_pn3n3_di_msNCPBUz3YD_zdk5v66zkPo4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Trade receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2024-01-01to2024-12-31" id="Fact000604" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">221</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2023-01-012023-12-31" id="Fact000605" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">309</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i02N_pn3n3_di_msNCPBUz3YD_z8af9qqBrRJg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Other accounts receivable and prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2024-01-01to2024-12-31" id="Fact000607" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">136</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-01-012023-12-31" id="Fact000608" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">558</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInInventories_i02N_pn3n3_di_msNCPBUz3YD_zifgqzWWujRd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2024-01-01to2024-12-31" id="Fact000610" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">541</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2023-01-012023-12-31" id="Fact000611" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">557</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInAccountsPayableTrade_i02_pn3n3_maNCPBUz3YD_zECv3vchnsh9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Trade payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="From2024-01-01to2024-12-31" id="Fact000613" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">91</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="From2023-01-012023-12-31" id="Fact000614" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">72</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_i02_pn3n3_maNCPBUz3YD_zvedKfV3KPp1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Other accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2024-01-01to2024-12-31" id="Fact000616" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">242</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2023-01-012023-12-31" id="Fact000617" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">18</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInDeferredRevenue_i02_pn3n3_maNCPBUz3YD_zeH46ka6YMEc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Deferred revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="From2024-01-01to2024-12-31" id="Fact000619" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">46</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="From2023-01-012023-12-31" id="Fact000620" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">67</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_ecustom--IncreaseDecreaseInAccruedSeverancePayNet_i02_pn3n3_maNCPBUz3YD_zpL7oAluiHZ7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Accrued severance pay, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl0622">-</span></p></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="NAOV:IncreaseDecreaseInAccruedSeverancePayNet" contextRef="From2023-01-012023-12-31" id="Fact000623" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_pn3n3_mtNCPBUz3YD_maCCERCzxOh_zCZ2SQbnu6rk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 1pt">Net cash used in operating activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000625" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,516</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-12-31" id="Fact000626" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,602</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash flows from investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_pn3n3_di_msNCPBUzaX9_zAMB86egTF3c" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Purchases of fixed assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2024-01-01to2024-12-31" id="Fact000631" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-01-012023-12-31" id="Fact000632" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_pn3n3_mtNCPBUzaX9_maCCERCzxOh_zJP45H9NLgd9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 1pt">Net cash used in investing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000634" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-012023-12-31" id="Fact000635" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_pn3n3_maNCPBUzYp0_znGWEB80FQGh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from sale of common stock, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0640">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-012023-12-31" id="Fact000641" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,215</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ProceedsFromStockOptionsExercised_i01_pn3n3_maNCPBUzYp0_zIWANDy1rbI8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Proceeds from exercise of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0643">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2023-01-012023-12-31" id="Fact000644" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ProceedsFromWarrantExercises_i01_pn3n3_maNCPBUzYp0_zYAkDBZkk0od" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Proceeds from exercise of prefunded warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-01-01to2024-12-31" id="Fact000646" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0647">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_pn3n3_mtNCPBUzYp0_maCCERCzxOh_zC21q6lPW799" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Net cash provided by financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000649" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-012023-12-31" id="Fact000650" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,222</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_pn3n3_maCCERCzxOh_zhNzMDTChqPa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Effects of currency translation on cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2024-01-01to2024-12-31" id="Fact000652" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2023-01-012023-12-31" id="Fact000653" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">49</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_pn3n3_mtCCERCzxOh_zbNr6OwNY4lc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Net (decrease) increase in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-01-01to2024-12-31" id="Fact000655" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,531</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-012023-12-31" id="Fact000656" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">570</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_pn3n3_z7apPB96iBTh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Cash at beginning of period</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-12-31" id="Fact000658" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,283</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-12-31" id="Fact000659" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,713</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_pn3n3_zzTph9luB0cc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Cash at end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-12-31" id="Fact000661" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">752</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-12-31" id="Fact000662" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,283</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 162 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_013"></span>NANOVIBRONIX,
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Amounts
in thousands except share and per share data)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000664" name="us-gaap:NatureOfOperations"><p id="xdx_80E_eus-gaap--NatureOfOperations_zTx9bxAIKo13" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1 - <span id="xdx_820_z5pEQZQsxCYb">DESCRIPTION OF BUSINESS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NanoVibronix,
Inc. (the &#8220;Company&#8221;), a Delaware corporation, commenced operations on October 20, 2003, and is a medical device company focusing
on non-invasive biological response-activating devices that target wound healing and pain therapy and can be administered at home, without
the assistance of medical professionals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s principal research and development activities are conducted in Israel through its wholly-owned subsidiary, NanoVibronix
Ltd., a company registered in Israel, which commenced operations in October 2003.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000666" name="NAOV:GoingConcernAndLiquidityTextBlock"><p id="xdx_80D_ecustom--GoingConcernAndLiquidityTextBlock_zPQQYVT6MEF8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 - <span id="xdx_829_zFVxoQP33I76">LIQUIDITY AND PLAN OF OPERATIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s ability to continue to operate is dependent mainly on its ability to successfully market and sell its products and the
receipt of additional financing until profitability is achieved. In 2024, the Company&#8217;s cash used in operations was $<span id="xdx_90C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20240101__20241231_zN6VgXKoB8ie" title="Net cash used in operating activities"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000668" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,516,000</ix:nonFraction></span>,
cash used in investing activities of $<span id="xdx_90B_eus-gaap--NetCashProvidedByUsedInInvestingActivities_c20240101__20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember_zcmKbZF9ZB8a" title="Investing activities"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-012024-12-31_us-gaap_PropertyPlantAndEquipmentMember" id="Fact000670" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000</ix:nonFraction></span> from the purchase of property plant and equipment, and received net proceeds of $<span id="xdx_907_ecustom--StockIssuedDuringPeriodValuePrefundedWarrantsExercised_c20240101__20241231_zeNBBZoFTwwe" title="Exercise of prefunded warrants"><ix:nonFraction name="NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised" contextRef="From2024-01-01to2024-12-31" id="Fact000672" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span> from
the exercise of prefunded warrants, leaving a cash balance of $<span id="xdx_903_eus-gaap--Cash_iI_c20241231__us-gaap--CollateralAxis__custom--SaleOfEquitySecuritiesMember_zXlDHlM32Ue1" title="Cash balance"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2024-12-31_custom_SaleOfEquitySecuritiesMember" id="Fact000674" format="ixt:numdotdecimal" decimals="0" unitRef="USD">752,000</ix:nonFraction></span> as of December 31, 2024. Because the Company does not have sufficient
resources to fund our operation for the next twelve months from the date of this filing, management has substantial doubt of the Company&#8217;s
ability to continue as a going concern. The Company will need to raise additional capital to finance its losses and negative cash flows
from operations and may continue to be dependent on additional capital raising as long as our products do not reach commercial profitability.</span></p>
<!-- Field: Split-Segment; Name: 001 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000676" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_806_eus-gaap--SignificantAccountingPoliciesTextBlock_zlUptZkB4Kwc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 - <span id="xdx_820_zLLj3krqIkTb">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000678" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_844_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z70ns3JxFLLc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Basis
of presentation and principles of consolidation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements include the accounts of NanoVibronix, Inc. and its wholly owned subsidiary. Intercompany
accounts and transactions have been eliminated. The consolidated financial statements and accompanying notes have been prepared in conformity
with U.S. generally accepted accounting principles (&#8220;US GAAP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000680" name="us-gaap:UseOfEstimates"><p id="xdx_84C_eus-gaap--UseOfEstimates_zMfdFD4yoxyb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Use
of estimates</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and
assumptions. The Company believes that the estimates, judgments and assumptions used are reasonable based upon information available
at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during
the reporting period. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 163 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000682" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p id="xdx_844_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zoYspOsZUoif" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Foreign
currency translation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-U.S.
dollar denominated transactions and balances have been re-measured to U.S. dollars. All gains and losses from re-measurement of monetary
balance sheet items denominated in non-U.S. dollar currencies are reflected in the statements of operations as other comprehensive income,
as appropriate. The cumulative translation losses and gains as of the years ended December 31, 2024, and 2023 were $<span id="xdx_90F_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_c20240101__20241231_zaXYHL6baVDi" title="Cumulative translation gains"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" contextRef="From2024-01-01to2024-12-31" id="Fact000684" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,000</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_c20230101__20231231_zv9MMW0ey4gf" title="Cumulative translation gains"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" contextRef="From2023-01-012023-12-31" id="Fact000686" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,000</ix:nonFraction></span>,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000688" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zESQdMF0jdxf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company holds cash in various banking institutions. Such funds are insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;)
up to $<span id="xdx_903_eus-gaap--CashFDICInsuredAmount_iI_c20241231_zNRbqRvwhYCc" title="Cash FDIC, insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2024-12-31" id="Fact000690" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>. Cash balances could exceed insured amounts at any given time. As of December 31, 2024, the company had cash in excess
of the FDIC insured amount totaling $<span id="xdx_90C_eus-gaap--TimeDepositsAtOrAboveFDICInsuranceLimit_iI_c20241231_zD2ktgj1NVY" title="Cash uninsured amount"><ix:nonFraction name="us-gaap:TimeDepositsAtOrAboveFDICInsuranceLimit" contextRef="AsOf2024-12-31" id="Fact000692" format="ixt:numdotdecimal" decimals="0" unitRef="USD">306,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000694" name="us-gaap:TradeAndOtherAccountsReceivablePolicy"><p id="xdx_847_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zQ4tFYMG8Xkh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Trade
receivables</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s trade receivable balance consists of amounts due from its customers. The Current Expected Credit Losses (&#8220;CECL&#8221;)
impairment model requires an estimate of expected credit losses, measured over the contractual life of an instrument, which considers
forecasts of future economic conditions in addition to information about past events and current conditions. Based on this model, the
Company considers many factors, including the age of the balance, collection history, and current economic trends. Credit losses are
written off after all collection efforts have ceased. Allowances for credit losses are recorded as a direct reduction from an asset&#8217;s
amortized cost basis. Credit losses and recoveries are recorded in selling, general and administrative expenses in the consolidated statements
of operations. Recoveries of financial assets previously written off are recorded when received. Trades receivables were $<span id="xdx_90F_eus-gaap--AccountsReceivableNet_iI_c20241231_zX8gOLg56R27" title="Trades receivables"><ix:nonFraction name="us-gaap:AccountsReceivableNet" contextRef="AsOf2024-12-31" id="Fact000696" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,000</ix:nonFraction></span> as of
December 31, 2024, and are not anticipated to possess substantial credit risk or expected credit losses. The Company&#8217;s current
policy is to not charge late fees or other penalties for late payments but may consider charging customers late fees in the future. Historically,
the Company has not had significant write offs of trade receivables. All sales are non-refundable. As of December 31, 2024, the Company
evaluated historical collections from vendors and collection policies and has estimated that current expected credit losses ( &#8220;CECL&#8221;)
to be $<span id="xdx_902_ecustom--ChangeInCurrentExpectedCreditLosses_pn3n3_c20240101__20241231_z9hUkZcKjFXh" title="Change in current expected credit losses"><ix:nonFraction name="NAOV:ChangeInCurrentExpectedCreditLosses" contextRef="From2024-01-01to2024-12-31" id="Fact000698" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000700" name="us-gaap:AdvertisingCostsPolicyTextBlock"><p id="xdx_84C_eus-gaap--AdvertisingCostsPolicyTextBlock_zXjraNwAjkrd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Advertising
and Marketing Costs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
associated with advertising are charged to expenses as incurred. For the year ended December 31, 2024, and 2023, the advertising and
marketing costs were $<span id="xdx_90E_eus-gaap--MarketingAndAdvertisingExpense_c20240101__20241231_ziUXw2ls3O3e" title="Advertising and marketing costs"><ix:nonFraction name="us-gaap:MarketingAndAdvertisingExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000702" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,000</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--MarketingAndAdvertisingExpense_c20230101__20231231_z6ebkWgsalOl" title="Advertising and marketing costs"><ix:nonFraction name="us-gaap:MarketingAndAdvertisingExpense" contextRef="From2023-01-012023-12-31" id="Fact000704" format="ixt:numdotdecimal" decimals="0" unitRef="USD">106,000</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000706" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zrzJQIvOlaeb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Earnings
per share</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
loss per share was computed using the weighted average number of common shares outstanding. Diluted loss per share includes the effect
of diluted common stock equivalents. Potentially dilutive securities from the exercise of stock option, warrants and exercise of preferred
stock as of December 31, 2024, and 2023, respectively, were excluded from the computation of diluted net loss per share because the effect
of their inclusion would have been antidilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000708" name="us-gaap:InventoryPolicyTextBlock"><p id="xdx_84A_eus-gaap--InventoryPolicyTextBlock_zVV543rKQYS9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Inventory</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
are stated at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course
of business, less reasonably predictable costs of completion, disposal, and transportation. Cost is determined using the &#8220;first-in,
first-out&#8221; method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
write-offs are provided to cover risks arising from slow-moving items or technological obsolescence. The Company periodically evaluates
the quantities on hand relative to current and historical selling prices and historical and projected sales volume. Based on this evaluation,
provisions are made when required to write-down inventory to its net market value. As of December 31, 2024, and 2023, there was <span id="xdx_90F_eus-gaap--InventoryAdjustments_iI_pn3n3_do_c20241231_zsWGdZVnBec4" title="Inventory allowance"><span id="xdx_902_eus-gaap--InventoryAdjustments_iI_pn3n3_do_c20231231_ztRrGcIKb95l" title="Inventory allowance"><ix:nonFraction name="us-gaap:InventoryAdjustments" contextRef="AsOf2024-12-31" id="Fact000710" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:InventoryAdjustments" contextRef="AsOf2023-12-31" id="Fact000712" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> allowance
on inventory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000714" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z8lUfCkwaB9c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Property
and equipment, net</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000716" name="NAOV:ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock"><p id="xdx_891_ecustom--ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock_zKKjFz17QRPb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the
estimated useful lives of the assets, at the following annual rates:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zLTUCzBGvf0b" style="display: none">SCHEDULE OF DEPRECIATION CALCULATED OVER ESTIMATED USEFUL LIVES OF ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">Years</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: justify">Computers and peripheral equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 16%; text-align: center"><span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zS8qn4YwxKkh" title="Estimated useful life"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_ComputerEquipmentMember" format="ixt-sec:duryear" id="Fact000718" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_z6mGGsDo1sLl" title="Estimated useful life"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_OfficeEquipmentMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000720" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span>-<span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zOxEAVxNuY0a" title="Estimated useful life"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_OfficeEquipmentMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000722" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">7</ix:nonNumeric></span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zmUz89Ndvjld" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 164 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000724" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_845_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zxgc8zi6ZLpi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Impairment
of Long-Lived Assets</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
reviews for impairment whenever events or changes in circumstances indicate that the carrying amount of property and equipment may not
be recoverable under the provisions of accounting for the impairment of long-lived assets. If it is determined that an impairment loss
has occurred based upon expected future cash flows, the loss is recognized in the Consolidated Statements of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000726" name="NAOV:SequencingPolicyTextBlock"><p id="xdx_84A_ecustom--SequencingPolicyTextBlock_zDvDjlG4oCrk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sequencing</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adopted a sequencing policy under ASC 815-40-35 whereby if reclassification of contracts from equity to liabilities is necessary
pursuant to ASC 815 due to the Company&#8217;s inability to demonstrate it has sufficient authorized shares. This was due to the Company
committing more shares than authorized. While temporary suspensions are in place to keep the potential exercises beneath the number authorized,
certain instruments are classified as liabilities, after allocating available authorized shares on the basis of the most recent grant
date of potentially dilutive instruments. Pursuant to ASC 815, issuances of securities granted as compensation in a share-based payment
arrangement are not subject to the sequencing policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000728" name="NAOV:SeverancePayPolicyTextBlock"><p id="xdx_840_ecustom--SeverancePayPolicyTextBlock_zeWMWwzAPh0j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Severance
pay</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s liability for severance pay is for its Israeli employees and is calculated pursuant to Israeli Severance Pay Law based
on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date and is in large
part covered by regular deposits with recognized pension funds, deposits with severance pay funds and purchases of insurance policies.
The value of these deposits and policies is recorded as an asset in the Company&#8217;s balance sheet. Accrued severance pay liability
on December 31, 2024, and 2023 was $<span id="xdx_906_ecustom--AccruedSeverancePayLiability_c20240101__20241231_zj57yXkQgAKl" title="Accrued severance pay liability"><ix:nonFraction name="NAOV:AccruedSeverancePayLiability" contextRef="From2024-01-01to2024-12-31" id="Fact000730" format="ixt:numdotdecimal" decimals="0" unitRef="USD">216,000</ix:nonFraction></span> and $<span id="xdx_90F_ecustom--AccruedSeverancePayLiability_c20230101__20231231_zuAPMFAUtJSi" title="Accrued severance pay liability"><ix:nonFraction name="NAOV:AccruedSeverancePayLiability" contextRef="From2023-01-012023-12-31" id="Fact000732" format="ixt:numdotdecimal" decimals="0" unitRef="USD">217,000</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000734" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_849_eus-gaap--LesseeLeasesPolicyTextBlock_z9a2mVAhxFN6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Leases</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for its leases in accordance with ASU 2016-02, &#8220;Leases&#8221; (Topic 842). This topic requires that a lessee recognize
the assets and liabilities that arise from operating leases. The Company recognizes right-of-use assets and lease liabilities on the
consolidated balance sheet for all leases with a term longer than 12 months and classifies them as operating leases. For leases with
a term of 12 months or less, the Company elects not to recognize lease assets and lease liabilities on those leases. The right-of-use
assets and lease liabilities have been measured by the present value of the Company&#8217;s remaining lease payments over the lease term
using our incremental borrowing rates or implicit rates, when readily determinable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000736" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock"><p id="xdx_848_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z7i2eOV0280i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue
recognition</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is the Company&#8217;s policy that revenues from product sales is recognized in accordance with ASC 606 &#8220;Revenue Recognition.&#8221;
Five basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that create(s) enforceable
rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services
to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects to
be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to the performance
obligations in the contract, which requires the company to allocate the transaction price to each performance obligation on the basis
of the relative standalone selling prices of each distinct good or services promised in the contract; and (5) Recognizing revenue when
(or as) the entity satisfies a performance obligation by transferring a promised good or service to a customer. The amount of revenue
recognized is the amount allocated to the satisfied performance obligation. Adoption of ASC 606 has not changed the timing and nature
of the Company&#8217;s revenue recognition and there has been no material effect on the Company&#8217;s financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 165 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from product sales is recorded at the net sales price, or &#8220;transaction price,&#8221; which includes estimates of variable consideration
that result from coupons, discounts, chargebacks and distributor fees, processing fees, as well as allowances for returns and government
rebates. The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue.
Collectability of revenue is reasonably assured based on historical evidence of collectability between the Company and its customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues
from sales to distributors are recognized at the time the products are delivered to the distributors (sell-in&#8221;). The Company does
not grant rights of return, credits, rebates, price protection, or other privileges on its products to distributors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000738" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_841_eus-gaap--IncomeTaxPolicyTextBlock_zlDPYCgQDXTe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Income
taxes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes in accordance with ASC 740, &#8220;Income Taxes&#8221;. This topic prescribes the use of the liability
method whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and
tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences
are expected to reverse. The Company provides full valuation allowance, to reduce deferred tax assets to the amount that is more likely
than not to be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company implements a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position
taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than
not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related
appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% (cumulative
basis) likely to be realized upon ultimate settlement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes interest and penalties related to uncertain tax positions on the income tax expense line in the accompanying consolidated
statement of operations. Accrued interest and penalties are included on the related tax liability line in the consolidated balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000740" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_84B_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zjOYKe1VDQC5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock-based
compensation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company selected the Black-Scholes-Merton option pricing model as the most appropriate fair value method for its stock-options awards.
The option-pricing model requires a number of assumptions, of which the most significant are the expected stock price volatility and
the expected option term. Expected volatility was calculated based upon similar traded companies&#8217; historical share price movements.
The expected option term represents the period that the Company&#8217;s stock options are expected to be outstanding. The Company currently
uses the simplified method and will continue to do so until sufficient historical exercise data supports using expected life assumptions.
The risk-free interest rate is based on the yield from U.S. Treasury zero-coupon bonds with an equivalent term. The expected dividend
yield assumption is based on the Company&#8217;s historical experience and expectation of no future dividend payouts. The Company has
historically not paid cash dividends and has no foreseeable plans to pay cash dividends in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000742" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z88NbAq5McIl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recently
adopted accounting standards</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13,
Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU 2016-13&#8221;)
and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, and ASU 2019-05 (collectively, &#8220;Topic
326&#8221;). Topic 326 requires measurement and recognition of expected credit losses for financial assets held. This ASU is effective
for interim and annual reporting periods beginning after December 15, 2022. The adoption of Topic 326 did not have a material effect
on the Company&#8217;s consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU No. 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>,
which requires an enhanced disclosure of significant segment expenses on an annual and interim basis. This guidance is effective for
annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption
is permitted. Upon adoption, the guidance should be applied retrospectively to all prior periods presented in the financial statements.
The adoption of Topic 280 did not have a material effect on the Company&#8217;s consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 166 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000744" name="us-gaap:OtherCurrentAssetsTextBlock"><p id="xdx_803_eus-gaap--OtherCurrentAssetsTextBlock_zC5HbPdO39vb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 - <span id="xdx_826_zyZ4hS3pijp8">PREPAID EXPENSES AND OTHER RECEIVABLES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000746" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"><p id="xdx_896_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zptYOgclK78a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses and other receivables consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_zIXtbmqLeCtf" style="display: none">SCHEDULE OF PREPAID EXPENSES AND OTHER RECEIVABLES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20241231_zNLVgVZZ6E8a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231_z6k4SgKwxMZg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PrepaidExpenseCurrent_iI_maPEAOAzR3N_zxd7TlgMEOJ7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Prepaid expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2024-12-31" id="Fact000748" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2023-12-31" id="Fact000749" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OtherAssetsCurrent_iI_maPEAOAzR3N_zFVKeo5BdjT2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Other receivables</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000751" format="ixt:numdotdecimal" decimals="0" unitRef="USD">170,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000752" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0d_mtPEAOAzR3N_zoxd9gzr2YC7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
    expenses and other receivables</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000754" format="ixt:numdotdecimal" decimals="0" unitRef="USD">290,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000755" format="ixt:numdotdecimal" decimals="0" unitRef="USD">154,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zm1OEeRg9xqh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000757" name="us-gaap:InventoryDisclosureTextBlock"><p id="xdx_80F_eus-gaap--InventoryDisclosureTextBlock_zWntBGAb5Qqk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5 &#8211; <span id="xdx_82A_zKgpE98lZTyj">INVENTORY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000759" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_z0ex8gZoucm8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
consists of the following components:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_z46b0dEx4fHa" style="display: none">SCHEDULE OF INVENTORY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20241231_zr49nADZJxh5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20231231_zaUoLdjiqAOa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--InventoryRawMaterials_iI_maINzmOi_zn52XfWNYKck" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Raw materials</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:InventoryRawMaterials" contextRef="AsOf2024-12-31" id="Fact000761" format="ixt:numdotdecimal" decimals="0" unitRef="USD">391,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:InventoryRawMaterials" contextRef="AsOf2023-12-31" id="Fact000762" format="ixt:numdotdecimal" decimals="0" unitRef="USD">210,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--InventoryFinishedGoods_iI_maINzmOi_zYks0Oxizgg4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2024-12-31" id="Fact000764" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,800,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2023-12-31" id="Fact000765" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,522,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--InventoryNet_iTI_pp0d_mtINzmOi_zjlTFRf5YeG3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2024-12-31" id="Fact000767" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,191,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2023-12-31" id="Fact000768" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,732,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_z6Ou2Ja9nDvl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000770" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zA1Lncml5pM9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6 - <span id="xdx_82F_zIPtKFwfplM4">STOCKHOLDERS&#8217; EQUITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Common
Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
common stock confers upon the holders the right to receive notice to participate and vote in general meetings of the Company, and the
right to receive dividends, if declared, and to participate in the distribution of the surplus assets and funds of the Company in the
event of liquidation, dissolution or winding up of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Reverse
stock splits</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 8, 2023, the Company effected a reverse stock split of its common stock at a ratio of 1 post-split share for every 20 pre-split
shares. The Company&#8217;s common stock begin trading on a split-adjusted basis when the market opened on February 9, 2023 (the &#8220;2023
Reverse Stock Split&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the effective time of the 2023 Reverse Stock Split, every 20 shares of the Company&#8217;s issued and outstanding common stock were converted
automatically into one issued and outstanding share of common stock without any change in the par value per share. Stockholders holding
shares through a brokerage account had their shares automatically adjusted to reflect the 2023 Reverse Stock Split. The 2023 Reverse
Stock Split affected all stockholders uniformly and did not alter any stockholder&#8217;s percentage interest in the Company&#8217;s
equity, except to the extent that the 2023 Reverse Stock Split resulted in a stockholder owning a fractional share. Any fractional share
of a stockholder resulting from the 2023 Reverse Stock Split was rounded up to the nearest whole number of shares. Proportional adjustments
were made to the number of shares of the Company&#8217;s common stock issuable upon exercise or conversion of the Company&#8217;s equity
awards, warrants and other convertible securities, as well as the applicable exercise or conversion price thereof. On February 16, 2023,
the Company rounded up fractional shares to its nearest whole number of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_c20230215__20230216_zKoKKPdwdVF1" title="Fractional shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" contextRef="From2023-02-152023-02-16" id="Fact000772" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,726</ix:nonFraction></span> shares. On March 31, 2024, the Company rounded up fractional
shares to its nearest whole number of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_c20240331__20240331_zHQg1LpGzjz" title="Fractional shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" contextRef="From2024-03-312024-03-31" id="Fact000774" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">47</ix:nonFraction></span> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 167 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 13, 2025, the Company effected a <span id="xdx_90A_eus-gaap--StockholdersEquityReverseStockSplit_c20250313__20250313_zyss9homDVh1" title="Reverse stock split"><ix:nonNumeric contextRef="From2025-03-132025-03-13" id="Fact000776" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-11 reverse stock split</ix:nonNumeric></span> (the &#8220;2025 Reverse Stock Split&#8221; and together with the
2023 Reverse Stock Split, the &#8220;Reverse Stock Splits&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the 2025 Reverse Stock Split, every 11 shares of issued and outstanding common stock was automatically combined into one
issued and outstanding share of common stock, without any change in the par value per share. No fractional shares were issued as a result
of the 2025 Reverse Stock Split. Any fractional shares that would otherwise have resulted from the Reverse Stock Split was rounded up
to the next whole number. The 2025 Reverse Stock Split reduced the number of shares of common stock outstanding from <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_pid_c20250312__20250312_zDgEBSjuatL2" title="Reverse stock split outstanding shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" contextRef="From2025-03-122025-03-12" id="Fact000778" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,716,327</ix:nonFraction></span> shares
to approximately <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_pid_c20250313__20250313_zfQ2Z0V5GHm7" title="Reverse stock split outstanding shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" contextRef="From2025-03-132025-03-13" id="Fact000780" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">792,394</ix:nonFraction></span> shares, subject to adjustment for the rounding up of fractional shares. The number of authorized shares of common
stock under the Company&#8217;s Amended and Restated Certificate of Incorporation, as amended remained unchanged at <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20250313_zYsbyDuNJqOj" title="Common stock shares remained unchanged"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-03-13" id="Fact000782" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000,000</ix:nonFraction></span> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
references in this Annual Report to the number of shares, price per share and weighted average number of shares of common stock outstanding
prior to the Reverse Stock Splits have been adjusted to reflect the Reverse Stock Splits on a retroactive basis, unless otherwise noted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Issuance
of common stock for cash</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Issuance
of common stock for cash through private placement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 30, 2023, the Company entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with an institutional
investor for the issuance and sale in a private placement (the &#8220;Private Placement&#8221;) of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230830__20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEUR0LxvsObg" title="Number of new share issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-08-302023-08-30_custom_PurchaseAgreementMember_us-gaap_CommonStockMember" id="Fact000784" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,363</ix:nonFraction></span> shares (the &#8220;Common Shares&#8221;)
of common stock, par value $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7JmHls8voi1" title="Common stock par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_us-gaap_CommonStockMember" id="Fact000786" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share (the &#8220;Common Stock&#8221;), pre-funded warrants (&#8220;Pre-Funded Warrants&#8221;)
to purchase up to <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zJhr7fZjtWfd" title="Number of securities called by warrants or rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_PreFundedWarrantsMember" id="Fact000788" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">247,907</ix:nonFraction></span> shares of common stock, with an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zFaM3bsJK8Va" title="Warrant exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_PreFundedWarrantsMember" id="Fact000790" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share, A-1 Warrants (the &#8220;A-1 Warrants&#8221;)
to purchase up to <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_zjCwBWkH5kl8" title="Number of securities called by warrants or rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_A1WarrantsMember" id="Fact000792" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">264,271</ix:nonFraction></span> shares of Common Stock, with an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_ztxwQp0ex1l1" title="Class of warrant or right exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_A1WarrantsMember" id="Fact000794" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">16.17</ix:nonFraction></span> per share, and A-2 Warrants (the &#8220;A-2 Warrants&#8221;
and together with the A-1 Warrants, the &#8220;Warrants<b><i>&#8221;</i></b> ) to purchase up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zwmVJDq06Uhb" title="Number of securities called by warrants or rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_A2WarrantsMember" id="Fact000796" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">264,270</ix:nonFraction></span> shares of Common Stock with
an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_z7A1CiwEHWR4" title="Class of warrant or right exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_A2WarrantsMember" id="Fact000798" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">16.17</ix:nonFraction></span> per share. The A-1 Warrants are exercisable immediately upon issuance and expire <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_zkjZ3XkNmCL3" title="Warrant expiration date"><ix:nonNumeric contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_A1WarrantsMember" format="ixt:datemonthdayyearen" id="Fact000800" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">March 1, 2029</ix:nonNumeric></span>. The A-2 Warrants
are exercisable immediately upon issuance and expire <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zJnzL34kUxxa" title="Warrant expiration date"><ix:nonNumeric contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_A2WarrantsMember" format="ixt:datemonthdayyearen" id="Fact000802" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">October 1, 2024</ix:nonNumeric></span>. The combined purchase price for one Common Share and the accompanying
Warrants was $<span id="xdx_900_eus-gaap--SharePrice_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zcEEYEAlI5D4" title="Common stock and warrant price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember" id="Fact000804" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.92</ix:nonFraction></span>, and the combined purchase price for one Pre-Funded Warrant and the accompanying Warrants was $<span id="xdx_908_ecustom--PrefundedWarrantAndAccompanyingWarrantPricePerShares_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znmfrt0dbJvk" title="Pre-Funded Warrant and accompanying warrant price per shares"><ix:nonFraction name="NAOV:PrefundedWarrantAndAccompanyingWarrantPricePerShares" contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_us-gaap_WarrantMember" id="Fact000806" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.92</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net proceeds to the Company from the Private Placement are approximately $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20230830__20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z9mEcQEWUqt4" title="Proceeds from issuance of private placement"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2023-08-302023-08-30_custom_PurchaseAgreementMember" id="Fact000808" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,215,000</ix:nonFraction></span>, after deducting placement agent fees and expenses
and estimated offering expenses payable by the Company. The Company intends to use the net proceeds received from the Private Placement
for general corporate purposes, including funding of our development programs, commercial planning and sales and marketing expenses,
potential strategic acquisitions, general and administrative expenses and working capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.C.
Wainwright &amp; Co., LLC (&#8220;Wainwright&#8221;) served as the Company&#8217;s exclusive placement agent in connection with the Private
Placement, pursuant to that certain engagement letter, dated as of July 5, 2023, as amended, between us and Wainwright (the &#8220;Engagement
Letter&#8221;). As part of Wainwright&#8217;s compensation, we issued to Wainwright or its designees warrants (the &#8220;Placement Agent
Warrants&#8221;) to purchase up to an aggregate of <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230705__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentWarrantsMember_zuEGsLZxDhbc" title="Number of securities called by warrants or rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-07-05_custom_HCWainwrightAndCoLLCMember_custom_PlacementAgentWarrantsMember" id="Fact000810" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,820</ix:nonFraction></span> shares of Common Stock at an exercise price equal to $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230705__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentWarrantsMember_zJXcVPUyzqah" title="Share price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-07-05_custom_HCWainwrightAndCoLLCMember_custom_PlacementAgentWarrantsMember" id="Fact000812" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">23.65</ix:nonFraction></span> per share. The
Placement Agent Warrants are exercisable immediately upon issuance and expire <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230705__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentWarrantsMember_zDGur9KXG0tl" title="Class of warrant or right expire date"><ix:nonNumeric contextRef="AsOf2023-07-05_custom_HCWainwrightAndCoLLCMember_custom_PlacementAgentWarrantsMember" format="ixt:datemonthdayyearen" id="Fact000814" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">March 1, 2029</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 168 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock-based
compensation and options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 28, 2014, stockholders approved the NanoVibronix, Inc. 2014 Long-Term Incentive Plan (the &#8220;2014 Plan&#8221;), which was
adopted by the Board on February 19, 2014. As of December 31, 2022, under the 2014 Plan, <span id="xdx_90D_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20221231__us-gaap--AwardTypeAxis__custom--TwoThousandFourteenLongTermIncentivePlanMember_zgG1nWXtJzkf" title="Stock reserved for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2022-12-31_custom_TwoThousandFourteenLongTermIncentivePlanMember" id="Fact000816" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">442,207</ix:nonFraction></span> shares of our common stock were reserved
for issuance. On February 9, 2023, the Company effected a <span id="xdx_908_eus-gaap--StockholdersEquityReverseStockSplit_c20230209__20230209__us-gaap--AwardTypeAxis__custom--TwoThousandFourteenLongTermIncentivePlanMember_zGkrYI8OhPf" title="Reverse stock split"><ix:nonNumeric contextRef="From2023-02-092023-02-09_custom_TwoThousandFourteenLongTermIncentivePlanMember" id="Fact000818" name="us-gaap:StockholdersEquityReverseStockSplit">one-for-twenty reverse stock split</ix:nonNumeric></span> of common stock. Consequently, the number
of shares of common stock of the Company reserved for issuance pursuant to awards under the 2014 Plan was reduced to <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20230209__us-gaap--AwardTypeAxis__custom--TwoThousandFourteenLongTermIncentivePlanMember_zBRUkizWfKd6" title="Number of common stock reserved for issuance for awards"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2023-02-09_custom_TwoThousandFourteenLongTermIncentivePlanMember" id="Fact000820" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,110</ix:nonFraction></span> shares. As
of December 31, 2023, there were <span id="xdx_90E_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20231231__us-gaap--AwardTypeAxis__custom--TwoThousandFourteenLongTermIncentivePlanMember_zSxL0REig5e3" title="Stock reserved for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2023-12-31_custom_TwoThousandFourteenLongTermIncentivePlanMember" id="Fact000822" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,866</ix:nonFraction></span> shares of common stock available to be issued under the plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 19, 2024, stockholders approved the NanoVibronix, Inc. 2024 Long-Term Incentive Plan (the &#8220;2024
Plan&#8221;), as a successor to the Nanovibronix 2014 Long-Term Incentive Plan, which was adopted by the Board on November 6, 2023. As
of December 31, 2024, under the 2024 Plan, <span id="xdx_900_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20241231__us-gaap--AwardTypeAxis__custom--TwoThousandAndTwentyFourLongTermIncentivePlanMember_zVfq8cRQJxRl" title="Stock reserved for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2024-12-31_custom_TwoThousandAndTwentyFourLongTermIncentivePlanMember" id="Fact000824" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">600,000</ix:nonFraction></span> shares of our common stock were reserved for issuance. On March 14, 2025, the Company
effected a one-for-eleven reverse stock split of common stock. Consequently, the number of shares of common stock of the Company reserved
for issuance pursuant to awards under the 2024 Plan was reduced to <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20250314__us-gaap--AwardTypeAxis__custom--TwoThousandAndTwentyFourLongTermIncentivePlanMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrFe8ZxUi7m3" title="Number of common stock reserved for issuance for awards"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2025-03-14_custom_TwoThousandAndTwentyFourLongTermIncentivePlanMember_us-gaap_SubsequentEventMember" id="Fact000826" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">54,545</ix:nonFraction></span> shares. As of December 31, 2024, there were <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandAndTwentyFourLongTermIncentivePlanMember_zBtYG3Amo0db" title="Number of share issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_custom_TwoThousandAndTwentyFourLongTermIncentivePlanMember" id="Fact000828" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,486</ix:nonFraction></span> shares of
common stock available to be issued under the plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2024, and 2023, <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_dxL_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zyWymLxcbBD8" title="Number of options, exercised::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0830">0</span></span> and <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zbs0TyLTt5v3" title="Number of options, exercised"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-01-012023-12-31_custom_EmployeeOptionsMember" id="Fact000832" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,426</ix:nonFraction></span> employee options were exercised, <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zlZ8Gk66VXq1" title="Number of employee options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember" id="Fact000834" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">34,818</ix:nonFraction></span> and <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zqyMvrvYUV4j" title="Number of employee options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-12-31_custom_EmployeeOptionsMember" id="Fact000836" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,273</ix:nonFraction></span> options were granted,
<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_dxL_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z8kw3xXs5lca" title="Number of employee options forfeited::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0838">0</span></span> and <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zC5UtL0B5nsf" title="Number of employee options forfeited"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2023-01-012023-12-31_custom_EmployeeOptionsMember" id="Fact000840" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,584</ix:nonFraction></span> options were forfeited and <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zfQLjQrLNjGi" title="Number of employee options expired"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember" id="Fact000842" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3</ix:nonFraction></span> and <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zV7A97cqlCS1" title="Number of employee options expired"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2023-01-012023-12-31_custom_EmployeeOptionsMember" id="Fact000844" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">368</ix:nonFraction></span> options were expired, respectively. The options granted during 2024 and 2023 vest
at different schedules ranging from date granted to <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zRZ27pnIZQp5" title="Fair value options vesting term"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zCY00yxij7d6" title="Fair value options vesting term"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember" format="ixt-sec:duryear" id="Fact000846" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_EmployeeOptionsMember" format="ixt-sec:duryear" id="Fact000848" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">9</ix:nonNumeric></ix:nonNumeric></span></span> years and were recorded at fair values of approximately $<span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zep8MH6yJT71" title="Number of options, vested"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember" id="Fact000850" format="ixt:numdotdecimal" decimals="0" unitRef="USD">226,000</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zECWcJ7AgF8h" title="Number of options, vested"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2023-01-012023-12-31_custom_EmployeeOptionsMember" id="Fact000852" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,000</ix:nonFraction></span>, respectively.
The maximum contractual term for granted options is <span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z3iB8Hyi5qke" title="Contractual term for granted options"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zRFG2QpKc2Eh" title="Contractual term for granted options"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember" format="ixt-sec:duryear" id="Fact000854" name="NAOV:ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_EmployeeOptionsMember" format="ixt-sec:duryear" id="Fact000856" name="NAOV:ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod">10</ix:nonNumeric></ix:nonNumeric></span></span> years. During the years ended December 31, 2024, and 2023, stock-based compensation
expense of approximately $<span id="xdx_903_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z9eSCXQ6wUea" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember" id="Fact000858" format="ixt:numdotdecimal" decimals="0" unitRef="USD">356,000</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zWWajw1dg0Tf" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2023-01-012023-12-31_custom_EmployeeOptionsMember" id="Fact000860" format="ixt:numdotdecimal" decimals="0" unitRef="USD">293,000</ix:nonFraction></span> was recorded for options that vested, respectively.</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000862" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zRnajz2rExNa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zvHhwC29emWg" style="display: none">SCHEDULE OF OPTIONS ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares Under</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>per Share</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life (Years)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">Outstanding &#8211; December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zt6aMefE1eT6" title="Options, Outstanding - Beginning balance" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31_custom_EmployeeOptionsMember" id="Fact000864" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,244</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2d_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zAlkVS6LDsh4" title="Weighted Average Exercise Price per Share, Exercisable - Ending balance" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_custom_EmployeeOptionsMember" id="Fact000866" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">13.10</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zuO8oC4yP1X4" title="Weighted Average Remaining Life (Years), Outstanding"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember" format="ixt-sec:duryear" id="Fact000868" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.41</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zsQvG6cqmyhj" title="Options, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember" id="Fact000870" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">34,818</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2d_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z9BEu7ef6R4" title="Weighted Average Exercise Price per Share, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember" id="Fact000872" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">7.47</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zDGrqQdtxMja" title="Weighted Average Remaining Life (Years), Granted"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember" format="ixt-sec:duryear" id="Fact000874" name="NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm">9.78</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_ztr66m7BmhLf" title="Options, Forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0876">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pp2d_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zDWotb2B7lQd" title="Weighted Average Exercise Price per Share, Forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0878">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zLrdckMjEYXg" title="Weighted Average Remaining Life (Years), Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0880">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z5uC7BOTCeG3" title="Options, Expired" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember" id="Fact000882" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pp2d_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zEp9r9PGCu22" title="Weighted Average Exercise Price per Share, Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember" id="Fact000884" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">39.20</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zMEgC7Bao9h7" title="Weighted Average Remaining Life (Years), Expired"><span style="-sec-ix-hidden: xdx2ixbrl0886">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zRwRMknXGpml" title="Options, Exercised" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0888">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pp2d_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zVND6xCk6zQf" title="Weighted Average Exercise Price per Share, Exercised" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0890">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zCDwLqTMiru7" title="Weighted Average Remaining Life (Years), Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0892">-</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding &#8211; December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z32ymmNLQzvb" title="Options, Outstanding - Ending balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31_custom_EmployeeOptionsMember" id="Fact000894" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,059</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pp2d_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zmKP5rPZlWYk" title="Weighted Average Exercise Price per Share, Outstanding - ending balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_custom_EmployeeOptionsMember" id="Fact000896" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">3.50</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zXQOqt9MjGl1" title="Weighted Average Remaining Life (Years), Outstanding"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember" format="ixt-sec:duryear" id="Fact000898" name="NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm">9.24</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable &#8211; December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zBOZ4VP6HmA9" title="Options, Exercisable - Ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31_custom_EmployeeOptionsMember" id="Fact000900" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,059</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zmZW1bX6kxRh" title="Weighted Average Exercise Price per Share, Outstanding - ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_custom_EmployeeOptionsMember" id="Fact000902" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.50</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zcQwM7Zl783b" title="Weighted Average Remaining Life (Years), Exercisable"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember" format="ixt-sec:duryear" id="Fact000904" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">9.24</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zuZRi4yTjchl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
outstanding options had <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_do_c20241231_zqiyBPHxPSB8" title="Aggregate intrinsic value"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_do_c20231231_zh3fe9HD20Sd" title="Aggregate intrinsic value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-12-31" id="Fact000906" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-12-31" id="Fact000908" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> aggregate intrinsic value as of December 31, 2024, and 2023. The intrinsic value is calculated as the difference
between the exercise price and the market value of the shares on the balance sheet date. The market values based on the closing bid price
as of December 31, 2024, and 2023 was $<span id="xdx_901_eus-gaap--SharePrice_iI_c20241231_zvSE8JS4J6Dk" title="Bid price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-12-31" id="Fact000910" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.49</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--SharePrice_iI_c20231231_zBVnWzCd9BU" title="Bid price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-12-31" id="Fact000912" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.65</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000914" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zsLdriktqh95" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value for options granted in 2024 and 2023 is estimated at the date of grant using a Black-Scholes-Merton options pricing model
with the following underlying assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_z7m2ZIRLlCl3" style="display: none">SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR OPTIONS GRANTED</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Price at valuation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$ <span id="xdx_907_eus-gaap--SharePrice_iI_pp2d_c20241231__srt--RangeAxis__srt--MinimumMember_za8ONnVvuOA4" title="Price at valuation"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-12-31_srt_MinimumMember" id="Fact000916" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">6.71</ix:nonFraction></span> &#8211; <span id="xdx_90C_eus-gaap--SharePrice_iI_pp2d_c20241231__srt--RangeAxis__srt--MaximumMember_zGIdXn4vZHY2" title="Price at valuation"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-12-31_srt_MaximumMember" id="Fact000918" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">9.90</ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
                                            <span id="xdx_909_eus-gaap--SharePrice_iI_pp2d_c20231231__srt--RangeAxis__srt--MinimumMember_zES0X3AIObf2"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-12-31_srt_MinimumMember" id="Fact000919" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">13.2</ix:nonFraction>
                                            </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;
                                            <span id="xdx_905_eus-gaap--SharePrice_iI_pp2d_c20231231__srt--RangeAxis__srt--MaximumMember_z8dRCxkxgmI9"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-12-31_srt_MaximumMember" id="Fact000920" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">13.64</ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$ <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_c20241231__srt--RangeAxis__srt--MinimumMember_z32dVIMMMHS3" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2024-12-31_srt_MinimumMember" id="Fact000922" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">6.71</ix:nonFraction></span> &#8211; <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_c20241231__srt--RangeAxis__srt--MaximumMember_zwtbjSMWQKfc" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2024-12-31_srt_MaximumMember" id="Fact000924" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">9.90</ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$ <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_c20231231__srt--RangeAxis__srt--MinimumMember_z5DpkXfdkl64"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2023-12-31_srt_MinimumMember" id="Fact000925" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">13.2</ix:nonFraction></span>
                                            &#8211; </span><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_c20231231__srt--RangeAxis__srt--MaximumMember_zvgho4L20uX6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2023-12-31_srt_MaximumMember" id="Fact000926" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">13.64</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240101__20241231_zQuXvMfriufb" title="Risk free interest, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2024-01-01to2024-12-31" id="Fact000928" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.14</ix:nonFraction></span> &#8211; <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20240101__20241231_zPlwZQjgY3K2" title="Risk free interest, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2024-01-01to2024-12-31" id="Fact000930" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.42</ix:nonFraction></span> %</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20231231_zDTpuVAjwNEe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2023-01-012023-12-31" id="Fact000931" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.83</ix:nonFraction>
                                            </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;
                                            <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20230101__20231231_zPsbcrB4FRM4"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2023-01-012023-12-31" id="Fact000932" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.42</ix:nonFraction>
                                            </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Expected term (in years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231_zLfmpjqveXC1" title="Expected term (in years)"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:duryear" id="Fact000934" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zMWbcPvC2XA5" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2023-01-012023-12-31" format="ixt-sec:duryear" id="Fact000935" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20240101__20241231_zd0ANHMofr2i" title="Volatility, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2024-01-01to2024-12-31" id="Fact000937" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">128.4</ix:nonFraction></span> &#8211; <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20240101__20241231_zctxGMrRbwOb" title="Volatility, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2024-01-01to2024-12-31" id="Fact000939" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">132.8</ix:nonFraction></span> %</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20230101__20231231_z5YdNzA8UOY5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2023-01-012023-12-31" id="Fact000940" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">133.1</ix:nonFraction>
                                            </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;
                                            <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20230101__20231231_zRC0RRDUiCw3"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2023-01-012023-12-31" id="Fact000941" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">133.6</ix:nonFraction>
                                            </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zgdH7n8KyQS6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000943" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zt5AGZJIb9ab" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total stock-based expense recognized in the financial statements for services received from employees and non-employees is shown in the
following table.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_zdfH3ioX8TDf" style="display: none">SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED SERVICES FROM EMPLOYEES AND NON-EMPLOYEES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20240101__20241231_z6XktNeSRnI9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20231231_z1cFdggzb4Id" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_znYUhzDywvF" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000945" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000946" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zfyhUw6y7Ru6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Selling and marketing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_us-gaap_SellingAndMarketingExpenseMember" id="Fact000948" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_SellingAndMarketingExpenseMember" id="Fact000949" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z8turcZgioZ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000951" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">334,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000952" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">259,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zi4G19ZLiGOl" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000954" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">356,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31" id="Fact000955" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">293,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zgWgiHEQD5d3" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Stock based compensation expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000957" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">356,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31" id="Fact000958" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">293,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AA_zHW4jhsLJcPe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 169 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, there was <span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_do_c20241231_zOLIn9aOYj8i" title="Non-vested stock options granted, unrecognized estimated compensation cost"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2024-12-31" id="Fact000960" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></span> unrecognized estimated compensation cost related to non-vested stock options granted prior to that
date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 30, 2023, the Company granted (a) Pre-Funded Warrants to purchase up to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zk9U07hNse97" title="Warrants issued to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-08-30_us-gaap_CommonStockMember" id="Fact000962" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">264,271</ix:nonFraction></span> shares of Common Stock with an exercise price
of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zu460JFrs7e8" title="Class of warrant or right exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-08-30_us-gaap_CommonStockMember" id="Fact000964" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share, (b) A-1 Warrants to purchase up to <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_zl6qUL86Nyfi" title="Warrants issued to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-08-30_custom_A1WarrantsMember" id="Fact000966" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">264,271</ix:nonFraction></span> shares of Common Stock with an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_zcUZBkksK2Le" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-08-30_custom_A1WarrantsMember" id="Fact000968" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">16.17</ix:nonFraction></span> per share and
(c) A-2 Warrants to purchase up to <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zVK6RWSk9vC3" title="Warrants issued to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-08-30_custom_A2WarrantsMember" id="Fact000970" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">264,271</ix:nonFraction></span> shares of Common Stock with an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zekCM2EQfi88" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-08-30_custom_A2WarrantsMember" id="Fact000972" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">16.17</ix:nonFraction></span> per share, or a total of <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20230830_zJ7pqCNaAEK1" title="Total warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2023-08-30" id="Fact000974" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">776,448</ix:nonFraction></span> warrants,
in conjunction with the Private Placement disclosed above. The A-1 Warrants and A-2 Warrants are exercisable immediately upon issuance
and expire on <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20230830__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_zEGvNpM1zdy" title="Class of warrant or right expire date"><ix:nonNumeric contextRef="AsOf2023-08-30_custom_A1WarrantsMember" format="ixt:datemonthdayyearen" id="Fact000976" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">March 1, 2029</ix:nonNumeric></span> and <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20230830__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zzOwXQEKo1Kk" title="Class of warrant or right expire date"><ix:nonNumeric contextRef="AsOf2023-08-30_custom_A2WarrantsMember" format="ixt:datemonthdayyearen" id="Fact000978" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">October 1, 2024</ix:nonNumeric></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the same Private Placement, the Company granted Placement Agent Warrants to Wainwright, or its designees, to purchase up to an aggregate
of <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zhOQ6Abei7C4" title="Warrants issued to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-08-30_custom_HCWainwrightAndCoLLCMember" id="Fact000980" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,820</ix:nonFraction></span> shares of Common Stock at an exercise price equal to $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230830__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_z1kXAAJkDpH9" title="Share price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-08-30_custom_HCWainwrightAndCoLLCMember" id="Fact000982" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">23.65</ix:nonFraction></span> per share. The Placement Agent Warrants are exercisable immediately
upon issuance and expire <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20230830__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zDPRjFoEDvqe" title="Class of warrant or right expire date"><ix:nonNumeric contextRef="AsOf2023-08-30_custom_HCWainwrightAndCoLLCMember" format="ixt:datemonthdayyearen" id="Fact000984" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">March 1, 2029</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000986" name="NAOV:ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock"><p id="xdx_893_ecustom--ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock_z3euBJXIJSt5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
estimating the warrants&#8217; fair value, the Company used the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zKsvv47MJk4g" style="display: none">SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR WARRANTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Risk free interest</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z46WZr2xiszl" title="Warrants, measurement input, percentage"><span style="-sec-ix-hidden: xdx2ixbrl0988">-</span></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zytQ8rdizZzl" title="Warrants, measurement input, percentage"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact000990" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">3.49</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zeKwKRN982D6" title="Warrants, measurement input, percentage"><span style="-sec-ix-hidden: xdx2ixbrl0992">-</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zEMWAx4Us7c2" title="Warrants, measurement input, percentage"><span style="-sec-ix-hidden: xdx2ixbrl0994">-</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zvxKzIId2dDj" title="Warrants, measurement input, percentage"><span style="-sec-ix-hidden: xdx2ixbrl0996">-</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zfvsuw3JbBoa" title="Warrants, measurement input, percentage"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact000998" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">147.6</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Contractual term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20241231_zqsnYIeqDdei" title="Contractual term (in years)"><span style="-sec-ix-hidden: xdx2ixbrl1000">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231_z5hF0H6D4Zqg" title="Contractual term (in years)"><ix:nonNumeric contextRef="AsOf2023-12-31" format="ixt-sec:duryear" id="Fact001002" name="us-gaap:WarrantsAndRightsOutstandingTerm">5</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_ztqOH4YdDmgh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BE_zTxbn4zuJUf9" style="display: none">SCHEDULE OF WARRANTS ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>Pre-RSS</b></td>
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Post - RSS</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Warrants</b></td>
    <td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Outstanding &#8211; December 31, 2022</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--PreWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zUWe2IdZGoc6" title="Warrants, Outstanding - Beginning balance" style="text-align: right; width: 16%"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-12-31_custom_PreWarrantMember_custom_PrivateInvestorsMember" id="Fact001004" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,389</ix:nonFraction></td>
    <td style="width: 1%">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--PostWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zIzVt1Uyv898" title="Warrants, Outstanding - Beginning balance" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-12-31_custom_PostWarrantMember_custom_PrivateInvestorsMember" id="Fact001006" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,389</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--PreWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zXF3Cjg6PSu3" title="Warrants, Outstanding - Beginning balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2023-01-012023-12-31_custom_PreWarrantMember_custom_PrivateInvestorsMember" id="Fact001008" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,758,954</ix:nonFraction></td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--PostWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zEFnkTxCyHLh" title="Warrants, Outstanding - Beginning balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2023-01-012023-12-31_custom_PostWarrantMember_custom_PrivateInvestorsMember" id="Fact001010" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">796,269</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Expired</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--PreWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zmxrUXihS9Fl" title="Warrants, Outstanding - Beginning balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1012">-</span></td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--PostWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zTI4Dq7OUOu7" title="Warrants, Outstanding - Beginning balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1014">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Cancelled</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--PreWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zzwewt1olZsa" title="Warrants, Outstanding - Beginning balance" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" contextRef="From2023-01-012023-12-31_custom_PreWarrantMember_custom_PrivateInvestorsMember" id="Fact001016" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">203,977</ix:nonFraction></td>
    <td style="padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--PostWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_z7BucyAHm4Id" title="Warrants, Outstanding - Beginning balance" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" contextRef="From2023-01-012023-12-31_custom_PostWarrantMember_custom_PrivateInvestorsMember" id="Fact001018" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,543</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding &#8211; December 31, 2023</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PreWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zctOm5KA3oIk" title="Warrants, Outstanding - Beginning balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-12-31_custom_PreWarrantMember_custom_PrivateInvestorsMember" id="Fact001020" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,633,229</ix:nonFraction></td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PostWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zfvM8K6tLHR8" title="Warrants, Outstanding - Beginning balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-12-31_custom_PostWarrantMember_custom_PrivateInvestorsMember" id="Fact001022" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">780,115</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PreWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zaLBljHjxDra" title="Warrants, Outstanding - Beginning balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1024">-</span></td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PostWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zT4KCyGwqwz4" title="Warrants, Outstanding - Beginning balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1026">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Expired</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PreWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_z2SFFBq1ndv" title="Warrants, Outstanding - Beginning balance" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2024-01-012024-12-31_custom_PreWarrantMember_custom_PrivateInvestorsMember" id="Fact001028" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,918,977</ix:nonFraction></td>
    <td>)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PostWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zU4X6An8BLD" title="Warrants, Outstanding - Beginning balance" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2024-01-012024-12-31_custom_PostWarrantMember_custom_PrivateInvestorsMember" id="Fact001030" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">265,362</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercised</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PreWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zZCOIG93pCq7" title="Warrants, Outstanding - Beginning balance" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2024-01-012024-12-31_custom_PreWarrantMember_custom_PrivateInvestorsMember" id="Fact001032" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,122,000</ix:nonFraction></td>
    <td>)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PostWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zcSyp1kmQnif" title="Warrants, Outstanding - Beginning balance" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2024-01-012024-12-31_custom_PostWarrantMember_custom_PrivateInvestorsMember" id="Fact001034" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">192,910</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Cancelled</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PreWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zQA7miZzDCn1" title="Warrants, Outstanding - Beginning balance" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1036">-</span></td>
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PostWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zqYfZaF6NBTe" title="Warrants, Outstanding - Beginning balance" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1038">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Outstanding &#8211; December 31, 2024</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PreWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_z1gMTs4V7sua" title="Warrants, Outstanding - Beginning balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2024-12-31_custom_PreWarrantMember_custom_PrivateInvestorsMember" id="Fact001040" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,592,252</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PostWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_ziZhRBEXtFU7" title="Warrants, Outstanding - Beginning balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2024-12-31_custom_PostWarrantMember_custom_PrivateInvestorsMember" id="Fact001042" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">321,843</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zRT6eHAqxxql" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001044" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_802_eus-gaap--LesseeOperatingLeasesTextBlock_z10TFwGETv15" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7 &#8211; <span id="xdx_823_zgK8HiPkV98i">LEASES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has operating lease agreements with terms up to <span id="xdx_906_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember_z0i3y4vVC2ri" title="Lease term"><ix:nonNumeric contextRef="AsOf2024-12-31_srt_MinimumMember" format="ixt-sec:duryear" id="Fact001046" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm">1</ix:nonNumeric></span>-<span id="xdx_907_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember_zvKH276tEYJ9" title="Lease term"><ix:nonNumeric contextRef="AsOf2024-12-31_srt_MaximumMember" format="ixt-sec:duryear" id="Fact001048" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm">3</ix:nonNumeric></span> years, including car and office space leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s weighted-average remaining lease term relating to its operating leases is <span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zI6o87YBPXd6" title="Weighted-average remaining lease term"><ix:nonNumeric contextRef="AsOf2024-12-31" format="ixt-sec:duryear" id="Fact001050" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">2.21</ix:nonNumeric></span> years, with a weighted-average discount
rate of <span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zPo9yZNRs9ci" title="Weighted-average discount rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2024-12-31" id="Fact001052" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company incurred $<span id="xdx_90F_eus-gaap--OperatingLeaseExpense_c20240101__20241231_z0lUNrn5a5f2" title="Operating lease, expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2024-01-01to2024-12-31" id="Fact001054" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,000</ix:nonFraction></span> of lease expense for its operating leases for the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001056" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_896_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zOU5r58QIyL6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information about the amount and timing of liabilities arising from the Company&#8217;s operating leases as
of December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;<span id="xdx_8B4_zGgbj7OTjX27" style="display: none">SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES</span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20241231_zxPtPQOlOC8a" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzL7T_zGXEahfPrLei" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left">2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2024-12-31" id="Fact001058" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzL7T_zTOe6HBlXKl7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2024-12-31" id="Fact001060" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzL7T_z39OzRFf7tF7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">2027</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2024-12-31" id="Fact001062" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzL7T_z6QTV7jPsWR7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total undiscounted operating lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2024-12-31" id="Fact001064" format="ixt:numdotdecimal" decimals="0" unitRef="USD">128,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_zLtKez6saP06" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: Imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2024-12-31" id="Fact001066" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iI_zMpPlSQGvR31" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Present value of operating lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-12-31" id="Fact001068" format="ixt:numdotdecimal" decimals="0" unitRef="USD">115,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zRfvqfIiAtFf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 170 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001070" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_805_eus-gaap--EarningsPerShareTextBlock_zc71vfFF3QLf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8 - <span id="xdx_827_zdUn3PGuiSld">LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per common share (&#8220;Basic EPS&#8221;) is computed by dividing net loss available to common shareholders by the weighted
average number of common shares outstanding during the period. All outstanding share options and warrants for the years ended December
31, 2024, and 2023 have been excluded from the calculation of the diluted net loss per share because all such securities are anti-dilutive
for all periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001072" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zlcoWaFYUOVf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s securities, in common share equivalents, which have been excluded from the calculation
of dilutive loss per share as their effect would be anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zX922lo9htWh" style="display: none">SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240101__20241231_zO8kDPjm9NOl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20230101__20231231_zliEkaTP3TNa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsEmployeeAndNonEmployeeMember_z69SwWeaMDY6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Stock options - employee and non-employee</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_custom_StockOptionsEmployeeAndNonEmployeeMember" id="Fact001074" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,059</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_StockOptionsEmployeeAndNonEmployeeMember" id="Fact001075" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,244</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zqzlHoQRu4kb" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember" id="Fact001077" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">326,568</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact001078" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">784,839</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zkQIg5ezY5U1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-01to2024-12-31" id="Fact001080" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">371,627</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31" id="Fact001081" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">795,083</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A4_zCrMg9MIqk2g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
diluted loss per share equals basic loss per share in the year ended December 31, 2024, and 2023 because the Company had a net loss and
the impact of the assumed exercise of stock options and the vesting of restricted stock would have been anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001083" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_807_eus-gaap--SegmentReportingDisclosureTextBlock_zNp5qHzhvmg7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9 - <span id="xdx_825_z6mwsRi0GGUb">GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summary
information about geographic areas:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company manages its business on the basis of one reportable segment and Brian Murphy, CEO, is the chief decision maker for the
segment. The Company derives revenues from selling its products directly to patients as well as through distributor agreements. The
following is a summary of revenues within geographic areas:</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001085" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock"><p id="xdx_89C_eus-gaap--RevenueFromExternalCustomersByGeographicAreasTableTextBlock_zPYDtD4lb4f2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span id="xdx_8BC_zWuHqRpHpZl3">SUMMARY
OF REVENUE WITHIN GEOGRAPHIC AREAS</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20241231_zYvtbqfa9mee" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20230101__20231231_z686t8clFGhc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__country--US_z5igr5BEUtd3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-12-31_country_US" id="Fact001087" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,450,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31_country_US" id="Fact001088" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,162,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__srt--EuropeMember_zlt75zO9MMR3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Europe</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-12-31_srt_EuropeMember" id="Fact001090" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31_srt_EuropeMember" id="Fact001091" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__country--AU_zXVYD0RrRDyj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Australia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-12-31_country_AU" id="Fact001093" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31_country_AU" id="Fact001094" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__country--IL_zZfEHqFWIzge" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Israel</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-12-31_country_IL" id="Fact001096" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31_country_IL" id="Fact001097" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__country--NZ_zqmBAPvQnye6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">New Zealand</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-12-31_country_NZ" id="Fact001099" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1100">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__custom--OtherCountryMember_zTZBuNVnqaZ3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-12-31_custom_OtherCountryMember" id="Fact001102" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1103">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0d_zviMUP09I6fh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-01to2024-12-31" id="Fact001105" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,558,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31" id="Fact001106" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,283,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0d_zOB0gakHaA76" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Revenues geographic areas</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-01to2024-12-31" id="Fact001108" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,558,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31" id="Fact001109" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,283,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AF_zcN3kKlqooTe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s long-lived assets are all located in Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year end December 31, 2024, the Company generated approximately $<span id="xdx_909_eus-gaap--Revenues_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerMember_z4AtByWI8I22" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-01-012024-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerMember" id="Fact001111" format="ixt:numdotdecimal" decimals="0" unitRef="USD">800,000</ix:nonFraction></span> in revenue from its largest direct medical distributor,
Ultra Pain Products, LLC. This represents approximately <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerMember_zuF342PYPh4i" title="Concentration risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-01-012024-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerMember" id="Fact001113" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">31</ix:nonFraction></span>% of the company&#8217;s total revenue for the year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 171 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001115" name="us-gaap:OtherAssetsDisclosureTextBlock"><p id="xdx_80E_eus-gaap--OtherAssetsDisclosureTextBlock_z58NV7IVZR27" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10 &#8211; <span id="xdx_829_zqcPGMjyMeTd">OTHER ASSETS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 9, 2020, pursuant to a licensing agreement entered into in March 2020, the Company received <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20200409__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zxWib95aXX9j" title="Warrants and rights outstanding term"><ix:nonNumeric contextRef="AsOf2020-04-09_custom_LicensingAgreementMember_custom_SanuwaveHealthIncMember" format="ixt-sec:duryear" id="Fact001117" name="us-gaap:WarrantsAndRightsOutstandingTerm">10</ix:nonNumeric></span>-year warrants to purchase <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20200409__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_znF23TDkPWWe" title="Warrants issued to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2020-04-09_custom_LicensingAgreementMember_custom_SanuwaveHealthIncMember" id="Fact001119" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">127,000</ix:nonFraction></span>
shares of Sanuwave Health, Inc. at a price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20200409__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_ziHQ9H53MNo8" title="Exercise price of warrants per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-04-09_custom_LicensingAgreementMember_custom_SanuwaveHealthIncMember" id="Fact001121" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.19</ix:nonFraction></span> per share. The fair value for warrants received is estimated at the date of grant
using a Black-Scholes-Merton pricing model with the following underlying assumptions:</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001123" name="NAOV:ScheduleOfWarrantsAssumptionsTableTextBlock"><p id="xdx_899_ecustom--ScheduleOfWarrantsAssumptionsTableTextBlock_zDKX714Vy246" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="display: none"><span id="xdx_8B0_ztgla8kCAZi">SCHEDULE OF WARRANTS ASSUMPTIONS</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Price at valuation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__custom--PriceAtValuationMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zDbiPnlSN1F3" title="Warrants and rights outstanding, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_custom_PriceAtValuationMember_custom_SanuwaveHealthIncMember" id="Fact001125" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__custom--PriceAtValuationMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zSCafcIMChM4" title="Warrants and rights outstanding, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_custom_PriceAtValuationMember_custom_SanuwaveHealthIncMember" id="Fact001127" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zB2R6yMLZG96" title="Warrants and rights outstanding, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_SanuwaveHealthIncMember" id="Fact001129" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.19</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zVU3v9oIQVtj" title="Warrants and rights outstanding, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_SanuwaveHealthIncMember" id="Fact001131" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.19</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zp6Zv0uSc7Fa" title="Warrants and rights outstanding, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_SanuwaveHealthIncMember" id="Fact001133" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">3.88</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zkfmBN6WiGU8" title="Warrants and rights outstanding, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_SanuwaveHealthIncMember" id="Fact001135" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">3.88</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zk9gYMzSEDha" title="Expected term (in years)"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_SanuwaveHealthIncMember_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:duryear" id="Fact001137" name="us-gaap:WarrantsAndRightsOutstandingTerm">7</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zygXJz8tDLH1" title="Expected term (in years)"><ix:nonNumeric contextRef="AsOf2023-12-31_custom_SanuwaveHealthIncMember_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:duryear" id="Fact001139" name="us-gaap:WarrantsAndRightsOutstandingTerm">7</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_z9skbkifx3Ud" title="Warrants and rights outstanding, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_SanuwaveHealthIncMember" id="Fact001141" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">147.8</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_z31oSP3O7shj" title="Warrants and rights outstanding, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_SanuwaveHealthIncMember" id="Fact001143" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">147.8</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_z5LGHEISuaJd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers this to be Level 3 inputs and is valued at each reporting period. As of September 12, 2024, the company terminated
the licensing agreement with Sanuwave and recognized $<span id="xdx_90A_eus-gaap--GainLossOnContractTermination_c20240912__20240912_zGpHzGbL6ypl" title="Gain loss on contract termination"><ix:nonFraction name="us-gaap:GainLossOnContractTermination" contextRef="From2024-09-122024-09-12" id="Fact001145" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000</ix:nonFraction></span> in gain/loss of termination of investment, offset by change in fair value
through the date of termination of $<span id="xdx_908_ecustom--IncreaseDecreaseInTerminationValueByOffset_iI_c20240912_zP7KOLx9smY1" title="Increase decrease in termination value by offset"><ix:nonFraction name="NAOV:IncreaseDecreaseInTerminationValueByOffset" contextRef="AsOf2024-09-12" id="Fact001147" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span>. The fair value of these warrants for the years ended December 31, 2024, and 2023 was $<span id="xdx_90C_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iI_c20241231_z6m1RFh24o52" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" contextRef="AsOf2024-12-31" id="Fact001149" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and
$<span id="xdx_900_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iI_c20231231_z4sIfkjBknDb" title="Warrants leaving balance"><ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" contextRef="AsOf2023-12-31" id="Fact001151" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span>, respectively. There was a net $<span id="xdx_901_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231_zjypg1q1po2h" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-01to2024-12-31" id="Fact001153" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231_z6IhbENHkvEe" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-12-31" id="Fact001155" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000</ix:nonFraction></span> change in fair value during the year ended December 31, 2024, and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Financial
Liabilities Measured at Fair Value on a Recurring Basis</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability
in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants
would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 inputs: Inputs, other than quoted prices included in Level 1, that are observable either directly or indirectly; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own
    assumptions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no transfers between Level 3 during the years ended December 31, 2024, and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001157" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"><p id="xdx_890_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_z2nhLDqF724i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents changes in Level 3 asset and liability measured at fair value for the years ended December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zzp8DjOUaIpc" style="display: none">SCHEDULE
OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Asset</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%">Balance &#8211; December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3d_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zhxGeSsFbK6a" title="Balance beginning" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" contextRef="AsOf2022-12-31_custom_DerivativeAssetMember" id="Fact001159" format="ixt:numdotdecimal" decimals="-3" unitRef="USD">3,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Fair value adjustments &#8211; Sanuwave warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FairValueAdjustmentOfWarrants_pn3d_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zCmWZcrsy9y2" title="Fair value adjustments - Sanuwave warrants" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-12-31_custom_DerivativeAssetMember" id="Fact001161" format="ixt:numdotdecimal" decimals="-3" sign="-" unitRef="USD">2,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance &#8211; December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3d_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_z5lKcZNPZI3g" title="Balance beginning" style="text-align: right"><ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" contextRef="AsOf2023-12-31_custom_DerivativeAssetMember" id="Fact001163" format="ixt:numdotdecimal" decimals="-3" unitRef="USD">1,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Fair value adjustments &#8211; Sanuwave warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FairValueAdjustmentOfWarrants_pn3d_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zAYie0zaomG9" title="Fair value adjustments - Sanuwave warrants" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-012024-12-31_custom_DerivativeAssetMember" id="Fact001165" format="ixt:numdotdecimal" decimals="-3" sign="-" unitRef="USD">1,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance &#8211; December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_pn3d_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zAkyyPVLxuR1" title="Balance beginning" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1167">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zN7iM67GH1Xe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001169" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zGOPWlPhDSh7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the Company&#8217;s assets and liabilities which are measured at fair value on a recurring basis by level
within the fair value hierarchy:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_zwWJeHXQDedf" style="display: none">SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_znBUdNv0qPEg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level I</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zgvMR1A6PpA7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level II</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z96DcWj5kHy" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level III</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20241231_z9DoxhMLDlZ5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level I</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level II</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level III</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 28%">Asset:</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"/><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherAssetsFairValueDisclosure_iI_zVcggDXizV32" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1171">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1172">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1173">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1174">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zxAKE3RGqrJ2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level I</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zCq33R0310w7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level II</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zULoEFsUUZf4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level III</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231_zdzGtmbO0cNe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level I</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level II</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level III</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 28%">Asset:</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"/><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OtherAssetsFairValueDisclosure_iI_zqdU7meWwT78" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1176">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1177">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001178" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsFairValueDisclosure" contextRef="AsOf2023-12-31" id="Fact001179" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zXY1icEwDNH9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>

<ix:exclude><!-- Field: Page; Sequence: 172 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001181" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_802_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zhLjX2eAYg3a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
11 - <span id="xdx_82C_z8P5fV4IYrAa">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Pending
and settled litigation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 26, 2021, Protrade Systems, Inc. (&#8220;Protrade&#8221;) filed a Request for Arbitration (the &#8220;Request&#8221;) with the
International Court of Arbitration (the &#8220;ICA&#8221;) of the International Chamber of Commerce alleging the Company is in breach
of an Exclusive Distribution Agreement dated March 7, 2019 (the &#8220;Exclusive Distribution Agreement&#8221;) between Protrade and
the Company. Protrade alleges, in part, that the Company has breached the Exclusive Distribution Agreement by discontinuing the manufacture
of the DV0057 Painshield MD device in favor of an updated 10-100-001 Painshield MD device. Protrade claims damages estimated at $<span id="xdx_904_eus-gaap--LossContingencyDamagesSoughtValue_pn6n6_c20210225__20210226_zKyz3tsCBDzi" title="Litigation damages sought value"><ix:nonFraction name="us-gaap:LossContingencyDamagesSoughtValue" contextRef="From2021-02-252021-02-26" id="Fact001183" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">3</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 15, 2022, the arbitrator issued a final award, which, determined that (i) the Company had the right to terminate the Exclusive
Distribution Agreement; (ii) the Company did not breach the duty of good faith and fair dealing with regard to the Exclusive Distribution
Agreement; and (iii) the Company did not breach any confidentiality obligations to Protrade. Nevertheless, the arbitrator determined
that the Company did not comply with the obligation to supply Protrade with a year&#8217;s supply of patches, and awarded Protrade $<span id="xdx_90F_eus-gaap--LossContingencyDamagesSoughtValue_c20220314__20220315_zwUzU7hOiKx9" title="Loss contingency damages sought value"><ix:nonFraction name="us-gaap:LossContingencyDamagesSoughtValue" contextRef="From2022-03-142022-03-15" id="Fact001185" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,500,250</ix:nonFraction></span>,
which consists of $<span id="xdx_905_eus-gaap--LossContingencyDamagesAwardedValue_c20220314__20220315_zxHPoZJvf5pf" title="Loss contingency damages sought value"><ix:nonFraction name="us-gaap:LossContingencyDamagesAwardedValue" contextRef="From2022-03-142022-03-15" id="Fact001187" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,432,000</ix:nonFraction></span> for &#8220;lost profits&#8221; and $<span id="xdx_902_eus-gaap--LossContingencyDamagesPaidValue_c20220314__20220315_z55qV5WmuNqa" title="Loss contingency damages paid value"><ix:nonFraction name="us-gaap:LossContingencyDamagesPaidValue" contextRef="From2022-03-142022-03-15" id="Fact001189" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,250</ix:nonFraction></span> as reimbursement of arbitration costs, on the grounds that the
Company allegedly failed to supply Protrade with certain patches utilized by users of DV0057 Painshield MD device. The arbitrator based
the decision on the testimony of Protrade&#8217;s president who asserted that a user would use in excess of 33 patches per each device.
The Company believes that the number of patches per device alleged by Protrade is grossly inflated, and that these claims were not properly
raised before the arbitrator. Accordingly, on April 13, 2022, the Company submitted an application for the correction of the award which
the arbitrator denied on June 22, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 22, 2022, the Company filed a cross-motion seeking to vacate arbitration award on the grounds that the arbitrator exceeded her authority,
that the award was procured by fraud, and that the arbitrator failed to follow procedures established by New York law. In particular,
the Company averred in its motion that Protrade&#8217;s witness made false statements in arbitration, and that the arbitrator resolved
a claim that was never raised by Protrade and that has no factual basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2022, the court issued a decision granting Protrade its petition to confirm the award and denying the cross-motion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 9, 2022, the Company filed a motion to re-argue and renew its cross-motion to vacate the arbitration decision based on newer
information that was not available during the initial hearing. On the same day, the Company also filed a notice of appeal with the Appellate
Division, Second Department. On March 21, 2023, the court denied the motion to re-argue and renew.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">On July 10, 2023, the Company filed its appeal with the Appellate Division,
Second Department. That appeal is now fully briefed. In February 2025, the Second Department informed counsel for the Company that the
Second Department was beginning to process the appeal for calendaring.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, and 2023, the Company accrued the amount of the arbitration award to Protrade of approximately $<span id="xdx_901_eus-gaap--LossContingencyDamagesAwardedValue_pn5n6_c20240101__20241231__srt--TitleOfIndividualAxis__custom--ArbitratorMember_zhiTbLeUGEFc" title="Damages awarded value"><ix:nonFraction name="us-gaap:LossContingencyDamagesAwardedValue" contextRef="From2024-01-012024-12-31_custom_ArbitratorMember" id="Fact001191" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.1</ix:nonFraction></span>
million and $<span id="xdx_900_eus-gaap--LossContingencyDamagesAwardedValue_pn5n6_c20230101__20231231__srt--TitleOfIndividualAxis__custom--ArbitratorMember_zendAHeQEsl7" title="Damages awarded value"><ix:nonFraction name="us-gaap:LossContingencyDamagesAwardedValue" contextRef="From2023-01-012023-12-31_custom_ArbitratorMember" id="Fact001193" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.0</ix:nonFraction></span> million, respectively, including interest which is classified in &#8220;Other accounts payable and accrued
expenses&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001195" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_804_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zVot36ortO2c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
12 &#8211; <span id="xdx_826_zwDHkBe8neqb">RELATED PARTY TRANSACTION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
firm of FisherBroyles LLP handled all our Protrade litigation and appeals through December 31, 2024. For the year ended December 31,
2024, we have been not been billed and have not paid any legal fees from FisherBroyles .Ms. Cassirer id not provide any legal services
or legal advice to the Company<b>.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 1, 2024, Ms. Cassirer and the lawyers responsible for handling our Protrade litigation left the firm of FisherBroyles to join
the firm of Pierson Ferdinand LLP. As of January1, 2024, the firm Pierson Ferdinand is the sole firm handling all our Protrade litigation
and appeals. For the year ended December 31, 2024, Pierson Ferdinand was paid $<span id="xdx_903_eus-gaap--PaymentsForFees_c20240101__20241231__srt--TitleOfIndividualAxis__custom--PiersonFerdinandMember_zqEkLgSkLWT8" title="Payments for fees"><ix:nonFraction name="us-gaap:PaymentsForFees" contextRef="From2024-01-012024-12-31_custom_PiersonFerdinandMember" id="Fact001197" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69,000</ix:nonFraction></span>. As was the case in prior years, Ms. Cassirer does
not provide any legal services or legal advice to the Company<b>.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 173 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001199" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_807_eus-gaap--IncomeTaxDisclosureTextBlock_zsUqwKH3qtb6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
13 &#8211; <span id="xdx_82A_zNAJtWIVdZm">INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the U.S. Company had federal and state net operating loss carry forward for tax purposes of approximately $<span id="xdx_909_eus-gaap--OperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zBGZKvTpHYLc" title="Net operating loss carry forward"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember" id="Fact001201" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,300,000</ix:nonFraction></span>
and $<span id="xdx_907_eus-gaap--OperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zIGSShdtXhUd" title="Net operating loss carry forward"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember" id="Fact001203" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,400,000</ix:nonFraction></span>, respectively. $<span id="xdx_907_ecustom--FederalNetOperatingLossCarriedForward_iI_c20231231_z6QJrpoOqda6" title="Federal net operating loss carried forward"><ix:nonFraction name="NAOV:FederalNetOperatingLossCarriedForward" contextRef="AsOf2023-12-31" id="Fact001205" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,400,000</ix:nonFraction></span> of the federal net operating loss can be carried forward indefinitely but can only offset up
to 80% of taxable income in a given year, and $<span id="xdx_903_ecustom--FederalNetOperatingLossOffsetAgainstTaxableIncome_c20230101__20231231_zF2q9G1AlL75" title="Federal net operating loss offset against taxable income"><ix:nonFraction name="NAOV:FederalNetOperatingLossOffsetAgainstTaxableIncome" contextRef="From2023-01-012023-12-31" id="Fact001207" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,000,000</ix:nonFraction></span> of the federal net operating loss can be used to fully offset taxable income
in the period it is utilized but can only be carried forward for <span id="xdx_903_ecustom--OperatingLossCarryforwardsExpirationTerm_dtY_c20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zoRaoxAFMUW9" title="Operating loss carryforwards expiration term"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_DomesticCountryMember" format="ixt-sec:duryear" id="Fact001209" name="NAOV:OperatingLossCarryforwardsExpirationTerm">20</ix:nonNumeric></span> years. Utilization of the U.S. net operating losses may be subject
to substantial limitations in the event of a change of ownership under the provisions of the Internal Revenue Code of 1986. The Company
has not performed an analysis, but the potential impact of any limitation would not be material to the financial statements due to the
fact that the respective DTAs are fully offset by a valuation allowance. It should be noted that the federal deferred income tax expense at December
31, 2023 included a one-time adjustment to the net operating loss carryforward amounting to approximately $<span id="xdx_903_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_iI_c20231231_z8fcrguwnRb7" title="Net operating loss carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="AsOf2023-12-31" id="Fact001211" format="ixt:numdotdecimal" decimals="0" unitRef="USD">400,000</ix:nonFraction></span> that will not affect
the financial statements due to the full valuation allowance on the deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001213" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zobxkIkXBd87" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax expense is comprised of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_z9NXsdQaVxSe" style="display: none">SCHEDULE
OF PROVISION FOR INCOME TAXES EXPENSES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20240101__20241231_zKiJQhJVt58l" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20231231_zuxtMajYHa74" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current Tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CurrentFederalTaxExpenseBenefit_maCITEBzPkK_zz1DCJAuasU" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Federal</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1215">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1216">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maCITEBzPkK_zFzO7nt8qYPe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">State</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1218">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1219">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CurrentForeignTaxExpenseBenefit_maCITEBzPkK_z0ewUR7hJsh5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Foreign</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0"><ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="Fact001221" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,677</ix:nonFraction></p></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact001222" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">25,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBzPkK_maOTEBzPz3_zgtwwKReysl1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="margin: 0"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="Fact001224" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,677</ix:nonFraction></p></td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact001225" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">25,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred Tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maDITEBzsCS_zNtT1JVqJ0I7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="margin: 0">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="Fact001227" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">815,484</ix:nonFraction></p></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact001228" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,226,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maDITEBzsCS_z2jwcZcrVCRe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">State</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">(<ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="Fact001230" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,269</ix:nonFraction></p></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact001231" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">43,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_maDITEBzsCS_zdb8op4KZaSh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Foreign</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0">(<ix:nonFraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="Fact001233" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,263</ix:nonFraction></p></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact001234" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_mtDITEBzsCS_maOTEBzPz3_zUkSjIa3EuF1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="margin: 0">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="Fact001236" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">830,015</ix:nonFraction></p></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact001237" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,267,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--ValuationAllowanceOfIncomeTaxExpenseBenefit_iN_di_msOTEBzPz3_zvkh7EoLm7dg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: Valuation Allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0"><ix:nonFraction name="NAOV:ValuationAllowanceOfIncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="Fact001239" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">830,015</ix:nonFraction></p></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="NAOV:ValuationAllowanceOfIncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact001240" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,267,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OtherTaxExpenseBenefit_iT_mtOTEBzPz3_zq28qJXkOSk5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total Tax</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="margin: 0"><ix:nonFraction name="us-gaap:OtherTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="Fact001242" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,677</ix:nonFraction></p></td><td style="padding-bottom: 2.5pt; text-align: left"/><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:OtherTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact001243" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">25,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_z709BMCptM4j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also recognized approximately $<span id="xdx_90F_ecustom--FranchiseFees_c20230101__20231231_zQp2XwuvHn27" title="Franchise fees"><ix:nonFraction name="NAOV:FranchiseFees" contextRef="From2023-01-012023-12-31" id="Fact001245" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000</ix:nonFraction></span> of state franchise fees during the year ended December 31, 2023. The difference between
the statutory tax rate of the Company and the effective tax rate is primarily the result of tax benefits generated by the Company and
its subsidiary which have not been recognized due to the uncertainty that such tax benefits will ultimately be realized. A reconciliation
of the statutory U.S Federal rate to the Company&#8217;s effective tax rate is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001247" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zrv6m6x4H7jb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="display: none"><span id="xdx_8BF_zy6isbGgFFHj">SCHEDULE
OF RECONCILIATION OF STATUTORY U.S. FEDERAL RATE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20240101__20241231_zo1qpy21NxQj" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_zuaiCLWSH0Ib" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_maETR_z08mTPio2hF7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Federal income tax benefit at statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><p style="margin: 0"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-01to2024-12-31" id="Fact001249" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.00</ix:nonFraction></p></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-012023-12-31" id="Fact001250" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.00</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_maETR_z0WtBKY24cWi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State income taxes, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2024-01-01to2024-12-31" id="Fact001252" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.31</ix:nonFraction></p></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-01-012023-12-31" id="Fact001253" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.13</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_maETR_zgi3HoYswTL2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign rate differential</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="From2024-01-01to2024-12-31" id="Fact001255" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.04</ix:nonFraction></p></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="From2023-01-012023-12-31" id="Fact001256" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.10</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_407_ecustom--EffectiveIncomeTaxRateReconciliationPermanentItems_pid_dp_maETR_z2zbMpdHaZX8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Permanent Items</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">-<ix:nonFraction name="NAOV:EffectiveIncomeTaxRateReconciliationPermanentItems" contextRef="From2024-01-01to2024-12-31" id="Fact001258" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.04</ix:nonFraction></p></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-<ix:nonFraction name="NAOV:EffectiveIncomeTaxRateReconciliationPermanentItems" contextRef="From2023-01-012023-12-31" id="Fact001259" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.63</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_maETR_zOvN0UqjO8Ud" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">-<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2024-01-01to2024-12-31" id="Fact001261" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">21.51</ix:nonFraction></p></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-01-012023-12-31" id="Fact001262" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">33.54</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_pid_dp_maETR_z8eeJ4Wu87g3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Return to provision adjustments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" contextRef="From2024-01-01to2024-12-31" id="Fact001264" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.40</ix:nonFraction></p></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" contextRef="From2023-01-012023-12-31" id="Fact001265" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.20</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_406_ecustom--EffectiveIncomeTaxRateReconciliationForfeitedOptions_pid_dp_maETR_zFm7YbMTTPql" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Forfeited options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><ix:nonFraction name="NAOV:EffectiveIncomeTaxRateReconciliationForfeitedOptions" contextRef="From2024-01-01to2024-12-31" id="Fact001267" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></p></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NAOV:EffectiveIncomeTaxRateReconciliationForfeitedOptions" contextRef="From2023-01-012023-12-31" id="Fact001268" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_maETR_zI863VO3wvn2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2024-01-01to2024-12-31" id="Fact001270" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.30</ix:nonFraction></p></td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2023-01-012023-12-31" id="Fact001271" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.01</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_mtETR_z1dnfdx1pM2a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Effective tax rate</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="margin: 0">-<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2024-01-01to2024-12-31" id="Fact001273" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.51</ix:nonFraction></p></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2023-01-012023-12-31" id="Fact001274" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.06</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_ziPJdL6rinP4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Foreign
tax</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
rates applicable to the income of the Israeli subsidiary:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Israeli corporate tax rate in 2024 and 2023 is <span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20240101__20241231__srt--StatementGeographicalAxis__country--IL_zBjOn3dBgtsk" title="Corporate tax rate"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20230101__20231231__srt--StatementGeographicalAxis__country--IL_zUclM5JiY825" title="Corporate tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-012024-12-31_country_IL" id="Fact001276" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-012023-12-31_country_IL" id="Fact001278" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">23</ix:nonFraction></ix:nonFraction></span></span>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 174 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
subsidiary has final tax assessments through 2017.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
before taxes:</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001280" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_z8kq8o1y2ys9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="display: none"><span id="xdx_8B5_z95j9vk6bTZd">SCHEDULE
OF INCOME BEFORE TAXES ON DOMESTIC AND FOREIGN</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20241231_zflRt6iwtLFh" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20230101__20231231_zh2ylrDK48Vc" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_maILFCOz5C4_zGWQb8RJ19ce" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Domestic</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><p style="margin: 0"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2024-01-01to2024-12-31" id="Fact001282" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,775,000</ix:nonFraction></p></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2023-01-012023-12-31" id="Fact001283" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,785,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_maILFCOz5C4_zh5XuOSYkMd9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Foreign</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="From2024-01-01to2024-12-31" id="Fact001285" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">89,000</ix:nonFraction></p></td><td style="padding-bottom: 1pt; text-align: left">)<br/>
</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="From2023-01-012023-12-31" id="Fact001286" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">103,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iNT_di_mtILFCOz5C4_z6Gc6eupoZMc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss before taxes</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="margin: 0"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-01-01to2024-12-31" id="Fact001288" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,686,000</ix:nonFraction></p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-01-012023-12-31" id="Fact001289" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,682,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zahqvlabvfk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Deferred
income taxes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial
purposes and the amounts used for income tax purposes. Significant components of the Company&#8217;s deferred tax assets are as follows:</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001291" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zNYO9gPUIDh6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="display: none"><span id="xdx_8B2_zqf9uXoQr892">SCHEDULE
OF DEFERRED TAX ASSETS</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20241231_zmAEAoSVgAI4" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20231231_za5qgwPsI8ih" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzNu2_zv8U2kJ3Ihtf" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Net operating loss carryforward</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><p style="margin: 0"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2024-12-31" id="Fact001293" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,032,000</ix:nonFraction></p></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31" id="Fact001294" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,486,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DeferredTaxAssetsOfCapitalLossCarryforward_iI_maDTAGzNu2_zAffx37hB6U" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Capital loss carryforward</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><ix:nonFraction name="NAOV:DeferredTaxAssetsOfCapitalLossCarryforward" contextRef="AsOf2024-12-31" id="Fact001296" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1297">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--DeferredTaxAssetsTaxDeferredExpenseAccruals_iI_maDTAGzNu2_zLxfObrePuZj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Arbitration accrual</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><ix:nonFraction name="NAOV:DeferredTaxAssetsTaxDeferredExpenseAccruals" contextRef="AsOf2024-12-31" id="Fact001299" format="ixt:numdotdecimal" decimals="0" unitRef="USD">414,000</ix:nonFraction></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NAOV:DeferredTaxAssetsTaxDeferredExpenseAccruals" contextRef="AsOf2023-12-31" id="Fact001300" format="ixt:numdotdecimal" decimals="0" unitRef="USD">414,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_iI_maDTAGzNu2_z9VaXSu4vkA3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Stock compensation and other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" contextRef="AsOf2024-12-31" id="Fact001302" format="ixt:numdotdecimal" decimals="0" unitRef="USD">849,000</ix:nonFraction></p></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" contextRef="AsOf2023-12-31" id="Fact001303" format="ixt:numdotdecimal" decimals="0" unitRef="USD">570,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzNu2_maDTALNzt1d_zNYrTbXgZi7k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred tax assets before valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2024-12-31" id="Fact001305" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,300,000</ix:nonFraction></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2023-12-31" id="Fact001306" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,470,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzt1d_ziepFG8hpcqa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-12-31" id="Fact001308" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,300,000</ix:nonFraction></p></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31" id="Fact001309" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,470,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzt1d_zTvmpeSxKzj4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax asset</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1311">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1312">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zLlNAwKlYRFb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2024, and 2023, the net increase in valuation allowance of $<span id="xdx_90B_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20240101__20241231_zdWUZmdn9IDa" title="Net increases in valuation allowance"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2024-01-01to2024-12-31" id="Fact001314" format="ixt:numdotdecimal" decimals="0" unitRef="USD">830,000</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20230101__20231231_znwa6UWAWFZb" title="Net increases in valuation allowance"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2023-01-012023-12-31" id="Fact001316" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,267,000</ix:nonFraction></span>, respectively, was primarily
driven by the increase in net operating loss carry forwards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
assessing the realization of deferred tax assets, management considers whether it is more likely than not that all or some portion of
the deferred tax assets will not be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which
temporary differences are deductible and net operating losses are able to be utilized. Based on consideration of these factors, the Company
concluded that all of its recorded deferred tax assets are not more likely than not realizable and recorded a full valuation allowance
at December 31, 2024, and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers the earnings of its non-U.S. subsidiary to be indefinitely invested outside the United States on the basis of estimates
that future domestic cash generation will be sufficient to meet future domestic cash needs and our specific plans for reinvestment of
those subsidiary earnings. We have not recorded a deferred tax liability related to the U.S. federal and state income taxes as an estimate
of undistributed earnings of foreign subsidiaries would not be practicable to estimate at this time. If the Company does decide to repatriate
the foreign earnings, we would need to adjust our income tax provision in the period we determined that the earnings will no longer be
indefinitely invested outside the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Reconciliation
of the theoretical tax expense to the actual tax expense</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
main reconciling items between the statutory tax rate of the Company and the effective tax rate are the non-recognition of tax benefits
from accumulated net operating loss carry forward among the Company and its subsidiary due to the uncertainty of the realization of such
tax benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s policy is to record interest and penalties associated with unrecognized tax benefits as additional income taxes in the
statement of operations. As of December 31, 2024, and 2023, the Company does not have any liabilities recorded for uncertain tax positions
and does not expect there to be any events which could potentially result in the need for a material liability to be recorded. There
were no changes in the Company&#8217;s unrecognized tax benefits during the years ended December 31, 2024, and 2023. The Company did
not recognize any interest or penalties during fiscal 2024 or 2023 related to unrecognized tax benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 175 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
federal and New York State income taxes are open for examination for years 2021-2024 and Israel tax returns are open for examination
for years 2020-2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001318" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_800_eus-gaap--SubsequentEventsTextBlock_zVnW4T3NxjT8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
14 - <span id="xdx_82D_zxjt7wXRCZ8h">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>January
2025 3(a)(9) Exchange</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 7, 2025, NanoVibronix, Inc. entered into a securities exchange agreement (the &#8220;Exchange Agreement&#8221;) with a
certain institutional investor (the &#8220;Holder&#8221;) pursuant to which the Company agreed to issue an aggregate of (i) </span><span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250107__20250107__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z7YnanCYZ2d" title="Number of new share issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-01-072025-01-07_custom_SecuritiesExchangeAgreementMember_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember" id="Fact001320" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">456,478</ix:nonFraction></span>
shares of common stock, (ii) a warrant to purchase up to <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250701__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zS8Mo5U1rMq8" title="Number of securities called by warrants or rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-07-01_custom_SecuritiesExchangeAgreementMember_us-gaap_WarrantMember_us-gaap_SubsequentEventMember" id="Fact001322" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">158,562</ix:nonFraction></span>
shares of Common Stock (the &#8220;Warrant&#8221; and such shares issuable upon exercise of the Warrant, the &#8220;Warrant
Shares&#8221;) and (iii) a pre-funded warrant to purchase up to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250107__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBXvyVcqNqO7" title="Number of securities called by warrants or rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-01-07_custom_SecuritiesExchangeAgreementMember_custom_PreFundedWarrantsMember_us-gaap_SubsequentEventMember" id="Fact001324" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">178,132</ix:nonFraction></span>
shares of common stock (the &#8220;Pre-Funded Warrant&#8221; and such shares of Common Stock issuable upon exercise of the
Pre-Funded Warrant, the &#8220;Pre-Funded Warrant Shares&#8221;), in exchange for a certain outstanding Series A-1 Warrant held by
the Holder to purchase up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250107__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zv9eRRiYWhyd" title="Number of securities called by warrants or rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-01-07_custom_SecuritiesExchangeAgreementMember_custom_A1WarrantsMember_us-gaap_SubsequentEventMember" id="Fact001326" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">264,271</ix:nonFraction> </span>
shares of common stock at an exercise price of $<span id="xdx_902_eus-gaap--WarrantExercisePriceIncrease_pid_c20250107__20250107__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBx2JX4I5v8k" title="Warrant exercise price"><ix:nonFraction name="us-gaap:WarrantExercisePriceIncrease" contextRef="From2025-01-072025-01-07_custom_SecuritiesExchangeAgreementMember_custom_A1WarrantsMember_us-gaap_SubsequentEventMember" id="Fact001328" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">16.17</ix:nonFraction></span>
per share (the &#8220;Exchange&#8221;). The Company cancelled the Series A-1 Warrant reacquired in the Exchange and such Series A-1
Warrant will not be reissued. The Warrant has substantially the same terms as the Series A-1 Warrant, except that the Warrant Shares
are subject to stockholder approval (the &#8220;January 2025 Stockholder Approval&#8221;) pursuant to the applicable rules and
regulations of the Nasdaq Capital Market, exercisable for a term of five and one half years from the date the January 2025
Stockholder Approval is received and deemed effective under Delaware law, and has an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250107__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zoaFDuVfyANj" title="Exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-01-07_custom_SecuritiesExchangeAgreementMember_custom_PreFundedWarrantsMember_us-gaap_SubsequentEventMember" id="Fact001330" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.82968</ix:nonFraction></span>
per share. During the months January and February 2025, the Holder exercised all <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zM9xUT4WaVb9" title="Warrant exercise, shares"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250228__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4yVUDKxbv56" title="Warrant exercise, shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-01-31_custom_SecuritiesExchangeAgreementMember_custom_PreFundedWarrantsMember_us-gaap_SubsequentEventMember" id="Fact001332" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-02-28_custom_SecuritiesExchangeAgreementMember_custom_PreFundedWarrantsMember_us-gaap_SubsequentEventMember" id="Fact001334" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">178,132</ix:nonFraction></ix:nonFraction></span></span>
shares of its Pre-Funded Warrants converting the Warrants into <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zNL2V0c5RO09" title="Warrant exercise, conversion shares"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250228__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zyvJcGvZ89k6" title="Warrant exercise, conversion shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-01-31_custom_SecuritiesExchangeAgreementMember_us-gaap_WarrantMember_us-gaap_SubsequentEventMember" id="Fact001336" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-02-28_custom_SecuritiesExchangeAgreementMember_us-gaap_WarrantMember_us-gaap_SubsequentEventMember" id="Fact001338" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">177,773</ix:nonFraction></ix:nonFraction></span></span>
shares of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Merger
with ENvue Medical Holdings, Corp.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2025, Nanovibronix, Inc., a Delaware corporation (the &#8220;Company&#8221;) entered into that certain Agreement and Plan
of Merger (the &#8220;Merger Agreement&#8221;) with NVEH Merger Sub I, Inc., a Delaware corporation (&#8220;First Merger Sub&#8221;),
NVEH Merger Sub II, LLC, a Delaware limited liability company (&#8220;Second Merger Sub&#8221;) and ENvue Medical Holdings, Corp. (&#8220;ENvue&#8221;).
Pursuant to the terms of the Merger Agreement, the Company and ENvue effected (i) a merger of First Merger Sub with and into ENvue, with
the First Merger Sub ceasing to exist and ENvue becoming a wholly-owned subsidiary the Company (the &#8220;First Effective Time&#8221;)
and (ii) the merger of ENvue with and into Second Merger Sub (the &#8220;Second Merger&#8221; and such effective time, the &#8220;Second
Effective Time&#8221; and, the Second Merger together with the First Merger, the &#8220;Merger&#8221;), with Second Merger Sub being
the surviving entity of the Second Merger (&#8220;Surviving Entity&#8221;). At the Second Effective Time, the certificate of formation
of the Surviving Entity was amended and restated to, among other things, to change the name of the Surviving Entity to &#8220;ENvue Medical
Holdings LLC.&#8221; In connection with the Merger Agreement, the Company issued (i) <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250214__20250214__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWQarZE0tpXk" title="Number of new share issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-02-142025-02-14_custom_MergerAgreementMember_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember" id="Fact001340" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,734,995</ix:nonFraction></span> shares (the &#8220;Merger Shares&#8221;)
of common stock to the holders of ENvue, which such number of shares represented no more than <span id="xdx_90D_ecustom--PercentageForNumberOfOutstandingCommonStock_pid_dp_uPure_c20250214__20250214__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MaximumMember_zNF2rx9MMAP1" title="Percentage for number of outstanding common stock"><ix:nonFraction name="NAOV:PercentageForNumberOfOutstandingCommonStock" contextRef="From2025-02-142025-02-14_custom_MergerAgreementMember_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember_srt_MaximumMember" id="Fact001342" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">19.9</ix:nonFraction></span>% (the &#8220;Exchange Cap&#8221;)
of the outstanding shares of common stock immediately prior to the First Effective Time and (ii) <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20250214__20250214__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4jB66F6WwG8" title="Convertible shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2025-02-142025-02-14_custom_MergerAgreementMember_custom_SeriesXPreferredStockMember_us-gaap_SubsequentEventMember" id="Fact001344" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">57,720</ix:nonFraction></span> shares of Series X Non-Voting
Convertible Preferred Stock (the &#8220;Series X Preferred Stock&#8221;), as further described below, in excess of the Exchange Cap to
the holders of ENvue in consideration for <span id="xdx_90A_ecustom--PercentageForExchangeCapitalForConsideration_pid_dp_uPure_c20250214__20250214__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zofx9pBUwHc7" title="Percentage for exchange capital for consideration"><ix:nonFraction name="NAOV:PercentageForExchangeCapitalForConsideration" contextRef="From2025-02-142025-02-14_custom_MergerAgreementMember_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember" id="Fact001346" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% of ENvue. Each share of Series X Preferred Stock will be convertible into <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20250214__20250214__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTyV8wTgHoB8" title="Convertible shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2025-02-142025-02-14_custom_MergerAgreementMember_custom_SeriesXPreferredStockMember_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember" id="Fact001348" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000</ix:nonFraction></span> shares
of common stock, subject to and contingent upon the affirmative vote of a majority of the shares of common stock present or represented
and entitled to vote at a meeting of stockholders of Company to approve, for purposes of the Nasdaq Listing Rules, the issuance of shares
of common stock to the stockholders of ENvue upon conversion of any and all shares of Series X Preferred Stock in accordance with the
terms of the Series X Certificate of Designations. The Merger was consummated and completed on February 14, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
giving effect to the Merger, pursuant to the terms and conditions of the Merger Agreement: (i) <span id="xdx_904_eus-gaap--ConvertiblePreferredStockTermsOfConversion_c20250214__20250214__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zdDj6Jhntzxi" title="Convertible description"><ix:nonNumeric contextRef="From2025-02-142025-02-14_custom_MergerAgreementMember_custom_SeriesXPreferredStockMember_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember" id="Fact001350" name="us-gaap:ConvertiblePreferredStockTermsOfConversion">the holders of the outstanding equity
of ENvue immediately prior to the First Effective Time own 19.9% of the common stock of the Company and 85.0% of the outstanding equity
of the Company (assuming the Series X Preferred Stock is converting at a ratio of 1,000:1) immediately following the First Effective
Time, which following Merger Stockholder Approval will allow the Series X Preferred Stock to convert to common stock of the Company which
may result in the holders of ENvue to own 85% of the common stock of the Company, and (ii) the holders of the Company&#8217;s outstanding
equity immediately prior to the First Effective Time own 80.1% of the common stock of the Company and 15.0% of the outstanding equity
of the Company (assuming the Series X Preferred Stock is converting at a ratio of 1,000:1) immediately following the First Effective
Time, which following Merger Stockholder Approval which will allow the Series X Preferred Stock to convert to common stock of the Company
which may result in our holders owning 15% of common stock of the Company.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Debenture
Financing and Senior Convertible Debenture</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 13, 2025, the Company entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with an institutional
investor (the &#8220;Investor&#8221;), pursuant to which the Company sold in a private placement, a senior convertible debenture (the
&#8220;Debenture&#8221;) due the earlier of (i) the date that is the 30-day anniversary of the effective date of stockholder approval
(the &#8220;Debenture Stockholder Approval&#8221;) of the issuance of the shares of common stock upon the conversion of the debenture
(the &#8220;Debenture Financing&#8221;) and (ii) the date that is nine months following the date of issuance of the Debenture (&#8220;Maturity
Date&#8221;), having an aggregate principal amount of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20250213__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztfn7uQ5nZmd" title="Debt principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2025-02-13_custom_SecuritiesExchangeAgreementMember_us-gaap_SubsequentEventMember" id="Fact001352" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></span>. In connection with the Debenture Financing, the Company also entered
into Registration Rights Agreement (the &#8220;Registration Rights Agreement&#8221;) with the Investor, pursuant which the Company is
required to prepare and file a resale registration statement with the SEC within 30 calendar days following the closing date of the Debenture
Financing (the &#8220;Filing Deadline&#8221;). The Company shall use its commercially reasonable efforts to cause such registration statement
to be declared effective by the SEC within 60 calendar days of the Filing Deadline (or within 90 calendar days if the SEC reviews the
resale registration statement). The closing of the Debenture Financing occurred on February 14, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">On March 26, 2025 we amended
and restated the Debenture to increase the Principal Amount to $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20250326__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--ENvueMedicalHoldingsCorpMember_z9s5Qh1nhyL1" title="Debt principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2025-03-26_us-gaap_SubsequentEventMember_custom_ENvueMedicalHoldingsCorpMember" id="Fact001354" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,300,000</ix:nonFraction></span> to provide for the funding by Alpha Capital Anstalt (the &#8220;Investor&#8221;)
to our subsidiary ENvue Medical Holdings, Corp. (&#8220;<b><i>ENvue</i></b>&#8221;), a wholly owned subsidiary of the Company of (i) an
aggregate of $<span id="xdx_908_eus-gaap--Investments_iI_c20250226__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--ENvueMedicalHoldingsCorpMember_z75NUxhiTEx3" title="Investments"><ix:nonFraction name="us-gaap:Investments" contextRef="AsOf2025-02-26_us-gaap_SubsequentEventMember_custom_ENvueMedicalHoldingsCorpMember" id="Fact001356" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> by the Investor to ENvue on February 6, 2025, (ii) an aggregate of $<span id="xdx_908_eus-gaap--Investments_iI_c20250304__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--ENvueMedicalHoldingsCorpMember_zUFZzGEUTw48" title="Investments"><ix:nonFraction name="us-gaap:Investments" contextRef="AsOf2025-03-04_us-gaap_SubsequentEventMember_custom_ENvueMedicalHoldingsCorpMember" id="Fact001358" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> by the Investor to ENvue on March 4,
2025, and (iii) and an aggregate of $<span id="xdx_903_eus-gaap--Investments_iI_c20250326__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--ENvueMedicalHoldingsCorpMember_zTYO8drNHNg9" title="Investments"><ix:nonFraction name="us-gaap:Investments" contextRef="AsOf2025-03-26_us-gaap_SubsequentEventMember_custom_ENvueMedicalHoldingsCorpMember" id="Fact001360" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></span> by the Investor to ENvue on March 26, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">On the Maturity Date, we shall pay the Investor in
cash or, at the option of the Investor, in the form of conversion shares, or a combination thereof, the entire outstanding principal amount
of the Debenture, together with accrued and unpaid interest thereon, the applicable exit fee and any other amounts due thereunder. Following
the receipt of Debenture Stockholder Approval, the Debenture shall be convertible, in whole or in part, into shares of common stock, at
the option of the Investor, at the initial conversion price of $<span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20250326__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--ENvueMedicalHoldingsCorpMember_zzitXf8keZIh" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2025-03-26_us-gaap_SubsequentEventMember_custom_ENvueMedicalHoldingsCorpMember" id="Fact001362" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.8906</ix:nonFraction></span> (the &#8220;Conversion Price&#8221;), which is subject to customary
anti-dilution adjustments, and which such Conversion Price shall not be lower than the floor price of $<span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20250326__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_zKUZEPIGWnr4" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2025-03-26_us-gaap_SubsequentEventMember_srt_MinimumMember" id="Fact001364" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.97812</ix:nonFraction></span>. The Debenture bears interest
at the rate of <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20250326__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--ENvueMedicalHoldingsCorpMember_zBwPu3twiGt8" title="Debt interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2025-03-26_us-gaap_SubsequentEventMember_custom_ENvueMedicalHoldingsCorpMember" id="Fact001366" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.0</ix:nonFraction></span>% per annum, payable on the Maturity Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2025
Reverse Stock Split</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 13, 2025, the Company effected the 2025 Reverse Stock Split. As a result of the 2025 Reverse Stock Split, every 11 shares of issued
and outstanding common stock were automatically combined into one issued and outstanding share of common stock, without any change in
the par value per share. No fractional shares were issued as a result of the 2025 Reverse Stock Split. Any fractional shares that would
otherwise have resulted from the Reverse Stock Split was rounded up to the next whole number. The 2025 Reverse Stock Split reduced the
number of shares of common stock outstanding from <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_pid_c20250312__20250312__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlSSQU1U9Pj3" title="Reverse stock split outstanding shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" contextRef="From2025-03-122025-03-12_us-gaap_SubsequentEventMember" id="Fact001368" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,716,327</ix:nonFraction></span> shares to approximately <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_pid_c20250313__20250313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTB7AsTcY3md" title="Reverse stock split outstanding shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" contextRef="From2025-03-132025-03-13_us-gaap_SubsequentEventMember" id="Fact001370" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">792,394</ix:nonFraction></span> shares, subject to adjustment for the rounding
up of fractional shares. The number of authorized shares of common stock under the Company&#8217;s Amended and Restated Certificate of
Incorporation, as amended remained unchanged at <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20250313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zcXkjfYohdO4" title="Common stock shares remained unchanged"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-03-13_us-gaap_SubsequentEventMember" id="Fact001372" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000,000</ix:nonFraction></span> shares.</span></p>

</ix:nonNumeric><p id="xdx_817_zgILroYl5wwa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 176 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Index
to Exhibits</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 0.5in; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315225006855/ex2-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement and Plan of Merger, dated February 14, 2025, by and among NanoVibronix, Inc., NVEH Merger Sub I, Inc., NVEH Merger Sub II, LLC and ENvue Medical Holdings, Corp. (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 14, 2025).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000114420415023396/v407400_ex3-1.htm" style="-sec-extract: exhibit">Amended and Restated Certificate of Incorporation (as presently in effect) (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on April 17, 2015).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000114420414026177/v376141_ex3-2.htm" style="-sec-extract: exhibit">Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to Amendment No. 3 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on April 30, 2014).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000114420414026177/v376141_ex3-3.htm" style="-sec-extract: exhibit">Certificate of Amendment of Certificate of Incorporation (creating the Series C Preferred Stock) (incorporated by reference to Exhibit 3.3 to Amendment No. 3 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on April 30, 2014).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000161577417006323/s108034_ex3-1.htm" style="-sec-extract: exhibit">Certificate
    of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock (incorporated by reference to Exhibit
    3.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on November 7, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000121390019024108/f10q0919ex4-1_nanovibronix.htm" style="-sec-extract: exhibit">Certificate of Designation, Preferences, Rights and Limitations of Series E Preferred Stock (incorporated by reference to Exhibit 4.1 to the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 19, 2019).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000121390019024350/f8k111819ex3-1_nanovibronix.htm" style="-sec-extract: exhibit">Certificate of Amendment of the Amended and Restated Certificate of Designation (incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on November 21, 2019).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315221028715/ex3-7.htm" style="-sec-extract: exhibit">Certificate of Amendment of Certificate of Incorporation (incorporated by reference to Exhibit 3.7 to the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 15, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315221027166/ex3-1.htm" style="-sec-extract: exhibit">Amendment
    to the Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the
    Securities and Exchange Commission on November 3, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315222025823/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Designation, Preferences, Rights and Limitations of Series F Preferred Stock (incorporated by reference to Exhibit 3.1 to the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315223003953/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Amendment of Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Current Report filed with the Securities and Exchange Commission on February 8, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">3.11</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315225006855/ex3-1.htm" style="-sec-extract: exhibit">Certificate
    of Designations of Preferences, Rights and Limitations of Series X Non-Voting Convertible Preferred Stock, dated February 14, 2025
    (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on
    February 14, 2025).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315225010040/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Amendment to the Amended and Restated Certificate of Incorporation, as amended, of NanoVibronix, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on March 12, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000114420414013884/v370657_ex4-2.htm" style="-sec-extract: exhibit">Form of Common Stock Certificate (incorporated by reference to Exhibit 4.2 to Amendment No. 1 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on March 6, 2014).</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 177; Options: NewSection; Value: 153 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->153<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000161577419008162/s118351_ex4-1.htm" style="-sec-extract: exhibit">Form of May 10 and May 15, 2019 Warrants (incorporated by reference to Exhibit 4.1 to the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 20, 2019).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000121390019011522/f8k062119ex4-2_nanovibronix.htm" style="-sec-extract: exhibit">Form of Warrant (incorporated by reference to Exhibit 4.2 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on June 26, 2019).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000121390019014211/f8k073119ex4-2_nanovibro.htm" style="-sec-extract: exhibit">Form of Preferred Warrant (incorporated by reference to Exhibit 4.2 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on July 31, 2019).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000121390019014211/f8k073119ex4-3_nanovibro.htm" style="-sec-extract: exhibit">Form of Common Warrant (incorporated by reference to Exhibit 4.3 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on July 31, 2019).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315220009519/ex4-10.htm" style="-sec-extract: exhibit">Form of Warrant Amendment (incorporated by reference to Exhibit 4.10 to the Annual Report on Form 10-K filed with the Securities and Exchange Commission on May 20, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315220016774/ex4-1.htm" style="-sec-extract: exhibit">Form of Underwriter Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on August 26, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315220018277/ex4-1.htm" style="-sec-extract: exhibit">Form of Underwriter Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on September 24, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315220023054/ex4-1.htm" style="-sec-extract: exhibit">Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on December 7, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315220023054/ex4-2.htm" style="-sec-extract: exhibit">Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.2 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on December 7, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315222034062/ex4-1.htm" style="-sec-extract: exhibit">Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on December 1, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315223031487/ex4-1.htm" style="-sec-extract: exhibit">Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on September 1, 2023).</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315223031487/ex4-3.htm" style="-sec-extract: exhibit">Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.3 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on September 1, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315225001116/ex4-1.htm" style="-sec-extract: exhibit">Form
    of Warrant issued on January 7, 2025 (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the
    Securities and Exchange Commission on January 7, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315225001116/ex4-2.htm" style="-sec-extract: exhibit">Form
    of Pre-Funded Warrant issued on January 7, 2025 (incorporated by reference to Exhibit 4.2 to the Current Report on Form 8-K filed
    with the Securities and Exchange Commission on January 7, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315225006855/ex4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Senior Convertible Debenture , issued on February 13, 2025(incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the
    Securities and Exchange Commission on February 14, 2025).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.17*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex4-17.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Securities.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000114420415007032/v400364_ex10-9.htm" style="-sec-extract: exhibit">Fourteenth Amended and Restated Securities Purchase Agreement, dated June 16, 2014, by and between NanoVibronix, Inc. and Globis Overseas Fund, Ltd. (incorporated by reference to Exhibit 10.9 to the Registration Statement on Form 10 filed with the Securities and Exchange Commission on February 9, 2015).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000114420415007032/v400364_ex10-10.htm" style="-sec-extract: exhibit">Fourteenth Amended and Restated Securities Purchase Agreement, dated December 11, 2014, by and between NanoVibronix, Inc. and Globis Capital Partners, L.P. (incorporated by reference to Exhibit 10.10 to the Registration Statement on Form 10 filed with the Securities and Exchange Commission on February 9, 2015).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000114420415007032/v400364_ex10-11.htm" style="-sec-extract: exhibit">Fifteenth Amended and Restated Secured Convertible Promissory Note, dated December 11, 2014, by NanoVibronix, Inc. in favor of and Globis Overseas Fund, Ltd. (incorporated by reference to Exhibit 10.11 to the Registration Statement on Form 10 filed with the Securities and Exchange Commission on February 9, 2015).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000114420415007032/v400364_ex10-12.htm" style="-sec-extract: exhibit">Fifteenth Amended and Restated Secured Convertible Promissory Note, dated December 11, 2014, by NanoVibronix, Inc. in favor of and Globis Capital Partners, L.P. (incorporated by reference to Exhibit 10.12 to the Registration Statement on Form 10 filed with the Securities and Exchange Commission on February 9, 2015).</a></span></td></tr>
</table>

<p style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></p>

<!-- Field: Page; Sequence: 178; Value: 153 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->154<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000114420414017621/v372463_ex10-13.htm" style="-sec-extract: exhibit">Form of Amended and Restated 2013 and 2014 Warrant to Purchase Common Stock (incorporated by reference to Exhibit 10.13 to Amendment No. 2 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on March 25, 2014).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000114420414013884/v370657_ex10-14.htm" style="-sec-extract: exhibit">NanoVibronix, Inc. 2004 Global Share Option Plan (incorporated by reference to Exhibit 10.14 to Amendment No. 1 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on March 6, 2014).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000114420414013884/v370657_ex10-15.htm" style="-sec-extract: exhibit">Personal Employment Agreement, dated March 1, 2008, by and between Nano-Vibronix (Israel 2003) Ltd and Jona Zumeris (incorporated by reference to Exhibit 10.15 to Amendment No. 1 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on March 6, 2014).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000114420414013884/v370657_ex10-16.htm" style="-sec-extract: exhibit">Form of Indemnification Agreement between NanoVibronix, Inc. and certain of its officers and directors (incorporated by reference to Exhibit 10.16 to Amendment No. 1 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on March 6, 2014).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000114420414013884/v370657_ex10-17.htm" style="-sec-extract: exhibit">Amendment to Subscription Agreement Convertible Promissory Notes, dated February 28, 2014, by and between NanoVibronix, Inc. and the note holders signatory thereto (incorporated by reference to Exhibit 10.17 to Amendment No. 1 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on March 6, 2014).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000114420414013884/v370657_ex10-19.htm" style="-sec-extract: exhibit">Second Amendment to Subscription Agreement Series B Convertible Preferred Stock and Warrants), dated February 28, 2014, by and between NanoVibronix, Inc. and the holders signatory thereto (incorporated by reference to Exhibit 10.19 to Amendment No. 1 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on March 6, 2014).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000114420414013884/v370657_ex10-20.htm" style="-sec-extract: exhibit">Third Amendment to Subscription Agreement Series B Convertible Preferred Stock and Warrants), dated February 28, 2014, by and between NanoVibronix, Inc. and the holders signatory thereto (incorporated by reference to Exhibit 10.20 to Amendment No. 1 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on March 6, 2014).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000114420414026177/v376141_ex10-27.htm" style="-sec-extract: exhibit">NanoVibronix, Inc. 2014 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.27 to Amendment No. 3 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on April 30, 2014).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000114420414039017/v381244_ex10-29.htm" style="-sec-extract: exhibit">First Amendment to Personal Employment Agreement, dated June 16, 2014, by and between NanoVibronix, Inc. and Dr. Jona Zumeris (incorporated by reference to Exhibit 10.29 to Amendment No. 8 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on June 23, 2014).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000114420415019323/v405877_ex10-35.htm" style="-sec-extract: exhibit">Services Agreement, dated March 25, 2015, by and between Multigon Industries, Inc. and NanoVibronix, Inc. (incorporated by reference to Exhibit 10.35 to the Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2015).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000114420415019323/v405877_ex10-36.htm" style="-sec-extract: exhibit">Employment Agreement, dated March 25, 2015, by and between William Stern and NanoVibronix, Inc. (incorporated by reference to Exhibit 10.36 to the Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2015).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000114420415019323/v405877_ex10-39.htm" style="-sec-extract: exhibit">Letter Agreement, dated March 25, 2015, by and between NanoVibronix, Inc. and Martin Goldstein (incorporated by reference to Exhibit 10.39 to the Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2015).</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: center"></p>

<!-- Field: Page; Sequence: 179; Value: 153 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->155<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000114420415019323/v405877_ex10-40.htm" style="-sec-extract: exhibit">Form of Incentive Stock Option Award Agreement under the 2014 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.40 to the Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2015).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000114420415019323/v405877_ex10-41.htm" style="-sec-extract: exhibit">Form of Nonqualified Stock Option Award Agreement under the 2014 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.41 to the Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2015).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000114420415019323/v405877_ex10-42.htm" style="-sec-extract: exhibit">Form of Restricted Stock Award Agreement under the 2014 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.42 to the Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2015).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000114420415019323/v405877_ex10-43.htm" style="-sec-extract: exhibit">Form of 3(i) Award Agreement under the Israeli Appendix to the 2014 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.43 to the Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2015).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000114420415019323/v405877_ex10-44.htm" style="-sec-extract: exhibit">Form of 102 Award Agreement under the Israeli Appendix to the 2014 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.44 to the Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2015).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000114420416128601/v450779_ex10-3.htm" style="-sec-extract: exhibit">Employment Agreement, dated October 13, 2016, by and between NanoVibronix, Inc. and Brian Murphy (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on October 19, 2016).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000114420417013197/v461321_ex10-1.htm" style="-sec-extract: exhibit">Form of Convertible Promissory Note (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on March 7, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000114420417016715/v462688_ex10-1.htm" style="-sec-extract: exhibit">Convertible Promissory Note, dated March 23, 2017, by and between NanoVibronix, Inc. and an individual investor (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on March 27, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000114420417018057/v462181_ex10-51.htm" style="-sec-extract: exhibit">First
    Amendment to Nonqualified Stock Option Agreement, dated March 30, 2017, between NanoVibronix, Inc. and Ira A. Greenstein
    (incorporated by reference to Exhibit 10.51 to the Annual Report on Form 10-K filed with the Securities and Exchange Commission on
    March 31, 2017)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000114420417018057/v462181_ex10-52.htm" style="-sec-extract: exhibit">First
    Amendment to Nonqualified Stock Option Agreement, dated March 30, 2017, between NanoVibronix, Inc. and Ira A. Greenstein
    (incorporated by reference to Exhibit 10.52 to the Annual Report on Form 10-K filed with the Securities and Exchange Commission on
    March 31, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000114420416128601/v450779_ex10-1.htm" style="-sec-extract: exhibit">Offer Letter, dated October 14, 2016, between NanoVibronix, Inc. and Christopher M. Fashek (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on October 19, 2016).</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b></b></span></p>

<!-- Field: Page; Sequence: 180; Value: 153 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->156<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000114420416128601/v450779_ex10-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nonqualified Stock Option Agreement, dated October 14, 2016, between NanoVibronix, Inc. and Christopher M. Fashek (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on October 19, 2016).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000114420417024725/v466226_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Convertible Promissory Note (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on May 5, 2017).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000161577417005081/s107502_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Letter Agreement, dated September 7, 2017, between NanoVibronix, Inc. and holders of the 2017 Notes (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K/A filed with the Securities and Exchange Commission on September 14, 2017).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000161577419005785/s116899_ex10-36.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Agreement dated as of February 21, 2019, between NanoVibronix, Inc and Bespoke Growth Partners, Inc. (incorporated by reference to Exhibit 10.36 to the Annual Report on Form 10-K/A filed with the Securities and Exchange Commission on May 13, 2019).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.32</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000161577419005785/s116899_ex10-37.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible Promissory Note (incorporated by reference to Exhibit 10.37 to the Annual Report on Form 10-K/A filed with the Securities and Exchange Commission on May 13, 2019).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.33</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000161577419005785/s116899_ex10-38.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible Promissory Note (incorporated by reference to Exhibit 10.38 to the Annual Report on Form 10-K/A filed with the Securities and Exchange Commission on May 13, 2019).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.34</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000161577419005785/s116899_ex10-39.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant (incorporated by reference to Exhibit 10.39 to the Annual Report on Form 10-K/A filed with the Securities and Exchange Commission on May 13, 2019).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.35</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000161577419008162/s118351_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible Promissory Note (Globis), May 10, 2019 (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 20, 2019).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.36</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000161577419008162/s118351_ex10-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible Promissory Note (AiGH), May 15, 2019 (incorporated by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 20, 2019).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.37+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000161577419009203/s118829_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CFO Consulting Agreement, dated as of June 1, 2019, between NanoVibronix Inc. and James S. Cardwell (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on June 4, 2019).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.38</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000121390019011522/f8k062119ex10-1_nanovibronix.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Purchase Agreement, dated as of June 21, 2019, by and among the Company and each investor identified on the signature pages thereto (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on June 26, 2019).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.39</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000121390019014211/f8k073119ex10-1_nanovibro.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Purchase Agreement, dated as of July 31, 2019, by and among the Company and each investor identified on the signature pages thereto (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on July 31, 2019).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.40</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000121390019014211/f8k073119ex10-2_nanovibro.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Purchase Agreement, dated as of July 31, 2019, by and among the Company and each investor identified on the signature pages thereto (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on July 31, 2019).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.41</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315220011864/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Note (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on June 26, 2020).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.42</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315220011864/ex10-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on June 26, 2020).</span></a></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 181; Value: 153 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->157<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.43</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315220016309/ex10-3.htm" style="-sec-extract: exhibit">Note with Cross River Bank (SBA-Payroll Protection Program loan) dated May 14, 2020 (incorporated by reference to Exhibit 10.3 to the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 19, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.44+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315220019127/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement, dated as of October 5, 2020, between NanoVibronix, Inc. and Stephen Brown (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on October 8, 2020).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.45+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315220020509/ex10-1.htm" style="-sec-extract: exhibit">Option Cancellation and Release Agreement, dated November 2, 2020, by and between NanoVibronix, Inc. and Brian Murphy (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on November 5, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.46+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315220020509/ex10-2.htm" style="-sec-extract: exhibit">Option Cancellation and Release Agreement, dated November 2, 2020, by and between NanoVibronix, Inc. and Christopher Fashek (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on November 5, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.47+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315220020509/ex10-3.htm" style="-sec-extract: exhibit">Option Cancellation and Release Agreement, dated November 2, 2020, by and between NanoVibronix, Inc. and Martin Goldstein (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on November 5, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.48+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315220020509/ex10-4.htm" style="-sec-extract: exhibit">Option Cancellation and Release Agreement, dated November 2, 2020, by and between NanoVibronix, Inc. and Michael Ferguson (incorporated by reference to Exhibit 10.4 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on November 5, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.49+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315220020509/ex10-5.htm" style="-sec-extract: exhibit">Option Cancellation and Release Agreement, dated November 2, 2020, by and between NanoVibronix, Inc. and Stephen Brown (incorporated by reference to Exhibit 10.5 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on November 5, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.50+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315220020509/ex10-6.htm" style="-sec-extract: exhibit">Option Cancellation and Release Agreement, dated November 2, 2020, by and between NanoVibronix, Inc. and Thomas Mika (incorporated by reference to Exhibit 10.6 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on November 5, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.51</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315220023054/ex10-1.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement, dated December 2, 2020 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on December 7, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.52</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: -10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315220023054/ex10-2.htm" style="-sec-extract: exhibit">Form of Registration Rights Agreement, dated December 2, 2020 (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on December 7, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.53#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315221008951/ex10-58.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Distribution Agreement for &#8220;Private Labeled&#8221; Products dated December 10, 2020 by and between NanoVibronix, Inc. and Ultra Pain Products Inc (incorporated by reference to Exhibit 10.58 to the Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 15, 2021).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.54+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000161577419006754/s117834_def14a.htm#a027_v1" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second Amendment to the NanoVibronix, Inc. 2014 Long-Term Incentive Plan. (incorporated by reference to Annex A to the Company&#8217;s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 30, 2019).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.55+</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315221032899/ex10-1.htm" style="-sec-extract: exhibit">Third Amendment to the NanoVibronix, Inc. 2014 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on December 30, 2021).</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>


<!-- Field: Page; Sequence: 182; Value: 153 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->158<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.56</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315222035628/ex10-1.htm" style="-sec-extract: exhibit">Fourth Amendment to the NanoVibronix, Inc. 2014 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on December 15, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.57    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315222034062/ex10-1.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement, dated November 29, 2022 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on December 1, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.58</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315223031487/ex10-1.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement, dated August 30, 2023 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on September 1, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.59</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315223031487/ex10-2.htm" style="-sec-extract: exhibit">Form of Registration Rights Agreement, dated August 30, 2023 (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on September 1, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.60+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315223043577/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option Cancellation and Release Agreement, dated November 29, 2023, by and between NanoVibronix, Inc. and Aurora Cassirer (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities Exchange Commission on December 4, 2023). </span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.61+</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315223043577/ex10-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option Cancellation and Release Agreement, dated November 29, 2023, by and between NanoVibronix, Inc. and Brian Murphy (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the Securities Exchange Commission on December 4, 2023). </span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.62+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315223043577/ex10-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option Cancellation and Release Agreement, dated November 29, 2023, by and between NanoVibronix, Inc. and Christopher Fashek (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed with the Securities Exchange Commission on December 4, 2023). </span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.63+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315223043577/ex10-4.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option Cancellation and Release Agreement, dated November 29, 2023, by and between NanoVibronix, Inc. and Harold Jacob (incorporated by reference to Exhibit 10.4 to the Current Report on Form 8-K filed with the Securities Exchange Commission on December 4, 2023). </span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.64+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315223043577/ex10-5.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option Cancellation and Release Agreement, dated November 29, 2023, by and between NanoVibronix, Inc. and Maria Schroeder (incorporated by reference to Exhibit 10.5 to the Current Report on Form 8-K filed with the Securities Exchange Commission on December 4, 2023). </span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.65+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315223043577/ex10-6.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option Cancellation and Release Agreement, dated November 29, 2023, by and between NanoVibronix, Inc. and Martin Goldstein (incorporated by reference to Exhibit 10.6 to the Current Report on Form 8-K filed with the Securities Exchange Commission on December 4, 2023). </span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.66+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315223043577/ex10-7.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option Cancellation and Release Agreement, dated November 29, 2023, by and between NanoVibronix, Inc. and Michael Ferguson (incorporated by reference to Exhibit 10.7 to the Current Report on Form 8-K filed with the Securities Exchange Commission on December 4, 2023). </span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.67+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315223043577/ex10-8.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option Cancellation and Release Agreement, dated November 29, 2023, by and between NanoVibronix, Inc. and Stephen Brown (incorporated by reference to Exhibit 10.8 to the Current Report on Form 8-K filed with the Securities Exchange Commission on December 4, 2023). </span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.68+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315223043577/ex10-9.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option Cancellation and Release Agreement, dated November 29, 2023, by and between NanoVibronix, Inc. and Thomas Mika (incorporated by reference to Exhibit 10.9 to the Current Report on Form 8-K filed with the Securities Exchange Commission on December 4, 2023). </span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.69</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315223040577/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second Amendment to the Amended and Restated Distribution Agreement for &#8220;Private-Labled&#8221; Products dated December 10, 2020 by and between NanoVibronix, Inc. and Ultra Pain Products Inc. (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 13, 2023). </span></a></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 183; Value: 153 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->159<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">10.70#</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315224013966/ex10-75.htm" style="-sec-extract: exhibit">Standalone Services Agreement, dated March 22, 2024, by and between NanoVibronix, Inc. and Veranex, Inc. (incorporated by reference to Exhibit 10.75 to the Annual Report on Form 10-K filed on April 8, 2024).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.71</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315224013966/ex10-76.htm" style="-sec-extract: exhibit">Research Agreement, dated October 1, 2023, by and between NanoVibronix Inc. and the Regents of the University of Michigan (incorporated by reference to Exhibit 10.76 to the Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 8, 2024).</a></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.72+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315224038139/ex10-1.htm" style="-sec-extract: exhibit">Employment Agreement, dated as of September 20, 2024, by and between Brian Murphy and NanoVibronix, Inc. (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on September 25, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.73+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315224038139/ex10-2.htm" style="-sec-extract: exhibit">Employment Agreement, dated as of September 20, 2024, by and between Stephen Brown and NanoVibronix, Inc. (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on September 25, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.74+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315224051047/ex10-1.htm" style="-sec-extract: exhibit">NanoVibronix, Inc. Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on December 20, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.75</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315225001116/ex10-1.htm" style="-sec-extract: exhibit">Form of Exchange Agreement, effective as of January 7, 2025 (incorporated by reference to the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 7, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.76</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315225006855/ex10-1.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement, dated as of February 13, 2025, by and between NanoVibronix, Inc. and the purchaser named therein (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 14, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.77</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315225006855/ex10-2.htm" style="-sec-extract: exhibit">Form of Registration Rights Agreement, dated as of February 13, 2025, by and between NanoVibronix, Inc. and the purchaser named therein (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 14, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">10.78*</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex10-78.htm">Amended and Restated Senior Convertible Debenture Due the Earlier of the Trigger Date and November 13, 2025</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="margin: 0"><a href="ex21-1.htm"><span style="font-family: Times New Roman, Times, Serif">List of Subsidiaries.</span></a></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex23-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Zwick CPA, PLLC, Independent Registered Public Accounting Firm.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">24.1*</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif"><a href="#me_007">Power of Attorney (attached to the signature page hereto).</a></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex31-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Executive Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex31-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Financial Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex32-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Executive Officer Pursuant to Section 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex32-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Financial Officer Pursuant to Section 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1326706/000149315224013966/ex97-1.htm" style="-sec-extract: exhibit">Compensation Recovery Policy, adopted by the Board of Directors on November 6, 2023 (incorporated by reference to Exhibit 97.1 to the Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 8, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS*</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
                                            XBRL Instance Document.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Labels Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnished
    herewith.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
    contract or compensatory plan or arrangement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Portions
    of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K under the Securities Act of 1933, as amended,
    because they are both (i) not material and (ii) the type that the registrant treats as private or confidential. A copy of the omitted
    portions will be furnished to the Securities and Exchange Commission upon its request.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 184; Value: 153 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->160<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_006"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NANOVIBRONIX,
    INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Brian Murphy</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    Murphy</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer (Principal Executive Officer)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Stephen Brown</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stephen
    Brown</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer (Principal Financial and Accounting Officer)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2025</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_007"></span>POWER
OF ATTORNEY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">KNOW
ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Brian Murphy as his true and lawful
attorneys-in-fact and agents, with full power of substitution and re-substitution, for him and in his name, place and stead, in any and
all capacities, to sign any and all amendments to this Form 10-K, and to file the same, with all exhibits thereto, and other documents
in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to
do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes
as he might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or any of them or their
or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
Registrant and in the capacities and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    BRIAN MURPHY</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    Murphy</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal
    executive officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    STEPHEN BROWN</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stephen
    Brown</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal
    financial and accounting officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    CHRISTOPHER FASHEK</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of the Board of Directors</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    Fashek</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    MARTIN GOLDSTEIN</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Martin
    Goldstein</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    DORON BESSER, M.D.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Doron
    Besser, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    THOMAS R. MIKA</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas
    R. Mika</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    <span style="text-transform: uppercase">Aurora Cassirer</span></i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aurora
    Cassirer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    <span style="text-transform: uppercase">ZEEV ROTSTEIN</span></i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zeev
    Rotstein, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 185; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->161<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.17
<SEQUENCE>2
<FILENAME>ex4-17.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><B>Exhibit 4.17</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B><U>DESCRIPTION OF SECURITIES REGISTERED PURSUANT
TO SECTION 12 OF THE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B><U>SECURITIES EXCHANGE ACT OF 1934</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">As of March 31, 2025, NanoVibronix, Inc., a Delaware
corporation (&ldquo;we,&rdquo; &ldquo;our&rdquo; and the &ldquo;Company&rdquo;) has its common stock, par value $0.001 per share, registered
under Section 12 of the Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The following description is intended as a summary
and is qualified in its entirety by reference to our Amended and Restated Certificate of Incorporation (as amended, the &ldquo;Certificate
of Incorporation&rdquo;) and the Amended and Restated Bylaws (as amended, the &ldquo;Bylaws&rdquo;) as currently in effect, copies of
which are filed as exhibits to this Annual Report on Form 10-K and are incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>Authorized Capital Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">As of March 31, 2025, our authorized capital stock
consists of shares, of which 40,000,000 shares are common stock, par value $0.001 per share, and 5,040,000 shares are preferred stock,
par value $0.001 per share, 3,000,000 of which have been designated as Series C Convertible Preferred Stock (&ldquo;Series C Preferred
Stock&rdquo;), 506 of which have been designated as Series D Convertible Preferred Stock (&ldquo;Series D Preferred Stock&rdquo;), 1,994,494
of which have been designated as Series E Convertible Preferred Stock (&ldquo;Series E Preferred Stock&rdquo;), 40,000 of which have been
designated as Series F Convertible Preferred Stock (&ldquo;Series F Preferred Stock&rdquo;), and 57,520 have been designated as Series
X Non-Voting Convertible Preferred Stock (&ldquo;Series X Preferred Stock&rdquo;). As of March 31, 2025, there were 759,297 shares of common
stock issued and outstanding, 0 shares of Series C Convertible Preferred Stock issued and outstanding, 0 shares of Series D Convertible
Preferred Stock issued and outstanding, 0 shares of Series E Convertible Preferred Stock issued and outstanding, 0 shares of Series F
Convertible Preferred Stock issued and outstanding, and 57,720 shares of Series X Preferred Stock issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Our Board, in consultation with counsel, determined
that it was in the best interests of the Company and our stockholders to ratify, pursuant to Section 204 of the Delaware General Corporation
Law (&ldquo;DGCL&rdquo;) and Delaware common law, an increase in the number of authorized shares of our common stock from 20,000,000 to
24,109,635 (the &ldquo;Authorized Share Increase&rdquo;) and the issuance of 4,109,635 shares of common stock (the &ldquo;Authorized Share
Increase Issuance&rdquo;) upon conversion of the Series C Preferred Stock and the exercise of certain December 2020 Warrants and Pre-Existing
Warrants (the &ldquo;Share Increase Ratification&rdquo;). On March 3, 2021, we filed a proxy statement in connection with a special meeting
of stockholders (the &ldquo;Special Meeting&rdquo;) to be held at 10:00 a.m. Eastern time on March 31, 2021, to (i) ratify the Authorized
Share Increase and the Authorized Share Increase Issuance, and (ii) further increase the number of our authorized shares of common stock.
On March 31, 2021, we did not have the requisite vote to approve the Share Increase Ratification and the meeting was adjourned. At the
reconvened Special Meeting on May 6, 2021, our stockholders voted to approve the ratification of the Authorized Share Increase, but the
stockholders did not approve the Share Increase Ratification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On August 17, 2021, at our 2021 Annual Meeting of
Stockholders, our stockholders voted to approve an amendment to our Certificate of Incorporation to increase the number of shares of our
common stock authorized for issuance from 24,109,635 shares to 40,000,000 shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>Voting Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Each stockholder has one vote for each share of common
stock held on all matters submitted to a vote of stockholders. A stockholder may vote in person or by proxy. Elections of directors are
determined by a plurality of the votes cast and all other matters are decided by a majority of the votes cast by those stockholders entitled
to vote and present in person or by proxy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Because our stockholders do not have cumulative voting
rights, stockholders holding a majority of the voting power of our shares of common stock will be able to elect all of our directors.
Our Certificate of Incorporation and Bylaws provide that stockholder actions may be effected at a duly called meeting of stockholders
or pursuant to written consent of the majority of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>Dividend Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The holders of outstanding shares of common stock
are entitled to receive dividends out of funds legally available at the times and in the amounts that the board of directors (the &ldquo;Board&rdquo;)
may determine, provided that required dividends, if any, on preferred stock have been paid or provided for. However, the current policy
of our Board is to retain earnings, if any, for operations and growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>No Preemptive or Similar Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The holders of our common stock have no preemptive,
subscription, redemption or conversion rights. The rights, preferences and privileges of holders of our common stock are subject to, and
may be adversely affected by, the rights of the holders of any series of preferred stock, which may be designated solely by action of
the Board and issued in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>Right to Receive Liquidation Distributions</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Upon liquidation, dissolution or winding-up, the holders
of our common stock are entitled to share ratably in all assets that are legally available for distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>The Nasdaq Capital Market Listing</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Our common stock is listed on the Nasdaq Capital Market
(&ldquo;Nasdaq&rdquo;) under the symbol &ldquo;NAOV.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>Transfer Agent and Registrar</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The transfer agent and registrar for our common stock
is VStock Transfer, LLC, 18 Lafayette Place, Woodmere, NY 11598.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>Options and Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">As of March 31, 2025, we had 45,059 shares of
common stock issuable upon exercise of outstanding options and 321,843 shares of common stock issuable up, on the exercise of warrants.
There are no other outstanding warrants or options at this time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We may issue any class of preferred stock in any series.
The Board has the authority, subject to limitations prescribed under Delaware law and the rights of the holders of any series of preferred
stock, to issue preferred stock in one or more series, to establish from time to time the number of shares to be included in each series
and to fix the designation, powers, preferences and rights of the shares of each series and any of its qualifications, limitations and
restrictions. The number of authorized shares of preferred stock may be increased or decreased (but not below the number of shares thereof
then outstanding) by the affirmative vote of the holders of a majority of the voting power of all of the then-outstanding shares of our
capital stock entitled to vote thereon, without a vote of the holders of the preferred stock, or of any series thereof, unless a vote
of any such holders is required pursuant to the terms of any preferred stock designation. The Board may authorize the issuance of preferred
stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of the common stock.
The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could,
among other things, have the effect of delaying, deferring or preventing a change in control of our company and may adversely affect the
market price of common stock and the voting and other rights of the holders of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>Series C Convertible Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>Conversion Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Each share of the Series C Preferred Stock is convertible
into one (1) share of common stock, provided that the holder will be prohibited from converting Series C Preferred Stock into shares of
common stock if, as a result of such conversion, the holder would own more than 9.99% of the number of shares of common stock outstanding
immediately after giving effect to the issuance of the shares of common stock issuable upon conversion of the Series C Preferred Stock,
or, at the election of a holder, together with its affiliates, would own more than 9.99% of the number of shares of common stock outstanding
immediately after giving effect to the issuance of the shares of common stock issuable upon conversion of the Series C Preferred Stock.
The conversion rate of the Series C Preferred Stock is subject to proportionate adjustments for stock splits, reverse stock splits and
similar events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>Dividend Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Shares of Series C Preferred Stock are not entitled
to receive any dividends, unless and until specifically declared by the Board. However, holders of Series C Preferred Stock are entitled
to receive dividends on shares of Series C Preferred Stock equal (on an as-if-converted-to-common-stock basis) to and in the same form
as dividends actually paid on shares of the common stock when such dividends are specifically declared by the Board. The Company is not
obligated to redeem or repurchase any shares of Series C Preferred Stock. Shares of Series C Preferred Stock are not otherwise entitled
to any redemption rights, or mandatory sinking fund or analogous fund provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>Voting Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Except as provided in the Designation, Preferences,
Rights and Limitations of Series C Preferred Stock or as otherwise required by law, each holder of Series C Preferred Stock will be entitled
to the number of votes equal to the number of shares of common stock into which such share of Series C Preferred Stock could be converted,
provided that the holder would be prohibited from converting Series C Preferred Stock if, as a result of such conversion, the holder,
together with its affiliates, would beneficially own more than 9.99% of the total number of shares of our common stock then issued and
outstanding, for purposes of determining the shares entitled to vote at any regular, annual or special meeting of stockholders of the
Company, and shall have voting rights and powers equal to the voting rights and powers of the common stock (except as otherwise expressly
provided herein or as required by law, voting together with the common stock as a single class) and shall be entitled to notice of any
stockholders&rsquo; meeting in accordance with the By-laws of the Company. Fractional votes shall not, however, be permitted and any fractional
voting rights shall be rounded to the nearest whole number (with one-half being rounded upward). We may not, without the written consent
of holders of a majority of the then issued and outstanding shares of Series C Preferred Stock, increase the number of authorized shares
of Series C Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>Liquidation Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Upon any liquidation, dissolution or winding-up of
the Company, whether voluntary or involuntary, the holders of Series C Preferred Stock are entitled to receive, pari passu with the holders
of common stock, out of the assets available for distribution to stockholders an amount equal to such amount per share as would have been
payable had all shares of Series C Preferred Stock been converted into common stock immediately before such liquidation, dissolution or
winding up, without giving effect to any limitation on conversion as a result of the Beneficial Ownership Limitation, as described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>Series D Convertible Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>Conversion Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Each share of the Series D Preferred Stock is convertible
into fifty (50) shares of common stock, provided that the holder will be prohibited from converting Series D Preferred Stock into shares
of common stock if, as a result of such conversion, the holder would own more than 9.99% of the number of shares of common stock outstanding
immediately after giving effect to the issuance of the shares of common stock issuable upon conversion of the Series D Preferred Stock,
or, at the election of a holder, together with its affiliates, would own more than 9.99% of the number of shares of common stock outstanding
immediately after giving effect to the issuance of the shares of common stock issuable upon conversion of the Series D Preferred Stock.
The conversion rate of the Series D Preferred Stock is subject to proportionate adjustments for stock splits, reverse stock splits and
similar events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>Dividend Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Shares of Series C Preferred Stock are not entitled
to receive any dividends, unless and until specifically declared by the Board. Series D Preferred Stockholders (&ldquo;Series D Holders&rdquo;)
are entitled to receive, and the Company shall pay, dividends on shares of Series D Preferred Stock equal (on an as-if-converted-to-common-stock
basis) to and in the same form as dividends actually paid on shares of the common stock when, as and if such dividends are paid on shares
of the common stock. No other dividends shall be paid on shares of Series D Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>&nbsp;</I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>Voting Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Except as provided in the Series D Preferred Stock
Certificate of Designation or as otherwise required by law, Series D Holders shall have no voting rights. However, as long as any shares
of Series D Preferred Stock are outstanding, the Company shall not, without the affirmative vote of the Series D Holders of a majority
of the then outstanding shares of the Series D Preferred Stock, (a) alter or change adversely the powers, preferences or rights given
to the Series D Preferred Stock or alter or amend the Series D Preferred Stock Certificate of Designation, (b) amend its Certificate of
Incorporation or other charter documents in any manner that adversely affects any rights of the Series D Holders, (c) increase the number
of authorized shares of Series D Preferred Stock, or (d) enter into any agreement with respect to any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>Liquidation Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Upon any liquidation, dissolution or winding-up of
the Company, whether voluntary or involuntary, the Series D Holders shall be entitled to receive out of the assets, whether capital or
surplus, of the Company the same amount that a holder of common stock would receive if the Series D Preferred Stock were fully converted
(disregarding for such purpose any conversion limitations hereunder) to common stock which amounts shall be paid pari passu with all holders
of common stock. The Company shall mail written notice of any such liquidation, not less than 30 days prior to the payment date stated
therein, to each Series D Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>Series E Convertible Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>Conversion Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Each share of Series E Preferred Stock is convertible
at any time and from time to time at the option of a holder of Series E Preferred Stock (a &ldquo;Series E Holder&rdquo;) into one twentieth
(1/20) of a share of our common stock, provided that each holder is prohibited from converting Series E Preferred Stock into shares of
our common stock if, as a result of such conversion, any such holder, together with its affiliates, would own more than 9.99% of the total
number of shares of our common stock then issued and outstanding. This limitation may be waived with respect to a holder upon such holder&rsquo;s
provision of not less than 61 days&rsquo; prior written notice to the Company. The conversion rate of the Series E Preferred Stock is
subject to proportionate adjustments for stock splits, reverse stock splits and similar events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>Dividend Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Shares of Series E Preferred Stock are not entitled
to receive any dividends, unless and until specifically declared by the Board. However, Series E Holders are entitled to receive dividends
on shares of Series E Preferred Stock equal (on an as-if-converted-to-common-stock basis) to and in the same form as dividends actually
paid on shares of the common stock when such dividends are specifically declared by the Board. The Company is not obligated to redeem
or repurchase any shares of Series E Preferred Stock. Shares of Series E Preferred Stock are not otherwise entitled to any redemption
rights, or mandatory sinking fund or analogous fund provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>Voting Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Each Series E Holder shall be entitled to the number
of votes equal to the number of shares of our common stock equal to the voting ratio, which, for each share of Series E Preferred Stock,
is equal to $2.00 divided by $3.53. Fractional votes shall not, however, be permitted and any fractional voting rights resulting from
the above formula (after aggregating all shares into which shares of Series E Preferred Stock held by each Series E Holder could be converted)
shall be rounded to the nearest whole number (with one-half being rounded upward).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>Liquidation Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Upon liquidation, dissolution or winding up of the
Company, whether voluntary or involuntary, each Series E Holder shall be entitled to receive the amount of cash, securities or other property
to which such holder would be entitled to receive with respect to such shares of Series E Preferred Stock if such shares had been converted
to our common stock immediately prior to such liquidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>Series F Convertible Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>Conversion Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Each share of Series F Preferred Stock is convertible
at any time and from time to time at the option of a holder of Series E Preferred Stock (a &ldquo;Series E Holder&rdquo;) into one twentieth
(1/20) of a share of our common stock, provided that each holder is prohibited from converting Series E Preferred Stock into shares of
our common stock if, as a result of such conversion, any such holder, together with its affiliates, would own more than 9.99% of the total
number of shares of our common stock then issued and outstanding. This limitation may be waived with respect to a holder upon such holder&rsquo;s
provision of not less than 61 days&rsquo; prior written notice to the Company. The conversion rate of the Series F Preferred Stock is
subject to proportionate adjustments for stock splits, reverse stock splits and similar events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>Dividend Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Shares of Series F Preferred Stock are not entitled
to receive any dividends, unless and until specifically declared by the Board. However, Series E Holders are entitled to receive dividends
on shares of Series F Preferred Stock equal (on an as-if-converted-to-common-stock basis) to and in the same form as dividends actually
paid on shares of the common stock when such dividends are specifically declared by the Board. The Company is not obligated to redeem
or repurchase any shares of Series F Preferred Stock. Shares of Series F Preferred Stock are not otherwise entitled to any redemption
rights, or mandatory sinking fund or analogous fund provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>Voting Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Each Series F Holder shall be entitled to the number
of votes equal to the number of shares of our common stock equal to the voting ratio, which, for each share of Series F Preferred Stock,
is equal to $2.00 divided by $3.53. Fractional votes shall not, however, be permitted and any fractional voting rights resulting from
the above formula (after aggregating all shares into which shares of Series F Preferred Stock held by each Series F Holder could be converted)
shall be rounded to the nearest whole number (with one-half being rounded upward).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>Liquidation Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Upon liquidation, dissolution or winding up of the
Company, whether voluntary or involuntary, each Series F Holder shall be entitled to receive the amount of cash, securities or other property
to which such holder would be entitled to receive with respect to such shares of Series F Preferred Stock if such shares had been converted
to our common stock immediately prior to such liquidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>Series X Non-Voting Convertible Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>Conversion Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The conversion price for each share of Series X Preferred
Stock shall be $0.6063. The conversion ratio (the &ldquo;Conversion Ratio&rdquo;) for each share of Series X Preferred Stock is determined
by dividing the Stated Value (as defined in the Series X Certificate of Designations) of each share of Series X Preferred Stock, initially
valued at $606.3756, divided by the conversion price which provides an implied Conversion Ratio of be 1,000 shares of common stock issuable
upon the conversion of each share of Series X Preferred Stock (the &ldquo;Conversion Shares&rdquo;), subject to adjustment as provided
in the Certificate of Designations of the Series X Non-Voting Convertible Preferred Stock (the &ldquo;Series X Certificate of Designations&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Effective as of 5:00 p.m. Eastern Time on the fourth
(4th) business day after the Series X Stockholder Approval (as defined below), each share of Series X Preferred Stock then outstanding
shall automatically convert into a number of shares of common stock equal to the Conversion Ratio, subject to applicable beneficial ownership
limitations. Subject the terms of the Series X Certificate of Designations, the Series X Preferred Stock is also convertible, at the option
of the holder, at any time and from time to time following 5:00 p.m. Eastern Time on the third (3rd) business day after the date that
the Series X Stockholder Approval, into a number of shares of Common Stock equal to the Conversion Ratio, subject to the applicable beneficial
ownership limitations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>Series X Stockholder Approval</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Pursuant to the terms of the Merger Agreement, the
issuance of shares of common stock to the stockholders upon conversion of any and all shares of the Series X Preferred Stock in accordance
with the terms of the Series X Certificate of Designations is subject to and contingent upon the approval from the Company&rsquo;s stockholders
of the issuance of the common stock upon conversion of the Series X Preferred Stock, for purposes of the Nasdaq Listing Rules, the issuance
of such shares of common stock (the &ldquo;Series X Stockholder Approval&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>Dividend Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Holders shall be entitled to receive, and the Company
shall pay, dividends on shares of Series X Preferred Stock, based on the Stated Value, at a rate of eight percent (8%) per annum, commencing
on the three (3) month anniversary of the Original Issue Date (as defined in the Series X Certificate of Designations) until the date
the Company obtains the Series X Stockholder Approval. Such dividends can be paid in the form of cash or additional issuances of shares
of Series X Preferred Stock based on the Stated Value, with such type of payment determined in the sole discretion of the Company, and
accrue and be compounded daily on the basis of a 360-day year and twelve (12) 30-day months and shall be paid the earlier of: (i) promptly
after conversion of the Series X Preferred Stock or (ii) quarterly starting on the six (6) month anniversary of the Original Issue Date.
No other dividends shall be paid on shares of Series X Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>Voting Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Except as otherwise provided in the Series X Certificate
of Designations, or as required by the DGCL, the Series X Preferred Stock shall have no voting rights. However, as long as any shares
of Series X Preferred Stock are outstanding, the Company shall not, without the affirmative vote or written approval, agreement or waiver
of the holders of seventy percent (70%) of the then outstanding shares of the Series X Preferred Stock, among other things, (i) alter
or change adversely the powers, preferences or rights given to the Series X Preferred Stock or alter or amend the Series X Certificate
of Designations, (ii) issue further shares of Series X Preferred Stock in excess of 57,720 or increase or decrease (other than by conversion)
the number of authorized shares of Series X Preferred Stock, (iii) prior to the Stockholder Approval, consummate either: (A) any Fundamental
Transaction (as defined therein) or (B) any merger or consolidation of the Company with or into another entity or any stock sale to, or
other business combination in which the stockholders of the Company immediately before such transaction do not hold at least a majority
of the voting power of the capital stock of the Company or such other entity immediately after such transaction, (iv) enter into any agreement
with respect to any of the foregoing that is not expressly conditioned upon Stockholder Approval, (v) prior to the Stockholder Approval:
(A) pay a stock dividend or otherwise make a distribution or distributions on shares of common stock or any other equity or equity equivalent
securities payable in shares of common stock (which, for avoidance of doubt, shall not include any shares of common stock issued by the
Company upon the issuance of the Conversion Shares), (B) subdivide outstanding shares of common stock into a larger number of shares,
(C) combine (including by way of reverse stock split) outstanding shares of common stock into a smaller number of shares, or (D) issue
by reclassification of shares of the common stock any shares of capital stock of the Company, (vi) grant, issue or sell any capital stock
or rights to purchase stock, warrants, securities or other securities of the Company or (vii) incur any indebtedness for borrowed money
or issue any debt securities or assume, guarantee or endorse, or otherwise become responsible for, the obligations of any person, or make
any loans or advances, or intentionally grant any security interest in any of its assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>Rank; Liquidation.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Except to the extent that the requisite number of
Series X Preferred Stock holders expressly consent to the creation of parity stock or senior preferred stock (as defined below), all shares
of common stock and all shares of capital stock of the Company authorized or designated after the date of the designation of the Series
X Preferred Stock shall be junior in rank to the Series X Preferred Stock with respect to the preferences as to dividends, distributions
and payments upon the liquidation, dissolution and winding up of the Company. Prior to the Stockholder Approval, upon any liquidation,
dissolution or winding-up of the Company, whether voluntary or involuntary (a &ldquo;Liquidation&rdquo;), the Holders shall be entitled
to receive out of the assets, whether capital or surplus, of the Corporation the greater of the following amounts: (a) twice the aggregate
stated value of the Series X Preferred Stock; or (b) the amount the holder would be entitled to receive if the Series X Preferred Stock
were fully converted (disregarding for such purposes any conversion limitations hereunder) to common stock which amounts shall be paid
pari passu with all holders of common stock. In addition, in the case of either (a) or (b) above, the holders will be entitled to the
payment of all accrued and unpaid dividends on the Series X Preferred Stock and, in the event any of such dividends are payable in shares
of common stock, the cash value of such shares of common stock upon Liquidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>Cash Settlement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Prior to the Stockholder Approval, if the Company
breaches any of its obligations or covenants as set forth in the Series X Certificate of Designation (including but not limited to failure
to obtain the requisite approval of the Series X Preferred Stock holders prior to taking any of the actions described under the section
&ldquo;&#727;Voting Rights&rdquo; above, then the Company shall, at the request of the requisite holders Series X Preferred Stock (the
&ldquo;Settlement Request&rdquo;), pay, out of funds legally available therefor, and prior to any payment in satisfaction of any redemption
rights of any other class or series of capital stock of the Company, an amount in cash equal to the stated value of the shares of Series
X Preferred Stock held by each holder, with such payment to be made within two (2) business days from the date of Settlement Request,
and upon payment in full of the stated value for such shares of Series X Preferred Stock, such shares shall be redeemed, retired and no
longer be outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>Delaware Anti-Takeover Law and Provisions of our
Certificate of Incorporation and Bylaws</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>Delaware Anti-Takeover Law</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We are subject to Section 203 of the Delaware General
Corporation Law (the &ldquo;DGCL&rdquo;). Section 203 generally prohibits a public Delaware corporation from engaging in a &ldquo;business
combination&rdquo; with an &ldquo;interested stockholder&rdquo; for a period of three years after the date of the transaction in which
the person became an interested stockholder, unless:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (i) shares owned by persons who are directors and also officers and (ii) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">on or subsequent to the date of the transaction, the business combination is approved by the board and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock which is not owned by the interested stockholder.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Section 203 defines a business combination to include:</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">any merger or consolidation involving the corporation and the interested stockholder;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">any sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; or</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In general, Section 203 defines an interested stockholder
as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated
with, or controlling, or controlled by, the entity or person. The term &ldquo;owner&rdquo; is broadly defined to include any person that,
individually, with or through that person&rsquo;s affiliates or associates, among other things, beneficially owns the stock, or has the
right to acquire the stock, whether or not the right is immediately exercisable, under any agreement or understanding or upon the exercise
of warrants or options or otherwise or has the right to vote the stock under any agreement or understanding, or has an agreement or understanding
with the beneficial owner of the stock for the purpose of acquiring, holding, voting or disposing of the stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The restrictions in Section 203 do not apply to corporations
that have elected, in the manner provided in Section 203, not to be subject to Section 203 of the DGCL or, with certain exceptions, which
do not have a class of voting stock that is listed on a national securities exchange or authorized for quotation on the Nasdaq Stock Market
or held of record by more than 2,000 stockholders. Our certificate of incorporation and bylaws do not opt out of Section 203.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Section 203 could delay or prohibit mergers or other
takeover or change in control attempts with respect to us and, accordingly, may discourage attempts to acquire us even though such a transaction
may offer our stockholders the opportunity to sell their stock at a price above the prevailing market price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>Amended and Restated Certificate of Incorporation,
as amended, and Amended and Restated Bylaws, as amended</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The provisions of our Certificate of Incorporation
and Bylaws may delay or discourage transactions involving an actual or potential change in our control or change in our management, including
transactions in which stockholders might otherwise receive a premium for their shares, or transactions that our stockholders might otherwise
deem to be in their best interests. Therefore, these provisions could adversely affect the price of our common stock. Among other things,
our Certificate of Incorporation and Bylaws:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">permit our board of directors to issue up to 11,000,000 shares of preferred stock, without further action by the stockholders, with any rights, preferences and privileges as they may designate, including the right to approve an acquisition or other change in control;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">provide that the authorized number of directors may be changed only by resolution of a majority of the total number of authorized directors whether or not there exist any vacancies in previously authorized directorships (the &ldquo;Whole Board&rdquo;);</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose);</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">provide that special meetings of our stockholders may be called only by a resolution adopted by a majority of the Whole Board; and</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">set forth an advance notice procedure with regard to the nomination, other than by or at the direction of our Board, of candidates for election as directors and with regard to business to be brought before a meeting of stockholders.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.78
<SEQUENCE>3
<FILENAME>ex10-78.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.78</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEITHER
THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON CONVERSION
OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Original
Issue Date: February 13, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1,300,000</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>AMENDED
AND RESTATED SENIOR CONVERTIBLE DEBENTURE DUE the earlier of the trigger date and November 13, 2025</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
AMENDED AND RESTATED SENIOR CONVERTIBLE DEBENTURE is one of a series of duly authorized and validly issued Senior Convertible Debentures
of NanoVibronix, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), having its principal place of business at 969 Pruitt
Avenue, Tyler, Texas 77569, designated as its Amended and Restated Senior Convertible Debenture due the earlier of the Trigger Date and
November 13, 2025 (this debenture, as amended and restated, the &ldquo;<U>Debenture</U>&rdquo; and, collectively with the other amended
and restated debentures of such series, the &ldquo;<U>Debentures</U>&rdquo;) and is issued pursuant to the Purchase Agreement (as defined
below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the Company promises to pay to Alpha Capital Anstalt or its registered assigns (the &ldquo;<U>Holder</U>&rdquo;), or
shall have paid pursuant to the terms hereunder, the principal sum of $1,300,000 the earlier to occur of the Trigger Date and November
13, 2025 (such earlier date, &ldquo;<U>Maturity Date</U>&rdquo;) or such earlier date as this Debenture is required or permitted to be
repaid as provided hereunder, and to pay interest to the Holder on the aggregate unconverted and then outstanding principal amount of
this Debenture in accordance with the provisions hereof. This Debenture is subject to the following additional provisions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1. Definitions</U>. For the purposes hereof, in addition to the terms defined elsewhere in this Debenture, (a) capitalized terms not
otherwise defined herein shall have the meanings set forth in the Purchase Agreement and (b) the following terms shall have the following
meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Bankruptcy
Event</U>&rdquo; means any of the following events: (a) the Company or any Subsidiary thereof commences a case or other proceeding under
any bankruptcy, reorganization, arrangement, adjustment of debt, relief of debtors, dissolution, insolvency or liquidation or similar
law of any jurisdiction relating to the Company or any Subsidiary thereof, (b) there is commenced against the Company or any Subsidiary
thereof any such case or proceeding that is not dismissed within 60 days after commencement, (c) the Company or any Subsidiary thereof
is adjudicated insolvent or bankrupt or any order of relief or other order approving any such case or proceeding is entered, (d) the
Company or any Subsidiary thereof suffers any appointment of any custodian or the like for it or any substantial part of its property
that is not discharged or stayed within 60 calendar days after such appointment, (e) the Company or any Subsidiary thereof makes a general
assignment for the benefit of creditors, (f) the Company or any Subsidiary thereof calls a meeting of its creditors with a view to arranging
a composition, adjustment or restructuring of its debts, (g) the Company or any Subsidiary thereof admits in writing that it is generally
unable to pay its debts as they become due, (h) the Company or any Subsidiary thereof, by any act or failure to act, expressly indicates
its consent to, approval of or acquiescence in any of the foregoing or takes any corporate or other action for the purpose of effecting
any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Base
Conversion Price</U>&rdquo; shall have the meaning set forth in Section 5(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Beneficial
Ownership Limitation</U>&rdquo; shall have the meaning set forth in Section 4(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York are generally
are open for use by customers on such day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Change
of Control Transaction</U>&rdquo; means the occurrence after the date hereof of any of (a) an acquisition after the date hereof by an
individual or legal entity or &ldquo;group&rdquo; (as described in Rule 13d-5(b)(1) promulgated under the Exchange Act) of effective
control (whether through legal or beneficial ownership of capital stock of the Company, by contract or otherwise) of in excess of 33%
of the voting power of the Company (other than by means of conversion of the Debentures and the Securities issued together with the Debentures),
(b) the Company merges into or consolidates with any other Person, or any Person merges into or consolidates with the Company and, after
giving effect to such transaction, the stockholders of the Company immediately prior to such transaction own less than 33% of the aggregate
voting power of the Company or the successor entity of such transaction, (c) the Company (and all of its Subsidiaries, taken as a whole)
sells or transfers all or substantially all of its assets to another Person, (d) a replacement at one time or within a three year period
of more than one-half of the members of the Board of Directors which is not approved by a majority of those individuals who are members
of the Board of Directors on the Original Issue Date (or by those individuals who are serving as members of the Board of Directors on
any date whose nomination to the Board of Directors was approved by a majority of the members of the Board of Directors who are members
on the date hereof), or (e) the execution by the Company of an agreement to which the Company is a party or by which it is bound, providing
for any of the events set forth in clauses (a) through (d) above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Conversion
Date</U>&rdquo; shall have the meaning set forth in Section 4(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Conversion
Price</U>&rdquo; shall have the meaning set forth in Section 4(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Conversion
Shares</U>&rdquo; means, collectively, the shares of Common Stock issuable upon conversion of this Debenture in accordance with the terms
hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Debenture
Register</U>&rdquo; shall have the meaning set forth in Section 2(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Delaware
Courts</U>&rdquo; shall have the meaning set forth in Section 10(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Disqualified
Stock</U>&rdquo; shall mean, with respect to any person, any Equity Interests of such person that, by its terms (or by the terms of any
security or other Equity Interests into which it is convertible or for which it is exchangeable) or upon the happening of any event or
condition (a) matures or is mandatorily redeemable, pursuant to a sinking fund obligation or otherwise, (b) is redeemable at the option
of the holder thereof, in whole or in part, (c) provides for the scheduled payments of dividends in cash, or (d) is or becomes convertible
into or exchangeable for Indebtedness or any other Equity Interests that would constitute Disqualified Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Effectiveness
Date</U>&rdquo; shall have the meaning set forth in the Registration Rights Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Effectiveness
Period</U>&rdquo; shall have the meaning set forth in the Registration Rights Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Equity
Conditions</U>&rdquo; means, during the applicable period, (a) the Company shall have duly honored all conversions and redemptions scheduled
to occur or occurring by virtue of one or more Notices of Conversion of the Holder, if any, (b) the Company shall have paid all liquidated
damages and other amounts owing to the Holder in respect of this Debenture, (c)(i) there is an effective Registration Statement pursuant
to which the Holder is permitted to utilize the prospectus thereunder to resell all of the shares of Common Stock issuable pursuant to
the Transaction Documents (and the Company believes, in good faith, that such effectiveness will continue uninterrupted for the foreseeable
future) or (ii) all of the Conversion Shares issuable pursuant to the Transaction Documents (and shares issuable in lieu of cash payments
of interest) may be resold pursuant to Rule 144 without volume or manner-of-sale restrictions or current public information requirements
as determined by the counsel to the Company as set forth in a written opinion letter to such effect, addressed and acceptable to the
Transfer Agent and the Holder, (d) the Common Stock is trading on a Trading Market and all of the shares issuable pursuant to the Transaction
Documents are listed or quoted for trading on such Trading Market (and the Company believes, in good faith, that trading of the Common
Stock on a Trading Market will continue uninterrupted for the foreseeable future), (e) there is a sufficient number of authorized but
unissued and otherwise unreserved shares of Common Stock for the issuance of all of the shares then issuable pursuant to the Transaction
Documents, (f) there is no existing Event of Default and no existing event which, with the passage of time or the giving of notice, would
constitute an Event of Default, (g) the shares issuable upon conversion in full of the Prepayment Amount to the Holder would not violate
the limitations set forth in Section 4(d), (h) there has been no public announcement of a pending or proposed Fundamental Transaction
or Change of Control Transaction (other the Merger Transaction) that has not been consummated, and (i) the applicable Holder is not in
possession of any information provided by the Company, any of its Subsidiaries, or any of their officers, directors, employees, agents
or Affiliates, that constitutes, or may constitute, material non-public information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Event
of Default</U>&rdquo; shall have the meaning set forth in Section 8(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Floor
Price</U>&rdquo; means $0.97812 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Indebtedness</U>&rdquo;
of a Person shall include (a) all obligations for borrowed money or the deferred purchase price of property or services (excluding trade
accounts payable incurred in the ordinary course of business), (b) all obligations evidenced by bonds, debentures, notes, or other similar
instruments and all reimbursement or other obligations in respect of letters of credit, surety bonds, bankers acceptances, current swap
agreements, interest rate hedging agreements, interest rate swaps or other financial products, (c) all capital lease obligations (as
determined in accordance with GAAP), (d) all obligations or liabilities secured by a Lien on any asset of such Person, irrespective of
whether such obligation or liability is assumed by such Person, (e) any obligation arising with respect to any other transaction that
is the functional equivalent of borrowing but which does not constitute a liability on the balance sheets of such Person, (f) Disqualified
Stock, and (g) any obligation guaranteeing or intended to guarantee (whether directly or indirectly guaranteed, endorsed, co-made, discounted
or sold with recourse) any of the foregoing obligations of any other Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Interest
Payment Date</U>&rdquo; shall have the meaning set forth in Section 2(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Investments</U>&rdquo;
means, as to any Person, any direct or indirect acquisition or investment by such Person, whether by means of (a) the purchase or other
acquisition (including by merger) of Equity Interests of another Person, (b) a loan, advance or capital contribution to, guarantee or
assumption of debt of, or purchase or other acquisition of any other debt or interest in, another Person, or (c) the purchase or other
acquisition (in one transaction or a series of transactions) of assets of another Person that constitute a business unit or all or a
substantial part of the business of, such Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Late
Fees</U>&rdquo; shall have the meaning set forth in Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Mandatory
Default Amount</U>&rdquo; means the sum of (a) the greater of (i) the outstanding principal amount of this Debenture, plus all accrued
and unpaid interest hereon, divided by the Conversion Price on the date the Mandatory Default Amount is either (A) demanded (if demand
or notice is required to create an Event of Default) or otherwise due or (B) paid in full, whichever has a lower Conversion Price, multiplied
by the VWAP on the date the Mandatory Default Amount is either (x) demanded or otherwise due or (y) paid in full, whichever has a higher
VWAP, or (ii) 115% of the outstanding principal amount of this Debenture, plus 100% of accrued and unpaid interest hereon, and (b) all
other amounts, costs, expenses and liquidated damages due in respect of this Debenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Notice
of Conversion</U>&rdquo; shall have the meaning set forth in Section 4(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Original
Issue Date</U>&rdquo; means the date of the first issuance of the Debentures, regardless of any transfers of any Debenture and regardless
of the number of instruments which may be issued to evidence such Debentures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Permitted
Indebtedness</U>&rdquo; means (a) the Indebtedness evidenced by the Debentures, (b) the Indebtedness existing on the Original Issue Date
and disclosed to the Holder prior to the date hereof, (c) lease obligations and purchase money indebtedness of up to $50,000, in the
aggregate, incurred in connection with the acquisition of capital assets and lease obligations with respect to newly acquired or leased
assets, (d) other unsecured Indebtedness not exceeding $50,000 in aggregate principal amount outstanding, and (e) Indebtedness that (1)
is expressly subordinate to the Debentures pursuant to a written subordination agreement with the Purchasers that is acceptable to each
Purchaser in its sole and absolute discretion and (2) matures at a date later than the 91<SUP>st</SUP> day following the Maturity Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Permitted
Lien</U>&rdquo; means the individual and collective reference to the following: (a) Liens for taxes, assessments and other governmental
charges or levies not yet due or Liens for taxes, assessments and other governmental charges or levies being contested in good faith
and by appropriate proceedings for which adequate reserves (in the good faith judgment of the management of the Company) have been established
in accordance with GAAP, (b) Liens imposed by law which were incurred in the ordinary course of the Company&rsquo;s business, such as
carriers&rsquo;, warehousemen&rsquo;s and mechanics&rsquo; Liens, statutory landlords&rsquo; Liens, and other similar Liens arising in
the ordinary course of the Company&rsquo;s business, and which (x) do not individually or in the aggregate materially detract from the
value of such property or assets or materially impair the use thereof in the operation of the business of the Company and its consolidated
Subsidiaries or (y) are being contested in good faith by appropriate proceedings, which proceedings have the effect of preventing for
the foreseeable future the forfeiture or sale of the property or asset subject to such Lien, (c) Liens incurred in connection with Permitted
Indebtedness under clauses (a) and (b) thereunder, (d) Liens incurred in connection with Permitted Indebtedness under clause (c) thereunder,
provided that such Liens are not secured by assets of the Company or its Subsidiaries other than the assets so acquired or leased, (e)
easements, rights of way, restrictions, minor defects or irregularities in title and other similar Liens, in each case, not interfering
in any material respect with the ordinary conduct of the Company&rsquo;s business, and (f) Liens existing on the date hereof and disclosed
to the Holder prior to the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Purchase
Agreement</U>&rdquo; means the Securities Purchase Agreement, dated as of February 13, 2025, among the Company and the original Holders,
as amended, modified or supplemented from time to time in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Share
Delivery Date</U>&rdquo; shall have the meaning set forth in Section 4(c)(ii).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York
Stock Exchange (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trigger
Date</U>&rdquo; means the date that is the 30-day anniversary of the Nasdaq Stockholder Approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2. Payments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Payment of Interest</U>. The Company shall pay interest to the Holder on the aggregate unconverted and then outstanding principal
amount of this Debenture at the rate of 8.0% per annum, payable on the Maturity Date (the &ldquo;<U>Interest Payment Date</U>&rdquo;)
(if the Interest Payment Date is not a Business Day, then the payment shall be due on the next succeeding Business Day), in cash or,
provided that no Event of Default has occurred or is continuing and subject to <U>Section 4(d)</U> hereof, at the option of the Holder,
in the form of Conversion Shares in accordance with <U>Section 4</U> hereof, or a combination thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Interest Calculations</U>. Interest shall be calculated on the basis of a 360-day year and the actual number of days elapsed, and
shall accrue daily commencing on the Original Issue Date until payment in full of the outstanding principal, together with all accrued
and unpaid interest, liquidated damages and other amounts which may become due hereunder, has been made. Interest hereunder will be paid
to the Person in whose name this Debenture is registered on the records of the Company regarding registration and transfers of this Debenture
(the &ldquo;<U>Debenture Register</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Late Fee</U>. All overdue accrued and unpaid interest to be paid hereunder shall entail a late fee at an interest rate equal to the
lesser of 18% per annum or the maximum rate permitted by applicable law (the &ldquo;<U>Late Fees</U>&rdquo;) which shall accrue daily
from the date such interest is due hereunder through and including the date of actual payment in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Prepayment</U>. With the prior written consent of the Holder, the Company may deliver a written notice (a &ldquo;<U>Prepayment Notice</U>&rdquo;
and the date that such Prepayment Notice is delivered the &ldquo;<U>Prepayment Notice Date</U>&rdquo;) to the Holder of its irrevocable
election to prepay all or a portion of the outstanding principal amount of this Debenture plus (i) accrued and unpaid interest thereon,
plus (ii) the Exit Fee (as defined below), and plus (iii) all other sums, if any, that shall have become due and payable (collectively,
the &ldquo;<U>Prepayment Amount</U>&rdquo;) for cash on the 5th Trading Day (or such period up to the 30th Trading Day as extended with
the consent of the Holder) after the Prepayment Notice Date (the &ldquo;<U>Prepayment Date</U>&rdquo; and such 5 to 30 Trading Day period,
the &ldquo;<U>Prepayment Period</U>&rdquo; and such prepayment, the &ldquo;<U>Prepayment</U>&rdquo;). The Company may only effect a Prepayment
if each of the Equity Conditions shall have been met (unless waived in writing by the Holder) on each Trading Day during the period commencing
on the Prepayment Notice Date through to the Prepayment Date and through and including the date payment of the Prepayment Amount is actually
made in full. If any of the Equity Conditions shall cease to be satisfied at any time during the Prepayment Period, then the Holder may
elect to nullify the Prepayment Notice by notice to the Company within three (3) Trading Days after the first day on which any such Equity
Condition has not been met in which case the Prepayment Notice shall be null and void, <I>ab initio</I>. For the avoidance of doubt,
the Holder may elect to convert all or a portion of the outstanding principal amount of this Debenture pursuant to Section 4 at any time,
and from time to time, prior to actual payment in cash of the Prepayment under this Section 2(d) by the delivery of a Notice of Conversion
to the Company. For the further avoidance of doubt, the Company shall honor all conversions occurring by virtue of one or more Notices
of Conversion of the Holder during the Prepayment Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Maturity Date</U>. On the Maturity Date, the Company shall pay to the Holder in cash or, at the option of the Holder, in the form
of Conversion Shares in accordance with Section 4 hereof, or a combination thereof, the entire outstanding principal amount of this Debenture,
together with all accrued and unpaid interest thereon, the applicable Exit Fee and any other amounts due hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Mandatory Redemption</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            the event the Company or any of its Subsidiaries conducts a public offering of its securities
                                            pursuant to a registration statement on Form S-1 following the consummation of the Merger
                                            Transaction (a &ldquo;<U>Public Offering</U>&rdquo;), the Company shall, at the option of
                                            the Holder, concurrently with the receipt of the proceeds of such Public Offering, apply
                                            100% of such gross proceeds towards the redemption (each, a &ldquo;<U>Public Offering Mandatory
                                            Redemption</U>&rdquo;) of the principal amount of this Debenture.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            principal amount of this Debenture redeemed pursuant to a Public Offering Mandatory Redemption
                                            shall be applied against the last principal amount of this Debenture scheduled to be redeemed
                                            hereunder, in reverse time order from the Maturity Date.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3. Registration of Transfers and Exchanges</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Different Denominations</U>. This Debenture is exchangeable for an equal aggregate principal amount of Debentures of different authorized
denominations, as requested by the Holder surrendering the same. No service charge will be payable for such registration of transfer
or exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Investment Representations</U>. This Debenture has been issued subject to certain investment representations of the original Holder
set forth in the Purchase Agreement and may be transferred or exchanged only in compliance with the Purchase Agreement and applicable
federal and state securities laws and regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Reliance on Debenture Register</U>. Prior to due presentment for transfer to the Company of this Debenture, the Company and any agent
of the Company may treat the Person in whose name this Debenture is duly registered on the Debenture Register as the owner hereof for
the purpose of receiving payment as herein provided and for all other purposes, whether or not this Debenture is overdue, and neither
the Company nor any such agent shall be affected by notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4. Conversion</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Voluntary Conversion</U>. At any time after the date of Nasdaq Stockholder Approval until this Debenture is no longer outstanding,
this Debenture shall be convertible, in whole or in part, into shares of Common Stock at the option of the Holder, at any time and from
time to time (subject to the conversion limitations set forth in Section 4(d)). The Holder shall effect conversions by delivering to
the Company a Notice of Conversion, the form of which is attached hereto as <U>Annex A</U> (each, a &ldquo;<U>Notice of Conversion</U>&rdquo;),
specifying therein the principal amount of this Debenture to be converted and the date on which such conversion shall be effected (such
date, the &ldquo;<U>Conversion Date</U>&rdquo;). If no Conversion Date is specified in a Notice of Conversion, the Conversion Date shall
be the date that such Notice of Conversion is deemed delivered hereunder. No ink-original Notice of Conversion shall be required, nor
shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Conversion form be required. To effect conversions
hereunder, the Holder shall not be required to physically surrender this Debenture to the Company unless the entire principal amount
of this Debenture, plus all accrued and unpaid interest thereon, has been so converted in which case the Holder shall surrender this
Debenture as promptly as is reasonably practicable after such conversion without delaying the Company&rsquo;s obligation to deliver the
shares on the Share Delivery Date. Conversions hereunder shall have the effect of lowering the outstanding principal amount of this Debenture
in an amount equal to the applicable conversion. The Holder and the Company shall maintain records showing the principal amount(s) converted
and the date of such conversion(s). The Company may deliver an objection to any Notice of Conversion within one (1) Business Day of delivery
of such Notice of Conversion. In the event of any dispute or discrepancy, the records of the Holder shall be controlling and determinative
in the absence of manifest error. <B>The Holder, and any assignee by acceptance of this Debenture, acknowledge and agree that, by reason
of the provisions of this paragraph, following conversion of a portion of this Debenture, the unpaid and unconverted principal amount
of this Debenture may be less than the amount stated on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: .5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Conversion Price</U>. The conversion price in effect on any Conversion Date shall be equal to $4.8906, subject to adjustment as provided
herein (the &ldquo;<U>Conversion Price</U>&rdquo;); <U>provided</U>, <U>that</U> the Conversion Price will at no time be lower than the
Floor Price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Mechanics of Conversion</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Conversion Shares Issuable Upon Conversion of Principal Amount</U>. The number of Conversion Shares issuable upon a conversion hereunder
shall be determined by the quotient obtained by dividing (x) the outstanding principal amount of this Debenture to be converted by (y)
the Conversion Price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
<U>Delivery of Conversion Shares Upon Conversion</U>. Not later than the earlier of (i) one (1) Trading Day and (ii) the number of Trading
Days comprising the Standard Settlement Period (as defined below) after each Conversion Date (the &ldquo;<U>Share Delivery Date</U>&rdquo;),
the Company shall deliver, or cause to be delivered, to the Holder (A) the Conversion Shares which, on or after the earlier of (i) the
six month anniversary of the Original Issue Date or (ii) the Effectiveness Date, shall be free of restrictive legends and trading restrictions
(other than those which may then be required by the Purchase Agreement) representing the number of Conversion Shares being acquired upon
the conversion of this Debenture and (B) a certified check (or wire transfer) in the amount of accrued and unpaid interest. On or after
the earlier of (i) the six-month anniversary of the Original Issue Date or (ii) the Effectiveness Date, the Company shall deliver any
Conversion Shares required to be delivered by the Company under this <U>Section 4(c)</U> electronically through the Depository Trust
Company or another established clearing corporation performing similar functions. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo;
means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect
to the Common Stock as in effect on the date of delivery of the Notice of Conversion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
<U>Failure to Deliver Conversion Shares</U>. If, in the case of any Notice of Conversion, such Conversion Shares are not delivered to
or as directed by the applicable Holder by the Share Delivery Date, the Holder shall be entitled to elect by written notice to the Company
at any time on or before its receipt of such Conversion Shares, to rescind such Notice of Conversion, in which event the Company shall
promptly return to the Holder any original Debenture delivered to the Company and the Holder shall promptly return to the Company the
Conversion Shares issued to such Holder pursuant to the rescinded Notice of Conversion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
<U>Obligation Absolute</U>. The Company&rsquo;s obligations to issue and deliver the Conversion Shares upon conversion of this Debenture
in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the
same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce
the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other
Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and irrespective
of any other circumstance which might otherwise limit such obligation of the Company to the Holder in connection with the issuance of
such Conversion Shares; <U>provided</U>, <U>however</U>, that such delivery shall not operate as a waiver by the Company of any such
action the Company may have against the Holder. In the event the Holder of this Debenture shall elect to convert any or all of the outstanding
principal amount hereof, the Company may not refuse conversion based on any claim that the Holder or anyone associated or affiliated
with the Holder has been engaged in any violation of law, agreement or for any other reason, unless an injunction from a court, on notice
to Holder, restraining and or enjoining conversion of all or part of this Debenture shall have been sought and obtained, and the Company
posts a surety bond for the benefit of the Holder in the amount of 150% of the outstanding principal amount of this Debenture, which
is subject to the injunction, which bond shall remain in effect until the completion of arbitration/litigation of the underlying dispute
and the proceeds of which shall be payable to the Holder to the extent it obtains judgment. In the absence of such injunction, the Company
shall issue Conversion Shares required to be delivered hereunder in accordance with the terms hereof. Nothing herein shall limit a Holder&rsquo;s
right to pursue actual damages or declare an Event of Default pursuant to <U>Section 8</U> for the Company&rsquo;s failure to deliver
Conversion Shares within the period specified herein and the Holder shall have the right to pursue all remedies available to it hereunder,
at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief. The exercise of any such
rights shall not prohibit the Holder from seeking to enforce damages pursuant to any other Section hereof or under applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
<U>Compensation for Buy-In on Failure to Timely Deliver Conversion Shares Upon Conversion</U>. In addition to any other rights available
to the Holder, if the Company fails for any reason to deliver to the Holder such Conversion Shares by the Share Delivery Date pursuant
to <U>Section 4(c)(ii)</U>, and if after such Share Delivery Date the Holder is required by its brokerage firm to purchase (in an open
market transaction or otherwise), or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction
of a sale by the Holder of the Conversion Shares which the Holder was entitled to receive upon the conversion relating to such Share
Delivery Date (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder (in addition to any other remedies
available to or elected by the Holder) the amount, if any, by which (x) the Holder&rsquo;s total purchase price (including any brokerage
commissions) for the Common Stock so purchased exceeds (y) the product of (1) the aggregate number of shares of Common Stock that the
Holder was entitled to receive from the conversion at issue multiplied by (2) the actual sale price at which the sell order giving rise
to such purchase obligation was executed (including any brokerage commissions) and (B) at the option of the Holder, either reissue (if
surrendered) this Debenture in a principal amount equal to the principal amount of the attempted conversion (in which case such conversion
shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued if the Company had
timely complied with its delivery requirements under <U>Section 4(c)(ii)</U>. For example, if the Holder purchases Common Stock having
a total purchase price of $11,000 to cover a Buy-In with respect to an attempted conversion of this Debenture with respect to which the
actual sale price of the Conversion Shares (including any brokerage commissions) giving rise to such purchase obligation was a total
of $10,000 under clause (A) of the immediately preceding sentence, the Company shall be required to pay the Holder $1,000. The Holder
shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the
Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s right to pursue any other remedies available
to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect
to the Company&rsquo;s failure to timely deliver Conversion Shares upon conversion of this Debenture as required pursuant to the terms
hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
<U>Reservation of Shares Issuable Upon Conversion</U>. The Company covenants that it will at all times reserve and keep available out
of its authorized and unissued shares of Common Stock for the sole purpose of issuance upon conversion of this Debenture, each as herein
provided, free from preemptive rights or any other actual contingent purchase rights of Persons other than the Holder (and the other
holders of the Debentures), not less than such aggregate number of shares of the Common Stock as shall (subject to the terms and conditions
set forth in the Purchase Agreement) be issuable (taking into account the adjustments and restrictions of Section 5) upon the conversion
of the then outstanding principal amount of this Debenture. The Company covenants that all shares of Common Stock that shall be so issuable
shall, upon issue, be duly authorized, validly issued, fully paid and nonassessable and, if the Registration Statement is then effective
under the Securities Act, shall be registered for public resale in accordance with such Registration Statement (subject to such Holder&rsquo;s
compliance with its obligations under the Registration Rights Agreement).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)
<U>Fractional Shares</U>. No fractional shares or scrip representing fractional shares shall be issued upon the conversion of this Debenture.
As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such conversion, the Company shall at its
election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Conversion
Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)
<U>Transfer Taxes and Expenses</U>. The issuance of Conversion Shares on conversion of this Debenture shall be made without charge to
the Holder hereof for any documentary stamp or similar taxes that may be payable in respect of the issue or delivery of such Conversion
Shares, provided that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the
issuance and delivery of any such Conversion Shares upon conversion in a name other than that of the Holder of this Debenture so converted
and the Company shall not be required to issue or deliver such Conversion Shares unless or until the Person or Persons requesting the
issuance thereof shall have paid to the Company the amount of such tax or shall have established to the satisfaction of the Company that
such tax has been paid. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Conversion and
all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day
electronic delivery of the Conversion Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Holder&rsquo;s Conversion Limitations</U>. The Company shall not effect any conversion of this Debenture, and a Holder shall not have
the right to convert any portion of this Debenture, to the extent that after giving effect to the conversion set forth on the applicable
Notice of Conversion, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting as a group together with
the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)) would beneficially own in
excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common
Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock
issuable upon conversion of this Debenture with respect to which such determination is being made, but shall exclude the number of shares
of Common Stock which would be issuable upon (i) conversion of the remaining, unconverted principal amount of this Debenture beneficially
owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or unconverted
portion of any other securities of the Company subject to a limitation on conversion or exercise analogous to the limitation contained
herein (including, without limitation, any other Debentures) beneficially owned by the Holder or any of its Affiliates or Attribution
Parties. Except as set forth in the preceding sentence, for purposes of this Section 4(d), beneficial ownership shall be calculated in
accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. To the extent that the limitation
contained in this Section 4(d) applies, the determination of whether this Debenture is convertible (in relation to other securities owned
by the Holder together with any Affiliates and Attribution Parties) and of which principal amount of this Debenture is convertible shall
be in the sole discretion of the Holder, and the submission of a Notice of Conversion shall be deemed to be the Holder&rsquo;s determination
of whether this Debenture may be converted (in relation to other securities owned by the Holder together with any Affiliates or Attribution
Parties) and which principal amount of this Debenture is convertible, in each case subject to the Beneficial Ownership Limitation, and
the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any
group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder. For purposes of this Section 4(d), in determining the number of outstanding shares of Common Stock, the Holder
may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report
filed with the Commission, as the case may be, (B) a more recent public announcement by the Company, or (C) a more recent written notice
by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request
of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock
then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion
or exercise of securities of the Company, including this Debenture, by the Holder or its Affiliates since the date as of which such number
of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 9.99% of the number
of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon conversion
of this Debenture. The Holder, upon notice to the Company, may decrease the Beneficial Ownership Limitation provisions of this Section
4(d), provided that the Beneficial Ownership Limitation provisions of this Section 4(d) shall continue to apply. Any decrease in the
Beneficial Ownership Limitation will not be effective until the 5<SUP>th</SUP> Business Day after such notice is delivered to the Company.
The Beneficial Ownership Limitation provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict
conformity with the terms of this Section 4(d) to correct this paragraph (or any portion hereof) which may be defective or inconsistent
with the intended Beneficial Ownership Limitation contained herein or to make changes or supplements necessary or desirable to properly
give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Debenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Holder of Record of Conversion Shares</U>. The Person in whose name any Conversion Share is issuable or deliverable upon conversion
of this Debenture will be deemed for all corporate purposes to hold such share as of the close of business on the date of receipt by
such Person of the Conversion Shares for such conversion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5. Certain Adjustments.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Stock Dividends and Stock Splits</U>. If the Company, at any time while this Debenture is outstanding: (i) pays a stock dividend or
otherwise makes a distribution or distributions payable in shares of Common Stock on shares of Common Stock or any Common Stock Equivalents
(which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon conversion of, or payment of
interest on, the Debentures), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including
by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues, in the event of a
reclassification of shares of the Common Stock, any shares of capital stock of the Company, then the Conversion Price shall be multiplied
by a fraction of which the numerator shall be the number of shares of Common Stock (excluding any treasury shares of the Company) outstanding
immediately before such event, and of which the denominator shall be the number of shares of Common Stock outstanding immediately after
such event. Any adjustment made pursuant to this Section shall become effective immediately after the record date for the determination
of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in
the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Subsequent Equity Sales</U>. If, at any time while this Debenture is outstanding, the Company or any Subsidiary, as applicable, sells
or grants any option to purchase or sells or grants any right to reprice, or otherwise disposes of or issues (or announces any sale,
grant or any option to purchase or other disposition), any Common Stock or Common Stock Equivalents entitling any Person to acquire shares
of Common Stock at an effective price per share that is lower than the then Conversion Price (such lower price, the &ldquo;<U>Base Conversion
Price</U>&rdquo; and such issuances, collectively, a &ldquo;<U>Dilutive Issuance</U>&rdquo;) (if the holder of the Common Stock or Common
Stock Equivalents so issued shall at any time, whether by operation of purchase price adjustments, reset provisions, floating conversion,
exercise or exchange prices or otherwise, or due to warrants, options or rights per share which are issued in connection with such issuance,
be entitled to receive shares of Common Stock at an effective price per share that is lower than the Conversion Price, such issuance
shall be deemed to have occurred for less than the Conversion Price on such date of the Dilutive Issuance), then simultaneously with
the consummation (or, if earlier, the announcement) of each Dilutive Issuance the Conversion Price shall be reduced to equal the Base
Conversion Price, provided that the Base Conversion Price shall not be less than the Floor Price (subject to adjustment for reverse and
forward stock splits, recapitalizations and similar transactions following the date of the Purchase Agreement). Notwithstanding the foregoing,
no adjustment will be made under this <U>Section 5(b)</U> in respect of an Exempt Issuance. The Company shall notify the Holder in writing,
no later than the Trading Day following the issuance of any Common Stock or Common Stock Equivalents subject to this <U>Section 5(b)</U>,
indicating therein the applicable issuance price, or applicable reset price, exchange price, conversion price and other pricing terms
(such notice, the &ldquo;<U>Dilutive Issuance Notice</U>&rdquo;). For purposes of clarification, whether or not the Company provides
a Dilutive Issuance Notice pursuant to this <U>Section 5(b)</U>, upon the occurrence of any Dilutive Issuance, the Holder is entitled
to receive a number of Conversion Shares based upon the Base Conversion Price on or after the date of such Dilutive Issuance, regardless
of whether the Holder accurately refers to the Base Conversion Price in the Notice of Conversion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 5(a) above, if at any time the Company grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire,
upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had
held the number of shares of Common Stock acquirable upon complete conversion of this Debenture (without regard to any limitations on
exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is
taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders
of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>,
that, to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the
Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial
ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall
be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial
Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Pro Rata Distributions</U>. During such time as this Debenture is outstanding, if the Company shall declare or make any dividend or
other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital
or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend,
spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Debenture, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete conversion of this Debenture (without regard to any limitations on conversion hereof, including without limitation, the
Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record
is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution
(<U>provided</U>, <U>however</U>, that, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result
in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution
to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the
portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would
not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Adjustment to Conversion Price</U>. Whenever the Conversion Price is adjusted pursuant to any provision of this <U>Section 5</U>,
the Company shall promptly deliver to each Holder a notice setting forth the Conversion Price after such adjustment and setting forth
a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Notice to Allow Conversion by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form)
on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock of rights or warrants to subscribe for or purchase any shares
of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company (and all of its Subsidiaries, taken as a whole)
is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the
Common Stock is converted into other securities, cash or property or (E) the Company shall authorize the voluntary or involuntary dissolution,
liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be filed at each office or agency
maintained for the purpose of conversion of this Debenture, and shall cause to be delivered to the Holder at its last address as it shall
appear upon the Debenture Register, at least twenty (20) calendar days prior to the applicable record or effective date hereinafter specified,
a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or
warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend,
distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger,
sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the
Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable
upon such reclassification, consolidation, merger, sale, transfer or share exchange, provided that the failure to deliver such notice
or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such
notice. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company
or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form
8-K. For the avoidance of doubt, the Holder shall remain entitled to convert this Debenture during the 20-day period commencing on the
date of such notice through the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Fundamental Transaction</U>. If, at any time while this Debenture is outstanding, (i) the Company, directly or indirectly, in one
or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company (and all
of its Subsidiaries, taken as a whole), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or
other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect,
purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common
Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders
of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects
any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common
Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly,
in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without
limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby
such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock
held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to,
such stock or share purchase agreement or other business combination) (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon
any subsequent conversion of this Debenture, the Holder shall have the right to receive, for each Conversion Share that would have been
issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction (without regard to any limitation in
Section 4(d)), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving
corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental
Transaction by a holder of the number of shares of Common Stock for which this Debenture is convertible immediately prior to such Fundamental
Transaction (without regard to any limitation in Section 4(d)). For purposes of any such conversion, the determination of the Conversion
Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable
in respect of one (1) share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Conversion Price among
the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration.
If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then
the Holder shall be given the same choice as to the Alternate Consideration it receives upon any conversion of this Debenture following
such Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the
survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Debenture
and the other Transaction Documents (as defined in the Purchase Agreement) in accordance with the provisions of this Section 5(g) pursuant
to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay)
prior to such Fundamental Transaction and shall, at the option of the holder of this Debenture, deliver to the Holder in exchange for
this Debenture a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this
Debenture which is convertible for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity)
equivalent to the shares of Common Stock acquirable and receivable upon conversion of this Debenture (without regard to any limitations
on the conversion of this Debenture) prior to such Fundamental Transaction, and with a conversion price which applies the conversion
price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to
such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such conversion
price being for the purpose of protecting the economic value of this Debenture immediately prior to the consummation of such Fundamental
Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Debenture and the other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity),
and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Debenture and
the other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>Calculations</U>. All calculations under this Section 5 shall be made to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this Section 5, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding any treasury shares of the Company) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Nasdaq Stockholder Approval</U>. Notwithstanding anything to the contrary in this Debenture or the Purchase Agreement, prior to the
receipt of Nasdaq Stockholder Approval, the Holder shall not be permitted to convert any portion of this Debenture for any Conversion
Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
6. Exit Fee</U>. Upon any prepayment by the Company in cash of all or any of the principal amount of this Debenture (whether on or prior
to the Maturity Date), the Company shall pay to the Holder concurrently with such prepayment an exit fee in an amount equal to 15% of
the principal amount of this Debenture being prepaid (an &ldquo;<U>Exit Fee</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
7. Covenants</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Negative Covenants</U>. As long as any portion of this Debenture remains outstanding, the Company shall not, and shall not permit
any of the Subsidiaries to, directly or indirectly:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
other than Permitted Indebtedness, except with the prior written consent of the Holder, enter into, create, incur, assume, guarantee
or suffer to exist any Indebtedness of any kind, including, but not limited to, a guarantee, on or with respect to any of its property
or assets now owned or hereafter acquired or any interest therein or any income or profits therefrom;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
other than Permitted Liens, enter into, create, incur, assume or suffer to exist any Liens of any kind, on or with respect to any of
its property or assets now owned or hereafter acquired or any interest therein or any income or profits therefrom;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
amend its charter documents, including, without limitation, its certificate of incorporation and bylaws, in any manner that materially
and adversely affects any rights of the Holder;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
repay, repurchase or offer to repay, repurchase or otherwise acquire more than a <U>de minimis</U> number of shares of its Common Stock
or Common Stock Equivalents other than as to (i) the Conversion Shares as permitted or required under the Transaction Documents, and
(ii) repurchases of Common Stock or Common Stock Equivalents of departing officers and directors of the Company, provided that such repurchases
shall not exceed an aggregate of $50,000 for all officers and directors during the term of this Debenture;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
repay, repurchase or offer to repay, repurchase or otherwise acquire any Indebtedness, other than the Debentures if on a pro-rata basis,
other than regularly scheduled principal and interest payments as such terms are in effect as of the Original Issue Date, provided that
such payments shall not be permitted if, at such time, or after giving effect to such payment, any Event of Default exist or occur;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
pay cash dividends or distributions on any equity securities of the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)
assign, sell, transfer, license, lease or otherwise dispose of any its assets other than (a) sales of inventory in the ordinary course
of business, and (b) other dispositions not to exceed $50,000 in the aggregate per year;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)
make or hold any Investments other than: (a) Investments existing on the date of the Purchase Agreement and that are disclosed in the
SEC Reports (provided, for clarity, that neither the Company nor any Subsidiary shall increase the size of its Investment in any such
Investment existing on the date of the Purchase Agreement other than in accordance with this Debenture and the other Transaction Documents),
(b) Investments in cash and cash equivalents held in deposit accounts at U.S. banks, (c) Investments in Subsidiaries; and (e) other Investments
that do not exceed $50,000 in the aggregate per calendar year;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)
enter into any transaction with any Affiliate of the Company which would be required to be disclosed in any public filing with the Commission,
unless such transaction is made on an arm&rsquo;s-length basis and expressly approved by a majority of the disinterested directors of
the Company (even if less than a quorum otherwise required for board approval); or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
enter into any agreement with respect to any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Affirmative Covenants</U>. As long as any portion of this Debenture remains outstanding, the Company shall, and shall cause each of
its Subsidiaries to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
preserve and maintain its legal existence, rights, franchises and privileges in the jurisdiction of its organization, and qualify and
remain qualified as a foreign business entity in each jurisdiction in which qualification is necessary in view of its business and operations
or the ownership of its properties and where failure maintain or qualify could reasonably be expected to have a Material Adverse Effect;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
provide to the Holder, promptly upon becoming aware thereof (and in any event within one (1) day after the occurrence thereof), a notice
of each Event of Default known to an executive officer of the Company, together with a statement of such executive officer setting forth
the details of such Event of Default and the actions which the Company has taken and proposes to take with respect thereto;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
(a) pay and discharge as the same shall become due and payable: (i) all tax liabilities, assessments and governmental charges or levies
upon it or its properties or assets, unless the same are being contested in good faith by appropriate proceedings diligently conducted
(which proceedings have the effect of preventing the forfeiture or sale of the property or assets subject to any such Lien) and adequate
reserves in accordance with GAAP are being maintained by the Company or such Subsidiary; (ii) all lawful claims which, if unpaid, would
by law become a Lien upon its property, unless the same are being contested in good faith by appropriate proceedings diligently conducted
(which proceedings have the effect of preventing the forfeiture or sale of the property or assets subject to any such Lien) and adequate
reserves in accordance with GAAP are being maintained by the Company or such Subsidiary; and (iii) all Indebtedness, as and when due
and payable, but subject to the terms of this Debenture; and (b) timely file all material tax returns required to be filed (subject to
any valid extension);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
(a) maintain, preserve and protect all of its material properties and equipment necessary in the operation of its business in good working
order and condition, ordinary wear and tear excepted; and (b) make all necessary repairs thereto and renewals and replacements thereof
except where the failure to do so could not reasonably be expected to have a Material Adverse Effect;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
comply in all material respects with the requirements of all applicable laws and all orders, writs, injunctions and decrees applicable
to it or to its business or property;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
[reserved];</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)
maintain (a) insurance with financially sound and reputable insurance companies in at least the amounts (and with only those deductibles)
customarily maintained, and against such risks as are typically insured against, by Persons of comparable size engaged in the same or
similar business as the Company and its Subsidiaries; and (b) all worker&rsquo;s compensation, employer&rsquo;s liability insurance or
similar insurance as may be required under the laws of any state or jurisdiction in which it may be engaged in business; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)
use reasonable efforts to cause the Company to remain eligible to use Form S-3 for a delayed or continuous offering pursuant to <I>Rule
415(a)(1)(x) </I>promulgated under the Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
8. Events of Default</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
&ldquo;<U>Event of Default</U>&rdquo; means, wherever used herein, any of the following events (whatever the reason for such event and
whether such event shall be voluntary or involuntary or effected by operation of law or pursuant to any judgment, decree or order of
any court, or any order, rule or regulation of any administrative or governmental body):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
any default in the payment of (A) the principal amount of any Debenture or (B) interest, liquidated damages and other amounts owing to
a Holder on any Debenture, as and when the same shall become due and payable (whether on a Conversion Date or the Maturity Date or by
acceleration or otherwise) which default, solely in the case of an interest payment or other default under clause (B) above, is not cured
within three (3) Trading Days;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
the Company shall fail to observe or perform any other covenant or agreement contained in the Debentures (other than a breach by the
Company of its obligations to deliver shares of Common Stock to the Holder upon conversion, which breach is addressed in clause (xii)
below) or in any Transaction Document, which failure is not cured, if possible to cure, within the earlier to occur of (A) five (5) Trading
Days after notice of such failure sent by the Holder or by any other Holder to the Company and (B) ten (10) Trading Days after the Company
has become or should have become aware of such failure;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
a default or event of default (subject to any grace or cure period provided in the applicable agreement, document or instrument) shall
occur under (A) any of the Transaction Documents or (B) any other material agreement, lease, document or instrument to which the Company
or any Subsidiary is obligated (and not covered by clause (vi) below);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
any representation or warranty made in this Debenture, any other Transaction Documents, any written statement pursuant hereto or thereto
or any other report, financial statement or certificate made or delivered to the Holder or any other Holder shall be untrue or incorrect
in any material respect as of the date when made or deemed made;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
the Company or any Subsidiary shall be subject to a Bankruptcy Event;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
the Company or any Subsidiary shall default on any of its obligations under any Indebtedness, that (a) involves an obligation greater
than $100,000, whether such Indebtedness now exists or shall hereafter be created, and (b) results in such Indebtedness becoming or being
declared due and payable prior to the date on which it would otherwise become due and payable;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)
the Common Stock shall not be eligible for listing or quotation for trading on a Trading Market and shall not be eligible to resume listing
or quotation for trading thereon within five Trading Days;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)
the Company (and all of its Subsidiaries, taken as a whole) shall be a party to any (A) Change of Control Transaction or shall agree
to sell or dispose of all or in excess of 33% of its assets in one transaction or a series of related transactions (whether or not such
sale would constitute a Change of Control Transaction) or (ii) Fundamental Transaction, in each case, other than the Merger Transaction;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)
any Person shall breach any agreement delivered to the initial Holders pursuant to Section 2.2 of the Purchase Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
the Initial Registration Statement (as defined in the Registration Rights Agreement) shall not have been (x) filed on or prior to the
Filing Deadline (as defined in the Registration Rights Agreement) or (y) declared effective by the Commission on or prior to the Effectiveness
Deadline (as defined in the Registration Rights Agreement) or the Company does not meet the current public information requirements under
Rule 144 in respect of the Registrable Securities (as defined in the Registration Rights Agreement);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xi)
if, during the Effectiveness Period (as defined in the Registration Rights Agreement), either (a) the effectiveness of the Registration
Statement lapses for any reason or (b) the Holder shall not be permitted to resell Registrable Securities (as defined in the Registration
Rights Agreement) under the Registration Statement for a period of more than 20 consecutive Trading Days or 30 non-consecutive Trading
Days during any 12 month period;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xii)
the Company shall fail for any reason to deliver Conversion Shares to a Holder prior to the fifth Trading Day after a Conversion Date
pursuant to <U>Section 4(c)</U> or the Company shall provide at any time notice to the Holder, including by way of public announcement,
of the Company&rsquo;s intention to not honor requests for conversions of any Debentures in accordance with the terms hereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiii)
the electronic transfer by the Company of shares of Common Stock through the Depository Trust Company or another established clearing
corporation is no longer available or is subject to a &ldquo;chill&rdquo;;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiv)
any monetary judgment, writ or similar final process shall be entered or filed against the Company, any subsidiary or any of their respective
property or other assets for more than $100,000, and such judgment, writ or similar final process shall remain unvacated, unbonded or
unstayed for a period of 45 calendar days;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xv)
[reserved]; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xvi)
the occurrence of a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Remedies Upon Event of Default</U>. If any Event of Default occurs and is continuing, the outstanding principal amount of this Debenture,
the Mandatory Default Amount, plus accrued but unpaid interest, liquidated damages and other amounts owing in respect thereof through
the date of acceleration, shall become, at the Holder&rsquo;s election, immediately due and payable in cash; provided that such acceleration
shall be automatic, without any notice or other action of the Required Holders required, in respect of an Event of Default occurring
pursuant to clause (v) of <U>Section 8(a)</U>. Commencing 5 days after the occurrence and continuance of any Event of Default, the interest
rate on this Debenture shall accrue at an interest rate equal to the lesser of 18.0% per annum or the maximum rate permitted under applicable
law. In connection with such acceleration described herein, the Holder need not provide, and the Company hereby waives, any presentment,
demand, protest or other notice of any kind, and the Holder may immediately and without expiration of any grace period enforce any and
all of its rights and remedies hereunder and all other remedies available to it under applicable law. Such acceleration may be rescinded
and annulled by Holder at any time prior to payment hereunder and the Holder shall have all rights as a holder of the Debenture until
such time, if any, as the Holder receives full payment pursuant to this <U>Section 8(b)</U>. No such rescission or annulment shall affect
any subsequent Event of Default or impair any right consequent thereon.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
9. </U>[RESERVED].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
10</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Notices</U>. Any and all notices or other communications or deliveries to be provided by the Holder hereunder, including, without
limitation, any Notice of Conversion, shall be in writing and delivered personally, by email attachment, or sent by a nationally recognized
overnight courier service, addressed to the Company, at the address set forth above, or such other email address, or address as the Company
may specify for such purposes by notice to the Holder delivered in accordance with this Section 10(a). Any and all notices or other communications
or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by email attachment, or sent by a
nationally recognized overnight courier service addressed to each Holder at the email address or address of the Holder appearing on the
books of the Company, or if no such email attachment or address appears on the books of the Company, at the principal place of business
of such Holder, as set forth in the Purchase Agreement. Any notice or other communication or deliveries hereunder shall be deemed given
and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via email attachment to the
email address set forth on the signature pages attached hereto prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading
Day after the date of transmission, if such notice or communication is delivered via email attachment to the email address set forth
on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading
Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service or (iv)
upon actual receipt by the party to whom such notice is required to be given.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Absolute Obligation</U>. Except as expressly provided herein, no provision of this Debenture shall alter or impair the obligation
of the Company, which is absolute and unconditional, to pay the principal of, liquidated damages and accrued interest, as applicable,
on this Debenture at the time, place, and rate, and in the coin or currency, herein prescribed. This Debenture is a direct debt obligation
of the Company. This Debenture ranks <U>pari passu</U> with all other Debentures now or hereafter issued under the terms set forth herein.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Lost or Mutilated Debenture</U>. If this Debenture shall be mutilated, lost, stolen or destroyed, the Company shall execute and deliver,
in exchange and substitution for and upon cancellation of a mutilated Debenture, or in lieu of or in substitution for a lost, stolen
or destroyed Debenture, a new Debenture for the principal amount of this Debenture so mutilated, lost, stolen or destroyed, but only
upon receipt of evidence of such loss, theft or destruction of such Debenture, and of the ownership hereof, reasonably satisfactory to
the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Debenture shall be
governed by and construed and enforced in accordance with the internal laws of the State of Delaware, without regard to the principles
of conflict of laws thereof. Each party agrees that all legal proceedings concerning the interpretation, enforcement and defense of the
transactions contemplated by any of the Transaction Documents (whether brought against a party hereto or its respective Affiliates, directors,
officers, shareholders, employees or agents) shall be commenced in the state and federal courts sitting in the State of Delaware (the
&ldquo;<U>Delaware Courts</U>&rdquo;). Each party hereto hereby irrevocably submits to the exclusive jurisdiction of the Delaware Courts
for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein
(including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert
in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of such Delaware Courts, or such Delaware
Courts are improper or inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents
to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight
delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Debenture and agrees that such
service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit
in any way any right to serve process in any other manner permitted by applicable law. Each party hereto hereby irrevocably waives, to
the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating
to this Debenture or the transactions contemplated hereby. If any party shall commence an action or proceeding to enforce any provisions
of this Debenture, then the prevailing party in such action or proceeding shall be reimbursed by the other party for its attorneys fees
and other costs and expenses incurred in the investigation, preparation and prosecution of such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Waiver</U>. Any waiver by the Company or the Holder of a breach of any provision of this Debenture shall not operate as or be construed
to be a waiver of any other breach of such provision or of any breach of any other provision of this Debenture. The failure of the Company
or the Holder to insist upon strict adherence to any term of this Debenture on one or more occasions shall not be considered a waiver
or deprive that party of the right thereafter to insist upon strict adherence to that term or any other term of this Debenture on any
other occasion. Any waiver by the Company or the Holder must be in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Severability</U>. If any provision of this Debenture is invalid, illegal or unenforceable, the balance of this Debenture shall remain
in effect, and if any provision is inapplicable to any Person or circumstance, it shall nevertheless remain applicable to all other Persons
and circumstances. If it shall be found that any interest or other amount deemed interest due hereunder violates the applicable law governing
usury, the applicable rate of interest due hereunder shall automatically be lowered to equal the maximum rate of interest permitted under
applicable law. The Company covenants (to the extent that it may lawfully do so) that it shall not at any time insist upon, plead, or
in any manner whatsoever claim or take the benefit or advantage of, any stay, extension or usury law or other law which would prohibit
or forgive the Company from paying all or any portion of the principal of or interest on this Debenture as contemplated herein, wherever
enacted, now or at any time hereafter in force, or which may affect the covenants or the performance of this Debenture, and the Company
(to the extent it may lawfully do so) hereby expressly waives all benefits or advantage of any such law, and covenants that it will not,
by resort to any such law, hinder, delay or impede the execution of any power herein granted to the Holder, but will suffer and permit
the execution of every such as though no such law has been enacted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Remedies, Characterizations, Other Obligations, Breaches and Injunctive Relief</U>. The remedies provided in this Debenture shall
be cumulative and in addition to all other remedies available under this Debenture and any of the other Transaction Documents at law
or in equity (including a decree of specific performance and/or other injunctive relief), and nothing herein shall limit the Holder&rsquo;s
right to pursue actual and consequential damages for any failure by the Company to comply with the terms of this Debenture. The Company
covenants to the Holder that there shall be no characterization concerning this instrument other than as expressly provided herein. Amounts
set forth or provided for herein with respect to payments, conversion and the like (and the computation thereof) shall be the amounts
to be received by the Holder and shall not, except as expressly provided herein, be subject to any other obligation of the Company (or
the performance thereof). The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the
Holder and that the remedy at law for any such breach may be inadequate. The Company therefore agrees that, in the event of any such
breach or threatened breach, the Holder shall be entitled, in addition to all other available remedies, to an injunction restraining
any such breach or any such threatened breach, without the necessity of showing economic loss and without any bond or other security
being required. The Company shall provide all information and documentation to the Holder that is requested by the Holder to enable the
Holder to confirm the Company&rsquo;s compliance with the terms and conditions of this Debenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>Next Business Day</U>. Whenever any payment or other obligation hereunder shall be due on a day other than a Business Day, such payment
shall be made on the next succeeding Business Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Headings</U>. The headings contained herein are for convenience only, do not constitute a part of this Debenture and shall not be
deemed to limit or affect any of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
11</U>. [RESERVED].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
12. Disclosure</U>. Upon receipt or delivery by the Company of any notice in accordance with the terms of this Debenture, in the event
that the Company believes that such notice contains material, non-public information relating to the Company or its Subsidiaries, the
Company shall so indicate in such notice that it contains material, non-public information relating to the Company or its Subsidiaries
and, simultaneously with the delivery of such notice to the Holder, the Company shall publicly disclose the contents of such notice in
a Current Report on Form 8-K filed with the Commission. If the Company does not indicate to the Holder with delivery of such notice that
it contains material, non-public information relating to the Company or its Subsidiaries, the Holder shall be allowed to presume that
all matters set forth in such notice do not constitute material, nonpublic information relating to the Company or its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Debenture to be duly executed by a duly authorized officer as of the date first above indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>NanoVibronix,
  Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/Brian Murphy&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Brian Murphy</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">CEO</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANNEX
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF CONVERSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reference
is made to the Amended and Restated Senior Convertible Debenture due the earlier to occur of the Trigger Date and November 13, 2025 (the
&ldquo;<U>Debenture</U>&rdquo;) of NanoVibronix, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned hereby elects to convert principal under the Debenture into shares of common stock of the Company (the &ldquo;<U>Common Stock</U>&rdquo;)
according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person
other than the undersigned, the undersigned will pay all issue, stamp, transfer and similar taxes payable with respect thereto and is
delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged
to the holder for any conversion, except for such issue, stamp, transfer and similar taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
the delivery of this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock
does not exceed the amounts specified under Section 4 of this Debenture, as determined in accordance with Section 13(d) of the Exchange
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer
of the aforesaid shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion
calculations: </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
to Effect Conversion:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
Amount of Debenture to be Converted:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
of Interest in Common Stock __ yes __ no</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
yes, $_____ of Interest Accrued on Account of Conversion at Issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
of shares of Common Stock to be issued:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Signature:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Address
for Delivery of Common Stock Certificates:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Or</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DWAC
Instructions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DTC
Participant Number:_______________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DTC
Participant Name:_______________________</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 2.5in"></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Account Number:____________________</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 2.5in"></P>

<!-- Field: Page; Sequence: 25; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>ex21-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><B>Exhibit 21.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>NANOVIBRONIX, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><B>Subsidiaries of the Registrant</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><B>State or Other Jurisdiction of Incorporation</B></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">NanoVibronix Ltd.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Israel</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">ENvue Medical Holdings LLC</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">Delaware</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>


<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><U>Independent
Registered Public Accounting Firm&rsquo;s Consent</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the incorporation by reference in the Registration Statement on Form S-8 of our report dated March 31, 2025, relating
to the consolidated financial statements of NanoVibronix, Inc. and Subsidiary appearing in its Annual Report (Form 10-K) for the year
ended&nbsp;December 31, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Zwick CPA, PLLC</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Southfield, Michigan</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT
TO RULE 13a-14(a)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">I, Brian Murphy, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">1.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">I have reviewed this Annual Report on Form 10-K of NanoVibronix, Inc. (the &ldquo;registrant&rdquo;);</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">2.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">3.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">4.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">a)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">b)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">c)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">d)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">5.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">a)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">b)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%">Date: March 31, 2025</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 5%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 45%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><I>/s/ Brian Murphy</I></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Name:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Brian Murphy</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Title:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Chief Executive Officer</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">(Principal Executive Officer)</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF CHIEF FINANCIAL OFFICER PURSUANT TO RULE 13a-14(a)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Stephen Brown, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this Annual Report on Form 10-K of NanoVibronix, Inc. (the &ldquo;registrant&rdquo;);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
    (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
    reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
    the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 31, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Stephen Brown</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stephen
    Brown</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 12; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>CERTIFICATION FURNISHED PURSUANT TO 18 U.S.C. SECTION
1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">This certification is furnished solely pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350) and accompanies the Annual Report on Form 10-K (the &ldquo;Form 10-K&rdquo;)
for the year ended December 31, 2024, of NanoVibronix, Inc. (the &ldquo;Company&rdquo;). I, Brian Murphy, the Chief Executive Officer
of the Company, certify that, based on my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">(1) </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Form 10-K fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">(2) </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">The information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the periods covered in this report.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%">Date: March 31, 2025</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 45%"><I>/s/ Brian Murphy</I></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Name:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Brian Murphy</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Title:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Chief Executive Officer <BR>
(Principal Executive Officer)</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The foregoing certification is being furnished as
an exhibit to the Form 10-K pursuant to Item 601(b)(32) of Regulation S-K and Section 906 of the Sarbanes-Oxley Act of 2002 (subsections
(a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) and, accordingly, is not being filed as part of the Form 10-K
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not incorporated by reference into any filing of
the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 13; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>ex32-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>CERTIFICATION FURNISHED PURSUANT TO 18 U.S.C. SECTION
1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">This certification is furnished solely pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350) and accompanies the Annual Report on Form 10-K (the &ldquo;Form 10-K&rdquo;)
for the year ended December 31, 2024, of NanoVibronix, Inc. (the &ldquo;Company&rdquo;). I, Stephen Brown, the Chief Financial Officer
of the Company, certify that, based on my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">(1)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Form 10-K fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">(2)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">The information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the periods covered in this report.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%">Date: March 31, 2025</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 45%"><I>/s/ Stephen Brown</I></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Name:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Stephen Brown</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Title:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Chief Financial Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">(Principal Financial and Accounting Officer)</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The foregoing certification is being furnished as
an exhibit to the Form 10-K pursuant to Item 601(b)(32) of Regulation S-K and Section 906 of the Sarbanes-Oxley Act of 2002 (subsections
(a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) and, accordingly, is not being filed as part of the Form 10-K
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not incorporated by reference into any filing of
the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>







</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>form10-k_001.jpg
<TEXT>
begin 644 form10-k_001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #T 8(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "F4X]*KS3")6+D)&JEFD/10* 'EP3C@?6H7O;>-MK7"*?3-?.WQ/\ VE+>
MUOY=-T:171&VO<*>I%<3:?%>YN9HWDN [OR?FK14^8S=11/L-+J&0?),I_&I
M5S_>!KY[\-_$GSW0>;R?>O3]%\4_:%3#Y]>:EPY2E+F.U/6E'6J-MJ:7+ $[
M/?UJZK#&0<^]24/HI"<"DW$G [4 .HI,\9Q2*V[/% #J*** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI,T +129S2T %)GV
MI-PSUI0<T &?:@'-&12%@.] KBGBDW4$@CCFD) ZD#ZT68[H7=1O]JB:YA3[
MTJ#ZL*IW&N6%L3ON5R.P:ERR)YC1#@]C06"C)X%<[-XWTY/N,9"/2LVX^(2E
M66*W8]LMTIJ$@YD=A)<I"K-(0BJ-S,QP /K45GJEKJ,9:UN(;D#J8I PKS7Q
M+K;^+-#O=+NV>UM[J/RF:(X8#U!KP*/]G?7O"@:Y\#>.K^PE!W"VNY"RM6D:
M;9$JB1]G&4#=G@ =3TKQW]IOQQ<>%?A\]M8R;+Z_;R@0<%4/4UY%;_&/XT?#
M1O*U_P /0^*=/08:>T'S_4BL[Q)^T1X4^*-_;1Z[#/I$ELNTV=W$5^8^AQBM
M%2:>I#JI['A-E9&.61?FE.XYW'ECW(K1%O+;;7&Y2._6O8]0\'>$_%UK''#,
ML49&4GLI0S*?PKD+OX#ZA;!Y=#\0";G_ %=T>?UK976QS2=]SG=/\47&FRH?
M-8\]C7JO@OXJF+"O*1CU:O+M1\(>*-(D*:CI):/^]&M9Z6LEJ>8Y8&/9P143
MC?<J$[;'VSX2\=6NJ1PAW&2/[U>@6EX5C+H=T(ZX-?!?AWQ;?:5<1@2,0O3!
MKVOP;\;+B%4CG<%,X(8]JPY#JA/F>I]+VUY'=K^[=21U&>16#J_B3=.L.GNM
MPT9VRE&!VGTKCHO$L#Z;=ZQ8S;6"$M&#UX]*^%KKX[W_ (;\1:U<:+JES! +
M@R21SL3AL]*:A<F=519^C]OXM157[2K1GH:V+?5;>X52CCYNF:^!?"/[=\0=
M(=:MH;A#\I=#R?>O;O#7[1W@?Q$T:P7PM9V RK/P*KV8XUHO0^E%F#-@8/T-
M.+D?PY'M7DJ?$S1M+M_M+>)+".+KEY 3BI-(_:&\):AXAMM$M]06[OKA@L8B
M.0QJ)0:-5)/8]75L]J=3%&#S3ZS&%%%% !1110 4444 %%%% !1110 44E!Z
M4 +13*7>* '44S<3V./6D<KCD_K1KT%=$E)FJ<M];0 A[A%QZFLRY\9:3:*1
M+=(3[&G9A==S?S2'K7$77Q,TZ'BW1Y*S9_BG(V5AMA[;NM-Q<=R>>+^%GI&<
M4A?Z?C7E$OQ!U:7[OEP@_K5&?Q#J=T#F^<9_A'2B/*^I+J*/Q'KTU[;VO^LF
MC3\:SKCQ9IMN,FY#'VKR22:YD.9)G?WS3EA;&=O_ 'T:T5-OX=2>>-3X']YZ
M//\ $+38L[-[MZ"LZ;XEASB&T(QW:N'-U#$"LTD28Z8P2*SIO$5A'+Y"EY9F
M]L$_2M%0E?9F;JP3LY([FX\>:A*#LVP@]_2L^;Q%J=US]H)^E<O+KTT6%%J$
M_P"O@9J!_$ESYCQQM$B=]B5HJ/<EU5T.FDFGD_ULCL/K4)"GJ5 '=FYKG+K4
M!,R!KU\ <(.]4XI9+A=RHVT'DL>*V4.Y/M;['7G4K.)2OFH&'4+47]KQ$8B@
MGE;L%'!KF[D2M:!XI(HY%/RE><_6M.7Q-/#90+',@E489@*5DAZO4TFN[V1?
MW>GG_@=,4:HXR]Q:6R_[9^:L>/5KN[O!)]J,_'W<=*4PS:A<M)%83.J_ZPMU
M)HL^A+MU-A9GMG!;6@KOU^7(:J>L^!M.U^W<ZKHNG:I%(.)-H5R.]-C\-ZC>
M.WF1- N/E)ZBK=IX1O+:)&N=4/D\X7/2C;<?*K7/&M?_ &=_#4AFN/#>HZCX
M=N%ZK$Y,0-<Z?"OQ-\*-$-.O['Q':1?>1SB0BOHNU\/:/;S&5]0,F.3&QX-5
M[M/#E_<8(EM)%X\R+H:%9[&,K=SP2V^-U]H$OD>)M#U+2 >K%/.3_OJNHT7Q
MMX2\;L1%>6<S-U68 &O2;O0+>_W0QW<&I1'K#,H.:X3Q-\ _#&NR9N]#FTF?
M.1=:>2.?7BG*#ZA:VPLOPTT&_P M;R&UD;^(?=/TJA<?!C5[,A[*6*ZC^\'!
MYJI'\$?%>@C=X2\9#50@S]@U <@>@JK+\0/B+\/S_P 5-X0NOL:GB?38RZC\
MO6LG&*+AS7N:AM]<T>&2*>">'(Q\F<&O(=6^$UGJ.ISW$4"L;N0BX7IBO<_"
MW[0WASQ--#9SZI%:2R\>1J*^7+'^==!XH_X0RT=I7BN-49E %UIKAXU]SBLF
MGT-].I\!_&G]D'Q+X4L9O%G@V.77-"C!DO;" _OH?=/:O*_AWKZZB%,+N)0Q
M5T9B&4CL?>OTFOM:F\":Q:26<LQT>]3$&Y>9/4./3M7B?QV_95TWX@SW'C7X
M90P:3XIC0RW6BPG$%T1RS+_M5G>2,Y035T>7:-:B>!)I_,<H#P[DC\J^@_V/
MO#!UWXMK>20*8=)@)/RY^8]*^>OAIJ;ZBC6=Y&UGJ=JQCN;.==KQL.N<]J^Z
M?V+O!JZ-X>U75W<M->S;0#_=K.384N:]F?2YZTX=*;3ATJ3O%HHHH **** "
MBBB@ HHHH *H:KJL.DV5Q=W,@C@@7<Q[XJ]TK@OC8#%\-];93AFCQD4X6;LR
M)7MH0:!\<_#&NSM$ET86#8!D'!KIY_&&F0)O^UI(G]Y3FOBBWC18XPB[ (U'
M'7/<UKZ3XBU+1Y1Y$QF4?\LY.0:W=)-G.JC1]5W?Q/TJ XC#S-_LBL:[^*DI
MXMK(ANV\UX[IGQ!L[A0M_";63NZBNFM;F"]C$EM<+<@^C<_E51II;B<VSI;O
MX@ZW<9&%BS_=[5F3:_J-S@R7KH1V!ZUSGB'Q*?#IB#VDLL<AQY@'"?[WI7%^
M+_C#_P (RT?E:;+J ?\ CMUW!:ZH8>51\L3GGBHT]9'HT]Q//)\T\K_B:58
M6^[M7N7YKPZ3XT>*M4G\K3=&GPP^4/'M)JM-<?$[Q LI*K8QIRQ9^1^%=RRO
M2\Y'F3S-MVIQN>\27EM""#+'$5Z[FK.NO&.B6'-S>P1 <G# FO%3\,O$]Y K
MZMKI8S#<QB)^3VH;X):7_:$+ZA?W4RN,%MQQFM88:A2^*5SGECL3/X:=CTF^
M^-_A2T+%+L2A>,'^E<KK/[2^F6IV65I-<Y_B1"<5-I_PI\.Z.T<?]FF=U.?W
MI^^*[FP72]*BQ8>&[2!X^K,@?)K1RPT=HB4L?46]D>81?&/QAXD21M(\/W!
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M>^)(YXU>,PON)4X#5]%_##XDP>/-+$JX74(5VM%GK[TN4N,CT)3D9'2EJ.(
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M)_!.'8[&S]*^[=?\#1S;ALS[@5Y'XI^'8?S"L#4 ?#VN^%?*<_+C%<9J&FO
M_ (-?67BGX<O\Q\D#\*\MUOP \;,?)'Y4 >#7-GYA8L/F'K6'J/A];@'Y5.[
MJ,5Z[JO@B8,Y5,>U8<_A"[4C$1Q4NX'AFJ^% C;?+R <@GJ/QK9\%_%GQ/\
M#:YQ;S-J.G@_/:3'[H]J](N_!MW,<"T9O?%<IK?PZNV21Q92DG^(+S51=A-7
M/;O ?Q]\,>/A#"MP-)U%RH,%P< MGUK[<\3ZCXJMM(\/Q>%K.&^::T4-.WS)
MG'8BOQB\:^&KK3K%K@V]Q#*C<2(A##\179_#+]O#XM?![1/[%T77WN+)1A5O
MEWE/IGI5J5B7&Y^J$GPA^(/B./S?$'B)-'M6&7C:18P!['-<;XFM_@1\)09_
M&/CRVU6<??MTF\QL_A7Y8>.?VE/BI\6+]Y-6\5ZI>-,2!;6CLJ_0 5L>$/V8
M/%?C+1&U74A/ TG*K<$F1OSJO:,GD/MKQ=_P4Q^$/P_BGL? '@I]5D3_ %=W
M<C8N:^?O'G_!4SXK^+87MM$BL/#<#<9MDRV/J:\4UG]F/Q?HYEQ:>>O4'!S7
MG^L>!_$FCRLEWIEP&!P2D>?Y"IYF:6-[Q/\ &CQUXVOWO-7\6:E<3L<D"8JH
M^@!KHO WQN\9^&"KB*'6H5ZBX 9L5Y/+:S6@W2V\\##^^A %365XT;JT<_DM
MWP>*2=]QV/L;P;^V?HC!8?$/A0Z<R\-- N<U[/X9_:$^'GB2%?L^MQV3MT2?
MBOSMM/%-W;'Y?*N!_P \W&<UJQ>++&\BQ?:+$(Q_SQ.UA6JC&743?+L?IYHD
M$7C0[='UG3KI3R/WZC/ZUW&E_ '5=3*M<7D#%L8"2J?ZU^3EAK&@,NZUU#4]
M'8'_ )8SLI'ZUUFF^/M?TH :/\2M4B48QYTS''IWJO9Q9+DS]>-"_9HBLXU,
MUHTS?WR<BN_TCX,16"J%LEC]U3FOQRL?VA/C98!5T_XDSW,8Z;IOZ&MZ#]K?
M]HVU4+#XP,@'<R@YJ?8D<Q^S%IX 6VC53;=.];,?AR&$;@H!]R *_$2Y_:S_
M &C+A61O$]SM/]V4"N8U/XZ?'?6,B[\4:AGU2Z*U7U=AS'[MZAK?A[PS;M/J
M>N6-@JC+>;.HQ^M>%_$W]OWX,_"X2QRZ]_;MTHR(;$;LGTS7XP:RWQ&\22,^
MI:S>76[[WVB\8C\LUB0>"-3DDQ/=6\?/S MNS2]@R>8^\_BS_P %;O%NN0W%
MGX'\/VVB6DA*QWMP=[X]<5\7^,OB9XS^,.LF37-6U/Q-=LV?*5FDC;/90.E8
MT?@S3(W<7>KEPO1(%/%=OX.\?-\/K.6S\-Q0VDC_ .LOG0&0CV)Z5I&ER[AS
M':>"OV7-3ETE=8^(>OVOPW\-!0XCN");^5/1$'W2?>NTTO\ :!\*?!>WFL/@
M?X5CAU3;Y3>+M>42W+]MT:'[IKQ.&37_ (G^(40_VGXIU*9O]65>7)Z $C@5
M]9?!;_@G-\1O']Q:W'BB&+P;HYPV -TY7V]#0IJ+,]9;'S5!:ZUX_P#%?VS4
M[B]\5^)+^7YII"9)2Q/0#^$5]W_LV_\ !/JZU,6OB#XFM]FMT(:'1DX\Q>H\
MROK'X+_LO> /@=I\<>AZ/%<:@,;]3NE#S2-W.3TKU*XEC5MKR=\ECU/L:RG5
M?0WA"VYE67AVQT'2(=+TBVBL--A4*D$*A1CW]:<J+&023D<<5)<:E %P#C\:
MI"_+MM1<KV-<]Y,UO;8T$N$8\9JW$P.,5G6\;R')7%:T%N0H-,+W)8<BK*=:
MB1=M3+Q0 ^BD'-+0 4444 %%%% !1110 4444 (1FF,OX5)36H @DMU<$L 3
M61J'A>"\ST&?:MW&:78* /*M=^%T-R&(12#[5YWK?P528MB('\*^F#&KC#+5
M633XI=P\L<T ?'FH_ =)"Q$8_*LF?X$A!Q$ ?I7V+<^'(W#%8A^59EQX7#$#
MRA^5 'R7!\%TA/SQC\16O:?"W3X23-:QR)Z%:^B+KP@Y<XB'Y5G/X%GG/RIQ
M0!X3<_"SPQ=PLD^A6<L;=1*@KD=3_9H^&5[*99_!MF7/4HM?40^&Y9LNO7M6
MK8?#FU0$O#NZ4 ?).C_L^^#]!E5]&\)V2^C&/++]*ZB#X/ZCJ#JRVRQPCA<K
M@CZ5]5VO@^V@QY<*+]15]=#C0 &)3]!0!\S:;^SC!<N'NG+@]5(KJ=._9N\.
MVX'F:-:W!/5IHP:]]BTZ%.L8%3BVC P%XH \ U']DCX;>)8/)U/PG8S^I5 H
MKS?Q7_P2U^"'BI6,6F7&CS-T:S?@?A7V0($7^'%'DJ>U 'YH^+/^"+GAVX9W
M\.>,KFS/51<+NQ7C?BK_ ((\_$[26=]'UW3]64#@2?*QK]D_)5>],&5&%W >
M]&O0+7/P0\4?\$Y/CQX;+I_PBRZA&OWI+<@YKS/5_P!F?XL>'5*7G@#4U"YR
MRPEA^E?T>;FQP3^ %1M#%-D21+)GL\8-.\D%C^9V[\!>+]&;_2O"VKVI'_3!
M\?RJH6UNV!66PU* #^]$_P#A7],%UX:T>]^6;2;&8=]\"G^E8]S\*/!UZY$_
MAC2I,^MJO^%/FD*R/YO8]=U&%</)J"MZ&-O\*?'K6I3G*G4&^D;5_1;/\ ?A
MS<<R>#M);_MW6JA_9S^&[2;E\(Z;'_NP@57M)#T/Y]M.T+Q5K,D:VFG:G=E^
M@\ML5Z!X7_9E^*7C*13;>&I8<\!K@[5^IK]U+?X'^"[,D6NBV\&.GEQ@8J\G
MPNT&W'[NW*KGE5Q4NI(+1/R@^'__  2]\:^(DBE\0^+]/T*W<9:.W +@5]$^
M O\ @F5\'_"Y@G\2^([[Q(T; K#NVJ?KBON!/A_I$1!6#?[,:L1>"])&,6J#
M'J:.>3"R."\ >"/AO\*[%;?PMX?L]-VC'F)"&<_\"/-=;-XTCF)\N OV R:W
MD\/:='\PM4J=+*TC^[!&/H*BSO<-.AR\FOZA=J$AM]@[;14?]GW]XX#DJIZF
MNQ6"/M&JCU J01 =,8I@<Q!X8*_?8FM&WT:.#&.U;&%II0$T 110J!TZ5,!V
M I ,4X=: $V>U+@TZB@!!TI:** "BBB@ HHHH **** "BBB@ HHHH **** &
MOTH3[HHHH &II&:** $V#TIE%% "@<4X=:** )&Z4VBB@ HHHH 5:=110 44
M44 )B@J#110 @4 TZBB@!E%%% !2'I110 VGT44 %&!Z444 *.M.HHH 93AT
6HHH 6BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>form10-k_002.jpg
<TEXT>
begin 644 form10-k_002.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $  /0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHI@;KSTXH ')49! Y[U'(Z0'=(ZHF/O.P %>(?M"?M#7OPWU+3/!W@[
M2$\3_$76P38Z:6(CMX^GGS'L@-<;:?LI^,OB5I+2_%?XCZC=:C<'S)++07^S
M00 _\LU(Y('K0!].+J-G.VR.[MW?N!(I/Y9J8J6').?[XXKY5N/^"=O@=49[
M'Q7XPL+G'RSQ:M(64^H!.*JWGAOXR?LO6"ZEI6N2_%'PA;#-SI]^-MY%$.K*
MW<@4 ?7.1ZTM<5\+OBIH?Q?\'V7B+P]<K<VLZ_O(<CS('[QN.S YKKXG+1[F
M8=3TH FHI@8GG((]J"2.N/PH ?132VT98X'J::&.0.?<XH DHJ)9&.?ER?3(
MIZMDX.,^E #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MA*Y9?3=NJ:H]IW9[9Z4 ?)O[/[)XI_;!^,^L:@B3:GIB06%H\G+0PX!(7T!K
MZPB!)/S'':OE:\LKGX,?MJG6)?+A\->/+%+:29N MTA^5?J:^JH 0&SD$G./
M2@!Y3/<U&UN&#CC8W52,Y^OM4U% 'RCXX_9Y\8?"'QY=_$/X(31*;]_,UKP=
M=/MM;TYY>+M&]=4?VI[V#0P]S\,O%(\0*-KZ9%;AD#^GF9QCWQ7T 4R!E1D=
M,=J0(W\6">WM0!\O#XR_M%>)I@='^#UCHEHW*R:OJ7SX[$J!Q3C!^U?J]PC&
MY\%:';9Y0JTKU]0E"3DL?H#2X/&>U 'R\/@Q^T)X@EDEU/XSVVBAND6E:<"%
M^A)IJ_LY_&ZPA:2R^/EY+<CE4N-.4Q-]1FOJ-DW?_KI@1@H4 +_N]* /DN_^
M+GQV_9_D2?XA^&[3X@>$D7=/K7AQ"MS;KGEFB[XKZ+^&WQ/\-_%7PY!K?AK4
MX=1L9@#\K?O(R?X77JK=>*Z5X=ZM&ZB2-@058#:01T([BOD[XN>"W_9<\9P?
M%;PA!]E\+74RP^(]"B_U0W-A9T Z8)YH ^M_,Y ((R<<T^L[1-5M==TZUU&R
MD\ZUN8EFBDSD,K#(Q6C0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !113!4N26X'RM_P %"-7N]!^''AZ]LM-CNIXM6CDBO7;;]BD7E7SZ'I7L
M'[.OQ(O/BO\ "?1?$6IVJV>IS1^5=0JVY1(O!(^O!KRK_@H=$C_ &1Y-ICCU
M&W+(Q^^-PJ'_ ()\W0E^#=_; AE@U*0KL/!! .15J,G'F1#E9V/J;-+4*D'&
M.1V)ZBI#P!4[;E[#J*04M%P"BBBF 4444 )BN:^(_A:V\;>"-:T"[19(-0M)
M(61AG.1_CBNFJ&X&0O('/!(Z'UH \'_8]\9'5_ %QX;N?W6J^&KEK&XMF/S*
MN3M/Y5[[FOEOXX> ?%?PE\>/\6_AQ8-J2L NO^'X!AKR,'F5?5@.:]<^$?QN
M\*_&?14OO#]\GVE4_?Z7.=EU;MW5XSR/K0!Z312#D#'% Z4 +1110 4444 %
M%%% !1110 4444 %%%% "$XI :1VVXSTIC/@<C&?6@"7(J RD-MR,^H->._'
M3]K/X=?L^6<C>)M90ZCC,>EVI$EQ)_P$=*^(OB!_P5K\1:C))%X,\'PZ=;$$
M+=ZF^YQ[[:^ERWAO-<WL\)2NN[T1RU,33I?$SO?^"A'B:ZN/BEX=T*XU-X-.
MAM/MD5BW^KFDW8+D=\#C%5_V(/%UQ%\7!IMM<216EW:N\EA&"(V*]']NM?#7
MQ9_:(\;_ !L\06VM>)=2634+6/R;>2W0((TW9*_C4_PR_:,\<_"?Q,-=T74Q
M->B-HE^V*'55/8"OT*'AKF[P\G)KF['E2Q\/:)IZ'[SH1N R,DYQGG-3YSQ7
MY<> ?^"LOB73YXH_%_A6UO[< !Y;%_+?Z@=_I7U1H7_!1#X1ZMX5AUFXU*YT
M]6 \RW>$M)"?]H#I7PV8<'YUE;O6H-KNM?R/1ACJ-3[1]09%+7!?##XT>#_C
M)I']I^$=;MM7LQPYB;YXV]&7M7<))\O2OD:L)46U45FCLA)35XDM%-5LGI3J
M2*"BBBF 4A4-U&:6B@!C* ,X.?:O"?B=^R?X:\::Y+XG\/7,_@GQHQ#'6M*8
MJ7(Z;UZ-^->\&F[#U+<^@Z4 ?,<'B;]HOX5QB+5_#^E_$[3E_P"7[3)1;W)'
MO&>IJ:7]L;4]!MR_B#X1>,-/V_>,%J9@/R%?2ZKM[YHV K@C(]#S0!\]>&OV
MY?AQK\GDW8UGP]/W35=-DB'YD5ZAX4^,W@KQO*(]$\4Z9?S'@P)<*)%_X">:
MZ'5/"VCZQ$8K[2[.[C;J)8%;/Z5Y-XS_ &.?A-XP=KJ?PS'I-_VOM(D:VE![
M'*G^E 'M0D9@"H!7&0P.14E?+,'P=^+WP+N&O/ OC*?Q[X?3)/AKQ$W[U5](
MI>Y^M=Y\,OVH_"WCO76\,:F9?"GC.,[7T+5/W<C'_IF3PP^E 'M=%0B4KN&"
MV...M/1RW48- KCZ***!A1110 4444 13?>3C)S7R5^W3^U^?V>_#2Z+X>99
M_&&I B+=RMNAZL?PKZPU*Y2RLYKB0X6%&D/T S7X4?M2^.'^)/Q=\0:Y=3/(
MWVMH+=&;(10>U??<%Y%'.\Q4:ZO3CJT>9C\0Z-/3<\IUO6=0\4:S<ZSK5[+J
MFK7$ADEN)F+%L]E)Z54R3U(*_P!UB210>.*2O[7P^'IX.G&EAZ:45L?(2J3J
M:L7H<C.#TS3F943+D*#W)QBF*<''1CAE-?6'[%WP)\,>/M)U'Q?XG@&IBTN3
M#!:N?W>1UW"O,SK.J&0X:6)KQYO)>8XT^;<^5//"A2P(4'AV3*FM#2=8FL+L
MW5M-M+MLD!^X_L17ZJ7/@WPO=:8;3_A%=*:T V_9S;@<=.&KX?\ VS?@_I7P
MQ\8:3J&@0K::1J\.[[/_  P.O4BOALAXWPV=8AY?*FTWM<TEAN57BSZ _P""
M9SV%G\1M9OM.U#[/!J%L8KG2SPOFY!#+^1K],XB-BD< <5^&'[*GCR;P)\6=
M,O89?*B::,.H/#9;']:_<JPF%U9PRCI(@<8]Q7X;XD98\OS?VBC:,SW\IJ2E
M"TBTM.IB<<4^OR9;'O!1115 %%%% !1110 4444 %-DX4XIU-;[IH B\KY1E
M5^7IMKR_XU_L\>%/CKI)AUFU%IK$(/V+7;+]W>63_P +HXY.#V->IM((AEB,
M5FRZY96TQ$DJ1C<HR>G-2Y)#M<\(_9I\6>-] \5:[\*O'VHPZ]J_A^!9K/6X
MQA[NU8_NVD']X# -?1,8"#' _P :^8OAAJD6L?M6_$[Q"TRK8:=9PZ>L@/#M
MP<?A7TG:ZE%-QGGCYO6ESIAREW-+31A2/>G58@HHHH **** .4^*=^-+^'GB
M*\9Q&(+"9]Q[?(:_G]\1W!N[MIF.YY)'8GU&37[E?M?ZQ_87[-OCZ[R5*Z9(
MH(]3@5^$]P2;>R5CEA#N;/J37] ^%='WJ]3T/FLVW17%(G6EH''2OZ=2:E<^
M?' G("_,RG>,]J]>_9]_:.U+X#W]U$+1-8\-WK![NQ8#<&_O+FO(?O)M/0G-
M&!Z"O-S+*\/FE&5"O\++C/D=S[SD_;Q^':V#21Z;J\DI&1 0 I)_A^E?*GQQ
M^-FK?'#Q:FI:A$MCIUHGD6=G'TB3L3[UYR!Z<?2C<1QG_P"O7S.4\'99DU?Z
MQ26I4Z[FK'2>$;IM+U:PO ?N7*J?^^@?Z5^^?PYU :MX#\/W:G(FLH6S_P
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M.U(WR@GKQ2XXI&Y!'M6G83V/S"_X*@S>9\;?!T Z)8EB/8FO@_7P$UJZ!7<
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MXC&UG7KRYI,]6C0C2!<]Z=117&CI"BBBF 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 )@48%+10 4444 %)@4M% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
,0 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>form10-k_003.jpg
<TEXT>
begin 644 form10-k_003.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $  8 # 2(  A$! Q$!_\0
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MU.<;C-2*N* N*=FJ0"4444P"BBB@: ]*$[4W.2!3AQ04%%%%00%*.M)2CK0
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M3Q!XC2YN[>&-\PP'+2DXKPZ>)^JRYH,]B.&YU=FIX?>:8 #(.><=*[ZU3$*
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MR]QMQW'>M2.*1L;.1W/2N>2OJ7%M;CO( Y;)-*JHO7^56$@&0&/-->>.'L&
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MM=3C44A1R.:6BB@MNX4ZFTXG:,GB@$T+CC-1RSK%C/.:BDGZXZ569MYYYII
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M[5HO]K78',L['&>_%>EVOP7\-6T15?!NG8(Z-#FO?(;."WP(X4&/05-Y:CG
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MPD^!R^#M3/BSQG<#Q+\0+D;I)+D[X[3/. .G%>H7VH!'DN+F5FG8?/(?NCV
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M&/\ $<5]:_!KX'>%_@%HBVVD1"ZU1QF\U*X&7E;V]!Z5\]F&8JDN6+U/;P>
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M0SW AP",FFALFD9(ASUJE+/O;!^[4<LOF'<3FJTLPZ=JHDD:45"\XP0:BEG
M7CK67=:EY0('+4$%NYOHXE)^\!_#ZUFJ\][*"!B,]J2WLY+EQ(6^@]*W[/30
MBASR10!7L=,. 36Q!;J@XIR)M08XJ6-0.U "*M2@8IO1N*?G-)C0#K3J7 Q2
;5)0444F>:"!RTZDQBEH*04444"84444"/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>form10-k_004.jpg
<TEXT>
begin 644 form10-k_004.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $( .L# 2(  A$! Q$!_\0
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ME'T%)_PF^O?]!*7\JR"I'2DP?6CV,1>VJ]S8_P"$WU[_ *"4OY4LGCC7 ?\
MD)3?E6-@^M-?+4>QB+VU7N;0\>:]&P9+^20]U?I74:#\698Y435(5\HX!E3L
M:\]1#GFB9MH! !.<;<=:F5&+14,15@[L^D+&_@U&%)H762-AD,#5C KP_P
M>*)?#^K+:S.7LISCDYV'M7M:R;E!'((KS*E/E9]!1Q//&[/G7XK7SWGC2=2?
M^/8[5![5R(_*NC^(N?\ A.-6[_/Q7.#..>M>K07NV/E:[O5U%!Q4BCO4=2#I
M5I6,V[ZDB#!IU-5A3J8APZ4Y::.E.6E8:)-_'2E7FFJ.?:E.>U,H>O-. Q3$
MZU)0%@ S4B]<4Q:D53D&@I"[?>E2EI$IH9:MSC%7"H<"J$3885H0<X[YX%5H
MA6N0.FQO;UJ,8D!9<LHZX'/Y5<NY([2W:XD=(HD)S(Y  ]:\[G^)%WXBOI;3
MPCI3ZT8CM?4+CY+=3['^+\*SE42.B%%M79W &>A!/MS2@8.#R>X7DCZUQMOH
M_CN5O,N=;L;9A_RQMXCLK2@U36]% .MVL5U:%@HNK$8*>[#J:A2?4V>'C;W9
M79ON0#P0?I30<FI7M]FQE998Y%W+,A^5A_C0$P16B::.24)0?O$=-5*GXH5/
M:BPTAA4*N:KR L<@XJU(1@CO4!4^E%KD];,B6,1X8,000Q/TKW_P]?-=:)9R
MNWS-&":\"89!&*]S\)C=X<L"!QY0KDKQ2/0PTFEH>%?$7_D>-5_WZYX]:Z_Q
M_P#\CIJG^]6 %S6U%VC<XZM.]5NYG8I_\)J]MH"C-6G<PY2HG2I<5;5%I<4P
MY2H.E.'6K5*M,.4@'2BK%% [$*=:DIU.'2@+#%J8=*1:<.M.PPIRIS4B=*<G
M:C8! NW!J?[0MNK2NWEQHA+.?X12)DC/IP*XSXA7<VHFR\-V;$7%_)ME([1C
M[U34T5C:G&\BNEE=_&'5)'N2]KX.LSLC1&VF[D'OZ5Z'!I\6EVD5O901VL,0
MPJPIM">ZKW-3:%I]OHVF6]A;)^XMAY2'^9K0E@)7-.$5:[-ISO[J,5OO&I5R
M3D%<XVLK#(8&II(OFIHB.\U329RKW7>)1TR%-.D?3-I?3YB9(@>L;=_SJS@J
MIR,29VE?04RZA(195Y:-PWX5>DCWS.PY#@-6*C[QU2O4IW>Y16/<:E:,*IJW
M'"8^34%PNZMKWT.?:**;+DDTTIQ4S1[1BH9!M(I;&9$R 9KW'P=SX8T[_KE_
M4UX>WW37N'@[_D6-._ZY?U-<N)Z'HX79GBWC_P#Y'35/]ZL%3Q6]X_\ ^1TU
M3_>K !Q54O@,:G\1CLF@G-(#FBK6QS"@XJ3(J*BK0F3C&*,XZ5$&P*4-FF(?
MDT]>:9VI5;% "TX=*;3ATH <.M2*.E1K4JC JD X<=*D44P#-2*.:8$J-MV]
MP&R17*^'XCJ?C?5;]DX@41Q,>P/7%=8BC![E@>?2L+P5RNH=-_G<GUYK&6LK
M'5#2FWV.HM@4(;."HVGZ5M6Z_:$QUK+B7S') P".E:FFG:V*T>VADG<J7-KL
M/ P:KB)O3)]:Z*XL]ZD@_I5'[,V>E":9I8S5@+"0$<%#46GDS#R^Z+6TEJ58
MY[@CI65H,8_M:_7.0J@5G-I,WIJ\66)8@$Z8-4Y4QVK5N$P:SI^!6JVN<+UT
M*<@X]ZJ2]15N0YS55TW$<T,5B%_NFO<?"7R^&]/ Z>4*\/<8!%>V^%9,>';
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M"#]ZH?0J.YJP6S*PR>^*YKP_&T7Q!U>W(R7B#"MJ+46! SD#FN=L;_R/BJY
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MNYUX=GH]O/E$S\S8S6O9,6 SQ7/63?O"<\=OPXK9MIP@ )P:JUXD*3NSPO\
M;]\=#PW^S]+I4$H2?6+E;90#AC&.3_*OS2C7:B#'10/TKZS_ ."COB_[;XU\
M*^'(SN6RMS<L@]6/!KY2V@' .<5^R<)X=8; P;6K/!QS]I4L(P8PRA<ABA (
M]:^\/V4/'WANZ^$-KI,5[:V.H61)GAG<1LQ]?>OA0  9)X_NCK1A@[,LDD3
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IUX8T[PGI4&F:7;1VEG"NU8T&/Q/O6L%*@ 8HHKRW[SNSZJ$5%61__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>form10-k_005.jpg
<TEXT>
begin 644 form10-k_005.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #( -8# 2(  A$! Q$!_\0
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DMW%64B<+FBBM42MA8T?=TIZQ^6<FBBMT8R)D.Y<T4451!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>form10-k_006.jpg
<TEXT>
begin 644 form10-k_006.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #N 38# 2(  A$! Q$!_\0
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M .@9!_WS1_P@7A__ *!D'_?-=)BC% '-_P#"!>'_ /H&0?\ ?-'_  @7A_\
MZ!D'_?-=)BC% '-_\()X>'_,+@_[YH_X07P]_P! N#_OFNDQ37XQ@XH YW_A
M!/#Q_P"87!_WS1_P@7A__H&0?]\UT*MAL$Y-/Q0!S?\ P@7A_P#Z!D'_ 'S1
M_P (%X?_ .@9!_WS71C_ 'LTPO\ -C<,^GI0!S__  @?AX?\PN#_ +YH_P"$
M$\/'_F%P?]\UT!<CG(Q]>M(6&?OD8ZB@# _X0+P__P! R#_OFC_A O#_ /T#
M(/\ OFNAW;N0V%]Z?B@#F_\ A O#_P#T#(/^^:/^$"\/_P#0,@_[YKI,48H
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M@!:*** "BBB@ KE/B;XU'P\\(7NO/ ;F&T&Z1%Z[>YKJZS=?T2U\1Z9/IM]
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M1GCI3GZK]:; ,0H/]D4Y^J_6@#C?B3_QY6?_ %T/\J*/B3_QY6?_ %T/\J*
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M<R<V]PHHHJ20HHHH 0]*L67_ "$;#_KJG\Z@J:PYU2Q';SD_G0!]/P_ZI/\
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MOYT">NYF_P!N+_S[7'_?%']N+_S[7'_?%:7S>B_G1\WHOYT+0=]+&;_;B_\
M/M<?]\4?VXO_ #[7'_?%:7S>B_G1\W]T?G1<1F_VXO\ S[7'_?%']N+_ ,^U
MQ_WQ6E\P_A'YT$L#@A<_6BX&;_;B_P#/M<?]\4?VXO\ S[7'_?%:7S>B_G1\
MWHOYTK@9O]N+_P ^UQ_WQ1_;B_\ /M<?]\5I?-Z+^=(6*C) _.BX&=_;B?\
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M0VSQACO6U[J0>]=II]E#IUI%:VZ>5#$H54/:JR:O9H,+,J^RBG?VS:'_ )>
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M]?!FM7?C0:S=2*FCRCBS!P0,<<5T\7@G3KIK.YU.W%SJ42*6F;KNKH'7><L
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M&:&&#<&8GD@]L5]6>%X8+?P_80VL!L[:.%5CMVZH .AJGX&);PMI^XE_DZ$
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M2^R['H?FQL.)$Z_WA6=J^NV.DZ9>W\DR2+".8U<$UP>G_#?7%\87=S=:F_\
M9<BD1H#[5J^$_A5;:!+J#WT[ZDMP<B.1LBJ>&P5/6=3F)^I8+#OFK5.8I_;;
M?XT^&IH896TRR#94EMKFNP\+:3;>&M&M]/CG1D@7!D9N6H@\*Z;9PNMO;)!#
M_=0XIMUI>E6:K)<A(4Z*9I,*3[5Q8G$JHO9T'RP[=3BQ>.C5C[*D^6';J;#7
M,;X.] 3V##-)Y\>,^8F,X^\*S_['TR,@.51RNY6,WRX]O6N#O_B=X2LO&O\
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M]80_ZI/]T4K]5^M-@&(4&,?*.*<_5?K0!QOQ)_X\K/\ ZZ'^5%'Q)_X\K/\
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MO:NIM/A;\4M-M]+6VUV5A)'(]\&DP5;^!5KV+_A:5K_SY3?]]"C_ (6E:_\
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%THH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>form10-k_007.jpg
<TEXT>
begin 644 form10-k_007.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (B 7<# 2(  A$! Q$!_\0
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M)L\I\CY!C[P]S7'1PRZ1<":VE:*3N4Z$>A'>I@G./,@C-,X2/7KE2&\V1V'
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MJBBBH+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[9E=.D6-)E8L2. .M>UQK@+[#!JX*S(EJB0##"G4W^(?2G5JB HHHI@%%%%
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M+_.LTM2F]#ZR@_U,?^Z/Y5)4<7^JC^@_E4E>B<P4444 %%%% !1110 4444
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M<]:?10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<M:NH5&R2=IQ7QGX+^;6K;/!+8 /!KWBZAA%M(&C'*XYK#L] TS[4D_V.,R
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M\1P,D53M8#ZU^"?CD^"_$$<-S.3I.HMY4B,^[RY#T8#M7U;">.N>^?:OS>\
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MXQC2_B#I.IVX\M[A(Y9,=R#@UZ'\.H&O[?40"2J7&57TW#./UKSOXN7*:_\
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# /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>form10-k_008.jpg
<TEXT>
begin 644 form10-k_008.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'G M # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)Q3NQ#J***H04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MOM0GPJ\'N6']A6.5."/+!(^OI3MC^\1WP/:7X%/_ (7OX)_Z#<-'_"]_!/\
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M"8.:=4C&J,4ZDQ2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^'TL[R;'N6,DK#T[UU2M!61FO>O8\;_:)\:O?&**!Y%GDG"6R1'D@?Q&NY^
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MQ7C/V_XR_P#/CIG_ 'W2?;_C)_SXZ9_WW1_:,?\ GW+[@_L^7_/R/WGL^/\
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M\>M?+7AW]GKQ#-\%O@3I.MZ)8/J_A[Q8][KMK/,C?9(7=V91SR#D<5T'C;X
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M88DGGD=J7)Q2I&"[G())R,5)Y0HL(A.3CFDV[AENW:IC$#370)TI<MQK0A;
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M3Y=SPZ/[=HYW6,[E0<J.C5UNB_%R[M\0WP$Q7 ._@BH?$'@[4O#<YWQB6/\
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MM[^"\5K>XC$D1/!92,CCM2TZLI*YU,DJIRS<"L+7_$]OHUM/<R$F.)"[[1G
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M:((P"4Q77VEH(UP!P/6FVMF(D 'ZUH(N!TI&(B#G[M/Q1TI: "BBB@ HHHH
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MX8_YX7W_ 'X-']H8;^</J.)_D9[!FC->/_\ #3/AC_GC>_\ ?@T?\-,^&/\
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M >@KK+/]HOPQ=@9OP.,_,M<_/!Z*0^2?\IZT9/>E5\]#7G5K\:O#=RQ(U.
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M9^F]E(Q^=-<K*M8L--J5M(@,=TX'<@-G\JJR^)[NV4+/#=KDX8B)J)M!NXY
MT.HQ.@7A<$'\P:J26FLV^P?:%D/5RDI_#&11RKN*Z(IO&;(&/F72,#QE6'%)
M-XZ!)"SW!!7OGK2L==5&(7=S][S0>/RIDTFML'\OG XR5//Y4N5A==BF/'.Q
M5/G3D?Q<GK59_&J2(P"74C;NOS8Q5W9K(V?)P1ER67@^W%494UMXNN/FQCS
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MTJ=+<#I09&-;Z*B@@* ?I6A#IH0=!5U8<>U.5,'.: (DMP@Y%2*%7I^5244
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -8<@^E026T9G
M64QH7 P)"HW#V!JS10!3N[&&\C$<\$<\?79,@9<^N#43Z5:FV^SFT@^SCGR3
M$IC/_ <8S6C28H SAI5L+8VZ6L"0,<M$(E\MO^ ]*=_9=LL7DI:0+&Q&Y!$H
M7CID8J_BB@"H;&+]Y^Z0>9P_R#YA[\<_C7$>/_A'!\02B7&L:EIUJL30FVL7
M58F##!X(.#CCBO0Z3I0!RW@'X=Z)\,O"&G>&?#MF-.TFQ3;%"ASR3EB3W)))
M)K?BM%AW%(D3<=S!% R?4^M6Z3% %"+2K:V+F"W@@,G+M%$JE_K@<T0Z5;0R
M&6*TMXIB"/,2)0WTR!5_%% &?)I-K+.LTUG;S3CI(\2EA^.,U>CC""GT4 %%
M%% "'I46TY/!J:B@"$J2.E1/%D\\?6K=(1F@"A);@XS4;6P(P#6BT8-((P >
M] &4;0,?>H)+$$ULF'=_#BFBV'.:JX&')I^>E5WTQ3U&371R6RG&!FHS"$ Z
M<^M',P,!-,4#I^=._LY%!^48-;;Q@=1GV%8/B7Q=HWA6V:;4;M(G49$*G,C?
MA42K0I+GJ.R+A"4WRP5V,FTQ"5 4%CVQ5.[MK:R3S+F2*!#WD8"O'O&/[0^H
M:G.UIH5I]E!X#8W2L/8=JYRR\ >/?B Z2W(FBA8\/=.1^E?/UL]CS>SPU-S?
MX'TE#(YJ/M,7-4UY[GI^M?$_PAHLDL;7PGF4?ZN)"V3Z UR5]\>M"B"BWTN>
M=B/F5\+BM'2?V78R0=6U.25CR4BX7\*Z^Q_9Z\)62X>R:XQWD8UA[?.*_P $
M8P]3H]EDM#2<I3?D>53?M!6625\-,WN9121_'C39@/,T!T]2) <5[0OP8\)Q
MKA=(C_$FHI?@AX0F7#:0@_W6(I^RSK_GY$/K.2;.G(\RL_C/X-NE7SX+BT4<
M.SQ9 _*NKT'7?"7B9<Z?J5K*2>$;Y#^1I=6_9K\-7B$VQFLVSD!6R!7 ^(OV
M7=1MV:;3+U+D#G:<HWYBH>*S3#ZU*?-Z%K#93B/X-5P?FCUO_A%[64 K%&ZG
MHR\@_C2KX5M.\*#/0@5\\PZC\0OA5,4$L\< X"7*F6+%>I^!?VB]'UJ1+3Q!
M;_V+>$A%G3YH')[Y[?2NW"YY0J/V=5<DO,X<5D]>A'VE)^TCW1VJ^%;0G_5+
M^5._X12TS_JA^5=9:);7D0FMY8YX6^[*A!#5/]B!Z=?0U] I1WBSY]MQW.13
MPU;+TA4_A3QX>MT.?*4?A75_8P/_ *U)]D5W([CFJO85VSESHD& /+4?04]=
M)B7H@&/:NG.G@=!1]A[=J+Q%<YK^S5+8V]!W%*--53T%=*++GL*<+$$]C2N%
MSFCIH;^#-/315<_<'Y5U$=CGL*F2V"] *E@SE!X<3O&*&\,1GI&!^%=@L*MP
M<?A3C;*.0,U).QP\GA&-Q]P?B*@;P;$W'E@_A7?K N>5XI/LZYSMH*YF>>/X
M&A//EK^5-_X06+_GFOY5Z*ULI_AI/LJC^"@.8\\'@:('/EJ/PIX\$Q@?=7\J
M] ^RK_=H^S+_ '* YCA(O!L:G!1<8]*LIX/@4\(,_2NS6V4?PTJP@'E:!79R
MT/A:)>/+&/7%78] BC48C%=!Y:XH*#&!0(RHM(0+C8![U-'IZ]-HQ[5H;!B@
M(!0!66R4= 13TMPC9Q5BB@"+RP<<8-.$8VX-/HH 8(PIS3Z** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGU&XOL==\Q' %-.\#G%<R/$0.,7L)_&I5UYF Q/$WXTW3=M"=>QN31":%XW
M9'&TK[&OC7Q4DWPF^+7]H6RE1;W'FH@'!C8X8?E7UDFL2GD-&Q^M?/G[3NG_
M &FZTZ] 53*IC9UZU\KGU%QI1Q2W@[_(^IX=DI5IX:6TU8^G-,O(=0LH;J%Q
M)%-&)$<=""*NQD9_"O//@7JK:U\+/#TY&&6W\D_\!XKT"$G<?:O<P]3VM&%3
MNCYNO#V565/LV3BEI*6NDR"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,UKQWI\=GJJ:1J&G:GKEG;R2IIXNU4LZ@G:Q!^49')[4?4ZW_/Y_@3]<H_\
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M!EAL)^<M&O0$#C/I7D'BKX3_ !H\;?%+P[KE[X>73[O1_&:W_GZ>J10'3AD
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.SZGQ33CHWJNAS8T-6R-@'%,?PZC?>0&NJ2W'0K3OLZ\C%"L+F.-D\.1D#"
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@!K-@=,TWS#Z&I** (FD/H13-_'.:GHP/2@"!GXXR:
M9D]=IJUM'I1B@5KE4-@GY2/PHW\]3^56Z3% 6*N_)/RDTH?U4U9Q1B@+(K,2
M_3]:$)4_-P.V*LT8I#(2X/<T"3'0G\JFP/2C ]*8$2N<GJ:=YA_NFGTM #58
MD],4ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>form10-k_009.jpg
<TEXT>
begin 644 form10-k_009.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &' M # 2(  A$! Q$!_\0
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MT_C1^FE?G!^W "?C]>?]@ZW_ )M7Z/=Z_.7]MSCX^W9_ZAL'_LU?I3V.JO\
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MI/X56]O-XLTD:=%-RC7EH!N_(UV\RZC5WL?I:) 3UQBK,,BJ#D_K7P!\&?\
M@HG#JTRV'Q%5M+EE?:FH6<7[D ]V'85]C_#:[MO$5I<ZW;:TFO6%^X>UN8N(
MPF,8 I<P-/J=;?2IL;YQT]:\P\>.KV9B+#YN2".J]Z](U'3XU@+;,CO@UY#X
MDL)_%FN2:3I9((0I)(3E8P>ISZXIDO8^2]4TSQ5^U;\19/!OA_?I/@K3)?\
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M@"ISRV<5!(><=ZM"17D4BOIK_@G@<_'N[P>/[+DKYHDZ&OIC_@G@N/CU=?\
M8+DKTLO7^U4_4VI_&C],:_.G]M8X^/MW_P!@ZW_]FK]%J_.S]M0?\7\NS_U#
MK?\ FU?ICV.FO\!X6L?J<GUJM<JK!TQP5(JYV-4+D?,<'%8LX%T/@OX@6HL_
M&.KQ*,*L[8_.I_ K?Z?(O]Y:=\3LGQUK.1@^>:A\$/MU;;ZJ:G$*]%^AZ$_X
M9Z)%P![U8B&#5:,]O2K*':WK7QDCRMC;TT;H..*L@9-5M*Y@?VJWMVFO*G\3
M&2*.V.?6NA\*^*]3\'Z@+S2[EK:<KM8KT8>AK 5,8-68_F ^E9QG*#YHEGIM
MS\=O$M]&5G$4_KE16!>>*+K6GS<VMN!WVH ?Y5S40QT.*NQ9/M^->DLXQ,8V
MN;J1T7]MJ]J( F0/NAN@JFK%@>>O6JD/S9/3%6D&"!ZUX^(Q52O+F;$Y<QSF
MA?#RTTS4IKJ9_M6Y]\:M_ :ZRRTZTL99);>VC@DD^\T:A2:6/V[583FIJXNO
M-_%H";L3P*$)(4!B>HJY&Y&,$@?6JBMCMFK"-STK#ZQ4_F8:EQ)Y >&Z>M6H
M[R;'+\$8(Q5%6(YJ2-R<T+%5E]MA=]36LM0EM!MC5%0]E45I1Z_<^B_E6%&>
M!]*MQ<XSWI_7L2OMDLZ*+Q1= *-L?_?-=/\ #()KWCNU.HQQSQCE4V\"O/TZ
M?C7<_"*0IXQM6%>YE./Q$\2H.5TQ(^8OVH-!BLOC5K4D<\D<;ME4C)"K[5PF
M@SF*9?\ 2Y<9[L:]I_:)^S'XC:L\I56,G5J\LTS[/]J4(R,N>N!7Z%*[>IM%
M'T/\ ]9TBR\4:9-K,YDL%.9%<Y'2N]UV&#Q/K%X^F1J]HTY**1P%S7FGPLTR
M"_O[6%E0AB.@XKUR>'[!/+!%B-5.WY1BL);F]CPOXA^%5T#QM8R1Y6*489,Y
M6L_Q5XLCT;QW;:#/;(VF7-LK,1U1O45UWQ2.=6TX$Y^?^M>6_%,'_A;-CQ_R
MZ+6\)\KN9R1ZK81:%XATL^$?%-I%/YG[S1]5 Q-$?[N\<\5ZQX;;Q_\ !RXT
M/3O$%U_PE/@VY 2WU0#]_9YZ!_4>]>$:I%YWA:"[C'[ZR99D(/(P>:^R-9U.
M'7?A7H%_"P>&ZL48XZ9Q_.GB:KII32T(AV.EC57&8V#J1D,.XJ15PH'I7"?"
MWQG'K]E+ITSA;VS.T@_Q+V-=Z!S3HU/:1YBA1U%*W- 7!ZYI<9XK8HGM2@62
M%_FBF&R0'ISWKY_^+/@T>'M3F(3?9RGHPRK U[V1A?Z51\7^'(O&/AV6W8![
MF%<KZD46N)GQY=:GK>F6DEC93&[L2#Y<4[8:/V4^E5;1+T6R/<Q+%(>2J'.*
MZ#6;.72+^>TN(\/&QQN':H+<B4Y!W*>E<LXWNF8R*/5<_I30,O\ 6M26UW*>
M!GUK-=&CEP1WK\XS7">PJ<R6C('YQ^%+MQFF G)R,4[=[5\]OL Y>?:G[J:H
M [T[(HL^P #FE7ALFDS@]Z7</0T6?8!Y;+>E(Q QGDU&SX/%(6)[4#YDA9&P
MI !J!6VN#^%2,3C-0L<=NA&*TIM1G&W<0@AA@MG5&42"9MZCJ >13$E(J.4D
M:G>!5'*IG\J8Q*FN_&17.@+B2 GK3C* *HAB@ZYH$Q)YKAY4!>$W.*#)QZU4
M$E!EXZ5-P+#2YQC^=->;ID'\ZA$A':@RY[8H7D!,K[@>U(7P>Y-0B7%'F<YI
MM /:0 \\$TQWP#_2F,P+=*'8;?2G$!<D5/#US5<-NSGBIX&Z<=J&!;5L'I[4
M_=GC!S40()%/K)@3H<5,N>M5P^%Z5,C[N*0$H;('M0.E ^4>M(C;L\4+<!RG
M Z4I? S^%1Y([4O++5WN UVZ<5!(,]?2I9.@^M02,0W2@"-CCWJ)VRWI4A;=
MSBH9.#FF@(F/KR*KRXP*L.NY?2JKCO56 K.< BH2<U,XR34'K6L=@()/N_A5
M>0X7%6)/N_A59P22,5: ;G(J"1?GS4V[:M1,=S55[ 0/\P-?37_!/$Y^/%V?
M^H7(*^9BO!Q7TS_P3QX^/-W_ -@N0_K7J9=_O5/U-*?QH_2^OSM_;5_Y+S=_
M]@^W_FU?HE7YV_MI\_'J['_4.M__ &:OTJ6QU5E>)X;ZU6GBRF[O5SR\]*CF
M3Y",<5B]CS[:(^#_ (O0&W^(>L+TS*369X+;;K4?N#74_'ZS-K\2=1RNT/AA
M7(>$WVZW![\4ZOO4I>AZ.],]-C&<U:49-5X,\YJY$?YXKXF;LSR7J:^CKNBE
M!JV>:IZ227D7L16DT&-N17E5-)!<<HS@5/$,''M42#YN*E3[QKG;-$6H5#&K
M\0&<>]4(/NY'6M"'. 36+U++,2!0<'K4\?)![BHH_NU+%VK&0%J/^*K,?2JL
M?'2IX2<X[5#V+N65Z?C5A:KJ/E_&K$72LGW%>Q910:D08;%1*2&&*E4$#/>I
M!NY8B8_I5J.0C\*IKE1QZ59B.3SWI,DO1DX_&NT^%LI3Q7:D>E<3"21S78?#
M1_+\3VQ/YU[.4?[U$#QG]H/08-<\=ZBTK,I$G\-<#I'@**2,1F1Q'G.X#FOM
MWQ5\&_#?B34VO;J)S/(X+$-Q7C/QA\%Q?#^_SI<'F6BJ#C.3FOUB<&FV:P=C
M4^">A;O$>D6<"[F+!0#WKT?Q-:O9Z[?PLN'BD((KYU\'?'RX\$ZU;:C;V:FX
MMGW(K]*Z>+]H*Y\8ZW-//:J+FZD+L%]3Z5R-79O>Y'\5'*Z[I8/&6'\Z\N^+
M<@3XL6K= +):](^+R7=AJV@/=P-$]QAPK<<$UY3\:)"/BG#C@"R7C\*(NS%(
M[+PQK*:C#=6&[(>!N/PKZ9^#.JMJG[.FFQNVYK.::W&?0'BOD;X<6TO]LM<'
M[BP/G\J^J?@% R?L_22D$+)?S.H/<9Q1B?>PVO0RA\5SG_!6LOH/C26ZC)V@
MX?'<9KZ8L;N._MHIXSE)!N4BOE73 #KEZ>G/05[1\+/$A*OIDSX8?-%N_E7R
M^7X_V6*=&;T%?4]+Y]#2J,GIQ2QNS-AA@8ZU*%&<'I7VWD:B8X!JS:RFUF$J
M=OO?2H@@/%/7CO[4(+'D/Q]^'P"IK-D@,;_.<?K7SV)'@?Y3A<\"ONFYL+?6
MM+GTRY *2*?+)['TKY&^)'@.^\*:]-"UM(L18E#MZCVJ))K4QDC"AU%G&T@9
M]!U(JYIFF77B*[%M86LUU<?W(DS^9[5ZG\#?V8M7^)+C4=69M)T=1N56XEN!
MZ*.U>]0^#-/\'6+:;I5DEA$HPY0?O'QW+=:Y,1@(8R'+4)Y6?*<OPGUN&/?=
M>3:'^Z[Y/Z55_P"%?W>['VRV_P#'J]Y\76T,63*PW=D/+?E7F5Y<M#,X2WF(
M'^QBO-7#V#C'E:;$U8Y)_ =S'C-W!S[&F_\ "#W"];N''L#72RWTFT 6LQ_
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MQ-U7Q9,R1M]@LLX6*'[Q'N:YJE:,=&2:&PO*8T(8J?7I2N!&=LDT,9_VG%<
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M2Q..U12S $\U2 20C-5I6QWXI7D!&0<U$S X-,"7<,>]1[C[5"\P-.\SCK0
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M;F%>LJ%*56?0W? OPIU#QA$+Z[;^R]$5L/=3#!D'<(._UKTM/$7A3X<P_9M
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MO6C<08R1Q5<PX%<5QO8I^7MYIKJ>*M^7GM4+I@TTT] 2NC/F&?RJK(F:U9(
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M%.!!--SE!SBA1\V:^1EJ>>AV*?'RN!31UZTZ+K60#7.#UIAYZ&G3##'W--)
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M#NC&WN-LT?ENO!'O7T5L&.>A'>L74?!-CJS[U86LW]['!-3RV(DCG-)B2*+
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M>M;,*]L\FN"=24MC8NB1I&W,2S]2Q.35J$;B/2JD:].:MVY.!Q7*VY;C+L0
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MB[SC_F#R?SKY-*@"OK7_ ()BC'[1=V?^H/+_ #KULO?^T0]1T_C1^L-?B_\
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MU9N!3+_7K#PM$R0LL]V1RR\A:]-TN1<U5V1YRJ<[Y*2NRY!IEGX=M1/?LIF
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M]J['4+B/#?O%/-</XBN(\/M=3QZU5R#@]0D;?]X]:V?#O$6>YKGM0G3S/O\
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?#%Z;S1_#VF:7=E=GGVEJD;[?3(&<44548Q3T2 __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>form10-k_010.jpg
<TEXT>
begin 644 form10-k_010.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &? M # 2(  A$! Q$!_\0
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MTE%^[;YW.ZJJM*C&JY)WZ'ZJ?\/D/AMW\%^)Q[?N?_BJ3_A\C\-O^A+\3_\
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M /A\C\-?^A+\4?E#_P#%4?\ #Y'X:_\ 0E^*/RA_^*K\D**/JM,/K50_6_\
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MK./[J@X''K46J:!:B6&UU#3'\,ZC."8)-^^WEP<8.>5.?PJ?J],?UFH?I_\
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M/^'R'PV_Z$OQ/^(A_P#BJ_)Z*W@@RCI)=3#[R1GY5I3:),N1;S6G^TRDI_\
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MQ/:W$0^S6VM02;K-AM9!C'SCODC=5.;7M$?3XXDO=1G0HL?]DL^W#[NN_P!
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M-=ET<SB[%YM;NV-TSLDAN<>86&<X.1_*J]YJ,]ZENDI4+ FQ JXP,YK+-^.
M8&---^XY$)_&CF1G[.3+I8G@FDQSQ5!K^4](L?A2?;IQT0C\*?M(+=![*3-
MT9^M9K7ET>0,?\!H^UW7?(_X#1[6'F-4?,T\_7\J7'L:R&FN2V?F_*FF6Y)Z
MO^M3[;R'['S-G'UHK#Q<GO)2[;GG_6?K1[;R*]A'N;.X4;@.N!]36(8;CT?\
MC3?(E_NN1]#_ (4>T8>PCW-PR(/XU_.FF:/_ )Z+^=8WV>7^Z_Y4AMI6XV-^
M5+VLNP_81[FT;F(=9%%--W#U$@-8XM)1T1S^%*+:8G_52?\ ?)H]K+L'L8]S
M7^VP]WI&O8/^>F/PK*^R3_\ /)_^^3_A2?99_P#GF_\ WR:3J3[#5&/<U1?0
M8QYA_*C^T+<9^8GZ"LG[)-_SRD_[Y-*+.8?\LY!_P$U/M)]A^QAU9K#5+=>I
M:E&KVV.C&LC[-,/^64A_X":/L<Q_Y8O_ -\FCVD^P>QIHV1K-J/X9*/[<MO^
M><GYBL;[#/G_ %4G_?)H^PSC_EE+_P!\FE[2?8?LJ9N?\)!:?\\)/^^A1_PD
M%L/^74\?[58?V.?'^JD/_ 33?L,__/&3\C3]I5#V-,W_ /A([7_GTY_WJ7_A
M)+;_ )\L^Q>N?^Q39_U$GY&G?8)A_P L)<_[IHYZ@>QIF_\ \)3 !C^SU_[[
M-*/%L(Z:=&?]YS6!]AGSGR91_P !-+]BG/6&0_533]I5#V5,WO\ A+HQTTR$
M_P# C2?\)BHZ:7!^+&L(64W:"3_ODTILIC_R[R?]\FCVM4/9T^QO#QKC_F%6
MWYFG-XY8G_D%6H'XUS_V&?\ Y]Y/^^31]AN/^>$O_?)J'4K7&J=+LCH%\>2*
M,+I=G^(-.'Q"E4_\@NR_%37/"PNO^>$O_?)H^P7/_/O+_P!\&CVE9![.EV1T
MG_"Q9O\ H%V7_?-*/B+<KTTRQ_[YKF38W.?^/>7_ +]G_"C^SKK_ )]I?^_9
M_P *?M:H>RI]CJ?^%DW/_0,L?^^*=_PLRZ_Z!>G_ /?JN6_L^Y'_ "[R_P#?
M!I/[-NL@?9Y?^^#1[6L3[*EV.K'Q.N5_YA6G_P#?JG'XI7)_YA.G9QC/E5R1
MTVZY_P!&E..N4-5]NXA57+'H *'4JKJ4J--]#M/^%GW?_0*T[_OW33\3;H==
M,T__ +]URGV"YR?]&E/L$-']GW7_ #Z2_P#?!_PI>UK![*GV.I_X65<G_F&6
M!^B4B_$><C)TNQ_[X-<O_9]P>MK(/^V9H_L^X[6TH_X :?M:H>RI=D=,?B))
MWTJS/T4TUOB SGG2[0?@17.?V?=?\^\O_?!H_LZZ_P"?:4_\ /\ A1[6J/V=
M/L=%_P )T&Y.E6V?8FFGQLI.?[+M_P S7/FPNEX-I+G_ '#2&SN>GV:4?\ -
M+VM47LZ;Z'0KXUCSSI<'X,:/^$P@)_Y!D7_?9KGOL-S_ ,^TO_?!H^Q7/_/M
M+_WP?\*?M:PO8T^QT(\86V,?V:OX24G_  E5G_T#_P#R)7._8[G/_'O+_P!\
M'_"E^Q7/_/"3_OV:'5K![*"Z&_\ \)/:8_X\3_WU2GQ-98_X]''ON%8!L9\?
M\>\G_?!IOV&X'_+"0_\  32]K56X>RAV-YO$=FYP8)!]&%)_;MBW'E2C\0:P
MC9W _P"6,@_X":3['<-UB<_\!-'M:@>QIF\VL61&-LH_ 4W^U[,=#(/PK"%G
M<'_EB_\ WR:7[!.?^6+_ /?)H]K4["]C3-LZO:8X=_\ OFF_VG:'_EHPQZBL
M86,XZ0N/HIH^PSG_ )9/_P!\FFJD^P_94S9_M"U/_+0G\*:VH0= ^5]*QS93
MC_EC(/\ @)H^R3_\\9/^^33]I/L'LH]SH],\23Z3<"XL[Q[>0<?(>"/0CN/:
MMAOB3J31N([B"W=^LUO;)')CV8#(KA!;3#K"_P#WR:46L_\ SR<?\!/^%'M)
M=4+V,5U-I[Q)G=VG+2/]YG.2:3SH\??7ZYZBL4VLY_Y9M_WR:<MK+T\MS^%+
MVDNPO91[G;67C75+.T6U%U'<6Z_<BN464)]-V<5'J_BG4M;B6*ZNQY"]+>(+
M'$#Z[5P,^]<6+>;_ )YO_P!\FE\F;_GG)_WR:OVC["]BMKF[N .<C/UJ>QU"
MYTRY2XLYWM;A#D20O@BN=\NX_N2?D:!'<@_=D_(T>T?87L5W.^/C_60Q=7MT
MG(_UZVT8?/KG'7WK!N[J:^F>6XFDGED.YW=LLQ]S6$OVI3G$@^@-.WW7I)^(
MH]H^PO8^9K=^ <>E:>D>)=3T19([6Y98)/\ 602C?&_U4\5RPENQV?\ [YI1
M<W2_PL?^ T_:KL+V+Z,[&\\9ZO=VS6PN$MH7&'6TB6'>/0E0":PR2>IK,6[N
MO[C'_@-*+RY!YC)_X":?M(K43HR[G7> _#J>+_&^@:%)(\2:C?0VS21@%T5G
M )7/<9[U]E>(_P!DR+P7#<2KXYU271K;4X;*63=&9+>!@NY@#R6)?@#' )KX
M+CU*YC971&5U.Y6 ((/J/>M&3Q?K,QD,U_J$S2.))"]S(=[#@$\\GW-2Y75D
M[%J+B>N?M%_!QOA+XCTZ&/5I-?LM1MC<0:FTH<3<]1@\ =.:\@ Z^O>H;C7+
MF\6-+F2XN$B&V-979@@] #T'TJ$WSDY\E_KBM5-)6;,Y4Y/9&C#=36_^J=D'
MH.E+/>7%S@2RLP'1<\"LW[>?^>3_ )4G]H?],F_*CGB]R?93+BC;BOU5_P""
M+?\ R3[XI?\ 8;MO_2>OR>.H@#)B;'K7ZN_\$59/-^'/Q0?UUNV_])ZXL2TT
MK'9A82C)MGUM^VK_ ,FG_%3_ + -Q_Z#7\\\)*P18.!M%?T,?MJ\?LG?%3_L
M W'_ *#7\\Z<1Q#_ *9C^51AMV=-?H/\QLYR0:4NQ'+&FGK2UVG"+YC]F-+Y
MTG]\_C3:*8#O/D_O&CSI/[QIM%(!XGD_OFE%U,.CFHZ*8#_M4Q/WS3X[F<_\
MM6J"@DCH:'8";[1<?\]&J3[5<_\ /5OSIL;!DZ<BI/RK#F)(FNIUQF4T?;KC
M_GLU/F167( JH",D'GWK6+N!/]ON!_RV:E%]<$\3-7K?@3]EGQ9\1?AU#XOT
MJ\TL6L[7*V]A-/MNK@6Z[IBBXQPO-9'BK]GKQIX7U;4;6'2+C7(=/MH;FYO-
M-A=X81)$)<$XSPIYI<T=B^0X%;NY_P">K?G0;RY'29Q^-=7;?"#QM=C2O)\*
M:K*-40R66RV;]^O7<O'0>OI4MA\%?'VKBY^Q>#M9NOLLKV\ZQ6;GRY1_">..
MN:?-$7)(X[[;=?\ /=_SI1?77/[]_P ZZR'X/^.+C5;[38_"6KR7]E$)[BV6
MU8O$A&58\=".<_6K&D?!/QYK::=/:^%-2:TU">."VNW@*PN[MM4;CP!GO4\Z
MZ!R2.-^W77_/=_SH^W7?_/=_SKT$? CQ-:_$?5_!&L1IHFNZ7;SW$\=RK,&$
M2EL+LSG('!Z5?\$?LQ?$;QKXST#PXOAN]T:76)3'!>:E R0)A=Q8G'3;S[T<
MX>SF>7_;KOM._P"=+]OO/^?A_P Z[GQ7\$/%_A6[U,?V+>ZCI=E>&R&K6]L_
MV>9PVWY21GD\4A^ /Q*6>2 ^!=<\^-0[Q"S;*KC(_$T<X<DD</\ VC>C_EXD
M_.E_M&[_ .?A_P ZZU?@IX^;5I-,7P?JYU&.$7+6QM6W",\!L>AY'UKK],_9
M0^(-[X>BUZ^TIM(T6;3[B_CN[A"PVPYRC!<E6)&!D4>TL'))GC[:I>;CBX?\
MZ8-6O/\ GY?\ZZ;_ (5!XX,6ER/X3U<)JN?L1-JP^T<;L+QUV\^XJMK'PQ\6
M^'VOUU3PYJ-@UC ES="> J(8G.$=O0$\"J57H');<Q!K%Z#G[2_YT]-6OG_Y
M>I/SJ@%W8'K5M(PBCCFDY-$LG74[[/\ Q]28IQU2]QG[2_YU!]:;(X12<9J>
M>3>@B4ZW>H<"ZDI&UV_)&+J3\ZH;MS$TM:W?4JQ=.N:@?^7N3\Z/[<U#_G[D
M_.J5%.[&7O[>U'&!=R4H\0Z@/^7R3/UJA2;1Z4K@7SKVHG_E\E_.E_M_4O\
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MPUX=M;?2X[.>VCD$US&^6N#GJ0>E2TQW1@C5[W_GYDS]:/[5O/\ GY?\ZA*
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M?$<1(_@'\J_H8_;6_P"33OBK_P!@&X_]!K^>>/\ U<7^X/Y5IAMV1B-D>Z>
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MZ&\:R^T<[JVCWNBW\UCJ-G-8WD!*R07$1C9?J#S5!XOF[ U]@>'_ -IGPO\
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M>M2BVC*#(8<#[K8.:EN@3 _TJ5%^7GM18S3=CK/A5\0;SX:^*[6\M[IUT]I
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MZS?\$2^?AE\3?^PU;?\ HBL*OPHZ*6Y]=?MJ_P#)IWQ4_P"P#<?^@U_/.O\
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MSBLINS$RB#1U_"FKTR:=V/TIW9).A)7FG4V/[M.I@%%%% !37X0XIU-?[AH
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M[F!./F/UJI*>#78>*?!T7A[5/LHUO3]07RUD,MLY*_,.G3J*YV32QR#?6O\
MWT?\*Y)'9 RGZ9[5W/PNLX]1MO%ED1 ;JXTIEMUF=5+.&!^4DCG%9D/@J.X\
M,W6KG7--1X)Q!]B:0^:^1G<!CI6,^FJ1C[?:_P#?1_PKG:L=2T(7MWM'NH9
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M+X@N_#.IVNB, POI;<K%@_=)/8'L33NA\LCFJ0]*6D/2F(V/"G_(:'_7-_\
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M:(PHD*]_+Z ]LU\LMZ'@5VW@;XV^/?AGIM[I_A3Q9J>@V-X2TUM:3%4+$8W
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M4]#1]:#T-;G.;'A3_D- _P#3-_\ T&L71?\ D-67IYR_SK:\)C=K*C_IF_\
MZ":Q-%_Y#-F/^FR_SJ)ZV14-F'B+_D.7W_79OYU0'2K_ (B_Y#E[_P!=G_G5
M#M6$UJS=;(*5>])2@XJ+M#L/7K3\\^U1 Y]J<C=:UCJ0T64D&!5A)!D<U1!)
M.:D23ZUHI6,7"YH+* >:DCFPY/:J(?/X5*CXX-:7,'&Q?\W/-6=.@:^U2RM
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M6HJQ;-4AV[BFT45#UW*L2P'*S?2OUI_X(E_\DR^)O_8:MO\ T17Y*VWW9_\
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M^/Z4?C^E,^VQC_EB?^^J5;Z'',!)_P!ZCVL1\@__ #THQ_G%-^WP_P#/N?\
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MT #UJ_\ :K$C_CR8?\#I!<V(/_'F_P#WW2Y8]P*.%]:0\=^*O-<V)X^R,/\
M@= FLC_RZM_WW1RI 4<T9JZTUGD?Z,W_ 'W2>=9_\^S?]]4BBGFBKGG6?_/L
MW_?5-,UG_P ^S?\ ?= %6BK/GVO:V;'^]2^=;?\ /JW_ 'U0(JYHJUYML/\
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MQHT!%G^SIC_ ,>["C^S9O[B_]]"JW7U_.CGW_.BP%G^S9_[B_P#?0H_LV?\
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M74S_ ,L5_P"_@_QI?^$4U0_\L5_[^#_&LL3..C-_WU09W_OG_OHT7IAJ:?\
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M)A_RS_)A2_V9/_SS/_?8JKEO[S?G1N.WJWYTO= M#3)S_P L_P V%)_9<_\
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MQ-OMRLF2/G.><5;M?C%\-;3QI-XXO=3%S_:FDV6B16)07-Y!$<B[:Y8@;G(
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MS?[M?K5_P1*_Y)C\3/\ L-6W_HBOR7@&V*;/7;BOUH_X(E?\DQ^)O_8:MO\
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M: /]9%_WU3NR78J&;!ZT[SN:G_LW)_UT7_?5+_9I_P">\7_?5:ZA9$?G,/\
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M  8__8U]P44<\NXN5'P]_P .@/@5Z^(3_P!Q'_[&E/\ P2!^!)_Z&'_P8_\
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M (,?_L:^X:*7-+N'*CX?_P"'0/P)_P"IA_\ !C_]C1_PZ!^!7_4P_P#@Q_\
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CZ-K>F>#&OS:ZO<I=7 OY_-(=4VC:<# Q7LM%)MO<:21__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>form10-k_011.jpg
<TEXT>
begin 644 form10-k_011.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &( M # 2(  A$! Q$!_\0
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MJ/\ X+)?\*?LJG\K%[6'\R/J&DS7R\?^"D7P/ _Y#>I?^"R7_"D_X>2? _\
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MY?\ "CV<^Q7/'N?4^:6OE;_AY=\"\_\ (;U/_P %4W^%'_#R_P"!?_0<U/\
M\%4W^%+V<^S%[2'<^J:*^53_ ,%,?@5_T'-3_P#!5+_A2'_@IE\"AUUW4_\
MP52_X4<DNP>T@^I]54M?*7_#S;X$9_Y#FI_^"J;_  I3_P %-O@0/^8[J?\
MX*IO\*?LY_RL?/%=3ZKS1FOE+_AYO\!_^@[J?_@JF_PIP_X*:? DC(UW4_\
MP53?X4N2?8/:0[GU7FEKY4_X>9? K_H.ZG_X*I?\*/\ AYE\"O\ H.ZG_P""
MN7_"CDEV%SQ[GU717RK_ ,/,O@5_T'=3_P#!7+_A2?\ #S+X$_\ 0=U/_P %
M<O\ A1R2[![2'<^JZ*^5/^'F7P*_Z#NI_P#@KE_PH_X>9_ K_H.ZG_X*I?\
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MU_Y]+?\ []BC[;_TZ6__ 'S4V?<-.J.9)?',S8_WJ:?>1C]6KJ?MI[VUN?\
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MFJ9R222222<FEHJ7O<+(G;G2)A_TU6OZ0_AI_P DY\*_]@FT_P#1*U_-X?\
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M/A/5)];FTGR!%>)*8&\UPJ*X.-NX\$UHV/BK3;3PUI^E2Z9/-);7ZWTDXN2
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M&#C%5)8\=JVIXNYK.F0<XZU$HE1,V1,>F*KL.>>:MRJ1GWJNZDGBL&M#0B;
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M))]ZC+Y6LFRR1Y6;16#,S8F'WN:_I!^&G_).?"O_ &";3_T2M?S>LI.CR?\
M7<5_2%\-/^2<>%?^P3:?^B5KFK=#JH=3I#7\W&K\^+/$_P#V$KC_ -&M7](Y
MZ5_-QJW_ "-?B?\ ["5Q_P"C6HH?$&(^R5L8-+2-U_&EKM.-[A1112 ****
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M?\DY\*_]@FT_]$K7/5Z'30ZG2'I7\W&K?\C7XG_["5Q_Z-:OZ1STK^;C5O\
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M?#KP_HEOX \8_#VPTZ)+W6/$NJ>3=P%CNF3RE(/RY...:^%_CN?"!^,7B=O
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M=@YH]S.I:T!X=U,]+.0_E1_PCNI_\^<@I<LNPN9=S.HK1_X1W4_^?.3]*/\
MA'=3_P"?.4_04^278.:/<SJ*DN+::T?9/$\+^CC&:C!W=*EJVY2UU1H^&_\
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M(H)W!MQS@XP:KVKEH)P25SE-2LA97*A&,D$B[X7_ -GT^HJJ#D9%64E:7PY
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M HLA'4 ],^U4_#7A'7?&=[)9Z!I%[K-S%&TLD=E"9#&BC)9L=!QUKW[3+KQ
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MI_\ UV'\JY_4_P#D/W/_ %]?^SUT'AQA_P )!IY'_/4'K7/:CSK]SG_GZ/\
MZ'63V1'VF7O'/_(U7OX?R%8=;7CAO^*JO0?48_(5B9/J*SFGS&L'[HM%'/\
MD4A;'6HL^Q=T+13=]&\4K/L%T.HIN[Z4;QZC\Z+/L%T.HI-WT_.DW#WIV?8+
MH<1D59TR_DTNZ$\0!< @9/2JH.?_ -=!&?;\:.5]@NB9I?,9F;DDY-)O]%_6
MH@ ON?K2[L?_ *Z:3[#)UD.WI[T_[0/[M5?,^E.# C)Q5:]@T+4<H4GY<\8Z
MT!UR/E_6JP?!SC]:56P1Q^M&O85T=U\.O#5IXSN[[39(W_M)(TGMRC8!1#^]
MS_P'-;?Q)\#:)X2L6N;5Y0E_(UQIS\ONME ')]VSS[5YM8ZM=Z5<"XL[B2UG
M"E/-B;#;3U'T-23>(-1GACBDOIWBCB\B-&;(2/.=@]!GFM+ >I^#_A';:QX4
M@U/48'DGN+B)U\J92J0'=\IP?O''2J$FC^&[3Q!H$U]836>D7MF\KVDA=_*E
M#%55B/FP<"O-;75KNQ0K;74UNI=9"L<A4%E.0?P-7F\9:U+>&[?5+AKDG/F,
MX)STHU$= ?!P?Q#K5M<LFFVNFQ_:)OLP,VU#]T(.IZ]^E;FG_"^QNK.)SKH2
M280,(S <J)B1'D_4<UYW;>(M2M-0DOX+^:*]ER))P_S.#U!]13AXAU-F+G4)
MR_R_,'_NG*_D>E*S'H)>HUC>7%LX#/!(T;$< D$@_P JA\\!C\@_.H)+EYI'
M>1C)(Q+,[')8GJ::91USS2=^HRR)A_<_6FNZXSTJ R9&#Q32=PP6I 2-*22<
M"DW^PJ,G ZTF_P!\_2INP+MEJ4E@9?+ Q*A1AZ@U5S43,6QVI.?\BC5B',<L
M>:2@#CO2$$&ILPT%HI<?7]*,>E%F,2@T!3ZBE*$=Z+,!N:6@J5__ %T<=S^M
M*S **/E]?UHXQU_6@"=_^05)_P!=17](7PS_ .2<>%/^P3:?^B5K^;YE_P")
M3)Z^:*_I!^&G_).?"O\ V";3_P!$K65;9'30W9TAZ&OYKO$-Y]D\7^(AL#[]
M1N>O_75J_I1/W37\W>J>'KG7?%/B9X&ABC@U*XW/,^T<RM103;T'B-C&_M;U
M@0?B:/[7'_/!?S-7?^$,NEZWNGG'_3P*!X.NC_R^Z>/K<"NQ4YO9'#S1[E+^
MV!_S[(?^!&@:R!_R[)_WT:O+X,NN]]I__@0*0^"KLDXO=/Q_U\BGR5$2IQV*
M7]LKCFVC_.G_ -LK_P ^L?YU9_X0N[!_X_-/_P# D4O_  AMU_S^Z?\ ^! K
M/DF5S0[E;^VU_P"?6/\ .C^VUQ_QZ(?;-6/^$.N_^?[3_P#O^*#X.NO^?VP_
M\"!5\E0+HK#7%'_+E'^=.&N*3S91X^M3CP;=9_X_+ _]O I?^$.NQUO+ ?2X
M%/DGV%<@_MU!_P N,9_X$:/[>B[V$?\ WT:E;PI<CK>V/X3BD_X16X/_ "^V
M7_?\4N2?8.9$7]OP_P#/A'_WT:0Z_'DXL(_^^C4I\*76>+RQ/_;<4?\ "*W0
MZWEE_P!_Q0H3ZBYO(A/B!<\6$>/]XTO_  D2\?\ $NB/_ C3CX6NNGVRR/\
MVV%'_"+7(_Y>[+_O\*?+(7-<!XAB_P"@=%_WV:#XCB/33HC]7-!\+W(!_P!-
MLO\ O\*:OAFX)YO+/_O\*=I] N/'B.-3_P @R$_\#)I1XEC(_P"07"/JQI!X
M9N/^?NR_[_"@^&KA<?Z7:?A,*+R06N._X26,?\PN!O\ @1H_X22,\C2X!^)J
M/_A';C_G[M/^_P */^$<G/6ZM?\ O\*.9E<J)1XFB'_,*MS_ ,":C_A)XO\
MH$V__?;5%_PC<_\ S]6O_?X4?\(W./\ EYM?^_PHYI!R(D/B:+_H%0_]]F@>
M)XL\Z1#_ -]&H_\ A'IO^?FT_P"_M-&@3?\ /U:_]_*F\A\B+ \3PDC_ (E$
M/_?9I?\ A)H<\:1!^+FJW]@3#G[3:_\ ?RD.AS8_X^;;_OY1>0<B+8\5P#KH
MUO\ ]]M3E\56YZZ-;_\ ?35170I>]Q;?]_:&T.0$8N+;_OY1>0E%(O\ _"4V
MV?\ D#6__?34G_"5V_\ T!+?_OIJH?V++_SWMS_VTI#HTV?]=;_]_*$Y,>BV
M-(>+[8?\P6V_-J3_ (2VV_Z MK_WVU9HT6;_ )^;8?\  Z/[%F_Y^+;_ +^5
M2<Q6N:8\76Y/_(%M3]&:G'Q;:Y_Y =M_WVU9/]BS#_EXMO\ OY2MI$P&?M-M
M_P!_*+S"R1K+XLM2>=$ML?[[4-XMM .-"MC_ -M&K&_LJ;_GO ?^!T'2I3_R
MWA'_  .ESR0K(V!XNM@/^0#:Y_ZZ-1_PF-M_T K0?\#:L?\ LF4?\MX/^^Z!
MI<H_Y;P?]]T^:0N5&Q_PF%MCC0K/_OMJ#XRM/^@#:?\ ?;5B_P!FR;_]=!_W
MW2_V8_\ SUA_[[I>UF7R(W[?QO;VD\<T6AVRR(<JPD;BN9N+MI[J2Y*A6>4R
M%?3G.*L?V;(3M#PD^@>JC#8^WJRG;S63G*2LQ*,6[G27?BZTOKAY[G0+2:9\
M;G9VYXZU$/$6F9Y\.6>/:1JRCID@(R\8 /=J4:6W:6('_>IN;3*Y%T-1O$.F
M'&/#EJ/^VC4G_"1:<O\ S+UH/K(U9O\ 94G_ #VB_P"^\4G]ER$\RP_]]T_:
MR8N1&G_PD>G'IH%H/^!M1_PD6GC_ )EZU/\ P-JS?[)?_GM#_P!]TG]D/_SU
MA/\ P.CGD'(C3_X2#3L_\@"V_P"_C4T^(+'I_P (_:X]?,:L_P#LJ3M-#_WW
M2?V5)_SVA_[[I\\@Y4C1_P"$@T__ * 5M_W\:C_A(+#_ * 5K_WVU9W]CRY'
M[^W_ ._E._L:8CB6WS_UTI\\B;)E[^WK ]-"ML_]=&IIUVQ/_,$ME_[:-5,:
M+<+R);?\9*7^Q;ANLUK_ -_*?/(:2+BZ[8 ?\@.V/_;1J1M>L<_\@*U_[^-5
M,:+.@_U]M^$M/719V&?/MO\ OZ*.>0[(L?V]8_\ 0#MO^^VI?[=L?^@+;?\
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MP_&<46F'NE+^T;;_ *!L?_?;4G]H6YX&G1#_ (&:N_\ "(7/_/[8?]_Q3_\
MA$;G'_'[8?\ ?\46J=@O$S_MUMCFPB_[[-#7ML?^7"(?\")K0/@^?_G^L/\
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M!\/I^.FH+_Z#7]%WPV_Y)SX5_P"P5:_^B5K^=7_FG4_.?^)@O/X5_15\-?\
MDG7A7_L%6G_HE:6)>Q>$^T=&>E?SBZP,GQ]_V%'_ /1SU_1T>AK^<76#\WQ
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M&6QBC@/TRJ@T24O@;2N83C"2=[IL]JTW]F3PAHGA=6\5V4MDJ0B228R;;MV
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M&!&X$'MQ4BO[5;\9:!'X0UR6V@NTN]-E_>V=RK B6$_=.?7':L<7D1'$B?\
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M*:/V1_@N.GPP\,#_ +AT?^%%%',PLA1^R1\&!_S3'PQ_X+H_\*4?LE_!D?\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>form10-k_012.jpg
<TEXT>
begin 644 form10-k_012.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &8 M # 2(  A$! Q$!_\0
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MED!-#>0)<&,C N(F&0P'9AWKEOBI:^,]0M-%T[P?<K;/>70CN-;WJ'M;?'.
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M\K?QVS=OPI;@*I4&%A*X(^6*X;_EG_TS?_Z_K2L 1,A@RN<RV8/*G^^A]/\
M&G,)=TI95>4#]["/NW"_WQ[_ .%-&TB$"8B,_P#'O=G[R'^XWZTP G_4OYV2
MPQ%<@<2#^XX[&F@)Y!PCK C?-'_RTM6]1ZBG$']_F'##_CYMNS#_ )Z)_.E(
MD\V,>:&GQ^XNOX9E_NM[T (N3,ZX#RNN60_ZNZ']Y??_ .O324,43;W\M3B.
MY'WH#_=?VH.WR?GW+:[N57[]J_M[9_G3R)?/;!3[7M^9/X+I/7ZXH 1P"\JO
M$2S -+;)TE]'3W'6E#$F%A-DGB*Z/1_^F<@I%P8XS')Y<!8^7*WWK=NZGV/2
MAMW[_=""P_X^;8='']]/>@! %*2KY+(@.9;7^*/_ &TIRY,R[7#S,ORR-_J[
ME?[I]&H'_+']_NS_ ,>UWZ'^X](^/+D\R,F$-^^ME^]$?[Z_7K0 QM@@/RR&
MW1NW^LM6[_44]P3*VY0\CI\R+]RZ7U'HU.(D\\8E476W]U-_#<)_=/OTIB[?
M*RI,4._Y@WWK63^\/]F@ 7:(Y5\EDB'^OM,\QGLZ4X;S+"=X\XC]S=#[LP[*
MP]:1679$PG+1#B&[/WHS_<?VH"G?*OE?O#S<6>>&']]/YT -/E!'W1ND2M\Z
MC[UJ_J/8U(RR>:1A7N67+)_!=)Z_6FACNB*W +'BWE;I(.Z/[CWI#L$3AD9(
M%/[Z$??MV_O+[4 )^[\@'>ZVZMA7_CM7]#[4[!#2H(0'QF>V_AD7^^GOWI06
M\Q"'1IRN(I2/DN5_NM[TP^6(@?,8VRM\K_QVS^A_V>U "H1NC*28<C$%RW1Q
M_P \W^G2@[/)D!B+0 _OK?/S0-_>3VIS;F>0,%EEP#-;C[LB_P!]/?O3=PVQ
M,9RHZ6]UW'^P_P#]?TH <=Q>,DB:4K^[?^&Y3^XWO33Y0MP<NMJ&P&'W[5_3
MZ4K?*)@R^2.MQ .J_P#32.G OYD9$BM,PQ%,?N7"_P!UO?M0 $/Y[*8T6Z9?
MGC_Y9W*>H]ZC5H]L3([HF[$-RWWHF_YYM[=:"8S$Z@.;8-^\B/\ K+9O5?:G
MY<R8WQRW!3F/^"YC]?\ >_PH Q/&]E<7_@[Q):6MJ9[N6PF1K%>=[E"%9/QK
MP/X>7>I^$_"6AZ;>_!.\U+4+7"C5/(A#2L6)&[<A/&>YSQ7TH3&(D)E9;<-B
M.?\ C@;^ZWMUI[%UDD5E"R[29HA]V9?[Z>]):.X/5'DWA/P[J=I\;OB'JMSI
M-S:Z5>65ND<Y'&\1KD(>^"#^1KSFS^&7BB3X%:581Z'<_P!LV/B ZHVF2X22
MZ@#'E0>">?RKZ>4X$3+/GC%O=MW_ -AZ0[2D@8,T2G,T*_?MV_O+[?X4!ON?
M/_Q)\(:AXL\0^'?'=QX3U;5-':Q:TO\ 0X[CRK^R?<VT_*PSR>F>_-9&I?#C
M6IOA+XTBT_P3)H=UJ=Q;-:Z5'+)<7=Q"CY\R3<S#<,]L=_:OIG+^>I\Q?M1'
M[M_^6=ROH?>F_NUCX=H(%;D?QVS^G^Z:=]&"TL>._%:V\4+8^!!8V^K77AZ,
M+'J::&P6^/R*!'G(( .1P17*>&_AWXAO$^+5M'X<OM'35M.B6QMM3G,KN0">
M9"3N8=2,\9 SQ7T?A_-<E$,[+^]A'W;A/[R^^.:9E?*C83EH <0W)^]"W]U_
M:AZW$M+'$_!B;4A\/M(LM2T:ZT'4["W%D%O,8NPB@9&.Q[?0UQOP(^&MM9>$
M-67Q9X6@2[;5[A@^H6:/-#&=NPY8$E#S^1KVI\GS0R^81@W%L.W^VG\_QI59
MB\6V=6E(/D2-]V=?[C^XZ4>86TL?-_BSX97FB_$_Q)J.H>"=0\9:?JY6>R_L
MF\:'RG P5<*P^7ISS@#BHM>^#^M?\()X(OAX:A9=*O+B:_\ #^F73JZQRL"5
M61F)W@*"<-UX%?2;>7Y)!#K;(?G0?ZRV;U'M3QYGFC!1KEU^5O\ EG=)Z>QI
M+1#>Y\Y:7\*K[Q!I/CE=,\$'PA%>:4+2T34KN26^G;>KG<"Y54R@[=_K6;XB
MB\9>,? W@+1?^$%U.SET.^M4GO)@NUMF%&Q0<E0 26/3BOIP%"D;"5C;@XBN
M3]^!O[K>U+\WF2 QC[01^^M?X95_O)[T^M_3\ Z6/$+CPEK)\?\ QFNFT2Y^
MR:CIBQ6D@3B6381\A[Y-8VN^"/$%U\ /A[HR:'>R:S:7=O)-:(GS",.Y)8=L
M BOH@$8A*7.U<XMYV'.>\;__ %Z0X5)08V6-3F> 'YHC_?3V[U-M+%)V=SY2
MU."?5]>^(D\.BZYJ7A5M4?\ M&/P[?Q06C! "V]9%+%ASNVD ]*]SL]4L_'7
MP9N;CPS921PWVC2Q6VGLF&D4(4"J!_$",<9I=5^!G@O6]2EO;C2A]HNV\PR0
M74L,%XW<2HC!2QZ'CFNPT[3[+2M,AM+*!;;3+4"-(85VFS(Z  ?PC^E5HU9H
MFUG<\[^"/P_L-)^&_A@:QX=L[3784W&YN;1/.28.Q"N2,YZ8/TKC;6T\5?#+
M6OB+IT?@[4/$EMX@GDNK2YL=I2-G##][DY7&[]*^@OWC2NI*RSE?G@'W)T_O
M+_M?X4TL@2-O.98LX@N?XHS_ '']OK0_>W!'SQX=^%WB+PGJGP9MVLVNUTPW
M<EY=6_S10F0[A&S>W(KLSX?O_P#AI*'7/[/NHM#31&MI+P+^[MY=WW=WK_C7
MJG*M)N41N>;B$=&'_/1/>@$DQ$3*7(Q!<G[LJ_W']Z+ZW]?Q%:Z^[\#PWPAX
M.U^Q\,_&"VGT^Z@O=6N;I["-X^+U&C8 H.^<C'UK"O\ PIXET/P)\(=5AT.]
MO9O#<[&^L(5'VF$L1\NT^Z_K7T: GER (QC4_OK?^. _WD]J>K2&5,3+).R?
M(?X+E/0_[5+_ ('X#_X/XGSK=^$_%WC3Q3\3[VX\+7&COK>@)%:P7#*0S#;C
M+ X#_+DCMGK27[^.)/AWX"M8_#^NZ=9Z=-]AU6#3RJWMQ$J@*8R#D(3GH<YK
MZ)+(L2XF:&!6PC'[]N_]UO\ 9IQW;Y%,0\PC,]N.DB_WT]Z /GOP/X/UJT\2
M_$>[3P1=)I]]I44=MI>N73.;@_W'FRQ!/)(R=N0,\50\ >%=>TCQMX:;PGH'
MB7PO:NY;6K+5[C=ISQ8Y6+).XGG'X>]?20VE8F$Y,><079^\A_N/_P#7H;!6
M564NF<SVRGF(_P!]/;_&GU3[!T:/*OC;X=U+7K_P%+IEG<W=G8:XD]R8DW-9
MH",EO1:V]:^%^D65UXQUW3M.,OB36-.FA=5.Y+D,A&8U_A8G!..N*[O+"2(^
M>HN",0S_ ,$R_P!U_?M3,HL4@+-! I_>(/OV[^H_V32:NK M'<^<(]#\;:%\
M&?AW:6]AJ\-G;74@U>VTP!-02,N<(O((SST/<5/X:\%:['K_ ,2YHO"VJ:;9
MZEX?\JTMM2F-Q/*Q7&-Y)RY/.W)QTKZ+S()B,(;AAEE'W+E/4>]-#1F%6$KF
MV5ODF_Y:6S>C>U.XCPG4_"&MW'[*5GH*Z3=MKHM(HX[1$S(Q$X)C*^H'/X53
MTKX=:MX4O=9T&+3+J?P[XNTQ5N+W9OFTB]\K;B9NOEEC^ ^E?0AW%Y%8"24C
M,UJO1U[.GO2!B3$4N 2>+>5NCCNDGO\ 7UI6*N?*^B_"K4H[/1] E^&%Q/K\
M,RBZU.]U*0Z;+$K9,J!9!\V,$ #\.:]'O=(UCPU\>YO$D&B7VI:#JEA!IWVV
MS92=/<$!FD!.0JXS]#7L!V"-P49( ?WT(^_;M_>7VIP+>8A#HT[+B*4CY+A?
M[K>],EG ?$Z_\7:1<V$^@Z%;^(-)W,NM:)L5I;A/X9(BWXYP#VX[UYGX/\&7
M^L?%RR\4:-X/NO >A6]I-#,UT%1KN1D8*NQ>.I _#/6OHG*>4")&-NK?*_\
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MH.N>)/C'I_B2T\$R^!=+MK*1+^VG=4;4F;/\" !CDYSCMG-:W[0<;647@'7
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MK&?E;_EK;-[^H_QI (1 VT.MGGYXS]^V?^\/:GYD\\8(^W!>&/\ J[E/3ZT
M#)(7D5HD>0@-*@/RSKV9/]JD!P(W$O'W8+D_P'_GG(/TIH\@*HWO'!NS&?XK
M>3N#[4\A@\FZ,&;'^D0#[LR_WU]^] "$966-H<G[T]J#PP_OH:4%A(A#*LKC
M$,W\$J_W']#_ (TT;"D>V4B'/^CW)ZQ-_<;VH&P)+B,F,G_2;?NIS]]?QSTH
M  $2+)B:.!&Y _UEN_<^Z_XTX>9YC!0AN'7+*?N7*^H]#_C2<K,I27S+H >7
M(WW9T_NGWZ_E328?+^97-INY ^_:R?X4"N.PI5"I/E(V(V?[UN_]UO5:&1L2
MH8?F^]/:@\2?[:'U[TI)9R9"#/M.[;]VYB[X]Z:!'LC D809S;SG[T+?W&]N
MU Q0Y)BD\T$'B"[';_8D%(5VI(&@VQ*VZ:%?O1M_ST3VI<D/*1%^\Q_I-O\
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M8RKO'RPW/9Q_SS>D"@K(GE_N>LUJ?O0M_?7V[T8.^4"#YB,SVW:1?[Z>_?\
M&C"@0L)#MZ6][W'HC_J* ';I2Z,C(\I&U)6QMN4_N'_:I@"B,>62D*-E68?-
M:OZ'_9I)%3]Z'@) .9[=?X#_ ,]$IS9WIN*S3,O[MQ]VY3^ZWO0 IR6D4Q!Y
M7'[ZV_AF7^^OO30P*HQN-T:_ZF[_ (HS_<>F_NQ ,LR6P;AOX[5_3Z5(!)]H
M<>4BW)7+Q_P7*]R/>@ (8B17@&S[T]LOWE/_ #T3VH#,'C<3*)B,17)^[.O]
MUO>F+Y>(BK,BYQ#<'K$W_/-O;K3@I_? VX8Y_P!(M/\ V=*  *,,@C98\YDA
M_BMW_OK_ +-.'F!\G8UTZX('W+I?4>]-)RL)$N_(Q;W!_B'_ #S?^5(1&(7'
MELENK?O(!]ZW?LR^U !E%109&%LA^23_ ):6K>A]NU..]F<-$C._^M@'2<=G
M7WQFC$GVA<%!=,OR3?P7*^A]\8I@\K8,!XX5;AOXK5_3Z$T .!;]VT<JL!\L
M-RW<=XW_ )4A5=KJ8BL6<S6X^] W]]?:E<?O)!)"))B/WL*_=F7M(ON* <B!
MA+[6]T>W^P] "[I&=7,B&<C$<X^Y<#^ZWO2$#R\,"ENAR-OW[1O?V)H50%F7
M[.44<W%IGE?]M*$)\V/RW_?$?NIV^[<K_=;WH 4>9YA/R?:&'SP\;+I?[R^]
M(,!%,4I6-#B*9Q\UNW=6]J:PC\@_NV-JK?,G\=JWJ/:GN"9<.JS3LN< ?)=)
M_C_A0 C 'S%,.2>9[4>G_/1*7>_F(WF(9\8BGQ\DZ_W&]^WX4P%!#&?,80AL
M13?QV[_W6]J<5XF'D8'6XM!Z?WT_G0 T*NQDVL;=>7@_Y:6S?WA[4\M*S!AY
M<LK+MS_#=)Z?44T9+PMYGS$?Z/>#H_\ L/\ RI&$063?"P0$&6%>L#?WU]C0
M XA1&HWLL*']W,?OVS?W6]J<=X=LHK3N/WL ^[<K_>7WI0',PR5>X*?*W\%U
M'Z'WJ/$8A_B2W5N5_CM7]O\ 9H 4-@1L9<;3B"Y'\/\ TS?]*"H_>)Y>5/,]
MGW7_ &T_G0%/F2 1CS2,RPG[MPO]]?>FY7;$V\^3G$%W_%$?[C>W:@!X:3<C
M)(DC[=L5PW29>Z-[_P"%)\JJ0 4B5LE3]ZT?L?\ =I&"[I1);EGQF>W3H?\
MIJG^>]*<EHB6$CLO[F;M,O\ SS;WH 4[][9C1IW'[R(?<N5_O+[TT%3&G[XF
M!#^ZN!]^W;^ZWM2$1^0<JRVP;YES\]J_J/;-2?O/M'W56Z*_]L[I/\: $VNQ
M</"I#C]_;C^/TD2DW',;B<!@-L%X>CC^X_O31Y05""\<0.(YC]ZV?^X?]FGL
MK;Y5,*O)C,]K_#*/[Z>_2@!I"A'3RCLSF>V[Q'_GHOMWIVZ3S V4:Y885_\
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M0["%#MCG/WX&_N/ZCZTI5PTR&$+*PS+;K]V5?[R>AH 1B/+D5T/DA@9H%^]
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MV1A"?*5LQLWWK=_[K?[.: !?^606;.?^/6Z]?]AOY<T@V%9<1G9TN;0]4/\
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MILE'DMY0.9[8GYD.?OI[4_:^\C8AG*Y:/_EG<KZCT:F;OD1C,2N<176.4/\
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MAR#/;)Z]I$]J4[FE9<)]H(R\'_+.Y7^\OH:=#"UPR"*4B/DI,?OPXZHWJ/\
M"@ 5>/M$DRK'$FXWAP$>(=0_;('>OE#X\_'MO%;2^&O#$S6_AN,E)[B,X-X?
M0>D?\_I5_P#:'^-X\237'A3P[*$T6%RMY<Q<"Z<'E5(_@!Z^I]J\%\OT K]"
MR/)E&V*Q*UZ+]6?C_$W$;JN6!P<O=^U)=?)/\R ( .N*/+'K5CRS[4>6?:OO
M+GYARHK^6/6CRQZU8\L^U'EGVHN%BOY8]:/+'K5CRS[4>6?:BX6*^P#O1M((
M*L0PY!'4'L:L>6?:@QGVI,+=3TO]I/3O^%D_";P7\2X$#WUJO]D:N5ZYS\K'
MZ.#_ -_!7S'Y9]:^M_@$T'C#1/%_PWU%Q]EUVS>:U+'[EP@QD>_"M_P"OEN_
MTVXTJ_N;&[C,5W:RO!,C#&UU.&'YBOB80^KU:F&Z1=U_A>J^[8_M[P^SI9KD
MT%.5YPT?]?UN9GEGWH\L^]7-A]J-A]JZ3]-N4_+/O08SCO5S8?:D,9QT% 7/
M:/&J_P#&!?AT'_H9Y/\ T9-7RYY?O7U3XW7_ (P2\/#_ *F>3_T9-7R_Y9]J
MX,$O=J?XI'\D<8O_ (6JWK^K*WE^]'E^]6?+/M1Y9]J]&Q\7<K>7[T>7[U9\
ML^U'EGVHL%RMY?O1Y?O5GRS[4>6?:BP7*WE^]'E^]6?+/M1Y9]J+!<K>7[T>
M7[U9\L^U'EGVHL%RMY?O08_>K/EGVH\L^U%@N53$&!#<CH<BOL3]DO\ :[?1
M9+/P1X[OC)IK$0Z9K-PV6MCT6&9C_!V5CTZ'CD?(OEGVI&A#*0P!'?-<V(PT
M,3#DJ?\ #';@\94P=15*;^71G[)W<$5N>2QM2=_[OK"W]]3Z>U1R$EV#X:9E
M^94X6[C]O]KZ5\?_ +'/[4$D?V+X=^,+PE&Q#HVJ3MG![6TI/7T4G_=/:OL.
M6/R R[MD:G+ =;=O[Z_[/M7P&)P\\+4=.?\ PY^J8/&4\9256G\UV&;E$<9$
MI6(-B&X_BA;^XWM]:4*=\R^1B0C,]H>D@_OI_P#6IQ+F0@!'N"O*G_5W2?T:
MHP4,6[S7:W4_++C]Y;-Z'U%<IW"J09(BDQWD8M[AONL/^>3^_6D8(8Y%,+M"
MK S6RGYH6_O+[4\K(7=61'?&9;9>DB_\]$]_\*3(_=MY^T'B&[/7_<DH 4EB
MZ'>'D9?W4W\-PG=&]Z:/+\H8WI:HW!)_>6K^A]J<>/,4Q["O,UN/X?\ II'_
M #H7>70^8KRL/W4^/DN!_=;WH ,/Y[?(!<L,NG_+.Z7U'OC^M1@QD1LLDBH#
MB&8]8&[HWM]:<63RVR'^SJ?GB_Y:6K>J^W]*=^],I&8Y)67.S^"Z3U]F'- #
M7 !E62)NH,]LGKVD3V]<4Y=Q>(B56F9<07!^[.O]Q_>FC[J,LVR+)$<[??A;
MO&WL>E*00TJM$,@9GM@?_(D= #0L7DN/*=;93F2 GY[=O[R^W>G)N,QVD/<N
MO);[ETOM[@49(\MO/WL>(;O'#?[$E*W"OO4B)3^\A3[]NW]Y?8]: (RT?E(Q
M9Q;*?DE_CMF]&]J?)DR2+(FZ5AF6!/NW"]F7WI=S^:O[Q!.P^1\?N[I??WIN
M\",D,88E/);[]JW]5/2@ ##;"1,<9Q;W7I_L/_\ 7IH">7*/*=8%.98#]^$_
MWU[X[U(=Y=U,:M-MS)#_  7"_P!]?0T@)/EGSP=W$%V>Y_N2"@!06,Z$.OVI
MA^[F/W+E?[K>]1GR@I!\R.)6Z#[UJ_K_ +IIP&0X\HE1S-9]T_VXS3LR;TVS
M(S,/W4K#B<?W']Q_6@ (D$L@*!KAES)$#\ERO]Y??OQ304\M"'9(%;]U*?OV
M[_W6]OK2DHL;$!U@4_,O_+2U;U'^S3@'\S&4>=ERIQ^[NE]#Z-0 P8_?*(]W
M>XMO[W_31/UI,Y,+^:=QXM[SL1_<>G;AL1O,/E X28??MV_NM[=OPH^8R2*$
M4RXS+:9^24?WT]^] #7"8E#QNB YF@3K"W_/1?:GMN+C<5>=T^5U^[=1XZ'_
M &J12<QLDX"G_4W#]1_TS?\ SVH( $GR>6J\S0YYA/\ ST3VH :#&($(=EMU
M;$<I/SVS_P!UO;ZTX*WG2KY0%PPS+ ?N3K_>7W^E+A]X&4:=E^5O^6=TOH?]
MJFC9Y1.YS;J>?^>MJW^%  I7,+)*PQQ!<L?N'_GF_P#GO0RKME5H"RYS/: \
MH?[Z>U./F%V7$;R%=S0@?+<+_?7_ &J3<H1&$S+'G$5U_%$?[C^U !D@Q'S=
MSD8@N3TD']Q_?M3 (_LYPLB6RM\T9_UELWJ.^*><DR QC>!F>V'W6'_/1/?O
M2C<3&1,K2,/W-T?NS#^XX]: $7<97  DN&7,B'[ETO'S+Z'&.E-/E[(VWMY"
MDB&Y_B@;NK^WUI>/*;=E85/S(GW[5O4>U._>&8 %/M##[O\ RSNE_P : &R*
M-TJR0DN>9[9#Q(.SI_\ 6I03F%EF!8C%O<GHX_N/_+\* P$8*RF*%6PLC_?M
MF_NGV/3\:5@VZ1&B&_&9K8?=D']^/WH 8-GE2J(F$0.9[;^*(_WT]J5=QF!2
M3?<,,+(WW+E/[I[9 I0_RQM]HW(>(;O'*G^X_M03\L@= 8UYEMDZQ?[:']:
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M_P"Q1M_V*L;!1L% 7*^W_8HV_P"Q5C8*-@H"Y7V_[%&W_8JQL%&P4!<K[?\
M8HV_[%6-@HV"@+E?;_L4;?\ 8JQL%&P4!<K[?]BC;_L58V"C8*07*^T@@@$$
M'((."#Z@U^@O[(O[0;?%#0X_"GB"Y5O%^E0Y@FF(!U&V [^KJ,!O7AO6O@+8
M/4UH>'M=U#PGKUAK.DW+6>I6$PGMYU_A8>OJ",@CN"17GXW"1Q=+E>ZV9ZF7
M8^> K*:^'JC];OW?D,#N2UW<@??M7]?I4FZ7[0I*(MWMY ^Y=)WQVS7'_!WX
MH6'QG\!67B73?+M]2 ^SZA9%N(Y@!N1O]D]5/H175KY?ER "3[+&1OC_ .6E
MNW8C_9K\]G&4).,U9H_6J=2-6*G!W3% B\M0I:.+?^ZN#U@?^XWM_C3P6\R4
M^0&E(_TBU[..SK_]:@>8TN"Z23.GS1?P7"?WA_M=OPIA9#"&\QUA1L13C[\+
M?W6]J@T%&-D6)"Z _P"C7!Z@_P#/-_KTYI?DV2@Q%(2<SVX^]"W]]?;Z4OS>
M8ZE5$C#,T0^[(O\ ?3W[]J16)$+K-END%T>C#^Y)0 N7,L?S(+C'[JX_@N%_
MNM[XP.:9^Y\M_D>.#=EC_%:O_@>*=M4F:/RBR#F:T[QG^\G\_P :7<YDC(F2
M25AB-S]VX3^ZW^T/ZT #!A(Q>(2W!7]Y&OW;A/[X]Q31CRX0LVU ?]'N3U0_
MW'I/D2-L2-! CC&?]9;OGI_NFGD,970HIF=<S0C[DZ_WD]Z  ?>E'V?:2/\
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M"N[R ^$)^_;2?W3[4,8O).X.+56^Z/\ 66S_ .%/8OYIW%3.4Y(^Y<I[?[5
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M!.(+C^*)NZ/[9X_"D!B%N-K/]E!X)_UELW]13_F,DHXDFQF>'^&9?[R>_>@
MPW[]?)!/_+S:=F_VT^M"ABT!C<2,>+:X;OZH_P"M,W)MA;SB$'%O<]T/]QZ<
MX4"82*4'6XMT[^DD= #<1^3)F-E@#?OH/XK=O[R^U2$2B=@0ANBO*?P72?XT
MGSEXF653*1^YN#]V9?[C^],7R_(.TN+0-U_Y:6S^ONM !E!"A+,+/.$E'^LM
MG]#[4\F3=+N@5Y=H,T8'RS)V=?>D&_SR#M-V5^9#_J[E/;T--!CV1E9GCB#?
MN7(^:!^ZMZB@!001 5G+*>+:Y/K_ ,\W_E2L 1.K1=.;FU _\B)_.ALYF!B&
M<?Z1;*>'']]* 1MA8387.+>Z/53_ ,\WH =\_FQ_,JSE<02G[LZ?W6]Z9A!
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M5(?-\V3<4EGV_O(!]VXC_OCW_P */WGG G8+HK\K_P#+.Y3T/O3 (S&I"M'
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MM?J=.K"K%3IRNGU1\A5HU*$W3JQ<9+HR (1T;&>O/6EV?2IO*4T>4M:&-NA
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MW]O>V-S+9WENXDAN('*21L.A5AR#7UC\,/VH-&^(EE;>&?BHB6U\%$5GXHB
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M070'RN/[KCUIF%6,AH6C@1OF4'Y[=_[P_P!G_&@;1YI$!"G_ (^K4]O]M/\
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MPI/EPAWG'_+*7T]FI@.YW*0P8D81^S#N&I.-N,'RP>5_BC/K]*1B/FWJ0/\
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M#(]A_O&C8?[QJ3 ]Z,#WH CV'^\:-A_O&I,#WHP/>@"/8?[QHV'^\:DP/>C
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M=JX[Q-\&;CQ%J'BL-?60M-5O;35[>&>T,QAO($1/G&X+)"RQC(X/S'GI6_\
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M(\KE@?E)&"<&NH\#^$]2\'ZKXB1[RUNM-U'4)=3MD2)EG5Y3ND1R258 XVD
M'UJ5JB3B(OBCK=Y\<-0\*075I-;65RHN=,2V!"6)MPS7K7.["NLI">5C@8]<
MUZ3XN\3V_A/PMJ&NRL94L[9IHF0_ZTX^2/W+,54?6O'O$'[.FMZOH,GARV\1
MZ;9Z$+B[NK/46L)#JL37#NTL,D@D"/&^]D8E<E<<9 (]!\7?#V7QKX<T/0-0
M-I'I=M-!)J^GVZN([N*)?EBCYRJ[PA.><+BF]AK<Y0?$[Q9X<^$OC&YUJQM[
M[QIX;5S=0VBB*$[HQ+#.%9A\@5L, <DHV*W_  [\2KZ+4/#_ (<O]+U/5/$M
MYIL>HW5PD4$<4<+2%"\I5]BXQG"DD@C&3FLC5/@#86\'B.W\*R6^A:?K^BRZ
M9<P,)) T^[,4W+'[H9U([@C'2NNT_P &26?CX>(FN$>!=#BTA[4(=P=)3)Y@
M/3!Z8ZT7OJA;?UZ&!H/Q:2?PWX<2RM=4\5ZOJL,UU#!%%#;S+%'(5>60EA'&
MH.U0,\DCCK6U/\2V?3])FL/#>LZC>ZG'([:>\"VQA6,X?SGE940YX S\W5<C
MFN9T/X0ZYX/M/"\^AZQI_P#;^E64^G2/?6SO:7D$LOFX(5@R,K8(.3GD$>D^
MK?"S6[^X\-W5WKEEX@?3[>>"[CUVT>2%I9) _GI&C !D **K9&SC.<D@KOJ=
MWX1\56/C7PSIVN6#2K97:YA>9-LD3 E61QV(8$'Z59NMHGG5@<% 9H1_&/[Z
M>XK$^%G@R;X>>!=,\.O=17T]BLBM+'%Y:3JTC.,+_#C=C'M6[<AA)'M;$>[$
M4IZV[^A]C3**_P"[$& LBVJMRI_UELWJ/:G@2>?D!/M3#[W_ "SNE_QQ1\V]
M#YRM*W^JN<?),.ZO3?EV/\C>2O\ K;8??@/]Y#Z4 (/*4(=\D<:L?+D/WK9^
MZM[&G$,7E5H09",SVR])1_?3WIQ\PN!NCDD894_P72^A_P!H4S*"(-O9+<'"
MRG_66S>A_P!F@!5(*0L)B$SBWN2.4/\ <?VI%V;)E$3>4#F>VYW1G^^GM3L.
M7*[%:<KN:+_EG<KZC_:I-V C>>2,XBN\<J?[C^W:@ 4GS@5D$ERR_+(WW+E/
M[I[9 II\KR1D.+56X(^_:O[_ .S_ (4XC </'\J8,MNG6(_WT]CUXI1N$BXE
M43,/W<^/DN%_NM[T $@8.XD4-*R_.B?=ND]1_M4F1LC(E(C!Q!<G[T3?W']J
M-P",0##$K?.A^_:M_>'^S2D.792B-.5RT?\ RSN4]1_M4 -"X>51;X<\SVG9
M_5T_^M2JP,D1CE)E(Q!<,/E<?\\W]^M-#)Y2N)6,&<)/_P M+9O[K>HIY#Y=
M6C1SC=+;+TD'_/1/>@!A$?ER PLUNK?O;<??@;^\OMWIY)+J2X>9EPDH^[<)
MW5O]JFY_U;>>0&_U-UZ_[$E+C&\>7MV',MO_ ,\S_P ]$]N] 'F7[1GA"/Q/
M\/%U6SB8W>BL9"F/G$1X=3].#^%?)^WT4D5^@,4<=PQM[IEECN(S'YF/DN$(
MQ@^]?%'Q'\%R^ ?&6H:.X;R$?S+9S_'">5/X=/J*^,SW#VFL3'9Z,_*^+L!R
M3CC8K1Z/UZ/[CE=O^R:-O^R:E">YI=GN:^3N?G5R';_LFC;_ +)J;9[FC9[F
MBX7(=O\ LFC;_LFIMGN:-GN:+A<AV_[)HV_[)J;9[FC9[FBX7(=O^R:-O^R:
MFV>YI4@DED2.)6ED=@J1KR68\ #W)HN"UT2)M$T*\\1ZM;:9IUNUQ>W+A(XU
M]?4^@'4GTKW+Q-=V/P=\*'P9H$RRZ[=*&U?4H_O+D?<![<< =A[FIM)TJW^
M/A/[5,L=QXZU:/"(<'[%'_\ 6_4\=!7E4S2W4\L\\C2S2L7DD8Y+,3DDFO4J
MOZA3=-?Q);_W4_U?X']/>'?!GL8QS3'QU?PI_P!?UMW*8A &!BC8M6?)%'DB
MOGW$_HGF*WEBCRQ5GROK1Y7UI<K#F96\M:/+%6?*^M'E?6CE8<S*VQ:/+%6?
M)J)I8$N%MS<0BY8;E@,BB1AZA<Y(]\4U!O83G;=D?EK1Y8J1I(%N4MS/$+AU
MW+"9%#L!W"YR13\)YIBWH95&XQA@6 [$CKBGR,7M%W_JUR#8M'EBK 16S@@X
M.#@YP?2E\JERE<WF5O+%'EK5GROK1Y7UI<K#F96\L4>6M6?*^M'E?6CE8<S*
MWEBCRQ5GROK1Y7UHY6',RMY8H\M:L^5]:/*^M'*PYF5O+6CRU]JL^5]:/*^M
M'*PYF5O+6MWPOXTUOP7<"72-0EME)^: G=$_U0\5E^5]:/)%:TY3I24X.S1E
M5ITZ\'"K%23Z,]/?QIX(^) $?C/1QI&IMP-8TT$ ^[ <X^H:N?\ %'P!U6SL
MSJ?AF\A\5Z0PW![0CSE'NN<-^'/M7(>37H/P-TS5+[QU;K87MQ96D/[^]:)\
M*T8_A(Z'<>/SK]$R/BW,L-4AAY>^F[:_U_D?D/$O 648NC/%0_=R2OI_7^9Z
M]\%_"#^!?A]9PS*;;5]3?[5,)5Z,?NQMZ84 ?7-=>1'Y3@PLT"M^]MQ]^!O[
MR^U3W,C33R?)YB@?-;$YWIVD0^M0Y_U;^>0&_P!3=]_]R2OJ:U65>I*K/=NY
M\7AJ$,-1A1I[15AV2SH2X:9EPDP^[<)W5O\ :Q308Q"N-Z6RGY6(_>6K^A]J
M7&-X\K;L.9K?_GF?^>D?MWI0'$B_.CSL/W<N/W=ROHWO6)T@ XF?$:FY(_>1
M_P#+.Y7U7WQC\Z8IC'E,LSJ 2()VZPGNC^WUI24\ICAS;J</%_RTM3ZCVS3R
M)&D*GRY)6&2@^Y=+_>'HPH C?:1*LD3*,@SVZ=CVD3^=/!??&5=3,1B&8_<N
M%_NM[T@(V(T<VR+.(IVY>,_\\V]0>E!&/,!AX7F>U7M_MQ_SH :OE>2X$;K;
M*?WD)SYENW]X>U/!/G'!$ERR_-N_U=TOMVR!BDR08SYX=CQ#=@</_L/0V C;
ME(B0_O(E^];-_>7V/6@!I\KRD.YQ;J<13?QVS>C>U/D!#RK+'ND*YF@3I..S
MI[T#>)0 R?:&&58_ZNZ7MGWI RA,JQB@4XW-]^U;T_W3_6@!<DB)A-[6]U_[
M(], C$+KY;"W!S+ ?OV[?WE]N]/(?>ZF-3-C,L ^Y.O]Y/0TG4QGSMQ;B&[/
M1O\ 8D'Z4 *-XF4Y'VIA\DN/W=ROH?>I;5X8D<^8T<*-_JV^];MW_#I4&1B0
M>6=J\S68ZQ_[:4X!RR;94=F'[N1A\MPO]Q_<4 :)E'F%3M,A&6C[2KZCWIGV
MB'RU<3 1@X67/,;?W36=E-A/SI"K8.?]9:M_\34GS^9CY'N&&0/^6=TO]&H
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MV^']X/._Y=[O^&4?W6]_K2*08XI%GW ';!>$<C_8>E"C?+'Y>>,SV?I_MQT
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M1*1B&XQ\DR_W7]Z#M5)1DP0J<RI_';O_ 'E_V30 G[L0*-["VW?NI3]ZV?\
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MSD??MI/4?[/^-(HC"3*L3^4#F>U/WHS_ 'T]J>I<S)MF62Y9?D9ON7$?H?\
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M=C_P7*^A]&H 3$OG_,L8NRO0?ZNY3T^M,!011G#16V[$,Q^_ _=6]L\4 1F
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M_P"Q1M_V*+!=D>RC94FW_8HV_P"Q18+LCV4;*DV_[%&W_8HL%V1[*-E2;?\
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MFH4!B82,H!VQ7+?P'_GFX]*-IQ,AM]W.9K0'IZ.E  -NSB,K%&WSPG[UL_\
M>'^S3R)-[(0C3N,N@_U=TOJ/]JD)R86\S?D;8K@_\M!_SSD]^U-P@MV78Z0H
MV7CS^\MF]5]10 FY=B/YC"!3B.4#]Y;'T;VIY1_WB-$C$_-- O28?\]$]_\
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MZ'WJ(>5Y*X9S99]?GM7[?A3F\O[.V5=;8-\\8^_;/ZK[4\^;YX!""Z*\,/\
M5W2>A]Z !O-WR!@LLH7][ .DZ?WQ[_X4WY2(<SE8CS;W0/,9[HW\J:#&(T(\
MR. -\DQ/SV[_ -T_[/\ C3B'\R4")6EQ^^MS]R8?WU]_I0 OS RYC"N/^/F
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MWSQ?QVS>H]LT?(89 T;+"#^^MP?F@;^^GM4G[SS5RRBY*_NY_P""X7^ZWO0
M8F+MDK)/MYC_ (;F/^]]1TIF8_+B_>,EJ3^YG/WX&_NM[=:0^4(\['2 -RW\
M=M)Z?[O?TJ0^89I!L1KG;^\B_@N%_O#WH 0[]\V8AYV/W\/\,R_WU]Z3#;H@
M)@S8_P!&N\\-_L-2?((HB'<0;OW4I^_ _P#=;V[4H&?-!@P1S/: _P#CZ?\
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MYAM7[61\\?\ RSN$]1[_ .%-!0)$5G:.,-B"4CYH6[H_M1\GV<#YOL8;*O\
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M1B%EF..EO=$=/^F;_P J3 Q*!$3@YN+3^Z?[\?\ .G'.Z;?"-Y'^DVHZ./\
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MPDQ^_;O_ '3_ +/^-/ ??*!"C2D?OK;^&4?WU]Z** $XV18D9D'$$[?>0_\
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M%% #@'\TX1?/*Y*X^2Z3U_WO\:9E3&ARQM=W[N;_ ):6S>A]J** '.&\R0/
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+8?\ /-_>BB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>22
<FILENAME>naov-20241231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWamCGbP9z5Z8+ekhvWB+bVnavywqwOA/0iXPkWc2QSgK -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:NAOV="http://nanovibronix.com/20241231" elementFormDefault="qualified" targetNamespace="http://nanovibronix.com/20241231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://nanovibronix.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss" id="StatementsOfOperationsAndComprehensiveLoss">
          <link:definition>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/StatementOfStockholdersEquity" id="StatementOfStockholdersEquity">
          <link:definition>00000005 - Statement - Consolidated Statement of Stockholders' Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/DescriptionOfBusiness" id="DescriptionOfBusiness">
          <link:definition>999014 - Disclosure - DESCRIPTION OF BUSINESS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/LiquidityAndPlanOfOperations" id="LiquidityAndPlanOfOperations">
          <link:definition>999015 - Disclosure - LIQUIDITY AND PLAN OF OPERATIONS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>999016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/PrepaidExpensesAndOtherReceivables" id="PrepaidExpensesAndOtherReceivables">
          <link:definition>999017 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/Inventory" id="Inventory">
          <link:definition>999018 - Disclosure - INVENTORY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/StockholdersEquity" id="StockholdersEquity">
          <link:definition>999019 - Disclosure - STOCKHOLDERS&#8217; EQUITY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/Leases" id="Leases">
          <link:definition>999020 - Disclosure - LEASES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/LossPerShareApplicableToCommonShareholder" id="LossPerShareApplicableToCommonShareholder">
          <link:definition>999021 - Disclosure - LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerData" id="GeographicInformationAndMajorCustomerData">
          <link:definition>999022 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/OtherAssets" id="OtherAssets">
          <link:definition>999023 - Disclosure - OTHER ASSETS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>999024 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/RelatedPartyTransaction" id="RelatedPartyTransaction">
          <link:definition>999025 - Disclosure - RELATED PARTY TRANSACTION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>999026 - Disclosure - INCOME TAXES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999027 - Disclosure - SUBSEQUENT EVENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>999028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>999029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/PrepaidExpensesAndOtherReceivablesTables" id="PrepaidExpensesAndOtherReceivablesTables">
          <link:definition>999030 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/InventoryTables" id="InventoryTables">
          <link:definition>999031 - Disclosure - INVENTORY (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
          <link:definition>999032 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/LeasesTables" id="LeasesTables">
          <link:definition>999033 - Disclosure - LEASES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/LossPerShareApplicableToCommonShareholderTables" id="LossPerShareApplicableToCommonShareholderTables">
          <link:definition>999034 - Disclosure - LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataTables" id="GeographicInformationAndMajorCustomerDataTables">
          <link:definition>999035 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/OtherAssetsTables" id="OtherAssetsTables">
          <link:definition>999036 - Disclosure - OTHER ASSETS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>999037 - Disclosure - INCOME TAXES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/LiquidityAndPlanOfOperationsDetailsNarrative" id="LiquidityAndPlanOfOperationsDetailsNarrative">
          <link:definition>999038 - Disclosure - LIQUIDITY AND PLAN OF OPERATIONS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsDetails" id="ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsDetails">
          <link:definition>999039 - Disclosure - SCHEDULE OF DEPRECIATION CALCULATED OVER ESTIMATED USEFUL LIVES OF ASSETS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/ScheduleOfPrepaidExpensesAndOtherReceivablesDetails" id="ScheduleOfPrepaidExpensesAndOtherReceivablesDetails">
          <link:definition>999041 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER RECEIVABLES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/ScheduleOfInventoryDetails" id="ScheduleOfInventoryDetails">
          <link:definition>999042 - Disclosure - SCHEDULE OF INVENTORY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails" id="ScheduleOfOptionsActivityDetails">
          <link:definition>999043 - Disclosure - SCHEDULE OF OPTIONS ACTIVITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForOptionsGrantedDetails" id="ScheduleOfFairValueAssumptionsForOptionsGrantedDetails">
          <link:definition>999044 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR OPTIONS GRANTED (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails" id="ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails">
          <link:definition>999045 - Disclosure - SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED SERVICES FROM EMPLOYEES AND NON-EMPLOYEES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForWarrantsDetails" id="ScheduleOfFairValueAssumptionsForWarrantsDetails">
          <link:definition>999046 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR WARRANTS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
          <link:definition>999047 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails" id="ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails">
          <link:definition>999048 - Disclosure - SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
          <link:definition>999049 - Disclosure - LEASES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails" id="SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails">
          <link:definition>999050 - Disclosure - SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails" id="SummaryOfRevenueWithinGeographicAreasDetails">
          <link:definition>999051 - Disclosure - SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative" id="GeographicInformationAndMajorCustomerDataDetailsNarrative">
          <link:definition>999052 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails" id="ScheduleOfWarrantsAssumptionsDetails">
          <link:definition>999053 - Disclosure - SCHEDULE OF WARRANTS ASSUMPTIONS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails" id="ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails">
          <link:definition>999054 - Disclosure - SCHEDULE OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" id="ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails">
          <link:definition>999055 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/OtherAssetsDetailsNarrative" id="OtherAssetsDetailsNarrative">
          <link:definition>999056 - Disclosure - OTHER ASSETS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>999057 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/RelatedPartyTransactionDetailsNarrative" id="RelatedPartyTransactionDetailsNarrative">
          <link:definition>999058 - Disclosure - RELATED PARTY TRANSACTION (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails" id="ScheduleOfProvisionForIncomeTaxesExpensesDetails">
          <link:definition>999059 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAXES EXPENSES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails" id="ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails">
          <link:definition>999060 - Disclosure - SCHEDULE OF RECONCILIATION OF STATUTORY U.S. FEDERAL RATE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/ScheduleOfIncomeBeforeTaxesOnDomesticAndForeignDetails" id="ScheduleOfIncomeBeforeTaxesOnDomesticAndForeignDetails">
          <link:definition>999061 - Disclosure - SCHEDULE OF INCOME BEFORE TAXES ON DOMESTIC AND FOREIGN (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/ScheduleOfDeferredTaxAssetsDetails" id="ScheduleOfDeferredTaxAssetsDetails">
          <link:definition>999062 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>999063 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>999064 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="naov-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="naov-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="naov-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="naov-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/cyd/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" />
    <element id="NAOV_SaleOfEquitySecuritiesMember" name="SaleOfEquitySecuritiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_PurchaseAgreementMember" name="PurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_PreFundedWarrantsMember" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_A1WarrantsMember" name="A1WarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_A2WarrantsMember" name="A2WarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_HCWainwrightAndCoLLCMember" name="HCWainwrightAndCoLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_PlacementAgentWarrantsMember" name="PlacementAgentWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_TwoThousandFourteenLongTermIncentivePlanMember" name="TwoThousandFourteenLongTermIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_TwoThousandAndTwentyFourLongTermIncentivePlanMember" name="TwoThousandAndTwentyFourLongTermIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_EmployeeOptionsMember" name="EmployeeOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_PreWarrantMember" name="PreWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_PrivateInvestorsMember" name="PrivateInvestorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_PostWarrantMember" name="PostWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_StockOptionsEmployeeAndNonEmployeeMember" name="StockOptionsEmployeeAndNonEmployeeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_OtherCountryMember" name="OtherCountryMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_CustomerMember" name="CustomerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_LicensingAgreementMember" name="LicensingAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_SanuwaveHealthIncMember" name="SanuwaveHealthIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_PriceAtValuationMember" name="PriceAtValuationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_DerivativeAssetMember" name="DerivativeAssetMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_ArbitratorMember" name="ArbitratorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_PiersonFerdinandMember" name="PiersonFerdinandMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_SecuritiesExchangeAgreementMember" name="SecuritiesExchangeAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_MergerAgreementMember" name="MergerAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_SeriesXPreferredStockMember" name="SeriesXPreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_ENvueMedicalHoldingsCorpMember" name="ENvueMedicalHoldingsCorpMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_SeveranceAssetsNoncurent" name="SeveranceAssetsNoncurent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_FinancialIncomeExpensesNet" name="FinancialIncomeExpensesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_StockIssuedDuringPeriodValuePrefundedWarrantsExercised" name="StockIssuedDuringPeriodValuePrefundedWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_StockIssuedDuringPeriodSharesPrefundedWarrantsExercised" name="StockIssuedDuringPeriodSharesPrefundedWarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_StockIssuedDuringPeriodValuesReverseStockSplits" name="StockIssuedDuringPeriodValuesReverseStockSplits" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_NoncashInterestExpense" name="NoncashInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_IncreaseDecreaseInAccruedSeverancePayNet" name="IncreaseDecreaseInAccruedSeverancePayNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_NoInsiderTradingFlag" name="NoInsiderTradingFlag" nillable="true" xbrli:periodType="duration" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_DisclosureLiquidityAndPlanOfOperationsAbstract" name="DisclosureLiquidityAndPlanOfOperationsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_GoingConcernAndLiquidityTextBlock" name="GoingConcernAndLiquidityTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_SequencingPolicyTextBlock" name="SequencingPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_SeverancePayPolicyTextBlock" name="SeverancePayPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock" name="ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock" name="ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_ScheduleOfWarrantsAssumptionsTableTextBlock" name="ScheduleOfWarrantsAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_ChangeInCurrentExpectedCreditLosses" name="ChangeInCurrentExpectedCreditLosses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_AccruedSeverancePayLiability" name="AccruedSeverancePayLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_PrefundedWarrantAndAccompanyingWarrantPricePerShares" name="PrefundedWarrantAndAccompanyingWarrantPricePerShares" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_IncreaseDecreaseInTerminationValueByOffset" name="IncreaseDecreaseInTerminationValueByOffset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_ValuationAllowanceOfIncomeTaxExpenseBenefit" name="ValuationAllowanceOfIncomeTaxExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_EffectiveIncomeTaxRateReconciliationPermanentItems" name="EffectiveIncomeTaxRateReconciliationPermanentItems" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_EffectiveIncomeTaxRateReconciliationForfeitedOptions" name="EffectiveIncomeTaxRateReconciliationForfeitedOptions" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_DeferredTaxAssetsOfCapitalLossCarryforward" name="DeferredTaxAssetsOfCapitalLossCarryforward" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_DeferredTaxAssetsTaxDeferredExpenseAccruals" name="DeferredTaxAssetsTaxDeferredExpenseAccruals" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_FederalNetOperatingLossCarriedForward" name="FederalNetOperatingLossCarriedForward" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_FederalNetOperatingLossOffsetAgainstTaxableIncome" name="FederalNetOperatingLossOffsetAgainstTaxableIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_OperatingLossCarryforwardsExpirationTerm" name="OperatingLossCarryforwardsExpirationTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_FranchiseFees" name="FranchiseFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_PercentageForNumberOfOutstandingCommonStock" name="PercentageForNumberOfOutstandingCommonStock" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_PercentageForExchangeCapitalForConsideration" name="PercentageForExchangeCapitalForConsideration" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>23
<FILENAME>naov-20241231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://nanovibronix.com/role/Cover" xlink:href="naov-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/BalanceSheets" xlink:href="naov-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/BalanceSheetsParenthetical" xlink:href="naov-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="naov-20241231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/StatementOfStockholdersEquity" xlink:href="naov-20241231.xsd#StatementOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/StatementsOfCashFlows" xlink:href="naov-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/DescriptionOfBusiness" xlink:href="naov-20241231.xsd#DescriptionOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/LiquidityAndPlanOfOperations" xlink:href="naov-20241231.xsd#LiquidityAndPlanOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="naov-20241231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/PrepaidExpensesAndOtherReceivables" xlink:href="naov-20241231.xsd#PrepaidExpensesAndOtherReceivables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/Inventory" xlink:href="naov-20241231.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/StockholdersEquity" xlink:href="naov-20241231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/Leases" xlink:href="naov-20241231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/LossPerShareApplicableToCommonShareholder" xlink:href="naov-20241231.xsd#LossPerShareApplicableToCommonShareholder" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerData" xlink:href="naov-20241231.xsd#GeographicInformationAndMajorCustomerData" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/OtherAssets" xlink:href="naov-20241231.xsd#OtherAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/CommitmentsAndContingencies" xlink:href="naov-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/RelatedPartyTransaction" xlink:href="naov-20241231.xsd#RelatedPartyTransaction" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/IncomeTaxes" xlink:href="naov-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SubsequentEvents" xlink:href="naov-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="naov-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="naov-20241231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/PrepaidExpensesAndOtherReceivablesTables" xlink:href="naov-20241231.xsd#PrepaidExpensesAndOtherReceivablesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/InventoryTables" xlink:href="naov-20241231.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/StockholdersEquityTables" xlink:href="naov-20241231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/LeasesTables" xlink:href="naov-20241231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/LossPerShareApplicableToCommonShareholderTables" xlink:href="naov-20241231.xsd#LossPerShareApplicableToCommonShareholderTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataTables" xlink:href="naov-20241231.xsd#GeographicInformationAndMajorCustomerDataTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/OtherAssetsTables" xlink:href="naov-20241231.xsd#OtherAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/IncomeTaxesTables" xlink:href="naov-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/LiquidityAndPlanOfOperationsDetailsNarrative" xlink:href="naov-20241231.xsd#LiquidityAndPlanOfOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsDetails" xlink:href="naov-20241231.xsd#ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="naov-20241231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfPrepaidExpensesAndOtherReceivablesDetails" xlink:href="naov-20241231.xsd#ScheduleOfPrepaidExpensesAndOtherReceivablesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfInventoryDetails" xlink:href="naov-20241231.xsd#ScheduleOfInventoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails" xlink:href="naov-20241231.xsd#ScheduleOfOptionsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForOptionsGrantedDetails" xlink:href="naov-20241231.xsd#ScheduleOfFairValueAssumptionsForOptionsGrantedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails" xlink:href="naov-20241231.xsd#ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForWarrantsDetails" xlink:href="naov-20241231.xsd#ScheduleOfFairValueAssumptionsForWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" xlink:href="naov-20241231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails" xlink:href="naov-20241231.xsd#ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/LeasesDetailsNarrative" xlink:href="naov-20241231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails" xlink:href="naov-20241231.xsd#SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails" xlink:href="naov-20241231.xsd#SummaryOfRevenueWithinGeographicAreasDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative" xlink:href="naov-20241231.xsd#GeographicInformationAndMajorCustomerDataDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails" xlink:href="naov-20241231.xsd#ScheduleOfWarrantsAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails" xlink:href="naov-20241231.xsd#ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:href="naov-20241231.xsd#ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/OtherAssetsDetailsNarrative" xlink:href="naov-20241231.xsd#OtherAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="naov-20241231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/RelatedPartyTransactionDetailsNarrative" xlink:href="naov-20241231.xsd#RelatedPartyTransactionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails" xlink:href="naov-20241231.xsd#ScheduleOfProvisionForIncomeTaxesExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails" xlink:href="naov-20241231.xsd#ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfIncomeBeforeTaxesOnDomesticAndForeignDetails" xlink:href="naov-20241231.xsd#ScheduleOfIncomeBeforeTaxesOnDomesticAndForeignDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:href="naov-20241231.xsd#ScheduleOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/IncomeTaxesDetailsNarrative" xlink:href="naov-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SubsequentEventsDetailsNarrative" xlink:href="naov-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_SeveranceAssetsNoncurent" xlink:label="loc_NAOVSeveranceAssetsNoncurent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_NAOVSeveranceAssetsNoncurent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapOtherAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="loc_us-gaapDeferredIncomeCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDeferredIncomeCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOtherAccruedLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="loc_us-gaapDeferredIncomeNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDeferredIncomeNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingAndMarketingExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_FinancialIncomeExpensesNet" xlink:label="loc_NAOVFinancialIncomeExpensesNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_NAOVFinancialIncomeExpensesNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/StatementOfStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statement of Stockholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_NoncashInterestExpense" xlink:label="loc_NAOVNoncashInterestExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_NAOVNoncashInterestExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaapEquitySecuritiesFvNiGainLoss" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapEquitySecuritiesFvNiGainLoss" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaapGainLossOnSaleOfInvestments" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnSaleOfInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_IncreaseDecreaseInAccruedSeverancePayNet" xlink:label="loc_NAOVIncreaseDecreaseInAccruedSeverancePayNet" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_NAOVIncreaseDecreaseInAccruedSeverancePayNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/DescriptionOfBusiness" xlink:title="999014 - Disclosure - DESCRIPTION OF BUSINESS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/LiquidityAndPlanOfOperations" xlink:title="999015 - Disclosure - LIQUIDITY AND PLAN OF OPERATIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/PrepaidExpensesAndOtherReceivables" xlink:title="999017 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/Inventory" xlink:title="999018 - Disclosure - INVENTORY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/StockholdersEquity" xlink:title="999019 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/Leases" xlink:title="999020 - Disclosure - LEASES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/LossPerShareApplicableToCommonShareholder" xlink:title="999021 - Disclosure - LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerData" xlink:title="999022 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/OtherAssets" xlink:title="999023 - Disclosure - OTHER ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/CommitmentsAndContingencies" xlink:title="999024 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/RelatedPartyTransaction" xlink:title="999025 - Disclosure - RELATED PARTY TRANSACTION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/IncomeTaxes" xlink:title="999026 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SubsequentEvents" xlink:title="999027 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/PrepaidExpensesAndOtherReceivablesTables" xlink:title="999030 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/InventoryTables" xlink:title="999031 - Disclosure - INVENTORY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/StockholdersEquityTables" xlink:title="999032 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/LeasesTables" xlink:title="999033 - Disclosure - LEASES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/LossPerShareApplicableToCommonShareholderTables" xlink:title="999034 - Disclosure - LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataTables" xlink:title="999035 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/OtherAssetsTables" xlink:title="999036 - Disclosure - OTHER ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/IncomeTaxesTables" xlink:title="999037 - Disclosure - INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/LiquidityAndPlanOfOperationsDetailsNarrative" xlink:title="999038 - Disclosure - LIQUIDITY AND PLAN OF OPERATIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsDetails" xlink:title="999039 - Disclosure - SCHEDULE OF DEPRECIATION CALCULATED OVER ESTIMATED USEFUL LIVES OF ASSETS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfPrepaidExpensesAndOtherReceivablesDetails" xlink:title="999041 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER RECEIVABLES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfInventoryDetails" xlink:title="999042 - Disclosure - SCHEDULE OF INVENTORY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaapInventoryRawMaterials" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryRawMaterials" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails" xlink:title="999043 - Disclosure - SCHEDULE OF OPTIONS ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForOptionsGrantedDetails" xlink:title="999044 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR OPTIONS GRANTED (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails" xlink:title="999045 - Disclosure - SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED SERVICES FROM EMPLOYEES AND NON-EMPLOYEES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForWarrantsDetails" xlink:title="999046 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR WARRANTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" xlink:title="999047 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails" xlink:title="999048 - Disclosure - SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/LeasesDetailsNarrative" xlink:title="999049 - Disclosure - LEASES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails" xlink:title="999050 - Disclosure - SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails" xlink:title="999051 - Disclosure - SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative" xlink:title="999052 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails" xlink:title="999053 - Disclosure - SCHEDULE OF WARRANTS ASSUMPTIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails" xlink:title="999054 - Disclosure - SCHEDULE OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:title="999055 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/OtherAssetsDetailsNarrative" xlink:title="999056 - Disclosure - OTHER ASSETS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999057 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/RelatedPartyTransactionDetailsNarrative" xlink:title="999058 - Disclosure - RELATED PARTY TRANSACTION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails" xlink:title="999059 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAXES EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentForeignTaxExpenseBenefit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentForeignTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherTaxExpenseBenefit" xlink:label="loc_us-gaapOtherTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_ValuationAllowanceOfIncomeTaxExpenseBenefit" xlink:label="loc_NAOVValuationAllowanceOfIncomeTaxExpenseBenefit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherTaxExpenseBenefit" xlink:to="loc_NAOVValuationAllowanceOfIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails" xlink:title="999060 - Disclosure - SCHEDULE OF RECONCILIATION OF STATUTORY U.S. FEDERAL RATE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="loc_NAOVEffectiveIncomeTaxRateReconciliationPermanentItems" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_NAOVEffectiveIncomeTaxRateReconciliationPermanentItems" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_EffectiveIncomeTaxRateReconciliationForfeitedOptions" xlink:label="loc_NAOVEffectiveIncomeTaxRateReconciliationForfeitedOptions" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_NAOVEffectiveIncomeTaxRateReconciliationForfeitedOptions" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfIncomeBeforeTaxesOnDomesticAndForeignDetails" xlink:title="999061 - Disclosure - SCHEDULE OF INCOME BEFORE TAXES ON DOMESTIC AND FOREIGN (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:title="999062 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_DeferredTaxAssetsOfCapitalLossCarryforward" xlink:label="loc_NAOVDeferredTaxAssetsOfCapitalLossCarryforward" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_NAOVDeferredTaxAssetsOfCapitalLossCarryforward" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_DeferredTaxAssetsTaxDeferredExpenseAccruals" xlink:label="loc_NAOVDeferredTaxAssetsTaxDeferredExpenseAccruals" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_NAOVDeferredTaxAssetsTaxDeferredExpenseAccruals" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/IncomeTaxesDetailsNarrative" xlink:title="999063 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SubsequentEventsDetailsNarrative" xlink:title="999064 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>24
<FILENAME>naov-20241231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://nanovibronix.com/role/Cover" xlink:href="naov-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/BalanceSheets" xlink:href="naov-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/BalanceSheetsParenthetical" xlink:href="naov-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="naov-20241231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/StatementOfStockholdersEquity" xlink:href="naov-20241231.xsd#StatementOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/StatementsOfCashFlows" xlink:href="naov-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/DescriptionOfBusiness" xlink:href="naov-20241231.xsd#DescriptionOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/LiquidityAndPlanOfOperations" xlink:href="naov-20241231.xsd#LiquidityAndPlanOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="naov-20241231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/PrepaidExpensesAndOtherReceivables" xlink:href="naov-20241231.xsd#PrepaidExpensesAndOtherReceivables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/Inventory" xlink:href="naov-20241231.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/StockholdersEquity" xlink:href="naov-20241231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/Leases" xlink:href="naov-20241231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/LossPerShareApplicableToCommonShareholder" xlink:href="naov-20241231.xsd#LossPerShareApplicableToCommonShareholder" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerData" xlink:href="naov-20241231.xsd#GeographicInformationAndMajorCustomerData" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/OtherAssets" xlink:href="naov-20241231.xsd#OtherAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/CommitmentsAndContingencies" xlink:href="naov-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/RelatedPartyTransaction" xlink:href="naov-20241231.xsd#RelatedPartyTransaction" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/IncomeTaxes" xlink:href="naov-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SubsequentEvents" xlink:href="naov-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="naov-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="naov-20241231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/PrepaidExpensesAndOtherReceivablesTables" xlink:href="naov-20241231.xsd#PrepaidExpensesAndOtherReceivablesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/InventoryTables" xlink:href="naov-20241231.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/StockholdersEquityTables" xlink:href="naov-20241231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/LeasesTables" xlink:href="naov-20241231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/LossPerShareApplicableToCommonShareholderTables" xlink:href="naov-20241231.xsd#LossPerShareApplicableToCommonShareholderTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataTables" xlink:href="naov-20241231.xsd#GeographicInformationAndMajorCustomerDataTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/OtherAssetsTables" xlink:href="naov-20241231.xsd#OtherAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/IncomeTaxesTables" xlink:href="naov-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/LiquidityAndPlanOfOperationsDetailsNarrative" xlink:href="naov-20241231.xsd#LiquidityAndPlanOfOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsDetails" xlink:href="naov-20241231.xsd#ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="naov-20241231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfPrepaidExpensesAndOtherReceivablesDetails" xlink:href="naov-20241231.xsd#ScheduleOfPrepaidExpensesAndOtherReceivablesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfInventoryDetails" xlink:href="naov-20241231.xsd#ScheduleOfInventoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails" xlink:href="naov-20241231.xsd#ScheduleOfOptionsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForOptionsGrantedDetails" xlink:href="naov-20241231.xsd#ScheduleOfFairValueAssumptionsForOptionsGrantedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails" xlink:href="naov-20241231.xsd#ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForWarrantsDetails" xlink:href="naov-20241231.xsd#ScheduleOfFairValueAssumptionsForWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" xlink:href="naov-20241231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails" xlink:href="naov-20241231.xsd#ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/LeasesDetailsNarrative" xlink:href="naov-20241231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails" xlink:href="naov-20241231.xsd#SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails" xlink:href="naov-20241231.xsd#SummaryOfRevenueWithinGeographicAreasDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative" xlink:href="naov-20241231.xsd#GeographicInformationAndMajorCustomerDataDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails" xlink:href="naov-20241231.xsd#ScheduleOfWarrantsAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails" xlink:href="naov-20241231.xsd#ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:href="naov-20241231.xsd#ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/OtherAssetsDetailsNarrative" xlink:href="naov-20241231.xsd#OtherAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="naov-20241231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/RelatedPartyTransactionDetailsNarrative" xlink:href="naov-20241231.xsd#RelatedPartyTransactionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails" xlink:href="naov-20241231.xsd#ScheduleOfProvisionForIncomeTaxesExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails" xlink:href="naov-20241231.xsd#ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfIncomeBeforeTaxesOnDomesticAndForeignDetails" xlink:href="naov-20241231.xsd#ScheduleOfIncomeBeforeTaxesOnDomesticAndForeignDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:href="naov-20241231.xsd#ScheduleOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/IncomeTaxesDetailsNarrative" xlink:href="naov-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SubsequentEventsDetailsNarrative" xlink:href="naov-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosureWithAdditionalMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpTable" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsToCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListsByExecutiveCategory" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpExecutiveCategoriesOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ForgoneRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#OutstandingRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardsCloseToMnpiDisc" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangemenstByInd" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/Defaults" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#Defaults" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaapSeriesDPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesDPreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaapSeriesEPreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesEPreferredStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaapSeriesFPreferredStockMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesFPreferredStockMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_110" xlink:to="loc_us-gaapAssetsCurrentAbstract_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_110" xlink:to="loc_us-gaapCash_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_110" xlink:to="loc_us-gaapAccountsReceivableNetCurrent_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_110" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_110" xlink:to="loc_us-gaapInventoryNet_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_110" xlink:to="loc_us-gaapAssetsCurrent_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_110" xlink:to="loc_us-gaapAssetsNoncurrentAbstract_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsNoncurrentAbstract_110" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsNoncurrentAbstract_110" xlink:to="loc_us-gaapOtherAssetsNoncurrent_110" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_SeveranceAssetsNoncurent" xlink:label="loc_NAOVSeveranceAssetsNoncurent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsNoncurrentAbstract_110" xlink:to="loc_NAOVSeveranceAssetsNoncurent_110" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsNoncurrentAbstract_110" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_110" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsNoncurrentAbstract_110" xlink:to="loc_us-gaapAssetsNoncurrent_110" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_110" xlink:to="loc_us-gaapAssets_110" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_110" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_110" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_110" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_110" xlink:to="loc_us-gaapAccountsPayableCurrent_110" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapOtherAccountsPayableAndAccruedLiabilities_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_110" xlink:to="loc_us-gaapOtherAccountsPayableAndAccruedLiabilities_110" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="loc_us-gaapDeferredIncomeCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_110" xlink:to="loc_us-gaapDeferredIncomeCurrent_110" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_110" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_110" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_110" xlink:to="loc_us-gaapLiabilitiesCurrent_110" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_110" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract_110" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesNoncurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_110" xlink:to="loc_us-gaapOtherAccruedLiabilitiesNoncurrent_110" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="loc_us-gaapDeferredIncomeNoncurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_110" xlink:to="loc_us-gaapDeferredIncomeNoncurrent_110" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_110" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_110" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_110" xlink:to="loc_us-gaapLiabilities_110" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_110" xlink:to="loc_us-gaapCommitmentsAndContingencies_110" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_110" xlink:to="loc_us-gaapStockholdersEquityAbstract_110" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_110" xlink:to="loc_us-gaapPreferredStockValue_110" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_110" xlink:to="loc_us-gaapCommonStockValue_110" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_110" xlink:to="loc_us-gaapAdditionalPaidInCapital_110" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_110" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_110" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_110" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_110" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_110" xlink:to="loc_us-gaapStockholdersEquity_110" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_110" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_110" xlink:type="arc" order="34" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaapSeriesDPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesDPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaapSeriesEPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesEPreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaapSeriesFPreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesFPreferredStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_110" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/StatementOfStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statement of Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaapSeriesDPreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesDPreferredStockMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaapSeriesEPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesEPreferredStockMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaapSeriesFPreferredStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesFPreferredStockMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_StockIssuedDuringPeriodValuePrefundedWarrantsExercised" xlink:label="loc_NAOVStockIssuedDuringPeriodValuePrefundedWarrantsExercised_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NAOVStockIssuedDuringPeriodValuePrefundedWarrantsExercised_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_StockIssuedDuringPeriodSharesPrefundedWarrantsExercised" xlink:label="loc_NAOVStockIssuedDuringPeriodSharesPrefundedWarrantsExercised_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NAOVStockIssuedDuringPeriodSharesPrefundedWarrantsExercised_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_100" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_100" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_StockIssuedDuringPeriodValuesReverseStockSplits" xlink:label="loc_NAOVStockIssuedDuringPeriodValuesReverseStockSplits_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NAOVStockIssuedDuringPeriodValuesReverseStockSplits_100" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_100" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_100" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/DescriptionOfBusiness" xlink:title="999014 - Disclosure - DESCRIPTION OF BUSINESS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/LiquidityAndPlanOfOperations" xlink:title="999015 - Disclosure - LIQUIDITY AND PLAN OF OPERATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/PrepaidExpensesAndOtherReceivables" xlink:title="999017 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/Inventory" xlink:title="999018 - Disclosure - INVENTORY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/StockholdersEquity" xlink:title="999019 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/Leases" xlink:title="999020 - Disclosure - LEASES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/LossPerShareApplicableToCommonShareholder" xlink:title="999021 - Disclosure - LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerData" xlink:title="999022 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/OtherAssets" xlink:title="999023 - Disclosure - OTHER ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/CommitmentsAndContingencies" xlink:title="999024 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/RelatedPartyTransaction" xlink:title="999025 - Disclosure - RELATED PARTY TRANSACTION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/IncomeTaxes" xlink:title="999026 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SubsequentEvents" xlink:title="999027 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/PrepaidExpensesAndOtherReceivablesTables" xlink:title="999030 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/InventoryTables" xlink:title="999031 - Disclosure - INVENTORY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/StockholdersEquityTables" xlink:title="999032 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/LeasesTables" xlink:title="999033 - Disclosure - LEASES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/LossPerShareApplicableToCommonShareholderTables" xlink:title="999034 - Disclosure - LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataTables" xlink:title="999035 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/OtherAssetsTables" xlink:title="999036 - Disclosure - OTHER ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/IncomeTaxesTables" xlink:title="999037 - Disclosure - INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/LiquidityAndPlanOfOperationsDetailsNarrative" xlink:title="999038 - Disclosure - LIQUIDITY AND PLAN OF OPERATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="loc_us-gaapPropertyPlantAndEquipmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapPropertyPlantAndEquipmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollateralAxis" xlink:label="loc_us-gaapCollateralAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapCollateralAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollateralDomain" xlink:label="loc_us-gaapCollateralDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCollateralAxis" xlink:to="loc_us-gaapCollateralDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollateralDomain" xlink:label="loc_us-gaapCollateralDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollateralAxis" xlink:to="loc_us-gaapCollateralDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_SaleOfEquitySecuritiesMember" xlink:label="loc_NAOVSaleOfEquitySecuritiesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollateralDomain" xlink:to="loc_NAOVSaleOfEquitySecuritiesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_StockIssuedDuringPeriodValuePrefundedWarrantsExercised" xlink:label="loc_NAOVStockIssuedDuringPeriodValuePrefundedWarrantsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_NAOVStockIssuedDuringPeriodValuePrefundedWarrantsExercised_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCash_40" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsDetails" xlink:title="999039 - Disclosure - SCHEDULE OF DEPRECIATION CALCULATED OVER ESTIMATED USEFUL LIVES OF ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfPrepaidExpensesAndOtherReceivablesDetails" xlink:title="999041 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER RECEIVABLES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfInventoryDetails" xlink:title="999042 - Disclosure - SCHEDULE OF INVENTORY (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails" xlink:title="999043 - Disclosure - SCHEDULE OF OPTIONS ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_EmployeeOptionsMember" xlink:label="loc_NAOVEmployeeOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NAOVEmployeeOptionsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" xlink:label="loc_NAOVSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NAOVSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" xlink:label="loc_NAOVSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NAOVSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm" xlink:label="loc_NAOVSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NAOVSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" xlink:label="loc_NAOVSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NAOVSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="loc_NAOVSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NAOVSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_40" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForOptionsGrantedDetails" xlink:title="999044 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR OPTIONS GRANTED (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_70" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails" xlink:title="999045 - Disclosure - SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED SERVICES FROM EMPLOYEES AND NON-EMPLOYEES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="loc_us-gaapSellingAndMarketingExpenseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapSellingAndMarketingExpenseMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForWarrantsDetails" xlink:title="999046 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR WARRANTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_90" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" xlink:title="999047 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_PurchaseAgreementMember" xlink:label="loc_NAOVPurchaseAgreementMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NAOVPurchaseAgreementMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_PreFundedWarrantsMember" xlink:label="loc_NAOVPreFundedWarrantsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NAOVPreFundedWarrantsMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_A1WarrantsMember" xlink:label="loc_NAOVA1WarrantsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NAOVA1WarrantsMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_A2WarrantsMember" xlink:label="loc_NAOVA2WarrantsMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NAOVA2WarrantsMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_PlacementAgentWarrantsMember" xlink:label="loc_NAOVPlacementAgentWarrantsMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NAOVPlacementAgentWarrantsMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_EmployeeOptionsMember" xlink:label="loc_NAOVEmployeeOptionsMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NAOVEmployeeOptionsMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_PreWarrantMember" xlink:label="loc_NAOVPreWarrantMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NAOVPreWarrantMember_300" xlink:type="arc" order="301" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_PostWarrantMember" xlink:label="loc_NAOVPostWarrantMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NAOVPostWarrantMember_310" xlink:type="arc" order="311" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_HCWainwrightAndCoLLCMember" xlink:label="loc_NAOVHCWainwrightAndCoLLCMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_NAOVHCWainwrightAndCoLLCMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_TwoThousandFourteenLongTermIncentivePlanMember" xlink:label="loc_NAOVTwoThousandFourteenLongTermIncentivePlanMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_NAOVTwoThousandFourteenLongTermIncentivePlanMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_TwoThousandAndTwentyFourLongTermIncentivePlanMember" xlink:label="loc_NAOVTwoThousandAndTwentyFourLongTermIncentivePlanMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_NAOVTwoThousandAndTwentyFourLongTermIncentivePlanMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_190" xlink:type="arc" order="192" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_PrivateInvestorsMember" xlink:label="loc_NAOVPrivateInvestorsMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_NAOVPrivateInvestorsMember_300" xlink:type="arc" order="302" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_410" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_410" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_410" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_410" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_410" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_410" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_410" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_410" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharePrice_410" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_PrefundedWarrantAndAccompanyingWarrantPricePerShares" xlink:label="loc_NAOVPrefundedWarrantAndAccompanyingWarrantPricePerShares_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NAOVPrefundedWarrantAndAccompanyingWarrantPricePerShares_410" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_410" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_410" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_410" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_410" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_410" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_410" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_410" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_410" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_410" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod" xlink:label="loc_NAOVShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NAOVShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod_410" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_410" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_410" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_410" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_410" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_410" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_410" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_410" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_410" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_410" xlink:type="arc" order="28" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails" xlink:title="999048 - Disclosure - SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/LeasesDetailsNarrative" xlink:title="999049 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense_50" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails" xlink:title="999050 - Disclosure - SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_StockOptionsEmployeeAndNonEmployeeMember" xlink:label="loc_NAOVStockOptionsEmployeeAndNonEmployeeMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_NAOVStockOptionsEmployeeAndNonEmployeeMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails" xlink:title="999051 - Disclosure - SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="loc_countryUS_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember" xlink:label="loc_srtEuropeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_srtEuropeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_AU" xlink:label="loc_countryAU_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryAU_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IL" xlink:label="loc_countryIL_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryIL_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_NZ" xlink:label="loc_countryNZ_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryNZ_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_OtherCountryMember" xlink:label="loc_NAOVOtherCountryMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_NAOVOtherCountryMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_150" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative" xlink:title="999052 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaapEntityWideRevenueMajorCustomerLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaapScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEntityWideRevenueMajorCustomerLineItems" xlink:to="loc_us-gaapScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="loc_srtMajorCustomersAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_CustomerMember" xlink:label="loc_NAOVCustomerMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NAOVCustomerMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEntityWideRevenueMajorCustomerLineItems" xlink:to="loc_us-gaapRevenues_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEntityWideRevenueMajorCustomerLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_20" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails" xlink:title="999053 - Disclosure - SCHEDULE OF WARRANTS ASSUMPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_PriceAtValuationMember" xlink:label="loc_NAOVPriceAtValuationMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_NAOVPriceAtValuationMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaapMeasurementInputExercisePriceMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExercisePriceMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_SanuwaveHealthIncMember" xlink:label="loc_NAOVSanuwaveHealthIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_NAOVSanuwaveHealthIncMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_110" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails" xlink:title="999054 - Disclosure - SCHEDULE OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_DerivativeAssetMember" xlink:label="loc_NAOVDerivativeAssetMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_NAOVDerivativeAssetMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:label="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_60" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:title="999055 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsFairValueDisclosure" xlink:label="loc_us-gaapOtherAssetsFairValueDisclosure_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapOtherAssetsFairValueDisclosure_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/OtherAssetsDetailsNarrative" xlink:title="999056 - Disclosure - OTHER ASSETS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_LicensingAgreementMember" xlink:label="loc_NAOVLicensingAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NAOVLicensingAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_SanuwaveHealthIncMember" xlink:label="loc_NAOVSanuwaveHealthIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_NAOVSanuwaveHealthIncMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnContractTermination" xlink:label="loc_us-gaapGainLossOnContractTermination_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapGainLossOnContractTermination_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_IncreaseDecreaseInTerminationValueByOffset" xlink:label="loc_NAOVIncreaseDecreaseInTerminationValueByOffset_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_NAOVIncreaseDecreaseInTerminationValueByOffset_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:label="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_80" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999057 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_ArbitratorMember" xlink:label="loc_NAOVArbitratorMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_NAOVArbitratorMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaapLossContingencyDamagesSoughtValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLossContingencyDamagesSoughtValue_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="loc_us-gaapLossContingencyDamagesAwardedValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLossContingencyDamagesAwardedValue_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="loc_us-gaapLossContingencyDamagesPaidValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLossContingencyDamagesPaidValue_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/RelatedPartyTransactionDetailsNarrative" xlink:title="999058 - Disclosure - RELATED PARTY TRANSACTION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_PiersonFerdinandMember" xlink:label="loc_NAOVPiersonFerdinandMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_NAOVPiersonFerdinandMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForFees_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails" xlink:title="999059 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAXES EXPENSES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails" xlink:title="999060 - Disclosure - SCHEDULE OF RECONCILIATION OF STATUTORY U.S. FEDERAL RATE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfIncomeBeforeTaxesOnDomesticAndForeignDetails" xlink:title="999061 - Disclosure - SCHEDULE OF INCOME BEFORE TAXES ON DOMESTIC AND FOREIGN (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:title="999062 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/IncomeTaxesDetailsNarrative" xlink:title="999063 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IL" xlink:label="loc_countryIL_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryIL_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_FederalNetOperatingLossCarriedForward" xlink:label="loc_NAOVFederalNetOperatingLossCarriedForward_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_NAOVFederalNetOperatingLossCarriedForward_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_FederalNetOperatingLossOffsetAgainstTaxableIncome" xlink:label="loc_NAOVFederalNetOperatingLossOffsetAgainstTaxableIncome_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_NAOVFederalNetOperatingLossOffsetAgainstTaxableIncome_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_OperatingLossCarryforwardsExpirationTerm" xlink:label="loc_NAOVOperatingLossCarryforwardsExpirationTerm_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_NAOVOperatingLossCarryforwardsExpirationTerm_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_FranchiseFees" xlink:label="loc_NAOVFranchiseFees_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_NAOVFranchiseFees_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_90" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SubsequentEventsDetailsNarrative" xlink:title="999064 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_SecuritiesExchangeAgreementMember" xlink:label="loc_NAOVSecuritiesExchangeAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NAOVSecuritiesExchangeAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_MergerAgreementMember" xlink:label="loc_NAOVMergerAgreementMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NAOVMergerAgreementMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_PreFundedWarrantsMember" xlink:label="loc_NAOVPreFundedWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NAOVPreFundedWarrantsMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_A1WarrantsMember" xlink:label="loc_NAOVA1WarrantsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NAOVA1WarrantsMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_100" xlink:type="arc" order="104" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_170" xlink:type="arc" order="172" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_SeriesXPreferredStockMember" xlink:label="loc_NAOVSeriesXPreferredStockMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NAOVSeriesXPreferredStockMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_ENvueMedicalHoldingsCorpMember" xlink:label="loc_NAOVENvueMedicalHoldingsCorpMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_NAOVENvueMedicalHoldingsCorpMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_220" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_220" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="loc_us-gaapWarrantExercisePriceIncrease_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantExercisePriceIncrease_220" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_220" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_PercentageForNumberOfOutstandingCommonStock" xlink:label="loc_NAOVPercentageForNumberOfOutstandingCommonStock_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NAOVPercentageForNumberOfOutstandingCommonStock_220" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_220" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_PercentageForExchangeCapitalForConsideration" xlink:label="loc_NAOVPercentageForExchangeCapitalForConsideration_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NAOVPercentageForExchangeCapitalForConsideration_220" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="loc_us-gaapConvertiblePreferredStockTermsOfConversion_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockTermsOfConversion_220" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_220" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Investments" xlink:label="loc_us-gaapInvestments_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestments_220" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_220" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_220" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_220" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_220" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_TwoThousandFourteenLongTermIncentivePlanMember" xlink:label="loc_NAOVTwoThousandFourteenLongTermIncentivePlanMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_NAOVTwoThousandFourteenLongTermIncentivePlanMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_TwoThousandAndTwentyFourLongTermIncentivePlanMember" xlink:label="loc_NAOVTwoThousandAndTwentyFourLongTermIncentivePlanMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_NAOVTwoThousandAndTwentyFourLongTermIncentivePlanMember" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>25
<FILENAME>naov-20241231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesDPreferredStockMember" xlink:to="us-gaap_SeriesDPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xml:lang="en-US">Series D Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="us-gaap_SeriesEPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesEPreferredStockMember" xlink:to="us-gaap_SeriesEPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesEPreferredStockMember_lbl" xml:lang="en-US">Series E Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="us-gaap_SeriesFPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesFPreferredStockMember" xlink:to="us-gaap_SeriesFPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesFPreferredStockMember_lbl" xml:lang="en-US">Series F Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentMember" xlink:to="us-gaap_PropertyPlantAndEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl" xml:lang="en-US">Property, Plant and Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollateralAxis" xlink:label="us-gaap_CollateralAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollateralAxis" xlink:to="us-gaap_CollateralAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollateralAxis_lbl" xml:lang="en-US">Collateral Held [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_SaleOfEquitySecuritiesMember" xlink:label="NAOV_SaleOfEquitySecuritiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_SaleOfEquitySecuritiesMember" xlink:to="NAOV_SaleOfEquitySecuritiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_SaleOfEquitySecuritiesMember_lbl" xml:lang="en-US">Sale of Equity Securities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_PurchaseAgreementMember" xlink:label="NAOV_PurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_PurchaseAgreementMember" xlink:to="NAOV_PurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_PurchaseAgreementMember_lbl" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_PreFundedWarrantsMember" xlink:label="NAOV_PreFundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_PreFundedWarrantsMember" xlink:to="NAOV_PreFundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_PreFundedWarrantsMember_lbl" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_A1WarrantsMember" xlink:label="NAOV_A1WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_A1WarrantsMember" xlink:to="NAOV_A1WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_A1WarrantsMember_lbl" xml:lang="en-US">A-1 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_A2WarrantsMember" xlink:label="NAOV_A2WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_A2WarrantsMember" xlink:to="NAOV_A2WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_A2WarrantsMember_lbl" xml:lang="en-US">A-2 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_HCWainwrightAndCoLLCMember" xlink:label="NAOV_HCWainwrightAndCoLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_HCWainwrightAndCoLLCMember" xlink:to="NAOV_HCWainwrightAndCoLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_HCWainwrightAndCoLLCMember_lbl" xml:lang="en-US">H.C. Wainwright &amp; Co., LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_PlacementAgentWarrantsMember" xlink:label="NAOV_PlacementAgentWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_PlacementAgentWarrantsMember" xlink:to="NAOV_PlacementAgentWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_PlacementAgentWarrantsMember_lbl" xml:lang="en-US">Placement Agent Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_TwoThousandFourteenLongTermIncentivePlanMember" xlink:label="NAOV_TwoThousandFourteenLongTermIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_TwoThousandFourteenLongTermIncentivePlanMember" xlink:to="NAOV_TwoThousandFourteenLongTermIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_TwoThousandFourteenLongTermIncentivePlanMember_lbl" xml:lang="en-US">2014 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_TwoThousandAndTwentyFourLongTermIncentivePlanMember" xlink:label="NAOV_TwoThousandAndTwentyFourLongTermIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_TwoThousandAndTwentyFourLongTermIncentivePlanMember" xlink:to="NAOV_TwoThousandAndTwentyFourLongTermIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_TwoThousandAndTwentyFourLongTermIncentivePlanMember_lbl" xml:lang="en-US">Two Thousand And Twenty Four Long Term Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_EmployeeOptionsMember" xlink:label="NAOV_EmployeeOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_EmployeeOptionsMember" xlink:to="NAOV_EmployeeOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_EmployeeOptionsMember_lbl" xml:lang="en-US">Employee Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_PreWarrantMember" xlink:label="NAOV_PreWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_PreWarrantMember" xlink:to="NAOV_PreWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_PreWarrantMember_lbl" xml:lang="en-US">Pre Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_PrivateInvestorsMember" xlink:label="NAOV_PrivateInvestorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_PrivateInvestorsMember" xlink:to="NAOV_PrivateInvestorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_PrivateInvestorsMember_lbl" xml:lang="en-US">Private Investors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_PostWarrantMember" xlink:label="NAOV_PostWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_PostWarrantMember" xlink:to="NAOV_PostWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_PostWarrantMember_lbl" xml:lang="en-US">Post Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpenseMember" xlink:to="us-gaap_SellingAndMarketingExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl" xml:lang="en-US">Selling and Marketing Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_StockOptionsEmployeeAndNonEmployeeMember" xlink:label="NAOV_StockOptionsEmployeeAndNonEmployeeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_StockOptionsEmployeeAndNonEmployeeMember" xlink:to="NAOV_StockOptionsEmployeeAndNonEmployeeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_StockOptionsEmployeeAndNonEmployeeMember_lbl" xml:lang="en-US">Stock Options - Employee and Non-employee [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US">UNITED STATES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EuropeMember" xlink:to="srt_EuropeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EuropeMember_lbl" xml:lang="en-US">Europe [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_AU" xlink:label="country_AU" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_AU" xlink:to="country_AU_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_AU_lbl" xml:lang="en-US">AUSTRALIA</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IL" xlink:label="country_IL" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_IL" xlink:to="country_IL_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_IL_lbl" xml:lang="en-US">ISRAEL</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_NZ" xlink:label="country_NZ" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_NZ" xlink:to="country_NZ_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_NZ_lbl" xml:lang="en-US">NEW ZEALAND</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_OtherCountryMember" xlink:label="NAOV_OtherCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_OtherCountryMember" xlink:to="NAOV_OtherCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_OtherCountryMember_lbl" xml:lang="en-US">Other Country [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_CustomerMember" xlink:label="NAOV_CustomerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_CustomerMember" xlink:to="NAOV_CustomerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_CustomerMember_lbl" xml:lang="en-US">Customer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_LicensingAgreementMember" xlink:label="NAOV_LicensingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_LicensingAgreementMember" xlink:to="NAOV_LicensingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_LicensingAgreementMember_lbl" xml:lang="en-US">Licensing Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_SanuwaveHealthIncMember" xlink:label="NAOV_SanuwaveHealthIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_SanuwaveHealthIncMember" xlink:to="NAOV_SanuwaveHealthIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_SanuwaveHealthIncMember_lbl" xml:lang="en-US">Sanuwave Health, Inc. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_PriceAtValuationMember" xlink:label="NAOV_PriceAtValuationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_PriceAtValuationMember" xlink:to="NAOV_PriceAtValuationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_PriceAtValuationMember_lbl" xml:lang="en-US">Price at Valuation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExercisePriceMember" xlink:to="us-gaap_MeasurementInputExercisePriceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xml:lang="en-US">Measurement Input, Exercise Price [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_DerivativeAssetMember" xlink:label="NAOV_DerivativeAssetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_DerivativeAssetMember" xlink:to="NAOV_DerivativeAssetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_DerivativeAssetMember_lbl" xml:lang="en-US">Derivative Asset [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_ArbitratorMember" xlink:label="NAOV_ArbitratorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_ArbitratorMember" xlink:to="NAOV_ArbitratorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_ArbitratorMember_lbl" xml:lang="en-US">Arbitrator [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_PiersonFerdinandMember" xlink:label="NAOV_PiersonFerdinandMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_PiersonFerdinandMember" xlink:to="NAOV_PiersonFerdinandMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_PiersonFerdinandMember_lbl" xml:lang="en-US">Pierson Ferdinand [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_SecuritiesExchangeAgreementMember" xlink:label="NAOV_SecuritiesExchangeAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_SecuritiesExchangeAgreementMember" xlink:to="NAOV_SecuritiesExchangeAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_SecuritiesExchangeAgreementMember_lbl" xml:lang="en-US">Securities Exchange Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_MergerAgreementMember" xlink:label="NAOV_MergerAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_MergerAgreementMember" xlink:to="NAOV_MergerAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_MergerAgreementMember_lbl" xml:lang="en-US">Merger Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_SeriesXPreferredStockMember" xlink:label="NAOV_SeriesXPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_SeriesXPreferredStockMember" xlink:to="NAOV_SeriesXPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_SeriesXPreferredStockMember_lbl" xml:lang="en-US">Series X Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_ENvueMedicalHoldingsCorpMember" xlink:label="NAOV_ENvueMedicalHoldingsCorpMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_ENvueMedicalHoldingsCorpMember" xlink:to="NAOV_ENvueMedicalHoldingsCorpMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_ENvueMedicalHoldingsCorpMember_lbl" xml:lang="en-US">ENvue Medical Holdings Corp [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorOpinionTextBlock_lbl" xml:lang="en-US">Auditor Opinion [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Trade receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Noncurrent assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Fixed assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_SeveranceAssetsNoncurent" xlink:label="NAOV_SeveranceAssetsNoncurent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_SeveranceAssetsNoncurent" xlink:to="NAOV_SeveranceAssetsNoncurent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_SeveranceAssetsNoncurent_lbl" xml:lang="en-US">Severance pay fund</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total non-current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Trade payables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Other accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeCurrent" xlink:to="us-gaap_DeferredIncomeCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeCurrent_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities, current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Non-current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl" xml:lang="en-US">Accrued severance pay</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="us-gaap_DeferredIncomeNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeNoncurrent" xlink:to="us-gaap_DeferredIncomeNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeNoncurrent_lbl" xml:lang="en-US">Deferred revenue &#8211; long term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities, non-current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock of $0.001 par value - Authorized: 40,000,000 shares at December 31, 2024, and December 31, 2023, respectively; Issued and outstanding: 378,941 and 186,028 shares at December 31, 2024, and December 31, 2023, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US">Selling and marketing</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_FinancialIncomeExpensesNet" xlink:label="NAOV_FinancialIncomeExpensesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_FinancialIncomeExpensesNet" xlink:to="NAOV_FinancialIncomeExpensesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_FinancialIncomeExpensesNet_lbl" xml:lang="en-US">Financial expense, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic net loss available for holders of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted net loss available for holders of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common stock outstanding, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common stock outstanding, diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US">Comprehensive loss:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss available to common stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Change in foreign currency translation adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss available to common stockholders</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_lbl" xml:lang="en-US">Currency translation adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of pre-funded warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_StockIssuedDuringPeriodValuePrefundedWarrantsExercised" xlink:label="NAOV_StockIssuedDuringPeriodValuePrefundedWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_StockIssuedDuringPeriodValuePrefundedWarrantsExercised" xlink:to="NAOV_StockIssuedDuringPeriodValuePrefundedWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_StockIssuedDuringPeriodValuePrefundedWarrantsExercised_lbl" xml:lang="en-US">Exercise of pre-funded warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_StockIssuedDuringPeriodSharesPrefundedWarrantsExercised" xlink:label="NAOV_StockIssuedDuringPeriodSharesPrefundedWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_StockIssuedDuringPeriodSharesPrefundedWarrantsExercised" xlink:to="NAOV_StockIssuedDuringPeriodSharesPrefundedWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NAOV_StockIssuedDuringPeriodSharesPrefundedWarrantsExercised_lbl" xml:lang="en-US">Exercise of pre-funded warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock upon exercise of pre-funded warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock upon exercise of pre-funded warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_StockIssuedDuringPeriodValuesReverseStockSplits" xlink:label="NAOV_StockIssuedDuringPeriodValuesReverseStockSplits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_StockIssuedDuringPeriodValuesReverseStockSplits" xlink:to="NAOV_StockIssuedDuringPeriodValuesReverseStockSplits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_StockIssuedDuringPeriodValuesReverseStockSplits_lbl" xml:lang="en-US">Rounding-up of fractional shares due to reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US">Rounding-up of fractional shares due to reverse stock split, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_NoncashInterestExpense" xlink:label="NAOV_NoncashInterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_NoncashInterestExpense" xlink:to="NAOV_NoncashInterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_NoncashInterestExpense_lbl" xml:lang="en-US">Noncash interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="us-gaap_EquitySecuritiesFvNiGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss_lbl" xml:lang="en-US">Change in fair value of equity investment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="us-gaap_GainLossOnSaleOfInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfInvestments" xlink:to="us-gaap_GainLossOnSaleOfInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfInvestments_lbl" xml:lang="en-US">Gain/Loss on termination of investment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Trade receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Other accounts receivable and prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US">Trade payables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Other accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_IncreaseDecreaseInAccruedSeverancePayNet" xlink:label="NAOV_IncreaseDecreaseInAccruedSeverancePayNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_IncreaseDecreaseInAccruedSeverancePayNet" xlink:to="NAOV_IncreaseDecreaseInAccruedSeverancePayNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_IncreaseDecreaseInAccruedSeverancePayNet_lbl" xml:lang="en-US">Accrued severance pay, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sale of common stock, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of prefunded warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Effects of currency translation on cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net (decrease) increase in cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingArrLineItems_lbl" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_NoInsiderTradingFlag" xlink:label="NAOV_NoInsiderTradingFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_NoInsiderTradingFlag" xlink:to="NAOV_NoInsiderTradingFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_NoInsiderTradingFlag_lbl" xml:lang="en-US">No insider trading flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Disclosure - Insider Trading Policies and Procedures</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="cyd_MaterialCybersecurityIncidentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentAbstract" xlink:to="cyd_MaterialCybersecurityIncidentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentAbstract_lbl" xml:lang="en-US">Material Cybersecurity Incident [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Nature [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Scope [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Timing [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">DESCRIPTION OF BUSINESS</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_DisclosureLiquidityAndPlanOfOperationsAbstract" xlink:label="NAOV_DisclosureLiquidityAndPlanOfOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_DisclosureLiquidityAndPlanOfOperationsAbstract" xlink:to="NAOV_DisclosureLiquidityAndPlanOfOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_DisclosureLiquidityAndPlanOfOperationsAbstract_lbl" xml:lang="en-US">Liquidity And Plan Of Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_GoingConcernAndLiquidityTextBlock" xlink:label="NAOV_GoingConcernAndLiquidityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_GoingConcernAndLiquidityTextBlock" xlink:to="NAOV_GoingConcernAndLiquidityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_GoingConcernAndLiquidityTextBlock_lbl" xml:lang="en-US">LIQUIDITY AND PLAN OF OPERATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">PREPAID EXPENSES AND OTHER RECEIVABLES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_DisclosureLeasesAbstract" xlink:label="NAOV_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_DisclosureLeasesAbstract" xlink:to="NAOV_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsDisclosureTextBlock" xlink:to="us-gaap_OtherAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">OTHER ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of presentation and principles of consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign currency translation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Trade receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xml:lang="en-US">Advertising and Marketing Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_SequencingPolicyTextBlock" xlink:label="NAOV_SequencingPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_SequencingPolicyTextBlock" xlink:to="NAOV_SequencingPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_SequencingPolicyTextBlock_lbl" xml:lang="en-US">Sequencing</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_SeverancePayPolicyTextBlock" xlink:label="NAOV_SeverancePayPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_SeverancePayPolicyTextBlock" xlink:to="NAOV_SeverancePayPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_SeverancePayPolicyTextBlock_lbl" xml:lang="en-US">Severance pay</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently adopted accounting standards</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock" xlink:label="NAOV_ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock" xlink:to="NAOV_ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DEPRECIATION CALCULATED OVER ESTIMATED USEFUL LIVES OF ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PREPAID EXPENSES AND OTHER RECEIVABLES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF INVENTORY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF OPTIONS ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR OPTIONS GRANTED</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED SERVICES FROM EMPLOYEES AND NON-EMPLOYEES</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock" xlink:label="NAOV_ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock" xlink:to="NAOV_ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR WARRANTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" xml:lang="en-US">SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_ScheduleOfWarrantsAssumptionsTableTextBlock" xlink:label="NAOV_ScheduleOfWarrantsAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_ScheduleOfWarrantsAssumptionsTableTextBlock" xlink:to="NAOV_ScheduleOfWarrantsAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_ScheduleOfWarrantsAssumptionsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF WARRANTS ASSUMPTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PROVISION FOR INCOME TAXES EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RECONCILIATION OF STATUTORY U.S. FEDERAL RATE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF INCOME BEFORE TAXES ON DOMESTIC AND FOREIGN</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DEFERRED TAX ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Investing activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_StockIssuedDuringPeriodValuePrefundedWarrantsExercised" xlink:to="NAOV_StockIssuedDuringPeriodValuePrefundedWarrantsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NAOV_StockIssuedDuringPeriodValuePrefundedWarrantsExercised_2_lbl" xml:lang="en-US">Exercise of prefunded warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Cash_2_lbl" xml:lang="en-US">Cash balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_lbl" xml:lang="en-US">Cumulative translation gains</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash FDIC, insured amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit" xlink:label="us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit" xlink:to="us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit_lbl" xml:lang="en-US">Cash uninsured amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNet_lbl" xml:lang="en-US">Trades receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_ChangeInCurrentExpectedCreditLosses" xlink:label="NAOV_ChangeInCurrentExpectedCreditLosses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_ChangeInCurrentExpectedCreditLosses" xlink:to="NAOV_ChangeInCurrentExpectedCreditLosses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_ChangeInCurrentExpectedCreditLosses_lbl" xml:lang="en-US">Change in current expected credit losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketingAndAdvertisingExpense" xlink:label="us-gaap_MarketingAndAdvertisingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketingAndAdvertisingExpense" xlink:to="us-gaap_MarketingAndAdvertisingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketingAndAdvertisingExpense_lbl" xml:lang="en-US">Advertising and marketing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryAdjustments" xlink:label="us-gaap_InventoryAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryAdjustments" xlink:to="us-gaap_InventoryAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryAdjustments_lbl" xml:lang="en-US">Inventory allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_AccruedSeverancePayLiability" xlink:label="NAOV_AccruedSeverancePayLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_AccruedSeverancePayLiability" xlink:to="NAOV_AccruedSeverancePayLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_AccruedSeverancePayLiability_lbl" xml:lang="en-US">Accrued severance pay liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">Prepaid expenses and other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US">Raw materials</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished goods</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_2_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options, Outstanding - Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price per Share, Exercisable - Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Life (Years), Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price per Share, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" xlink:label="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" xlink:to="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Remaining Life (Years), Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Options, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price per Share, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" xlink:label="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" xlink:to="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Remaining Life (Years), Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Options, Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price per Share, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm" xlink:label="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm" xlink:to="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Remaining Life (Years), Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Options, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price per Share, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" xlink:label="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" xlink:to="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Remaining Life (Years), Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Options, Outstanding - Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price per Share, Outstanding - ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Remaining Life (Years), Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options, Exercisable - Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price per Share, Outstanding - ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Life (Years), Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Price at valuation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk free interest, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk free interest, maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Volatility, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Volatility, maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Warrants, measurement input, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Contractual term (in years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_2_lbl" xml:lang="en-US">Reverse stock split outstanding shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_2_lbl" xml:lang="en-US">Common stock shares remained unchanged</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Number of share issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Common stock par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants issued to purchase common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Class of warrant or right expire date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_2_lbl" xml:lang="en-US">Bid price</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_PrefundedWarrantAndAccompanyingWarrantPricePerShares" xlink:label="NAOV_PrefundedWarrantAndAccompanyingWarrantPricePerShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_PrefundedWarrantAndAccompanyingWarrantPricePerShares" xlink:to="NAOV_PrefundedWarrantAndAccompanyingWarrantPricePerShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_PrefundedWarrantAndAccompanyingWarrantPricePerShares_lbl" xml:lang="en-US">Pre-Funded Warrant and accompanying warrant price per shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from issuance of private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Stock reserved for future issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Number of common stock reserved for issuance for awards</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xml:lang="en-US">Number of options, exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Number of employee options granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Number of employee options forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xml:lang="en-US">Number of employee options expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Fair value options vesting term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Number of options, vested</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod" xlink:label="NAOV_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod" xlink:to="NAOV_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod_lbl" xml:lang="en-US">Contractual term for granted options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Non-vested stock options granted, unrecognized estimated compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Total warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Warrants, Outstanding - Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Warrants, Outstanding - Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xml:lang="en-US">Warrants, Outstanding - Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xml:lang="en-US">Warrants, Outstanding - Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Warrants, Outstanding - Beginning balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Warrants, Outstanding - Beginning balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_DisclosureLeasesAbstract" xlink:to="NAOV_DisclosureLeasesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NAOV_DisclosureLeasesAbstract_2_lbl" xml:lang="en-US">Schedule Of Liabilities Arising From Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total undiscounted operating lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: Imputed interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US">Lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted-average remaining lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted-average discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating lease, expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xml:lang="en-US">Revenues geographic areas</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_lbl" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="us-gaap_EntityWideRevenueMajorCustomerLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="us-gaap_EntityWideRevenueMajorCustomerLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EntityWideRevenueMajorCustomerLineItems_lbl" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration risk, percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_2_lbl" xml:lang="en-US">Warrants and rights outstanding, measurement input</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xml:lang="en-US">Expected term (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsTable" xlink:label="us-gaap_OffsettingAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsTable" xlink:to="us-gaap_OffsettingAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsTable_lbl" xml:lang="en-US">Offsetting Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="us-gaap_OffsettingAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsLineItems" xlink:to="us-gaap_OffsettingAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsLineItems_lbl" xml:lang="en-US">Offsetting Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_lbl" xml:lang="en-US">Balance beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Fair value adjustments - Sanuwave warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_2_lbl" xml:lang="en-US">Balance beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="srt_PlatformOperatorCryptoAssetTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetTable" xlink:to="srt_PlatformOperatorCryptoAssetTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetTable_lbl" xml:lang="en-US">Platform Operator, Crypto Asset [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="srt_PlatformOperatorCryptoAssetLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetLineItems" xlink:to="srt_PlatformOperatorCryptoAssetLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetLineItems_lbl" xml:lang="en-US">Platform Operator, Crypto Asset [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsFairValueDisclosure" xlink:label="us-gaap_OtherAssetsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsFairValueDisclosure" xlink:to="us-gaap_OtherAssetsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAssetsFairValueDisclosure_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_3_lbl" xml:lang="en-US">Warrants and rights outstanding term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Exercise price of warrants per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnContractTermination" xlink:label="us-gaap_GainLossOnContractTermination" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnContractTermination" xlink:to="us-gaap_GainLossOnContractTermination_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnContractTermination_lbl" xml:lang="en-US">Gain loss on contract termination</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_IncreaseDecreaseInTerminationValueByOffset" xlink:label="NAOV_IncreaseDecreaseInTerminationValueByOffset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_IncreaseDecreaseInTerminationValueByOffset" xlink:to="NAOV_IncreaseDecreaseInTerminationValueByOffset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_IncreaseDecreaseInTerminationValueByOffset_lbl" xml:lang="en-US">Increase decrease in termination value by offset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_3_lbl" xml:lang="en-US">Warrants leaving balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xml:lang="en-US">Fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDamagesSoughtValue" xlink:to="us-gaap_LossContingencyDamagesSoughtValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyDamagesSoughtValue_lbl" xml:lang="en-US">Loss contingency damages sought value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="us-gaap_LossContingencyDamagesAwardedValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDamagesAwardedValue" xlink:to="us-gaap_LossContingencyDamagesAwardedValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyDamagesAwardedValue_lbl" xml:lang="en-US">Damages awarded value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="us-gaap_LossContingencyDamagesPaidValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDamagesPaidValue" xlink:to="us-gaap_LossContingencyDamagesPaidValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyDamagesPaidValue_lbl" xml:lang="en-US">Loss contingency damages paid value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees" xlink:label="us-gaap_PaymentsForFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForFees_lbl" xml:lang="en-US">Payments for fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">State</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">State</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_ValuationAllowanceOfIncomeTaxExpenseBenefit" xlink:label="NAOV_ValuationAllowanceOfIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_ValuationAllowanceOfIncomeTaxExpenseBenefit" xlink:to="NAOV_ValuationAllowanceOfIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="NAOV_ValuationAllowanceOfIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Less: Valuation Allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherTaxExpenseBenefit" xlink:label="us-gaap_OtherTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherTaxExpenseBenefit" xlink:to="us-gaap_OtherTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherTaxExpenseBenefit_lbl" xml:lang="en-US">Total Tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal income tax benefit at statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income taxes, net of federal benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Foreign rate differential</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="NAOV_EffectiveIncomeTaxRateReconciliationPermanentItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:to="NAOV_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xml:lang="en-US">Permanent Items</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xml:lang="en-US">Return to provision adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_EffectiveIncomeTaxRateReconciliationForfeitedOptions" xlink:label="NAOV_EffectiveIncomeTaxRateReconciliationForfeitedOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_EffectiveIncomeTaxRateReconciliationForfeitedOptions" xlink:to="NAOV_EffectiveIncomeTaxRateReconciliationForfeitedOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_EffectiveIncomeTaxRateReconciliationForfeitedOptions_lbl" xml:lang="en-US">Forfeited options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">Domestic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US">Foreign</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Loss before taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforward</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_DeferredTaxAssetsOfCapitalLossCarryforward" xlink:label="NAOV_DeferredTaxAssetsOfCapitalLossCarryforward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_DeferredTaxAssetsOfCapitalLossCarryforward" xlink:to="NAOV_DeferredTaxAssetsOfCapitalLossCarryforward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_DeferredTaxAssetsOfCapitalLossCarryforward_lbl" xml:lang="en-US">Capital loss carryforward</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_DeferredTaxAssetsTaxDeferredExpenseAccruals" xlink:label="NAOV_DeferredTaxAssetsTaxDeferredExpenseAccruals" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_DeferredTaxAssetsTaxDeferredExpenseAccruals" xlink:to="NAOV_DeferredTaxAssetsTaxDeferredExpenseAccruals_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_DeferredTaxAssetsTaxDeferredExpenseAccruals_lbl" xml:lang="en-US">Arbitration accrual</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_lbl" xml:lang="en-US">Stock compensation and other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Deferred tax assets before valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry forward</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_FederalNetOperatingLossCarriedForward" xlink:label="NAOV_FederalNetOperatingLossCarriedForward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_FederalNetOperatingLossCarriedForward" xlink:to="NAOV_FederalNetOperatingLossCarriedForward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_FederalNetOperatingLossCarriedForward_lbl" xml:lang="en-US">Federal net operating loss carried forward</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_FederalNetOperatingLossOffsetAgainstTaxableIncome" xlink:label="NAOV_FederalNetOperatingLossOffsetAgainstTaxableIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_FederalNetOperatingLossOffsetAgainstTaxableIncome" xlink:to="NAOV_FederalNetOperatingLossOffsetAgainstTaxableIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_FederalNetOperatingLossOffsetAgainstTaxableIncome_lbl" xml:lang="en-US">Federal net operating loss offset against taxable income</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_OperatingLossCarryforwardsExpirationTerm" xlink:label="NAOV_OperatingLossCarryforwardsExpirationTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_OperatingLossCarryforwardsExpirationTerm" xlink:to="NAOV_OperatingLossCarryforwardsExpirationTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_OperatingLossCarryforwardsExpirationTerm_lbl" xml:lang="en-US">Operating loss carryforwards expiration term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_FranchiseFees" xlink:label="NAOV_FranchiseFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_FranchiseFees" xlink:to="NAOV_FranchiseFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_FranchiseFees_lbl" xml:lang="en-US">Franchise fees</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xml:lang="en-US">Corporate tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Net increases in valuation allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Number of new share issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Warrant exercise, conversion shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="us-gaap_WarrantExercisePriceIncrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceIncrease" xlink:to="us-gaap_WarrantExercisePriceIncrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceIncrease_lbl" xml:lang="en-US">Warrant exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xml:lang="en-US">Exercise price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_PercentageForNumberOfOutstandingCommonStock" xlink:label="NAOV_PercentageForNumberOfOutstandingCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_PercentageForNumberOfOutstandingCommonStock" xlink:to="NAOV_PercentageForNumberOfOutstandingCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_PercentageForNumberOfOutstandingCommonStock_lbl" xml:lang="en-US">Percentage for number of outstanding common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US">Convertible shares</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_PercentageForExchangeCapitalForConsideration" xlink:label="NAOV_PercentageForExchangeCapitalForConsideration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_PercentageForExchangeCapitalForConsideration" xlink:to="NAOV_PercentageForExchangeCapitalForConsideration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_PercentageForExchangeCapitalForConsideration_lbl" xml:lang="en-US">Percentage for exchange capital for consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" xml:lang="en-US">Convertible description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Investments" xlink:label="us-gaap_Investments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Investments" xlink:to="us-gaap_Investments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Investments_lbl" xml:lang="en-US">Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt interest rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_NoInsiderTradingFlag" xlink:to="NAOV_NoInsiderTradingFlag_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_NoInsiderTradingFlag_doc" xml:lang="en-US">No Insider Trading Flag.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_SeveranceAssetsNoncurent" xlink:to="NAOV_SeveranceAssetsNoncurent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_SeveranceAssetsNoncurent_doc" xml:lang="en-US">Severance pay fund.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_FinancialIncomeExpensesNet" xlink:to="NAOV_FinancialIncomeExpensesNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_FinancialIncomeExpensesNet_doc" xml:lang="en-US">Financial income expenses, net.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_StockIssuedDuringPeriodValuePrefundedWarrantsExercised" xlink:to="NAOV_StockIssuedDuringPeriodValuePrefundedWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_StockIssuedDuringPeriodValuePrefundedWarrantsExercised_doc" xml:lang="en-US">Stock issued during period value prefunded warrants exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_StockIssuedDuringPeriodValuesReverseStockSplits" xlink:to="NAOV_StockIssuedDuringPeriodValuesReverseStockSplits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_StockIssuedDuringPeriodValuesReverseStockSplits_doc" xml:lang="en-US">Rounding-up of fractional shares due to reverse stock split.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_StockIssuedDuringPeriodSharesPrefundedWarrantsExercised" xlink:to="NAOV_StockIssuedDuringPeriodSharesPrefundedWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_StockIssuedDuringPeriodSharesPrefundedWarrantsExercised_doc" xml:lang="en-US">Stock issued during period shares prefunded warrants exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_NoncashInterestExpense" xlink:to="NAOV_NoncashInterestExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_NoncashInterestExpense_doc" xml:lang="en-US">Noncash interest expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_IncreaseDecreaseInAccruedSeverancePayNet" xlink:to="NAOV_IncreaseDecreaseInAccruedSeverancePayNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_IncreaseDecreaseInAccruedSeverancePayNet_doc" xml:lang="en-US">Increase decrease in accrued severance pay net.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_ChangeInCurrentExpectedCreditLosses" xlink:to="NAOV_ChangeInCurrentExpectedCreditLosses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_ChangeInCurrentExpectedCreditLosses_doc" xml:lang="en-US">Change in current expected credit losses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock" xlink:to="NAOV_ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock_doc" xml:lang="en-US">Schedule of depreciation calculated over estimated useful lives of assets [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_SequencingPolicyTextBlock" xlink:to="NAOV_SequencingPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_SequencingPolicyTextBlock_doc" xml:lang="en-US">Sequencing [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_SeverancePayPolicyTextBlock" xlink:to="NAOV_SeverancePayPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_SeverancePayPolicyTextBlock_doc" xml:lang="en-US">Severance Pay [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_GoingConcernAndLiquidityTextBlock" xlink:to="NAOV_GoingConcernAndLiquidityTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_GoingConcernAndLiquidityTextBlock_doc" xml:lang="en-US">Going Concern And Liquidity [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_SaleOfEquitySecuritiesMember" xlink:to="NAOV_SaleOfEquitySecuritiesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_SaleOfEquitySecuritiesMember_doc" xml:lang="en-US">Sale of Equity Securities [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_PurchaseAgreementMember" xlink:to="NAOV_PurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_PurchaseAgreementMember_doc" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_PreFundedWarrantsMember" xlink:to="NAOV_PreFundedWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_PreFundedWarrantsMember_doc" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_A1WarrantsMember" xlink:to="NAOV_A1WarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_A1WarrantsMember_doc" xml:lang="en-US">A1 Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_A2WarrantsMember" xlink:to="NAOV_A2WarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_A2WarrantsMember_doc" xml:lang="en-US">A2 Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_PlacementAgentWarrantsMember" xlink:to="NAOV_PlacementAgentWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_PlacementAgentWarrantsMember_doc" xml:lang="en-US">Placement Agent Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_TwoThousandFourteenLongTermIncentivePlanMember" xlink:to="NAOV_TwoThousandFourteenLongTermIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_TwoThousandFourteenLongTermIncentivePlanMember_doc" xml:lang="en-US">2014 Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_EmployeeOptionsMember" xlink:to="NAOV_EmployeeOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_EmployeeOptionsMember_doc" xml:lang="en-US">Employee Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod" xlink:to="NAOV_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award contractual period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" xlink:to="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" xlink:to="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Weighted average remaining contractual term for option awards forfeited, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm" xlink:to="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Weighted average remaining contractual term for option awards expired, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" xlink:to="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Weighted average remaining contractual term for option awards exercised, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock" xlink:to="NAOV_ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock_doc" xml:lang="en-US">Schedule Of Estimating Fair Value Of Warrants Assumptions [Table Text Blcok]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_PrivateInvestorsMember" xlink:to="NAOV_PrivateInvestorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_PrivateInvestorsMember_doc" xml:lang="en-US">Private Investors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_CustomerMember" xlink:to="NAOV_CustomerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_CustomerMember_doc" xml:lang="en-US">Customer [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_LicensingAgreementMember" xlink:to="NAOV_LicensingAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_LicensingAgreementMember_doc" xml:lang="en-US">Licensing Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_SanuwaveHealthIncMember" xlink:to="NAOV_SanuwaveHealthIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_SanuwaveHealthIncMember_doc" xml:lang="en-US">Sanuwave Health, Inc. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_PriceAtValuationMember" xlink:to="NAOV_PriceAtValuationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_PriceAtValuationMember_doc" xml:lang="en-US">Price at Valuation [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_IncreaseDecreaseInTerminationValueByOffset" xlink:to="NAOV_IncreaseDecreaseInTerminationValueByOffset_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_IncreaseDecreaseInTerminationValueByOffset_doc" xml:lang="en-US">Increase decrease in termination value by offset.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_DerivativeAssetMember" xlink:to="NAOV_DerivativeAssetMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_DerivativeAssetMember_doc" xml:lang="en-US">Derivative Asset [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_ArbitratorMember" xlink:to="NAOV_ArbitratorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_ArbitratorMember_doc" xml:lang="en-US">Arbitrator [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_PiersonFerdinandMember" xlink:to="NAOV_PiersonFerdinandMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_PiersonFerdinandMember_doc" xml:lang="en-US">Pierson Ferdinand [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_FederalNetOperatingLossCarriedForward" xlink:to="NAOV_FederalNetOperatingLossCarriedForward_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_FederalNetOperatingLossCarriedForward_doc" xml:lang="en-US">Represents information related to federal net operating loss carried forward.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_FederalNetOperatingLossOffsetAgainstTaxableIncome" xlink:to="NAOV_FederalNetOperatingLossOffsetAgainstTaxableIncome_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_FederalNetOperatingLossOffsetAgainstTaxableIncome_doc" xml:lang="en-US">Represents information related to federal net operating loss offset against taxable income.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_OperatingLossCarryforwardsExpirationTerm" xlink:to="NAOV_OperatingLossCarryforwardsExpirationTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_OperatingLossCarryforwardsExpirationTerm_doc" xml:lang="en-US">Represents as a operating loss carryforwards expiration term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_ValuationAllowanceOfIncomeTaxExpenseBenefit" xlink:to="NAOV_ValuationAllowanceOfIncomeTaxExpenseBenefit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_ValuationAllowanceOfIncomeTaxExpenseBenefit_doc" xml:lang="en-US">Valuation allowance of income tax expense benefit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_FranchiseFees" xlink:to="NAOV_FranchiseFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_FranchiseFees_doc" xml:lang="en-US">Franchise fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:to="NAOV_EffectiveIncomeTaxRateReconciliationPermanentItems_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_EffectiveIncomeTaxRateReconciliationPermanentItems_doc" xml:lang="en-US">Effective income tax rate reconciliation,permanent items, percent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_EffectiveIncomeTaxRateReconciliationForfeitedOptions" xlink:to="NAOV_EffectiveIncomeTaxRateReconciliationForfeitedOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_EffectiveIncomeTaxRateReconciliationForfeitedOptions_doc" xml:lang="en-US">Effective income tax rate reconciliation,forfeited options, percent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_DeferredTaxAssetsTaxDeferredExpenseAccruals" xlink:to="NAOV_DeferredTaxAssetsTaxDeferredExpenseAccruals_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_DeferredTaxAssetsTaxDeferredExpenseAccruals_doc" xml:lang="en-US">Deferred tax assets tax deferred expense accruals.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_SecuritiesExchangeAgreementMember" xlink:to="NAOV_SecuritiesExchangeAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_SecuritiesExchangeAgreementMember_doc" xml:lang="en-US">Securities Exchange Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_MergerAgreementMember" xlink:to="NAOV_MergerAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_MergerAgreementMember_doc" xml:lang="en-US">Merger Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_SeriesXPreferredStockMember" xlink:to="NAOV_SeriesXPreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_SeriesXPreferredStockMember_doc" xml:lang="en-US">Series X Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_ScheduleOfWarrantsAssumptionsTableTextBlock" xlink:to="NAOV_ScheduleOfWarrantsAssumptionsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_ScheduleOfWarrantsAssumptionsTableTextBlock_doc" xml:lang="en-US">Schedule of Warrants Assumptions [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_AccruedSeverancePayLiability" xlink:to="NAOV_AccruedSeverancePayLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_AccruedSeverancePayLiability_doc" xml:lang="en-US">Accrued severance pay liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_PrefundedWarrantAndAccompanyingWarrantPricePerShares" xlink:to="NAOV_PrefundedWarrantAndAccompanyingWarrantPricePerShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_PrefundedWarrantAndAccompanyingWarrantPricePerShares_doc" xml:lang="en-US">Prefunded warrant and accompanying warrant price per, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_HCWainwrightAndCoLLCMember" xlink:to="NAOV_HCWainwrightAndCoLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_HCWainwrightAndCoLLCMember_doc" xml:lang="en-US">H.C. Wainwright &amp; Co., LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_PercentageForNumberOfOutstandingCommonStock" xlink:to="NAOV_PercentageForNumberOfOutstandingCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_PercentageForNumberOfOutstandingCommonStock_doc" xml:lang="en-US">Percentage for number of outstanding common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_PercentageForExchangeCapitalForConsideration" xlink:to="NAOV_PercentageForExchangeCapitalForConsideration_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_PercentageForExchangeCapitalForConsideration_doc" xml:lang="en-US">Percentage for exchange capital for consideration.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_OtherCountryMember" xlink:to="NAOV_OtherCountryMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_OtherCountryMember_doc" xml:lang="en-US">Other Country [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_StockOptionsEmployeeAndNonEmployeeMember" xlink:to="NAOV_StockOptionsEmployeeAndNonEmployeeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_StockOptionsEmployeeAndNonEmployeeMember_doc" xml:lang="en-US">Stock Options - Employee and Non-employee [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_PostWarrantMember" xlink:to="NAOV_PostWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_PostWarrantMember_doc" xml:lang="en-US">Post Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_PreWarrantMember" xlink:to="NAOV_PreWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_PreWarrantMember_doc" xml:lang="en-US">Pre Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_ENvueMedicalHoldingsCorpMember" xlink:to="NAOV_ENvueMedicalHoldingsCorpMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_ENvueMedicalHoldingsCorpMember_doc" xml:lang="en-US">ENvue Medical Holdings Corp [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense, Operating and Nonoperating</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_StockIssuedDuringPeriodSharesPrefundedWarrantsExercised" xlink:to="NAOV_StockIssuedDuringPeriodSharesPrefundedWarrantsExercised_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_StockIssuedDuringPeriodSharesPrefundedWarrantsExercised_3_lbl" xml:lang="en-US">StockIssuedDuringPeriodSharesPrefundedWarrantsExercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="us-gaap_EquitySecuritiesFvNiGainLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss_2_lbl" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfInvestments" xlink:to="us-gaap_GainLossOnSaleOfInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfInvestments_2_lbl" xml:lang="en-US">Gain (Loss) on Sale of Investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_2_lbl" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_2_lbl" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_2_lbl" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_2_lbl" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_3_lbl" xml:lang="en-US">Weighted Average Remaining Life (Years), Outstanding - ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_2_lbl" xml:lang="en-US">Revenues [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsFairValueDisclosure" xlink:to="us-gaap_OtherAssetsFairValueDisclosure_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsFairValueDisclosure_2_lbl" xml:lang="en-US">Other Assets, Fair Value Disclosure</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_ValuationAllowanceOfIncomeTaxExpenseBenefit" xlink:to="NAOV_ValuationAllowanceOfIncomeTaxExpenseBenefit_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_ValuationAllowanceOfIncomeTaxExpenseBenefit_3_lbl" xml:lang="en-US">Valuation allowance of income tax expense benefit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherTaxExpenseBenefit" xlink:to="us-gaap_OtherTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherTaxExpenseBenefit_2_lbl" xml:lang="en-US">Other Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>26
<FILENAME>naov-20241231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://nanovibronix.com/role/Cover" xlink:href="naov-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/BalanceSheets" xlink:href="naov-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/BalanceSheetsParenthetical" xlink:href="naov-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="naov-20241231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/StatementOfStockholdersEquity" xlink:href="naov-20241231.xsd#StatementOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/StatementsOfCashFlows" xlink:href="naov-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/DescriptionOfBusiness" xlink:href="naov-20241231.xsd#DescriptionOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/LiquidityAndPlanOfOperations" xlink:href="naov-20241231.xsd#LiquidityAndPlanOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="naov-20241231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/PrepaidExpensesAndOtherReceivables" xlink:href="naov-20241231.xsd#PrepaidExpensesAndOtherReceivables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/Inventory" xlink:href="naov-20241231.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/StockholdersEquity" xlink:href="naov-20241231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/Leases" xlink:href="naov-20241231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/LossPerShareApplicableToCommonShareholder" xlink:href="naov-20241231.xsd#LossPerShareApplicableToCommonShareholder" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerData" xlink:href="naov-20241231.xsd#GeographicInformationAndMajorCustomerData" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/OtherAssets" xlink:href="naov-20241231.xsd#OtherAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/CommitmentsAndContingencies" xlink:href="naov-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/RelatedPartyTransaction" xlink:href="naov-20241231.xsd#RelatedPartyTransaction" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/IncomeTaxes" xlink:href="naov-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SubsequentEvents" xlink:href="naov-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="naov-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="naov-20241231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/PrepaidExpensesAndOtherReceivablesTables" xlink:href="naov-20241231.xsd#PrepaidExpensesAndOtherReceivablesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/InventoryTables" xlink:href="naov-20241231.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/StockholdersEquityTables" xlink:href="naov-20241231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/LeasesTables" xlink:href="naov-20241231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/LossPerShareApplicableToCommonShareholderTables" xlink:href="naov-20241231.xsd#LossPerShareApplicableToCommonShareholderTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataTables" xlink:href="naov-20241231.xsd#GeographicInformationAndMajorCustomerDataTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/OtherAssetsTables" xlink:href="naov-20241231.xsd#OtherAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/IncomeTaxesTables" xlink:href="naov-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/LiquidityAndPlanOfOperationsDetailsNarrative" xlink:href="naov-20241231.xsd#LiquidityAndPlanOfOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsDetails" xlink:href="naov-20241231.xsd#ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="naov-20241231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfPrepaidExpensesAndOtherReceivablesDetails" xlink:href="naov-20241231.xsd#ScheduleOfPrepaidExpensesAndOtherReceivablesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfInventoryDetails" xlink:href="naov-20241231.xsd#ScheduleOfInventoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails" xlink:href="naov-20241231.xsd#ScheduleOfOptionsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForOptionsGrantedDetails" xlink:href="naov-20241231.xsd#ScheduleOfFairValueAssumptionsForOptionsGrantedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails" xlink:href="naov-20241231.xsd#ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForWarrantsDetails" xlink:href="naov-20241231.xsd#ScheduleOfFairValueAssumptionsForWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" xlink:href="naov-20241231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails" xlink:href="naov-20241231.xsd#ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/LeasesDetailsNarrative" xlink:href="naov-20241231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails" xlink:href="naov-20241231.xsd#SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails" xlink:href="naov-20241231.xsd#SummaryOfRevenueWithinGeographicAreasDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative" xlink:href="naov-20241231.xsd#GeographicInformationAndMajorCustomerDataDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails" xlink:href="naov-20241231.xsd#ScheduleOfWarrantsAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails" xlink:href="naov-20241231.xsd#ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:href="naov-20241231.xsd#ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/OtherAssetsDetailsNarrative" xlink:href="naov-20241231.xsd#OtherAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="naov-20241231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/RelatedPartyTransactionDetailsNarrative" xlink:href="naov-20241231.xsd#RelatedPartyTransactionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails" xlink:href="naov-20241231.xsd#ScheduleOfProvisionForIncomeTaxesExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails" xlink:href="naov-20241231.xsd#ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfIncomeBeforeTaxesOnDomesticAndForeignDetails" xlink:href="naov-20241231.xsd#ScheduleOfIncomeBeforeTaxesOnDomesticAndForeignDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:href="naov-20241231.xsd#ScheduleOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/IncomeTaxesDetailsNarrative" xlink:href="naov-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SubsequentEventsDetailsNarrative" xlink:href="naov-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="loc_deiAuditorOpinionTextBlock" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorOpinionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaapSeriesDPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesDPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaapSeriesEPreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesEPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaapSeriesFPreferredStockMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesFPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_SeveranceAssetsNoncurent" xlink:label="loc_NAOVSeveranceAssetsNoncurent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_NAOVSeveranceAssetsNoncurent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapOtherAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="loc_us-gaapDeferredIncomeCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredIncomeCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesNoncurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="loc_us-gaapDeferredIncomeNoncurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapDeferredIncomeNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaapSeriesDPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesDPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaapSeriesEPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesEPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaapSeriesFPreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesFPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingAndMarketingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_FinancialIncomeExpensesNet" xlink:label="loc_NAOVFinancialIncomeExpensesNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_NAOVFinancialIncomeExpensesNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaapNetIncomeLossAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLossAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLossAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLossAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLossAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/StatementOfStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statement of Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="90" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="90" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaapSeriesDPreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapSeriesDPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaapSeriesEPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapSeriesEPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaapSeriesFPreferredStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapSeriesFPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_StockIssuedDuringPeriodValuePrefundedWarrantsExercised" xlink:label="loc_NAOVStockIssuedDuringPeriodValuePrefundedWarrantsExercised" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NAOVStockIssuedDuringPeriodValuePrefundedWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_StockIssuedDuringPeriodSharesPrefundedWarrantsExercised" xlink:label="loc_NAOVStockIssuedDuringPeriodSharesPrefundedWarrantsExercised" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NAOVStockIssuedDuringPeriodSharesPrefundedWarrantsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_StockIssuedDuringPeriodValuesReverseStockSplits" xlink:label="loc_NAOVStockIssuedDuringPeriodValuesReverseStockSplits" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NAOVStockIssuedDuringPeriodValuesReverseStockSplits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_NoncashInterestExpense" xlink:label="loc_NAOVNoncashInterestExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_NAOVNoncashInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaapEquitySecuritiesFvNiGainLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapEquitySecuritiesFvNiGainLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaapGainLossOnSaleOfInvestments" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_IncreaseDecreaseInAccruedSeverancePayNet" xlink:label="loc_NAOVIncreaseDecreaseInAccruedSeverancePayNet" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_NAOVIncreaseDecreaseInAccruedSeverancePayNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_NoInsiderTradingFlag" xlink:label="loc_NAOVNoInsiderTradingFlag" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_NAOVNoInsiderTradingFlag" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="loc_cydCybersecurityRiskRoleOfManagementTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskRoleOfManagementTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="loc_cydMaterialCybersecurityIncidentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentNatureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentNatureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentScopeTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentScopeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentTimingTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentTimingTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/DescriptionOfBusiness" xlink:title="999014 - Disclosure - DESCRIPTION OF BUSINESS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNatureOfOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/LiquidityAndPlanOfOperations" xlink:title="999015 - Disclosure - LIQUIDITY AND PLAN OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_DisclosureLiquidityAndPlanOfOperationsAbstract" xlink:label="loc_NAOVDisclosureLiquidityAndPlanOfOperationsAbstract" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_GoingConcernAndLiquidityTextBlock" xlink:label="loc_NAOVGoingConcernAndLiquidityTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NAOVDisclosureLiquidityAndPlanOfOperationsAbstract" xlink:to="loc_NAOVGoingConcernAndLiquidityTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/PrepaidExpensesAndOtherReceivables" xlink:title="999017 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="loc_us-gaapOtherCurrentAssetsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherCurrentAssetsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/Inventory" xlink:title="999018 - Disclosure - INVENTORY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaapInventoryDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/StockholdersEquity" xlink:title="999019 - Disclosure - STOCKHOLDERS&#8217; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/Leases" xlink:title="999020 - Disclosure - LEASES">
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_DisclosureLeasesAbstract" xlink:label="loc_NAOVDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NAOVDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/LossPerShareApplicableToCommonShareholder" xlink:title="999021 - Disclosure - LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerData" xlink:title="999022 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/OtherAssets" xlink:title="999023 - Disclosure - OTHER ASSETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaapOtherAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/CommitmentsAndContingencies" xlink:title="999024 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/RelatedPartyTransaction" xlink:title="999025 - Disclosure - RELATED PARTY TRANSACTION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/IncomeTaxes" xlink:title="999026 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SubsequentEvents" xlink:title="999027 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaapTradeAndOtherAccountsReceivablePolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapTradeAndOtherAccountsReceivablePolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaapAdvertisingCostsPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAdvertisingCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_SequencingPolicyTextBlock" xlink:label="loc_NAOVSequencingPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_NAOVSequencingPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_SeverancePayPolicyTextBlock" xlink:label="loc_NAOVSeverancePayPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_NAOVSeverancePayPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock" xlink:label="loc_NAOVScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_NAOVScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/PrepaidExpensesAndOtherReceivablesTables" xlink:title="999030 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/InventoryTables" xlink:title="999031 - Disclosure - INVENTORY (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/StockholdersEquityTables" xlink:title="999032 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock" xlink:label="loc_NAOVScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_NAOVScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/LeasesTables" xlink:title="999033 - Disclosure - LEASES (Tables)">
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_DisclosureLeasesAbstract" xlink:label="loc_NAOVDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NAOVDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/LossPerShareApplicableToCommonShareholderTables" xlink:title="999034 - Disclosure - LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataTables" xlink:title="999035 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="loc_us-gaapRevenueFromExternalCustomersByGeographicAreasTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapRevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/OtherAssetsTables" xlink:title="999036 - Disclosure - OTHER ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_ScheduleOfWarrantsAssumptionsTableTextBlock" xlink:label="loc_NAOVScheduleOfWarrantsAssumptionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_NAOVScheduleOfWarrantsAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:label="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/IncomeTaxesTables" xlink:title="999037 - Disclosure - INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/LiquidityAndPlanOfOperationsDetailsNarrative" xlink:title="999038 - Disclosure - LIQUIDITY AND PLAN OF OPERATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_DisclosureLiquidityAndPlanOfOperationsAbstract" xlink:label="loc_NAOVDisclosureLiquidityAndPlanOfOperationsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NAOVDisclosureLiquidityAndPlanOfOperationsAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="loc_us-gaapPropertyPlantAndEquipmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapPropertyPlantAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollateralAxis" xlink:label="loc_us-gaapCollateralAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapCollateralAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollateralDomain" xlink:label="loc_us-gaapCollateralDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollateralAxis" xlink:to="loc_us-gaapCollateralDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_SaleOfEquitySecuritiesMember" xlink:label="loc_NAOVSaleOfEquitySecuritiesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollateralDomain" xlink:to="loc_NAOVSaleOfEquitySecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_StockIssuedDuringPeriodValuePrefundedWarrantsExercised" xlink:label="loc_NAOVStockIssuedDuringPeriodValuePrefundedWarrantsExercised" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_NAOVStockIssuedDuringPeriodValuePrefundedWarrantsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsDetails" xlink:title="999039 - Disclosure - SCHEDULE OF DEPRECIATION CALCULATED OVER ESTIMATED USEFUL LIVES OF ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit" xlink:label="loc_us-gaapTimeDepositsAtOrAboveFDICInsuranceLimit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapTimeDepositsAtOrAboveFDICInsuranceLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaapAccountsReceivableNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAccountsReceivableNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_ChangeInCurrentExpectedCreditLosses" xlink:label="loc_NAOVChangeInCurrentExpectedCreditLosses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_NAOVChangeInCurrentExpectedCreditLosses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketingAndAdvertisingExpense" xlink:label="loc_us-gaapMarketingAndAdvertisingExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapMarketingAndAdvertisingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryAdjustments" xlink:label="loc_us-gaapInventoryAdjustments" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_AccruedSeverancePayLiability" xlink:label="loc_NAOVAccruedSeverancePayLiability" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_NAOVAccruedSeverancePayLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfPrepaidExpensesAndOtherReceivablesDetails" xlink:title="999041 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER RECEIVABLES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfInventoryDetails" xlink:title="999042 - Disclosure - SCHEDULE OF INVENTORY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaapInventoryRawMaterials" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryRawMaterials" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails" xlink:title="999043 - Disclosure - SCHEDULE OF OPTIONS ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_EmployeeOptionsMember" xlink:label="loc_NAOVEmployeeOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NAOVEmployeeOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" xlink:label="loc_NAOVSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NAOVSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" xlink:label="loc_NAOVSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NAOVSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm" xlink:label="loc_NAOVSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NAOVSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" xlink:label="loc_NAOVSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NAOVSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="loc_NAOVSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NAOVSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForOptionsGrantedDetails" xlink:title="999044 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR OPTIONS GRANTED (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails" xlink:title="999045 - Disclosure - SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED SERVICES FROM EMPLOYEES AND NON-EMPLOYEES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="loc_us-gaapSellingAndMarketingExpenseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapSellingAndMarketingExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForWarrantsDetails" xlink:title="999046 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR WARRANTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" xlink:title="999047 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_PurchaseAgreementMember" xlink:label="loc_NAOVPurchaseAgreementMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NAOVPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_PreFundedWarrantsMember" xlink:label="loc_NAOVPreFundedWarrantsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NAOVPreFundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_A1WarrantsMember" xlink:label="loc_NAOVA1WarrantsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NAOVA1WarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_A2WarrantsMember" xlink:label="loc_NAOVA2WarrantsMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NAOVA2WarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_PlacementAgentWarrantsMember" xlink:label="loc_NAOVPlacementAgentWarrantsMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NAOVPlacementAgentWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_EmployeeOptionsMember" xlink:label="loc_NAOVEmployeeOptionsMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NAOVEmployeeOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_PreWarrantMember" xlink:label="loc_NAOVPreWarrantMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NAOVPreWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_PostWarrantMember" xlink:label="loc_NAOVPostWarrantMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NAOVPostWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_HCWainwrightAndCoLLCMember" xlink:label="loc_NAOVHCWainwrightAndCoLLCMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_NAOVHCWainwrightAndCoLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAwardTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_TwoThousandFourteenLongTermIncentivePlanMember" xlink:label="loc_NAOVTwoThousandFourteenLongTermIncentivePlanMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_NAOVTwoThousandFourteenLongTermIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_TwoThousandAndTwentyFourLongTermIncentivePlanMember" xlink:label="loc_NAOVTwoThousandAndTwentyFourLongTermIncentivePlanMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_NAOVTwoThousandAndTwentyFourLongTermIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtTitleOfIndividualAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_PrivateInvestorsMember" xlink:label="loc_NAOVPrivateInvestorsMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_NAOVPrivateInvestorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_PrefundedWarrantAndAccompanyingWarrantPricePerShares" xlink:label="loc_NAOVPrefundedWarrantAndAccompanyingWarrantPricePerShares" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NAOVPrefundedWarrantAndAccompanyingWarrantPricePerShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod" xlink:label="loc_NAOVShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NAOVShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails" xlink:title="999048 - Disclosure - SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES (Details)">
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_DisclosureLeasesAbstract" xlink:label="loc_NAOVDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NAOVDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NAOVDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NAOVDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NAOVDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NAOVDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NAOVDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/LeasesDetailsNarrative" xlink:title="999049 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_DisclosureLeasesAbstract" xlink:label="loc_NAOVDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NAOVDisclosureLeasesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails" xlink:title="999050 - Disclosure - SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_StockOptionsEmployeeAndNonEmployeeMember" xlink:label="loc_NAOVStockOptionsEmployeeAndNonEmployeeMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_NAOVStockOptionsEmployeeAndNonEmployeeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails" xlink:title="999051 - Disclosure - SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="loc_countryUS" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember" xlink:label="loc_srtEuropeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_srtEuropeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_AU" xlink:label="loc_countryAU" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryAU" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IL" xlink:label="loc_countryIL" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryIL" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_NZ" xlink:label="loc_countryNZ" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryNZ" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_OtherCountryMember" xlink:label="loc_NAOVOtherCountryMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_NAOVOtherCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative" xlink:title="999052 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaapScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaapEntityWideRevenueMajorCustomerLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="loc_us-gaapEntityWideRevenueMajorCustomerLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="loc_srtMajorCustomersAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_CustomerMember" xlink:label="loc_NAOVCustomerMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NAOVCustomerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEntityWideRevenueMajorCustomerLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEntityWideRevenueMajorCustomerLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails" xlink:title="999053 - Disclosure - SCHEDULE OF WARRANTS ASSUMPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_PriceAtValuationMember" xlink:label="loc_NAOVPriceAtValuationMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_NAOVPriceAtValuationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaapMeasurementInputExercisePriceMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExercisePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_SanuwaveHealthIncMember" xlink:label="loc_NAOVSanuwaveHealthIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_NAOVSanuwaveHealthIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails" xlink:title="999054 - Disclosure - SCHEDULE OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_DerivativeAssetMember" xlink:label="loc_NAOVDerivativeAssetMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_NAOVDerivativeAssetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:label="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:label="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:title="999055 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_srtPlatformOperatorCryptoAssetLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsFairValueDisclosure" xlink:label="loc_us-gaapOtherAssetsFairValueDisclosure" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapOtherAssetsFairValueDisclosure" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/OtherAssetsDetailsNarrative" xlink:title="999056 - Disclosure - OTHER ASSETS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_LicensingAgreementMember" xlink:label="loc_NAOVLicensingAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NAOVLicensingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_SanuwaveHealthIncMember" xlink:label="loc_NAOVSanuwaveHealthIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_NAOVSanuwaveHealthIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnContractTermination" xlink:label="loc_us-gaapGainLossOnContractTermination" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapGainLossOnContractTermination" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_IncreaseDecreaseInTerminationValueByOffset" xlink:label="loc_NAOVIncreaseDecreaseInTerminationValueByOffset" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_NAOVIncreaseDecreaseInTerminationValueByOffset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:label="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999057 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_ArbitratorMember" xlink:label="loc_NAOVArbitratorMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_NAOVArbitratorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaapLossContingencyDamagesSoughtValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLossContingencyDamagesSoughtValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="loc_us-gaapLossContingencyDamagesAwardedValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLossContingencyDamagesAwardedValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="loc_us-gaapLossContingencyDamagesPaidValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLossContingencyDamagesPaidValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/RelatedPartyTransactionDetailsNarrative" xlink:title="999058 - Disclosure - RELATED PARTY TRANSACTION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_PiersonFerdinandMember" xlink:label="loc_NAOVPiersonFerdinandMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_NAOVPiersonFerdinandMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForFees" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails" xlink:title="999059 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAXES EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentForeignTaxExpenseBenefit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentForeignTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_ValuationAllowanceOfIncomeTaxExpenseBenefit" xlink:label="loc_NAOVValuationAllowanceOfIncomeTaxExpenseBenefit" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_NAOVValuationAllowanceOfIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherTaxExpenseBenefit" xlink:label="loc_us-gaapOtherTaxExpenseBenefit" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOtherTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails" xlink:title="999060 - Disclosure - SCHEDULE OF RECONCILIATION OF STATUTORY U.S. FEDERAL RATE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="loc_NAOVEffectiveIncomeTaxRateReconciliationPermanentItems" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_NAOVEffectiveIncomeTaxRateReconciliationPermanentItems" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_EffectiveIncomeTaxRateReconciliationForfeitedOptions" xlink:label="loc_NAOVEffectiveIncomeTaxRateReconciliationForfeitedOptions" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_NAOVEffectiveIncomeTaxRateReconciliationForfeitedOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfIncomeBeforeTaxesOnDomesticAndForeignDetails" xlink:title="999061 - Disclosure - SCHEDULE OF INCOME BEFORE TAXES ON DOMESTIC AND FOREIGN (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:title="999062 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_DeferredTaxAssetsOfCapitalLossCarryforward" xlink:label="loc_NAOVDeferredTaxAssetsOfCapitalLossCarryforward" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_NAOVDeferredTaxAssetsOfCapitalLossCarryforward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_DeferredTaxAssetsTaxDeferredExpenseAccruals" xlink:label="loc_NAOVDeferredTaxAssetsTaxDeferredExpenseAccruals" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_NAOVDeferredTaxAssetsTaxDeferredExpenseAccruals" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/IncomeTaxesDetailsNarrative" xlink:title="999063 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_srtStatementGeographicalAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IL" xlink:label="loc_countryIL" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryIL" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_FederalNetOperatingLossCarriedForward" xlink:label="loc_NAOVFederalNetOperatingLossCarriedForward" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_NAOVFederalNetOperatingLossCarriedForward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_FederalNetOperatingLossOffsetAgainstTaxableIncome" xlink:label="loc_NAOVFederalNetOperatingLossOffsetAgainstTaxableIncome" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_NAOVFederalNetOperatingLossOffsetAgainstTaxableIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_OperatingLossCarryforwardsExpirationTerm" xlink:label="loc_NAOVOperatingLossCarryforwardsExpirationTerm" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_NAOVOperatingLossCarryforwardsExpirationTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_FranchiseFees" xlink:label="loc_NAOVFranchiseFees" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_NAOVFranchiseFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SubsequentEventsDetailsNarrative" xlink:title="999064 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_SecuritiesExchangeAgreementMember" xlink:label="loc_NAOVSecuritiesExchangeAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NAOVSecuritiesExchangeAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_MergerAgreementMember" xlink:label="loc_NAOVMergerAgreementMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NAOVMergerAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_PreFundedWarrantsMember" xlink:label="loc_NAOVPreFundedWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NAOVPreFundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_A1WarrantsMember" xlink:label="loc_NAOVA1WarrantsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NAOVA1WarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_SeriesXPreferredStockMember" xlink:label="loc_NAOVSeriesXPreferredStockMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NAOVSeriesXPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_ENvueMedicalHoldingsCorpMember" xlink:label="loc_NAOVENvueMedicalHoldingsCorpMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_NAOVENvueMedicalHoldingsCorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="loc_us-gaapWarrantExercisePriceIncrease" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantExercisePriceIncrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_PercentageForNumberOfOutstandingCommonStock" xlink:label="loc_NAOVPercentageForNumberOfOutstandingCommonStock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NAOVPercentageForNumberOfOutstandingCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20241231.xsd#NAOV_PercentageForExchangeCapitalForConsideration" xlink:label="loc_NAOVPercentageForExchangeCapitalForConsideration" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NAOVPercentageForExchangeCapitalForConsideration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="loc_us-gaapConvertiblePreferredStockTermsOfConversion" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockTermsOfConversion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Investments" xlink:label="loc_us-gaapInvestments" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NanoVibronix, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001326706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">01-0801232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">969 Pruitt Ave<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Tyler<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(914)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">233-3004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NAOV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">759,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text">None<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of NanoVibronix, Inc. (the &#8220;Company&#8221;) as of December 31, 2024,
and the related consolidated statements of operations, comprehensive loss, stockholders&#8217; equity and cash flows for the year then
ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements
present fairly, in all material respects, the financial position of the Company as of December 31, 2024, and the results of its operations
and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Zwick
CPA, PLLC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Southfield,
Michigan<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 752,000<span></span>
</td>
<td class="nump">$ 3,283,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade receivables</a></td>
<td class="nump">98,000<span></span>
</td>
<td class="nump">318,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other accounts receivable</a></td>
<td class="nump">290,000<span></span>
</td>
<td class="nump">154,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">2,191,000<span></span>
</td>
<td class="nump">2,732,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">3,331,000<span></span>
</td>
<td class="nump">6,487,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Noncurrent assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_SeveranceAssetsNoncurent', window );">Severance pay fund</a></td>
<td class="nump">173,000<span></span>
</td>
<td class="nump">174,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="nump">116,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">298,000<span></span>
</td>
<td class="nump">187,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">3,629,000<span></span>
</td>
<td class="nump">6,674,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Trade payables</a></td>
<td class="nump">47,000<span></span>
</td>
<td class="nump">138,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities', window );">Other accounts payable and accrued expenses</a></td>
<td class="nump">2,608,000<span></span>
</td>
<td class="nump">2,265,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeCurrent', window );">Deferred revenue</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">46,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">52,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,722,000<span></span>
</td>
<td class="nump">2,454,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesNoncurrent', window );">Accrued severance pay</a></td>
<td class="nump">216,000<span></span>
</td>
<td class="nump">217,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeNoncurrent', window );">Deferred revenue &#8211; long term</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">64,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">3,002,000<span></span>
</td>
<td class="nump">2,686,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock of $0.001 par value - Authorized: 40,000,000 shares at December 31, 2024, and December 31, 2023, respectively; Issued and outstanding: 378,941 and 186,028 shares at December 31, 2024, and December 31, 2023, respectively</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">70,505,000<span></span>
</td>
<td class="nump">70,149,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="num">(80,000)<span></span>
</td>
<td class="num">(67,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(69,801,000)<span></span>
</td>
<td class="num">(66,096,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">627,000<span></span>
</td>
<td class="nump">3,988,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">3,629,000<span></span>
</td>
<td class="nump">6,674,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember', window );">Series E Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember', window );">Series F Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_SeveranceAssetsNoncurent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Severance pay fund.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_SeveranceAssetsNoncurent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481174/470-10-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481174/470-10-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">378,941<span></span>
</td>
<td class="nump">186,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">378,941<span></span>
</td>
<td class="nump">186,028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">506<span></span>
</td>
<td class="nump">506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember', window );">Series E Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,999,494<span></span>
</td>
<td class="nump">1,999,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember', window );">Series F Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 2,558,000<span></span>
</td>
<td class="nump">$ 2,283,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="nump">1,050,000<span></span>
</td>
<td class="nump">746,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">1,508,000<span></span>
</td>
<td class="nump">1,537,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">909,000<span></span>
</td>
<td class="nump">185,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing</a></td>
<td class="nump">720,000<span></span>
</td>
<td class="nump">864,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">3,461,000<span></span>
</td>
<td class="nump">3,924,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">5,090,000<span></span>
</td>
<td class="nump">4,973,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(3,582,000)<span></span>
</td>
<td class="num">(3,436,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(135,000)<span></span>
</td>
<td class="num">(135,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_FinancialIncomeExpensesNet', window );">Financial expense, net</a></td>
<td class="nump">31,000<span></span>
</td>
<td class="num">(111,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes</a></td>
<td class="num">(3,686,000)<span></span>
</td>
<td class="num">(3,682,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(19,000)<span></span>
</td>
<td class="num">(29,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,705,000)<span></span>
</td>
<td class="num">$ (3,711,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss available for holders of common stock</a></td>
<td class="num">$ (13.73)<span></span>
</td>
<td class="num">$ (23.32)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss available for holders of common stock</a></td>
<td class="num">$ (13.73)<span></span>
</td>
<td class="num">$ (23.32)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common stock outstanding, basic</a></td>
<td class="nump">269,848<span></span>
</td>
<td class="nump">159,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common stock outstanding, diluted</a></td>
<td class="nump">269,848<span></span>
</td>
<td class="nump">159,105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to common stockholders</a></td>
<td class="num">$ (3,705,000)<span></span>
</td>
<td class="num">$ (3,711,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Change in foreign currency translation adjustments</a></td>
<td class="num">(13,000)<span></span>
</td>
<td class="num">(49,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss available to common stockholders</a></td>
<td class="num">$ (3,718,000)<span></span>
</td>
<td class="num">$ (3,760,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_FinancialIncomeExpensesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial income expenses, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_FinancialIncomeExpensesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series C Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series D Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series E Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series F Preferred Stock [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 65,634,000<span></span>
</td>
<td class="num">$ (18,000)<span></span>
</td>
<td class="num">$ (62,385,000)<span></span>
</td>
<td class="nump">$ 3,233,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">149,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">293,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">293,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(49,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(49,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of pre-funded warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_StockIssuedDuringPeriodValuePrefundedWarrantsExercised', window );">Exercise of pre-funded warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_StockIssuedDuringPeriodSharesPrefundedWarrantsExercised', window );">Exercise of pre-funded warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon exercise of pre-funded warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4,215,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4,215,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon exercise of pre-funded warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_StockIssuedDuringPeriodValuesReverseStockSplits', window );">Rounding-up of fractional shares due to reverse stock split</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Rounding-up of fractional shares due to reverse stock split, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (3,711,000)<span></span>
</td>
<td class="num">$ (3,711,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">70,149,000<span></span>
</td>
<td class="num">(67,000)<span></span>
</td>
<td class="num">(66,096,000)<span></span>
</td>
<td class="nump">3,988,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">186,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">356,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">356,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(13,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(13,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_StockIssuedDuringPeriodValuePrefundedWarrantsExercised', window );">Exercise of pre-funded warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_StockIssuedDuringPeriodSharesPrefundedWarrantsExercised', window );">Exercise of pre-funded warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon exercise of pre-funded warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon exercise of pre-funded warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_StockIssuedDuringPeriodValuesReverseStockSplits', window );">Rounding-up of fractional shares due to reverse stock split</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Rounding-up of fractional shares due to reverse stock split, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (3,705,000)<span></span>
</td>
<td class="num">$ (3,705,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 70,505,000<span></span>
</td>
<td class="num">$ (80,000)<span></span>
</td>
<td class="num">$ (69,801,000)<span></span>
</td>
<td class="nump">$ 627,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">378,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_StockIssuedDuringPeriodSharesPrefundedWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares prefunded warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_StockIssuedDuringPeriodSharesPrefundedWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_StockIssuedDuringPeriodValuePrefundedWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value prefunded warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_StockIssuedDuringPeriodValuePrefundedWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_StockIssuedDuringPeriodValuesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rounding-up of fractional shares due to reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_StockIssuedDuringPeriodValuesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,705,000)<span></span>
</td>
<td class="num">$ (3,711,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">356,000<span></span>
</td>
<td class="nump">293,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_NoncashInterestExpense', window );">Noncash interest expense</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">135,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Change in fair value of equity investment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gain/Loss on termination of investment</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade receivable</a></td>
<td class="nump">221,000<span></span>
</td>
<td class="num">(309,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Other accounts receivable and prepaid expenses</a></td>
<td class="num">(136,000)<span></span>
</td>
<td class="nump">558,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">541,000<span></span>
</td>
<td class="num">(557,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Trade payables</a></td>
<td class="num">(91,000)<span></span>
</td>
<td class="nump">72,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Other accounts payable and accrued expenses</a></td>
<td class="nump">242,000<span></span>
</td>
<td class="num">(18,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(46,000)<span></span>
</td>
<td class="num">(67,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_IncreaseDecreaseInAccruedSeverancePayNet', window );">Accrued severance pay, net</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(2,516,000)<span></span>
</td>
<td class="num">(3,602,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of fixed assets</a></td>
<td class="num">(3,000)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(3,000)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,215,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of prefunded warrants</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">4,222,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effects of currency translation on cash</a></td>
<td class="num">(13,000)<span></span>
</td>
<td class="num">(49,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash</a></td>
<td class="num">(2,531,000)<span></span>
</td>
<td class="nump">570,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at beginning of period</a></td>
<td class="nump">3,283,000<span></span>
</td>
<td class="nump">2,713,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at end of period</a></td>
<td class="nump">$ 752,000<span></span>
</td>
<td class="nump">$ 3,283,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_IncreaseDecreaseInAccruedSeverancePayNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accrued severance pay net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_IncreaseDecreaseInAccruedSeverancePayNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_NoncashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_NoncashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (3,705)<span></span>
</td>
<td class="num">$ (3,711)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_NoInsiderTradingFlag', window );">No insider trading flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_NoInsiderTradingFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>No Insider Trading Flag.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_NoInsiderTradingFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock', window );">Disclosure - Insider Trading Policies and Procedures</a></td>
<td class="text">We
maintain an insider trading policy that applies to our officers and directors that prohibits trading our securities during certain established
periods and when in possession of material non-public information. It also prohibits, unless approved in advance in limited circumstances
by the policy administrator, the hedging of our securities, including short sales or purchases or sales of derivative securities based
on our securities, and the use of our securities to secure a margin or other loan. Since the adoption of our insider trading policy,
the policy administrator has not granted any such exemptions to the policy&#8217;s general prohibition on hedging or pledging. While
the Company is not subject to the insider trading policy, the company does not trade in its securities when it is in possession of material
nonpublic information other than pursuant to previously adopted Rule 10b5-1 trading plans.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
operate in the biotechnology sector, which is subject to various cybersecurity risks that could adversely affect our business, financial
condition, and results of operations, including intellectual property theft; fraud; extortion; harm to employees or customers; violation
of privacy laws and other litigation and legal risk; and reputational risk. We recognize the critical importance of developing, implementing,
and maintaining robust cybersecurity measures to safeguard our information systems and protect the confidentiality, integrity, and availability
of our data. We currently have security measures in place to protect our clients, patients, customers, employees,&#8204; and vendor information
and prevent data loss and other security breaches, including a cybersecurity risk assessment program. We also only use third party software
for accounting, billing and payroll that have successful SOC 1 type 2 compliance. Both management and the Board are actively involved
in the continuous assessment of risks from cybersecurity threats, including prevention, mitigation, detection, and remediation of cybersecurity
incidents.</span>ur
current cybersecurity risk <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zf9DwAAmVsKk">assessment</span> program consists of an annual review of our risks and policies. The program outlines governance,
policies and procedures, and technology we use to oversee and identify risks from cybersecurity threats and is informed by previous cybersecurity
incidents we have observed both within the Company and in our industry.<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90D_ecyd--CybersecurityRiskBoardOfDirectorsOversightTextBlock_dbF_c20240101__20241231_zEXGSX4wxK0l">Our
General Manager, who is responsible for overseeing our business operations, with oversight from senior management and the nominating
and the Corporate Governance Committee of our Board are responsible for day-to-day assessment and management of risks from cybersecurity
threats, including the prevention, mitigation, detection, and remediation of cybersecurity incidents. We also use the services of an
outside consulting firm to monitor activity and advise the company of cybersecurity protocols.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90A_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_dbF_c20240101__20241231_zy1oEP85IMt8">The
Nominating and Corporate Governance Committee of the Board is responsible for oversight of risks from cybersecurity threats in conjunction
with management.</span> <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_902_ecyd--CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_dbF_c20240101__20241231_zHh5FebJQeR">The committee receives interim reports and updates from the senior management, and management has committed to updating
the full Board on a quarterly basis with respect to the management of risks from cybersecurity threats. Such reports cover the Company&#8217;s
information technology security program, including its current status, capabilities, objectives and plans, as well as the evolving cybersecurity
threat landscape.</span> <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90C_ecyd--CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_c20240101__20241231_zmxUV4IcXI02">Additionally, the Nominating and Corporate Governance Committee considers risks from cybersecurity threats as part
of its oversight of the Company&#8217;s business strategy, risk management, and financial oversight by requiring quarterly updates from
management at its Board meetings.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_908_ecyd--CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_dbF_c20240101__20241231_zDHf85LkjJv2">We
routinely undertake activities to prevent, detect, and minimize the effects of cybersecurity incidents, including an annual risk review,
policy reviews and revisions. In addition, we maintain business continuity, contingency, and recovery plans for use in the event of a
cybersecurity incident by the administering of local and cloud based back up of files. and emails.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
engaged and used the advice of a <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_908_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_zBTCkr33832l">third-party</span> consultant to help us assess and identify risks from cybersecurity threats, including the
threat of a cybersecurity incident, and manage our risk assessment program. Among other things, these providers have recommended installation
of Check Point Firewall and ESET Protect Advanced cloud based anti-virus, as well as site periodic evaluations of the work stations and
onsite storage equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also engaged third party consultants to prepare policies and procedures to oversee and identify the risks from cybersecurity threats
associated with our use of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90C_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20240101__20241231_zdVmydKWbCKj">third-party</span> service providers and we continue to monitor that all third-party software providers remain in
compliance with SOC 1 protocols.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this report, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90F_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240101__20241231_z7DONbS7NdSi">no</span> cybersecurity incident (or aggregation of incidents) or cybersecurity threat has materially affected our
results of operations or financial condition. However, an actual or perceived breach of our security could damage our reputation, and
cause existing clients/customers to discontinue. As well as prevent us from attracting new clients/customers, and interfere with the
progress of our clinical trials, or interfere with our efforts to pursue regulatory approvals for our product candidates, or subject
us to third-party lawsuits, regulatory fines or other actions or liabilities, any of which could adversely affect our business, operating
results or financial condition. For further information, see &#8220;Risk Factors-<i>Our business and operations would suffer in the event
of computer system failures, cyber-attacks or deficiencies in our cyber-security</i>&#8221; in Item 1A of this Annual Report on Form
10-K. We currently do not carry a cyber liability insurance policy, but are evaluating whether to acquire one to mitigate any financial
impact of a cybersecurity breach.</span></p>

<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>O<span id="xdx_C04_gBFCRMPFAIAMT-VZ_zCWam0ACpJCc">ur
current cybersecurity risk <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zf9DwAAmVsKk">assessment</span> program consists of an annual review of our risks and policies. The program outlines governance,
policies and procedures, and technology we use to oversee and identify risks from cybersecurity threats and is informed by previous cybersecurity
incidents we have observed both within the Company and in our industry.</span></span></span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text">Our
General Manager, who is responsible for overseeing our business operations, with oversight from senior management and the nominating
and the Corporate Governance Committee of our Board are responsible for day-to-day assessment and management of risks from cybersecurity
threats, including the prevention, mitigation, detection, and remediation of cybersecurity incidents. We also use the services of an
outside consulting firm to monitor activity and advise the company of cybersecurity protocols.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">The
Nominating and Corporate Governance Committee of the Board is responsible for oversight of risks from cybersecurity threats in conjunction
with management.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">The committee receives interim reports and updates from the senior management, and management has committed to updating
the full Board on a quarterly basis with respect to the management of risks from cybersecurity threats. Such reports cover the Company&#8217;s
information technology security program, including its current status, capabilities, objectives and plans, as well as the evolving cybersecurity
threat landscape.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">Additionally, the Nominating and Corporate Governance Committee considers risks from cybersecurity threats as part
of its oversight of the Company&#8217;s business strategy, risk management, and financial oversight by requiring quarterly updates from
management at its Board meetings.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text">We
routinely undertake activities to prevent, detect, and minimize the effects of cybersecurity incidents, including an annual risk review,
policy reviews and revisions. In addition, we maintain business continuity, contingency, and recovery plans for use in the event of a
cybersecurity incident by the administering of local and cloud based back up of files. and emails.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">DESCRIPTION OF BUSINESS</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--NatureOfOperations_zTx9bxAIKo13" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1 - <span id="xdx_820_z5pEQZQsxCYb">DESCRIPTION OF BUSINESS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NanoVibronix,
Inc. (the &#8220;Company&#8221;), a Delaware corporation, commenced operations on October 20, 2003, and is a medical device company focusing
on non-invasive biological response-activating devices that target wound healing and pain therapy and can be administered at home, without
the assistance of medical professionals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s principal research and development activities are conducted in Israel through its wholly-owned subsidiary, NanoVibronix
Ltd., a company registered in Israel, which commenced operations in October 2003.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY AND PLAN OF OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_DisclosureLiquidityAndPlanOfOperationsAbstract', window );"><strong>Liquidity And Plan Of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_GoingConcernAndLiquidityTextBlock', window );">LIQUIDITY AND PLAN OF OPERATIONS</a></td>
<td class="text"><p id="xdx_80D_ecustom--GoingConcernAndLiquidityTextBlock_zPQQYVT6MEF8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 - <span id="xdx_829_zFVxoQP33I76">LIQUIDITY AND PLAN OF OPERATIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s ability to continue to operate is dependent mainly on its ability to successfully market and sell its products and the
receipt of additional financing until profitability is achieved. In 2024, the Company&#8217;s cash used in operations was $<span id="xdx_90C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20240101__20241231_zN6VgXKoB8ie" title="Net cash used in operating activities">2,516,000</span>,
cash used in investing activities of $<span id="xdx_90B_eus-gaap--NetCashProvidedByUsedInInvestingActivities_c20240101__20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember_zcmKbZF9ZB8a" title="Investing activities">3,000</span> from the purchase of property plant and equipment, and received net proceeds of $<span id="xdx_907_ecustom--StockIssuedDuringPeriodValuePrefundedWarrantsExercised_c20240101__20241231_zeNBBZoFTwwe" title="Exercise of prefunded warrants">1,000</span> from
the exercise of prefunded warrants, leaving a cash balance of $<span id="xdx_903_eus-gaap--Cash_iI_c20241231__us-gaap--CollateralAxis__custom--SaleOfEquitySecuritiesMember_zXlDHlM32Ue1" title="Cash balance">752,000</span> as of December 31, 2024. Because the Company does not have sufficient
resources to fund our operation for the next twelve months from the date of this filing, management has substantial doubt of the Company&#8217;s
ability to continue as a going concern. The Company will need to raise additional capital to finance its losses and negative cash flows
from operations and may continue to be dependent on additional capital raising as long as our products do not reach commercial profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_DisclosureLiquidityAndPlanOfOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_DisclosureLiquidityAndPlanOfOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_GoingConcernAndLiquidityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Going Concern And Liquidity [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_GoingConcernAndLiquidityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_806_eus-gaap--SignificantAccountingPoliciesTextBlock_zlUptZkB4Kwc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 - <span id="xdx_820_zLLj3krqIkTb">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z70ns3JxFLLc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Basis
of presentation and principles of consolidation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements include the accounts of NanoVibronix, Inc. and its wholly owned subsidiary. Intercompany
accounts and transactions have been eliminated. The consolidated financial statements and accompanying notes have been prepared in conformity
with U.S. generally accepted accounting principles (&#8220;US GAAP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--UseOfEstimates_zMfdFD4yoxyb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Use
of estimates</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and
assumptions. The Company believes that the estimates, judgments and assumptions used are reasonable based upon information available
at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during
the reporting period. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zoYspOsZUoif" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Foreign
currency translation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-U.S.
dollar denominated transactions and balances have been re-measured to U.S. dollars. All gains and losses from re-measurement of monetary
balance sheet items denominated in non-U.S. dollar currencies are reflected in the statements of operations as other comprehensive income,
as appropriate. The cumulative translation losses and gains as of the years ended December 31, 2024, and 2023 were $<span id="xdx_90F_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_c20240101__20241231_zaXYHL6baVDi" title="Cumulative translation gains">19,000</span> and $<span id="xdx_905_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_c20230101__20231231_zv9MMW0ey4gf" title="Cumulative translation gains">49,000</span>,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zESQdMF0jdxf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company holds cash in various banking institutions. Such funds are insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;)
up to $<span id="xdx_903_eus-gaap--CashFDICInsuredAmount_iI_c20241231_zNRbqRvwhYCc" title="Cash FDIC, insured amount">250,000</span>. Cash balances could exceed insured amounts at any given time. As of December 31, 2024, the company had cash in excess
of the FDIC insured amount totaling $<span id="xdx_90C_eus-gaap--TimeDepositsAtOrAboveFDICInsuranceLimit_iI_c20241231_zD2ktgj1NVY" title="Cash uninsured amount">306,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zQ4tFYMG8Xkh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Trade
receivables</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s trade receivable balance consists of amounts due from its customers. The Current Expected Credit Losses (&#8220;CECL&#8221;)
impairment model requires an estimate of expected credit losses, measured over the contractual life of an instrument, which considers
forecasts of future economic conditions in addition to information about past events and current conditions. Based on this model, the
Company considers many factors, including the age of the balance, collection history, and current economic trends. Credit losses are
written off after all collection efforts have ceased. Allowances for credit losses are recorded as a direct reduction from an asset&#8217;s
amortized cost basis. Credit losses and recoveries are recorded in selling, general and administrative expenses in the consolidated statements
of operations. Recoveries of financial assets previously written off are recorded when received. Trades receivables were $<span id="xdx_90F_eus-gaap--AccountsReceivableNet_iI_c20241231_zX8gOLg56R27" title="Trades receivables">98,000</span> as of
December 31, 2024, and are not anticipated to possess substantial credit risk or expected credit losses. The Company&#8217;s current
policy is to not charge late fees or other penalties for late payments but may consider charging customers late fees in the future. Historically,
the Company has not had significant write offs of trade receivables. All sales are non-refundable. As of December 31, 2024, the Company
evaluated historical collections from vendors and collection policies and has estimated that current expected credit losses ( &#8220;CECL&#8221;)
to be $<span id="xdx_902_ecustom--ChangeInCurrentExpectedCreditLosses_pn3n3_c20240101__20241231_z9hUkZcKjFXh" title="Change in current expected credit losses">0</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--AdvertisingCostsPolicyTextBlock_zXjraNwAjkrd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Advertising
and Marketing Costs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
associated with advertising are charged to expenses as incurred. For the year ended December 31, 2024, and 2023, the advertising and
marketing costs were $<span id="xdx_90E_eus-gaap--MarketingAndAdvertisingExpense_c20240101__20241231_ziUXw2ls3O3e" title="Advertising and marketing costs">53,000</span> and $<span id="xdx_909_eus-gaap--MarketingAndAdvertisingExpense_c20230101__20231231_z6ebkWgsalOl" title="Advertising and marketing costs">106,000</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zrzJQIvOlaeb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Earnings
per share</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
loss per share was computed using the weighted average number of common shares outstanding. Diluted loss per share includes the effect
of diluted common stock equivalents. Potentially dilutive securities from the exercise of stock option, warrants and exercise of preferred
stock as of December 31, 2024, and 2023, respectively, were excluded from the computation of diluted net loss per share because the effect
of their inclusion would have been antidilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_84A_eus-gaap--InventoryPolicyTextBlock_zVV543rKQYS9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Inventory</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
are stated at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course
of business, less reasonably predictable costs of completion, disposal, and transportation. Cost is determined using the &#8220;first-in,
first-out&#8221; method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
write-offs are provided to cover risks arising from slow-moving items or technological obsolescence. The Company periodically evaluates
the quantities on hand relative to current and historical selling prices and historical and projected sales volume. Based on this evaluation,
provisions are made when required to write-down inventory to its net market value. As of December 31, 2024, and 2023, there was <span id="xdx_90F_eus-gaap--InventoryAdjustments_iI_pn3n3_do_c20241231_zsWGdZVnBec4" title="Inventory allowance"><span id="xdx_902_eus-gaap--InventoryAdjustments_iI_pn3n3_do_c20231231_ztRrGcIKb95l" title="Inventory allowance">no</span></span> allowance
on inventory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z8lUfCkwaB9c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Property
and equipment, net</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_ecustom--ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock_zKKjFz17QRPb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the
estimated useful lives of the assets, at the following annual rates:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zLTUCzBGvf0b" style="display: none">SCHEDULE OF DEPRECIATION CALCULATED OVER ESTIMATED USEFUL LIVES OF ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">Years</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: justify">Computers and peripheral equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 16%; text-align: center"><span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zS8qn4YwxKkh" title="Estimated useful life">3</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_z6mGGsDo1sLl" title="Estimated useful life">5</span>-<span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zOxEAVxNuY0a" title="Estimated useful life">7</span></td></tr>
  </table>

<p id="xdx_8AC_zmUz89Ndvjld" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zxgc8zi6ZLpi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Impairment
of Long-Lived Assets</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
reviews for impairment whenever events or changes in circumstances indicate that the carrying amount of property and equipment may not
be recoverable under the provisions of accounting for the impairment of long-lived assets. If it is determined that an impairment loss
has occurred based upon expected future cash flows, the loss is recognized in the Consolidated Statements of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_ecustom--SequencingPolicyTextBlock_zDvDjlG4oCrk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sequencing</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adopted a sequencing policy under ASC 815-40-35 whereby if reclassification of contracts from equity to liabilities is necessary
pursuant to ASC 815 due to the Company&#8217;s inability to demonstrate it has sufficient authorized shares. This was due to the Company
committing more shares than authorized. While temporary suspensions are in place to keep the potential exercises beneath the number authorized,
certain instruments are classified as liabilities, after allocating available authorized shares on the basis of the most recent grant
date of potentially dilutive instruments. Pursuant to ASC 815, issuances of securities granted as compensation in a share-based payment
arrangement are not subject to the sequencing policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_ecustom--SeverancePayPolicyTextBlock_zeWMWwzAPh0j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Severance
pay</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s liability for severance pay is for its Israeli employees and is calculated pursuant to Israeli Severance Pay Law based
on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date and is in large
part covered by regular deposits with recognized pension funds, deposits with severance pay funds and purchases of insurance policies.
The value of these deposits and policies is recorded as an asset in the Company&#8217;s balance sheet. Accrued severance pay liability
on December 31, 2024, and 2023 was $<span id="xdx_906_ecustom--AccruedSeverancePayLiability_c20240101__20241231_zj57yXkQgAKl" title="Accrued severance pay liability">216,000</span> and $<span id="xdx_90F_ecustom--AccruedSeverancePayLiability_c20230101__20231231_zuAPMFAUtJSi" title="Accrued severance pay liability">217,000</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--LesseeLeasesPolicyTextBlock_z9a2mVAhxFN6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Leases</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for its leases in accordance with ASU 2016-02, &#8220;Leases&#8221; (Topic 842). This topic requires that a lessee recognize
the assets and liabilities that arise from operating leases. The Company recognizes right-of-use assets and lease liabilities on the
consolidated balance sheet for all leases with a term longer than 12 months and classifies them as operating leases. For leases with
a term of 12 months or less, the Company elects not to recognize lease assets and lease liabilities on those leases. The right-of-use
assets and lease liabilities have been measured by the present value of the Company&#8217;s remaining lease payments over the lease term
using our incremental borrowing rates or implicit rates, when readily determinable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z7i2eOV0280i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue
recognition</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is the Company&#8217;s policy that revenues from product sales is recognized in accordance with ASC 606 &#8220;Revenue Recognition.&#8221;
Five basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that create(s) enforceable
rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services
to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects to
be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to the performance
obligations in the contract, which requires the company to allocate the transaction price to each performance obligation on the basis
of the relative standalone selling prices of each distinct good or services promised in the contract; and (5) Recognizing revenue when
(or as) the entity satisfies a performance obligation by transferring a promised good or service to a customer. The amount of revenue
recognized is the amount allocated to the satisfied performance obligation. Adoption of ASC 606 has not changed the timing and nature
of the Company&#8217;s revenue recognition and there has been no material effect on the Company&#8217;s financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from product sales is recorded at the net sales price, or &#8220;transaction price,&#8221; which includes estimates of variable consideration
that result from coupons, discounts, chargebacks and distributor fees, processing fees, as well as allowances for returns and government
rebates. The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue.
Collectability of revenue is reasonably assured based on historical evidence of collectability between the Company and its customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues
from sales to distributors are recognized at the time the products are delivered to the distributors (sell-in&#8221;). The Company does
not grant rights of return, credits, rebates, price protection, or other privileges on its products to distributors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--IncomeTaxPolicyTextBlock_zlDPYCgQDXTe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Income
taxes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes in accordance with ASC 740, &#8220;Income Taxes&#8221;. This topic prescribes the use of the liability
method whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and
tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences
are expected to reverse. The Company provides full valuation allowance, to reduce deferred tax assets to the amount that is more likely
than not to be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company implements a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position
taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than
not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related
appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% (cumulative
basis) likely to be realized upon ultimate settlement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes interest and penalties related to uncertain tax positions on the income tax expense line in the accompanying consolidated
statement of operations. Accrued interest and penalties are included on the related tax liability line in the consolidated balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zjOYKe1VDQC5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock-based
compensation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company selected the Black-Scholes-Merton option pricing model as the most appropriate fair value method for its stock-options awards.
The option-pricing model requires a number of assumptions, of which the most significant are the expected stock price volatility and
the expected option term. Expected volatility was calculated based upon similar traded companies&#8217; historical share price movements.
The expected option term represents the period that the Company&#8217;s stock options are expected to be outstanding. The Company currently
uses the simplified method and will continue to do so until sufficient historical exercise data supports using expected life assumptions.
The risk-free interest rate is based on the yield from U.S. Treasury zero-coupon bonds with an equivalent term. The expected dividend
yield assumption is based on the Company&#8217;s historical experience and expectation of no future dividend payouts. The Company has
historically not paid cash dividends and has no foreseeable plans to pay cash dividends in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z88NbAq5McIl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recently
adopted accounting standards</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13,
Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU 2016-13&#8221;)
and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, and ASU 2019-05 (collectively, &#8220;Topic
326&#8221;). Topic 326 requires measurement and recognition of expected credit losses for financial assets held. This ASU is effective
for interim and annual reporting periods beginning after December 15, 2022. The adoption of Topic 326 did not have a material effect
on the Company&#8217;s consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU No. 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>,
which requires an enhanced disclosure of significant segment expenses on an annual and interim basis. This guidance is effective for
annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption
is permitted. Upon adoption, the guidance should be applied retrospectively to all prior periods presented in the financial statements.
The adoption of Topic 280 did not have a material effect on the Company&#8217;s consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER RECEIVABLES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">PREPAID EXPENSES AND OTHER RECEIVABLES</a></td>
<td class="text"><p id="xdx_803_eus-gaap--OtherCurrentAssetsTextBlock_zC5HbPdO39vb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 - <span id="xdx_826_zyZ4hS3pijp8">PREPAID EXPENSES AND OTHER RECEIVABLES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zptYOgclK78a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses and other receivables consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_zIXtbmqLeCtf" style="display: none">SCHEDULE OF PREPAID EXPENSES AND OTHER RECEIVABLES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20241231_zNLVgVZZ6E8a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231_z6k4SgKwxMZg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PrepaidExpenseCurrent_iI_maPEAOAzR3N_zxd7TlgMEOJ7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Prepaid expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">120,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">47,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OtherAssetsCurrent_iI_maPEAOAzR3N_zFVKeo5BdjT2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Other receivables</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">170,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">107,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0d_mtPEAOAzR3N_zoxd9gzr2YC7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
    expenses and other receivables</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">290,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">154,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zm1OEeRg9xqh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--InventoryDisclosureTextBlock_zWntBGAb5Qqk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5 &#8211; <span id="xdx_82A_zKgpE98lZTyj">INVENTORY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_z0ex8gZoucm8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
consists of the following components:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_z46b0dEx4fHa" style="display: none">SCHEDULE OF INVENTORY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20241231_zr49nADZJxh5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20231231_zaUoLdjiqAOa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--InventoryRawMaterials_iI_maINzmOi_zn52XfWNYKck" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Raw materials</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">391,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">210,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--InventoryFinishedGoods_iI_maINzmOi_zYks0Oxizgg4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,800,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,522,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--InventoryNet_iTI_pp0d_mtINzmOi_zjlTFRf5YeG3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,191,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,732,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_z6Ou2Ja9nDvl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zA1Lncml5pM9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6 - <span id="xdx_82F_zIPtKFwfplM4">STOCKHOLDERS&#8217; EQUITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Common
Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
common stock confers upon the holders the right to receive notice to participate and vote in general meetings of the Company, and the
right to receive dividends, if declared, and to participate in the distribution of the surplus assets and funds of the Company in the
event of liquidation, dissolution or winding up of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Reverse
stock splits</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 8, 2023, the Company effected a reverse stock split of its common stock at a ratio of 1 post-split share for every 20 pre-split
shares. The Company&#8217;s common stock begin trading on a split-adjusted basis when the market opened on February 9, 2023 (the &#8220;2023
Reverse Stock Split&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the effective time of the 2023 Reverse Stock Split, every 20 shares of the Company&#8217;s issued and outstanding common stock were converted
automatically into one issued and outstanding share of common stock without any change in the par value per share. Stockholders holding
shares through a brokerage account had their shares automatically adjusted to reflect the 2023 Reverse Stock Split. The 2023 Reverse
Stock Split affected all stockholders uniformly and did not alter any stockholder&#8217;s percentage interest in the Company&#8217;s
equity, except to the extent that the 2023 Reverse Stock Split resulted in a stockholder owning a fractional share. Any fractional share
of a stockholder resulting from the 2023 Reverse Stock Split was rounded up to the nearest whole number of shares. Proportional adjustments
were made to the number of shares of the Company&#8217;s common stock issuable upon exercise or conversion of the Company&#8217;s equity
awards, warrants and other convertible securities, as well as the applicable exercise or conversion price thereof. On February 16, 2023,
the Company rounded up fractional shares to its nearest whole number of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_c20230215__20230216_zKoKKPdwdVF1" title="Fractional shares">15,726</span> shares. On March 31, 2024, the Company rounded up fractional
shares to its nearest whole number of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_c20240331__20240331_zHQg1LpGzjz" title="Fractional shares">47</span> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 13, 2025, the Company effected a <span id="xdx_90A_eus-gaap--StockholdersEquityReverseStockSplit_c20250313__20250313_zyss9homDVh1" title="Reverse stock split">1-for-11 reverse stock split</span> (the &#8220;2025 Reverse Stock Split&#8221; and together with the
2023 Reverse Stock Split, the &#8220;Reverse Stock Splits&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the 2025 Reverse Stock Split, every 11 shares of issued and outstanding common stock was automatically combined into one
issued and outstanding share of common stock, without any change in the par value per share. No fractional shares were issued as a result
of the 2025 Reverse Stock Split. Any fractional shares that would otherwise have resulted from the Reverse Stock Split was rounded up
to the next whole number. The 2025 Reverse Stock Split reduced the number of shares of common stock outstanding from <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_pid_c20250312__20250312_zDgEBSjuatL2" title="Reverse stock split outstanding shares">8,716,327</span> shares
to approximately <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_pid_c20250313__20250313_zfQ2Z0V5GHm7" title="Reverse stock split outstanding shares">792,394</span> shares, subject to adjustment for the rounding up of fractional shares. The number of authorized shares of common
stock under the Company&#8217;s Amended and Restated Certificate of Incorporation, as amended remained unchanged at <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20250313_zYsbyDuNJqOj" title="Common stock shares remained unchanged">40,000,000</span> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
references in this Annual Report to the number of shares, price per share and weighted average number of shares of common stock outstanding
prior to the Reverse Stock Splits have been adjusted to reflect the Reverse Stock Splits on a retroactive basis, unless otherwise noted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Issuance
of common stock for cash</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Issuance
of common stock for cash through private placement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 30, 2023, the Company entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with an institutional
investor for the issuance and sale in a private placement (the &#8220;Private Placement&#8221;) of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230830__20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEUR0LxvsObg" title="Number of new share issued">16,363</span> shares (the &#8220;Common Shares&#8221;)
of common stock, par value $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7JmHls8voi1" title="Common stock par value">0.001</span> per share (the &#8220;Common Stock&#8221;), pre-funded warrants (&#8220;Pre-Funded Warrants&#8221;)
to purchase up to <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zJhr7fZjtWfd" title="Number of securities called by warrants or rights">247,907</span> shares of common stock, with an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zFaM3bsJK8Va" title="Warrant exercise price per share">0.0001</span> per share, A-1 Warrants (the &#8220;A-1 Warrants&#8221;)
to purchase up to <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_zjCwBWkH5kl8" title="Number of securities called by warrants or rights">264,271</span> shares of Common Stock, with an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_ztxwQp0ex1l1" title="Class of warrant or right exercise price">16.17</span> per share, and A-2 Warrants (the &#8220;A-2 Warrants&#8221;
and together with the A-1 Warrants, the &#8220;Warrants<b><i>&#8221;</i></b> ) to purchase up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zwmVJDq06Uhb" title="Number of securities called by warrants or rights">264,270</span> shares of Common Stock with
an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_z7A1CiwEHWR4" title="Class of warrant or right exercise price">16.17</span> per share. The A-1 Warrants are exercisable immediately upon issuance and expire <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_zkjZ3XkNmCL3" title="Warrant expiration date">March 1, 2029</span>. The A-2 Warrants
are exercisable immediately upon issuance and expire <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zJnzL34kUxxa" title="Warrant expiration date">October 1, 2024</span>. The combined purchase price for one Common Share and the accompanying
Warrants was $<span id="xdx_900_eus-gaap--SharePrice_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zcEEYEAlI5D4" title="Common stock and warrant price per share">18.92</span>, and the combined purchase price for one Pre-Funded Warrant and the accompanying Warrants was $<span id="xdx_908_ecustom--PrefundedWarrantAndAccompanyingWarrantPricePerShares_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znmfrt0dbJvk" title="Pre-Funded Warrant and accompanying warrant price per shares">18.92</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net proceeds to the Company from the Private Placement are approximately $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20230830__20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z9mEcQEWUqt4" title="Proceeds from issuance of private placement">4,215,000</span>, after deducting placement agent fees and expenses
and estimated offering expenses payable by the Company. The Company intends to use the net proceeds received from the Private Placement
for general corporate purposes, including funding of our development programs, commercial planning and sales and marketing expenses,
potential strategic acquisitions, general and administrative expenses and working capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.C.
Wainwright &amp; Co., LLC (&#8220;Wainwright&#8221;) served as the Company&#8217;s exclusive placement agent in connection with the Private
Placement, pursuant to that certain engagement letter, dated as of July 5, 2023, as amended, between us and Wainwright (the &#8220;Engagement
Letter&#8221;). As part of Wainwright&#8217;s compensation, we issued to Wainwright or its designees warrants (the &#8220;Placement Agent
Warrants&#8221;) to purchase up to an aggregate of <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230705__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentWarrantsMember_zuEGsLZxDhbc" title="Number of securities called by warrants or rights">19,820</span> shares of Common Stock at an exercise price equal to $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230705__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentWarrantsMember_zJXcVPUyzqah" title="Share price">23.65</span> per share. The
Placement Agent Warrants are exercisable immediately upon issuance and expire <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230705__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentWarrantsMember_zDGur9KXG0tl" title="Class of warrant or right expire date">March 1, 2029</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock-based
compensation and options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 28, 2014, stockholders approved the NanoVibronix, Inc. 2014 Long-Term Incentive Plan (the &#8220;2014 Plan&#8221;), which was
adopted by the Board on February 19, 2014. As of December 31, 2022, under the 2014 Plan, <span id="xdx_90D_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20221231__us-gaap--AwardTypeAxis__custom--TwoThousandFourteenLongTermIncentivePlanMember_zgG1nWXtJzkf" title="Stock reserved for future issuance">442,207</span> shares of our common stock were reserved
for issuance. On February 9, 2023, the Company effected a <span id="xdx_908_eus-gaap--StockholdersEquityReverseStockSplit_c20230209__20230209__us-gaap--AwardTypeAxis__custom--TwoThousandFourteenLongTermIncentivePlanMember_zGkrYI8OhPf" title="Reverse stock split">one-for-twenty reverse stock split</span> of common stock. Consequently, the number
of shares of common stock of the Company reserved for issuance pursuant to awards under the 2014 Plan was reduced to <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20230209__us-gaap--AwardTypeAxis__custom--TwoThousandFourteenLongTermIncentivePlanMember_zBRUkizWfKd6" title="Number of common stock reserved for issuance for awards">22,110</span> shares. As
of December 31, 2023, there were <span id="xdx_90E_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20231231__us-gaap--AwardTypeAxis__custom--TwoThousandFourteenLongTermIncentivePlanMember_zSxL0REig5e3" title="Stock reserved for future issuance">11,866</span> shares of common stock available to be issued under the plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 19, 2024, stockholders approved the NanoVibronix, Inc. 2024 Long-Term Incentive Plan (the &#8220;2024
Plan&#8221;), as a successor to the Nanovibronix 2014 Long-Term Incentive Plan, which was adopted by the Board on November 6, 2023. As
of December 31, 2024, under the 2024 Plan, <span id="xdx_900_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20241231__us-gaap--AwardTypeAxis__custom--TwoThousandAndTwentyFourLongTermIncentivePlanMember_zVfq8cRQJxRl" title="Stock reserved for future issuance">600,000</span> shares of our common stock were reserved for issuance. On March 14, 2025, the Company
effected a one-for-eleven reverse stock split of common stock. Consequently, the number of shares of common stock of the Company reserved
for issuance pursuant to awards under the 2024 Plan was reduced to <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20250314__us-gaap--AwardTypeAxis__custom--TwoThousandAndTwentyFourLongTermIncentivePlanMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrFe8ZxUi7m3" title="Number of common stock reserved for issuance for awards">54,545</span> shares. As of December 31, 2024, there were <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandAndTwentyFourLongTermIncentivePlanMember_zBtYG3Amo0db" title="Number of share issued">9,486</span> shares of
common stock available to be issued under the plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2024, and 2023, <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_dxL_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zyWymLxcbBD8" title="Number of options, exercised::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0830">0</span></span> and <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zbs0TyLTt5v3" title="Number of options, exercised">5,426</span> employee options were exercised, <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zlZ8Gk66VXq1" title="Number of employee options granted">34,818</span> and <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zqyMvrvYUV4j" title="Number of employee options granted">7,273</span> options were granted,
<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_dxL_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z8kw3xXs5lca" title="Number of employee options forfeited::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0838">0</span></span> and <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zC5UtL0B5nsf" title="Number of employee options forfeited">9,584</span> options were forfeited and <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zfQLjQrLNjGi" title="Number of employee options expired">3</span> and <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zV7A97cqlCS1" title="Number of employee options expired">368</span> options were expired, respectively. The options granted during 2024 and 2023 vest
at different schedules ranging from date granted to <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zRZ27pnIZQp5" title="Fair value options vesting term"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zCY00yxij7d6" title="Fair value options vesting term">9</span></span> years and were recorded at fair values of approximately $<span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zep8MH6yJT71" title="Number of options, vested">226,000</span> and $<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zECWcJ7AgF8h" title="Number of options, vested">87,000</span>, respectively.
The maximum contractual term for granted options is <span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z3iB8Hyi5qke" title="Contractual term for granted options"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zRFG2QpKc2Eh" title="Contractual term for granted options">10</span></span> years. During the years ended December 31, 2024, and 2023, stock-based compensation
expense of approximately $<span id="xdx_903_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z9eSCXQ6wUea" title="Stock-based compensation expense">356,000</span> and $<span id="xdx_90A_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zWWajw1dg0Tf" title="Stock-based compensation expense">293,000</span> was recorded for options that vested, respectively.</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zRnajz2rExNa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zvHhwC29emWg" style="display: none">SCHEDULE OF OPTIONS ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares Under</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>per Share</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life (Years)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">Outstanding &#8211; December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zt6aMefE1eT6" style="width: 14%; text-align: right" title="Options, Outstanding - Beginning balance">10,244</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2d_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zAlkVS6LDsh4" style="width: 14%; text-align: right" title="Weighted Average Exercise Price per Share, Exercisable - Ending balance">13.10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zuO8oC4yP1X4" title="Weighted Average Remaining Life (Years), Outstanding">8.41</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zsQvG6cqmyhj" style="text-align: right" title="Options, Granted">34,818</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2d_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z9BEu7ef6R4" style="text-align: right" title="Weighted Average Exercise Price per Share, Granted">7.47</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zDGrqQdtxMja" title="Weighted Average Remaining Life (Years), Granted">9.78</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_ztr66m7BmhLf" style="text-align: right" title="Options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0876">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pp2d_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zDWotb2B7lQd" style="text-align: right" title="Weighted Average Exercise Price per Share, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0878">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zLrdckMjEYXg" title="Weighted Average Remaining Life (Years), Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0880">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z5uC7BOTCeG3" style="text-align: right" title="Options, Expired">(3</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pp2d_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zEp9r9PGCu22" style="text-align: right" title="Weighted Average Exercise Price per Share, Exercised">39.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zMEgC7Bao9h7" title="Weighted Average Remaining Life (Years), Expired"><span style="-sec-ix-hidden: xdx2ixbrl0886">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zRwRMknXGpml" style="border-bottom: Black 1pt solid; text-align: right" title="Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0888">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pp2d_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zVND6xCk6zQf" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price per Share, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0890">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zCDwLqTMiru7" title="Weighted Average Remaining Life (Years), Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0892">-</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding &#8211; December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z32ymmNLQzvb" style="text-align: right" title="Options, Outstanding - Ending balance">45,059</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pp2d_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zmKP5rPZlWYk" style="text-align: right" title="Weighted Average Exercise Price per Share, Outstanding - ending balance">3.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zXQOqt9MjGl1" title="Weighted Average Remaining Life (Years), Outstanding">9.24</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable &#8211; December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zBOZ4VP6HmA9" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Exercisable - Ending balance">45,059</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zmZW1bX6kxRh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price per Share, Outstanding - ending balance">3.50</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zcQwM7Zl783b" title="Weighted Average Remaining Life (Years), Exercisable">9.24</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zuZRi4yTjchl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
outstanding options had <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_do_c20241231_zqiyBPHxPSB8" title="Aggregate intrinsic value"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_do_c20231231_zh3fe9HD20Sd" title="Aggregate intrinsic value">no</span></span> aggregate intrinsic value as of December 31, 2024, and 2023. The intrinsic value is calculated as the difference
between the exercise price and the market value of the shares on the balance sheet date. The market values based on the closing bid price
as of December 31, 2024, and 2023 was $<span id="xdx_901_eus-gaap--SharePrice_iI_c20241231_zvSE8JS4J6Dk" title="Bid price">6.49</span> and $<span id="xdx_905_eus-gaap--SharePrice_iI_c20231231_zBVnWzCd9BU" title="Bid price">12.65</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zsLdriktqh95" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value for options granted in 2024 and 2023 is estimated at the date of grant using a Black-Scholes-Merton options pricing model
with the following underlying assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_z7m2ZIRLlCl3" style="display: none">SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR OPTIONS GRANTED</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Price at valuation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$ <span id="xdx_907_eus-gaap--SharePrice_iI_pp2d_c20241231__srt--RangeAxis__srt--MinimumMember_za8ONnVvuOA4" title="Price at valuation">6.71</span> &#8211; <span id="xdx_90C_eus-gaap--SharePrice_iI_pp2d_c20241231__srt--RangeAxis__srt--MaximumMember_zGIdXn4vZHY2" title="Price at valuation">9.90</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
                                            <span id="xdx_909_eus-gaap--SharePrice_iI_pp2d_c20231231__srt--RangeAxis__srt--MinimumMember_zES0X3AIObf2">13.2
                                            </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;
                                            <span id="xdx_905_eus-gaap--SharePrice_iI_pp2d_c20231231__srt--RangeAxis__srt--MaximumMember_z8dRCxkxgmI9">13.64</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$ <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_c20241231__srt--RangeAxis__srt--MinimumMember_z32dVIMMMHS3" title="Exercise price">6.71</span> &#8211; <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_c20241231__srt--RangeAxis__srt--MaximumMember_zwtbjSMWQKfc" title="Exercise price">9.90</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$ <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_c20231231__srt--RangeAxis__srt--MinimumMember_z5DpkXfdkl64">13.2</span>
                                            &#8211; </span><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_c20231231__srt--RangeAxis__srt--MaximumMember_zvgho4L20uX6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.64</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240101__20241231_zQuXvMfriufb" title="Risk free interest, minimum">4.14</span> &#8211; <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20240101__20241231_zPlwZQjgY3K2" title="Risk free interest, maximum">4.42</span> %</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20231231_zDTpuVAjwNEe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.83
                                            </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;
                                            <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20230101__20231231_zPsbcrB4FRM4">4.42
                                            </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Expected term (in years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231_zLfmpjqveXC1" title="Expected term (in years)">5</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zMWbcPvC2XA5" style="font-family: Times New Roman, Times, Serif">5</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20240101__20241231_zd0ANHMofr2i" title="Volatility, minimum">128.4</span> &#8211; <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20240101__20241231_zctxGMrRbwOb" title="Volatility, maximum">132.8</span> %</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20230101__20231231_z5YdNzA8UOY5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">133.1
                                            </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;
                                            <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20230101__20231231_zRC0RRDUiCw3">133.6
                                            </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zgdH7n8KyQS6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p id="xdx_89C_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zt5AGZJIb9ab" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total stock-based expense recognized in the financial statements for services received from employees and non-employees is shown in the
following table.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_zdfH3ioX8TDf" style="display: none">SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED SERVICES FROM EMPLOYEES AND NON-EMPLOYEES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20240101__20241231_z6XktNeSRnI9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20231231_z1cFdggzb4Id" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_znYUhzDywvF" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">6,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zfyhUw6y7Ru6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Selling and marketing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z8turcZgioZ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">334,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">259,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zi4G19ZLiGOl" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">356,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">293,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zgWgiHEQD5d3" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Stock based compensation expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">356,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">293,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AA_zHW4jhsLJcPe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, there was <span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_do_c20241231_zOLIn9aOYj8i" title="Non-vested stock options granted, unrecognized estimated compensation cost">no</span> unrecognized estimated compensation cost related to non-vested stock options granted prior to that
date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 30, 2023, the Company granted (a) Pre-Funded Warrants to purchase up to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zk9U07hNse97" title="Warrants issued to purchase common stock">264,271</span> shares of Common Stock with an exercise price
of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zu460JFrs7e8" title="Class of warrant or right exercise price">0.0001</span> per share, (b) A-1 Warrants to purchase up to <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_zl6qUL86Nyfi" title="Warrants issued to purchase common stock">264,271</span> shares of Common Stock with an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_zcUZBkksK2Le" title="Warrant exercise price">16.17</span> per share and
(c) A-2 Warrants to purchase up to <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zVK6RWSk9vC3" title="Warrants issued to purchase common stock">264,271</span> shares of Common Stock with an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zekCM2EQfi88" title="Warrant exercise price">16.17</span> per share, or a total of <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20230830_zJ7pqCNaAEK1" title="Total warrants">776,448</span> warrants,
in conjunction with the Private Placement disclosed above. The A-1 Warrants and A-2 Warrants are exercisable immediately upon issuance
and expire on <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20230830__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_zEGvNpM1zdy" title="Class of warrant or right expire date">March 1, 2029</span> and <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20230830__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zzOwXQEKo1Kk" title="Class of warrant or right expire date">October 1, 2024</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the same Private Placement, the Company granted Placement Agent Warrants to Wainwright, or its designees, to purchase up to an aggregate
of <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zhOQ6Abei7C4" title="Warrants issued to purchase common stock">19,820</span> shares of Common Stock at an exercise price equal to $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230830__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_z1kXAAJkDpH9" title="Share price">23.65</span> per share. The Placement Agent Warrants are exercisable immediately
upon issuance and expire <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20230830__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zDPRjFoEDvqe" title="Class of warrant or right expire date">March 1, 2029</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_ecustom--ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock_z3euBJXIJSt5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
estimating the warrants&#8217; fair value, the Company used the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zKsvv47MJk4g" style="display: none">SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR WARRANTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Risk free interest</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z46WZr2xiszl" title="Warrants, measurement input, percentage"><span style="-sec-ix-hidden: xdx2ixbrl0988">-</span></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zytQ8rdizZzl" title="Warrants, measurement input, percentage">3.49</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zeKwKRN982D6" title="Warrants, measurement input, percentage"><span style="-sec-ix-hidden: xdx2ixbrl0992">-</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zEMWAx4Us7c2" title="Warrants, measurement input, percentage"><span style="-sec-ix-hidden: xdx2ixbrl0994">-</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zvxKzIId2dDj" title="Warrants, measurement input, percentage"><span style="-sec-ix-hidden: xdx2ixbrl0996">-</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zfvsuw3JbBoa" title="Warrants, measurement input, percentage">147.6</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Contractual term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20241231_zqsnYIeqDdei" title="Contractual term (in years)"><span style="-sec-ix-hidden: xdx2ixbrl1000">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231_z5hF0H6D4Zqg" title="Contractual term (in years)">5</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_ztqOH4YdDmgh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BE_zTxbn4zuJUf9" style="display: none">SCHEDULE OF WARRANTS ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>Pre-RSS</b></td>
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Post - RSS</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Warrants</b></td>
    <td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Outstanding &#8211; December 31, 2022</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--PreWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zUWe2IdZGoc6" style="text-align: right; width: 16%" title="Warrants, Outstanding - Beginning balance">2,389</td>
    <td style="width: 1%">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--PostWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zIzVt1Uyv898" style="width: 16%; text-align: right" title="Warrants, Outstanding - Beginning balance">2,389</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--PreWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zXF3Cjg6PSu3" style="text-align: right" title="Warrants, Outstanding - Beginning balance">8,758,954</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--PostWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zEFnkTxCyHLh" style="text-align: right" title="Warrants, Outstanding - Beginning balance">796,269</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Expired</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--PreWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zmxrUXihS9Fl" style="text-align: right" title="Warrants, Outstanding - Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1012">-</span></td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--PostWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zTI4Dq7OUOu7" style="text-align: right" title="Warrants, Outstanding - Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1014">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Cancelled</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--PreWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zzwewt1olZsa" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants, Outstanding - Beginning balance">(203,977</td>
    <td style="padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--PostWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_z7BucyAHm4Id" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants, Outstanding - Beginning balance">(18,543</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding &#8211; December 31, 2023</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PreWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zctOm5KA3oIk" style="text-align: right" title="Warrants, Outstanding - Beginning balance">8,633,229</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PostWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zfvM8K6tLHR8" style="text-align: right" title="Warrants, Outstanding - Beginning balance">780,115</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PreWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zaLBljHjxDra" style="text-align: right" title="Warrants, Outstanding - Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1024">-</span></td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PostWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zT4KCyGwqwz4" style="text-align: right" title="Warrants, Outstanding - Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1026">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Expired</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PreWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_z2SFFBq1ndv" style="text-align: right" title="Warrants, Outstanding - Beginning balance">(2,918,977</td>
    <td>)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PostWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zU4X6An8BLD" style="text-align: right" title="Warrants, Outstanding - Beginning balance">(265,362</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercised</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PreWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zZCOIG93pCq7" style="text-align: right" title="Warrants, Outstanding - Beginning balance">(2,122,000</td>
    <td>)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PostWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zcSyp1kmQnif" style="text-align: right" title="Warrants, Outstanding - Beginning balance">(192,910</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Cancelled</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PreWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zQA7miZzDCn1" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants, Outstanding - Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1036">-</span></td>
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PostWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zqYfZaF6NBTe" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants, Outstanding - Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1038">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Outstanding &#8211; December 31, 2024</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PreWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_z1gMTs4V7sua" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding - Beginning balance">3,592,252</td>
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PostWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_ziZhRBEXtFU7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding - Beginning balance">321,843</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zRT6eHAqxxql" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text"><p id="xdx_802_eus-gaap--LesseeOperatingLeasesTextBlock_z10TFwGETv15" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7 &#8211; <span id="xdx_823_zgK8HiPkV98i">LEASES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has operating lease agreements with terms up to <span id="xdx_906_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember_z0i3y4vVC2ri" title="Lease term">1</span>-<span id="xdx_907_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember_zvKH276tEYJ9" title="Lease term">3</span> years, including car and office space leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s weighted-average remaining lease term relating to its operating leases is <span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zI6o87YBPXd6" title="Weighted-average remaining lease term">2.21</span> years, with a weighted-average discount
rate of <span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zPo9yZNRs9ci" title="Weighted-average discount rate">10</span>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company incurred $<span id="xdx_90F_eus-gaap--OperatingLeaseExpense_c20240101__20241231_z0lUNrn5a5f2" title="Operating lease, expense">70,000</span> of lease expense for its operating leases for the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zOU5r58QIyL6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information about the amount and timing of liabilities arising from the Company&#8217;s operating leases as
of December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;<span id="xdx_8B4_zGgbj7OTjX27" style="display: none">SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES</span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20241231_zxPtPQOlOC8a" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzL7T_zGXEahfPrLei" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left">2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">60,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzL7T_zTOe6HBlXKl7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">58,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzL7T_z39OzRFf7tF7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">2027</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzL7T_z6QTV7jPsWR7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total undiscounted operating lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">128,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_zLtKez6saP06" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: Imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">13,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iI_zMpPlSQGvR31" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Present value of operating lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">115,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zRfvqfIiAtFf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER</a></td>
<td class="text"><p id="xdx_805_eus-gaap--EarningsPerShareTextBlock_zc71vfFF3QLf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8 - <span id="xdx_827_zdUn3PGuiSld">LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per common share (&#8220;Basic EPS&#8221;) is computed by dividing net loss available to common shareholders by the weighted
average number of common shares outstanding during the period. All outstanding share options and warrants for the years ended December
31, 2024, and 2023 have been excluded from the calculation of the diluted net loss per share because all such securities are anti-dilutive
for all periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zlcoWaFYUOVf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s securities, in common share equivalents, which have been excluded from the calculation
of dilutive loss per share as their effect would be anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zX922lo9htWh" style="display: none">SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240101__20241231_zO8kDPjm9NOl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20230101__20231231_zliEkaTP3TNa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsEmployeeAndNonEmployeeMember_z69SwWeaMDY6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Stock options - employee and non-employee</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">45,059</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">10,244</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zqzlHoQRu4kb" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">326,568</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">784,839</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zkQIg5ezY5U1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">371,627</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">795,083</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A4_zCrMg9MIqk2g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
diluted loss per share equals basic loss per share in the year ended December 31, 2024, and 2023 because the Company had a net loss and
the impact of the assumed exercise of stock options and the vesting of restricted stock would have been anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA</a></td>
<td class="text"><p id="xdx_807_eus-gaap--SegmentReportingDisclosureTextBlock_zNp5qHzhvmg7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9 - <span id="xdx_825_z6mwsRi0GGUb">GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summary
information about geographic areas:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company manages its business on the basis of one reportable segment and Brian Murphy, CEO, is the chief decision maker for the
segment. The Company derives revenues from selling its products directly to patients as well as through distributor agreements. The
following is a summary of revenues within geographic areas:</span></p>

<p id="xdx_89C_eus-gaap--RevenueFromExternalCustomersByGeographicAreasTableTextBlock_zPYDtD4lb4f2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span id="xdx_8BC_zWuHqRpHpZl3">SUMMARY
OF REVENUE WITHIN GEOGRAPHIC AREAS</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20241231_zYvtbqfa9mee" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20230101__20231231_z686t8clFGhc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__country--US_z5igr5BEUtd3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,450,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,162,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__srt--EuropeMember_zlt75zO9MMR3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Europe</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__country--AU_zXVYD0RrRDyj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Australia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__country--IL_zZfEHqFWIzge" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Israel</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__country--NZ_zqmBAPvQnye6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">New Zealand</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1100">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__custom--OtherCountryMember_zTZBuNVnqaZ3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">46,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1103">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0d_zviMUP09I6fh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,558,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,283,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0d_zOB0gakHaA76" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Revenues geographic areas</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,558,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,283,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AF_zcN3kKlqooTe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s long-lived assets are all located in Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year end December 31, 2024, the Company generated approximately $<span id="xdx_909_eus-gaap--Revenues_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerMember_z4AtByWI8I22" title="Revenues">800,000</span> in revenue from its largest direct medical distributor,
Ultra Pain Products, LLC. This represents approximately <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerMember_zuF342PYPh4i" title="Concentration risk, percentage">31</span>% of the company&#8217;s total revenue for the year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsDisclosureTextBlock', window );">OTHER ASSETS</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--OtherAssetsDisclosureTextBlock_z58NV7IVZR27" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10 &#8211; <span id="xdx_829_zqcPGMjyMeTd">OTHER ASSETS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 9, 2020, pursuant to a licensing agreement entered into in March 2020, the Company received <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20200409__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zxWib95aXX9j" title="Warrants and rights outstanding term">10</span>-year warrants to purchase <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20200409__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_znF23TDkPWWe" title="Warrants issued to purchase common stock">127,000</span>
shares of Sanuwave Health, Inc. at a price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20200409__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_ziHQ9H53MNo8" title="Exercise price of warrants per share">0.19</span> per share. The fair value for warrants received is estimated at the date of grant
using a Black-Scholes-Merton pricing model with the following underlying assumptions:</span></p>

<p id="xdx_899_ecustom--ScheduleOfWarrantsAssumptionsTableTextBlock_zDKX714Vy246" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="display: none"><span id="xdx_8B0_ztgla8kCAZi">SCHEDULE OF WARRANTS ASSUMPTIONS</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Price at valuation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__custom--PriceAtValuationMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zDbiPnlSN1F3" title="Warrants and rights outstanding, measurement input">0.01</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__custom--PriceAtValuationMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zSCafcIMChM4" title="Warrants and rights outstanding, measurement input">0.01</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zB2R6yMLZG96" title="Warrants and rights outstanding, measurement input">0.19</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zVU3v9oIQVtj" title="Warrants and rights outstanding, measurement input">0.19</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zp6Zv0uSc7Fa" title="Warrants and rights outstanding, measurement input">3.88</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zkfmBN6WiGU8" title="Warrants and rights outstanding, measurement input">3.88</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zk9gYMzSEDha" title="Expected term (in years)">7</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zygXJz8tDLH1" title="Expected term (in years)">7</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_z9skbkifx3Ud" title="Warrants and rights outstanding, measurement input">147.8</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_z31oSP3O7shj" title="Warrants and rights outstanding, measurement input">147.8</span></td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8A1_z5LGHEISuaJd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers this to be Level 3 inputs and is valued at each reporting period. As of September 12, 2024, the company terminated
the licensing agreement with Sanuwave and recognized $<span id="xdx_90A_eus-gaap--GainLossOnContractTermination_c20240912__20240912_zGpHzGbL6ypl" title="Gain loss on contract termination">3,000</span> in gain/loss of termination of investment, offset by change in fair value
through the date of termination of $<span id="xdx_908_ecustom--IncreaseDecreaseInTerminationValueByOffset_iI_c20240912_zP7KOLx9smY1" title="Increase decrease in termination value by offset">1,000</span>. The fair value of these warrants for the years ended December 31, 2024, and 2023 was $<span id="xdx_90C_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iI_c20241231_z6m1RFh24o52" title="Fair value of warrants">0</span> and
$<span id="xdx_900_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iI_c20231231_z4sIfkjBknDb" title="Warrants leaving balance">1,000</span>, respectively. There was a net $<span id="xdx_901_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231_zjypg1q1po2h" title="Fair value of warrants">3,000</span> and $<span id="xdx_906_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231_z6IhbENHkvEe" title="Fair value of warrants">2,000</span> change in fair value during the year ended December 31, 2024, and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Financial
Liabilities Measured at Fair Value on a Recurring Basis</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability
in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants
would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 inputs: Inputs, other than quoted prices included in Level 1, that are observable either directly or indirectly; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own
    assumptions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no transfers between Level 3 during the years ended December 31, 2024, and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_z2nhLDqF724i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents changes in Level 3 asset and liability measured at fair value for the years ended December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zzp8DjOUaIpc" style="display: none">SCHEDULE
OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Asset</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%">Balance &#8211; December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3d_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zhxGeSsFbK6a" style="width: 14%; text-align: right" title="Balance beginning">3,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Fair value adjustments &#8211; Sanuwave warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FairValueAdjustmentOfWarrants_pn3d_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zCmWZcrsy9y2" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants">(2,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance &#8211; December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3d_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_z5lKcZNPZI3g" style="text-align: right" title="Balance beginning">1,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Fair value adjustments &#8211; Sanuwave warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FairValueAdjustmentOfWarrants_pn3d_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zAYie0zaomG9" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants">(1,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance &#8211; December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_pn3d_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zAkyyPVLxuR1" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance beginning"><span style="-sec-ix-hidden: xdx2ixbrl1167">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zN7iM67GH1Xe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zGOPWlPhDSh7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the Company&#8217;s assets and liabilities which are measured at fair value on a recurring basis by level
within the fair value hierarchy:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_zwWJeHXQDedf" style="display: none">SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_znBUdNv0qPEg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level I</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zgvMR1A6PpA7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level II</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z96DcWj5kHy" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level III</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20241231_z9DoxhMLDlZ5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level I</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level II</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level III</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 28%">Asset:</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherAssetsFairValueDisclosure_iI_zVcggDXizV32" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1171">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1172">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1173">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1174">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zxAKE3RGqrJ2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level I</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zCq33R0310w7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level II</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zULoEFsUUZf4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level III</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231_zdzGtmbO0cNe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level I</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level II</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level III</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 28%">Asset:</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OtherAssetsFairValueDisclosure_iI_zqdU7meWwT78" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1176">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1177">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zXY1icEwDNH9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_802_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zhLjX2eAYg3a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
11 - <span id="xdx_82C_z8P5fV4IYrAa">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Pending
and settled litigation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 26, 2021, Protrade Systems, Inc. (&#8220;Protrade&#8221;) filed a Request for Arbitration (the &#8220;Request&#8221;) with the
International Court of Arbitration (the &#8220;ICA&#8221;) of the International Chamber of Commerce alleging the Company is in breach
of an Exclusive Distribution Agreement dated March 7, 2019 (the &#8220;Exclusive Distribution Agreement&#8221;) between Protrade and
the Company. Protrade alleges, in part, that the Company has breached the Exclusive Distribution Agreement by discontinuing the manufacture
of the DV0057 Painshield MD device in favor of an updated 10-100-001 Painshield MD device. Protrade claims damages estimated at $<span id="xdx_904_eus-gaap--LossContingencyDamagesSoughtValue_pn6n6_c20210225__20210226_zKyz3tsCBDzi" title="Litigation damages sought value">3</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 15, 2022, the arbitrator issued a final award, which, determined that (i) the Company had the right to terminate the Exclusive
Distribution Agreement; (ii) the Company did not breach the duty of good faith and fair dealing with regard to the Exclusive Distribution
Agreement; and (iii) the Company did not breach any confidentiality obligations to Protrade. Nevertheless, the arbitrator determined
that the Company did not comply with the obligation to supply Protrade with a year&#8217;s supply of patches, and awarded Protrade $<span id="xdx_90F_eus-gaap--LossContingencyDamagesSoughtValue_c20220314__20220315_zwUzU7hOiKx9" title="Loss contingency damages sought value">1,500,250</span>,
which consists of $<span id="xdx_905_eus-gaap--LossContingencyDamagesAwardedValue_c20220314__20220315_zxHPoZJvf5pf" title="Loss contingency damages sought value">1,432,000</span> for &#8220;lost profits&#8221; and $<span id="xdx_902_eus-gaap--LossContingencyDamagesPaidValue_c20220314__20220315_z55qV5WmuNqa" title="Loss contingency damages paid value">68,250</span> as reimbursement of arbitration costs, on the grounds that the
Company allegedly failed to supply Protrade with certain patches utilized by users of DV0057 Painshield MD device. The arbitrator based
the decision on the testimony of Protrade&#8217;s president who asserted that a user would use in excess of 33 patches per each device.
The Company believes that the number of patches per device alleged by Protrade is grossly inflated, and that these claims were not properly
raised before the arbitrator. Accordingly, on April 13, 2022, the Company submitted an application for the correction of the award which
the arbitrator denied on June 22, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 22, 2022, the Company filed a cross-motion seeking to vacate arbitration award on the grounds that the arbitrator exceeded her authority,
that the award was procured by fraud, and that the arbitrator failed to follow procedures established by New York law. In particular,
the Company averred in its motion that Protrade&#8217;s witness made false statements in arbitration, and that the arbitrator resolved
a claim that was never raised by Protrade and that has no factual basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2022, the court issued a decision granting Protrade its petition to confirm the award and denying the cross-motion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 9, 2022, the Company filed a motion to re-argue and renew its cross-motion to vacate the arbitration decision based on newer
information that was not available during the initial hearing. On the same day, the Company also filed a notice of appeal with the Appellate
Division, Second Department. On March 21, 2023, the court denied the motion to re-argue and renew.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">On July 10, 2023, the Company filed its appeal with the Appellate Division,
Second Department. That appeal is now fully briefed. In February 2025, the Second Department informed counsel for the Company that the
Second Department was beginning to process the appeal for calendaring.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, and 2023, the Company accrued the amount of the arbitration award to Protrade of approximately $<span id="xdx_901_eus-gaap--LossContingencyDamagesAwardedValue_pn5n6_c20240101__20241231__srt--TitleOfIndividualAxis__custom--ArbitratorMember_zhiTbLeUGEFc" title="Damages awarded value">2.1</span>
million and $<span id="xdx_900_eus-gaap--LossContingencyDamagesAwardedValue_pn5n6_c20230101__20231231__srt--TitleOfIndividualAxis__custom--ArbitratorMember_zendAHeQEsl7" title="Damages awarded value">2.0</span> million, respectively, including interest which is classified in &#8220;Other accounts payable and accrued
expenses&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTION</a></td>
<td class="text"><p id="xdx_804_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zVot36ortO2c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
12 &#8211; <span id="xdx_826_zwDHkBe8neqb">RELATED PARTY TRANSACTION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
firm of FisherBroyles LLP handled all our Protrade litigation and appeals through December 31, 2024. For the year ended December 31,
2024, we have been not been billed and have not paid any legal fees from FisherBroyles .Ms. Cassirer id not provide any legal services
or legal advice to the Company<b>.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 1, 2024, Ms. Cassirer and the lawyers responsible for handling our Protrade litigation left the firm of FisherBroyles to join
the firm of Pierson Ferdinand LLP. As of January1, 2024, the firm Pierson Ferdinand is the sole firm handling all our Protrade litigation
and appeals. For the year ended December 31, 2024, Pierson Ferdinand was paid $<span id="xdx_903_eus-gaap--PaymentsForFees_c20240101__20241231__srt--TitleOfIndividualAxis__custom--PiersonFerdinandMember_zqEkLgSkLWT8" title="Payments for fees">69,000</span>. As was the case in prior years, Ms. Cassirer does
not provide any legal services or legal advice to the Company<b>.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_807_eus-gaap--IncomeTaxDisclosureTextBlock_zsUqwKH3qtb6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
13 &#8211; <span id="xdx_82A_zNAJtWIVdZm">INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the U.S. Company had federal and state net operating loss carry forward for tax purposes of approximately $<span id="xdx_909_eus-gaap--OperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zBGZKvTpHYLc" title="Net operating loss carry forward">41,300,000</span>
and $<span id="xdx_907_eus-gaap--OperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zIGSShdtXhUd" title="Net operating loss carry forward">5,400,000</span>, respectively. $<span id="xdx_907_ecustom--FederalNetOperatingLossCarriedForward_iI_c20231231_z6QJrpoOqda6" title="Federal net operating loss carried forward">27,400,000</span> of the federal net operating loss can be carried forward indefinitely but can only offset up
to 80% of taxable income in a given year, and $<span id="xdx_903_ecustom--FederalNetOperatingLossOffsetAgainstTaxableIncome_c20230101__20231231_zF2q9G1AlL75" title="Federal net operating loss offset against taxable income">14,000,000</span> of the federal net operating loss can be used to fully offset taxable income
in the period it is utilized but can only be carried forward for <span id="xdx_903_ecustom--OperatingLossCarryforwardsExpirationTerm_dtY_c20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zoRaoxAFMUW9" title="Operating loss carryforwards expiration term">20</span> years. Utilization of the U.S. net operating losses may be subject
to substantial limitations in the event of a change of ownership under the provisions of the Internal Revenue Code of 1986. The Company
has not performed an analysis, but the potential impact of any limitation would not be material to the financial statements due to the
fact that the respective DTAs are fully offset by a valuation allowance. It should be noted that the federal deferred income tax expense at December
31, 2023 included a one-time adjustment to the net operating loss carryforward amounting to approximately $<span id="xdx_903_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_iI_c20231231_z8fcrguwnRb7" title="Net operating loss carryforwards">400,000</span> that will not affect
the financial statements due to the full valuation allowance on the deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zobxkIkXBd87" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax expense is comprised of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_z9NXsdQaVxSe" style="display: none">SCHEDULE
OF PROVISION FOR INCOME TAXES EXPENSES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20240101__20241231_zKiJQhJVt58l" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20231231_zuxtMajYHa74" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current Tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CurrentFederalTaxExpenseBenefit_maCITEBzPkK_zz1DCJAuasU" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Federal</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1215">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1216">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maCITEBzPkK_zFzO7nt8qYPe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">State</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1218">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1219">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CurrentForeignTaxExpenseBenefit_maCITEBzPkK_z0ewUR7hJsh5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Foreign</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0">18,677</p></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(25,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBzPkK_maOTEBzPz3_zgtwwKReysl1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="margin: 0">18,677</p></td><td style="text-align: left"></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(25,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred Tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maDITEBzsCS_zNtT1JVqJ0I7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="margin: 0">(815,484</p></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1,226,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maDITEBzsCS_z2jwcZcrVCRe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">State</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">(11,269</p></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(43,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_maDITEBzsCS_zdb8op4KZaSh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Foreign</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0">(3,263</p></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_mtDITEBzsCS_maOTEBzPz3_zUkSjIa3EuF1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="margin: 0">(830,015</p></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1,267,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--ValuationAllowanceOfIncomeTaxExpenseBenefit_iN_di_msOTEBzPz3_zvkh7EoLm7dg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: Valuation Allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0">830,015</p></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,267,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OtherTaxExpenseBenefit_iT_mtOTEBzPz3_zq28qJXkOSk5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total Tax</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="margin: 0">18,677</p></td><td style="padding-bottom: 2.5pt; text-align: left"></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(25,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8AE_z709BMCptM4j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also recognized approximately $<span id="xdx_90F_ecustom--FranchiseFees_c20230101__20231231_zQp2XwuvHn27" title="Franchise fees">4,000</span> of state franchise fees during the year ended December 31, 2023. The difference between
the statutory tax rate of the Company and the effective tax rate is primarily the result of tax benefits generated by the Company and
its subsidiary which have not been recognized due to the uncertainty that such tax benefits will ultimately be realized. A reconciliation
of the statutory U.S Federal rate to the Company&#8217;s effective tax rate is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p><p id="xdx_89A_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zrv6m6x4H7jb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="display: none"><span id="xdx_8BF_zy6isbGgFFHj">SCHEDULE
OF RECONCILIATION OF STATUTORY U.S. FEDERAL RATE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20240101__20241231_zo1qpy21NxQj" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_zuaiCLWSH0Ib" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_maETR_z08mTPio2hF7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Federal income tax benefit at statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><p style="margin: 0">21.00</p></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_maETR_z0WtBKY24cWi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State income taxes, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">0.31</p></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.13</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_maETR_zgi3HoYswTL2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign rate differential</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">0.04</p></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0.10</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_407_ecustom--EffectiveIncomeTaxRateReconciliationPermanentItems_pid_dp_maETR_z2zbMpdHaZX8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Permanent Items</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">-0.04</p></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0.63</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_maETR_zOvN0UqjO8Ud" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">-21.51</p></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-33.54</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_pid_dp_maETR_z8eeJ4Wu87g3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Return to provision adjustments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">0.40</p></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.20</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_406_ecustom--EffectiveIncomeTaxRateReconciliationForfeitedOptions_pid_dp_maETR_zFm7YbMTTPql" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Forfeited options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">0.00</p></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_maETR_zI863VO3wvn2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0">0.30</p></td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-0.01</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_mtETR_z1dnfdx1pM2a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Effective tax rate</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="margin: 0">-0.51</p></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.06</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p id="xdx_8AD_ziPJdL6rinP4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Foreign
tax</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
rates applicable to the income of the Israeli subsidiary:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Israeli corporate tax rate in 2024 and 2023 is <span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20240101__20241231__srt--StatementGeographicalAxis__country--IL_zBjOn3dBgtsk" title="Corporate tax rate"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20230101__20231231__srt--StatementGeographicalAxis__country--IL_zUclM5JiY825" title="Corporate tax rate">23</span></span>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
subsidiary has final tax assessments through 2017.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
before taxes:</span></p>

<p id="xdx_893_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_z8kq8o1y2ys9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="display: none"><span id="xdx_8B5_z95j9vk6bTZd">SCHEDULE
OF INCOME BEFORE TAXES ON DOMESTIC AND FOREIGN</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20241231_zflRt6iwtLFh" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20230101__20231231_zh2ylrDK48Vc" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_maILFCOz5C4_zGWQb8RJ19ce" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Domestic</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><p style="margin: 0">3,775,000</p></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">3,785,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_maILFCOz5C4_zh5XuOSYkMd9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Foreign</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0">(89,000</p></td><td style="padding-bottom: 1pt; text-align: left">)<br/>
</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(103,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iNT_di_mtILFCOz5C4_z6Gc6eupoZMc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss before taxes</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="margin: 0">3,686,000</p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,682,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zahqvlabvfk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Deferred
income taxes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial
purposes and the amounts used for income tax purposes. Significant components of the Company&#8217;s deferred tax assets are as follows:</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zNYO9gPUIDh6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="display: none"><span id="xdx_8B2_zqf9uXoQr892">SCHEDULE
OF DEFERRED TAX ASSETS</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20241231_zmAEAoSVgAI4" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20231231_za5qgwPsI8ih" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzNu2_zv8U2kJ3Ihtf" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Net operating loss carryforward</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><p style="margin: 0">9,032,000</p></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">8,486,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DeferredTaxAssetsOfCapitalLossCarryforward_iI_maDTAGzNu2_zAffx37hB6U" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Capital loss carryforward</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">5,000</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1297">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--DeferredTaxAssetsTaxDeferredExpenseAccruals_iI_maDTAGzNu2_zLxfObrePuZj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Arbitration accrual</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">414,000</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">414,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_iI_maDTAGzNu2_z9VaXSu4vkA3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Stock compensation and other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0">849,000</p></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">570,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzNu2_maDTALNzt1d_zNYrTbXgZi7k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred tax assets before valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">10,300,000</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,470,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzt1d_ziepFG8hpcqa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0">(10,300,000</p></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(9,470,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzt1d_zTvmpeSxKzj4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax asset</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1311">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1312">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zLlNAwKlYRFb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2024, and 2023, the net increase in valuation allowance of $<span id="xdx_90B_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20240101__20241231_zdWUZmdn9IDa" title="Net increases in valuation allowance">830,000</span> and $<span id="xdx_90E_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20230101__20231231_znwa6UWAWFZb" title="Net increases in valuation allowance">1,267,000</span>, respectively, was primarily
driven by the increase in net operating loss carry forwards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
assessing the realization of deferred tax assets, management considers whether it is more likely than not that all or some portion of
the deferred tax assets will not be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which
temporary differences are deductible and net operating losses are able to be utilized. Based on consideration of these factors, the Company
concluded that all of its recorded deferred tax assets are not more likely than not realizable and recorded a full valuation allowance
at December 31, 2024, and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers the earnings of its non-U.S. subsidiary to be indefinitely invested outside the United States on the basis of estimates
that future domestic cash generation will be sufficient to meet future domestic cash needs and our specific plans for reinvestment of
those subsidiary earnings. We have not recorded a deferred tax liability related to the U.S. federal and state income taxes as an estimate
of undistributed earnings of foreign subsidiaries would not be practicable to estimate at this time. If the Company does decide to repatriate
the foreign earnings, we would need to adjust our income tax provision in the period we determined that the earnings will no longer be
indefinitely invested outside the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Reconciliation
of the theoretical tax expense to the actual tax expense</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
main reconciling items between the statutory tax rate of the Company and the effective tax rate are the non-recognition of tax benefits
from accumulated net operating loss carry forward among the Company and its subsidiary due to the uncertainty of the realization of such
tax benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s policy is to record interest and penalties associated with unrecognized tax benefits as additional income taxes in the
statement of operations. As of December 31, 2024, and 2023, the Company does not have any liabilities recorded for uncertain tax positions
and does not expect there to be any events which could potentially result in the need for a material liability to be recorded. There
were no changes in the Company&#8217;s unrecognized tax benefits during the years ended December 31, 2024, and 2023. The Company did
not recognize any interest or penalties during fiscal 2024 or 2023 related to unrecognized tax benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
federal and New York State income taxes are open for examination for years 2021-2024 and Israel tax returns are open for examination
for years 2020-2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_800_eus-gaap--SubsequentEventsTextBlock_zVnW4T3NxjT8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
14 - <span id="xdx_82D_zxjt7wXRCZ8h">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>January
2025 3(a)(9) Exchange</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 7, 2025, NanoVibronix, Inc. entered into a securities exchange agreement (the &#8220;Exchange Agreement&#8221;) with a
certain institutional investor (the &#8220;Holder&#8221;) pursuant to which the Company agreed to issue an aggregate of (i) </span><span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250107__20250107__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z7YnanCYZ2d" title="Number of new share issued">456,478</span>
shares of common stock, (ii) a warrant to purchase up to <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250701__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zS8Mo5U1rMq8" title="Number of securities called by warrants or rights">158,562</span>
shares of Common Stock (the &#8220;Warrant&#8221; and such shares issuable upon exercise of the Warrant, the &#8220;Warrant
Shares&#8221;) and (iii) a pre-funded warrant to purchase up to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250107__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBXvyVcqNqO7" title="Number of securities called by warrants or rights">178,132</span>
shares of common stock (the &#8220;Pre-Funded Warrant&#8221; and such shares of Common Stock issuable upon exercise of the
Pre-Funded Warrant, the &#8220;Pre-Funded Warrant Shares&#8221;), in exchange for a certain outstanding Series A-1 Warrant held by
the Holder to purchase up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250107__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zv9eRRiYWhyd" title="Number of securities called by warrants or rights">264,271 </span>
shares of common stock at an exercise price of $<span id="xdx_902_eus-gaap--WarrantExercisePriceIncrease_pid_c20250107__20250107__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBx2JX4I5v8k" title="Warrant exercise price">16.17</span>
per share (the &#8220;Exchange&#8221;). The Company cancelled the Series A-1 Warrant reacquired in the Exchange and such Series A-1
Warrant will not be reissued. The Warrant has substantially the same terms as the Series A-1 Warrant, except that the Warrant Shares
are subject to stockholder approval (the &#8220;January 2025 Stockholder Approval&#8221;) pursuant to the applicable rules and
regulations of the Nasdaq Capital Market, exercisable for a term of five and one half years from the date the January 2025
Stockholder Approval is received and deemed effective under Delaware law, and has an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250107__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zoaFDuVfyANj" title="Exercise price per share">6.82968</span>
per share. During the months January and February 2025, the Holder exercised all <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zM9xUT4WaVb9" title="Warrant exercise, shares"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250228__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4yVUDKxbv56" title="Warrant exercise, shares">178,132</span></span>
shares of its Pre-Funded Warrants converting the Warrants into <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zNL2V0c5RO09" title="Warrant exercise, conversion shares"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250228__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zyvJcGvZ89k6" title="Warrant exercise, conversion shares">177,773</span></span>
shares of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Merger
with ENvue Medical Holdings, Corp.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2025, Nanovibronix, Inc., a Delaware corporation (the &#8220;Company&#8221;) entered into that certain Agreement and Plan
of Merger (the &#8220;Merger Agreement&#8221;) with NVEH Merger Sub I, Inc., a Delaware corporation (&#8220;First Merger Sub&#8221;),
NVEH Merger Sub II, LLC, a Delaware limited liability company (&#8220;Second Merger Sub&#8221;) and ENvue Medical Holdings, Corp. (&#8220;ENvue&#8221;).
Pursuant to the terms of the Merger Agreement, the Company and ENvue effected (i) a merger of First Merger Sub with and into ENvue, with
the First Merger Sub ceasing to exist and ENvue becoming a wholly-owned subsidiary the Company (the &#8220;First Effective Time&#8221;)
and (ii) the merger of ENvue with and into Second Merger Sub (the &#8220;Second Merger&#8221; and such effective time, the &#8220;Second
Effective Time&#8221; and, the Second Merger together with the First Merger, the &#8220;Merger&#8221;), with Second Merger Sub being
the surviving entity of the Second Merger (&#8220;Surviving Entity&#8221;). At the Second Effective Time, the certificate of formation
of the Surviving Entity was amended and restated to, among other things, to change the name of the Surviving Entity to &#8220;ENvue Medical
Holdings LLC.&#8221; In connection with the Merger Agreement, the Company issued (i) <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250214__20250214__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWQarZE0tpXk" title="Number of new share issued">1,734,995</span> shares (the &#8220;Merger Shares&#8221;)
of common stock to the holders of ENvue, which such number of shares represented no more than <span id="xdx_90D_ecustom--PercentageForNumberOfOutstandingCommonStock_pid_dp_uPure_c20250214__20250214__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MaximumMember_zNF2rx9MMAP1" title="Percentage for number of outstanding common stock">19.9</span>% (the &#8220;Exchange Cap&#8221;)
of the outstanding shares of common stock immediately prior to the First Effective Time and (ii) <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20250214__20250214__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4jB66F6WwG8" title="Convertible shares">57,720</span> shares of Series X Non-Voting
Convertible Preferred Stock (the &#8220;Series X Preferred Stock&#8221;), as further described below, in excess of the Exchange Cap to
the holders of ENvue in consideration for <span id="xdx_90A_ecustom--PercentageForExchangeCapitalForConsideration_pid_dp_uPure_c20250214__20250214__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zofx9pBUwHc7" title="Percentage for exchange capital for consideration">100</span>% of ENvue. Each share of Series X Preferred Stock will be convertible into <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20250214__20250214__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTyV8wTgHoB8" title="Convertible shares">1,000</span> shares
of common stock, subject to and contingent upon the affirmative vote of a majority of the shares of common stock present or represented
and entitled to vote at a meeting of stockholders of Company to approve, for purposes of the Nasdaq Listing Rules, the issuance of shares
of common stock to the stockholders of ENvue upon conversion of any and all shares of Series X Preferred Stock in accordance with the
terms of the Series X Certificate of Designations. The Merger was consummated and completed on February 14, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
giving effect to the Merger, pursuant to the terms and conditions of the Merger Agreement: (i) <span id="xdx_904_eus-gaap--ConvertiblePreferredStockTermsOfConversion_c20250214__20250214__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zdDj6Jhntzxi" title="Convertible description">the holders of the outstanding equity
of ENvue immediately prior to the First Effective Time own 19.9% of the common stock of the Company and 85.0% of the outstanding equity
of the Company (assuming the Series X Preferred Stock is converting at a ratio of 1,000:1) immediately following the First Effective
Time, which following Merger Stockholder Approval will allow the Series X Preferred Stock to convert to common stock of the Company which
may result in the holders of ENvue to own 85% of the common stock of the Company, and (ii) the holders of the Company&#8217;s outstanding
equity immediately prior to the First Effective Time own 80.1% of the common stock of the Company and 15.0% of the outstanding equity
of the Company (assuming the Series X Preferred Stock is converting at a ratio of 1,000:1) immediately following the First Effective
Time, which following Merger Stockholder Approval which will allow the Series X Preferred Stock to convert to common stock of the Company
which may result in our holders owning 15% of common stock of the Company.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Debenture
Financing and Senior Convertible Debenture</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 13, 2025, the Company entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with an institutional
investor (the &#8220;Investor&#8221;), pursuant to which the Company sold in a private placement, a senior convertible debenture (the
&#8220;Debenture&#8221;) due the earlier of (i) the date that is the 30-day anniversary of the effective date of stockholder approval
(the &#8220;Debenture Stockholder Approval&#8221;) of the issuance of the shares of common stock upon the conversion of the debenture
(the &#8220;Debenture Financing&#8221;) and (ii) the date that is nine months following the date of issuance of the Debenture (&#8220;Maturity
Date&#8221;), having an aggregate principal amount of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20250213__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztfn7uQ5nZmd" title="Debt principal amount">500,000</span>. In connection with the Debenture Financing, the Company also entered
into Registration Rights Agreement (the &#8220;Registration Rights Agreement&#8221;) with the Investor, pursuant which the Company is
required to prepare and file a resale registration statement with the SEC within 30 calendar days following the closing date of the Debenture
Financing (the &#8220;Filing Deadline&#8221;). The Company shall use its commercially reasonable efforts to cause such registration statement
to be declared effective by the SEC within 60 calendar days of the Filing Deadline (or within 90 calendar days if the SEC reviews the
resale registration statement). The closing of the Debenture Financing occurred on February 14, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">On March 26, 2025 we amended
and restated the Debenture to increase the Principal Amount to $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20250326__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--ENvueMedicalHoldingsCorpMember_z9s5Qh1nhyL1" title="Debt principal amount">1,300,000</span> to provide for the funding by Alpha Capital Anstalt (the &#8220;Investor&#8221;)
to our subsidiary ENvue Medical Holdings, Corp. (&#8220;<b><i>ENvue</i></b>&#8221;), a wholly owned subsidiary of the Company of (i) an
aggregate of $<span id="xdx_908_eus-gaap--Investments_iI_c20250226__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--ENvueMedicalHoldingsCorpMember_z75NUxhiTEx3" title="Investments">250,000</span> by the Investor to ENvue on February 6, 2025, (ii) an aggregate of $<span id="xdx_908_eus-gaap--Investments_iI_c20250304__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--ENvueMedicalHoldingsCorpMember_zUFZzGEUTw48" title="Investments">250,000</span> by the Investor to ENvue on March 4,
2025, and (iii) and an aggregate of $<span id="xdx_903_eus-gaap--Investments_iI_c20250326__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--ENvueMedicalHoldingsCorpMember_zTYO8drNHNg9" title="Investments">300,000</span> by the Investor to ENvue on March 26, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">On the Maturity Date, we shall pay the Investor in
cash or, at the option of the Investor, in the form of conversion shares, or a combination thereof, the entire outstanding principal amount
of the Debenture, together with accrued and unpaid interest thereon, the applicable exit fee and any other amounts due thereunder. Following
the receipt of Debenture Stockholder Approval, the Debenture shall be convertible, in whole or in part, into shares of common stock, at
the option of the Investor, at the initial conversion price of $<span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20250326__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--ENvueMedicalHoldingsCorpMember_zzitXf8keZIh" title="Conversion price">4.8906</span> (the &#8220;Conversion Price&#8221;), which is subject to customary
anti-dilution adjustments, and which such Conversion Price shall not be lower than the floor price of $<span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20250326__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_zKUZEPIGWnr4" title="Conversion price">0.97812</span>. The Debenture bears interest
at the rate of <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20250326__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--ENvueMedicalHoldingsCorpMember_zBwPu3twiGt8" title="Debt interest rate">8.0</span>% per annum, payable on the Maturity Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2025
Reverse Stock Split</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 13, 2025, the Company effected the 2025 Reverse Stock Split. As a result of the 2025 Reverse Stock Split, every 11 shares of issued
and outstanding common stock were automatically combined into one issued and outstanding share of common stock, without any change in
the par value per share. No fractional shares were issued as a result of the 2025 Reverse Stock Split. Any fractional shares that would
otherwise have resulted from the Reverse Stock Split was rounded up to the next whole number. The 2025 Reverse Stock Split reduced the
number of shares of common stock outstanding from <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_pid_c20250312__20250312__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlSSQU1U9Pj3" title="Reverse stock split outstanding shares">8,716,327</span> shares to approximately <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_pid_c20250313__20250313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTB7AsTcY3md" title="Reverse stock split outstanding shares">792,394</span> shares, subject to adjustment for the rounding
up of fractional shares. The number of authorized shares of common stock under the Company&#8217;s Amended and Restated Certificate of
Incorporation, as amended remained unchanged at <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20250313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zcXkjfYohdO4" title="Common stock shares remained unchanged">40,000,000</span> shares.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation and principles of consolidation</a></td>
<td class="text"><p id="xdx_844_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z70ns3JxFLLc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Basis
of presentation and principles of consolidation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements include the accounts of NanoVibronix, Inc. and its wholly owned subsidiary. Intercompany
accounts and transactions have been eliminated. The consolidated financial statements and accompanying notes have been prepared in conformity
with U.S. generally accepted accounting principles (&#8220;US GAAP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--UseOfEstimates_zMfdFD4yoxyb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Use
of estimates</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and
assumptions. The Company believes that the estimates, judgments and assumptions used are reasonable based upon information available
at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during
the reporting period. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign currency translation</a></td>
<td class="text"><p id="xdx_844_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zoYspOsZUoif" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Foreign
currency translation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-U.S.
dollar denominated transactions and balances have been re-measured to U.S. dollars. All gains and losses from re-measurement of monetary
balance sheet items denominated in non-U.S. dollar currencies are reflected in the statements of operations as other comprehensive income,
as appropriate. The cumulative translation losses and gains as of the years ended December 31, 2024, and 2023 were $<span id="xdx_90F_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_c20240101__20241231_zaXYHL6baVDi" title="Cumulative translation gains">19,000</span> and $<span id="xdx_905_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_c20230101__20231231_zv9MMW0ey4gf" title="Cumulative translation gains">49,000</span>,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash</a></td>
<td class="text"><p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zESQdMF0jdxf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company holds cash in various banking institutions. Such funds are insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;)
up to $<span id="xdx_903_eus-gaap--CashFDICInsuredAmount_iI_c20241231_zNRbqRvwhYCc" title="Cash FDIC, insured amount">250,000</span>. Cash balances could exceed insured amounts at any given time. As of December 31, 2024, the company had cash in excess
of the FDIC insured amount totaling $<span id="xdx_90C_eus-gaap--TimeDepositsAtOrAboveFDICInsuranceLimit_iI_c20241231_zD2ktgj1NVY" title="Cash uninsured amount">306,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Trade receivables</a></td>
<td class="text"><p id="xdx_847_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zQ4tFYMG8Xkh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Trade
receivables</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s trade receivable balance consists of amounts due from its customers. The Current Expected Credit Losses (&#8220;CECL&#8221;)
impairment model requires an estimate of expected credit losses, measured over the contractual life of an instrument, which considers
forecasts of future economic conditions in addition to information about past events and current conditions. Based on this model, the
Company considers many factors, including the age of the balance, collection history, and current economic trends. Credit losses are
written off after all collection efforts have ceased. Allowances for credit losses are recorded as a direct reduction from an asset&#8217;s
amortized cost basis. Credit losses and recoveries are recorded in selling, general and administrative expenses in the consolidated statements
of operations. Recoveries of financial assets previously written off are recorded when received. Trades receivables were $<span id="xdx_90F_eus-gaap--AccountsReceivableNet_iI_c20241231_zX8gOLg56R27" title="Trades receivables">98,000</span> as of
December 31, 2024, and are not anticipated to possess substantial credit risk or expected credit losses. The Company&#8217;s current
policy is to not charge late fees or other penalties for late payments but may consider charging customers late fees in the future. Historically,
the Company has not had significant write offs of trade receivables. All sales are non-refundable. As of December 31, 2024, the Company
evaluated historical collections from vendors and collection policies and has estimated that current expected credit losses ( &#8220;CECL&#8221;)
to be $<span id="xdx_902_ecustom--ChangeInCurrentExpectedCreditLosses_pn3n3_c20240101__20241231_z9hUkZcKjFXh" title="Change in current expected credit losses">0</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising and Marketing Costs</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--AdvertisingCostsPolicyTextBlock_zXjraNwAjkrd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Advertising
and Marketing Costs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
associated with advertising are charged to expenses as incurred. For the year ended December 31, 2024, and 2023, the advertising and
marketing costs were $<span id="xdx_90E_eus-gaap--MarketingAndAdvertisingExpense_c20240101__20241231_ziUXw2ls3O3e" title="Advertising and marketing costs">53,000</span> and $<span id="xdx_909_eus-gaap--MarketingAndAdvertisingExpense_c20230101__20231231_z6ebkWgsalOl" title="Advertising and marketing costs">106,000</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per share</a></td>
<td class="text"><p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zrzJQIvOlaeb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Earnings
per share</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
loss per share was computed using the weighted average number of common shares outstanding. Diluted loss per share includes the effect
of diluted common stock equivalents. Potentially dilutive securities from the exercise of stock option, warrants and exercise of preferred
stock as of December 31, 2024, and 2023, respectively, were excluded from the computation of diluted net loss per share because the effect
of their inclusion would have been antidilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--InventoryPolicyTextBlock_zVV543rKQYS9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Inventory</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
are stated at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course
of business, less reasonably predictable costs of completion, disposal, and transportation. Cost is determined using the &#8220;first-in,
first-out&#8221; method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
write-offs are provided to cover risks arising from slow-moving items or technological obsolescence. The Company periodically evaluates
the quantities on hand relative to current and historical selling prices and historical and projected sales volume. Based on this evaluation,
provisions are made when required to write-down inventory to its net market value. As of December 31, 2024, and 2023, there was <span id="xdx_90F_eus-gaap--InventoryAdjustments_iI_pn3n3_do_c20241231_zsWGdZVnBec4" title="Inventory allowance"><span id="xdx_902_eus-gaap--InventoryAdjustments_iI_pn3n3_do_c20231231_ztRrGcIKb95l" title="Inventory allowance">no</span></span> allowance
on inventory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment, net</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z8lUfCkwaB9c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Property
and equipment, net</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_ecustom--ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock_zKKjFz17QRPb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the
estimated useful lives of the assets, at the following annual rates:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zLTUCzBGvf0b" style="display: none">SCHEDULE OF DEPRECIATION CALCULATED OVER ESTIMATED USEFUL LIVES OF ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">Years</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: justify">Computers and peripheral equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 16%; text-align: center"><span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zS8qn4YwxKkh" title="Estimated useful life">3</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_z6mGGsDo1sLl" title="Estimated useful life">5</span>-<span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zOxEAVxNuY0a" title="Estimated useful life">7</span></td></tr>
  </table>

<p id="xdx_8AC_zmUz89Ndvjld" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p id="xdx_845_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zxgc8zi6ZLpi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Impairment
of Long-Lived Assets</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
reviews for impairment whenever events or changes in circumstances indicate that the carrying amount of property and equipment may not
be recoverable under the provisions of accounting for the impairment of long-lived assets. If it is determined that an impairment loss
has occurred based upon expected future cash flows, the loss is recognized in the Consolidated Statements of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_SequencingPolicyTextBlock', window );">Sequencing</a></td>
<td class="text"><p id="xdx_84A_ecustom--SequencingPolicyTextBlock_zDvDjlG4oCrk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sequencing</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adopted a sequencing policy under ASC 815-40-35 whereby if reclassification of contracts from equity to liabilities is necessary
pursuant to ASC 815 due to the Company&#8217;s inability to demonstrate it has sufficient authorized shares. This was due to the Company
committing more shares than authorized. While temporary suspensions are in place to keep the potential exercises beneath the number authorized,
certain instruments are classified as liabilities, after allocating available authorized shares on the basis of the most recent grant
date of potentially dilutive instruments. Pursuant to ASC 815, issuances of securities granted as compensation in a share-based payment
arrangement are not subject to the sequencing policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_SeverancePayPolicyTextBlock', window );">Severance pay</a></td>
<td class="text"><p id="xdx_840_ecustom--SeverancePayPolicyTextBlock_zeWMWwzAPh0j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Severance
pay</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s liability for severance pay is for its Israeli employees and is calculated pursuant to Israeli Severance Pay Law based
on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date and is in large
part covered by regular deposits with recognized pension funds, deposits with severance pay funds and purchases of insurance policies.
The value of these deposits and policies is recorded as an asset in the Company&#8217;s balance sheet. Accrued severance pay liability
on December 31, 2024, and 2023 was $<span id="xdx_906_ecustom--AccruedSeverancePayLiability_c20240101__20241231_zj57yXkQgAKl" title="Accrued severance pay liability">216,000</span> and $<span id="xdx_90F_ecustom--AccruedSeverancePayLiability_c20230101__20231231_zuAPMFAUtJSi" title="Accrued severance pay liability">217,000</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_849_eus-gaap--LesseeLeasesPolicyTextBlock_z9a2mVAhxFN6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Leases</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for its leases in accordance with ASU 2016-02, &#8220;Leases&#8221; (Topic 842). This topic requires that a lessee recognize
the assets and liabilities that arise from operating leases. The Company recognizes right-of-use assets and lease liabilities on the
consolidated balance sheet for all leases with a term longer than 12 months and classifies them as operating leases. For leases with
a term of 12 months or less, the Company elects not to recognize lease assets and lease liabilities on those leases. The right-of-use
assets and lease liabilities have been measured by the present value of the Company&#8217;s remaining lease payments over the lease term
using our incremental borrowing rates or implicit rates, when readily determinable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><p id="xdx_848_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z7i2eOV0280i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue
recognition</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is the Company&#8217;s policy that revenues from product sales is recognized in accordance with ASC 606 &#8220;Revenue Recognition.&#8221;
Five basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that create(s) enforceable
rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services
to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects to
be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to the performance
obligations in the contract, which requires the company to allocate the transaction price to each performance obligation on the basis
of the relative standalone selling prices of each distinct good or services promised in the contract; and (5) Recognizing revenue when
(or as) the entity satisfies a performance obligation by transferring a promised good or service to a customer. The amount of revenue
recognized is the amount allocated to the satisfied performance obligation. Adoption of ASC 606 has not changed the timing and nature
of the Company&#8217;s revenue recognition and there has been no material effect on the Company&#8217;s financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from product sales is recorded at the net sales price, or &#8220;transaction price,&#8221; which includes estimates of variable consideration
that result from coupons, discounts, chargebacks and distributor fees, processing fees, as well as allowances for returns and government
rebates. The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue.
Collectability of revenue is reasonably assured based on historical evidence of collectability between the Company and its customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues
from sales to distributors are recognized at the time the products are delivered to the distributors (sell-in&#8221;). The Company does
not grant rights of return, credits, rebates, price protection, or other privileges on its products to distributors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><p id="xdx_841_eus-gaap--IncomeTaxPolicyTextBlock_zlDPYCgQDXTe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Income
taxes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes in accordance with ASC 740, &#8220;Income Taxes&#8221;. This topic prescribes the use of the liability
method whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and
tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences
are expected to reverse. The Company provides full valuation allowance, to reduce deferred tax assets to the amount that is more likely
than not to be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company implements a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position
taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than
not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related
appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% (cumulative
basis) likely to be realized upon ultimate settlement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes interest and penalties related to uncertain tax positions on the income tax expense line in the accompanying consolidated
statement of operations. Accrued interest and penalties are included on the related tax liability line in the consolidated balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-based compensation</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zjOYKe1VDQC5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock-based
compensation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company selected the Black-Scholes-Merton option pricing model as the most appropriate fair value method for its stock-options awards.
The option-pricing model requires a number of assumptions, of which the most significant are the expected stock price volatility and
the expected option term. Expected volatility was calculated based upon similar traded companies&#8217; historical share price movements.
The expected option term represents the period that the Company&#8217;s stock options are expected to be outstanding. The Company currently
uses the simplified method and will continue to do so until sufficient historical exercise data supports using expected life assumptions.
The risk-free interest rate is based on the yield from U.S. Treasury zero-coupon bonds with an equivalent term. The expected dividend
yield assumption is based on the Company&#8217;s historical experience and expectation of no future dividend payouts. The Company has
historically not paid cash dividends and has no foreseeable plans to pay cash dividends in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently adopted accounting standards</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z88NbAq5McIl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recently
adopted accounting standards</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13,
Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU 2016-13&#8221;)
and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, and ASU 2019-05 (collectively, &#8220;Topic
326&#8221;). Topic 326 requires measurement and recognition of expected credit losses for financial assets held. This ASU is effective
for interim and annual reporting periods beginning after December 15, 2022. The adoption of Topic 326 did not have a material effect
on the Company&#8217;s consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU No. 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>,
which requires an enhanced disclosure of significant segment expenses on an annual and interim basis. This guidance is effective for
annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption
is permitted. Upon adoption, the guidance should be applied retrospectively to all prior periods presented in the financial statements.
The adoption of Topic 280 did not have a material effect on the Company&#8217;s consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_SequencingPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sequencing [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_SequencingPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_SeverancePayPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Severance Pay [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_SeverancePayPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-15<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock', window );">SCHEDULE OF DEPRECIATION CALCULATED OVER ESTIMATED USEFUL LIVES OF ASSETS</a></td>
<td class="text"><p id="xdx_891_ecustom--ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock_zKKjFz17QRPb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the
estimated useful lives of the assets, at the following annual rates:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zLTUCzBGvf0b" style="display: none">SCHEDULE OF DEPRECIATION CALCULATED OVER ESTIMATED USEFUL LIVES OF ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">Years</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: justify">Computers and peripheral equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 16%; text-align: center"><span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zS8qn4YwxKkh" title="Estimated useful life">3</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_z6mGGsDo1sLl" title="Estimated useful life">5</span>-<span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zOxEAVxNuY0a" title="Estimated useful life">7</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of depreciation calculated over estimated useful lives of assets [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">SCHEDULE OF PREPAID EXPENSES AND OTHER RECEIVABLES</a></td>
<td class="text"><p id="xdx_896_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zptYOgclK78a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses and other receivables consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_zIXtbmqLeCtf" style="display: none">SCHEDULE OF PREPAID EXPENSES AND OTHER RECEIVABLES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20241231_zNLVgVZZ6E8a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231_z6k4SgKwxMZg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PrepaidExpenseCurrent_iI_maPEAOAzR3N_zxd7TlgMEOJ7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Prepaid expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">120,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">47,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OtherAssetsCurrent_iI_maPEAOAzR3N_zFVKeo5BdjT2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Other receivables</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">170,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">107,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0d_mtPEAOAzR3N_zoxd9gzr2YC7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
    expenses and other receivables</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">290,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">154,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">SCHEDULE OF INVENTORY</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_z0ex8gZoucm8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
consists of the following components:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_z46b0dEx4fHa" style="display: none">SCHEDULE OF INVENTORY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20241231_zr49nADZJxh5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20231231_zaUoLdjiqAOa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--InventoryRawMaterials_iI_maINzmOi_zn52XfWNYKck" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Raw materials</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">391,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">210,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--InventoryFinishedGoods_iI_maINzmOi_zYks0Oxizgg4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,800,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,522,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--InventoryNet_iTI_pp0d_mtINzmOi_zjlTFRf5YeG3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,191,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,732,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">SCHEDULE OF OPTIONS ACTIVITY</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zRnajz2rExNa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zvHhwC29emWg" style="display: none">SCHEDULE OF OPTIONS ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares Under</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>per Share</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life (Years)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">Outstanding &#8211; December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zt6aMefE1eT6" style="width: 14%; text-align: right" title="Options, Outstanding - Beginning balance">10,244</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2d_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zAlkVS6LDsh4" style="width: 14%; text-align: right" title="Weighted Average Exercise Price per Share, Exercisable - Ending balance">13.10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zuO8oC4yP1X4" title="Weighted Average Remaining Life (Years), Outstanding">8.41</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zsQvG6cqmyhj" style="text-align: right" title="Options, Granted">34,818</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2d_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z9BEu7ef6R4" style="text-align: right" title="Weighted Average Exercise Price per Share, Granted">7.47</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zDGrqQdtxMja" title="Weighted Average Remaining Life (Years), Granted">9.78</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_ztr66m7BmhLf" style="text-align: right" title="Options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0876">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pp2d_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zDWotb2B7lQd" style="text-align: right" title="Weighted Average Exercise Price per Share, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0878">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zLrdckMjEYXg" title="Weighted Average Remaining Life (Years), Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0880">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z5uC7BOTCeG3" style="text-align: right" title="Options, Expired">(3</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pp2d_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zEp9r9PGCu22" style="text-align: right" title="Weighted Average Exercise Price per Share, Exercised">39.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zMEgC7Bao9h7" title="Weighted Average Remaining Life (Years), Expired"><span style="-sec-ix-hidden: xdx2ixbrl0886">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zRwRMknXGpml" style="border-bottom: Black 1pt solid; text-align: right" title="Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0888">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pp2d_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zVND6xCk6zQf" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price per Share, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0890">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zCDwLqTMiru7" title="Weighted Average Remaining Life (Years), Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0892">-</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding &#8211; December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z32ymmNLQzvb" style="text-align: right" title="Options, Outstanding - Ending balance">45,059</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pp2d_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zmKP5rPZlWYk" style="text-align: right" title="Weighted Average Exercise Price per Share, Outstanding - ending balance">3.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zXQOqt9MjGl1" title="Weighted Average Remaining Life (Years), Outstanding">9.24</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable &#8211; December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zBOZ4VP6HmA9" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Exercisable - Ending balance">45,059</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zmZW1bX6kxRh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price per Share, Outstanding - ending balance">3.50</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zcQwM7Zl783b" title="Weighted Average Remaining Life (Years), Exercisable">9.24</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR OPTIONS GRANTED</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zsLdriktqh95" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value for options granted in 2024 and 2023 is estimated at the date of grant using a Black-Scholes-Merton options pricing model
with the following underlying assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_z7m2ZIRLlCl3" style="display: none">SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR OPTIONS GRANTED</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Price at valuation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$ <span id="xdx_907_eus-gaap--SharePrice_iI_pp2d_c20241231__srt--RangeAxis__srt--MinimumMember_za8ONnVvuOA4" title="Price at valuation">6.71</span> &#8211; <span id="xdx_90C_eus-gaap--SharePrice_iI_pp2d_c20241231__srt--RangeAxis__srt--MaximumMember_zGIdXn4vZHY2" title="Price at valuation">9.90</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
                                            <span id="xdx_909_eus-gaap--SharePrice_iI_pp2d_c20231231__srt--RangeAxis__srt--MinimumMember_zES0X3AIObf2">13.2
                                            </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;
                                            <span id="xdx_905_eus-gaap--SharePrice_iI_pp2d_c20231231__srt--RangeAxis__srt--MaximumMember_z8dRCxkxgmI9">13.64</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$ <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_c20241231__srt--RangeAxis__srt--MinimumMember_z32dVIMMMHS3" title="Exercise price">6.71</span> &#8211; <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_c20241231__srt--RangeAxis__srt--MaximumMember_zwtbjSMWQKfc" title="Exercise price">9.90</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$ <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_c20231231__srt--RangeAxis__srt--MinimumMember_z5DpkXfdkl64">13.2</span>
                                            &#8211; </span><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_c20231231__srt--RangeAxis__srt--MaximumMember_zvgho4L20uX6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.64</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240101__20241231_zQuXvMfriufb" title="Risk free interest, minimum">4.14</span> &#8211; <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20240101__20241231_zPlwZQjgY3K2" title="Risk free interest, maximum">4.42</span> %</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20231231_zDTpuVAjwNEe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.83
                                            </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;
                                            <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20230101__20231231_zPsbcrB4FRM4">4.42
                                            </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Expected term (in years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231_zLfmpjqveXC1" title="Expected term (in years)">5</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zMWbcPvC2XA5" style="font-family: Times New Roman, Times, Serif">5</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20240101__20241231_zd0ANHMofr2i" title="Volatility, minimum">128.4</span> &#8211; <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20240101__20241231_zctxGMrRbwOb" title="Volatility, maximum">132.8</span> %</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20230101__20231231_z5YdNzA8UOY5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">133.1
                                            </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;
                                            <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20230101__20231231_zRC0RRDUiCw3">133.6
                                            </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED SERVICES FROM EMPLOYEES AND NON-EMPLOYEES</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zt5AGZJIb9ab" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total stock-based expense recognized in the financial statements for services received from employees and non-employees is shown in the
following table.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_zdfH3ioX8TDf" style="display: none">SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED SERVICES FROM EMPLOYEES AND NON-EMPLOYEES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20240101__20241231_z6XktNeSRnI9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20231231_z1cFdggzb4Id" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_znYUhzDywvF" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">6,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zfyhUw6y7Ru6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Selling and marketing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z8turcZgioZ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">334,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">259,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zi4G19ZLiGOl" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">356,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">293,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zgWgiHEQD5d3" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Stock based compensation expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">356,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">293,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock', window );">SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR WARRANTS</a></td>
<td class="text"><p id="xdx_893_ecustom--ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock_z3euBJXIJSt5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
estimating the warrants&#8217; fair value, the Company used the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zKsvv47MJk4g" style="display: none">SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR WARRANTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Risk free interest</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z46WZr2xiszl" title="Warrants, measurement input, percentage"><span style="-sec-ix-hidden: xdx2ixbrl0988">-</span></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zytQ8rdizZzl" title="Warrants, measurement input, percentage">3.49</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zeKwKRN982D6" title="Warrants, measurement input, percentage"><span style="-sec-ix-hidden: xdx2ixbrl0992">-</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zEMWAx4Us7c2" title="Warrants, measurement input, percentage"><span style="-sec-ix-hidden: xdx2ixbrl0994">-</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zvxKzIId2dDj" title="Warrants, measurement input, percentage"><span style="-sec-ix-hidden: xdx2ixbrl0996">-</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zfvsuw3JbBoa" title="Warrants, measurement input, percentage">147.6</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Contractual term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20241231_zqsnYIeqDdei" title="Contractual term (in years)"><span style="-sec-ix-hidden: xdx2ixbrl1000">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231_z5hF0H6D4Zqg" title="Contractual term (in years)">5</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Estimating Fair Value Of Warrants Assumptions [Table Text Blcok]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES</a></td>
<td class="text"><p id="xdx_896_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zOU5r58QIyL6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information about the amount and timing of liabilities arising from the Company&#8217;s operating leases as
of December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;<span id="xdx_8B4_zGgbj7OTjX27" style="display: none">SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES</span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20241231_zxPtPQOlOC8a" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzL7T_zGXEahfPrLei" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left">2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">60,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzL7T_zTOe6HBlXKl7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">58,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzL7T_z39OzRFf7tF7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">2027</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzL7T_z6QTV7jPsWR7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total undiscounted operating lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">128,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_zLtKez6saP06" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: Imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">13,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iI_zMpPlSQGvR31" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Present value of operating lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">115,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zlcoWaFYUOVf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s securities, in common share equivalents, which have been excluded from the calculation
of dilutive loss per share as their effect would be anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zX922lo9htWh" style="display: none">SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240101__20241231_zO8kDPjm9NOl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20230101__20231231_zliEkaTP3TNa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsEmployeeAndNonEmployeeMember_z69SwWeaMDY6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Stock options - employee and non-employee</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">45,059</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">10,244</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zqzlHoQRu4kb" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">326,568</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">784,839</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zkQIg5ezY5U1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">371,627</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">795,083</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--RevenueFromExternalCustomersByGeographicAreasTableTextBlock_zPYDtD4lb4f2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span id="xdx_8BC_zWuHqRpHpZl3">SUMMARY
OF REVENUE WITHIN GEOGRAPHIC AREAS</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20241231_zYvtbqfa9mee" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20230101__20231231_z686t8clFGhc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__country--US_z5igr5BEUtd3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,450,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,162,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__srt--EuropeMember_zlt75zO9MMR3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Europe</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__country--AU_zXVYD0RrRDyj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Australia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__country--IL_zZfEHqFWIzge" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Israel</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__country--NZ_zqmBAPvQnye6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">New Zealand</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1100">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__custom--OtherCountryMember_zTZBuNVnqaZ3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">46,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1103">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0d_zviMUP09I6fh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,558,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,283,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0d_zOB0gakHaA76" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Revenues geographic areas</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,558,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,283,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_ScheduleOfWarrantsAssumptionsTableTextBlock', window );">SCHEDULE OF WARRANTS ASSUMPTIONS</a></td>
<td class="text"><p id="xdx_899_ecustom--ScheduleOfWarrantsAssumptionsTableTextBlock_zDKX714Vy246" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="display: none"><span id="xdx_8B0_ztgla8kCAZi">SCHEDULE OF WARRANTS ASSUMPTIONS</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Price at valuation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__custom--PriceAtValuationMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zDbiPnlSN1F3" title="Warrants and rights outstanding, measurement input">0.01</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__custom--PriceAtValuationMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zSCafcIMChM4" title="Warrants and rights outstanding, measurement input">0.01</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zB2R6yMLZG96" title="Warrants and rights outstanding, measurement input">0.19</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zVU3v9oIQVtj" title="Warrants and rights outstanding, measurement input">0.19</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zp6Zv0uSc7Fa" title="Warrants and rights outstanding, measurement input">3.88</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zkfmBN6WiGU8" title="Warrants and rights outstanding, measurement input">3.88</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zk9gYMzSEDha" title="Expected term (in years)">7</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zygXJz8tDLH1" title="Expected term (in years)">7</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_z9skbkifx3Ud" title="Warrants and rights outstanding, measurement input">147.8</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_z31oSP3O7shj" title="Warrants and rights outstanding, measurement input">147.8</span></td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock', window );">SCHEDULE OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE</a></td>
<td class="text"><p id="xdx_890_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_z2nhLDqF724i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents changes in Level 3 asset and liability measured at fair value for the years ended December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zzp8DjOUaIpc" style="display: none">SCHEDULE
OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Asset</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%">Balance &#8211; December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3d_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zhxGeSsFbK6a" style="width: 14%; text-align: right" title="Balance beginning">3,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Fair value adjustments &#8211; Sanuwave warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FairValueAdjustmentOfWarrants_pn3d_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zCmWZcrsy9y2" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants">(2,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance &#8211; December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3d_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_z5lKcZNPZI3g" style="text-align: right" title="Balance beginning">1,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Fair value adjustments &#8211; Sanuwave warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FairValueAdjustmentOfWarrants_pn3d_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zAYie0zaomG9" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants">(1,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance &#8211; December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_pn3d_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zAkyyPVLxuR1" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance beginning"><span style="-sec-ix-hidden: xdx2ixbrl1167">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zGOPWlPhDSh7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the Company&#8217;s assets and liabilities which are measured at fair value on a recurring basis by level
within the fair value hierarchy:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_zwWJeHXQDedf" style="display: none">SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_znBUdNv0qPEg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level I</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zgvMR1A6PpA7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level II</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z96DcWj5kHy" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level III</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20241231_z9DoxhMLDlZ5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level I</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level II</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level III</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 28%">Asset:</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherAssetsFairValueDisclosure_iI_zVcggDXizV32" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1171">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1172">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1173">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1174">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zxAKE3RGqrJ2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level I</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zCq33R0310w7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level II</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zULoEFsUUZf4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level III</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231_zdzGtmbO0cNe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level I</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level II</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level III</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 28%">Asset:</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OtherAssetsFairValueDisclosure_iI_zqdU7meWwT78" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1176">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1177">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_ScheduleOfWarrantsAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Warrants Assumptions [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_ScheduleOfWarrantsAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">SCHEDULE OF PROVISION FOR INCOME TAXES EXPENSES</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zobxkIkXBd87" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax expense is comprised of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_z9NXsdQaVxSe" style="display: none">SCHEDULE
OF PROVISION FOR INCOME TAXES EXPENSES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20240101__20241231_zKiJQhJVt58l" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20231231_zuxtMajYHa74" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current Tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CurrentFederalTaxExpenseBenefit_maCITEBzPkK_zz1DCJAuasU" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Federal</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1215">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1216">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maCITEBzPkK_zFzO7nt8qYPe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">State</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1218">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1219">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CurrentForeignTaxExpenseBenefit_maCITEBzPkK_z0ewUR7hJsh5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Foreign</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0">18,677</p></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(25,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBzPkK_maOTEBzPz3_zgtwwKReysl1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="margin: 0">18,677</p></td><td style="text-align: left"></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(25,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred Tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maDITEBzsCS_zNtT1JVqJ0I7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="margin: 0">(815,484</p></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1,226,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maDITEBzsCS_z2jwcZcrVCRe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">State</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">(11,269</p></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(43,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_maDITEBzsCS_zdb8op4KZaSh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Foreign</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0">(3,263</p></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_mtDITEBzsCS_maOTEBzPz3_zUkSjIa3EuF1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="margin: 0">(830,015</p></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1,267,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--ValuationAllowanceOfIncomeTaxExpenseBenefit_iN_di_msOTEBzPz3_zvkh7EoLm7dg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: Valuation Allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0">830,015</p></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,267,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OtherTaxExpenseBenefit_iT_mtOTEBzPz3_zq28qJXkOSk5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total Tax</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="margin: 0">18,677</p></td><td style="padding-bottom: 2.5pt; text-align: left"></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(25,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">SCHEDULE OF RECONCILIATION OF STATUTORY U.S. FEDERAL RATE</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zrv6m6x4H7jb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="display: none"><span id="xdx_8BF_zy6isbGgFFHj">SCHEDULE
OF RECONCILIATION OF STATUTORY U.S. FEDERAL RATE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20240101__20241231_zo1qpy21NxQj" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_zuaiCLWSH0Ib" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_maETR_z08mTPio2hF7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Federal income tax benefit at statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><p style="margin: 0">21.00</p></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_maETR_z0WtBKY24cWi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State income taxes, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">0.31</p></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.13</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_maETR_zgi3HoYswTL2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign rate differential</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">0.04</p></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0.10</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_407_ecustom--EffectiveIncomeTaxRateReconciliationPermanentItems_pid_dp_maETR_z2zbMpdHaZX8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Permanent Items</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">-0.04</p></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0.63</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_maETR_zOvN0UqjO8Ud" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">-21.51</p></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-33.54</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_pid_dp_maETR_z8eeJ4Wu87g3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Return to provision adjustments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">0.40</p></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.20</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_406_ecustom--EffectiveIncomeTaxRateReconciliationForfeitedOptions_pid_dp_maETR_zFm7YbMTTPql" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Forfeited options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">0.00</p></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_maETR_zI863VO3wvn2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0">0.30</p></td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-0.01</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_mtETR_z1dnfdx1pM2a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Effective tax rate</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="margin: 0">-0.51</p></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.06</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">SCHEDULE OF INCOME BEFORE TAXES ON DOMESTIC AND FOREIGN</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_z8kq8o1y2ys9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="display: none"><span id="xdx_8B5_z95j9vk6bTZd">SCHEDULE
OF INCOME BEFORE TAXES ON DOMESTIC AND FOREIGN</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20241231_zflRt6iwtLFh" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20230101__20231231_zh2ylrDK48Vc" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_maILFCOz5C4_zGWQb8RJ19ce" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Domestic</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><p style="margin: 0">3,775,000</p></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">3,785,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_maILFCOz5C4_zh5XuOSYkMd9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Foreign</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0">(89,000</p></td><td style="padding-bottom: 1pt; text-align: left">)<br/>
</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(103,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iNT_di_mtILFCOz5C4_z6Gc6eupoZMc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss before taxes</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="margin: 0">3,686,000</p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,682,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">SCHEDULE OF DEFERRED TAX ASSETS</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zNYO9gPUIDh6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="display: none"><span id="xdx_8B2_zqf9uXoQr892">SCHEDULE
OF DEFERRED TAX ASSETS</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20241231_zmAEAoSVgAI4" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20231231_za5qgwPsI8ih" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzNu2_zv8U2kJ3Ihtf" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Net operating loss carryforward</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><p style="margin: 0">9,032,000</p></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">8,486,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DeferredTaxAssetsOfCapitalLossCarryforward_iI_maDTAGzNu2_zAffx37hB6U" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Capital loss carryforward</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">5,000</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1297">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--DeferredTaxAssetsTaxDeferredExpenseAccruals_iI_maDTAGzNu2_zLxfObrePuZj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Arbitration accrual</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">414,000</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">414,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_iI_maDTAGzNu2_z9VaXSu4vkA3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Stock compensation and other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0">849,000</p></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">570,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzNu2_maDTALNzt1d_zNYrTbXgZi7k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred tax assets before valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">10,300,000</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,470,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzt1d_ziepFG8hpcqa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0">(10,300,000</p></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(9,470,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzt1d_zTvmpeSxKzj4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax asset</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1311">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1312">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY AND PLAN OF OPERATIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="nump">$ 2,516,000<span></span>
</td>
<td class="nump">$ 3,602,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Investing activities</a></td>
<td class="num">(3,000)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_StockIssuedDuringPeriodValuePrefundedWarrantsExercised', window );">Exercise of prefunded warrants</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash balance</a></td>
<td class="nump">752,000<span></span>
</td>
<td class="nump">$ 3,283,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollateralAxis=NAOV_SaleOfEquitySecuritiesMember', window );">Sale of Equity Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash balance</a></td>
<td class="nump">752,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Property, Plant and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Investing activities</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_StockIssuedDuringPeriodValuePrefundedWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value prefunded warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_StockIssuedDuringPeriodValuePrefundedWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAxis=NAOV_SaleOfEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAxis=NAOV_SaleOfEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF DEPRECIATION CALCULATED OVER ESTIMATED USEFUL LIVES OF ASSETS (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax', window );">Cumulative translation gains</a></td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="nump">$ 49,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash FDIC, insured amount</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit', window );">Cash uninsured amount</a></td>
<td class="nump">306,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Trades receivables</a></td>
<td class="nump">98,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_ChangeInCurrentExpectedCreditLosses', window );">Change in current expected credit losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketingAndAdvertisingExpense', window );">Advertising and marketing costs</a></td>
<td class="nump">53,000<span></span>
</td>
<td class="nump">106,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryAdjustments', window );">Inventory allowance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_AccruedSeverancePayLiability', window );">Accrued severance pay liability</a></td>
<td class="nump">$ 216,000<span></span>
</td>
<td class="nump">$ 217,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_AccruedSeverancePayLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued severance pay liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_AccruedSeverancePayLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_ChangeInCurrentExpectedCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in current expected credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_ChangeInCurrentExpectedCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of inventory reserves for last-in first-out (LIFO) and other inventory valuation methods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketingAndAdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total expense recognized in the period for promotion, public relations, and brand or product advertising.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketingAndAdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of time deposit liabilities, including certificates of deposit, in denominations that meet or exceed the Federal Deposit Insurance Corporation (FDIC) insurance limit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478353/942-405-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF PREPAID EXPENSES AND OTHER RECEIVABLES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="nump">$ 47,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">170,000<span></span>
</td>
<td class="nump">107,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other receivables</a></td>
<td class="nump">$ 290,000<span></span>
</td>
<td class="nump">$ 154,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF INVENTORY (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 391,000<span></span>
</td>
<td class="nump">$ 210,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">1,800,000<span></span>
</td>
<td class="nump">2,522,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">$ 2,191,000<span></span>
</td>
<td class="nump">$ 2,732,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF OPTIONS ACTIVITY (Details) - Employee Options [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, Outstanding - Beginning balance</a></td>
<td class="nump">10,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Exercisable - Ending balance</a></td>
<td class="nump">$ 13.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Life (Years), Outstanding</a></td>
<td class="text">8 years 4 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, Granted</a></td>
<td class="nump">34,818<span></span>
</td>
<td class="nump">7,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Granted</a></td>
<td class="nump">$ 7.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Life (Years), Granted</a></td>
<td class="text">9 years 9 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(9,584)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Life (Years), Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options, Expired</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(368)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Exercised</a></td>
<td class="nump">$ 39.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Life (Years), Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(5,426)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Life (Years), Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, Outstanding - Ending balance</a></td>
<td class="nump">45,059<span></span>
</td>
<td class="nump">10,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Outstanding - ending balance</a></td>
<td class="nump">$ 3.50<span></span>
</td>
<td class="nump">$ 13.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Life (Years), Outstanding</a></td>
<td class="text">9 years 2 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options, Exercisable - Ending balance</a></td>
<td class="nump">45,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Outstanding - ending balance</a></td>
<td class="nump">$ 3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Life (Years), Exercisable</a></td>
<td class="text">9 years 2 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards exercised, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards expired, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards forfeited, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=NAOV_EmployeeOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=NAOV_EmployeeOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR OPTIONS GRANTED (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price at valuation</a></td>
<td class="nump">$ 6.49<span></span>
</td>
<td class="nump">$ 12.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest, minimum</a></td>
<td class="nump">4.14%<span></span>
</td>
<td class="nump">3.83%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest, maximum</a></td>
<td class="nump">4.42%<span></span>
</td>
<td class="nump">4.42%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, minimum</a></td>
<td class="nump">128.40%<span></span>
</td>
<td class="nump">133.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, maximum</a></td>
<td class="nump">132.80%<span></span>
</td>
<td class="nump">133.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price at valuation</a></td>
<td class="nump">$ 6.71<span></span>
</td>
<td class="nump">$ 13.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">6.71<span></span>
</td>
<td class="nump">13.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price at valuation</a></td>
<td class="nump">9.90<span></span>
</td>
<td class="nump">13.64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 9.90<span></span>
</td>
<td class="nump">$ 13.64<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED SERVICES FROM EMPLOYEES AND NON-EMPLOYEES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="nump">$ 356,000<span></span>
</td>
<td class="nump">$ 293,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Selling and Marketing Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="nump">17,000<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="nump">$ 334,000<span></span>
</td>
<td class="nump">$ 259,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR WARRANTS (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Contractual term (in years)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input, percentage</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3.49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input, percentage</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input, percentage</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">147.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 13, 2025</div></th>
<th class="th"><div>Mar. 12, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Aug. 30, 2023</div></th>
<th class="th"><div>Feb. 16, 2023</div></th>
<th class="th"><div>Feb. 09, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 14, 2025</div></th>
<th class="th"><div>Jul. 05, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Reverse stock split outstanding shares</a></td>
<td class="nump">792,394<span></span>
</td>
<td class="nump">8,716,327<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">1-for-11 reverse stock split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares remained unchanged</a></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Bid price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.49<span></span>
</td>
<td class="nump">$ 12.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Non-vested stock options granted, unrecognized estimated compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Total warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">776,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Reverse stock split outstanding shares</a></td>
<td class="nump">792,394<span></span>
</td>
<td class="nump">8,716,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares remained unchanged</a></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=NAOV_TwoThousandFourteenLongTermIncentivePlanMember', window );">2014 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-for-twenty reverse stock split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">442,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of common stock reserved for issuance for awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=NAOV_TwoThousandAndTwentyFourLongTermIncentivePlanMember', window );">Two Thousand And Twenty Four Long Term Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=NAOV_TwoThousandAndTwentyFourLongTermIncentivePlanMember', window );">Two Thousand And Twenty Four Long Term Incentive Plan [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of common stock reserved for issuance for awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=NAOV_HCWainwrightAndCoLLCMember', window );">H.C. Wainwright &amp; Co., LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Class of warrant or right expire date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  01,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Reverse stock split outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">1,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,091<span></span>
</td>
<td class="nump">16,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=NAOV_A1WarrantsMember', window );">A-1 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Class of warrant or right expire date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  01,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=NAOV_A2WarrantsMember', window );">A-2 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Class of warrant or right expire date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct.  01,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=NAOV_PlacementAgentWarrantsMember', window );">Placement Agent Warrants [Member] | H.C. Wainwright &amp; Co., LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Class of warrant or right expire date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  01,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=NAOV_EmployeeOptionsMember', window );">Employee Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of employee options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,818<span></span>
</td>
<td class="nump">7,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of employee options forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">9,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of employee options expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Fair value options vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Number of options, vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 226,000<span></span>
</td>
<td class="nump">$ 87,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod', window );">Contractual term for granted options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 356,000<span></span>
</td>
<td class="nump">$ 293,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=NAOV_PreWarrantMember', window );">Pre Warrant [Member] | Private Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants, Outstanding - Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,633,229<span></span>
</td>
<td class="nump">2,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Warrants, Outstanding - Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,758,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Warrants, Outstanding - Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,918,977)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations', window );">Warrants, Outstanding - Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(203,977)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants, Outstanding - Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,122,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants, Outstanding - Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,592,252<span></span>
</td>
<td class="nump">8,633,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=NAOV_PostWarrantMember', window );">Post Warrant [Member] | Private Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants, Outstanding - Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">780,115<span></span>
</td>
<td class="nump">2,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Warrants, Outstanding - Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">796,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Warrants, Outstanding - Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(265,362)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations', window );">Warrants, Outstanding - Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(18,543)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants, Outstanding - Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(192,910)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants, Outstanding - Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">321,843<span></span>
</td>
<td class="nump">780,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NAOV_PurchaseAgreementMember', window );">Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Bid price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,215,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NAOV_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NAOV_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">247,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NAOV_PurchaseAgreementMember', window );">Purchase Agreement [Member] | A-1 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Class of warrant or right expire date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  01,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NAOV_PurchaseAgreementMember', window );">Purchase Agreement [Member] | A-2 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Class of warrant or right expire date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct.  01,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NAOV_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_PrefundedWarrantAndAccompanyingWarrantPricePerShares', window );">Pre-Funded Warrant and accompanying warrant price per shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_PrefundedWarrantAndAccompanyingWarrantPricePerShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prefunded warrant and accompanying warrant price per, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_PrefundedWarrantAndAccompanyingWarrantPricePerShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award contractual period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were either cancelled or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=NAOV_TwoThousandFourteenLongTermIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=NAOV_TwoThousandFourteenLongTermIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=NAOV_TwoThousandAndTwentyFourLongTermIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=NAOV_TwoThousandAndTwentyFourLongTermIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=NAOV_HCWainwrightAndCoLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=NAOV_HCWainwrightAndCoLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=NAOV_A1WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=NAOV_A1WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=NAOV_A2WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=NAOV_A2WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=NAOV_PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=NAOV_PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=NAOV_EmployeeOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=NAOV_EmployeeOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=NAOV_PreWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=NAOV_PreWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=NAOV_PrivateInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=NAOV_PrivateInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=NAOV_PostWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=NAOV_PostWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=NAOV_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=NAOV_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=NAOV_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=NAOV_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 60,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">58,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted operating lease payments</a></td>
<td class="nump">128,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="nump">13,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">$ 115,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">2 years 2 months 15 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease, expense</a></td>
<td class="nump">$ 70,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lease term</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lease term</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">371,627<span></span>
</td>
<td class="nump">795,083<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=NAOV_StockOptionsEmployeeAndNonEmployeeMember', window );">Stock Options - Employee and Non-employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">45,059<span></span>
</td>
<td class="nump">10,244<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">326,568<span></span>
</td>
<td class="nump">784,839<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=NAOV_StockOptionsEmployeeAndNonEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=NAOV_StockOptionsEmployeeAndNonEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues geographic areas</a></td>
<td class="nump">$ 2,558,000<span></span>
</td>
<td class="nump">$ 2,283,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues geographic areas</a></td>
<td class="nump">2,450,000<span></span>
</td>
<td class="nump">2,162,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues geographic areas</a></td>
<td class="nump">17,000<span></span>
</td>
<td class="nump">101,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_AU', window );">AUSTRALIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues geographic areas</a></td>
<td class="nump">29,000<span></span>
</td>
<td class="nump">19,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IL', window );">ISRAEL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues geographic areas</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_NZ', window );">NEW ZEALAND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues geographic areas</a></td>
<td class="nump">12,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=NAOV_OtherCountryMember', window );">Other Country [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues geographic areas</a></td>
<td class="nump">$ 46,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_AU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_AU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_NZ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_NZ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=NAOV_OtherCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=NAOV_OtherCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Details Narrative) - Revenue Benchmark [Member] - Customer Concentration Risk [Member] - Customer [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">31.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=NAOV_CustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=NAOV_CustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF WARRANTS ASSUMPTIONS (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected term (in years)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=NAOV_PriceAtValuationMember', window );">Price at Valuation [Member] | Sanuwave Health, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="nump">0.01<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember', window );">Measurement Input, Exercise Price [Member] | Sanuwave Health, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="nump">0.19<span></span>
</td>
<td class="nump">0.19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3.49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Sanuwave Health, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="nump">3.88<span></span>
</td>
<td class="nump">3.88<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Sanuwave Health, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected term (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">147.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Sanuwave Health, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="nump">147.8<span></span>
</td>
<td class="nump">147.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=NAOV_PriceAtValuationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=NAOV_PriceAtValuationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=NAOV_SanuwaveHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=NAOV_SanuwaveHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Balance beginning</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustments - Sanuwave warrants</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Balance beginning</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=NAOV_DerivativeAssetMember', window );">Derivative Asset [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Balance beginning</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustments - Sanuwave warrants</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Balance beginning</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=NAOV_DerivativeAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=NAOV_DerivativeAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsFairValueDisclosure', window );">Other assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsFairValueDisclosure', window );">Other assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsFairValueDisclosure', window );">Other assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsFairValueDisclosure', window );">Other assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_PlatformOperatorCryptoAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.FF.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476188/405-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_PlatformOperatorCryptoAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER ASSETS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 12, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Apr. 09, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnContractTermination', window );">Gain loss on contract termination</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_IncreaseDecreaseInTerminationValueByOffset', window );">Increase decrease in termination value by offset</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Warrants leaving balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NAOV_LicensingAgreementMember', window );">Licensing Agreement [Member] | Sanuwave Health, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_IncreaseDecreaseInTerminationValueByOffset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in termination value by offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_IncreaseDecreaseInTerminationValueByOffset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=NAOV_LicensingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=NAOV_LicensingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=NAOV_SanuwaveHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=NAOV_SanuwaveHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 15, 2022</div></th>
<th class="th"><div>Feb. 26, 2021</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss contingency damages sought value</a></td>
<td class="nump">$ 1,500,250<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded value</a></td>
<td class="nump">1,432,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesPaidValue', window );">Loss contingency damages paid value</a></td>
<td class="nump">$ 68,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=NAOV_ArbitratorMember', window );">Arbitrator [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesPaidValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages paid to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesPaidValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=NAOV_ArbitratorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=NAOV_ArbitratorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTION (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=NAOV_PiersonFerdinandMember', window );">Pierson Ferdinand [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payments for fees</a></td>
<td class="nump">$ 69,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=NAOV_PiersonFerdinandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=NAOV_PiersonFerdinandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF PROVISION FOR INCOME TAXES EXPENSES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">18,677<span></span>
</td>
<td class="num">(25,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">18,677<span></span>
</td>
<td class="num">(25,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(815,484)<span></span>
</td>
<td class="num">(1,226,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(11,269)<span></span>
</td>
<td class="num">(43,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(3,263)<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="num">(830,015)<span></span>
</td>
<td class="num">(1,267,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_ValuationAllowanceOfIncomeTaxExpenseBenefit', window );">Less: Valuation Allowance</a></td>
<td class="nump">830,015<span></span>
</td>
<td class="nump">1,267,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherTaxExpenseBenefit', window );">Total Tax</a></td>
<td class="nump">$ 18,677<span></span>
</td>
<td class="num">$ (25,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_ValuationAllowanceOfIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation allowance of income tax expense benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_ValuationAllowanceOfIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF RECONCILIATION OF STATUTORY U.S. FEDERAL RATE (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income tax benefit at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">0.31%<span></span>
</td>
<td class="nump">1.13%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="nump">0.04%<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_EffectiveIncomeTaxRateReconciliationPermanentItems', window );">Permanent Items</a></td>
<td class="num">(0.04%)<span></span>
</td>
<td class="num">(0.63%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(21.51%)<span></span>
</td>
<td class="num">(33.54%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes', window );">Return to provision adjustments</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">12.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_EffectiveIncomeTaxRateReconciliationForfeitedOptions', window );">Forfeited options</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="num">(0.01%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="num">(0.51%)<span></span>
</td>
<td class="nump">0.06%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_EffectiveIncomeTaxRateReconciliationForfeitedOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation,forfeited options, percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_EffectiveIncomeTaxRateReconciliationForfeitedOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_EffectiveIncomeTaxRateReconciliationPermanentItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation,permanent items, percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_EffectiveIncomeTaxRateReconciliationPermanentItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF INCOME BEFORE TAXES ON DOMESTIC AND FOREIGN (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="nump">$ 3,775,000<span></span>
</td>
<td class="nump">$ 3,785,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(89,000)<span></span>
</td>
<td class="num">(103,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes</a></td>
<td class="nump">$ 3,686,000<span></span>
</td>
<td class="nump">$ 3,682,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF DEFERRED TAX ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 9,032,000<span></span>
</td>
<td class="nump">$ 8,486,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_DeferredTaxAssetsOfCapitalLossCarryforward', window );">Capital loss carryforward</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_DeferredTaxAssetsTaxDeferredExpenseAccruals', window );">Arbitration accrual</a></td>
<td class="nump">414,000<span></span>
</td>
<td class="nump">414,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther', window );">Stock compensation and other</a></td>
<td class="nump">849,000<span></span>
</td>
<td class="nump">570,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets before valuation allowance</a></td>
<td class="nump">10,300,000<span></span>
</td>
<td class="nump">9,470,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(10,300,000)<span></span>
</td>
<td class="num">(9,470,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_DeferredTaxAssetsOfCapitalLossCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_DeferredTaxAssetsOfCapitalLossCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_DeferredTaxAssetsTaxDeferredExpenseAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets tax deferred expense accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_DeferredTaxAssetsTaxDeferredExpenseAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from compensation and benefits, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_FederalNetOperatingLossCarriedForward', window );">Federal net operating loss carried forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_FederalNetOperatingLossOffsetAgainstTaxableIncome', window );">Federal net operating loss offset against taxable income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_FranchiseFees', window );">Franchise fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Corporate tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Net increases in valuation allowance</a></td>
<td class="nump">$ 830,000<span></span>
</td>
<td class="nump">$ 1,267,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IL', window );">ISRAEL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Corporate tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_OperatingLossCarryforwardsExpirationTerm', window );">Operating loss carryforwards expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_FederalNetOperatingLossCarriedForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents information related to federal net operating loss carried forward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_FederalNetOperatingLossCarriedForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_FederalNetOperatingLossOffsetAgainstTaxableIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents information related to federal net operating loss offset against taxable income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_FederalNetOperatingLossOffsetAgainstTaxableIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_FranchiseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Franchise fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_FranchiseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_OperatingLossCarryforwardsExpirationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents as a operating loss carryforwards expiration term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_OperatingLossCarryforwardsExpirationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 13, 2025</div></th>
<th class="th"><div>Mar. 12, 2025</div></th>
<th class="th"><div>Feb. 14, 2025</div></th>
<th class="th"><div>Jan. 07, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Feb. 16, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jul. 01, 2025</div></th>
<th class="th"><div>Mar. 26, 2025</div></th>
<th class="th"><div>Mar. 04, 2025</div></th>
<th class="th"><div>Feb. 28, 2025</div></th>
<th class="th"><div>Feb. 26, 2025</div></th>
<th class="th"><div>Feb. 13, 2025</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Aug. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Reverse stock split outstanding shares</a></td>
<td class="nump">792,394<span></span>
</td>
<td class="nump">8,716,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">15,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares remained unchanged</a></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Reverse stock split outstanding shares</a></td>
<td class="nump">792,394<span></span>
</td>
<td class="nump">8,716,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares remained unchanged</a></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | ENvue Medical Holdings Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.8906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.97812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of new share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,091<span></span>
</td>
<td class="nump">16,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant exercise, conversion shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Reverse stock split outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">1,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=NAOV_A1WarrantsMember', window );">A-1 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant exercise, conversion shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NAOV_SecuritiesExchangeAgreementMember', window );">Securities Exchange Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NAOV_SecuritiesExchangeAgreementMember', window );">Securities Exchange Agreement [Member] | Common Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of new share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">456,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NAOV_SecuritiesExchangeAgreementMember', window );">Securities Exchange Agreement [Member] | Warrant [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant exercise, conversion shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NAOV_SecuritiesExchangeAgreementMember', window );">Securities Exchange Agreement [Member] | Pre-Funded Warrants [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant exercise, conversion shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.82968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NAOV_SecuritiesExchangeAgreementMember', window );">Securities Exchange Agreement [Member] | A-1 Warrants [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant exercise, conversion shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NAOV_MergerAgreementMember', window );">Merger Agreement [Member] | Subsequent Event [Member] | Series X Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Convertible shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NAOV_MergerAgreementMember', window );">Merger Agreement [Member] | Common Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of new share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,734,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_PercentageForExchangeCapitalForConsideration', window );">Percentage for exchange capital for consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NAOV_MergerAgreementMember', window );">Merger Agreement [Member] | Common Stock [Member] | Subsequent Event [Member] | Series X Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Convertible shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockTermsOfConversion', window );">Convertible description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the holders of the outstanding equity
of ENvue immediately prior to the First Effective Time own 19.9% of the common stock of the Company and 85.0% of the outstanding equity
of the Company (assuming the Series X Preferred Stock is converting at a ratio of 1,000:1) immediately following the First Effective
Time, which following Merger Stockholder Approval will allow the Series X Preferred Stock to convert to common stock of the Company which
may result in the holders of ENvue to own 85% of the common stock of the Company, and (ii) the holders of the Company&#8217;s outstanding
equity immediately prior to the First Effective Time own 80.1% of the common stock of the Company and 15.0% of the outstanding equity
of the Company (assuming the Series X Preferred Stock is converting at a ratio of 1,000:1) immediately following the First Effective
Time, which following Merger Stockholder Approval which will allow the Series X Preferred Stock to convert to common stock of the Company
which may result in our holders owning 15% of common stock of the Company.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NAOV_MergerAgreementMember', window );">Merger Agreement [Member] | Common Stock [Member] | Subsequent Event [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_PercentageForNumberOfOutstandingCommonStock', window );">Percentage for number of outstanding common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_PercentageForExchangeCapitalForConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage for exchange capital for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_PercentageForExchangeCapitalForConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_PercentageForNumberOfOutstandingCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage for number of outstanding common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_PercentageForNumberOfOutstandingCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockTermsOfConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of conversion terms for preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockTermsOfConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(h))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=NAOV_ENvueMedicalHoldingsCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=NAOV_ENvueMedicalHoldingsCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=NAOV_A1WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=NAOV_A1WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=NAOV_SecuritiesExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=NAOV_SecuritiesExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=NAOV_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=NAOV_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=NAOV_MergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=NAOV_MergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=NAOV_SeriesXPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=NAOV_SeriesXPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>89
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ,-S?UI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( ,-S?UK6F"5F\@   "L"   1
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( ,-S?UH;-'FQ*@D   @W   8
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&ULM9M=4^,X%H;O^16J3-<4716(/T*
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MQ#19_L>O!8B-@#.G)L K KQW 6ZW)L O OQ= [I%0%>1659%<1C@#%]="+Y
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M@+^_3%/VO%'<*FUWS\')_U!+ P04    " ##<W]:44MN^O4%  "Q&@  &
M 'AL+W=O<FMS:&5E=',O<VAE970V+GAM;*U9;6_;-A#^*X0W#"U0QR;EER1S
M#"1.NQ58NZ!9M\^T=+*Y2J)+TG:R7[\CI5AV1#%.X2^QI!R/S[WPGCMILI7J
MFUX"&/*09X6^ZBR-65WV>CI>0L[UF5Q!@?])I<JYP5NUZ.F5 IZX17G68_W^
MJ)=S472F$_?L3DTG<FTR4<"=(GJ=YUP]WD FMU<=VGEZ\$4LEL8^Z$TG*[Z
M>S!?5W<*[WH[+8G(H=!"%D1!>M6YII>SR"UP$G\+V.J]:V)-F4OYS=Y\3*XZ
M?8L(,HB-5<'Q9P,SR#*K"7%\KY1V=GO:A?O73]H_../1F#G7,)/9/R(QRZO.
M>8<DD/)U9K[([>]0&32T^F*9:?>7;$O9\:A#XK4V,J\6(X)<%.4O?Z@<L;>
MMBU@U0+V?,&@94%4+8B<H24R9]8M-WPZ47)+E)5&;?;"^<:M1FM$8<-X;Q3^
M5^ Z,YW)0LM,)-Q 0NX-_F",C"8R)3.NE^0#QEF3+OEZ?TO>_/QVTC.XJ5W:
MBZL-;LH-6,L&E)%/LC!+3=X7"22'"GJ(=@>9/4&^84&-MQ"?D8B^(ZS/!AY
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M:W8)/N.:4@/& OQ5-Q,LW$R\3U.(RW>B\1I;GR)^) 9#H;-JE"R<;5[HOH;
M5Q ]<H/VD8/5G0-[N7-XDT"L *GG+=;Q\LK6]%;,WIXA\KF\*>F:^!;44=TQ
M1.&IW=5Q;L@<%J(H;(;8DP!*R,2'.&J.ZA$[][C9(\C&M/U-3U2S>Q1F]R?$
M@&U\&"MMO.@<#SW]NT?NN4TEU-[>R_\<U,)]$]'$C1?E2_7=T_*[RPV]G+G/
M$\^>7]/+:_<5HE>K*3_F?.(*XZ!)!BFJ[)^-L0BJ\OM(>6/DRGUBF$MC9.XN
MEX"#F+("^/]42O-T8S?8?:6:_@]02P,$%     @ PW-_6@IQ/PA3 @  J@4
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M;2C]J['9>]DH0V-H4;GE6@EM5M4="R.F(&V N5\+H?>&3=#)<_H;4$L#!!0
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M9AWM/!$+Z0HR6Q65L6N% ,#_L=)AWXE8:FM820*-E=-+F:Z%D2O/UEC(=<+
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MTOOX/@+3RG.[<50'25R38X$-2^YMCL8[\/F&R.TW/L'A&SGY!U!+ P04
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M='S:#4 W+:C96%7YLG]2EIJ(7Q;4M5$[ [K/E;*;C7.P_0\,?@-02P,$%
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M8"L;2VRDD$:1),LD:ZI*E]E>G*L0)5S;<D@FE.3PT;1"9BVM=[&^$Q*'B[3
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MAXM*B7#>Z)YW=.QP*RU4WD]>8.1X_N#NV!JNX=$[<4>W'1BJ4F*7XH!*]HW
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M>J?=,P=$M;$J1?'2;HD55WKG6#'32QZ%<=#G*>=JIY@$S=_&\#=02P,$%
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MGD>4-L&L9T+HK6,W:!_<^!]02P,$%     @ PW-_6D<D439E#   [A\  !D
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M \30E-VA)KW6(7E1P^.+"B#M*RH3IIVIH(K9@4V/]P3]CD$WF(SF'SOC_.J
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M9T6N:0.^7RELYN4-&:A/G\=_ 5!+ P04    " ##<W]:S@@E)70&  !T#P
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M(\L3,#XWQK<O;*"[:)__!U!+ P04    " ##<W]:;"-IHCT#  ""!P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6R55=MNVS@0??=7#-2B3X$ERVXV
M36T#MI-@N\C%<-P6B\4^T-)(XI8B59*.ZK_OD%)4I[5=[(M$SN7,F1ER.*Z5
M_F(*1 O?2B'-)"BLK2[#T"0%ELST5862-)G2);.TU7EH*HTL]4ZE".,H.@]+
MQF4P'7O94D_':FL%E[C48+9ER?1NCD+5DV 0/ M6/"^L$X33<<5R?$3[L5IJ
MVH4=2LI+E(8K"1JS23 ;7,Y'SMX;?.)8F[TUN$PV2GUQFP_I)(@<(1286(?
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MT9!2-<M)%A7$0;$B75"2ZG\*:<CLR*@F9OH,AR"B&@"-,P]:AA.;I6*,T33
M5BO",-7?J#-ZD+W(#%4=>A-,$LAV1[F.8@L;L=.[TG>CL9Z$YZ5M*FDQ$^(L
MP[WW>Y-?TZ2I/M8$*>S.44F\\AZ-SE:RB]SG!>$PGX>23');PH.\UB9QA/)F
MJ>-EM)LRJ.@0NAS]A/10N%Y.GV%=V3G@8.YU</!"\EB850#7W4.4%S@0&.N:
M=1J(L#9.<TJ99Z07"(CCJ<72B]<8@A#>&;, ;NE%I4@"*^C?D6H1MGXC95M;
M,]5S_I C2/H,Z+C2[,QD^SPGU;I>@91&&$&NFD<OG3V@TQ!>N2=MQ8$@XP&
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M$'($CFT NC+E.0TL:&+-_FRT7\*&VAFOOA,72I(P-EM'+^5"?D5<7:&F2V3
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M@UJUCBMF[S$:JD5#U99NKM3@)K9%'B\RS:$C5?46)S6Y1%,VF_O89/1 Y#8
M>=;X/1/8Q*EFENS?W#J)07.Y1,QC:I!O4;(>;1KSP>/:K<Q,O#"9J<C9T>?4
MV"0K;%WR74'*I'@DPL?6R"XI7ZB[P+X[&XFE/<)0"1'GM>9G]'?@#0MJ:0UU
M7T5A#9N +DT!@SQ/JAH;X)X1?''HHLZ(>9R[5,NRV&"KHBVQ0<-XWAC&\T'#
M  I C(?RU66I\V0OGB-[U+4.4NLW$K=%U+>%^ESD8U+T*(6/BTM@C[QP+JKK
MQ$B.BSC#+73<3ZG'&^AC31X()L$V(Z0@G_,L4RN .'?'A:4[8%&&96Q,N*]-
MD>L*7C5RFRC!CP:7;3M<P5)SQ[3;R0N/E8<-9$GX3)ZENV[9.78"^!3O@*?Q
M!1X !=AFJ=<$#'$RN,1BHT<P815OMV4!)PD"SF77FYIDA\?:<G2'HW.Z$S>Z
MN]<0AM($410 AMXLL*$'&:+$^.M4[31X_T5-7XTFDXEZ)O\,J-B+1L5>#*K8
M16S7?:HTN*I?E8@4^UCORQ 94_(/^!JROH]A2;6%GN1W9%F00V6JVOG >9VL
MU;+.4[DE_,A:L]BSE#[JE,(4)+0MK*D06_$S*\)%4<)41<P^1GW\<'7A U14
M;TGU?E&SLPG+['3R_$>R>]G([N6@[&Y*^$HH5*+-/3G4WL U2*)?D$PW:M%M
M2Y4.-GWQQI*"=7;W!LCQS%CG>9W/2^'LV+8(L@C(UZ4//6P@E;J$(V3#N(#D
M(>1KT5HOU8O+B^M&J@:\F)+-<U.D.@M1$-' .T$.ZIYH(D3%%$:J\0O%/13>
MA6%&ON1F,[/DU7'.:E+6M-,(6,M 2_A\T <;(:AIJ)<<=5E7(*@T?H8[2.@Q
M;,B6#.V+4_E RM")A@LDCFH+(HIB@HLXB1-)H'&LWG,X)0IK &$^]8@8;]2]
MX8N0P%XM<9:BQ%$%5)+*,ZQ<:6_[[L)&6)GYG!&TL6H_ZK#1G*G"QQ2\7+2%
M2083[4I359HP#:2V!/)40'5MPGJ)0U?..R>:#L,^N-B)U\:OW3MRWC(I2O)-
MY.T0[TH*\WBJ%J*L4A3_*5A[S8R@= B>?]&E%Y#K@M#[ YYQ/"*.VS>'>^&Z
MD$3#5%8C#U %=:1P\X;R(_:P3>!VCKR#XX)7CSI>_5A]"[N2UC38P0$.F.$]
M^2E XHY,VPSNUAS<R/(8K),EVK8C\.[ZU4OV-8/>YE7C;5X->IOS%%Q7QI(B
MD30^Q>6=9HQR 2GW^IY!@OV^I[5+U+.+_)?@:Y$8%C2CX;C-&TZ>K.-R)4&_
MN:68TRO2:(@,L*,)?S^.?B.QG*X HDW#6L*L.9F?G;+,IS_V\]-)*%E,!F5_
M&9<Y-K($!X$]<,3>@L0@D7YY>\I10YD<C4DBLI.PG=K%EG%(33*OK?<F.ZX!
MD7U"-N1:\IIER%AZ ]@DRZ'J=063R,D-':L/)F,Z!WNX[-=*VL&0GHPG=4][
M@E61W"ER]_=Q1@9VK+XB[01PYSR2GR;SM!J7+:#= 60R6:3$1M(]H5-P%@'7
M'I<(Z,[]MA^#J("QH321+!#H-*@L."\%'3"1P9&R6NCO?+0TL"+";!)!?TC@
MS$.Q+!!CD%\=2 6?3"DBXWKACC."@'UQ&.-E,9@,3%N%L^F@%E[E%*$0'7J5
M;W!MO_(U!)7_"[<5T9G9?:8^VT*0\#H%?P[3)2DAT\S,7XP\H @U#OFYYUME
M;">+3;UKI^)"$IPW'"L\<4E1M"XE<5^0FFN+" J/:D-FNR>=2$U2\2YB^Z+O
MVTR+-B&K!%",LU&HMU!"Q[=]S#Z,^$HUXB1"2L>B'-I9FM)68Y./(OD+]N/
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M5W>]&K3=P',N)<N,@7IPV/;:T'*#%AR[K;9#IW6*W"P=F3\G?%YP2:.#.GR
M^K'KU^QD[OA:Z"U^!! T#FN-8ZB[C1K9\H,UC#DH_T(-=A"D41*D\6:"7'0'
M([CO7MV%T(VBN^LBEQ?#49G7RU'W9ASVMU%GIYWMU!G/T9DR+N&))4L$NAM
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M%%6[54T4+VS'LN9*]S]VN-,M*@ACH+]O.%<O$Q.@;GJC?P%02P,$%     @
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M!V$2]/J*<_42F);1_"'BOU!+ P04    " ##<W]:"K9X&<4$  "C&   &0
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MB_^$'#E?%JO58K;^\"I++[*\7*#X^Z^+Q>KADW(%=XO\C_5FG_T_4$L#!!0
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M(K87)\(9W3#.-&M_+487)>BZ@TM7]EEO,6WZ@<H=RQ5J;!'HW SQPF7=^NI
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M;N)($/V5DE<:[4J;^ 8&LF")BZ-!XK8X9'8UVH>.78 5V^WI;H?,WV^W;3Q
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M9*%F14##_^[>4(33R O:2/ :5_#FY$BB ^%@PV@(W#=!6(0#,$Q:21@'./+
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M:'K5DC9XO$IN*QYBSN,P>5P"G@&5'<3W>1SSEX:\ ,DOO(:_ %!+ P04
M" ##<W]:G&GHQS<#  !."P  &0   'AL+W=O<FMS:&5E=',O<VAE970U,2YX
M;6RU5FMOVC 4_2M7V32UTMJ\*+0=1 H05B3Z4"F=IFH?3+A MB1FMH'NW\].
M0AI*B+:5?0';N??XG!M?YS37E/W@<T0!SU$8\Y8V%V)QJ>O<GV-$^"E=8"R?
M3"F+B)!3-M/Y@B&9)$E1J%N&4=<C$L2:TTS6[IC3I$L1!C'>,>#+*"+L5QM#
MNFYIIK99N ]F<Z$6=*>Y(#,<HA@M[IB<Z3G*)(@PY@&-@>&TI;GF9<=,$I*(
MQP#7O# &)65,Z0\UZ4]:FJ$888B^4!!$_JVP@V&HD"2/GQFHEN^I$HOC#7HO
M$2_%C G'#@V_!!,Q;VGG&DQP2I:AN*?K*\P$G2D\GX8\^85U%FMHX"^YH%&6
M+!E$09S^D^>L$(4$L[XGP<H2K-<)M3T)=I9@)T)39HFL+A'$:3*Z!J:B)9H:
M)+5)LJ6:(%:O<2B8?!K(/.$,.U=>=S3PX+8'G2OWYK,WA/X-#+Q';P VN#==
M&/3==G_0?_@*UYX['-U[77 ?H.?V[^'1'8P\..JB($'(C^$$1L,N'+T_;NI"
MDE-;Z'Y&I)T2L?80,2VXIK&8<_#B"4ZV 72I*I=F;:2UK4K$+OJG8)L?P3*L
M6@FASI^GVQ5T[+S2=H)G[\&[G4XY"A'$,W"Y''%X&L@0Z N,^+>R@J5XM7(\
MU=^7?$%\;&FR@3FR%6K.AW=FW?A4)O9 8%O2:[GT6A6ZTR8AB7V$,<Z".)85
M*%.;0C02"'7YK!S3,(RFOBJJJ-SG'U6<Y2K.*E7T2,!@1<(E IE\EZTI;S/Y
M%D]@2.+EFJP0UH0Q(M?*Y*78]8(\>U?>V4X-K&+0%NUZ3KO^]N+7=]B]IK8;
M8>ZEULBI-2JI=9$%*Z+N\;0EX.D:HS&RTFZHA/K;;C@0V);J\USU^8$O@O-#
M2C\0V);TBUSZQ=O/XD7U24M5[ ;9>X^C:;Q\#(W_V.(9>)'420GULK#];6X6
MON3FVXM;C5'^^J'L&&5 >^_K5(1><"81LEEBV#CX=!F+]$N>KZ:FL*U,H7(V
MK]:E6703BZ2_P*1.\YHPJ9=#B%,):9PVY"7*4O.63@1=)/YG3(5T4\EP+@TO
M,A4@GT\I%9N)VB"WT,YO4$L#!!0    ( ,-S?UIZ#3$M P,  .0-   9
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MH=LK3 35%=^<^CS^A>UN;E-.GJ^YH$$"EA$$7KA[DJ?$B#V 67L#8"4 ZZ.
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MA!:B\V.#/(T[GF;,H[XX&]LT#*.M;W)BKZ6QUPIC'Q"/P1WQUUB!81BM!:_
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M+I!_A[]A3NAF1]2BY I)(J-WH,:)7E6A3>/.YH[5V"3,-PD+#,$:GKG.\_[
M^;]7F64&AHPT2O.-T@)3M*:7M;V>^Y^L-;NQ1QMDDN8;I07_(*#KM"UAFVYX
MSVYXA[D1"['!)4@&V8:'D5X1A2Q-U4I(;?_#^U9'.M%'.V*2YANE!25M6%\4
M>*/ZS-:4_WGW['9NZZ;! _(P5EIG7$U,]?D<,C6.B8CPUC51-_9HZ8WNBHW2
M@I)V5E^Q]=RS%\+;M<.G%/DZ/_43Z@W>4%F<[%1WBY/%2_?<SP_@7MR?N>>S
M_)S-?L84QY4WA*]CJE>L*X5T>B.U?>'%"6!1D"S+C[@63$J6YI<1DB5R74$]
M7S$FGPJZ@>H<=OH34$L#!!0    ( ,-S?UH['32@$P,  .4+   9    >&PO
M=V]R:W-H965T<R]S:&5E=#4T+GAM;*U676_:,!3]*U8V39VTD4]"U4$D2M(-
M:="JM-O#M >37"!J$F>V@?;?SW9"!B5$90H/Q';N.??Z^".GOR7TB:T .'I.
MDXP-M!7G^96NLW %*68=DD,FWBP(33$77;K464X!1PJ4)KIE&*Z>XCC3O+X:
MNZ->GZQY$F=P1Q%;IRFF+]>0D.U ,[7=P'V\7'$YH'O]'"]A!OPQOZ.BIU<L
M49Q"QF*2(0J+@38TKX*>C%<!/V+8LKTVDC.9$_(D.^-HH!FR($@@Y)(!B\<&
M1I DDDB4\:?DU*J4$KC?WK'?J+F+N<PQ@Q%)?L817PVT2PU%L,#KA-^3[3<H
MY].5?"%)F/I'VR+6-304KADG:0D6%:1Q5CSQ<ZG#'L!T3@"L$F"]%6"7 /LU
MP#T!<$J \]8,W1*@IJX7<U?"^9ACKT_)%E$9+=AD0ZFOT$*O.)/[9,:I>!L+
M'/=&MY/)^&$23!]F:#CUT>AV^C">?@VFHW$P0Q<^<!PG#$TQI5@NZ4?T&3W.
M?'3Q_F-?YZ( 2:.'93*_2&:=2&9::$(ROF(HR"*(#@ET47E5OK4K_]IJ9)Q@
MVD%F]Q.R#,NJ*6C4#+^!>0=9KH*;=?-IAOL0=I!M*KA3 P_>#K<;Q+"KM;05
MGW."[SMA#(5"X#A;0A:^H BGXJPSQ,A:'!>TP<D::LJ\+FA[BE9>+!O/[!J&
MU37Z^F9?S.,XVU"_PSB_L4QY\UVQ'(<PT,35QH!N0/,^O#-=XTN=ABV1'2CJ
M5(HZC8KZI8!XBZG8L*<5+&C<?04=VSI29M28[DQE_#;)@I;(#F3N5C)W_V_C
MYCAN$+U[M!W=R^--VYCZ7,G;) M:(CN0W*TD=QLE'])YS,653BCZ-8%T#O1W
MG<2-)&?.=]0FF=\F6= 2V<%*]*J5Z+5SQS32G+L6;9+YO:.#:)DUWX6@)N[5
M]Z-04-_S,RG0I3*2\H989[SP!M5HX55]X565IWLU+CSL4%DW_1]-88"%<5C&
M&4,)+ 2ET>F)PT@+4UET.,F5:YH3+CR8:JZ$#P<J \3[!2%\UY$)*F?O_050
M2P,$%     @ PW-_6E_\.FPT @  HP0  !D   !X;"]W;W)K<VAE971S+W-H
M965T-34N>&UL?51A;]HP$/TKEC=-K33A$"C=6!(I0*M6&@P!W31-^V"2"[&:
MV)EM2/OO9SLA8U+A2^*S[[U[Y]Q+4 OYK'( C5[*@JL0YUI78T)4DD-)54]4
MP,U))F1)M0GECJA* DT=J"R([WDC4E+&<12XO:6, K'7!>.PE$CMRY+*UPD4
MH@YQ'Q\W5FR7:[M!HJ"B.UB#?JJ6TD2D8TE9"5PQP9&$+,1Q?SP9VGR7\)U!
MK4[6R':R%>+9!H]IB#TK" I(M&6@YG6 *12%)3(R_K2<N"MI@:?K(_N]Z]WT
MLJ4*IJ+XP5*=A_@31BED=%_HE:@?H.WGQO(EHE#NB>HF=SC"*-DK+<H6;!24
MC#=O^M+>PPG ]\\ _!;@.]U-(:=R1C6- BEJ)&VV8;,+UZI#&W&,VX^RUM*<
M,H/3T>KN:[RYFZ%EO-K\1)M5O%C'T\WCMP6ZFH&FK%!H0:6D]NZN Z)-20LD
M24L_:>C],_1]'\T%U[E"=SR%]'\"8K1V@OVCX(E_D7$&20\-^A^1[_E#]+2>
MH:OWUQ=X!]U%#!SO\ SODH%49DSN0::,4YZB7W,HMR!_O]7U12YKI+&J: (A
M-DY1( ^ HP_O^B/ORP6EPT[I\+)2^FI<H14RED09@'I+8$-QZRBL,0_1Z+/G
M>0$YG%8F)X-3@MPY>RB4B#W7S0QUNYT#XV;P_J4W]IU3N6-<H0(R _5ZMS<8
MR<823:!%Y<9P*[09:K?,S5\$I$TPYYD0^AC8 MU_*?H+4$L#!!0    ( ,-S
M?UKM*NTI30,  *0+   9    >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;*U6
M:V_:,!3]*U8V3:VT-HD#X3&(1(&J2&U!T':5IGTPX0)1DYC9!KI_/SL)X5&3
M=71?P';N.?><&SN^C35E+WP.(-!K%,:\:<R%6-1-D_MSB B_I N(Y9,I91$1
M<LIF)E\P(),$%(4FMBS7C$@0&UXC61LPKT&7(@QB&##$EU%$V.\K".FZ:=C&
M9F$8S.9"+9A>8T%F, +QN!@P.3-SEDD00<P#&B,&TZ;1LNMMVU& ).(I@#7?
M&2-E94SIBYKT)DW#4HH@!%\H"B+_5M"&,%1,4L>OC-3(<RK@[GC#?IV8EV;&
MA$.;AM^#B9@WC:J!)C ERU ,Z?H&,D-EQ>?3D">_:)W&NC+87W)!HPPL%41!
MG/Z3UZP0.P#;/0+ &0 ? DI' $X&2"IGILH26QTBB-=@=(V8BI9L:I#4)D%+
M-T&L7N-(,/DTD#CAC=HWW<[C;1?UK]%@V'_JC7K]>W3='Z+>?;M_UT4/K>?N
M"'6?!]W[D1R<=4"0(.3GZ (]CCKH[/-YPQ12B*(S_2SI59H4'TEJ8W1'8S'G
MJ!M/8+)/8$H'N0V\L7&%"QD[X%\BQ_Z*L(5+&D'M]\.= CE.7E4GX7..\/5B
MGT: 'L@KZ@3<#RE?,D _6F,NF-RX/W4E2QE+>D9UFNM\07QH&O*X<F K,+PO
MGVS7^J:S^Y_(]LR7<O.E(G;O&B; 2*CS6 C4RT(Z>Q_GV7-6SIV5"YV-!!&@
M\U4(^P=?'^?9\^7FOMSB-T:9_-S%.F<IT$V ZDI8>7;5K50:YFI7]]NH"URV
M+"L/VY-5R655"F4]4*'?1I5WB7H;522JFHNJGKJ[JV\35NURJ5HZ$*:)LS%V
MCTJKY=)JIVW/FB:AC=W:@2Y-6,DYJLJVME>,=>KVRI![.1WL.@?*-&'XN+"=
MN\\^;8-EN/U7*4MAEP^%:0)E92O'Q>&M.%PH[A8XKZ,G$BY)TO"T0MERD=C7
MON&,:U>'7N_;N&*YVQO/+KQ3TEJJ&T\K+\56_G)B-6':(VON]#L1L%G2!G+D
MTV4LTIXA7TU;S2O5:JI^Z6!=MJ"MI/$RMS1I_WI'V"R(.0IA*BFMRXK\-+.T
M)4PG@BZ2KFI,A>S1DN%<MM' 5(!\/J54;"8J0=Z8>W\ 4$L#!!0    ( ,-S
M?UH]PSM<K0,  *,+   9    >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;*U6
M;8_:.!#^*U9.=]I*51(GP+X4(K' JDC;L@+V3J?J/IAD FX3F[,=V/[[LY-L
M%E@3^N'X0&QGYO'S3,;CZ>^Y^"$W  J]Y!F3 V>CU/;.\V2\@9Q(EV^!Z3<I
M%SE1>BK6GMP*($GIE&=>X/L]+R>4.5&_7'L249\7*J,,G@2219X3\?,>,KX?
M.-AY79C3]4:9!2_J;\D:%J">MT]"S[P&):$Y,$DY0P+2@3/$=R,<&(?2XD\*
M>WDP1D;*BO,?9C)-!HYO&$$&L3(01#]V,((L,TB:Q[\UJ-/L:1P/QZ_H#Z5X
M+69%)(QX]A=-U&;@W#@H@904F9KS_6>H!74-7LPS6?ZC?67;T\9Q(17/:V?-
M(*>L>I*7.A '#KAWQB&H'8)3A\X9A[!V"$NA%;-2UI@H$O4%WR-AK#6:&92Q
M*;VU&LK,9UPHH=]2[:>BQ>CS9/S\.$&S!S2?C&9?1]/'Z7 YG7TU*XOE</F\
MG,W_1L_NPD4/D_%D/GQ$\^%R@J[&H C-Y(>^IS01 ^?%]:;WU:;!F4UQ@+YP
MIC8235@"R3& IQ4T,H)7&?=!*^(88A>%^",*_*!C(33Z=?>PA4[81#4L\<(S
M>%,6\QS0DKR@,95QQF4A 'T;KJ02.G'_L86L0NS8$<UIOI-;$L/ T<=5@MB!
M$_WQ&^[YGVQR_R>P(_&=1GRG#3UZ@ 0$R1"M@J!T$%; (*4*$86D(JI07/Q$
M@BBP!:)"QQ6\*4.[R'<#W/=VAPHO61U1[S;4NZW4%YH<'! '^1$Q74MYBM):
M52W%1KS"QOX1)=\/3ZG;[3 .[>1[#?E>>]RYT$6+E7%%"4U3$, 4)9F-:\_.
MU>^<<&W?\LIWL?_[AY:DN6[(7[<B/8&NR4SS15,%N;11;@?05/S.*95*PT7'
M7MBJX:;1<-.*--H0MC;I@W8D*TAU367ZHB0LMF9Z.]Q5@-TNMDNZX!F&;O==
M,(XTW3::;ENAYJ *P9#B:"OXCI:W-TF^ZXM)W^7*^IUN[:EUFEE6,QP$]D.
M_;<+S;]T#%*@"A+$M^836#G6&,?EXX1@N\TQNX/K%K>RFZD-""LC?*9ZG+)J
MQS?'X%W.'',-WK@&K5@374+*+JNLX>?*]0403>A<$M>>[XM0]_;X=Q)T[Z#=
MR4&LRRY0HI@73%4M0[-:=9KWIM,T[=+)NNY AV7?Y;W!5.WK%R+6E$F40:HA
M??=:UVQ1=8351/%MV52MN-(M6CG<Z"X:A#'0[U/.U>O$;-#TY=%_4$L#!!0
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MAXG\*"%3!7)_1JG8352#ZC/G_P%02P,$%     @ PW-_6E*_4'$$ P  ?0D
M !D   !X;"]W;W)K<VAE971S+W-H965T-3DN>&ULK99O;YLP$,:_BL6FJ9/6
M0H DI$N0TI"JE?:G"FTW:=H+!RZ)58.9[83VV\\&BA)!:*3M3;#A[KG?XV ?
MXYSQ)[$!D.@YH:F8&!LILTO3%-$&$BPN6 :I>K)B/,%23?G:%!D''!=)"35M
MRQJ8"2:IX8^+>W?<'[.MI"2%.X[$-DDP?[D"RO*)T3->;RS(>B/U#=,?9W@-
M(<B'[(ZKF5FKQ"2!5!"6(@ZKB3'M7<Y&.KX(>"20B[TQTDZ6C#WIR6T\,2P-
M!!0BJ16PNNQ@!I1J(87QI](TZI(Z<7_\JGY=>%=>EEC C-$?)):;B>$9*(85
MWE*Y8/D-5'[Z6B]B5!2_*"]C^[:!HJV0+*F2%4%"TO**GZMUV$OHN4<2["K!
M/C7!J1*<PFA)5M@*L,3^F+,<<1VMU/2@6)LB6[DAJ?X70\G54Z+RI!_.;N;!
MPY<Y^GZ-@OGU?+&8!^A^^A--PW!^'Z*S "0F5'Q$Y^@A#-#9^X]C4ZK".MV,
MJB)791'[2)$ H@OD]#XAV[+=EO39Z>G.8;JI[-:>[=JS7>@Y1_1NTX@E@.[Q
M,PJ(B"@36P[HUW0I)%>OU>\V@Z6BVZZHM]JER' $$T/M)0%\!X;_X5UO8'UN
ML_N?Q [,.[5YITO=_Z9.!G4&<"Q)ND;*NT 1YOQ%'0@YYG&;]U)P6 CJ4V'G
MCRQ''1/6V-SMVVK&>:XWV(\[('9K8K>3>(8S(C$]C;64&NPQ])N@G?7:UQ]U
M+'V_-M+O-#+E2R+UPA?'5\2WF+99Z#<LN#VW:>+-L /&0<TXZ&0,)8N>D-H?
MJDV("C6-$9,;X&VP@P:%YXZ:L,VP_M Z"CNL88>=L &L@'.(D51;&0L!4J E
MJ+<#T [3;85/5:?":01M^,,&5\]R+*MIH!DX<CL<>+4#K]/!XVF87J/Z^1'.
MELA.T%$-.GKSV(@;R]W&VJESTN8JG?R[3FG4W&N.^L/D*^9KD@I$8:64K8NA
MVDB\;/;E1+*LZ)=+)E7W+88;]7T$7 >HYRO&Y.M$M^#ZB\O_"U!+ P04
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M"JN+H](06C4JI<C"YU76Q4O>"'EQ (Z56*=6H]L'-Q4Q\&5Z@:/<99M$9M<
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MD32</JT6BW)Q56?3-HG*Q5JU'!2WRF8Y>TB6]X?3H%TXC5Z_9@>[?P?Q)!U
MS\=J2F(ZB1DD9I*8U?5(V5TW=,CAN23FD9A/8@&)A206D5@,8:TPNWP)LTMI
MF'W>?,G%OS9B62CZ8_7UOWVQ^"*R_SF67U*JYUY_(K$IB>DD9I"826(6B=DD
MYI"82V(>B?DD%I!82&(1B<40ULK*\4M6CO]#J])QMU7IZ\V.KTJEP^R;=B1F
MD)A)8A:)V23FD)A+8AZ)^206D%A(8A&)Q1#62KO)2]I-_D/+W$G79:YT 'VG
M@"2FDYA!8B:)621FDYA#8BZ)>23FDUA 8B&)12060U@K%*]>0O'JQY;+RO\J
M>O"X$8HO;M-9,E>LU;R:%.;*IU6VEJZJI3WV7563V)3$=!(S2,PD,8O$;!)S
M2,PE,8_$?!(+2"PDL8C$8@AK1>KU2Z1>2R-U*KX4RCI+E[-T7>9FLEAMEL6Q
MG)0R?7.2Q*8DII.806(FB5DD9I.80V+N#IOLOP<_/+(4\LA.?1(+2"PDL8C$
M8@AK1: Z>,G ZM))20C:RT>1%XMR1GGT_*&\==_L0[4IJNFH9J":B6H6JMFH
MYJ":6VO[(7@T X]LIUV^WLY'1Q=T[#5$>XU0+::T=GKM76&L?N=4X;)Z9Z0J
M.2@G<C-Q-,*D1.\(([4IJNFH9J":B6H6JMFHYJ":6VM5G4%S4OO\ZGHP/LPP
MLEL?U0)4"U$M0K68TMIYJ#5YJ'U_29LN"U'BA9(EQ?%$E"*]$Y'4IJBFHYJ!
M:B:J6:AFHYJ#:FZMJ:.]1!R<#ZX.\Y#LU$>U -5"5(M0+::T=AXVU1RJO)Q#
M]JZ)GR[3Q68A?8=$SO=.2E*;HIJ.:@:JF:AFH9J-:@ZJN:CFH9J/:@&JA:@6
MH5I,:>U ;2I0JE^K_^Z"6TKT#DU2FZ*:CFH&JIFH9J&:C6H.JKFU5I7<[TTO
MKR=7JG8XPR3[]5$M0+40U2)4BRFM'8A-%8LJ+V.I+U;\O+U843J51&M84&V*
M:CJJ&:AFHIJ%:C:J.:CFHIJ':CZJ!:@6HEJ$:C&EM9.SJ6E1Y44MP:;*2F5U
MIRS%T^XZ;R7-\\WQ2[OE6._X)+4IJNFH9J":B6J6^KKL:#P97*L'E<Y'-E/'
MP_%!#9.#CLU%-0_5?%0+4"U$M0C58DIK!UY3UJ+*ZUK^67WHU;)0Q%>1S=)<
MO%5FS6KZ= F?7.V=?&CI"ZKIJ&:@FHEJ%JK9J.:@FHMJ'JKYJ!:@6HAJ$:K%
MZNLZ.VT\TB;-+^YV0C8U+JJ\R$6ODW%W;E%9E]/#;2X>C46T>@75IJBFHYJ!
M:B:J6:AFHYJ#:BZJ>:CFHUJ :B&J1:@6UUKK4JW!^6 P.)6+3:&**J]4^?'/
M?Y##O5,2+5Y!-1W5#%0S4<VJM5:9^^&2^?4FZFAX^,E@Z+!<5/-0S4>U -5"
M5(M0+::T]H<Q-\4IFKPXY>,OJE*OFG/IFRMRIV_,H=H4U714,U#-1#4+U6Q4
M<U#-134/U7Q4"U M1+4(U6)*:R=G4QBCR0MC?O!<HUSMG:-HK0RJZ:AFH)J)
M:A:JV:CFH)J+:AZJ^:@6H%J(:A&JQ;76]5RCIC4)*2^5Z7.N44[UCD6T8 ;5
M=%0S4,U$-0O5;%1S4,U%-0_5?%0+4"U$M0C5XEJ[;ET3<:Y.3J1B4S"C?:=@
M1LPV65JD(E?TK[M/6E0^WF="+ ZJ9WI]?+>\T][YB9;1H)J.:@:JF:AFH9J-
M:@ZJN:CFH9J/:@&JA:@6H5I,:>V8;<IHRINRF.W\T6-RIW=RDMH4U714,U#-
M1#4+U6Q4<U#-134/U7Q4"U MK+7]3P:Z//*Y11'::TQI[4QL*FFT[_Q!F*Y3
MSZ,E-[VGI&@Y#JI-44U'-0/53%2S4,U&-0?57%3S4,U'M0#50E2+4"VFM';\
M-N4X&EF.(\=ZQR=:CH-JNO:Z^F1T.1Y-#CYOQD![-5'-0C4;U1Q4<U'-0S4?
MU0)4"U$M0K68TMK!V)3M:/*RG<[STN?WW']X2HH6^J#:%-5T5#-0S40U"]5L
M5'-0S44U#]5\5 M0+42U"-5B2FLG;U,.I,G+@7[T(B:T,@C5IJBFHYJ!:B:J
M6:AFHYI3:ZV+[2^O+L<'GQ?DHKUZJ.8?VX=)^6_8WH< [35$M:CC/L14K^U4
M:XIY-'DQ3^?Y9)2)7XS-\E;<OKX(OO?<$JT#0K4IJNFH9J":B6H6JMFHYJ":
MBVH>JOFH%J!:B&H1JL64UDKA85-:-)27%OW@W%*N]LU15)NBFEYK[=^F5^KP
M8%9CH+V:J&:AFHUJ#JJYJ.:AFM_QF12@O8:H%G7<AYCJM9UJ3=G/4%[VT^>B
M=CG5.\K06A]4TVNM]9&NX_,K[7I\^"8.VJ^):A:JV:CFH)J+:AZJ^:@6H%J(
M:A&JQ936#D:M"49YM4_G1??1DO.^JVWY8'I'*UHOA&HZJAFH9J*:A6HVJCFH
MYJ*:AVH^J@6H%J):A&HQI;7CMRDK&LK+BGYTM8W6#:':%-7T6I.4N=8)B58$
MH9J%:C:J.:CFHIJ':CZJ!:@6HEJ$:C&EM1.RJ0@J;_9)R--_7D<.]0Y%4INB
MFEYKIXM<ZTPD.S51S4(U&]4<5'-1S4,U']4"5 M1+4*UF-+:F=A4! WE%4&^
MR.Y%UK/^O/J9R*J%_G]5[Z#?B2P3MQW^/H]\++UC%2T(0C4=U0Q4,U'-0C4;
MU1Q4<U'-0S4?U0)4"U$M0K68TMKIVQ0$#>4%0;L_]5BD7^9"MD1'"X%0;3I\
M7;IS.9EH!U6T.MJI@6HFJEFH9J.:@VHNJGFHYJ-:@&HAJD6H%E-:.P^;.J"A
MO Y(-AM%2M+E_?>.4K3^!]5T5#-0S40U"]5L5'-0S44U#]5\5 M0+42U"-5B
M2FLG;E/_,Y37__0K29=CO>,3+?L9'BM-&(ZNKR\/YZ)H10^JF:AFH9J-:@ZJ
MN:CFH9J/:@&JA:@6H5I,:>UD;&J(AO(:HDADLW(ZF=P+Y6Z5*>+YDJ99LDZ+
M9+Z]<[9:YNFMR)(B72V/!B9:$X1JTUI31_N)>9B5:*4/JIFH9J&:C6H.JKFH
MYJ&:CVH!JH6H%J%:3&FMK!PUE3XC>:4/NF[_T7>7Y&/LF[6H-D4U'=4,5#-1
MS4(U&]4<5'-1S4,U']4"5 M1+4*UF-+:J=Q4*HWDE4K=WEV2([UC$ZU1&KW^
MRR3JJX]HU=$^#50S4<U"-1O5'%1S4<U#-1_5 E0+42U"M9C2VG&H-7$HKT_:
MC\-;D<^R='UJV2Z7>F<B6ESTG;TL'H3RL)K?BBROSNI6W^[_&>-RQIT6W]Z4
M/]&#QXU0TL5"W*9)(>;?JLMA5YE2K+:-C#3+RYGYW9V8%>FC4/Z>+DKI::FH
MU^?7?WFF9[O)_>Z/)M?WE1/^=;+\II0]*E>7YX._R,>QW^2G),\WB^KGU;TG
M5P%I7M<V%-6F2:$DRO843-61^K;\!?%._;FU9W>K^7SU].P>[-J;:M?>*D\/
MZ>QA;\MZ3;/M<?> *A_7ZVSUF,R5IW0^5Y)J2_E R\>R'NCNYND':]O[FT7R
M32F? IMYH:1+Y>!0[@Y8Z51'X>JRRS%XNST(/Z7ISX?8WD9__=.5ID[^EN\?
MGS>[X_,#3X^KP;G:^>FA_C]]>FRWQ9\D;W9N^TFRVF3-<7U:5D-3=\\-B71^
M=%6)UAFBFHEJ%JK9J.:@FHMJ'JKYJ!:@6HAJ$:K%E-:>1C5UAB-YG2%]KL]/
MOJ:+S4)^:@\M4D2U*:KIJ&:@FHEJ%JK9J.:@FHMJ'JKYJ!:@6HAJ$:K%E-8.
MX::4L;S9X\WIY<M5//N3Z/T)X-%4E?;1.U5);5IKZF#OU%^YLKB^/CSW1_9J
MH)J):A:JV:CFH)J+:AZJ^:@6H%J(:A&JQ92VR\N+_$&(8IH4R<W[134?_23F
M\VK5OUF6?'5&\.7><JE\5[YZU'>V>G;QZOZ/ZKN/6G7_1</<O%^7N>HGV7VZ
MS)6YN"O)P?GD\DS)TON'EV^*U;K,IS/ERZHH5HOMS0>1E.OP:H/RYW>K5?'\
M3=7!TRK[8SOLF_\#4$L#!!0    ( ,-S?UJB'7YV8@,  -06   -    >&PO
M<W1Y;&5S+GAM;-U8;6_:,!#^*U&Z3JTT-82L@:R M"%5FK1-E=H/^U89XH E
MQ\D<TT%__7RQ$U[J8[0?5KH@B'V/[[G'YTOB,*C4BM/;.:7*6^9<5$-_KE3Y
M*0BJZ9SFI+HH2BHTDA4R)TIWY2RH2DE)6H%3SH-NIQ,'.6'"'PW$(K_.5>5-
MBX500S]I39XY?4V'?AA_]#U#-RY2.O3OS][_6A3JZIUGSB<?3DXZ%YW[\ZM=
MY,Q"YW[@)+X\@!BEQ4CC@]1V]NGMH.2]P\CW<6/4_6WJ9OBIYFI]3S'GQ.F\
MX8HX]CH'9FM_NE#ZT*%K/2-L.KWNH:K^(LOH"FR9CP99(=;5'OG&H!60G'H/
MA _],>%L(AEX921G?&7,73!,"UY(3^G+3$L*P5(]&C@T/;@"+4_.1"'KV":"
M^9W8X3M TP.!C/-68-<WAM&@)$I1*:YUIQY<&Y] GFW?K4JM<";)*NQ>^FN'
M^J2#3 J94MF&"?W&-!IPFH$<R69S.*NB# !4JLAU(V5D5@A2:V@\;$/33BGG
MMW![^IEM<2^SC;6MZTVT32W(-@V-Z0#_)IOAWJ2-7\3KE>RA4%\6>CJB[D.]
MT!M),[:L^\NL%8"QAS@[*4N^^LS93.343/[@@*,!:?R\>2'9HXX&I3+5!BI]
M[X%*Q::;EM^2E'=TJ9IR6F:XYNX;U/QO\SRC@DK"-T7KVC_F++]8L7V>OX;F
M^K:RJ]@I,NH=OT:[?SEVD?%;$/DFEKM__"*CY/@UVMWJD8OLO=J=_3DBP[<@
MLGN4(@.[I]S8N&YM6UNK!Z\'0_\'O)#P=5!OLF!<,6%[<Y:F5#S9O6IZ12;Z
ME7V+7X]/:4867-VUX-!?M[_3E"WRI!UU XFPH];M;S ]O15NWDUT+"92NJ3I
MV';E;%(W/=W04>T!#KO(=7VX$<S'8&X$,"P.I@#S,5Y8G/]I/GUT/@;#M/6=
M2!_UZ:,^QLN%C.L/%L?MD^C#/=,DB:(XQC(Z'CL5C+&\Q3%\W6R8-O# XD"D
MY^4:7VV\0O;7 ;:F^RH$FRE>B=A,\5P#XLX;>"2)>[6Q.."!K0)6.Q#?'0=J
MRNT31;"JF#;L"L:1),$0J$5WC<8QDIT8/N[UP:Z2*$H2-P*86T$480A<C3B"
M*0 -&!)%]7-PYWD4-,^I8/T_]N@/4$L#!!0    ( ,-S?UJ7BKL<P    !,"
M   +    7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8
M$@6*19V_K]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*N
MU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I
M2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3
MZ:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ PW-_6A\K
MY*V%!0  =R@   \   !X;"]W;W)K8F]O:RYX;6S%FEUSFS@40/^*QD_=EW7,
MA]MFFL[(H,3:Q< "3INGCH+EA F&C"!)TU^_%XA;T7CO[(N<)QNPX7 EW:,K
M^/14J[OKNKXCWW=EU9Q-;MOV_G0Z;?);N1/-G_6]K.#(ME8[T<*FNIDV]TJ*
M37,K9;LKI];)R7RZ$T4U^?QI?ZY83?6-NI5Y6]05[.QV7!;RJ?EUO-LDCT53
M7!=ET3Z?3?KOI9R075$5N^*'W)Q-3B:DN:V?EK4J?M15*\HT5W59GDUFPX%+
MJ=HB?[4[[2 S<=WT>UIQG0@ .9O,3^"$VT(U;?^+_OP"&!\E_'C8>FCK\Z)L
MI?)%*R]4_7!?5#?=:> NIMIM]''8?PY!/%7_)XSU=EODTJ_SAYVLVB&.2I8=
M8-7<%O?-A%1B)\\F7OTH57<_< &^&>ZM!2@M4NJT@ .*;WH\DRA54Y?%!JZ^
M(0M1BBJ7I ]AHP%:"*#U9H#D72PT2!N!M(\(F780W1\:4F])=#]J:@>!=-X"
MLF-,VSJ_TR!=!-)]LTAZHKG5(.<(Y-PL9"R>R6-#8JGZOW<]TB^:O*R;!R4U
MQ/<(XGNSB+QJBHU4)%-B VF.4*5$=3,$4R/\@!!^."YA#,V>%[(AHMJ06!\S
M'Q'(CX:[X_.U5(W,'Q2(C"1%<T=6HA)#((F>?68G6!(_,8OIL]1+>)SQ*"31
M.5FL4QZR--7Q4,<8EDS _UESGV=7A(8^B0/:4T8Q2VB'K&-BIID95DVZ7JUH
M<M6QI?PBY.?<HV%&J.=%ZS#C.B;FFIEAV<0)BRGW"?L:LS!E:1_4*%NRA"3,
M8SHF9IN98=WP\)*%691<Z4"866:&U9)FD??W,@I\EJ3?"(,NF8W8,*',#!LE
M8!1:4J?!W#$S+(\@2E,"HY.D2YHP0N,X@*&P"!C)(N)%.B8FD)EA@URPZ"*A
M\9)[A(?G4;+JLTD_'%;TKQ$FII"988<,0Y.F*<OT%K8P85B&A>%%JQ7/5C!
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M    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( ,-S?UK6F"5F\@   "L"   1              "  <,   !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( ,-S?UJ97)PC$ 8  )PG   3
M      "  >0!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ PW-_
M6ALT>;$J"0  "#<  !@              ("!)0@  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( ,-S?UI5X,5_ 0<  (<G   8
M      " @841  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M" ##<W]:.LD?^<<#  #W%   &               @(&\&   >&PO=V]R:W-H
M965T<R]S:&5E=#,N>&UL4$L! A0#%     @ PW-_6L43MSX;!0  YA0  !@
M             ("!N1P  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4
M Q0    ( ,-S?UH -7\LTP<  ']0   8              " @0HB  !X;"]W
M;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " ##<W]:44MN^O4%  "Q
M&@  &               @($3*@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL
M4$L! A0#%     @ PW-_6@IQ/PA3 @  J@4  !@              ("!/C
M 'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( ,-S?UI.ZR_I
M"P(  *\$   8              " @<<R  !X;"]W;W)K<VAE971S+W-H965T
M."YX;6Q02P$"% ,4    " ##<W]:](T9%J<#  !Q"   &
M@($(-0  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ PW-_
M6J1*X\VL"   R2   !D              ("!Y3@  'AL+W=O<FMS:&5E=',O
M<VAE970Q,"YX;6Q02P$"% ,4    " ##<W]::??^Y6@#   O!P  &0
M        @('(00  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0
M   ( ,-S?UI0RO%UQP(  !,&   9              " @6=%  !X;"]W;W)K
M<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ PW-_6GHA:3#S%   I38
M !D              ("!94@  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q0
M2P$"% ,4    " ##<W]:@NFM4;0"  !"!@  &0              @(&/70
M>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( ,-S?UK"5EWT
MA (  'P%   9              " @7I@  !X;"]W;W)K<VAE971S+W-H965T
M,34N>&UL4$L! A0#%     @ PW-_6D<D439E#   [A\  !D
M ("!-6,  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " ##
M<W]:OY ]G!P#  #4!@  &0              @('1;P  >&PO=V]R:W-H965T
M<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( ,-S?UKMFP_&1@0  (P)   9
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M970R,BYX;6Q02P$"% ,4    " ##<W]:ERKFR:T)  #Y%P  &0
M    @(%&C   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    (
M ,-S?UJ;[L%XL @  &(8   9              " @2J6  !X;"]W;W)K<VAE
M971S+W-H965T,C0N>&UL4$L! A0#%     @ PW-_6E#[CZM6%@  =T   !D
M             ("!$9\  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"
M% ,4    " ##<W]:Y1"2KPD#  !4!@  &0              @(&>M0  >&PO
M=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( ,-S?UH^"9 VM (
M "<&   9              " @=ZX  !X;"]W;W)K<VAE971S+W-H965T,C<N
M>&UL4$L! A0#%     @ PW-_6M.E;^R! @  > 4  !D              ("!
MR;L  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " ##<W]:
M*V./4&4%   Y#0  &0              @(&!O@  >&PO=V]R:W-H965T<R]S
M:&5E=#(Y+GAM;%!+ 0(4 Q0    ( ,-S?UH<U,L)T (  #(&   9
M      " @1W$  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%
M  @ PW-_6KSR]"D[ P  T 8  !D              ("!),<  'AL+W=O<FMS
M:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " ##<W]:E9EU>=0"   3!@
M&0              @(&6R@  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+
M 0(4 Q0    ( ,-S?UJK4VJ_)P0  !(+   9              " @:'-  !X
M;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ PW-_6FGJ5U (
M!0  R0P  !D              ("!_]$  'AL+W=O<FMS:&5E=',O<VAE970S
M-"YX;6Q02P$"% ,4    " ##<W]:DMHSFG8#  "+#0  &0
M@($^UP  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( ,-S
M?UIH'GQ[I0(  !@)   9              " @>O:  !X;"]W;W)K<VAE971S
M+W-H965T,S8N>&UL4$L! A0#%     @ PW-_6G-[;3I_ P    L  !D
M         ("!Q]T  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
M    " ##<W]:&</.P9,"  "5!@  &0              @(%]X0  >&PO=V]R
M:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( ,-S?UJ"'8.N7P(  "T&
M   9              " @4?D  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL
M4$L! A0#%     @ PW-_6@JV>!G%!   HQ@  !D              ("!W>8
M 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " ##<W]:*C.R
M18,#  "7#   &0              @('9ZP  >&PO=V]R:W-H965T<R]S:&5E
M=#0Q+GAM;%!+ 0(4 Q0    ( ,-S?UHWV4?R)0,  !D*   9
M  " @9/O  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @
MPW-_6N?[<?A' P  I0X  !D              ("![_(  'AL+W=O<FMS:&5E
M=',O<VAE970T,RYX;6Q02P$"% ,4    " ##<W]:7!-VZH,7  "$@ $ &0
M            @(%M]@  >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4
M Q0    ( ,-S?UH8G+O+CP(  (L&   9              " @2<. 0!X;"]W
M;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ PW-_6BT"M,.< @
M< <  !D              ("![1 ! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX
M;6Q02P$"% ,4    " ##<W]:!R">E5D#  "8"P  &0              @('
M$P$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( ,-S?UHB
MK#H?%P0  ((6   9              " @5 7 0!X;"]W;W)K<VAE971S+W-H
M965T-#@N>&UL4$L! A0#%     @ PW-_6E96J/N) @  F04  !D
M     ("!GAL! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,-S?UH['32@$P,  .4+   9              "
M@0HN 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ PW-_
M6E_\.FPT @  HP0  !D              ("!5#$! 'AL+W=O<FMS:&5E=',O
M<VAE970U-2YX;6Q02P$"% ,4    " ##<W]:[2KM*4T#  "D"P  &0
M        @(&_,P$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0
M   ( ,-S?UH]PSM<K0,  *,+   9              " @4,W 0!X;"]W;W)K
M<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ PW-_6L31X]*S @  \@8
M !D              ("!)SL! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q0
M2P$"% ,4    " ##<W]:4K]0<00#  !]"0  &0              @($1/@$
M>&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( ,-S?UJ?W) 9
M)P0  %X3   9              " @4Q! 0!X;"]W;W)K<VAE971S+W-H965T
M-C N>&UL4$L! A0#%     @ PW-_6A8G-74O#P  I.8  !D
M ("!JD4! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    " ##
M<W]:HAU^=F(#  #4%@  #0              @ $050$ >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( ,-S?UJ7BKL<P    !,"   +              "  9U8
M 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( ,-S?UH?*^2MA04  '<H   /
M          "  899 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " ##<W]:
M]4F2S $"  !>)   &@              @ $X7P$ >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    " ##<W]:UDS DN !  #C(P  $P
M        @ %Q80$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     10!% -H2
(  ""8P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>186</ContextCount>
  <ElementCount>315</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>63</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statement of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/StatementOfStockholdersEquity</Role>
      <ShortName>Consolidated Statement of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>999014 - Disclosure - DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/DescriptionOfBusiness</Role>
      <ShortName>DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999015 - Disclosure - LIQUIDITY AND PLAN OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/LiquidityAndPlanOfOperations</Role>
      <ShortName>LIQUIDITY AND PLAN OF OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999017 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/PrepaidExpensesAndOtherReceivables</Role>
      <ShortName>PREPAID EXPENSES AND OTHER RECEIVABLES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999018 - Disclosure - INVENTORY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/Inventory</Role>
      <ShortName>INVENTORY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999019 - Disclosure - STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999020 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/Leases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999021 - Disclosure - LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/LossPerShareApplicableToCommonShareholder</Role>
      <ShortName>LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999022 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/GeographicInformationAndMajorCustomerData</Role>
      <ShortName>GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999023 - Disclosure - OTHER ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/OtherAssets</Role>
      <ShortName>OTHER ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999024 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999025 - Disclosure - RELATED PARTY TRANSACTION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/RelatedPartyTransaction</Role>
      <ShortName>RELATED PARTY TRANSACTION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999026 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999027 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanovibronix.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999030 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/PrepaidExpensesAndOtherReceivablesTables</Role>
      <ShortName>PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanovibronix.com/role/PrepaidExpensesAndOtherReceivables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999031 - Disclosure - INVENTORY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/InventoryTables</Role>
      <ShortName>INVENTORY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanovibronix.com/role/Inventory</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999032 - Disclosure - STOCKHOLDERS??? EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanovibronix.com/role/StockholdersEquity</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999033 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/LeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanovibronix.com/role/Leases</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999034 - Disclosure - LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/LossPerShareApplicableToCommonShareholderTables</Role>
      <ShortName>LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanovibronix.com/role/LossPerShareApplicableToCommonShareholder</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999035 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataTables</Role>
      <ShortName>GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanovibronix.com/role/GeographicInformationAndMajorCustomerData</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999036 - Disclosure - OTHER ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/OtherAssetsTables</Role>
      <ShortName>OTHER ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanovibronix.com/role/OtherAssets</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999037 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanovibronix.com/role/IncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999038 - Disclosure - LIQUIDITY AND PLAN OF OPERATIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/LiquidityAndPlanOfOperationsDetailsNarrative</Role>
      <ShortName>LIQUIDITY AND PLAN OF OPERATIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanovibronix.com/role/LiquidityAndPlanOfOperations</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999039 - Disclosure - SCHEDULE OF DEPRECIATION CALCULATED OVER ESTIMATED USEFUL LIVES OF ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsDetails</Role>
      <ShortName>SCHEDULE OF DEPRECIATION CALCULATED OVER ESTIMATED USEFUL LIVES OF ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999041 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER RECEIVABLES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/ScheduleOfPrepaidExpensesAndOtherReceivablesDetails</Role>
      <ShortName>SCHEDULE OF PREPAID EXPENSES AND OTHER RECEIVABLES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999042 - Disclosure - SCHEDULE OF INVENTORY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/ScheduleOfInventoryDetails</Role>
      <ShortName>SCHEDULE OF INVENTORY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999043 - Disclosure - SCHEDULE OF OPTIONS ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails</Role>
      <ShortName>SCHEDULE OF OPTIONS ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999044 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR OPTIONS GRANTED (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForOptionsGrantedDetails</Role>
      <ShortName>SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR OPTIONS GRANTED (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999045 - Disclosure - SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED SERVICES FROM EMPLOYEES AND NON-EMPLOYEES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails</Role>
      <ShortName>SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED SERVICES FROM EMPLOYEES AND NON-EMPLOYEES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999046 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR WARRANTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForWarrantsDetails</Role>
      <ShortName>SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR WARRANTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999047 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanovibronix.com/role/StockholdersEquityTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>999048 - Disclosure - SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails</Role>
      <ShortName>SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>999049 - Disclosure - LEASES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/LeasesDetailsNarrative</Role>
      <ShortName>LEASES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanovibronix.com/role/LeasesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>999050 - Disclosure - SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails</Role>
      <ShortName>SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>999051 - Disclosure - SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails</Role>
      <ShortName>SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>999052 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative</Role>
      <ShortName>GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>999053 - Disclosure - SCHEDULE OF WARRANTS ASSUMPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails</Role>
      <ShortName>SCHEDULE OF WARRANTS ASSUMPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>999054 - Disclosure - SCHEDULE OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails</Role>
      <ShortName>SCHEDULE OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>999055 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails</Role>
      <ShortName>SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>999056 - Disclosure - OTHER ASSETS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/OtherAssetsDetailsNarrative</Role>
      <ShortName>OTHER ASSETS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanovibronix.com/role/OtherAssetsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>999057 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanovibronix.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>999058 - Disclosure - RELATED PARTY TRANSACTION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/RelatedPartyTransactionDetailsNarrative</Role>
      <ShortName>RELATED PARTY TRANSACTION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanovibronix.com/role/RelatedPartyTransaction</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>999059 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAXES EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails</Role>
      <ShortName>SCHEDULE OF PROVISION FOR INCOME TAXES EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>999060 - Disclosure - SCHEDULE OF RECONCILIATION OF STATUTORY U.S. FEDERAL RATE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails</Role>
      <ShortName>SCHEDULE OF RECONCILIATION OF STATUTORY U.S. FEDERAL RATE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>999061 - Disclosure - SCHEDULE OF INCOME BEFORE TAXES ON DOMESTIC AND FOREIGN (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/ScheduleOfIncomeBeforeTaxesOnDomesticAndForeignDetails</Role>
      <ShortName>SCHEDULE OF INCOME BEFORE TAXES ON DOMESTIC AND FOREIGN (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>999062 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/ScheduleOfDeferredTaxAssetsDetails</Role>
      <ShortName>SCHEDULE OF DEFERRED TAX ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>999063 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanovibronix.com/role/IncomeTaxesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>999064 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanovibronix.com/role/SubsequentEvents</ParentRole>
      <Position>61</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="form10-k.htm">form10-k.htm</File>
    <File>naov-20241231.xsd</File>
    <File>naov-20241231_cal.xml</File>
    <File>naov-20241231_def.xml</File>
    <File>naov-20241231_lab.xml</File>
    <File>naov-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form10-k_001.jpg</File>
    <File>form10-k_002.jpg</File>
    <File>form10-k_003.jpg</File>
    <File>form10-k_004.jpg</File>
    <File>form10-k_005.jpg</File>
    <File>form10-k_006.jpg</File>
    <File>form10-k_007.jpg</File>
    <File>form10-k_008.jpg</File>
    <File>form10-k_009.jpg</File>
    <File>form10-k_010.jpg</File>
    <File>form10-k_011.jpg</File>
    <File>form10-k_012.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="690">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="11">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="1">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>95
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-k.htm": {
   "nsprefix": "NAOV",
   "nsuri": "http://nanovibronix.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    },
    "schema": {
     "local": [
      "naov-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "naov-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "naov-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "naov-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "naov-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 280,
   "keyCustom": 35,
   "axisStandard": 20,
   "axisCustom": 0,
   "memberStandard": 36,
   "memberCustom": 26,
   "hidden": {
    "total": 196,
    "http://fasb.org/us-gaap/2024": 154,
    "http://nanovibronix.com/20241231": 39,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 186,
   "entityCount": 1,
   "segmentCount": 63,
   "elementCount": 589,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 690,
    "http://xbrl.sec.gov/dei/2024": 39,
    "http://xbrl.sec.gov/cyd/2024": 11,
    "http://xbrl.sec.gov/ecd/2024": 1
   },
   "report": {
    "R1": {
     "role": "http://nanovibronix.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://nanovibronix.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://nanovibronix.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss",
     "longName": "00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CostOfRevenue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://nanovibronix.com/role/StatementOfStockholdersEquity",
     "longName": "00000005 - Statement - Consolidated Statement of Stockholders' Equity",
     "shortName": "Consolidated Statement of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://nanovibronix.com/role/StatementsOfCashFlows",
     "longName": "00000006 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "NAOV:NoInsiderTradingFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "NAOV:NoInsiderTradingFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ecd:InsiderTrdPoliciesProcNotAdoptedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ecd:InsiderTrdPoliciesProcNotAdoptedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://nanovibronix.com/role/DescriptionOfBusiness",
     "longName": "999014 - Disclosure - DESCRIPTION OF BUSINESS",
     "shortName": "DESCRIPTION OF BUSINESS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://nanovibronix.com/role/LiquidityAndPlanOfOperations",
     "longName": "999015 - Disclosure - LIQUIDITY AND PLAN OF OPERATIONS",
     "shortName": "LIQUIDITY AND PLAN OF OPERATIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "NAOV:GoingConcernAndLiquidityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "NAOV:GoingConcernAndLiquidityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://nanovibronix.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "999016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://nanovibronix.com/role/PrepaidExpensesAndOtherReceivables",
     "longName": "999017 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES",
     "shortName": "PREPAID EXPENSES AND OTHER RECEIVABLES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://nanovibronix.com/role/Inventory",
     "longName": "999018 - Disclosure - INVENTORY",
     "shortName": "INVENTORY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://nanovibronix.com/role/StockholdersEquity",
     "longName": "999019 - Disclosure - STOCKHOLDERS\u2019 EQUITY",
     "shortName": "STOCKHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://nanovibronix.com/role/Leases",
     "longName": "999020 - Disclosure - LEASES",
     "shortName": "LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://nanovibronix.com/role/LossPerShareApplicableToCommonShareholder",
     "longName": "999021 - Disclosure - LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER",
     "shortName": "LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerData",
     "longName": "999022 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA",
     "shortName": "GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://nanovibronix.com/role/OtherAssets",
     "longName": "999023 - Disclosure - OTHER ASSETS",
     "shortName": "OTHER ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://nanovibronix.com/role/CommitmentsAndContingencies",
     "longName": "999024 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://nanovibronix.com/role/RelatedPartyTransaction",
     "longName": "999025 - Disclosure - RELATED PARTY TRANSACTION",
     "shortName": "RELATED PARTY TRANSACTION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://nanovibronix.com/role/IncomeTaxes",
     "longName": "999026 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://nanovibronix.com/role/SubsequentEvents",
     "longName": "999027 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "999028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "999029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "NAOV:ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "NAOV:ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://nanovibronix.com/role/PrepaidExpensesAndOtherReceivablesTables",
     "longName": "999030 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)",
     "shortName": "PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://nanovibronix.com/role/InventoryTables",
     "longName": "999031 - Disclosure - INVENTORY (Tables)",
     "shortName": "INVENTORY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://nanovibronix.com/role/StockholdersEquityTables",
     "longName": "999032 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://nanovibronix.com/role/LeasesTables",
     "longName": "999033 - Disclosure - LEASES (Tables)",
     "shortName": "LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://nanovibronix.com/role/LossPerShareApplicableToCommonShareholderTables",
     "longName": "999034 - Disclosure - LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER (Tables)",
     "shortName": "LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataTables",
     "longName": "999035 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Tables)",
     "shortName": "GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://nanovibronix.com/role/OtherAssetsTables",
     "longName": "999036 - Disclosure - OTHER ASSETS (Tables)",
     "shortName": "OTHER ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "NAOV:ScheduleOfWarrantsAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "NAOV:ScheduleOfWarrantsAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://nanovibronix.com/role/IncomeTaxesTables",
     "longName": "999037 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://nanovibronix.com/role/LiquidityAndPlanOfOperationsDetailsNarrative",
     "longName": "999038 - Disclosure - LIQUIDITY AND PLAN OF OPERATIONS (Details Narrative)",
     "shortName": "LIQUIDITY AND PLAN OF OPERATIONS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "NAOV:GoingConcernAndLiquidityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_SaleOfEquitySecuritiesMember",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "NAOV:GoingConcernAndLiquidityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://nanovibronix.com/role/ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsDetails",
     "longName": "999039 - Disclosure - SCHEDULE OF DEPRECIATION CALCULATED OVER ESTIMATED USEFUL LIVES OF ASSETS (Details)",
     "shortName": "SCHEDULE OF DEPRECIATION CALCULATED OVER ESTIMATED USEFUL LIVES OF ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_ComputerEquipmentMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "NAOV:ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_ComputerEquipmentMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "NAOV:ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "999040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://nanovibronix.com/role/ScheduleOfPrepaidExpensesAndOtherReceivablesDetails",
     "longName": "999041 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER RECEIVABLES (Details)",
     "shortName": "SCHEDULE OF PREPAID EXPENSES AND OTHER RECEIVABLES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://nanovibronix.com/role/ScheduleOfInventoryDetails",
     "longName": "999042 - Disclosure - SCHEDULE OF INVENTORY (Details)",
     "shortName": "SCHEDULE OF INVENTORY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails",
     "longName": "999043 - Disclosure - SCHEDULE OF OPTIONS ACTIVITY (Details)",
     "shortName": "SCHEDULE OF OPTIONS ACTIVITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_custom_EmployeeOptionsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_EmployeeOptionsMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForOptionsGrantedDetails",
     "longName": "999044 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR OPTIONS GRANTED (Details)",
     "shortName": "SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR OPTIONS GRANTED (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails",
     "longName": "999045 - Disclosure - SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED SERVICES FROM EMPLOYEES AND NON-EMPLOYEES (Details)",
     "shortName": "SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED SERVICES FROM EMPLOYEES AND NON-EMPLOYEES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForWarrantsDetails",
     "longName": "999046 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR WARRANTS (Details)",
     "shortName": "SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR WARRANTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "NAOV:ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R44": {
     "role": "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative",
     "longName": "999047 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "From2025-03-132025-03-13",
      "name": "us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-03-132025-03-13",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails",
     "longName": "999048 - Disclosure - SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES (Details)",
     "shortName": "SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://nanovibronix.com/role/LeasesDetailsNarrative",
     "longName": "999049 - Disclosure - LEASES (Details Narrative)",
     "shortName": "LEASES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails",
     "longName": "999050 - Disclosure - SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE (Details)",
     "shortName": "SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails",
     "longName": "999051 - Disclosure - SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS (Details)",
     "shortName": "SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_country_US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative",
     "longName": "999052 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Details Narrative)",
     "shortName": "GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerMember",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerMember",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails",
     "longName": "999053 - Disclosure - SCHEDULE OF WARRANTS ASSUMPTIONS (Details)",
     "shortName": "SCHEDULE OF WARRANTS ASSUMPTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "NAOV:ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_PriceAtValuationMember_custom_SanuwaveHealthIncMember",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "NAOV:ScheduleOfWarrantsAssumptionsTableTextBlock",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails",
     "longName": "999054 - Disclosure - SCHEDULE OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE (Details)",
     "shortName": "SCHEDULE OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_custom_DerivativeAssetMember",
      "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails",
     "longName": "999055 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (Details)",
     "shortName": "SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:OtherAssetsFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:OtherAssetsFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://nanovibronix.com/role/OtherAssetsDetailsNarrative",
     "longName": "999056 - Disclosure - OTHER ASSETS (Details Narrative)",
     "shortName": "OTHER ASSETS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "NAOV:ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-09-122024-09-12",
      "name": "us-gaap:GainLossOnContractTermination",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "999057 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "From2022-03-142022-03-15",
      "name": "us-gaap:LossContingencyDamagesSoughtValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-03-142022-03-15",
      "name": "us-gaap:LossContingencyDamagesSoughtValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://nanovibronix.com/role/RelatedPartyTransactionDetailsNarrative",
     "longName": "999058 - Disclosure - RELATED PARTY TRANSACTION (Details Narrative)",
     "shortName": "RELATED PARTY TRANSACTION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_PiersonFerdinandMember",
      "name": "us-gaap:PaymentsForFees",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_PiersonFerdinandMember",
      "name": "us-gaap:PaymentsForFees",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails",
     "longName": "999059 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAXES EXPENSES (Details)",
     "shortName": "SCHEDULE OF PROVISION FOR INCOME TAXES EXPENSES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CurrentForeignTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CurrentForeignTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://nanovibronix.com/role/ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails",
     "longName": "999060 - Disclosure - SCHEDULE OF RECONCILIATION OF STATUTORY U.S. FEDERAL RATE (Details)",
     "shortName": "SCHEDULE OF RECONCILIATION OF STATUTORY U.S. FEDERAL RATE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://nanovibronix.com/role/ScheduleOfIncomeBeforeTaxesOnDomesticAndForeignDetails",
     "longName": "999061 - Disclosure - SCHEDULE OF INCOME BEFORE TAXES ON DOMESTIC AND FOREIGN (Details)",
     "shortName": "SCHEDULE OF INCOME BEFORE TAXES ON DOMESTIC AND FOREIGN (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://nanovibronix.com/role/ScheduleOfDeferredTaxAssetsDetails",
     "longName": "999062 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)",
     "shortName": "SCHEDULE OF DEFERRED TAX ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://nanovibronix.com/role/IncomeTaxesDetailsNarrative",
     "longName": "999063 - Disclosure - INCOME TAXES (Details Narrative)",
     "shortName": "INCOME TAXES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "NAOV:FederalNetOperatingLossCarriedForward",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "NAOV:FederalNetOperatingLossCarriedForward",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative",
     "longName": "999064 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "From2025-03-132025-03-13",
      "name": "us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-26_us-gaap_SubsequentEventMember_custom_ENvueMedicalHoldingsCorpMember",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "NAOV_A1WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "A1WarrantsMember",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative",
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "A-1 Warrants [Member]",
        "documentation": "A1 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NAOV_A2WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "A2WarrantsMember",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "A-2 Warrants [Member]",
        "documentation": "A2 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "country_AU": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "AU",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AUSTRALIA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade payables",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r661"
     ]
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trades receivables",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r546",
      "r607",
      "r679",
      "r890",
      "r891"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade receivables",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "NAOV_AccruedSeverancePayLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "AccruedSeverancePayLiability",
     "crdr": "credit",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued severance pay liability",
        "documentation": "Accrued severance pay liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r150",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r400"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive income",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r66",
      "r138",
      "r474",
      "r495",
      "r496"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r150",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r400"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://nanovibronix.com/role/StatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r12",
      "r23",
      "r369",
      "r372",
      "r416",
      "r491",
      "r492",
      "r813",
      "r814",
      "r815",
      "r821",
      "r822",
      "r823",
      "r824"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r661",
      "r922"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://nanovibronix.com/role/StatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r821",
      "r822",
      "r823",
      "r824",
      "r860",
      "r923"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://nanovibronix.com/role/StatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdvertisingCostsPolicyTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advertising and Marketing Costs",
        "documentation": "Disclosure of accounting policy for advertising cost."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r715",
      "r726",
      "r740",
      "r766"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r718",
      "r729",
      "r743",
      "r769"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r754"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r761"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r719",
      "r730",
      "r744",
      "r761",
      "r770",
      "r774",
      "r782"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r319"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "NAOV_ArbitratorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "ArbitratorMember",
     "presentation": [
      "http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arbitrator [Member]",
        "documentation": "Arbitrator [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://nanovibronix.com/role/OtherAssetsDetailsNarrative",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative",
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r108",
      "r134",
      "r161",
      "r195",
      "r203",
      "r214",
      "r217",
      "r226",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r364",
      "r366",
      "r390",
      "r469",
      "r551",
      "r635",
      "r636",
      "r661",
      "r686",
      "r844",
      "r845",
      "r881"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r143",
      "r161",
      "r226",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r364",
      "r366",
      "r390",
      "r661",
      "r844",
      "r845",
      "r881"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r226",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r364",
      "r366",
      "r390",
      "r844",
      "r845",
      "r881"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncurrent assets:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r698",
      "r700",
      "r722"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r698",
      "r700",
      "r722"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r698",
      "r700",
      "r722"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r773"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of presentation and principles of consolidation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets",
      "http://nanovibronix.com/role/LiquidityAndPlanOfOperationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "verboseLabel": "Cash balance",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r471",
      "r521",
      "r545",
      "r661",
      "r686",
      "r806"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash at beginning of period",
        "periodEndLabel": "Cash at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r73",
      "r158"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (decrease) increase in cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r73"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash FDIC, insured amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "NAOV_ChangeInCurrentExpectedCreditLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "ChangeInCurrentExpectedCreditLosses",
     "crdr": "credit",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in current expected credit losses",
        "documentation": "Change in current expected credit losses."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets",
      "http://nanovibronix.com/role/BalanceSheetsParenthetical",
      "http://nanovibronix.com/role/StatementOfStockholdersEquity",
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r135",
      "r136",
      "r137",
      "r161",
      "r183",
      "r184",
      "r187",
      "r189",
      "r197",
      "r198",
      "r226",
      "r245",
      "r247",
      "r248",
      "r249",
      "r252",
      "r253",
      "r259",
      "r260",
      "r262",
      "r265",
      "r271",
      "r390",
      "r501",
      "r502",
      "r503",
      "r504",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r522",
      "r537",
      "r560",
      "r580",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r801",
      "r817",
      "r825"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://nanovibronix.com/role/OtherAssetsDetailsNarrative",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative",
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share price",
        "verboseLabel": "Exercise price of warrants per share",
        "terseLabel": "Exercise price per share",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total warrants",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://nanovibronix.com/role/OtherAssetsDetailsNarrative",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative",
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants issued to purchase common stock",
        "verboseLabel": "Warrant exercise, conversion shares",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://nanovibronix.com/role/OtherAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_CollateralAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollateralAxis",
     "presentation": [
      "http://nanovibronix.com/role/LiquidityAndPlanOfOperationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collateral Held [Axis]",
        "documentation": "Information by category of collateral or no collateral, from lender's perspective."
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "us-gaap_CollateralDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollateralDomain",
     "presentation": [
      "http://nanovibronix.com/role/LiquidityAndPlanOfOperationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category of collateral or no collateral, from lender's perspective."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r101",
      "r470",
      "r536"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r239",
      "r240",
      "r609",
      "r838",
      "r840"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock reserved for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://nanovibronix.com/role/StatementOfStockholdersEquity",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative",
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r677",
      "r678",
      "r680",
      "r681",
      "r682",
      "r683",
      "r821",
      "r822",
      "r824",
      "r860",
      "r921",
      "r923"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheetsParenthetical",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "verboseLabel": "Common stock par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheetsParenthetical",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative",
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "verboseLabel": "Common stock shares remained unchanged",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r537"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r55",
      "r537",
      "r557",
      "r923",
      "r924"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock of $0.001 par value - Authorized: 40,000,000 shares at December 31, 2024, and December 31, 2023, respectively; Issued and outstanding: 378,941 and 186,028 shares at December 31, 2024, and December 31, 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r473",
      "r661"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r96"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss available to common stockholders",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r145",
      "r147",
      "r153",
      "r463",
      "r482",
      "r483"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r43",
      "r44",
      "r224",
      "r608"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r43",
      "r44",
      "r224",
      "r498",
      "r608"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r43",
      "r44",
      "r224",
      "r608",
      "r804"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration risk, percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r43",
      "r44",
      "r224"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r43",
      "r44",
      "r224",
      "r608"
     ]
    },
    "us-gaap_ConvertiblePreferredStockTermsOfConversion": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockTermsOfConversion",
     "presentation": [
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible description",
        "documentation": "Description of conversion terms for preferred stock."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r36",
      "r37",
      "r54",
      "r86",
      "r87"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of revenues",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r161",
      "r226",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r390",
      "r635",
      "r844"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r805",
      "r819",
      "r859"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r805",
      "r819"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails": {
       "parentTag": "us-gaap_OtherTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r819"
     ]
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r805",
      "r819",
      "r859"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r224"
     ]
    },
    "NAOV_CustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "CustomerMember",
     "presentation": [
      "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Member]",
        "documentation": "Customer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r708",
      "r792"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r708",
      "r792"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r794"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r794"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r794"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r703",
      "r787"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r704",
      "r788"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r704",
      "r788"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r702",
      "r786"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r789"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r707",
      "r791"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r707",
      "r791"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r708",
      "r792"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r711",
      "r795"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r709",
      "r793"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r706",
      "r790"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r256"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt principal amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r403",
      "r404",
      "r642",
      "r643",
      "r659"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r255"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/PrepaidExpensesAndOtherReceivablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF PREPAID EXPENSES AND OTHER RECEIVABLES",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r819",
      "r858",
      "r859"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r819",
      "r858"
     ]
    },
    "us-gaap_DeferredIncomeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred revenue",
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "us-gaap_DeferredIncomeNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred revenue \u2013 long term",
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails": {
       "parentTag": "us-gaap_OtherTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r123",
      "r819"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r819",
      "r858",
      "r859"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets before valuation allowance",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax asset",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "NAOV_DeferredTaxAssetsOfCapitalLossCarryforward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "DeferredTaxAssetsOfCapitalLossCarryforward",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital loss carryforward"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforward",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "NAOV_DeferredTaxAssetsTaxDeferredExpenseAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseAccruals",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arbitration accrual",
        "documentation": "Deferred tax assets tax deferred expense accruals."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock compensation and other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from compensation and benefits, classified as other."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "crdr": "debit",
     "presentation": [
      "http://nanovibronix.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r195",
      "r207",
      "r217",
      "r635",
      "r636"
     ]
    },
    "NAOV_DerivativeAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "DerivativeAssetMember",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Asset [Member]",
        "documentation": "Derivative Asset [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r528",
      "r542",
      "r543",
      "r544",
      "r547",
      "r548",
      "r549",
      "r550",
      "r552",
      "r553",
      "r554",
      "r555",
      "r568",
      "r569",
      "r570",
      "r571",
      "r574",
      "r575",
      "r576",
      "r577",
      "r594",
      "r595",
      "r596",
      "r597",
      "r676",
      "r678",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r873",
      "r874"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r42",
      "r99",
      "r526",
      "r528",
      "r542",
      "r543",
      "r544",
      "r547",
      "r548",
      "r549",
      "r550",
      "r552",
      "r553",
      "r554",
      "r555",
      "r568",
      "r569",
      "r570",
      "r571",
      "r574",
      "r575",
      "r576",
      "r577",
      "r594",
      "r595",
      "r596",
      "r597",
      "r627",
      "r676",
      "r678",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r873",
      "r874"
     ]
    },
    "NAOV_DisclosureLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "DisclosureLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "verboseLabel": "Schedule Of Liabilities Arising From Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "NAOV_DisclosureLiquidityAndPlanOfOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "DisclosureLiquidityAndPlanOfOperationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity And Plan Of Operations"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r698",
      "r700",
      "r722"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r698",
      "r700",
      "r722",
      "r762"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://nanovibronix.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "NAOV_ENvueMedicalHoldingsCorpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "ENvueMedicalHoldingsCorpMember",
     "presentation": [
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ENvue Medical Holdings Corp [Member]",
        "documentation": "ENvue Medical Holdings Corp [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic net loss available for holders of common stock",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r180",
      "r183",
      "r187",
      "r188",
      "r189",
      "r194",
      "r359",
      "r362",
      "r376",
      "r377",
      "r464",
      "r484",
      "r629"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted net loss available for holders of common stock",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r183",
      "r187",
      "r188",
      "r189",
      "r194",
      "r359",
      "r362",
      "r376",
      "r377",
      "r464",
      "r484",
      "r629"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r191"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/LossPerShareApplicableToCommonShareholder"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r190",
      "r192",
      "r193"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effects of currency translation on cash",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://nanovibronix.com/role/ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r652"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://nanovibronix.com/role/ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/IncomeTaxesDetailsNarrative",
      "http://nanovibronix.com/role/ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal income tax benefit at statutory rate",
        "verboseLabel": "Corporate tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r327",
      "r350",
      "r652"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://nanovibronix.com/role/ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r652",
      "r820",
      "r852"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://nanovibronix.com/role/ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign rate differential",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r331",
      "r652",
      "r820",
      "r852"
     ]
    },
    "NAOV_EffectiveIncomeTaxRateReconciliationForfeitedOptions": {
     "xbrltype": "percentItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationForfeitedOptions",
     "calculation": {
      "http://nanovibronix.com/role/ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited options",
        "documentation": "Effective income tax rate reconciliation,forfeited options, percent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://nanovibronix.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r328",
      "r652"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://nanovibronix.com/role/ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r652",
      "r820",
      "r852",
      "r853"
     ]
    },
    "NAOV_EffectiveIncomeTaxRateReconciliationPermanentItems": {
     "xbrltype": "percentItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentItems",
     "calculation": {
      "http://nanovibronix.com/role/ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Permanent Items",
        "documentation": "Effective income tax rate reconciliation,permanent items, percent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes",
     "calculation": {
      "http://nanovibronix.com/role/ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return to provision adjustments",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense."
       }
      }
     },
     "auth_ref": [
      "r820",
      "r852",
      "r853"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://nanovibronix.com/role/ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State income taxes, net of federal benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r652",
      "r820",
      "r852"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://nanovibronix.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r328",
      "r652"
     ]
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense",
        "documentation": "Amount of expense for employee benefit and equity-based compensation."
       }
      }
     },
     "auth_ref": []
    },
    "NAOV_EmployeeOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "EmployeeOptionsMember",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Options [Member]",
        "documentation": "Employee Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-vested stock options granted, unrecognized estimated compensation cost",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://nanovibronix.com/role/OtherAssetsDetailsNarrative",
      "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative",
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "presentation": [
      "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Major Customer [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails",
      "http://nanovibronix.com/role/StatementOfStockholdersEquity",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative",
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r128",
      "r149",
      "r150",
      "r151",
      "r165",
      "r166",
      "r167",
      "r169",
      "r174",
      "r176",
      "r178",
      "r196",
      "r227",
      "r228",
      "r234",
      "r273",
      "r348",
      "r349",
      "r356",
      "r357",
      "r358",
      "r360",
      "r361",
      "r362",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r375",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r400",
      "r405",
      "r407",
      "r416",
      "r481",
      "r491",
      "r492",
      "r493",
      "r510",
      "r580"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of equity investment",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r836"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r715",
      "r726",
      "r740",
      "r766"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r712",
      "r723",
      "r737",
      "r763"
     ]
    },
    "srt_EuropeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EuropeMember",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]"
       }
      }
     },
     "auth_ref": [
      "r925",
      "r926",
      "r927",
      "r928"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://nanovibronix.com/role/OtherAssetsDetailsNarrative",
      "http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value adjustments - Sanuwave warrants",
        "verboseLabel": "Fair value of warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r9"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForWarrantsDetails",
      "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r381",
      "r382",
      "r655"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForWarrantsDetails",
      "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r381",
      "r382",
      "r655"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r386",
      "r387",
      "r389",
      "r425",
      "r426",
      "r427",
      "r642",
      "r643",
      "r647",
      "r648",
      "r649",
      "r653",
      "r655"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r285",
      "r290",
      "r379",
      "r387",
      "r425",
      "r647",
      "r648",
      "r649",
      "r653"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r285",
      "r290",
      "r379",
      "r380",
      "r387",
      "r426",
      "r642",
      "r643",
      "r647",
      "r648",
      "r649",
      "r653"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r379",
      "r380",
      "r381",
      "r382",
      "r387",
      "r427",
      "r642",
      "r643",
      "r647",
      "r648",
      "r649",
      "r653",
      "r655"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r386",
      "r387",
      "r389",
      "r425",
      "r426",
      "r427",
      "r642",
      "r643",
      "r647",
      "r648",
      "r649",
      "r653",
      "r655"
     ]
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/OtherAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE",
        "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r385",
      "r388"
     ]
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs",
     "crdr": "debit",
     "presentation": [
      "http://nanovibronix.com/role/OtherAssetsDetailsNarrative",
      "http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance beginning",
        "periodEndLabel": "Balance beginning",
        "label": "Warrants leaving balance",
        "documentation": "Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r388"
     ]
    },
    "NAOV_FederalNetOperatingLossCarriedForward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "FederalNetOperatingLossCarriedForward",
     "crdr": "debit",
     "presentation": [
      "http://nanovibronix.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal net operating loss carried forward",
        "documentation": "Represents information related to federal net operating loss carried forward."
       }
      }
     },
     "auth_ref": []
    },
    "NAOV_FederalNetOperatingLossOffsetAgainstTaxableIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "FederalNetOperatingLossOffsetAgainstTaxableIncome",
     "crdr": "debit",
     "presentation": [
      "http://nanovibronix.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal net operating loss offset against taxable income",
        "documentation": "Represents information related to federal net operating loss offset against taxable income."
       }
      }
     },
     "auth_ref": []
    },
    "NAOV_FinancialIncomeExpensesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "FinancialIncomeExpensesNet",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial expense, net",
        "documentation": "Financial income expenses, net."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency translation",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r719",
      "r730",
      "r744",
      "r770"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r719",
      "r730",
      "r744",
      "r770"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r719",
      "r730",
      "r744",
      "r770"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r719",
      "r730",
      "r744",
      "r770"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r719",
      "r730",
      "r744",
      "r770"
     ]
    },
    "NAOV_FranchiseFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "FranchiseFees",
     "crdr": "credit",
     "presentation": [
      "http://nanovibronix.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Franchise fees",
        "documentation": "Franchise fees."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnContractTermination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnContractTermination",
     "crdr": "credit",
     "presentation": [
      "http://nanovibronix.com/role/OtherAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain loss on contract termination",
        "documentation": "Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_GainLossOnSaleOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfInvestments",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain/Loss on termination of investment",
        "label": "Gain (Loss) on Sale of Investments",
        "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r562"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "NAOV_GoingConcernAndLiquidityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "GoingConcernAndLiquidityTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/LiquidityAndPlanOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIQUIDITY AND PLAN OF OPERATIONS",
        "documentation": "Going Concern And Liquidity [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r69",
      "r107",
      "r161",
      "r226",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r390",
      "r631",
      "r635",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r844"
     ]
    },
    "NAOV_HCWainwrightAndCoLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "HCWainwrightAndCoLLCMember",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "H.C. Wainwright &amp; Co., LLC [Member]",
        "documentation": "H.C. Wainwright &amp; Co., LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "country_IL": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "IL",
     "presentation": [
      "http://nanovibronix.com/role/IncomeTaxesDetailsNarrative",
      "http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ISRAEL"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r698",
      "r700",
      "r722"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r82"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/ScheduleOfIncomeBeforeTaxesOnDomesticAndForeignDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfIncomeBeforeTaxesOnDomesticAndForeignDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r326"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://nanovibronix.com/role/ScheduleOfIncomeBeforeTaxesOnDomesticAndForeignDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfIncomeBeforeTaxesOnDomesticAndForeignDetails",
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before taxes",
        "negatedTotalLabel": "Loss before taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r103",
      "r107",
      "r465",
      "r479",
      "r631",
      "r635",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/ScheduleOfIncomeBeforeTaxesOnDomesticAndForeignDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfIncomeBeforeTaxesOnDomesticAndForeignDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r326"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r237",
      "r238",
      "r384",
      "r385",
      "r388",
      "r488",
      "r490",
      "r565",
      "r621",
      "r654",
      "r893"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238",
      "r384",
      "r385",
      "r388",
      "r488",
      "r490",
      "r565",
      "r621",
      "r654",
      "r893"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://nanovibronix.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r327",
      "r328",
      "r336",
      "r344",
      "r652",
      "r855"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://nanovibronix.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r327",
      "r328",
      "r336",
      "r344",
      "r652",
      "r855"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r322",
      "r327",
      "r333",
      "r334",
      "r335",
      "r337",
      "r343",
      "r351",
      "r353",
      "r354",
      "r355",
      "r506",
      "r652"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r124",
      "r177",
      "r178",
      "r195",
      "r208",
      "r217",
      "r325",
      "r327",
      "r352",
      "r486",
      "r652"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r323",
      "r324",
      "r337",
      "r338",
      "r342",
      "r346",
      "r500"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Trade payables",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Trade receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "NAOV_IncreaseDecreaseInAccruedSeverancePayNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "IncreaseDecreaseInAccruedSeverancePayNet",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued severance pay, net",
        "documentation": "Increase decrease in accrued severance pay net."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Deferred Revenue",
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other accounts payable and accrued expenses",
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other accounts receivable and prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "NAOV_IncreaseDecreaseInTerminationValueByOffset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "IncreaseDecreaseInTerminationValueByOffset",
     "crdr": "debit",
     "presentation": [
      "http://nanovibronix.com/role/OtherAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase decrease in termination value by offset",
        "documentation": "Increase decrease in termination value by offset."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r719",
      "r730",
      "r744",
      "r761",
      "r770",
      "r774",
      "r782"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r701",
      "r785"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r701",
      "r785"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure - Insider Trading Policies and Procedures"
       }
      }
     },
     "auth_ref": [
      "r701",
      "r785"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Operating and Nonoperating",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r203",
      "r206",
      "r209",
      "r217",
      "r402",
      "r635",
      "r636"
     ]
    },
    "us-gaap_InventoryAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryAdjustments",
     "crdr": "credit",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory allowance",
        "documentation": "Amount of inventory reserves for last-in first-out (LIFO) and other inventory valuation methods."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r811"
     ]
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/Inventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INVENTORY",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r229"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/ScheduleOfInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finished goods",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://nanovibronix.com/role/ScheduleOfInventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets",
      "http://nanovibronix.com/role/ScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory",
        "totalLabel": "Inventory",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r625",
      "r661"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventory",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r132",
      "r139",
      "r229",
      "r230",
      "r231",
      "r431",
      "r628"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/ScheduleOfInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Raw materials",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "us-gaap_Investments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Investments",
     "crdr": "debit",
     "presentation": [
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r468",
      "r674",
      "r675"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://nanovibronix.com/role/OtherAssetsDetailsNarrative",
      "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative",
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total undiscounted operating lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less: Imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://nanovibronix.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r878"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASES",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r46",
      "r47",
      "r48",
      "r50",
      "r51",
      "r52",
      "r53",
      "r161",
      "r226",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r365",
      "r366",
      "r367",
      "r390",
      "r535",
      "r630",
      "r686",
      "r844",
      "r881",
      "r882"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r102",
      "r476",
      "r661",
      "r818",
      "r837",
      "r875"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r131",
      "r161",
      "r226",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r365",
      "r366",
      "r367",
      "r390",
      "r661",
      "r844",
      "r881",
      "r882"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "NAOV_LicensingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "LicensingAgreementMember",
     "presentation": [
      "http://nanovibronix.com/role/OtherAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licensing Agreement [Member]",
        "documentation": "Licensing Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyDamagesAwardedValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyDamagesAwardedValue",
     "crdr": "debit",
     "presentation": [
      "http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Damages awarded value",
        "documentation": "Amount of damages awarded to the plaintiff in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r841",
      "r842",
      "r843"
     ]
    },
    "us-gaap_LossContingencyDamagesPaidValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyDamagesPaidValue",
     "crdr": "credit",
     "presentation": [
      "http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss contingency damages paid value",
        "documentation": "Amount of damages paid to the plaintiff in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r841",
      "r842",
      "r843"
     ]
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyDamagesSoughtValue",
     "crdr": "debit",
     "presentation": [
      "http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss contingency damages sought value",
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r841",
      "r842",
      "r843"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r224",
      "r646",
      "r670",
      "r673",
      "r848",
      "r892",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920"
     ]
    },
    "us-gaap_MarketingAndAdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketingAndAdvertisingExpense",
     "crdr": "debit",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advertising and marketing costs",
        "documentation": "The total expense recognized in the period for promotion, public relations, and brand or product advertising."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "cyd_MaterialCybersecurityIncidentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r733",
      "r734"
     ]
    },
    "cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r733",
      "r735"
     ]
    },
    "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r733",
      "r736"
     ]
    },
    "cyd_MaterialCybersecurityIncidentNatureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentNatureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Nature [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r733",
      "r736"
     ]
    },
    "cyd_MaterialCybersecurityIncidentScopeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentScopeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Scope [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r733",
      "r736"
     ]
    },
    "cyd_MaterialCybersecurityIncidentTimingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentTimingTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Timing [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r733",
      "r736"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://nanovibronix.com/role/LeasesDetailsNarrative",
      "http://nanovibronix.com/role/ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsDetails",
      "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForOptionsGrantedDetails",
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r244",
      "r291",
      "r320",
      "r382",
      "r430",
      "r487",
      "r489",
      "r497",
      "r527",
      "r528",
      "r587",
      "r589",
      "r591",
      "r592",
      "r598",
      "r619",
      "r620",
      "r640",
      "r644",
      "r650",
      "r655",
      "r656",
      "r657",
      "r658",
      "r671",
      "r846",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "us-gaap_MeasurementInputExercisePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExercisePriceMember",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Exercise Price [Member]",
        "documentation": "Measurement input using agreed upon price for exchange of underlying asset."
       }
      }
     },
     "auth_ref": [
      "r863",
      "r864",
      "r865"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r863",
      "r864",
      "r865"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r863",
      "r864",
      "r865"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForWarrantsDetails",
      "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r655",
      "r863",
      "r864",
      "r865"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForWarrantsDetails",
      "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r863",
      "r864",
      "r865"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForWarrantsDetails",
      "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r381",
      "r382",
      "r655"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForWarrantsDetails",
      "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r381",
      "r382",
      "r655"
     ]
    },
    "NAOV_MergerAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "MergerAgreementMember",
     "presentation": [
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Merger Agreement [Member]",
        "documentation": "Merger Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://nanovibronix.com/role/LeasesDetailsNarrative",
      "http://nanovibronix.com/role/ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsDetails",
      "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForOptionsGrantedDetails",
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r244",
      "r291",
      "r320",
      "r382",
      "r430",
      "r487",
      "r489",
      "r497",
      "r527",
      "r528",
      "r587",
      "r589",
      "r591",
      "r592",
      "r598",
      "r619",
      "r620",
      "r640",
      "r644",
      "r650",
      "r655",
      "r656",
      "r657",
      "r671",
      "r846",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "country_NZ": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "NZ",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW ZEALAND"
       }
      }
     },
     "auth_ref": []
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative"
     ],
     "auth_ref": [
      "r224",
      "r646",
      "r670",
      "r673",
      "r848",
      "r892",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://nanovibronix.com/role/DescriptionOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DESCRIPTION OF BUSINESS",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r125"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/LiquidityAndPlanOfOperationsDetailsNarrative",
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/LiquidityAndPlanOfOperationsDetailsNarrative",
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "negatedLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r74",
      "r75"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementOfStockholdersEquity",
      "http://nanovibronix.com/role/StatementsOfCashFlows",
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Net loss",
        "verboseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r75",
      "r104",
      "r129",
      "r144",
      "r146",
      "r151",
      "r161",
      "r168",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r177",
      "r178",
      "r185",
      "r226",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r359",
      "r362",
      "r377",
      "r390",
      "r480",
      "r559",
      "r578",
      "r579",
      "r684",
      "r844"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive loss:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss available to common stockholders",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r170",
      "r171",
      "r172",
      "r173",
      "r180",
      "r181",
      "r186",
      "r189",
      "r362"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently adopted accounting standards",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "NAOV_NoInsiderTradingFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "NoInsiderTradingFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No insider trading flag",
        "documentation": "No Insider Trading Flag."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "NAOV_NoncashInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "NoncashInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash interest expense",
        "documentation": "Noncash interest expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OffsettingAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OffsettingAssetsLineItems",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offsetting Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OffsettingAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OffsettingAssetsTable",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offsetting Assets [Table]",
        "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r631",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://nanovibronix.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease, expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Present value of operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities, current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities, non-current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use assets, net",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://nanovibronix.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r660"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://nanovibronix.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average remaining lease term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r660"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://nanovibronix.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carry forward",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "NAOV_OperatingLossCarryforwardsExpirationTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "OperatingLossCarryforwardsExpirationTerm",
     "presentation": [
      "http://nanovibronix.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carryforwards expiration term",
        "documentation": "Represents as a operating loss carryforwards expiration term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccountsPayableAndAccruedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other accounts payable and accrued expenses",
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued severance pay",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/ScheduleOfPrepaidExpensesAndOtherReceivablesDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfPrepaidExpensesAndOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other receivables",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r661"
     ]
    },
    "us-gaap_OtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/OtherAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER ASSETS",
        "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other assets",
        "label": "Other Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of other assets."
       }
      }
     },
     "auth_ref": [
      "r861",
      "r862",
      "r872"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax",
     "crdr": "debit",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative translation gains",
        "documentation": "Amount of tax expense (benefit), before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r5",
      "r392",
      "r393",
      "r399"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementOfStockholdersEquity",
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in foreign currency translation adjustments",
        "verboseLabel": "Currency translation adjustment",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r481"
     ]
    },
    "NAOV_OtherCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "OtherCountryMember",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Country [Member]",
        "documentation": "Other Country [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCurrentAssetsTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/PrepaidExpensesAndOtherReceivables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PREPAID EXPENSES AND OTHER RECEIVABLES",
        "documentation": "The entire disclosure for other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "us-gaap_OtherTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Tax",
        "label": "Other Tax Expense (Benefit)",
        "documentation": "Amount of other income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r851",
      "r857"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r717",
      "r728",
      "r742",
      "r768"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r720",
      "r731",
      "r745",
      "r771"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r720",
      "r731",
      "r745",
      "r771"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r749"
     ]
    },
    "us-gaap_PaymentsForFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForFees",
     "crdr": "credit",
     "presentation": [
      "http://nanovibronix.com/role/RelatedPartyTransactionDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for fees",
        "documentation": "Amount of cash outflow for fees classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of fixed assets",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "NAOV_PercentageForExchangeCapitalForConsideration": {
     "xbrltype": "percentItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "PercentageForExchangeCapitalForConsideration",
     "presentation": [
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage for exchange capital for consideration",
        "documentation": "Percentage for exchange capital for consideration."
       }
      }
     },
     "auth_ref": []
    },
    "NAOV_PercentageForNumberOfOutstandingCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "PercentageForNumberOfOutstandingCommonStock",
     "presentation": [
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage for number of outstanding common stock",
        "documentation": "Percentage for number of outstanding common stock."
       }
      }
     },
     "auth_ref": []
    },
    "NAOV_PiersonFerdinandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "PiersonFerdinandMember",
     "presentation": [
      "http://nanovibronix.com/role/RelatedPartyTransactionDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pierson Ferdinand [Member]",
        "documentation": "Pierson Ferdinand [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NAOV_PlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "PlacementAgentWarrantsMember",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent Warrants [Member]",
        "documentation": "Placement Agent Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_PlatformOperatorCryptoAssetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "PlatformOperatorCryptoAssetLineItems",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto Asset [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "srt_PlatformOperatorCryptoAssetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "PlatformOperatorCryptoAssetTable",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto Asset [Table]"
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "NAOV_PostWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "PostWarrantMember",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post Warrant [Member]",
        "documentation": "Post Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "NAOV_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative",
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Funded Warrants [Member]",
        "documentation": "Pre-Funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NAOV_PreWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "PreWarrantMember",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Warrant [Member]",
        "documentation": "Pre Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://nanovibronix.com/role/StatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r677",
      "r680",
      "r681",
      "r682",
      "r683",
      "r921",
      "r923"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r259"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r537"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r259"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r537",
      "r557",
      "r923",
      "r924"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock value",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r472",
      "r661"
     ]
    },
    "NAOV_PrefundedWarrantAndAccompanyingWarrantPricePerShares": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "PrefundedWarrantAndAccompanyingWarrantPricePerShares",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Funded Warrant and accompanying warrant price per shares",
        "documentation": "Prefunded warrant and accompanying warrant price per, shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://nanovibronix.com/role/ScheduleOfPrepaidExpensesAndOtherReceivablesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets",
      "http://nanovibronix.com/role/ScheduleOfPrepaidExpensesAndOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other accounts receivable",
        "totalLabel": "Prepaid expenses and other receivables",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/ScheduleOfPrepaidExpensesAndOtherReceivablesDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfPrepaidExpensesAndOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r232",
      "r233",
      "r626"
     ]
    },
    "NAOV_PriceAtValuationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "PriceAtValuationMember",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Price at Valuation [Member]",
        "documentation": "Price at Valuation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NAOV_PrivateInvestorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "PrivateInvestorsMember",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Investors [Member]",
        "documentation": "Private Investors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of common stock, net",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of private placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r18"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of prefunded warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://nanovibronix.com/role/LiquidityAndPlanOfOperationsDetailsNarrative",
      "http://nanovibronix.com/role/ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r414"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://nanovibronix.com/role/LiquidityAndPlanOfOperationsDetailsNarrative",
      "http://nanovibronix.com/role/ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentMember",
     "presentation": [
      "http://nanovibronix.com/role/LiquidityAndPlanOfOperationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Member]",
        "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed assets, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r414",
      "r466",
      "r478",
      "r661"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r119",
      "r122",
      "r477"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://nanovibronix.com/role/LiquidityAndPlanOfOperationsDetailsNarrative",
      "http://nanovibronix.com/role/ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r414"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated useful life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "NAOV_PurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "PurchaseAgreementMember",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreement [Member]",
        "documentation": "Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://nanovibronix.com/role/LeasesDetailsNarrative",
      "http://nanovibronix.com/role/ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsDetails",
      "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForOptionsGrantedDetails",
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r244",
      "r284",
      "r291",
      "r314",
      "r315",
      "r316",
      "r320",
      "r382",
      "r428",
      "r429",
      "r430",
      "r487",
      "r489",
      "r497",
      "r527",
      "r528",
      "r587",
      "r589",
      "r591",
      "r592",
      "r598",
      "r619",
      "r620",
      "r640",
      "r644",
      "r650",
      "r655",
      "r656",
      "r657",
      "r658",
      "r671",
      "r678",
      "r839",
      "r846",
      "r864",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://nanovibronix.com/role/LeasesDetailsNarrative",
      "http://nanovibronix.com/role/ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsDetails",
      "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForOptionsGrantedDetails",
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r244",
      "r284",
      "r291",
      "r314",
      "r315",
      "r316",
      "r320",
      "r382",
      "r428",
      "r429",
      "r430",
      "r487",
      "r489",
      "r497",
      "r527",
      "r528",
      "r587",
      "r589",
      "r591",
      "r592",
      "r598",
      "r619",
      "r620",
      "r640",
      "r644",
      "r650",
      "r655",
      "r656",
      "r657",
      "r658",
      "r671",
      "r678",
      "r839",
      "r846",
      "r864",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r712",
      "r723",
      "r737",
      "r763"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/RelatedPartyTransaction"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTION",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r507",
      "r508",
      "r509",
      "r563",
      "r564",
      "r565",
      "r584",
      "r586"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r621",
      "r635",
      "r889"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r713",
      "r724",
      "r738",
      "r764"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r714",
      "r725",
      "r739",
      "r765"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r721",
      "r732",
      "r746",
      "r772"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r88",
      "r475",
      "r494",
      "r496",
      "r505",
      "r538",
      "r661"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://nanovibronix.com/role/StatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r165",
      "r166",
      "r167",
      "r169",
      "r174",
      "r176",
      "r178",
      "r227",
      "r228",
      "r234",
      "r348",
      "r349",
      "r356",
      "r357",
      "r358",
      "r360",
      "r361",
      "r362",
      "r368",
      "r370",
      "r371",
      "r373",
      "r375",
      "r405",
      "r407",
      "r491",
      "r493",
      "r510",
      "r923"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss",
      "http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "verboseLabel": "Revenues geographic areas",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r195",
      "r204",
      "r205",
      "r213",
      "r217",
      "r220",
      "r222",
      "r224",
      "r282",
      "r283",
      "r432"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue recognition",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r623"
     ]
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS",
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "presentation": [
      "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenues",
        "label": "Revenues [Default Label]",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r152",
      "r161",
      "r195",
      "r204",
      "r205",
      "r213",
      "r217",
      "r220",
      "r222",
      "r224",
      "r226",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r390",
      "r465",
      "r635",
      "r844"
     ]
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "NAOV_SaleOfEquitySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "SaleOfEquitySecuritiesMember",
     "presentation": [
      "http://nanovibronix.com/role/LiquidityAndPlanOfOperationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Equity Securities [Member]",
        "documentation": "Sale of Equity Securities [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r803"
     ]
    },
    "NAOV_SanuwaveHealthIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "SanuwaveHealthIncMember",
     "presentation": [
      "http://nanovibronix.com/role/OtherAssetsDetailsNarrative",
      "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sanuwave Health, Inc. [Member]",
        "documentation": "Sanuwave Health, Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/LossPerShareApplicableToCommonShareholderTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://nanovibronix.com/role/OtherAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF PROVISION FOR INCOME TAXES EXPENSES",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF DEFERRED TAX ASSETS",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "NAOV_ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF DEPRECIATION CALCULATED OVER ESTIMATED USEFUL LIVES OF ASSETS",
        "documentation": "Schedule of depreciation calculated over estimated useful lives of assets [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF RECONCILIATION OF STATUTORY U.S. FEDERAL RATE",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r652",
      "r852"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED SERVICES FROM EMPLOYEES AND NON-EMPLOYEES",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "presentation": [
      "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "documentation": "Disclosure of information about the extent of the entity's reliance on its major customers."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "NAOV_ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR WARRANTS",
        "documentation": "Schedule Of Estimating Fair Value Of Warrants Assumptions [Table Text Blcok]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/OtherAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r861",
      "r862"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF INCOME BEFORE TAXES ON DOMESTIC AND FOREIGN",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/InventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF INVENTORY",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r61",
      "r62",
      "r63"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://nanovibronix.com/role/LiquidityAndPlanOfOperationsDetailsNarrative",
      "http://nanovibronix.com/role/ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r414"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r67"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF OPTIONS ACTIVITY",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r91"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR OPTIONS GRANTED",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "NAOV_ScheduleOfWarrantsAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "ScheduleOfWarrantsAssumptionsTableTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/OtherAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF WARRANTS ASSUMPTIONS",
        "documentation": "Schedule of Warrants Assumptions [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "NAOV_SecuritiesExchangeAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "SecuritiesExchangeAgreementMember",
     "presentation": [
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Exchange Agreement [Member]",
        "documentation": "Securities Exchange Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://nanovibronix.com/role/IncomeTaxesDetailsNarrative",
      "http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails"
     ],
     "auth_ref": [
      "r222",
      "r223",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r523",
      "r524",
      "r525",
      "r588",
      "r590",
      "r593",
      "r599",
      "r606",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r624",
      "r645",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r672",
      "r678",
      "r848",
      "r892",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerData"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r195",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r210",
      "r211",
      "r212",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r224",
      "r632",
      "r633",
      "r634",
      "r635",
      "r637",
      "r638",
      "r639"
     ]
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling and marketing",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingAndMarketingExpenseMember",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling and Marketing Expense [Member]",
        "documentation": "Primary financial statement caption encompassing selling and marketing expense."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "NAOV_SequencingPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "SequencingPolicyTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sequencing",
        "documentation": "Sequencing [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesCPreferredStockMember",
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets",
      "http://nanovibronix.com/role/BalanceSheetsParenthetical",
      "http://nanovibronix.com/role/StatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Preferred Stock [Member]",
        "documentation": "Series C preferred stock."
       }
      }
     },
     "auth_ref": [
      "r807",
      "r808",
      "r847"
     ]
    },
    "us-gaap_SeriesDPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesDPreferredStockMember",
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets",
      "http://nanovibronix.com/role/BalanceSheetsParenthetical",
      "http://nanovibronix.com/role/StatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series D Preferred Stock [Member]",
        "documentation": "Series D preferred stock."
       }
      }
     },
     "auth_ref": [
      "r807",
      "r808",
      "r847"
     ]
    },
    "us-gaap_SeriesEPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesEPreferredStockMember",
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets",
      "http://nanovibronix.com/role/BalanceSheetsParenthetical",
      "http://nanovibronix.com/role/StatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series E Preferred Stock [Member]",
        "documentation": "Series E preferred stock."
       }
      }
     },
     "auth_ref": [
      "r807",
      "r808",
      "r847"
     ]
    },
    "us-gaap_SeriesFPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesFPreferredStockMember",
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets",
      "http://nanovibronix.com/role/BalanceSheetsParenthetical",
      "http://nanovibronix.com/role/StatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series F Preferred Stock [Member]",
        "documentation": "Series F preferred stock."
       }
      }
     },
     "auth_ref": [
      "r807",
      "r808",
      "r847"
     ]
    },
    "NAOV_SeriesXPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "SeriesXPreferredStockMember",
     "presentation": [
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series X Preferred Stock [Member]",
        "documentation": "Series X Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NAOV_SeveranceAssetsNoncurent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "SeveranceAssetsNoncurent",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance pay fund",
        "documentation": "Severance pay fund."
       }
      }
     },
     "auth_ref": []
    },
    "NAOV_SeverancePayPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "SeverancePayPolicyTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance pay",
        "documentation": "Severance Pay [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value options vesting term",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "NAOV_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual term for granted options",
        "documentation": "Share based compensation arrangement by share based payment award contractual period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volatility, maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volatility, minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk free interest, maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk free interest, minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Warrants, Outstanding - Beginning balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Warrants, Outstanding - Beginning balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations",
        "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Warrants, Outstanding - Beginning balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations",
        "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants, Outstanding - Beginning balance",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Warrants, Outstanding - Beginning balance",
        "periodEndLabel": "Warrants, Outstanding - Beginning balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of common stock reserved for issuance for awards",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Options, Exercisable - Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price per Share, Outstanding - ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options, Expired",
        "label": "Number of employee options expired",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r302"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price per Share, Exercised",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options, Forfeited",
        "label": "Number of employee options forfeited",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options, Granted",
        "verboseLabel": "Number of employee options granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate intrinsic value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options, Outstanding - Beginning balance",
        "periodEndLabel": "Options, Outstanding - Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r296"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price per Share, Exercisable - Ending balance",
        "periodEndLabel": "Weighted Average Exercise Price per Share, Outstanding - ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r296"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Exercise Price per Share, Exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price per Share, Forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price per Share, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForOptionsGrantedDetails",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Price at valuation",
        "verboseLabel": "Bid price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Life (Years), Exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Life (Years), Exercised",
        "documentation": "Weighted average remaining contractual term for option awards exercised, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Life (Years), Expired",
        "documentation": "Weighted average remaining contractual term for option awards expired, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Life (Years), Forfeited",
        "documentation": "Weighted average remaining contractual term for option awards forfeited, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Life (Years), Granted",
        "documentation": "Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Remaining Life (Years), Outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted Average Remaining Life (Years), Outstanding - ending balance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Life (Years), Outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options, vested",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://nanovibronix.com/role/StatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r159"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://nanovibronix.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets",
      "http://nanovibronix.com/role/BalanceSheetsParenthetical",
      "http://nanovibronix.com/role/StatementOfStockholdersEquity",
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r135",
      "r136",
      "r137",
      "r161",
      "r183",
      "r184",
      "r187",
      "r189",
      "r197",
      "r198",
      "r226",
      "r245",
      "r247",
      "r248",
      "r249",
      "r252",
      "r253",
      "r259",
      "r260",
      "r262",
      "r265",
      "r271",
      "r390",
      "r501",
      "r502",
      "r503",
      "r504",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r522",
      "r537",
      "r560",
      "r580",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r801",
      "r817",
      "r825"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails",
      "http://nanovibronix.com/role/StatementOfStockholdersEquity",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative",
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r55",
      "r58",
      "r59",
      "r128",
      "r149",
      "r150",
      "r151",
      "r165",
      "r166",
      "r167",
      "r169",
      "r174",
      "r176",
      "r178",
      "r196",
      "r227",
      "r228",
      "r234",
      "r273",
      "r348",
      "r349",
      "r356",
      "r357",
      "r358",
      "r360",
      "r361",
      "r362",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r375",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r400",
      "r405",
      "r407",
      "r416",
      "r481",
      "r491",
      "r492",
      "r493",
      "r510",
      "r580"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://nanovibronix.com/role/IncomeTaxesDetailsNarrative",
      "http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r222",
      "r223",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r523",
      "r524",
      "r525",
      "r588",
      "r590",
      "r593",
      "r599",
      "r606",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r624",
      "r645",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r672",
      "r678",
      "r848",
      "r892",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets",
      "http://nanovibronix.com/role/BalanceSheetsParenthetical",
      "http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://nanovibronix.com/role/LeasesDetailsNarrative",
      "http://nanovibronix.com/role/RelatedPartyTransactionDetailsNarrative",
      "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForOptionsGrantedDetails",
      "http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails",
      "http://nanovibronix.com/role/StatementOfStockholdersEquity",
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r196",
      "r407",
      "r432",
      "r499",
      "r522",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r537",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r547",
      "r548",
      "r549",
      "r550",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r558",
      "r561",
      "r562",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r580",
      "r679"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets",
      "http://nanovibronix.com/role/BalanceSheetsParenthetical",
      "http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://nanovibronix.com/role/LeasesDetailsNarrative",
      "http://nanovibronix.com/role/RelatedPartyTransactionDetailsNarrative",
      "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForOptionsGrantedDetails",
      "http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails",
      "http://nanovibronix.com/role/StatementOfStockholdersEquity",
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r196",
      "r225",
      "r407",
      "r432",
      "r499",
      "r522",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r537",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r547",
      "r548",
      "r549",
      "r550",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r558",
      "r561",
      "r562",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r580",
      "r679"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r716",
      "r727",
      "r741",
      "r767"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "presentation": [
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible shares",
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r36",
      "r54",
      "r55",
      "r88"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://nanovibronix.com/role/StatementOfStockholdersEquity",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative",
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock upon exercise of pre-funded warrants, shares",
        "verboseLabel": "Number of share issued",
        "terseLabel": "Number of new share issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r54",
      "r55",
      "r88",
      "r501",
      "r580",
      "r601"
     ]
    },
    "NAOV_StockIssuedDuringPeriodSharesPrefundedWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesPrefundedWarrantsExercised",
     "presentation": [
      "http://nanovibronix.com/role/StatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise of pre-funded warrants, shares",
        "documentation": "Stock issued during period shares prefunded warrants exercised.",
        "label": "StockIssuedDuringPeriodSharesPrefundedWarrantsExercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "presentation": [
      "http://nanovibronix.com/role/StatementOfStockholdersEquity",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative",
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rounding-up of fractional shares due to reverse stock split, shares",
        "verboseLabel": "Reverse stock split outstanding shares",
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails",
      "http://nanovibronix.com/role/StatementOfStockholdersEquity",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of pre-funded warrants, shares",
        "negatedLabel": "Options, Exercised",
        "verboseLabel": "Number of options, exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r54",
      "r55",
      "r88",
      "r300"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://nanovibronix.com/role/StatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock upon exercise of pre-funded warrants",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r54",
      "r55",
      "r88",
      "r510",
      "r580",
      "r601",
      "r685"
     ]
    },
    "NAOV_StockIssuedDuringPeriodValuePrefundedWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "StockIssuedDuringPeriodValuePrefundedWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://nanovibronix.com/role/LiquidityAndPlanOfOperationsDetailsNarrative",
      "http://nanovibronix.com/role/StatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of pre-funded warrants",
        "verboseLabel": "Exercise of prefunded warrants",
        "documentation": "Stock issued during period value prefunded warrants exercised."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://nanovibronix.com/role/StatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r55",
      "r58",
      "r59",
      "r88"
     ]
    },
    "NAOV_StockIssuedDuringPeriodValuesReverseStockSplits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "StockIssuedDuringPeriodValuesReverseStockSplits",
     "presentation": [
      "http://nanovibronix.com/role/StatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rounding-up of fractional shares due to reverse stock split",
        "documentation": "Rounding-up of fractional shares due to reverse stock split."
       }
      }
     },
     "auth_ref": []
    },
    "NAOV_StockOptionsEmployeeAndNonEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "StockOptionsEmployeeAndNonEmployeeMember",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options - Employee and Non-employee [Member]",
        "documentation": "Stock Options - Employee and Non-employee [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets",
      "http://nanovibronix.com/role/StatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r58",
      "r59",
      "r80",
      "r539",
      "r557",
      "r581",
      "r582",
      "r661",
      "r686",
      "r818",
      "r837",
      "r875",
      "r923"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://nanovibronix.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS\u2019 EQUITY",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r160",
      "r258",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r273",
      "r374",
      "r583",
      "r585",
      "r605"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse stock split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative",
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r423"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative",
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r423"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative",
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r423"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r424"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TimeDepositsAtOrAboveFDICInsuranceLimit",
     "crdr": "credit",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash uninsured amount",
        "documentation": "Amount of time deposit liabilities, including certificates of deposit, in denominations that meet or exceed the Federal Deposit Insurance Corporation (FDIC) insurance limit."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://nanovibronix.com/role/RelatedPartyTransactionDetailsNarrative",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r831",
      "r880"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://nanovibronix.com/role/RelatedPartyTransactionDetailsNarrative",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Trade receivables",
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r833",
      "r834",
      "r835"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "NAOV_TwoThousandAndTwentyFourLongTermIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "TwoThousandAndTwentyFourLongTermIncentivePlanMember",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand And Twenty Four Long Term Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NAOV_TwoThousandFourteenLongTermIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "TwoThousandFourteenLongTermIncentivePlanMember",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2014 Plan [Member]",
        "documentation": "2014 Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://nanovibronix.com/role/OtherAssetsDetailsNarrative",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative",
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33",
      "r117",
      "r118",
      "r120",
      "r121"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://nanovibronix.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net increases in valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "NAOV_ValuationAllowanceOfIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanovibronix.com/20241231",
     "localname": "ValuationAllowanceOfIncomeTaxExpenseBenefit",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails": {
       "parentTag": "us-gaap_OtherTaxExpenseBenefit",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Valuation Allowance",
        "documentation": "Valuation allowance of income tax expense benefit.",
        "label": "Valuation allowance of income tax expense benefit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantExercisePriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantExercisePriceIncrease",
     "presentation": [
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant exercise price",
        "documentation": "Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative",
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative",
      "http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r677",
      "r680",
      "r681",
      "r682",
      "r683"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of warrant or right expire date",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r863",
      "r864",
      "r865"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForWarrantsDetails",
      "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants, measurement input, percentage",
        "verboseLabel": "Warrants and rights outstanding, measurement input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r863",
      "r864",
      "r865"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://nanovibronix.com/role/OtherAssetsDetailsNarrative",
      "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForWarrantsDetails",
      "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual term (in years)",
        "verboseLabel": "Expected term (in years)",
        "terseLabel": "Warrants and rights outstanding term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r863",
      "r864",
      "r865"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common stock outstanding, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r189"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common stock outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r189"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478353/942-405-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "330",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-4"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.FF.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476188/405-10-S99-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-9"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-5"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-21"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(h))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 6-K",
   "Section": "General Instruction",
   "Subsection": "B"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "Instruction",
   "Paragraph": "2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "a"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481174/470-10-25-2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>96
<FILENAME>0001641172-25-001613-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001641172-25-001613-xbrl.zip
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M>:\4O='A1>'H"+Z9THDX.AK#48W02X-AF[G\0?HR!]("QFFX(!,:=5\L;1R
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M_1-U:MGBC52NP*X?RW];\"I*+DN*Y=36,-N'1^[4L$93/B[LYG@19XEZ)?C
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MDB/K$7^'_9W0;;J^62^4^XX:7)1%5;GWU,55C!$^[HL>V]$(35QXV>:9<W2
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M;KRH94OK>2E^ <J6(WSN1@0*K8.W6YDI8L5PKU(J\L):A"6S^(;HW XCH2[
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M].Z^O?I^1X:E"<)OX,I\BU?FL1\H9A7AN"&&!RM*G&>PU?7>HENNI$ N5^
M.244*'&S=,+8K="UL/)5E:G97^ZT W54NP?&BI:36WY3;H<+R$KY1Q??I B
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MIZ+PUJT<.'B[2Z"C/A*>@L+X+NV5\E*8]H&ZUV',ZJO/WN9:;U%/M2I]>RZ
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M!S06UZF+XXE73B.M-IY;6_:?'@]>%8!N^OQ6&>/KM[/-Q!^/'Y.2QEV=&NX
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M9.$C? I+.47G#QX+IRP1\G*N$_J@TKPIFHK308C%PRN&\?3TV=L&[_-O#Y_
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MD9V44K<JJ4\-_7,DI2"8S)DZ<W0:7#VXLL5E@^9LX@JJRX:T[1G6B\<CL^U
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M@ZHZ*,U>F@E'\, )LO=-Q.[MOM&-8S*0T[+(08R4WKO#$+*QV'E]41;-XD*
M2\3FBRS>[TH81Q@M8=\1R!E<&&EU ;=#DIFXI*/8KWA%T"!B+L1-=@G[F&X8
M]*>%O"A:\3:Y2+-,H/?W;9WNJ_ I=@ $R5!N@DLTP+ _^5DE8V].A66(:Z>J
MG.N6# #.J6+7@28U!@QF3)YC@W1!J>BT5)L9K@1B;[,L/((R9S\MGHI.X7"1
M-PI*-$1!>).^2\I8DU_&"8??FGQ:8*86)2HV, 9*%FOK/-\^<135LWVTXFX,
M:O3Q,DSFWO,HWXE!P;KI]>A1+:(^M(FQ8Y]F>1N96+=%F_P6X59HK;Y'Y'-?
M+M]!=#KO+RI& L$Y16FE";V6,]DC4>Y->VI!X5C&?H4?Q*0XZ4N.Z >3:)4U
M%:K<98-HR:865KQ/2Y3RO,3*.RKZFQ!U"D.^G\4T"5*EJ#J;LTFL94$Z) <,
MESBST%"V[L!"I";$SWT5%?UW:DE%C- VR&( UI"KG\I5-!C<;:]J2S3,7@1)
MZ-<@E6;X3UJ.\KB[]K+?22WU[3D+4QWCPYYU]\,H'K/ H&(,YP3.]!.ZHOL)
M6X7!"*4FUE.E1\XF$F[C=1X.2H'1M,B[)1Q-$L(VI,L@HY\@56"FIB12(S+1
MZ^$/!P__1H4OP';$.@#<SV7\,5W"GZ64Q1"OCZ"6/+Z9++Z"+4)9 [GQRBUT
M%A-L[BHITZF7 NMYF7*LRX&FJ(C$Q)+!6NI7^!'9NZ"E"3)4\*9B[,Y H<(2
MSD1(57GY<BX#P-5YUM;E]<C<X$NL\FJ@G)F/J]0ER#H$MZAD!F,S"5=II)Q<
M#X @!7>9X$-.&AR'@K\$K2!857G V3K,Y=.>\XBF_+PSOY;%HDKPV)Q))6!8
MU2QCB+4,UO<P6!>'9AF&W>OX 9FN"M57&1K"*2X$(CL/\U80%IMF4O$1WT89
M'JR/5W[3I4D,KFHT;] 1(CWQ=QT)>[#9IK+9S@JMQ K#EM =RW*V=.G07 69
M;0VT \B]7_=L>K NE\@&%MEZR>Q7Y.<%.71K.?E?ZCK\.B[Y&X3#'CW<A\-N
M,QSVZ.$^'/;)\GM'MN47&9)/>?+C081G^/]]>W)^\O:WD^/_]^=RG>Q7[P^M
MWN%#OH#ALU_3"O20+,Y-T51_/FG-9QWUUW(9W@IM#:S5&2G#6AI(\EDEPHM?
M.+49[+QEDTOME,K+C>+*/A0.5OLM3*2U.J07J[)V&Y@,*5@3L59_64=G5C]_
MX:4>6],/&=8PIDSAV9F'1%P1:A&>6A,K'?I30=.KZSBY8#<L>F ES3>.<GHC
M/HWZ9K'(87) 1R;6&='SFC*ERA7E98I%;ERR<Y@";(U?>0!K77"="V7@4*8>
MB75PQ_AAILB1'X8D>,@;".HI&*58+L;2_8 >S%4NINO>@* W(YNJ.*K:?/@0
MQ.!&RTXP^FO7W;?1V'CXS*LW'/0N7[1Q]<+%(T"KLWXHVN4OBK\F8L7HTZL5
M!Z>DI.9P,"V*#^W:XM19L&UR,4;:@PG6G%JLM$1G?W/22><X(@+BR"M^2\%=
M>IF&A6-?$ 5QT87=\NJW_2;!HK>V>L^B2IKB J$F;&8Z*&7AY^I73/^3CKT,
MH#F'%[52(LX;C</U*>Q-6GE2<YG&W=E5A&BXIFXRI$M8P#@FPW3%[C%J0?P1
M: *K+?SDI\</H]7!\B :X0'[SZ+\$+U BA\T8L>:U(6CF3!L'EO/X?0.0"6>
MU^=V!QYM&#>(R&X#IU0;+"Q$;CCA9(@#K -F[,2U@OYWFR!_,B9218*Z8Y"X
M.VC>,:#YTX7#HJL#9TJ. BH+>]/#@-(;, )#!!=Q4C>4CYN8=&5)(&P&R-5%
ML0P6)NW4G"#!WWL![L2H;(7$*1CUF SSVB93LA)TPCSN<>756[47G+HJ\X(_
MJ_I+)XJ7*:LY'T=\2.3PM6]KPW&4"P5I5;1O>)0VN>6UC['4.OGF6M=!,=_H
M\-<@@8L,Q#Y#^$1.A;"V,U\W[*.CJX8]I"4=<5*2C'#I!=>T$R<VC($GB%RQ
M[-T]B-Z%C>/XI"AMA'FD6Z:D\]L2ZS^CB0&[,X5YJ*J&$%1<B,SZ3CUD$F:[
M%J67X JG;1-0I3)(R=T./((#$))[)OGW=#\GO)]?%>SC_[6I4TZ/LU)@XW:]
MNQ3.[Z7^!G91@5NDJHO,B.)3U66QQJ^Z&#TN<V=\379"1 _F8\()=@P&F7+B
MG2:>TJXF:B74RS./"=/UQ*?%X)Q!4)\:?(C_ZC8:=%WT=.E[P+$!FLF5-PES
MB?!<'Y3$$A:[S10&))&!7"Y8O5FQ_" >H[G'OP2M4):[F=>VD<9&[>B1@"!D
MIKJQ*\#)(<N)7U0#><"K>9Q0[!1I0/Q#Y;[M@*]C7]_$6W^X]];?JK?^<.^M
MO^_>^B]VW<[XNOT[6U=@H;V*K\1["#<B(<;)/PA*:R)/L*:8VY-]PM7X4BS+
M*.%R,E]9L80] -IC'=?;5.LIF/?,$,U>)P%/X"L,5]"0AC<XP01!@3!,K>F
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M\32^BJMZCU>[(5[M3T:/_9DR^\WSU\?_I,WXR[M?7SW[_P%02P,$%     @
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MRH=.Y:]PD]#P7)-7&L4=A[P*^0=02P,$%     @ PW-_6K]5+EDO P  DQ(
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M%5RAB6,?K:/B3YZEQZ[X<BZF$7JM7>?V,U6:18MUDOM.RZ49EM5?0) 7#K0
M/:/ >"!D(B313'# =4DCW,@#LY3MR#6QW##11-.YL<?!'LH))M87$!&(5*(I
M.M(0XI80#H@,9K!=K\)6;6NGBHLQ,3(JEY:1#1 1LWQWQ#CA 2,QJ"*",FZ'
MA(MCYDO!V7D5!CS8!,)#F*2^8B$C<@$$U4RDT2?B96C5YCQ%/^,<S(<,9+UF
M??N(:9%9Y 4:E$M&\V%>]1X-Z-RGLH#[:?.5ZN!VD7OMCMN';M]U)Z-V=S#\
MNENI5;+QJ-WK%>,')^",A7IFMM8VFN +&5)I!2*.2:(04/&MDO4(CC=^>(#?
M5&H6D+A(6)[9RK+I<+Q>X7(9O,A\)R;!+ZAC@$R >9X>Q&FGMK'.LMC*SC'_
M.&.(K#MJ5V'DNMV+0GF]FZ2>&O2*EA B7L:/4,W[=XG_D^PSA?6*:S 1J9Y%
MC,9A%0Y8,&-3PM\J\I1DKS_C7U0M[.RAUWIK5Y\!EU46[RP+_VS@.6_ B$QI
M$PU/4].2HD$3#A/3B:H&N$1IL*Q":[W!<8'F+DZ?S=R_FP)$==D676V#5MND
MZRW&S?YFI0^Z2?[R5V'UK"/^ZZDW;:*QN#A55UQ?2J+0>:%QQ\;4%%FZDEO;
M)#=/X(N5SNW'P#8OE?*W3.9EU%]02P,$%     @ PW-_6FCCF]N2!P  :S<
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M Y&&P(C QBN,6 ,ZYUHL2 )DBLD DX00!=M['!G1F@?]0U8).;9>PQ*I@ )
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MII79;>#T^ADLP2N?!OY>HO\!1?R=Q;\!4$L#!!0    ( ,-S?UKBEI/(/04
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ML2>PO%TYM];<!7<![==PVW :XP8X]EBO*Y?:W5[+*!P"C,]RP)HLENY%2(=
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MVE.U72O C:YK>E)#01)B$>N2"W7%W3.U34^KI'<)DW2'%TZL:R2O[':W2FJ
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MZ\N%Y$XLT52R#L;]GXT-\2$"WG\C/LDK]18>_K-$'!;F$!L;.FSY[NCD%[,
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MI(LIJ!\9BA=[P=;>Z\H#JH4'*!Z :H2BI6[HT_6?4F?O=G>V@^]?['8A6<Z
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MX5JU]@K7)SS/KGNA%=A-0*"Q\UM.SZ)Z[[,JA0ZG'.E0I[G-'641[2=-A?Q
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M!V='OR,%/O_Q\J?3]_\/4$L#!!0    ( ,-S?UI+\MI\;N$$ (FC)0 ,
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M\6=\IUFMM[3=LIZ=OWSX(35%SX^]*)CD/RQ^3+T0!M'TZN'+]*B3&=/##VF
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MB7:O%X]BUXJ83;91G#=@0YC:N6'<(CD+0H7KO.L)H0L668['[",K\$"N"&>
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MP&<QYOZA<.:^*?!9C)=_V.1R"\_ NC]L<KF%IW#JXC*UUFKC#W,Z%I>QM59
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M<'IL*8#)*#7G#P;.:3R"E?>6L#;L)*6[[7!EW?M1K3L?VBP+XPLV F8/%.D
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MWN?-)N8:DV]E:@EA9 71(=SH3\E.Y#C);]FWF&<G[]".D[EM_0WYM3Z[_$Z
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M0;8.ASYZJ&4@2C2THNS:;ZWT*NE"T<MB#^],R[/-M\UW)FZQ"\(&_-S]"S:
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MWPP3&R2@QSW.,D,&KDBC>@Y]G;Z&"?J'LK9Z*,?0M4^*T>+>)OZ:,#7V7;)
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M>JSAC:RDN;N]5VGN[<Y$'P[NS<,>+;/_\.S@^[>CTZM+LW-Z<'9Q?G;1Q@*
MG_\P+XZ.CRZ.3@^.EI)F\&P7Y+YB6&&27\[LSY,+;)C%0 :]@L$^NX!^^6S]
MG_[$"@^'Y]W1X\-6&9"L,0;63MF<MW)KI]V[5/(>S(ISWCPT3<YP=65$M;*@
M"Q82585'GZ.,Z$-.)@5 G/8CC()%G7NX'UH#.0JFX3$SRR$#W!TJG#E.GP7!
M7%^)J'T[-5? K.MJEP&]AO6,:7WZ:3Y\<!W6SP?FY=#IT_;IV6^=SQ=GIYW?
M*TBK:\NN^4(50K'VI@E_49VJ/X[:%^;1Z2'PA\.C@Z-OGX\NI*RPZ46JKMJ?
M3XZPX-;!V>D5LL-E0U=N2<VR[K$(>2E%_W%P<'1T?*P[YF$_ECD,D/7]A_6S
M7F^\^73>OK@R.X"OUNRL[$5RIP-G,$R(=[VV[7@@W3_ K?J K"B9&>:R/@&Z
MUMPF\I/:6_/-I\[5$5P2H(S?+SNG1Y>7?)-/V>#3MS1U*@MO*KSE)\9WU08V
MV[F$Z]\^N#J[*&1K.\T5'1?M3)W7YWWS^^G%T>79R6^\V/7Q,16=YA>_@!.L
M?UCM&;;D3@_VS8,_@$Z+$H-_K,?NGG2*6V)O31!B+L[.CRZP<&(Q^]I;[:EM
MBYVU]LV3HR_M$]P?#'C8.?U2S 8;]54>W([8WM:^^0V(I7G9/CZZ^L,\[%P>
MG)Q=?K\HZ!2?O,E[N!KM95>RM:+X&BY\5;R,=O1!G,XVG$[[XM>C*Q+[+HZ^
M="ZQL.F5,!M=$J$\.S6/_O<[T),*/''2YBT#S@Y^_7IV<@A"X;?VU170G J5
M]>]<7GZ'[\Z_7QQ\;5\>7:*4Q5_6"I\6<_(KYIQ[ H0[^^;_!]A\= '<Y?\O
M9F>KY)N-NMC7+J+&:?O+$3)*A0]X?[]3MP8Z;GC@Y(_+#AWS<0?4EH,.4#(0
MJP]Y:5Q\!H#S_>2*'D$"WL8?"D*!UDI1H"&%IUT0GOX72_]VKF!WOQW1MN&+
M$_E9HWIF^_/9]RMYZU#D*@04S97BC)2U/NQK6$!M1;BU$>%Q^?W\_(0^MR^
M#[2OVNNQ\2?B@!2^]D#VHF+.:%NE#<.AM[]<' D0_.A<?37;!P=GWP$ ^ 7>
M#OX1.#Z]D( NP9?U@-&3D$.*<'MP2U#AOC@[X1A! L]A8:+ JC%!"G1[H'"<
M77T%+M@Y1;,*$;QB=KCUO.>H>]%I/13DB2Z6?3,>CS'R':T)&3A(R6\/U)%#
M)T1'9QPPS!NS G)2'?L!@U6:_]8J:HIXD?. 8<LYL^-AG6'Z08A<TQ'K*X'@
M N)B(Q$7"Y07F]NKO,-27FS4X4P[%T=D(ZB81[^#3$<<[NSXN'.@I$#E6S*_
MG/UV=(%DK2!*]E0H//&.2Z&OT=C7-@]"\OG1Z65Q%[WU5,'FL8<]8KI-")1N
M:4HPSWZ<PO%^[9R3W13T\#:PN<]'IT=P[LBR^.]T^HG8*.2_F3I#(<#:6IWY
MA<"E#$V@R4O T)Y1S@6 7::@0'TCVM0=0EP6>9^ 71P>G:/%O:C;LO54$\>3
MT$B9I;;0=M,!R>8<\"01@<SC(]$+#I4GH![%H,/V4BP"G*#_5ENHTJBP7>>O
M.E5H;$5'(T6RQC:2L:^=SYTK0,8<T=V\//@*(MI)46>S.A&-]BU%M 8H[8G'
MZ_+[-U#'BK&6/GF'F7/-[@"$J\O.E]/V56%B\T[&CE)(PE.NUVNN2[KYT3P;
MD\"WC^.+J/J/YF\8T;<<CW5>U;X%(@K>I/SZ<@<?3>Q?N&^>^+<L(.!\-+'&
M&-_IJ8_K=U).:ODF!35LN*<\W\NY%%_JT>_G)R!@ ,/\PSP]NUIJP)+XTO&P
MN+SR0BX[ .;,,X]9-XBM8 +,4T;GA:HK-X:K4YJ59XN /V.Z+:#69$X/;=4?
MA&%X\4DJV,%[-9H7*@,,U+01)Y !<WG +.:$A68_#B@$W&9A+W"Z,!E\8HY7
M,?2 >NH"Q8*1R&<!Y:X'5,ER/+,]"!@E"=" YZ[E430B"P98',&F1&@>H3@%
M!O,M#BL*#_ WDN%$Q8%W%8,2!F"0D0_JYG1?G=0H!ZER!>_,T]^.OHK%F)=Q
ME[^!-1MD[Q%3;\Y TP 8?=>=5/U;C'7'@W)L!Y:-F3B9X<R.7(*8_M@)PDA[
M0&UB^DUX]>3D(+44UQDY""[7L;J.ZT03%7T_O3 C69B,$SV0H?IB,9<\:#EO
M-714 ;,!K<+0#\RCTYN855*CY#XBD@%AC6^==Z9EC/C8>+B9G<L44<P6 /S)
MF8P>P!FG7NTQBZ*IX3UVYX31C+5T87\C3#&<>613&WKKP++QRV3AT^.F5SX%
MQ12^I7[5RFD +/T!SZW(W2>'=0KUD].A-Z;G[3*9 Q/&P8US@Y]XX0*MSE;R
MCJ'P0#W-XW/E1#6S':4S/,W(&;'<P?AZ\<[SKAST% _/Y1U4^"N9F3 (V0"V
M230,(2IRBK#63T5<:%\DH,!;(4+-%&DD.)YL6I4[-J7YT ;YL7UCF.+BFE]]
M%X7'$*]73>QU<^,GC^YZ;$R]N@A0MP[F:]V-L7R^.TD2J@7-)O;A>,G!4(KA
M?'Y@^TS6(-03$+TP'J5/5Z B<1E>-1/83QQBII?5]6_@2ON]'M8[LC7V9@CF
M(9*T*&5+K)<R@XL/;<WMA#G/X)F6=99;Y.\!BSJP8H0^<IY3/\J87(%?V-43
MW[^F4MDJ3V_E#<X+28N8CZ\8H@V"1RAO?U] P^70,)*L154(B0M&(N_6U.\'
M"4."U_3C"$W;9+.&Y8J/27HM' Z]"%)^1?\Z\/\2UFV0ZR*,\!XXL%\#KBE\
M;XE?*!D2"!>26>;=."#!**DI4%78:N8/'RLE4 4T2^UQ9$VFJCH-_=BUL]_V
M\KZ\U;\TQ)= 0M!:'V8?'@.N 8&UW.FA,=4>.'?F>[[-J7% <'2PL0>(FMF?
M.&2S"\*2 IX]O1Z0**>^[#+7@7.:^A[8"V5()3\@>$.0JUR4I3G=Y.<!P,6B
MP-0%46$,T$YY[K"8$,X9Y3*^,EZASN&=J29F!NU,/?GZ>.9O)C\VHK==3.VQ
M2#JVS %(Q@ RAOS.$$O0$(X7V0AC-^*".R"$',-"HHL<662HRRIBMT,J:PEX
M-&.<6P>WWXMB*BM((PT1JO;4!K0[10#AZ;W$7I*K=,O,H07(3?/RQ.+,:R/+
MYBW8XB"O],3 QSHC%@H_=+Y]H3?PPH% 0PP2C&#Y8U&I,W-C24H.F%[+T](R
MK (GO!9/Q9Y07W@] -*$@-^--><5W22S9V%M% XD'8Z&!D>8QG9 A,)- 85T
M")R\02Y/K^9HQQ-GJ3CB8 "(RE.A28V;@TI70P9#T-(Y#'VD23%.H30V0Q02
M$)?@ AXV,1W%#T)Y#4+62UCY7/I:,SLC_!(5OSX?9!H@A%9\TVCT""5M!64M
MCFB=B)Q2GXG\(OI^\/^7H[0O/_SZ4?U#93.*K?'=W'84F>?V=G;W,@6BSN"^
MP*'!49"D[_I8HX6P5F,Q^(LDT;9XIK848^"K GZ>>5&)*E]<OXN=JP#NH(GV
MZ$C&/FCNI(B C!))11Y_@:?Z+K%<Q=Z%J$U? ]&+;K$4\07(U(Z%K] BOE\'
M0*A815Q RP8 A)@#;)':1M14IC?K<@EJ;X[L.2EI%2")/V;<W+$4]'BUMW0N
MHG2\7B",&L R1<'=QYYG)?\T:2%8I<L*AV;?]6_+\WVV\[T@_LPMJR0FDDE"
M23:YAZA*$B!M2(XQ)9FZH/.Y%:D? /VGU7!B,AJ[#HET(ZSL%83E83_382,[
MEG0=CAJH<X@B&<_9!UF.BYAD,7=&/(\?B+?K4 %O&#FVI=!)@BO*85CQ#$0P
MWU94_S"(!V;;AO<I]Y\(AK(R'[:5@9O*0MS $$@+8&'PR8Z!BO0PWQZM[R45
M>#XJH*ZI:?6F5(DI0L^+J(N"(3YZ8$:(%'VA(?&3Q?ID_$C+@WRV@^1U5ZAD
M\SCB:G.?NR*HLR8<$M:]+,_EN<_EV+KQ P( W)'8ZZN/6 TDY)7+NGX<Z90P
MY*KX  W/W.*FN&F(5?W".* 3YJXVH,Q2CE*."=#,QU8 Q'YL3; 8V=NDR>K!
MM\MWY?$_KY1%38,YDTL<I7!57<L9A8KU6C>6X\I?J3:=..CG/*ZY,3*M%Q8.
M\Y+C8?A4K^HF9L7< ?.8,#.+TK^\ G5)_HH$^I0BB6PIQIISX22,V CMXVX<
M"/VA-^D"A0#U#TA#*88L$_O]+@4[!9J$+Q4O=!F)')B_]!R8\CR*/(_ORF,S
MP5,0GG >#-/KB<KD*/8I13M"3TRHU"DE#L)YV:!XN_X8I<'RE)9*OA#RB6T+
M8=\) XNY%3,1HI7%O)*VI(_P]F$4EV9(+X^KR..Z2ED@X*BT(NE.:-[X:*EV
M142<\N:)!NWP:SQZ5G'ZQ1_(@\R.0 0=3P0#.!02HQN%5=2AYA,4]@N]IR4>
MO"@Z*RV/5'(47<ADNR*2JE<;I:B!+JK<.!XZM?OH^N]9'KI\;1_4DQ(G5H03
M"A&2B,Z%&W5PS1GQ:L3LB8QS<1A'"AG9 $=M7:/7HK0K/]\I_V 44F'=V]!/
M#WJB6)R @<P#=]1.,K?]+HQN:=;ID3411WS-.!.@>^Z2:RJ*9)-1C'WR;AA&
M(91'7[BJ@=?4Q>C;F$<4@LB$!D<XWCY(1S[W$:8O.SP527]Q_NN4%%8>UC+U
MPH#U@MB149Q$>_^&,R#"F=(6>? [HR+=^$%303"N+/0]C[GE416K,J)>'F)(
M#<\I(/UCR"PW&O9XAQ-GU(V#D*<O]7W5%J5TOSV+ZF'9_EB&KO%C(5VP-U'G
M18R,_R).# ,PRY,H\B1.T*^ V3R:3!C"#<"P3HR@M4%=X$TGPGC,PT532GUY
M&D6>QJ&#/8]BE^O@GA+IA90W8@%O]84=,S"(.L887=X=J6<A2&2P(7PH32;%
MG\]!PDGP&O#\$;@%0V?,=>YK-N&UF;N855H*R\^H)VEG0SF>21<A2\;!@@#F
M47*@M!:+K!R,<A<=3BD(P+QQV"W/7);9(Y%/BXC+ RU<H!9.+>GO E8C,CV4
M_#R('30X>:7987EN%0?S>6RX3,%$QJ)10#M<'I2/,2:5XE6[;&C=.'Y0GD21
M)_&%_.M:,H$*%9897T3-M&\EF1-YSZ!1HB5?'F%Y.D6>SC'/- M!ZB+> 0QA
MP,PN=N[1>8DRDU=$SBGFZ26!GPYP%V&QX48V<KZ4)U6H ,W&P#I$RKKT58G+
M(X0V_:!F -_(QAR)J*GIF*D,?.<$?&V]M("OEQOQM<*.@ B7@8](JQ5FP 12
MGBQNLKNAA<_?,'+H854:D0"BS/GHGI.%%NY-,97Y]*J(!*6+H?\OE?UYRWT0
M\!T\*)R+8C9*"37(9L8-T-.)L5HV;)(7;LO[."__]=QE%B:<,I7>VL$PJ$:[
M9N;DN1IDQ+,YA\254#P")\79*'R-&*=2<7(3_FOF-S@7A&F%8K\#$>B  FH
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M)#N%I\_QIC+M> "DU&PV9%,"&*62#X>LTJ8Y@.U8%E!W>%=33%3,]#)V?6\
MPA/> 0F4'[PI<W*G&1Z015N5;67)8LOW#-L72:S:OOC&-YA-_\B 59-CDAH]
M729[M)J6D8JT0TLFD)2(=SFY9?,I9)IF_ KOV' 7WI(0%"-4Z;JY$Y%8(V19
MV<?EM[893D*X"7AT!N5/,$:MD.^APWI#%+F&!]'-J;Z0*?9B2*J:DO-XF((
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M0)()3&\%D0(8E._5C!]3\AFZ'T.T%COAD-FI.R,U;-5^#LN;XHHH1%?D?O=
M/,+H95F>@%<O%V^BQQXU;B:35ZG;.L8[<!6)=Q[N9]PT\#]Y!DI&EQV> E\6
M]>8F=5W"UP]5-D01*ZEH%;-CI@LB2)$PK $Q3OH907BPN>W"5'DF;, [-A&!
MXL8$U^J"KM2=YVY\ILLWU\.T5WJ8ENAAVBH]3$OT,*U*)T;/?>@G/F3D)L)
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MJL44?11W [)U AL88,0.Q;62>5>\J.;N^?08K[=!5E(TLHKBC\K(*,*-R:Q
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MZ-Z3*(>[QM2XT;BU:FK=>9\*%@(04OMV!?9&=/\FW (0BB_X0PL9&8/6>0Q
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M2$J& I3X<QKXI_>T,3]*/RY>CM<0]VHP6$>9^*D)_KO(<Y'<$0_QR3ZMH[L
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M'*4[A_L'Q[N[<E4MZ2NSPS++V9.BT,9#L@G!(;LQ77!"EFZ_4.QHA5V_W7>
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M30D-K5Y7IB)F:JSZF%5WS]<41S#B"$!(]2"K484'"L9W9M7K!7.WDTJ&H9P
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M2.)=A%M>1$ ;\.X>6*NJ1*968#8,(U]Z'8OT)6FW!IV6=)6T4ELPTQX&>E?
MW(NXX4(R&L.\-X:.SJ" +*""2"L4Q2&I HW>I!(\SOHJK\>^>]^0&-B/CVY:
M"9QZ3=\\&W7YF'-1C91^ZRBP$H,E7!&R 4JVHX -F=,3RF7<;SKMJ!;MK1P"
M2?>!OB5 YH$V$!CDC$-A*>Q(C$O!<#WFN\AORS,OJ&=5TR8\3AN&OM?/'/5'
M$NS"@L#=*QE_+B[D7?WRNTI6EGO76W[?(E?,&5(L8VY:8SW Y8OF^Z/+]G"+
MK[=V#_O.0-*\7*&V:DB8XDE\WTG$HF+=ZC>P]P7@H-_#P^<;PPU>R!OWB=F
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MP+7=\)(/?_+22;;>=CO0R-JV8!F-FVW0XB[+@8Y3C9QII1*B-UG@Q</J<E&
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MGV<CB#Q ?)XK)" /?B(96[KWZ>FD=M(NPU)3?PU?CHMYQLX[04#%Y>?D$OM
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MOB[3TVY"FY4>^GH1>DJV=AWDV?2^!=D)L"WBXN'.6K**FDT]!"TX_Q'J>&8
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M3+$=LYTF?S_<'SQ,AS"'I>,)Q*Q:20PO$\& D79Z,:$K_??OAP\&A_X[0W0
M'CY(.4SQY/2[MSCW]T_02J6=8'CD'G]FARM!$%*1RR*[TC!UK/X;8_@>$2E\
M:W>)(A:W6!ARK4J,!B#A.-=H78COIJ>-KNFF2T%0^CHBV/1U03\_?^U+@HHR
MH9MS/].%Y';NP$@[3H]I7>8ZYWP<)"!=3X9 PB49VU"T'#/C6K^\EO4[V'_H
MGT ?.'CT<'^9 E=7)X%;T6*WC&-=;%E^<+_P\YUWH4P,@&:^-MOTK*/WT7?3
MG</]_9/=3&*6TDO^GLQ?)Z$YKH7"=\SQ%V "2:KUNR7]''$BZ%PAC%:T8NYF
M\A'!_;-&PJ[I!+8=1?]^J:1%QN)MJ)-$%D&"J4OF>6Y+E.@1."4+&O6(Z>.N
M+F-O/5OB\CU^>+_'Y1O*D.;*"A+1B9>EC)/+M?%@CZ KNWE?O;)DB;I4.C8Y
MP(D U()4TNA:^^ 5]E 4&[#M35=( @8QU3CK*O=6+BR+[M!>)(_H$<LF8S<J
MA#*5EY04,RXKI^MT4VCM_J\K</Y4IV$,(U:,'%1$Z$KE0\6@_T #EB6(!J0%
M5[UZU;CJ*_E6M 9"1TK1O/](4A?"NB+!$F%BT4H[^:$80\2)5@)'>,?=G^9\
M7F,0,UB?U:(_=8V^Q,W_='"0"$OZAR\\RD=4+3^#3# ;QKQX8)&%4T?C&Z2O
M2R=DXO'#V# !Y H?'+)$$'CFR!N3UI[#V[5!N)G"%+##27+0]1:/N8*7@5SX
MJ'%=; XZV]K__IJ/0L]#Y<%I;':N21V.15SB2.GA3FSS4/ JB2A2ZVAC8 PF
MVE+SI.NBX>BRGX_/!T71S]]P(+97DX)OE_;<M86G<^QU*VR[E1 Q76M\9!QO
MK&PGSJ'F;86 5Q:D C UGSS-$!^]M#I-&L.<VP?H0:_<8DI#7,P$?0CX*"1N
M1ER1FS' %P[3M)K;8/C]>Q:B,<FLQNJ S'^G@I],<PG T/G55(EF,EC-EKA
MGN4]+EM?CNEW(K;UBSHW^9J\!B$DSR:-@U"Z]JJJ+T0ARF?")9 (U*2XE$*9
MN23\])7V1KET&KX*=?0C;?Y85GHLL[ E%L&87>^AF6/"\;DLD7=BMAR"D_?2
M,LUSTGX0 D[[54>%4S%XQ76@984>D"G+$L%_Z3B.78_W$&R]-G>A7B&"IR%^
M"QP$F$::N$Q$>_'&^.4F':I130:HZ>H1#BE/:,3RW,\>8 +3JFJXT?:\HK6
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MS*X0TF]B4G-<0E5Q24LK]<Z7Z#= E<"WU47Z[@G0H1,W\SG_U;%&TB.4%'S
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M<F2HXRA.97TGG)S7^R1HE&4H7YWK='@5>5H4F?B[;,YD%(JLGA9EZ]'QL@8
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M6ZX:'4KD Y3,U^ >7_V"QXYWA(UY)KF(LL&<-:.*B<*RV34H4P+C!##K#%F
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M[&I(+D8S4 V*Z+<NI$\XGS-H!_*B9[N0V(E#ZMQ1YH8=[XRUR$"VA1G)?Z=
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M5LWCUMT)AI?MYL&;IJ0'&2Z+F_7.EW7 ?XV!M:OX/;P0\LY,V+@H+=[+,UD
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M='??=5\SIN;^\E;N+_+BK6+K9!5'.)IF,W']1C,6.DXM-EK4 LTNZM%JCJ_
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M3W[<'Z3(+,_V+8ORQK.<X"H67JQ+J9P\//I.2&^J9KFWN"9;3T?GSLN7N_%
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M*L!XIR+V*+E*% ?YX>)&7[NE3AI3W08* +%033!^[!DA&=%RR"53F=)>2SJ
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MJ(=SZ2=&M>;<>=8I7$K+AQ$$![38WZF95G3:C&60D+95DC51HW'2+EZ0D!^
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M%%RH2.5_ORP1I]!W\Y&F$%FFYQ*G0#I3\0PWV^QH':1K=EL(!NQ5/MK"9*<
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MF$8,<K-%E,TB%YP6U@"K*&HW"C^@+O/Q <^"<R9"7OIXC=[L_R[_8Y#8$,D
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M^\P\&KN0R33CYY7+3_(/O^79AY0)HN+U='!))QDT1GZH6Z0(HVX9-,/P-L8
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M$AS/:I3K0TP)YS9-[7J4JB64V_'?QQP=W_$%GLL%SI;]0F(8\X$.(+[)\Z
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MJ)7%'W.0L5VT*&4!--*T_X[J2>\^LA9A\FJO26C'@:\?NDX158CZ-:I(3D<
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M3@8OK<*)TA8XSE;X7$U@QMD6/:D<+2OSOM(V^M_^X?'BV:-'BR?/'BTRR<(
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M\>-[*W8HLV*%K 9 ZK(2M^(&25X;WU@<-0,#\#Q:8[=+9 J77[DEO3^E#8:
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MNG8\^R,P#,5JJ+\LP\A+F'=65"$6')WJ. 3$SQG2/F7G+%45X!3TN%V$?!>
MO4<J@WL&V7I->V4HJPUKF3?7"W@/[#2DS4CR);G)KK%$E\6&?MO=<G[LJ/$S
MM[[X0'B:_5(Q7;=<L()&6G-B6IBG8!,QZ,3R#<99$/,*>G>+E%[=%4M-R0$*
MGQ6=3CVJV#@5X<LDZ66GRQO?)?J:R+2L,;K^:?XR[HN;]"*24YRQ::9S9K.7
M/O2(GN9_C5[EN@?)X!CS*J>VNSFC@W8ELF7-T(X;4_8ABKB]?P6CXS];A3NW
M"HE'$Q"P8OP+L^IC\YUZ%EZL@G=CG@\^WHFG%)RD":G,$M=@5K/WM?B7ZVSL
M$=Y.P))X"LDM8XG,/MS'SM_G8ZL;P07*7^9B9[_0Q<YOQ\7.?J&+G81EBHDS
MOK[?%(ME8Z_M< R6_Y88[$C/T%$K #$1I 8B9;]JG,R'_.= -U[OA(D+?L"3
M1W]L74RWQ!\^_J-,AJ2;B(9_^N77GQ6?!WZO%<DC#STPPT-_D38)39(HX'V5
M<=<_&AVD>97.._]N[>AG/(>0/:&^>#>[Y_>Z^.](2Q[8F7P[M%S\7L0.! _'
M4+U#F_SAD@75K=I\XXI:A\RFDI9%DC9KD?MQ(WZ;_OB074[U21%K%*]0LL0T
M79!E(>$$<X,VZ2T;"O;(#EXP6UV;5^#! 3SC?<(,&+HK0 \&;N^@P)+[=6RG
MZ1H6I 7Q1] $/,= 5A$D )592E0%7,MN\KGKKS&1E_VMHK0.G_P*4-=%KJ:T
MIZT86VS]SPDC+0Z_];BM\G19\#>XSUM>8PCU5A 2'%5Z!>=%5WJ/ZN:G3B]_
MFO]97G/&KWE#EX2R7Q;5<I"<2^?(#Z)_<:C>R@L^KW#1Z1?LW@G1&S=U\L)C
M(2"7AS_C*W3D_H!E9BF6A=Y>9J^ZYW?(.&_<-7S,[DEWFI^1<YA(B!><U9Y,
MG0=.Z_@GDI':_S*]BOKBA!/J4S_#,_@10:--P7^R.TJ'L.%770AD'6^SO?&]
MT?[!*Y011$WMLAW2^BI0@<)Y7[1.\[\>6&](H-1-?;)LZ)BP3TP20Q:<C'Q,
M[5C6R)&L2.SI8_]2,N0PR)1C<SQ)_:&#B(O3UOR$(X.O]F5@$;65X0U*(V^$
MW6<4?:%,*F=3;S9+I#R0]Q_V>0\<)R\1R0G?.\HR7 S)(>]Z^SW(IHZW/Z8?
M)A;\57T,6](%]DP6NRHL,6:(353Y5>7>>LK^X4US_69N)KC-9H(OYF:"N9G@
MCH/:(UVV1W/?5 D_4 I+)\VL>]>.X=_G24M;7/;8FR48)LDL,IOZD62.0S:,
M\VL36(>.SI@FZ-04 3T B"8R9CP7L]C)P$2UVW- ?X^+?Y_4W82_^"#!&KD<
MYE["GS.0KY6)]O*-XJ%[:N^B#VXNT%,;#!;![4C*MIQ8)/%: -O2,"%]M9-4
MQ#0U8Q#EI.+LY?Z]D[NF'LS/*(GFPZX+$$MW4;RASX,D:)3B%5=0+I<=7'-2
M1\M_B!8I 6U4Y^<2X9HV:2E4<G+Z0&<-)]7W4NN3,Q5.'4<6R,=GER4];8N?
M5'@R%W^#/K$I?%K&IV"BNVRNP6#78]20OC[5+0-]D.@<WE/^E90E^?I#;:5Y
M#M(ZM-3*Z%7ZT& M^E+$_Z7GW@A'QMI>JSW2:?ZGMBE6MIL"%UC1.6K]QBS@
MCV.P&OY7@Q0_R7<1QONJ\L)ULF7@M#>^M);[G6R$G*<5Y>!(:<J%:[Z#PSYT
M::ET+&U3HCDZBQ+B+W0 0Z5U5BYY2[?RP7>4RM";)D0>)JN\,3=/LIO2$FD:
MAK;*=MO9Y(A;:F<Y:B4_]^+\&A"OWO[)%]MW'_\%'A/<N*RO''1TIU2RA5B1
MB$7;BG-*'C4-*=[''C.U9-NH;1V5'>\?63[C^C^MMW],9Z[7B21CV!>8NZP;
M;<'_%;6L 5'FVBMVU3!4UI-(+SGE63=7ZA:1TSAU0FT2[:&3:\3L3&!#^N!3
M%)*CD([YB#Z 31 GV,AY8@#-/P>*8!RB%W)*R5YV<AY7SOZ#"9-YD,$"=#U,
MT=->2+7&%2W*E%KH&<T?NO%D!M!R'-&UP<1^BA)S%*+R29[7(SJID1$U)[:2
MP!5Y)8^2DT_IU%R66\32[(?B(*+6*U1M]%](3R@PD/Z+"RCGC6=9^$=#D7E.
M9QN8:_Q=2X@(7,M>K7331L-%H CZ7VV39WO\  1L/M_W^OI#LLRL<=\:U2/.
MS@<E*35KA^;S3VPCYV,T'Z,/.D;B:QK7/&=T-$N=)G@3U$GA*P=BSGY91>!3
MV^WYK,UG[4/6JF4@G1? ARDJ^2!8;.CW%%+Z6H\T^-$QVF#*HC^8@@9L0A')
M*BRARJ79V8,>9'2VS7Y.S'OZU&1E/JGS2?V0M:(OU[C /J!HJJ5)P(@C7$N,
M677OW') X42;PLN6!T//IG ^8+_+ Q8P89X_+()6LR?:%GQR!.%Q$%DS>1(_
MM7V=3]5\JG[%J;(>J 3.Q4BTZ;/U05$<'[#9;LTG['=YPJQ$?] ,13,Y))YR
M3"9K9;I/;>?F<S.?FP^JQIT'LX3R&_#$C*$6VI_<\-%A9.*6(BC0O'#GVW9H
MNT''[U3%89SUI[;!\_&:C]>'K%7G?-KQVCCR]\":TB)W"/*;I456";]Z?C&4
M*]BH3VWGYG,SGYM?6?TZG&!04$?7MV@_:)UTDER5*P=(<U.5R]W"AO.673<4
M'$:1I0K=,PMF_.NT!Z5OR_/!5]*JHKV0$ZR4 ^A%OR&]."TU#YJM^2@['6[L
M]_[JT=SO+;^XG7[O9W._]R?2[WUW_4*'AO)^_*:>]QJZV\]&W&2ONDL_;?:0
MB_%!XV(GGV(LLN/K?4KO.<&2RK 3P6^"K:C!;)/ZPLKG*/:M2=?T2?UOY<ZE
M3Q3<=/TN<@GFG?EM.U-4NXZ;M5W1+B_I'UMY]V!9 KOFJ@A,!!&P?O3GA;:@
M]G#"\'-\'3QBJ[:X+BIUQH0'?-ZQW[*"%5BZ&"?-[]C(&?D-OW51WF=^S;_I
M-9?==NCU)4><WA$^:&H(-<<H^V.MM2^%;M):&_AYI9><-=AO6H$TVMJ[1)#7
MN@LPV@'/15N4,!/<0#$A/0.@*?B 2OG[F@=NW+K?U?9$)J/8;BG&9S>V*JYA
M8H;*L:7A_1(S@JZPY1+,C$R1@./BRZZ"E5WM:EK+\L9Q9_/1^9 5)*TT # :
M]<:&S\-:9PDH>PHHN]]_-$C#-=4=#<(Z:GZ)VZ>!K9D&=EMT_2*BQ1%F0E:#
M >Y@R3OVT*HJ)F;91T#0+R,^&H]*5R%(LW5A<,BR*L!>(!RRD4&]9-Y%SS-3
MUO0B^@$FM@"W9<=,+"EY3#(X(TS?8)KUZ=][B<U48A?*EJ33PYBG,=#:A^DS
MA<S@Z/1>F_<,XH@J<@>."O.99CJ8@\(:D'G:'!+FI54JU73."CX6OMJ.WGVY
MDAI@WS/%C_["' N8L=:1DX*[1I>Q!V8*5N:2R2;MX*9XZQ+>J&VQX\!M'A!R
M%XQSSS6EKB<R3&N)IE);]Z7:Q76S' [[-0<9L638B,E_P=Q=+6D KFS)[3.A
M2+V)?G4>7'Y'ZKP'0^_T\ D<YL7D1H_&>P@!K<A+IPQ3@-=$:JLVK/7>^$N]
M=^9%$E""T_PYB:3->%JP&+%';E+T?MXZ-B9%Q5,^MDA$2))H=)U#AR$[=!AX
M\:>C9]!"+^O/80FL!&:I[,S"!5+M-[NN=YN$A8R'<[#+%,A$>$1*I"RK7;8J
M2:&7W:7.N0J[-#WA(W"T%;0*,@<P0&8?4G*@@Y.;0-S'13,ZTS)HDOM2F"]L
M\OV_3ZLP&3?>HXVF#"_K@)B9J^!'%,D<$NQGQW;&:Y(Q-_JD4!RGK;FYU/5X
M+G7=9JGKR[G4]8F4NH[&)@>.8 I\L5MM%)6X"/' PP#\9"P>V4:A26GLO8F-
MWJ,+9AU<E6]!&L=-'F)9 N/^F!!XC[*5DY7K2@Y$F ZP0>S2SE2_][GX[\R:
M)D.D96J7MKS1%I-SP0UQON^-O#W\A:SWDDG.VOR"8[YD)&<7S+*2\?)@2;I:
M5;)'@L#52&EC@5E8]%%<7(#(M*?86KR7I3AJ(),MMN0&O2LW,C'DRV?_>I"E
MN!EZA-9<R$N,?'Z&6302@RPTSD_6GREM8M]<.'A>"_&4-,W$Z0J38F%'M?"6
M%W>%:7B[]P^3C@N-_.8K'75##^3?.%,0^\L"E12%R-'$C6A6*7QC^UP_RC>H
M!\"CZBG,KCGYAK2%^)4IJ_<6LVZPH T</![E&RD9'/*@4N2R1=4U\H9B9DEZ
M"%<5.YXI =^5$WX\=F]ZW4KJO+\B!(U7)8DV.<-!'#ZAT13'L_B#(Z;]]#;N
M8$<JY[HM>W>R(EEAOU[^DU0*9]X-C"=3&%=( 11ENU&=(C*PO$115P^8./8:
MK\1'P)A-LQ"S(-:9:(I?'.#^YL$J$A$BT9B.LA7*XUTS\!09' R)7V5L-%UH
M!RKP$#+.1NT>%W]68<+GQ64ZSA297@C!P!SLJP'CMF@)[)20M'#<O9!Q/+3=
MR <GX:P*(+8Y_ [*K*B0[.6LM8;/0(^ZP)>-@>.:6$ F(<T(! ) _OKT=5H\
M#?0EO2MZ ZUE8UFY)@]B ?-0,]S!K1:2D2WZS$@F8 [)];N!U%^L&U\*2;J*
M#7O1EIT;F<R)Z=3@FU_*\9??A?,/"C5__/%B79\H 9>D YA# P,A/E GA%2B
M3I#(OU7CEKZA..^2 ?Q+T@<?Q"98T6.^I=L/M>#NZ5'X$WX\?@<+Y4!V5\K8
M_K;&PX5OV?YAMAP/YB*9)4/)[Y)>;E=V/ ^5W?!)PG2Z-ASM6@KXW=M<8#*E
M/9-(MQ4F]%7HZ^<!7(".T7O>='ZV!NXM6A-Y5O2%,O\ZO5K1E55):GN%&1^>
M\GT_?V/H'']/*W_4!6^?JDK(#Y#1G.8RO>R+.' 9MZIQSU'42^Z 70<PRQ=N
M3K.7M4>9+ [=65[[6YN;'H&Y,& !I2(>1]&<\Q9C $5Q18X'#RAQ[88MDYR^
MV9VX-W?B%;K$R);;. ?=F21;>48! 5<(%IAH7+2IPZ'[&WF-P67&' P2S:B:
MQI8[B@W"L#=2\AG62O_U_^2O6K=V+>[P1N;G =21?'<45?R=[0=.W,50D.WH
MG0NV(_%H6<7*"IW(LT03L_=PCXO_&>,KLP\40/Q7\'4A41K$A$Y(&8><HD\B
M897P6,A*72JNO61V/DAD#XLKG(CQ<,+WR/!"9I?HP3K?99(T[U;%/_._DOG"
MK5\+>H8'.:5AFG-&TTKVZ-*122A0[D&)NC-(#;^(-)6O"8>0O]I[XYEXY'ZR
M8D\;R19UV%@ @=)YA2JW'QJ-JI#,/T=Z%85J 9?@F2,4G/Z:S&O!R& R54 !
M7]J+\^_W.?+-"#IZGH7^PB$**<0ZT1=KW(G>;%7Y(:UXD9CZHH\5-OO@GMFK
M_ S?UUFY;[C>SF[0:[F@SLO]?)%M"WI(!<BL![!H5F1VD2DIKHJR$CL'QY8>
MR=R7$@+6\-O0"CO#$.A)NG7A\P_X,ZW+;;8"/V0XH?U!?3%&5I!OU\GC1#,X
M39C\M%NZ SLGR4Q,DF:X64F%Y@,$FR7K?">#8N6-+=BIRAB/8 \E8K@I5LX/
M%KYN\L^>?)[_R:I0+XI=-,IB!<^(;SQ^X?+JAFU3QZ\,GF1(@X9'R7CR4C1^
M\X:'621?9/&18'H%T5_!2^YE<BTMH$8$6N-H""S*M,%I_@87V5]W)HZ928#S
M'FH8-X33,!D6S_[0_?A#KQ%.9*\#W'<R5O,B?%?.@M2$YHU*'->_NTPS4C(8
MC>V+1*':B>"TBQL;B?BHK <G99$P\C")U4BGE>Y*>5O)6L-3D'&)6GBY4Q=Q
MWO51T43\PW79@5V)YV=CZ/F*O(&EVYR39G[Z>)$_>?3D"]E_^M=3]A<O"V#Z
M:G(N>, W[&A2QOC#T].O<EI498"^^(-%5$:!5\.V3F=23%WKR>FS]%I/3I].
M7XO3.NS,?,#R:R"DAXU.;5]Q&K[/]F__U:/31^G]O_SR]/&A!?P]/B+)L5A+
M;%ZY0L&4->TNOW2%Q_@3E?F?XE(U?ASU2W3.O86;R'.SOVL:,:8OVN&"O$7&
MS%C]]#-UN;Y[<68^5NJ8_]PV;RY1X%Y$\__P6MRV9^@+O8U7=&3M2^JW(MJS
M"I$XJCZS@01U16M@MBZ8YL[PG-P7A<;T-L;^Q".$;";76D8-8HT.ZJ3KFB47
MVC).-?F^!*%RKDJL-&3)KC4U)K$"=U>U2\YB<>6&7FKMXCE&U\XK*\RVU%FO
MPI';XUK(NY2.)W&*B&:L_% S:^(MXL*6JKM$Q4'Y19<^J >/4H?\8OC.DQF^
M<YOPG:]F^,X,W[DO^,[S41]+J%IR0"E]R^QBRK#=%DV8F(6+ZL)%(\ &$M>V
MSL^+KE2O<]6P=M8AJV1J\ QR+2E-&1; YZJR4L)870\0G6&,M_=;BVY\5\P<
M]J1$J+/%W0RK9D#S-.?ZHXM/4>YY0SYQBSDE>G^+GY)1$HR!?!=&^I/O2Z:<
M_\76AEVNWR[$[#8A TJ_WL*/ZS2!!J_$0]VDD.BA1N,,%ODY+& ZRIH=2##G
M Q$PM-)O:478T_R%8!'PK>#69Q-^\90D<VIKZ,2#BI %UR3.B3=.ONR5(F#P
MD_.BLBG,?_CJV9/%HT>/\B)QR#.[\6G^)Q?&+]LY736N"R6^Q/4R8#T(+0<T
M,2+M&9:F:6;QJ?MK5Z%21R_\<C\AEG&! N"M^F(1LY!]A ,_J5.2PE\?1)!O
MR'X^9\2"!]U=-FU_@JR]$#:,ABG(;+ 8:J0CY]\KM:)),Z])T0X5:=-X,ID(
MJ' -Z'-R9AE)4DD;QV+KNZIL8MC>UV+QY3+^OM;&<VM^STL$0P ^1',?J4;Z
M5-2IHBRTB-069>>2F% 3Z2,Z6LLML91'10RQ^[[DSLIE7377>IA'8"<>Y1XE
MH\[1$+B%QJLIGJ^GUH$%LN+J. 7-6FH(#2GF<DBA)<20HY!-^T50O9U V$1B
MG/E2CXGRP3<$W""7ZZ+*?D,OB]3(A$\3]9-,!+MXQ?Z1Z$UE]MAZLP5]8[1Q
MCKXL*,LK[3TE]431:L5 EB5&B,Y)]8?@;O^Y:LC<9LDLGC"(!PV[B=INZG55
M<KY#FEP[;7*4CTDRR6:2,_-Z(+5=\$]^?DO24COK\-56JK32XD%?V00^$0)S
MJ!1SYRZP?EBR4J ?G#XKZUFB=/$_#FWH1EQZ537:<:Z@0^=(E'] \J))4E:F
M)$'[N68/^TU?&!<,D@OT//0X;=FM2H%U9WL3I7Z]X)[F?[\L:9W7SK2YXL9V
M"C]$_JY58#I='+@&UZ9S6('?=Z54A^'? +#8:Z<\O5+QGK6?$TYQR5PUMKB%
MIC[%>>OH?)AQ"\V0[AV0:(95%/R60MQCV&5)[T]Z#6@+ZL*FD\1H^^05R\J^
M'<"F0T)"?Y/SJ*_I,W=Z<;J@7>.>>[SFW3E.9U\LWW)[1-<.6_/<D F]V&5L
M?Q>YZY>GGT<T(N$:8"9CZ"'[>!^@-7"5?VLDB\KO?P=87$GR&EIC==XMW9<B
MIV;G7)?!#ND&JJ/ ,\JP8KY4Y);K54.RUX"7UV)];7&&'XP6-YNV>S-M+V5P
M.9IYT&Y51+0+-UNA7X*2AQ1YMW*V2 ],$%[:OB^R2%E:J[T$P47'[&W2 '2^
M,WRX 8C]Y_CV!>+86J)<=I2AS*&FKMF#OS:GUBF% ]"+FZV4N8?V/))#7)T-
MB8].I%&CL^YRM8N&[6V8<\5NIZ,742A4=SZUC $8?G"%&0I.;:D8\)"M"$M4
MFRL0XD6J<O7E[-MVWQL5]:4<[J//?NVY6XP.7OYFZY:<*&" FQ34%)GGJ:EA
M% T\UX7>S4S!6+SKU]+L4(KNT!D-PJ6H?^X<@PZC*$_3'-%]:$%GRV73PJIZ
M&@9]KS#MKKXJVZ86W*2WO[XEP5R4TFLP"EB=])1QH"KOLU,*(/.M&?%=HC3<
M=3[$9%QAFP^\3/)@9L-T_X9IG2E8.^2D#@7R(LM3M?"IRK>UN[!L*SRN8>A
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M<LU<5] &]PDF=_B6>W?"1S9%9'R2;/B&R*#:R1X"W(E*_GW9B1EA,DM*E,F
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MSKO # <18P1J1R9;J@UD9V#V3>(R,+Z-\A;M06M?/G%!?2M2&&N8FS/A*(Y
M96Q9L16X0HP4,9-^\HE%51E*J*S=^C-4A4OJ;J=>+1GLM93U"@2M4S%P0@1Y
MF\_\"27U'\[@.8+[JP7[NTW0@ 'EI:XP]V!XM;*1V+34 D-]?PYRSAOD^/XG
MR/- VWOP8@'OG&-ON\L:>"O*\TWY-&.;G\8Y+]:4ZQZ8)"<&7(PKNML"-+9[
MV^S!M1OH9:-,@&JTP]TL=L4FPL8<CU^[@HI-@=C #)2I'MEL]A*=OT\N(#CA
M!Y;C.9%_WV.4;IL,JNJDSJD21W>4-1LG6^FL\@5;2G4?#26%5>K#A!8F992)
MDQ&XUV7VHY+FLW8$-J4+'H"OB.PS8M6NQ$;E%^U.W@[Y.%7]\/350J[MAB-(
M.Y2U.$D;Z!R/.ZL(=MI4J5U0Y)\7FB\H@1L4-&^LZ&>2?"B])G*!5B/XZ<3]
MN+A/^I\Q?W3,>WX,X.(05 V5#XB,!QF-<O$1-@O+/U[Z%$ZRW")1M\MP(?K4
M1\LWI%/EI@E:$2=FP]]0.,.IN:>0/]Y8>F8?W2'\#CLXX8KF-'8L'B5QGVZ3
MH(-E;K7^-S;QA$GY@UX#A4"EIN5XKMSJ&EHDG(=>="TQ1.64CC<[VRF:_<B3
M-M&2B7%<"A02F_!.D:XH6-?,3?PBNT&P!R1+6?]M0/CLPM>-72%#"97?E8%
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MR0P1\.@MEY/1@G1'RFGSA+VW5^'.B9"&K)JE.S5RQ>?E@L<[1"B]K(@+JO4
M066N9@IVHJRO 8W>%(1(0[\;^RVAJTYF??8GSS/S(7Q3QLCB$. R2?#/W SG
M=!EG]U!I(>,V1<"50YV"4 Z$Z[2KF-@PQM,P]. 8!^4AU:+6K9>).A. H28X
M3=<7ZS7#*P"B+1?4VV&\L@H1Z3QG;Y5^.7D59P4PMHX<T0L&>.DWJ%BB7$#<
MK@!CHL"V&,HMLN>) I 9(84C-&V 3O Y1+IOQ5 OM\I$'A.9$'"H(T*\=>"=
M5(><GF/<FFNUPF2XPJ1\40Q&8^JB=,;H'.RTO0YM.!>@B3SQ\@/=GP)DE-?-
MU[&B"J>9ND0\47A*?P$A+ +$QU\A'D34E<'ULT!"PBT6:3&+6]M[4$!=VWJP
M4@3#L6';&5!\AL'_X.)$9]M1]LP-)D7H6J.93Q=,V.#O,_^"%DOLD%M?-?=F
MM$V5$=1008%QXY,9FY.(L#;@V$?WDT;6\0<Q$"!:R-C/OO  RC(Q@Z$%%>-(
MP:'I#EM29UE\34J0^HN>>G?N:=#F4=OJ]";)9)-0%TJQW!(-$WTWI&RS3=O<
M](K@)QAGBJNS*QHROQ-_?_A?T7$0H';^K(]5E7(U-.OD782;)A2[,9 OCR[M
MF]G%9:2(C(KB@:[47Q&X5VJ\G8O5]\%*_!64'PE8^69K:9W<6#7A 4)S2]/1
MB<SC:%<%AENZ=M2Y8.+]$=,SZX%"C:+NA)V7SCU9.E-\LQ(O8C&\L8?(+^.>
MS$9EG6@!O;%V'Y>C\(NHT6L*O9TL1OO6+@?I95*[9/954<](K_O5UC\!?I)U
MD/L, Q$_]-Q9+FP40>DK\N^I$J*+Y#)[VB$Y08UU['F+0 D:Z+!*+BCU;7?[
MJCE8Z8OIRK?D/HP^X^-Z8NC,/$,P>^%N\6>]YQZ-1MC;8D?W"8V-?L!*9C/]
M-N*4R]$[B!Y:: ND3U6C$,^!@(MON=BK"@)H]#=\_I^F,Q@3 PPU- <ZJ0ZZ
MH=5-S;0SH7]^Q/TD@:7W# 4LCX>QU*%!5%)F^I%//2MQB:#%]+@C\K:^TL2<
M^"81WX-)7JAZKH$U0$P."NZ, N2^(XYMJ4.VXQ*#K:_+MJG9N-&:6[N?M&DK
MI= .J/-#*PF0/?<DU(7%?A=!!5,^U>RW2*1\U+#%+E]@X^)N#V[0F5I4P<).
MO.&<73,3';G")ENVXV5::B-LVM-!)G?,6 G?D9J9-9!/IT/XH_C-:/0?-YO0
MWE069UE9Q(J?\#_X!/.>W 3FZA2/6F^<2I 1* ]@A4_<C[B]6^*KN5OB+KLE
M'LW=$G.WQ#F\<3A?I%T3D2YS#H9B-#:&\9E-_@(VWI%WS1X-_8!3$;-7?7Y0
M>>%K;@DQCSB]Z@F'"AV.YAH5@N#D:B8G\EA5;B DJT$R14PDN"FB=#FO^\:,
M.HJ[@?P=NB23AVOF"O<6[I(X!^8^Y&1><[S$0GZ-A 8KKS0C+?/.JT43=.L\
MO-RPIY?K59(((O)Y4M\_\6*$DA%$1J0VY?-5117GMT85!GE;Y*)UUC S>,<>
M*K=N\Y"Q[<0-3SNB.UN733(!P2^2]O)1=W_\.)[12GI@^6IFZFJ7V8^"^4S*
M*&%Y3+VF(]*FAOU5Z;71FQ C9.X=.#8UY,T*B+1+7;5CW3!?BN &<TJOUEMJ
MJ/G@R6!48_VWH:;R)==C<!7?2)TN3N%N4S4&SDY*.<P+'TC&51:EAFWOG0$U
M209TKH&<]5",=#>TUYX#IENHT93IEPCTF$E,&J_Y''6^L)#EN>5<O!&6GTEF
M0EX61,B/[TA.<SY1SWNBMG93M"OE\R#B/2[_GEP:RGL@G!>0Y^L5"R__'2M@
M=W18K4 1X@QDK_]$[4@Y"\!I:>IB)PF8)901B8ZDB=-1E =!B>?ZPY;P@JG&
MZ0RJE3\ZSYC569/X[I.JN#'\DR0-I SA Q,K>N4.&DY42'3?6Y<K-K0J@(0R
M?LV+O\-)($R2K8V+BG1>A).'D $5TA"=R%#R_8E+4/Z0WFAT/:T*TC]NMLU.
M*#*H+.&3 +'/R]Q8!2?]^B;7<MZR:D!?3L-@WAR/T-VWI24NL+(FO2EFL/#\
M+YR>B5]=4DR50J94X]SIM>\\%J,G*W++! ?21ZU[QHF/7=E1?X@;8!$OY1-C
M9J P3V+@E1^Y'J):F3 D$OT&DT8^T,W_T"T7K1:Q/<F.W0M?Z*0M<NN>)'>F
M65F=H;#7HBQ*[7Z)0!2YNRU1&XG@G]O63*QB".E""^WXKID2,"O;J6AZ$;&@
M&$_HJ5I! FEL41W>;>6$Z).=4^=]ZO7BVJ(2M[OK)T*&BH=AEE2APW''>[GB
M1D5;$VB)N73E+N$1E:]%=U\1)6\-)<^/F%C)-V#Z%\G1RZ7(F++OB1""Z8,0
MPNM1D3(8WJ:7-#USYOM IAV=1M%A%!]?T4E8)G208R)OYF+.@XJ3)4:KM2@1
M:*UCTP@7KG\$$\N'>GOH18H"Z2VY2G0JQ=3X(Y&Y=QR$K'X9N/Q#]&-& FB%
M[ZFCR4X>?D2UER)-/(&IM\E#ZQ8T,56Z$^' $%LZ)/@I<L'&N&V>FT1@-<*^
M(00/;,"G']#+OH983F9R75:L+,L:>E*#2!\J!>1]XCGQAV?B-\[ 8IO__EJ-
MY)313S_"ROE^P/*@&7ZV=6$J]X[&T.VFE0Y/D:<FNQ%=@<YWX\^$T5XA*BW\
M\O=?7[W^\<7W/SU/F <%Z[@OQ69QYR&<(+H;[./+@OC0'U\]?H*-_)]#)?]^
M<A4X9?F88VM@I@X78LQ@4W T$O75;T)PKRJR1V.CG(2\[#P=Z'.[M/K6'E]]
M\0C%RY=<^Z0_?#'[0&<8_)]YKOR1'RV$7YZ^^)E70A[]=_;+3[^_SK._OOK]
MY^?RE^E5ZF;UZ; 96&C&+<<GDR<NQPD_V$4[.*_:\$K^.FR]/-IW+[JVT%+V
M>%5/NDS_S,/HHC?_ED7_&B0XT:J_PEC&.V%>^&<8_,NFAI,)@SC4PL+Q#[OR
MW*ZG':$N0#]]81UY623H%2<R<JGBP%$R"A/$HH9^Q8[PJ1!T<DR)!&_$8(R@
MU(U@XOG8XP?=0;B+Y2#:$*J=G/;\G8D1:(@2/#I/<G;*K1[%PQ'H,6$%#Z3J
M&B!3PL;%QB >I3U87#<E^[;=$J?QK=-S-"[N5KBY14;#5IV]X:",B.69 +]B
M86B# $MRWLH[SS[@$4'G$$@N3TS32+EX9PM$-EPG?*<+;I2^DAAMF7[ O^T&
M_0$P.SZ9*MYW[3R4?=,J5_D.E*D)%7]U4#+^5;:VK$V6TIZ#=I.IPB3U>D+$
M];BM@]= )(B;A:(JJ:S!N5]CW%R%D+BN :LHM<&1L_^3_^_<HVJ+SA2HC)7@
MN5\SO0X'/ 5P1!)=>Q\]G^J8(?I]0+,XZZ-[5Y87O21*(8;>'2Z8,->R!_Z8
M^%T!ECTJ;^B0"=7/MPI/YV'>U!V82.GY\&FH@QX?=!K&+SI<S4"_3 BN24I7
ME&X4]C]T<7@568JN=_MRO(/I!)/YN3UVDDWW0(^"#T;]?#VC?NX2]?-X1OW,
MJ)]S%#C1Q*%U>*H9A>X)SJI)3:,=]BIQDY)R T0MYW-#31;X]GZ@3B4-1<CU
M$DKK=7K\T6\X84#BD__S__WF\:.OO^MNM;KI67UT_K!+PN5SRA_2<3-73,_+
M5B-"M =;H")'P@1$TDH$K3'&)/(4)OU72H#&Q5,NA[W#-\;!#H<(OCYE3]4M
M(#@\$OV;(G(B;RAUOW1OHMF1HMBVX3@B5;RX#MZ<4E1HD1:9KOU!%^S1>,V[
MI-5&38Q!!C<>*V2D%,V3^,8M_EHW]05+"R\)T2]T7:'V<6.-.+3A2>FADEC,
MOI\6',%BDE&S:L9TCQ@H\EOM@S#A9X=WW,=70HJV['S20?2+PC6E_RP&IK^O
MG3!!4(!"PA7'E7"T15@@ME_M<=P:7/JB[YT?Y#M!J$:$VO-[A'/PL?E-N?\Y
MT&BX[-W2_T.)P4T7:S,1@5OE5C47O]2EMBLM%Y$SG:YXD6*)-AM;>FK;X.#;
MAP/C1OD()?929)7'"U"D%.+WKX*+H6$B$E:D)',D_-JY]5B4B72S836MMR=>
M6_0DZ&#PMZ.^>4Y;('H3FD.TN39,S4SM CH4.E)\*$T=T*3 (7@N]]K=*"R2
M=H4_Z&+DWH#TWJY!Z""3ASK*'[6;A51O""BGX#)"3'J%Z];B^>5;_%*<I];6
M]M#)R>@"5DF_W3"NTY<AZ95CW7-P'>Q2D:5'J^0-?5OO;<OP.VIHIB+3KGA#
M"I95N42$R201)%,>Q+1]:J-@V0T!$X=XO&6E$4DYG38K7EOR.\'YT>X+=:H8
M:N 7E*$V0BZ?)I;Z.P5P1L"3> ;B<+-M#D75'S@B7U*35 05B?$?HM;"%,UD
MG2A4M290HR;BD.ZL'%V:S+F_.,VJEBCSJ(/QNB@KKB9KJ312A*%[LM@ER05Q
MI%P?J'$_:+-H%D*?:?JUQQG@%#^+U<NO1LK?-(]-;;D53G3(W4-^+WP!7%=W
M)JDG,7$EC]5,3K1=Q8)A&JOKD=&*[5TB%0J!D\[V?:7OCDY?[?P)-L;/!2^.
M3KE"=J>S%T='PFUX36<!.&?SWUOZ\^[T[)C]W!WMS9)]$3H&1^<6'[FSBW_>
MNC/A$Y+D9R[@F+"QHWY$I*B'DG3;O,?$)Q*A*2R.1,7*9_1-V;-N#RYM6W/Q
MNHO.3T7.&3F:W:49(L@(0BU!*VS0#:ZV:QI!7[RE;X?.3( =142..7%85V'=
M%@,CSHL%:6*S,T1,9BPX%63@(BDPL8.?4+[PX0S^56VTVIH]_BI'N?51GOW2
M-@QI>LU] #GIKV>?P4UZ?/6=?DS_?/3=YX#$D"_U*Y)S'4'=LJ?MHE1PU6=8
M]?)C^8[_K;#@6/,"_D<MO0G9,W?ND/=\ZCHOGCWUUQ!W:72%;:%EU6?,J2&N
MEPA_JUI\1EGR##G"Y9:\USK[_JW;-H3F>1Y3T#Q5?X0JO2L!+'R-U_;HVV1T
M_IM^C O;WR"<]^]6$5HRC,OH$W(0.X"8R#W-/1K/CYFR S1BB4##T!:49HHZ
MZZ7%1$7O]6T]_\O5U9=?9[] *VV+I&+V4NO=!'IC%V-M():\Y^=]='7QZ.KJ
MXNKJT>3/HD<0JZ7>.F@,=W0)]QQ_>.+BPJJB8LYOT3-=EYNFY<H2AY3R:'PM
MPQ$L P[U/K/-.(_-X(7_Z$LR&(]%0%,V*B02&3E5D&]89<5-T:XD,9G'(3@M
MZ\_*ST=+>Q7B!M)YD2(8]W[YK6FFM^9W[H*C*Z[*%5>X:,-P)]C @=2F:5:H
MP<I)MD9[_LJ=;-@W9)FTF:%);Y[8!1/='%=Q [A]!,QHEV+NFT55^C1;$U:X
MFQA48K:V(@=\]*;#RS1'-D)O2KF!@S>TT9VTT[ *.TI;'I&+]%&Q? >=CT7O
M3([@=&A>W33ZW_[A4?[EU57^^,NK4 9UD9P@4-VG7SQYG%]=7=$!(9:R0@:#
M^2\Z,99T\3]\]0TNA"QZ:\O=8FB[D!:/S@0A,I TTH90P9TWF$9?1N&U+M=$
M\WWRT:5&JD^:N1EFT3-G=IQ30\7UVVPGV[1HBDB(RW#[X;+D!!(/MB>SV-3T
M9N-#E5,1+L*B!4()5F_].(U 0Y%@=.@8%/N64+;N4D^>^-'OD>7!DI/!F=C@
M+FP%1H?PMN(6U^@"<BAHWB*ROS@[W2OO6#AL7;$J!I]LBA_7L^#&2M,K1]35
MP;1%"?$QKLN-5O9E]G2Y;%JXKH!>8(?OV[+*'CV);8X^23<L=F5/YTL=@[Z\
ML# !,WTC$MT*BY=MDCG:5'7)VFG_.3B?'#?#+3\NC'=1+-_P:D89MVG_B+'V
M]JR5[F_F2O==5KJ?S)7NN=+]T7TYMJO>E?.F78.Z7Y0#RSL0KX<]VDQ"C(;[
M_9^F?>.6=-<5 SZHG4O36?N& A!I96QW'*K \EYFKR*3;C[ I(LKYN*_] 9D
MX/%EV[;P0>O(S'LQ3$)V0? >&VOL,9FF=N=8!Z'WQQ=/G-LQ=*Q>?GP6<C:E
M/>AHGDQ\G<Z]4;Q"SD%7[)+S!N>[N,QP6<1=EE.('B(\_MQ+<G]V#G57J'>0
MKE[=/$LX1Q<@T&CJ>+E>%TOJ%8X<65ZI)_S8>+FPI+J[/-6*53$P#P& N#;,
MLK8<6EZ#E)U+G;/XJL$M7KL3M+GA1.,*^,]8WQ57\MN]*FZHI!*H+7(3OX7"
MG:PM)S>1H9370'<_<G>==:E9>0VVIZ@ZR_W4OK84O:O33Z&%$E,(J(9K^1"\
M11B5J<MY&.=AO"QNMI;V8F<SRD^=SNQ!;;=7R[Y!=))$ $LZ@WS"P8=8U("!
MS19"%?"6Z%DV.I)XQU"5W]8'39K%FW=>"/=G(?S<7'/'S+>WF5ZU-BAM7KBA
M#EK^A$0!%4QBVQQL<FQ1J*E'EY1W(FHP4IJXY3]8&8C&^9JTLYZZEK1[=VL+
M_(W<GUY]@16*0XGA1$.3/HB[9LERV,X/L.X:WA%[ZOY=(>@VS\MK&B3>&\JP
MV7,+HPSC2;?BA!UR^V@-C+=.Y&;<]L;F3.L9?8Q'5_&\I0L=*_GDNLAN71>_
M42J)?UMB[=YDC(]9M*5=$Q-^G87RT-7C+WD 1Y<2^@M+PB!U9RN?=]&Q^K/Z
MZ+?FAH".[NW6XAN%?G&KH\/E7(".?@[:/9HH?*#S^J 7Y5.BX/)=BT_8IGS!
M/MGQ*BV6RW;0.(:49GP&[LCYC?+>8N[:YJU"]_[P^/(19X8?7UX9J2#EI*BK
MY'8Q%!0@'I#K*+40Q6-=QSR]SIV4]/,K1EPNEZR!LR\.9+DIO<TC-\J\)HMN
M]@3NR4(,-&13J%5"NG+#&JGE:$* &RJI5W\''$0K9'?:B0?(Q<$M[ L/4$70
MSRIMR])ZFA'^4F==?.6BKQE><UX$/=6U4"TH2$I[:$/?;M1Z9RD[;(4?O>M1
M=NB -206EU71%V,+,D&.XTG:^?NCAEX3T6$%_]#'F,IQA\I3:0GM[QL+DQ\L
M@.I+Y<6\+F#/+8<@ N6.5<7LM!8ED^[2O.;N6:J<#"TCSR\80L[$ZZAC[9W[
MBX%JQ4O'EKR0(WZPE)Z+TEG8 Y:I:VQ-3).,T>\2'[D\IF&+MBINXU\=4=K8
MS0$::-V^%*?<,XP66L?1W8?6V8[WKF+'V[JH_!8WG>)8>"(:A=@FM$5UH)QI
MZ3 !\O)ZJ*">HBW4A&=@7+VW']=E.W2X]ZZHW#%FJ>F_:W;\WV0G)/EB:C34
M J);=D77R_PC75EV.[<^"S0H6[?D6(EZ&18/_@B>./A"I^T4_\$]OAL0MP^H
M6!1#8\!.1%_?4E:%>KO=M('JGJ%:6+6D-SHF-"80K7Z'2\3*[1:1A4[^E!<)
MH(ITIH=)4\1-&S51'=&D,@O/])-F_DGC;;LXA*G9NN_36U8JE@W>2"VP6%K:
M="&=!/06( W$DCD"0"<>(1(M""727%0BE):O:_9;:-LM_=H$J&VW9\@+#YO9
MI/S<T"(2%BM<^*9IE5O"W_32/*54N%N5 AU0E!_X=7>E=-VXB76_?A-8G^)]
M1V9N)5U%0?>*I@_5VOVPJ,IE=5!Z/I*]=@,X[*F8B_H\YLA=QOG?EYD?$%\!
M+R(F#0@<?WS&1H:CN94RC]&-JLT0?1C-+;%\DE5:6)IJ14!1<#%AXT2&(<96
MVPT,@P=51G!*P/<5DXB$J,<UTZ"@)]@2+I,3K=J@WQ/-97E=+!D@$2"/T1-$
M78+*%AY,7]HW/R52+JV&;'S8=IH KTY;_HYX".(S<([BS]E-BEZ#8LF= SHC
M5E>A'/)$GM?N] @LEX!=E#A4NR/\<$R?UEH6#,/G"MWUG6=T4^;,G8'@YQS\
MST7=_*5<M$U=ODV60]2^<VIEG%X6. ]95_%OC3M@,D0X5+<Y5I@\KGEZ$!"U
M!7(?F;;O%<.&TSM]%[1;O2V!"%W\0/HP7?P(S!]+9Q5^S/J.]&1Q_T]NRGZ*
MB&)B5=/92C<B?A,Z&L/M2G=T"$O&I+@93NU-*VG>7>8)S?7IS,@E52$ T/NX
M5WJ9/C!&[(Y*I [<V> \ PO\:J(%B3V[\D*^>03$I7\FRIF$"ZSM3>@9XW/+
MMW(6$_-/\Q3V=Y8JQ"N!D'LI= 5^H9*4+MO 8A5L1BM\\7@;^$.8[]_(A:!,
M8: II1OF4C34AQA;'4TX[Q:$^PSR"F#:$Z5.RH8?G-]%1$!^8'UC9"-J$W'=
M<;=">NZ%(_Y6KOFI<?@:9))'<)- F:5/Z="\'=[U[0SONDMXUQ<SO&N&=YW#
M]7S&"1[C0KCEFVU34?9'H@6.4KD7>5WQBE1B,YR.SI[&1]X[8HWXJ^IGBG7E
MH731 7NZ=;2/-2'>?4VEVZ?GF_W;>^+?ZJF:+CLB65#"D4P(1P@91=0$Z@ZK
MW#DU8G1$37BT$FV]$;%*E(D(N%<NRUX7E]#89='MB>>_Z8HJ]%/>E*3#XW>!
M> JR!2ZS9P4T&S<UB3XD3W+T960A?#*%BECJ89#2)W+-S<[B>3M3,0B)B:E!
M"A%APSQU=;=M(*=JR>_W=Y:=X0FJN7-37*XNVE,D+3%X5S-DLE9VX3PV.#?N
M:X;T+B'*FO-=J'&[=<\D$8AJF5,+@KCN6]*I*%NOE'69_1IXC[F&^Y9Z7-#C
M$%/1Z' 7!Y&G[_KDM1KAZA,.C@DR;6EZU0N=L$2W^GGOL$&YN=4(^<N,S,Y]
M[QU_0#WNOZ*QW?P:"'LGW_^O=C-4@/WQ.D%$*S'12VXIGH^!,V>\R.@-) [+
M7"6]D.2'/#P9*IK'41Z?>@"#I %VX>^7KR^S']"RA_E^W@Z;[.F*=*0\CH#D
M,#C9O*QLP4H:TF$49UF=F5F53$TM9"(<AEMI8%\CHI^\&N=B [(KA.]!%X8)
M4&=/Y'R#=X>$42 1YF6A^M4_/'\:YK7L,JB8]-M#/E)P&)&EWGBR+M*I:*5Y
M@)2<(X6(X\6%%(>)=%HX08$CC5H1NZT6USQ##8-C,,Q58P51R#_VR_#42K[]
MVKDY8OB:<L 9-"'*E,1'G1ZM=C4C8.[)(O^3\ZG4N+W+:J7&*5HUP$7D)S]+
MT J>T%K)1&)> >>[G33WP<+#\4N,OS8P2*ZTG^3D9M^1$JTMT47]$&BSX_9F
M:9195#95PQFE"*=XR')*7 HT+<IFLIOYQSM=(1]U=8=,4)SY&6>&/OCYDAR0
MR;(H ?>^%_E_)#L4DDWO?_O)))^,Z?$7^[>3&;^C]YR^NV^_^OK;\/+ZU;\P
MO#LV!.ZTH+&A#T)W^P^H%WWQS1.8@;\6+1U^/]F>42><Q?&>S\I*Y.IKBLYN
M<#,0L_WI#H:O314"HG],J8,0*S+NB,92\;TR5;6++Q%M^N0%4\+PGBR>3WF]
MK.$"T.B"=746D8$9S@UB*KMY:LXP-4.-QJ5E"2;*%8V2&1Y+*NG.4W*&*:%J
M*F\7YZ$D 003[(F/1280'[=V/70,<SQRW8MC-VN>U#-,JO+087RMA?()'6"V
M_(?;9_.,G&%&"+8K,#D:I'-B$K@$;Z(8!#W;PW-,E">!E<T3%*P?]'3\\T'6
MPYDZ$''6R[##6N^;ATD$T+Z15M<4JAJG9X'R51D@MT,!FQ7VX],) L_3[;__
MG0SC(:^;A[H6EFT)7KV*!@BTDUT."A&=F V!<<SYOK,V.FFV68EGICW1N'#B
MKN>1B4>!>*H9#3H\49Z^+:MH(H]7*=9C[8^(YC?))6KV,,TG3IL*+?.RP4D?
M2.5SC+P#GZV[HRS=G)'[5ZT73.>DA3V_/2421G%EL!S_/C ?IP!0OCOGD73\
M"I.,YKU\G_^^K9+X_O?!LWP@*_K?-P.R%WAO*.![GHDSS$15+"R!X>[#V_]O
MYRE3";RG#I;Y_9\G5\?<1#3"SU*,D/MP6R[8*6X("XKON@]%NSTFFV[6ZPO:
M2DH@@\;MS^<Y/4=2/2)0GR?@#!-@W^Z;MI]?_1E>?6OQZC7JD"@6A2.EXO!]
M:V\AQH>FC&.9)_PFTHH+C:(%N-;16-=1M$UB(.YR!&Z!L,:20=R^$.6!^AC,
M>AI8(\)QA!E?"\L!7\4C;M ;3]3]\XHZ0TI>\8WLJP=(HJ9MN@0-QH>BKK9=
MLXHF59:CS^8PWK\$]X'XH$%I]+]9IO#6]LEOKN;V2?[%W;1/?CFW3\[MDQ\W
MWRX=#,3&&N%:RYHI!QG-JF<W*2&+&H_7_)5^%)42FDJ[TX%=2'O"=&K<)*GQ
M6Q'I.AIJK<>G3+^S/L3#$7% ^@' ?D)/HS9?&'EB#QW0%H74QMK%L6*Q)^$G
M;6MZ:>\<(2F\BGHSL/3NR#IT)2#[.4D95D*6Q#),Z&,#%]'6O8!*.BZNB[9$
M::,K^T%/,%;:16>?O[)OR@# GBDBQD)4-S8B04]0Q;67I0YS:"+!IMS+(_.C
M^I528&];\(%MR%&;P$WRO9<"NM^5TE0@/$3,4PTEMV,NBR6KVI5$D6'*G3-$
M< [C@SMJ<?0H?OZB<QUG&/\],3/H57$[PO>U);4N[$]N,.5B7'#M HP^PM?[
M=B;D089J4WC-*&F4Y/;(4<TN+M.9#RO3'<O88X-3^TBY;9I5GM4%RPYZO7'2
M79L8>S!(M'D-]0DSV1%XN\I.OH:P(VK[NM9F4&4HD1;2(Y82[%)O%Q>^IJA*
MW'CD6$89PF*@'XE- 779@@1,F+'#:Q]Q,Y'7[&X9?M"TR??]0(CQ[31GR;!G
M&(:Y8PZO>3>JZTO-B[^WS6M2=C-;H75?0+V3(BA 8]K0T15\ +?6Z73J<,(0
M8=P&HKZ>Y[UW'BY6?VNO2S<>G/N$)[WPU](@C;JT2;'M#$V$L[&^'8/QVNY[
M)K]^?/7X*O<>C7V+X[@34O;OH[/^>=DM6ZNXC8+T56+W2MT+O^HB(=:CCJA(
M&L^$W%&N.>ZC:RR]2B!80$E6]?<.!&#.,_GLQ>_//L^NOGET>77UU1^3,:_"
MF"%\Q%*>F\&=$@3\@/W#0RN.=HG+_>^7_Y5]YMZ_.RB:=M^ ;<K9Y@:SL,QN
M8.B869/9KLB7:5A$:6B)"HQY<%<WDFA8%N[I@#Y!N@)/$/7=/GOUEQ?/+QY]
MZ^(X]TR[<OFY)/5-HAPHK\<?KJ>FQ>[<>-VY \=*=B"Q<H*O G)2^)B;D/W[
ME9=/7<D3 S,ZL-S]>@<*<7=M^Q9_]0HC(V("=[H[AYIEI+BOV#/IRV3Z^S@'
MMG<K%7-3-BNW)CK-!.(85P;>C%.-N7%''QTTWI)!58*XT$GQV/L8PFY]XBU!
MD6?H-/X0QKC@GC)2T I7YO0U#):0\PUJRRU#@_MYA:L5+ \9!A4-2>X+T@@&
M:-"7HH!JT:P.3#2K&Z>3G"4?[T6YTKTDE&@8"J2AG_[^VPN<_J()QLJ?I<",
ME&:N:NH-$W%,+$Y/D0N:\)J98A]] 5$/.O0W1,W7SM[V/3'@OX&86K>[;T7C
M.20-%XK">-G Y/ I?0=&S;R/4>-%328F\IGA8CAO<&DOO#@RFROIXMNZ,3IO
MU>V]UHUM>0CFVL7G[@+50>6/[,I<EX6WZY&H5DCL[T&L0R'P";/ ^YU["H-Y
MQ+OTI K1,^JCL?UP!M'YX) Z][(^$)$8Z;^6:YB(54/VBY/=:2-.TNLL'AE=
MNDA$7\-#G;!.\JSCX>3>WI$51:[':ZS;HZ,\O ,]OS%_;.DP:A*GZ@+#10>*
M<V@JLLE/EJ0J*2L[9K-<$L5YZ/1WB[XF1NJU)Q&(F1HW ]Y*;R/* LH"+QJ2
M3./"@%O,S0ZA'CVC\O]DLD"A2NB?2=3HB>91J8'" Y-*,E]%=H6EKY+1':Q0
MFH)I,L1(^FI)H8T2*)KEH.,HIFXP44-[A$G50]*/8[:V]\3:<C0E[?IP5V7S
MQLW GHVC]CSM?W/FHEMI0P(O2J$R'80Z/>)=2<#'B[8I5C/WREE#)-)?X#25
M\4;B"",>Y54GR$S4-"1ISFQ$,<$F=!K.CGRK4.;7?7O $<.F-"EO,B];M1H=
M.,RBWT<)\9,#1055:8V'GC00CEDL;L@BWU@C9UA1.3]B=? B'%/[@99]FE">
M^)JDGJ!ID>P:T5V(7PYE'805QR!Q;CO5LJ!7Q.EF^L_+["5%!4JY(4U!_OE1
M %@5+5CC]L7R3;%AZM]55"4>%3F@?L!!5-QL9-RKW2%O"%4,!FR1[)CF.?-D
M#B6WXE[TC7MF]P#K=9Q4<R[X0%U(Q-]6O#VNLR@PPEF9W0(J,9R*KU>&7:8E
MEL.^.-"?1=B"7Z2?E<5A0DTBI3$!_;1D0[V:U(A02'*4GG2($JGNC#>CO*2+
MJ(CX.V$9LA?:!AFIPN!D;;K^P@^TZX<542D[LPGG(/&7MJ2Z9O5XA=C;JU!W
M@*$69X2J$9J>\KLF+G9H+<BY(NHZKS@>Y,;IC,S]TI;[GNHZ(C8K*!/ZY-KR
MCJLMEF81KVZ3X!8^\7/]=H#!HQE@<)< @Z]F@,$,,#B'=RPP W]"A&HWEPXX
M'%(/9-0!3[%/XEH%Q0&2^9P]X;,"2$1?0X)FL$SP--;N0*TRRH.2;M"D7QG-
MHV?>'MK69W Z2%;1%6OWAU]MW32OW\#%(-=1\1JZ8HRLF 2IPMB^KEA;D;*R
M$*^ FM'B,,JP!HHV]POG?6ULKY[OF+B3? UW,45GJ,?D+]A=FO<LUD9R(&/X
MP[ZRH@U'"19B-!S?*/*GQ?,5]*/N%S/:+ZGWV;]_13DH@:24D&[P.PUG*&->
M(*<R=-Y#RMV#=>#X,22+(@F]J<T^&ES  .W D$URJ^GXQL9"W^C*6LCU0AJ3
ME"U).*.C ,L-HULV>W[ASJ_NUH?)MYGZU@TGH'125K($H5XB^JTKNW,+EO1+
M4GOE[@-'TJW >/UAV7Q"RAL/9_!\)OWHPR'36HI 5&/Q?73&1N2B3+QX%D+<
M.3EW>RW[*%.A)H_RW(@0/=R0)7GDXZ/:WP(U85%'Q(GD 3O7-L;*P(0H7[[D
M;T+D+3J=L$4W"!P#'NB?6&S9#W8%$4?1>H79J8H;&,I6TRV0F&1) !IC3CJ"
M],J,K8%UBE%'$8@J: TE@*%3CR6)A)SX__%N^"3')Z56Y 7H1SJL  HYTV@-
MEXCEB-<L29)"ZVPK.9-G[!?PRQAAIJYM%I0/$E)'VMG12/V]XUGA(1 K) $4
MJ9VD8$1C \W&&[I6G%$9.Z6<0\&%]#'I:]ZFL*1B<5"T65"IY;?DEGX_4,>,
M4O.KI!-7KZ-'D(=RYUY?\K-[X5B[2F%:,IV"B&1\)Y<I6**"<#O5F#O7N2X_
M$)BMP'4Y<?$+UXQ)OER@P1CHT[4;RXK<EZ<\V,=7CZYR40ZH<+"N;2NI'A$8
MC7[S#,_C?ICK2^OB+6;H)75C8AY.!7)J"O^V-70T=G+&KV53Q.DN$9G,1W/H
M92VPHJ!?RTG;!;P7+[AKQ*45Z5Q8!7F=7C NKEL>WY6M"[NKNJL$[^!E,-WU
M:\Y<TD\^\230PSD_R(,W_J0   H40LCF_<TM1C+'K,Q0;X!K89?8K:L*K.N"
M&=>6-Q9;TTKMQ"Y@HX(:8>%6Q[)8V<OL1V=[W%_<,O2_?#V@D@I\D[-R 5,[
M2.>26_X:I*S*;E=V(&I$6M*]P<'=3W+_.YBJH%NX1#54!ZZ_GQBCZ9L+PM^X
M)_K/P857CZ\>/\H!!W1^LRW:2(!QZ@EE'T!*VUWA0FP<_H&<JUAX,F]:\42\
MTUE+EV&CADRR&4%R;RCX#%%).@6G1N.1N&-P*ZFM#_T2QQFY Y+6%97N@@36
M#T94  ,LF5:*L(H%6<&G?ESZ\O\$,$Z"\74_HM2_5&1LB"S]$2)99O>"#GC1
MD"1<XAX;E!@BPT,,QWR67FC4O6_+I8CD1 +4+MKJ939\E()EOFUN,,S(#$HS
MPPG?A%Z1H:J K':$VG1)FAAF93IE&R>PW?&!AO0X&6I10;;>Q+L?_P<)-Y/K
M W/J'L]HM)R[,?;2"8$B5$DQMH<LA^-3'7[&*=<3FHJCAH5WPC-X8.9T,T.2
MR_+A?;((H0,2G<$!P28[C+T86I7N;5FIR7EYYW7LWP1G(ZY/C]V9R/]RZT^7
MW$1%$5&Y)FEX .3DN8OG$\7,@02WW>N(AGU\K^RZJ0:RQ;=$7ZEV*>9>W!R_
M&O=5H87!X#"K^\/Z*N;8E4JP]ZHH7[NCQ2VU&]YMO %6%ED,+(DX$D"S0-,>
MI8@(:8.4DKM+Q5J?,'2ZM+%QXZ6/K>!12E1!D^F&%TXE9GE%R60I!X1*5R@T
M*'HDMY+:D1Y9'G^.C;MJ08*VRB,#Q&'1'J)828-%%!%4'E5)GB0PC!3_!+\M
M<M/4J1YY8;FW32;5BHTB H$\1BU.:08K$D8O#MB)ZK^S>8D7NI\4"@;<,]=4
M-N[8T!!#JSM3P+UV%*.E#W[*%HX$<AZDV_.@?39.[[Q8&VEW&S>[>7.[/@J?
MQT% X(X7O"$9C:GNF%,-<D8Y*'E'E]=N/)Y^GK.!;Z4',(1D+VG9RTG._RA7
M410CH4AT:-TF"!RWULBP*7] 09\WJ',5Y8R#?UI51D+P.,TC:VM;[D5F/%Z%
M40)!5RE .(U^D+1):A:%<B-)@)S%_IAAD6QW^U9-Y+Y!1QN#']B6AS/FW1L(
M6R7_@&VD )$&,$GROB- *WR7(VN;JIF#\L67'IQC_R;QHNY6X^;\8?7=TVQ^
MEYW$0]PW39RKR\?NE<_$V'$/+O'?R*9]ZG;UQ7^5RS<+@&A>D^]F]6Q1RC%.
MV#7N+&ES18WEB0XM)U05^T1A"KG4U 2X&VK9GAR\.E^=&<[6]"MD!BDHU:0%
MW-*BH_\0A+:0L10M.LSQCS7J<'Q/1!JATRA<(_VI7)$R("70;K$]9&;HXD ;
MQUDU/7GS<.SB[K4J_-QB.S\24\Q9\5F/9WS67>*SOI[Q63,^Z\[&.?L*LZ_P
MGF.5PK+PY56H#! ;6O#9.9(=*:H=Q-\?(:7H L_X E3KXUJHN!C34I7.;X9J
M^P!\M.AX( SI/:#_34V$^%3?MAVGT\@Q /A(--J))(0^1#9+'H&048)_IRM-
MG_D\G%#9HU%,'/N>C,?*FT)2$E'04)&OA%1=0<+WA7R!(B6Z/4JBUTVY0F,M
M2]?3 S3.Z%-4E04&'D+*%TQ4C;=^T+*&>B1AI-..R#W8;'>[NQ(C?)\WU_%0
M']HD/52S-@Z!& *6O:@54?A+T_9:02%TPY( C_HG03@\^O;;KVAC__CBEZ=/
MCT.F8)JT\L\5("D>(],M)JWHT:;=B[GBSPEEU"VW=B<=)II323 @G*CIU0J1
MQ5IP\XT+8W:VJ#NN3!R9I(S2VW4': .K6XF-U$0F(T=W);X12P:SV>%/]Q;)
M]N:&DT%"<["2P@GUVJX.8LN@,<'E9_\$6?P(*LZ#Q\@5X7KR'>*!W*H@8R^&
M4ODZ80#QW\,^SH>NJ?(3C'!]\)_)Y2*+["40W:5K0;GXG#$X'91E-CY#FG;J
ML;J):'.VS/?;/LR6^5QOGBVIR' XAY A@Y)F]F8:B27VAGZSRVT-Z@GFKOG>
M[==F)^+.SQ01+K_SN+2K;Z5)L^^2*NRHC@-KSB,!P:-TA49<B)*SCOMPZ^G,
M?*Y_IJHTWSRRX807</??-B#ICYLWN0'!F65BX;SF4RODO94G6U&%TD&I0".?
M[!<(S8Z_5M;7377-I=J!3P50/%0-,5>Z-Q1\;I H,JMF26$B#UJ,HY^%7%D_
MN[TT[P+B#C:&2+J@O$:G!2,YET,KV 0=ZKMN&=]NMI[W>P_/UO.^^+6]\V;=
MQ5L0XZ26*CAIDR#<(]T11G'<BN;]97OH4#&LLU_8(V(GZO6 PF4M%V8768;2
M!5[VF&F3V/O; =&_@%J<+ULROU 7@]J4MS,*O17C0<]##TF#F [MGVW+:N5>
MCH=.'L<!XE53]S9U]!=US4;*_>D9)379O$Z7ZE^+!?:._K.7K_/8EJG GX3U
MHD[HRZ0T@6MY)]?(N-,7]4T+Z Z\ 9BK;=/MR]Z=5E)I=5YYBZ(Q'W;UM>UZ
MG\$@@(L%VGTK9#;CJ]+1 SJW54D575J3[M4#[#1[L/?<$LPV^%QO_FE=.$OE
M/#D:(:,AXG;-:= 0 X@[__V^O'BC)5GZ]3CYJJ94<+)$!62)+8M;&@EZ 953
M%5YABXVV&'9]1R%I0,>1,2!EU)!*%&Q'W=07R1]'B#N;8A_)Z2.$>,=T[IRU
ME%0"CW]5HJ;,"5CB/V'#-VHX(OP=V30"Z@F!(O&#(&_"8]93S[T>I):'3HC@
M(?=!L$-EA:=A6)Q[_<?2]7@H=:8[WQY_LM04;"27A#+E"L3U:\&9^^U!R-NB
M;7&*=;[E(4!+[=NEW8<XC)IJMT6[ ,];<5V4%68PGX9]2W-:"HA#@,5UA2E^
M>]]'(*X3V(Z136HX9/+DUR-(JN#TXZCP&&I,Q,M=[SR1C7M&9NG7=W&9?<\+
ME1*#=1 72!%0!(L0WTX256YG,L+?!CQJC))JK=\2/?W&1!"K=^*SN/\IBB2)
MW\<]ML20A(=W!J#HA4%7IB!!S^9!5('4"I@;U:R;@4#DU !09]?.]RN4F8K@
M[](>$F#?O"SL$?4X#Y#R?>'9QM@T7^09/[29PG:*P8V61M(9B7)8GB5@SQ&#
MNT=].O>VV!4;_,>:26)=&+YIVHW H<N=>W]=0[8V-R-X:-1JMAXH23)5DPH'
MRZ1_FGNN^P'@:AV-<W4'S@(3?5*[P\CH&;9V9834,&Z_M 4AN_VAM'Q_1*I?
MP_DT''74\NK&RUOKTKS@Q1"YK9,3&>"1<>F0]LC-UKW(J-VW >UFM*?0<R0K
M47CT*2.<:)V85!:,FXH/$ZM$ET0N)=-C:O_.7;0?]SCZ:>]NGW<SFO=X(B9;
M*.(V%B$SGH2PGP()/\C3YT$?G?_?XG_]6G9O.O-KB!E_+NKF+Z7S_NKRK0]C
M7X7=XQ;LBZXM;)7-D.XS$Q_!= W'_4M^AB[1/,K&+?KK.!<C#D71]P@-G-?[
MH[/:2<K >?F-.S=P/&Z*6KAU.]]48/Y<_*/(7O=MN<^]H^4..7)7\&^^KU],
M-X6S%1LT!E+/G3L+J%ERJA=K;AVX!XZU\,N[54,4WF0H0K:/]5F"+TV^FEB(
MDTXBK5MN6M-%>2O^WKEPJQ+R6/[$X0#-2G4FI^:KGED=-[:)_D79/1Q, !,M
M)_;#9?:Z9,X?=VYW"-.<5Z*M\]04G3X5NK<>??O%-REE1P$Z<"(&=V<W<F#4
MKKLDQQ*>?W^#[M?HO<#AJ5W\OG7Q!0>3RA;*&;CI/4<QA=5>5-YDU)/8V?'-
MQ97&TSL_N<+LM.4;3/BV<6NEPC?6924MPI+AT_ON_ XEWP(Y6":MHA>G_<,(
M!CKCWXSZ""R68#?DA"0SIO,[.0\/=)M\,-3YR0QUODNH\S<SU'F&.G]<$_"B
M-J^6?1,$#]B%\D:\"Z;6'KE#73/ S:H%TQQZ-8-;I2)R<FH6R+'BI,"Y0VX;
M 0744IODR!.S?:EN'9 '53'42Q=YLZ@<*)2SMEF2?$*X'(; 0RW=Z;I7G3FN
M_*R&CECQ9&UV6=4LZ>$*R+V,'M'(DWF\T^C)P-M$GF8!I"I]3?@*1D<O6NZ@
M_Z2N*X\V/WJC"@=P0;0[;WI@8"NH$IG8]0QN;A$Y",5N7R"I'CFH)PYCYB.H
ME^S&N*,0Z;Q*P+-EZPF^5O[=^O/5R&O^A(Z\AS-XOX1,6$(A[&GJ=^Q/M[GM
M/Q8X'@$AR7ZR"Q<P,\-*NK?$[4(:BN9?/*QNVS2L=L-KP.A*T[WFUR*439#]
M:9MFW\615.D6V0V[3G73\N!T@[RH"37C/"LK2['3A^1,DK^&\UB9$WY9M,Z:
MK(Q[SL2E9<L!IDMV'/%N:$S.G<4N%VQI\CK\R]+W@E$O[&:HU7XQ7EW)SC<M
MY<.\KV\FKA'<RD[(+Z1OF!+8G7,YN"3D-6-;<8PYNT<^\4Q[=4]VGSLJ0RWC
M15LH\1 (\'7G<*@7GT5^=>,'I>PT80>FK)5DAMU*Q?'C3MN*O3YN ($ E=W!
M@&.][;LT?@HI;38!;@GB@)K>Z+R'?L02=5L5,D="#O=_\%\);V]KW0AY.T,E
M2N^<O3ZXDY.W<UO\G;A\Y8+8Y6'_)X?-HNCXH*'[Y/S _HV=\ @V5;, J&5;
M[O>$1FP&(4?&0_P*WDI;>&T'\( =O_HDUHN.XGE#W8\-]=JM72,:?"0N4;.<
ME@A$B!W$"1.W'W :/V9@2 VI5O]#3H&<-]I_FKW8M\W;0&OMUNUJ55GC/#@T
M7E'(7QZY@B%/P^Y06T#BV_IR& $^>4!TP],9$EG;[JNE%5HF+V-NE'C,F8%R
M%9*2X>184Z6/F3SER;'+B'=Q=LO.0E12'PPGID0(QA=:?8:P564AYT0/>Z4(
M<+Y^7Y25S]C1DI(80O)MQ/DQF8'#MPE8XJQ;36 38A.S<3&+ &\)ZW9#U:^B
M^P!&L5MJD7P-8B$O>Z[_ \,"'KU>= YI+Q=@$UP6!,B[S'Z10GQ2=T0B/:XX
MTBD!<$)/LX$XJ!153_?DUQRNR"L1E4'61.V8YLUMOA[P 3/4@/;1%"!@Q#D(
M"4!JBJ'1,8EZ)>)5.(P3 ,$6JJDJ4*.$MFQ:PK:-:DO\3ICMW7_>&5:"&K'Y
M$N:3.W>H!CK O7#_+:S[?"DIMRK;"]"GL1P[\3\42UU\PIC3#0LM9P,$XH=G
MB&F8,N"-2D,1XSP-A.!!#5>/@_J. (@\:,%]L!(/.@AJ,I=]I[\F]:$E?EXI
M_B"ETPV2?GRWY/[O_9K)FPH,LONIE<4.UJ:U,J-A>TJ/ ,&@HBL#6,9Q.E,K
M'CS&2AH>4HTFC9EW+BY( <5$,!UNO!_:;BBXQ954*-TL_LT.;00J)ED"]NG\
M[V:;?@\X;L7F.'-9=@TKHW4=94A"_7ELE_)8\HSR4O0%/M1%)(O^L^SD4.A8
MI,Q?D973&'L#%J>VC\E FV[,;'V9/<4>B4X T=D*Z'"F$V04"B Q6W1W;MAP
M^+]S&XP8<G&40$I)UL9@%T>7B#K5N5'2[5LY5/(QNH(.I%@"@N3/7R<&K/6'
M5! HS4=\\$Q>:497']%LTI-Z+/TI'3_A'??$HR.!59BBLDNL>IQIX&DT0KQ)
M:R)H\X33,JY<TT^T0J<F^*3,8"K'4D#7E^!2G%C [ ]MS;1WYA3(2*D^CSA;
MTQ<V/8(Y7+HG)BDA3#;2>Z KQUV@V'A9P\P=RU5SL):KUC[#S<X<>/#B&O+6
MPOEQ;_UB7Q5"LWK3M&\ND,^_V (@ZHG?(\S5A9@@$PL[8I'YW(+$2=[F<:I\
MWZ(ZS]_NG>]%- [%:@6J<":MJC<-1TUR_F/OJZ>!O@LQF*,'-\F#2]@6KW;&
MVG%A-SV\5P4NVQ?=QTULS\O]'?U;+Y[_( J1BL ,*:90ND=6C62QEFU)^/>0
MAV9 ?YY@#Z7-*F"F+[.?"<',.RG=.O)#4L8<756/7C=(;F+USL(2]10ZP/%5
MRYS;!/5?R9\HQ86>4$B7'H*\%G9J169YJ"->%YQ(X$W%_Q,]^1&,NP_R+ OK
M\P-^R" SP&WI;AC>A63T8G[WT$0Q1>,KXIZ%49>!H-YO2GI4TA6GMU U#%#W
MXATT;6 N<-_;"/XY"'XZGUG)7 *K.D>#L WLPJ HP-UUGA,&?K+<E/'MM,M#
M/K2AFO[.2@(E=&9 JQ<H:R)+6,=DXN'Q:2;=!*A*BP)"Q()(Z4V=$9,(B4R$
MRGE6E7\?RA4-D,AXNFVVKIJ;3\FUOQTX\L4,'+E+X,BW,W!D!HY\Y&I8#X;\
M($M)+6C^2&J\!@F1Q S"=TH]=F"DZ7T =.3L(8QR%E1-[5%G1&Q7G1TV$_T0
MDC\ZNK0;<%OLRQ5J!KX7AF)Q$AVB(R&D-6,O\P2\,P\I78I%I7^'SX?H7.*N
M*'0@"M^%.W)L.X[&.$T:Z;6@J4$:$]VY3C=@? A%@''</7NM]V1;,,)=\<>%
M]S:1NY&N+7(R20">LDC(###4%@TUM)](BD&I_XI("V6%(ZK-3[L:FAW:,JAW
MH?UARX-95\-2L]&"75J+%,8,53_?X/]JC;1<14)TXO:KH)\+-FJB;XR2R=P1
MZ+9@P[JQR'658*-PJRA:*QT+>&3?#VW302,*K<DHN@^+KB^XHBAKTQRMS?1*
MWT$!B62WW.]/K.<\SEYV155H:9\@ZCZR*I-JEI*&$>U#VVL[K(99H6DM_5EH
M\2A[2LGFS,T/K@GW34R! H9>;^T;6W%V\N<7K_,4NQ<V7=JP:HX>,YPU$(#I
M:?L2903N]^+UZ<L^18C*.S:7SDZAY5\I9Z5NU"S:J,36W[$&C/O5BGOOA""/
MP".(J3SBCX(?^LE()ZGD-XHAAM;:+D$*3M@7/#PA+7ENS7AEJ:TI-]Y2844M
MRSU6P*CY-QK"C476YY;;C_X@9!_2I'PT!_$$B!X1U0H_H>#JX0Q>=&9Z(XO#
M5Q$HUF;>%2E(]F,-6N[JYLH8DB5_&U8;X1(C%D=D,&7)#)VGH.>=R>B?ANU=
M@WNR5_3Q#C:.6.:%H-GJ"EJ*JA-*GBYOUS@AC61,*2)M(SEB]/$VPV8K=@^'
M&PM&(G7K!D"DG92N=I?W[GD$P$ZN=VD28Q21'OC%(J4X7494\I6LHQ=6X^1Y
MS5Y7 /6,7;71DR 8P&MHS>2YZRD3W(-USCGSF>L/>%^C$Z;LL]OWGXFVVJEW
M]L%[$(PH;+:G-F-< O-7-1PF<F/>7J#[W!->E1H:1<)IWC70,"AIXDN'+X/C
MSKZ>]2K'LI/\HDSRHHC%RSD?/9]!Z;V4=@8K42L>;;DI:R;KDZ1G-%530[OT
MCLD2:J5\DK9VC9"!#G5@_4_?'2I 5(B<N(J 17K5,HVH)[ "AETL7PBP'*:#
MDZ9\\<OL>^>"FA*$ ND-V/OLLC!"^H%?;2OK[-\.[&9>[%1_3RPT3)HC;Y7^
M@L1]HF1$L\^C^(%3V#E&HK_ #V(^C/#CW =:0+T(GBJZMK_"SEDZID!O@+\%
M])W8<#U)@'MJ7)E2[A<H*@P[U9^&CC5+AR\I$T%_\Z1M?2_EN*#>R&)D (91
M5GZL%!6]'>IW[BAO1_*1AV;0'1Q5K;!;KEG_D^(# I0P5R> 15:1)R>$W,:[
MYI_<R+-?=:_Y#F+H->;^=9CUCQSCSXFB=SK**')"Z=-[(]$>E?U_380_E0U8
M8%8#S6[[W<H9?>IUN5'&6?=5&!47:\_IGGN1[O&'Y*EYI%A6DP$V%5J]S%Y&
MBX 11]%/W<7<"5T=+CHJU(X48\':XVR$B^BIT+DMX1+B"]6!Z]=!"]O]1==?
M$L][H0W!EX(S>>@\'LV=TS!(CZ^^@]'*?N!OT9\>?8>!>NMDJ\[>L%"V_/ I
MD8IFOU+Z(9<VL+7'L<*%O&/-PD],GO AZPH]5.)+XIZ"DZA<MU309N>0/\!&
M"74G*3L%-!XAPB/@_DQ?>H997!?738O]J;,XU/Y/R#)*4%HLT'^:MEFP:G8%
MA?.!\?ZL#C+F+?/83EH12K7L+72@<8LP+*K/Z'SQ>5F<85D@"TU2" G,NAW*
M7A"6%!'^W<V[.Z_M*L'O,@+3'<Z(N$/IF578*?]3VVJ>U3/,ZG*+IA\O=N-3
M93X=%]0:&$=?5(>N]Q^[R1,\H:9\?%*2*C*>"*-,NF'T2_.4GW_*N>H5],6Y
MC>B-/3 T; $"L6:VN?=AJJ(P&,5!CRY2\E7=7CA(;5]J"BN<J^BZX/Q?5[H1
M%=0/-\QS>P_F%AMN/@K/.2$K=Y"QL)$<9=IK+%M.;"4+H+@[-LLW\SR=?^/0
MG'"3-6 >PY)A_0J)%S01>M2D[7:=Y(RT1UV *,Q<'L"(*[OHYUD^PRSW(F2T
M:0M69B-D#Q(%'<V1PJIX(V;-WK=P<^0(?2%P9]P4[6H^X,XQ@RT$.;DDHU8U
MDA#E\&!ET;ZTB AJR\YG2HFJ'7TVI[.J%*#,D_OQ)W=C:R\++N<C);95?3%"
MI7\<>97[U_WSY=S]<X?=/]]<S=T_<_?/QS4!+T!41>3[!Q=R=[EPJ,/_8!O(
M!0ZQC<+YAL)G6S+O*//::?&3N.>::G!_2-H4(DXM"?H79=,'F=N.T"F7YD_@
M_(JMK]"\'GSA$$7Q2.(:_1&3M?3.?6+C](&/<*C^2?5:H@E;>SI7H1T";%UJ
MI:5OZ3VZ?B$YB,.8\I7PZY$[OJP*$6)R ZA"ERRH)%GXBTJU$>),X#R&"LMR
M%U42NK%M1*L.\!J0<9+Y"%<G;#IW/U$<D, 5 7\*4BBA[]X_"2!0M59VC5<S
M"A)2*TB%*S0\$G#@-^I1WQ%'FBRFJ+?:+R*\^NA]IT0J87H,D^-[GC0W!S'+
MOI)"!9TM][RM)]"/Z?>YATS9N'X=NDZX$']_TP(9&?.<)M@P(:TW*KASF3U5
MBEV?N+IQB]36Y-WSG2L4!H25A990]'"R7?318X6A^H2R4*A5F&*Y)")[CA3S
M?U%[2)@=IE?[T1YZH.;N0=MJ+[JB3*.11%<@LKDAUC/=X/M(6$%EQ8IJVC R
M<#>.2!FS$06B>G'/41=52\A<)?> K2;]"6;]8:SK^RPO4JWBYH^<&<C*M,H"
M .D*/:$&K*%S>\ 9N3\QTX8.Q.GU>/H@UJ-U/RR<1=9%H4;PQ+E^=!%FAR+B
M0I,2%V9CXD)NP^VW+?4CR%)M(-6II8;43WB%@Q/_N6VJE7868%#Z;^T\&'H<
MKI19U1UBDNWW(3L+6X7ZA.,SN]BA2>']7R,W3L>MR\;?]98967-O1%'9Z<F9
MY+\.^YI;HT_M:!"UV)71@JS;X6Z!K7*&]"\.2@D2!+KGP^?^##XAS5;$8!#M
M/-HFHRTR=2H11O\#5[HY6I, _%O*CS8MM27PV9.*'S4D["#_)GJ VQA/CPQ'
MW,K/GA/YHVQ':.%CQR"%RRG:1I.U%]I%&P4$"5E/!HEWI@5B_KIR*6T7:)>R
M=I=A2[@[(SC'4X0VD)DJX)YL#?;+GDJ?&_-'>!.;GE74!-Y16U&=_5QTJ^+O
M'*IY^@WQ[52<0 MV'%1K<XLZ]HA)N&F7%TZ()4#:FPM*:34@4/?416Y4^91-
MG;'DYVNQ_.>63B2!UQUVBZ;2LL+/3U_])5>4=KJ$IFJ^=*Q34"[+CIR7HE:I
MMU'56%DQ3XR4NM= +Z"8..:^]IV?2!N0<[+H?'7RQ*U *D\L8=W1 H_6-KLD
M\?J>R/D\A3X0\+D=5V1\W.M%<C3Y):8\\6?-E#^;SD_/PKT><<]&/4J9Q&V)
MRRUD(S)I'-@E+0#H#7-N&]Y"N0/BW]EZ O0CIVNH""QC*-1]=:]T/@SNQUZ6
MOODU)"O7;AJ%G76O:@(]\V&++!-V-/?]N<7;"B.(6UIZ-!SM5.T&MF(+O*S
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M<8%&,#BP4 06L6]5QI2?)RZLKIKE@%N*VZN.-]&W.9^J9 @V2RA*<LMK]:S
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MF++0&;3#!&B'C+/BW:"%6_(1I<6R<Z^7D$:&CEI;8\50.VMSDVPR+$_PET5
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MT_IUAX!A\27L.Z!50W=6/@95ITI9'-1WWF ^VY:U,WTO[=MRV>1>%XRSMWD
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M[/D0:K_&TKTJ"^Y23S14&JO"Q1];Q!W>%VN;)35'ALMIAGG?[ =%2I&S2QP
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MLT\_>?;VN6%RHA]-K!!35CAYGE$4\O(E)SL;_\/G&/:=2RHI(%#CTF,F3'_
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M4@]C: .B5Q2^)TTXE8+\%.^1*]T^.M':\X)O7#XGR#,K8W$9,%PYD^B)DF-
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M_.H5$S,D->I!X*X#"HK0D6!W.HO\/4#C8(O3/#:49SB1)@G.B[;U,32V#^:
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MHT#8)<DY%A9'MH;N@L(C&;/\INLJH3>C9 0KB\O4"C!7G$I2$"SX+.P:)\]
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M/LX"];SR@O#+%&O!O@7S"BP7VOHZPATP4?1-.WNRO*BGK1;9=3",@Y45)?M
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M1:JC](%*E3$:\DA[!CL2X7 @W#_4)VT!,E3[TDD3!S(/9^-YOQ9#D(5)1(-
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MX2;$0C<U-5CZ&>^@"D0R0&<&'0X^"*PB6T^\B&7KCEREE+V!MR_*#N&6*5V
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M#Z*"/&MS,-16FGK(P<&5WB[$L0!NJLB 9J XV>TXN6TMU+Y5H3:)XE;(5N2
M<6F\*)6_D=#. %[E)3M)7YX2M1F*.+7++$(Q: E%&*(S;7--(DF^BKG:=>]"
M=/1IU'Z]W<=N1SYK'0GZ.DY&I_-@DEQ-> ?';$66E:-<,PG=89%_)".M(6+E
MS:A5-?4,YO5R@]1](8S1$WS!KBD,V+Z[ZVO'.9 724MT!E?EV%HO5?"HW1>V
MSBBKB#F?:BK.#5IFR(/<[ _ZI-Y3P!OS(7)FI:G7IDI+%P)FKR?Y,Q*DC+40
M7EE=<]!Q:-NE&LM6O6=.-_KK@>.OKB(I<Y=@E*-HZU'_&<5=*U#TL&<L6R;X
MW"V#7B\IW!.-?F=69-&@%%)G3F)A%)P9NRU!Y*0=%?W91]F'-W!E/P$:U  $
M$ &3?@-_'MJ^],_:IIWJ!]2.>R?H_.">!6P2VUQK*+\B77);7KP"+^E\E#6D
M(BJ& 5Y@P[ FB%BQ]3TMRY[%$B7@NQEW*(2U %^1 *>')?$_GY0WOV]M;3\Q
MXO;D\NAMT'^Y&;X_/3^Z.'OSX>A5>'$Y.#X.#\_>OCTZO;Q8R^;5#/XTS]0#
M'?J#GO?%T[+3.BV'F^'AKR^/SB^.#M^?GUS^^H!/B/Y8LUB+WX )^!1_^OU@
M_^AW-9K'&QN'?ID["O7>VL;>=URPJ<KCO!C@O_#53H2.4?]SD,5OI6GT<@(?
MO;S4G_82G&N_)R]_'VDK8W>KO]7__7?\J[^]T__]ZN7QX?G;=\>#D\';RXT/
MO_W^9_K;;^.KO?'[K7KT!!W*9<DCG$VRZO?SU^F?OVY_NA[M?)C_=C&H3HY.
M]WZ=?IB/MC_\$?_GIUG\X\>K]]/TSVC^\O377_8FOVU_J'[[96_KY/5Q_=OA
MR\OXQY\F\>L/F;IX>13]Y_2/X>N#/_5]Z6#P^^]/OO"")I^^S_+LM)[J>T?<
M6?:I.E?C?SX!91EF9&.KK_^_RNG?_>V-G?X3EX8;5/]\<IAG[[?T_^T^U]<]
M"56I%3^2QD6MGM!2'FM/BR]X$H*UYY]/])I^_V66]&_N,C4$#Y+-&":Y1S2H
M!U_EA8ED-AO2#$YFLS^#V]2\>N+.ELR.CKK@/AUUOOW<#1=0@?%=?VD1U?$/
M0/MB(_0'3A4!Y,D'4+99F!^$PQO 7@2'R57J5([N<!:\AGW;7TU?;.B;O,X-
M_)J0G=&UJ W"/SD58'G?3>LM&]4^-95MA<!/"[BX1:XGKVK-NIBZS.P5C=55
M'15<X.E#.9LN."D.JKAP334H3ZF7S#68<82:$=*X^U8\ !2],TUG712,.TV-
M=8M#@C.01J-%>, T$6;?J))_N>IY#U $09:M79[A:Y7%>>.CI-*)$"VY$I^R
M<&[-[(!093*:J,8>BCIV+S%UE>54T(&OBFCJ>$'SC('B&\1:93ZN0+A'O%^H
M,*QY[?1A8I(Q&F,T+W**O!A^00\KXN+L,.Q3)V&X[54,;(8O]4>T(1ZP9"]S
M+# U19C^9X,S$MBR>Y)@.*+>%^GEXR/*H":-KZ]8TC3:A83L&*=R:G=_C\CK
M1OYA!=1Z9#J(&H\-;,N6\U :,OFQ]F#?49BVLRY,^Z*%:?OKPK3'4IC6[?0X
M&WKO,VSH$])M*,MU1G(\[#22_]S[</SG?_Y]<%'NCM<V\:UV[XO/M7L[EN%O
M=;YHJYPY;Q/+=KBUV^'X'/X23;<&A[.?#D<\,Z(X(\F=+/$#MGD&FJ[!O^HB
M$(.HR[)H#N=@Z^ O[=OC-+K26_:R>\^.#U[=# ;3#^7/'[_RGOVKVXIMN7\^
M23Y5WP_S/%51UK'#]O_Z#L.$/?F7,X(6[0_:+<;:HWAZ4K+O 2"Y+*NI:$W
M;AE4AHPH,NRT.AY1C=TE P33,_*Z2N'B2#<L%>P'YE)C@0M7A>!G.+?KAILX
MA7^L5,S>G(A[>*<!QU>78B8+EK[0V2RSS2R73#Y$<A,WP?1$R:K8DX?$>3,W
M/%KL7#"ASB;-J']N7,"C^9].PP\:UYW1YQUG],V@^OFF>/YV]-O'SSFC.XMG
M%.'9QV9H/AQ%WA: KY8)0/)OSL:ODH(B$.49(2=<32I?:1]W2\"C_[R^^,_N
MS:>?M]('(@%O4:P'MXJ]NZ?I";&%OI9.(1:3%-#)(2&X.)?)GZG*C,7-0A.2
M'X&A*O;<O(C%4*FR!/WLBXYJEC/%N3#\L" Q4&&OK6R$=-'^9:5LBM%YN.U!
MQM%<F]\;^C^^8]MB@;_%SPTZ_%PNGON??5T'3^)"!K44@1H,#-8J 3)[A"+
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M?R,5T;+)MK?W>SM[NTMTWR.2T0]G\#!R;'2F;2O)YFD:Q[VEEDC'7SHVCS'
MVIL@6,9;9-6[Q($7C)E%!X,J7*F[77]2H02,F/IP\#C&^V+[I!$0($,CN)"H
MEOENUXA@/)[!J'J@Z_V@-RL'#L[J(F@"W9V41:32=<Q@=8-_J2@.")#NB"#;
M3/-;@W%0&^XVI,< X.CII<43,(_"AS#D)KH,$$[LR/&EO08:-M_8N"E@E/+4
MP# RZA/:B/)I,NJ%,VWIDC'9"Z]4[OV$1TW1'P?YY=5XVE=OAA>$]TYBJ81%
ME)031I04&='\*H3)^P>[^[T&;U-4:/<&SQ]K'ZPJ&3W"YNJ'JKH!DH0W+PC%
M9BJYFFA+FH%.ZJPJ#(*A-MX*_?L2O15749;\:6:"G:<DDQ34%0&X7!((8>OE
M I.(KR]+A*ZU1$P^8L$GN=XKU$4R3M+*3K+WVJG6\1$B-^$HN0:#>";(8#1O
MUU$!BAC*45&/A5E##N0PYCX,!"8?=0MFEK=S&1[H*7G01_RMW@E!03 9@.+1
MBW$VJG)L:09U^C&:(NYA-F/IMHQ>3EXWBP53YC64>1:R:^@B!:^C/R-]B(ID
M9NNL:X%D*KD*,Q\'455IIY6:\.V6:QQ=V7^;,B;B?DNC.AM-D'\ (2J!W17:
MWE#:('&/XV$F6D+,)!(B#9AQC1.!U"@Y2V68YH0>$T0IF@=;GR=?9?,[K:\R
ML+&05<"VX41&A_CPTL@<M:&1]A9FDPV3>3#23BOX#&RNY28J[.F4N:!^7R?D
MHNDLTCO&7E61>%@F4B@?I 5@+&GG*$V5H9I+"FD: Z"2F5HK)\PL;X9OM=<+
M AIIY4Q1-] A\WY4?PX1)IC@56_4,,J0E$<%K0*W N;)E!(PP*[$I;4)""Q6
MD7=1&AA1UPL)2BH1 "BZ-<L+WH<03YXR8N!1J!GY13X>([24V(4W2>H*%!X<
MROJ43+D:^;O^YCZF.*74*%YAFLL0TM;#+-9EO"MI^<CF >LSMN)9ZR7V_%+I
M"==!8-/64BQ1@+ZCBI+4*OH"GH4<6[-!BF6*V\"*8(N!5!%O(8UL6O&I;$.+
M!FP0@U@9YH0@$NFK&6<XBND7:0-:VC=['!!T$[E:Y"B>,8T^(JW+[;T +DY&
M^GJT3X<UY7*+"&Z6,*1LAN_TB#%/),=N)EI$"P=+G#O]3!J\S*>JHM6 Z"'N
M7 B%(KIF\2!3(E143$-%XYS JM'R6(L,<-*1P E)/N.TZY%1%IM'1\./4@#,
M1$SM"H?R2K"3;\!UFE%KA19LEH^8CGY8)E7-XMRM&,^)I*_-W\N C[X'/8KU
MD([S.155:EE6PR1!65X>8X+X49) (.<5G:Q)B;G6WC @G/G+];_,YA.)4-9#
M2,U"T)#M\ )B.9<$"^>QN3W5MH!RF%[_)E5:$&NA3)XY3*U<VW!#O5/T'V+!
M+ZBTSZO-<2WQRUI+09I?NAM@UB:1XD+_WE8,W//I;8WWWWN:206[UH=9U\ZB
MG613B/[QU!N&>OS1&>L].8T2Z27AG,J</ 8L0ZX-\RMI\#=W6QTUG28"@F<\
M$\+J=B_VXPO8@MCT?ZBZ$*Y3FCN,@WGE[7UKF;Z:^%4AU%V$OR<R1XO+I,S)
M8$RF,R*F)+K9U&R*MFSJ65R((N'H3VX>1FHAUK?.69C&22FZH6P^-,"K"H$T
M5)_XWY"70V5'T;!9@!&I?^,I LF#Z:V%!)TX> 9<7D]#.=$/C:Y8?MC?TP"-
M/$\8LE!OU1$+'>8^L(_PX"ZXV%*J_1A@$P#X+;UD=9*4$[^_:,BQPNHJJ?"C
MY^K/#IS.TE\?B<[RGNZJB_2"RI<:::E\&00!%1-E 4^('1&U1T#QZ'?H>S-4
M7EY.DM(7[H'O>KME!&D797J9]JNI3GVT?;K%^/=&$H^7#6\X-VE4;>5IX:"M
M96!8!E(0J5>_+F 48G@L\.S:&!UO9RN[?<*Z1["60JNP+(7: KY%+Y@26ZY5
MI![O" F&Z2S-YTIQ?,NX$R)]$@Y9VVC31,'>V4BR#6K^X?+8O/BX 8]Y P#J
MVE2)RIKB\E<XB!E>M"'B)O $&CFX4WV)'8F1E1: %01V3.B@#[NVMHBJ(XKC
M H8>U0]G5SD'H$3C0[H9VR)A'F#(QM9W!XWO%K_5W]@VU8\NU8:ZCB,\MHK*
MCX]I9]^>P]_>6N?POV@.?V^=PU_G\+^!P2/Y>O+JF"-AW.RBS0 ;G/.BY4E)
M/3%9.2J26:6\6&<)II61:@ XF7I*KCEC1^T4Q5FBD9HJ2&Y$&4'[J<9<U8.4
M@BMC9P-'G2UI7*I?/ZPK)BR*Y5=0-U<U>&/CNC(1-RW1H?%2,F7JC$U(COXF
M*)_+ _QW,SRAGDOQ9)7U\ IE(:[&-87NW) !*877TMLPO(UZ5C;M[9[7A^^%
M46PL(V8XAB@P9C9UM7Y,Z%/3:$@E#?I?.2-_-7M]/V;YC;X.]1>XR(8B] @K
M.*/P*8RN-H$4*%DV^\&U$C-0;JRX91!6O+ST6FM!49<]<3LY1$2SQAGUI(@W
MX%?/J3=*?Q=D">-BJ4\1P)W\SZ>5U M@F-=,#D94L02*C0$?> ;\7?QHY%(@
MJ#M.\YO'I+0?SN!/*E 4.])A8J.V9XDZ5>)$@.GCVC!,:ST-W&(/MF/!W(//
MI)?>[)&\24S<:X4=@P[&.@D9+3P9-:#1+(GU:)4)^W M* &RTU9VD4S?S%R2
M".ZY*"ZAW=&)$/_1/T]TQ.%MST7"35$TVG*\.# :62N?^G)+GC+40>'Y/F&!
MYV*O#\#*"D7>%3F%Z@/]CY$B9NX5U(@\.N:%'XA*ZXK(2. 0Y,7W4"R5^E+@
M'=)UV.^%9D7#BWFIW<ZR!9)L_FS[2]"&AWSG.4S\LB)E."B&B:GW\ILDY)J%
M7L'@)).4 YW\0WW8*0NT[#DGAX,VDD7K"5K&2#CJD ,Z2&NDZLJD>;W^0FT"
MP-,840913^W1IU%:4_+Z%:K6DB&WT+K"-P:]YFY-ZM[I'S1&M]B#8])6=FY-
M@9Y!'/+^@E$BFF6;CFT[@QDS2O)YQ*8MPPYM2.$!R1&;;VU$_*0Y],/6UMX+
M8G4KF<?M[2M#8(?JTN@:\;IQH*>CGO'W]K<VM,NS 4C7KMN\3Z"D@;;THBE%
M4?6")X*!687?[9BL;;,G\CJYRO5N+Q'?4&-AJIV89P5163+'D/Y \YZO(O77
M/,5+V"GV2%YL2P^_G-/<\481[VW*5$1B%/?TTJ*?A7.7V-4&$L?M;*'%1<:2
M<VJXG#%BE#N90??)_,'ARI@GQHDD#>F\B#7&%LE5GL=ZIQL$</TOI""88I$$
M4T%$JUX%;(=8"+R7N_:R6T9 Q%;:(DN@JA!EQF XE<8QP=QM<+TP\#\F*B7+
MKS73;C*#!1%A7DJ(LW-7)>/>1&XEVV3VX$JK(#J+7.$+7X.2X*C2$D?P VA=
M5>SN_:[? W0.P$(D$$_@RR5[,?JONSO;!/H!_2""4CMY%3%/^MP=^N'?/=_'
M@SCSDTR'M7:03&% Y*F$D;X?%C'[GZPM2RLO PNB1R(59J]>8^-1=WVZ\>GE
M2\,:90Q_LM2I2PDWWR(Z6:1Y2S2,2EH=:LU.2I/RFJ#Z!U(Q9P@77Z?2I,\X
M3)T1Z5AHA1]]641#D?0&-9'[2-D[.W;TL+%IR\G@ E_>#E6:*) VVZWC$CC^
M T0GR!3ZXA>J4T]Y65*ISS@5HJ\LMH\LK2H@)C3RD IX#]K9)6L_]H')W;1M
MA@-":=8'D?)E^H3/BB0UN G;382 LAYJ[Y_C^Z;GK@'7K!]52+6YZ>;'YF69
M%"P<JBQA-(:?ZDR%>!E>N?8P5M0D7>O=91:AN>[&[AQA#VY,<T8;4.JCE&-<
M1X3A[<L+7O<EXL+?!3A/"N*-*@CK:D+HZSTG9V4'1:7D@/EHC(NH;IT!_ZE.
M^C#@!-VK8@I6V4IG?A(FZ=>\^(AR;B)VIVJ.49U&1<_'*M5N-H-ZHK,;F?!<
MT'STVQ>DBI9QY,13T\8X2DL5>L3HR/.ZN5K^%7JT5,<<1'RZ^2),109M%9J3
M/6];NQ%W]68Y\:V#YH^ZF=9':S5'RU06-X3JB#PO:\-9K76%MB(<+"?]4<2C
MJL38$F33<$I13@>'EK*YQ57Q#NIZT5>SZ*?(36/5#VX3J4:*(&B^H8=:*\F=
M9_I=A%GCRUPG:WU)@;_8[4-V$!&A*VT*:-?6T<DXZ:'- PD:ILJ4,58>8M9$
MFZ7Z=YNA(*<1&$ <S5M<1JB",Q^BGRG=ZMHP4(1'+8;P0/^,:CRX$EQNUC,L
M.*\ ,435:_0J067J&V)E=TS$5B 7^Y896U.0?CO[G^R)_I:_ELW-C]V]=*^$
MM^Z52[+.^5Z F6H%CRY=;6L7B1H#[>+$ P%CS!?I>6P^*N3S0?U+=5:JU)JR
MEI3%Z.6%>P,<I2'B7)G8061DE);6%Z,;4_J( 9UPHL3W6N_3;V.?#JB)ZY4:
ML:C>8=&SRR;9XL8U2(NTP!;(MBV+62=[T061BGY/Q?9FG_WO[<VM0,)T;7IP
M5[1GX1PM$"$:3<IDG+ ]*D[^&;?AC$8,XFBP_BB(P",/U">42UM,H$<N,.\H
M3.JO"Y.^:&'2\W5ATF,I3.(4I/G2!]V9SI_R4O+L+8[T;R*?^E52D@]:;_,:
M,IR77L%Q,DJT:)E+JR696J4619DVZ%Z)9_0UUW:=RFH,_A<5N.J=."?_$WR(
MXN!)EVV8"K&AH-!RK*S)?6CPXK6GB(9<DRGGOWH,K!37OTXDRYF4 )I5<2]P
M >XM8^G=* ^N3:O&"NVV?H[Y#?W*)>%-<[?A8?QWK6?.];!YSD6#A;.*QF,+
M9:^_ZM)]%=/OR#>]>7.(#FUZGG2#]<2K=]P0@IL[3&*'$H>RG4,&(.('&E<&
M(+QZ9&I4,TZMD7R$+VORY<Y;8I3,73I+/%D'WER9=)==OVF2)=-ZVAS+=_W-
MK2T/_-  "[,_U%[QP''4^\UJ'7R7X=[>WA9P;+:?-6;W91(+HC:N:F(!\_IQ
MM$(FUB1X]/=0OD1X"N+ ('@BE\<H.]S=2?1=^RUL7FHWTI:VGB$3X7MA9HHP
MS6&K4YP"W>C^0ZV_VQRW_?I@V=?O][>>CIX]W7GV=,"@D68Y[O^.X7QQM(QV
M:'^_+[\7O$2*[9"K44L,OUDAQG/H%>S&RAQE.BSRE#I#;A5S+BU.!9>HT+F3
MB).?I9+;C#@/6)PW"&SPFP:&9FEAQ-!F<:_7T$-,+2E<>D(%U;-AO<(].1 ^
M@J>,RK[\@4KF!ZU6_"!K_Z!3GF=^E6/L[ 2)5EI93M*Y+7;QJ"P/ 8D!0:;_
M4(Y-%%+[[7NFO";P"75-.Y PQGFZ3)\8*MFJJ'%NJ7 ;/GO:;PJW(WZ4+]GN
MDJ,L^1I?960>SFZ69QM=HL)[DV2]F:N!F)V5Q<KEDRAQ,3D)KIPUX,)U!C/U
MII\!]<;<?2J?;=K&G2SQ),;Z4*WF4%G!)Y6*"T:2339T6$O&W Z7F4V\>6R6
M2YM<R32I')*-U [H47I0#K'29@WAVJG[Z#A3\^?OY\X3$]H3T^@XH1X+2WGB
MJKV9!I6KRT6%M.TF1A>GM@X&PAJBS@7,0EU8P;99D%YYKKACELVW"_V5ILY*
M"QGW2DZ32*QRSR.RH1<J@SFUY(F8G!YWGT0@C45S<Y)1,4XD=ENG>4DU3771
MY%5EY&1C N(JE36,30,7 GOI!RG9:LQ?Q\<T#,:EBQ]T2JTA91<(9:$>ILG(
M&/]UX>T6D"EPRM0]&%)^@R"@[Q",IOCL^NY5N=^'2"U8FM[E"F&RC7CW24ZV
M+1G4C;??[!ZCDT=2UN=]KW+#ZC%JTK 3_P;I*VF0;]&TGU@P/$G#\8:KD>##
M5!%09L>^:[?JB\TI-8X[9MIN>X2>ZA$RD;:_ECP]PXYG.422,AAD&:H>SA50
M"XB!"SVX_:V-GWL6F\.9S2I>6 Z[  0GKA^[5DDK&_R/^0WV E7C%(23#[,D
MHVJ]FK!<G#<G[70&M<:*-K>^F^')&)>B1(C*$\FN0^B(N\;%,/,-MX;J"&1K
M],R5)5E9W,EC"._$OK0&5T-HRB!':'?O\IHH>TEM<8"SJ>R+>"_.4(E:!:P7
M)<O8*'LDCY,>2H4C1<Y0';Y/FT8D@JE\U=IBILC5'NRH[8*Q[F[6#"XL"IHD
MM6Y7]U@4S(R\PGSZ_]7YJ.UU/NJ+YJ->K/-1CR@?93[S(2>B#@L&ZPT&G+2G
MNC]]F$<&+.E"OYR,+ZV&CJ2[IURG,5:$;Z M2P<#8XM]X6+496G@5?4%Z1RA
M#N*266@9O@7;4-]CR_>@&]W=KGA8(I4>1I@0]3&[-FEF9\:^W[S8#%\/!N\X
M(,271EZ!OC:PN]YBS)_2!RLTW672=:R-+T:>+[E8.W*.;$%V-YP0X1.%7U&6
M2AKQM1DR%,"MGN^@,8$J#@%A^G3>8,)./F6@_8+ GR<3!.@:3 '+2BH'34F,
M7PAI[^'P/UED2^>67 HL'*-1F%E"-$[OF"HO"'L1KRD24CCB^A@P:4'/=?-)
MS^.ND9#I!CVR0H<_/DJ*43T%;]-(E;#*J-+;;"U"MDSTFA2!B;V4_AHF8Q^,
MFJ]TOJ(WFLWPEPD\17(A/7$4.9$ULR(+8)/PAKD<+U9 ^!C2W@Q.<[UB.P;"
MPF3N<HQ%?^2QW847=@TE>-1KS(<?FEDZAI'(51/,,95Y^5@?8&I;\+_$FY2L
M?4:6G<.U)[BRM/^)@1U^X(4H#WHIS"( GY%@=RK3=XSSQE3&),\9!!<XW@4Z
M/O\D(78--P=-EXN_A1;$(UPO,T IA!A[I"P&#GF@S&R ID6DU!UR!V4:K="<
M&X@0-L%SZ90DCUAQ"X[60MI--JP)E?9@2V@ $@.;X2&^(BG]IMJZ-+I")-DX
M*4IXD[V _Y77IBD]G*IJHI7( UWI1[%-Y\&-5@EJ(Q^/64.8E#\WU% W55)^
MQ-^2TF:N2[V/-Z8YP;<D0&A@/.?1),O3_(H43#[4SK=6<RHS3:FF6)A-!UQ$
M*#!Z;Y-5@"WS7R3Y!7!4&PEL$0*PF!6^%,LP@HNS(%KGH/5701+]@X/_8 <N
MP^L\K8$_]=)8E0B.FK%@WP<. IAU-S7H GO:CUOSU,7Y3>8@WXFJE(@\ )1%
ME2MRJ#DD>U=-->+QW*(609E31#_WGK\^+:O3KR!1**C%02_D&R1&WE#F;T 6
M^5KKKI"UQ(&0&C9P!*<3NV)T>*DYE&+'#').=&*D.!LN@ZT,<$TNHZ@HJ(O0
M=3=P'WG%M940"E0J2^Y%EE<!.2<D0%O>B2=9X/TY0]V4I7F#UA=0_BWE!#-M
M,XK3)VVURYYFYM\,_+H [:Z.<\A5R\'K(H$HM!H.RJTGADI9"F-KKAV"/QVF
M]:$>.<*J9((XGP1C/;,N^UI*K4Q*2?AV-2A8#WHMODIY^:6/"A+G,\-Z9!:-
M_?6Y"(S!Q6&XW]_;V-W:V-ECOIKA'"&*0IE.IY%UR0W#A!0+2:65MD?\,!':
M @UF9>!7E<JK##JFU]YE WH-#'L_:9\8MNPQ5Y)5!K$ <H,9( 6Q';;-XAL"
MIFL@,4AA$F&-U%(M\QYE(B[=-!?,2!<R@K9^_D>E9BQQ\XJ!;BS'),I[,Q5)
M$8/ CKCW] *?JKZH6<!1_,2UE^D/:<3KJ&B$C#8IE7.=Q N380 @N/1+HG53
M.%/,O,5E0(&)Y=D/H*+MM!;"-SNTS?#=XD+V0D/X26_P2LGHX?P%</7T_$6&
MS2/B 6ZPIIA%<\;U=@PLEGNC516TL('7&F!E&N"<@[B!Z.[J*S=YK!>E"Z:U
M2YZ*J"?;32+O(KL-X0.[JPMV6#ODCB/_?.NYPSCD*/ZYVP"FP3HXIE8'+7=&
M^N/4K RG^HL):9F"QPX0R:0"I(+!#>"'$(6X#!XV=M :HGR>EL\,B)?A">$/
M'!%C&_ZL,J+;@6@,"&9-0%T=!)E^Q?;B*SQ^H 9>F1BF9@0..EG/XI2C%DP%
MDY6(Y0-T34!="?VZ#*BFPXQ6OWOGF36MS;OI[H@AG"C.T /*L_VS<PM,5; G
M4LW *&1 Y?3@)T:@8RYV."+]\!CHERFOL3)TQ^07R."96(L^2U^U\"5A^TMV
MG_D:J?-#;"K 8U^Z=7;Y$VPBC/\HH "Y>9U:_C("!.M>RX9>#"P9BT2 X)[%
M8&)4[9"/OI)AQJA:1L\T >OY$V/GK/4Y4K6X]\QN<"XOY+T/IS%XBHJ@DA'U
M9-5,S3O@VI=\"4K"_46+FLOF#:ZY: +@9O=3T13F) !*?\^9";<H@:X@OWMH
MF^$ =J<8C49T3 3_A#<=9P@K)MXBG/,(;J)9DK8@,_/E:1R39BP4@X4B(YOE
MC@5'RGOSK/.!Z\S2-S)X8TLLUTJ$P6@ _)3YH\A(![2X*$!-%L!P)@'4095>
MTE%O-J2")3GAB=5 -";QS-'(1CFB&I(UIVQV#SNYN%)#(GT50B_&S 0.FL)'
M2_:3@B_T"]"T NF;V&0E^LJ1I$*!T8D?Y AX]*D<$AM3(\ ]8K](&^CV8&AI
M<)5<"Q2ZIQ\J1B(#)R K2:J6I,3W#;#(P>W'\D&/=4@S45#]+R+L5CAL:H\R
M317R.!;LW+PY:>1[J#+41H):B7C$_;.1E!LTGF>:(1N8'T)\:=G 'M'YO*,>
M<6==C_A%ZQ'WU_6(CZ4>\3$HOY*U'RLV1+Z<(BFEE\7:9J((M0I3)MK/'(:X
M#C7EUZIPIEKC2:9I'[;M1I(UF[5-H"S.%=MI%,0)Q7TB>0\%U8.;%2=0?Z*:
M>F)XZX%4#$%+6MDPP8%875UQ1$K*XBT+I#^Z1R3<'\[@):"/Y@B.R 5^O&X=
MTUDI<D>!'GIQ7TC#;UR,)CEU1<VLE<L![5CP\\2T-:XXP;US;0\"M&Z9&2G-
M!FI[MAR3,G;7.?QALLNTDVPM.3S1L^;L5<)"/5.J,'ZZ=;/\]IM-Z2C+I=;R
M2F7:2D7(^9H(NY$[)7*Q(JQN<D)H+VWW:L#BB +69"+;FZD>MU+9!FZP;C<*
M,A%@03;30^*,AGDM:+]>U6?M^^U1"@ABX[WZD^:?#8/G!O.WV5Y.=94[-,CG
M?Z'F<BT'5UC>B,ZPH(H^J76MQ6IEGU0M<(T%+4M(R[(L-OUB=ZMGB7/X^DM<
M;PX5YP:U89Z,B'B BJ,YR@5Z 8DZF73;7 H' Y,/!5T+%3CH0725Q\]-F87V
M>U/VZ=D<L^435HIRO;>B:XS7ZX)17/YN8F)X&VZD2.6RJGQT!!26OM>OCU19
MQ/WH^C&%;1](HQN)!9CV0,2".5A&!6AL-[I1XNE&-P34XTC]P03[8MHN474>
MVNHV%]OH<5.DMOA4YR2*F2J11AI54G*&-DT^0@%2AA;VJ*W')[J*M9A<S<%,
M4+D+?455!5I/;R#)PSWOD4%=$F>%J=AY7X9U9E+>6/Y97OHT?E2X2^DBBCWG
MMFJ3?1WO!N:3#HB_0,P5WAC,,\U$[MCOY*T05Y27:$GXG-\HXM[!H;(I=!N<
M,K59<DB2I3LR8(0PBD1[I9U&F%"U*EE*4SV=E90]-;[%',!2+Q5WP^-A=8R>
M?8=!2V0$M7DT(F.4L&"D 7T<2LQ&ZLA!)>AH@H8EPR=[DVN6Q(P'I0ICX%.P
M0$P1U=3+T74HZ=OWMOX1/AW5TUK2)I1,>1:8Z6F<4RX&JU,.N<)4JGC_K _P
MJKP*<SHMMC$5,&MED9)",9M+K^.2,VN< :>832N7WH:9)?N%2B1OP$2E;5&?
M3;D$C38\ZF\GF.<E0^,"' KC6X_$#E>/PJEC?QR-5XM^#LN)4NL]N,H2DA%A
MQ06&A\.5J7(65KNG*['!S=Q^C7>=>%AW#O/\>'#QTM"3#"[>TU\VM@Z(HQ+^
M"1FVX=-+,F:UX?N,#-]^_X?P9 I[3,IE]?EUEC#XW*394]_J/168G>XG/^G.
MY;Z<CS9:+F)T%Q+XO<# >_I88YY,\!@P*$:H9R9)Y[Y\H?,+M0"AI U@?7YM
M9K=A]<^B)#9Y:P.2(Z=;CSX@@DLAH(;QD$T$FT0*!-"E:T!J+5J'MONUU9HI
MP\%MQ^WZ8D6#ZE?8@(9]O]C%!A 'GDH@T\/])SY% 9?NV;468L%=^20O66X7
MU>)+4G@C<FGMC=OSVKZP"Y8DN1^6O'C0PNX8NT+;=],IBDDIBD[EEW[[;)%G
M.32M["IF=Q/$%H:P\?179\]XJ53(3;[6";YPK_20#+K0#DR6W!;,>F_KBE,Y
M#:Q/X+NHJ,*3#UHVZ;_J?6UPH,+E.%!KI;L:I7O.[>E!HXUB'>):I1'TJXJ*
MX(C45D?7'HEVR>7ARK#[RIUUJ'*%ZVB+H<E:W0R.I<>*LQ=JV=JZCDQ(>%N:
M2WC.;<*:WM[>/K'*,FU-;WM_!S^V26O0FY6A!I9;LIM/Z6__@[*RWVV_V..;
M_8H;,5C8'#$/\3LIS._B5A6Q+<WA'S\@U*+',8@1;RF%EB<81R,_6EE-BKR^
MFH0W>?%1S[&?*W*M GKP5T4$6E60PU(*W$0/<T"C\.O%.^7$>:$0V=4JBJ(2
M!NA03Z\$-+2]"H[4<*IB+D>R+75^X99^')MF9_["H.ENG-:,MLA57+!ZP?5&
M^KFF2="W4P15?3+(;G[ZG;'L^-* <%UH8, >'TT0Y36H%S9%+K@H2(H)&CI5
M2N;>+7*)P= SJ"F7"%RC-*5' :.K(K^I)B$A ,OJ)IG]NF X1V-T 1M5N@L1
MPH$/K:6.#%M_"3&  ?J<B03023U*9K:-L;F336Q9R["1D)HS@V["**14!MH
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M_)#MP_T46QW%\"^#6QQZ1 7(CE\,TD@\H,<U%-)PN!#($>"7)1IRAVQ*B)?
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MQ+92%]SFRC0K9(+Z>0\?>HC1+)+26)RE:7O%(+@%VL2>1+0W-@!YNM_(87A
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M-TYW,:)A6]_X+%_Z0_%TN=9(HL HTA:_F8_Y6$4?@<"C9C0AA6QE=:<30U3
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ME15Q+QS61%%CQ2(8DZD/@FS2[\.GR3-3[FV0,_5PU$3K>WB,SB<DZ$T.>\G
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MS_; .CQN!S/M6W]@5')LOH$?WN." %@>#D76<&IDI2X27G=LQ@26&29[Q4X
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MP0,I^(ML UBLDX[3I*2:34MW&+Z9X\G#)/]BJK0Q6:4$%(/;4.L<"<^2&M?
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M+HHO)'[/4WB$;)SG%<26CLRX">XSDM.UX?] E:&CX/M:^]'W"6*AFCDQB=D
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M+)/YU!99@"N9N[KA92?&A*2J(M,&O8LD+#YMNT/:$?"CI@@I6 YPI,AO@/L
MIM&9-E$%KSOQ"?>HXJ_8Z@TTKF0&CLLL&5.ZI2)76_"-*.6I>0S\F[J[8Z]6
MYH*BHYK43%B+K47S"N=E4X-F&>0*:(HFS.8U-X.GX\^77NN=BDGP:'X)@SW"
M75"!&)#N5MAI:![(@$Z?N^7K3L.;86?6JL%?I5S^,D\]H)==-[2C\K&EYW&D
MS" 8TVX/LIZ!P5>I?DXL8$\ZX_=E(<"J>RM=S&8(NN%U""2'.8W*\'22V5B
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MSEN^>,:FB':.'L'"'1YO%>+]$Q@6HS$@?W%PN%IHU-.T7"TS\!RBL,# ,J%
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M7_ND--8DJJOGX9>B>C$'CPH766#@E.5!\4'??L[5I2"FZW RSR-=810A!8'
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M0' '3^Z5RY)S;$M*=&I8[F0HD9QPPE0"RR<"$&)BE./\\#-F.V(_0>%;AFC
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M\2$E@N[ )SN&5FL)A!#!VR *:^N:6!3@V'-" BCA;BQ1:$)\,<4=80%9QOH
M,M#&%QQ+*U+F"0.1FG&DN!VLI07#K +/>15_N:6UO,(*/+< VCB:%A?(OQ=;
M;0>WG#"*5>3N/TJRA2E9#B)0OJ./E<2ZQ,'X@6J5E"76))/P@Y%DJ6X,Y(W
M)/.B- %ML@ XZX$1/FM ^Y@G%,&M97I \F -7N-HB]>X5;S&TRU>X\'@-1X&
M)4U8<>GRT$&J\9L57*8(R/0 UWWUEH-;J+=$'R6LG'3EENH6RRT'Z\LMHU:Y
MI>J66PZ^3;EEY)5;JKLLMW0 375SY9:#_G)+-"M-?66TK+Y27;V^<K"MK[PG
M]94LZVZOOK*+C+AOI97)52HK[;TXZ;@FU-O@),\;(NY!.YMXP1 S?7BP]S<*
M.F/1TQ,?1?*LNU*/@EI4Y18,E_["$/<'"<7EKMWV9MV#2D\']@@EZ>V4=K99
MI-17LTC=4F&HNDIA:/3UA:$]L8^^LE"UMBST>H6.G3!^?UEHVJH*56LKW+Y=
M5:CJ1&%M)N#;%(6BZ:E:5N3=E(&J3AEHVP#\)F6@JJ\,-+J=,M!D>16H6EH%
M:F_;-Z@!57=_0Z)$;6M []/@-ZD&-!"'VQK0;0WHM@;TX=6 ;L[@K9MRXD,*
M/E&M1Y_+@COKL%Z6FF8YJZMQ74Y//CG7!?V.B' =,#4,&)'S2JBF2:FU17S@
METS)"!RS?S?Y2(RF>FHE_$JH#UXWJC6A9^W3_XW0QZH1:!BUI()X% HCAWQ]
M2)(Z"8=7YB8,7R<<SF7,G:>I\&D=0/!R4YJWQ"$H<-*(X1!_Z#HNC_J:]Z^,
M(H>F/(ZL9<'79@:^%:]NE,SE&E8\#- SX55HPN/HOY;&I6V_T\&\LO&NKFN\
M!Q0N>=&Y9F0G$1/I<E.=*=*\^Z26?ZF-NVS!\OKN,WW%/GL_>HDA:0S:I4+R
MR#A+,?5\-*KB(C,/6\I6'6E-K_H,!S,LT!T)$ ;MQ7I BFA-<OMXF]R^U>3V
MLVUR>YO<OE=S^&3]3'5JF[^[7TH4%3.7US'_.K7%G*'M*SC>]]_&C5W)@:@X
M;[JN LJ+ZX(,&F,(&[U(Q%75,)2*X5"Q.%B(MEK,T6D9)8QWST>$B13(NX,[
M@1N"1>9CL+IBYQJ+CG'@V-1'NJ.-)]Y@D')=%F:+6_XRAL4GE)&W"\(X: 7Z
M"7M6I#XEMU-/G17DE>5,/.I(!@2[ /F2Z ,&V@W0?2P9+M<*4SFE;$PV<E=Y
MQZV;F]2X +/6>G@E/\LG8BK')0B"UFXS1*.$"@#*M/J"M?>>R>2?*E[I7)+B
MQL452*"<A)ZH2?M 6S. G6:;7@BR_()X<+6L;*N6K;ANS&M#2]4Y_%3RU[MM
MQH)D^$0O^AR^3)^5>ARQHOC#;.?S'[!Z/D;X.46CNB.5" XONQ>^,+U*A@MO
MC]W(O (2MQO/U?*5$%/-VZFPYI<#"X1'Y U;42O&8W&'WC02<9\4$D(Y1E*T
M*QDD\A=(5,4]Q[4+Q-A)?%0U5QO&IM2MP$B>6-UT.QIIT3,'*00ZC6#^L!!.
MMK2.JS_J?>P=@R9Y$L NE\$C(@/66%HG%X?^K(#)T3SO-L)Q$J%+%$';,G&2
MI/+P[U)4'L8](X.GIV [QM.=J%&>[$[YCIG39-[1&8"7O$E]3'\<2K?S0A)N
MH5"3*]H6@D1(;G@M*@97;6-.=\:](QNA7CF"D6L'G9+E/"4]S9YBDV2GX!-B
M]8J<Q0 <#8_0A+Q&BD]I^#95$%-P"J\N6A=>I7$0/>I3O",0JBCBAQ0:+FR:
M:QJ<1)2:*,&4ZP1"-"CR^27:V^E5 S9G<5#AI?$#R\3L:JHL>]5AG_@U)4O+
ME]BFA3L:7F)!+[M?K61)>!OQLTZB]&ZGXG?Y[# CJA^JLX4']G%90"K(2_-S
MD"J\-#Y^WY9^B9XSGR1]X*>Y6Q$QX8;V(U4L0";PL!5+9*KSPI+MV!9X=0(4
MYJD;>K,W72Q]=/: \FMKEL%VNMQ)-D_8VNOV]8W[:BZ[!T+)@3!'S_H,[L[Y
M8V#W83_Z*"5QQH!C^X62;,SR0AA2RH67>L\"4UM/LQ81)6F:JG+\"W+193@U
MHX,[PU@;#(:K<H:1_&6/D!@O!V:5*?3SZH:,;#9:'X&L&,/M3D-J+7$&&$JQ
M58.^]0V;5419@4G52GK1N2"N@?F"=<+^*G^[[2.U\@^2GJL=D-?6@:=!9;8%
M;QT\.W'VU5A('X33+$NY 02\5;6,P78!^K+G64AT\%W7N@;K%YN4/$!3Z$IG
MD+(K5.IM?;RT!&<:_;417"O5083$)L_G4GQQL/^FUI<S+>;BM$U5\[J>NV;V
MSC08P]RH"G.?9 04N/#H4QK&LM3:KQTW,/:SD\'0[8"7W9<9T1:0NZ8*VMCT
M7)N#0^=*(Y DY< <=J)M3'&I-)$4 @3#$!8COX' WV(+AD.$&>:W&R$GF7C.
M1E)9S#<FO?T)DH+DRF!"FBYBERA!Y$W<@^F9%6,#0U\RT<B?*%?8MCZMI+9;
M:E/#(55,. 4^K,0?>E9^JPSO7AG^@#*4=>')\A)2GR#$$VU7\;O]$@Z_0Y,E
MRP./'*YHFB@)M5Q0=8SO'++])L*9(HA^IR<&=+62063FV6R;>46 A?56(7HA
M'S!Y[.\4V?(3^/YS>'15/\<Z%<398NT\&(+P'[J^^*ZQ'M:,U(#_SK.FDI+7
MYT06,2S*DD81BX7,\-Z:25#H.R4M4$6EI!.JZ"!%5B>7SY6&:1>S="1_>Q[I
MI,SQT^935&8#@HL5$A;$+_],S!] 8>WR^:S*0+""[\ \6L_!""JJ2@ZH>QQ>
M>,E;[\ ND61"FX-L#7BR<!WRCU; )9D7-0%_*:UVGYN_PMZ8A\,Z)W.0H!GA
M^]%904'TG/]5L4B2GU4&>Y'AW\SBB!4_'F/LS&Y,]R6D=N0U%;V%V2<< L9]
MAQX#+\&$:N0=!]Q4V0R%/\MQP!\1<&BL&+M6'*[#\"NJ^6IJKLI,EZ VL"P
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MW+0DIM*$_Z:%N=B.YN<\N;GQJ'%!\ K*6'+6+1@9U<8[',6D*=FOQ^P!7X"
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MSWU>GBIG*SG(]"<!W3:R:,] ?*=,V,UH+=5+9&_NOF$OI80^\Y=ZQ0""]\)
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MK3]3(!XZ5A64QPF2: ]_D?0U%$J4%WO[R8][?->WCIXIZ@RP(52&.4I"5LF
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M%)RB%PFAOI&!ORG4#L&'_2M?R&5SN1P@5E/-[AF.!TQ$NME) UN9H6H*:J0
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M78INE8+1Q/4Q? 1_A7:KNE B/&/(!Z),,,=(EF'8H37A(K$2R;#[='09[*F
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M>$UU]UY8"\$9NZI>-EUW7S?K[AV%C!E:;[T?)?7XU/;Y)AGG0+D].N7[!@W
M9DC 59L:(I3EP*8=D)Y#D@ZF46+V+XP/\4,L"$@HFX93"]R\*F+S*9_/WX_5
MHEK$7IHTFY5N)LKW]B-6'=,1!G]&/OC1-K/B4%@PK#!";78XW>0>&. ]0.?
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MY$BT+W$[![(JJI),[#Y6/6AL#S/\9N#%F7__S^&A<"HCI?]1N!(?,&_>8&V
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M58"0ZQZAX7UCA-V"B9&15:Q(M*F!3VP(Z$5"(%Z'5.?T!8P1]B^,,/'#'B&
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M;8OE>C$7RR#^N"\M%?")$/!-FX#'SJ!W%L>4Z8V)?%+X497E46\CAK2/_,:
M"@J9";-I]@\W!V\ESG?<0B0Q7<S%.FR\F*V&6+B07)&=B#L+DM'10F'^-Y:&
M5/9)7F]%U+)1HL>B(4NT?T16IC U267B5Q"?1%DA,YLP[0IL5B=T6$N.'5YT
M4[+0%*S%]V2X)WDH^^.)^X]!U)KP0:>N'6GV+"*?^<Z7>1($6^OXW-.5GD_.
MRU>39N/JTMJ11N]DN7O 8@F665.(QD-U<O^M>#WLG]U-?GTOY]K-W,/70GTJ
M%>J&^)W\_K%]VLG]_'&M]+[?3?OGEP^]PL^'V^*Q(HU.<^)W_-G9\; W^@K?
MFTCGGQ7Q[ Y_7RG\NCF^[!4[KXW&_?T\*DX6H.*$4I@_,FY^/O]6?A9.?_P<
MF,@XB426VT)'@";Q)(Z(5D#8LBZR),Y3E83<6.MSC1'!#AN&"@%VOGCD692V
M<,U=*,D3R;;9+9FUB%&=,FMN^-EI5:O?7/[X_5I!>R&S<DO(K#ED=$?]6>]N
M<'):4-ZZS JR@L.&ES8JL0* SH<MLP@!=*%X5/0*FJ]57J66_7Y8]I^^DQ%U
ML)X:/P[&/=MEAV-?=0)QDBA@8F2)U=(5?C[8EBR-):+?2YL;=AW+*;E!";DS
MA?&=W<'<QN0 U^GQ:IR31Z,?[?.AJ7E#,TD6WRW58XDP05K!Z&%*;'[QMB^"
MU&KNZ?P5C<Z^Y*,@J&]JS>V@:*&*7XJ&HKDJ^;!1NRB;PI>\Y(@G6,I'G#M!
M 1;^E99>)![98@E7HK>#PJ^QLO";<SM^_OF"AF7U\E>OMO/"KQZ#\)M#D)*O
MY<_12;W[D,J^I9V>I8(T6Y!\0? OY6G.P9\OU[-YSZ38^N5>VB*4#,? RJ'7
M_7+HMH%O]Z^%ZY,B^MD;Z*.'=78].K=60&PI]?:B7&K!]U)YI.Y6:Q+M8%]4
M1W6R?=9-L]WIWK[*G1RF@)/G0K5X]OBM5MA:19Q5/&$+.4XTAZ)C9]EN<>R2
M.(]F_A9B[6,(5RB1N#+D.# =H&X+L:ZH#E?>L%Q7FCU!VYT,D>Z0H[9*;4W'
MUHG:G.HZ4J79K2ZJ!@6@H?;)OQ12NMWH_YX:$QC#A]';'<#R Q^I<'UYGI<'
MU9]&64K$[)/F4%2QY2NK<&-P5D%BAQ4FUOD$T3S@+D]%"6HQ7PLE1)15L9;G
MYV.;U;''1;@;O/X@ 1KKD(+2&HMYO7L'/)!HEXM6J:E-,$['/[[EOOX<#'YN
MM=ATWJ .;3GM'T<LN,=H4JT8K3A]@640VTKY/19LRUYC@'0J1ILTX'^)E=CF
M?[D$U$H+MY.]/',W#[1O>[?7NN]X\2+O2BY=Y+WZ(N]BNL@[7>0=>9%W_BTO
M\@8!;0\7_>__U KYZC]"Z\]4GLSVY?A>Y!ME<76)+ZY6KNK7W=_U\K L+K^X
MVHWS_\NPG=15U8XK"-[1ZFT0)W.?+$T.AK)3M[>M^KAR;VW/X$1$20:< GR'
MV'QJO,B&]3&S,8?0V259I>SQD";DP;L#\B'G VB+3]/S.:_-Z>5+?9@3?_2K
M<5](8Z1-U3"SN'9^E?%ND%YQ6Z1WXDUZA9_G!=1\OCRMY%/2VV_2RVV+]%K>
MI'?6/9O^Z$A?'WZEI+?GI'>Z+=([]2:]V6FI\^=V='XL_TY);[])K[DTZ=ER
M_IQ>IOF+7+=SG'O\\?"6Z,7"8GEI+#;P^R!H+2I7HMQOJTUQ+$]$A6/T9CA]
M?JZ)[8$HQHU1]J:DHW1Y)Z0A2=/15 'GUR\KR]'[36N,M8ONH/M4BQN]]$5)
MQ^[RQLXUFHBRBOJ\+9*C4FK>'FNG3P_Y\]@EZ D:R)*<>.9OW+\^GD^^W<G?
MC[^\*G$C@4?&5L<!27 %U@0G,0Y3B1NI[L@ZBQ;.QPIA%2>=3$+">$+,_UD"
MCKG9)^-P^<[-,D8";NHDO:D=N:E6>E.[<5.9TW][^M]O%5W4X0DW<FJKCFLX
M8'S\+-,?$< A$0X%6=W?PUJ>@D!<!<'A*[R%<^_M&>E>3H\<<VPF=(C&NB0:
MT6\JP/5V@E#IG:9WFMYI>J?[>M+T3O?OI&_G3A.=;'D[B8\WE)=(=/;!U?]7
M+'F.W4&VW)3EQE%0[N4;7A3[XS'_]/KM1/\]**VE^8]5M)9*[V"ZGB*J$LH*
M)T@BB2^AF,\*&.*"&S>\#O;=PKXO\U,A6KS,&4>UJATU<U., #,^@XS"E(:$
M*\8,FS<,*%5Y':/;ZDOA>U>Z5&SC?QF2#3I#)P!9CCE9[*.'!I(.Y9?#H=SO
M(_P9C+>"_-+3E5RQ5#SX=.@S96>9ZXCOGN>&,L=ST&+B#NI+T,>;)&CO$L^X
M"'IT5_[3R5_^^#6N;XJ@RTF[YW41="EI!_4EZ---$K1WX6A<!*TT3WJ75]<O
ME=_531%T-6GWO"Z"3ASG^A)T>9,$[5V.&A=!/P\&7V\+,_GVHK<I@JXG[9[7
M1="5I!UT(S9T !EZ5,IV>_FOC6*[TU%*J]+@PND- 1,P&Y@-P7FADQHXQ/=S
M #MG.)276F,P/Q&S5,_FZ\'3SW:#,Q:C?\YOC0/_Q6CCG5Q;.E/\^^)_85&V
MZRZB35MRWD6EG*T42_MQ(0'C9*+>2-B:;M?M1%M"[#<(+7A>T$),SDT)VI?;
M\:X)=UY%*=;I395"MEA;484DX#KBO T7NJ/-67*/5RH4@X?_A19+@=,TK0%X
MQJWF(X3YVBC4!QF !0 9G4=0U1W#C\8UPK@RY G"SL23+*$K[%-H_6LD:0\J
M>2(/'.LO:OMKH74COPPV.T[SX!.!][ 'QX"I<.8Y.&[7--[U<-%G-CAZ.:P_
M45X0PMP2Z#N'P@5!LQ2%X5"X($R3HC <"A<$!E(4AD/A@JCHMD!?:+YL2)N'
MFT(9Q;<KQ^';%>K!%E32*6]!^#+AH%=RR0-]=YC&R0Z5.%R*U=G!TXMHKG\F
M/W,:'HW6MV'_LJ77Y"UNYF@NGK.?JDZG%$C=B)51F+H1*Z,P=2-61F'J1JR,
MP@2Z$6%!KR4.] 1O!5DU=U*)-7<28H_(@@C]E@FOFCPO(L&$YR2C:JP+'U8A
M(T_'H>:N,F\;QA3U3Z8Z-L*IVW0G*E-D]ZY:+TB79.Q^<9_@<BS=5E]'S1]&
M%)\@="+AX!-_,XQRUB@PJ7ISLFIJZJ^,PM347QF%J:F_,@JW9>K[E AZZP9:
MT^:C'-990*A]/9W\_*75ND@R"PCMV@$K_L,!5C*H+SR+.E;J$V.NL#!:0<)2
M2%C25 TH?*L55RH\+-4KNQZ*KR;0>XM",OXVU?K2.=4XTCG5G:>@W4WFU)+G
MAFV%^%U",8ZTS*ID[>E;'=\C"7N0VFBQ:P5=&D13?6>*:LZ_^C(][;3J=]_5
MO+BAG(O3U?)0IJFUYF3-U.!=&85I;'ME%";/.MHY%&XKQFZY7?E M4$-^D5Z
M8YVNU^73^?45RM\]M)7UNUZ=1O=NL=_ECX9XG:]Z>;6NKUJV7-KY4JC:[EK/
M]01:SV%!S^\NZ(7=!3UR*-W3&RB%S+1TT#/YB\&M_W;AQW1ZTRZ<5<J;;M,
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M]WHW[C^?&/EU:8^"#PG9P291"=$&[YKO8;&H"H/0B(JCDH =PKN&U2"]4$T
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MWGA-A\L\9@Q,JSLH_)NRC9<EN]!8C\CH<11^%$JKDF-R9.AJ^ [B_6C>B%_
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ML #)KZ5[MN7#$>2XW3&\QFB](%V2L7STXXCV]T;G9);7>^W:AOJBW*R &(C
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M((X&BCI5Z,&(DZ(2,&P$ W,'GQ9(S6@-=*6/)5@Z&<?_G\S$B4P3L47.39
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M"P_NC!'8]O 9&/<G7->VNG<16R(REACPE,H#I]KLC@%M'DL62$P01*P62=$
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M(C,$$46-A;N88A%FB#5 AX@120M&JA'O(Q<PG:M]3*FOHX+%-#8(&M0185@
ME5JE85H (IZ+J!*/RT01D&2%'O&*C<@33  9@P[HH-2[$>=,5P\6ZZH1^R2M
M$B&V)8E#\C0!Z=&PI*"I]T:Y(UX?MEVT&'C8L=JC2QW.H#Z?0_AK94+E$<UO
M)4%3(]D5#!='"+*OS'1NB@?A(!#'PGP#1A)KC!/NE,0P801('":K)DK8-,W,
M>4'X=<X-\5H458NS5!K0MR299H0,=P[;L#@)F""J!?'8^*EYW#$-<TTZ_E/
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MSV</8^L.0X8DV3=+Y[RTRBK$O#;S2)>BP$G^ON#L^H)32'HR&\L"R7S0"!"
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MD-%=CK$H<$/ R3?\X9:Q8'3/X0B&&8M>@)HF+S7<!T;:2LQTEW.N%HE&KF3
MU&S8_8(Q"7.Z>!:6B6"?1W#&S)_#R;N^1&4]F#$56Q5.F^Y1B$9CI_9.[N%&
MZ"V>6X^7*'57O:GDCN>*U8$F$+1F*6:O:/J^;GV]I=D%L$92XECLD@2( )03
M\+H35UC8@JDP-9W-M'80VAPS#4_*-8C)AK\F#3UY4669;.P>9:1(DBXB"3H8
M%IWOO"JP.@?Z6<+Y JN/LJVZ ]RN$SI"'/ZF+F]S(O:>H#PS2TSCCG8QH<ZN
M-P4,#GIY@[N6_7=LN6#JG5BMH&U/D(XP5I&+K2!>$_%^\"KM0"JP +](;Z*I
MPC\.H/(Q15B'V4R4-Q:L)>3PFPE<#FF:H&;D'8B*8&$+N$/!]AXO5$^YC%Q'
M6QJ'TYT"J^,[UTQCMV2-I F2X#C;4U"#Q.0$22W*M-944#@-=#0FD[U*U>X9
M-]K+8-W'X]],IZ03,[VUFA,D/:]M.TVI M#SB:&*D*6,:5FL9MVO26<\")71
M8,;M20=Z$A,;=<XMD*HD:'R#ZRM0B$,S;F1;2QVVZXY=$$1BSPLQ.K(U,<^K
MW9O@6#GL&+D5T#X[,+AIY,N* :%@O SR.V&+G'LSYK78V-8=E]R(I[PH4.@%
MXV&KS2P,K #?D+PA*-N5B=T.%1^N1YQ->(]2['V*(>)!/\/S+9N '=>J(BM@
MUI+S3RV)Y1:)'6QPW:%ZBV*QV2^_YJX&=>EX3),V*1?$$LNL];< 46CZ$U8U
M1VNG''_E15V._9[A^Q.445#?QYGI-+7X'W!DZ%9SIPK^'^XG\PF?E3NG1K",
MU.L#2I/?8[=34A%J/%?NW)J/-9436L61RL1CUMOK%CX D?KI?V@/:Z[!&G?3
MTHY,.O_7W]P5=988]TSG+[$B\!W6/AMC!F8'<.+_E;#29:N"9O D:05<+EBJ
MTQ&8=U6$%#,\^&@F$@?ZWT9I2C&1*L6-/TJ))"OPM#[(<3^-7N:TLQN;$EE<
M#"_.%HHTUFO9;Q/;LFD7%RO=#5(0_5N>@]5HN<:9GWB,%3!SY\/LH$\+\5V#
MZXA&"R!/;D+]X@QQW'2J4Y,)'.^8=XD/CZ))F/6M .> A7J:)1/:TOVL50E8
MU](.]&_X)^[$O%B (>"X\?\Y67K_]DW)U#]:R=0$XQW8QVJX# +'%#283ZGP
M@%K80IPCL DC<AK:)F\R.9$N)K&<J$\@H(+,PTM_1@PXX\FJJ WP0<''BNBU
M>,R57DQ2I<=PRDFZ#OLM@2BQ79$T-IK9:IHZH-G)(7DI[$ 1ORP[>8;\<!P_
M.*\Q]F#8@Y:).]YA/ 96N0AQ,>ATP^KY5PV5Q3<U7I7FYJF%XH$I..MU'2!M
M;L'H-[ZCFV0N0QN37"%\)\+W6 (JH")=5:SJ89:@#9<U+&.,:;+KF)4<[7NN
M8_ZB!&_T"E$2=*?X0T7)$3MC-DSXS7\G_&Z?\%OZ3O@]N&/M@?W>]0W= VG0
M@MRW"O6#L39#_I?Q9,9V&5_R5&]1R5WTKX56IO1V+'V)L''7;'5KL2R7<'4H
M+*;SO<7\*3ON9*;B\[3XX]=UNW9=KE>YVL-UK=FI=;ARL\JUNA>U-M>N56KU
MN_)IHV:UGSE28W$?;;RRGNKB*LNW(:&J"C\5=1I.O\8W(UX4RK) &)=RK&57
M!O7NRMLX?MNA>XNI_M@:#:3+0I$_DF/!UAXS;6I2I$F2:0'52GP#74+-.%'3
MC0P/LU'6GGIC[5M6[*==5KFWJ#_H_<EK U7T89AV66L*IH/MB^58XC]<A.VF
M'+M&LYU@/ G;DJ&[:N$E .7^WX_T#W.WLJ4S&^I7LW$WNGMZRM=L<F"5*>LS
M([]F/?"2$/W ?,;;'RG*-LBN_$NV,[I\_[AZ&NV %)DH2$&:K^RFNUFD-,Y'
M34 [%%YDA-Q5H[BHV?5/.98'?.;VVE/0AR;VH4AET;*!=C:NC12F"'7U]",V
M6(V:8.Q*!FV[)OQUK=PJ+]J99F_Q(12ZTNBJUOI=^+&<IENU0\QG@]HALFF:
M[M?MFA_^U\^#\I^ ,5/N23&J+V]S[DO7\)W8L\5-P1Y3Z60 V*/_ZGQIX2\U
MOC"1?1$ULZ5-B9P- M3<D,:^Q_3,[3"AE\.@,WIV=XF4W*GPW$UO<$;#=XH,
M4!4M][UMGXUEEW'M.N.$XCKO7H0_U[G4QN>Z$.Y<^RK,L+3ZT_;(5RSD-@;:
M327#R84-]FBW[8@WM7M\'E^VS2MME[ #'M!D?$5W(=#"<CKZ3%G>K?>FTZ30
MF^@VB:Y\"*710DT_5C:QNK:1Z.F3G,<7Y?*;1.+Y@[DM]_XY.ID&GR VX75%
M%7F,$Y09?E4H<V7-43:P8GP99 T%D]T8);RTF8(AJ]]<Q?R).^>O=G(;JYU<
M=G<[MU[WX+/>8I)JU5![5/IX'1])G.(S<J%S!2^R!3125-3YRL"3X^:P[+'>
MXE[63\_+_=S-Z]$TI&.QUAS)O$RE_O%$7,N]Q>5H6BL5I:?N_/G'KWKSKM;L
MMMJ/WT'5"/BVY.;;SF",A)F$6D.3%9EL[()$"0J>VGDX[!"]11)]%$=/RFPP
M*1X)/YLKCK$XJ.8)A)+B*6R4R;KV'1/=(B9:Z2VR^7X2Z_/L\((/$Q/UBH[O
ML&>$L;Z"+>RI9DMRN?KT^V.<^W/B*Q8ILK:P)W^K-(1G\;7<VD4$^%/"GM^A
MS>_0YF$=O0,^5]^AS4#'VZG?S:?-OU^QB@&-ADWJS<6D)?86<B[],+QO/EX.
M7CXGKHFG9E8S''Y0TY>BX7U3^8V#'YE2ZH\):H8GLJ\;*;]%F\"((\>^)S3C
M=T+/1%G4\!WO'/I-.(_HXXN6;'V(B]$H^QEA36-FM!7&T<;+_'=BC:.]L=LY
M%2\FOR.;.]DI?_FPL9LY'<^ET]_QS>_X9C99]!/B3>0(9!H"_%GJGK6'N4=T
MGCFR**:Y\C\@2&G?Y3740F%S89,*:?-]QR/#;Y*_1M@XUS =+V0VTP@["#VF
M>XM\:Y;^S9?DZMO1(/8$PT+L.@)9\,!"$EC#L2)AOM5JKS-1GS<5':T.1]JU
M1>@Q>HMRJB$/)E)N>E4ZGMTDL<F\3QWH66]1O]8OS]Z'4^DJ^^-7I]NJ7%ZT
M&M5:NV-@XM5N;NO=/S),>21+^U?\55$F$T6.D7-PM"A41[R%7=+'&_:0H\"1
M6-(.L3"CJ)80EV72C2(<$\AS"L^. /M%5G36D7'*@PTL3@%&"U+?WA2=P!Z/
MD(Q4@E^. .]&<W6YCAM]#V.>L4V PCA KF.]+?$J$M@#SA>*1OL"UI7&AJ".
MI?!4FFGV/@K#&: >.N?!AHA!/Q]2FRN)KP 30U%C\, 6?+K*O8L$/1/3R#7*
M-P++%UL:ZQJM:BA&V1]?IT3]>!$#CW@K6W+L#/75&:_.N:*!,F4_X11="3 B
MC5XFG&W/X2237FQV8<CK\&,0 O!U"G#G\4O)SRF*+T#/P5AS_#[ A:)?QLB7
M3@17&XR3[04$W8J !H,\ :0J.IL$+P")*,:PJ%D=6C!17Y .2/6LTX.YYA)=
M,_<3?L9@^N"#&&-PCNAHK@/#FZA]1\D)1\SD99TB5IO@:SK^O:&$R/;[[';<
M8E'*F%Q 6V(&7$<RURV0:"?'OD.'8FPD@,\+NH?,,"UXG8$2B_BZSD&_Z8"1
MZ*$AS1'M0XKZ&/^*="5A/;R90L<ZGB&*3Y%*GS[A['<N8IW@D=F)PP^IRFP$
MS=3[JO*"#8\1,GLTC7EB:(BJ007GW,T31TR0(6!>+J4J/=WV;V.V;SG>E#:2
M1-=I3'DFB^"?D.:LI2;%@N,E0+<CL.S6C\V=P<N'V#L_LF%@B[XP<3%$KJ%Q
MZ(>.IKH! 8K9$AE]6):MBK4$I=AVO'TNG/).8?BX(7.+&%CF)UP93]O]*?2^
M=@Y AR:M0@&C>^DT &F=>$X)P+JQ"AGQ9.GO@%)O X<WY.VUJA!<13(+NJ$$
M&2]&N';""V;W=O>S04?"P:C U20)CAC')J0YU@'T0&@VN],]$-V6& 6_C^/U
MJ="ET5XFP@Z5""_0T&"FDDY?CHZJI)<)0!4.:+LA_QFPSO'0Q$P9GG MFY(
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MFC8P#$BI(8G<0!3>E%N0AN=1B79>(H,0F;X#/;<8U&J/M;)4SU6S_KYCDG#
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M&3:3-WTIYSKAVUW[<]EX+AL<0;1,73_O4':IJ1NZ\8(%C$/[+:22K-_"#I7
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M&JG^3C,B5#Y_)KI\_I7T^/$K%W5;@\-C+0_@XVY9RR/:K^[[@^NW2OJAG-O
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M6IO2>HV+2-C$?H\!E@\RP+:',[08K[8!XSUB0Z[[KGCXK=M"^8M3Z>%2*FS
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MIG#()$W_.:?T@ ^>.R:0\3<]*G@H<.#=8UO+,#^H"Q*_M:QI4&@H=/F/WIB
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M/3?Z>4.K$UGII;!\;?A9^S&+W6S1"0 3Z8_([C15LJ5H[]R)Q1.C%J_:02,
M0=B/X(U,@'_Y.QK>B__$H2'UDMHJ42]?KD928>F2Z+-5&$+5!".+"S%RLM%7
MO=>J-;X^/-;4C3-R3E&BP@JE\F:Q,4JI"QU2G&2!9M$AB=]+^WF/CP:?M,^G
M8-GH;4WI9US4U6 (%WC1_"<;X99N!!V0S(-B@6 Q2!C/0-VQJ9'>L/ZV5]JD
M>C8N*7&.*&;' F3I:OJ8=:G0KK?* +\,/X)LT&;M+=5/TX$CI44ZU.JT=I4
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M4 *32M.M'MHLPOD)%FC4VJQWPZ-!6 W,<X:4.V+N &RV ]#.D8\%9M;N*]K
M J8.%*Q%!N(!QQ.;9FY-M-@(YM5AKRM?(8].Z !-; AED\/3W5 OZD62A2KF
M)*E LE#QI^+=R_?1BVQ;QT<G+YJ7/WKFH9E'C45&HXE@\\YO<^F)S+\&.T<Z
MD K>3\60:1.[=@$\" 82SJ,X43UG:@,. (X^_/YZ2B;NR=0 NBG^B 5:B(OV
MNU,87F*I8\LBG?, GQ$0E2?%[+#:J]E@@P("(V^U=R$HH0A"_!:D:8+;0&\<
M6#+1P/(1!@R-V-$Z@F[8#*!HPS;'QEYHPKUA=##?$E0!VA8D\[*C N\ D(B"
M,-5[()Z0,175,H&7XRA P&P*6"/"+BWKKI!"AT:KSP" ="5T(>H0%@9/LSVU
MKUK6!*=]9F8F,-E]*38B[(\\?1=X$^E5X0SQ4P\2R=<44EC1RWAEWP%^#14;
M(-ZB!4_)NL(R>L].0.;I0I")8"GE9#%/P!)_*MR]/-V\W)1Z%]KW9[_<!0XE
MM/VQ-@B9TD%./A#SWD^%$&0NW:Q(S!9RN:Q4F-Y;*T,SC$D'2\NV(AL,%N8R
MO$H7;0;'G[]>&G^^/78+P^XF.!XD:"F6K]!:,"_/[A&%]B0SK."T;0M#T^AJ
MML6,J.A.7-+<)0"C9!;_"X5_MX6? Z?Q3YG/?])99@7N>[0LQ?JEO;W%\BQ1
MQ]@34]4&+<>TJ+6(!E[ 'F_#8F"=?IHO3^^4+,\J]9J]4L.U ] %P-YGO7FB
M\*X-"*L0ZY; F^!@,V-LO@I6JF-A:6@,A9ENB=(^E %<)JUWB#F-3+!(/U!*
MK$V,3$,G<!H\T!"DQ?*X1"N MC3(W99INXI2(:0(8UUZU.>V2AN9RK)'_1"^
M1?0,(RYS'= *+;6O@4;QN27 JK'C2G  9F(S%B(C/);!N058;EG 1DWO]M%@
MI@K!'=+R+&M68YOLG"'V-\J8BH9=B:@[,Z3.#H5JNVV8>-3OC\CR5H>FUA=$
M.6AHN#.QG-9 LXFUK@L*K*K6IM+A%@>&H;#A FO&2EZ%6$,-D<R$)M4UVK7H
MFZ.K@D1[^4K<.MVQJ8%U^LT!R707<%QF7(=!&^7W8& 0X;!4]8&<0 U TC8:
MFD&LH3(S!6J"$H1[445[B%Q+.W;/,,&PR_J&&9,^!;>YT2850F!;=4W%">V?
MX*@^<M$R)>19M0-/D_.J L:<U:,C(9-^&^:#T%>>#H6ZSKI[.7W%S :/]H("
M%J5)NYA@BP/&!O+V"40"?-018@:X\[N YBHL$_"(!@EBXR&?5]-G =0:_4>
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M+;3_[S7YJ_';>KH^DS84FL$(I*Z13H"RW=SY\_B]) +$=1_.18#<LD';ZT:
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M\^JEZ&T;GY7D+M!?GF! 3G"59[9'66!AMKB?D#EW8[P)[;"%_+*88XRE6:7
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M^%T+>*O8CJF2I'(+_V:J@.4I07ZIR*%_GZCBT)\@]/-LPR6A/P^(3Z"_)$=
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MY17\MW'=S-+0(%6!/3I43<O0A:>>805[^2C#H:J8>&78-YXP0 C(M!V;Q?7
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M5+.\GUI+'O#_@O9[[_?84VH%*R^P9G5$J'YOS,</;R1>3\'?&%-J6Y>,^#H
MGA]1..^!!;;[#=1SXWFGJ0[L_@0C7*%"H17.=*940CN>#8H)-3:8(E8KLWKF
MQ>899^>E3,^.X,SX=&VZ:S_07\K;-W,%-^U&S^[K%*#D>QZR6U?]T""W7$EX
M"5]N;*_W&:+^HF.?(UJ&<;P1;9WF*. H![0_4>9HBMM2SK@[U?ADR+#X /!E
MG-)Q6I_-])S% %>\)1\ Y+6_:VI\&K++=]O90T5#)J,\[-?'9E]CURA36A2^
M4BK?;94W>]K^-C7%^J)+1F7J??*%M6,Y54V"1%HLLSUE8,V79Y=GY5>M\B7+
MKA<!?LDC(W!U6FJ#H < W!_F?ZOLNB7I7*N4<<%N6WS)/F?\&*9<E'CW):9G
M_WU<4<E[_&^.X/3FV4>C_G!3P-? -IT(?3XZESP'_(2!B#]R3=+S-TQ>L^5(
M[79[/*:WLZ8+:(JP[$S= ^JOX+0FRKILS_P(,>K; J^)^=J_:"'4']FJT8"/
M]-;8R0G,<!WERF-+T^7=[7M\-:U2T9$E T/^&YNM<L]S<$M+%^="U*WODEO!
MJ[%BH]KX3VI['?O$[AR1TD$M[L*T-O5?#0V(CA%_!^V+RC%/-!"'2WO-?!FE
M\L^0ZCE&,6>_;T6*5R2\XH6(8Y,R<RL6/!5.%MC &>^O)-==IZ,;@-QU$XR(
M!X -E%3)NA&UDE>,^;;N7:ZA)HL0A_"@1;JCR6?@!Q!%.[H51=&XB&L^1,^"
M5&N_WBS)C\W^@<"/1S,]J9?T+(;*=+$"?"'!-E51%4LH5:=HQ,*C=L7P6BE5
M)?PRZM/$^^O*/'ET0U"K8Z^\EXV@R,<? /"TXQFQS]WD@ => <4^R?!C<!!:
MI%.&!%QM?2R7IIPE1F?@Q9IEPC5,5FRP2,S?HX[W .!U>EX7WQ'F.W-62@?$
M _D(, ]_JLR[Z>K:*E5$*?9Y$RRO\S.0?G@V\1N$-<@<4#J"QD'R]YP^ &A$
M@OC:^XO"SWZ/%-^V@3GI<]?'?& AJT93ZPE<:YE/HR _N^#/Y]JI]/?$TR\I
M9,L=-UG6O<W;)KI7:T5")=6%A%WWX@U4^9D5<MN-JN[=)SWS[LE'%.U,>**U
M?LK2&8!#HWW'>3BRY'S%L[!N[>[B(*KKJ@RM^FN__R*$7G0E7'3CW.SXSBRT
MPM=7VIO#=(@;DU[K*9@S*!WX[I_!;@S2.F%]^2DNHVX^L[U/4G]*R<5JS"&A
M3!U6QB)(DDMF$,:*A%$SPD*.=SZ2L)?NG<MHQZ&N1X)@$I6>8JKM?*XGI=WM
MP NRQYNQP^V!=[&MK]Q7(\%>;$1FTY_9;INN8E6N]M<+"Z\C0!F;#C8E"U4Q
M6^/N"^A?^^D7\&:H^3%>9?3ZH9Z>!R_H8%%69KE\\[?V5MO/LZ9]#2:NVO7I
M_&/:B!?9V/]7%-LWEXNK)_<MCP:(/C,>]4'"W2J)-SZ_AHC,_]%@R.N7%]5O
M$6#WL7V3#7%%];=(O$M5H"7];OF4<7<;'?(3V^G&0"EK10>&R5T1^K1!T *(
M5F1R79IO3T3RJBHF>5$Q)$%'Q,3P&MP2;<2+I\Z-5WOON''">D97#R+Z6S E
M7,B%P9##5D3,;A;YER-JWEN.>8VCW&:PX0]^"TI#(]Y!Z>B)OQ\9[1PYA<=3
MCI&/&YSC@R-EE@_U$\'7T>,DJ95!W_ K7#.?H[E0NV%2^=4#SP=^X!/>7Q8X
M^_%C>AX !".*?^VJ][ > #'+'KB5Q69_M4YZMS.YA<[C=V:6-"6SA$XZD':Z
M ,.C0Y._5_#'B1N*$77*MQ4B"EDDTN_1AQQEZLYHB5YB+N[ZUT4O]:^ P1XO
MX:KCBC\EQQKLG9N.*4T,WQ((#%"8M,!J*ELM<C^YNOH\DG7YV@E#ZZ!&>B_C
M>/86=BU>+?6S^&G:/UE+2;W+(=ZCN]3AB:)=<H;-T]M3MW,9;:=(4,F$9,0J
MMV-6UU7?]O'UYGAVW2</[\O4MO^T_Z9OH.Z:A7S'22.<A2KJ:990!%[89<QN
M7Q8=1QQ]H5.=SNT+#3E\YGE=\PP"FQHA9<IE?^DKWQ:_10&Q0(>&4RI,2\I\
ME;W)[K>7LT,[];[HV-FWH'+^^>217NGNO?A<4"(%;EOF"G9O*3=QA>[6WE#4
M!.]L'L;"M['X>I43-2U?3JJR,)>UY'4'[R)C,.;*TD6+_^GWNTSE4($=M+*N
MM4ET?SL9*/&,\/VV'5U)1PJ<KG.S23Y<$./=;-9]^AQ?)N-3+6KY=$FH>YDW
M%O5\[=Y]0M+8[J9R7KSDLYV.W;[?7RB?P^^ [7&&\<5*^EA[^^5.IEP8P^'O
M<T^]KZ#B9@KG]ON+96N=RT@77 -U'\69 O*T\Y^A[^,1+TOY:SU*E;^,\@IT
M+BFQ>*W]]"#'!L*RB)2M$;2"(DE/$\KODYH+[J.=W6(="C7!K[Y<A:G$#A=5
M5\VRF;G:ZKR' !.<%RKV\P0#M>9H7V;)1O0JLB4,BHN%V> 5&BY+OQBJGF$T
M[G ;_4IJ25NGS+SB::K1&/<W(JK2_G;^6E*8\Q V2,G/[1%,?YFCE9Z16VD(
MU^ ^^4;IZZ'#S[BXN/ )9S89K^BTKL>7>G+<&G@VY%GY[099Y.^F%+"T7# :
M?X$O5NFJ?5<A9"R];#[M0!(,#5<0-'X]4D7S35?4WKI17(9Z:G^R(<SQM)$&
MO\59JR.4WQ*X2Z=2LMO<[CX'!?NZ['.![5ET)@=_LS16F&X,1)PKON#O=MQA
M>81P$Q"OQBRWVR0;AA5W^1WK[%_51C,.OW*$)SN/4"[I*A2@J;JDF<-J5@T'
M1[H>;;4+B\,C("I_/>P]?&+?Z0+F+R)1G /,+,^1TU84#1*5A&..U>52_,@/
MHAT-KT$=H>\NEU4OHE%^"20I<>7PO4BCS+(; U69'\T.@5F:@L'EAW07@FB%
MG#HXW_RRYGL)O5S;!T"5]$\2[N;*RIGO8H##"K.[Q-#8UJL?IF*][G\E1;3O
MLB'RSJQ#U._M3D66$P03?/>@I!!?3+3Y(9M@>V/0YN(8PX)B@:]4X?V$Z>-6
M7LK6*D7!(@_?N>E%(PRP9RJHNKJ.=<KB$4+J2P_!^I!*_ >74?NLVHI/J ?
MXZ7=#EJK&" 5A$NX9IDLZWTX-LWEF&''7;)9<% [&1HO+[LFAC<CLA<J?B&Q
M&B%,WE<]/^H [-:+^"?KJ[A5@5GVO <3PR84DW<\VS:<(FZQI3E#Z@8Z+=)?
M$+<V2&A@%L69$]ZM00"O7#>L\48J-LP!@?7I3"<F%+2C;NE'A^GG^=QO+*RK
MS\N!CY5T<UG9L@'O>0*-A1*>.Y$.L:3]81$Q^#BP8EMD\M'_<#<"K?EGI%\'
M8H_1=UUK\_'VW.YZ.5^3W['_Q&X?XV]447LP/MN<AVAG\YMH9\0T64/D<LH-
M;,*KP@L:Z$_;PG9-^E!E/9Q=]T0S;@-1BN[49I9:MXKSK?@]TI*SM\2NU,YY
M4K4:DDA%7E,Y3Y$!8>E7-?H.UG)\'O3A5Z%U%JQ%/]G<,=2UG5>BU$=S="\-
MN+#&>%_]W[*IM7L15]2JW@/@*U3\F"<0\T_=L?V/IA8F/+4;DD9)QBU)MDY]
MDO\T,'#O1>B=BB^N4ILG_,V7K_'I'2MBU]-O>.<R!GXZ"1I:Q->B==;;N+F\
MM>W:ON\*K89=7M3#\8JP30TR&<(8S(X-4#(AK7*4:3S^A<H(Z]6DK/[6JR1T
M[ _FW%R*6(D7WRAF%BH%DTPVAU\GU,6JMOY"N-4^1O7Y.L6FV )((\9CCN:1
M%R C1=$'@/[3 UGO+3<H[=["DU\A!TM%MZ>)R94QJP/>S.WR[77F]8D/@ G+
M#5!U^7;!: 8-Z1>'/X,+GC^,#?*K-'XHR&44EKQ\/[QS3)T8%H.=/:9?CQJ=
MW[MD?%R<^N;*T"[&OF"\Q*=(!2_O$<S'=WJ2I$1H)BE X.LRK5554\,LI;)C
M-DR$0:E U(HYV48S4.-;(TPUJZ9XKUBYO"'K+0P;L9"NX/XHD=7L.\B_&/(.
MI1=JKI2FI>P!_.GQ&=A?'\-<>QXQ.5XH$"3-R["0(===OV*)ZI-:RCYYTZ\Y
M73F$+,G]:3"@%(V#<FG";KUVBO*CBV!7!7+L:8NJ6JZL1ELL0[31P?-T\JBM
M61EOPT*"[WJ:L_8=86M>&=1W/7/YLQ#98?3 YB+M R E I_F*<PZ[T+V9$]
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MEQ?2K5,C-V%;TA\RQ^[V#BJ=^?[D=2=TOF9.WEX1JF.T;DSE%I9W4W@]*5,
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M_;ZC+)]7)NS6GG?:A$0XAIKLLP\BRNXZZ'1I>7&)]=/>O(BT\>SKJL7&\P?
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M34SXU-;/K7VJ=$C8^AU52]K))Z&+'PR"DLLCL1R<UGV,.7M>#T4F17WQTD.
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M2W.K2MXG4U.KJ[90=[$$;V4G[/"8I[ZXBC27Q6)#YB7\Q<X$<V_K_%:>&)9
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M)?DX=+LMTQ&QGF6=9C\G4MYDDX6W6N0JG33\:.HZ@XO-28J0K >^*_5U-C7
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MF5YUQ=KHRL#D@PE&8+5&*I1[! FGLF<</1P-WQ+NP5@W=Y#="F'<4>5>"\
MH&'KTZ-D#\M[T-X\+>U:B&L*2S.O\,+X#/XPT4HI&&2<. CQ07M<U& 0ZU)O
M?26Z5G#%:=. RYE/U,>BO".N#/O_9:#MXK>:&?T-ODB>'YNBK][&1)YUPN<7
MM_4KY4KE!3)+APD'VM@S:CT$ME;Z_ZB@G@P:D0WGS&X)!^?Z.?OUK=9 8T#0
M&#]:M$)-P=*?77&KR2;8UFUZO1@.["ZU%OWNN$2-7+)&F6LQOLMDZ5N?5T/H
M+9.[ST\^OMR \6<FRK./@@%'FBI7&Q=Q=_7_5##9HJDGY[I:QP)CTL;!)>S(
M(\PPA_ !,%^J@DR*W\NJBSU,Q._QL4%!@[9BWZ.31WT<^5B>%20P'_@TU$'D
MUP_)3-$BX6930OX<=<@VN\NK&(^3@=2X"^RF#BQ/)R,T/'Q&"74KB GL8XSZ
MF:+[I)[Y1$E3EF>GZ=9C??7WXKM&U'; 5AT:VB_UP<N[L-K0MSY3\R-^-N ;
MS9\G_$%(U_;MVOT.<HC@#3GD>2W*+Y%-O*.7>/!VR$R7I-_Z9GR[.L!S#.),
MCV@U1?YQ)QZRFK\U+1LG=!O!Q<_%^J-;5<LK8H@NBA2^:F!^CC:!/]?G2./;
M3!PT?<=4=N9Z87*7XM!._FX!$2:9=DQKU)N-_G$X,P5=."_BR(7/LC35[KC+
MU(AT+D(#_8@UA4'2SV8!L MSL:'#LPNX'?!U<=4II8 K8G57N\C@].^Q1$WS
MZ_>Z<IV=!;D1>/]U#G5:L&M7(_<[SYC=TSQ<5Z/QJO4?E9'^]&PW>I]FYP$Q
MMCA=$)VUC[:KEQ;P L_CB'OFV#2*QYG)%PI%>7W?6B-.'P 4GN)BS+)EF5(O
M<-:=J#Q)\^+'N_J\VAO6]1K,OUTC%E:X4<\<'@ M8M=Z\9ZIG47;Q P;8LCO
MTKKM,\*A+UN)MD&DM Q#W22()L_4+FTN:-S]Q^V%K%"3E;=$F2]P^OZ)9D)H
M!86"I>)>]">81A'<DW)'/7=IR!%KI'=4!?'+]+?-LT#8MCO9XX*A9T4;"MG?
M5A]WV/,8*R.K$6NT,ZC<;SLKA6W[:O/_K8LKCX;"[?Z#4"3KV)DL2994B(J9
M[%'9F>RIAI@RR=*DR5BR+_-%VTO(3I8)21C&.A+9LF1K9DP28Y@IRS"+UWM^
MO]\YO_/^\;G/'\^Y]X_/.?<^]W/.?>Y:DZST$X72UMA$6]])^CJ6K-C(I?)$
M*5-6')E^!+ Z\Q$26TXT>=FY5%LV/ 4L]<DZ9@3>S5P[LUB3DOBCZ4!X',,'
MF0KVZ;R,ZI*W+XF!/.D^BX4E[L*:O2J7_Q:%Y)B;N7C^]1YVJB\>YW2+0OV6
M_3Q6TIZ/.W NGOR#Q=QY\SZ]G$_0FT+U\UMQX*:5?%80V;8<!C_?D0\H7[OS
M9.(>L_1U@[A:3OKF0]XI@39*.Y_9I8VMO+N'5_-BRP)\QNK5V'G5JMN_6U1Q
MR]Z<XDU1@ZXR+Y]5J.!Z+>Y.D6$,5XM9N$@0+6&B@AX8*=\9:,.LN!:%%+>L
M.G]649F]0K%G??5?Q8NQ(>1V LLUP0'FDN.M--)%E/AAL8T'(K%K[\\.6BT_
MVR,%-.A-DP5CO#LJJM#!\R>/ ^ZH3^6J6_QZHM#ZBG8DT.2K-*:8&/S(E,?_
MCSRLH(+A0CC.>3EE*C'9-C !/0&AF95XHDN8+MV@>UG&'G*1TV??H?R9]11H
M1-R536$-4JE%;M]72YT9ZCF4=%ON>1P#G^XNV]K01)"AR]4HC$BQQ9GA1^-(
MU.F43DN?7? DI1$%GMABQ8);ZA9\<W9>S),*AS\8[ .2HL YFDXP.;5_-KY:
M5.:.!NM5S?MQI[)U;ND=81KJ)ID9=@(PW2T^5Q<K>@ME<[87H*SSDCNW8V[S
MUCQV=]?=<>29$;BN$["X=U.G]L<R)[^I4'\]N#AK2.G8TD^)52.7A?KU]5!/
M,3/$S1DKLS4'N]6U#@5DGD>67=<V<J2R[ILU)W<=X:/@^/J3"<WSY4:;MGW2
MOV:H1R3IK)&;^=658QN(.GJ]IUWGIC$VC#Z]ME,^T[#8"YY_.+G2"NFY=-7X
M61!<_JF5M'D+21Z4$)%'KZVG''H$)/[&BR"./LY* =*DE:7B9MS<CJ;FFZ?&
M$\"Z=&R/KJJ/3>_L4GG:K7<WRGH2ADT%/0V$2X95F8%JM$ ;P5+_BP/>R[WY
M@=UXOO +$1A9ZL<]G_<N#00)D=X*UEOH".2#(!NH.FS8.A8MM;+XB]PH.W4:
M*E3"&A-B:O<JZS'T^D3%T]JC_CHQK+%A&M)C82:9O9N62OSAUKGSW=?V0!0$
MK621F!8$3BK29R*ZXG_^J1U6OK,V#K(C<X^BU*>X.L$;<'+7L?PRKWW YZN]
M1H%?FIK,!L_<GJ 83OU&-W9@Z-^N-C! _1D!I@)]WX;JZ2%O2,2%.+"3)B@\
MZE<+/M5/80N??CZ2"_H6SD+SH(R_=5R]+FRO[#<KA99:NZ#.FC:W#3][OW$4
M9<$8N<+T@J%)?K&C]>?T<FJ9Z^0PT[_AD,!]0&!M*%XX6I8*AC D[G9(-^8X
M3X;D&>G;"6LM;UQJKCUX4AKQ:^V+B RC2'C9S,<L<B7Q?M]F=9/YL:(POTJ0
M0(<8$DJ:3LJQI??EUJ3C.SJ>1_]QF<]QNJ"Y9MR35S3$'48W["1%"ZPX.:B>
M+EKTD#22^:O4I<"J7O&=.9J7>63@4!;-'(<<MJ=,FS)LY#[7V=H.S*\X+HTV
MY&M94MUHJ]T1E5;93E92G9K%J8#_X%I 1O'+5$"F/9+F=OH#XZSZ;8VZAE\9
M!<]Y"/ ":8\2Q',)^"#.A@35,!>+=MOXTPVJA?G]3HFL,5Z>C0&?9SC$RLIH
M@,$O?OJ>I-LK91)&QCMHTVP1Q;G$(5:LK\UB89(_N_N](0!E6L>$?@G[0P$2
M@N7AG6Q>D:>P@TN]OR!UT6Y<LQ>=CS"$RMIU%(SWGME-2!-]'36E7$+>^B2X
MY-)6V1>U7DU*B;_@VM_D/T(6;E(35W1MBR7G8A-XSQ/UCBO&16$('U$RC,#>
M?8!(72A"/_@B$F):VK^."=Y,PPLL##W0E6MG>)<WTU=IV3;2SMGH9#U#ITA)
MJ&E;)QJ$.DLA']5^8)!O]26>OZM3M]"3%=:[ATFM_8 1[2/#C1&Y<"N12ZB!
M-Y&J>%D<G%Q=>[&O3J2]]UQ)J*K*48BX3V&/WES/XG0739(E8S7]8W' &HAX
M]=BA/,JMZL8KA<)W$B@59ORB,9LHADPQ>.(NAYRU2N=9"_-&I-1R#Z%."*!E
MF7_FW-X\987G#=WC G?]*86S+HL5?6D[.>X,WRKD-PG^II(&["B/E[(8Y[4)
ME*(KWN1SQ8'/]DMMEX8U>[6]Y.0_+'@?D>X">@8172SH[U06>NINN0^ /GIX
M_C1\>4,9W>4"UF9^E/DXIOJ>/B]"N)^CBZG"2DVA R ROW]Y>SZF3B@J3A=2
ME049&ACM$S_^]4!642)K>5>H("#H]I,#5N5-(BCP'=PDVZ/*V[Y?_4AJY1X
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MO66BEU%BM-$',QSO=[[OG//'>UW?.;_KMYY]_[7W\US[WL^]UEYK[ZO?5TL
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M)^7<;)7_ZX16X3]M,8L,..E]4%>*2PC;Y/*DZVL #G;1UW_)8ED^#ZG*7%Z
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M)_T*CC+&/<!_4?#&0+N[+,; XE)_WA58-0B GRN&P4?SEZO<,0=>+MG5:[K
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MHY199(8FU=N\?W^ ^*WA4@J85>%2:C%BA:."4]GN$6PZH_1G;B6LJ+=6TY^
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M;0DZ>=$K/-*DSGDC\^^VL_;/=-*?TFZ4D> $$G#OO'^%EF0^7K;-6/A@CA?
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M6U2BL"\"68D\*95ZV,J*K@QKEL/2^YWSR3[XYS<%, LHEC_N]5%#!VPM5_Y
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M0++=8:D ^[F,[[^;#,8.=/#DXU6DF89C8HL6*%X 3)Y#3\>!1\&:+MA<PNG
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M6M!YOQ8'YIW'ED=9_YV7EJ >&S%XZ@ZZ<B$5""C;?$Y-,)W2I-3[(J9%3O>
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M&1X$V/)?$P"]CB;ZB4,0>71_3L88#HQGJE<@9RV_K[BX3-9JG29/;%<#O[V
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MM2^^5:QW$!#.C!8;='U'*YL^I9C[I(E"6ALB,>&4H#\F0BP5V^^)T^WM5\+
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MS((A3R@4DO*K.YZR".D=4EJYC^%1L0HOLQW]B_:?9/]W8*'_7V3_ _:_7#,
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M+IX(580OL(1[:S^B5N5X3:'8C54>,U[M28IE5^[8!,.<!4 :[Z$_!-8)P/Y
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M< B,D,E(5"M.X*&?,?,)=? @?ESV5<@3U)?4R4D64J?6D4&9<ZLQ>[E(;4:
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M'-2+7_J0&*N"9WDQ B3@FU7W"0 W._AX(WL@IZ1,;EQ$PUT.D@D$0\#'!03
M6[_#Z'CD.G'"P_]-C26&8;91%"V.^*9L/PA"EV,7I%_X&,E2M*OB\K$&7DY(
M=RK' Q;S^/+M3FJV;Q1&7M_5@D$HR6N35SFCY.^W=_A.'K90L]AJVV3$K2)"
M9</0-9;9/7[F-N_H-6C?JWEF^SMDN11C=DIX.8 8,Q[/'YKQ]5<RV/8HALJ,
MON)B2+6FH8XSZ0OM<@+*Y%QBTSJA(&)G1(V?B0\G /G3P<1>7H38FD[%$C>/
M2<[#7B@0VB&$&Y[-W@T47U4YU_$;P?D;<@J:C3T:_N_'1_\3/G4/.A J"6M@
MP0=70'9B( T&?P##T\$LN_D>"/ARU_[*,[[@;QE2=?8DKBL7,=&6KL1Y>1PY
M YO0$)I?3"F<;-4NPKAU;\L7PK\A::[ S9>"M)!F>-[I]>/XK'S1^+@;\F2R
M9\&!>^^^0IUW##0/E>+$J!&(0J@OV-;*8*&WO+ZQ6:D\I6_ZTP=4*U5(,G*&
M16M\RBSAPW*=8("#8*_/%4S(A]D%P=0)_L8;5&[@V=+O=#]4+(-=S!O?C.!F
M:!7[-Q?6AW'CM(I?=BO5WPO69#NNG[0[L5BJL3(W<,88)_:O=61RRN3A?98^
M-2GT&70F>_FE%GE,&A+WT/+W!"!4'^8FCCVQA,TQ%?X,E\9/>M+ [_8$X,]Q
MQO^ @%IU3OL_BSO,.\3;4MW]@'AV#-;!<6B-WY Y]#*>_FA(&Q3. C$7H_B/
M28CF>O\4--+XKY6,, M)J&#7&L_-_9Y4TY']E#33=Z2S=VB&?_3%>1DG(,<$
M"$"8P=:2\-NO@@ZP.7Z]'9U#T(9L0/0?*^KY61JMA)<7!*%O<8Z@>$PR > P
MANT/$0 A@7^Z 2WO(-Q5G/;<2:&=)=/KN]%1+Y(DF5377#9A)%%0BK4N+3:3
M$R$W/WX1CXEV4]P;$193%$NXZ+UPLW*$ZU2N5\IJ.WFPPOS3Q7J4<2Q;38 '
M(I<W(X,\ARY5=]W:#]V'OQ%)K(,WL9L2G G'-PYWI]3('O/B=;GV!X1@"7[H
MZ_-\J6;2937YXN_Z@0 %&/@D+]NPHZZL$7>,0T#J72&KC=@WI-M,VB?VH_A'
MB9\3MU_K'GV'" $M:OKX;[4$(&OQ1_Z?N%"Q8<..7RQ_C<13.HRU: 8:B6^7
MJL@U6K5U;N@ZLYC5T-<F*H]0:"K/".6S\+LPG;KIN5R_W-R)]HNVZ&Z6ZMW/
MTPAXQ'F:1D.A-+T:$RL>6^FCQ*.@/JHAU'!+5GFAW)^RZ\":.F'986S.T(GN
M>M\ 1/[ Z:[3L.7^7.Z>X3OORZ6O6??Q>@CI+.5+&%]![/4'Z$B%B<GF9X\F
MG8J_72\V5W-QRS*\(F!T'5%ZJ=(^@EJBLCK&[Z _EP"DA;K$,L3$N\]T:QXH
M3EM?6; (-RZJ5]L=>?VG9]@W?WE=";F=!4]Q.V%Q? N=DL[>G?T5FAW=="4J
M8AQTZNSE!P3PB&HN E!@EW!9KM_01/J]==Z[[XKN2(PXVX"K^0CUH+BH2XLD
M9Y )4QY^*.3<1!VMYP!">/OX[B5C1SI>>.&#-X8;CP/CA2833+'>;>C)B#KA
MP5-KGIDZHGUGY[C5YA<51YS3..E;->:5E)#C#VIUSZ099\<]L?Q![O@&)LDT
M>)\KZ?U*GOAYSZ?=]@934DNSEX84[4JG'<\ZX25B9H7M#7Q)YV]J6#N[)$:F
M-K0K-* 5LT3&R$K.&=72W'CP*,/HT2G892^.\N4ZUHL1UD:Y_OPFPUBS,A?*
M#Y,,7V=R345YSZM[3+S%^*FA9Z-R-O6F_:OG#,8<?%U$U_&E"9(:[Z)VJ5\>
MD%L>% J&ZH"1UD+>.T_E5[O#BJ'^>2-]/>")[_0)DD-C[;PHF>C]?L[K-1'P
M$8355_G7)3RL$G%>AB4CYG*45S;%'[DR]1B/3/>D>>Z9T0E-9'HPN$C?B6UL
M'UZ]9#NHY-(GI?MX]OQ$JT'1YB%B'#>SGT<>C^UZJQL49IY%C_'*78,R<:&-
MVLO]1+^<7#Q1+$@9")8WU,E4L)805,CVF(I_QP5ROR X2"Q[IH).V;V'?Z85
M#D;N5_!^ETSXE\M6,*Q_!@._@7((W7M4[DD2X"[>!PC0/,["0$;:6&ZT-XSO
MQ;K$FGZ>ZF,5."<]'TP;%'RBJL496;M-:321H]W/L3##5=7?+5#W(KM=/0!>
M&'P?=?A%^?0P]71LM:N=LM_A!]FK)%D$@ JK*(98,B-/R?["9QI7'SC!";?0
MU CSK2XAO0=Z^/'\9/YGS,7PX,U^O+(EJS+G])<S33$J4YJ;$4:LNRT\N;I9
M>3$S62JB7/?T1?,HW:_)CP1'SN']-8Y,!.?%.;-9-;S=MA&=2 6[W4 E7X'/
M:^<E7@ZB2SZ6;R"+U17['7T7'J9<GF/C/J'MP*(2\4?Y6]($8+<+<K)2K)>4
M?JK7J]#':]"MA_-N W%!T!. N:M_B"< 06-??.-&YM$)JCOI9YMN_(V"FI7.
MPRTAF#Z <;/T95F:]XB(3? "' B1ZO$_MG*PK*N#4ELRW>7:Y7^ZR-/R[J6&
MT0D\_TEG'[UP6[P2[(/R!=1*/GG\PIO69_CO7$V\"?"1IGV4?9W?HFK9C&9)
M_F?9&DHR&H]>;[0_OTZSBT*FSK3EAAY/ZJOF[Q5ADP%]@ 6[U_:V]6,TX[NJ
MI5RTCT,1VMMSK2[RL'"L[.JFYCB3:YY>@J9>>L"[!BXPWV6EM_J/#XLEA<*]
MFKQ"39ZY=)4(&ODE[5:7"M5XE99R,TN_]R"SPX-NUDO#\::_W*[P99)CAT37
M=*6O*NJBV;MGJ1NK&B:D9%WYV](^1TI\XST>[TH.5#N#6_4**"M_<:_[S.'=
M7L'1>5D"H!'O-9,69DE7B>Z^.1KD=!<9JZT0B]-!TR1)\']_SU&\;NCM'HD7
MAYUS3F^O67":TVJ&3CM59>^;53Q1%4]449B:T;@Q6B[F5B$F,D)M]0$9 :IA
MZMG(9@OB=)G_A-4NOG$\7J9A$SFB]&55]E(1RN]]&V57E,GN_:;Q9'U[)[L6
MS[Y^7S;^Q[50.J=/=D5.OO6^;UN"&A=9E;&CUIT/U(LS,(F+BO+N47N9!CJH
M)P=YXI_M^6)?JN+WM18NF,#]9KF'<X>P,NXN>3,VTS.W2!PCA<=155NGV42<
M@=.UMB])V$,!TF_GLP2;AV)J]33GO>?"E=E&L*[BT877'U5^;+F7:J]L=J W
M9.+$D7B7CKC$/LSRK(KI7Z8.U@VL93GDN;C[MGYY!I%IN5NIMT]ADJA;&\H4
M@Q PC&.*)XW0<5'P!0+HT6MU4DS)+[*VC+FDC9=<+ZN;R"%,XG""D)KM=O?I
M2W0:.MFZ-ZO4=-K@MO0.E)Q-UQ/D&,,_SV@*4PERA!?GQ3]Z$K.J6^=XP.X8
M<U)Y%7G?C1J6#]_U.7)V%IP643V@MKERX(_&;YN.EG-;6?<^=M;-R$C:T3+X
MBGYKFFV6?#3<.%ALPQJM_*+ IG+B*6R<?^AGD3U6:/,OB^N7G-)8Z&O+L;I*
MJO5=?_M%2U2<S;G<2-K.EUF:2E508W]K5E$LY"YM&<4 0M;(KL'M#;#FG!T6
M[4[M=!(-2\X%%AI>KW M5O:%K:N<;SOL::.8.-I:&N/93:J7+_EDL.8"6K0B
M5F*/N3ZUDCTWO A3/_>F ,.4&V^[HQ>YX).^H,H;FA&N6HC9++:8]J>U3?;]
M>E\-I)CEO"AF=6?T>4O":J1_]K6&B3WVU^Q.W#7/C7#3239,4A_$2OQ07EU:
M%Z:SI]2RV3L'A(?4H^Y)8^,/@YW9*VF=_.A??A=M'V7G8&KJ#6Q\X%<#:S.)
MWKKK)3L:7AR=*/\H#PK>1&T>7V79^,2:Y&GPD!Q&U>R6*\+2KP+/$2&IE$>O
M=I?B;@8K8@*OWV7485,I'S.HQ#--S_F'#QJPM6XDO3&)RR!U\8OH,DJK,Y)S
M;TA:$^F@ALP^LM;>:N&(6OG0'<U0>?C$P?EX.R&YR'KNDX3FNP0[$[))RF*L
MS"3+!Q8_&?/7!.#^QP+UT!/CRL=X)@O'LQO@8(4-[8>>%Y.JA;+8R77-QE;X
M-TQ%%%;*#5X6'TS!XI79TEGONTI\E#9,1:RT@*F=I&?9ALOW,*OJFBP4ZF[F
M3Q6%B[YU;;H_>'8=-R9;-.,4:)1>EL;-K1-CGTRE6^=AZR&4=^#-*:+@(UOE
MOS:>6%UP='>JY-WDE7:Z/;(#&DFM57C<473<X@[5(!X^>I%+SM"S)25N3DRI
MS26B Y.)%!9G(P!=?*Y, [EE9+ND71*2^Q4"^J4R.Z47NYT1'&E\/7HW1EK?
M)%7RO8HD?XB8[.WG=0R,GXNZKTOOS%Q:)2JJ*00=::JD"8*@?5L6@@.A+):]
M[LAO\&.^\IJ@KX<54UW9U$'B\Z^=;(=KE^L3S)0]=7DGV@?B."KUS-H2A'94
MT28?Y@!$O/EV*Y-B N]EA#(OJQ*MST$'59#4@9*TD@[B@OW*)\/RF5&WX.XV
M;WU'XY8I[NA!J[&Y+6'=[PVX??W-NN^]I+?==%*93S]L4+[=/"VT948J-J]$
M4C*A>1@IECN(CEHWA+US!:.(U-JX, ?<! %H+\WR>BTRO,MPLDD @JEHAA./
M'+,/A\K^DDJDLX<]Z=AY^TR\EM@,#MX@LCSA2CE]LOZ3//\O*6_P[VLXN^8.
MQP'H;/:<[LF:7AND_:<< O"G((T#IN)#"_QQ#BWM.F[OIQ3VT3^$#.*[:O&;
ML#E#V%USF ]1%3#T_T0&Z7KB3U1)F7W<AC'HB^71)^SUB6J=)TZ_/'H;+'ZC
M.M%H=$FE\_%ZI_(>R?YCR$8R;O@FSF3S=J@M(RO\LVPQQ.AXB)(=S8]7)"K8
MS,4;ZOT-OD,1]8\GN3<IAN'.JT&DD(7D4;B[6#-MCRNQTR9Y#RH,F(/K'M%/
MX5LJ=RO:H6>=/HDDM6%YC!2"JJ=C%ML5FHO#S/K"6%-,DT?/;5XSL?$_WH,>
MJLDWQHLORCR6BH?HMS:,JS2,0C\U>A9'7G!NFX2[4TSYJP;=3 ]K&I6L\7;V
MU/&P>"OQB.I  9MM;K32"N\AEEE[B6 GA-IRQ6M8*;Q$L_1<# \I:'H,,=@;
MK-/](= XW@6IW5>J4#LG^B,Q5>PE1:VI'Y]]Y^?5@@90Q961/)4!O^1=SE9X
MJ'!_&9[;OXL P)L3XA2Y>>4-3[%1'T&I5MYB?+L7(-$)+4X+%K%6S!\";IKW
MN77(WBR,U/85'9CJQ4L.*X)S9YR/VQ;47*BV/8N]Y Y(&X/MNHWG:I6?%,Q9
M]OG=1]8FW8^P8PSP.)[H"%.F69]E0BTAK(L]Q&.L[?OZ0OP2VL+6K<;K'DLS
M5R$ZJ=3<SY!<5)&N',E$:B#I5T.X,1>*_6--A\6@)F,YL;<?B%:^O/9ND;U#
MZ+MHD%+!5ZO8%BME!/OSH ZY.^=.@4YF7%2XJ1O(XE;YRP7T\P'7<P/D=^5_
M9#VA*U#<7TE>V;L:-!OYCK6QL @[&YGX>F@(].:_&7KK D#JRCHVJV'RE;N!
M;%G=?@?E"22#&=F/$HBY1P;=2%[_F7I:=#>T,APNE/S;ME?C/>2'T%=8DT7"
M:=IWR^CW2N1W?SZ[NZUX\&,SA^K4WF$.F+T5(U<RMUD#U0XXF_9"4[K4>_#F
M$&:GX!6>L^ 2<G&*AQO4%IB<:#6^.G=^DH-ZL& 3NU[LX$W97T_<E!3N.G@Y
MD:?SM<WMB)T1P"UR[)ECA5#[J<^NOGF0?UNA),)F*MM\\VMB&FY8V_S$Z9#!
MY,HBJJW:HO>4+4\LZ56JRZ&!AODWO%E9:CARS@:[W.$0X)>B\PR^]K%/7E H
M1ER,46"#/=W]X&)JG_47C\. )>-R)M&&,1'["Y3O6ANIUYO#\NS*Q^;"RBUC
MG#8-W'+M)$\8\%G%V#4\,;V+2PB _&C>VX-SKW#1!$#7 .\-LX6-CA& 3*=A
M39K!+=WCP.S=_#\X-G5B@"^_N2!5D/4-V$#M6L[_=V0[;ZL*'?$Z5;8AXU=#
M;V7(#08V&)C"/IKWX5OX=W/ Q4C@6JCW^\*0TOV"*)Q^,+GP/K0<\.@X"UO\
M/(AOYEQ6X_P'"#CZ4^/5+D#P39/J'=[!PAF_?VI^S,'XZ Z)\)/SZ;L="2^5
M3_%R*.[A?1P64E^7.U]VZM;85=;JOJ57]6.UC;\'<MJ90Q357__:P>L\PWTS
MA)KH:#G@__K7CQQ697-D/N/I3+?U0:<X9;[K8D99YHL:)]OUQFU^O+@GDTK,
MWKP6S1 JE]%/ FF&#>R0\9"MW=NZX8B3;RW2)6[\ Y3?^P&/6I/[_)VZ9_A>
M7ME(73&(2Q2),6L_C0DS8U;2!]&?P"\(@.+R6J0Q?!5EFVP;SP+\-Y?3>3""
M%74],<<9"B8X,^JX(<IS:KYW@A@G"[2,K73(DT)V/F6,WL4(5N+B/OIHTBS-
MBZ>J 1Y[)E8RG5!Z\1>;):IM ZQVA=KBG1>\+6]4;;P+<#_L\/7/H9.(V9HD
M>N"&@&P+W)*=?]++3 #(ZU8E4L=R].D8!#-^*;J-LN@AG55WU9G^K+Q&OY#?
M2%0$)W-+?\$WJ!<#+#E6#$## S<4;Z87D(.A,^FZ&/W 502VJJ1[V:YB^@XE
M.]%4+,-DW/.2L7D29:1@QD@O2A=Z6:&]A.19\-"9&&!1H *.9TQ\>ON-5TGG
M01P*R"/*V^.^N?'LBA+,UQ&4D-<BB=+HX;EO.#9_);O==R&5,]P<V9PJ/39_
M(I_X8HMWB))%S5>8:"5X9=4@[!IN<&;A&981#=2+^;#>F,F'FP.+:Q4#NN'I
MV(?Y\)*I5U,[8)%%1EV4KG6D8ZJH/H@=5O;YEZ?9J(*Z47^#$WUPS>)%P715
ME+:5[S/E4M(\7-=%GE#9S^G=^&L3T/UOD$P?#RP#FGJJ-K&D:S2Q61IM8!YT
M?F)[=F+EM@Z+XS=M+F@@<+#V5S4_*AHYY?_!ZPDP.O?O=KCK__C?%!\(.#%1
MF!<_8O0F ,>K5FRXX;T<,@%V.<9/%TF5)7\D $K.YM<D!$ 9J/K"-\Y),TI[
M=]GD/E]B<=-O!O/Y;\(#F47;+BM'M&FIG&?I&63;R#H3+'BU7VJ?HJ61_N-&
M$SV_ITM=Q-D>DH&'I[<G"IYS\]\Y=7AN)2/&T"9CB%0^M&G@RFP3F-S:12:M
MN=0Y6;#6[#/B;=%HP_1A14]<'$?*V?<,"J25'O! X!D7 +XYWWX1DVV.&GN#
M<&W, M';^BZ5FL",5NH8ZBUH(,WJ:H"M/X-QTV2KC*M/("6"-:B'QFNOO%RE
MU=B@]:+$V[/YTU2IK,;TCXW4MMY>)A>!TU_9.Y<#%AH)\EE@3V1<9S:A+WLV
M??%5%[S!Z8+<MG7Y.V,R#MZA[^Y!3\7+TO?I)C0S;\7H/O M[\F0W@H%ELY'
M)&VJG#?I23RSV<Z9('<U5L^+5=W>\MY*!58234L 8A3%R0]*3H?O1\]PS#1B
MA=WO=-36VAZZTVBR<!<^S,'[\,6/MTSQI@XROKM,8LXCG9V;0\VB\/RT]957
MI,^;]GL#SD/.*!J 8Z_V*[N('HQ^-E8_?:@QT>8X<YVW\E32K1@)$\5Q)WW6
M)09%#XVZ=B=.$&<\ /U*IU0Z&'()\^&P.S RF_Q%+MN#G>L<6XF5SCOQ'\_Q
MZ5RFT[B87B)O;FU9?3-)<4VBW3;<,-@11(G,Z@A84"+_7FFJ$/V*J<OU(\?X
MF-7E^KJ43NHZ[7MCE^O:,YDOIPX[L"(-I6[=9X"'AH7)=LHQDBRDPAB";GN4
MF8NHW1LU1_4*U\K:O-K&2VUOQ(Z%U+T\^][RU+#HX^G:FP!9D@E/1XQ#$GU*
MEM@%HS"A8 %0+*9P88H 4)LC8 X?2STDY[EO3SU10T7T(N9BO?N^^;3<=?6@
MF6*@KF4Z-O%2BC/1J=9F]&S^D64;45_04*?]<(I1;/$Y +\*K*M_G8F43-A?
MEN:01S,BMK??1=^O34#;F<4%/1W4(P"3E:;WI^47<K4%%D6,Z&7./WM[6;<<
MN,5X1C@&D[^@0#1A#3VS_K[N_3,02UI'X&&O[[ZUBUKZ-2MC-3C5HNQ5DLX@
M(71[U:)"_*V-0*]U]%0*O7"1#,@Z=''):V@WQA1IVG>&T6'(]D7)^\Y.1I(E
M^>(XK(%XM'OM)H^^P)):S'4Z=;#E\629A3K^VBN=>USW8LA?N%Q"LU&(IKJV
MIE<EF@/ ^P+B 51X#I2N\>\>;K(*(T45.=JM?OW+L;6FLX->M PK91,^8'P$
M:16V"A$V)]DUTP%7F0,[CA5@/'-=&O9H.L1% ROJ(GZTVXB="%7X+!Q! )Z4
MWR< RGZ<Z<,_IZ /'_0=(I5#]R-FG@ @7<Q@@YGPE5I8UT0U <A62.QW!+7F
M-4(PYA/0W56/HW).%+'H6AU8W"5J$?A76NYU7\E>WMRVE/D]^"+(N)I8Z?_4
M!.9$F[RG]9RR1DN7(I_J?SBYTYQ@*L9\[29X8:&I+SL"QE96>S):A$GW@EU5
M-2K(7H9:>D"OP;K&_S3("89T,B=V5B_F#H=RP*QHEG#%8/XH;P6K:Q23=9I;
MUK.V/R[D75-&%T.Q%] S\%!%\?RUX\S9R(.D!D2//K9W-ZG_$2=69,KLNLS7
MPB/YH*['F-P'I<GW92#;,0 J"J.*=MM0.^OR_$..W1>&^Z\Y9PLG0YBP%F@R
M&<3MB:*%3TC<3)=6N 4HYC 18V[<L;LL@]L3($:UT(4850/8W+50Y8=U&&WT
MP)Q."VWEIY5>7MC]. @YR:K4-\PF,JJGDG[SLG;QAOT'BH:X6VN8+S$4,//]
MP7\ERGM<F1;K.%$A93\F=72IGJK2A<P]_DM;:4DMQ@*M?;MA9&+**N5QTL?#
MSH).8SRY^8'XOY+DEDB<X ^Q+<(MI?TZCONW^P],(F&-DG,Q!^+AYN 8[S9K
MO"O,EPW!9#/W8\3R0H\)E)@>-R?Q044_&T=)/'-F-O3=%VJ?;BK@^S.F.Z<_
M%9M0* M]$^>T(\YOXN\$ ?Q>F%#^(['R?V>(RH5EIDX"\(_$^ELF#E$&J#V$
M_4XMR.\\))G5L^3\G47_I&6"N%Z0L-^4RYA<%YF9FM>)QJ2A?)CGL*$_NTH3
M3C3E@FB-J5GR??'C;JS=2 Q ^/8_ %!+ P04    " ##<W]:/EK1Y.M.   7
M50  $    &9O<FTQ,"UK7S P-RYJ<&>DNW58'-WV+MA(T 0"P37!W0E.AR2X
M!7<([N[:(01(L X02'!W"^X0W-T;=X=NM /=S?"=N7?N/#/WSCWG-[OK??J/
M757/7K7?]:ZU=M5^6'S8 #Q7DE.4 Z"AH0'\'G^ AV7 .P &.OH_QV/#?#R>
MX#QY@HGY! \;&POG*=[3I_AX^/C/"(B?/R,@(L#'?T[VG.@%"2DIZ5-"<@HR
M$@IB$E*2?VZ"AO%X#>83W"=/<$F>X3\C^8_;PQ\ $0XZ YHO!AH# )T(#8,(
M[:$70 \ H#U!^U<#_+>&AOXX1BQL'%P\_,<3ZI\#T-$P,- Q,?X9]6-O\&,_
M )/H"?$K?AFL%QKFV SN) *A\3DXC&^KNT@UIZ!,@A8>GW'QR,@I**F865C9
MV#F$A%^+B(J)OWLO*R>OH*BDI:VCJZ=O8&AI96UC:V?OX.GE[>/KYQ\0]B4\
M(O+KMZB$Q!])R3]_I:3FYN47%!85EY36U-;5-S0V-;=T]_3V]0\,#@U/S\S.
MS2\L+D$VM[9W=O?V#PZ/8!>75]<WM_"_=__8A0; 0/OO[7]J%]&C7>B8F!B8
MV/_8A8;N^\\)1)A/7O%C$<MH8)N[OV 0",4A>1N?4]V%RRBH"26U\)C"(V,2
MVF2&_6/:ORS[]PS[_%^R[/\R['_8!0$\Q4![G#P,(@ 0@-3*C6(#_"^ )C@?
M)7]H$-#YM5Q(\'EK4GS!?52IHA!:6:;[6G*S((SS[5.95.<_VW3*6I&]&;A@
M1+ XTL+\#:T."[_Q$?Q21I15,P;4WJ>4^7IR$59J] !8U_X\NI9;,]-[IY+E
MJ]$(A/)KQ=IT19)_I\___.7L"82C],@G=GJ/\<I=BPO6N1IO=#!KC,N6OR(E
MOR\G<V#_J4XS1(B^_Q-9U%MWQ2;+"H!XE"M=G54 J@YPQ-[ZYUQN\X@-;5:3
M#& KJ8F%W?[8K?KGMB ;/8KM/P*F93A+V_X6QM\.AND<[&=4@O1."[E9*>H.
ME^KD>V9T[]N3T1"Q&%= ?J#3.>3GEFWW P#"JPV="!,^/T&^YO3;(3NE<&__
MQ+0/J^)J0#8![=CBTQWF:W,)4S)GB0R #>/Y/\WJ][\QVW3W5K-LCO/EMAU=
MFGUU,K*W^H@E[9*5Y/T6S^B74GYR9(WL ^ ))OP8MT<:S$\3>_-F_[JL&M0E
MCQ*!;(_.M$FQT8Y]PD357\[^5!9,=MJY_H/2<?>>4]C6LJ8I /R-\@BI#QGF
MFH ,WE'QPMF+^HHGSMM$<D:!2PT#UV4P4->'$(;>/\H;8]Q=)]F5CKM+YWG)
MNMZZ8%8)'37LZ63NMZ++>S9 G?R#+B=A0_EYH@= EU:0"?W=>F0RS^J-L< #
M0&FZ\0'PN=SA"!L20AMZO&O:"-<;/"Q==O_) 5HMXSLFX_AEW^^Y^HQ9CGO1
MI59^L:$3JM,:1%COAX4,?N\; RIP, 1UZ2)$L<^#J"N6[TZ;6$EA27%EV76Q
M-TMSB?1L:@3!_F6P53^91E#Y!+7:3G]($D@7[!'<>A)<@HT@]>URPD[)]XM;
M"2ASJ3!RA7-T]C1@C()(NTZX>T"&<)6>38/XT1J.3K<<?FW7JW;<RB5NS!=O
M^$C7[2SA>.I/6V/U@L%3$H1PCI\][Q:,8)CTUVN#H%@7PT=#/X10#F.=4YCT
M/0!,*C@OGQ\8&G_*JNF!ZY!!S]+U'P!Y;/O5Q7Z!WMQZ9^!Y"7HXNV\/)18A
MN (-> E9BKRJ..:%LYGU+&^1 ;^*4TP@KF+#0V0.37%FZ@,C8G^\Q?*W^;,5
M 7<M'+*[P'XSO*RP^N=N-I"0_]Y[$?FK'MD4],)'_N=VY]-AX'$.9<4(<!F_
M>^&EO^G+21ZI^1/N$*:L\'E-XRY,%\7O5C>,A\=Z=0^ 4%_#RO *AYN$,.O\
MTOHN>_3?F!O/!2>DDP3S-RH7 ^UN@*[.G0XF5 >??J8*Y36;R(B'L+3R8@79
M3@>9%7?9NC[GYN>DF51@!DN'AX,D4R._:/9W54H>XN#I P;J0QY)QWDE&[UA
M&V&5Z)O"?7TZK[^3]0M-@\-%O&:;F1O<&;I?(/Y+&KJ7]2$*CRWWUQ,2C3?_
M%EX=*LL"^) SIO95S6E;F+O^2^@E-UOM_$T,;8U:0?!.@Z!MA]/!.TW+J%D$
M$%E2%5=PKPD_4L,KV/]!.&G1'%CUK,>1/ 79:,XC]Y;S^;J*CU#GBVNYN0YQ
M^#SBM=&]9M +U$@2*LD61490U43Y0CWE#X97P[ B1F'P<0,03XRUS,;C0/55
MMP,9<W7ZW\7]F6.MOLV1XJ)&NN"ZM"Y/HBP:@NS,V5J__@M]YF\G==M[MCS<
M<AN*$R316R6_OL^_?M;T= \M'6^H-%HA3ZI!^-K_2DI:'[+=8]?A .7F;60;
M,!LOYJG>]-5=S5YGYTZR.R<AI4N/*D&6\NP]J;LW9L-PJ,0";.6U-<?MS<JE
M!K<18R1RO=^KCP1"WK9R.=R&T*;./A-1G^/FP4)SC/X13[@!$([#Q1\G+.X3
MXA'P".FHB_%8 B8Y.O/H;IWOYP:_QE#[XA^774H*2+P@^#$<W/I$0,3YU_ZQ
MPFN>0U\ZLD 5!W#QNX!R^3-20TF?;<KR"B4CT?,"$_%7PCE IL02 OF@.8&T
M?0[LI[T+EIN$A! 39>$^A/5)19Z 0I2;E?FMGE2M;"5G7GI-Q+U.DD5=M?VO
M])"3YT#QZ5DAF?S>^!&^P*T0O^Q$C]S[+#.'H\+92E[N^7F^Y.2R:<B23]'L
M_?UT5[[,YPFZS?@D[ I'*J>A,1K)[Q3QQD)1XV+48.% [:EZ?$X*EPKKP#%I
MG6=[LH.QK64$_>U&?:E8H02A.2 ;H<2VJ5:5&98)]@MI&7";U)C[5 ]/O!M+
M0U)N8K/:EP"BM4+<<<E!1J%Q8JF 7077U_+F?Y@VP Y';<*59B.;[18XO#EQ
MG!$ZF6L?5&+$S[32=9-N(HO@:>H=S<I^)]?*UB\$WO/]Q$6\Y[606,#VQ4SF
M4N$:;+_)K$_?6(N9[2P?X\DP#\BRB]J-;?!\U$.]UACZ$,X;?!1N27XT<.FV
MZZF,KB,EZ]VYN5ETRX_1%M6=\MZZF.J$@%3D%/)+76T!@A2:U*G.*Q<)! N'
M&Q@?Y(,+R='"%57H_;2.TQ?9<J, _PD</63]YNL#-+?[R)N[HL0(W!?P')=H
MME.A])2FP6E=:V(MXZ\-5W^[WMOT:EJ_1[#.L=S;Q@6I>OD+')$39I5_F?E4
MCN30<A=>[=H9XQ0#:J5.G9O 3(]$TVZ_,$)BMA.[2)KVA6($X[59E!)(K<W_
M2#D8[.#YL-^O(DM;/FMAP/W'1#LV.W,D\>IS?BWTGWC^R=^.T9@P,^0P4& _
M*,CS_J"?": ]C,A_MSO0*5FR@G-B3S),-M7FRZQ/:BT9-JN7[1>RQ^E,KQD[
MK@)C^Q#L:2P<>Z_J9I4LNN,CQASN0];XNYQ#M2V8/U2'4)#=+&=V\?!F'?JE
M(_OY \#NF>I' 6\ZQ9ATRP6A/JW?4 _QZ</;@XZGLUJ#)F7>-&%T37WO[$L-
M1MB(&3E>7#J%>!Z:E$!X!AB_3?IEN@H$&KW)L6QH?$^Q\5K>K,+B$.+@T-BA
M,JK)%*&H8%ID-PZD6IO?GVE[7WBK7)\@4>;7;6SPM]D"6][,S%V_Q7H%M&2X
M"\DK95+&\?#793U#"<>RTIF^OWX796,;>?/F+J/+^6MR@ESI0.46/WBXR=EU
M%SO.W83G0.=U%A_[$=JQ\4U-P^5(]2Y?R=&)*&EZO;B%QT)784W<JH=*+1O]
M-U(D9LA(ZH?I#JJ#FV6?.BKG<MN5D[$0G*Z/C1W<T-T?! D#W%><+=*QR:1(
M @3KS'1/SPXK_H6<U.=LTOTYP\73HER)3V(%N0DUPF3_8>:#4TGPZOL#H :4
M%#0"LX';/P PVP)]U("3/%@AQ3UW"].W8S7C/H=?7'?-F%#3=U^G.ZTGOI)3
M_GDM ![=OIL4KH87;:[_Q<:XVJMK#)O<RX4J&W4G)Y@,["UC/3U,=Z$XS)Q;
M501MVJO\^ITIM>X5'3Y\[[77CN,41U=$0LV28110:]]IY=V(/;IZ<<[H1A]N
M01,ZN%<F8[I5PB@4&=KX>^^3?\[@4+:B ZWXS&FOLSO.KQ]A?L0"%V]O&:&%
M/L#A^KHRB<!OI"Y:5DR>#.E9P_EE^0[J]AN_70RYE3] L%[J?K6>:/?8_ P9
M56^J&+IJU6F_V/PRXH+] @,\7>VM,(TOIWV@OP&V5,ET3"$;MXQ7=[F>6EI#
M?+)ISEM/U_XF&4_#/D%7S^]C(:7(FP/>G"Z1<*FL?W/4N1YN^3(KVX4S;\:I
M'&'M\$*M-LXD"FO$&GUO)72$] &0'+TNY3C,<UV?/*%:%P/FF6<Y7N!:<@FI
MYTDI427(P1_@^JXT\#&!G&U1RI^DB"!0Z-3"4&*P;K'.68Y;R<1FBCO[E[3S
MLL!OVH8;UB*A(6'O9FC6-];W[*2[5U:\MV^<>X3W"V&Z<O$DZ(K[[0Y&\"@V
MQ*MR?3%ZNU2%_)C]PIF)0T69HM%=-^6FD8PW/.YPJKUZSCRA2&SINJ%S4ZV+
M!.QVO9?I=YG70:L:CIZ5\'?FR")8[1\RT<$TG4^653"]*T$HBI>SIV3=LQJE
M Z>^Y[+/@G36W?8L^NR?+(R(L2(S'6_WNXS]/"9F2X 5[F.K&?&+:[E1G +=
M_QD!\_^,PS S=2.#_M[_KD9R;H&70;JH$62\Y ?_7MC?(%#=5L<8+&.P#MI0
M\.H4ESXC"/<Q0::<#1FZ9S9Y0_U,>$5Y8$%(7C?J8&+$[.FBC"]QGQ0B((#C
M 5#^G?_9<@S>_&R;B%3!*-_A+8;A)9;R<AF;UB+M'S0#0^XK0^=>.6O?QH'Q
MZ)@L%=L"WY\!J&];;UA:.^:XSMYR '*"LK%5PFE2#W[LXG.:T 6EB4EDX&O-
MG%HT-\5:Z@T"1BE#:7]SM'1Y])S]IO6G%#X(("O9-,'7KFN.5$XS(*)I[G0C
MS\QG.SX>4Z]:7W*D0O9M9+@PICTU%,5\ ZIM7'0W>NN1H<QV8'LJ"18U,LI9
M^O0 \(FO.-/#C !"J:Z$&F=^N?U!J@H$.@/MT6Y@DWJVM9?D4G=T?M89 GC$
MP%62@;;E3X=AJ%/ORQZTU23-#+"G_FTR](L%?^I0-V2EGFDNIF".$7^$\'ZK
MO(LDM;WW]??BI!1W&KML,M:L0VV>T^VN'79:_K6TGPH,7O$Y'_5^B#+&9<^&
MNNI,F\DVD=TV]*\Y6>71K8=K/W^S[OOL 8 N'$ 1V[-G8&@!C-/E&H )5]L6
M=O>1 ZI?VA[9,[N)5;LT_9']LW].E4!"-E[#$,'A.?+"M @8RLW=II0JUA*U
MPI&3L&>*9> Y,U/ON H7E)URR0N_VFV^Q#[;"?P^ M9J++ 58VM]?L3D%_HE
M0$1Z+]>.Q%>LRGX.0;]YX%1X8>57!?N5(-C!<CUT:AQ7L!GH->/L^AQ0Z_(D
MF()N+8]4(_JG3$D)#6ZLS-#$OH+&FS/UCZK.IH<:[*(8T/*2BB]JL3&5[E%!
M#9-YJYT?D2+W1C>5D_D00PDC@[V@S"]L5:N=!/*[!\F<GX!>A*3PZD<EG)B6
MRX$] 'KUPF6,G+F3!!>K^T(6[;^G!4M#!'N8' AWC;563N/Z2MERLW__?Q35
M_^\B.TI"<^H-35%OLTH(00=C!_9F*N+LL:[*<K"WOY<\F._K1A9]B EV>Q:2
M ,^2B>Y-E9PG'H5R?:'GQU)@:"OJ!]7Z),+0A_%YG_<5'>OR\=GEM$6ZZ=*X
M#%0PY]$E5R/N><KL!IM_H&/QJZOJSKDW;-.MZ)UY/0!^@WJF0\R>P-V1B,_
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M\:J:C'SD@HS?QZMYR?>1R$55K304[K/-J9E>.A9Z!7,A5/4LN"QO0TQ2@Y'
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MH5N6LN4?SW9CP7C5D6_3BA,Q*8>S5X[[GU0][(1*AFP8& .L='@+G<?#KDC
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MJ*T6A$@%HRUZ[M"91*;E5E9XJG3LYJD::EAYT+:AT?\'Y1!F:0+VH1G/X0.
M\GK;BOEBLB$ (_5>?<!2&G>A/:3OGUISXQS#ON=#Q^^&[=N$\$H'B+"EOL&9
MPY%9?4C)9C3N6>&T[."78@YZRA$TI*.-&83E4CLI&S7.3\]NS:46<%-%"8_.
M*8,<?W#_NO>!#WB8NZ#GFB-P+)+-+L&]99HTOA)+K">A#C<6Z;P\ (E7^<)R
M+U9L3]JV7]HTQ^>/(AF9 F8%#U1$VG9X!J/9$(ZL8MX\0YF;T(!E;7CKLY,R
M/Z$<YSB\,^[4JU HIZ9K^Y8D^&Z+,P'YG=PYLR:PFO0J8KV['<]>240L'^(C
MZ8DBH=U^T=JK"G_+80U'Q_F+>.>F'O2><\'G?JKKW,B#02QE)VP#G:"#H64
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M/67@YDK9@I[6(FIH-KE)-AKGJ@?F.]][9>$OPCT5:J>OEKT:?M?&O'NJT 1
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M=JAE[097OC8*.IT6AT4 HG+]41(60[3B77838US4GJ&TC HQIX?RZ^S!L-(
MR%,$CM2*7@2%I65"?I:''1D4=I'5.W.3*3,< (X+TLH;VCBU!M:]])BOS-&H
M482XFU'">??F*VJ[N#\18K5O'5'(UH7FT52*E4M(8:C<:ZK?B(Y^VI'F<^0
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M,#P+445EEM6=U%L224S%L>K&1)'URR%I7>9$!SQPQ^%UWRGQ'L\D=R]8Y06
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M;WS-1IY@S]'!M8*W7RUQ/@&.ST0-T(+*#3]SPZVV)5?(!PE\$L\'[Z>BKQU
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M1CKF&>Z:6VC?.L2U>2+R*G#U1YQ<(5:L#@@4>-&&<_%];,FE*KPA$BBI'"I
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MNL YS2-J[$X-B*].H5PL\>[91*#.=G"8H6D<Q4>C$DK]T"RP9XF/^>0J AT
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MTD<ZU7^<SND]6IMC+3^%5>?NERG^[I>DKO)(\-9K>[V\/'Y1UU^J2:C7$\
M=Q;#L\2>\UVIVE[G2_1*.@//2A)?<2'#"=3:TKAI%XJ0AQQ0>7'+KH@@(L$Q
MF?N[YHQ+?D+5]BF'GEJQ+7PB@7J:KR=+QOMSEPJ6=%S@"H(LAX%O@6:G^/JK
M#5YK*O9V$E0M#\IJO&&YN[G51NM+RXWV/O9&/TO'RTC-UW!$]-Y3Y7BR/IT0
M37B(:*Z..H>M\,L@D6M_?DMIO2\N,JFP'O4&7.0P:O79Q3UK?B]),30^4>C,
MGAH-CO$ $=_.-+_)%!&<X.2VO"&<0O%Q/H!8-]]Z?P#E]KX ^+R_)VT3G8J
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M1N<UE_U7Z61=EEQT72S/_:CPV>+\$-K7'U\ ":)C5[UE?],?>_QDH^FKE&0
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MLVS+;%+*N",*59/+\.9KCW/4HPOQ\=XU(CHAN0WFIH R"(>+.BRHXL"^/K#
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MKD3)1N< )*C&<T=82S5RR4#F4I$0JE;D;EB2.,8T\J.A#@,UV/!L;_H%4!=
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MB1WPZF#\,-%NHC?_CT#W#O1GRAQQ-$;DZQKV5+0X6Y[O+0U4L5GEKPS!4A,
M0H7[Z$G8MD3C7>NSF.3P4J\IU::(]PD%WPK3@X@;\5UB;V*ERW5!/R;H?L/P
M(XZOZK@/ZZ.+#QVYXSA&QL;=B/>0S+#0U4+2E*+166>6'0<VRC.\SOD EIWR
M%K7XL1LE]N6[8^4#HE-OL958T([JHN2-RD7;<$GG\$#_K4I DWADB8!("9U;
MO,B*L5V"+-C:L>[.L(B$$R+>&GL(;CD/"%YD2ITA:Z3G&UDX7#N.554ZY_C*
M7DN.-KVQ46?/(_<$^&)<45_K\VYEI#S>X09L M!CGCIZO5L74>1F,GGR?15
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MQ!M_U->7!;^0P@%3R7$2> &T1R:Z-GD4,I=([DPG:)6TR<,'MXZ=;14J%E-
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M$0(%.LN,*]\I!2=28*AO2X<W'$@NE?V%'=YV7MVX\BSR59%]RRS5)AMKUP/
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M0_1^QJO=?_EE2<'R"ACY2^#/.;$Z (0K=41F]2\.OO]& OT^]0=02P,$%
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M[N5U*:"[6:,C^8O\W^'QP_);TN._VC%Z.3IE(X4WX@U!:ZV3N* A?J<C5'V
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MB$>Y-[L%4(, 8'I3U.13:5>]:60QQX%':@GCK4%W>0:?;O<7$JPP1KN:1S@
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MPOG87HDW\2UZY_P3[<'XTW([G39/YUPNN1GQ9\)-2B!#3Z:XNXQW/9L5UO\
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M*L2V^W/H*KNA5<^E6A",2.E-+D=Z:VX=3FDQD<U0$ADPGO3?,SWIH')]JCW
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MTY.K=ZBMWW,<\59B4'/J>U, 5?F'!K.UGPQ;ZU T3H$)Y+ =:V!&0.G-2X(
MXH YB^\'K/ID%O;A(Y8B")"O)Q6GI>E2V%P'$:@$88CN:UH\Y/%31J22<8I
M+''DX%,NAM1^.U6D7:W3C'6H+]UCMW9CM5>6)Z4(#Q[XA7"Q3#+;$7YF/M7&
M:-K<\FHQZC"7B@MW_<*#RY'K[5<\?ZO_ ,))JC6<1Q;J<LZ=Z;HFEO<S000K
MG& H X%69/4^E_"WB6/6M%AO"RQY3]YDXVGOFO-?B7\;O)$VE>'I-S_=EOO[
MI[A?\:Z!_ <FH^$TTN*_DT\M@RO$,E_K5'1/@3H&G%'O'EU!UYPWRK6$N9Z1
M%RGS^Z7&H7#.?,N;B1LNV"Q-;VC_  K\3:SM-OILD<;?\M)OE&*^H-)\,:=I
MNV'3]-@C/;:@)'XUT,\=GH-H;G5;A4"CB//-8NE&*]X%'4\"\,_LN7NH8?5=
M22WBZLL Z#ZUU%_X'^'OP_@Q!IXU?45'W[EMRY^E7O%GQ3N-3S;:5_H]IT+#
MJ:\[U6Y=+>:61R[8/S$]:\K$5XTXOE-7&QP_BSQ#)K6I2XBBMH5.$BB4*H%8
MR,"HR:9/+YTK-GDL>M,#8K\MQ5:56HY2.:1.6POM5&YE^8U8:0"/&:S[E_F-
M<+(*MR]8]T^Y<'K6A._O69=3#MUJH@95YU-5<>HJ:Y?G&:K^9DXS6J </EZ4
M]&).#4>X'H>:?&K/(H0<G@4#1>LLM( O)-=;IFGQV4*W%SVY"UE:99+I<(GN
M,;NRFG7&H27LX.3MZ!:T2MJ,V9]4:[?Y,JAZ**T+"!+=!+/\H[*>YK-LHDL4
M$LIRQZ+4DET]W-EC\HZ5C.1>AK&[>9^P'I4J,>:HP<XJX'&,9KGYF!()"W2E
MZ4R+@&E+K@\U "LP(IC]!1N I&.<8]:!JXG\)HZ@4<^E+]1B@T(I%R1]*38N
M.>2*>_KCVJ:SLI;Z39$A]W["DDWL(J-#YC!57=Z #FMNQ\.P6J"ZU0^7$.5C
M'5JL":V\/*=NVYNR.6QD+61=7DVH3&65R[>AZ"MKQAJ,T+[Q'++ ;:Q7[':#
MH%X9OJ:P4MVFE5%'F.QZGO4XB/8__7KN?!GA7[,1J%V,G'RH1T%=5-2JZ=!F
MSX&T&+PQ8/=W)'G,-S,?X5]*\Q^(GBN3Q3JCL"5M(CMB7/?N:Z3Q_P"+Q>EK
M"S8K AP[J>2?2O.+E@ <\$]*Z:M?D7LXD[K0YZ]0AR>U9DJDDYXK:NE#'.>#
M6?,(SQN&>_-<,;O9&3:6[,:6/).*@,?!%:<D2]>H]JK21CH.M5&315C-DCQG
MUJ&0#;N/ '7VK0:-I'"(A=V. J#)/X5W_A?X<0Z5&FL>)\11CY[?33]^0]F?
MT%>GA<-4Q,K=#@Q6)IX=:ZOL3_#+2)/!VC77B"]7RKF]B,-K"W78>K^U<3XS
MU FZ<] W4]A76^(/$KZS=M(S$1I\JH/N@=@*])_9@^$?A7XC>)I=8\6:M9I:
MZ>^Z'1990LD[>I!ZK7TN+K0HX;V%/9'BX##RQ.*]K/=GE?PZ^ ?C_P")]N)]
M%T25;%B/]/NAY<>/49ZBOT"^#6EZ)\ _A59>'+K4(;V^BW2W,L71Y#UQ7F?Q
MU_:/L_#$4?A_0(PKJ!%;VEH,#TP *^>?%?Q!UC1]/DN=5EDAN'0_N&;E2>F:
M^,E5G5=C](I8>CA%S2^(O_M7_&/_ (2/5)=,L'&UF)< ]%]*^:-O7'3' INH
M:Q+JM[+<SMNE<\D^E$/[TC!YKTJ5.T4D>)BZ\ZM2[V%24J!FI$<L>N:GM]/:
M3H-U:=IX?>0[B#7HPP<Y]#RYXRG!#++[-)@/#(3WVGK70:9J*Z5N.GV:0W&,
M?:)?F=1[=J73?#\DK@11LQ]A7H&A_#)UMFOM5=-.L4&6N+IMJ@?UKW\)E=66
MMK+N?.XO,Z47RMW?8Y/0O#-UKM\CA7GDD;KUS73>//%EI\-="ET'3&63Q#=Q
M[9ID.?LL9ZC/]XUE^*?C/IOAFQ?3/!:^;=-E9-5D'"COY8]?>O&KB\DN)Y)I
M9&GED.Z25OO.?<UMB\51P<'0PTKS?7H1A,'5QM15<2N6GVZLE,FW.3D]RW<U
M]2?\$W9%;]H&[ '_ #"9/YU\HO+N[U]4?\$USG]H.Z_[!,O\Z^?P+OB8/S/M
M:7Q+2Q^I9Z5^._\ P4R('[5NH9_Z UI_-Z_8FOQT_P""FC?\987XQ_S!K3^;
MU]=F/\$WK_"?+/\  *>AI@(*XZ4JG!Z5\C(X%HB1ON\<T^,$8/:H]X-/1QTY
MK-C$F8%@<U$Q!/K3I.2!WII'K5(E[C7'%7[$_NB#ZUG29/2K]CDQ8[TI_"!=
MA.15F$;I$3@98+GZU4A?'%60.>#@GK7&]&*.C/L*+2SH7@+3K>!256V!RHX/
MO7G_ -K*!F8X/H:C^#7QUF46?A?7+0:A:G]U;S$_,@/\Z]?U?PIX2O 9+J.X
MLL\95#BOO<'4AB*45#IN=<6>&:CK0&0&S7.75_O/4YKW2?X2>![]B5UUHB>@
M;(JC)^SKHM^3]B\50A3_ 'F']:]6,;#YF>%2W'J:S+FX')W5[M>?LJZLZ.UA
MK%M=X&0H89/ZUY3XW^%7B3P<3]MM&> 9_>Q\@?6AIH:;N<+=398\YK/DD.[(
M)X-6FM)YY,1(7SU]JT]-\#:CJKK@"-3W-9--O0KF1-X8\1RZ1= HYP2*^D?
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MFJK#?\DY^8]2>]<C'>GTQGDFM.VN-RK@\FLVN@'5V]T6()-:=HS3.$0;BQP
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MN;>>/DT *U GO-$4.-_9^SHX5[/^ZY4.G@8)Z0YG>/[E*ELF%FFHOOJ8D]W
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M344-GJR6L;?2?N;]_%'JFV1Q?5ETXHYXXIJ0I!QV<K=D) 3KW@^:U]:;,9N
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M/F'T9O->/[C# F%;W'\305MXFU2=3@Q+9J+O=!W,Q;B:YFE-H#.D^H90)YA
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MW^\[W[FN<\Z&_4=VUJPU<\\]LV96-FX2MPBXJ:*@K  @("  >./_ +@9P%,
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M#D.+=BF&H)_[P*[@-<K!/^GPEQ+K6O3FZ+Q^S2%/[6D,#K"@<WZ R/_9?.V
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MMJ*>["E'%>FO6N@=7WHB/TS8,2PZ^RZ8=6+)>_4@.&I/A))47Y$EY?V>AU&
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M!]#AQAS:H,A6L :JEVJ:#@>$[Q9\@2(^&(('B$'[F8IH3OIVK(D&$*X+G-R
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M/>M"H0LRUQ6\3I-O?6L@R3A^Q+$.!U#XN%+Z8BR@(4+'N'P3D#E:6/_QVT@
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M+W5S.N, T^+96%-.]!:XTA%?-UQ.N*.WF _YHINH9D:TO:$91^4ZWC56<V.
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MP.0G.$!X'^5I-&^G."F?-2]492_Q-*EY/)!#>=G$3/5'39Q-+Q?3C2</U,Y
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M=?Y4H[25B)$ZZ][X'N^#$4QQC^ZF-+2EZI:U7- $S$CQR?4 <H%Y)/.AD%U
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MW[@ZNI9B[PVU Z*H8H'=DV@:>[%$,L:0;::2D/N_.KJ^@"(5\ZN\17ON/^!
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ML#>,++75^'[Y_9)JC7K(\L)MD[Y99F:_B62Q3 \V+[^&D.$8I:ZG*69[&3Y
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M!UWLUWZ7?Y:*6(V6$F^<Q8HW(*6A"E<<DG?8*9O11LD*+)<AOUB#3BE0;BO
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MJX5=#!;.>8'Y^2X0F]\Q52:H90Q<O,/4H0%_*MN$T8 TP*I/OW>E*2D;^/,
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MW^/3I\EI<\VP]6=M*8OS(S?K3DZHQMU']+Q_#'4 ,_><:KT2E8<-_^;*1V6
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MJM[4269$TAY7_%80_*+KF^P3GNRP77W%,,DU51UNUT%%[K@[?)IO<I;+X4U
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MK-4/D,L@C0]9'X02F D!X9)SOZ%%L<[WQ_-VD'45B+_E/SQR-1-IOA\AJ/V
M^U?D'"#AZK/?BAURD]19)X/V$6=4&MIX +B^/^%R:$VQ[>/[X>N:.4T&X=W
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M.G<4U?L BZLIHG_--3+#*IC\16P75S@=;^I4_<C>269QX>*7!AE'GO$!=PS
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MC03E!T4F,["D" G^()^]D/";DD@0O5U]&+@?6Q6VA#/_^,%G1R951-T8[#L
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MU4]N=B:>H#.5\O@YP$9&HEQN]#2I=;*4=VWL!$%9^H&%/'7%>7]2I#%,[Y:
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M23 @?5 _7.U./[VO#N^8NNH2#:29/-EG[SBM2LM_.SKYHSZ!NOMW.'<[=[0
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MC3T[DE2WH)G]07<NV[X)+P'+:I!8_P2%7"5/SBK5B+SEMW?% >/SVL3B[1B
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M6%F3B$R>$FI_</+&H.G5YIGI]?<J")&=$V_+ ^\S_ F/XFXL,0=+\&0;&?R
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MFZDW2N;6DN_AARC3AC(TV^,M;^-0$PX:DDE&?/'*5%UT/)NQJA6F-C&8Z^&
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M^A81*#??(P,32^^>S Z<]*G#%WKO]<'LBV1>B1&TJK%A@6T^Q592SOK#]AT
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M69=S3-'EDYUXN\CJ00%ID62MM5LV.R[H<!/"E(#*??A:[[-1E6'",>(3S)^
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M?J\H;T0Y7P]I(OE"G"M5OTL57L;X=E YL5ARG[R&_,ZH,^>XK&LMSAXP#:N
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MUXVUTQ6!DJUGLJUM&O%3WF>&XL,$7'&NI[SVN+B>Q>)5B&0$\T<A,)G5;$*
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M KSU2[ &X?J14OD+"%LW"^)IF8&<E5FYUE74DCW>$WJ:[B[Y,9I",.$6X..
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M?1:H=1<:IFA\.?&H0J7LIL>L><E]B\2JO?PS;2YOAH__>G\GFL[QY#:673L
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MWB$V$WGK-KV"3?"F0;3?Q(B7D:1SZS?0HIM^1W.1Q&ANZ#BMC@.+JF@VQ9M
MX4??=O1$;.@>I$DTLQ5)SJ5)A60='&I7Y%'1+$1N!US&5)OLYFW."<#1^ "9
MB<8"TJ_Y<V20399%:XKB]Q?Z&OE!7[UEE=EP:06X8HMF'<%.4Y<D-U?_@K[<
M9)8&529KRGCOVRI#%"5D$ /I6Y#2B.CY3Q]-9W [*@$UIHBP-5:*E/+!J\?C
M> ;S<GB+6^X/>VP6/29>TQ6MHPR57WOOG&'0N#YY);837SQE+(]>8-X,8FS
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M=BGE./Z\1NN8$=393H_8.>,8FO4'>^L>DWQ&88BEXFW197\E72?W<*&5@;_
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MA>06K^^>A?:?R/[?!?;A_U=D_QO8_XEK%F"DIJ(,'C4+  &(8KR&B-?L#\)
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MFFIR.(K>#4<L/MBI]C)N'HK/64!6>S>@L\RLIGK?A_9L3, #_/5:K@U^;RF
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MI7ORX$GX#1;^@=I?A%$%W/3LAZNLF-!/PZ>Z145X!S(P54#SCZ_*NG5U=OW
ME=B50QNT/\AW8K/:_8ST?350)59V92]E->R'[:K+B8/C BF/8 >$JLVIEV8'
M^0RC:F%8D'V0U7X7'?Z=V34R4%(/A98"C$E7$XV%?.F8;E'O#35G0&;S:<\I
ML.[B7I]-G[6LD(/">+Y;L5ANKBH.DJBO4@@:RA_2VR!ETWWZ@!HST(HR#SH
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M8). 4)",(RQ?G2 KB9O>R>]X_4!Y2H0,2$R_6H8@7?87@KD9JKI>)FF^?J#
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M*XX;)H"1<]%-]9J]$.QP;2!7/9(3OP/OV\^)^L[&_.:N:G]>[AKA$N$[:8@
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M];J\@WF_"$\!,[R*&8<+8;0(AQ!B^M]W"2/KG3=NY#!N?',X6,GQYO1G"_$
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M-\SR"^+N087SSAKLC8U)%#0*P14;D\Z]:=J>E'(YQXR?>T]O>;QKK2_QF!!
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MDM;SESFWQ0HMU:"1Q._,R(,)Q,&7C>)O4;)^]*_P"X#/.-$<<"FK(B/@S>#
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M)=^;IDD Q!P$<&ML()=]0D"NN7'R_(=!!.2:. $3L":BW_^U4V:O 1'[*H_
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MHZ-1LZC,B_PMIF>3#8H61W#=8_+,9-;)4FV[5V5>GRME+5B#RWB^T,5%408
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M*+'FR7&DUVSVPQ$,/EH!$<(4LXT@P$-O/% VF84OJ]C#)*5J.)W/4^4-S^/
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M_/^N98TG18!7,1GX:,'XID;640_PK C_%QKAO)2?:60Y_S3>7-;TS-/,^,8
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M$G^.7<5[<KRMK8E&\F7NAL"P>G/0 YCLNVF:F54>1NO%'>@"'*?^:Q4";G!
MW'V_8K%C%SG@19/17WI?[L#[RZ6'S6'01;[G&@=/J03\GWCJ[W8:DXP+9[R+
M=/VH%FAB_?R]:]P8L[9\RV(8<A$H_/#-#%83Z.S"IL$8*G-K6(R]X,T!+6F#
M$.NKU9@R'.SYXJ+ _BG@$_MZG%]QTG+V?A*D,BFF>^4'MT3K=O?\^>2AM-.(
M^=@G)T;/FEU:::FQ@_5C[LF[,UM'"YA0:VA*N>I\]DNZH(3,H/2*XQL&]5*@
M5>(PW 2L,IA7-:JC]?;1UU7DUKE;U4"BFGIKI++]3Z!K%V"C*8SL9=8)B2R2
M$7(;NYW;%VK/R(\ZBL&NU"7W,,+GCI46"8UM_;DO:@OUMHVUFT4R[&Y%%_;=
MGXC1^-#[EM?_L/]EO-AV>O>H<!_]&1^%XC*,W,CZ=KZUZ+ =]%FD_FT".&FL
M@L(-&\EA ^9J #M8%/R"?)%M<@C$&M;\(SUBAZ:A.IE>[GW<6]=7BZTD+6 5
MFT^T&CAE,"3=$E:HZ_O$A-Q:U%N[M,#@=I6RMK)4MB;<3OM=J0!=2G]<#B>A
MZ/P079$_U058;:QJZ);!?$MAVPHYSR9V'%'YY+.!0$U200,/ZC0NW&*VIL+A
M.=WS*Y#BZ-+PZ:ZR2"MU=55%B"D<+HMJYI"C)KNBX!S4><^0VI$)/'[E1_XL
MAVW&ENUCMRPEM/X1%G2N'ZH>=DM0D[&!!;^B5JXPWN\--46.5>+M,!*@\RLO
M<<J*#E\!BBTP".P,O^$<$GOJC!E3X'_,?$M3 ^E\\LK/KX-7=2B)'C<UXZX!
M>ZU?19U,8'S0>)5!*7+ ,T7>-H:OT#1(J/H.AV#]W8/W6<M/#C('WO"S,)27
M6<%UH1?O M:A+ ,@+Y\W4CC4#T5^%721'Z+#\IV'\"H^;?G,'IQ2 2EOQ4'%
MF5GSH=[-GU;#HYD>Z^#=7.,<5&O  T!;:4H(,0_MIVN ];NH-.^#V"A'L+OZ
M]EG> :QA"(U(P4%EX7L?9T/O^EW\60<B0P#"(0*G#C\\NQ;P1A/OZ@CWW]TH
M<"T8HD/![^ I3:RUENBZ:TPW5M>=EI/\@(WJM2"!1]5M-1^N 305JX=^3V\P
M\O;(QVL_81[" 2R6Z8EOH2=F#KULIJB,4IRV4[=PD?N.M!WKA9-/IO4;1^J<
M7XWT>&FV*U%BXZQF\6&=31'5 @)UKTI."E$3I3M2T0JMJF(M6C[Q,&$(GJIP
M(?8^'Z5>BYG S8%1]7D\@8?=34IIV5P %B& 9V_HVY>YI;&W'/2[6OOR"=A_
M^@1/-J#22=:VM\1HZ?/V:!6U>ZA"A"PB@UE;8&;Q/_'_BU/POB 1F+H/<$K&
MG_PMA&$RQP%E2SVTR1=QH<RUCO'0 W#-MO+[S+=IP:DTS7X L!2> ^6';$U#
M=I)E F#(MO&AC[@/,G=.Z([7FE6D3X/;-<#L#8"5[(/15+*E25S8G4]XTKNY
MSD?T5@8?+X#_0D=7J)B'I/(+$/0?Q93A5K)7!1;H]D>)@SJ4O8MX*^J%4\#G
M#U0UB"3'-^BC:P!1[S7 T_N!V26D[H-[M% XKZKN+-9+%*Y/G+16@UFNUCC)
MQKN*+>3,Y$J;)D;W<.\U=*!I*7&5\$=_!!DK1=B>I2&:7KK9H?LI+H< 5';P
M6]G2LM+>2,_FD95!#P=Z=/$9UPI7.9KK./(UVX5<@FL9]*H;![6F-4Y+^Y^O
M8&;\B'R;/F*V^#1.%IXF:''PL5]^+TTYO%)?1V&37'ND Z%<4SJ#<Q>1B>AF
MR"B4;_&T.%/G=T[O.34.F?F;-&_+XX3_IWL3K048)Y'3A\1P;B;Z$3$IGOZO
M8GB7F5+3UZU[!;CF$[W\KP%YAO_#229D6A57[RD"<PUX4XMK[/\KV!C"I/,;
MAR4UIB,6CN1CGBV&23.'Z1V=Y_#"?$#D\,0D2.WC4XMS<(CEI7$KE'VF2+'C
M1%Y.T_8-^1O> ;<=OX0E6 33/4SV:LPHLN<H!?IRU12\A<RE*%0UO 9\0K=A
M?FQ+$COY+#D]?$AE .>?W8FKRLVN5208G"!N%@,=<5XHFW]XE)AH(:9M3"(5
M+E6\=1@"JKJ1(>%$CE:4_UM9..T_4,*YL3$2-L^'-[D%IGH,^!T8M%=$LP=W
M2G24H)@V'C1R7J3J))R[?9]LJ$ZY2%'5.I&X!D1FTF>T@BI.Q26[-6<](UZ_
ME%]XB: &(WMH3L)2L".EY<W6NS9HYZ/0SET9^4EF4;7YG]5*&XYA=OY'YH5K
MG\Y*H2+\K$RD7^_*,Z,F=[RH_[[E<MCMOP;(K$SW5G_8!5<F-*OD,NF="7M9
MC8^C5,0C1,H.N+9^^AIU2U;LX"![4=&Y:&&.N7<$-RTS+I?3)YU?,+7P/3IZ
MY^EOPR!<#LI]E0[#71<1+<3A+2 NAZMHZX>[CA.+)/J_V(RMDJ6=3^$3C>08
M35.8VI\Q7(NY'^S=#L3?V;W\/F.-H:V#\,]TZ_3%K6@P-K>VQZ@W-4]DMWJI
MHJJ5W)P69&&9TWA2XO&RM2D]&K.UZ<X/P=> >_NHOH.G<JPO5QS:H:<^WZ61
MJ'LZ*X?ND-==RR\#5MQ8K&M-$4IH6J68L$6ZPI9(LUBFYUJ_0?AH4IA19Y4_
MC[40LU9Z^SZ=D ;8T'$>D_F;#$N=I!2DRJ+[,J1N<9\"%OWX<XM@;RE)O)D0
M-ZF_GKP-[9Q:03A)1D)'U1A%\YX"1\%[Z!=].D(/U/GA-G:[X!OV0T!GB03?
MH2G(Q0V+\'X <*2USYK=?S'0D>FE>CX\VI7 :?_>R@(SOH]TU$&5'!!3#VOT
M17V9_DY\=RY3GP4S>5X0J_26WK?__9Q^Z=&5.$0<$'7IK_B$8>_'HKC59I7_
MQ7E!C;D(_:M)LMH9BGO;X'8W]-,YWVX%V#W*<%YG1"^X#GL:)1.C/)L=Q3A
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MK+A)%27L!=X;^8B7R^G;'3:?^'4IMJ\P0G3SZQ+95[)15?42?3FBF'H[B*3
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M^/]T $3M_,_!'$I^V_L^8)0S;.)K7FIG#[/+B[N&8.QG]EWE=LOG+7'!8M<
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MRXN*+-*^2?@W'#31M/O_</;>04U%[=?H05!044!14)2 =%"Z= @*TD0#HJ*
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M=:_7/2WA@9KM@UL\@><8,<\DSGU+>([RW9\.CE.8Y\\740P(QF_4$X[V%%"
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MTG,7@OFA>.( <2%1W$3P7+%^*^L,I!9$L=[D,_)L:1A]J5=G;=X<8J='@[\
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M0#2UB]6-V!5HTQM:E#&E @RYQ'7<7AZ77IMFC'7_D4H'CA?L)&[8Z0S [ZQ
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MQ56^B)8]Q&_-W,'(;XH/S%KC830.XV<7,Q].1CE@^B69!8\RO%P3*)R#&8P
MA-E^.2%%NH-[:'=JV40-<%@%%]P%IH)T+PK]_Z#W47R*8DRW0WZ7Q@.6"^?W
MNOCTY9K/&N-&6].@YT2294"BK+P<>?9&#UY)9S:-(2Q@)(L%TP6!L2.MT*>6
MW##@YS-)0?1:UEB^M K'Y!YG*:S=.JS"N-Y[+FYAY0E["GR]8.0)C#BTJW\Z
MYWJIJ]F46YV'Q*#'W9,R+Z6F'U2%'1O A6X;Z)L*GM^(+ S:-\*19W?L0I8&
M5B1#5ZO4MHJ(P!^!/%/B0*34JU-1<7=CI>>"X6A?4DR8^&0->M@U-<OS-G8
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M^F=QEJ'RVU",JOJ'3_E%AFCF9%\V\\!)1@NCK" @=,+$<9II_:DZ TD7Z[H
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MY8'7!44DZ@<U<.(%$)(7F.&69*'+R^!RB"#@-)T9L)V;M): N\G)"6?O$+C
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M@.(_=;=\F2-U*8ZA-YM0?Y17J#Q,DERZR:6/Z?'7RLL?>>3-!H]- W[ZGC2
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M+KZ=FGZ8/U=6A7?)?<ZTD;K0P'&J,W"ABYDZF:M]HB*=V^7L\'85GB7GJ$^
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M!DV@<VNP$^8%-)9E0;B_@DB4#<8JW:HUH&2)AJ3_08EM7G![;XW\"ZC_1[D
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MKM [\;I"G;\>C?>W2YVA$E1?Z@Q=Z@P5A.U29^A29TB)0/*ESM"ESE KJF^
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M\+P$/)]=P#/6;3J#L1LEHXL%/?.[M23PR>)9H2/\"9F\F!O07'((E"EK+,*
M>I'0*H!I13ST7/ 4#8L6BQ0H% AESQ"6ET7A(&C*V.9!D6DJ*YI6!(A\HM4+
MHP%W 'B8,+O=?U ?'SX#H*]$'E;\U'XN;J)#R J'%L*P$#/JQ4=/\_IYX.6W
MO_^D/E(,RD&?BKS,@DM:*.MD)"UV=DD+5><P=$D+O:2%MB)?JG!:J+R[<E6G
MA4J*MU22%JIFO>K*TT+;D;D+TPY.(LD059@6FK=@JP<13#NX$;7V4O ;Q>/(
M$,W*^> *1/9S N+*PY!/LG+[OF;]%OIQ3:@Y!MQ2$2_7AH^BL#ZQ=*,X?*1H
MXW44DI\BHFF^'2"R'FQLD^9FV=B:(A,O8T!8OKQ&"%!?8QH5!+@N2ZTV"E0+
MN<$>LI=N7/36W,X]@S!N1JBY5O23$\GA($%^%99ZOJ>^EM7)-QA?D+K7QYEN
MO= CBW \&Z+TT?2DT9^09]H^*_.O\%#JJT))EL#(A&(HQSMP-3 SQFHMSER>
MP)!%2:"AE^88:DC/%2'-U/MN>&3]"9@01L^XE1I,80S/90H,<#0"8JQC5:'(
M&ZV=,(IQ!>$HK8@D2RE'Z$?T%V;,2J"[PH 69P-"4%K92:8^EH?PI']K,<SE
M _2BE VLE-@4R1EO@SP_MM%F:\?.?<20MW'DC*(P5*6Y 0&3&.!GJ)L0M")Z
MVRITSV%(O3@-.10?SM0P?$?-U <GAUQ0]"DODLP;25W#?[QQ\ _@\M%'\<M'
M=*1.,E0UMXPBV'QDOEKBS6MS:\74=[</5,E-HOW!=FK[OP\-UUA&=$15(3U"
MU'+;LWUZGR,\W/X]8NSJ+6'FT(9REAZV0\?M' :.KE/MANZDQZZ3TR'YG&<;
MSA%I1,%LBV9S<1A\=\K@;K033G?CU<!5OO;UD&]Z=G2:'B^N0Y_,J<S5MR]?
MOKRY>G_*04^?=:?]R;P_'G7&-YWKNUE_I,]F]9([L/\(;8L6*'6MB6.XZ4M\
M>51_.*5ZT/_77;_7G__:T4:]SF2@1<2/)_I4HYS43/XL7*T,;SM>S.RE:R]L
MDYR;DE<BZ>9!YG+ZF8\T(Q]/&9G=#8?:]%=*_:Q_.^K?]+O::-[1NMWQW6C>
M']UV)N-!O]O7:V:)' /7AFWI3]2Y'Y6"C1RV4V0B>T,SZ7+9^73*SF2J3[1^
MKZ/_,M%',WT6P3.>?]6GG:G>U?O?M.M!W:STW0V9>M@[O1T94?SYE.+^Z)L^
MFH^GO]9]C9-S=S.B[DM&/>;C[O]^'0]Z^G3VWW_Y_/;JT]\[.E']><WD1H\?
MY4'^]DUF*NK:K&Y(Z=:_*[N@K8D19E*5G./DN@']=2S;/(JO,A2/9[,.62HZ
MLZ_:5.]HDPF9850Q._-QISL>#LE2&/TI%GR]K-TBO/2,]:-M]MT%]E9&$O88
M&K]AKQOZ ;%\O)X1&'FL93;<6WU\.]4F7_M=HM@WX^DP6@ZC63C4_CF>=KIW
M1*6&A/>>-M?JY2Q^NN[HK?LT[9F]-%XFM-E,G]>L3@)O,Z4IS>R95$?Z\R%9
M-^(%KCN.EFI]5/\Z/451XO_$\()TG"R/[,RF.=4'VEPGVZ4V)1OG?*J-9EJ7
MZD?=ZS&UWN?&4[YT,UMB?T3D2^:B]DO=PIR%#S[Z(Z27_^B6D4M>9HN;W5W/
MR!),P._H=.M0PM9@V!QO,UN>N,W1^>MNX+^IP.4<,D3>9C?. CS&P];,(=_
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MWUE8BX_TYP"\J&39AXBF-[NY9U 7>5I"A\T@(8;^YX'(B_SF_P-02P,$%
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M/?1K8??G JDP"-+8(%3.%FTEU&AYXM$D37=!\H"W&='1IROFFC4RD'VRM&5
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M^U8E C@X&F*ZS>&H17$P^3[*AH&'I77!J,RH7!7=&<JA;-+95L;88 '[8M]
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MR_O$H*( ]H4Q^/6W96YF#VPE0>D/Y0[,P5IEEBMNI[&R3.I^V&QGE)R^>EV
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M.]]5F20$/=9I0^#TMTGT7[N\8(YDD[/:V'7D.EYZ@0Z^E- R!3"#N@U*S7.
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M3MKCJD [D0\KTCOA3VN'&.&6A;^@L*7($SEG(#9<!9,_$CI%V-9/)>R5OAW
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MV%V*P)#C <X(?BF+,U4>NG JOE4I)#4#R0 L:(?;)YAPER3"A@= PX]1BW%
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M$82#[B 3/1#F\=EAD(6(ED(]6)!'L\/N1Y'#[MCX(%P/CLT/*!2#DP\,TB\
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MMW$5E@)R\GOVD@E5NR'P3-%B8D0D*L,$3J\H!\TM/?GB39#E5G;W*^($$46
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M#V3:W% 2'MMFC3A5WX:.7U9M+>^?JY#=X>5K;:4(/+ "I:WTM72C_D(Z>^B
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MNP[X1[@.6!Y&*$9DBX/L#5?Z2_FT4:\!>V&HY<2M L*E#P6;39S+P#?35,K
M7A=2 C'D=AX$Y:(#]+2QCW D"T3CEH:](,2!LK8QX8IY8=27\6]SXL[(*B)V
M%.-M"M,]BI]"3\* 6DW8*T)2-G3$O[01/HGI( Y85C"5"4A0'/:"D)0#J:!P
MT_TTC']!ARD4R8:$6DW8&T12.G3$OS SMU3<,$#%SH)NV/C6:5Y9V/M$4O3%
M(EZ1P[8BR"A!JS!_F9+N"(-U2-QT?\*=T+0:@+VLI,NJ"ABP0ROMX1<<^BF"
ML_7G<(N&[ 4XLI\XW[0X$[<">]-)<Y_<%B0#N*2'K]_IR1:OL9OW=N6\W*
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M[_'<.!'RRH%9%GMF;).N_]'-_E@F?U(V%>(H2>"Q%V79[GT4;AT<\/GKYVO
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M)D/&\#AXILV%9-\T5/]22^\P_6)/5[/%+S"C\=!9G9$FK 0SBAJZI#",Q+6
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MG@M>2\ZFXQ)UZ%R>X$NZO!=1K<HM@$>UZ^9RT@7'D'%53ZC#'V"U% +\[$[
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M:%=AC.Z1DYXN%;4>'\,P2+.^)H[/7?C8%[K\ /@5I"YLV=TC#CX?%0DZ;E"
MUCAUG#5+R9]@-)H OU/1T8RAC1HXS^=NTDI^U#'594P!<]-9KK]-L^"3JGID
MNNF\=U; ]:X8*4M$GK&+F@6>AFF(/\IV;M$JC!V__/=A&,73,/X%Q0ODAIN
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M$-#I__ !97\#>SFO!:!'67I*%)U?PD\_)C2:-A6$>Z5,!TI>[PVQO>7;S,S
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MMZ=?V]-N[': 8^L[/#IF^7[XS0G<U&ZFRB=K0JL%16+_8@"QVK*U9?CGC.$
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M-S@N:'1M4$L! A0#%     @ PW-_6C772&>9 @  $1$   H
M ( !X6X  &5X,C$M,2YH=&U02P$"% ,4    " ##<W]:OU4N62\#  "3$@
M"@              @ &B<0  97@R,RTQ+FAT;5!+ 0(4 Q0    ( ,-S?UIH
MXYO;D@<  &LW   *              "  ?ET  !E>#,Q+3$N:'1M4$L! A0#
M%     @ PW-_6@BYY U."   ;E$   H              ( !LWP  &5X,S$M
M,BYH=&U02P$"% ,4    " ##<W]:XI:3R#T%  #J%@  "@
M@ $IA0  97@S,BTQ+FAT;5!+ 0(4 Q0    ( ,-S?UHM&O2=0P4  'H7   *
M              "  8Z*  !E>#,R+3(N:'1M4$L! A0#%     @ PW-_6EUK
MJYMD)@  704!  H              ( !^8\  &5X-"TQ-RYH=&U02P$"% ,4
M    " ##<W]:2_+:?&[A! ")HR4 #               @ &%M@  9F]R;3$P
M+6LN:'1M4$L! A0#%     @ PW-_6C\=Q1433P  /E   !
M ( !'9@% &9O<FTQ,"UK7S P,2YJ<&=02P$"% ,4    " ##<W]:F/]*T0H@
M  #Y(0  $               @ %>YP4 9F]R;3$P+6M?,# R+FIP9U!+ 0(4
M Q0    ( ,-S?UKZULJM7#H  "L[   0              "  98'!@!F;W)M
M,3 M:U\P,#,N:G!G4$L! A0#%     @ PW-_6GJW*)LK+0  W2T  !
M         ( !($(& &9O<FTQ,"UK7S P-"YJ<&=02P$"% ,4    " ##<W]:
M>BHSQN\<  !_'0  $               @ %Y;P8 9F]R;3$P+6M?,# U+FIP
M9U!+ 0(4 Q0    ( ,-S?UJ*<0_25RL  /$Q   0              "  9:,
M!@!F;W)M,3 M:U\P,#8N:G!G4$L! A0#%     @ PW-_6CY:T>3K3@  %U4
M !               ( !&[@& &9O<FTQ,"UK7S P-RYJ<&=02P$"% ,4
M" ##<W]:R1E^UO^(  !?E   $               @ $T!P< 9F]R;3$P+6M?
M,# X+FIP9U!+ 0(4 Q0    ( ,-S?UJ<-F=2#KP  ,J]   0
M  "  6&0!P!F;W)M,3 M:U\P,#DN:G!G4$L! A0#%     @ PW-_6K02?7DP
MJ0  4+0  !               ( !G4P( &9O<FTQ,"UK7S Q,"YJ<&=02P$"
M% ,4    " ##<W]:MAQP6D:R  "NN@  $               @ '[]0@ 9F]R
M;3$P+6M?,#$Q+FIP9U!+ 0(4 Q0    ( ,-S?UI8">D!9AL! #\E 0 0
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7;%!+!08     &@ : "X&  "_\@L    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:NAOV="http://nanovibronix.com/20241231"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="naov-20241231.xsd" xlink:type="simple"/>
    <context id="From2024-01-01to2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeriesEPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_SeriesEPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeriesFPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_SeriesFPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_PropertyPlantAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SaleOfEquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">NAOV:SaleOfEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_OfficeEquipmentMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_OfficeEquipmentMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2023-02-152023-02-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <startDate>2023-02-15</startDate>
            <endDate>2023-02-16</endDate>
        </period>
    </context>
    <context id="From2024-03-312024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <startDate>2024-03-31</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2025-03-132025-03-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <startDate>2025-03-13</startDate>
            <endDate>2025-03-13</endDate>
        </period>
    </context>
    <context id="From2025-03-122025-03-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <startDate>2025-03-12</startDate>
            <endDate>2025-03-12</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <instant>2025-03-13</instant>
        </period>
    </context>
    <context id="From2023-08-302023-08-30_custom_PurchaseAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-30</startDate>
            <endDate>2023-08-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-08-30_custom_PurchaseAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-30</instant>
        </period>
    </context>
    <context id="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-30</instant>
        </period>
    </context>
    <context id="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_A1WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:A1WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-30</instant>
        </period>
    </context>
    <context id="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_A2WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:A2WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-30</instant>
        </period>
    </context>
    <context id="AsOf2023-08-30_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-30</instant>
        </period>
    </context>
    <context id="AsOf2023-08-30_custom_PurchaseAgreementMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-30</instant>
        </period>
    </context>
    <context id="From2023-08-302023-08-30_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-30</startDate>
            <endDate>2023-08-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-07-05_custom_HCWainwrightAndCoLLCMember_custom_PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:HCWainwrightAndCoLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-05</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_TwoThousandFourteenLongTermIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">NAOV:TwoThousandFourteenLongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-02-092023-02-09_custom_TwoThousandFourteenLongTermIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">NAOV:TwoThousandFourteenLongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-09</startDate>
            <endDate>2023-02-09</endDate>
        </period>
    </context>
    <context id="AsOf2023-02-09_custom_TwoThousandFourteenLongTermIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">NAOV:TwoThousandFourteenLongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-09</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TwoThousandFourteenLongTermIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">NAOV:TwoThousandFourteenLongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandAndTwentyFourLongTermIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">NAOV:TwoThousandAndTwentyFourLongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-14_custom_TwoThousandAndTwentyFourLongTermIncentivePlanMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">NAOV:TwoThousandAndTwentyFourLongTermIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-14</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TwoThousandAndTwentyFourLongTermIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">NAOV:TwoThousandAndTwentyFourLongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_EmployeeOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EmployeeOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-08-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-30</instant>
        </period>
    </context>
    <context id="AsOf2023-08-30_custom_A1WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:A1WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-30</instant>
        </period>
    </context>
    <context id="AsOf2023-08-30_custom_A2WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:A2WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-30</instant>
        </period>
    </context>
    <context id="AsOf2023-08-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <instant>2023-08-30</instant>
        </period>
    </context>
    <context id="AsOf2023-08-30_custom_HCWainwrightAndCoLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:HCWainwrightAndCoLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_PreWarrantMember_custom_PrivateInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PrivateInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:PreWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_PostWarrantMember_custom_PrivateInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PrivateInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:PostWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_PreWarrantMember_custom_PrivateInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PrivateInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:PreWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_PostWarrantMember_custom_PrivateInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PrivateInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:PostWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PreWarrantMember_custom_PrivateInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PrivateInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:PreWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PostWarrantMember_custom_PrivateInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PrivateInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:PostWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_PreWarrantMember_custom_PrivateInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PrivateInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:PreWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_PostWarrantMember_custom_PrivateInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PrivateInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:PostWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PreWarrantMember_custom_PrivateInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PrivateInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:PreWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PostWarrantMember_custom_PrivateInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PrivateInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:PostWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_EmployeeOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_EmployeeOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_SellingAndMarketingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_SellingAndMarketingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_StockOptionsEmployeeAndNonEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">NAOV:StockOptionsEmployeeAndNonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_StockOptionsEmployeeAndNonEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">NAOV:StockOptionsEmployeeAndNonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_country_AU">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_country_AU">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_country_IL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_country_IL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_country_NZ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NZ</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_country_NZ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NZ</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_OtherCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">NAOV:OtherCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_OtherCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">NAOV:OtherCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NAOV:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-04-09_custom_LicensingAgreementMember_custom_SanuwaveHealthIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:LicensingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-09</instant>
        </period>
    </context>
    <context id="From2024-09-122024-09-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <startDate>2024-09-12</startDate>
            <endDate>2024-09-12</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <instant>2024-09-12</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PriceAtValuationMember_custom_SanuwaveHealthIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">NAOV:PriceAtValuationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PriceAtValuationMember_custom_SanuwaveHealthIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">NAOV:PriceAtValuationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_SanuwaveHealthIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_SanuwaveHealthIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_SanuwaveHealthIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_SanuwaveHealthIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SanuwaveHealthIncMember_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SanuwaveHealthIncMember_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_SanuwaveHealthIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_SanuwaveHealthIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_DerivativeAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_DerivativeAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_DerivativeAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_DerivativeAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_DerivativeAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2021-02-252021-02-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <startDate>2021-02-25</startDate>
            <endDate>2021-02-26</endDate>
        </period>
    </context>
    <context id="From2022-03-142022-03-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <startDate>2022-03-14</startDate>
            <endDate>2022-03-15</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ArbitratorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:ArbitratorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ArbitratorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:ArbitratorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_PiersonFerdinandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PiersonFerdinandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-072025-01-07_custom_SecuritiesExchangeAgreementMember_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:SecuritiesExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-07</startDate>
            <endDate>2025-01-07</endDate>
        </period>
    </context>
    <context id="AsOf2025-07-01_custom_SecuritiesExchangeAgreementMember_us-gaap_WarrantMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:SecuritiesExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-01</instant>
        </period>
    </context>
    <context id="AsOf2025-01-07_custom_SecuritiesExchangeAgreementMember_custom_PreFundedWarrantsMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:SecuritiesExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-07</instant>
        </period>
    </context>
    <context id="AsOf2025-01-07_custom_SecuritiesExchangeAgreementMember_custom_A1WarrantsMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:A1WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:SecuritiesExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-07</instant>
        </period>
    </context>
    <context id="From2025-01-072025-01-07_custom_SecuritiesExchangeAgreementMember_custom_A1WarrantsMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:A1WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:SecuritiesExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-07</startDate>
            <endDate>2025-01-07</endDate>
        </period>
    </context>
    <context id="AsOf2025-01-31_custom_SecuritiesExchangeAgreementMember_custom_PreFundedWarrantsMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:SecuritiesExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-02-28_custom_SecuritiesExchangeAgreementMember_custom_PreFundedWarrantsMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:SecuritiesExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="AsOf2025-01-31_custom_SecuritiesExchangeAgreementMember_us-gaap_WarrantMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:SecuritiesExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-02-28_custom_SecuritiesExchangeAgreementMember_us-gaap_WarrantMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:SecuritiesExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="From2025-02-142025-02-14_custom_MergerAgreementMember_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-14</startDate>
            <endDate>2025-02-14</endDate>
        </period>
    </context>
    <context id="From2025-02-142025-02-14_custom_MergerAgreementMember_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-14</startDate>
            <endDate>2025-02-14</endDate>
        </period>
    </context>
    <context id="From2025-02-142025-02-14_custom_MergerAgreementMember_custom_SeriesXPreferredStockMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NAOV:SeriesXPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-14</startDate>
            <endDate>2025-02-14</endDate>
        </period>
    </context>
    <context id="From2025-02-142025-02-14_custom_MergerAgreementMember_custom_SeriesXPreferredStockMember_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NAOV:SeriesXPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-14</startDate>
            <endDate>2025-02-14</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-13_custom_SecuritiesExchangeAgreementMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:SecuritiesExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-13</instant>
        </period>
    </context>
    <context id="AsOf2025-03-26_us-gaap_SubsequentEventMember_custom_ENvueMedicalHoldingsCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:ENvueMedicalHoldingsCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-26</instant>
        </period>
    </context>
    <context id="AsOf2025-02-26_us-gaap_SubsequentEventMember_custom_ENvueMedicalHoldingsCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:ENvueMedicalHoldingsCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-26</instant>
        </period>
    </context>
    <context id="AsOf2025-03-04_us-gaap_SubsequentEventMember_custom_ENvueMedicalHoldingsCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:ENvueMedicalHoldingsCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-04</instant>
        </period>
    </context>
    <context id="AsOf2025-03-26_us-gaap_SubsequentEventMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-26</instant>
        </period>
    </context>
    <context id="From2025-03-122025-03-12_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-12</startDate>
            <endDate>2025-03-12</endDate>
        </period>
    </context>
    <context id="From2025-03-132025-03-13_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-13</startDate>
            <endDate>2025-03-13</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-13_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-13</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-01-01to2024-12-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2024-01-01to2024-12-31" id="Fact000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2024-01-01to2024-12-31" id="Fact000005">0001326706</dei:EntityCentralIndexKey>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0093"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeNoncurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0135"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0139"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0144"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0150"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0151"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0169"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0170"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0188"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0189"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0207"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0208"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0333"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0335"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0336"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0343"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0345"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0347"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0349"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0353"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0355"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0357"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0359"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0360"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0365"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0366"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0368"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0370"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0373"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0375"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0376"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0377"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0379"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0380"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0385"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0386"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0387"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0388"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0390"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0391"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0392"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0393"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0397"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0398"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0399"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0400"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0401"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0403"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0404"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0409"
      unitRef="Shares"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0410"
      unitRef="Shares"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0411"
      unitRef="Shares"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0412"
      unitRef="Shares"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0413"
      unitRef="Shares"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0414"
      unitRef="Shares"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0415"
      unitRef="Shares"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0416"
      unitRef="Shares"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0417"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0421"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0422"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0423"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0424"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0425"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0426"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0427"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0431"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0432"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0433"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0434"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0441"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0443"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0445"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0447"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0451"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0452"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0453"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0454"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0461"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0463"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0465"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0467"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0471"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0472"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0473"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0474"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0475"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0477"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0478"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0481"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0482"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0483"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0484"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0485"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0486"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0488"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0491"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0492"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0493"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0494"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0496"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0497"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0498"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0503"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0504"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0505"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0506"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0507"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0508"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0509"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0510"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0511"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0515"
      unitRef="Shares"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0516"
      unitRef="Shares"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0517"
      unitRef="Shares"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0518"
      unitRef="Shares"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0519"
      unitRef="Shares"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0520"
      unitRef="Shares"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0521"
      unitRef="Shares"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0522"
      unitRef="Shares"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0523"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0527"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0528"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0529"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0530"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0531"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0532"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0533"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0537"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0538"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0539"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0540"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0547"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0549"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0551"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0553"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0557"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0558"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0559"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0560"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0567"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0569"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0571"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0573"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0595"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0599"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:IncreaseDecreaseInAccruedSeverancePayNet
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0622"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0640"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0643"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0647"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember"
      id="xdx2ixbrl0830"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember"
      id="xdx2ixbrl0838"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember"
      id="xdx2ixbrl0876"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember"
      id="xdx2ixbrl0878"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm
      contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember"
      id="xdx2ixbrl0880"
      xsi:nil="true"/>
    <NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm
      contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember"
      id="xdx2ixbrl0886"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember"
      id="xdx2ixbrl0888"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember"
      id="xdx2ixbrl0890"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm
      contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember"
      id="xdx2ixbrl0892"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      id="xdx2ixbrl0988"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputExpectedDividendRateMember"
      id="xdx2ixbrl0992"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember"
      id="xdx2ixbrl0994"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember"
      id="xdx2ixbrl0996"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1000"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2023-01-012023-12-31_custom_PreWarrantMember_custom_PrivateInvestorsMember"
      id="xdx2ixbrl1012"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2023-01-012023-12-31_custom_PostWarrantMember_custom_PrivateInvestorsMember"
      id="xdx2ixbrl1014"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2024-01-012024-12-31_custom_PreWarrantMember_custom_PrivateInvestorsMember"
      id="xdx2ixbrl1024"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2024-01-012024-12-31_custom_PostWarrantMember_custom_PrivateInvestorsMember"
      id="xdx2ixbrl1026"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2024-01-012024-12-31_custom_PreWarrantMember_custom_PrivateInvestorsMember"
      id="xdx2ixbrl1036"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2024-01-012024-12-31_custom_PostWarrantMember_custom_PrivateInvestorsMember"
      id="xdx2ixbrl1038"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_country_NZ"
      id="xdx2ixbrl1100"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_custom_OtherCountryMember"
      id="xdx2ixbrl1103"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="AsOf2024-12-31_custom_DerivativeAssetMember"
      id="xdx2ixbrl1167"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherAssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1171"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherAssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1172"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherAssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1173"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherAssetsFairValueDisclosure
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1174"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherAssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1176"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherAssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1177"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1215"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1216"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1218"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1219"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:DeferredTaxAssetsOfCapitalLossCarryforward
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1297"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1311"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1312"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2024-01-01to2024-12-31" id="Fact000011">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2024-01-01to2024-12-31" id="Fact000012">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2024-01-01to2024-12-31" id="Fact000013">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2024-01-01to2024-12-31" id="Fact000014">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2024-01-01to2024-12-31" id="Fact000015">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2024-01-01to2024-12-31" id="Fact000016">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2024-01-01to2024-12-31" id="Fact000017">001-36445</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2024-01-01to2024-12-31" id="Fact000018">NanoVibronix, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-01-01to2024-12-31" id="Fact000019">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2024-01-01to2024-12-31" id="Fact000020">01-0801232</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2024-01-01to2024-12-31" id="Fact000021">969 Pruitt Ave</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2024-01-01to2024-12-31" id="Fact000022">Tyler</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2024-01-01to2024-12-31" id="Fact000023">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2024-01-01to2024-12-31" id="Fact000024">77569</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2024-01-01to2024-12-31" id="Fact000025">(914)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2024-01-01to2024-12-31" id="Fact000026">233-3004</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2024-01-01to2024-12-31" id="Fact000027">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2024-01-01to2024-12-31" id="Fact000028">NAOV</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2024-01-01to2024-12-31" id="Fact000029">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2024-01-01to2024-12-31" id="Fact000030">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2024-01-01to2024-12-31" id="Fact000031">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2024-01-01to2024-12-31" id="Fact000032">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2024-01-01to2024-12-31" id="Fact000033">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2024-01-01to2024-12-31" id="Fact000034">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2024-01-01to2024-12-31" id="Fact000035">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-01-01to2024-12-31" id="Fact000036">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2024-01-01to2024-12-31" id="Fact000037">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2024-01-01to2024-12-31" id="Fact000038">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2024-01-01to2024-12-31" id="Fact000039">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2024-06-30"
      decimals="-5"
      id="Fact000040"
      unitRef="USD">1900000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000041"
      unitRef="Shares">759297</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000042">None</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000046">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
operate in the biotechnology sector, which is subject to various cybersecurity risks that could adversely affect our business, financial
condition, and results of operations, including intellectual property theft; fraud; extortion; harm to employees or customers; violation
of privacy laws and other litigation and legal risk; and reputational risk. We recognize the critical importance of developing, implementing,
and maintaining robust cybersecurity measures to safeguard our information systems and protect the confidentiality, integrity, and availability
of our data. We currently have security measures in place to protect our clients, patients, customers, employees,&#x200c; and vendor information
and prevent data loss and other security breaches, including a cybersecurity risk assessment program. We also only use third party software
for accounting, billing and payroll that have successful SOC 1 type 2 compliance. Both management and the Board are actively involved
in the continuous assessment of risks from cybersecurity threats, including prevention, mitigation, detection, and remediation of cybersecurity
incidents.&lt;/span&gt;ur
current cybersecurity risk &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zf9DwAAmVsKk"&gt;assessment&lt;/span&gt; program consists of an annual review of our risks and policies. The program outlines governance,
policies and procedures, and technology we use to oversee and identify risks from cybersecurity threats and is informed by previous cybersecurity
incidents we have observed both within the Company and in our industry.&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90D_ecyd--CybersecurityRiskBoardOfDirectorsOversightTextBlock_dbF_c20240101__20241231_zEXGSX4wxK0l"&gt;Our
General Manager, who is responsible for overseeing our business operations, with oversight from senior management and the nominating
and the Corporate Governance Committee of our Board are responsible for day-to-day assessment and management of risks from cybersecurity
threats, including the prevention, mitigation, detection, and remediation of cybersecurity incidents. We also use the services of an
outside consulting firm to monitor activity and advise the company of cybersecurity protocols.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90A_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_dbF_c20240101__20241231_zy1oEP85IMt8"&gt;The
Nominating and Corporate Governance Committee of the Board is responsible for oversight of risks from cybersecurity threats in conjunction
with management.&lt;/span&gt; &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_902_ecyd--CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_dbF_c20240101__20241231_zHh5FebJQeR"&gt;The committee receives interim reports and updates from the senior management, and management has committed to updating
the full Board on a quarterly basis with respect to the management of risks from cybersecurity threats. Such reports cover the Company&#x2019;s
information technology security program, including its current status, capabilities, objectives and plans, as well as the evolving cybersecurity
threat landscape.&lt;/span&gt; &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90C_ecyd--CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_c20240101__20241231_zmxUV4IcXI02"&gt;Additionally, the Nominating and Corporate Governance Committee considers risks from cybersecurity threats as part
of its oversight of the Company&#x2019;s business strategy, risk management, and financial oversight by requiring quarterly updates from
management at its Board meetings.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_908_ecyd--CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_dbF_c20240101__20241231_zDHf85LkjJv2"&gt;We
routinely undertake activities to prevent, detect, and minimize the effects of cybersecurity incidents, including an annual risk review,
policy reviews and revisions. In addition, we maintain business continuity, contingency, and recovery plans for use in the event of a
cybersecurity incident by the administering of local and cloud based back up of files. and emails.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
engaged and used the advice of a &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_908_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_zBTCkr33832l"&gt;third-party&lt;/span&gt; consultant to help us assess and identify risks from cybersecurity threats, including the
threat of a cybersecurity incident, and manage our risk assessment program. Among other things, these providers have recommended installation
of Check Point Firewall and ESET Protect Advanced cloud based anti-virus, as well as site periodic evaluations of the work stations and
onsite storage equipment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
also engaged third party consultants to prepare policies and procedures to oversee and identify the risks from cybersecurity threats
associated with our use of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90C_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20240101__20241231_zdVmydKWbCKj"&gt;third-party&lt;/span&gt; service providers and we continue to monitor that all third-party software providers remain in
compliance with SOC 1 protocols.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of the date of this report, &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90F_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240101__20241231_z7DONbS7NdSi"&gt;no&lt;/span&gt; cybersecurity incident (or aggregation of incidents) or cybersecurity threat has materially affected our
results of operations or financial condition. However, an actual or perceived breach of our security could damage our reputation, and
cause existing clients/customers to discontinue. As well as prevent us from attracting new clients/customers, and interfere with the
progress of our clinical trials, or interfere with our efforts to pursue regulatory approvals for our product candidates, or subject
us to third-party lawsuits, regulatory fines or other actions or liabilities, any of which could adversely affect our business, operating
results or financial condition. For further information, see &#x201c;Risk Factors-&lt;i&gt;Our business and operations would suffer in the event
of computer system failures, cyber-attacks or deficiencies in our cyber-security&lt;/i&gt;&#x201d; in Item 1A of this Annual Report on Form
10-K. We currently do not carry a cyber liability insurance policy, but are evaluating whether to acquire one to mitigate any financial
impact of a cybersecurity breach.&lt;/span&gt;&lt;/p&gt;

&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000047">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span&gt;O&lt;span id="xdx_C04_gBFCRMPFAIAMT-VZ_zCWam0ACpJCc"&gt;ur
current cybersecurity risk &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zf9DwAAmVsKk"&gt;assessment&lt;/span&gt; program consists of an annual review of our risks and policies. The program outlines governance,
policies and procedures, and technology we use to oversee and identify risks from cybersecurity threats and is informed by previous cybersecurity
incidents we have observed both within the Company and in our industry.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="From2024-01-01to2024-12-31" id="Fact000048">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000049">Our
General Manager, who is responsible for overseeing our business operations, with oversight from senior management and the nominating
and the Corporate Governance Committee of our Board are responsible for day-to-day assessment and management of risks from cybersecurity
threats, including the prevention, mitigation, detection, and remediation of cybersecurity incidents. We also use the services of an
outside consulting firm to monitor activity and advise the company of cybersecurity protocols.</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000050">The
Nominating and Corporate Governance Committee of the Board is responsible for oversight of risks from cybersecurity threats in conjunction
with management.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000051">The committee receives interim reports and updates from the senior management, and management has committed to updating
the full Board on a quarterly basis with respect to the management of risks from cybersecurity threats. Such reports cover the Company&#x2019;s
information technology security program, including its current status, capabilities, objectives and plans, as well as the evolving cybersecurity
threat landscape.</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000052">Additionally, the Nominating and Corporate Governance Committee considers risks from cybersecurity threats as part
of its oversight of the Company&#x2019;s business strategy, risk management, and financial oversight by requiring quarterly updates from
management at its Board meetings.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000053">We
routinely undertake activities to prevent, detect, and minimize the effects of cybersecurity incidents, including an annual risk review,
policy reviews and revisions. In addition, we maintain business continuity, contingency, and recovery plans for use in the event of a
cybersecurity incident by the administering of local and cloud based back up of files. and emails.</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="From2024-01-01to2024-12-31" id="Fact000054">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="From2024-01-01to2024-12-31" id="Fact000055">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="From2024-01-01to2024-12-31" id="Fact000056">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <NAOV:NoInsiderTradingFlag contextRef="From2024-01-01to2024-12-31" id="Fact000058">true</NAOV:NoInsiderTradingFlag>
    <ecd:InsiderTrdPoliciesProcNotAdoptedTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000060">We
maintain an insider trading policy that applies to our officers and directors that prohibits trading our securities during certain established
periods and when in possession of material non-public information. It also prohibits, unless approved in advance in limited circumstances
by the policy administrator, the hedging of our securities, including short sales or purchases or sales of derivative securities based
on our securities, and the use of our securities to secure a margin or other loan. Since the adoption of our insider trading policy,
the policy administrator has not granted any such exemptions to the policy&#x2019;s general prohibition on hedging or pledging. While
the Company is not subject to the insider trading policy, the company does not trade in its securities when it is in possession of material
nonpublic information other than pursuant to previously adopted Rule 10b5-1 trading plans.</ecd:InsiderTrdPoliciesProcNotAdoptedTextBlock>
    <dei:AuditorFirmId contextRef="From2024-01-01to2024-12-31" id="Fact000061">549</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000062">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have audited the accompanying consolidated balance sheets of NanoVibronix, Inc. (the &#x201c;Company&#x201d;) as of December 31, 2024,
and the related consolidated statements of operations, comprehensive loss, stockholders&#x2019; equity and cash flows for the year then
ended, and the related notes (collectively referred to as the &#x201c;financial statements&#x201d;). In our opinion, the financial statements
present fairly, in all material respects, the financial position of the Company as of December 31, 2024, and the results of its operations
and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.&lt;/span&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName contextRef="From2024-01-01to2024-12-31" id="Fact000063">Zwick CPA, PLLC</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2024-01-01to2024-12-31" id="Fact000064">Southfield, Michigan</dei:AuditorLocation>
    <us-gaap:Cash
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000072"
      unitRef="USD">752000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000073"
      unitRef="USD">3283000</us-gaap:Cash>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000075"
      unitRef="USD">98000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000076"
      unitRef="USD">318000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000078"
      unitRef="USD">290000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000079"
      unitRef="USD">154000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:InventoryNet
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000081"
      unitRef="USD">2191000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000082"
      unitRef="USD">2732000</us-gaap:InventoryNet>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000084"
      unitRef="USD">3331000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000085"
      unitRef="USD">6487000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000090"
      unitRef="USD">9000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000091"
      unitRef="USD">7000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000094"
      unitRef="USD">1000</us-gaap:OtherAssetsNoncurrent>
    <NAOV:SeveranceAssetsNoncurent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000096"
      unitRef="USD">173000</NAOV:SeveranceAssetsNoncurent>
    <NAOV:SeveranceAssetsNoncurent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000097"
      unitRef="USD">174000</NAOV:SeveranceAssetsNoncurent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000099"
      unitRef="USD">116000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000100"
      unitRef="USD">5000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000102"
      unitRef="USD">298000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000103"
      unitRef="USD">187000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000105"
      unitRef="USD">3629000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000106"
      unitRef="USD">6674000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000114"
      unitRef="USD">47000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000115"
      unitRef="USD">138000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000117"
      unitRef="USD">2608000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000118"
      unitRef="USD">2265000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:DeferredIncomeCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000120"
      unitRef="USD">15000</us-gaap:DeferredIncomeCurrent>
    <us-gaap:DeferredIncomeCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000121"
      unitRef="USD">46000</us-gaap:DeferredIncomeCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000123"
      unitRef="USD">52000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000124"
      unitRef="USD">5000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000126"
      unitRef="USD">2722000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000127"
      unitRef="USD">2454000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000132"
      unitRef="USD">216000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000133"
      unitRef="USD">217000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
    <us-gaap:DeferredIncomeNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000136"
      unitRef="USD">15000</us-gaap:DeferredIncomeNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000138"
      unitRef="USD">64000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000141"
      unitRef="USD">3002000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000142"
      unitRef="USD">2686000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000153"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000155"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000157"
      unitRef="Shares">3000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000159"
      unitRef="Shares">3000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000161"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000163"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000165"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000167"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      id="Fact000172"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      id="Fact000174"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      id="Fact000176"
      unitRef="Shares">506</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      id="Fact000178"
      unitRef="Shares">506</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      id="Fact000180"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      id="Fact000182"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      id="Fact000184"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      id="Fact000186"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31_us-gaap_SeriesEPreferredStockMember"
      decimals="INF"
      id="Fact000191"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_us-gaap_SeriesEPreferredStockMember"
      decimals="INF"
      id="Fact000193"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31_us-gaap_SeriesEPreferredStockMember"
      decimals="INF"
      id="Fact000195"
      unitRef="Shares">1999494</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_us-gaap_SeriesEPreferredStockMember"
      decimals="INF"
      id="Fact000197"
      unitRef="Shares">1999494</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31_us-gaap_SeriesEPreferredStockMember"
      decimals="INF"
      id="Fact000199"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_SeriesEPreferredStockMember"
      decimals="INF"
      id="Fact000201"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31_us-gaap_SeriesEPreferredStockMember"
      decimals="INF"
      id="Fact000203"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_SeriesEPreferredStockMember"
      decimals="INF"
      id="Fact000205"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31_us-gaap_SeriesFPreferredStockMember"
      decimals="INF"
      id="Fact000210"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_us-gaap_SeriesFPreferredStockMember"
      decimals="INF"
      id="Fact000212"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31_us-gaap_SeriesFPreferredStockMember"
      decimals="INF"
      id="Fact000214"
      unitRef="Shares">40000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_us-gaap_SeriesFPreferredStockMember"
      decimals="INF"
      id="Fact000216"
      unitRef="Shares">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31_us-gaap_SeriesFPreferredStockMember"
      decimals="INF"
      id="Fact000218"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_SeriesFPreferredStockMember"
      decimals="INF"
      id="Fact000220"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31_us-gaap_SeriesFPreferredStockMember"
      decimals="INF"
      id="Fact000222"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_SeriesFPreferredStockMember"
      decimals="INF"
      id="Fact000224"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000232"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000234"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000236"
      unitRef="Shares">40000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000238"
      unitRef="Shares">40000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000240"
      unitRef="Shares">378941</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000242"
      unitRef="Shares">378941</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000244"
      unitRef="Shares">186028</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000246"
      unitRef="Shares">186028</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000229"
      unitRef="USD">3000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000230"
      unitRef="USD">2000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000248"
      unitRef="USD">70505000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000249"
      unitRef="USD">70149000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000251"
      unitRef="USD">-80000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000252"
      unitRef="USD">-67000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000254"
      unitRef="USD">-69801000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000255"
      unitRef="USD">-66096000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000257"
      unitRef="USD">627000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000258"
      unitRef="USD">3988000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000260"
      unitRef="USD">3629000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000261"
      unitRef="USD">6674000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000263"
      unitRef="USD">2558000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000264"
      unitRef="USD">2283000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000266"
      unitRef="USD">1050000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000267"
      unitRef="USD">746000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000269"
      unitRef="USD">1508000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000270"
      unitRef="USD">1537000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000275"
      unitRef="USD">909000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000276"
      unitRef="USD">185000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000278"
      unitRef="USD">720000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000279"
      unitRef="USD">864000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000281"
      unitRef="USD">3461000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000282"
      unitRef="USD">3924000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000284"
      unitRef="USD">5090000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000285"
      unitRef="USD">4973000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000287"
      unitRef="USD">-3582000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000288"
      unitRef="USD">-3436000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000290"
      unitRef="USD">135000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000291"
      unitRef="USD">135000</us-gaap:InterestExpense>
    <NAOV:FinancialIncomeExpensesNet
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000293"
      unitRef="USD">31000</NAOV:FinancialIncomeExpensesNet>
    <NAOV:FinancialIncomeExpensesNet
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000294"
      unitRef="USD">-111000</NAOV:FinancialIncomeExpensesNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000296"
      unitRef="USD">-3686000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000297"
      unitRef="USD">-3682000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000299"
      unitRef="USD">19000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000300"
      unitRef="USD">29000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000302"
      unitRef="USD">-3705000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000303"
      unitRef="USD">-3711000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000305"
      unitRef="USDPShares">-13.73</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000307"
      unitRef="USDPShares">-13.73</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000309"
      unitRef="USDPShares">-23.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000311"
      unitRef="USDPShares">-23.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000313"
      unitRef="Shares">269848</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000315"
      unitRef="Shares">269848</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000317"
      unitRef="Shares">159105</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000319"
      unitRef="Shares">159105</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000324"
      unitRef="USD">-3705000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000325"
      unitRef="USD">-3711000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000327"
      unitRef="USD">-13000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000328"
      unitRef="USD">-49000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000330"
      unitRef="USD">-3718000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000331"
      unitRef="USD">-3760000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000351"
      unitRef="Shares">149195</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000337"
      unitRef="USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000338"
      unitRef="USD">65634000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000339"
      unitRef="USD">-18000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000340"
      unitRef="USD">-62385000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000341"
      unitRef="USD">3233000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000358"
      unitRef="USD">293000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000361"
      unitRef="USD">293000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000369"
      unitRef="USD">-49000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000371"
      unitRef="USD">-49000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000383"
      unitRef="Shares">496</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000378"
      unitRef="USD">7000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000381"
      unitRef="USD">7000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <NAOV:StockIssuedDuringPeriodSharesPrefundedWarrantsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000395"
      unitRef="Shares">18543</NAOV:StockIssuedDuringPeriodSharesPrefundedWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000407"
      unitRef="Shares">16364</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000402"
      unitRef="USD">4215000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000405"
      unitRef="USD">4215000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000419"
      unitRef="Shares">1430</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000428"
      unitRef="USD">-3711000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000429"
      unitRef="USD">-3711000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000449"
      unitRef="Shares">186028</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000435"
      unitRef="USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000436"
      unitRef="USD">70149000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000437"
      unitRef="USD">-67000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000438"
      unitRef="USD">-66096000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000439"
      unitRef="USD">3988000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000469"
      unitRef="Shares">186028</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000455"
      unitRef="USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000456"
      unitRef="USD">70149000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000457"
      unitRef="USD">-67000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000458"
      unitRef="USD">-66096000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000459"
      unitRef="USD">3988000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000476"
      unitRef="USD">356000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000479"
      unitRef="USD">356000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000487"
      unitRef="USD">-13000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000489"
      unitRef="USD">-13000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <NAOV:StockIssuedDuringPeriodSharesPrefundedWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000501"
      unitRef="Shares">125818</NAOV:StockIssuedDuringPeriodSharesPrefundedWarrantsExercised>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000495"
      unitRef="USD">1000</NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000499"
      unitRef="USD">1000</NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000513"
      unitRef="Shares">67091</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000525"
      unitRef="Shares">4</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000534"
      unitRef="USD">-3705000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000535"
      unitRef="USD">-3705000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000555"
      unitRef="Shares">378941</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000541"
      unitRef="USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000542"
      unitRef="USD">70505000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000543"
      unitRef="USD">-80000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000544"
      unitRef="USD">-69801000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000545"
      unitRef="USD">627000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000575"
      unitRef="Shares">378941</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000561"
      unitRef="USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000562"
      unitRef="USD">70505000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000563"
      unitRef="USD">-80000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000564"
      unitRef="USD">-69801000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000565"
      unitRef="USD">627000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000580"
      unitRef="USD">-3705000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000581"
      unitRef="USD">-3711000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000586"
      unitRef="USD">1000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000587"
      unitRef="USD">1000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000589"
      unitRef="USD">356000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000590"
      unitRef="USD">293000</us-gaap:ShareBasedCompensation>
    <NAOV:NoncashInterestExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000592"
      unitRef="USD">100000</NAOV:NoncashInterestExpense>
    <NAOV:NoncashInterestExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000593"
      unitRef="USD">135000</NAOV:NoncashInterestExpense>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000596"
      unitRef="USD">-2000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000598"
      unitRef="USD">-1000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000604"
      unitRef="USD">-221000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000605"
      unitRef="USD">309000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000607"
      unitRef="USD">136000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000608"
      unitRef="USD">-558000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000610"
      unitRef="USD">-541000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000611"
      unitRef="USD">557000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000613"
      unitRef="USD">-91000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000614"
      unitRef="USD">72000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000616"
      unitRef="USD">242000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000617"
      unitRef="USD">-18000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000619"
      unitRef="USD">-46000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000620"
      unitRef="USD">-67000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <NAOV:IncreaseDecreaseInAccruedSeverancePayNet
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000623"
      unitRef="USD">-1000</NAOV:IncreaseDecreaseInAccruedSeverancePayNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000625"
      unitRef="USD">-2516000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000626"
      unitRef="USD">-3602000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000631"
      unitRef="USD">3000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000632"
      unitRef="USD">1000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000634"
      unitRef="USD">-3000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000635"
      unitRef="USD">-1000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000641"
      unitRef="USD">4215000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000644"
      unitRef="USD">7000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000646"
      unitRef="USD">1000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000649"
      unitRef="USD">1000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000650"
      unitRef="USD">4222000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000652"
      unitRef="USD">-13000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000653"
      unitRef="USD">-49000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000655"
      unitRef="USD">-2531000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000656"
      unitRef="USD">570000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000658"
      unitRef="USD">3283000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000659"
      unitRef="USD">2713000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000661"
      unitRef="USD">752000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000662"
      unitRef="USD">3283000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NatureOfOperations contextRef="From2024-01-01to2024-12-31" id="Fact000664">&lt;p id="xdx_80E_eus-gaap--NatureOfOperations_zTx9bxAIKo13" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
1 - &lt;span id="xdx_820_z5pEQZQsxCYb"&gt;DESCRIPTION OF BUSINESS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NanoVibronix,
Inc. (the &#x201c;Company&#x201d;), a Delaware corporation, commenced operations on October 20, 2003, and is a medical device company focusing
on non-invasive biological response-activating devices that target wound healing and pain therapy and can be administered at home, without
the assistance of medical professionals.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s principal research and development activities are conducted in Israel through its wholly-owned subsidiary, NanoVibronix
Ltd., a company registered in Israel, which commenced operations in October 2003.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NatureOfOperations>
    <NAOV:GoingConcernAndLiquidityTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000666">&lt;p id="xdx_80D_ecustom--GoingConcernAndLiquidityTextBlock_zPQQYVT6MEF8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2 - &lt;span id="xdx_829_zFVxoQP33I76"&gt;LIQUIDITY AND PLAN OF OPERATIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s ability to continue to operate is dependent mainly on its ability to successfully market and sell its products and the
receipt of additional financing until profitability is achieved. In 2024, the Company&#x2019;s cash used in operations was $&lt;span id="xdx_90C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20240101__20241231_zN6VgXKoB8ie" title="Net cash used in operating activities"&gt;2,516,000&lt;/span&gt;,
cash used in investing activities of $&lt;span id="xdx_90B_eus-gaap--NetCashProvidedByUsedInInvestingActivities_c20240101__20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember_zcmKbZF9ZB8a" title="Investing activities"&gt;3,000&lt;/span&gt; from the purchase of property plant and equipment, and received net proceeds of $&lt;span id="xdx_907_ecustom--StockIssuedDuringPeriodValuePrefundedWarrantsExercised_c20240101__20241231_zeNBBZoFTwwe" title="Exercise of prefunded warrants"&gt;1,000&lt;/span&gt; from
the exercise of prefunded warrants, leaving a cash balance of $&lt;span id="xdx_903_eus-gaap--Cash_iI_c20241231__us-gaap--CollateralAxis__custom--SaleOfEquitySecuritiesMember_zXlDHlM32Ue1" title="Cash balance"&gt;752,000&lt;/span&gt; as of December 31, 2024. Because the Company does not have sufficient
resources to fund our operation for the next twelve months from the date of this filing, management has substantial doubt of the Company&#x2019;s
ability to continue as a going concern. The Company will need to raise additional capital to finance its losses and negative cash flows
from operations and may continue to be dependent on additional capital raising as long as our products do not reach commercial profitability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</NAOV:GoingConcernAndLiquidityTextBlock>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000668"
      unitRef="USD">-2516000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-012024-12-31_us-gaap_PropertyPlantAndEquipmentMember"
      decimals="0"
      id="Fact000670"
      unitRef="USD">3000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000672"
      unitRef="USD">1000</NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised>
    <us-gaap:Cash
      contextRef="AsOf2024-12-31_custom_SaleOfEquitySecuritiesMember"
      decimals="0"
      id="Fact000674"
      unitRef="USD">752000</us-gaap:Cash>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000676">&lt;p id="xdx_806_eus-gaap--SignificantAccountingPoliciesTextBlock_zlUptZkB4Kwc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
3 - &lt;span id="xdx_820_zLLj3krqIkTb"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z70ns3JxFLLc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Basis
of presentation and principles of consolidation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements include the accounts of NanoVibronix, Inc. and its wholly owned subsidiary. Intercompany
accounts and transactions have been eliminated. The consolidated financial statements and accompanying notes have been prepared in conformity
with U.S. generally accepted accounting principles (&#x201c;US GAAP&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--UseOfEstimates_zMfdFD4yoxyb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Use
of estimates&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and
assumptions. The Company believes that the estimates, judgments and assumptions used are reasonable based upon information available
at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during
the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zoYspOsZUoif" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Foreign
currency translation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Non-U.S.
dollar denominated transactions and balances have been re-measured to U.S. dollars. All gains and losses from re-measurement of monetary
balance sheet items denominated in non-U.S. dollar currencies are reflected in the statements of operations as other comprehensive income,
as appropriate. The cumulative translation losses and gains as of the years ended December 31, 2024, and 2023 were $&lt;span id="xdx_90F_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_c20240101__20241231_zaXYHL6baVDi" title="Cumulative translation gains"&gt;19,000&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_c20230101__20231231_zv9MMW0ey4gf" title="Cumulative translation gains"&gt;49,000&lt;/span&gt;,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zESQdMF0jdxf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Cash&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company holds cash in various banking institutions. Such funds are insured by the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;)
up to $&lt;span id="xdx_903_eus-gaap--CashFDICInsuredAmount_iI_c20241231_zNRbqRvwhYCc" title="Cash FDIC, insured amount"&gt;250,000&lt;/span&gt;. Cash balances could exceed insured amounts at any given time. As of December 31, 2024, the company had cash in excess
of the FDIC insured amount totaling $&lt;span id="xdx_90C_eus-gaap--TimeDepositsAtOrAboveFDICInsuranceLimit_iI_c20241231_zD2ktgj1NVY" title="Cash uninsured amount"&gt;306,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zQ4tFYMG8Xkh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Trade
receivables&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s trade receivable balance consists of amounts due from its customers. The Current Expected Credit Losses (&#x201c;CECL&#x201d;)
impairment model requires an estimate of expected credit losses, measured over the contractual life of an instrument, which considers
forecasts of future economic conditions in addition to information about past events and current conditions. Based on this model, the
Company considers many factors, including the age of the balance, collection history, and current economic trends. Credit losses are
written off after all collection efforts have ceased. Allowances for credit losses are recorded as a direct reduction from an asset&#x2019;s
amortized cost basis. Credit losses and recoveries are recorded in selling, general and administrative expenses in the consolidated statements
of operations. Recoveries of financial assets previously written off are recorded when received. Trades receivables were $&lt;span id="xdx_90F_eus-gaap--AccountsReceivableNet_iI_c20241231_zX8gOLg56R27" title="Trades receivables"&gt;98,000&lt;/span&gt; as of
December 31, 2024, and are not anticipated to possess substantial credit risk or expected credit losses. The Company&#x2019;s current
policy is to not charge late fees or other penalties for late payments but may consider charging customers late fees in the future. Historically,
the Company has not had significant write offs of trade receivables. All sales are non-refundable. As of December 31, 2024, the Company
evaluated historical collections from vendors and collection policies and has estimated that current expected credit losses ( &#x201c;CECL&#x201d;)
to be $&lt;span id="xdx_902_ecustom--ChangeInCurrentExpectedCreditLosses_pn3n3_c20240101__20241231_z9hUkZcKjFXh" title="Change in current expected credit losses"&gt;0&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--AdvertisingCostsPolicyTextBlock_zXjraNwAjkrd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Advertising
and Marketing Costs&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Costs
associated with advertising are charged to expenses as incurred. For the year ended December 31, 2024, and 2023, the advertising and
marketing costs were $&lt;span id="xdx_90E_eus-gaap--MarketingAndAdvertisingExpense_c20240101__20241231_ziUXw2ls3O3e" title="Advertising and marketing costs"&gt;53,000&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--MarketingAndAdvertisingExpense_c20230101__20231231_z6ebkWgsalOl" title="Advertising and marketing costs"&gt;106,000&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zrzJQIvOlaeb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Earnings
per share&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
loss per share was computed using the weighted average number of common shares outstanding. Diluted loss per share includes the effect
of diluted common stock equivalents. Potentially dilutive securities from the exercise of stock option, warrants and exercise of preferred
stock as of December 31, 2024, and 2023, respectively, were excluded from the computation of diluted net loss per share because the effect
of their inclusion would have been antidilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--InventoryPolicyTextBlock_zVV543rKQYS9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Inventory&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories
are stated at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course
of business, less reasonably predictable costs of completion, disposal, and transportation. Cost is determined using the &#x201c;first-in,
first-out&#x201d; method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory
write-offs are provided to cover risks arising from slow-moving items or technological obsolescence. The Company periodically evaluates
the quantities on hand relative to current and historical selling prices and historical and projected sales volume. Based on this evaluation,
provisions are made when required to write-down inventory to its net market value. As of December 31, 2024, and 2023, there was &lt;span id="xdx_90F_eus-gaap--InventoryAdjustments_iI_pn3n3_do_c20241231_zsWGdZVnBec4" title="Inventory allowance"&gt;&lt;span id="xdx_902_eus-gaap--InventoryAdjustments_iI_pn3n3_do_c20231231_ztRrGcIKb95l" title="Inventory allowance"&gt;no&lt;/span&gt;&lt;/span&gt; allowance
on inventory.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z8lUfCkwaB9c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Property
and equipment, net&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_ecustom--ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock_zKKjFz17QRPb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the
estimated useful lives of the assets, at the following annual rates:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zLTUCzBGvf0b" style="display: none"&gt;SCHEDULE OF DEPRECIATION CALCULATED OVER ESTIMATED USEFUL LIVES OF ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;Years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; text-align: justify"&gt;Computers and peripheral equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 16%; text-align: center"&gt;&lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zS8qn4YwxKkh" title="Estimated useful life"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_z6mGGsDo1sLl" title="Estimated useful life"&gt;5&lt;/span&gt;-&lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zOxEAVxNuY0a" title="Estimated useful life"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zmUz89Ndvjld" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zxgc8zi6ZLpi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Impairment
of Long-Lived Assets&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
reviews for impairment whenever events or changes in circumstances indicate that the carrying amount of property and equipment may not
be recoverable under the provisions of accounting for the impairment of long-lived assets. If it is determined that an impairment loss
has occurred based upon expected future cash flows, the loss is recognized in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_ecustom--SequencingPolicyTextBlock_zDvDjlG4oCrk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Sequencing&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company adopted a sequencing policy under ASC 815-40-35 whereby if reclassification of contracts from equity to liabilities is necessary
pursuant to ASC 815 due to the Company&#x2019;s inability to demonstrate it has sufficient authorized shares. This was due to the Company
committing more shares than authorized. While temporary suspensions are in place to keep the potential exercises beneath the number authorized,
certain instruments are classified as liabilities, after allocating available authorized shares on the basis of the most recent grant
date of potentially dilutive instruments. Pursuant to ASC 815, issuances of securities granted as compensation in a share-based payment
arrangement are not subject to the sequencing policy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_ecustom--SeverancePayPolicyTextBlock_zeWMWwzAPh0j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Severance
pay&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s liability for severance pay is for its Israeli employees and is calculated pursuant to Israeli Severance Pay Law based
on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date and is in large
part covered by regular deposits with recognized pension funds, deposits with severance pay funds and purchases of insurance policies.
The value of these deposits and policies is recorded as an asset in the Company&#x2019;s balance sheet. Accrued severance pay liability
on December 31, 2024, and 2023 was $&lt;span id="xdx_906_ecustom--AccruedSeverancePayLiability_c20240101__20241231_zj57yXkQgAKl" title="Accrued severance pay liability"&gt;216,000&lt;/span&gt; and $&lt;span id="xdx_90F_ecustom--AccruedSeverancePayLiability_c20230101__20231231_zuAPMFAUtJSi" title="Accrued severance pay liability"&gt;217,000&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--LesseeLeasesPolicyTextBlock_z9a2mVAhxFN6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for its leases in accordance with ASU 2016-02, &#x201c;Leases&#x201d; (Topic 842). This topic requires that a lessee recognize
the assets and liabilities that arise from operating leases. The Company recognizes right-of-use assets and lease liabilities on the
consolidated balance sheet for all leases with a term longer than 12 months and classifies them as operating leases. For leases with
a term of 12 months or less, the Company elects not to recognize lease assets and lease liabilities on those leases. The right-of-use
assets and lease liabilities have been measured by the present value of the Company&#x2019;s remaining lease payments over the lease term
using our incremental borrowing rates or implicit rates, when readily determinable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z7i2eOV0280i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Revenue
recognition&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;It
is the Company&#x2019;s policy that revenues from product sales is recognized in accordance with ASC 606 &#x201c;Revenue Recognition.&#x201d;
Five basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that create(s) enforceable
rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services
to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects to
be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to the performance
obligations in the contract, which requires the company to allocate the transaction price to each performance obligation on the basis
of the relative standalone selling prices of each distinct good or services promised in the contract; and (5) Recognizing revenue when
(or as) the entity satisfies a performance obligation by transferring a promised good or service to a customer. The amount of revenue
recognized is the amount allocated to the satisfied performance obligation. Adoption of ASC 606 has not changed the timing and nature
of the Company&#x2019;s revenue recognition and there has been no material effect on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue
from product sales is recorded at the net sales price, or &#x201c;transaction price,&#x201d; which includes estimates of variable consideration
that result from coupons, discounts, chargebacks and distributor fees, processing fees, as well as allowances for returns and government
rebates. The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue.
Collectability of revenue is reasonably assured based on historical evidence of collectability between the Company and its customers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenues
from sales to distributors are recognized at the time the products are delivered to the distributors (sell-in&#x201d;). The Company does
not grant rights of return, credits, rebates, price protection, or other privileges on its products to distributors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--IncomeTaxPolicyTextBlock_zlDPYCgQDXTe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Income
taxes&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes in accordance with ASC 740, &#x201c;Income Taxes&#x201d;. This topic prescribes the use of the liability
method whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and
tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences
are expected to reverse. The Company provides full valuation allowance, to reduce deferred tax assets to the amount that is more likely
than not to be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company implements a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position
taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than
not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related
appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% (cumulative
basis) likely to be realized upon ultimate settlement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes interest and penalties related to uncertain tax positions on the income tax expense line in the accompanying consolidated
statement of operations. Accrued interest and penalties are included on the related tax liability line in the consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zjOYKe1VDQC5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Stock-based
compensation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company selected the Black-Scholes-Merton option pricing model as the most appropriate fair value method for its stock-options awards.
The option-pricing model requires a number of assumptions, of which the most significant are the expected stock price volatility and
the expected option term. Expected volatility was calculated based upon similar traded companies&#x2019; historical share price movements.
The expected option term represents the period that the Company&#x2019;s stock options are expected to be outstanding. The Company currently
uses the simplified method and will continue to do so until sufficient historical exercise data supports using expected life assumptions.
The risk-free interest rate is based on the yield from U.S. Treasury zero-coupon bonds with an equivalent term. The expected dividend
yield assumption is based on the Company&#x2019;s historical experience and expectation of no future dividend payouts. The Company has
historically not paid cash dividends and has no foreseeable plans to pay cash dividends in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z88NbAq5McIl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Recently
adopted accounting standards&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-13,
Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#x201c;ASU 2016-13&#x201d;)
and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, and ASU 2019-05 (collectively, &#x201c;Topic
326&#x201d;). Topic 326 requires measurement and recognition of expected credit losses for financial assets held. This ASU is effective
for interim and annual reporting periods beginning after December 15, 2022. The adoption of Topic 326 did not have a material effect
on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the FASB issued ASU No. 2023-07, &lt;i&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/i&gt;,
which requires an enhanced disclosure of significant segment expenses on an annual and interim basis. This guidance is effective for
annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption
is permitted. Upon adoption, the guidance should be applied retrospectively to all prior periods presented in the financial statements.
The adoption of Topic 280 did not have a material effect on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000678">&lt;p id="xdx_844_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z70ns3JxFLLc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Basis
of presentation and principles of consolidation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements include the accounts of NanoVibronix, Inc. and its wholly owned subsidiary. Intercompany
accounts and transactions have been eliminated. The consolidated financial statements and accompanying notes have been prepared in conformity
with U.S. generally accepted accounting principles (&#x201c;US GAAP&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2024-01-01to2024-12-31" id="Fact000680">&lt;p id="xdx_84C_eus-gaap--UseOfEstimates_zMfdFD4yoxyb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Use
of estimates&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and
assumptions. The Company believes that the estimates, judgments and assumptions used are reasonable based upon information available
at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during
the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000682">&lt;p id="xdx_844_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zoYspOsZUoif" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Foreign
currency translation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Non-U.S.
dollar denominated transactions and balances have been re-measured to U.S. dollars. All gains and losses from re-measurement of monetary
balance sheet items denominated in non-U.S. dollar currencies are reflected in the statements of operations as other comprehensive income,
as appropriate. The cumulative translation losses and gains as of the years ended December 31, 2024, and 2023 were $&lt;span id="xdx_90F_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_c20240101__20241231_zaXYHL6baVDi" title="Cumulative translation gains"&gt;19,000&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_c20230101__20231231_zv9MMW0ey4gf" title="Cumulative translation gains"&gt;49,000&lt;/span&gt;,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000684"
      unitRef="USD">19000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000686"
      unitRef="USD">49000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000688">&lt;p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zESQdMF0jdxf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Cash&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company holds cash in various banking institutions. Such funds are insured by the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;)
up to $&lt;span id="xdx_903_eus-gaap--CashFDICInsuredAmount_iI_c20241231_zNRbqRvwhYCc" title="Cash FDIC, insured amount"&gt;250,000&lt;/span&gt;. Cash balances could exceed insured amounts at any given time. As of December 31, 2024, the company had cash in excess
of the FDIC insured amount totaling $&lt;span id="xdx_90C_eus-gaap--TimeDepositsAtOrAboveFDICInsuranceLimit_iI_c20241231_zD2ktgj1NVY" title="Cash uninsured amount"&gt;306,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000690"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:TimeDepositsAtOrAboveFDICInsuranceLimit
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000692"
      unitRef="USD">306000</us-gaap:TimeDepositsAtOrAboveFDICInsuranceLimit>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="From2024-01-01to2024-12-31" id="Fact000694">&lt;p id="xdx_847_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zQ4tFYMG8Xkh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Trade
receivables&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s trade receivable balance consists of amounts due from its customers. The Current Expected Credit Losses (&#x201c;CECL&#x201d;)
impairment model requires an estimate of expected credit losses, measured over the contractual life of an instrument, which considers
forecasts of future economic conditions in addition to information about past events and current conditions. Based on this model, the
Company considers many factors, including the age of the balance, collection history, and current economic trends. Credit losses are
written off after all collection efforts have ceased. Allowances for credit losses are recorded as a direct reduction from an asset&#x2019;s
amortized cost basis. Credit losses and recoveries are recorded in selling, general and administrative expenses in the consolidated statements
of operations. Recoveries of financial assets previously written off are recorded when received. Trades receivables were $&lt;span id="xdx_90F_eus-gaap--AccountsReceivableNet_iI_c20241231_zX8gOLg56R27" title="Trades receivables"&gt;98,000&lt;/span&gt; as of
December 31, 2024, and are not anticipated to possess substantial credit risk or expected credit losses. The Company&#x2019;s current
policy is to not charge late fees or other penalties for late payments but may consider charging customers late fees in the future. Historically,
the Company has not had significant write offs of trade receivables. All sales are non-refundable. As of December 31, 2024, the Company
evaluated historical collections from vendors and collection policies and has estimated that current expected credit losses ( &#x201c;CECL&#x201d;)
to be $&lt;span id="xdx_902_ecustom--ChangeInCurrentExpectedCreditLosses_pn3n3_c20240101__20241231_z9hUkZcKjFXh" title="Change in current expected credit losses"&gt;0&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AccountsReceivableNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000696"
      unitRef="USD">98000</us-gaap:AccountsReceivableNet>
    <NAOV:ChangeInCurrentExpectedCreditLosses
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000698"
      unitRef="USD">0</NAOV:ChangeInCurrentExpectedCreditLosses>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000700">&lt;p id="xdx_84C_eus-gaap--AdvertisingCostsPolicyTextBlock_zXjraNwAjkrd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Advertising
and Marketing Costs&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Costs
associated with advertising are charged to expenses as incurred. For the year ended December 31, 2024, and 2023, the advertising and
marketing costs were $&lt;span id="xdx_90E_eus-gaap--MarketingAndAdvertisingExpense_c20240101__20241231_ziUXw2ls3O3e" title="Advertising and marketing costs"&gt;53,000&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--MarketingAndAdvertisingExpense_c20230101__20231231_z6ebkWgsalOl" title="Advertising and marketing costs"&gt;106,000&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:MarketingAndAdvertisingExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000702"
      unitRef="USD">53000</us-gaap:MarketingAndAdvertisingExpense>
    <us-gaap:MarketingAndAdvertisingExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000704"
      unitRef="USD">106000</us-gaap:MarketingAndAdvertisingExpense>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000706">&lt;p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zrzJQIvOlaeb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Earnings
per share&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
loss per share was computed using the weighted average number of common shares outstanding. Diluted loss per share includes the effect
of diluted common stock equivalents. Potentially dilutive securities from the exercise of stock option, warrants and exercise of preferred
stock as of December 31, 2024, and 2023, respectively, were excluded from the computation of diluted net loss per share because the effect
of their inclusion would have been antidilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000708">&lt;p id="xdx_84A_eus-gaap--InventoryPolicyTextBlock_zVV543rKQYS9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Inventory&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories
are stated at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course
of business, less reasonably predictable costs of completion, disposal, and transportation. Cost is determined using the &#x201c;first-in,
first-out&#x201d; method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory
write-offs are provided to cover risks arising from slow-moving items or technological obsolescence. The Company periodically evaluates
the quantities on hand relative to current and historical selling prices and historical and projected sales volume. Based on this evaluation,
provisions are made when required to write-down inventory to its net market value. As of December 31, 2024, and 2023, there was &lt;span id="xdx_90F_eus-gaap--InventoryAdjustments_iI_pn3n3_do_c20241231_zsWGdZVnBec4" title="Inventory allowance"&gt;&lt;span id="xdx_902_eus-gaap--InventoryAdjustments_iI_pn3n3_do_c20231231_ztRrGcIKb95l" title="Inventory allowance"&gt;no&lt;/span&gt;&lt;/span&gt; allowance
on inventory.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryAdjustments
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000710"
      unitRef="USD">0</us-gaap:InventoryAdjustments>
    <us-gaap:InventoryAdjustments
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000712"
      unitRef="USD">0</us-gaap:InventoryAdjustments>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000714">&lt;p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z8lUfCkwaB9c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Property
and equipment, net&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_ecustom--ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock_zKKjFz17QRPb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the
estimated useful lives of the assets, at the following annual rates:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zLTUCzBGvf0b" style="display: none"&gt;SCHEDULE OF DEPRECIATION CALCULATED OVER ESTIMATED USEFUL LIVES OF ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;Years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; text-align: justify"&gt;Computers and peripheral equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 16%; text-align: center"&gt;&lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zS8qn4YwxKkh" title="Estimated useful life"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_z6mGGsDo1sLl" title="Estimated useful life"&gt;5&lt;/span&gt;-&lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zOxEAVxNuY0a" title="Estimated useful life"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zmUz89Ndvjld" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <NAOV:ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000716">&lt;p id="xdx_891_ecustom--ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock_zKKjFz17QRPb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the
estimated useful lives of the assets, at the following annual rates:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zLTUCzBGvf0b" style="display: none"&gt;SCHEDULE OF DEPRECIATION CALCULATED OVER ESTIMATED USEFUL LIVES OF ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;Years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; text-align: justify"&gt;Computers and peripheral equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 16%; text-align: center"&gt;&lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zS8qn4YwxKkh" title="Estimated useful life"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_z6mGGsDo1sLl" title="Estimated useful life"&gt;5&lt;/span&gt;-&lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zOxEAVxNuY0a" title="Estimated useful life"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</NAOV:ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_ComputerEquipmentMember"
      id="Fact000718">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_OfficeEquipmentMember_srt_MinimumMember"
      id="Fact000720">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_OfficeEquipmentMember_srt_MaximumMember"
      id="Fact000722">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000724">&lt;p id="xdx_845_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zxgc8zi6ZLpi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Impairment
of Long-Lived Assets&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
reviews for impairment whenever events or changes in circumstances indicate that the carrying amount of property and equipment may not
be recoverable under the provisions of accounting for the impairment of long-lived assets. If it is determined that an impairment loss
has occurred based upon expected future cash flows, the loss is recognized in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <NAOV:SequencingPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000726">&lt;p id="xdx_84A_ecustom--SequencingPolicyTextBlock_zDvDjlG4oCrk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Sequencing&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company adopted a sequencing policy under ASC 815-40-35 whereby if reclassification of contracts from equity to liabilities is necessary
pursuant to ASC 815 due to the Company&#x2019;s inability to demonstrate it has sufficient authorized shares. This was due to the Company
committing more shares than authorized. While temporary suspensions are in place to keep the potential exercises beneath the number authorized,
certain instruments are classified as liabilities, after allocating available authorized shares on the basis of the most recent grant
date of potentially dilutive instruments. Pursuant to ASC 815, issuances of securities granted as compensation in a share-based payment
arrangement are not subject to the sequencing policy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</NAOV:SequencingPolicyTextBlock>
    <NAOV:SeverancePayPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000728">&lt;p id="xdx_840_ecustom--SeverancePayPolicyTextBlock_zeWMWwzAPh0j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Severance
pay&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s liability for severance pay is for its Israeli employees and is calculated pursuant to Israeli Severance Pay Law based
on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date and is in large
part covered by regular deposits with recognized pension funds, deposits with severance pay funds and purchases of insurance policies.
The value of these deposits and policies is recorded as an asset in the Company&#x2019;s balance sheet. Accrued severance pay liability
on December 31, 2024, and 2023 was $&lt;span id="xdx_906_ecustom--AccruedSeverancePayLiability_c20240101__20241231_zj57yXkQgAKl" title="Accrued severance pay liability"&gt;216,000&lt;/span&gt; and $&lt;span id="xdx_90F_ecustom--AccruedSeverancePayLiability_c20230101__20231231_zuAPMFAUtJSi" title="Accrued severance pay liability"&gt;217,000&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</NAOV:SeverancePayPolicyTextBlock>
    <NAOV:AccruedSeverancePayLiability
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000730"
      unitRef="USD">216000</NAOV:AccruedSeverancePayLiability>
    <NAOV:AccruedSeverancePayLiability
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000732"
      unitRef="USD">217000</NAOV:AccruedSeverancePayLiability>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000734">&lt;p id="xdx_849_eus-gaap--LesseeLeasesPolicyTextBlock_z9a2mVAhxFN6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for its leases in accordance with ASU 2016-02, &#x201c;Leases&#x201d; (Topic 842). This topic requires that a lessee recognize
the assets and liabilities that arise from operating leases. The Company recognizes right-of-use assets and lease liabilities on the
consolidated balance sheet for all leases with a term longer than 12 months and classifies them as operating leases. For leases with
a term of 12 months or less, the Company elects not to recognize lease assets and lease liabilities on those leases. The right-of-use
assets and lease liabilities have been measured by the present value of the Company&#x2019;s remaining lease payments over the lease term
using our incremental borrowing rates or implicit rates, when readily determinable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000736">&lt;p id="xdx_848_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z7i2eOV0280i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Revenue
recognition&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;It
is the Company&#x2019;s policy that revenues from product sales is recognized in accordance with ASC 606 &#x201c;Revenue Recognition.&#x201d;
Five basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that create(s) enforceable
rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services
to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects to
be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to the performance
obligations in the contract, which requires the company to allocate the transaction price to each performance obligation on the basis
of the relative standalone selling prices of each distinct good or services promised in the contract; and (5) Recognizing revenue when
(or as) the entity satisfies a performance obligation by transferring a promised good or service to a customer. The amount of revenue
recognized is the amount allocated to the satisfied performance obligation. Adoption of ASC 606 has not changed the timing and nature
of the Company&#x2019;s revenue recognition and there has been no material effect on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue
from product sales is recorded at the net sales price, or &#x201c;transaction price,&#x201d; which includes estimates of variable consideration
that result from coupons, discounts, chargebacks and distributor fees, processing fees, as well as allowances for returns and government
rebates. The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue.
Collectability of revenue is reasonably assured based on historical evidence of collectability between the Company and its customers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenues
from sales to distributors are recognized at the time the products are delivered to the distributors (sell-in&#x201d;). The Company does
not grant rights of return, credits, rebates, price protection, or other privileges on its products to distributors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000738">&lt;p id="xdx_841_eus-gaap--IncomeTaxPolicyTextBlock_zlDPYCgQDXTe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Income
taxes&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes in accordance with ASC 740, &#x201c;Income Taxes&#x201d;. This topic prescribes the use of the liability
method whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and
tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences
are expected to reverse. The Company provides full valuation allowance, to reduce deferred tax assets to the amount that is more likely
than not to be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company implements a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position
taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than
not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related
appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% (cumulative
basis) likely to be realized upon ultimate settlement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes interest and penalties related to uncertain tax positions on the income tax expense line in the accompanying consolidated
statement of operations. Accrued interest and penalties are included on the related tax liability line in the consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000740">&lt;p id="xdx_84B_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zjOYKe1VDQC5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Stock-based
compensation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company selected the Black-Scholes-Merton option pricing model as the most appropriate fair value method for its stock-options awards.
The option-pricing model requires a number of assumptions, of which the most significant are the expected stock price volatility and
the expected option term. Expected volatility was calculated based upon similar traded companies&#x2019; historical share price movements.
The expected option term represents the period that the Company&#x2019;s stock options are expected to be outstanding. The Company currently
uses the simplified method and will continue to do so until sufficient historical exercise data supports using expected life assumptions.
The risk-free interest rate is based on the yield from U.S. Treasury zero-coupon bonds with an equivalent term. The expected dividend
yield assumption is based on the Company&#x2019;s historical experience and expectation of no future dividend payouts. The Company has
historically not paid cash dividends and has no foreseeable plans to pay cash dividends in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000742">&lt;p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z88NbAq5McIl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Recently
adopted accounting standards&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-13,
Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#x201c;ASU 2016-13&#x201d;)
and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, and ASU 2019-05 (collectively, &#x201c;Topic
326&#x201d;). Topic 326 requires measurement and recognition of expected credit losses for financial assets held. This ASU is effective
for interim and annual reporting periods beginning after December 15, 2022. The adoption of Topic 326 did not have a material effect
on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the FASB issued ASU No. 2023-07, &lt;i&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/i&gt;,
which requires an enhanced disclosure of significant segment expenses on an annual and interim basis. This guidance is effective for
annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption
is permitted. Upon adoption, the guidance should be applied retrospectively to all prior periods presented in the financial statements.
The adoption of Topic 280 did not have a material effect on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000744">&lt;p id="xdx_803_eus-gaap--OtherCurrentAssetsTextBlock_zC5HbPdO39vb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
4 - &lt;span id="xdx_826_zyZ4hS3pijp8"&gt;PREPAID EXPENSES AND OTHER RECEIVABLES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zptYOgclK78a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
expenses and other receivables consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BA_zIXtbmqLeCtf" style="display: none"&gt;SCHEDULE OF PREPAID EXPENSES AND OTHER RECEIVABLES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20241231_zNLVgVZZ6E8a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20231231_z6k4SgKwxMZg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--PrepaidExpenseCurrent_iI_maPEAOAzR3N_zxd7TlgMEOJ7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;120,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;47,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OtherAssetsCurrent_iI_maPEAOAzR3N_zFVKeo5BdjT2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Other receivables&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;170,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;107,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0d_mtPEAOAzR3N_zoxd9gzr2YC7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
    expenses and other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;290,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;154,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zm1OEeRg9xqh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000746">&lt;p id="xdx_896_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zptYOgclK78a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
expenses and other receivables consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BA_zIXtbmqLeCtf" style="display: none"&gt;SCHEDULE OF PREPAID EXPENSES AND OTHER RECEIVABLES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20241231_zNLVgVZZ6E8a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20231231_z6k4SgKwxMZg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--PrepaidExpenseCurrent_iI_maPEAOAzR3N_zxd7TlgMEOJ7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;120,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;47,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OtherAssetsCurrent_iI_maPEAOAzR3N_zFVKeo5BdjT2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Other receivables&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;170,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;107,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0d_mtPEAOAzR3N_zoxd9gzr2YC7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
    expenses and other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;290,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;154,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000748"
      unitRef="USD">120000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000749"
      unitRef="USD">47000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000751"
      unitRef="USD">170000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000752"
      unitRef="USD">107000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000754"
      unitRef="USD">290000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000755"
      unitRef="USD">154000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000757">&lt;p id="xdx_80F_eus-gaap--InventoryDisclosureTextBlock_zWntBGAb5Qqk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
5 &#x2013; &lt;span id="xdx_82A_zKgpE98lZTyj"&gt;INVENTORY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_z0ex8gZoucm8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory
consists of the following components:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BC_z46b0dEx4fHa" style="display: none"&gt;SCHEDULE OF INVENTORY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20241231_zr49nADZJxh5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20231231_zaUoLdjiqAOa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--InventoryRawMaterials_iI_maINzmOi_zn52XfWNYKck" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;391,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;210,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--InventoryFinishedGoods_iI_maINzmOi_zYks0Oxizgg4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,800,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,522,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--InventoryNet_iTI_pp0d_mtINzmOi_zjlTFRf5YeG3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,191,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,732,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_z6Ou2Ja9nDvl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000759">&lt;p id="xdx_89F_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_z0ex8gZoucm8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory
consists of the following components:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BC_z46b0dEx4fHa" style="display: none"&gt;SCHEDULE OF INVENTORY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20241231_zr49nADZJxh5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20231231_zaUoLdjiqAOa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--InventoryRawMaterials_iI_maINzmOi_zn52XfWNYKck" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;391,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;210,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--InventoryFinishedGoods_iI_maINzmOi_zYks0Oxizgg4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,800,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,522,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--InventoryNet_iTI_pp0d_mtINzmOi_zjlTFRf5YeG3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,191,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,732,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000761"
      unitRef="USD">391000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000762"
      unitRef="USD">210000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryFinishedGoods
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000764"
      unitRef="USD">1800000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000765"
      unitRef="USD">2522000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000767"
      unitRef="USD">2191000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000768"
      unitRef="USD">2732000</us-gaap:InventoryNet>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000770">&lt;p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zA1Lncml5pM9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
6 - &lt;span id="xdx_82F_zIPtKFwfplM4"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Common
Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
common stock confers upon the holders the right to receive notice to participate and vote in general meetings of the Company, and the
right to receive dividends, if declared, and to participate in the distribution of the surplus assets and funds of the Company in the
event of liquidation, dissolution or winding up of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Reverse
stock splits&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 8, 2023, the Company effected a reverse stock split of its common stock at a ratio of 1 post-split share for every 20 pre-split
shares. The Company&#x2019;s common stock begin trading on a split-adjusted basis when the market opened on February 9, 2023 (the &#x201c;2023
Reverse Stock Split&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the effective time of the 2023 Reverse Stock Split, every 20 shares of the Company&#x2019;s issued and outstanding common stock were converted
automatically into one issued and outstanding share of common stock without any change in the par value per share. Stockholders holding
shares through a brokerage account had their shares automatically adjusted to reflect the 2023 Reverse Stock Split. The 2023 Reverse
Stock Split affected all stockholders uniformly and did not alter any stockholder&#x2019;s percentage interest in the Company&#x2019;s
equity, except to the extent that the 2023 Reverse Stock Split resulted in a stockholder owning a fractional share. Any fractional share
of a stockholder resulting from the 2023 Reverse Stock Split was rounded up to the nearest whole number of shares. Proportional adjustments
were made to the number of shares of the Company&#x2019;s common stock issuable upon exercise or conversion of the Company&#x2019;s equity
awards, warrants and other convertible securities, as well as the applicable exercise or conversion price thereof. On February 16, 2023,
the Company rounded up fractional shares to its nearest whole number of &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_c20230215__20230216_zKoKKPdwdVF1" title="Fractional shares"&gt;15,726&lt;/span&gt; shares. On March 31, 2024, the Company rounded up fractional
shares to its nearest whole number of &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_c20240331__20240331_zHQg1LpGzjz" title="Fractional shares"&gt;47&lt;/span&gt; shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 13, 2025, the Company effected a &lt;span id="xdx_90A_eus-gaap--StockholdersEquityReverseStockSplit_c20250313__20250313_zyss9homDVh1" title="Reverse stock split"&gt;1-for-11 reverse stock split&lt;/span&gt; (the &#x201c;2025 Reverse Stock Split&#x201d; and together with the
2023 Reverse Stock Split, the &#x201c;Reverse Stock Splits&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a result of the 2025 Reverse Stock Split, every 11 shares of issued and outstanding common stock was automatically combined into one
issued and outstanding share of common stock, without any change in the par value per share. No fractional shares were issued as a result
of the 2025 Reverse Stock Split. Any fractional shares that would otherwise have resulted from the Reverse Stock Split was rounded up
to the next whole number. The 2025 Reverse Stock Split reduced the number of shares of common stock outstanding from &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_pid_c20250312__20250312_zDgEBSjuatL2" title="Reverse stock split outstanding shares"&gt;8,716,327&lt;/span&gt; shares
to approximately &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_pid_c20250313__20250313_zfQ2Z0V5GHm7" title="Reverse stock split outstanding shares"&gt;792,394&lt;/span&gt; shares, subject to adjustment for the rounding up of fractional shares. The number of authorized shares of common
stock under the Company&#x2019;s Amended and Restated Certificate of Incorporation, as amended remained unchanged at &lt;span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20250313_zYsbyDuNJqOj" title="Common stock shares remained unchanged"&gt;40,000,000&lt;/span&gt; shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
references in this Annual Report to the number of shares, price per share and weighted average number of shares of common stock outstanding
prior to the Reverse Stock Splits have been adjusted to reflect the Reverse Stock Splits on a retroactive basis, unless otherwise noted.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Issuance
of common stock for cash&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Issuance
of common stock for cash through private placement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 30, 2023, the Company entered into a securities purchase agreement (the &#x201c;Purchase Agreement&#x201d;) with an institutional
investor for the issuance and sale in a private placement (the &#x201c;Private Placement&#x201d;) of &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230830__20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEUR0LxvsObg" title="Number of new share issued"&gt;16,363&lt;/span&gt; shares (the &#x201c;Common Shares&#x201d;)
of common stock, par value $&lt;span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7JmHls8voi1" title="Common stock par value"&gt;0.001&lt;/span&gt; per share (the &#x201c;Common Stock&#x201d;), pre-funded warrants (&#x201c;Pre-Funded Warrants&#x201d;)
to purchase up to &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zJhr7fZjtWfd" title="Number of securities called by warrants or rights"&gt;247,907&lt;/span&gt; shares of common stock, with an exercise price of $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zFaM3bsJK8Va" title="Warrant exercise price per share"&gt;0.0001&lt;/span&gt; per share, A-1 Warrants (the &#x201c;A-1 Warrants&#x201d;)
to purchase up to &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_zjCwBWkH5kl8" title="Number of securities called by warrants or rights"&gt;264,271&lt;/span&gt; shares of Common Stock, with an exercise price of $&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_ztxwQp0ex1l1" title="Class of warrant or right exercise price"&gt;16.17&lt;/span&gt; per share, and A-2 Warrants (the &#x201c;A-2 Warrants&#x201d;
and together with the A-1 Warrants, the &#x201c;Warrants&lt;b&gt;&lt;i&gt;&#x201d;&lt;/i&gt;&lt;/b&gt; ) to purchase up to &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zwmVJDq06Uhb" title="Number of securities called by warrants or rights"&gt;264,270&lt;/span&gt; shares of Common Stock with
an exercise price of $&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_z7A1CiwEHWR4" title="Class of warrant or right exercise price"&gt;16.17&lt;/span&gt; per share. The A-1 Warrants are exercisable immediately upon issuance and expire &lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_zkjZ3XkNmCL3" title="Warrant expiration date"&gt;March 1, 2029&lt;/span&gt;. The A-2 Warrants
are exercisable immediately upon issuance and expire &lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zJnzL34kUxxa" title="Warrant expiration date"&gt;October 1, 2024&lt;/span&gt;. The combined purchase price for one Common Share and the accompanying
Warrants was $&lt;span id="xdx_900_eus-gaap--SharePrice_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zcEEYEAlI5D4" title="Common stock and warrant price per share"&gt;18.92&lt;/span&gt;, and the combined purchase price for one Pre-Funded Warrant and the accompanying Warrants was $&lt;span id="xdx_908_ecustom--PrefundedWarrantAndAccompanyingWarrantPricePerShares_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znmfrt0dbJvk" title="Pre-Funded Warrant and accompanying warrant price per shares"&gt;18.92&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
net proceeds to the Company from the Private Placement are approximately $&lt;span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20230830__20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z9mEcQEWUqt4" title="Proceeds from issuance of private placement"&gt;4,215,000&lt;/span&gt;, after deducting placement agent fees and expenses
and estimated offering expenses payable by the Company. The Company intends to use the net proceeds received from the Private Placement
for general corporate purposes, including funding of our development programs, commercial planning and sales and marketing expenses,
potential strategic acquisitions, general and administrative expenses and working capital.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;H.C.
Wainwright &amp;amp; Co., LLC (&#x201c;Wainwright&#x201d;) served as the Company&#x2019;s exclusive placement agent in connection with the Private
Placement, pursuant to that certain engagement letter, dated as of July 5, 2023, as amended, between us and Wainwright (the &#x201c;Engagement
Letter&#x201d;). As part of Wainwright&#x2019;s compensation, we issued to Wainwright or its designees warrants (the &#x201c;Placement Agent
Warrants&#x201d;) to purchase up to an aggregate of &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230705__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentWarrantsMember_zuEGsLZxDhbc" title="Number of securities called by warrants or rights"&gt;19,820&lt;/span&gt; shares of Common Stock at an exercise price equal to $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230705__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentWarrantsMember_zJXcVPUyzqah" title="Share price"&gt;23.65&lt;/span&gt; per share. The
Placement Agent Warrants are exercisable immediately upon issuance and expire &lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230705__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentWarrantsMember_zDGur9KXG0tl" title="Class of warrant or right expire date"&gt;March 1, 2029&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Stock-based
compensation and options&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 28, 2014, stockholders approved the NanoVibronix, Inc. 2014 Long-Term Incentive Plan (the &#x201c;2014 Plan&#x201d;), which was
adopted by the Board on February 19, 2014. As of December 31, 2022, under the 2014 Plan, &lt;span id="xdx_90D_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20221231__us-gaap--AwardTypeAxis__custom--TwoThousandFourteenLongTermIncentivePlanMember_zgG1nWXtJzkf" title="Stock reserved for future issuance"&gt;442,207&lt;/span&gt; shares of our common stock were reserved
for issuance. On February 9, 2023, the Company effected a &lt;span id="xdx_908_eus-gaap--StockholdersEquityReverseStockSplit_c20230209__20230209__us-gaap--AwardTypeAxis__custom--TwoThousandFourteenLongTermIncentivePlanMember_zGkrYI8OhPf" title="Reverse stock split"&gt;one-for-twenty reverse stock split&lt;/span&gt; of common stock. Consequently, the number
of shares of common stock of the Company reserved for issuance pursuant to awards under the 2014 Plan was reduced to &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20230209__us-gaap--AwardTypeAxis__custom--TwoThousandFourteenLongTermIncentivePlanMember_zBRUkizWfKd6" title="Number of common stock reserved for issuance for awards"&gt;22,110&lt;/span&gt; shares. As
of December 31, 2023, there were &lt;span id="xdx_90E_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20231231__us-gaap--AwardTypeAxis__custom--TwoThousandFourteenLongTermIncentivePlanMember_zSxL0REig5e3" title="Stock reserved for future issuance"&gt;11,866&lt;/span&gt; shares of common stock available to be issued under the plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On December 19, 2024, stockholders approved the NanoVibronix, Inc. 2024 Long-Term Incentive Plan (the &#x201c;2024
Plan&#x201d;), as a successor to the Nanovibronix 2014 Long-Term Incentive Plan, which was adopted by the Board on November 6, 2023. As
of December 31, 2024, under the 2024 Plan, &lt;span id="xdx_900_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20241231__us-gaap--AwardTypeAxis__custom--TwoThousandAndTwentyFourLongTermIncentivePlanMember_zVfq8cRQJxRl" title="Stock reserved for future issuance"&gt;600,000&lt;/span&gt; shares of our common stock were reserved for issuance. On March 14, 2025, the Company
effected a one-for-eleven reverse stock split of common stock. Consequently, the number of shares of common stock of the Company reserved
for issuance pursuant to awards under the 2024 Plan was reduced to &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20250314__us-gaap--AwardTypeAxis__custom--TwoThousandAndTwentyFourLongTermIncentivePlanMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrFe8ZxUi7m3" title="Number of common stock reserved for issuance for awards"&gt;54,545&lt;/span&gt; shares. As of December 31, 2024, there were &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandAndTwentyFourLongTermIncentivePlanMember_zBtYG3Amo0db" title="Number of share issued"&gt;9,486&lt;/span&gt; shares of
common stock available to be issued under the plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the years ended December 31, 2024, and 2023, &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_dxL_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zyWymLxcbBD8" title="Number of options, exercised::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0830"&gt;0&lt;/span&gt;&lt;/span&gt; and &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zbs0TyLTt5v3" title="Number of options, exercised"&gt;5,426&lt;/span&gt; employee options were exercised, &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zlZ8Gk66VXq1" title="Number of employee options granted"&gt;34,818&lt;/span&gt; and &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zqyMvrvYUV4j" title="Number of employee options granted"&gt;7,273&lt;/span&gt; options were granted,
&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_dxL_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z8kw3xXs5lca" title="Number of employee options forfeited::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0838"&gt;0&lt;/span&gt;&lt;/span&gt; and &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zC5UtL0B5nsf" title="Number of employee options forfeited"&gt;9,584&lt;/span&gt; options were forfeited and &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zfQLjQrLNjGi" title="Number of employee options expired"&gt;3&lt;/span&gt; and &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zV7A97cqlCS1" title="Number of employee options expired"&gt;368&lt;/span&gt; options were expired, respectively. The options granted during 2024 and 2023 vest
at different schedules ranging from date granted to &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zRZ27pnIZQp5" title="Fair value options vesting term"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zCY00yxij7d6" title="Fair value options vesting term"&gt;9&lt;/span&gt;&lt;/span&gt; years and were recorded at fair values of approximately $&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zep8MH6yJT71" title="Number of options, vested"&gt;226,000&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zECWcJ7AgF8h" title="Number of options, vested"&gt;87,000&lt;/span&gt;, respectively.
The maximum contractual term for granted options is &lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z3iB8Hyi5qke" title="Contractual term for granted options"&gt;&lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zRFG2QpKc2Eh" title="Contractual term for granted options"&gt;10&lt;/span&gt;&lt;/span&gt; years. During the years ended December 31, 2024, and 2023, stock-based compensation
expense of approximately $&lt;span id="xdx_903_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z9eSCXQ6wUea" title="Stock-based compensation expense"&gt;356,000&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zWWajw1dg0Tf" title="Stock-based compensation expense"&gt;293,000&lt;/span&gt; was recorded for options that vested, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zRnajz2rExNa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zvHhwC29emWg" style="display: none"&gt;SCHEDULE OF OPTIONS ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Shares Under&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;per Share&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life (Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;Outstanding &#x2013; December 31, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zt6aMefE1eT6" style="width: 14%; text-align: right" title="Options, Outstanding - Beginning balance"&gt;10,244&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2d_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zAlkVS6LDsh4" style="width: 14%; text-align: right" title="Weighted Average Exercise Price per Share, Exercisable - Ending balance"&gt;13.10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zuO8oC4yP1X4" title="Weighted Average Remaining Life (Years), Outstanding"&gt;8.41&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zsQvG6cqmyhj" style="text-align: right" title="Options, Granted"&gt;34,818&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2d_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z9BEu7ef6R4" style="text-align: right" title="Weighted Average Exercise Price per Share, Granted"&gt;7.47&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zDGrqQdtxMja" title="Weighted Average Remaining Life (Years), Granted"&gt;9.78&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_ztr66m7BmhLf" style="text-align: right" title="Options, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0876"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pp2d_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zDWotb2B7lQd" style="text-align: right" title="Weighted Average Exercise Price per Share, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0878"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zLrdckMjEYXg" title="Weighted Average Remaining Life (Years), Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0880"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z5uC7BOTCeG3" style="text-align: right" title="Options, Expired"&gt;(3&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pp2d_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zEp9r9PGCu22" style="text-align: right" title="Weighted Average Exercise Price per Share, Exercised"&gt;39.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zMEgC7Bao9h7" title="Weighted Average Remaining Life (Years), Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0886"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zRwRMknXGpml" style="border-bottom: Black 1pt solid; text-align: right" title="Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0888"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pp2d_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zVND6xCk6zQf" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price per Share, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0890"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zCDwLqTMiru7" title="Weighted Average Remaining Life (Years), Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0892"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Outstanding &#x2013; December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z32ymmNLQzvb" style="text-align: right" title="Options, Outstanding - Ending balance"&gt;45,059&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pp2d_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zmKP5rPZlWYk" style="text-align: right" title="Weighted Average Exercise Price per Share, Outstanding - ending balance"&gt;3.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zXQOqt9MjGl1" title="Weighted Average Remaining Life (Years), Outstanding"&gt;9.24&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable &#x2013; December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zBOZ4VP6HmA9" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Exercisable - Ending balance"&gt;45,059&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zmZW1bX6kxRh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price per Share, Outstanding - ending balance"&gt;3.50&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zcQwM7Zl783b" title="Weighted Average Remaining Life (Years), Exercisable"&gt;9.24&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zuZRi4yTjchl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
outstanding options had &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_do_c20241231_zqiyBPHxPSB8" title="Aggregate intrinsic value"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_do_c20231231_zh3fe9HD20Sd" title="Aggregate intrinsic value"&gt;no&lt;/span&gt;&lt;/span&gt; aggregate intrinsic value as of December 31, 2024, and 2023. The intrinsic value is calculated as the difference
between the exercise price and the market value of the shares on the balance sheet date. The market values based on the closing bid price
as of December 31, 2024, and 2023 was $&lt;span id="xdx_901_eus-gaap--SharePrice_iI_c20241231_zvSE8JS4J6Dk" title="Bid price"&gt;6.49&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--SharePrice_iI_c20231231_zBVnWzCd9BU" title="Bid price"&gt;12.65&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zsLdriktqh95" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value for options granted in 2024 and 2023 is estimated at the date of grant using a Black-Scholes-Merton options pricing model
with the following underlying assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_z7m2ZIRLlCl3" style="display: none"&gt;SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR OPTIONS GRANTED&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Price at valuation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$ &lt;span id="xdx_907_eus-gaap--SharePrice_iI_pp2d_c20241231__srt--RangeAxis__srt--MinimumMember_za8ONnVvuOA4" title="Price at valuation"&gt;6.71&lt;/span&gt; &#x2013; &lt;span id="xdx_90C_eus-gaap--SharePrice_iI_pp2d_c20241231__srt--RangeAxis__srt--MaximumMember_zGIdXn4vZHY2" title="Price at valuation"&gt;9.90&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$
                                            &lt;span id="xdx_909_eus-gaap--SharePrice_iI_pp2d_c20231231__srt--RangeAxis__srt--MinimumMember_zES0X3AIObf2"&gt;13.2
                                            &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2013;
                                            &lt;span id="xdx_905_eus-gaap--SharePrice_iI_pp2d_c20231231__srt--RangeAxis__srt--MaximumMember_z8dRCxkxgmI9"&gt;13.64&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$ &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_c20241231__srt--RangeAxis__srt--MinimumMember_z32dVIMMMHS3" title="Exercise price"&gt;6.71&lt;/span&gt; &#x2013; &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_c20241231__srt--RangeAxis__srt--MaximumMember_zwtbjSMWQKfc" title="Exercise price"&gt;9.90&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$ &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_c20231231__srt--RangeAxis__srt--MinimumMember_z5DpkXfdkl64"&gt;13.2&lt;/span&gt;
                                            &#x2013; &lt;/span&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_c20231231__srt--RangeAxis__srt--MaximumMember_zvgho4L20uX6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;13.64&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240101__20241231_zQuXvMfriufb" title="Risk free interest, minimum"&gt;4.14&lt;/span&gt; &#x2013; &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20240101__20241231_zPlwZQjgY3K2" title="Risk free interest, maximum"&gt;4.42&lt;/span&gt; %&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20231231_zDTpuVAjwNEe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.83
                                            &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2013;
                                            &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20230101__20231231_zPsbcrB4FRM4"&gt;4.42
                                            &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Expected term (in years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231_zLfmpjqveXC1" title="Expected term (in years)"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zMWbcPvC2XA5" style="font-family: Times New Roman, Times, Serif"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20240101__20241231_zd0ANHMofr2i" title="Volatility, minimum"&gt;128.4&lt;/span&gt; &#x2013; &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20240101__20241231_zctxGMrRbwOb" title="Volatility, maximum"&gt;132.8&lt;/span&gt; %&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20230101__20231231_z5YdNzA8UOY5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;133.1
                                            &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2013;
                                            &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20230101__20231231_zRC0RRDUiCw3"&gt;133.6
                                            &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zgdH7n8KyQS6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zt5AGZJIb9ab" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
total stock-based expense recognized in the financial statements for services received from employees and non-employees is shown in the
following table.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BA_zdfH3ioX8TDf" style="display: none"&gt;SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED SERVICES FROM EMPLOYEES AND NON-EMPLOYEES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240101__20241231_z6XktNeSRnI9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20231231_z1cFdggzb4Id" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Year Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_znYUhzDywvF" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;5,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;6,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zfyhUw6y7Ru6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Selling and marketing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z8turcZgioZ" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;334,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;259,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zi4G19ZLiGOl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;356,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;293,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zgWgiHEQD5d3" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Stock based compensation expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;356,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;293,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AA_zHW4jhsLJcPe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, there was &lt;span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_do_c20241231_zOLIn9aOYj8i" title="Non-vested stock options granted, unrecognized estimated compensation cost"&gt;no&lt;/span&gt; unrecognized estimated compensation cost related to non-vested stock options granted prior to that
date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 30, 2023, the Company granted (a) Pre-Funded Warrants to purchase up to &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zk9U07hNse97" title="Warrants issued to purchase common stock"&gt;264,271&lt;/span&gt; shares of Common Stock with an exercise price
of $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zu460JFrs7e8" title="Class of warrant or right exercise price"&gt;0.0001&lt;/span&gt; per share, (b) A-1 Warrants to purchase up to &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_zl6qUL86Nyfi" title="Warrants issued to purchase common stock"&gt;264,271&lt;/span&gt; shares of Common Stock with an exercise price of $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_zcUZBkksK2Le" title="Warrant exercise price"&gt;16.17&lt;/span&gt; per share and
(c) A-2 Warrants to purchase up to &lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zVK6RWSk9vC3" title="Warrants issued to purchase common stock"&gt;264,271&lt;/span&gt; shares of Common Stock with an exercise price of $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zekCM2EQfi88" title="Warrant exercise price"&gt;16.17&lt;/span&gt; per share, or a total of &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20230830_zJ7pqCNaAEK1" title="Total warrants"&gt;776,448&lt;/span&gt; warrants,
in conjunction with the Private Placement disclosed above. The A-1 Warrants and A-2 Warrants are exercisable immediately upon issuance
and expire on &lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20230830__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_zEGvNpM1zdy" title="Class of warrant or right expire date"&gt;March 1, 2029&lt;/span&gt; and &lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20230830__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zzOwXQEKo1Kk" title="Class of warrant or right expire date"&gt;October 1, 2024&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the same Private Placement, the Company granted Placement Agent Warrants to Wainwright, or its designees, to purchase up to an aggregate
of &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zhOQ6Abei7C4" title="Warrants issued to purchase common stock"&gt;19,820&lt;/span&gt; shares of Common Stock at an exercise price equal to $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230830__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_z1kXAAJkDpH9" title="Share price"&gt;23.65&lt;/span&gt; per share. The Placement Agent Warrants are exercisable immediately
upon issuance and expire &lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20230830__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zDPRjFoEDvqe" title="Class of warrant or right expire date"&gt;March 1, 2029&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_ecustom--ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock_z3euBJXIJSt5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
estimating the warrants&#x2019; fair value, the Company used the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zKsvv47MJk4g" style="display: none"&gt;SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR WARRANTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Risk free interest&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z46WZr2xiszl" title="Warrants, measurement input, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0988"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zytQ8rdizZzl" title="Warrants, measurement input, percentage"&gt;3.49&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zeKwKRN982D6" title="Warrants, measurement input, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0992"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zEMWAx4Us7c2" title="Warrants, measurement input, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0994"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zvxKzIId2dDj" title="Warrants, measurement input, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0996"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zfvsuw3JbBoa" title="Warrants, measurement input, percentage"&gt;147.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Contractual term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20241231_zqsnYIeqDdei" title="Contractual term (in years)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1000"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231_z5hF0H6D4Zqg" title="Contractual term (in years)"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_ztqOH4YdDmgh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BE_zTxbn4zuJUf9" style="display: none"&gt;SCHEDULE OF WARRANTS ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;Pre-RSS&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;Post - RSS&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Outstanding &#x2013; December 31, 2022&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--PreWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zUWe2IdZGoc6" style="text-align: right; width: 16%" title="Warrants, Outstanding - Beginning balance"&gt;2,389&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--PostWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zIzVt1Uyv898" style="width: 16%; text-align: right" title="Warrants, Outstanding - Beginning balance"&gt;2,389&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--PreWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zXF3Cjg6PSu3" style="text-align: right" title="Warrants, Outstanding - Beginning balance"&gt;8,758,954&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--PostWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zEFnkTxCyHLh" style="text-align: right" title="Warrants, Outstanding - Beginning balance"&gt;796,269&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--PreWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zmxrUXihS9Fl" style="text-align: right" title="Warrants, Outstanding - Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1012"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--PostWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zTI4Dq7OUOu7" style="text-align: right" title="Warrants, Outstanding - Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1014"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;Cancelled&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--PreWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zzwewt1olZsa" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants, Outstanding - Beginning balance"&gt;(203,977&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--PostWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_z7BucyAHm4Id" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants, Outstanding - Beginning balance"&gt;(18,543&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding &#x2013; December 31, 2023&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PreWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zctOm5KA3oIk" style="text-align: right" title="Warrants, Outstanding - Beginning balance"&gt;8,633,229&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PostWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zfvM8K6tLHR8" style="text-align: right" title="Warrants, Outstanding - Beginning balance"&gt;780,115&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PreWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zaLBljHjxDra" style="text-align: right" title="Warrants, Outstanding - Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1024"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PostWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zT4KCyGwqwz4" style="text-align: right" title="Warrants, Outstanding - Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1026"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PreWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_z2SFFBq1ndv" style="text-align: right" title="Warrants, Outstanding - Beginning balance"&gt;(2,918,977&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PostWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zU4X6An8BLD" style="text-align: right" title="Warrants, Outstanding - Beginning balance"&gt;(265,362&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PreWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zZCOIG93pCq7" style="text-align: right" title="Warrants, Outstanding - Beginning balance"&gt;(2,122,000&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PostWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zcSyp1kmQnif" style="text-align: right" title="Warrants, Outstanding - Beginning balance"&gt;(192,910&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;Cancelled&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PreWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zQA7miZzDCn1" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants, Outstanding - Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1036"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PostWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zqYfZaF6NBTe" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants, Outstanding - Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1038"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding &#x2013; December 31, 2024&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PreWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_z1gMTs4V7sua" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding - Beginning balance"&gt;3,592,252&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PostWarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_ziZhRBEXtFU7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding - Beginning balance"&gt;321,843&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zRT6eHAqxxql" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="From2023-02-152023-02-16"
      decimals="INF"
      id="Fact000772"
      unitRef="Shares">15726</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="From2024-03-312024-03-31"
      decimals="INF"
      id="Fact000774"
      unitRef="Shares">47</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2025-03-132025-03-13" id="Fact000776">1-for-11 reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="From2025-03-122025-03-12"
      decimals="INF"
      id="Fact000778"
      unitRef="Shares">8716327</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="From2025-03-132025-03-13"
      decimals="INF"
      id="Fact000780"
      unitRef="Shares">792394</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-03-13"
      decimals="INF"
      id="Fact000782"
      unitRef="Shares">40000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-08-302023-08-30_custom_PurchaseAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000784"
      unitRef="Shares">16363</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000786"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact000788"
      unitRef="Shares">247907</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact000790"
      unitRef="USDPShares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_A1WarrantsMember"
      decimals="INF"
      id="Fact000792"
      unitRef="Shares">264271</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_A1WarrantsMember"
      decimals="INF"
      id="Fact000794"
      unitRef="USDPShares">16.17</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_A2WarrantsMember"
      decimals="INF"
      id="Fact000796"
      unitRef="Shares">264270</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_A2WarrantsMember"
      decimals="INF"
      id="Fact000798"
      unitRef="USDPShares">16.17</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_A1WarrantsMember"
      id="Fact000800">2029-03-01</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_A2WarrantsMember"
      id="Fact000802">2024-10-01</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:SharePrice
      contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000804"
      unitRef="USDPShares">18.92</us-gaap:SharePrice>
    <NAOV:PrefundedWarrantAndAccompanyingWarrantPricePerShares
      contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000806"
      unitRef="USDPShares">18.92</NAOV:PrefundedWarrantAndAccompanyingWarrantPricePerShares>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2023-08-302023-08-30_custom_PurchaseAgreementMember"
      decimals="0"
      id="Fact000808"
      unitRef="USD">4215000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-07-05_custom_HCWainwrightAndCoLLCMember_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact000810"
      unitRef="Shares">19820</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-07-05_custom_HCWainwrightAndCoLLCMember_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact000812"
      unitRef="USDPShares">23.65</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2023-07-05_custom_HCWainwrightAndCoLLCMember_custom_PlacementAgentWarrantsMember"
      id="Fact000814">2029-03-01</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2022-12-31_custom_TwoThousandFourteenLongTermIncentivePlanMember"
      decimals="INF"
      id="Fact000816"
      unitRef="Shares">442207</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="From2023-02-092023-02-09_custom_TwoThousandFourteenLongTermIncentivePlanMember"
      id="Fact000818">one-for-twenty reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2023-02-09_custom_TwoThousandFourteenLongTermIncentivePlanMember"
      decimals="INF"
      id="Fact000820"
      unitRef="Shares">22110</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2023-12-31_custom_TwoThousandFourteenLongTermIncentivePlanMember"
      decimals="INF"
      id="Fact000822"
      unitRef="Shares">11866</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2024-12-31_custom_TwoThousandAndTwentyFourLongTermIncentivePlanMember"
      decimals="INF"
      id="Fact000824"
      unitRef="Shares">600000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2025-03-14_custom_TwoThousandAndTwentyFourLongTermIncentivePlanMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000826"
      unitRef="Shares">54545</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_custom_TwoThousandAndTwentyFourLongTermIncentivePlanMember"
      decimals="INF"
      id="Fact000828"
      unitRef="Shares">9486</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-012023-12-31_custom_EmployeeOptionsMember"
      decimals="INF"
      id="Fact000832"
      unitRef="Shares">5426</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember"
      decimals="INF"
      id="Fact000834"
      unitRef="Shares">34818</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-12-31_custom_EmployeeOptionsMember"
      decimals="INF"
      id="Fact000836"
      unitRef="Shares">7273</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2023-01-012023-12-31_custom_EmployeeOptionsMember"
      decimals="INF"
      id="Fact000840"
      unitRef="Shares">9584</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember"
      decimals="INF"
      id="Fact000842"
      unitRef="Shares">3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2023-01-012023-12-31_custom_EmployeeOptionsMember"
      decimals="INF"
      id="Fact000844"
      unitRef="Shares">368</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember"
      id="Fact000846">P9Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="From2023-01-012023-12-31_custom_EmployeeOptionsMember"
      id="Fact000848">P9Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember"
      decimals="0"
      id="Fact000850"
      unitRef="USD">226000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2023-01-012023-12-31_custom_EmployeeOptionsMember"
      decimals="0"
      id="Fact000852"
      unitRef="USD">87000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <NAOV:ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod
      contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember"
      id="Fact000854">P10Y</NAOV:ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod>
    <NAOV:ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod
      contextRef="From2023-01-012023-12-31_custom_EmployeeOptionsMember"
      id="Fact000856">P10Y</NAOV:ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember"
      decimals="0"
      id="Fact000858"
      unitRef="USD">356000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2023-01-012023-12-31_custom_EmployeeOptionsMember"
      decimals="0"
      id="Fact000860"
      unitRef="USD">293000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000862">&lt;p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zRnajz2rExNa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zvHhwC29emWg" style="display: none"&gt;SCHEDULE OF OPTIONS ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Shares Under&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;per Share&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life (Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;Outstanding &#x2013; December 31, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zt6aMefE1eT6" style="width: 14%; text-align: right" title="Options, Outstanding - Beginning balance"&gt;10,244&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2d_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zAlkVS6LDsh4" style="width: 14%; text-align: right" title="Weighted Average Exercise Price per Share, Exercisable - Ending balance"&gt;13.10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zuO8oC4yP1X4" title="Weighted Average Remaining Life (Years), Outstanding"&gt;8.41&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zsQvG6cqmyhj" style="text-align: right" title="Options, Granted"&gt;34,818&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2d_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z9BEu7ef6R4" style="text-align: right" title="Weighted Average Exercise Price per Share, Granted"&gt;7.47&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zDGrqQdtxMja" title="Weighted Average Remaining Life (Years), Granted"&gt;9.78&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_ztr66m7BmhLf" style="text-align: right" title="Options, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0876"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pp2d_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zDWotb2B7lQd" style="text-align: right" title="Weighted Average Exercise Price per Share, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0878"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zLrdckMjEYXg" title="Weighted Average Remaining Life (Years), Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0880"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z5uC7BOTCeG3" style="text-align: right" title="Options, Expired"&gt;(3&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pp2d_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zEp9r9PGCu22" style="text-align: right" title="Weighted Average Exercise Price per Share, Exercised"&gt;39.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zMEgC7Bao9h7" title="Weighted Average Remaining Life (Years), Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0886"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zRwRMknXGpml" style="border-bottom: Black 1pt solid; text-align: right" title="Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0888"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pp2d_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zVND6xCk6zQf" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price per Share, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0890"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zCDwLqTMiru7" title="Weighted Average Remaining Life (Years), Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0892"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Outstanding &#x2013; December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z32ymmNLQzvb" style="text-align: right" title="Options, Outstanding - Ending balance"&gt;45,059&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pp2d_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zmKP5rPZlWYk" style="text-align: right" title="Weighted Average Exercise Price per Share, Outstanding - ending balance"&gt;3.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zXQOqt9MjGl1" title="Weighted Average Remaining Life (Years), Outstanding"&gt;9.24&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable &#x2013; December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zBOZ4VP6HmA9" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Exercisable - Ending balance"&gt;45,059&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zmZW1bX6kxRh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price per Share, Outstanding - ending balance"&gt;3.50&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zcQwM7Zl783b" title="Weighted Average Remaining Life (Years), Exercisable"&gt;9.24&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_EmployeeOptionsMember"
      decimals="INF"
      id="Fact000864"
      unitRef="Shares">10244</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_EmployeeOptionsMember"
      decimals="2"
      id="Fact000866"
      unitRef="USDPShares">13.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember"
      id="Fact000868">P8Y4M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember"
      decimals="INF"
      id="Fact000870"
      unitRef="Shares">34818</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember"
      decimals="2"
      id="Fact000872"
      unitRef="USDPShares">7.47</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm
      contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember"
      id="Fact000874">P9Y9M10D</NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember"
      decimals="INF"
      id="Fact000882"
      unitRef="Shares">3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember"
      decimals="2"
      id="Fact000884"
      unitRef="USDPShares">39.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_EmployeeOptionsMember"
      decimals="INF"
      id="Fact000894"
      unitRef="Shares">45059</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_custom_EmployeeOptionsMember"
      decimals="2"
      id="Fact000896"
      unitRef="USDPShares">3.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember"
      id="Fact000898">P9Y2M26D</NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31_custom_EmployeeOptionsMember"
      decimals="INF"
      id="Fact000900"
      unitRef="Shares">45059</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_custom_EmployeeOptionsMember"
      decimals="INF"
      id="Fact000902"
      unitRef="USDPShares">3.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-01-012024-12-31_custom_EmployeeOptionsMember"
      id="Fact000904">P9Y2M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000906"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000908"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharePrice
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000910"
      unitRef="USDPShares">6.49</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000912"
      unitRef="USDPShares">12.65</us-gaap:SharePrice>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000914">&lt;p id="xdx_897_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zsLdriktqh95" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value for options granted in 2024 and 2023 is estimated at the date of grant using a Black-Scholes-Merton options pricing model
with the following underlying assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_z7m2ZIRLlCl3" style="display: none"&gt;SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR OPTIONS GRANTED&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Price at valuation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$ &lt;span id="xdx_907_eus-gaap--SharePrice_iI_pp2d_c20241231__srt--RangeAxis__srt--MinimumMember_za8ONnVvuOA4" title="Price at valuation"&gt;6.71&lt;/span&gt; &#x2013; &lt;span id="xdx_90C_eus-gaap--SharePrice_iI_pp2d_c20241231__srt--RangeAxis__srt--MaximumMember_zGIdXn4vZHY2" title="Price at valuation"&gt;9.90&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$
                                            &lt;span id="xdx_909_eus-gaap--SharePrice_iI_pp2d_c20231231__srt--RangeAxis__srt--MinimumMember_zES0X3AIObf2"&gt;13.2
                                            &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2013;
                                            &lt;span id="xdx_905_eus-gaap--SharePrice_iI_pp2d_c20231231__srt--RangeAxis__srt--MaximumMember_z8dRCxkxgmI9"&gt;13.64&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$ &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_c20241231__srt--RangeAxis__srt--MinimumMember_z32dVIMMMHS3" title="Exercise price"&gt;6.71&lt;/span&gt; &#x2013; &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_c20241231__srt--RangeAxis__srt--MaximumMember_zwtbjSMWQKfc" title="Exercise price"&gt;9.90&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$ &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_c20231231__srt--RangeAxis__srt--MinimumMember_z5DpkXfdkl64"&gt;13.2&lt;/span&gt;
                                            &#x2013; &lt;/span&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_c20231231__srt--RangeAxis__srt--MaximumMember_zvgho4L20uX6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;13.64&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240101__20241231_zQuXvMfriufb" title="Risk free interest, minimum"&gt;4.14&lt;/span&gt; &#x2013; &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20240101__20241231_zPlwZQjgY3K2" title="Risk free interest, maximum"&gt;4.42&lt;/span&gt; %&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20231231_zDTpuVAjwNEe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.83
                                            &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2013;
                                            &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20230101__20231231_zPsbcrB4FRM4"&gt;4.42
                                            &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Expected term (in years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231_zLfmpjqveXC1" title="Expected term (in years)"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zMWbcPvC2XA5" style="font-family: Times New Roman, Times, Serif"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20240101__20241231_zd0ANHMofr2i" title="Volatility, minimum"&gt;128.4&lt;/span&gt; &#x2013; &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20240101__20241231_zctxGMrRbwOb" title="Volatility, maximum"&gt;132.8&lt;/span&gt; %&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20230101__20231231_z5YdNzA8UOY5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;133.1
                                            &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2013;
                                            &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20230101__20231231_zRC0RRDUiCw3"&gt;133.6
                                            &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharePrice
      contextRef="AsOf2024-12-31_srt_MinimumMember"
      decimals="2"
      id="Fact000916"
      unitRef="USDPShares">6.71</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2024-12-31_srt_MaximumMember"
      decimals="2"
      id="Fact000918"
      unitRef="USDPShares">9.90</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2023-12-31_srt_MinimumMember"
      decimals="2"
      id="Fact000919"
      unitRef="USDPShares">13.2</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2023-12-31_srt_MaximumMember"
      decimals="2"
      id="Fact000920"
      unitRef="USDPShares">13.64</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2024-12-31_srt_MinimumMember"
      decimals="2"
      id="Fact000922"
      unitRef="USDPShares">6.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2024-12-31_srt_MaximumMember"
      decimals="2"
      id="Fact000924"
      unitRef="USDPShares">9.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2023-12-31_srt_MinimumMember"
      decimals="2"
      id="Fact000925"
      unitRef="USDPShares">13.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2023-12-31_srt_MaximumMember"
      decimals="2"
      id="Fact000926"
      unitRef="USDPShares">13.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000928"
      unitRef="Pure">0.0414</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000930"
      unitRef="Pure">0.0442</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000931"
      unitRef="Pure">0.0383</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000932"
      unitRef="Pure">0.0442</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2024-01-01to2024-12-31" id="Fact000934">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2023-01-012023-12-31" id="Fact000935">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000937"
      unitRef="Pure">1.284</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000939"
      unitRef="Pure">1.328</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000940"
      unitRef="Pure">1.331</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000941"
      unitRef="Pure">1.336</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000943">&lt;p id="xdx_89C_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zt5AGZJIb9ab" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
total stock-based expense recognized in the financial statements for services received from employees and non-employees is shown in the
following table.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BA_zdfH3ioX8TDf" style="display: none"&gt;SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED SERVICES FROM EMPLOYEES AND NON-EMPLOYEES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240101__20241231_z6XktNeSRnI9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20231231_z1cFdggzb4Id" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Year Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_znYUhzDywvF" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;5,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;6,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zfyhUw6y7Ru6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Selling and marketing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z8turcZgioZ" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;334,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;259,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zi4G19ZLiGOl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;356,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;293,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zgWgiHEQD5d3" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Stock based compensation expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;356,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;293,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact000945"
      unitRef="USD">5000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact000946"
      unitRef="USD">6000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_us-gaap_SellingAndMarketingExpenseMember"
      decimals="-3"
      id="Fact000948"
      unitRef="USD">17000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_SellingAndMarketingExpenseMember"
      decimals="-3"
      id="Fact000949"
      unitRef="USD">28000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact000951"
      unitRef="USD">334000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact000952"
      unitRef="USD">259000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000954"
      unitRef="USD">356000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000955"
      unitRef="USD">293000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000957"
      unitRef="USD">356000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000958"
      unitRef="USD">293000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000960"
      unitRef="USD">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-08-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000962"
      unitRef="Shares">264271</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-08-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000964"
      unitRef="USDPShares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-08-30_custom_A1WarrantsMember"
      decimals="INF"
      id="Fact000966"
      unitRef="Shares">264271</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-08-30_custom_A1WarrantsMember"
      decimals="INF"
      id="Fact000968"
      unitRef="USDPShares">16.17</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-08-30_custom_A2WarrantsMember"
      decimals="INF"
      id="Fact000970"
      unitRef="Shares">264271</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-08-30_custom_A2WarrantsMember"
      decimals="INF"
      id="Fact000972"
      unitRef="USDPShares">16.17</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2023-08-30"
      decimals="INF"
      id="Fact000974"
      unitRef="Shares">776448</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2023-08-30_custom_A1WarrantsMember"
      id="Fact000976">2029-03-01</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2023-08-30_custom_A2WarrantsMember"
      id="Fact000978">2024-10-01</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-08-30_custom_HCWainwrightAndCoLLCMember"
      decimals="INF"
      id="Fact000980"
      unitRef="Shares">19820</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-08-30_custom_HCWainwrightAndCoLLCMember"
      decimals="INF"
      id="Fact000982"
      unitRef="USDPShares">23.65</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2023-08-30_custom_HCWainwrightAndCoLLCMember"
      id="Fact000984">2029-03-01</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <NAOV:ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000986">&lt;p id="xdx_893_ecustom--ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock_z3euBJXIJSt5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
estimating the warrants&#x2019; fair value, the Company used the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zKsvv47MJk4g" style="display: none"&gt;SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR WARRANTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Risk free interest&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z46WZr2xiszl" title="Warrants, measurement input, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0988"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zytQ8rdizZzl" title="Warrants, measurement input, percentage"&gt;3.49&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zeKwKRN982D6" title="Warrants, measurement input, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0992"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zEMWAx4Us7c2" title="Warrants, measurement input, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0994"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zvxKzIId2dDj" title="Warrants, measurement input, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0996"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zfvsuw3JbBoa" title="Warrants, measurement input, percentage"&gt;147.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Contractual term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20241231_zqsnYIeqDdei" title="Contractual term (in years)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1000"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231_z5hF0H6D4Zqg" title="Contractual term (in years)"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</NAOV:ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact000990"
      unitRef="Pure">3.49</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact000998"
      unitRef="Pure">147.6</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2023-12-31" id="Fact001002">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_PreWarrantMember_custom_PrivateInvestorsMember"
      decimals="INF"
      id="Fact001004"
      unitRef="Shares">2389</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_PostWarrantMember_custom_PrivateInvestorsMember"
      decimals="INF"
      id="Fact001006"
      unitRef="Shares">2389</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2023-01-012023-12-31_custom_PreWarrantMember_custom_PrivateInvestorsMember"
      decimals="INF"
      id="Fact001008"
      unitRef="Shares">8758954</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2023-01-012023-12-31_custom_PostWarrantMember_custom_PrivateInvestorsMember"
      decimals="INF"
      id="Fact001010"
      unitRef="Shares">796269</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2023-01-012023-12-31_custom_PreWarrantMember_custom_PrivateInvestorsMember"
      decimals="INF"
      id="Fact001016"
      unitRef="Shares">203977</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2023-01-012023-12-31_custom_PostWarrantMember_custom_PrivateInvestorsMember"
      decimals="INF"
      id="Fact001018"
      unitRef="Shares">18543</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_PreWarrantMember_custom_PrivateInvestorsMember"
      decimals="INF"
      id="Fact001020"
      unitRef="Shares">8633229</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_PostWarrantMember_custom_PrivateInvestorsMember"
      decimals="INF"
      id="Fact001022"
      unitRef="Shares">780115</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2024-01-012024-12-31_custom_PreWarrantMember_custom_PrivateInvestorsMember"
      decimals="INF"
      id="Fact001028"
      unitRef="Shares">2918977</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2024-01-012024-12-31_custom_PostWarrantMember_custom_PrivateInvestorsMember"
      decimals="INF"
      id="Fact001030"
      unitRef="Shares">265362</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2024-01-012024-12-31_custom_PreWarrantMember_custom_PrivateInvestorsMember"
      decimals="INF"
      id="Fact001032"
      unitRef="Shares">2122000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2024-01-012024-12-31_custom_PostWarrantMember_custom_PrivateInvestorsMember"
      decimals="INF"
      id="Fact001034"
      unitRef="Shares">192910</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_PreWarrantMember_custom_PrivateInvestorsMember"
      decimals="INF"
      id="Fact001040"
      unitRef="Shares">3592252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_PostWarrantMember_custom_PrivateInvestorsMember"
      decimals="INF"
      id="Fact001042"
      unitRef="Shares">321843</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001044">&lt;p id="xdx_802_eus-gaap--LesseeOperatingLeasesTextBlock_z10TFwGETv15" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
7 &#x2013; &lt;span id="xdx_823_zgK8HiPkV98i"&gt;LEASES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has operating lease agreements with terms up to &lt;span id="xdx_906_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember_z0i3y4vVC2ri" title="Lease term"&gt;1&lt;/span&gt;-&lt;span id="xdx_907_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember_zvKH276tEYJ9" title="Lease term"&gt;3&lt;/span&gt; years, including car and office space leases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s weighted-average remaining lease term relating to its operating leases is &lt;span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zI6o87YBPXd6" title="Weighted-average remaining lease term"&gt;2.21&lt;/span&gt; years, with a weighted-average discount
rate of &lt;span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zPo9yZNRs9ci" title="Weighted-average discount rate"&gt;10&lt;/span&gt;%.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company incurred $&lt;span id="xdx_90F_eus-gaap--OperatingLeaseExpense_c20240101__20241231_z0lUNrn5a5f2" title="Operating lease, expense"&gt;70,000&lt;/span&gt; of lease expense for its operating leases for the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zOU5r58QIyL6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information about the amount and timing of liabilities arising from the Company&#x2019;s operating leases as
of December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;span id="xdx_8B4_zGgbj7OTjX27" style="display: none"&gt;SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES&lt;/span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20241231_zxPtPQOlOC8a" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzL7T_zGXEahfPrLei" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;60,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzL7T_zTOe6HBlXKl7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;58,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzL7T_z39OzRFf7tF7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;10,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzL7T_z6QTV7jPsWR7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total undiscounted operating lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;128,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_zLtKez6saP06" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: Imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;13,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iI_zMpPlSQGvR31" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Present value of operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;115,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zRfvqfIiAtFf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="AsOf2024-12-31_srt_MinimumMember"
      id="Fact001046">P1Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="AsOf2024-12-31_srt_MaximumMember"
      id="Fact001048">P3Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2024-12-31" id="Fact001050">P2Y2M15D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001052"
      unitRef="Pure">0.10</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001054"
      unitRef="USD">70000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001056">&lt;p id="xdx_896_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zOU5r58QIyL6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information about the amount and timing of liabilities arising from the Company&#x2019;s operating leases as
of December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;span id="xdx_8B4_zGgbj7OTjX27" style="display: none"&gt;SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES&lt;/span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20241231_zxPtPQOlOC8a" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzL7T_zGXEahfPrLei" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;60,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzL7T_zTOe6HBlXKl7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;58,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzL7T_z39OzRFf7tF7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;10,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzL7T_z6QTV7jPsWR7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total undiscounted operating lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;128,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_zLtKez6saP06" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: Imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;13,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iI_zMpPlSQGvR31" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Present value of operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;115,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001058"
      unitRef="USD">60000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001060"
      unitRef="USD">58000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001062"
      unitRef="USD">10000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001064"
      unitRef="USD">128000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001066"
      unitRef="USD">13000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001068"
      unitRef="USD">115000</us-gaap:OperatingLeaseLiability>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001070">&lt;p id="xdx_805_eus-gaap--EarningsPerShareTextBlock_zc71vfFF3QLf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
8 - &lt;span id="xdx_827_zdUn3PGuiSld"&gt;LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
net loss per common share (&#x201c;Basic EPS&#x201d;) is computed by dividing net loss available to common shareholders by the weighted
average number of common shares outstanding during the period. All outstanding share options and warrants for the years ended December
31, 2024, and 2023 have been excluded from the calculation of the diluted net loss per share because all such securities are anti-dilutive
for all periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zlcoWaFYUOVf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s securities, in common share equivalents, which have been excluded from the calculation
of dilutive loss per share as their effect would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zX922lo9htWh" style="display: none"&gt;SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240101__20241231_zO8kDPjm9NOl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20230101__20231231_zliEkaTP3TNa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsEmployeeAndNonEmployeeMember_z69SwWeaMDY6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Stock options - employee and non-employee&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;45,059&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;10,244&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zqzlHoQRu4kb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;326,568&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;784,839&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zkQIg5ezY5U1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;371,627&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;795,083&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A4_zCrMg9MIqk2g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
diluted loss per share equals basic loss per share in the year ended December 31, 2024, and 2023 because the Company had a net loss and
the impact of the assumed exercise of stock options and the vesting of restricted stock would have been anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001072">&lt;p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zlcoWaFYUOVf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s securities, in common share equivalents, which have been excluded from the calculation
of dilutive loss per share as their effect would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zX922lo9htWh" style="display: none"&gt;SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240101__20241231_zO8kDPjm9NOl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20230101__20231231_zliEkaTP3TNa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsEmployeeAndNonEmployeeMember_z69SwWeaMDY6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Stock options - employee and non-employee&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;45,059&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;10,244&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zqzlHoQRu4kb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;326,568&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;784,839&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zkQIg5ezY5U1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;371,627&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;795,083&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_custom_StockOptionsEmployeeAndNonEmployeeMember"
      decimals="INF"
      id="Fact001074"
      unitRef="Shares">45059</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_StockOptionsEmployeeAndNonEmployeeMember"
      decimals="INF"
      id="Fact001075"
      unitRef="Shares">10244</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001077"
      unitRef="Shares">326568</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001078"
      unitRef="Shares">784839</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001080"
      unitRef="Shares">371627</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001081"
      unitRef="Shares">795083</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001083">&lt;p id="xdx_807_eus-gaap--SegmentReportingDisclosureTextBlock_zNp5qHzhvmg7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
9 - &lt;span id="xdx_825_z6mwsRi0GGUb"&gt;GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Summary
information about geographic areas:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company manages its business on the basis of one reportable segment and Brian Murphy, CEO, is the chief decision maker for the
segment. The Company derives revenues from selling its products directly to patients as well as through distributor agreements. The
following is a summary of revenues within geographic areas:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--RevenueFromExternalCustomersByGeographicAreasTableTextBlock_zPYDtD4lb4f2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8BC_zWuHqRpHpZl3"&gt;SUMMARY
OF REVENUE WITHIN GEOGRAPHIC AREAS&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240101__20241231_zYvtbqfa9mee" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20230101__20231231_z686t8clFGhc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__country--US_z5igr5BEUtd3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;2,450,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;2,162,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__srt--EuropeMember_zlt75zO9MMR3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Europe&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;101,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__country--AU_zXVYD0RrRDyj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Australia&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__country--IL_zZfEHqFWIzge" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Israel&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__country--NZ_zqmBAPvQnye6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;New Zealand&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1100"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__custom--OtherCountryMember_zTZBuNVnqaZ3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;46,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1103"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0d_zviMUP09I6fh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,558,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,283,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0d_zOB0gakHaA76" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Revenues geographic areas&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,558,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,283,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AF_zcN3kKlqooTe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s long-lived assets are all located in Israel.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year end December 31, 2024, the Company generated approximately $&lt;span id="xdx_909_eus-gaap--Revenues_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerMember_z4AtByWI8I22" title="Revenues"&gt;800,000&lt;/span&gt; in revenue from its largest direct medical distributor,
Ultra Pain Products, LLC. This represents approximately &lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerMember_zuF342PYPh4i" title="Concentration risk, percentage"&gt;31&lt;/span&gt;% of the company&#x2019;s total revenue for the year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001085">&lt;p id="xdx_89C_eus-gaap--RevenueFromExternalCustomersByGeographicAreasTableTextBlock_zPYDtD4lb4f2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8BC_zWuHqRpHpZl3"&gt;SUMMARY
OF REVENUE WITHIN GEOGRAPHIC AREAS&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240101__20241231_zYvtbqfa9mee" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20230101__20231231_z686t8clFGhc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__country--US_z5igr5BEUtd3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;2,450,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;2,162,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__srt--EuropeMember_zlt75zO9MMR3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Europe&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;101,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__country--AU_zXVYD0RrRDyj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Australia&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__country--IL_zZfEHqFWIzge" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Israel&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__country--NZ_zqmBAPvQnye6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;New Zealand&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1100"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__custom--OtherCountryMember_zTZBuNVnqaZ3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;46,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1103"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0d_zviMUP09I6fh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,558,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,283,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0d_zOB0gakHaA76" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Revenues geographic areas&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,558,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,283,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_country_US"
      decimals="0"
      id="Fact001087"
      unitRef="USD">2450000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_country_US"
      decimals="0"
      id="Fact001088"
      unitRef="USD">2162000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_srt_EuropeMember"
      decimals="0"
      id="Fact001090"
      unitRef="USD">17000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_srt_EuropeMember"
      decimals="0"
      id="Fact001091"
      unitRef="USD">101000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_country_AU"
      decimals="0"
      id="Fact001093"
      unitRef="USD">29000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_country_AU"
      decimals="0"
      id="Fact001094"
      unitRef="USD">19000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_country_IL"
      decimals="0"
      id="Fact001096"
      unitRef="USD">4000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_country_IL"
      decimals="0"
      id="Fact001097"
      unitRef="USD">1000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_country_NZ"
      decimals="0"
      id="Fact001099"
      unitRef="USD">12000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_custom_OtherCountryMember"
      decimals="0"
      id="Fact001102"
      unitRef="USD">46000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001105"
      unitRef="USD">2558000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001106"
      unitRef="USD">2283000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001108"
      unitRef="USD">2558000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001109"
      unitRef="USD">2283000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="From2024-01-012024-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerMember"
      decimals="0"
      id="Fact001111"
      unitRef="USD">800000</us-gaap:Revenues>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-01-012024-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerMember"
      decimals="INF"
      id="Fact001113"
      unitRef="Pure">0.31</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:OtherAssetsDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001115">&lt;p id="xdx_80E_eus-gaap--OtherAssetsDisclosureTextBlock_z58NV7IVZR27" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
10 &#x2013; &lt;span id="xdx_829_zqcPGMjyMeTd"&gt;OTHER ASSETS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 9, 2020, pursuant to a licensing agreement entered into in March 2020, the Company received &lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20200409__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zxWib95aXX9j" title="Warrants and rights outstanding term"&gt;10&lt;/span&gt;-year warrants to purchase &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20200409__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_znF23TDkPWWe" title="Warrants issued to purchase common stock"&gt;127,000&lt;/span&gt;
shares of Sanuwave Health, Inc. at a price of $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20200409__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_ziHQ9H53MNo8" title="Exercise price of warrants per share"&gt;0.19&lt;/span&gt; per share. The fair value for warrants received is estimated at the date of grant
using a Black-Scholes-Merton pricing model with the following underlying assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_ecustom--ScheduleOfWarrantsAssumptionsTableTextBlock_zDKX714Vy246" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8B0_ztgla8kCAZi"&gt;SCHEDULE OF WARRANTS ASSUMPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Price at valuation&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__custom--PriceAtValuationMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zDbiPnlSN1F3" title="Warrants and rights outstanding, measurement input"&gt;0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__custom--PriceAtValuationMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zSCafcIMChM4" title="Warrants and rights outstanding, measurement input"&gt;0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zB2R6yMLZG96" title="Warrants and rights outstanding, measurement input"&gt;0.19&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zVU3v9oIQVtj" title="Warrants and rights outstanding, measurement input"&gt;0.19&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zp6Zv0uSc7Fa" title="Warrants and rights outstanding, measurement input"&gt;3.88&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zkfmBN6WiGU8" title="Warrants and rights outstanding, measurement input"&gt;3.88&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zk9gYMzSEDha" title="Expected term (in years)"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zygXJz8tDLH1" title="Expected term (in years)"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_z9skbkifx3Ud" title="Warrants and rights outstanding, measurement input"&gt;147.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_z31oSP3O7shj" title="Warrants and rights outstanding, measurement input"&gt;147.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_z5LGHEISuaJd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers this to be Level 3 inputs and is valued at each reporting period. As of September 12, 2024, the company terminated
the licensing agreement with Sanuwave and recognized $&lt;span id="xdx_90A_eus-gaap--GainLossOnContractTermination_c20240912__20240912_zGpHzGbL6ypl" title="Gain loss on contract termination"&gt;3,000&lt;/span&gt; in gain/loss of termination of investment, offset by change in fair value
through the date of termination of $&lt;span id="xdx_908_ecustom--IncreaseDecreaseInTerminationValueByOffset_iI_c20240912_zP7KOLx9smY1" title="Increase decrease in termination value by offset"&gt;1,000&lt;/span&gt;. The fair value of these warrants for the years ended December 31, 2024, and 2023 was $&lt;span id="xdx_90C_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iI_c20241231_z6m1RFh24o52" title="Fair value of warrants"&gt;0&lt;/span&gt; and
$&lt;span id="xdx_900_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iI_c20231231_z4sIfkjBknDb" title="Warrants leaving balance"&gt;1,000&lt;/span&gt;, respectively. There was a net $&lt;span id="xdx_901_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231_zjypg1q1po2h" title="Fair value of warrants"&gt;3,000&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231_z6IhbENHkvEe" title="Fair value of warrants"&gt;2,000&lt;/span&gt; change in fair value during the year ended December 31, 2024, and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Financial
Liabilities Measured at Fair Value on a Recurring Basis&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability
in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants
would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2 inputs: Inputs, other than quoted prices included in Level 1, that are observable either directly or indirectly; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own
    assumptions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were no transfers between Level 3 during the years ended December 31, 2024, and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_z2nhLDqF724i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents changes in Level 3 asset and liability measured at fair value for the years ended December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_zzp8DjOUaIpc" style="display: none"&gt;SCHEDULE
OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Asset&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%"&gt;Balance &#x2013; December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3d_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zhxGeSsFbK6a" style="width: 14%; text-align: right" title="Balance beginning"&gt;3,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Fair value adjustments &#x2013; Sanuwave warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FairValueAdjustmentOfWarrants_pn3d_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zCmWZcrsy9y2" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants"&gt;(2,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance &#x2013; December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3d_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_z5lKcZNPZI3g" style="text-align: right" title="Balance beginning"&gt;1,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Fair value adjustments &#x2013; Sanuwave warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FairValueAdjustmentOfWarrants_pn3d_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zAYie0zaomG9" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants"&gt;(1,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance &#x2013; December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_pn3d_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zAkyyPVLxuR1" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1167"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zN7iM67GH1Xe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zGOPWlPhDSh7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table sets forth the Company&#x2019;s assets and liabilities which are measured at fair value on a recurring basis by level
within the fair value hierarchy:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B4_zwWJeHXQDedf" style="display: none"&gt;SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_znBUdNv0qPEg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level I&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zgvMR1A6PpA7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level II&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z96DcWj5kHy" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level III&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20241231_z9DoxhMLDlZ5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value Measurements as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level I&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level II&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level III&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 28%"&gt;Asset:&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OtherAssetsFairValueDisclosure_iI_zVcggDXizV32" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Other assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1171"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1172"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1173"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1174"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zxAKE3RGqrJ2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level I&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zCq33R0310w7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level II&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zULoEFsUUZf4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level III&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20231231_zdzGtmbO0cNe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value Measurements as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level I&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level II&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level III&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 28%"&gt;Asset:&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OtherAssetsFairValueDisclosure_iI_zqdU7meWwT78" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Other assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1176"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1177"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zXY1icEwDNH9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OtherAssetsDisclosureTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2020-04-09_custom_LicensingAgreementMember_custom_SanuwaveHealthIncMember"
      id="Fact001117">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2020-04-09_custom_LicensingAgreementMember_custom_SanuwaveHealthIncMember"
      decimals="INF"
      id="Fact001119"
      unitRef="Shares">127000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-04-09_custom_LicensingAgreementMember_custom_SanuwaveHealthIncMember"
      decimals="INF"
      id="Fact001121"
      unitRef="USDPShares">0.19</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <NAOV:ScheduleOfWarrantsAssumptionsTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001123">&lt;p id="xdx_899_ecustom--ScheduleOfWarrantsAssumptionsTableTextBlock_zDKX714Vy246" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8B0_ztgla8kCAZi"&gt;SCHEDULE OF WARRANTS ASSUMPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Price at valuation&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__custom--PriceAtValuationMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zDbiPnlSN1F3" title="Warrants and rights outstanding, measurement input"&gt;0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__custom--PriceAtValuationMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zSCafcIMChM4" title="Warrants and rights outstanding, measurement input"&gt;0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zB2R6yMLZG96" title="Warrants and rights outstanding, measurement input"&gt;0.19&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zVU3v9oIQVtj" title="Warrants and rights outstanding, measurement input"&gt;0.19&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zp6Zv0uSc7Fa" title="Warrants and rights outstanding, measurement input"&gt;3.88&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zkfmBN6WiGU8" title="Warrants and rights outstanding, measurement input"&gt;3.88&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zk9gYMzSEDha" title="Expected term (in years)"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zygXJz8tDLH1" title="Expected term (in years)"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_z9skbkifx3Ud" title="Warrants and rights outstanding, measurement input"&gt;147.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_z31oSP3O7shj" title="Warrants and rights outstanding, measurement input"&gt;147.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</NAOV:ScheduleOfWarrantsAssumptionsTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_custom_PriceAtValuationMember_custom_SanuwaveHealthIncMember"
      decimals="INF"
      id="Fact001125"
      unitRef="USDPShares">0.01</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_custom_PriceAtValuationMember_custom_SanuwaveHealthIncMember"
      decimals="INF"
      id="Fact001127"
      unitRef="USDPShares">0.01</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_SanuwaveHealthIncMember"
      decimals="INF"
      id="Fact001129"
      unitRef="Pure">0.19</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_SanuwaveHealthIncMember"
      decimals="INF"
      id="Fact001131"
      unitRef="Pure">0.19</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_SanuwaveHealthIncMember"
      decimals="INF"
      id="Fact001133"
      unitRef="Pure">3.88</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_SanuwaveHealthIncMember"
      decimals="INF"
      id="Fact001135"
      unitRef="Pure">3.88</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-31_custom_SanuwaveHealthIncMember_us-gaap_MeasurementInputExpectedTermMember"
      id="Fact001137">P7Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-12-31_custom_SanuwaveHealthIncMember_us-gaap_MeasurementInputExpectedTermMember"
      id="Fact001139">P7Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_SanuwaveHealthIncMember"
      decimals="INF"
      id="Fact001141"
      unitRef="Pure">147.8</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_SanuwaveHealthIncMember"
      decimals="INF"
      id="Fact001143"
      unitRef="Pure">147.8</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:GainLossOnContractTermination
      contextRef="From2024-09-122024-09-12"
      decimals="0"
      id="Fact001145"
      unitRef="USD">3000</us-gaap:GainLossOnContractTermination>
    <NAOV:IncreaseDecreaseInTerminationValueByOffset
      contextRef="AsOf2024-09-12"
      decimals="0"
      id="Fact001147"
      unitRef="USD">1000</NAOV:IncreaseDecreaseInTerminationValueByOffset>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001149"
      unitRef="USD">0</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001151"
      unitRef="USD">1000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001153"
      unitRef="USD">3000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001155"
      unitRef="USD">2000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001157">&lt;p id="xdx_890_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_z2nhLDqF724i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents changes in Level 3 asset and liability measured at fair value for the years ended December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_zzp8DjOUaIpc" style="display: none"&gt;SCHEDULE
OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Asset&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%"&gt;Balance &#x2013; December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3d_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zhxGeSsFbK6a" style="width: 14%; text-align: right" title="Balance beginning"&gt;3,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Fair value adjustments &#x2013; Sanuwave warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FairValueAdjustmentOfWarrants_pn3d_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zCmWZcrsy9y2" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants"&gt;(2,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance &#x2013; December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3d_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_z5lKcZNPZI3g" style="text-align: right" title="Balance beginning"&gt;1,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Fair value adjustments &#x2013; Sanuwave warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FairValueAdjustmentOfWarrants_pn3d_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zAYie0zaomG9" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants"&gt;(1,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance &#x2013; December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_pn3d_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zAkyyPVLxuR1" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1167"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="AsOf2022-12-31_custom_DerivativeAssetMember"
      decimals="-3"
      id="Fact001159"
      unitRef="USD">3000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-12-31_custom_DerivativeAssetMember"
      decimals="-3"
      id="Fact001161"
      unitRef="USD">-2000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="AsOf2023-12-31_custom_DerivativeAssetMember"
      decimals="-3"
      id="Fact001163"
      unitRef="USD">1000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-12-31_custom_DerivativeAssetMember"
      decimals="-3"
      id="Fact001165"
      unitRef="USD">-1000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001169">&lt;p id="xdx_894_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zGOPWlPhDSh7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table sets forth the Company&#x2019;s assets and liabilities which are measured at fair value on a recurring basis by level
within the fair value hierarchy:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B4_zwWJeHXQDedf" style="display: none"&gt;SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_znBUdNv0qPEg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level I&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zgvMR1A6PpA7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level II&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z96DcWj5kHy" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level III&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20241231_z9DoxhMLDlZ5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value Measurements as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level I&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level II&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level III&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 28%"&gt;Asset:&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OtherAssetsFairValueDisclosure_iI_zVcggDXizV32" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Other assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1171"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1172"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1173"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1174"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zxAKE3RGqrJ2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level I&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zCq33R0310w7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level II&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zULoEFsUUZf4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level III&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20231231_zdzGtmbO0cNe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value Measurements as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level I&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level II&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level III&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 28%"&gt;Asset:&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OtherAssetsFairValueDisclosure_iI_zqdU7meWwT78" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Other assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1176"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1177"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:OtherAssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001178"
      unitRef="USD">1000</us-gaap:OtherAssetsFairValueDisclosure>
    <us-gaap:OtherAssetsFairValueDisclosure
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001179"
      unitRef="USD">1000</us-gaap:OtherAssetsFairValueDisclosure>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001181">&lt;p id="xdx_802_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zhLjX2eAYg3a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
11 - &lt;span id="xdx_82C_z8P5fV4IYrAa"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Pending
and settled litigation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 26, 2021, Protrade Systems, Inc. (&#x201c;Protrade&#x201d;) filed a Request for Arbitration (the &#x201c;Request&#x201d;) with the
International Court of Arbitration (the &#x201c;ICA&#x201d;) of the International Chamber of Commerce alleging the Company is in breach
of an Exclusive Distribution Agreement dated March 7, 2019 (the &#x201c;Exclusive Distribution Agreement&#x201d;) between Protrade and
the Company. Protrade alleges, in part, that the Company has breached the Exclusive Distribution Agreement by discontinuing the manufacture
of the DV0057 Painshield MD device in favor of an updated 10-100-001 Painshield MD device. Protrade claims damages estimated at $&lt;span id="xdx_904_eus-gaap--LossContingencyDamagesSoughtValue_pn6n6_c20210225__20210226_zKyz3tsCBDzi" title="Litigation damages sought value"&gt;3&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 15, 2022, the arbitrator issued a final award, which, determined that (i) the Company had the right to terminate the Exclusive
Distribution Agreement; (ii) the Company did not breach the duty of good faith and fair dealing with regard to the Exclusive Distribution
Agreement; and (iii) the Company did not breach any confidentiality obligations to Protrade. Nevertheless, the arbitrator determined
that the Company did not comply with the obligation to supply Protrade with a year&#x2019;s supply of patches, and awarded Protrade $&lt;span id="xdx_90F_eus-gaap--LossContingencyDamagesSoughtValue_c20220314__20220315_zwUzU7hOiKx9" title="Loss contingency damages sought value"&gt;1,500,250&lt;/span&gt;,
which consists of $&lt;span id="xdx_905_eus-gaap--LossContingencyDamagesAwardedValue_c20220314__20220315_zxHPoZJvf5pf" title="Loss contingency damages sought value"&gt;1,432,000&lt;/span&gt; for &#x201c;lost profits&#x201d; and $&lt;span id="xdx_902_eus-gaap--LossContingencyDamagesPaidValue_c20220314__20220315_z55qV5WmuNqa" title="Loss contingency damages paid value"&gt;68,250&lt;/span&gt; as reimbursement of arbitration costs, on the grounds that the
Company allegedly failed to supply Protrade with certain patches utilized by users of DV0057 Painshield MD device. The arbitrator based
the decision on the testimony of Protrade&#x2019;s president who asserted that a user would use in excess of 33 patches per each device.
The Company believes that the number of patches per device alleged by Protrade is grossly inflated, and that these claims were not properly
raised before the arbitrator. Accordingly, on April 13, 2022, the Company submitted an application for the correction of the award which
the arbitrator denied on June 22, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 22, 2022, the Company filed a cross-motion seeking to vacate arbitration award on the grounds that the arbitrator exceeded her authority,
that the award was procured by fraud, and that the arbitrator failed to follow procedures established by New York law. In particular,
the Company averred in its motion that Protrade&#x2019;s witness made false statements in arbitration, and that the arbitrator resolved
a claim that was never raised by Protrade and that has no factual basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 3, 2022, the court issued a decision granting Protrade its petition to confirm the award and denying the cross-motion.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 9, 2022, the Company filed a motion to re-argue and renew its cross-motion to vacate the arbitration decision based on newer
information that was not available during the initial hearing. On the same day, the Company also filed a notice of appeal with the Appellate
Division, Second Department. On March 21, 2023, the court denied the motion to re-argue and renew.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;On July 10, 2023, the Company filed its appeal with the Appellate Division,
Second Department. That appeal is now fully briefed. In February 2025, the Second Department informed counsel for the Company that the
Second Department was beginning to process the appeal for calendaring.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, and 2023, the Company accrued the amount of the arbitration award to Protrade of approximately $&lt;span id="xdx_901_eus-gaap--LossContingencyDamagesAwardedValue_pn5n6_c20240101__20241231__srt--TitleOfIndividualAxis__custom--ArbitratorMember_zhiTbLeUGEFc" title="Damages awarded value"&gt;2.1&lt;/span&gt;
million and $&lt;span id="xdx_900_eus-gaap--LossContingencyDamagesAwardedValue_pn5n6_c20230101__20231231__srt--TitleOfIndividualAxis__custom--ArbitratorMember_zendAHeQEsl7" title="Damages awarded value"&gt;2.0&lt;/span&gt; million, respectively, including interest which is classified in &#x201c;Other accounts payable and accrued
expenses&#x201d;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="From2021-02-252021-02-26"
      decimals="-6"
      id="Fact001183"
      unitRef="USD">3000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="From2022-03-142022-03-15"
      decimals="0"
      id="Fact001185"
      unitRef="USD">1500250</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="From2022-03-142022-03-15"
      decimals="0"
      id="Fact001187"
      unitRef="USD">1432000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesPaidValue
      contextRef="From2022-03-142022-03-15"
      decimals="0"
      id="Fact001189"
      unitRef="USD">68250</us-gaap:LossContingencyDamagesPaidValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="From2024-01-012024-12-31_custom_ArbitratorMember"
      decimals="-5"
      id="Fact001191"
      unitRef="USD">2100000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="From2023-01-012023-12-31_custom_ArbitratorMember"
      decimals="-5"
      id="Fact001193"
      unitRef="USD">2000000.0</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001195">&lt;p id="xdx_804_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zVot36ortO2c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
12 &#x2013; &lt;span id="xdx_826_zwDHkBe8neqb"&gt;RELATED PARTY TRANSACTION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
firm of FisherBroyles LLP handled all our Protrade litigation and appeals through December 31, 2024. For the year ended December 31,
2024, we have been not been billed and have not paid any legal fees from FisherBroyles .Ms. Cassirer id not provide any legal services
or legal advice to the Company&lt;b&gt;.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 1, 2024, Ms. Cassirer and the lawyers responsible for handling our Protrade litigation left the firm of FisherBroyles to join
the firm of Pierson Ferdinand LLP. As of January1, 2024, the firm Pierson Ferdinand is the sole firm handling all our Protrade litigation
and appeals. For the year ended December 31, 2024, Pierson Ferdinand was paid $&lt;span id="xdx_903_eus-gaap--PaymentsForFees_c20240101__20241231__srt--TitleOfIndividualAxis__custom--PiersonFerdinandMember_zqEkLgSkLWT8" title="Payments for fees"&gt;69,000&lt;/span&gt;. As was the case in prior years, Ms. Cassirer does
not provide any legal services or legal advice to the Company&lt;b&gt;.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:PaymentsForFees
      contextRef="From2024-01-012024-12-31_custom_PiersonFerdinandMember"
      decimals="0"
      id="Fact001197"
      unitRef="USD">69000</us-gaap:PaymentsForFees>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001199">&lt;p id="xdx_807_eus-gaap--IncomeTaxDisclosureTextBlock_zsUqwKH3qtb6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
13 &#x2013; &lt;span id="xdx_82A_zNAJtWIVdZm"&gt;INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, the U.S. Company had federal and state net operating loss carry forward for tax purposes of approximately $&lt;span id="xdx_909_eus-gaap--OperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zBGZKvTpHYLc" title="Net operating loss carry forward"&gt;41,300,000&lt;/span&gt;
and $&lt;span id="xdx_907_eus-gaap--OperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zIGSShdtXhUd" title="Net operating loss carry forward"&gt;5,400,000&lt;/span&gt;, respectively. $&lt;span id="xdx_907_ecustom--FederalNetOperatingLossCarriedForward_iI_c20231231_z6QJrpoOqda6" title="Federal net operating loss carried forward"&gt;27,400,000&lt;/span&gt; of the federal net operating loss can be carried forward indefinitely but can only offset up
to 80% of taxable income in a given year, and $&lt;span id="xdx_903_ecustom--FederalNetOperatingLossOffsetAgainstTaxableIncome_c20230101__20231231_zF2q9G1AlL75" title="Federal net operating loss offset against taxable income"&gt;14,000,000&lt;/span&gt; of the federal net operating loss can be used to fully offset taxable income
in the period it is utilized but can only be carried forward for &lt;span id="xdx_903_ecustom--OperatingLossCarryforwardsExpirationTerm_dtY_c20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zoRaoxAFMUW9" title="Operating loss carryforwards expiration term"&gt;20&lt;/span&gt; years. Utilization of the U.S. net operating losses may be subject
to substantial limitations in the event of a change of ownership under the provisions of the Internal Revenue Code of 1986. The Company
has not performed an analysis, but the potential impact of any limitation would not be material to the financial statements due to the
fact that the respective DTAs are fully offset by a valuation allowance. It should be noted that the federal deferred income tax expense at December
31, 2023 included a one-time adjustment to the net operating loss carryforward amounting to approximately $&lt;span id="xdx_903_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_iI_c20231231_z8fcrguwnRb7" title="Net operating loss carryforwards"&gt;400,000&lt;/span&gt; that will not affect
the financial statements due to the full valuation allowance on the deferred tax assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zobxkIkXBd87" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
tax expense is comprised of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_z9NXsdQaVxSe" style="display: none"&gt;SCHEDULE
OF PROVISION FOR INCOME TAXES EXPENSES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240101__20241231_zKiJQhJVt58l" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20231231_zuxtMajYHa74" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current Tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--CurrentFederalTaxExpenseBenefit_maCITEBzPkK_zz1DCJAuasU" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 64%; text-align: left"&gt;Federal&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1215"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1216"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maCITEBzPkK_zFzO7nt8qYPe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;State&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1218"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1219"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CurrentForeignTaxExpenseBenefit_maCITEBzPkK_z0ewUR7hJsh5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="margin: 0"&gt;18,677&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(25,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBzPkK_maOTEBzPz3_zgtwwKReysl1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;18,677&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(25,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred Tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maDITEBzsCS_zNtT1JVqJ0I7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;(815,484&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,226,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maDITEBzsCS_z2jwcZcrVCRe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;State&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;(11,269&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(43,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_maDITEBzsCS_zdb8op4KZaSh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="margin: 0"&gt;(3,263&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_mtDITEBzsCS_maOTEBzPz3_zUkSjIa3EuF1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;(830,015&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,267,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--ValuationAllowanceOfIncomeTaxExpenseBenefit_iN_di_msOTEBzPz3_zvkh7EoLm7dg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: Valuation Allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="margin: 0"&gt;830,015&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,267,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OtherTaxExpenseBenefit_iT_mtOTEBzPz3_zq28qJXkOSk5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total Tax&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;p style="margin: 0"&gt;18,677&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(25,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_z709BMCptM4j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company also recognized approximately $&lt;span id="xdx_90F_ecustom--FranchiseFees_c20230101__20231231_zQp2XwuvHn27" title="Franchise fees"&gt;4,000&lt;/span&gt; of state franchise fees during the year ended December 31, 2023. The difference between
the statutory tax rate of the Company and the effective tax rate is primarily the result of tax benefits generated by the Company and
its subsidiary which have not been recognized due to the uncertainty that such tax benefits will ultimately be realized. A reconciliation
of the statutory U.S Federal rate to the Company&#x2019;s effective tax rate is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;/p&gt;&lt;p id="xdx_89A_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zrv6m6x4H7jb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8BF_zy6isbGgFFHj"&gt;SCHEDULE
OF RECONCILIATION OF STATUTORY U.S. FEDERAL RATE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20240101__20241231_zo1qpy21NxQj" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231_zuaiCLWSH0Ib" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_maETR_z08mTPio2hF7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Federal income tax benefit at statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;p style="margin: 0"&gt;21.00&lt;/p&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;21.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_maETR_z0WtBKY24cWi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State income taxes, net of federal benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;0.31&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.13&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_maETR_zgi3HoYswTL2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Foreign rate differential&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;0.04&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-0.10&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--EffectiveIncomeTaxRateReconciliationPermanentItems_pid_dp_maETR_z2zbMpdHaZX8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Permanent Items&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;-0.04&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-0.63&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_maETR_zOvN0UqjO8Ud" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;-21.51&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-33.54&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_pid_dp_maETR_z8eeJ4Wu87g3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Return to provision adjustments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;0.40&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12.20&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--EffectiveIncomeTaxRateReconciliationForfeitedOptions_pid_dp_maETR_zFm7YbMTTPql" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Forfeited options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_maETR_zI863VO3wvn2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="margin: 0"&gt;0.30&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-0.01&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_mtETR_z1dnfdx1pM2a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Effective tax rate&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;p style="margin: 0"&gt;-0.51&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.06&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_ziPJdL6rinP4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Foreign
tax&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Tax
rates applicable to the income of the Israeli subsidiary:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Israeli corporate tax rate in 2024 and 2023 is &lt;span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20240101__20241231__srt--StatementGeographicalAxis__country--IL_zBjOn3dBgtsk" title="Corporate tax rate"&gt;&lt;span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20230101__20231231__srt--StatementGeographicalAxis__country--IL_zUclM5JiY825" title="Corporate tax rate"&gt;23&lt;/span&gt;&lt;/span&gt;%.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
subsidiary has final tax assessments through 2017.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss
before taxes:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_z8kq8o1y2ys9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8B5_z95j9vk6bTZd"&gt;SCHEDULE
OF INCOME BEFORE TAXES ON DOMESTIC AND FOREIGN&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240101__20241231_zflRt6iwtLFh" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20230101__20231231_zh2ylrDK48Vc" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_maILFCOz5C4_zGWQb8RJ19ce" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Domestic&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;p style="margin: 0"&gt;3,775,000&lt;/p&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;3,785,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_maILFCOz5C4_zh5XuOSYkMd9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="margin: 0"&gt;(89,000&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;br/&gt;
&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(103,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iNT_di_mtILFCOz5C4_z6Gc6eupoZMc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss before taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;p style="margin: 0"&gt;3,686,000&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,682,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zahqvlabvfk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Deferred
income taxes&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial
purposes and the amounts used for income tax purposes. Significant components of the Company&#x2019;s deferred tax assets are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zNYO9gPUIDh6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8B2_zqf9uXoQr892"&gt;SCHEDULE
OF DEFERRED TAX ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20241231_zmAEAoSVgAI4" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20231231_za5qgwPsI8ih" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzNu2_zv8U2kJ3Ihtf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Net operating loss carryforward&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;p style="margin: 0"&gt;9,032,000&lt;/p&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;8,486,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--DeferredTaxAssetsOfCapitalLossCarryforward_iI_maDTAGzNu2_zAffx37hB6U" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Capital loss carryforward&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;5,000&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1297"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--DeferredTaxAssetsTaxDeferredExpenseAccruals_iI_maDTAGzNu2_zLxfObrePuZj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Arbitration accrual&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;414,000&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;414,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_iI_maDTAGzNu2_z9VaXSu4vkA3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Stock compensation and other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="margin: 0"&gt;849,000&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;570,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzNu2_maDTALNzt1d_zNYrTbXgZi7k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets before valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;10,300,000&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,470,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzt1d_ziepFG8hpcqa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="margin: 0"&gt;(10,300,000&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(9,470,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzt1d_zTvmpeSxKzj4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax asset&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1311"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1312"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zLlNAwKlYRFb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2024, and 2023, the net increase in valuation allowance of $&lt;span id="xdx_90B_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20240101__20241231_zdWUZmdn9IDa" title="Net increases in valuation allowance"&gt;830,000&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20230101__20231231_znwa6UWAWFZb" title="Net increases in valuation allowance"&gt;1,267,000&lt;/span&gt;, respectively, was primarily
driven by the increase in net operating loss carry forwards.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
assessing the realization of deferred tax assets, management considers whether it is more likely than not that all or some portion of
the deferred tax assets will not be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which
temporary differences are deductible and net operating losses are able to be utilized. Based on consideration of these factors, the Company
concluded that all of its recorded deferred tax assets are not more likely than not realizable and recorded a full valuation allowance
at December 31, 2024, and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers the earnings of its non-U.S. subsidiary to be indefinitely invested outside the United States on the basis of estimates
that future domestic cash generation will be sufficient to meet future domestic cash needs and our specific plans for reinvestment of
those subsidiary earnings. We have not recorded a deferred tax liability related to the U.S. federal and state income taxes as an estimate
of undistributed earnings of foreign subsidiaries would not be practicable to estimate at this time. If the Company does decide to repatriate
the foreign earnings, we would need to adjust our income tax provision in the period we determined that the earnings will no longer be
indefinitely invested outside the United States.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Reconciliation
of the theoretical tax expense to the actual tax expense&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
main reconciling items between the statutory tax rate of the Company and the effective tax rate are the non-recognition of tax benefits
from accumulated net operating loss carry forward among the Company and its subsidiary due to the uncertainty of the realization of such
tax benefits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s policy is to record interest and penalties associated with unrecognized tax benefits as additional income taxes in the
statement of operations. As of December 31, 2024, and 2023, the Company does not have any liabilities recorded for uncertain tax positions
and does not expect there to be any events which could potentially result in the need for a material liability to be recorded. There
were no changes in the Company&#x2019;s unrecognized tax benefits during the years ended December 31, 2024, and 2023. The Company did
not recognize any interest or penalties during fiscal 2024 or 2023 related to unrecognized tax benefits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;U.S.
federal and New York State income taxes are open for examination for years 2021-2024 and Israel tax returns are open for examination
for years 2020-2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember"
      decimals="0"
      id="Fact001201"
      unitRef="USD">41300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="0"
      id="Fact001203"
      unitRef="USD">5400000</us-gaap:OperatingLossCarryforwards>
    <NAOV:FederalNetOperatingLossCarriedForward
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001205"
      unitRef="USD">27400000</NAOV:FederalNetOperatingLossCarriedForward>
    <NAOV:FederalNetOperatingLossOffsetAgainstTaxableIncome
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001207"
      unitRef="USD">14000000</NAOV:FederalNetOperatingLossOffsetAgainstTaxableIncome>
    <NAOV:OperatingLossCarryforwardsExpirationTerm
      contextRef="From2023-01-012023-12-31_us-gaap_DomesticCountryMember"
      id="Fact001209">P20Y</NAOV:OperatingLossCarryforwardsExpirationTerm>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001211"
      unitRef="USD">400000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001213">&lt;p id="xdx_893_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zobxkIkXBd87" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
tax expense is comprised of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_z9NXsdQaVxSe" style="display: none"&gt;SCHEDULE
OF PROVISION FOR INCOME TAXES EXPENSES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240101__20241231_zKiJQhJVt58l" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20231231_zuxtMajYHa74" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current Tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--CurrentFederalTaxExpenseBenefit_maCITEBzPkK_zz1DCJAuasU" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 64%; text-align: left"&gt;Federal&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1215"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1216"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maCITEBzPkK_zFzO7nt8qYPe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;State&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1218"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1219"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CurrentForeignTaxExpenseBenefit_maCITEBzPkK_z0ewUR7hJsh5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="margin: 0"&gt;18,677&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(25,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBzPkK_maOTEBzPz3_zgtwwKReysl1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;18,677&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(25,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred Tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maDITEBzsCS_zNtT1JVqJ0I7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;(815,484&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,226,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maDITEBzsCS_z2jwcZcrVCRe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;State&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;(11,269&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(43,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_maDITEBzsCS_zdb8op4KZaSh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="margin: 0"&gt;(3,263&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_mtDITEBzsCS_maOTEBzPz3_zUkSjIa3EuF1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;(830,015&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,267,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--ValuationAllowanceOfIncomeTaxExpenseBenefit_iN_di_msOTEBzPz3_zvkh7EoLm7dg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: Valuation Allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="margin: 0"&gt;830,015&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,267,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OtherTaxExpenseBenefit_iT_mtOTEBzPz3_zq28qJXkOSk5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total Tax&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;p style="margin: 0"&gt;18,677&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(25,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001221"
      unitRef="USD">18677</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001222"
      unitRef="USD">-25000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001224"
      unitRef="USD">18677</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001225"
      unitRef="USD">-25000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001227"
      unitRef="USD">-815484</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001228"
      unitRef="USD">-1226000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001230"
      unitRef="USD">-11269</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001231"
      unitRef="USD">-43000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001233"
      unitRef="USD">-3263</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001234"
      unitRef="USD">2000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001236"
      unitRef="USD">-830015</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001237"
      unitRef="USD">-1267000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <NAOV:ValuationAllowanceOfIncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001239"
      unitRef="USD">-830015</NAOV:ValuationAllowanceOfIncomeTaxExpenseBenefit>
    <NAOV:ValuationAllowanceOfIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001240"
      unitRef="USD">-1267000</NAOV:ValuationAllowanceOfIncomeTaxExpenseBenefit>
    <us-gaap:OtherTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001242"
      unitRef="USD">18677</us-gaap:OtherTaxExpenseBenefit>
    <us-gaap:OtherTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001243"
      unitRef="USD">-25000</us-gaap:OtherTaxExpenseBenefit>
    <NAOV:FranchiseFees
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001245"
      unitRef="USD">4000</NAOV:FranchiseFees>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001247">&lt;p id="xdx_89A_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zrv6m6x4H7jb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8BF_zy6isbGgFFHj"&gt;SCHEDULE
OF RECONCILIATION OF STATUTORY U.S. FEDERAL RATE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20240101__20241231_zo1qpy21NxQj" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231_zuaiCLWSH0Ib" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_maETR_z08mTPio2hF7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Federal income tax benefit at statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;p style="margin: 0"&gt;21.00&lt;/p&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;21.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_maETR_z0WtBKY24cWi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State income taxes, net of federal benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;0.31&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.13&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_maETR_zgi3HoYswTL2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Foreign rate differential&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;0.04&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-0.10&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--EffectiveIncomeTaxRateReconciliationPermanentItems_pid_dp_maETR_z2zbMpdHaZX8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Permanent Items&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;-0.04&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-0.63&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_maETR_zOvN0UqjO8Ud" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;-21.51&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-33.54&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_pid_dp_maETR_z8eeJ4Wu87g3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Return to provision adjustments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;0.40&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12.20&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--EffectiveIncomeTaxRateReconciliationForfeitedOptions_pid_dp_maETR_zFm7YbMTTPql" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Forfeited options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_maETR_zI863VO3wvn2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="margin: 0"&gt;0.30&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-0.01&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_mtETR_z1dnfdx1pM2a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Effective tax rate&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;p style="margin: 0"&gt;-0.51&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.06&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001249"
      unitRef="Pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001250"
      unitRef="Pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001252"
      unitRef="Pure">0.0031</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001253"
      unitRef="Pure">0.0113</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001255"
      unitRef="Pure">0.0004</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001256"
      unitRef="Pure">-0.0010</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <NAOV:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001258"
      unitRef="Pure">-0.0004</NAOV:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <NAOV:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001259"
      unitRef="Pure">-0.0063</NAOV:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001261"
      unitRef="Pure">-0.2151</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001262"
      unitRef="Pure">-0.3354</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001264"
      unitRef="Pure">0.0040</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001265"
      unitRef="Pure">0.1220</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <NAOV:EffectiveIncomeTaxRateReconciliationForfeitedOptions
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001267"
      unitRef="Pure">0.0000</NAOV:EffectiveIncomeTaxRateReconciliationForfeitedOptions>
    <NAOV:EffectiveIncomeTaxRateReconciliationForfeitedOptions
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001268"
      unitRef="Pure">0.0000</NAOV:EffectiveIncomeTaxRateReconciliationForfeitedOptions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001270"
      unitRef="Pure">0.0030</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001271"
      unitRef="Pure">-0.0001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001273"
      unitRef="Pure">-0.0051</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001274"
      unitRef="Pure">0.0006</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-012024-12-31_country_IL"
      decimals="INF"
      id="Fact001276"
      unitRef="Pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-012023-12-31_country_IL"
      decimals="INF"
      id="Fact001278"
      unitRef="Pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001280">&lt;p id="xdx_893_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_z8kq8o1y2ys9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8B5_z95j9vk6bTZd"&gt;SCHEDULE
OF INCOME BEFORE TAXES ON DOMESTIC AND FOREIGN&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240101__20241231_zflRt6iwtLFh" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20230101__20231231_zh2ylrDK48Vc" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_maILFCOz5C4_zGWQb8RJ19ce" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Domestic&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;p style="margin: 0"&gt;3,775,000&lt;/p&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;3,785,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_maILFCOz5C4_zh5XuOSYkMd9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="margin: 0"&gt;(89,000&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;br/&gt;
&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(103,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iNT_di_mtILFCOz5C4_z6Gc6eupoZMc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss before taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;p style="margin: 0"&gt;3,686,000&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,682,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001282"
      unitRef="USD">3775000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001283"
      unitRef="USD">3785000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001285"
      unitRef="USD">-89000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001286"
      unitRef="USD">-103000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001288"
      unitRef="USD">-3686000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001289"
      unitRef="USD">-3682000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001291">&lt;p id="xdx_890_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zNYO9gPUIDh6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8B2_zqf9uXoQr892"&gt;SCHEDULE
OF DEFERRED TAX ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20241231_zmAEAoSVgAI4" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20231231_za5qgwPsI8ih" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzNu2_zv8U2kJ3Ihtf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Net operating loss carryforward&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;p style="margin: 0"&gt;9,032,000&lt;/p&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;8,486,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--DeferredTaxAssetsOfCapitalLossCarryforward_iI_maDTAGzNu2_zAffx37hB6U" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Capital loss carryforward&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;5,000&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1297"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--DeferredTaxAssetsTaxDeferredExpenseAccruals_iI_maDTAGzNu2_zLxfObrePuZj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Arbitration accrual&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;414,000&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;414,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_iI_maDTAGzNu2_z9VaXSu4vkA3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Stock compensation and other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="margin: 0"&gt;849,000&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;570,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzNu2_maDTALNzt1d_zNYrTbXgZi7k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets before valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;10,300,000&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,470,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzt1d_ziepFG8hpcqa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="margin: 0"&gt;(10,300,000&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(9,470,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzt1d_zTvmpeSxKzj4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax asset&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1311"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1312"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001293"
      unitRef="USD">9032000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001294"
      unitRef="USD">8486000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <NAOV:DeferredTaxAssetsOfCapitalLossCarryforward
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001296"
      unitRef="USD">5000</NAOV:DeferredTaxAssetsOfCapitalLossCarryforward>
    <NAOV:DeferredTaxAssetsTaxDeferredExpenseAccruals
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001299"
      unitRef="USD">414000</NAOV:DeferredTaxAssetsTaxDeferredExpenseAccruals>
    <NAOV:DeferredTaxAssetsTaxDeferredExpenseAccruals
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001300"
      unitRef="USD">414000</NAOV:DeferredTaxAssetsTaxDeferredExpenseAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001302"
      unitRef="USD">849000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001303"
      unitRef="USD">570000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001305"
      unitRef="USD">10300000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001306"
      unitRef="USD">9470000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001308"
      unitRef="USD">10300000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001309"
      unitRef="USD">9470000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001314"
      unitRef="USD">830000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001316"
      unitRef="USD">1267000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001318">&lt;p id="xdx_800_eus-gaap--SubsequentEventsTextBlock_zVnW4T3NxjT8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
14 - &lt;span id="xdx_82D_zxjt7wXRCZ8h"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;January
2025 3(a)(9) Exchange&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 7, 2025, NanoVibronix, Inc. entered into a securities exchange agreement (the &#x201c;Exchange Agreement&#x201d;) with a
certain institutional investor (the &#x201c;Holder&#x201d;) pursuant to which the Company agreed to issue an aggregate of (i) &lt;/span&gt;&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250107__20250107__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z7YnanCYZ2d" title="Number of new share issued"&gt;456,478&lt;/span&gt;
shares of common stock, (ii) a warrant to purchase up to &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250701__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zS8Mo5U1rMq8" title="Number of securities called by warrants or rights"&gt;158,562&lt;/span&gt;
shares of Common Stock (the &#x201c;Warrant&#x201d; and such shares issuable upon exercise of the Warrant, the &#x201c;Warrant
Shares&#x201d;) and (iii) a pre-funded warrant to purchase up to &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250107__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBXvyVcqNqO7" title="Number of securities called by warrants or rights"&gt;178,132&lt;/span&gt;
shares of common stock (the &#x201c;Pre-Funded Warrant&#x201d; and such shares of Common Stock issuable upon exercise of the
Pre-Funded Warrant, the &#x201c;Pre-Funded Warrant Shares&#x201d;), in exchange for a certain outstanding Series A-1 Warrant held by
the Holder to purchase up to &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250107__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zv9eRRiYWhyd" title="Number of securities called by warrants or rights"&gt;264,271 &lt;/span&gt;
shares of common stock at an exercise price of $&lt;span id="xdx_902_eus-gaap--WarrantExercisePriceIncrease_pid_c20250107__20250107__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBx2JX4I5v8k" title="Warrant exercise price"&gt;16.17&lt;/span&gt;
per share (the &#x201c;Exchange&#x201d;). The Company cancelled the Series A-1 Warrant reacquired in the Exchange and such Series A-1
Warrant will not be reissued. The Warrant has substantially the same terms as the Series A-1 Warrant, except that the Warrant Shares
are subject to stockholder approval (the &#x201c;January 2025 Stockholder Approval&#x201d;) pursuant to the applicable rules and
regulations of the Nasdaq Capital Market, exercisable for a term of five and one half years from the date the January 2025
Stockholder Approval is received and deemed effective under Delaware law, and has an exercise price of $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250107__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zoaFDuVfyANj" title="Exercise price per share"&gt;6.82968&lt;/span&gt;
per share. During the months January and February 2025, the Holder exercised all &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zM9xUT4WaVb9" title="Warrant exercise, shares"&gt;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250228__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4yVUDKxbv56" title="Warrant exercise, shares"&gt;178,132&lt;/span&gt;&lt;/span&gt;
shares of its Pre-Funded Warrants converting the Warrants into &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zNL2V0c5RO09" title="Warrant exercise, conversion shares"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250228__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zyvJcGvZ89k6" title="Warrant exercise, conversion shares"&gt;177,773&lt;/span&gt;&lt;/span&gt;
shares of common stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Merger
with ENvue Medical Holdings, Corp.&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 14, 2025, Nanovibronix, Inc., a Delaware corporation (the &#x201c;Company&#x201d;) entered into that certain Agreement and Plan
of Merger (the &#x201c;Merger Agreement&#x201d;) with NVEH Merger Sub I, Inc., a Delaware corporation (&#x201c;First Merger Sub&#x201d;),
NVEH Merger Sub II, LLC, a Delaware limited liability company (&#x201c;Second Merger Sub&#x201d;) and ENvue Medical Holdings, Corp. (&#x201c;ENvue&#x201d;).
Pursuant to the terms of the Merger Agreement, the Company and ENvue effected (i) a merger of First Merger Sub with and into ENvue, with
the First Merger Sub ceasing to exist and ENvue becoming a wholly-owned subsidiary the Company (the &#x201c;First Effective Time&#x201d;)
and (ii) the merger of ENvue with and into Second Merger Sub (the &#x201c;Second Merger&#x201d; and such effective time, the &#x201c;Second
Effective Time&#x201d; and, the Second Merger together with the First Merger, the &#x201c;Merger&#x201d;), with Second Merger Sub being
the surviving entity of the Second Merger (&#x201c;Surviving Entity&#x201d;). At the Second Effective Time, the certificate of formation
of the Surviving Entity was amended and restated to, among other things, to change the name of the Surviving Entity to &#x201c;ENvue Medical
Holdings LLC.&#x201d; In connection with the Merger Agreement, the Company issued (i) &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250214__20250214__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWQarZE0tpXk" title="Number of new share issued"&gt;1,734,995&lt;/span&gt; shares (the &#x201c;Merger Shares&#x201d;)
of common stock to the holders of ENvue, which such number of shares represented no more than &lt;span id="xdx_90D_ecustom--PercentageForNumberOfOutstandingCommonStock_pid_dp_uPure_c20250214__20250214__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MaximumMember_zNF2rx9MMAP1" title="Percentage for number of outstanding common stock"&gt;19.9&lt;/span&gt;% (the &#x201c;Exchange Cap&#x201d;)
of the outstanding shares of common stock immediately prior to the First Effective Time and (ii) &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20250214__20250214__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4jB66F6WwG8" title="Convertible shares"&gt;57,720&lt;/span&gt; shares of Series X Non-Voting
Convertible Preferred Stock (the &#x201c;Series X Preferred Stock&#x201d;), as further described below, in excess of the Exchange Cap to
the holders of ENvue in consideration for &lt;span id="xdx_90A_ecustom--PercentageForExchangeCapitalForConsideration_pid_dp_uPure_c20250214__20250214__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zofx9pBUwHc7" title="Percentage for exchange capital for consideration"&gt;100&lt;/span&gt;% of ENvue. Each share of Series X Preferred Stock will be convertible into &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20250214__20250214__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTyV8wTgHoB8" title="Convertible shares"&gt;1,000&lt;/span&gt; shares
of common stock, subject to and contingent upon the affirmative vote of a majority of the shares of common stock present or represented
and entitled to vote at a meeting of stockholders of Company to approve, for purposes of the Nasdaq Listing Rules, the issuance of shares
of common stock to the stockholders of ENvue upon conversion of any and all shares of Series X Preferred Stock in accordance with the
terms of the Series X Certificate of Designations. The Merger was consummated and completed on February 14, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;After
giving effect to the Merger, pursuant to the terms and conditions of the Merger Agreement: (i) &lt;span id="xdx_904_eus-gaap--ConvertiblePreferredStockTermsOfConversion_c20250214__20250214__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zdDj6Jhntzxi" title="Convertible description"&gt;the holders of the outstanding equity
of ENvue immediately prior to the First Effective Time own 19.9% of the common stock of the Company and 85.0% of the outstanding equity
of the Company (assuming the Series X Preferred Stock is converting at a ratio of 1,000:1) immediately following the First Effective
Time, which following Merger Stockholder Approval will allow the Series X Preferred Stock to convert to common stock of the Company which
may result in the holders of ENvue to own 85% of the common stock of the Company, and (ii) the holders of the Company&#x2019;s outstanding
equity immediately prior to the First Effective Time own 80.1% of the common stock of the Company and 15.0% of the outstanding equity
of the Company (assuming the Series X Preferred Stock is converting at a ratio of 1,000:1) immediately following the First Effective
Time, which following Merger Stockholder Approval which will allow the Series X Preferred Stock to convert to common stock of the Company
which may result in our holders owning 15% of common stock of the Company.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Debenture
Financing and Senior Convertible Debenture&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 13, 2025, the Company entered into a Securities Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with an institutional
investor (the &#x201c;Investor&#x201d;), pursuant to which the Company sold in a private placement, a senior convertible debenture (the
&#x201c;Debenture&#x201d;) due the earlier of (i) the date that is the 30-day anniversary of the effective date of stockholder approval
(the &#x201c;Debenture Stockholder Approval&#x201d;) of the issuance of the shares of common stock upon the conversion of the debenture
(the &#x201c;Debenture Financing&#x201d;) and (ii) the date that is nine months following the date of issuance of the Debenture (&#x201c;Maturity
Date&#x201d;), having an aggregate principal amount of $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20250213__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztfn7uQ5nZmd" title="Debt principal amount"&gt;500,000&lt;/span&gt;. In connection with the Debenture Financing, the Company also entered
into Registration Rights Agreement (the &#x201c;Registration Rights Agreement&#x201d;) with the Investor, pursuant which the Company is
required to prepare and file a resale registration statement with the SEC within 30 calendar days following the closing date of the Debenture
Financing (the &#x201c;Filing Deadline&#x201d;). The Company shall use its commercially reasonable efforts to cause such registration statement
to be declared effective by the SEC within 60 calendar days of the Filing Deadline (or within 90 calendar days if the SEC reviews the
resale registration statement). The closing of the Debenture Financing occurred on February 14, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;On March 26, 2025 we amended
and restated the Debenture to increase the Principal Amount to $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20250326__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--ENvueMedicalHoldingsCorpMember_z9s5Qh1nhyL1" title="Debt principal amount"&gt;1,300,000&lt;/span&gt; to provide for the funding by Alpha Capital Anstalt (the &#x201c;Investor&#x201d;)
to our subsidiary ENvue Medical Holdings, Corp. (&#x201c;&lt;b&gt;&lt;i&gt;ENvue&lt;/i&gt;&lt;/b&gt;&#x201d;), a wholly owned subsidiary of the Company of (i) an
aggregate of $&lt;span id="xdx_908_eus-gaap--Investments_iI_c20250226__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--ENvueMedicalHoldingsCorpMember_z75NUxhiTEx3" title="Investments"&gt;250,000&lt;/span&gt; by the Investor to ENvue on February 6, 2025, (ii) an aggregate of $&lt;span id="xdx_908_eus-gaap--Investments_iI_c20250304__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--ENvueMedicalHoldingsCorpMember_zUFZzGEUTw48" title="Investments"&gt;250,000&lt;/span&gt; by the Investor to ENvue on March 4,
2025, and (iii) and an aggregate of $&lt;span id="xdx_903_eus-gaap--Investments_iI_c20250326__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--ENvueMedicalHoldingsCorpMember_zTYO8drNHNg9" title="Investments"&gt;300,000&lt;/span&gt; by the Investor to ENvue on March 26, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;On the Maturity Date, we shall pay the Investor in
cash or, at the option of the Investor, in the form of conversion shares, or a combination thereof, the entire outstanding principal amount
of the Debenture, together with accrued and unpaid interest thereon, the applicable exit fee and any other amounts due thereunder. Following
the receipt of Debenture Stockholder Approval, the Debenture shall be convertible, in whole or in part, into shares of common stock, at
the option of the Investor, at the initial conversion price of $&lt;span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20250326__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--ENvueMedicalHoldingsCorpMember_zzitXf8keZIh" title="Conversion price"&gt;4.8906&lt;/span&gt; (the &#x201c;Conversion Price&#x201d;), which is subject to customary
anti-dilution adjustments, and which such Conversion Price shall not be lower than the floor price of $&lt;span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20250326__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_zKUZEPIGWnr4" title="Conversion price"&gt;0.97812&lt;/span&gt;. The Debenture bears interest
at the rate of &lt;span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20250326__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--ENvueMedicalHoldingsCorpMember_zBwPu3twiGt8" title="Debt interest rate"&gt;8.0&lt;/span&gt;% per annum, payable on the Maturity Date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;2025
Reverse Stock Split&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 13, 2025, the Company effected the 2025 Reverse Stock Split. As a result of the 2025 Reverse Stock Split, every 11 shares of issued
and outstanding common stock were automatically combined into one issued and outstanding share of common stock, without any change in
the par value per share. No fractional shares were issued as a result of the 2025 Reverse Stock Split. Any fractional shares that would
otherwise have resulted from the Reverse Stock Split was rounded up to the next whole number. The 2025 Reverse Stock Split reduced the
number of shares of common stock outstanding from &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_pid_c20250312__20250312__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlSSQU1U9Pj3" title="Reverse stock split outstanding shares"&gt;8,716,327&lt;/span&gt; shares to approximately &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_pid_c20250313__20250313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTB7AsTcY3md" title="Reverse stock split outstanding shares"&gt;792,394&lt;/span&gt; shares, subject to adjustment for the rounding
up of fractional shares. The number of authorized shares of common stock under the Company&#x2019;s Amended and Restated Certificate of
Incorporation, as amended remained unchanged at &lt;span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20250313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zcXkjfYohdO4" title="Common stock shares remained unchanged"&gt;40,000,000&lt;/span&gt; shares.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-072025-01-07_custom_SecuritiesExchangeAgreementMember_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001320"
      unitRef="Shares">456478</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-07-01_custom_SecuritiesExchangeAgreementMember_us-gaap_WarrantMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001322"
      unitRef="Shares">158562</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-01-07_custom_SecuritiesExchangeAgreementMember_custom_PreFundedWarrantsMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001324"
      unitRef="Shares">178132</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-01-07_custom_SecuritiesExchangeAgreementMember_custom_A1WarrantsMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001326"
      unitRef="Shares">264271</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="From2025-01-072025-01-07_custom_SecuritiesExchangeAgreementMember_custom_A1WarrantsMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001328"
      unitRef="USDPShares">16.17</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-01-07_custom_SecuritiesExchangeAgreementMember_custom_PreFundedWarrantsMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001330"
      unitRef="USDPShares">6.82968</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-01-31_custom_SecuritiesExchangeAgreementMember_custom_PreFundedWarrantsMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001332"
      unitRef="Shares">178132</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-02-28_custom_SecuritiesExchangeAgreementMember_custom_PreFundedWarrantsMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001334"
      unitRef="Shares">178132</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-01-31_custom_SecuritiesExchangeAgreementMember_us-gaap_WarrantMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001336"
      unitRef="Shares">177773</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-02-28_custom_SecuritiesExchangeAgreementMember_us-gaap_WarrantMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001338"
      unitRef="Shares">177773</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-02-142025-02-14_custom_MergerAgreementMember_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001340"
      unitRef="Shares">1734995</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <NAOV:PercentageForNumberOfOutstandingCommonStock
      contextRef="From2025-02-142025-02-14_custom_MergerAgreementMember_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001342"
      unitRef="Pure">0.199</NAOV:PercentageForNumberOfOutstandingCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2025-02-142025-02-14_custom_MergerAgreementMember_custom_SeriesXPreferredStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001344"
      unitRef="Shares">57720</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <NAOV:PercentageForExchangeCapitalForConsideration
      contextRef="From2025-02-142025-02-14_custom_MergerAgreementMember_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001346"
      unitRef="Pure">1</NAOV:PercentageForExchangeCapitalForConsideration>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2025-02-142025-02-14_custom_MergerAgreementMember_custom_SeriesXPreferredStockMember_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001348"
      unitRef="Shares">1000</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:ConvertiblePreferredStockTermsOfConversion
      contextRef="From2025-02-142025-02-14_custom_MergerAgreementMember_custom_SeriesXPreferredStockMember_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember"
      id="Fact001350">the holders of the outstanding equity
of ENvue immediately prior to the First Effective Time own 19.9% of the common stock of the Company and 85.0% of the outstanding equity
of the Company (assuming the Series X Preferred Stock is converting at a ratio of 1,000:1) immediately following the First Effective
Time, which following Merger Stockholder Approval will allow the Series X Preferred Stock to convert to common stock of the Company which
may result in the holders of ENvue to own 85% of the common stock of the Company, and (ii) the holders of the Company&#x2019;s outstanding
equity immediately prior to the First Effective Time own 80.1% of the common stock of the Company and 15.0% of the outstanding equity
of the Company (assuming the Series X Preferred Stock is converting at a ratio of 1,000:1) immediately following the First Effective
Time, which following Merger Stockholder Approval which will allow the Series X Preferred Stock to convert to common stock of the Company
which may result in our holders owning 15% of common stock of the Company.</us-gaap:ConvertiblePreferredStockTermsOfConversion>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-02-13_custom_SecuritiesExchangeAgreementMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001352"
      unitRef="USD">500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-03-26_us-gaap_SubsequentEventMember_custom_ENvueMedicalHoldingsCorpMember"
      decimals="0"
      id="Fact001354"
      unitRef="USD">1300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:Investments
      contextRef="AsOf2025-02-26_us-gaap_SubsequentEventMember_custom_ENvueMedicalHoldingsCorpMember"
      decimals="0"
      id="Fact001356"
      unitRef="USD">250000</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="AsOf2025-03-04_us-gaap_SubsequentEventMember_custom_ENvueMedicalHoldingsCorpMember"
      decimals="0"
      id="Fact001358"
      unitRef="USD">250000</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="AsOf2025-03-26_us-gaap_SubsequentEventMember_custom_ENvueMedicalHoldingsCorpMember"
      decimals="0"
      id="Fact001360"
      unitRef="USD">300000</us-gaap:Investments>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2025-03-26_us-gaap_SubsequentEventMember_custom_ENvueMedicalHoldingsCorpMember"
      decimals="INF"
      id="Fact001362"
      unitRef="USDPShares">4.8906</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2025-03-26_us-gaap_SubsequentEventMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001364"
      unitRef="USDPShares">0.97812</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2025-03-26_us-gaap_SubsequentEventMember_custom_ENvueMedicalHoldingsCorpMember"
      decimals="INF"
      id="Fact001366"
      unitRef="Pure">0.080</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="From2025-03-122025-03-12_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001368"
      unitRef="Shares">8716327</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="From2025-03-132025-03-13_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001370"
      unitRef="Shares">792394</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-03-13_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001372"
      unitRef="Shares">40000000</us-gaap:CommonStockSharesAuthorized>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
